0001840199-25-000025.txt : 20250320 0001840199-25-000025.hdr.sgml : 20250320 20250320160612 ACCESSION NUMBER: 0001840199-25-000025 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 129 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250320 DATE AS OF CHANGE: 20250320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Waldencast plc CENTRAL INDEX KEY: 0001840199 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-40207 FILM NUMBER: 25756470 BUSINESS ADDRESS: STREET 1: 81 FULHAM ROAD CITY: LONDON STATE: X0 ZIP: SW3 6RD BUSINESS PHONE: 44 (0)20 3196 0264 MAIL ADDRESS: STREET 1: 81 FULHAM ROAD CITY: LONDON STATE: X0 ZIP: SW3 6RD FORMER COMPANY: FORMER CONFORMED NAME: Waldencast Acquisition Corp. DATE OF NAME CHANGE: 20210112 20-F 1 wald-20241231.htm 20-F wald-20241231
0001840199FALSEFY2024X00.33333100.33P12MP12Moneonehttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantsxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purewald:segmentwald:directorwald:operatingLeasewald:individualwald:tranchewald:installment00018401992024-01-012024-12-310001840199dei:BusinessContactMember2024-01-012024-12-310001840199us-gaap:CommonClassAMember2024-01-012024-12-310001840199us-gaap:WarrantMember2024-01-012024-12-310001840199us-gaap:CommonClassAMember2024-12-310001840199us-gaap:CommonClassBMember2024-12-3100018401992024-12-3100018401992023-12-310001840199us-gaap:NonrelatedPartyMember2024-12-310001840199us-gaap:NonrelatedPartyMember2023-12-310001840199us-gaap:RelatedPartyMember2024-12-310001840199us-gaap:RelatedPartyMember2023-12-310001840199us-gaap:CommonClassAMember2023-12-310001840199us-gaap:CommonClassAMembersrt:ParentCompanyMember2024-12-310001840199us-gaap:CommonClassBMember2023-12-310001840199us-gaap:CommonClassBMembersrt:ParentCompanyMember2024-12-3100018401992023-01-012023-12-3100018401992022-07-292022-12-310001840199wald:ObagiSkincareMember2022-01-012022-07-2700018401992022-01-012022-07-270001840199us-gaap:CommonStockMemberwald:ObagiCosmeceuticalsLLCMember2021-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:ObagiCosmeceuticalsLLCMember2021-12-310001840199us-gaap:RetainedEarningsMemberwald:ObagiCosmeceuticalsLLCMember2021-12-310001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:ObagiCosmeceuticalsLLCMember2021-12-310001840199wald:ObagiCosmeceuticalsLLCMember2021-12-310001840199us-gaap:RetainedEarningsMemberwald:ObagiCosmeceuticalsLLCMember2022-01-012022-07-270001840199wald:ObagiCosmeceuticalsLLCMember2022-01-012022-07-270001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:ObagiCosmeceuticalsLLCMember2022-01-012022-07-270001840199us-gaap:AdditionalPaidInCapitalMemberwald:ObagiCosmeceuticalsLLCMember2022-01-012022-07-270001840199us-gaap:CommonStockMemberwald:ObagiCosmeceuticalsLLCMember2022-07-270001840199us-gaap:AdditionalPaidInCapitalMemberwald:ObagiCosmeceuticalsLLCMember2022-07-270001840199us-gaap:RetainedEarningsMemberwald:ObagiCosmeceuticalsLLCMember2022-07-270001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:ObagiCosmeceuticalsLLCMember2022-07-270001840199wald:ObagiCosmeceuticalsLLCMember2022-07-270001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-07-270001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-07-270001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2022-07-270001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2022-07-270001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2022-07-270001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2022-07-270001840199wald:WaldencastPlcMember2022-07-270001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-07-282022-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2022-07-282022-12-310001840199wald:WaldencastPlcMember2022-07-282022-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-07-282022-12-310001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2022-07-282022-12-310001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2022-07-282022-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2022-01-012022-07-270001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2022-07-282022-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2022-12-310001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2022-12-310001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2022-12-310001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2022-12-310001840199wald:WaldencastPlcMember2022-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2023-01-012023-12-310001840199wald:WaldencastPlcMember2023-01-012023-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-01-012023-12-310001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2023-01-012023-12-310001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2023-01-012023-12-310001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2023-01-012023-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2023-12-310001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2023-12-310001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2023-12-310001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2023-12-310001840199wald:WaldencastPlcMember2023-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-01-012024-12-310001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2024-01-012024-12-310001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2024-01-012024-12-310001840199wald:WaldencastPlcMember2024-01-012024-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2024-01-012024-12-310001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2024-01-012024-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-12-310001840199wald:WaldencastPlcMemberus-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-12-310001840199us-gaap:AdditionalPaidInCapitalMemberwald:WaldencastPlcMember2024-12-310001840199us-gaap:RetainedEarningsMemberwald:WaldencastPlcMember2024-12-310001840199us-gaap:AccumulatedOtherComprehensiveIncomeMemberwald:WaldencastPlcMember2024-12-310001840199us-gaap:NoncontrollingInterestMemberwald:WaldencastPlcMember2024-12-310001840199wald:WaldencastPlcMember2024-12-310001840199wald:ObagiMergerMember2024-01-012024-12-310001840199wald:ObagiMergerMember2023-01-012023-12-310001840199wald:ObagiMergerMember2022-07-292022-12-310001840199wald:ObagiMergerMember2022-01-012022-07-270001840199wald:MilkTransactionMember2024-01-012024-12-310001840199wald:MilkTransactionMember2023-01-012023-12-310001840199wald:MilkTransactionMember2022-07-292022-12-310001840199wald:MilkTransactionMember2022-01-012022-07-2700018401992022-12-3100018401992022-07-2800018401992021-12-3100018401992022-07-2700018401992022-07-282022-12-310001840199us-gaap:IPOMember2021-03-182021-03-180001840199us-gaap:CommonStockMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2021-03-182021-03-180001840199us-gaap:CommonStockMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2021-03-180001840199us-gaap:IPOMember2021-03-1800018401992021-07-150001840199us-gaap:WarrantMemberus-gaap:IPOMember2021-03-182021-03-180001840199wald:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310001840199wald:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001840199wald:VendorOneMemberus-gaap:SupplierConcentrationRiskMemberwald:InventoryPurchasesMember2024-01-012024-12-310001840199wald:VendorTwoMemberus-gaap:SupplierConcentrationRiskMemberwald:InventoryPurchasesMember2024-01-012024-12-310001840199wald:VendorOneMemberus-gaap:SupplierConcentrationRiskMemberwald:InventoryPurchasesMember2023-01-012023-12-310001840199wald:VendorOneMemberus-gaap:LenderConcentrationRiskMemberus-gaap:AccountsPayableMember2023-01-012023-12-310001840199wald:CorporateCreditCardsMember2024-12-310001840199wald:LeaseDepositsMember2024-12-310001840199srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001840199wald:ComputerHardwareSoftwareAndEquipmentMember2024-12-310001840199srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2024-12-310001840199srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2024-12-310001840199srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310001840199srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310001840199srt:MinimumMember2024-01-012024-12-310001840199srt:MaximumMember2024-01-012024-12-310001840199wald:FounderAwardsMember2022-08-310001840199wald:ObagiMergerMember2022-07-280001840199wald:ObagiMergerMemberus-gaap:CommonClassAMember2022-07-282022-07-280001840199wald:ObagiMergerMember2022-07-282022-07-280001840199wald:MilkTransactionMemberus-gaap:CommonClassBMember2022-07-282022-07-280001840199wald:MilkTransactionMember2022-07-282022-07-280001840199us-gaap:CommonClassAMember2022-07-280001840199wald:MilkTransactionMember2022-07-280001840199wald:WaldencastPlcMemberwald:ObagiChinaBusinessMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberwald:CedarwalkMember2022-07-280001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2022-01-012022-07-270001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:ObagiSkincareMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:MilkMakeupMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:RelatedPartyMemberwald:ObagiSkincareMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:RelatedPartyMemberwald:MilkMakeupMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:RelatedPartyMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:ObagiSkincareMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:MilkMakeupMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMember2022-07-280001840199wald:ObagiSkincareMember2022-07-282022-12-310001840199wald:ObagiSkincareMember2024-01-012024-12-310001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:RelatedPartyMember2024-01-012024-12-310001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:RelatedPartyMember2022-07-282022-12-310001840199wald:TretinoinDistributionAndSupplyAgreementMember2024-01-012024-12-310001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:TrademarksAndTradeNamesMemberwald:ObagiSkincareMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:TrademarksAndTradeNamesMemberwald:MilkMakeupMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:TrademarksAndTradeNamesMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:TrademarksAndTradeNamesMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:CustomerRelationshipsMemberwald:ObagiSkincareMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:CustomerRelationshipsMemberwald:MilkMakeupMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:CustomerRelationshipsMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberus-gaap:CustomerRelationshipsMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:TretinoinDistributionAndSupplyAgreementMemberwald:ObagiSkincareMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:TretinoinDistributionAndSupplyAgreementMemberwald:MilkMakeupMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:TretinoinDistributionAndSupplyAgreementMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:TretinoinDistributionAndSupplyAgreementMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:FormulationsMemberwald:ObagiSkincareMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:FormulationsMemberwald:MilkMakeupMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:FormulationsMember2022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMemberwald:FormulationsMember2022-07-282022-07-280001840199wald:ObagiAndMilkBusinessCombinationsMember2022-07-282022-12-310001840199wald:ObagiAndMilkBusinessCombinationsMember2022-01-012022-12-310001840199wald:ObagiVietnamImportExportTradingMTVCompanyLimitedMember2023-03-012023-03-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMemberwald:ObagiSkincareMember2024-01-012024-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMemberwald:MilkMakeupMember2024-01-012024-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMember2024-01-012024-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMemberwald:ObagiSkincareMember2024-01-012024-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMemberwald:MilkMakeupMember2024-01-012024-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMember2024-01-012024-12-310001840199us-gaap:ProductMemberwald:ObagiSkincareMember2024-01-012024-12-310001840199us-gaap:ProductMemberwald:MilkMakeupMember2024-01-012024-12-310001840199us-gaap:ProductMember2024-01-012024-12-310001840199us-gaap:RoyaltyMemberwald:ObagiSkincareMember2024-01-012024-12-310001840199us-gaap:RoyaltyMemberwald:MilkMakeupMember2024-01-012024-12-310001840199us-gaap:RoyaltyMember2024-01-012024-12-310001840199wald:MilkMakeupMember2024-01-012024-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMemberwald:ObagiSkincareMember2023-01-012023-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMemberwald:MilkMakeupMember2023-01-012023-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMember2023-01-012023-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMemberwald:ObagiSkincareMember2023-01-012023-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMemberwald:MilkMakeupMember2023-01-012023-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMember2023-01-012023-12-310001840199us-gaap:ProductMemberwald:ObagiSkincareMember2023-01-012023-12-310001840199us-gaap:ProductMemberwald:MilkMakeupMember2023-01-012023-12-310001840199us-gaap:ProductMember2023-01-012023-12-310001840199us-gaap:RoyaltyMemberwald:ObagiSkincareMember2023-01-012023-12-310001840199us-gaap:RoyaltyMemberwald:MilkMakeupMember2023-01-012023-12-310001840199us-gaap:RoyaltyMember2023-01-012023-12-310001840199wald:ObagiSkincareMember2023-01-012023-12-310001840199wald:MilkMakeupMember2023-01-012023-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMemberwald:ObagiSkincareMember2022-07-292022-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMemberwald:MilkMakeupMember2022-07-292022-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMember2022-07-292022-12-310001840199us-gaap:SalesChannelDirectlyToConsumerMemberus-gaap:ProductMember2022-01-012022-07-270001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMemberwald:ObagiSkincareMember2022-07-292022-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMemberwald:MilkMakeupMember2022-07-292022-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMember2022-07-292022-12-310001840199us-gaap:SalesChannelThroughIntermediaryMemberus-gaap:ProductMember2022-01-012022-07-270001840199us-gaap:ProductMemberwald:ObagiSkincareMember2022-07-292022-12-310001840199us-gaap:ProductMemberwald:MilkMakeupMember2022-07-292022-12-310001840199us-gaap:ProductMember2022-07-292022-12-310001840199us-gaap:ProductMember2022-01-012022-07-270001840199us-gaap:RoyaltyMemberwald:ObagiSkincareMember2022-07-292022-12-310001840199us-gaap:RoyaltyMemberwald:MilkMakeupMember2022-07-292022-12-310001840199us-gaap:RoyaltyMember2022-07-292022-12-310001840199us-gaap:RoyaltyMember2022-01-012022-07-270001840199wald:ObagiSkincareMember2022-07-292022-12-310001840199wald:MilkMakeupMember2022-07-292022-12-310001840199wald:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310001840199wald:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310001840199wald:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310001840199wald:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001840199wald:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001840199wald:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-282022-12-310001840199wald:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-282022-12-310001840199wald:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-282022-12-310001840199wald:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-07-270001840199wald:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-07-270001840199srt:NorthAmericaMemberus-gaap:ProductMember2024-01-012024-12-310001840199srt:NorthAmericaMemberus-gaap:ProductMember2023-01-012023-12-310001840199srt:NorthAmericaMemberus-gaap:ProductMember2022-07-282022-12-310001840199srt:NorthAmericaMemberus-gaap:ProductMember2022-01-012022-07-270001840199wald:RestOfTheWorldMemberus-gaap:ProductMember2024-01-012024-12-310001840199wald:RestOfTheWorldMemberus-gaap:ProductMember2023-01-012023-12-310001840199wald:RestOfTheWorldMemberus-gaap:ProductMember2022-07-282022-12-310001840199wald:RestOfTheWorldMemberus-gaap:ProductMember2022-01-012022-07-270001840199us-gaap:ProductMember2022-07-282022-12-310001840199us-gaap:RoyaltyMember2022-07-282022-12-310001840199country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310001840199country:USus-gaap:ProductMember2024-01-012024-12-310001840199country:USus-gaap:ProductMember2023-01-012023-12-310001840199country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-282022-12-310001840199country:USus-gaap:ProductMember2022-07-282022-12-310001840199country:CNus-gaap:ProductMember2022-07-282022-12-310001840199country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-07-270001840199country:USus-gaap:ProductMember2022-01-012022-07-270001840199country:VNus-gaap:ProductMember2022-01-012022-07-270001840199wald:ObagiSkincareMember2022-12-310001840199wald:MilkMakeupMember2022-12-310001840199wald:ObagiSkincareMember2023-12-310001840199wald:MilkMakeupMember2023-12-310001840199wald:ObagiSkincareMember2024-12-310001840199wald:MilkMakeupMember2024-12-310001840199wald:ObagiSkincareMember2022-01-012022-12-310001840199us-gaap:TrademarksAndTradeNamesMember2024-12-310001840199us-gaap:CustomerRelationshipsMember2024-12-310001840199wald:TretinoinDistributionAndSupplyAgreementMember2024-12-310001840199wald:FormulationsMember2024-12-310001840199us-gaap:PatentsMember2024-12-310001840199us-gaap:TrademarksAndTradeNamesMember2023-12-310001840199us-gaap:CustomerRelationshipsMember2023-12-310001840199wald:TretinoinDistributionAndSupplyAgreementMember2023-12-310001840199wald:FormulationsMember2023-12-310001840199us-gaap:PatentsMember2023-12-310001840199wald:A2022TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2024-12-310001840199wald:A2022TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-12-310001840199wald:NotePayableDirectorsAndOfficersInsuranceMemberus-gaap:NotesPayableOtherPayablesMember2024-12-310001840199wald:NotePayableDirectorsAndOfficersInsuranceMemberus-gaap:NotesPayableOtherPayablesMember2023-12-310001840199wald:A2022RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310001840199wald:A2022RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310001840199wald:NotePayableDirectorsAndOfficersInsuranceMemberus-gaap:NotesPayableOtherPayablesMember2024-07-310001840199wald:NotePayableDirectorsAndOfficersInsuranceMemberus-gaap:NotesPayableOtherPayablesMember2024-07-012024-07-310001840199wald:NotePayableDirectorsAndOfficersInsuranceMemberus-gaap:NotesPayableOtherPayablesMember2023-08-310001840199wald:NotePayableDirectorsAndOfficersInsuranceMemberus-gaap:NotesPayableOtherPayablesMember2023-08-012023-08-310001840199wald:A2022TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2022-06-300001840199wald:A2022RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-06-300001840199wald:A2022TermLoanMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-06-302022-06-300001840199wald:A2022TermLoanMemberus-gaap:LineOfCreditMemberwald:AlternateBaseRateMemberwald:VariableRateComponentOneMember2022-06-302022-06-300001840199wald:A2022TermLoanMemberus-gaap:LineOfCreditMemberwald:ApplicableRateMemberwald:VariableRateComponentThreeMember2022-06-302022-06-300001840199wald:A2022TermLoanMemberus-gaap:LineOfCreditMemberwald:AlternateBaseRateMemberwald:VariableRateComponentOneMember2024-01-012024-12-3100018401992022-06-300001840199wald:A2022TermLoanMemberus-gaap:LineOfCreditMember2024-12-310001840199wald:A2022TermLoanMember2024-12-310001840199wald:A2022RevolvingCreditFacilityMember2024-12-310001840199wald:A2022CreditAgreementMember2024-12-310001840199wald:A2022RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-04-262024-04-260001840199wald:A2022RevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-04-260001840199srt:MinimumMember2024-12-310001840199srt:MaximumMember2024-12-310001840199stpr:TXsrt:WarehouseMember2024-01-012024-12-310001840199stpr:TXsrt:OfficeBuildingMember2024-01-012024-12-310001840199wald:InterestRateCollarMember2024-12-310001840199wald:InterestRateCollarInitialFixedPaymentMember2024-01-012024-12-310001840199wald:InterestRateCollarMember2023-12-310001840199wald:InterestRateCollarMember2024-01-012024-12-310001840199wald:InterestRateCollarMember2023-01-012023-12-310001840199wald:InterestRateCollarMember2022-07-282022-12-310001840199wald:InterestRateCollarInitialFixedPaymentMember2022-07-282022-12-310001840199wald:PublicWarrantsMember2021-03-182021-03-180001840199wald:SponsorWarrantsMember2021-03-182021-03-180001840199us-gaap:CommonClassAMemberwald:BurwellMountainTrustAndZenoInvestmentMasterFundMember2021-12-202021-12-200001840199wald:SponsorWarrantsMemberwald:BurwellMountainTrustAndZenoInvestmentMasterFundMember2021-12-202021-12-200001840199us-gaap:CommonClassAMemberwald:BeautyVenturesLLCMember2021-03-012021-03-010001840199wald:SponsorWarrantsMemberwald:BeautyVenturesLLCMember2021-03-012021-03-010001840199wald:BeautyVenturesLLCMember2021-03-012021-03-010001840199wald:SponsorWarrantsMember2022-07-282022-07-280001840199wald:PublicWarrantsMember2024-01-012024-12-310001840199wald:PublicWarrantsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-12-310001840199wald:PublicWarrantsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-12-310001840199wald:PublicWarrantsMember2024-12-310001840199wald:PrivatePlacementWarrantsMember2024-01-012024-12-310001840199wald:PublicDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel1Memberwald:PublicDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel2Memberwald:PublicDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel3Memberwald:PublicDerivativeWarrantLiabilitiesMember2024-12-310001840199wald:PrivateDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel1Memberwald:PrivateDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel2Memberwald:PrivateDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel3Memberwald:PrivateDerivativeWarrantLiabilitiesMember2024-12-310001840199us-gaap:FairValueInputsLevel1Memberwald:InterestRateCollarMember2023-12-310001840199us-gaap:FairValueInputsLevel2Memberwald:InterestRateCollarMember2023-12-310001840199us-gaap:FairValueInputsLevel3Memberwald:InterestRateCollarMember2023-12-310001840199wald:PublicDerivativeWarrantLiabilitiesMember2023-12-310001840199us-gaap:FairValueInputsLevel1Memberwald:PublicDerivativeWarrantLiabilitiesMember2023-12-310001840199us-gaap:FairValueInputsLevel2Memberwald:PublicDerivativeWarrantLiabilitiesMember2023-12-310001840199us-gaap:FairValueInputsLevel3Memberwald:PublicDerivativeWarrantLiabilitiesMember2023-12-310001840199wald:PrivateDerivativeWarrantLiabilitiesMember2023-12-310001840199us-gaap:FairValueInputsLevel1Memberwald:PrivateDerivativeWarrantLiabilitiesMember2023-12-310001840199us-gaap:FairValueInputsLevel2Memberwald:PrivateDerivativeWarrantLiabilitiesMember2023-12-310001840199us-gaap:FairValueInputsLevel3Memberwald:PrivateDerivativeWarrantLiabilitiesMember2023-12-310001840199wald:WaldencastPlcMember2021-12-310001840199wald:WaldencastPlcMember2022-01-012022-07-270001840199wald:ComputerHardwareSoftwareAndEquipmentMember2023-12-310001840199us-gaap:FurnitureAndFixturesMember2024-12-310001840199us-gaap:FurnitureAndFixturesMember2023-12-310001840199us-gaap:MachineryAndEquipmentMember2024-12-310001840199us-gaap:MachineryAndEquipmentMember2023-12-310001840199us-gaap:SoftwareDevelopmentMember2024-12-310001840199us-gaap:SoftwareDevelopmentMember2023-12-310001840199us-gaap:LeaseholdImprovementsMember2024-12-310001840199us-gaap:LeaseholdImprovementsMember2023-12-310001840199us-gaap:EmployeeStockMemberwald:A2022IncentiveAwardPlanMember2024-12-310001840199us-gaap:EmployeeStockMemberwald:A2022IncentiveAwardPlanMember2024-01-012024-12-310001840199wald:ShareBasedPaymentArrangementEmployeesAndNonEmployeesMemberwald:LongTermIncentiveAwardsMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001840199wald:ShareBasedPaymentArrangementFounderMemberwald:LongTermIncentiveAwardsMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001840199wald:ShareBasedPaymentArrangementBoardOfDirectorsMemberwald:LongTermIncentiveAwardsMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:LongTermIncentiveAwardsMember2023-05-012023-05-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:LongTermIncentiveAwardsMember2023-01-012023-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:LongTermIncentiveAwardsMember2024-01-012024-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:OneTimStockGrantMember2022-11-300001840199us-gaap:RestrictedStockUnitsRSUMemberwald:OneTimStockGrantMember2022-11-012022-11-300001840199wald:StockGrowthIncentive2027AwardsSGIAwardsMember2024-01-012024-12-310001840199wald:StockGrowthIncentive2027AwardsSGIAwardsMember2024-08-012024-08-3100018401992024-04-012024-04-300001840199wald:StockGrowthIncentiveAwardsSGIAwardsMember2024-01-012024-12-310001840199wald:StockGrowthIncentive2025AwardsSGIAwardsMember2023-01-012023-01-3100018401992023-01-012023-01-310001840199wald:StockGrowthIncentive2025AwardsSGIAwardsMember2023-01-012023-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:WaldencastPlcMember2023-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:WaldencastPlcMember2024-01-012024-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:WaldencastPlcMember2024-12-310001840199wald:ObagiMergerMember2022-07-272022-07-270001840199us-gaap:RestrictedStockUnitsRSUMemberwald:ObagiMergerMember2022-07-272022-07-270001840199wald:MilkTransactionMember2022-07-272022-07-270001840199us-gaap:StockAppreciationRightsSARSMemberwald:MilkTransactionMember2022-07-272022-07-270001840199wald:ObagiAndMilkBusinessCombinationsMember2022-07-272022-07-270001840199wald:ObagiAndMilkBusinessCombinationsMember2022-07-270001840199wald:ShareBasedPaymentArrangementFounderMember2022-08-122022-08-1200018401992022-08-122022-08-120001840199us-gaap:EmployeeStockOptionMemberwald:ShareBasedPaymentArrangementFounderMember2022-08-012022-08-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:ShareBasedPaymentArrangementFounderMember2022-08-122022-08-120001840199wald:FounderAwardsMember2022-07-292022-12-310001840199wald:ReplacementAwardsMember2022-07-292022-12-310001840199wald:FounderAwardsMembersrt:MinimumMember2022-07-292022-12-310001840199wald:FounderAwardsMembersrt:MaximumMember2022-07-292022-12-310001840199srt:MinimumMember2022-07-282022-12-310001840199srt:MaximumMember2022-07-282022-12-310001840199us-gaap:RestrictedStockUnitsRSUMember2024-12-310001840199us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001840199us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001840199wald:PredecessorIncentivePlanMember2021-01-310001840199us-gaap:EmployeeStockOptionMemberwald:PredecessorIncentivePlanMember2021-01-012021-01-310001840199wald:PredecessorIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-01-310001840199wald:PredecessorIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-310001840199wald:PredecessorIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-12-012021-12-310001840199wald:PredecessorIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-01-310001840199wald:PredecessorIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-310001840199wald:PredecessorIncentivePlanMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-12-012021-12-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:PredecessorIncentivePlanMember2021-01-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:PredecessorIncentivePlanMember2021-01-012021-01-310001840199us-gaap:RestrictedStockUnitsRSUMemberwald:LongTermIncentiveAwardsMember2022-11-012022-11-300001840199us-gaap:WarrantMember2024-01-012024-12-310001840199us-gaap:WarrantMember2023-01-012023-12-310001840199us-gaap:WarrantMember2022-07-282022-12-310001840199us-gaap:WarrantMember2022-01-012022-07-270001840199us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001840199us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001840199us-gaap:EmployeeStockOptionMember2022-07-282022-12-310001840199us-gaap:EmployeeStockOptionMember2022-01-012022-07-270001840199us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310001840199us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001840199us-gaap:RestrictedStockUnitsRSUMember2022-07-282022-12-310001840199us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-07-270001840199wald:BailiwickOfJerseyAndTheCaymanIslandsMember2024-01-012024-12-310001840199country:GB2024-01-012024-12-310001840199us-gaap:DomesticCountryMember2024-12-310001840199us-gaap:DomesticCountryMember2023-12-310001840199us-gaap:StateAndLocalJurisdictionMember2024-12-310001840199us-gaap:StateAndLocalJurisdictionMember2023-12-310001840199us-gaap:ForeignCountryMemberus-gaap:InlandRevenueHongKongMember2024-12-310001840199us-gaap:ForeignCountryMemberus-gaap:InlandRevenueHongKongMember2023-12-310001840199us-gaap:ForeignCountryMemberwald:GeneralDepartmentOfTaxationVietnamMember2024-12-310001840199us-gaap:ForeignCountryMemberwald:GeneralDepartmentOfTaxationVietnamMember2023-12-310001840199us-gaap:CommonClassAMember2023-09-012023-09-300001840199us-gaap:CommonClassAMember2023-09-300001840199us-gaap:CommonClassAMember2023-09-012023-11-300001840199us-gaap:CommonClassAMember2023-11-012023-11-300001840199wald:PrivatePlacementWarrantsMemberus-gaap:RelatedPartyMember2021-03-182021-03-180001840199us-gaap:RelatedPartyMember2024-01-012024-12-310001840199us-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2022-08-012022-08-310001840199us-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberwald:SponsorMember2022-08-012022-08-310001840199us-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberwald:InvestorDirectorsMember2022-08-012022-08-310001840199us-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberwald:AaronChatterleyMember2022-08-012022-08-310001840199wald:ObagiMergerMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2022-08-012022-08-310001840199wald:MilkTransactionMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2022-08-012022-08-310001840199wald:MilkTransactionMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassBMember2022-08-012022-08-310001840199us-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2022-08-012022-08-310001840199us-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberwald:ForwardPurchaseAgreementMember2022-08-012022-08-310001840199wald:PrivatePlacementWarrantsMemberus-gaap:RelatedPartyMemberus-gaap:CommonClassAMember2022-08-012022-08-310001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMemberus-gaap:ProductMember2024-01-012024-12-310001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMemberus-gaap:ProductMember2023-01-012023-12-310001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMemberus-gaap:ProductMember2022-07-282022-12-310001840199us-gaap:SupplyCommitmentMemberus-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2024-01-012024-12-310001840199us-gaap:SupplyCommitmentMemberus-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2023-01-012023-12-310001840199us-gaap:SupplyCommitmentMemberus-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2022-07-282022-12-310001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2024-12-310001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2023-12-310001840199us-gaap:RelatedPartyMemberwald:ObagiChinaBusinessMember2022-07-282022-12-310001840199us-gaap:RelatedPartyMemberwald:MilkMakeupMember2024-01-012024-12-310001840199us-gaap:RelatedPartyMemberwald:MilkMakeupMember2022-07-282022-12-310001840199wald:SkintrinsiqDevicesMember2024-01-012024-12-3100018401992022-07-272022-07-270001840199us-gaap:EmployeeStockOptionMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2025-03-110001840199us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2025-03-120001840199us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMembersrt:ScenarioForecastMember2027-03-120001840199us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:ScenarioForecastMember2026-03-120001840199us-gaap:EmployeeStockOptionMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2025-03-112025-03-110001840199wald:A2025TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2025-03-182025-03-180001840199wald:A2025TermLoanMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2025-03-180001840199wald:A2025TermLoanMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SubsequentEventMember2025-03-180001840199srt:ParentCompanyMember2024-12-310001840199srt:ParentCompanyMember2023-12-310001840199us-gaap:CommonClassAMembersrt:ParentCompanyMember2023-12-310001840199us-gaap:CommonClassBMembersrt:ParentCompanyMember2023-12-310001840199us-gaap:CommonClassBMembersrt:ParentCompanyMember2022-12-310001840199srt:ParentCompanyMember2024-01-012024-12-310001840199srt:ParentCompanyMember2023-01-012023-12-310001840199srt:ParentCompanyMember2022-07-292022-12-310001840199srt:ParentCompanyMember2022-12-310001840199srt:ParentCompanyMember2022-07-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 20-F
(Mark One)
oREGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:
For the fiscal year ended December 31, 2024
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
oSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-40207
Waldencast plc
(Exact name of Registrant as specified in its charter)
Not applicableJersey
(Translation of Registrant’s name into English)(Jurisdiction of incorporation or organization)
81 Fulham Road
London, SW3 6RD
United Kingdom
(Address of principal executive offices)
Michel Brousset
Chief Executive Officer
London, SW3 6RD
United Kingdom
+44 (0)20 3196 0264
Legal@Waldencast.com
(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)
Name of exchange
on which registered
Class A ordinary shares, par value $0.0001 per shareWALDNasdaq Stock Market LLC
Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per shareWALDWNasdaq Stock Market LLC
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the report:
On December 31, 2024, the issuer had 122,692,968 ordinary shares outstanding, consisting of 112,026,440 Waldencast plc Class A ordinary shares, par value $0.0001 per share, and 10,666,528 Waldencast plc Class B ordinary shares, par value $0.0001 per share.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes o No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated fileroNon-accelerated filerx
Emerging growth companyx
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. o
The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting over Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. o
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP
xInternational Financial Reporting Standards as issued by the International Accounting Standards Boardo
Other
o
If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 o Item 18 o
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x



TABLE OF CONTENTS
F-1
104


INTRODUCTION AND USE OF CERTAIN TERMS
Waldencast plc (“Waldencast”) publishes consolidated financial statements expressed in U.S. dollars. Our consolidated financial statements responsive to Item 18 of this Annual Report filed on Form 20-F (including information incorporated by reference herein, this “Report”) with the U.S. Securities and Exchange Commission (“SEC”) are prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”).
Unless the context requires otherwise, the words “we,” “our,” “us,” “Company,” “Waldencast” and similar words or phrases in this Report refer to Waldencast plc (formerly known as Waldencast Acquisition Corp.), a public limited company incorporated under the laws of the Bailiwick of Jersey (“Jersey”), and its consolidated subsidiaries, including, but not limited to, Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, “Obagi”) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively, “Milk”), which Waldencast acquired on July 27, 2022 (the “Closing Date”), as more fully described in “Item 4. Information on the Company” and “Item 10. Additional Information—C. Material Contracts” in this Report (the “Business Combination”).
In accounting for the Business Combination, Waldencast was deemed to be the accounting acquirer, and Obagi was deemed to be the predecessor entity for purposes of financial reporting. As a result, when reading our financial statements and information about historical financial results in this Report, you should note there is a clear division between the predecessor periods that include financial statements up to the Closing Date (the “Predecessor Period(s)”), and successor periods that include all periods after the close of the Business Combination (the “Successor Periods”). The predecessor and successor results shown are not comparable, as the Predecessor Periods include only the financial statements of Obagi (which prior to the Business Combination also included its business in the China Region (as defined below), which was not acquired by Waldencast) and the Successor Periods include the consolidated financial statements of Waldencast, which also include Obagi and Milk. The Successor Periods reflect that since the Closing Date, we have organized our business into two reporting units - the business of Obagi, which we refer to as our “Obagi® Medical” reporting unit and the business of Milk, which we refer to as our “Milk Makeup™” reporting unit.
In this Report, in addition to the terms already defined above, unless stated or the context suggests otherwise, all references to:
2022 Credit Agreement” means the Credit Agreement, dated as of June 24, 2022, by and among the 2022 Credit Agreement Borrower, the 2022 Credit Agreement Parent Guarantor, the 2022 Credit Agreement Lenders and the 2022 Credit Agreement Administrative Agent, as amended, restated or otherwise modified from time to time;
2022 Credit Agreement Administrative Agent” means JPMorgan Chase Bank, N.A. in its capacity as the administrative agent under the 2022 Credit Agreement;
2022 Credit Agreement Borrower” means Waldencast Finco Limited, a wholly-owned subsidiary of Waldencast incorporated under the laws of Jersey;
2022 Credit Agreement Lenders” means the lenders party to the 2022 Credit Agreement;
2022 Credit Agreement Parent Guarantor” means Waldencast LP in its capacity as parent guarantor under the 2022 Credit Agreement;
2023 PIPE Investment” means the subscription agreements with certain investors for the issuance and sale of 14,000,000 Class A ordinary shares in a private placement to (i) one stakeholder of Beauty Ventures LLC, which is a beneficial owner of 21.6% of our Class A ordinary shares (ii) certain other existing equityholders, who qualified as accredited investors, including certain members of the Sponsor, and (iii) Michel Brousset, Waldencast’s founder and Chief Executive Officer, and Hind Sebti, founder and Chief Growth Officer, at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70 million;
2025 Credit Agreement” means the Credit Agreement, dated as of March 18, 2025, by and among the 2025 Credit Agreement Borrower, the 2025 Credit Agreement Parent Guarantor, the 2025 Credit Agreement Lenders and the 2025 Credit Agreement Administrative Agent, as amended, restated or otherwise modified from time to time;
2025 Credit Agreement Administrative Agent” means TCW Asset Management Company LLC. in its capacity as the administrative agent under the 2025 Credit Agreement;
2025 Credit Agreement Borrowers” means Milk Makeup LLC, a Delaware limited liability company, and Obagi Cosmeceuticals LLC, a Delaware limited liability company;
2025 Credit Agreement Lenders” means the lenders party to the 2025 Credit Agreement;
1

2025 Credit Agreement Parent Guarantor” means Waldencast in its capacity as parent guarantor under the 2025 Credit Agreement;
affiliate” means, with respect to any specified Person, any Person that, directly or indirectly, controls, is controlled by, or is under common control with, such specified Person, whether through one or more intermediaries or otherwise. The term “control” (including the terms “controlling,” “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise;
Board” means the board of directors of Waldencast;
CARES Act” means Coronavirus Aid, Relief, and Economic Security Act;
Cedarwalk” means Cedarwalk Skincare Ltd.
Class A ordinary shares” means our Class A ordinary shares, par value $0.0001 per share;
Class B ordinary shares” means our Class B ordinary shares, par value $0.0001 per share;
cGMP” means current Good Manufacturing Practice regulations enforced by the FDA;
China Region” means the People’s Republic of China (the “PRC”), including the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan;
Code” means the U.S. Internal Revenue Code of 1986, as amended;
COVID-19” means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemics or disease outbreaks;
EMA” means the European Medicines Agency, an agency of the European Union (“EU”);
Equityholder Representative” means Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members;
Exchange Act” means the Securities Exchange Act of 1934, as amended;
FDA” means the U.S. Food and Drug Administration;
FDCA” means the Federal Food, Drug, and Cosmetic Act;
Holdco 1” means Obagi Holdco 1 Limited, a private limited company incorporated under the laws of Jersey and a wholly-owned subsidiary of Waldencast;
International” means the entire world except the U.S.;
IRS” means the U.S. Internal Revenue Service;
Jersey” means the Bailiwick of Jersey, Channel Islands, a British crown dependency;
Jersey Companies Law” means the Companies (Jersey) Law 1991, as amended;
MoCRA” means the Modernization of Cosmetics Regulation Act of 2022;
Merger Sub” means Obagi Merger Sub, Inc., a Cayman Islands exempted company;
Milk Members” means the holders of the common and preferred membership units of Milk Makeup LLC prior to the Business Combination;
Milk Purchase Agreement” means the Equity Purchase Agreement, dated as of November 15, 2021, by and among Waldencast, Waldencast LP, Holdco 1, Milk, the Milk Members and the Equityholder Representative;
Nasdaq” means The Nasdaq Stock Market LLC;
Obagi China Business” means all sales of Obagi products in the China Region prior to the Business Combination;
Obagi Merger Agreement” means the Agreement and Plan of Merger, dated as of November 15, 2021, by and among Waldencast, Merger Sub and Obagi;
Obagi Vietnam” means Obagi Vietnam Import Export Trading MTV Company Limited.
Ordinary Shares” means our Class A ordinary shares and Class B ordinary shares, collectively;
Person” means any individual, firm, corporation, partnership, exempted limited partnership, limited liability company, exempted company, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or instrumentality or other entity of any kind;
PIPE Subscription Agreements” means, collectively, the deSPAC Subscription Agreements and the 2023 Subscription Agreements;
2

SA Distributor” means Southeast Asia Distributor, a former distributor of Obagi, then responsible for distribution within Vietnam, South Korea, and other regions of Southeast Asia;
Securities Act” means the Securities Act of 1933, as amended;
Sponsor” means Waldencast Long-Term Capital LLC, a Cayman Islands limited liability company;
United States dollars,” “U.S. dollars,” “USD” or “$” are to the lawful currency of the U.S.;
Waldencast LP” means Waldencast Partners LP, a Cayman Islands exempted limited partnership and indirect subsidiary of Waldencast; and
Waldencast Purchasers” means Holdco 1 and Waldencast LP.
All product and/or brand names, whether designated by notice (®/™) or not, are trademarks of Waldencast and/or its affiliates. This Report also contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Report may appear without the ® or  symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Any reference in this Report to the websites maintained by Waldencast, Obagi, Milk or any other company is not deemed to incorporate by reference any information available on such websites into this Report and such information does not form part of this Report.
This Report contains certain industry and market data that was obtained from third-party sources, such as industry surveys and industry publications, including, but not limited to, those issued by the U.S. Census Bureau, the American Society of Plastic Surgeons, Euromonitor International and others. In addition, the Report also contains other industry and market data, including market size estimates, growth and other projections and information regarding our competitive position, prepared by our management on the basis of such industry sources and our management's knowledge of and experience in the industry and markets in which we operate (including management's estimates and assumptions relating to such industry and markets based on that knowledge). Our management has developed its knowledge of such industry and markets through its experience and participation in these markets.
In addition, industry surveys and industry publications generally state that the information they contain has been obtained from sources believed to be reliable but that the accuracy and completeness of such information is not guaranteed and that any projections they contain are based on a number of significant assumptions. Forecasts, projections and other forward-looking information obtained from these sources involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section “Cautionary Note Regarding Forward-Looking Statements” below. You should not place undue reliance on these statements.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and variations of such words and similar expressions but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include assumptions and relate to our future prospects, developments and business strategies. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:
the impact of the material weaknesses in our internal control over financial reporting, including associated investigations, our efforts to remediate such material weakness and the timing of remediation and resolution of associated investigations;
our ability to achieve the anticipated benefits from any acquired business, including the Obagi and Milk acquisitions;
our ability to successfully implement our management’s plans and strategies;
the overall economic and market conditions, sales forecasts and other information about our possible or assumed future results of operations or our performance;
3

the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities;
the impact of any legal proceedings or investigations, including the outcome of any litigation or investigation related to or arising out of the restatement of our financial results or material weakness in internal control over financial reporting;
the impact of adverse economic conditions in the United States or other key markets, which could negatively affect our business, financial condition, and results of operations;
our ability to manage expenses, our liquidity and our investments in working capital;
any failure to obtain governmental and regulatory approvals related to our business and products;
risks related to our Class A ordinary shares and warrants, including continued price volatility;
the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations;
the impact of any disruptions in our operations, including supply chain interruptions, as a result of trade disputes, inflation or increases in interest rates;
our ability to raise additional capital or complete desired acquisitions;
our ability to comply with financial covenants imposed by the 2025 Credit Agreement and the impact of debt service obligations and restrictive debt covenants;
the impact of any unfavorable publicity on our business or products;
our ability to implement our strategic initiatives and continue to innovate Obagi’s and Milk’s existing products and anticipate and respond to market trends and changes in consumer preferences;
our dependence on a limited number of retailers for a significant portion of our net sales, with the loss of or challenges faced by these retailers potentially adversely affecting our results of operations;
changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies;
our ability to retain the listing of our securities on Nasdaq and our ability to meet Nasdaq’s continued listing standards, including the Periodic Filing Rule (as defined in “Item 3. Key Information—D. Risk Factors”) during the one-year panel monitor period; and
other risks and uncertainties described from time to time in our filings with the SEC.
We undertake no obligation to update or revise the forward-looking statements included in this Report, whether as a result of new information, future events or otherwise, after the date of this Report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in “Item 5. Waldencast’s Operating and Financial Review and Prospects” as well as in “Item 3. Key Information—D. Risk Factors” included herein.
PART I
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
A.Directors and Senior Management
Not applicable.
B.Advisers
Not applicable.
C.Auditors
Not applicable.
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
4

ITEM 3. KEY INFORMATION
A.[Reserved]
B.Capitalization and Indebtedness 
Not applicable.
C.Reasons for the Offer and Use of Proceeds 
Not applicable.
D.Risk Factors
RISK FACTORS
In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky, in addition to the other information in this Report. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cashflows, liquidity and share price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.
SUMMARY OF KEY RISKS
1.Risks Related to Internal Controls and Financial Reporting
We are subject to an ongoing SEC investigation related to the restatement of our financial results and material weaknesses in our internal controls, which may result in litigation, regulatory penalties, increased costs, and reputational harm. Additionally, we have identified material weaknesses in internal control over financial reporting, which could impact the accuracy and timeliness of our financial disclosures. While remediation efforts are underway, failure to fully address these issues may affect investor confidence, lead to further regulatory scrutiny, and negatively impact our business, financial condition, and ability to raise capital.
2.Risks Related to Growth Strategy and Investment Decisions
Our growth strategy involves significant investments in innovation, marketing, geographic expansion, and partnerships, but there is no guarantee these initiatives will succeed or yield the expected benefits. Challenges such as unmet consumer preferences, regulatory hurdles, operational strain, and unsuccessful expansions or partnerships could negatively impact our financial performance, growth, and shareholder value.
3.Risks Related to Cash Flow and Liquidity
Maintaining adequate cash flow and profitability is crucial for sustaining operations, meeting obligations, and funding growth, but challenges such as declining sales, loss of key customers, increased competition, or rising costs could weaken financial stability and limit strategic investments. Failure to effectively manage cash flow, comply with debt covenants, or offset elevated costs may lead to defaults, reduced market competitiveness, and adverse impacts on financial performance, investor confidence, and long-term business prospects.
4.Risks of Conducting International Business
Operating in international markets exposes us to risks such as economic instability, currency fluctuations, trade restrictions, and varying regulatory environments, which can increase costs and impact market access. Failure to navigate these
5

challenges, including adapting to local conditions or managing geopolitical tensions, could disrupt operations, reduce profitability, and hinder our ability to grow internationally.
5.Risks Related to Global Economic, Geopolitical, Social and Emerging Conditions
Global economic, political, and social conditions, including inflation, recessions, trade restrictions, and geopolitical tensions, pose risks to our operations, potentially reducing consumer spending and disrupting supply chains. Failure to manage these challenges effectively could lead to increased costs, reduced revenues, and operational disruptions, adversely affecting our financial performance and growth prospects.
6.Legal Risks and Risks Related to Litigation
We face litigation risks, including product liability claims, intellectual property disputes, and regulatory challenges, which could lead to financial losses, operational disruptions, and reputational harm. Even unfounded claims or successfully defended cases can result in costly legal proceedings, product recalls, or fines, ultimately impacting our profitability and ability to achieve strategic goals.
7.Risks Related to SEC and Nasdaq Compliance, Securities Issuances, Share Price Volatility and Limitations on Investor Rights
Compliance with SEC and Nasdaq requirements, securities issuances, and broader market conditions can impact our share price, with risks including regulatory penalties, delisting, or reputational harm from non-compliance. Additionally, stock dilution, market fluctuations, and negative investor sentiment may lead to heightened volatility or a decline in our share value, adversely affecting investment in our Company.
As an emerging growth company and foreign private issuer incorporated in Jersey, our investors face limitations compared to U.S. companies, including reduced disclosure requirements, differences in shareholder rights, and the need to resolve legal disputes under Jersey law. These factors, along with potential dilution from equity decisions, may reduce transparency, complicate the exercise of investor rights, and affect the attractiveness of our securities.
8.Risks Related to Dependence on Third Parties for Manufacturing, Distribution, E-Commerce, and Other Vendors
We depend on third-party partners for manufacturing, distribution, e-commerce, and other critical services, making us vulnerable to disruptions, quality issues, or regulatory non-compliance that could harm our operations and reputation. Failures or changes in these partnerships, such as logistical challenges, system outages, or policy shifts, could increase costs, disrupt customer experiences, and negatively impact our business and growth prospects.
9.Risks Related to Intense Competition in the Cosmetics Industry
The cosmetics industry is highly competitive, with established brands and agile niche players vying for market share through innovation, marketing, and competitive pricing. Failure to adapt to shifting consumer trends or compete effectively in this dynamic environment could result in reduced sales, profitability, and brand relevance, ultimately impacting long-term growth and shareholder value.
10.Risks Related to Supply Chain and Operational Disruption
Our business relies on a complex global supply chain and efficient operations to meet customer demand, and disruptions from natural disasters, geopolitical events, or labor challenges could harm our financial performance. Reliance on third-party suppliers, rising costs, or manufacturing issues may lead to shortages, delays, or increased expenses, damaging customer relationships, brand reputation, and profitability.
11.Regulatory Risks That Could Adversely Impact our Business
Our business operates under extensive and evolving regulations across federal, state, and international levels, covering areas such as product formulation, labeling, and distribution, with non-compliance potentially leading to fines, recalls, or reputational harm. Changes in laws or regulatory scrutiny may result in higher compliance costs, delays, product reformulation, or market withdrawals, especially as we expand into new regions with unfamiliar regulations.
6

12.Risks Related to Our Reputation and Threats to Our Good Standing
Our reputation is a critical asset influencing consumer trust, brand loyalty, and competitive position, but negative publicity regarding product quality, ethics, or sustainability could lead to customer loss and operational disruptions. The rapid spread of information via social media amplifies the risk of reputational harm, which could also impact stakeholder relationships, attract regulatory scrutiny, and adversely affect our financial performance.
13.Risks Related to Technology, E-Commerce, and Cybersecurity
Our reliance on technology, including e-commerce platforms and digital marketing, is critical, and disruptions or cybersecurity threats could compromise operations, data security, and customer trust, leading to financial and reputational harm. Failure to adapt to evolving e-commerce trends, enhance digital capabilities, or integrate emerging technologies effectively could weaken our competitive position and hinder revenue growth.
14.Risks Related to Taxation in an International Environment
Operating across multiple jurisdictions subjects us to complex and evolving tax laws, creating compliance challenges, potential disputes, and increased tax liabilities that could impact our financial results. Changes in global tax regulations, foreign exchange fluctuations, and differing treatments of foreign earnings may further affect our profitability, cash flow, and shareholder value.
1.Risks Related to Internal Controls and Financial Reporting
We are subject to an investigation by the SEC and may face litigation and other risks as a result of the previously filed restatement of our financial results and material weaknesses in our internal control over financial reporting.
As a result of the restatement of our financial results for certain Predecessor Periods, the associated material weaknesses in our internal control over financial reporting described below, and other matters raised or that may in the future be raised by the SEC, we are subject to an ongoing investigation by the SEC and may be exposed to a number of additional risks and uncertainties, including (i) potential litigation or other disputes or investigations that may include, among others, claims invoking the federal and state securities laws, contractual claims or other claims arising from the material weaknesses in our internal control over financial reporting and preparation and/or restatement of our financial statements for certain Predecessor Periods; (ii) significant costs for accounting, advisory and legal fees in connection with or related to such matters which may be difficult to forecast appropriately; (iii) diversion of the efforts and attention of management and other personnel from our business operations; and (iv) fines, penalties or other actions required as the outcome of government investigations, all of which could result in a potential loss of investor confidence and/or a negative impact on the price of our securities.
As previously disclosed, we proactively and voluntarily self-reported our review of the historical accounting used by Obagi to the SEC. In connection with this matter, we received a document subpoena in September 2023. Although we are fully cooperating with the SEC’s investigation and continue to respond to requests related to this matter, we cannot predict when such matters will be completed or the outcome or potential impact of this matter on our business, investor confidence or the price of our securities. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, which may be imposed on us in connection with this matter could have a material adverse effect on our business, financial condition and results of operations. Additionally, the investigation has resulted in substantial costs and we are likely to continue to incur substantial costs, regardless of the outcome of the investigation.
As of the date of this Report, other than the investigation noted above, we have no knowledge of any other litigation or dispute arising from the material weaknesses in our internal control over financial reporting, the preparation of our financial statements and/or the restatement of our financial results for certain Predecessor Periods. However, we cannot assure you that such litigation or dispute will not arise in the future. Any such litigation or dispute, whether successful or not, could have a material adverse effect on our business, results of operations and financial condition. We cannot assure you that the SEC or another regulatory body will not make further regulatory inquiries or pursue action against us and our senior officers.
7

We have identified material weaknesses in our internal control over financial reporting. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results.
During the preparation of our consolidated financial statements we identified material weaknesses in our internal control over financial reporting, which have not been fully remediated as of December 31, 2024. We identified material weaknesses in our internal control over financial reporting related to implementation of control activities, monitoring of the control environment, the implementation of a formal risk assessment process, and the implementation of the delegation of authority. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.
Management has been actively engaged in ongoing remediation efforts to address the material weaknesses. We have made enhancements to the control environment throughout 2024 and to-date, by improving oversight, hiring additional key personnel, communication of expectations, emphasizing the importance of internal controls and creating a more robust internal control environment. We will continue to improve the operating effectiveness of our internal controls over financial reporting and the timeliness of those procedures during the calendar year-ended December 31, 2025. Notwithstanding the identified material weaknesses, our management has concluded that the consolidated financial statements included in this Report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with GAAP. See “Item 15- Controls and Procedures” for further information.
Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. As noted above, we have taken a number of measures to remediate the material weaknesses and continue to evaluate steps to enhance our internal controls. However, these remediation measures have been and may continue to be time consuming and costly and we cannot assure you that these initiatives will ultimately have the intended effects. If we are unable to remediate our material weaknesses in a timely manner or identify additional material weaknesses, we may be unable to provide required financial information in a timely and reliable manner and may incorrectly report financial information. If our financial statements continue to not be filed on a timely basis, we could be subject to sanctions or additional investigations by the Nasdaq, the SEC or other regulatory authorities. Failure to timely file has caused us to be ineligible to utilize short form registration statements on Form F-3 or Form F-4, which may impair our ability to obtain capital in a timely fashion, to provide liquidity to our employees and shareholders, to execute our business strategies or issue shares to effect an acquisition. Any of these events, whether they have or were to occur, could have a material adverse effect on our business.
In addition, the existence of material weaknesses in internal control over financial reporting could adversely affect our reputation or investor perceptions of us, which could have a negative effect on the trading price of our securities.
We cannot assure you that the measures we have taken and plan to take in the future will remediate the material weaknesses identified or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting. Even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our financial statements.
2.Risks Related to Growth Strategy and Investment Decisions
We may not be able to successfully implement our growth strategy, and the historical growth of our Obagi Skincare and Milk Makeup Businesses may not be indicative of our future performance.
The future growth, profitability, and cash flows of our Obagi Skincare and Milk Makeup businesses depend upon our ability to successfully implement our growth strategy, which, in turn, is dependent upon a number of key initiatives, including our ability to:
a.grow the awareness and relevance of the Obagi and Milk brands and products;
b.maintain a regular supply of core existing products and execute effective go-to-market strategies to grow them;
c.maintain and further strengthen our relationships with our physician customers, international distributors and retail partners in each geographic market where we sell products;
8

d.maintain and enhance our reputation as a provider of high-quality products; secure new points of distribution in new markets;
e.maintain the ability to sell our products within our existing retail partners for Milk products and operate and ship from our own e-commerce platforms without interruption;
f.enhance the productivity of our brands within our points of distribution; maintain and enhance our digital platforms and capabilities;
g.execute our go-to-market strategies effectively; protect our key talent from leaving;
h.ensure that we are able to sell our products with attractive margins that deliver profit;
i.achieve our growth targets with the financial investments outlined in our plans for each business; and predict our growth and manage our financial investments appropriately to reach our targets.
We cannot assure you that we will successfully achieve any or all of the above initiatives in the manner or time period that we expect. Further, achieving these objectives will require investments that may result in short-term cost increases with net sales materializing on a longer-term horizon and therefore may be dilutive to our earnings. We cannot assure you that we will realize, in full or in part, the anticipated benefits we expect our growth strategy will achieve. The failure to realize those benefits could have a material adverse effect on our business, financial condition and results of operations.
We may not be successful in executing our growth strategy, and even if we achieve our strategic plan, we may not be able to achieve or sustain profitability in our business. You should not regard the historical growth rates of our Obagi Skincare and Milk Makeup businesses as indicative of future performance. In the future our revenue from our Obagi Skincare and/or Milk Makeup business could be reduced or grow more slowly than we expect. We also may incur significant losses in the future for a number of reasons, including the following risks and the other risks described in this Report, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors:
a.we may lose one or more significant customers or key retailers, or sales of our products through these customers or retailers may decrease;
b.our products may be the subject of regulatory actions, including, but not limited to, actions by the FDA, the Federal Trade Commission (“FTC”) and the Consumer Product Safety Commission (“CPSC”) in the U.S. and comparable foreign authorities outside the U.S.;
c.the ability of our third-party suppliers to produce our products and of our distributors to distribute our products could be disrupted, particularly if they are not able to comply with the new regulations promulgated by the FDA under MoCRA;
d.the integration of the companies may be more costly or take longer than anticipated;
e.we may be unable to introduce new products that appeal to consumers or otherwise successfully compete with our competitors in the skincare or cosmetics industries; and
f.we may be unsuccessful in enhancing the recognition and reputation of the Obagi and Milk brands, and our brands may be damaged as a result of, among other reasons, our failure, or alleged failure, to comply with applicable ethical, social, product, labor or environmental standards.
If we are able to successfully acquire additional companies and/or expand our Obagi Skincare and Milk Makeup businesses, we will experience growth in the number of our employees and the scope of our operations. To the extent that we acquire and launch additional products, the resulting growth and expansion of the required sales force to sell those products will place a significant demand on our financial, managerial, compliance and operational resources. Since many of the new products we are working on may involve new technologies or entering new geographical markets, we may not be able to accurately forecast the number of employees required and the timing of their hire or the associated costs. The extent of any expansion we may experience will be driven largely by the success of our new products and expanded distribution channels. As a result, management’s ability to project the size of any such expansion and its cost to Waldencast is limited by the following uncertainties: (a) we will not have previously sold any of the new products and the ultimate success of these new products is unknown; (b) we may be entering new geographic markets and/or distribution channels; and (c) the costs associated with any expansion will be partially driven by factors that may not be fully in our control (e.g., timing of hire, market salary rates). Due to the uncertainty surrounding the timing of our strategic initiatives, new product lines or the stabilization of the global markets, our costs to hire significant numbers of new employees could be higher than anticipated. Our success will also depend on the ability of our executive officers and senior management team to continue to implement and improve our operational, information management and financial control systems, and to expand, train and manage our employee base. Our inability to manage growth effectively could cause our operating costs to grow even faster than we currently anticipate and adversely affect our results of operations.
9

We may make investments into or acquire other companies, which could divert our management’s attention, result in dilution to our shareholders and otherwise disrupt our operations, and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition and results of operations.
As part of our business strategy, we may seek to acquire or invest in additional businesses that we believe could complement or expand our existing and future offerings or otherwise offer growth opportunities. The success of any attempts to grow our business through acquisitions to complement our business depends in part on the availability of, our ability to identify and our ability to engage and pursue suitable acquisition candidates. We may not be able to find suitable acquisition candidates, and we may not be able to complete acquisitions on favorable terms, if at all. If we are able to complete future acquisitions, we cannot assure you that they will ultimately strengthen our competitive position or that they will be viewed positively by customers, financial markets or investors.
The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated, and the costs incurred likely would not be recoverable. In addition, we have limited experience in acquiring other businesses and may have difficulty integrating acquired businesses or assets, or otherwise realizing any of the anticipated benefits of acquisitions. If we acquire additional businesses, we may not be able to integrate the acquired operations and technologies successfully, or effectively manage the combined business following the acquisition. Integration may prove to be difficult due to the necessity of integrating personnel with disparate business backgrounds, different geographical locations and who may be accustomed to different corporate cultures. Additionally, with multiple business combinations, we could face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations and services or products of multiple acquired companies with different businesses in a single operating business.
We also may not achieve the anticipated benefits from any acquired business due to a number of factors, including:

a.inability to integrate or benefit from acquired products or technologies in a profitable manner;
b.unanticipated costs or liabilities, including legal liabilities, associated with any such acquisition, or other accounting consequences; diversion of management’s attention or resources from other business concerns;
c.adverse effects on our business relationships with existing customers, members or strategic partners as a result of the acquisition; potential loss of the acquired company’s customers;
d.failure to develop further the acquired company’s technology;
e.complexities associated with managing the geographic separation of acquired businesses and consolidating multiple physical locations;
f.becoming subject to new regulations as a result of an acquisition, including if we acquire a business serving customers in a regulated industry or acquire a business with customers or operations in a country in which we do not already operate;
g.coordination of product development and sales and marketing functions; the potential loss of key employees;
h.acquisition targets not having as robust internal controls over financial reporting as would be expected of a public company;
i.possible cash flow interruption or loss of revenue as a result of transitional matters; and
j.use of substantial portions of our available cash or issuance of dilutive equity to consummate an acquisition.
We may issue equity securities or incur indebtedness to pay for any such acquisition or investment, which could adversely affect our business, financial condition or results of operations. Any such issuances of additional capital stock may cause shareholders to experience significant dilution of their ownership interests.
In addition, we may not realize benefits from any business combination that we undertake. If we fail to successfully integrate such businesses, or the technologies associated with such business combinations into our Company, the revenue and operating results of the combined company could be adversely affected. If our customers are uncertain about our ability to operate on a combined basis, they could delay or cancel orders for our products. We may not successfully evaluate or utilize the acquired technology or accurately forecast the financial impact of a combination, including accounting charges or volatility in the stock price of the combined entity.
10

3.Risks Related to Cash Flow and Liquidity
The financial performances of our brands are unpredictable, with histories of net losses and potential future declines in sales and operating results.
Our quarterly operating results have been historically variable and are likely to remain so due to numerous factors, many beyond our control. These include fluctuations in consumer spending, demand for our products, and changes in market acceptance or treatment practices. Operational challenges, such as higher manufacturing costs, supply chain disruptions, or increased competition, also contribute to the unpredictability of our results. Additionally, external factors like economic slowdowns, legal costs, and changes in tax rates can impact performance. Seasonal trends, such as reduced summer sales and higher fourth-quarter demand, further add to this variability, making it difficult to rely on quarterly comparisons or predict future performance with accuracy. Investors should exercise caution when evaluating our quarterly results.
Our financial results may also be impacted by the unique challenges faced by our Obagi Skincare and Milk Makeup businesses, whose historical performance does not fully reflect our current operations or future potential. As standalone entities, these businesses did not bear the public company costs we now incur, such as compliance with Sarbanes-Oxley and investor relations. The financial conditions presented in historical reports are affected by significant costs from our business combination and adjustments to our capital structure, making future comparisons challenging. Investors may find it difficult to evaluate trends or assess our relative performance based on past data.
The Milk Makeup business has a history of operating losses and may face continued challenges in achieving profitability. Despite increasing distribution channels and investments in product development, marketing, and operations, Milk Makeup's net revenue growth may fall short of expectations. Success depends heavily on anticipating and adapting to rapidly shifting consumer beauty trends and preferences. Challenges such as acceptance of new product launches, delays in supply chains, and potential cannibalization of existing product sales could impede growth and profitability. These risks, combined with the competitive nature of the cosmetics industry, could materially affect our financial condition and operations.
If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize new products.
We expect capital and operating expenditures to increase over the next several years as we expand our international footprint and distribution channels, as well as invest in innovation, marketing activities and group infrastructure for our Obagi Skincare and Milk Makeup businesses. In order to fund these activities and our growth strategy, in September 2023, we entered into subscription agreements (the “2023 Subscription Agreements”) with certain investors for the issuance and sale of 14,000,000 Class A ordinary shares in connection with the 2023 PIPE Investment.
We believe that net cash provided by operating activities and existing cash and cash equivalents, including proceeds received from the 2025 Credit Agreement will be sufficient for our current needs. However, our present and future funding requirements will depend on many factors, including, among other things:
a.acquisitions of additional businesses in the beauty and wellness industry; costs relating to regulatory investigations or litigation;
b.the level of selling, marketing and innovation investment required to maintain and improve our competitive positions in the skincare and makeup markets; the success of our product sales and related collections of accounts receivable;
c.our need or decision to acquire or license complementary products or technologies for our Obagi Skincare and/or Milk Makeup businesses; costs relating to the expansion of our distribution channels and setting up direct distribution channels in certain international markets;
d.costs relating to the expansion of the sales force, management and operational support; competing technological and market developments;
e.costs relating to changes in regulatory policies or laws, including as a result of executive orders, that affect our operations; and
f.working capital needs driven by inventory and account receivables relating to our U.S. and international expansion.
11

To the extent we are unable to generate sufficient cash flow, we may be forced to cancel, reduce or delay marketing initiatives, investments or acquisitions. Alternatively, we may need to draw down on the revolving loan facility under the 2025 Credit Agreement or raise additional funds, and we cannot be certain that such funds will be available on acceptable terms when needed, if at all. As of the date of this Report, we have drawn down a total of $15.0 million from the initially available $30.0 million revolving credit facility under the 2025 Credit Agreement, which as of the date of this Report, has an available balance of $15.0 million. We may have to raise additional funds, and we cannot be certain that such funds will be available on acceptable terms when needed, if at all. The incurrence of additional indebtedness would result in increased debt service obligations and operating and financing covenants that could restrict our operations and the issuance of any additional equity could result in dilution to our existing shareholders.
Failure to comply with any of the covenants under our 2025 Credit Agreement could result in an event of default, which may accelerate our outstanding indebtedness and have a material adverse effect on our business, liquidity position and financial position.
We are subject to various financial covenants under the 2025 Credit Agreement. Our ability to comply with the financial covenants under the 2025 Credit Agreement will depend on the success of our businesses, our operating results, and our ability to achieve our financial forecasts. Various risks, uncertainties and events beyond our control, including general or industry-specific economic downturns, could affect our ability to comply with the financial covenants and terms of the 2025 Credit Agreement. In addition, the 2025 Credit Agreement also requires us, among other things, to timely deliver certain financial statements to the 2025 Credit Agreement Lenders.
Failure to comply with the covenants and other terms could result in an event of default and the acceleration of amounts owing under the 2025 Credit Agreement unless we are able to negotiate a waiver. The Lenders could condition any such waiver on an amendment to the 2025 Credit Agreement on terms that may be unfavorable to us. We could also be blocked from borrowing under the 2025 Credit Agreement, and the 2025 Credit Agreement could be terminated by the 2025 Credit Agreement Lenders. Under these circumstances, other sources of capital may not be available or may be available only on unfavorable terms.
If we fail to comply with the covenants and other terms under the 2025 Credit Agreement and we are unable to negotiate a covenant waiver or replace or refinance the credit agreement on favorable terms, our business, financial condition and results of operations could be materially and adversely impacted.
We may face impairment of intangible assets, unknown or contingent liabilities and other charges or write-downs that could negatively impact our financial condition, profitability, and the value of our securities.
We face potential exposure to unknown or contingent liabilities, which could negatively impact our financial condition and the value of our securities. Despite thorough due diligence during the acquisitions of Obagi Skincare and Milk Makeup, we cannot guarantee that all material risks have been identified. Furthermore, unforeseen factors outside our control may emerge, potentially requiring us to write down or write off assets, restructure operations, or incur impairment charges. For example, after reassessing the Obagi Skincare business, we recorded a $68.7 million non-cash impairment charge due to discrepancies between projected and actual performance post-acquisition. These risks, compounded by the lack of indemnification rights in the acquisition agreements, could significantly reduce the value of equityholder investments and contribute to negative market perceptions of our securities.
The impairment of intangible assets, which form a substantial portion of our total assets, poses another challenge to profitability. Our intangible assets, including goodwill and trademarks, rely on fair value estimates based on management’s assumptions and judgments, which may prove inaccurate. As of December 31, 2024, intangible assets and goodwill constituted approximately 87.7% of our total assets. A further reduction in the fair value of our intangible assets could materially impact our financial performance.
The Obagi Skincare reporting unit remains particularly sensitive to impairment risks, given the reporting unit recorded a $5.0 million impairment in 2024 and therefore has no margin between carrying value and fair value. Factors like inflation, competitor valuations, changes in working capital, or market downturns could lead to further impairments if revenue or profitability growth fails to meet projections. Such impairments would adversely affect our financial results and increase the likelihood of additional charges in future reporting periods. As of December 31, 2024, the reporting unit had a goodwill balance of $194.5 million.
12

Similarly, the Milk Makeup reporting unit, with a goodwill balance of $135.1 million as of December 31, 2024, also faces risks, though no impairments were recorded in the most recent evaluations, and there is a significant margin between carrying value and fair value. Despite a stable assessment, any changes in market conditions, consumer demand, or business performance could necessitate a revaluation of its fair value. Continued vigilance is required to ensure that these reporting units maintain their projected growth rates. Any further impairments across our intangible assets could significantly erode profitability and weaken our overall financial condition.
If we fail to manage our inventory of Obagi products effectively, our results of operations, financial condition and liquidity may be materially and adversely affected.
The Obagi Skincare business requires us to manage large volumes of inventory effectively. We depend on our forecasts of demand for, and popularity of, various products to make purchase decisions and to manage our inventory of stock-keeping units (“SKUs”). Demand for products, however, can change significantly between the time inventory or components are ordered and the date of sale due to the long lead times required to manufacture our products. Demand may be affected by new product launches, changes in customer preferences, demand or spending patterns, changes in product cycles and pricing, product defects and promotions. It may be difficult to accurately forecast demand and determine appropriate levels of products or components. Our ability to accurately forecast demand may be further hindered in the future as we expand the percentage of our sales made outside of the U.S. because we depend on our international distributors to provide us with forecasts for demand for our products in their respective territories.
If we or our distributors overestimate demand, our distributors may not be able to sell their existing inventory to their customers, which may affect their ability to timely pay us and their demand for products in the future. We may be required to recognize inventory write-offs and increase our reserves for product returns in the future, particularly if our estimates relating to demand in certain of our markets or with respect to certain of our product lines are incorrect. On the other hand, if we or our distributors underestimate demand, we may not have sufficient inventory of products to ship to our customers. Obagi products have expiration dates that generally range from 24 to 36 months from the date of manufacture. We estimate the amount of potentially excess, dated or otherwise impaired inventories that we may have to write down. Although our estimates are reviewed quarterly for reasonableness, our product return activity could differ significantly from our estimates. Judgment is required in estimating the amount of inventory that may be written down and we rely on data from third parties, including, but not limited to, distributor forecasts and independent market research reports. The actual amounts could be different from our estimates, and differences are accounted for in the period in which they become known. If we determine that the actual amounts exceed our reserve amounts, we will record a charge to earnings to approximate the difference. A material reduction in earnings resulting from a charge would have a material adverse effect on our net income, results of operations and financial condition.
Our only material asset is our indirect interest in Waldencast LP, and we are accordingly dependent upon distributions from Waldencast LP to pay dividends, taxes and other expenses.
We are a holding Company with no material assets other than indirect equity interests in Waldencast LP. As such, we do not have any independent means of generating revenue or cash flow, and our ability to pay taxes and operating expenses or declare and pay dividends in the future, if any, will be dependent upon the results of operations and cash flows of Waldencast LP and its subsidiaries, including Obagi and Milk. We intend to cause Waldencast LP to make distributions to its members, including Holdco 1, in an amount at least sufficient to allow for the payment of all applicable taxes, and to pay our corporate and other overhead expenses and those of Holdco 1. We cannot assure you, however, that Waldencast LP and its subsidiaries will generate sufficient cash flow to distribute funds to Holdco 1, or that applicable legal and contractual restrictions, including negative covenants in Waldencast LP’s debt instruments, will permit such distributions. It could materially and adversely affect our liquidity and financial condition if Waldencast LP is restricted from, or otherwise unable to, distribute sufficient cash to us.
Our warrants are accounted for as liabilities and the changes in value of our warrants could have a material effect on our financial results.
In April 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by SPACs entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies” (the “SEC Statement”). Specifically, the SEC Statement focused on certain settlement terms and provisions related to tender offers following a business combination, which terms are similar to those contained in the Warrant Agreement (defined below). As a result of the SEC Statement, we reevaluated the accounting treatment of our 11,500,000
13

public warrants and 5,933,333 private placement warrants and determined to classify the warrants as derivative liabilities measured at fair value, with changes in fair value each period reported in earnings.
As a result, we have included derivative liabilities related to embedded features contained within our warrant in our balance sheet as of December 31, 2024 and 2023. Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging (“ASC 815”), provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value being recognized in earnings in the statement of operations. As a result of the recurring fair value measurement, our financial statements and results of operations may fluctuate quarterly based on factors that are outside of our control. Due to the recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our warrants each reporting period and that the amount of such gains or losses could be material.
The obligations associated with being the publicly traded entity in the “Up-C” structure involve significant expenses and require significant resources and management attention, which may divert from our business operations.
As the publicly traded entity in an Up-C structure, we are subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. The Exchange Act requires the filing of annual, quarterly and current reports with respect to a public company’s business and financial condition. The Sarbanes-Oxley Act requires, among other things, that a public company establish and maintain effective internal control over financial reporting. As a result, we incur significant legal, accounting and other expenses. Our entire management team and many of our other employees will continue to need to devote substantial time to compliance matters related to the Up-C structure and regulatory requirements associated with being a publicly traded entity. We bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws.
In addition, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act, and the related rules and regulations implemented by the SEC and Nasdaq, have increased legal and financial compliance costs and will make some compliance activities more time-consuming. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified people to serve on our Board, our Board committees or as executive officers.
We may lose our foreign private issuer status in the future, which could result in significant additional cost and expense.
In order to maintain our current status as a foreign private issuer, either (a) more than 50% of our outstanding voting securities must be either directly or indirectly owned of record by non-residents of the U.S. or (b)(i) a majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50% of our assets cannot be located in the U.S. and (iii) our business must be administered principally outside the U.S. On an annual basis, we are required to assess whether we meet these criteria as of the last business day of our second fiscal quarter. Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. For example, the annual report on Form 10-K requires domestic issuers to disclose executive compensation information on an individual basis with specific disclosure regarding the domestic compensation philosophy, objectives, annual total compensation (base salary, bonus, and equity compensation) and potential payments in connection with change in control, retirement, death or disability, while this Report permits us to disclose compensation information on an aggregate basis. We would also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors, and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. We may also be required to modify certain of our policies to comply with good governance practices associated with U.S. domestic issuers. The additional requirements that we would become subject to and any modification of our policies if we were to lose our foreign private issuer status could lead us to incur significant additional legal, accounting and other expenses. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers.
14

Sales of Milk products may suffer due to retailers reducing inventory levels to manage cash and reduce space of existing products to make room for new categories.
If our distributors or retailers reduce their inventory for our products, it could result in lower sales for us during that period, leading to a mismatch in expected sales. If inventory levels fall too low by the retailer, we risk stockouts on retail shelves, which would reduce retail sales and, in turn, decrease demand for further inventory. As we do not have control over the inventory management decisions made by our retailers, their actions directly influence our sales volume and could create significant fluctuations in our revenues, ultimately impacting our operating results.
4.Risks of Conducting International Business
Conducting international business exposes us to risks such as currency fluctuations, cash repatriation restrictions, and changes in laws and regulations, which could negatively impact our operations and financial performance.
The international expansion of Obagi Skincare and Milk Makeup products is a core growth strategy for the Company. With an increasing share of revenue derived from international sales, the company has expanded its presence in Southeast Asia, including acquiring Obagi Vietnam Import Export Trading MTV Company Limited. However, challenges such as declining revenues in Vietnam and the complexities of setting up direct distribution networks in new markets have arisen. Establishing a presence in these markets requires significant investments in facilities, personnel, and product registration, with potential delays in revenue realization due to regulatory and market entry hurdles. While these efforts aim to strengthen the Company’s foothold in new regions, success is uncertain due to the many risks associated with global expansion.
The Company’s success in international markets depends on securing necessary licenses, building local relationships, and tailoring products to local consumer preferences. Economic, political, and regulatory environments in regions like Vietnam pose additional challenges. For instance, Vietnam’s regulatory landscape is complex and often lacks clarity, making it difficult to obtain and maintain necessary licenses. The Company faces risks such as evolving regulations, differences in legal interpretations, and uncertainties in enforcing legal rights, which could disrupt operations. These challenges are compounded by the need to navigate the legal nuances of new markets, such as the limited precedential value of court cases in Vietnam.
Expanding into international markets also entails compliance with diverse regulations and intellectual property protections. Countries like Vietnam may have less robust intellectual property laws, increasing the risk of counterfeit products. Additionally, obtaining and maintaining regulatory approvals in multiple jurisdictions is time-consuming and fraught with uncertainties, similar to FDA approval processes. External factors like changes in labeling requirements or adverse regulatory evaluations could hinder operations and reduce the Company’s ability to compete effectively in global markets. Furthermore, the third parties we rely on internationally may disclose our confidential information or intellectual property to competitors or third parties, which could result in the illegal distribution and sale of counterfeit versions of our products. If any of these events occur, our business, financial condition and results of operations could be materially and adversely affected.
The Company’s reliance on international sales exposes it to broader risks inherent in global operations. These include economic instability, fluctuating exchange rates, local consumer preferences, trade disputes, including the imposition of new or increased tariffs or sanctions, and compliance with anti-bribery and competition laws. Moreover, factors like natural disasters or the failure of distribution partners could negatively impact the business. With its revenue denominated in various currencies, the Company is also vulnerable to foreign exchange rate fluctuations and potential restrictions on cash repatriation, which could affect financial performance and operational flexibility.
Regulatory changes in international markets, especially concerning product classifications and safety standards, could impact the Company’s ability to operate. For example, in the EU, evolving standards for ingredients like alpha- and beta-arbutin, used in Obagi’s products, highlight the complexities of compliance. Uncertainty around their safety, stability, and aggregate exposure has led to calls for additional scientific data. Regulatory restrictions on key ingredients such as hydroquinone further complicate market entry and product formulation, demonstrating the regulatory risks that could significantly affect the Company’s growth and operations in international markets.
Our business is subject to complex and evolving U.S. and foreign laws and regulations regarding privacy and data protection. Many of these laws and regulations are subject to change and uncertain interpretation, and any failure or perceived failure to comply could result in claims, changes to our business practices, monetary penalties or increased costs of operations, or otherwise could harm our business.
15

We are subject to a variety of laws and regulations in the U.S. and abroad regarding privacy and data protection, some of which can be enforced by private parties or government entities and some of which provide for significant penalties for noncompliance. Such laws and regulations govern the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with sales on our e-commerce websites or during clinical trials of our products. Implementation standards, interpretations and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, or result in additional liability for us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, claims by third parties, government investigations and enforcement actions, including injunctions, fines and/or criminal penalties if we knowingly obtain or disclose individuals’ health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state or foreign laws, any of which could have a material adverse effect on our operations, financial performance and business.

In the U.S., numerous federal and state laws and regulations, including federal and state health information privacy laws, state data breach notification laws, and federal and state consumer protection laws that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. For example, the California Consumer Privacy Act (the “CCPA”), which went into effect on January 1, 2020, creates individual privacy rights for California consumers, including the right to opt out of certain disclosures of personal information, increases the privacy and security obligations of entities handling certain personal information, and also establishes significant penalties for noncompliance. The CCPA also provides for a private right of action for data breaches, which is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Additionally, in November 2020, California voters passed the California Privacy Rights Act (the “CPRA”). The CPRA, which went into effect on January 1, 2023, significantly expands the CCPA, including by introducing additional obligations such as data minimization and storage limitations, granting additional rights to consumers such as correction of personal information and additional opt-out rights and creating a new entity, the California Privacy Protection Agency, to implement and enforce the law. The CPRA may require us to modify our data collection or processing practices and policies, cause us to incur substantial costs and expenses to comply, and increase our potential exposure to regulatory enforcement and/or litigation. Other U.S. states have also enacted or are considering enacting stricter data privacy laws. For example, in March 2021, Virginia enacted the Virginia Consumer Data Protection Act and, in March 2022, Utah enacted the Utah Consumer Privacy Act, comprehensive privacy statutes that are similar to the CCPA and CPRA.

Further, the FTC and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, violating consumers’ privacy rights or failing to take appropriate steps to keep consumers’ personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section S(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.

We are also subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the EU’s General Data Protection Regulation 2016/679 (the “EU GDPR”) and the U.K. General Data Protection Regulation and the U.K.'s Data Protection Act 2018 (the “U.K. GDPR”, and together with the EU GDPR, the “GDPR”) governs certain collection and other processing activities involving personal data. The U.K. GDPR is likely to be subject to divergence from the EU GDPR over time. Among other things, the GDPR imposes requirements regarding the security of personal data and the rights of data subjects (e.g., to access and delete personal data), requirements to rely on an appropriate lawful basis to process personal data, includes requirements relating to the consent of individuals to whom the personal data relates (such consent relates to the lawful processing of personal data under the GDPR and is distinct from others consents obtained from individuals in collection with clinical trial participation), requires transparency notices for all data subjects (including for clinical trial participants and investigators) and regulates transfers of personal data from within the UK or EEA (as applicable) to third countries that have not been found to provide adequate protection to such personal data, including the U.S. (and these restrictions have heightened in light of recent case law and regulatory guidance). In addition, the EU GDPR imposes substantial administrative fines for breaches and violations, which, depending on the nature of the breach, range from €10.0 million to €20.0 million or 2% to 4% of our annual global revenue, whichever is higher and the U.K. GDPR imposes separate and additional fines, which, depending on the nature of the breach, range from £8.7 million to £17.5 million or 2% to 4% of total worldwide annual revenue, whichever is higher. The GDPR also confers a private right of action on data subjects to lodge complaints with supervisory authorities, seek judicial remedies (including
16

data subject-led class actions and injunctions) and obtain compensation for damages resulting from violations of the GDPR.

We are also subject to EEA and U.K. rules with respect to cross-border transfers of personal data outside of the EEA and U.K. to third countries. The GDPR generally prohibits the transfer of EEA and U.K. personal data to non-adequate third countries (i.e. third countries which have not been approved by the European Commission in respect of EU GDPR regulated transfers, or the UK Secretary of State in respect of UK GDPR regulated transfers) , unless a valid data transfer mechanism has been implemented or an Article 49 GDPR derogation applies. Legal developments in the EEA and U.K. have created complexity and uncertainty regarding transfers of personal data. As supervisory authorities issue further guidance on personal data transfer mechanisms, transfer risk assessments, and supplementary measures for the security of transferred personal data or start taking enforcement action, we could be subject to additional costs, complaints or regulatory investigations or fines, or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we operate our business and could harm our business, financial condition and results of operations. In October 2022, President Biden signed an Executive Order on “Enhancing Safeguards for United States Signals Intelligence Activities”, which introduced new binding safeguards to address the concerns raised by the Court of Justice of the European Union in its Schrems 11 judgment. Although this Executive Order is intended to form the basis of a new EU-US Data Privacy Framework (the “Framework”), the Framework is still in development and its route to implementation remains uncertain (particularly in light of the new administration in the US). In June 2021, the European Commission published a new set of modular standard contractual clauses (the “New SCCs”). The New SCCs must be used for all relevant UK GDPR regulated transfers of personal data outside the EEA (since December 2022) and organizations must ensure that all new and existing contracts involving the transfer of personal data outside the EEA contain New SCCs, unless other appropriate safeguards or derogations can be relied upon. Although the European Commission adopted an adequacy decision for the U.K. in June 2021 allowing the continued flow of personal data from the EEA to the U.K., this decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision. The decision will be regularly reviewed by the European Commission going forward and may be revoked if the U.K. diverges from its current data protection laws and the European Commission deems the U.K. to no longer provide adequate protection of personal data.

In March 2022, the U.K. implemented its own U.K.-specific international data transfer agreement (“IDTA”) and addendum to the New SCCs (“U.K. Addendum”). For all contracts involving transfers of UK GDPR regulated personal data to non-adequate third countries, organizations are required to use the IDTA, or the U.K. Addendum. Existing contracts involving transfers of UK GDPR regulated transfers of personal data relying on standard contractual clauses must be migrated to the IDTA, or the U.K. Addendum by March 2024. The cross-border data transfer landscape in the EEA and U.K. is continually developing, and we are monitoring these developments. We may, in addition to other impacts, experience additional costs associated with increased compliance burdens and be required to engage in new contract negotiations with third parties that aid in processing data on our behalf or localize certain data. We may experience reluctance or refusal by current or prospective European customers to use our products, and we may find it necessary or desirable to make further changes to our handling of personal data of EEA and U.K.-based data subjects.

The cross-border data transfer landscape globally (including in the EEA, U.K. and U.S.) is continually evolving, and other countries outside of Europe have enacted or are considering enacting cross-border data transfer restrictions and laws requiring data localization, which may affect our ability to process or transfer personal data from Europe or elsewhere. Inability to import personal data to the U.S. may significantly and negatively impact our business.

Regulators in the EEA and the U.K. are increasingly focusing on compliance with requirements in cookies and tracking technologies and the online behavioral advertising ecosystem, with a notable rise in enforcement activity from supervisory authorities across the EEA in relation to cookies-related violations, resulting in significant fines as supervisory authorities increasing adopt a fact-based approach. In the U.K., it is possible that we will be subject to separate and additional legal regimes with respect to ePrivacy, which may result in further costs and may necessitate changes to our business practices. The GDPR requires opt-in, informed consent for the placement of cookies on a customer's device, and imposes conditions on obtaining valid consent (e.g., a prohibition on prechecked consents). Increased regulation of cookies tracking technologies and online behavioral advertising may lead to broader restrictions and impairments on our online activities, including our ability to identify and potentially target users, lead to substantial costs, require significant systems changes, negatively impact our efforts to understand our customers and subject us to additional liabilities.

There may be further changes to the U.K. data protection regime, with the UK Government introducing the new Data (Use and Access) Bill. (“DUAB”) Depending on whether the DUAB is approved (and any subsequent amendments that may be made to the Bill before it becomes law), compliance with the approved law may lead to substantial compliance costs and increased regulatory enforcement risks (e.g., the Bill currently proposes aligning the fines for electronic direct marketing breaches to those set out in the UK GDPR, and not those set out in the Privacy & Electronic Communications Regulations 2003 (as amended)), There is also a risk that the European Commission does not renew or revokes its adequacy decision in favor of the UK, in light of the DUAB.
17


Compliance with existing, not yet effective, and proposed privacy and data protection laws and regulations can be costly and can delay or impede our ability to market and sell our products, affect our ability to conduct business through websites and mobile applications we and our partners may operate, require us to modify or amend our information practices and policies, change and limit the way we use consumer information in operating our business, increase our operating costs, or require significant management time and attention. Failure to comply could result in negative publicity or subject us to inquiries or investigations, claims or other remedies, including significant fines and penalties, or demands that we modify or cease existing business practices. We may also face civil claims, including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, and diversion of internal resources. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.
5.Risks Related to Global Economic, Geopolitical, Social and Emerging Conditions
Emerging risks such as economic downturns, global conflicts, and public health emergencies could significantly impact consumer spending and adversely affect our operations and financial performance.
Emerging risks for our business stem from economic pressures, geopolitical uncertainties, and public health challenges. Adverse economic conditions, such as inflation, rising interest rates, or an economic slowdown, could reduce consumer disposable income and significantly diminish spending on discretionary beauty and wellness products. As our products are not reimbursable by health insurers and rely on consumer choice, a shift in spending priorities could negatively affect our sales and profitability. Economic uncertainties may also disrupt our supply chain as suppliers or third-party partners face financial or operational challenges, leading to material shortages or service disruptions that could impair our operations.
Global or regional geopolitical and security issues pose additional risks. Armed conflicts, political instability, trade policy changes, natural disasters, and public health emergencies have the potential to disrupt supply chains and hinder business operations. These events, along with changes in import/export regulations, tariffs, or sanctions, could impose additional costs or reduce access to key markets, thereby negatively affecting our ability to deliver products efficiently or maintain market presence. Newly imposed U.S. tariffs could result in the adoption of retaliatory tariffs by other countries, leading to a global trade war. Trade restrictions implemented by the U.S. or other countries in connection with a global trade war could materially and adversely affect our business, financial condition and results of operations.
The expiration of the COVID-19 public health emergency in 2024 does not eliminate the risk of future disruptions. New pandemics, variants, or other unforeseen events could replicate the supply chain, operational, and consumer behavior challenges previously encountered. Any future pandemic, epidemic, natural disaster or other unanticipated event could require us to make similar unplanned investments or adversely affect our business, financial condition and results of operations.
6.Legal Risks and Risks Related to Litigation
The design, development, manufacture and sale of our products involve the risk of product liability and other claims by consumers and other third parties, and our insurance may be insufficient to cover any such claims.
The design, development, manufacture, and sale of skincare and cosmetic products carry inherent risks of product liability claims, which could result in significant costs and harm to the business. Adverse reactions, even when products are used as directed, could lead to negative publicity, regulatory sanctions, or product recalls. Monitoring for adverse events is essential, as increases in complaints may indicate changes in product specifications or efficacy. Additionally, liability risks may arise from issues such as contamination, inadequate instructions or warnings, or side effects. Product liability claims could exceed insurance coverage, impacting financial resources, and requiring higher insurance premiums or deductibles. This risk is heightened with the introduction of new products, and past industry cases have shown substantial damage awards for similar claims.
Beyond product liability, the Company may face claims or investigations related to compliance, product regulation, environmental or safety concerns, employment practices, or intellectual property disputes. Negative publicity, whether valid or not, about product safety, efficacy, or side effects can harm market acceptance, reduce consumer trust, and lead to increased claims or litigation. Such issues could result in substantial financial losses, restrictions on sales, and damage to the Company's reputation, potentially impacting stock prices and business operations significantly.
18

If intellectual property used by our companies, our contract manufacturers, or suppliers is breached, terminated, or disputed, our ability to commercialize dependent products may be potentially compromised, any resulting claims or litigation could further divert our resources, expose us to significant liabilities, and lead to substantial litigation expenses or the loss of proprietary rights.
We rely on licensing agreements with third parties for certain product and device technologies. If these licenses are terminated, breached, or disputed, our ability to develop and commercialize products that depend on these technologies could be significantly impacted. Additionally, licensors may not uphold their contractual obligations or prevent third parties from infringing on licensed technologies, which could lead to legal disputes and financial consequences. Any loss of key licenses could materially and adversely affect our financial condition and operating results.
We source products from manufacturers and suppliers who hold patent licenses from third parties. If disputes arise over these licensed rights, we may face legal action from third-party licensors, potentially resulting in financial damages or injunctions that could disrupt our supply chain and sales. Additionally, disagreements over patent validity or royalty obligations could lead to complex and costly disputes, which may negatively affect our operations and ability to commercialize licensed products.
We may also need to engage in litigation to protect or enforce our intellectual property rights, or we may become the target of infringement claims from competitors or other third parties. Given the extensive number of issued and pending patents in our industry, we could face challenges to our patents, be involved in interference proceedings, or be required to defend our patent applications in foreign jurisdictions. Such legal proceedings can be expensive, time-consuming, and resource-intensive, diverting management’s focus from business operations.
Any legal proceedings, investigations or claims against us could be costly and time-consuming to defend, and, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations and could harm our reputation regardless of the outcome. In addition, our business and operations could be negatively affected if they become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of business and growth strategy and impact our share price.
We are and may in the future become subject to legal proceedings, investigations, such as the SEC investigation described elsewhere herein, and claims, including claims that arise in the ordinary course of business, such as claims by customers, claims or investigations brought by regulators or employment claims made by our current or former employees and independent contractors. Such claims may also involve our directors or management.
In general, claims made by or against us in disputes and other legal or regulatory proceedings can be expensive and time-consuming to bring or defend against, requiring us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. These potential claims include, but are not limited to, personal injury claims, class action lawsuits, intellectual property claims, employment litigation and regulatory investigations and causes of action relating to the advertising and promotional claims about our products. For instance, we may face claims of trademark or copyright infringement for the use of images, pictures, or materials used in promotional materials on social media platforms. Any adverse determination against us in these proceedings, or even the allegations contained in the claims, regardless of whether they are ultimately found to be without merit, may also result in settlements, injunctions or damages that could have a material adverse effect on our business, financial condition and results of operations.
We are not currently a party to any pending or, to our knowledge, threatened litigation that will or could be expected to have a material impact on our business, financial condition and results of operations, other than the SEC investigation described in “Item 4. Information on the Company—B. Business Overview—Legal Proceedings” and “Item 8. Financial Information—Note 17. Commitments and Contingencies.” Any litigation, investigation or claim, whether meritorious or not, could harm our reputation, will increase our costs and may divert management’s attention, time and resources, which may in turn harm our business, financial condition and results of operations. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims and might not continue to be available on terms acceptable to us. A claim brought against us for which we are uninsured or underinsured could result in unanticipated costs, potentially harming our business, financial position and results of operations.
In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. Shareholder activism, which could take many forms or arise in a variety of situations. Volatility in the share price of our Class A ordinary shares, impediments to our securityholders’ ability to trade
19

our restricted securities, regulatory investigations or litigation relating to the restatement of our financial statements for certain Predecessor Periods or other reasons may in the future cause us to become the target of securities litigation or shareholder activism. Securities litigation and shareholder activism, including potential proxy contests, could result in substantial costs and divert management’s and our Board’s attention and resources from our business. Additionally, such securities litigation and shareholder activism could give rise to perceived uncertainties as to our future, adversely affect our relationships with suppliers and service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to incur significant legal fees and other expenses related to any securities litigation and activist shareholder matters. Further, our share price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities litigation and shareholder activism.
We are subject to the U.K. Bribery Act, the FCPA and other anti-corruption laws and anti-money laundering laws. Failure to comply with these laws could subject us to penalties and other adverse consequences.
Our operations are subject to anti-corruption laws, including the Bribery Act, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, and other anti-corruption laws and anti-money laundering laws that apply in countries where we conduct activities or may conduct activities in the future. The Bribery Act, the FCPA and these other anti-corruption laws generally prohibit us and our employees, agents, representatives, distributors, retailers, other business partners, and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, improper or prohibited payments, or anything else of value, to or from recipients in the public or private sector in order to obtain or retain business or gain some other business advantage. These laws have been enforced aggressively in recent years and are interpreted broadly. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. Additionally, we are required to comply with all applicable economic and financial sanctions and trade embargoes, and export/import control laws.
We sell our products in several countries outside of the U.S. and will continue to rely on local distributors and partners to expand and build out our operations in relevant markets. We, or any of our local distributors and other third parties may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these local distributors and partners, even if we do not explicitly authorize or have actual knowledge of such activities. While we strive to put in place the relevant controls to identify high-risk individuals and entities before contracting with them, we will be operating in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations. The Bribery Act and FCPA present particular challenges in the prescription product industry, because, in many countries, hospitals and clinics are run by the government, and doctors and other hospital or clinic employees may therefore be considered foreign officials. We cannot assure you that all of our local distributors or other third parties will comply with all applicable laws, for which we may be ultimately held responsible. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted and as we increase our international sales and business, our risks under these laws may increase.
In February 2025, the U.S. administration issued an executive order pausing the U.S. Department of Justice’s (“DOJ”) enforcement of the FCPA for 180 days until the attorney general issues revised FCPA enforcement guidance. Due to the changing nature of and uncertainties related to the regulatory environment, we cannot be certain if or how the DOJ’s enforcement of the FCPA will change or its impact on our business.
Some of these anti-corruption laws also require that we keep accurate books and records and maintain internal controls and compliance procedures reasonably designed to prevent any corrupt conduct. While we have policies and procedures to address compliance with those laws, we cannot assure you that none of our employees, agents, representatives, business partners or third-party intermediaries will take actions that violate our policies and applicable law, for which we may be ultimately held responsible. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.
Any violations of these anti-corruption laws, or even allegations of such violations, can lead to an investigation and/or enforcement action, which could disrupt our operations, involve significant management distraction and lead to significant costs and expenses, including legal fees. If we, or our local distributors or other third parties, are found to have engaged in practices that violate these laws and regulations, we could suffer hefty fines and severe penalties, profit disgorgement, injunctions on future conduct, securities litigation, bans on transacting government business, delisting from securities exchanges and other consequences that could have a material adverse effect on our business, financial condition and results of operations. In addition, our brand and reputation, our sales activities or our stock price could be adversely affected if we
20

become the subject of any negative publicity related to actual or potential violations of anti-corruption, anti-bribery or trade control laws and regulations.
The UK City Code on Takeovers and Mergers, or the Takeover Code, may apply to the Company.
Up until February 2, 2027, the Takeover Code applies, among other things, to an offer for a public company whose registered office is in the UK (or the Channel Islands or the Isle of Man) and whose securities are not admitted to trading on a regulated market in the UK (or the Channel Islands or the Isle of Man) if the company is considered by the Panel on Takeovers and Mergers (the “Takeover Panel”) to have its place of central management and control in the UK (or the Channel Islands or the Isle of Man). This is known as the “residency test.” Under the Takeover Code, the Takeover Panel will assess the company’s place of central management and control by looking at various factors, including the structure of the company’s board of directors, the functions of the directors and where they are resident. From February 3, 2027, the Takeover Code will only apply to offers for public companies who have their registered office in the UK (or the Channel Islands or the Isle of Man) and have their securities admitted to trading on a regulated market, multilateral trading facility or stock exchange in the UK (or the Channel Islands or the Isle of Man).
If, at the time of a takeover offer made prior to February 2, 2027, the Takeover Panel determines that the Company’s place of central management and control is in the UK, the Company would be subject to a number of rules and restrictions imposed by the Takeover Code, including but not limited to: (i) the Company’s ability to enter into deal protection arrangements with a bidder would be extremely limited; (ii) the Company might not, without the approval of shareholders, be able to perform certain actions that could have the effect of frustrating an offer, such as issuing shares or carrying out material acquisitions or disposals; and (iii) the Company would be obliged to provide equality of information to all bona fide competing bidders.
A majority of the Board currently resides outside of the UK, the Channel Islands and the Isle of Man. Accordingly, for the purposes of the Takeover Code, the Company is considered to have its place of central management and control outside the UK, the Channel Islands or the Isle of Man. The Takeover Code therefore does not currently apply to the Company. It is possible that, in the future, circumstances, in particular the composition of our Board, could change, which may cause the Takeover Code to apply to the Company.
7.Risks Related to SEC and Nasdaq Compliance, Securities Issuances, Share Price Volatility and Limitations on Investor Rights
The price of our securities may be volatile.
The price of our securities, may fluctuate due to a variety of factors, including:
a.the volume of our Class A ordinary shares available for public sale;
b.the ability of our shareholders to trade restricted securities pursuant to Rule 144 or a shelf registration statement;
c.changes in the markets in which we and our customers operate;
d.developments involving our competitors;
e.changes in laws and regulations affecting our Obagi Skincare and/or Milk Makeup businesses;
f.variations in operating performance and the performance of competitors in general; actual or anticipated fluctuations in our quarterly or annual operating results;
g.publication of research reports by securities analysts about us or our competitors or our industry;
h.the public’s reaction to our press releases, our other public announcements and our filings with the SEC;
i.actions by shareholders, including the sale of substantial amounts of our Class A ordinary shares by any of our significant shareholders, or the perception that such sales may occur;
j.additions and departures of key personnel;
k.commencement of, or involvement in, litigation;
l.changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; and
m.general economic and political conditions, such as the effects of, recessions, interest rates, inflation, tariffs or trade wars, local and national elections, prices for fuel and consumer goods, international currency fluctuations, corruption, political instability, acts of war or terrorism, or a pandemic or epidemic.
21

These market and industry factors may materially reduce the market price of our Class A ordinary shares and warrants regardless of our operating performance.
If we fail to maintain compliance with the continued listing standards of Nasdaq, our securities may be delisted and the price of our Class A ordinary shares and our ability to access the capital markets could be negatively impacted.
Our securities are listed on Nasdaq. If we fail to maintain compliance with the continued listing standards of Nasdaq, including the Period Listing Rule during the one-year Nasdaq panel monitor, our securities may be delisted and the price of our Class A ordinary shares and our ability to access the capital markets could be negatively impacted. On May 4, 2023, we received a written notice from Nasdaq indicating that, as a result of not having timely filed our 2022 Form 20-F, we were not in compliance with Nasdaq Listing Rule 5250(c)(l), which requires timely filing of all required periodic financial reports with the SEC. On October 31, 2023, we received a written notice from Nasdaq indicating that, based upon our non-compliance with the filing requirement as of October 30, 2023, Nasdaq had determined to delist our securities from Nasdaq by opening of business on November 9, 2023 unless we timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). On November 7, 2023, by requesting a hearing (the “Hearing”) before Panel, we appealed the determination of to the Panel and requested that the stay of delisting be extended until the Panel issued a final decision. On November 22, 2023, Nasdaq granted our request to extend the stay. On January 3, 2024, we received an additional notice of non-compliance from Nasdaq because we had not filed interim financial statements for the period ended June 30, 2023 with the SEC by December 31, 2023, as required by Nasdaq’s Listing Rules. We subsequently filed the 2022 Form 20-F with the SEC on January 16, 2024.
Following the Hearing and the publication by us of our interim financial statements for the period ended June 30, 2023 with the SEC on March 21, 2024, we received formal notice from the Panel confirming that we had regained compliance with Nasdaq’s filing requirements (the “Periodic Filing Rule”). In line with the applicable Nasdaq Listing Rules in such circumstances, the notice also indicated that Nasdaq had imposed a “Mandatory Panel Monitor” for a period of one year from the date of the compliance determination (March 21, 2024), pursuant to which in the event we fail to timely satisfy the Periodic Filing Rule during the one-year monitor period, the Company will not have the opportunity to provide a compliance plan for Nasdaq's review; rather, Nasdaq would instead issue a delist determination pursuant to which the Company could request a hearing and stay of the delist determination pending another hearing before the Panel.
In the event we fail to comply with Nasdaq’s continued listing standards and the Panel does not grant our request to extend the stay of a delisting decision or the Panel does not grant any requests we may make for further extensions, our securities may be delisted from Nasdaq. In addition, our Board may determine that the cost of maintaining the listing on a national securities exchange outweighs the benefits of such listing. A delisting of our securities would materially impair our shareholders’ ability to buy and sell our Class A ordinary shares and/or our warrants and could have an adverse effect on the market price of, and the efficiency of the trading market for, our securities. The delisting of our securities could significantly impair our ability to raise capital and the value of your investment.
We may issue additional securities without your approval, which would dilute your ownership interests and may depress the market price of our Class A ordinary shares.
Certain directors, key employees and consultants of the Company and of our subsidiaries have been granted equity awards under the Waldencast 2022 Incentive Award Plan and the Waldencast 2022 Inducement Award Plan. You will experience additional dilution when those equity awards vest and are settled or exercisable, as applicable, for our Class A ordinary shares.
In September 2023, in connection with the 2023 PIPE Investment, we entered into the 2023 Subscription Agreements with certain investors for the issuance and sale of 14,000,000 Class A ordinary shares in a private placement to (i) one stakeholder of Beauty Ventures, (ii) certain other existing equity holders, including certain members of the Sponsor, and (iii) Michel Brousset and Hind Sebti at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment resulted in dilution of the equity interests of other existing holders of our securities who did not participate in the transaction. In the future, we may issue additional Class A ordinary shares or other equity securities of equal or senior rank in connection with, among other things, acquisitions or repayment of outstanding indebtedness, without shareholder approval, in a number of circumstances. The issuance of additional Class A ordinary shares or other equity securities could significantly dilute the equity interests of existing holders of our securities and may adversely affect prevailing market prices for our Class A ordinary shares or warrants.
22

Warrants will be exercisable for our Class A ordinary shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders, and a sale of a substantial number of our securities in the public market could cause the price of our securities to decline.
Outstanding warrants to purchase an aggregate of 29,533,282 Class A ordinary shares are exercisable in accordance with the terms of the Warrant Agreement, dated March 15, 2021, between Waldencast Acquisition Corp. and Continental Stock Transfer & Trust Company, as amended on December I, 2022, by and among Waldencast pie (f/k/a Waldencast Acquisition Corp.), Continental Stock Transfer & Trust Company and American Stock Transfer & Trust Company LLC (the “Warrant Agreement”) governing those securities at an exercise price of $11.50 per share. These warrants will expire five years after the completion of our Business Combination (July 27, 2027), at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. To the extent such warrants are exercised, additional Class A ordinary shares will be issued, which will result in dilution to our existing Class A ordinary shareholders and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such warrants may be exercised could adversely affect the market price of our Class A ordinary shares. However, there is no guarantee that the public warrants will ever be in the money prior to their expiration and as such, the warrants may expire worthless. In addition, our shareholders who exercised their redemption rights with respect to their public shares in connection with the Business Combination retained their public warrants, which may be exercised by such redeeming shareholders for our Class A ordinary shares resulting in further dilution.
A significant number of our shares are held by members of the Sponsor and the former owner of Obagi.
As of February 28, 2025, members of the Sponsor and its affiliates own a combined ownership interest of 45.1% of our Class A ordinary shares, comprised of the following: (i) Burwell Mountain Trust (“Burwell”) holds an ownership interest of 10.2% of the Class A ordinary shares, (ii) Zeno Investment Master Fund (f/k/a Dynamo Master Fund) (“Zeno”) holds an ownership interest of 17.3% of the Class A ordinary shares, (iii) Michel Brousset (individually and as beneficial owner of the shares held by Waldencast Ventures LP) holds an ownership interest of 6.8% of the Class A ordinary shares, and (iv) Beauty Ventures holds an ownership interest of 10.8% of the Class A ordinary shares. In addition, Cedarwalk Skincare Ltd., the owner of Obagi immediately prior to the close of the Business Combination (“Cedarwalk”), holds an ownership interest of 25.6% the Class A ordinary shares. See Item 7. “Major Shareholders and Related Party Transactions” for more information.
As a result of such ownership, members of the Sponsor and their affiliates and Cedarwalk exercise significant influence over all matters requiring shareholder approval, including the election and removal of directors, appointment and removal of officers, any amendment of our memorandum and articles of association (the “Constitutional Document”), and any approval of significant corporate transactions. Additionally, the interests of the Sponsor and its affiliates and/or Cedarwalk may differ from those of other shareholders. As a result, the concentration of voting power with members of the Sponsor and their affiliates and Cedarwalk may have an adverse effect on the price of our securities.
As a former shell company, resales of shares of our restricted Class A ordinary shares in reliance on Rule 144 of the Securities Act are subject to the requirements of Rule 144(i).
Prior to the closing of the Business Combination, we were deemed a “shell company” under applicable SEC rules and regulations because we had no or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents, or assets consisting of any amount of cash and cash equivalents and nominal other assets. As a result, sales of our securities pursuant to Rule 144 under the Securities Act cannot be made unless, among other things, at the time of a proposed sale, we are subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and have filed all reports and other materials required to be filed by Section 13 or 15(d) of the Securities Exchange Act, as applicable, during the preceding 12 months, other than Form 6-K reports. Because, as a former shell company, the reporting requirements of Rule 144(i) will apply regardless of holding period, restrictive legends on our securities cannot be removed except in connection with an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registration requirements of, the Securities Act. In addition, because our unregistered securities cannot be sold pursuant to Rule 144 unless we continue to meet such requirements, any unregistered securities we issue will have limited liquidity unless we can comply with such requirements. In addition, our previous status as a shell company could also limit our use of our securities to pay for any acquisitions we may seek to pursue in the future. The lack of liquidity of our securities as a result of the inability to sell under Rule 144 for a longer period of time than a non-former shell company could cause the market price of our securities to decline.
23

Your rights and responsibilities as a shareholder are governed by Jersey law, which differs in some material respects with respect to the rights and responsibilities of shareholders of U.S. companies.
We are organized under the laws of the Bailiwick of Jersey, Channel Islands, a British crown dependency that is an island located off the coast of Normandy, France. Jersey is not a member of the EU. Jersey legislation regarding companies is largely based on English corporate law principles. The rights and responsibilities of the holders of our Class A ordinary shares are governed by the Constitutional Document and by Jersey law, including the provisions of the Jersey Companies Law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. corporations.
In particular, Jersey law significantly limits the circumstances under which shareholders of companies may bring derivative actions and, in most cases, only the corporation may be the proper claimant or plaintiff for the purposes of maintaining proceedings in respect of any wrongful act committed against it. Neither an individual nor any group of shareholders has any right of action in such circumstances. Jersey law also does not afford appraisal rights to dissenting shareholders in the form typically available to shareholders of a U.S. corporation. However, we cannot assure you that Jersey law will not change in the future or that it will serve to protect our investors in a similar fashion afforded under corporate law principles in the U.S., which could adversely affect your rights.
It may be difficult to enforce a U.S. judgment against us or our directors and officers outside the U.S., or to assert U.S. securities law claims outside the U.S.
Investors may have difficulties pursuing an original action brought in a court in a jurisdiction outside the U.S., including Jersey, for liabilities under the securities laws of the U.S. The U.S. and Jersey currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments (as opposed to arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment rendered by any federal or state court in the U.S. based on civil liability, whether or not predicated solely upon U.S. federal securities laws, would not automatically be recognized and is not directly enforceable in Jersey. Rather, a judgment of a U.S. court constitutes a cause of action which may be enforced by Jersey courts provided that:
a.the applicable U.S. courts had jurisdiction over the case, as recognized under Jersey law; the judgment is given on the merits and is final, conclusive and non-appealable;
b.the judgment relates to the payment of a sum of money, not being taxes, fines or similar governmental penalties; the defendant is not immune under the principles of public international law;
c.the same matters at issue in the case were not previously the subject of a judgment or disposition in a separate court; the judgment was not obtained by fraud; and
d.the recognition and enforcement of the judgment is not contrary to public policy in Jersey.
Subject to the foregoing, investors may be able to enforce judgments in civil and commercial matters in Jersey that have been obtained from U.S. federal or state courts. However, it is doubtful that an original action based on U.S. federal or state securities laws could be brought before Jersey courts. In addition, a plaintiff who is not resident in Jersey may be required to provide a security bond in advance to cover the potential of the expected costs of any case initiated in Jersey.
We may amend the terms of the warrants in a manner that may be adverse to holders with the approval by the holders of at least 65% of the then outstanding public warrants.
Our public warrants were issued in registered form under a Warrant Agreement between our transfer agent for our warrants and Waldencast. The Warrant Agreement provides that (a) the terms of the warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or correcting any mistake, including to conform the provisions of the Warrant Agreement to the description of the terms of the warrants and the Warrant Agreement set forth in this Report, or defective provision or (ii) adding or changing any provisions with respect to matters or questions arising under the Warrant Agreement as the parties to the Warrant Agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the warrants under the Warrant Agreement and (b) all other modifications or amendments require the vote or written consent of at least 65% of the then outstanding public warrants; provided that any amendment that solely affects the terms of the private placement warrants or any provision of the Warrant Agreement solely with respect to the private placement warrants will also require at least 65% of the then outstanding private placement warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders of at least 65% of the then outstanding public warrants approve of such amendment. Although our ability to amend the terms of the public warrants with the consent of at least 65% of the then outstanding public warrants is
24

unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease the number of our Class A ordinary shares purchasable upon exercise of a warrant.
We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
We have the ability to redeem the outstanding public warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant if, among other things, the last reported sale price of our Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders equals or exceeds $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like). Redemption of the outstanding warrants as described above could force you to: (l) exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so; (2) sell your warrants at the then current market price when you might otherwise wish to hold your warrants; or (3) accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, we expect would be substantially less than the market value of your warrants. None of the private placement warrants will be redeemable by us (subject to limited exceptions) so long as they are held by the Sponsor or its permitted transferees.
In addition, we have the ability to redeem the outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant if, among other things, the last reported sale price of our Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like). In such a case, the holders will be able to exercise their warrants prior to redemption for a number of our Class A ordinary shares determined based on the redemption date and the fair market value of our Class A ordinary shares. The value received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants, because the number of Class A ordinary shares received is capped at 0.361 Class A ordinary shares per warrant (subject to adjustment) irrespective of the remaining life of the warrants.
We do not intend to pay cash dividends for the foreseeable future.
We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board and will depend on our financial condition, results of operations, capital requirements, restrictions contained in any future agreements and financing instruments, business prospects and such other factors as our Board deems relevant.
If analysts do not publish research about our business or if they publish inaccurate or unfavorable research, our stock price and trading volume could decline.
The trading market for our Class A ordinary shares will depend in part on the research and reports that analysts publish about us. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our Class A ordinary shares or publish inaccurate or unfavorable research about our businesses, the price of our Class A ordinary shares could decline. If few analysts cover us, the demand for our shares could decrease and our stock price and trading volume may decline. Similar results may occur if one or more of these analysts stop covering us in the future or fail to publish reports on us regularly.
We are currently an emerging growth company within the meaning of the Securities Act, and to the extent we have taken advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.
We are currently an “emerging growth company” within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-
25

Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, our shareholders may not have access to certain information they may deem important. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile.
Further, Section 102(b)(l) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
If we cease to be an emerging growth company, we will no longer be able to take advantage of certain exemptions from reporting, and, absent other exemptions or relief available from the SEC, we will also be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes­ Oxley Act. We will incur additional expenses in connection with such compliance and our management will need to devote additional time and effort to implement and comply with such requirements.
As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of the ordinary shares.
We have determined that we are a foreign private issuer, as such term is defined in Rule 405 under the Securities Act, however, under Rule 405, the determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter and, accordingly, the next determination regarding our status will be made on June 30, 2025.
As a foreign private issuer, we are not subject to all of the disclosure requirements applicable to public companies organized within the U.S. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act (including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer and the other two most highly compensated executive officers on an individual, rather than an aggregate, basis). In addition, our officers and directors are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we may elect to voluntarily submit quarterly interim consolidated financial data to the SEC under cover of the SEC's Form 6-K, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and are not required to file quarterly reports on Form 10-Q or current reports on Form 6-K under the Exchange Act. We also are exempt from the requirements to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. In addition, as a foreign private issuer, we are exempt from the provisions of Regulation FD, which prohibits issuers from making selective disclosure of material nonpublic information.
Furthermore, our Class A ordinary shares are not listed and we do not currently intend to list our Ordinary Shares on any market in the Bailiwick of Jersey, our home country. As a result, we are not subject to the reporting and other requirements of companies listed in the Bailiwick of Jersey. For instance, we are not required to publish quarterly or semi-annual financial statements (although we are required to comply with Nasdaq's continued listing standards to publicly disclose an interim balance sheet and income statement as of the end of our second quarter each fiscal year). Accordingly, there may be less publicly available information concerning our business than there would be if we were a U.S. public company and you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.
26

As a public limited company incorporated under the laws of Jersey, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to securityholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.
As a public limited company incorporated under the laws of Jersey and listed on Nasdaq, we are subject to Nasdaq corporate governance listing standards. However, Nasdaq rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in Jersey, which is our home country, may differ significantly from Nasdaq corporate governance listing standards. Currently, we follow our home country practice in lieu of the provisions under Rule 5620(a), Rule 5635(c), Rule 5635(d) and Rule 5250(b)(3) of the Nasdaq Stock Market Marketplace Rules (the “Rules”) by relying on the exemption provided for foreign private issuers under Rule 5615(a)(3) of the Rules. Rule 5620(a) of the Rules requires that the Company hold an annual meeting of shareholders no later than one year after the end of the Company's fiscal year-end; Rule 5635(c) of the Rules requires shareholder approval for share incentive plans; Rule 5635(d) of the Rules requires shareholder approval for the issuance of securities, other than in a public offering, equal to 20% or more of the voting power outstanding before the issuance for less than the greater of book or market value of the stock; and Rule 5250(b)(3) of the Rules requires disclosure of third-party director and nominee compensation. The corporate governance practice in our home country, Jersey, does not require the Company to follow or comply with the requirements of Rule 5620(a), Rule 5635(c), Rule 5635(d) and Rule 5250(b)(3). We will continue to comply with other corporate governance requirements of the Rules. However, in the future, we may consider following home country practice in lieu of additional requirements under the Rules with respect to certain corporate governance standards. Any foreign private issuer exemptions we avail ourselves of in the future may reduce the scope of information and protection to which you are otherwise entitled as an investor. As a result, there may be less publicly available information concerning our business than there would be if we were a U.S. public company and you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.
Jersey law and our Constitutional Document contain certain provisions, including anti-takeover provisions that limit the ability of shareholders to take certain actions and could delay or discourage takeover attempts that shareholders may consider favorable.
Jersey law and our Constitutional Document contain provisions that could have the effect of rendering more difficult, delaying or preventing an acquisition that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for our Class A ordinary shares, and therefore depress the trading price of our Class A ordinary shares. These provisions could also make it difficult for shareholders to take certain actions, including electing directors who are not nominated by the current members of our Board or taking other corporate actions, including effecting changes in our management. Among other things, the Constitutional Document includes provisions regarding:
a.providing for a classified board of directors with staggered, three-year terms;
b.the ability of our Board to issue shares of preferred stock, and to determine the price and other terms of those shares, including preferences and voting rights, without shareholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
c.subject to the Investor Rights Agreement, our Board will have the exclusive right to elect directors to fill a vacancy created by the expansion of our Board or the resignation, death or removal of a director, which will prevent shareholders from being able to fill vacancies on our Board; and
d.the limitation of the liability of, and the indemnification of, our directors and officers.
These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our Board or management.
27

8.Risks Related to Dependence on Third Parties for Manufacturing, Distribution, E-Commerce, and Other Vendors
Obagi and Milk Makeup rely heavily on third party providers, making us vulnerable to disruptions that could adversely affect our business, financial condition, and operations.
Reliance on Third-Party Logistics Providers
Obagi and Milk Makeup depend on third-party logistics providers for storage, distribution, and delivery of products to both domestic and international customers. Securing alternative logistics providers that meet our standards may be difficult, and the time and effort required to oversee these relationships could strain internal resources. Specifically, Obagi’s operations in the U.S. heavily depend on a single distributor (the “Physician Channel Provider”), which manages sales to healthcare professionals in the physician-dispensed channel as well as retail and spa customers. This provider accounted for a significant portion of Obagi’s net revenue in recent years. The Physician Channel Provider performs critical functions, including warehousing, order fulfillment, customer service, and regulatory compliance for prescription products. Any disruption in their services could materially and adversely affect Obagi’s business, financial condition, and results of operations.
Obagi and Milk Makeup’s reliance on third-parties for distribution, manufacturing, and logistics introduces significant risks that could materially impact its operations. Any disruptions or cost increases from these providers could impair our ability to meet customer demand, reduce profit margins, and adversely affect financial performance. Managing these third-party relationships requires significant oversight, and failure to do so effectively could exacerbate these challenges.
Dependence on Contract Manufacturers
Obagi and Milk Makeup rely entirely on third-party Contract Manufacturers (“CMOs”) for the production of its products, exposing the Company to risks associated with capacity constraints, delays, and regulatory compliance issues. While multiple CMOs are qualified for certain key products, some items, are supplied by a single source. Termination or disruption in these arrangements could lead to supply chain delays, harm customer relationships, and impact the brand’s reputation. Finding alternative manufacturers for critical products could be challenging and time-consuming. Additionally, reliance on CMOs introduces risks such as breaches of manufacturing agreements, production quality, non-compliance with regulatory standards, increased production costs, and delays in transferring manufacturing operations to alternative providers.
Milk Makeup relies significantly on third-parties, such as resellers, suppliers, and sales forces, making it vulnerable to disruptions that could harm its brand, operations, and financial performance.
Dependence on Sephora and Retailers for Sales
Milk Makeup’s business is significantly reliant on Sephora, which accounted for a large majority of its U.S. net revenue in 2024 and prior periods. Milk Makeup’s business will also be significantly reliant on Ulta Beauty, as it has expanded its distribution to Ulta Beauty in Q1 2025. The loss of Sephora, Ulta Beatury, or other key distributors, or a material decrease in sales to such partners, could adversely affect Milk Makeup’s business, financial condition, and results of operations. Additionally, the company is exposed to risks tied to its retailers’ performance, including economic downturns, consumer demand fluctuations, or reputational issues, which could significantly impact Milk Makeup’s results.
Quality Control and Regulatory Compliance
The reliance on third-party suppliers for Milk Makeup products also introduces risks associated with quality control and regulatory compliance. Issues such as substandard ingredients or products not meeting specifications can lead to regulatory actions, product shortages, or reputational harm. Any inability to comply with the Controlled Substances Act, FDCA, MoCRA, or other applicable regulations could result in legal prohibitions or penalties, impacting sales and creating financial losses due to unusable inventory.
Dependence on Third-Party Sales Agencies and Direct Sales Forces
Milk Makeup relies on third-party agencies and direct sales forces for product sales in the U.S. and internationally. The company does not have long-term contracts with these personnel, making it vulnerable to turnover or the loss of key
28

contributors. Additionally, expanding the sales force to support growth in new and existing markets requires substantial training and time to build customer relationships. Challenges in retaining, replacing, or adequately training these personnel could materially harm Milk Makeup’s revenues, gross margins, and market share.
These dependencies on third parties introduce significant risks, and any disruptions in these relationships could materially and adversely affect Milk Makeup’s business and operational results.
9.Risks Related to Intense Competition in the Cosmetics Industry
The cosmetics and skincare industry is highly competitive, and challenges in product success, marketing effectiveness, and competition from larger companies could adversely affect our sales and overall performance.
Intense Competition in the Cosmetics and Skincare Market
The cosmetics industry is highly competitive, with numerous multinational companies and independent brands vying for market share across a wide range of distribution channels. Obagi Skincare and Milk Makeup faces competition based on factors such as product innovation, quality, pricing, brand recognition, and marketing initiatives. Many competitors possess greater financial, technical, and marketing resources, allowing them to respond more effectively to market trends and economic shifts. Competitors’ substantial investments in research and development (“R&D”) and marketing can result in technological and product advancements that surpass current offerings, potentially rendering its products less competitive or obsolete. Advancements by competitors in R&D could outpace Obagi’s capabilities, negatively affecting its growth prospects.
Challenges with New Product Introductions
Success in the industry heavily relies on the timely and successful introduction of new products that align with rapidly shifting consumer trends. Obagi Skincare and Milk Makeup’s ability to anticipate and adapt to changes in consumer preferences, shopping habits, and attitudes is critical. Despite established processes for product development, new product launches carry risks, including potential rejection by consumers or retailers, pricing misalignment, or ineffective marketing strategies. Supply chain challenges, such as manufacturing or shipping delays, may further hinder successful product launches. Additionally, the introduction of new products can cannibalize sales of existing offerings. These factors collectively pose a risk to Obagi Skincare and Milk Makeup’s ability to meet sales objectives and sustain growth.
We are subject to risks related to our dependency on our directors and officers and on key personnel, as well as risks related to attracting, retaining and developing human capital in a highly competitive market.
Our operations are dependent upon a relatively small group of individuals and in particular, Michel Brousset and Hind Sebti, our Chief Growth Officer. We believe that our success depends on the continued service of our directors and officers. The unexpected loss of the services of one or more of our directors or officers could have a detrimental effect on us.
Additionally, our success and future growth depend upon the services of Obagi’s and Milk’s management teams and other key employees, including highly skilled experts in their respective fields. The loss of one or more members of Obagi’s or Milk’s management teams or key employees could harm our business, and we may not be able to find adequate replacements in a timely manner.
Our success depends on our continued ability to attract, retain and motivate highly qualified management, business development, sales and marketing, product development and other personnel for our Obagi Skincare and Milk Makeup businesses. We may have difficulty recruiting and retaining such qualified personnel due to current market conditions, their inability to trade their equity awards and the existence of many similar competitive job openings. There is intense competition in our industry and failure to attract and retain qualified personnel could have a significant negative impact on our future product sales and business results.
Although we currently maintain directors’ and officers’ (“D&O”) liability insurance coverage, such coverage may not be sufficient to cover the types or extent of claims or loss that may be incurred or received. Additionally, such coverage may make it difficult for us to retain and attract talented and skilled directors and officers to serve our Company, which could adversely affect our business.
29

10. Risks Related to Supply Chain and Operational Disruption
Operational complications in the transport and distribution of our products could adversely affect our business, net revenues, and earnings.
Disruptions to Operations
Our global operations are exposed to various risks, including industrial accidents, environmental incidents, natural disasters, labor disputes, and pandemics, as well as external factors such as acts of terrorism or geopolitical instability. These risks also affect our third-party suppliers, brokers, and delivery service providers. Any damage to or loss of critical manufacturing facilities or distribution centers could significantly disrupt our operations, impacting our ability to meet customer demands and materially affecting our business, financial condition, and results of operations.
Dependence on Third-Party Logistics and Delivery Providers
We rely heavily on third-party delivery service providers for the transportation of our products to distribution facilities, retailers, and customers. Interruptions or failures in these services, whether due to inclement weather, natural disasters, or labor unrest, could result in delays or damaged shipments. Such disruptions could lead to rejected shipments, reduced customer confidence, and harm to our brand reputation. Any sustained interruptions could have a material adverse effect on our operations and financial performance.
Third-Party Suppliers and Supply Chain Risks
We rely on various third-party suppliers, both domestic and international, for the production, assembly, and packaging of our products. Some suppliers operate on a purchase-order basis, which can create uncertainties in maintaining consistent supply. Milk Makeup is particularly dependent on a limited number of suppliers for certain critical components. Disruptions in relationships with these suppliers or their inability to meet demand due to financial, operational, or capacity constraints could lead to production delays, inefficiencies, and supply interruptions.
Vulnerability of Distribution Facilities
Our inventory is primarily stored in third-party distribution facilities, making their proper functioning critical to our operations. Damage to these facilities or the inventory stored within, whether from natural disasters, accidents, or other events, could disrupt supply chains and hinder our ability to fulfill customer orders. Insurance coverage may not fully compensate for such losses, leaving us exposed to financial and operational impacts that could materially harm our business.
Risks from Freight Carrier Disruptions and Rising Shipping Costs
Our dependence on commercial freight carriers for domestic and international product deliveries exposes us to risks of operational disruptions. Delays or interruptions in freight services could result in untimely deliveries, driving customers to competitors and affecting our net revenues. Additionally, rising fuel and freight costs, particularly for international shipments, could increase our shipping expenses. If we are unable to pass on these costs to customers or mitigate them through operational efficiencies, our gross margins and profitability may decline, adversely affecting our financial results.
Operational disruptions at any point in our supply chain could hinder our ability to meet customer expectations, jeopardize relationships with key stakeholders, and materially affect our financial condition and operational stability.
Our revenues and financial results depend significantly on sales of our Obagi Nu-Derm® products. If we are unable to manufacture or sell the Nu-Derm products in sufficient quantities and in a timely manner, or maintain physician and/or patient acceptance of Nu-Derm products, our business will be materially and adversely impacted.
To date, a substantial portion of our Obagi Skincare revenues have resulted from sales of our principal product line, the Obagi Nu-Derm System and related products. Nu-Derm products accounted for a significant portion of the total products shipped for the years ended December 31, 2024, and 2023, and the periods from July 28, 2022 to December 31, 2022, and January l, 2022 to July 27, 2022 (Predecessor Period). Although we currently offer other products such as Obagi-C® Rx, Professional-C®, ELASTiderm®, CLENZlderm®, and Blue Peel® products, and intend to introduce additional new products, we still expect sales of our Obagi Nu-Derm System and related products to account for a substantial portion of
30

sales for the Obagi Skincare business for the foreseeable future. Because this business is highly dependent on Nu-Derm products, factors adversely affecting the regulation of, pricing of, or demand for, these products could have a material and adverse effect on our business.
Additionally, our commercial success depends in large part on our ability to sustain market acceptance of the Nu-Derm System. If existing users of our products determine that Obagi products do not satisfy their requirements, if our competitors develop a product that is perceived by patients or physicians to better satisfy their respective requirements or if state or federal regulations or enforcement actions prohibit sales of the Nu-Derm System, individual products within the system or any related products, sales of these products may decline and our total net revenue may correspondingly decline. We cannot assure you that we will be able to continue to manufacture these products in commercial quantities at acceptable costs. Our inability to do so would adversely affect our operating results and cause our business to suffer.
Our ability to commercially distribute products may be significantly harmed if we or our CMOs fail to comply with applicable laws and regulations.
We do not currently have the infrastructure or internal capability to manufacture our products. We rely, and expect to continue to rely, on third-party CMOs for the production of all our products. Our products and the facilities in which they are manufactured are subject to regulation under the FDCA and FDA implementing regulations, state laws and comparable regulatory frameworks in foreign markets. Federal, state and foreign authorities may inspect the facilities of our CMOs periodically to determine if we and our CMOs are complying with applicable provisions of the FDCA, FDA and foreign regulations.
Manufacturing facilities for our products are required to comply with the FDA's cGMPs and with similar requirements outside the U.S. If the FDA finds a violation of cGMPs, it may enjoin our CMO’s operations, seize our products, restrict importation of goods, or impose administrative, civil or criminal penalties, among other things. In addition to new cGMP requirements, cosmetic manufacturing and processing facilities are required to be registered with FDA. The MoCRA also requires manufacturers and responsible persons to list their cosmetic products with FDA and to report serious adverse events associated with the use of their cosmetic products in the U.S. to the FDA. Our operations could be harmed if regulatory authorities make determinations that our CMOs are not in compliance with these regulations as they take effect. We cannot assure you that the CMOS of all of our products will be able to comply with all of these new regulations in a timely manner or that they will not decide to pass the increased costs of having to comply with the regulations onto us, which would increase our costs and negatively impact net income. In addition, FDA regulations prohibit or otherwise restrict the use of certain ingredients in cosmetic products. Similar or stricter requirements may apply in foreign jurisdictions.
We do not have complete control over all aspects of the manufacturing process and are dependent on our contract manufacturing partners for compliance with cGMP and similar regulations. Our contract manufacturing partners may be found in violation of applicable requirements, which could have a material adverse effect on us and our business. If we or our CMOs fail to comply with these applicable standards, laws, and regulations, it could lead to customer complaints, adverse events, product withdrawal or recall, or increase the likelihood that our products are rendered adulterated or misbranded, any of which could result in negative publicity, remedial costs, or regulatory enforcement that could impact our ability to continue selling certain products.
Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and harm our business and results of operations.
11.Regulatory Risks That Could Adversely Impact our Business
Risks Related to Our Obagi Medical Business
Our failure to successfully in-license or acquire additional products and technologies would impair our ability to grow the Obagi Medical business.
We intend to in-license, acquire, develop and market new products and technologies. Because we have limited internal research capabilities, our business model depends in part on our ability to license patents, products and/or technologies
31

from third parties. The success of this strategy also depends upon our ability and the ability of our third-party formulators to formulate products under such licenses, as well as our ability to manufacture, market and sell such licensed products.
We may not be able to successfully identify any new products to in-license, acquire or internally develop. Moreover, negotiating and implementing an economically viable acquisition is a lengthy and complex process. Other companies, including those with substantially greater financial, marketing and sales resources, may compete with us for the acquisition of products or technologies. We may not be able to acquire or in-license the rights to such products on terms that we find acceptable, or at all. As a result, our ability to grow the Obagi Medical business or increase our profits could be adversely impacted.
Obagi Regulatory Risks
Legal and Regulatory Risks That Could Adversely Impact Our Business
Laws, regulations, enforcement trends or changes in existing regulations governing the formulation, manufacturing, testing, approval, distribution, marketing and sale of our products to consumers could harm our business.
Our products are subject to regulation by the FDA, FTC, and comparable state, local and foreign regulatory authorities, including the European Commission, and, over time, the regulatory landscape for our products has become more complex with increasingly strict requirements. If the laws and regulations governing our products continue to change, we may find it necessary to alter some of the ways we have traditionally marketed our products to stay in compliance with applicable regulations, and this could add to the costs of our operations and have a material adverse effect on our business. To the extent federal, state, local or foreign regulatory requirements regarding consumer protection, or the ingredients, claims or safety of our products continue to change in the future, such changes could require us to reformulate or discontinue certain products, apply for new or different marketing authorizations, revise product packaging or labeling, or adjust operations and systems, any of which could result in, among other things, increased costs, delays in product launches, product returns or recalls and lower net sales, and therefore could have a material adverse effect on our business, financial condition and results of operations. Noncompliance with applicable regulations could result in enforcement action by the FDA, FTC, or other regulatory authorities within or outside the U.S., including, but not limited to, product seizures, injunctions, product recalls, and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.
The MoCRA, enacted by Congress in late December 2022, introduced new compliance obligations for manufacturers and other “responsible persons” who sell cosmetic products in the U.S. and significantly expanded the FDA’s authority to regulate cosmetic products. Under MoCRA, companies will be obligated to adhere to new requirements for cosmetics, such as new labeling standards for specific products, safety substantiation, facility registration, product listing, adverse event reporting, compliance with cGMPs, mandatory recalls and record-keeping requirements for such products and the manufacturing facilities in which they are produced, among other things. Our operations could be harmed if regulatory authorities make determinations that we or our CMOs are not in compliance with regulatory requirements.
We are also subject to FTC rules and regulations as well as state consumer protection laws. If we are unable to show adequate substantiation for our product claims, our claims are otherwise perceived to be unlawful or deceptive, our promotional materials make claims that exceed the scope of allowed claims for the classification of the specific product, or we do not adhere to certain disclosures, the FDA, the FTC or other regulatory authorities could take enforcement action or impose penalties or fines, require us to revise our marketing materials, amend our claims or stop selling certain products, all of which could harm our business, financial condition and results of operations. Any regulatory action or penalty could lead to class actions, or private parties could seek to challenge our claims even in the absence of formal regulatory actions, which could harm our business, financial condition and results of operations.
Our products may also be subject to regulation by the CPSC in the U.S. under the provisions of the Consumer Product Safety Act, as amended by the Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban consumer products that fail to comply with applicable product safety laws, regulations and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury and may seek penalties for regulatory noncompliance under certain circumstances. The CPSC also requires manufacturers of consumer products to report certain types of information regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.
32

Moreover, new or revised government laws, regulations or guidelines could result in additional compliance costs and, in the event of non-compliance, civil remedies, including fines, injunctions, withdrawals, recalls or seizures and confiscations, as well as potential criminal sanctions, any of which could have an adverse effect on our business, financial condition, results of operations and prospects.
Our products containing the active ingredient, hydroquinone, are marketed as prescription-use only drugs but have not received required premarket authorization from the FDA or other regulatory authorities, and the FDA could require us to remove these products from the market until we obtain approval of the required NDA, and we could be found to be marketing and selling these products in violation of the law.
We market Obagi products that contain hydroquinone (“HQ”) on a prescription-only (i.e., not OTC) basis, and we have not sought nor obtained premarket approval from the FDA to market these products in the U.S., nor have we sought marketing authorizations in other jurisdictions. Sales of Obagi products containing HQ accounted for a significant portion of total products for the year ended December 31, 2023, and the periods from July 28, 2022 to December 31, 2022, and January 1, 2022 to July 27, 2022 (Predecessor Period). Although, to date, neither the FDA nor any other regulators have taken action against us for selling our prescription HQ products in the U.S. and in other jurisdictions without marketing approval, there can be no assurance the FDA or any other regulatory authorities will not take enforcement action against us, or otherwise require us to obtain premarket approval or similar authorization of our prescription HQ products, and we may be required to suspend marketing of our prescription HQ products unless and until such products are approved.
Based on the historical evolution of the legal and regulatory framework applicable to drugs in the U.S., the FDA acknowledges that there are some drugs on the market that lack required FDA approval for marketing. The FDA has historically utilized a risk-based enforcement approach with respect to drugs marketed without required approvals. In 2003, the FDA issued a Compliance Policy Guide (“CPG”), which was finalized in 2006 and subsequently amended in 2011, in which it announced a drug safety initiative to remove unapproved drugs from the market and established enforcement priorities and a policy of enforcement discretion with respect to marketed unapproved products. Under this policy, the FDA indicated that it intended to give higher priority to enforcement actions involving unapproved drug products in certain categories, including drugs with potential safety risks and ineffective drugs that could be used in lieu of effective treatments. Although this CPG was withdrawn and the drug safety initiative was terminated on the basis of a Federal Register notice in 2020, a subsequent Federal Register notice in May 2021 withdrew the prior notice terminating the program and the CPG, and the FDA indicated that it plans to continue to prioritize enforcement based on its existing general approach, which involves risk-based prioritization in light of all the facts of a given circumstance, and issue new guidance on this topic.
We believe our prescription-only HQ products do not fall within the previously established categories of unapproved drugs for which the FDA has indicated it prioritizes enforcement. We have not received any communications from the FDA or any similar regulatory authority regarding these HQ products or any of our other products. However, the FDA has issued a Warning Letter to at least one contract manufacturer of prescription-only HQ that cited and objected to another company’s sale of prescription-only HQ on grounds that the product was both an unapproved drug and failed to comply with cGMPs in violation of the FDCA. In addition, although our prescription-only HQ products are made with 4% HQ, the FDA has expressed concerns regarding the safety of 2% HQ products marketed as OTC. In addition, the CARES Act implemented a number of changes to regulation of OTC drugs, one of which prohibited the sale of any drug without a proposed or final Administrative Order, including HQ (at any concentration level), from being marketed in the U.S. as an OTC drug without FDA approval effective September 2020. In April 2022, the FDA announced that it had issued warning letters to 12 companies for continuing to sell 2% HQ products on an OTC basis in violation of the CARES Act. The FDA’s announcement also cited reports describing serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling, and skin discoloration. See “Item 3. Key Information—D. Risk Factors—Our products may cause adverse events or side effects, or could be associated with safety issues, that could result in recalls, withdrawals, or regulatory enforcement action. For example, the FDA has historically expressed concerns regarding the safety of HQ products, including risks for potentially serious side effects, including skin rashes, facial swelling, skin discoloration, carcinogenicity and reproductive toxicity.” Furthermore, in June and July of 2022, the FDA issued warning letters to two other manufacturers of products containing HQ. In the future, the FDA may pursue an enforcement action against us or suspend marketing of our prescription HQ products until we obtain marketing approval.
If we are required to seek FDA approval or foreign authorities’ authorization of these products, our attention and resources will be dedicated to the clinical development and regulatory approval processes, which will be time-consuming and very expensive. We may also not successfully obtain such approvals or may be delayed in obtaining such approvals if one of our competitors obtains approval and non-patent marketing exclusivity for the same uses for which we intend to seek
33

approvals. In addition, if we are determined to be marketing our prescription HQ products unlawfully, or if patients experience adverse events from using our prescription HQ products, we may be required to recall or cease distribution of these products and may be subject to product liability claims or enforcement action. If we are required to suspend or cease marketing our prescription HQ products for any reason, our business would be materially adversely affected.
In addition, even if we obtain regulatory approvals for any of our prescription HQ products, such approvals will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. In addition, if the FDA or foreign regulatory authorities approve our products, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements, any of which may materially increase our costs and limit our ability to maintain profitability.
The drug regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are required to seek and obtain any regulatory approvals that may be required for our products, we may be unable to obtain or maintain such regulatory approvals, which would substantially harm our business.
Any products that are regulated by the FDA as drugs must generally obtain premarket approval from the FDA, unless subject to the OTC monograph process or subject to other limited exceptions. The FDA approves new drugs through the New Drug Application (“NDA”) or Abbreviated New Drug Application (“ANDA”) pathways before they may be legally marketed in the U.S. In the NDA pathway, an applicant must generally demonstrate through well-controlled clinical trials that a drug is safe and effective for its intended uses. The Hatch-Waxman Act established the ANDA pathway, which is an abbreviated FDA approval procedure for drugs that are shown to be bioequivalent to proprietary drugs previously approved by the FDA through its NDA pathway. Premarket applications for generic drugs are termed “abbreviated” because such applications generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must demonstrate that its product is bioequivalent to the innovator drug. In certain situations, an applicant may obtain ANDA approval of a generic drug with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability Petition. Similar requirements apply in foreign jurisdictions.
Certain Obagi products, including our tretinoin-based products, are marketed pursuant to an ANDA held by Bausch Health or dispensed under the category of unlicensed medicines in the United Kingdom. However, we have not sought or obtained FDA premarket approval or foreign regulatory authorities’ authorization for any of our products. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the applicable regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions.
The FDA or any foreign regulatory authorities can delay, limit or deny approval or require us to conduct additional nonclinical or clinical testing or abandon a program for, among others, the following reasons:
the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of any clinical trials we may be required to conduct;
we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product is safe and effective for its proposed indication or bioequivalent to a listed drug;
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
serious and unexpected drug-related adverse events experienced by participants in our clinical trials or by individuals using drugs similar to our products;
we may be unable to demonstrate that a product’s clinical and other benefits outweigh its safety risks;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials may not be acceptable or sufficient to support the submission of an NDA, ANDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and we may be required to conduct additional clinical studies;
34

the FDA’s or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our products;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party CMOs with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for any approvals.
The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approvals to market our products, which could significantly harm our business, results of operations and prospects.
Our products may cause adverse events or side effects, or could be associated with safety issues, that could result in recalls, withdrawals, or regulatory enforcement action. For example, the FDA has historically expressed concerns regarding the safety of HQ products, including risks for potentially serious side effects, including skin rashes, facial swelling, skin discoloration, carcinogenicity and reproductive toxicity.
Adverse events or other undesirable side effects caused by our products could cause us or regulatory authorities to issue warnings about our products or could lead to recalls or regulatory enforcement action. For example, our HQ products could be subject to enforcement action and/or recalls based on the FDA’s concerns regarding HQ-based products. Specifically, in August 2006, the FDA issued a proposed rule that cited certain preclinical evidence suggesting that HQ may be a carcinogen, if orally administered, may present fertility risks and may be related to a skin condition called ochronosis, which results in the darkening and thickening of the skin and the appearance of small bumps and grayish-brown spots, after continued use of concentrations as low as 1 to 2 percent. The FDA also concluded that it could not rule out the potential carcinogenic risk from topically applied HQ. Accordingly, the FDA recommended that additional studies be conducted to determine if there is a risk to humans from the use of HQ. The FDA nominated HQ for further study by the National Toxicology Program (the “NTP”), and in December 2009, the NTP Board of Scientific Counselors approved the nomination and has been conducting studies related to HQ.
Obagi Nu-Derm Clear, Blender and Sunfader products, and the Obagi-C Rx C-Clarifying Serum and Obagi-C Rx C-Night Therapy Cream products, which are part of Obagi’s prescription-based Obagi-C Rx Systems, all contain HQ at 4% concentration. Until the completion of the NTP studies, the FDA recommended classifying OTC (nonprescription) skin-bleaching drug products, including HQ, as not generally recognized as safe and effective (“GRASE”), as misbranded, and as new drugs within the meaning of the FDCA, meaning that such products would need to be approved through the NDA pathway in order to be legally marketed in the U.S.
The FDA’s cited concerns regarding the safety of HQ in OTC products at concentrations as low as 1% or 2% could trigger regulatory scrutiny of our prescription-only HQ products. To the extent that the FDA were to determine that our prescription-use only HQ products present safety concerns, the FDA could determine that the products should be recalled, and such determination could trigger the FDA to require marketing authorization for these products based on the FDA’s established enforcement priorities for drugs marketed without an approved NDA. See “Item 3. Key Information—D. Risk Factors—Obagi Regulatory Risks—Legal and Regulatory Risks That Could Adversely Impact Our Obagi Skincare Business—Our products containing the active ingredient, hydroquinone, are marketed as prescription-use only drugs but have not received required premarket authorization from the FDA or other regulatory authorities, and the FDA could require us to remove these products from the market until we obtain approval of the required NDA, and we could be found to be marketing and selling these products in violation of the law.
If our products are associated with undesirable side effects or adverse events, a number of potentially significant negative consequences could result, including, but not limited to:
regulatory authorities may suspend, limit or withdraw approvals of such products (to the extent subject to such approvals), or seek an injunction against its manufacture or distribution;
regulatory authorities may require warnings or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the products;
we may be required to change the way the products are administered or conduct clinical trials;
we may be subject to fines, injunctions or the imposition of criminal penalties;
we could be sued and held liable for harm caused to patients; and
35

our reputation may suffer.
Any of these events could seriously harm our business.
Failure to obtain regulatory approvals or to comply with regulations in foreign jurisdictions would prevent us from marketing our products internationally.
A key part of the growth strategy for our Obagi Skincare business is to expand the sale of Obagi products in international markets. To market our products in many non-U.S. jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. In some countries, we do not have to obtain prior regulatory approval but do have to comply with other regulatory restrictions on the manufacture, importation, distribution, marketing and sale of our products. We may be unable to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market.
The approval procedure varies among countries and can involve additional testing and data review. The time required to obtain approval in non-U.S. jurisdictions may differ from that required to obtain FDA approval and could be lengthy. We may not obtain foreign regulatory approvals on a timely basis, if at all, or may choose not to implement a country’s labeling requirements if to do so would have a negative impact on our international or domestic operations. If any of our products receives FDA approval, such approvals do not ensure approval by regulatory agencies in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory agencies in other foreign countries or by the FDA. The failure to obtain any required approvals could materially harm our business.
In some jurisdictions, the entity that obtains approval from the applicable regulatory authority must be a domestic company. In those cases, we are required to rely on the distributor in such country to obtain the appropriate regulatory approvals, which subjects us to additional risks, such as their potential inability to effectively obtain and maintain required regulatory approvals. Furthermore, in the event that an exclusive distributor in a country terminates its agreement with us, it may not be able to transfer the approvals to a successor that we appoint, and we may face significant delays in our ability to import products to that country while the new distributor applies for the appropriate approvals, which it may not be able to obtain.
In the U.K., certain of Obagi products may be deemed medicinal products and therefore subject to regulation by the Medicines and Healthcare products Regulatory Agency (“MHRA”) under the medicines regime. We have not obtained a marketing authorization for such products in the U.K., however the U.K.’s Human Medicines Regulations 2012 allow for supply of medicinal products that have not been authorized for marketing to patients with special needs at the request of the healthcare professional responsible for the treatment of individual patients. Unlicensed medicines should not, however, be supplied where an equivalent licensed medicinal product can meet special needs of the patient. The responsibility for deciding whether an individual patient has “special needs,” that a licensed product cannot meet, is a matter for the healthcare professional. Examples of “special needs” include an intolerance or allergy to a particular ingredient, or an inability to ingest solid oral dosage forms. The MHRA has a wide range of enforcement powers and failure to comply with regulatory restrictions or obtain regulatory approvals if required could harm our business. If the MHRA were to decide that our products do not meet the “specials” requirements, we may need to cease supply of these products and obtain a marketing authorization in the U.K.
In addition, if foreign regulatory authorities were to ban or restrict the use of certain ingredients in cosmetic products, and we are unable to comply with the applicable requirements and regulations for those products, we may be unable to continue to market those products in that jurisdiction.
If we fail to comply with governmental regulations, we could face substantial penalties and our business, financial condition and results of operations could be adversely affected.
The healthcare industry in and outside the U.S. is heavily regulated and closely scrutinized by federal, state, local and foreign authorities. Although our offerings are not currently covered by any commercial third-party payor or government healthcare program, our business activities may nonetheless be subject to regulation and enforcement by the U.S. Department of Justice, the Department of Health and Human Services and other federal, state and foreign governmental authorities.
In addition, HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business
36

associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information, may apply to us in certain circumstances. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions.
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws and other laws can result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations and exclusion from participation in federal, state and foreign healthcare programs and imprisonment. Our failure to accurately anticipate the application of these laws and regulations to our business or any other failure to comply with regulatory requirements could create liability for us and negatively affect our business. In addition, any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business and result in adverse publicity, or otherwise result in a material adverse effect on our business, results of operations, financial condition, cash flows and/or reputation.
Legal and Regulatory Risks That Could Adversely Impact Our Milk Makeup Business
New laws, regulations, enforcement trends or changes in existing regulations governing the introduction, marketing and sale of Milk Makeup products to consumers could harm our business.
Our Milk Makeup products are subject to regulation by the FDA, the FTC, the CPSC, and comparable state, local and foreign regulatory authorities, including the European Commission, and over time, the regulatory landscape for our products has become more complex with increasingly strict requirements. There has been an increase in regulatory activity and activism in the U.S. and abroad, including the adoption of the MoCRA, which significantly expanded the FDA’s enforcement authorities over cosmetics products and imposes new obligations on the cosmetics industry, including requirements relating to cGMP, labeling, safety substantiation, facility registration and product listing with the FDA, adverse event reporting and recordkeeping, among others. Pursuant to MoCRA, the FDA promulgated several regulations relating to cosmetics that went into effect in 2024, and will also include cGMP requirements that will be finalized on December 29, 2025. As a result, the regulatory landscape for Milk Makeup products is becoming more complex with increasingly strict requirements. If this trend continues, we may find it necessary to alter some of the ways we have traditionally manufactured and marketed Milk Makeup products to stay in compliance with a changing regulatory landscape, and this could add to the costs of our operations and have an adverse impact on our business. To the extent federal, state, local or foreign regulatory changes regarding consumer protection, or the ingredients, claims or safety of our products, occurs in the future, they could require us to reformulate or discontinue certain of our products, revise the product packaging or labeling, change the manufacturers at which our products are made, or adjust operations and systems, any of which could result in, among other things, increased costs, delays in product launches, product returns or recalls and lower net sales, and therefore could have a material adverse effect on the business, financial condition and results of operations of our Milk Makeup business. Noncompliance with applicable regulations could result in enforcement action by regulatory authorities within or outside the U.S., including, but not limited to, warning letters, import restrictions, product seizures, injunctions, product recalls and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.
In the U.S., with the exception of color additives, the FDA does not currently require pre-market approval for products intended to be sold as cosmetics. However, the FDA may in the future require pre-market approval, clearance or registration/notification of cosmetic products. Moreover, such products could also be regulated as both drugs and cosmetics simultaneously, as the categories are not mutually exclusive. The statutory and regulatory requirements applicable to drugs are extensive and require significant resources and time to ensure compliance. For example, if any of our products intended to be sold as cosmetics were to be regulated as drugs, we might be required to conduct, among other things, clinical trials to demonstrate the safety and efficacy of these products. We may not have sufficient resources to conduct any required clinical trials or to ensure compliance with the manufacturing requirements applicable to drugs. If the FDA determines that any of our products intended to be sold as cosmetics should be classified and regulated as drug products and we are unable to comply with applicable drug requirements, we may be unable to continue to market those products. Any inquiry into the regulatory status of our cosmetics and any related interruption in the marketing and sale of these products could damage our reputation and image in the marketplace.
37

In recent years, the FDA has issued warning letters to several cosmetic companies alleging improper claims regarding their cosmetic products, including improper drug claims. If the FDA determines that we have made inappropriate drug claims regarding our products intended to be sold as cosmetics, we could receive a warning or untitled letter, be required to modify our product claims or take other actions to satisfy the FDA, including the recall of products from the market. In addition, plaintiffs’ lawyers have filed class action lawsuits against cosmetic companies after receipt of these types of FDA warning letters. There can be no assurance that we will not be subject to state and federal government actions or class action lawsuits, which could harm our business, financial condition and results of operations.
Our products are also subject to regulation by the CPSC in the U.S. under the provisions of the Consumer Product Safety Act, as amended by the Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban from the market consumer products that fail to comply with applicable product safety laws, regulations and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury, and may seek penalties for regulatory noncompliance under certain circumstances. The CPSC also requires manufacturers of consumer products to report certain types of information to the CPSC regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.
Our products and facilities are subject to regulation by federal and state regulators.
Our products and the facilities in which they are manufactured are generally subject to regulation under the FDCA and the FDA implementing regulations and state laws. The FDA or state authorities may inspect any or all of our CMOs’ facilities periodically to determine if such facilities comply with the FDCA and FDA regulations and state laws. In addition, our facilities for manufacturing OTC drug products must comply with the FDA’s cGMP that require our CMOs to maintain, among other things, good manufacturing processes, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.
Pursuant to MoCRA, the FDA also is required to promulgate regulations relating to cGMPs for cosmetics. In addition to cGMP requirements, cosmetic manufacturing and processing facilities are required to be registered with FDA. MoCRA also requires manufacturers and responsible persons to list their cosmetic products with FDA and to report serious adverse events associated with the use of their cosmetic products in the U.S. to the FDA. Adulterated or misbranded cosmetic products will be subject to recalls that are mandated by FDA, similar to medical devices. In addition, FDA regulations prohibit or otherwise restrict the use of certain ingredients in cosmetic products. Similar or stricter requirements may apply in foreign jurisdictions. For instance, in the EU, cosmetic products must be manufactured in compliance with good manufacturing practice and EU regulations equally prohibit or otherwise restrict the use of certain ingredients in cosmetic products, including tretinoin.
We rely on third parties to manufacture Milk products in accordance with our specifications and in compliance with applicable laws and regulations, including the MoCRA and FDA cosmetic guidelines and applicable cGMPs and other requirements for drug products. Compliance with these standards can increase the cost of manufacturing our products as we work with our vendors to assure they are qualified and in compliance. We do not have complete control over all aspects of the manufacturing process and are dependent on our contract manufacturing partners for compliance with cGMP and similar regulations. Our contract manufacturing partners may be found in violation of applicable requirements, which could have a material adverse effect on us and our business. If we or our CMOs fail to comply with these applicable standards, laws, and regulations, it could lead to customer complaints, adverse events, product withdrawal or recall, or increase the likelihood that our products are rendered adulterated or misbranded, any of which could result in negative publicity, remedial costs, or regulatory enforcement that could impact our ability to continue selling certain products.
Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.
38

12.Risks Related to Our Reputation and Threats to Our Good Standing
Damage to our reputation or brand, including through social media, or issues with product quality, efficacy, or safety, could significantly impact our business, financial condition, and operations.
Brand Reputation and Consumer Perception
The success of our business depends significantly on maintaining and enhancing the reputation and perceived uniqueness of the Milk and Obagi brands. Factors such as compliance with ethical, social, product, labor, and environmental standards are critical to preserving consumer trust. Any actual or perceived failures in these areas could damage our brand reputation and diminish consumer confidence. Additionally, low brand awareness compared to competitors and the growing importance of brand recognition in a competitive market intensify the need to protect and promote our brand image.
Challenges in Consumer Experience and Product Quality
Our ability to deliver a high-quality consumer experience, including offering innovative, effective, and competitively priced products, is vital for maintaining brand loyalty. Issues such as product contamination, safety concerns, or perceived quality failures could tarnish our reputation. Even unfounded allegations regarding product safety or effectiveness may lead to recalls, adverse publicity, or regulatory scrutiny, further eroding consumer trust. Counterfeit products in the market also pose risks to brand integrity by creating potential safety hazards and disappointing consumer expectations.
Marketing and Social Media Risks
The effectiveness of our marketing efforts directly impacts brand perception. Marketing campaigns or product initiatives that fail to resonate with consumers could harm the brand's image and hinder growth. Additionally, negative commentary, false information, or user-generated content on social media and e-commerce platforms can spread rapidly, damaging our reputation. Our reliance on social media for marketing amplifies these risks, especially as platforms and regulations evolve. Failure to comply with these evolving laws could result in legal liability, regulatory penalties, and significant costs.
Impact of Adverse Publicity
Adverse publicity, whether related to product safety, ethical concerns, or operational missteps, could severely damage our brand value. This includes consumer perceptions of irresponsible actions, product failures, or diminished quality. Negative publicity could lead to consumer boycotts, loss of market share, or a decline in sales, materially affecting our business and financial results.
Risks Associated with E-Commerce and Social Media Regulations
As we increasingly rely on digital platforms for marketing and sales, evolving laws governing these platforms introduce additional risks. Non-compliance could expose us to investigations, lawsuits, fines, or other penalties. The need to monitor and ensure compliance with applicable laws for online content, data privacy, and product claims creates further operational challenges, and any lapses could negatively impact our business.
Damage to our reputation, whether from internal missteps or external factors, could have a material adverse effect on our financial condition, operational performance, and long-term success.
13.Risks Related to Technology, E-Commerce, and Cybersecurity
We are dependent on information technology systems and infrastructure; if we, or the third parties we rely on, fail to protect sensitive information of our consumers and information technology systems against security breaches, it could damage our reputation and brand and substantially harm our business.
We rely to a large extent on our information technology systems and infrastructure, which have and may in the future experience breakdowns, malicious intrusion, and attacks. We rely on these networks and systems to market and sell our products, process electronic and financial information, assist with sales tracking and reporting, manage a variety of business processes and activities and comply with regulatory, legal and tax requirements. We are also increasingly dependent on a variety of information systems and third-party partners to effectively process consumer orders from our e-commerce websites for Obagi Skincare and Milk Makeup products. A key component of our growth strategy entails
39

expanding our e-commerce efforts both in the U.S. and internationally. Our e-commerce websites serve as an effective extension of our marketing strategies by introducing potential new consumers to our brands, product offerings, retailers and enhanced content. Due to the increasing importance of our e-commerce operations, we are vulnerable to website downtime and other technical failures. Our failure to successfully respond to these risks in a timely manner could reduce e-commerce sales and damage our brands’ reputations. We collect, maintain, transmit and store data about our customers, suppliers and others, including personal data, financial information, such as consumer payment information, as well as other confidential and proprietary information important to our business. We also frequently employ third-party service providers that collect, store, process and transmit personal data, and confidential, proprietary and financial information on our behalf, such as credit card processing vendors and logistics providers, and as a result a number of third-party vendors may or could have access to our confidential information. If our third-party service providers fail to protect their information technology systems and our confidential and proprietary information, we may experience disruptions in service and unauthorized access to our confidential or proprietary information and we could incur liability and reputational damage.
We have in place certain technical and organizational measures designed to maintain the security and safety of critical proprietary, personal, employee, customer and financial data that we continue to maintain and upgrade. However, advances in technology, the increasing ingenuity of criminals, new exposures via cryptography, acts or omissions by our employees, contractors or service providers or other events or developments could result in a compromise or breach in the security of confidential or personal data. Further, attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. We and our service providers may not be able to prevent third parties, including criminals, competitors or others, from breaking into or altering our systems, disrupting business operations or communications infrastructure through denial-of-service attacks, attempting to gain access to our systems, information or monetary funds through phishing or social engineering campaigns, installing viruses or malicious software on our e-commerce websites or mobile applications or devices used by our employees or contractors, or carrying out other activity intended to disrupt our systems or gain access to confidential or sensitive information in our or our service providers' systems. We may also face increased cybersecurity risks due to our reliance on Internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Actual or anticipated attacks have and may in the future cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees and engage third-party experts and consultants. If a material security breach were to occur, our reputation and brands could be damaged, and we could be required to expend significant capital and other resources to alleviate problems caused by such breaches, including exposure of litigation or regulatory action and a risk of loss and possible liability.
Payment methods used on our e-commerce websites subject us to third-party payment processing-related risks.
We accept payments from our consumers using a variety of methods, including online payments with credit cards and debit cards issued by major banks, payments made with gift cards processed by third-party providers and payment through third-party online payment platforms such as Afterpay. We also rely on third parties to provide payment processing services. For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise our operating costs and lower our profit margins. We may also be subject to fraud and other illegal activities in connection with the various payment methods we offer, including online payment options and gift cards. Transactions on our e-commerce websites and mobile applications are card-not-present transactions, so they present a greater risk of fraud. Criminals are using increasingly sophisticated methods to engage in illegal activities such as unauthorized use of credit or debit cards and bank account information. Requirements relating to consumer authentication and fraud detection with respect to online sales are complex. We may ultimately be held liable for the unauthorized use of a cardholder's card number in an illegal activity and be required by card issuers to pay charge-back fees. Chargebacks result not only in our loss of fees earned with respect to the payment, but also leave us liable for the underlying money transfer amount. If our chargeback rate becomes excessive, card associations also may require us to pay fines or refuse to process our transactions. In addition, we may be subject to additional fraud risk if third-party service providers or our employees fraudulently use consumer information for their own gain or facilitate the fraudulent use of such information. Overall, we may have little recourse if we process a criminally fraudulent transaction.
40

14.Risks Related to Taxation in an International Environment
Any disparity between the U.S. corporate tax rate and the U.S. tax rate applicable to non-corporate Members of Waldencast LP may complicate our ability to maintain its intended capital structure, which could impose transaction costs on it and require management attention.
Waldencast LP is treated as a partnership for U.S. federal income tax purposes and, as such, generally is not subject to U.S. federal income tax. Instead, its taxable income is generally allocated to its members, including Holdco 1. If and when Waldencast LP generates taxable income, it will generally make cash distributions, or tax distributions, to each of its members, including Holdco 1, based on each member's allocable share of net taxable income (calculated under certain assumptions) multiplied by an assumed tax rate. The assumed tax rate for this purpose will be the highest effective marginal combined federal, state, and local income tax rate applicable to an individual or corporate member (whichever is higher). In the event of any disparity between the tax rates applicable to corporate and non-corporate taxpayers, Holdco 1 could receive tax distributions from Waldencast LP in excess of its actual tax liability, which could result in it accumulating cash in excess of its tax liability. This would complicate our ability to maintain certain aspects of our capital structure. Such cash, if retained, could cause the value of a Waldencast LP Unit to deviate from the value of a Class A ordinary share. In addition, such cash, if used to purchase additional Waldencast LP Units, could result in deviation from the one-to-one relationship between our Class A ordinary shares outstanding and Waldencast LP Units unless a corresponding number of additional Class A ordinary shares are distributed as a stock dividend. We may, if permitted under our debt agreements, choose to pay dividends to all holders of our Class A ordinary shares with any excess cash. These considerations could have unintended impacts on the pricing of our Class A ordinary shares and may impose transaction costs and require management efforts to address on a recurring basis. To the extent that we do not distribute such excess cash as dividends on our Class A ordinary shares and instead, for example, hold such cash balances or lend them to Waldencast LP, holders of Waldencast LP Units during a period in which we hold such cash balances could benefit from the value attributable to such cash balances as a result of redeeming or exchanging their Waldencast LP Units and obtaining ownership of our Class A ordinary shares (or a cash payment based on the value of our Class A ordinary shares). In such case, these holders of Waldencast LP Units could receive disproportionate value for their Waldencast LP Units exchanged during this time frame.
Failure to comply with applicable transfer pricing and similar regulations could harm our business and financial results.
In many countries, including the U.S., we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned in each jurisdiction and are taxed accordingly. Although we believe that we are in substantial compliance with all applicable regulations and restrictions, we are subject to the risk that governmental authorities could audit our transfer pricing and related practices and assert that additional taxes are owed. In the event that the audits or assessments are concluded adversely to us, we may or may not be able to offset or mitigate the consolidated effect.
We may be a passive foreign investment company (“PFIC”), which could result in adverse U.S. federal income tax consequences to U.S. Holders.
If we are a PFIC for any taxable year, or portion thereof, that is included in the holding period of a U.S. Holder (as defined herein), such U.S. Holder may be subject to certain adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. We are not expected to be treated as a PFIC for the taxable year ending on December 31, 2024, or the foreseeable future. However, the facts on which any determination of PFIC status are based may not be known until the close of each taxable year in question. Additionally, there is uncertainty regarding the application of the start-up exception.
We may be treated as a corporation resident in the U.S. for U.S. federal income tax purposes.
A corporation is generally considered a tax resident in the jurisdiction of its organization or incorporation in the absence of information to the contrary. As a corporation incorporated under the laws of Jersey, and from October 29, 2024, a tax resident in the United Kingdom with associated governance protocols, we should generally be classified as a non-U.S. corporation (and therefore as a non-U.S. tax resident) for U.S. federal income tax purposes. In certain circumstances, however, under section 7874 of the Code, a corporation organized outside the U.S. will be treated as a U.S. corporation (and, therefore, as a U.S. tax resident).
41

Based on the rules in effect currently, we do not expect to be treated as a U.S. corporation for U.S. federal income tax purposes by virtue of section 7874. Nevertheless, because the section 7874 rules and exceptions are complex, subject to factual and legal uncertainties, and may change in the future (possibly with retroactive effect), there can be no assurance that we will not be treated as a U.S. corporation for U.S. federal income tax purposes. In addition, it is possible that a future acquisition of the stock or assets of a U.S. corporation could result in our being treated as a U.S. corporation.
We operate as a Jersey incorporated, and effective October 29, 2024, United Kingdom resident company, but the tax authorities of other jurisdictions may treat us as also being a resident of, or as having a taxable presence in, another jurisdiction for tax purposes.
Our residence for tax purposes (including, for the avoidance of doubt, withholding tax and tax treaty eligibility purposes) was exclusively in Jersey for the period until October 29, 2024 and the United Kingdom in the period thereafter on account of the company moving its place of central management and control. We have no taxable presence in the form of a fixed place of business or permanent establishment in any other jurisdiction and have protocols in place such that we were exclusively resident in Jersey until October 29, 2024 and exclusively resident in the United Kingdom after this date.
However, the determination of our tax residence, which primarily depends as mentioned upon our place of effective management, as well as the characterization of fixed places of business or permanent establishments outside our jurisdiction of incorporation, are questions of fact based on all circumstances. Because such determinations are highly fact-sensitive, no assurance can be given regarding their outcome.
A failure to maintain exclusive tax residence could result in significant adverse tax consequences for shareholders. The impact of this risk would differ based on the views taken by each relevant tax authority and in respect of the taxation of shareholders on their specific situation.
Changes in tax law could significantly affect our reported earnings and cashflows.
We have business operations and assets in different jurisdictions, which are subject to different tax regimes. Changes in tax regimes, such as the reduction or elimination of tax benefits, or limitations on the deductibility of interest expense, could have a material adverse effect on our results and cash flows.

Whilst in the current period the OECD/G20 “Two Pillars Solution”, which broadly provides an effective global minimum tax rate of 15% on profits generated by multinational companies with consolidated revenues of at least €750 million, was not considered to be relevant to the company it may in the future have application and have a negative impact on our financial condition, results of operations and cash flows.
Changes in international trade, namely in relation to global customs duties and indirect taxes could significantly affect our reported earnings and cashflows.
Waldencast and its associated brands operate in a globally regulated industry with its supply chain and distribution channels operating across borders. Changes in trade policies, customs duties, VAT/GST and other indirect taxes could impact our cost structure and operational efficiency. Shifts in global trade policy may lead to changes in tariff rates, trade agreements, or enforcement priorities, affecting our imports and exports. Additionally, evolving regulations on product classification, sustainability requirements, and ethical sourcing—such as restrictions on certain ingredients or increased compliance with supply chain due diligence—could introduce additional costs and complexities. While we continuously monitor and adapt to regulatory changes, unexpected shifts in tax laws, trade policies, or customs enforcement could materially impact our financial performance and global supply chain.
ITEM 4. INFORMATION ON THE COMPANY
A.History and Development of the Company
Waldencast was a blank check company that was incorporated on December 8, 2020 as Waldencast Acquisition Corp., a Cayman Islands exempted company. In connection with the Business Combination, on July 26, 2022, with the approval of the Company’s shareholders, and in accordance with the Cayman Companies Act (the “Cayman Act”), the Jersey Companies Law and the Company’s Constitutional Document, the Company’s jurisdiction of incorporation was changed from the Cayman Islands to Jersey and its name changed to Waldencast (the “Domestication”). As a result of the Domestication, (i) each then issued and outstanding Waldencast Acquisition Corp. Class A ordinary share was converted automatically, on a one-for-one basis, into a Class A ordinary share of Waldencast, (ii) each then issued and outstanding
42

Waldencast Acquisition Corp. Class B ordinary share was converted automatically, on a one-for-one basis, into a Class A ordinary share of Waldencast, (iii) each then issued and outstanding Waldencast Acquisition Corp. warrant was converted automatically into a warrant to purchase Class A ordinary shares of Waldencast and (iv) each then issued and outstanding Waldencast Acquisition Corp. Unit was canceled and the holders thereof were entitled to one Class A ordinary share of Waldencast and one-third of one warrant.
On the Closing Date, pursuant to the Obagi Merger Agreement, Merger Sub merged with and into Obagi, with Obagi surviving as an indirect subsidiary of Waldencast LP. In addition, on the Closing Date, pursuant to the Milk Purchase Agreement, Waldencast LP acquired from the Milk Members all of their equity in Milk in exchange for cash, Waldencast LP common units (“Waldencast LP Units”) and Waldencast Class B ordinary shares, which are non-economic voting shares. The Waldencast LP Units are redeemable at the option of the holder of such units into an equal number of Waldencast Class A ordinary shares or cash, at the sole discretion of Waldencast. The equity interests of Obagi and Milk are held by Waldencast LP. We, in turn, hold our interests in Obagi Medical and Milk Makeup through Waldencast LP and Holdco 1. As a result of the Business Combination, we are organized as an “Up-C” structure, whereby the Milk Members retain a direct equity ownership in Waldencast LP, an entity that is classified as a partnership for U.S. federal income tax purposes, in the form of their Waldencast LP Units. The material terms of the Business Combination are described in “Item 10. Additional Information—C. Material Contracts” of this Report. See “Item 5B. Operating and Financial Review and Prospects - Liquidity and Capital Resources” for information regarding historical capital expenditures and planned future capital expenditures.
Each holder of a Class A ordinary share (a “Public Share”) was entitled to redeem such share in connection with the consummation of the Business Combination for a pro rata portion of the cash then on deposit in the trust account created in connection with our IPO. Such pro rata portion was calculated as of two business days prior to the consummation of the Business Combination including interest earned on the funds held in the trust account and not previously released to us (net of taxes payable). A total of 30,021,946 Public Shares were redeemed in connection with the Business Combination.
The Company’s legal and commercial name is “Waldencast plc.” Waldencast’s registered office is 2nd Floor Sir Walter Raleigh House, 48-50 Esplanade, St. Helier, Jersey JE2 3QB, and its principal executive office is 81 Fulham Road, London, SW3 6RD, United Kingdom, and its telephone number is +44 (0)20 3196 0264.
The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC which is accessible at http://www.sec.gov. Since Waldencast is a “foreign private issuer,” it is exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and its officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions contained in Section 16 of the Exchange Act with respect to their purchase and sale of our shares. In addition, we are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. public companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC an Annual Report on Form 20-F containing financial statements audited by an independent accounting firm.
Waldencast’s principal website address is www.waldencast.com. The information contained on Waldencast’s website does not form a part of, and is not incorporated by reference into, this Report.
B.Business Overview
Unless the context otherwise requires, all references in this section to “we,” “our,” “us,” the “Company,” or “Waldencast” generally refer to Waldencast plc.
General
Founded by Michel Brousset and Hind Sebti, our ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Our vision is fundamentally underpinned by our brand-led business model that ensures proximity to our customers, business agility and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing our vision was the Business Combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, our brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands.
43

Properties
The Company leases the following properties:
Location
Principal use(s)
Floor space (approximate square footage)
Expiration date
London, United KingdomOffice1,500
August 2025
Long Beach, CaliforniaOffice28,300
May 2026
The Woodlands, TexasWe have entered into a sublease for this office space that will run through December 2025. 16,500
January 2033
Conroe, Texas
We have entered into a sublease for this warehouse and office space that will run through February 2032.
35,000 square feet of warehouse space and 4,200 square feet of office space.
February 2032
New York, New YorkOffice and in-house studio17,500
November 2030
Los Angeles, CaliforniaOffice and in-house studio1,500
Sublease from Milk Studios Los Angeles LLC on a month-to-month basis for a fee of $0.015 million per month
We consider our current office spaces adequate for our current operations.
Employees
We currently have 3 executive officers and 332 full-time employees across the Waldencast group. As of December 31, 2024, Obagi Medical had 174 employees and all non-unionized. As of December 31, 2024, Milk Makeup had 142 full-time employees and all non-unionized. We believe our relations with our employees are good.
Principal Markets
Please refer to “Item 8. Financial Information—Note 4. Revenue” for a description of the principal markets in which the Company operates.
Legal Proceedings
We are not involved in any material litigation nor, to management’s knowledge, was any material litigation threatened against us, which if adversely determined could have a material adverse effect on the Company, except as described below.
SEC Investigation
As previously disclosed, we proactively and voluntarily self-reported our review of the historical accounting used by Obagi Medical to the SEC. In connection with this matter, we received a document subpoena in September 2023. Although we are fully cooperating with the SEC’s investigation and continue to respond to requests related to this matter, we cannot predict when such matters will be completed or the outcome or potential impact of this matter on our business, investor confidence, or the price of our securities. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, which may be imposed on us in connection with this matter could have a material adverse effect on our business, financial condition and results of operations. Additionally, the investigation has resulted in substantial costs and is likely to continue to incur substantial costs, regardless of the outcome of the investigation.
44

Emerging Growth Company
We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with certain other public companies difficult or impossible because of the potential differences in accounting standards used.
We will remain an emerging growth company until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1,235.0 million or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700.0 million as of the end of the prior fiscal year’s second fiscal quarter; and (2) the date on which we have issued more than $1,000 million in non-convertible debt securities during the prior three-year period. References herein to “emerging growth company” shall have the meaning associated with it in the JOBS Act.
Foreign Private Issuer
We are a “foreign private issuer” under SEC rules and will report under the Exchange Act as a non-U.S. company with “foreign private issuer” status and will be subject to the reporting requirements under the Exchange Act applicable to foreign private issuers. This means that, even after we no longer qualify as an “emerging growth company,” as long as we qualify as a “foreign private issuer” under the Exchange Act, we will be exempt from certain provisions of and intend to take advantage of certain exemptions from the Exchange Act that are applicable to U.S. public companies. Such exemptions include the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act and the sections of the Exchange Act requiring insiders to file public reports of their stock ownership.
Additionally, we will not be required to file our annual report on Form 20-F until 120 days after the end of each fiscal year and we will furnish reports on Form 6-K to the SEC regarding certain information required to be publicly disclosed by us in Jersey or that is distributed or required to be distributed by us to our shareholders. Further, based on our foreign private issuer status, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as a U.S. company whose securities are registered under the Exchange Act. We will also not be required to comply with Regulation FD, which addresses certain restrictions on the selective disclosure of material information. In addition, among other matters, our officers, directors and principal shareholders will be exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Class A ordinary shares.
We may take advantage of these reporting exemptions until such time as we are no longer a “foreign private issuer.” We could lose our status as a “foreign private issuer” under current SEC rules and regulations if more than 50% of our outstanding voting securities become directly or indirectly held of record by U.S. Holders and any one of the following is true: (i) the majority of our directors or executive officers are U.S. citizens or residents; (ii) more than 50% of our assets are located in the U.S.; or (iii) our business is administered principally in the U.S.
We may choose to take advantage of some but not all of these reduced burdens. We have taken advantage of reduced reporting requirements in this Report. Accordingly, the information contained in this Report may be different from the information you receive from our competitors that are public companies, or other public companies in which you have
45

made an investment. See “Item 3. Key Information—Risk Factors—Risks Related to SEC and Nasdaq Compliance, Securities Issuances, Share Price Volatility and Limitations on Investor Rights—As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of the ordinary shares.
Our Professional Skincare Segment: Obagi Medical
Our professional skincare segment consists of the Obagi Medical business. Unless the context otherwise requires, all references in this section to “Obagi,” “we,” “us,” “our” and the “company” refer to the business of Obagi Medical and its subsidiaries.
Overview
Acquired through the Business Combination in July 2022, Obagi Medical originates in science and is backed by over 35 years of clinical research leveraging cutting-edge technologies and pharma-grade ingredients that deliver transformative, visible results for all skin concerns, skin types, and skin tones. The product portfolio is formulated to address the most common, visible skin concerns such as fine lines and wrinkles, elasticity, photodamage, hyperpigmentation (spots or patches of skin that are darker than surrounding areas of skin), acne, oxidative stress, environmental damage, and dehydration. Our portfolio today includes over 125 cosmetic, OTC, and prescription products, sold in over 80 countries around the world. Our hydroquinone (“HQ”) based prescription products, have not been approved by the FDA or other similar regulatory authorities.
Our core distribution is through the physician-dispensed channel, with a large account base consisting of more than 4,000 active medical provider accounts in the United States as of December 2024, resulting in broad distribution of Obagi products. Physicians’ offices includes dermatologists, plastic surgeons, medical spas, and other physicians and licensed medical professionals who buy our products and then dispense the products in-office directly to their patients. Additionally, we also sell our OTC and cosmetic products directly to consumers (“DTC”) via our website and through other e-commerce channels.
Obagi Medical
As pioneers of medical-grade skincare, we transformed the industry with a commitment to unmatched safety & efficacy standards performing up to 10 tests every innovation, 345+ studies conducted, and over 7,000+ participants involved. None of these studies have been used to support an application for marketing approval with the FDA or other similar regulatory authority. Consequently, they were not designed to fulfill the specific requirements of such regulatory application process and should not be viewed as a substitute for clinical trials that would be conducted in connection with the application to the FDA or similar regulatory authority. We have also amassed over 70 global patents on product and technology innovations as well as partnered with over 40+ R&D partners, which we believe sets us apart from our competitors and furthers our commitment to science. Although a number of these patents will expire over the coming years, we do not believe the expiration of such patents will have a material effect on our business or results of operations because the formulations for the products covered by such patents are still treated as trade secrets, which are known only by a limited number of need-to-know employees, CMOs of the products who are bound by strict confidentiality provisions, and regulatory authorities as required.
Obagi Medical is anchored by the Obagi Nu-Derm® System, setting the foundation for transformative medical-grade skincare and which we believe is the leading prescription-based topical skin health system on the market. The Obagi Nu-Derm System and related products accounted for a significant portion of the total products shipped in year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period). Sales of Obagi Nu-Derm products experience seasonality. We believe this is due to variability in patient compliance that relates to several factors such as a tendency to travel and/or engage in other disruptive activities during the summer months. While we have earned a strong reputation for offering premier hyperpigmentation solutions, our portfolio has expanded over time to include a line of Vitamin C powered antioxidant products, our Obagi Professional-C® line, as well as the ELASTIderm® line, which leverages our patented Bi-Mineral Contour Complex™ technology to address elasticity and firmness in the skin. Other products within the comprehensive Obagi Medical franchise include products to address hydration, sun protection, and acne. These solutions incorporate a range of individual prescription and non-prescription therapeutic agents, as well as cosmetic ingredients to address the needs of consumers who seek advanced skincare in a customized skincare regimen designed by a professional.
46

As we look ahead, our growth strategy continues to be:
1.Double down on our brand DNA
2.Accelerate cutting-edge, science-backed innovation
3.Grow brand awareness and footprint
Certain of our products, including Nu-Derm® Clear, Blender and Sunfader, as well as the Obagi-C® Rx C-Clarifying Serum and C-Night Therapy Cream, which are part of the Obagi-C® Rx System, contain 4% HQ. These products are marketed as prescription-only drugs, however, we have not sought nor obtained the required premarket approval from the FDA to market these products in the U.S. The FDA has historically utilized a risk-based enforcement approach with respect to drugs marketed without approval in accordance with its active CPG, issued in 2006 and subsequently amended in 2011, in which the FDA announced a drug safety initiative to remove unapproved drugs from the market and established enforcement priorities and a policy of enforcement discretion with respect to marketed unapproved products. While the FDA has expressed its view that all prescription HQ products should be reviewed and approved by the FDA, we believe our prescription-only HQ products do not fall within the previously established categories of unapproved drugs for which the FDA has indicated it prioritizes enforcement. We have not received any communications from the FDA or any similar regulatory authorities regarding our Nu-Derm HQ or any other products. However, whether due to safety concerns or otherwise, in the future the FDA may choose to pursue an enforcement action against us and determine that our HQ products should be removed from the market until we obtain approval of a NDA. For example, although our prescription-only HQ products are made with 4% HQ, the FDA has historically expressed concerns regarding the safety of 2% HQ products, sold on an OTC basis. In particular, in August 2006, the FDA issued a proposed rule that cited certain preclinical evidence suggesting that HQ may be carcinogenic, if orally administered, and may be related to a skin condition called ochronosis, which results in the darkening and thickening of the skin, and the appearance of small bumps and grayish-brown spots, after continued use of concentrations as low as 1 to 2 percent. The FDA also concluded that it could not rule out the potential carcinogenic risk from topically applied HQ, and classified OTC skin-bleaching drug products, including HQ, as not GRASE, as misbranded, and as new drugs within the meaning of the FDCA, meaning that such products would need to be approved through the NDA process in order to be legally marketed in the U.S. Although this proposed rule was never finalized, in March 2020 the CARES Act was enacted, which among other things deemed any OTC drugs that were identified as not GRASE in the FDA’s most recent proposed rulemaking for such OTC drugs to be “new drugs” and misbranded within the meaning of the FDCA, meaning that such drugs could not be marketed without an approved drug application as of September 23, 2020. As a result, products containing HQ are prohibited from being marketed in the U.S. as OTC drug products without an approved NDA. Subsequently, on April 19, 2022, the FDA announced that it had issued warning letters to 12 companies for continuing to sell 2% HQ products on an OTC basis, citing violations of the applicable CARES Act provisions. Furthermore, in June and July of 2022, the FDA issued warning letters to two other manufacturers of products containing HQ.
The FDA’s announcement also cited reports describing serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling, and skin discoloration. The FDA’s safety concerns regarding these lower-concentration OTC HQ products could prompt the FDA to assert that our higher-concentration, prescription-only HQ products represent a higher priority for enforcement pursuant to the active CPG. In many countries, including the EU, Canada, Australia and Japan, HQ is regulated as a drug and requires a prescription. We have not sought nor obtained regulatory approval to distribute our HQ products in these countries, and instead offer our Nu-Derm Fx and Obagi-C Fx solutions, which contain the skin brightening agent arbutin, for these markets. In the EU, the European Commission has expressed concerns on the potential use of (alpha and beta) arbutin in cosmetic products and this has led to additional consultation with the SCCS (Scientific Committee on Consumer Safety), further to which a call for data was launched which ended in April 2021. In January 2023, the SCCS issued its final opinion on the safety of alpha arbutin and beta arbutin in cosmetic products. The main conclusions in this opinion were that: (i) that alpha-arbutin used in face creams up to a maximum concentration of 2% and in body lotions up to a concentration of 0.5% is safe, also when used together; (ii) beta-arbutin used in face creams up to a maximum concentration of 7% is safe; (iii) HQ should remain as low as possible in formulations containing alpha-or beta-arbutin and should not be higher than the unavoidable traces in both arbutins, and (iv) aggregate exposure of alpha-arbutin (2% in face cream and 0.5% in body lotion) with beta-arbutin (7% in face cream) are considered safe. No amendments were made to the EU Cosmetics Regulation prohibiting or restricting the use of alpha- and/or beta-arbutin following this final opinion. In addition, Obagi’s arbutin products are permitted to be sold in the Asia-Pacific region countries in which Obagi distributes such products. See “Item 3. Key Information—D. Risk Factors—Risks Related to Our Obagi Medical Business—Obagi Regulatory Risks—Legal and Regulatory Risks That Could Adversely Impact Our Obagi Skincare Business.”
47

Obagi Clinical
Our Obagi Clinical line, launched in December 2018, was designed to meet the needs of “skin-tellectual” consumers who may not yet regularly visit a dermatologist or skincare professional. The product line was primarily targeted for Southeast Asian markets. In connection with the restructuring of Obagi Medical’s business in Southeast Asia, in 2023, the Company decided to discontinue the Obagi Clinical range and focus on selling the flagship Obagi Medical range in the region.
Obagi Medical Science
Innovative Research and Development
Over the course of our over 35-year legacy, Obagi Medical has amassed a robust global portfolio of registered patents on product and technology innovations, which we believe sets us apart from our competitors. Although a number of our patents will expire over the next five years, we do not believe the expiration of such patents will have a material effect on our business or results of operations because the formulations for the products covered by such patents are still treated as trade secrets, which are known only by a limited number of need-to-know employees, CMOs of the products who are bound by strict confidentiality provisions, and regulatory authorities as required.
Research and Development (R&D) Program
Our R&D program aims to design products and execute studies that demonstrate the high-quality design of our formulas and powerful performance of our products. We apply a scientific approach to all of our products, from inception to development and testing. After formulation, all of our products are tested for integrity, safety, and performance.
Bausch Health, the manufacturer of our tretinoin products, holds an ANDA for such products, meaning the FDA has found such products to be bioequivalent to other tretinoin products approved through the NDA process. To approve a NDA for a product, the FDA generally requires applicants to demonstrate the safety and efficacy of the product through successful completion of well-controlled clinical trials usually employing several hundred to a few thousand subjects. None of our other products are distributed under a NDA or ANDA approved by the FDA. However, the FDA may require us to conduct well-controlled clinical trials to establish the safety and efficacy of our prescription strength HQ products and to obtain a NDA to continue marketing our HQ products. Nonetheless, we do conduct thorough testing of all of products, whether they are cosmetics, OTC drugs, or prescription-strength products, to evaluate their safety and performance. Prior to launch, our products undergo several safety tests, including, but not limited to, human repeat insult patch tests, used to help predict the likelihood for induced allergic contact dermatitis, comedogenicity tests, to ensure the product does not clog pores, and cumulative irritation tests. In addition to these safety and tolerability studies, we have conducted more than 30 studies with the leading academic institutions and key independent experts in dermatology and aesthetic medicine for our products. None of these studies have been used to support an application for marketing approval with the FDA or other similar regulatory authority. Consequently, they were not designed to fulfill the specific requirements of such regulatory application process and should not be viewed as a substitute for clinical trials that would be conducted in connection with the application to the FDA or similar regulatory authority.
Sales and Marketing
Domestic
In the U.S., we sell our Obagi Medical systems and related products to physicians, including physicians on site at medical spas, through our direct sales force. The licensed medical professionals we sell to then dispense our products in-office, directly to their patients, a distribution method commonly referred to as the “physician-dispensed” channel.
All of the Obagi Medical products for the physician-dispensed channel are sold through the Physician Channel Provider, which purchases products from us to maintain a sufficient inventory for this channel and operates and manages the ordering portal for our physician customers, receives and fulfills orders, and provides customer service functions (including call center services), processes product returns, runs customer credit checks, and offers invoicing, and collection, accounts receivable and chargeback services. Although the Physician Channel Provider is considered to be our customer as they purchase products from us for physicians and customers who purchase products from us on our e-commerce platform, we maintain control of the product inventory in their warehouse and manage the relationship with the end customer until immediately prior to their sale and do not recognize revenue for sales to the Physician Channel Provider until sell through
48

to the end customer. See “Item 5. Waldencast’s Operating and Financial Review and Prospects” for more information on the recognition of revenue from the Physician Channel Provider.
We also sell products to consumers via e-commerce platforms through www.obagi.com and www.amazon.com, as well as a number of other authorized e-retailers and distributors. We intend to continue to develop these sales channels to grow our brand awareness and footprint.
The North American market accounted for the majority of our net revenue for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period), respectively.
International
International markets accounted for a significant portion of our net revenue for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) respectively. We address international markets through 36 international distribution partners that have sales and marketing activities in over 82 countries outside of the U.S., and a trademark and know-how license agreement and a license distribution agreement for the retail drug store channel in Japan. We target distribution partners who are capable and willing to mirror our sales and distribution model in the U.S. and who have an established business and reputation with physicians. The products that we sell internationally are generally the same formulations as those sold in the U.S.; however, in some instances, formulations have been modified to comply with the regulatory requirements of certain countries, particularly in the U.K., Europe and Asia. These distributors use a model similar to our business model in the U.S., addressing their territories through direct sales representatives who sell to physicians, or through alternative distribution channels, depending on regulatory requirements and industry practices. Our distribution agreements typically grant distributors the right to distribute and sell our products to licensed medical professionals and skincare clinics within a specified territory, require them to purchase a specified minimum amount of our products each year, and have a term of two to five years.
Similar to our domestic sales channels, we intend to increasingly develop our online and e-commerce distribution channels and generally reserve the rights to distribute our products through other channels and e-commerce in such territories.
Although we have a broad base of international distributors, our SA Distributor historically accounted for a significant portion of Obagi Medical’s net revenue for the period from July 28, 2022 to December 31, 2022 and the period from January 1, 2022 to July 27, 2022 (Predecessor Period). See “Item 5. Waldencast’s Operating and Financial Review and Prospects” for more information regarding net revenue from Obagi Medical’s SA Distributor. Obagi Medical’s agreement with the SA Distributor granted the SA Distributor a non-exclusive right to distribute our products in Vietnam and South Korea, contained minimum purchase requirements and had a term that expired on December 31, 2026.
In March 2023, as part of our strategy to internalize distribution channels in key markets, certain of Obagi’s subsidiaries entered into and consummated a Purchase Agreement (the “Vietnam Purchase Agreement”) with Obagi Vietnam and the Company’s Southeast Asia Distributor (“SA Distributor”), pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, an indirect subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve months ending December 31, 2026, subject to setoff for any owed obligations. The acquisition was determined to be an asset acquisition with the primary asset being the recovery of $1.6 million of inventory held by the SA Distributor. Further, the Company concluded that it was unlikely that the earnout projections were going to be attained and therefore did not record an earnout liability. Due to non-performance by the SA Distributor of its obligations pursuant to the Vietnam Purchase Agreement and certain other matters, we took further steps in 2023 to restructure the business of Obagi Vietnam by hiring a new local management, finance and sales team to replace the previous SA Distributor team, entering into new on line and off line distribution agreements with reputable partners and re-applying for all product registrations, which were obtained in June 2023. In June 2024, Obagi entered into a Settlement and Release Agreement with the SA Distributor, which, among other things, extinguished the SA Distributor’s right to receive an earnout and the SA Distributor’s 40% interest in the outstanding equity of Obagi Blue Sea Holding, LLC.
We intend to continue expanding our international presence in key locations, such as Asia, Europe and South America, by entering into strategic relationships or building our own distribution structure. We believe that there is potential for
49

significant sales growth of our products in international markets, particularly in Southeast Asia, Europe and Brazil, due to cultural emphasis on overall skin health and appearance, and the continued development and acceptance of surgical and non-surgical cosmetic procedures throughout many countries of the world.
Licensing
In Japan, we built an alternative model to build a presence and brand awareness for our products. We entered into a Trademark and Know-How License Agreement with Rohto to market and sell products in Japan using the Obagi brand name. Under our current agreement, Rohto is licensed to manufacture and sell a series of OTC and cosmetic products developed by it under the Obagi brand name in the Japanese drug store channel, for which it pays us a license fee. In 2008, we expanded that relationship to provide for collaboration on the development of new products and to pursue the higher end department store channel in Japan.
Concurrently with the Business Combination, on the Closing Date we entered into an Intellectual Property License Agreement (the “IP License Agreement”) and Global Supply Services Agreement (the “Supply Agreement”) with Obagi Hong Kong Limited, a subsidiary of Cedarwalk Skincare Ltd. (“Obagi Hong Kong”) for the sale of Obagi Medical products throughout the China Region. Under these agreements, we will supply, or cause to be supplied through certain CMOs (as defined in the Supply Agreement), Obagi Medical products to Obagi Hong Kong and its affiliates, and Obagi Hong Kong will purchase such products, with the exclusive right to distribute and sell such products in the China Region. In return, Obagi Hong Kong will pay us a royalty of five and a half percent (5.5%) of gross sales of licensed products, subject to certain deductions. See “Item 7. Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” for a description of these related party transactions.
Competition
The market for aesthetic and therapeutic skin health products is highly competitive and we expect the intensity of competition to increase in the future. We also expect to encounter increased competition as we enter new markets and/or distribution channels, attempt to penetrate existing markets with new products and expand into new distribution channels.
Manufacturing
We currently outsource all our product manufacturing to third-party CMOs. We have two or more qualified CMOs for some of our key products, however, certain products are currently supplied by a single source. The termination of our agreement with a single source supplier or any loss or disruption of services under such agreement could be difficult for us to replace upon the same favorable terms. The transfer of technology required to begin using a new CMO is also a lengthy process, which can take six to 18 months to achieve. We believe our manufacturing processes provide us with a competitive advantage, which we have developed through years of experience formulating skin care products. For all of our proprietary product concepts, we believe we own the related manufacturing processes, methods, and formulations.
In the U.S., we use FDA-compliant CMOs who specialize in the manufacture of prescription and OTC pharmaceutical and/or cosmetic products. The CMOs manufacture products pursuant to our specifications. All of our CMOs are required by law to comply with cGMPs. We require all CMOs with whom we have agreements to represent and warrant to us that the products they produce for us are made in accordance with cGMPs, including documentation, recordkeeping, building and facility design, equipment maintenance and personnel requirements. We pre-qualify and continually monitor our CMOs for quality and compliance. We also require documentation of compliance and quality from those CMOs for whom we act as representative in connection with the promotion and sale of their products.
Bausch Health, which formerly owned the business of Obagi Medical, is our only supplier and manufacturer of tretinoin. We have a contract with Bausch Health that has an initial termination date in 2027. While there are several other manufacturers of generic tretinoin, the termination of this agreement or any loss of services under the agreement could be difficult for us to replace upon the same or similarly favorable terms.
Intellectual Property
The design of our systems and products is generally proprietary to us, and we hold patents worldwide for the composition of many of these products. Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent
50

others from infringing our proprietary rights. We also rely on trade secrets, trade dress, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.
We have pursued an aggressive trademark registration policy aimed at achieving brand recognition and product differentiation in the market. We have also acquired rights to market, distribute, sell and, in some cases, make products pursuant to license agreements with other third parties that grant us the right to use the product formulas, trademarks and other trade secrets; these agreements do not include products that have underlying patents.
Our “Clean” Makeup Segment: Milk
Our “clean” Makeup Segment consists of the Milk Makeup business. Unless the context otherwise requires, all references in this section to “we,” “our,” “us,” the “company,” or “Milk Makeup” generally refer to Milk and its consolidated subsidiaries.
Milk Makeup’s Dream and Mission
Company Overview
Milk Makeup was launched in 2016 with the goal of building a global movement to challenge and broaden the definition of beauty. Milk Makeup is a leading, award-winning clean prestige makeup brand with unique products, a strong following among Gen-Z and Gen-Alpha consumers and an emerging global presence. We believe that our ability to authentically connect with culture while developing unique, effective and easy to use products that are also 100% vegan, clean and cruelty-free sets us apart from other brands
The brand is currently distributed online via www.milkmakeup.com, in omni-channel retail through Sephora (in the U.S. (including Sephora at Kohl’s), Canada, EU, Middle East, India, and Australia), and on Amazon (in the U.S., Canada, United Kingdom, and Germany). In the U.K., the brand is distributed at Sephora, Space NK and online at Cult Beauty and ASOS.
Our plan is to continuously renew relevance with our younger core demographic while expanding into more mature demographics, who tend to have higher disposable income, through awareness building and product storytelling. This will create strong future growth potential for the brand.
Product Overview
Milk Makeup offers an portfolio of over 250 makeup and skincare SKUs. We currently have bestselling products at Sephora in the U.S. in the primer, blush, and setting spray categories with our Hydro Grip Primer, Hydro Grip Set & Refresh Spray, Cooling Water Jelly Tint, and Lip + Cheek. We also have strong positions in the bronzer category with Matte Bronzer, mascara category with Kush Mascara and brow category with Kush Brow, showcasing the versatility of the brand. We currently have offerings in the foundation and concealer categories as well as liner, eyeshadow and lip color. We also believe that we can expand further into other beauty categories such as skincare, haircare, bath/shower and fragrance.
Sales and Distribution Strategy
Milk Makeup has had a strong exclusive relationship with Sephora covering most markets, including the U.S., Canada, Europe, the Middle East, India, Australia, and New Zealand. Selling through Sephora has also allowed us to internationalize efficiently due to the synergies within the Sephora ecosystem in terms of common management, terms, and merchandising. For the year ended December 31, 2024 and December 31, 2023, Milk Makeup’s international retail revenue accounted for a substantial portion of its total net revenue. Milk Makeup has entered into distribution or vendor agreements with Sephora North America, Sephora Canada, Sephora Middle East and Sephora Australia and New Zealand. Pursuant to those agreements, we grant Sephora the exclusive right to import and distribute our selected products within the territories described in the agreements. In addition, those agreements contain a term of exclusivity of up to three years, which can be automatically renewed by either party. Each of these agreements can be terminated without penalty by either party by giving advance written notice to the other party. None of our agreements with Sephora contain any minimum purchase requirements. In early 2023, Milk entered into new amendments with respect to the Sephora agreements that updated certain terms and extended the exclusivity of the Milk brand with Sephora through 2024 in certain of the above regions.
51

As of December 2024, Milk Makeup was present in approximately 1,430 Sephora locations in the U.S. and 100 in Canada, including Sephora inside JCPenney and Sephora at Kohl’s locations. In Europe, Milk Makeup was present through Sephora in France, Germany, Spain, Sweden, Denmark, India, Italy, Poland, Portugal, Switzerland, Greece, the Czech Republic and the Balkans and Turkey.
Our e-commerce site, www.milkmakeup.com, is a direct-to-consumer, platform that currently ships across the U.S. For the year ended December 31, 2024, milkmakeup.com accounted for an insignificant portion of our net revenue.
We continuously assess new channels and other e-commerce expansion opportunities across regions.
Competition
Our main competitors are Unilever P.L.C., Coty Inc., e.l.f. Beauty Inc., L’Oréal S.A., LVMH Moet Hennessy Louis Vuitton SE, The Estée Lauder Companies Inc., P&G, Revlon Inc., and Shiseido Company, Limited. These companies own both legacy brands as well as younger previously independent brands. Milk Makeup also competes directly with privately held brands, including ONE/SIZE, Merit Beauty, Pat McGrath Labs, Ilia, Kosas, Rare Beauty, Anastasia Beverly Hills, Huda Beauty, Forma, Saie, Tarte, and Tower 28. Merit Beauty, Ilia, Saie, Kosas, and Tarte, which are also clean beauty brands and have partnerships with Sephora, are the key competitors of Milk Makeup. Among other areas, Milk Makeup believes that it competes against other cosmetics brands on price, quality of products and packaging, perceived value, innovation, in-store presence and visibility, and e-commerce and mobile commerce initiatives. Milk Makeup is focused on expanding its market share in the color cosmetics industry and continuing to be a leader in clean make-up.
Values and Commitments
“Clean” Products
From day one, we have always strived to create breakthrough, effective products that are also clean, vegan and cruelty-free. When we launched, we called our product ethos “cool, clean beauty that works.” At Milk Makeup, we use the word “clean” to describe how we formulate our products. We define “clean” using the following factors:
No Animal Products and Byproducts: All of our products are Leaping Bunny Certified, which means that Milk Makeup does not test on animals at any stage in its supply chain. Additionally, our products have no animal derivatives and are 100% vegan.
“Clean” Ingredients: We are dedicated to creating natural products, which means our products will never contain any of the over 2,500 controversial and potentially harmful or irritating ingredients, including parabens, sulfates, BHA, BPA, plastic microbeads, talc, urea, retinyl palmitate, mercury or mercury-containing ingredients, resorcinol, formaldehyde, aluminum salts, and mineral oil. We publish a complete and growing list of ingredients we will never use in our “Ingredient No List.”
Natural Products: Milk Makeup follows ISO 16128 guidelines, where “natural” means plant, mineral, and/or microbiologically derived ingredients. We want to bring products that are as natural as possible to our community, while also not compromising on quality and performance. We are always striving to improve, and are currently working toward making new formulas that are over 80% natural.
Ethically Sourced Ingredients: We have committed to ethical and responsible sourcing for our formulas from start to finish. For any products containing mica or palm-derived ingredients, we only use ethically sourced and sustainable mica and sustainability certified palm-derived ingredients. Milk Makeup also exclusively works with cGMP compliant factories.
Dedication to More Sustainable Packaging
Since our launch, we have focused on creating packaging that is iconic, innovative, easy to use, and pairs perfectly with our formulas. We are also committed to reducing our overall impact on the environment.
52

Intellectual Property
Milk Makeup believes that our intellectual property has substantial value and has contributed significantly to the success of our business. We rely on a combination of trademark, trade dress, copyright and trade secret protection to protect our brands, formulas and other intellectual property. Milk Makeup’s primary intellectual property includes our brands and trademark rights, including the Milk Makeup brand, which has significant consumer recognition. Milk Makeup’s trademarks are valuable assets that reinforce the distinctiveness of our brand and customers’ favorable perception of our products.
We have trademarks registered and applications pending throughout the world for our stylized logos in Australia, Bahrain, Brazil, Canada, China, the EU, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, Qatar, Russia, Saudi Arabia, Singapore, South Korea, Thailand, the UAE, the U.K. and the U.S. From time to time, we apply to register trademarks for our other brands in the U.S. and other countries. The registrations of these trademarks in the U.S. and foreign jurisdictions are generally effective for terms of ten years and require periodic renewals, which for our trademark registrations in the U.S., are presently scheduled between 2027 and 2031. In addition to trademark protection, Milk Makeup owns numerous domain name registrations, including milkmakeup.com. We do not have any issued patents or pending patent applications.
Seasonality and Quarterly Results
Milk Makeup’s business is subject to moderate seasonal fluctuations driven by retail consumer purchasing habits and timing of purchases by our retail customers. As a result of moderate seasonal fluctuations, results for any interim period are not necessarily indicative of the results that may be achieved for the full fiscal year. Additionally, because a significant percentage of our net sales are currently concentrated in a limited number of customers, a change in the order pattern or product restocking by one or more of our large retail customers driven by new product launches, new store openings and/or promotions could cause a significant fluctuation of our quarterly results or impact our liquidity.
Government Regulation
U.S. Regulation of Cosmetics Products
Our products are subject to regulation by the FDA the FTC and comparable state, local and foreign regulatory authorities and, over time, the regulatory landscape for our products has become more complex with increasingly strict requirements. These laws and regulations govern, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, disposal, record-keeping, promotion, advertising, distribution, marketing, export and import of drugs and cosmetic products. Noncompliance with applicable regulations could result in enforcement action by the FDA, FTC, or other regulatory authorities within or outside the U.S., including, but not limited to, product seizures, injunctions, product recalls, and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.
The majority of our products are cosmetics. The FDCA defines cosmetics as articles or components of articles intended for application to the human body to cleanse, beautify, promote attractiveness, or alter the appearance with the exception of “soap” as defined by FDA, the regulation of which varies based on its intended use. The labeling of cosmetic products is subject to the requirements of the FDCA, the Fair Packaging and Labeling Act, and other laws and regulations. Cosmetics are not subject to pre-market approval by the FDA; however certain ingredients, such as color additives, must be pre-approved for the specific intended use in the product and are subject to certain restrictions on their use. The FDA may, by regulation, require warning statements on certain cosmetic products for specified hazards associated with such products. FDA regulations also prohibit or otherwise restrict the use of certain types of ingredients in cosmetic products.
In addition, the FDA requires that cosmetic labeling and claims be truthful and not misleading. Moreover, cosmetics may not be marketed or labeled for their use in treating, preventing, mitigating, or curing diseases or other conditions or in affecting the structure or function of the body, as such claims would render the product to be a drug and subject to regulation as a drug. The FDA evaluates the “intended use” of a product to determine whether it is a drug, cosmetic product, or both. The FDA may also consider labeling claims in determining the intended use of a product. If the FDA considers label claims for cosmetic products to be claims affecting the structure or function of the human body, or intended for a disease condition, then such products may be regulated as “new drugs” within the meaning of the FDCA, meaning that such products would generally require premarket review and approval by the FDA to be legally marketed in the U.S. In addition to FDA requirements, state consumer protection laws and regulations can subject a cosmetics company to a
53

range of requirements and theories of liability, including similar standards regarding false and misleading product claims, under which state enforcement or class- action lawsuits may be brought.
We market certain products, such as chemical peels, as cosmetics, with stronger peels sold only to licensed healthcare providers for professional use only. However, the FDA may disagree with our determination that these products do not require FDA premarket review and approval. Similar risks may apply in foreign jurisdictions. If any of our products we intend to sell as cosmetics were to be regulated as drugs, we might be required to conduct, among other things, clinical trials to demonstrate the safety and efficacy of these products and to apply for pre-market approval of such products from the FDA.
The FTC, FDA, and other governmental authorities also regulate advertising and product claims regarding the safety, performance and benefits of our products. These regulatory authorities typically require a safety assessment of the product or ingredient, and reasonable basis to support any marketing claims. As such, product claims must be adequately substantiated. What constitutes a reasonable basis for substantiation of claims can vary widely from market to market, and we cannot assure you that our efforts to support our claims will be considered sufficient. The most significant area of risk for such activities relates to improper or unsubstantiated claims about the use and safety of our products. If the products or any ingredient is or is alleged to be adulterated or misbranded, or if the safety or effectiveness of the products or ingredients has not been adequately substantiated, or if any other product claims lack adequate substantiation or are alleged to be false or misleading, regulators may take enforcement action or impose penalties, such as monetary consumer redress, or consumer lawyers can bring claims or an action against us, including, among other things, seeking damages, an amendment of the claims, and/or injunctive or other equitable relief, such as requiring us to revise our marketing materials, preventing us from making certain claims about the products or ingredients, stop selling certain products, or requiring us to add a specific warning label or disclaimer about the products or ingredients. Any of which could harm our business, financial condition and results of operations. Other warnings or disclaimers may also be mandated pursuant to federal or state laws and regulations. We may also be subject to regulatory action if the FDA or other regulators determine our products, product ingredients, or operations do not comply with any applicable laws or regulations, and we could be required to stop selling, withdraw, recall, re-label or re-package any products on the market.
Our advertising for products is also regulated by the FTC under the Federal Trade Commission Act. Cosmetics and personal care products must be advertised and promoted truthfully and otherwise in compliance with state consumer protection laws prohibiting false advertising and unfair or deceptive trade practices. Also, under the federal Lanham Act, competitors and others can initiate litigation relating to advertising claims. A company that is found to have violated these laws may be subject to significant liability.
Regulatory authorities monitor cosmetic products’ regulatory compliance through market surveillance and inspection of cosmetics manufacturers and distributors to ensure, among other things, that the products’ labeling and advertising is not false nor misleading and is compliant with legal requirements, that the products do not contain false nor misleading labeling or harmful ingredients, that they are manufactured under sanitary conditions, or pursuant to cGMPs. Inspections also may arise from consumer or competitor complaints filed with or brought to the attention of regulatory authorities, including FDA or FTC. In the event a regulatory authority or a court identifies false or misleading labeling, unsanitary conditions, harmful ingredients, or otherwise a failure to comply with cGMPs or legal requirements, we may be requested or required by a regulatory authority or required by a court, or we may independently decide to conduct a recall or market withdrawal of our product or to make changes to our manufacturing processes or product formulations, labeling or marketing, which could result in an insufficient amount of our products in the market, impact our sales and/or harm our reputation. Fines or other payments may also be required by a regulator or a court.
Significant changes to the regulatory landscape for cosmetic products are anticipated for the coming years as a result of the enactment of MoCRA. Under MoCRA, companies will be obligated to adhere to new requirements for cosmetics, such as new labeling standards for specific products, safety substantiation, facility registration, product listing, adverse event reporting, compliance with cGMPs, mandatory recalls and record-keeping requirements for such products and the manufacturing facilities in which they are produced, among other things. Companies will need to be in compliance with many of the new requirements no later than July 1, 2024. MoCRA requires the FDA to issue regulations governing cGMP for cosmetic manufacturers by December 2025. We already require all third-party CMOs who enter into agreements to produce our products to represent and warrant to us that the products are made in accordance with cGMPs, including documentation, recordkeeping, building and facility design, equipment maintenance and personnel requirements.
The FDA or other regulators may determine that our products cannot be marketed as is or do not meet the regulatory requirements, including, without limitation with respect to labeling, marketing, or ingredient formulation, for the
54

classification of product in which they are marketed. The FDA may take the position that we failed to satisfy premarket requirements for color additives, or that our products contain otherwise impermissible ingredients, in which case some or all of our products may be deemed adulterated or misbranded in violation of the FDCA. Furthermore, the FDA may determine that one or more of our products has not been accurately classified as cosmetics and should be regulated as a drug, which would require lengthy and expensive clinical trials and be cost prohibitive.
We are also subject to a number of federal, state and foreign laws and regulations that affect companies conducting business on the Internet, or advertising on social media, including consumer protection regulations that regulate retailers and govern the promotion and sale of merchandise, including by third parties. Many of these laws and regulations are still evolving and being tested in courts, and could be interpreted in ways that could harm our business. These may involve user privacy, data protection, content, intellectual property, distribution, electronic contracts and other communications, competition, protection of minors, consumer protection, telecommunications, product liability, taxation, economic or other trade prohibitions or sanctions and online payment services. In particular, we are subject to federal, state and foreign laws regarding privacy and protection of people’s data. U.S. federal and state and foreign laws and regulations are constantly evolving and can be subject to significant change. In addition, the application, interpretation and enforcement of these laws and regulations are often uncertain, and may be interpreted and applied inconsistently from country to country and inconsistently with our current policies and practices.
Our products are also subject to regulation by the CPSC under the provisions of the Consumer Product Safety Act, as amended by the Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban consumer products that fail to comply with applicable product safety laws, regulations and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury and may seek penalties for regulatory noncompliance under certain circumstances. The CPSC also requires manufacturers of consumer products to report certain types of information regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.
U.S. Regulation of Drug Products
In the U.S., the FDA regulates drugs under the FDCA and its implementing regulations. Our prescription-only products containing hydroquinone are regulated as drugs, however, to date, we have not sought or obtained required NDAs or other FDA approvals for these products. We believe our prescription-only HQ products do not fall within the previously established categories of unapproved drugs for which the FDA has indicated it prioritizes enforcement. To date, we have not received any communications from the FDA or any similar regulatory authorities regarding our Nu-Derm HQ or any other products and neither the FDA nor any other regulators have prohibited us from selling our prescription HQ products in the U.S. or in other jurisdictions. However, there can be no assurance the FDA or any other regulatory authorities will not take enforcement action against us, or otherwise require us to obtain premarket approval or similar authorization of our prescription HQ products.
Hatch-Waxman Act
Section 505(j) of the FDCA establishes an abbreviated approval process for a generic version of approved drug products through the submission of an ANDA. Certain of our products, including tretinoin products, are marketed pursuant to an ANDA held by Bausch Health. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product.
Over-the-Counter Drug Products
We currently market certain non-prescription drug products, including certain products that are intended to treat acne or be used as sunscreens, which are regulated as OTC drug products by the FDA. Certain OTC drug products are subject to regulation pursuant to the FDA’s “monographs,” which provide rules applicable to each therapeutic category of non-prescription drug, and establishes conditions, such as active ingredients, uses (indications), doses, labeling, and testing procedures, under which an OTC drug within that particular category may be GRASE, and therefore can be marketed without obtaining pre-market approval of an NDA or ANDA. To be legally marketed, among other things, OTC drug products marketed under an OTC monograph must be manufactured in compliance with the FDA’s cGMP requirements for drug products, and the failure to maintain compliance with these requirements could lead to FDA enforcement action.
55

Moreover, a failure to comply with the OTC monograph requirements could lead the FDA to determine that the drug is not GRASE, and thus is a “new drug” requiring approval in accordance with the NDA process.
U.S. Regulation of Medical Devices
Medical devices are subject to extensive and rigorous regulation by the FDA and by other federal, state and local authorities. The Federal Food, Drug, and Cosmetic Act and related regulations govern the conditions of safety, efficacy, clearance, approval, manufacturing, quality system requirements, labeling, packaging, distribution, storage, recordkeeping, reporting, marketing, advertising, and promotion of medical devices. Unless an exemption applies, each medical device commercially distributed in the U.S. requires either FDA clearance of a 510(k) premarket notification or approval of a premarket approval application (a “PMA”). Under the FDCA, medical devices are classified into one of three classes—Class I, Class II or Class III—depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA’s General Controls for medical devices, which include facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising and promotional materials. Class II devices are subject to the FDA’s General Controls, and special controls, which can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life- supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA. Some pre-amendment devices are unclassified but are subject to the FDA’s premarket notification and clearance process in order to be commercially distributed. We believe that, based on its intended use, our Skintrinsiq® device does not meet the FDCA’s definition of a medical device, and we have not sought FDA premarket review of this product. However, the FDA may disagree with our determination and subject the Skintrinsiq® device to medical device regulations. Similar risks may apply in foreign jurisdictions where we market our products.
Foreign Government Regulation
A key part of the growth strategy for our business is to expand the sale of products in international markets. To market our products in many non-U.S. jurisdictions we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. In several countries, we rely on distributors or other third parties to comply with and obtain any relevant approvals, licenses or registrations. The approval procedure varies among countries and can involve additional testing and data review. The time required to obtain approval in non-U.S. jurisdictions may differ from that required to obtain FDA approval and could be lengthy. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. In addition, many countries from time to time evaluate the regulatory status of various products and ingredients. We may not obtain foreign regulatory approvals on a timely basis, if at all, or may choose not to implement a country’s labeling requirements if to do so would have a negative impact on our international or domestic operations.
For additional information on the regulatory environment in which we operate, see “Item 3. Key Information—D. Risk Factors—Risks of Conducting International Business—Conducting international business exposes us to risks such as currency fluctuations, cash repatriation restrictions, and changes in laws and regulations, which could negatively impact our operations and financial performance.”
C.Organizational Structure
Upon consummation of the Business Combination, Waldencast became organized in an “Up-C” structure, whereby the equity interests of Obagi Medical and Milk Makeup are held by Waldencast LP, which is an indirect subsidiary of
56

Waldencast. Obagi Holdco 1, a wholly owned subsidiary of Waldencast, owns 91.3% of the partnership units in Waldencast LP. The following table sets out the subsidiaries of Waldencast, as of the date of this Report.
Company NameCountry of IncorporationProportion of Ownership Interest
Waldencast Vietnam LimitedVietnam
91.3%
Milk Makeup LLCU.S., Delaware
91.3%
Milk Makeup Europe, S.L.Barcelona
91.3%
Milk Makeup UK LimitedEngland & Wales
91.3%
Obagi AsiaPac LimitedHong Kong
91.3%
Obagi Blue Sea Holding, LLCCayman Islands
91.3%
Obagi Cosmeceuticals LLCU.S., Delaware
91.3%
Obagi Global Holdings LimitedCayman Islands
91.3%
Obagi Holdco 1 Limited Jersey100%
Obagi Holdco 2 Limited Jersey
91.3%
Obagi Holdings Company LimitedCayman Islands
91.3%
Obagi Netherlands B.V.The Netherlands
91.3%
Obagi Viet Nam Import Export Trading MTV Company LimitedVietnam
91.3%
Waldencast Cayman LLCCayman Islands100%
Waldencast Finco Limited Jersey
91.3%
Waldencast Malaysia SDN. BHD.Malaysia
91.3%
Waldencast Partners LPCayman Islands
91.3%
Waldencast Singapore Pte. Ltd.Singapore
91.3%
Waldencast (Thailand) Co., Ltd.Thailand
91.3%
Waldencast UK Operations LimitedEngland & Wales
91.3%
D.Property, Plants and Equipment
Waldencast’s property and equipment are held directly and through Obagi Medical and Milk Makeup. Information regarding Waldencast, Obagi Medical and Milk Makeup’s property and equipment is described above.
ITEM 4A. UNRESOLVED STAFF COMMENTS
None / Not applicable.
ITEM 5. WALDENCAST’S OPERATING AND FINANCIAL REVIEW AND PROSPECTS
The following discussion and analysis should be read in conjunction with the other sections of this Report, including “Item 4. Information on the Company,” and our audited consolidated financial statements and notes thereto found in “Item 8. Financial Information.” For purposes of this section, the “Company,” “we,” or “our” refer to (i) Waldencast plc, and its subsidiaries (“Waldencast”) for year ended December 31, 2024 and the year ended December 31, 2023.
The following discussion contains forward-looking statements that reflect future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that may be outside of our control. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” included elsewhere in this Report. Certain amounts may not foot due to rounding.
Overview
Waldencast, formerly known as Waldencast Acquisition Corp., is a Jersey incorporated company and UK tax resident. Waldencast, together with its consolidated subsidiaries, is a global multi-brand beauty and wellness platform whose ambition is to build a global best-in-class beauty and wellness multi-brand platform by creating, acquiring and accelerating
57

the next generation of high-growth, purpose-driven brands that can benefit from the Company’s strong product and brand development capabilities. The first step in realizing our vision was the Business Combination with Obagi Medical and Milk Makeup. Our business is organized into two reportable segments—Obagi Medical and Milk Makeup.Obagi Medical sells industry-leading, advanced skin care products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Obagi Medical offers over 125 products in the U.S. through various channels including physician-dispensed and direct to consumer, as well as in over 80 countries through international distributors, royalty agreements and several entities based in Southeast Asia. Milk Makeup creates vegan, cruelty-free, clean formulas and is headquartered in downtown New York City. Currently, Milk currently offers over 250 products primarily through its U.S. and international retail partners and online through www.milkmakeup.com.
Recent Events
Indebtedness
2025 Credit Agreement
On March 18, 2025, the 2025 Credit Agreement Borrowers, each a wholly owned subsidiary of Company, the 2025 Credit Agreement Parent Guarantor, TCW and the 2025 Credit Agreement Lenders entered into the 2025 Credit Agreement. The 2025 Credit Agreement provides for a five-year secured first lien (i) term loan facility in an aggregate principal amount of $175.0 million (the “Term Loans”) and (ii) revolving loan facility in an aggregate principal amount of up to $30.0 million (the “Revolving Commitments”). The proceeds of initial borrowing under the 2025 Credit Agreement were and will be used to (i) repay in full all outstanding amounts under, and terminate, the 2022 Credit Agreement, (ii) pay fees and expenses relating to certain transactions contemplated by the 2025 Credit Agreement and (iii) fund working capital and for general corporate purposes. Borrowings under the 2025 Credit Agreement will accrue interest at a rate per annum equal to, at the 2025 Credit Agreement Borrowers’ option, (i) the Alternate Base Rate (as defined in the 2025 Credit Agreement) plus an additional margin ranging from 5.25% per annum to 6.50% per annum or (ii) the Adjusted Term SOFR Rate (as defined in the 2025 Credit Agreement and based on SOFR) plus an additional margin ranging from 6.25% per annum to 7.50% per annum, each depending on the Total Leverage Ratio (as defined in the 2025 Credit Agreement) for the applicable determination period. The applicable margin will increase by 0.25% per annum if the 2025 Credit Agreement Borrowers elect to refinance the Revolving Commitments with the ABL Facility (as defined in the 2025 Credit Agreement). The 2025 Credit Agreement Borrowers may elect to pay up to 3.00% of the accrued interest in kind at a rate equal to the applicable interest rate of such loan plus an additional 0.50% per annum for each 1.00% of cash interest that is elected to be paid in kind. The Term Loans will amortize at (i) 1.00% per annum payable in quarterly installments beginning on June 30, 2025 and prior to June 30, 2026, and (ii) 5.0% per annum payable in quarterly installments beginning on June 30, 2026 and thereafter.
With respect to the Term Loans and Revolving Commitments, certain prepayment, termination or reduction on or prior to the fourth anniversary of the Closing Date (as defined in the 2025 Credit Agreement) will be subject to a prepayment premium equal to (i) if made prior to the first anniversary of the Closing Date, 5.00% of the principal of the Term Loans so prepaid or of the Revolving Commitments so terminated or reduced, (ii) if made on or after the first anniversary of the Closing Date, but prior to the second anniversary of the Closing Date, 3.00% of the principal amount of the Term Loans so prepaid or of the Revolving Commitments so terminated or reduced, (iii) if made on or after the second anniversary of the Closing Date, but prior to the third anniversary of the Closing Date, 2.00% of the principal amount of the Term Loans so prepaid or of the Revolving Commitments so terminated or reduced, and (iv) if made on or after the third anniversary of the Closing Date, but prior to the fourth anniversary of the Closing Date, 1.00% of the principal amount of the Term Loans so prepaid or of the Revolving Commitments so terminated or reduced, in each case, subject to certain exceptions set forth in the 2025 Credit Agreement.
Obligations under the 2025 Credit Agreement will be guaranteed by and secured by a first priority lien on substantially all of the assets of the 2025 Credit Agreement Borrowers, the 2025 Credit Agreement Parent Guarantor and certain of their subsidiaries, subject to customary exceptions and limitations. The 2025 Credit Agreement contains (i) customary representations and warranties and affirmative covenants, (ii) negative covenants, including restrictions on incurring debt and liens, selling assets, certain fundamental changes, making investments and restricted payments, entering into certain transactions with affiliates, hoarding certain cash and other negative covenants as more fully described therein, and (iii) events of defaults, including, among other things, nonpayment, misrepresentation, breach of covenants, cross default with other indebtedness, loss of certain licenses, certain bankruptcy related events, indictment of a loan party and other events of default as more fully described therein.
58

Additionally, the 2025 Credit Agreement Credit Agreement requires the 2025 Credit Agreement Borrowers, the 2025 Credit Agreement Parent Guarantor and their certain subsidiaries to comply with certain financial covenants, including maintaining (i) a maximum Total Leverage Ratio (as defined in the 2025 Credit Agreement) of 5.75 to 1.00 which steps down over time to 2.50 to 1.00, (ii) a minimum Fixed Charge Coverage Ratio (as defined in the 2025 Credit Agreement) of 1.15 to 1.00 which steps up over time to 1.50 to 1.00, in each case, commencing on March 31, 2025 and (iii) a minimum liquidity of $12.5 million for any period of three consecutive business days. The foregoing description of the 2025 Credit Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the 2025 Credit Agreement, which is attached hereto as Exhibit 4.18 and incorporated in this item by reference.
Components of Results of Operations
Net Revenue
Net revenue is generated through both of our operating segments and is recognized net of provisions for estimate volume rebates, discounts, markdowns, margin adjustments, returns and payments to distributors.
Net Product Revenue
Our Obagi Medical segment generates net revenue through direct product sales, sales to distributors and royalties. Direct sales predominantly consists of sales through our direct to physician channel, within which an Obagi Medical salesforce manages relationships with a large network of physicians and similar accounts across the U.S., and DTC sales on www.obagi.com and Amazon. While all channels depend on the company’s ability to effectively drive demand for products, through innovation and effective marketing, the direct to physician channel performance is also directly linked to the performance of the sales team in opening new physician accounts and maintaining relationships with existing accounts.
Obagi Medical distributor revenue consists mostly of sales to international distributors across over 80 countries across Europe, Latin America, the Middle East, and Asia. To a more limited extent, Obagi Medical sells products in the U.S. for sale on third-party e-commerce websites, spas and through liquidation channels.
Mike Makeup generates the majority of its net revenue through direct sales, made up of DTC sales through its U.S. website www.milkmakeup.com and U.S. and international retail partners, including Sephora, Lyko and select retailers in Scandinavia, and Space NK and Boots in the UK. Increasing retail sales of Milk Makeup products is a key driver of the brand’s success, through existing partners and building new partnerships in the U.S. and internationally. The brand has recently announced that it will be launching in Ulta Beauty across the U.S. in Spring 2025. A much smaller proportion of Milk Makeup net revenues are generated through a distributor selling Milk Makeup via an online marketplace distributor.
Related Party Revenue
In connection with the Obagi China Distribution we entered into the IP License Agreement, the Supply Agreement, and a Transition Services Agreement (the “Transition Services Agreement”) with the Obagi China Business. See “Item 7. Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” for a description of the IP License, Supply and Transition Services Agreements.
Under the IP License Agreement, we granted an exclusive license to certain intellectual property relating to the Obagi Medical brand to Obagi Hong Kong, and we retain the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. Obagi Hong Kong purchases inventory from the U.S. for resale in the China Region and pays us a royalty on gross sales of licensed products.
Under the Supply Agreement, we supply, or cause to be supplied through certain of our CMOs, products to Obagi Hong Kong for distribution and sale in the China Region. The parties operated under an interim supply agreement, which terminated in July 2023. However, the parties continued to operate under the interim supply agreement terms until December 2024, at which point the remaining related party liability was amortized and released as the Company had fulfilled its contractual obligations related to pricing. The Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products until the Obagi China Business has been added as a party to Obagi’s CMO agreements, at which time it will then order directly from the CMOs.
59

Royalties
Our Obagi Medical segment generates royalty revenue from the sale of products in China by Obagi Hong Kong and in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi Medical brand name in the Japanese retail skincare channels. Performance of royalty revenue is impacted by the success of Rohto, as well as exchange rate fluctuations.
Cost of Goods Sold
Cost of goods sold (“COGS”) consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, freight and inventory inspection costs, depreciation and amortization of product-related intangible asset and supply agreements, and amortization of the inventory fair value step-up related to the Business Combination. Finished goods are primarily purchased directly from third-party contract manufacturers, with the increase in COGS being proportionate to increases in revenue.
Selling, General, and Administrative
Selling, general and administrative costs (“SG&A”) include expenses we incur in the ordinary course of business relating to personnel and stock-based compensation, marketing, supply chain, office costs, I.T., regulatory, research and development, and professional fees. We expect SG&A expenses to increase in absolute dollars as we continue to invest in building and maintaining our customer base, growing our business, enhancing our brand awareness, hiring additional personnel and upgrading and expanding our systems, processes, and controls to support the growth in our business, as well as our increased compliance and reporting requirements as a public company.
Depreciation and Amortization
Depreciation and amortization expenses are related to our property and equipment and intangible assets. Product-related intangible asset amortization is presented in cost of goods sold in the consolidated statement of operations and comprehensive loss. Depreciation and amortization expenses not classified in cost of goods sold are presented in SG&A expenses.
Loss on Impairment of Goodwill
Impairment of goodwill recognizes the difference between the carrying value and fair value of goodwill. The process of evaluating goodwill for impairment is subjective and requires significant judgment and estimates. At least annually, and more frequently if events and circumstances warrant, we test goodwill for impairment. This is performed first through an optional qualitative assessment and then, if indicators of impairment exist, through a quantitative assessment. When performing the optional qualitative analysis, we consider many factors including general economic conditions, industry and market conditions, financial performance, key business drivers, and long-term operating plans.
60

Results of Operations
For discussion related to our financial condition, changes in financial condition, and results of operations for 2023 compared to 2022, refer to Part I, Item 5. Operating and Financial Review and Prospects, in our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the SEC on April 30, 2024.
The following tables summarize our consolidated statements of operations data for the periods presented:
(In thousands)
Year ended December 31, 2024Year ended December 31, 2023
Change ($)
Change (%)
Net revenue
$273,868 $218,138 $55,730 25.5 %
Cost of goods sold
82,124 76,561 5,563 7.3 
Gross profit$191,744 $141,577 $50,167 35.4 
Selling, general and administrative245,297 223,508 21,789 9.7 
Loss on impairment of goodwill5,031 — 5,031 — 
Total operating expenses$250,328 $223,508 $26,820 12.0 
Operating loss$(58,584)$(81,931)$23,347 (28.5)
Interest expense, net17,155 18,906 (1,751)(9.3)
Change in fair value of derivative warrant liabilities(23,627)10,337 (33,964)(328.6)
Other (income) expense, net
(3,574)1,769 (5,343)(302.0)
Total other (income) expenses, net$(10,046)$31,012 $(41,058)(132.4)
Loss before income taxes(48,538)(112,943)64,405 (57.0)
Income tax expense (benefit)110 (6,975)7,085 (101.6)
Net loss$(48,648)$(105,968)$57,320 (54.1)
Net Revenue
Net revenue increased $55.7 million, or 25.5%, to $273.9 million for the year ended December 31, 2024 from $218.1 million for the year ended December 31, 2023. The increase in revenue was primarily attributable to increases in direct to consumer digital channels of $33.7 million, growth in the U.S. retail channels of $16.8 million and continued international growth and expansion of $14.0 million. Specifically in Q4 2023, Obagi Medical moved the management of Amazon in-house to become a direct sales model from a distributor model, which improved profitability and growth in the digital channel. The offsetting $8.9 million reduction in growth was primarily driven by the loss of sales of the former SA distributor and a drop in related party revenue with the Obagi China Business.
Cost of Goods Sold
COGS increased $5.6 million, or 7.3%, to $82.1 million for the year ended December 31, 2024 from $76.6 million for the year ended December 31, 2023. The increase in COGS was primarily due to an increase in revenue which drove the absolute dollars up, an increase in liquidations of product that was previously written down in prior periods, offset by a decrease of $1.7 million related to the amortization of the inventory fair value step-up related to the Business Combination.
Selling, General and Administrative
SG&A expense increased $21.8 million, or 9.7%, to $245.3 million for the year ended December 31, 2024 from $223.5 million for the year ended December 31, 2023. Selling, marketing and distribution expenses increased $24.8 million, or 35.2%, as a direct result of distribution expansion and marketing investment to grow awareness and community. Milk Makeup sales included four new retail channels, including initial shipments to the recently announced partnership with Ulta Beauty. Obagi Medical continued its international expansion and growth of its direct-to-consumer channel capabilities, for which the costs incurred as a result of internalization annualized in 2024. General and administrative costs increased $12.5 million, or 22.7%, as the Company continues to invest in people and infrastructure to support future growth and build Group capabilities. Partially offsetting these increases, non-recurring costs (predominantly related to the SEC investigation), declined by $12.3 million, or 34.4%, following the successful completion of the Company’s restated
61

financial statement filing in the first half of the year ended December 31, 2024. Other significant components of SG&A, share based compensation and depreciation and amortization, remained in line with the prior year.
Loss on Impairment of Goodwill
The Company performed its annual goodwill impairment analysis using the quantitative approach on October 1, 2024, and the analysis indicated there was an impairment of goodwill. Through a qualitative analysis, we determined that it was more likely than not that the fair value of the reporting unit associated with the Obagi Medical reporting unit was less than its carrying amount and a quantitative analysis was performed, at an interim date. As a result, the Company recorded a non-cash goodwill impairment charge of $5.0 million during the year ended December 31, 2024.
Since the carrying value of the reporting unit is now equal to its fair value, as of the annual impairment test date due to the impairment recognized in the period, if we are not successful in meeting our projected revenue or profitability growth rates, or if market conditions including inflation, the valuation of its competitors, a market capitalization decrease, or other negative factors exist, there could be a future decrease in the fair value of the Obagi Medical reporting unit below the carrying value resulting in additional future impairments.
The Company performed a qualitative review of the Milk Makeup reporting unit, which did not indicate that the fair value of the reporting unit was less than the carrying value. On that basis, management concluded that there was no change in the fair value. As a result, the goodwill balance for the Milk Makeup reporting unit has not changed.
No impairment of goodwill was recorded during the year ended December 31, 2023.
Interest Expense, net
Interest expense, net decreased $1.8 million, or 9.3%, to $17.2 million for the year ended December 31, 2024 from $18.9 million for the year ended December 31, 2023 primarily due to interest expense on the 2022 Term Loan and a lower average draw on the 2022 Revolving Credit Facility throughout the year. As of December 31, 2024, the Company had unpaid principal of $153.1 million and $15.0 million on the 2022 Term Loan and the 2022 Revolving Credit Facility, respectively, with a weighted average interest rate of 8.7% and 8.7%, respectively, outstanding under the 2022 Credit Agreement.
Change in Fair Value of Derivative Warrant Liabilities
The change in fair value of derivative warrant liabilities changes according to the remeasurement of the fair value of the warrants at the end of each reporting period following the Business Combination. The change in fair value of the warrant liabilities was the result of decreases in market prices of our common stock and other observable inputs deriving the value of the financial instruments.
Other (Income) Expense, Net
Other (income) expense, net totaled $3.6 million of income for the year ended December 31, 2024, consisting primarily of $3.4 million of income related to the release of the below market contract liability due to the termination of the interim Supply Agreement. See “Item 8. Financial Information—Note 16. Related Party Transactions.”
Income Tax Expense (Benefit)
Income tax expense for the year ended December 31, 2024 was $0.1 million with a corresponding effective tax rate of (0.2)% compared to an income tax benefit of $7.0 million with a corresponding effective tax rate of 6.2% for the year ended December 31, 2023. The change in effective tax rate was predominantly driven by the Company migrating its place of residence to the United Kingdom, prior year true-ups, and rate differences.
For the year ended December 31, 2024 and the year ended December 31, 2023, the Company recognized a valuation allowance of $22.5 million and $19.8 million, respectively, to account predominantly for the portion of the deferred tax asset that was more likely than not to not be realized due to cumulative loss incurred at Obagi Holdco 1 Limited for its investment in Waldencast LP, and associated net operating losses.
62

Non-GAAP Financial Measures
In addition to our results of operations and measures of performance determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), we believe that certain non-GAAP financial measures are useful in evaluating and comparing our financial and operational performance over multiple periods, identifying trends affecting our business, formulating business plans, and making strategic decisions, as they are similar to measures reported by our public competitors.
Comparable Net Revenue, Comparable Growth, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA are key performance measures that our management uses to assess our financial performance and for internal planning and forecasting purposes. These metrics are not intended to be substitutes for any GAAP financial measures and, as calculated, may not be comparable to other similarly titled measures of performance of other companies in other industries or within the same industry. Additionally, investors should not solely rely on our non-GAAP financial measures as they do not reflect our current or future cash requirements and working capital needs.
There are limitations to non-GAAP financial measures because they exclude charges and credits that are required to be included in GAAP financial presentation. The items excluded from GAAP financial measures such as net income/loss to arrive at non-GAAP financial measures are significant components for understanding and assessing our financial performance. Non-GAAP financial measures should be considered together with, and not alternatives to, financial measures prepared in accordance with GAAP.
Comparable Net Revenue and Comparable Growth
We define and calculate Comparable Net Revenue as net revenue excluding sales related to the former Obagi China Business, which was not acquired by Waldencast at the time of the Business Combination. The sales to the Obagi China Business have a below market sales price for a defined period of time after the acquisition of Obagi Medical. As a result of the acquisition, a below market contract liability was recognized and is amortized based on sales.
Comparable Growth is defined as the growth in Comparable Net Revenue period over period expressed as a percentage. We adjust for this item because the sales to a related party with below market sales prices does not reflect the recurring metrics of the business.
(In thousands, except for percentages)Year ended December 31, 2024Year ended December 31, 2023
Net Revenue$273,868 $218,138 
Obagi Medical China Business2,804 5,619 
Comparable Net Revenue$271,064 $212,519 
Comparable Growth27.5 %
Adjusted Gross Profit and Adjusted Gross Margin
We define and calculate Adjusted Gross Profit as GAAP gross profit excluding the impact of inventory fair value adjustments, amortization of supply agreements and formulation intangible assets, discontinued product write-off, and the amortization of the fair value of the related party liability to Obagi China, which management believes is not reflective of core operating performance given the nature, size and non-recurring nature of the Business Combination, see “Item 8. Financial Information—Note 3. Business Combinations.” We define and calculate Adjusted Gross Margin as Adjusted Gross Profit as a percentage of net revenue. We adjust for these items because we do not believe they reflect normal, recurring activity, may obscure underlying business trends and make comparisons of long-term performance challenging.
63

The table below presents our Adjusted Gross Profit and Adjusted Gross Margin based on the Company’s segments reconciled to our gross profit and gross margin, the closest GAAP measures for the periods indicated:
Year ended December 31, 2024
(In thousands, except for percentages)
Obagi
Medical
Milk
Makeup
Waldencast (Total)
Net revenue
$149,266 $124,602 $273,868 
Gross Profit106,760 84,984 191,744 
Gross Margin %71.5 %68.2 %70.0 %
Gross Margin Adjustments:
Amortization of the fair value of the related party liability(1)
(2,260)— (2,260)
Discontinued product write-off(2)
2,864 — 2,864 
Amortization expense of intangible assets(3)
11,205 — 11,205 
Adjusted Gross Profit$118,569 $84,984 $203,553 
Adjusted Gross Margin %79.4 %68.2 %74.3 %
(1) Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.
(2) Relates to the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the distribution contract was terminated.
(3) The Supply Agreement and Formulations intangible assets are amortized to COGS.

Year ended December 31, 2023
(In thousands, except for percentages)
Obagi
Medical
Milk
Makeup
Waldencast (Total)
Net revenue
$117,651 $100,487 $218,138 
Gross Profit76,582 64,995 141,577 
Gross Margin %65.1 %64.7 %64.9 %
Gross Margin Adjustments:
Amortization of the fair value of the related party liability(1)
(4,058)— (4,058)
Amortization of the inventory fair value adjustment(2)
— 1,691 1,691 
Amortization impact of intangible assets(3)
11,205 — 11,205 
Adjusted Gross Profit$83,729 $66,686 $150,415 
Adjusted Gross Margin %71.2 %66.4 %69.0 %
(1) Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.
(2) Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.
(3) The Supply Agreement and Formulations intangible assets are amortized to COGS.
Adjusted EBITDA and Adjusted EBITDA Margin
We define and calculate Adjusted EBITDA as GAAP net income (loss) before interest income or expense, income tax (benefit) expense, depreciation and amortization, and further adjusted for the items as described in the reconciliation below. We believe this information will be useful for investors to facilitate comparisons of our operating performance and better identify trends in our business. We define and calculate Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of net revenue.
Adjusted EBITDA excludes certain expenses that are required to be presented in accordance with GAAP because management believes they are non-core to our regular business. These include:
non-cash expenses, such as depreciation and amortization, stock-based compensation, inventory fair value adjustments, the amortization of fair value and release of the related party liability to Obagi China, change in fair value of financial instruments, loss on impairment of goodwill and leases, and foreign currency translation loss (gain);
interest expense and income tax expense or benefit; and
expenses that are not related to our underlying business performance, such as:
transaction-related costs which includes mainly legal, advisory and consulting fees related to the restatement, and legal expenses in connection with the Business Combination;
non-recurring inventory recovery and discontinuation related to the termination of the relationship with the SA Distributor;
64

contract termination fees with certain distributors; and
other non-recurring costs including restructuring, and legal settlements.

The tables below presents our Adjusted EBITDA reconciled to our net income (loss), the closest GAAP measure for the periods indicated:
Year ended December 31, 2024
(In thousands, except for percentages)
Obagi
Medical
Milk
Makeup
Central costsWaldencast (Total)
Net (Loss) Income$(31,524)$8,803 $(25,927)$(48,648)
Adjusted For:
Depreciation and amortization41,591 18,424 — 60,015 
Interest expense (income), net12,391 (1)4,765 17,155 
Income tax expense(141)32 219 110 
Stock-based compensation expense(328)1,167 8,553 9,392 
Legal and advisory non-recurring costs(1)
5,054 — 16,439 21,493 
Change in fair value of derivative warrant liabilities and interest rate collar— — (23,679)(23,679)
Amortization and release of related party liability(2)
(5,678)— — (5,678)
Loss on impairment of goodwill
5,031 — — 5,031 
Other non-recurring costs(3)
4,120 639 334 5,093 
Adjusted EBITDA$30,516 $29,064 $(19,296)$40,284 
Net Revenue$149,266 $124,602 $ $273,868 
Net Loss % of Net Revenue(21.1)%7.1 %N/A(17.8)%
Adjusted EBITDA Margin20.4 %23.3 %N/A14.7 %
(1) Includes mainly legal, advisory and consultant fees related to the financial restatement 2020-2022 periods and associated regulatory investigation.
(2) Relates to the fair value of the related party liability for the unfavorable discount to the Obagi Medical China Business as part of the Business Combination.
(3) Other costs include legal settlements, foreign currency translation losses, product discontinuation costs related to advanced purchases for the SA Distributor, and restructuring costs.

Year ended December 31, 2023
(In thousands, except for percentages)
Obagi
Medical
Milk
Makeup
Central costsWaldencast (Total)
Net Loss$(32,214)$(5,655)$(68,099)$(105,968)
Adjusted For:
Depreciation and amortization41,984 18,514 — 60,498 
Interest expense, net12,644 590 5,654 18,888 
Income tax (benefit) expense(6,997)10 12 (6,975)
Stock-based compensation expense726 2,352 6,157 9,235 
Legal and advisory non-recurring costs(1)
1,702 27 31,054 32,783 
Change in fair value of derivative warrant liabilities and interest rate collar— — 10,443 10,443 
Amortization of related party liability(2)
(4,058)— — (4,058)
Other non-recurring costs(3)
7,027 2,566 (44)9,549 
Adjusted EBITDA$20,814 $18,404 $(14,823)$24,395 
Net Revenue$117,651 $100,487 $ $218,138 
Net Loss % of Net Revenue(27.4)%(5.6)%N/A(48.6)%
Adjusted EBITDA Margin17.7 %18.3 %N/A11.2 %
(1) Includes mainly legal, advisory and consultant fees related to the Business Combination and the financial restatement of the 2020-2022 periods.
(2) Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.
(3) Other costs include the amortization of the fair value step-up as a result of the business combination, legal settlements, foreign currency translation losses, the write-down and subsequent recovery of inventory from the SA Distributor, product discontinuation costs related to advanced purchases for the SA Distributor, lease impairments and contract termination fees.
65

Liquidity and Capital Resources
We measure liquidity in terms of our ability to fund the cash requirements of our business operations, including working capital needs, capital expenditures, contractual obligations, debt service, acquisitions, and other commitments with cash flows from operations and other sources of funding. Our principal sources of capital and liquidity have been proceeds from the 2022 and 2023 PIPE Investments, private placements, and borrowings from banks.
In June 2022, we entered into the 2022 Credit Agreement which provided the Company with the 2022 Term Loan of $175.0 million (the “2022 Term Loan”) and 2022 Revolving Credit Facility with a borrowing capacity up to $45.0 million (the “2022 Revolving Credit Facility”). At the Closing Date (July 27, 2022) the total outstanding balance was $186.1 million. The proceeds from these borrowings along with the FPA and PIPE investments were primarily used to fund the $587.7 million of consideration paid, net of cash acquired, for the Obagi and Milk Business Combinations, as well as for debt issuance costs of $6.3 million, to settle the outstanding balance on the credit agreement previously entered into by Obagi Medical.
2022 Credit Agreement
Borrowings under the 2022 Credit Agreement may accrue interest at a rate per annum equal to, at the 2022 Credit Agreement Borrower’s election, either an alternate base rate plus an applicable margin of 2.5% per annum or a term benchmark rate plus an applicable margin of 3.5% per annum. In connection with the issuance of the 2022 Credit Agreement, we incurred $6.3 million of debt issuance costs.
As of December 31, 2024, we had an unpaid principal amount of $153.1 million, and unamortized debt issuance costs of $1.9 million on the 2022 Term Loan. The interest rate on the 2022 Term Loan was 8.9% and there was $1.3 million accrued interest as of December 31, 2024. As of December 31, 2024, we had an unpaid principal amount of $15.0 million, and unamortized debt issuance costs of $0.5 million on the 2022 Revolving Credit Facility. The interest rate on the 2022 Revolving Credit Facility was 8.4% and there was $0.1 million accrued interest as of December 31, 2024.
As of December 31, 2024, the current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $15.3 million and $15.0 million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and 2022 Revolving Credit Facility was $1.2 million and $0.5 million, respectively. The weighted-average interest rate on the 2022 Term Loan was 8.7% and the 2022 Revolving Credit Facility was 8.7% and there was $1.4 million of accrued interest as of December 31, 2024.
In February 2024, we drew $15.0 million on the 2022 Revolving Credit Facility at an interest rate of 8.9%. For further information about the 2022 Credit Agreement and its subsequent amendments, see “Item 8. Financial Information—Note 7. Debt
PIPE Investments
In September 2023, we entered into the 2023 Subscription Agreements with the 2023 PIPE Investors where they collectively subscribed for 14,000,000 Class A ordinary shares in a private placement at a purchase price of $5.00 per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment was anchored by a $50.0 million investment by a stakeholder in Beauty Ventures, which was the beneficial holder of 20.0% of our Class A ordinary shares as of April 15, 2024. The remainder of the 2023 PIPE Investors were certain existing shareholders including Cedarwalk, certain members of the Sponsor, and Mr. Brousset and Ms. Sebti. The 2023 Subscription Agreements relating to approximately $68.0 million of proceeds were consummated on the First PIPE Closing Date. The remaining approximately $2.0 million of Subscription Agreements closed on the Second PIPE Closing Date, following receipt of regulatory approvals (the “PIPE Closings”). No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment.
For information about the 2023 Subscription Agreements and their related Lock-Up Agreements, see “Item 7. Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” in this Report and “Item 8. Financial Information—Note 16. Related Party Transactions.”
If our net cash provided by operating activities and existing cash and cash equivalents are not sufficient to fund our operations in the future, or if we seek to expand or diversify through accretive acquisitions, we may need to seek additional credit or raise additional funds, and we cannot be certain that such funds will be available to us on acceptable terms when
66

needed, if at all. If we are required to seek additional credit, our ability to in-license new technologies, develop future products or expand our pipeline of products could all be negatively impacted, which would have an adverse effect on our ability to grow our business and remain competitive. Further, we may decide to raise additional proceeds by issuing equity securities or securities that are convertible into our equity. If we sell such securities, investors may be materially diluted as a result of such offerings. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, we may be required to relinquish potentially valuable rights to our future products or proprietary technologies or grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to expand our operations, develop new products, take advantage of future opportunities or respond to competitive pressures or unanticipated customer requirements.
We expect capital and operating expenditures to increase over the next several years as we expand our infrastructure, distribution channels and our commercialization, clinical trial, research and development and manufacturing activities. Further we expect to have future legal expenditures related to the ongoing SEC investigation and associated matters that will have an impact to operating cash flow. We believe that net cash provided by our operating activities and existing cash and cash equivalents, including access to credit facilities, will be sufficient to fund our operations for the foreseeable future.
As of December 31, 2024, we had cash and cash equivalents of $14.8 million, of which $2.4 million is held in other currencies, primarily Thai Baht. As of December 31, 2023, we had cash and cash equivalents of $21.1 million.
Consolidated Cash Flow Data
In summary, our cash flows for each period were as follows:
(In thousands)
Year ended December 31, 2024Year ended December 31, 2023
Change ($)
Change (%)
Net cash used in operating activities$(8,820)$(29,775)$20,955 (70.4)%
Net cash used in investing activities$(2,920)$(1,994)$(926)46.4 %
Net cash provided by financing activities$5,582 $44,329 $(38,747)(87.4)%
Cash Flows from Operating Activities
Net cash used in operating activities of $8.8 million for the year ended December 31, 2024 was driven by the following:
Net loss of $48.6 million primarily due to non-cash charges and SG&A expenses related to non-recurring legal and advisory costs. Non-cash charges included: (i) depreciation and amortization expenses of $60.0 million, (ii) stock-based compensation of $9.4 million, and (iii) loss on impairment of goodwill of $5.0 million. The net loss was favorably impacted by non-cash income (i) of $23.6 million related to the change in fair value of derivative warrant liabilities and (ii) amortization and release of related party liability of $5.9 million.
Cash outflows resulting from the net change in operating assets and liabilities of $6.8 million, primarily driven by a decrease in operating lease liabilities of $2.7 million, decrease in accounts payable of $3.0 million, and an increase in accounts receivable of $3.2 million, offset by a decrease in inventories of $2.6 million.
Non-cash reconciling credits related to deferred income taxes of $1.2 million.
Net cash used in operating activities of $29.8 million for the year ended December 31, 2023 was driven by the following:
Net loss of $106.0 million resulting from the impact of higher operating expenses during the year ended December 31, 2023 primarily due to SG&A expenses related to legal and advisory non-recurring costs. A large portion of this loss resulted from non-cash charges related to: (i) depreciation and amortization expenses of $60.5 million, (ii) stock-based compensation of $9.2 million (iii) loss on impairment of lease related assets of $3.6 million and (iv) change in fair value of derivative warrant liabilities of $10.3 million.
Cash outflows resulting from the net change in operating assets and liabilities of $0.1 million, primarily driven by a decrease in operating lease liabilities of $2.6 million, an increase in accounts receivable of $2.1 million, and a decrease in other current liabilities of $1.7 million, offset by an increase in accounts payable of $4.4 million.
Non-cash reconciling credits related to deferred income taxes of $7.0 million.
67

Cash Flows from Investing Activities
Net cash used in investing activities was $2.9 million for the year ended December 31, 2024 which was primarily driven by the increases in capital expenditures of $3.0 million.
Net cash used in investing activities was $2.0 million for the year ended December 31, 2023, primarily driven by the increases in capital expenditures of $2.0 million.
Cash Flows from Financing Activities
Net cash provided by financing activities was $5.6 million for the year ended December 31, 2024. The change was primarily driven by: (i) an increase in proceeds of $15.0 million from the 2022 Revolving Credit Facility and (ii) a decrease in repayment of $10.5 million for the 2022 Term Loan and note payable.
Net cash provided by financing activities was $44.3 million for the year ended December 31, 2023. The change was primarily driven by: (i) proceeds from the PIPE Investments of $70.0 million, (ii) an increase in proceeds of $35.0 million from the 2022 Revolving Credit Facility, and (iii) a decrease in proceeds from repayment of $59.3 million for the 2022 Term Loan, 2022 Revolving Credit facility, and note payable.
Critical Accounting Estimates
The preparation of our audited annual consolidated financial statements and related notes requires us to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time. We periodically review our estimates and make adjustments when facts and circumstances dictate. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company’s consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statements of shareholders’ equity, and consolidated statements of cash flows.
An accounting estimate policy is considered to be critical if it requires an estimate to be made based on assumptions about matters that are highly uncertain at the time it is made. An accounting estimate policy is also considered critical if our audited consolidated financial statements could be materially impacted by (i) reasonable, alternative estimates or (ii) changes in the accounting estimates that are reasonably likely to occur on a periodic basis. We believe that our critical accounting policies reflect the more significant estimates and assumptions used in the preparation of our audited consolidated financial statements. The critical accounting policies, judgments and estimates should be read in conjunction with the financial statements and the notes thereto within this Report.
We believe the following critical accounting policies, estimates and assumptions may have a material impact on our reported financial condition and operating performance and may involve significant levels of judgment to account for highly uncertain matters or are matters susceptible to significant change.
Revenue Recognition
We recognize revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”), which establishes principles for recognizing revenue at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. Our revenue is derived from two main sources: (1) product sales and (2) royalties from brand name licensing.
Revenue from the sale of products to customers is recognized at a point in time when control of the product transfers to the customer, based on assessment of payment and shipping terms impacting our right to payment, transfer of legal title, physical possession, and assumption of risks and rewards. When promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.
Royalty revenue from the licensing arrangements is recognized when the product sale occurs.
68

We sell products directly to consumers via our e-commerce platforms, to distributors in the U.S. and internationally, and through retailers. Our distributors may resell products to retailers, spas or other end consumers.
To determine when to recognize revenue under ASC 606, in cases where we sell products to the Physician Channel Provider or distributors who then resell the products to end customers, we use judgment to determine which party controls the products and when that control transfers from us to the distributor. We analyze various factors including our ability to direct products physically held by distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end customer. When we are able to direct products physically held by a distributor – such as determining which end customers’ orders are fulfilled when there is limited product inventory – we conclude that the distributor does not control the product for purposes of ASC 606 until we relinquish those abilities.
In addition, Obagi Medical’s distributors charge fees for certain services that they render to us. The services provided are in connection with the distribution of our products and include packing and shipping, marketing and advertising, monitoring product reviews, providing customer service, and generating data and analytical reports on product sales. Fees to distributors for these services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors’ purchase of products.
Typically, customers are required to pay either in advance or between 30 and 90 days from delivery of the product or invoicing. However, in certain circumstances, we offer extended payment terms to customers. In addition, certain customers may not comply with formal payment terms specified in their written agreements with us. If the period between the transfer of control of the products and payment is expected to be greater than one year, we adjust the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which we are effectively financing the customer, a portion of the transaction price is recognized as interest income rather than revenue using a discount rate that reflects the rate that would be used in a separate financing transaction between us and the customer. We exercise judgment to determine an appropriate interest rate considering the customer’s credit characteristics and current economic conditions. For the periods included in the financial statements in this Report, a 5% change in the discount rate would not have had a material impact on the amount of net revenue or interest income recorded.
When payment terms are significantly extended after the execution of a written agreement or a customer has a pattern of late or insufficient payments, we perform an assessment to determine whether it is probable that we will collect substantially all of the consideration owed to us from that customer. When making this assessment, we consider various factors including our history with the customer and the customer’s payment history, credit rating, current financial condition, and any known facts that could otherwise impact the customer’s intent or ability to pay us. If we determine that it is not probable that we will collect substantially all of the consideration owed by the customer, we record an impairment of the customer’s accounts receivable balance.
Customers place orders for products through separate purchase orders under our written agreements with them. If the written agreement with a customer does not meet all of the criteria for a contract under ASC 606, each purchase order for products is regarded as a contract separate and apart from the written agreement between us and the customer. If we determine that it is not probable that we will collect substantially all of the consideration from the customer, we generally recognize revenue for each purchase order only after we have transferred the related products and received all or substantially all of the payment for that purchase order.
Goodwill
We assess goodwill annually on October 1st each year for impairment and at an interim date if indicators of a potential impairment exist. We have two goodwill reporting units, which we test for impairment at the reporting unit level.
Our initial review for impairment of goodwill includes considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If we determine that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is then performed to identify goodwill impairment.
Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. The fair value of our reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of
69

judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by our management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the most recent projected long-term financial forecasts for revenue, earnings, capital expenditures and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the applicable reporting unit. Under the guideline public company method, we estimate fair value by using market multiples of various financial metrics observed for comparable public companies to the reporting unit.
The Company performed its annual goodwill impairment analysis using the quantitative approach on October 1, 2024, and the analysis indicated there was an impairment of goodwill. As a result, we recorded a non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit as of December 31, 2024, as reflected in the consolidated financial statements.
As of December 31, 2024, the Obagi Medical reporting unit had a goodwill balance of $194.5 million. For the Obagi Medical reporting unit, the carrying value of the reporting unit was equal to its fair value as of the annual impairment test date due to the impairment recognized in the period, leaving no remaining fair value cushion.
Given this lack of margin, if we are not successful in meeting our projected revenue or profitability growth rates, or if market conditions including inflation, the valuation of our peer group, a market capitalization decrease, or other negative factors exist, there could be a decrease in the fair value of the Obagi Medical reporting unit below the carrying value resulting in additional impairments in the near term. We continue to monitor these conditions closely and will reassess impairment as necessary, in advance of our annual impairment assessment.
The Milk Makeup reporting unit had a goodwill balance of $135.1 million as of December 31, 2024. We have not performed a quantitative review of the reporting unit during 2024, as qualitative factors and circumstances did not indicate that the fair value of the reporting unit was less than the carrying value on October 1, 2024. As a result, the goodwill balance for the reporting unit has not changed.
For the year ended December 31, 2023 the annual impairment assessment performed did not indicate any impairment of goodwill for Obagi Medical or Milk Makeup.
Further impairment charges, if any, may be material to our results of operations and financial position. See “Item 3.D. Risk Factors—We may face impairment of intangible assets, unknown or contingent liabilities and other charges or write-downs that could negatively impact our financial condition, profitability, and the value of our securities.
Deferred Tax Assets (and Related Valuation Allowance)
We recognize net deferred tax assets to the extent that we believe these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If we determine that deferred tax assets may be able to be recognized in the future in excess of their net recorded amount, we adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. We record uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. This requires management to make judgments and estimates regarding: (i) the timing and amount of the reversal of taxable temporary differences; (ii) expected future taxable income; and (iii) the impact of tax planning strategies. Future changes to tax rates would also impact the amounts of deferred tax assets and liabilities and could adversely affect our financial statements. A valuation allowance of $22.5 million was recorded as of December 31, 2024 and has been provided for predominantly on the deferred tax assets related to the Company’s investment in Waldencast Partners LP. As of December 31, 2023, the Company had recorded a valuation allowance of $19.8 million. See “Item 8. Financial Information—Note 15, Income Tax Benefit.”
70

Business Combinations
When we acquire a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.
Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received and may not exceed one year from the acquisition date. We may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in our consolidated statements of operations and comprehensive loss.
Emerging Growth Company Accounting Election
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. We are an “emerging growth company” as defined in Section 2(a) of the Securities Act, and have elected to take advantage of the benefits of this extended transition period, which means that when a standard is issued or revised and has different application dates for public or private companies, we, for so long as we remain an emerging growth company, will adopt the new or revised standard at the time private companies are required to adopt the new or revised standard.
Recent Accounting Pronouncements
See “Item 8. Financial Information—Note 2. Summary of Significant Accounting Policies” for more information regarding recent accounting pronouncements.
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks in the ordinary course of our business, which primarily relate to fluctuations in interest rates, foreign exchange and inflation.
Interest Rates
We have interest rate risk with respect to our indebtedness. As of December 31, 2024, we had an aggregate face value of $169.0 million of outstanding indebtedness, all of which has variable interest rates. A one percent increase or decrease in the annual interest rate on our variable rate borrowings of $169.0 million would have increased or decreased our annual cash interest expense by approximately $1.7 million.
Foreign Exchange Fluctuations
We transact business in multiple currencies worldwide, of which the most significant currency for the year ended December 31, 2024 and the year ended December 31, 2023 was the U.S. dollar. Our international revenue, as well as costs and expenses denominated in foreign currencies, expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. As of December 31, 2024, the effect of a hypothetical 10% change in foreign currency exchange rates would not have been material to our financial condition or results of operations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.
Inflation
We do not believe that inflation has had a material effect on our business, financial condition, or results of operations to date; however, we continue to monitor the effects of the global macroeconomic environment, including inflationary
71

pressures. Generally, we have been able to introduce new products at higher prices, increase prices on select products and implement other operating efficiencies to sufficiently offset cost increases.
Trend Information
Other than as disclosed elsewhere in this Report, we are not aware of any trends, uncertainties, demands, commitments or events for the year ended December 31, 2024 that are reasonably likely to have a material effect on our net sales or revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results of operations or financial condition.
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A.Directors and Senior Management
The following table sets forth the names, ages and positions of our current directors and executive officers as of the date of this Report:
NameAgePosition
Executive Officers/Directors
Michel Brousset52Chief Executive Officer and Class III Director
Hind Sebti46
Chief Growth Officer and Class II Director
Manuel Manfredi49Chief Financial Officer
Non-Employee Directors
Felipe Dutra59Class III Director
Cristiano Souza50Class II Director
Kelly Brookie
57
Class I Director
Juliette Hickman51Class II Director
Lindsay Pattison52Class I Director
Zack Werner36Class I Director
Aaron Chatterley58Class II Director
Simon Dai33Class III Director
Roberto Thompson Motta
67
Class III Director
Executive Officers
Michel Brousset has served as a director on our Board and our Chief Executive Officer since January 2021. Mr. Brousset has more than 25 years of experience leading, operating and building global brands at L’Oréal (PAR: OR) and Procter & Gamble (NYSE: PG) where he worked to launch and build iconic brands across multiple geographies. Most recently, Mr. Brousset founded Waldencast Ventures LP (“Waldencast Ventures”), a holding company and investment vehicle, in 2019 and has been the Chief Executive Officer since its inception. Waldencast Ventures partners with, creates, incubates and accelerates next-generation and early-stage beauty and wellness brands. Mr. Brousset has led investments in the current and former Waldencast Ventures portfolio companies.
Prior to founding Waldencast Ventures, Mr. Brousset was the Group President of L’Oréal’s Consumer Products Division in North America from July 2016 to April 2019. In this role, Mr. Brousset managed each of the Presidents of key L’Oréal brands and the Presidents and cross-functional teams of L’Oréal Canada CPD and L’Oréal Caribe, as well as the heads of supply chain, finance, human resources (“HR”), information technology (“IT”), legal, research and development and consumer and market intelligence (“CMI”). As the Group President of L’Oréal’s Consumer Products Division in North America, Mr. Brousset led multiple strategic initiatives and acquisitions.
Additionally, Mr. Brousset was the Chief Executive Officer and Managing Director of L’Oréal U.K. & Ireland between July 2013 and July 2016, where he managed a broad portfolio of brands and all the divisions of L’Oréal for the U.K, and Ireland. In addition, he managed across all functional areas including supply chain, finance, HR, IT, CMI, legal and regulatory. Mr. Brousset also spent nearly 14 years at Procter & Gamble in various marketing and brand management roles across North America and Western Europe.
72

Mr. Brousset currently serves as a member of the board of directors of several Waldencast Ventures portfolio companies. Our Board has implemented guidelines, pursuant to which, unless and until we and Waldencast Ventures merge or otherwise become affiliated entities, Mr. Brousset will spend on average at least 90% of his monthly average working time providing services to us, such that a maximum of 10% may be spent to provide services to Waldencast Ventures. Mr. Brousset holds a B.S. in Economics from the Universidad del Pacífico in Peru and an M.B.A. from the University of North Carolina - Kenan-Flagler Business School.
Hind Sebti has served as our Chief Growth Officer since February 2021 and as a director on our Board since September 2024. Ms. Sebti has more than 20 years of experience leading and managing beauty brands across multiple categories and stages during her tenures at L’Oréal (PAR: OR) and Procter & Gamble (NYSE: PG). Ms. Sebti co-founded Waldencast Ventures alongside Mr. Brousset in 2019. Ms. Sebti brings in-depth knowledge and understanding of the beauty industry as well as consumer insights to identify and invest in the next-generation beauty brands. Importantly, Ms. Sebti plays a key role in helping portfolio brands scale, leveraging her extensive multi-category and brand management experience. Previously, Ms. Sebti also served as Chief Executive Officer of Waldencast Brands, a subsidiary of Waldencast Ventures, to incubate and commercialize new brands, where she led the brand creation process, with a focus on creative and operational optimization, through all stages from conception and product development to go-to-market strategy. She remains involved in the business, however pursuant to guidelines implemented by the Board, unless and until we and Waldencast Ventures merge or otherwise become affiliated entities, Ms. Sebti will spend on average at least 80% of her monthly average working time providing services to us, such that a maximum of 20% may be spent to provide services to Waldencast Ventures.
Prior to Waldencast Ventures, Ms. Sebti held various leadership positions at L’Oréal from April 2013 to December 2018. She was the General Manager for Maybelline and Essie in the U.K. from July 2017 to December 2018. She also held the position of General Manager of professional haircare brands Redken, Pureology and Mizani from September 2015 to July 2017, where she focused on digitalization and consumer centricity to drive growth. Ms. Sebti began her tenure at L’Oréal as the Marketing Director of L’Oréal Paris and Consumer Division Category Director. Prior to L’Oréal, Ms. Sebti held various Business Leader and Brand Manager positions at Procter & Gamble in the U.K., Ireland and France across brands such as Olay Skin Care and Gillette Venus from January 2002 to March 2013. Ms. Sebti serves as a member of the board of directors of Cosmetic Executive Women U.K. and holds a Master’s degree in Industrial Engineering from The National Institute of Applied Science of Lyon. Ms. Sebti currently serves as Chairperson of the board of directors of Kjaer Weis, a Waldencast Ventures portfolio company.
Manuel Manfredi has served as our Chief Financial Officer since April 2024. Mr. Manfredi has a proven track record of performance having led financial organizations in the beauty and consumer products industries for nearly 25 years. Most recently, Mr. Manfredi served as Chief Financial Officer at L’Oréal Spain and Portugal, a role he has occupied since 2022. Previously Mr. Manfredi served as Chief Financial Officer for Italy (2019-2022), Chief Financial Officer for Spain (2015-2019) and in other senior financial roles at L’Oréal, managing multi-billion-dollar businesses across Europe and North America. While at L’Oréal, Mr. Manfredi played a key role in the acquisition and integration of a new cosmetics brand, executed several transformation projects of the finance, commercial, and back-office functions, and helped unlock value and growth through strong industry and operational expertise. Mr. Manfredi began his finance career at Procter & Gamble Europe in 1998, and holds a Business Management degree from the Universidad of Sevilla.
Non-Employee Directors
Felipe Dutra has been a director and the executive chairman of the Board since January 2021. Mr. Dutra served as the Chief Financial Officer at Anheuser-Busch InBev (Euronext: ABI) (NYSE: BUD) (MEXBOL: ANB) (JSE: ANH) from January 2005 to April 2020 and played an instrumental role in building AB InBev from a regional Brazilian brewer into the world’s largest brewer and a top five global consumer goods company according to sales through numerous landmark acquisitions. Mr. Dutra’s contributions to AmBev, AB InBev’s current subsidiary, stretch back to 1990. He held multiple leadership positions in Treasury and Finance at AmBev before being appointed to Chief Financial Officer in 2000. In addition to being a seasoned deal maker, over the course of his 15-year tenure as Chief Financial Officer of AB InBev, Mr. Dutra took on the additional role of Chief Technology Officer in 2014 to lead the company’s adoption of digital technology and implementation of data analytics. Mr. Dutra also served as a Board Director of AmBev (BOVESPA: ABEV) (NYSE: ABEV) from January 2005 to May 2020, Grupo Modelo from December 2010 to June 2013 and Budweiser APAC from
73

September 2019 to June 2020. He holds a degree in Economics from Universidade Candido Mendes and an M.B.A. from Universidade de São Paulo in Brazil. Mr. Dutra serves as a member of our Finance Committee.
Cristiano Souza has been a director of Waldencast since January 2021. Mr. Souza is the managing partner at Zeno Equity Partners LLP (“ZEP”). Based out of the United Kingdom, ZEP is the investment manager of the Zeno Investment Fund (ZIF) (f/k/a Dynamo Investment Fund) an investment fund focused on long-term equity investments. Prior to becoming managing partner at ZEP, Mr. Souza spent 29 years as a partner of Dynamo Administração de Recursos and nine years as a partner of Dynamo Capital LLC, where he was an analyst and portfolio manager of funds managed and advised by both entities. Mr. Souza has a Bachelor’s degree in Economics from Candido Mendes University in Rio de Janeiro. Mr. Souza serves as the Chairperson of our Finance Committee.
Juliette Hickman has served as an independent director on our Board since March 2021. Ms. Hickman served as an investment analyst at the Capital Group Companies for more than 20 years, with exposure to a broad range of industries on a global basis and specific expertise and focus on the global beverage industry. Throughout her career, Ms. Hickman has gained extensive expertise in corporate strategy, valuation, mergers and acquisitions, financial analysis, and risk assessment. She also serves on the Board of Keurig Dr Pepper. Ms. Hickman holds a Bachelor’s of Arts (hons) degree in Politics and Public Administration from the Nottingham Trent University and a Postgraduate Certificate in Sustainable Business from the Cambridge Institute of Sustainability Leadership (CISL). Ms. Hickman serves as the Chairperson of our Audit and Governance Committee and also serves as a member of our Compensation and Nominating Committee, and as a member of our Finance Committee.
Lindsay Pattison has served as an independent director on our Board since March 2021. In January 2024, Ms. Pattison was appointed Chief People Officer of WPP, reporting to CEO Mark Read. In this role Ms. Pattison plays a pivotal role in shaping the workforce strategy for WPP’s 113,000 employees and oversees initiatives aimed at maximizing the potential of WPP’s scale while fostering long-term career opportunities for its workforce. Ms. Pattison’s areas of focus encompass a wide range of crucial aspects including the impact of AI on the workforce, talent acquisition, learning and development, employee engagement, impact and inclusion, and HR information systems.
Prior to this Ms. Pattison served as Chief Client Officer from 2018 with a focus on client centricity, and overseeing 40+ Global Client Leaders, who led the largest accounts with 35,000 colleagues globally. As CCO, she ensured that WPP’s major clients had access to the combined strengths of WPP, that the best talent were working on the client teams, and that they collaborate effectively with WPP companies and Country Managers to deliver fully integrated solutions for clients.
The CCO role followed Ms. Pattison’s role as Chief Transformation Officer for GroupM and WPP. She was previously global CEO of Maxus, a WPP media agency. Her experience also includes roles at Young and Rubicam and PHD Media, as well as a client-side role with Sony Ericsson.
Ms. Pattison is a passionate advocate for business leaders taking meaningful action to improve gender equality, launching a WPP-wide, global initiative (‘Walk the Talk’) to help senior women overcome the barriers to achieving their potential. She is also an ex-President of WACL (Women in Advertising & Communications London), a non-executive director on the board of Design Bridge, Senior Independent NED for the Rugby World Cup (England 2025), serves on the Board of Waldencast, and sits on the Advisory Board of Planet First Partners. Ms. Pattison serves as the Chairperson of our Compensation and Nominating Committee.
Zack Werner has served as an independent director on our Board since March 2021. Mr. Werner founded The Maze Group in 2016, a highly technical strategic consultancy focused on data architecture and driving growth through digital marketing. Maze partners with private equity owned and public clients such as LVMH, HelloFresh, JC Penney, General Electric, and Pat McGrath Labs to optimize customer acquisition, conversion rate, and retention as well as provide strategies around technology platform and infrastructure transformation. The Maze Group also partners with private equity clients to co-invest in consumer companies. Mr. Werner also started his career at Universal Music Group from 2011 until 2013, where he focused on digital distribution deals, customer relationship management and integrated marketing systems. In addition, in 2017, Mr. Werner became an advisor for Stadium Goods, a sneaker and streetwear marketplace, to oversee e-commerce and growth. Mr. Werner serves as a member of our Audit and Governance Committee and as a member of our Compensation and Nominating Committee Meeting.
Simon Dai has served as a director on our Board since the consummation of the Business Combination. Mr. Dai has served on the board of directors of Obagi Medical since September 2019, including as its Chairman since July 2020, and has led several investments in the healthcare space. Since January 2020, Mr. Dai has served as the Co-Chairman and Chief
74

Executive Officer of Presbia PLC, a medical device company focused on the development of the presbyopia-correcting lens, an innovative solution for the common age-related loss of the ability to read or focus on near objects. He also co-founded Oxford MEStar in October 2013, a spin-out company from the Institute of Biomedical Engineering of Oxford University specializing in automation solution, serving as its Chief Executive Officer from October 2016 until August 2020. Previously, Mr. Dai focused on impact investing at Bill & Melinda Gates Foundation, where he was a Liaison Officer based in Ethiopia. Mr. Dai received a BA in Sociology from Manchester University, an MSc. in Finance from the London School of Economics and an MBA from the UCLA Anderson School of Management.
Mr. Dai has been appointed to our Board of by Cedarwalk pursuant to the Investor Rights Agreement, dated as of July 27, 2022, by and among us, Cedarwalk and CWC Skincare Ltd. as guarantor of Cedarwalk’s obligations thereunder (the “Investor Rights Agreement”). For additional information regarding the Investor Rights Agreement, see “Item 7. Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” in this Report.
Aaron Chatterley has served as an independent director on our Board since December 2021. Mr. Chatterley founded the web development company SP New Media in 1996, where he served as the Chief Executive Officer until selling the company in 2000. In 2005, Mr. Chatterley co-founded the online beauty retailer, feelunique, where he served as the Chief Executive Officer until April 2014. Mr. Chatterley led the partial sale of feelunique to Palamon Capital Partners in December 2012, as well as the sale of feelunique to LVMH/Sephora in September 2021. In October 2021 he co-founded the teen beauty brand indu. In addition, since 2016 Mr. Chatterley has served as a Non-Executive Director of Digital Jersey, an economic development agency, and currently serves as an audit and risk committee member. Mr. Chatterley also serves as an Ambassador for The Prince’s Trust Women Supporting Women, a youth charity organization. Mr. Chatterley services a a member on our Compensation and Nominating Committee. Mr. Chatterley serves as a member of the Audit and Governance Committee and the Compensation and Nomination Committee .
Kelly Brookie has served as an independent director on our Board since September 2024. Ms. Brookie has years of experience in the areas of corporate strategy, valuation, financial analysis, and risk assessment. She served as an audit partner with Deloitte and has over 25 years of experience working with companies on accounting and auditing matters, transactions, transformation and strategic risks. Throughout her career, she has gained extensive expertise in financial accounting and reporting, internal controls processes, and governance. She is active in supporting multiple non-profit organizations including serving on boards and committees. She is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants. Ms. Brookie received her Bachelor's Degree in Political Science from the University of Washington and a Master of Accounting from University of Southern California. Ms. Brookie serves as a member of the Audit and Governance Committee.

Roberto Thompson Motta has served as an independent director on our Board since September 2024. Mr. Thompson is a co-founder and member of the Investment Committee of 3G Capital, a global investment firm headquartered in New York. Mr. Thompson currently serves in the board of directors of AB InBev as strategic advisor and served as a board member since 2004. Mr. Thompson has served on the board of directors of AmBev S.A, Restaurant Brands International, Lojas Americanas S.A., and StoneCo Ltd. He was one of the founding partners of GP Investments Ltd. and a member of its board of directors until 2010. He received a BS in Mechanical Engineering from Pontifícia Universidade Católica do Rio de Janeiro and an MBA from The Wharton School of the University of Pennsylvania. Mr. Thompson is a member of The Graduate Executive Board of The Wharton School of the University of Pennsylvania, and of The International Council of The Metropolitan Museum of Art in New York. He is also a Patron of the Museum of Modern Art of São Paulo. Mr. Thompson serves as a member of the Finance Committee.
Family Relationships
There are no family relationships between any of our executive officers and directors.
Board Diversity
Waldencast’s mission is to build a global best-in-class beauty and wellness operating platform by creating, nurturing, and scaling conscious, high growth, purpose-driven brands. Brands that aim to make the beauty industry a little better every day: more sustainable, more inclusive and more transparent.
For that reason, it is fundamental that our Board not only reflects our commitment to economic performance, but also our desire to create, nurture, and scale brands with a soul. Brands that marry purpose, art, beauty, and design with science, industry, and commerce to make the planet and the lives of those in it better. Our Board includes a variety of skills,
75

professional and industry backgrounds, geographical experience and expertise, gender, tenure, ethnicity, and diversity of thought.
We firmly believe that a diverse Board with a range of views, insights, perspectives, and opinions will support good decision making and be of benefit to the Company’s shareholders and all other stakeholders.
Board Diversity Matrix (as of December 31, 2024)
Country of Principal Executive Offices:
United Kingdom
Foreign Private IssuerYes
Disclosure Prohibited under Home Country LawNo
Total Number of Directors
11
Part I: Gender Identity
 FemaleMaleNon-BinaryDid not Disclose
Directors47
Part II: Demographic Background
Underrepresented in Home Country Jurisdiction4
LGBTQ+1
Did Not Disclose Demographic Background
B.Compensation
Fiscal Year 2024 Executive Officer and Director Compensation
The aggregate compensation paid and share-based compensation and other payments expensed by us and our subsidiaries to our executive officers with respect to the year ended December 31, 2024 was $9.7 million. For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer and other two most highly compensated executive officers on an individual, rather than an aggregate, basis.
During the year ended on December 31, 2024, our Chairman received $0.02 million in cash compensation for services rendered. None of the other directors received any cash compensation for services rendered to us.
Our Equity Plans
We maintain two equity incentive plans: (i) our 2022 Incentive Award Plan (the “2022 Plan”), which became effective upon the closing of the Business Combination, and (ii) our 2022 Inducement Incentive Award Plan (the “2022 Inducement Plan”), which became effective on September 16, 2022 (collectively, the “Equity Plans”).
Type of Awards
Under the 2022 Plan we may grant eligible officers, employees, non-employee directors and consultants restricted share units (“RSUs”) and performance-vested share units (“PSUs”), restricted stock, non-qualified options or “Incentive stock options,” share appreciation rights (“SARs”), other stock-based awards (valued in whole or in part by reference to, or otherwise based on, our ordinary shares, including divided equivalents) and bonuses payable in fully vested ordinary shares and awards that are payable solely in cash.
Under the 2022 Inducement Plan, we may grant RSUs, PSUs, non-qualified options, SARs, other stock-based awards (valued in whole or in part by reference to, or otherwise based on our ordinary shares, including dividend equivalents) and bonuses payable in fully vested ordinary shares to individuals who satisfy the standards for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules and the related guidance issued thereunder.
Share Reserves
As of December 31, 2024, we had reserved a total of 23,042,449 Class A ordinary shares for issuance under the 2022 Plan subject to adjustment for changes in capitalization as provided under the 2022 Plan. The share reserve under the 2022 Plan will automatically increase on January 1st of each calendar year (each, an “Evergreen Date”), prior to the tenth anniversary
76

of the Effective Date (as such term is defined in the 2022 Plan), in an amount equal to the lesser of (i) 3% of the total number of our Class A ordinary shares issued and outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) a number of our Class A ordinary shares determined by the plan administrator, including zero. All of our ordinary shares reserved for issuance under the 2022 Plan as of the Effective Date may be granted as incentive stock options.
As of December 31, 2024, we had a total of 1,852,352 Class A ordinary shares available for issuance under the 2022 Plan, subject to adjustment for changes in capitalization as provided under the 2022 Plan.
Administration
Our 2022 Plan is administered by our Board, unless the Board appoints a committee of directors to administer certain aspects of the 2022 Plan. In August 2022, the Board appointed the Compensation Committee as the “plan administrator” of the 2022 Plan. Our 2022 Inducement Plan is administered by our Board, unless the Board appoints a committee of directors to administer certain aspects of the 2022 Inducement Plan.
Terms of Awards
Under the terms of the Equity Plans, the exercise price of all options and stock appreciation granted under the Equity Plans will be determined by the plan administrator, but in no event may the exercise price be less than 100% of the fair market value of our related Class A ordinary shares on the date of grant, unless otherwise set forth in the applicable award agreement for an award grant under the 2022 Plan. Each stock option and free-standing SAR will vest and become exercisable (including in the event of the optionee’s termination of employment or service) at such time and subject to such terms and conditions as determined by the plan administrator in the applicable individual option agreement.
Under the Equity Plans, the plan administrator may grant RSUs, PSUs, restricted stock awards, stock options and SARs that are subject to vesting, forfeiture and other terms and conditions as determined by the plan administrator in the applicable award agreement. The applicable individual award agreement may provide for the lapse of restrictions in installments or the acceleration or waiver of restrictions (in whole or part) under certain circumstances as set forth in the applicable individual award agreement, including the attainment of certain performance goals, a recipients’ termination of employment or service, or a recipient’s death or disability.
In the event that a “change in control” (as such term is defined in the Equity Plans) occurs, each award granted under the Equity Plans, as applicable, will continue to operate in accordance with its terms, subject to adjustment (including, without limitation, assumption or conversion into equivalent awards of the acquirer’s equity).
Under the Equity Plans, if (i) a change in control occurs and (ii) either (x) an outstanding award is not assumed or substituted in connection with such change in control or (y) an outstanding award is assumed or substituted in connection with such change in control and a recipient’s employment or service is terminated without cause or by the recipient for good reason (if applicable) within 12 months following the change in control, then, except as provided in the applicable award agreement, (i) any unvested or unexercisable portion of an award carrying a right to exercise will become fully vested and exercisable and (ii) the restrictions, deferral limitations, payment conditions and forfeiture conditions applicable to any other award granted under the 2022 Plan will lapse, the awards will vest in full and any performance conditions will be deemed to be achieved at target performance levels.
Amendments and Plan Termination
The Equity Plans provide the Board with the authority to amend, alter or terminate the Equity Plans, but no such action may adversely affect the rights of any recipient with respect to outstanding awards without the recipient’s consent. The applicable plan administrator may amend an award, prospectively or retroactively, but no such amendment may adversely affect the rights of any recipient without the recipient’s consent. Shareholder approval of any such action under the 2022 Plan will be obtained if required to comply with applicable law.
No award will be granted pursuant to the 2022 Plan on or after July 27, 2032, but awards granted before that date may extend beyond that date.
All awards granted under the Equity Plans will be subject to the provisions of any clawback policy implemented by us (including the policy adopted by us in November 2023 in accordance with the requirements of the Dodd-Frank Wall Street
77

Reform and Consumer Protection Act and the applicable Nasdaq listing standards) to the extent set forth in such clawback policy, and will be further subject to such deductions and clawback as may be required to be made pursuant to any law, government regulation or stock exchange listing standard.
Grants Made to Executive Officers of the Company under the Equity Plans
During the year ended on December 31, 2024, the Company granted our Chief Financial Officer 588,016 strategic growth incentive performance vested share units in an amount up to 200% of the target share units allocated to the program, which are based on meeting the respective Company’s net revenue and EBITDA targets for the year ended December 31, 2027. The Company also granted 396,444 restricted stock units to its Chief Executive Officer, 290,723 restricted stock units to its Chief Growth Officer, and 118,933 restricted stock units to its Chief Financial Officer. The restricted stock units vest in equal installments over three years beginning on the first anniversary of the grant date.
During the year ended on December 31, 2023, the Company granted our then-current Chief Financial Officer a strategic growth incentive award of 250,000 performance share units at target (the “CFO SGI Award”) under the 2022 Inducement Plan. In connection with our former Chief Financial Officer’s voluntary termination of employment in January 2024, the CFO SGI Award was fully forfeited and cancelled, in accordance with the applicable award agreement, without payment of any consideration by the Company. During the year ended on December 31, 2023, none of our other executive officers were granted equity incentive awards under the Equity Plans.
C.Board Practices
Composition of the Board of Directors
Our business and affairs are managed under the direction of our Board. As of the date of this Report, our Board consists of eleven directors. Subject to the terms of the Investor Rights Agreement, our Constitutional Document provides that the number of directors on our Board will be fixed by our Board.
When considering whether directors and director nominees have the experience, qualifications, attributes and skills, taken as a whole, to enable our Board to satisfy its oversight responsibilities effectively in light of its business and structure, our Board focuses primarily on each person’s background and experience in order to provide an appropriate mix of experience and skills relevant to the size and nature of the business.
Pursuant to our Investor Rights Agreement with Cedarwalk, the Sponsor and CWC Skincare Ltd., the guarantor of Cedarwalk’s obligation thereunder, we have agreed to take all necessary action to cause our Board to be comprised of one director nominated by Cedarwalk for as long as Cedarwalk owns 5% of our then outstanding Ordinary Shares. Mr. Simon Dai has been elected as the initial director nominee of Cedarwalk, and serves as a Class III director. See “Item 7. Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” for more information on the Investor Rights Agreement.
Classified Board of Directors
In accordance with the terms of our Constitutional Document, our Board may consist of no less than five, but no more than 15 natural persons, such number to be set by the Board by resolution from time to time. Our Board is divided into classes of directors that will serve staggered three-year terms. At each annual meeting of shareholders, a class of directors will be elected for a three-year term to succeed the same class whose term is then expiring. As a result, only one class of directors will be elected at each annual meeting of our shareholders, with the other classes continuing for the remainder of their respective three-year terms. Our Board is divided among the three classes as follows:
the Class I directors, which are Lindsay Pattison, Zack Werner and Kelly Brookie, and their terms will expire at the annual meeting of shareholders to be held in 2026;
the Class II directors, which are Aaron Chatterley, Juliette Hickman, Cristiano Souza and Hind Sebti, and their terms will expire at the annual meeting of shareholders to be held in 2027; and
the Class III directors, which are Michel Brousset, Felipe Dutra, Simon Dai and Roberto Thompson Motta, and their terms will expire at the annual meeting of shareholders to be held in 2025.
78

Each director’s term will continue until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our Board may have the effect of delaying or preventing changes in control our company.
Director Independence
As a result of our Class A ordinary shares being listed on Nasdaq, we are required to comply with the applicable rules of the Nasdaq in determining whether a director is independent. We believe that each of Ms. Kelly Brookie, Ms. Juliette Hickman, Ms. Lindsay Pattison, Mr. Zack Werner and Mr. Aaron Chatterley qualifies as “independent” as defined under the applicable Nasdaq rules.
Foreign Private Issuer Status
For so long as we qualify as a foreign private issuer, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:
the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and imposing liability for insiders who profit from trades made within a short period of time;
the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;
the rules under the Exchange Act requiring the filing with the SEC of an annual report on Form 10-K (although we will file annual reports on a corresponding form for foreign private issuers), quarterly reports on Form 10-Q containing unaudited financial and other specified information (although we will file semi-annual financial information on a current reporting form for foreign private issuers), or current reports on Form 8-K, upon the occurrence of specified significant events; and
Regulation Fair Disclosure or Regulation FD, which regulates selective disclosure of material non-public information by issuers.
Accordingly, there may be less publicly available information concerning our business, executive compensation and other matters than there would be if we were a U.S. public company. Additionally, certain accommodations in the Nasdaq corporate governance standards allow foreign private issuers, such as us, to follow “home country” corporate governance practices in lieu of the otherwise applicable corporate governance standards. To that end, we have elected to follow our home country practices, which do not require us to have a majority of independent directors on our Board. However, we continue to comply with the applicable requirements of the Nasdaq listing rules and SEC rules, including with respect to the composition of our Audit and Governance Committee and to our Compensation and Nomination Committee, as further detailed below.
Committees of the Board of Directors
Our Board directs the management of our business and affairs, as provided by Jersey law, and conducts its business through meetings of our Board and standing committees. We have three standing committees: (i) an audit and governance committee (the “Audit and Governance Committee”), (ii) a compensation and nomination committee (the “Compensation and Nomination Committee”) and (iii) a finance committee (the “Finance Committee”).
In addition, from time to time, special committees may be established under the direction of our Board when it deems it necessary or advisable to address specific issues. Copies of the charters for each committee are available on our website, www.waldencast.com, as required by applicable SEC and Nasdaq rules. The information on or available through our website is not deemed incorporated in this Report and does not form part of this Report.
79

Audit and Governance Committee
The Audit and Governance Committee’s responsibilities include, among other things:
assisting board oversight of (i) the integrity of our financial statements, (ii) our compliance with legal and regulatory requirements, (iii) our independent auditor’s qualifications and independence and (iv) the performance of our internal audit function and independent auditors;
the appointment, compensation, retention, replacement and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us;
pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;
reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence;
monitoring compliance by the independent auditors with the audit partner rotation requirements contained in applicable laws and regulations;
discuss guidelines and policies governing the process by which senior management of the Company assess and manage the Company’s exposure to risk, as well as the Company’s major financial risk exposures and the steps management has taken to monitor and control such exposures;
monitoring our compliance with the employee conflict of interest requirements contained in applicable laws and regulations;
obtaining and reviewing a report from the independent auditors describing (i) all critical accounting policies and practices to be used; (ii) any critical audit matters arising from the current period audit; (iii) all alternative treatments of financial information that have been discussed by the independent auditors and management, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent auditors; (iv) all other material written communications between the independent auditors and management, such as any management letter and any schedule of unadjusted audit differences; and (v) any material financial arrangements which do not appear on our financial statements;
reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures on a regular basis;
obtaining and reviewing a report, at least annually, from our management, attested to by the independent auditors, assessing the effectiveness of our internal control over financial reporting and stating management’s responsibility for establishing and maintaining adequate internal control over financial reporting prior to its inclusion in our Annual Report on Form 20-F or Form 10-K, as applicable;
meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor;
reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction;
reviewing with our legal advisors, when appropriate, any legal, regulatory matters, including any matters (i) that may have a material impact on our financial statements and (ii) involving potential or ongoing material violations of law or breaches of fiduciary duty by us or any of our directors, officers, employees, or agents or breaches of fiduciary duty to us;
establishing procedures for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, and (ii) the confidential, anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters;
reviewing the corporate governance principles adopted by the Board and recommending changes as necessary;
considering other corporate governance issues as they arise and developing appropriate recommendations;
periodically reviewing the size of the Board and recommending changes;
making recommendations on the frequency and structure of Board meetings;
making recommendations concerning any other aspect of Board procedures;
recommending to the Board the size and composition of each standing committee, including identifying individuals qualified to serve on committees, and recommending directors to fill any committee vacancies;
monitoring the functioning and effectiveness of the Board committees and recommending any changes, including the creation or elimination of committees;
80

reviewing annually committee assignments and the policy on rotation of committee memberships and/or chairpersonships, and reporting any recommendations to the Board; and
recommending the establishment of special committees by the Board to address ethical, legal, or other matters.
The Audit and Governance Committee consists of Juliette Hickman, Aaron Chatterley, Kelly Brookie and Zack Werner, with Juliette Hickman serving as chair. Our Board has determined that each of the members of the Audit and Governance Committee qualifies as independent under the Nasdaq rules applicable to members of our Board generally and under the Nasdaq rules and Exchange Act Rule 10A-3 specific to audit committee members and that each of the members of the Audit and Governance Committee meets the requirements for financial sophistication under the applicable Nasdaq rules. In addition, our Board has determined that Juliette Hickman qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K.
Compensation and Nomination Committee
The functions of the Compensation and Nomination Committee include, among other things:
reviewing and approving compensation plans for the Company’s executive officers and recommending to the Board for approval;
evaluating on an annual basis the performance of the Company’s executive officers, taking into consideration, among other things the short-term and long-term goals and objectives of the Company’s executive compensation plans and determining and approving the remuneration of our executive officers (other than our Chief Executive Officer and our Chief Growth Officer) and recommending to our Board the remuneration of our Chief Executive Officer and our Chief Growth Officer; in each case, based on such evaluations;
reviewing and making recommendations to our Board with respect to the compensation, and any incentive-compensation and equity-based plans that are subject to the Board’s approval;
determining and approving any grants of equity awards to be made to eligible participants (other than our Chief Executive Officer and our Chief Growth Officer) and recommending to the Board for approval any equity awards to be made to our Chief Executive Officer and our Chief Growth Officer;
implementing and administering our incentive compensation and equity-based remuneration plans;
assisting management in complying with our proxy statement and annual report disclosure requirements and recommending to the Board for approval, if necessary;
approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;
producing a report on executive compensation to be included in our annual report on Form 20-F or Form 10-K, as applicable;
reviewing and approving the terms of any compensation “clawback” or similar policy or agreement between the Company and our executive officers or other employees, as deemed necessary or as required by applicable law;
reviewing, evaluating and recommending changes, if appropriate, to the remuneration for non-employee directors;
assisting in identifying, recruiting, and evaluating Board candidates, establishing procedures for shareholder nominations, and recommending director nominees to the Board based on established criteria and qualifications;
reviewing the suitability of current directors for continued service;
reviewing the composition of the Board annually, ensuring the appropriate balance of knowledge, experience, skills, expertise, diversity, and compliance with applicable regulatory requirements;
making recommendations on committee memberships and filling vacancies;
developing and recommending succession plans for the chief executive officer and senior management positions; and
overseeing an annual evaluation of the Board and management and reporting on performance and effectiveness, establishing procedures for this evaluation.
The Compensation and Nomination Committee consists of Lindsay Pattison, Aaron Chatterley, Zack Werner and Juliette Hickman, with Lindsay Pattison serving as chair. Our Board has determined that each of the members of the compensation committee meets the independence requirements under Nasdaq and SEC rules. Our Board has determined that each member of this committee will also be a “non-employee director” within the meaning of Rule 16b-3 under the Exchange Act.
81

The composition and function of the Compensation and Nomination Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and regulations. We will comply with future requirements to the extent they become applicable.
Finance Committee
The oversight functions of the Finance Committee include, among other things:
help ensure the review the Company’s capital structure and borrowing position to support the Company’s strategic objectives;
reviewing the annual budget and long range plans, including three-year forecasts and submitting recommendations to the Board;
reviewing material capital expenditure not included in the annual budget and providing recommendations to the board;
reviewing and monitoring the Company’s quarterly performance;
reviewing and monitoring the Company’s treasury management;
reviewing and monitoring the Company’s mergers and acquisitions process;
periodically reviewing and assessing the Company’s tax structure and submitting any amendments for recommendation to the Board;
reviewing material reduction-in-force or layoff’s; and
assisting the Board and the Company’s management in ensuring that the Company communicates effectively with the financial community.
The Finance Committee consists of Cristiano Souza, Juliette Hickman, Felipe Dutra and, Roberto Thompson Motta, with Cristiano Souza serving as the chair. Our Board has determined that each member of the Finance Committee qualifies for service on the committee.
Compensation and Nomination Committee Interlocks and Insider Participation
None of the members of the Compensation and Nomination Committee is currently, or has been at any time, one of our officers or employees. None of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or compensation committee.
D.Employees
Information pertaining to Waldencast’s employees is set forth in “Item 4 Information on the Company—4.B. Business Overview” of this Report.
E.Share Ownership
Information pertaining to Waldencast’s share ownership is set forth in “Item 7. Major Shareholders and Related Party Transactions—7.A. Major Shareholders” of this Report.
F.Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation
Not applicable.
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A.Major Shareholders
The following table sets forth information regarding the beneficial ownership of Ordinary Shares as of February 28, 2025 by:
each person known by us to be the beneficial owner of more than 5% of Ordinary Shares;
82

each of our directors and executive officers; and
all our directors and executive officers as a group.
Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if that person possesses sole or shared voting or investment power over that security. A person is also deemed to be a beneficial owner of securities that such person has a right to acquire within 60 days including, without limitation, through the exercise of any option, warrant or other right or the conversion of any other security. Such securities, however, are deemed to be outstanding only for the purpose of computing the percentage beneficial ownership of that person but are not deemed to be outstanding for the purpose of computing the percentage beneficial ownership of any other person. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities.
As of February 28, 2025, there were 112,054,383 Class A ordinary shares (not including 3,833,332 Class A ordinary shares subject to outstanding stock options held by our executive officers that are currently exercisable, but have not yet been settled) and 10,666,528 Waldencast Class B ordinary shares issued and outstanding.
Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all voting shares beneficially owned by them.
Name and Address of Beneficial Owner(1)
Class A
Ordinary Shares
% of
Class A
Ordinary
Shares
Outstanding
Class B
Ordinary
Shares(13)
% of
Combined
Voting
Power(14)
5% Holders
Cedarwalk Skincare Ltd(2)
28,637,50625.6 %23.3 %
Zeno Investment Master Fund(3)
20,360,70917.3 %15.8 %
Waldencast Long-Term Capital LLC (the Sponsor)(4)
12,412,26710.8 %9.9 %
Burwell Mountain Trust(5)
11,826,11010.2 %9.3 %
Annapurna Investment Fund Ltd(6)
6,662,2605.9 %5.3 %
Santa Venerina Inv. & Arbitrage Ltd.(7)    
10,000,0008.9 %8.1 %
Main Post Growth Capital, L.P.(8)
6,090,0585.4 %5.0 %
Directors and Executive Officers
Simon Dai(2)
28,637,50625.6 %23.3 %
Cristiano Souza(3)
20,360,70917.3 %15.8 %
Michel Brousset(9)
7,976,1136.8 %6.8 %
Hind Sebti(10)
1,086,666**
Sarah Brown(11)
20,000**
Aaron Chatterley20,000**
Juliette Hickman20,000**
Lindsay Pattison20,000**
Zack Werner20,000**
Philippe Gautier(12)
3,379**
Kelly Brookie— — 
Felipe Dutra(5)
— — 
Manuel Manfredi(12)
— — 
Roberto Thompson Motta— — 
All Waldencast directors and executive officers as a group (14 individuals)
58,164,37345.4 %41.9 %
*Less than one percent.

1.Unless otherwise noted, the business address for each of those listed in the table above is c/o Waldencast plc, 81 Fulham Rd., London, United Kingdom, SW3 6RD.
83

2.This information is based on (i) a Schedule 13D filed with the SEC on August 5, 2022 by Cedarwalk Skincare Ltd. (“Cedarwalk”), and (ii) information provided to the Company via written correspondence on March 7, 2025. According to the information provided to the Company on March 7, 2025, Cedarwalk directly holds 28,637,506 Class A ordinary shares, and Simon Dai may be deemed to be the beneficial owner of the 28,637,506 Class A ordinary shares. Mr. Dai’s business address is c/o Cedarwalk Skincare Limited, Rm 3001-3010, 30/F, China Resource Building, 26 Harbour Road, Wanchai, Hong Kong.
3.This information is based on a Schedule 13D/A filed with the SEC on February 9, 2024 by Zeno Investment Master Fund, (f/k/a Dynamo Master Fund) who beneficially owns 20,500,709 Class A ordinary shares (comprised of 14,382,933 Class A ordinary shares and 5,777,776 Class A ordinary shares issuable upon exercise of the Private Placement Warrants). Zeno Equity Partners LLP, a British limited liability partnership, is the investment manager of Zeno Investment Master Fund. Cristiano Souza is the controlling shareholder of Zeno Equity Partners LLP. The business address of Zeno Equity Partners LLP, Zeno Investment Master Fund is 272 Kings Road, College House 3rd floor, London SW3 5AW.
4.Reflects securities held directly by Beauty Ventures consisting of (i) 9,309,200 Class A ordinary shares and (ii) 3,103,067 Class A ordinary shares issuable upon exercise of warrants held by Beauty Ventures. Waldencast Long-Term Capital LLC, (the “Sponsor”), is the managing member of Beauty Ventures. The voting and investment power of the Sponsor is exercised jointly by Waldencast Ventures, LP, Burwell Mountain Trust, and Zeno Investment Master Fund (f/k/a Dynamo Master Fund). Waldencast Ventures, LP is controlled by Michel Brousset. See footnote 7 for further details. Burwell Mountain PTC LLC is the trustee of Burwell Mountain Trust, a non-grantor, fully discretionary dynasty trust duly organized under Wyoming law. See footnote 5 for further details. Zeno Investment Master Fund is controlled by Cristiano Souza. See footnote 4 for further details.
5.This information is based on a Schedule 13D filed with the SEC on August 8, 2022 by Burwell Mountain Trust. According to this Schedule 13D, Burwell Mountain Trust directly holds 7,848,333 Class A ordinary shares and Private Placement Warrants exercisable for 3,977,777 Class A ordinary shares. Burwell Mountain PTC LLC, as trustee of Burwell Mountain Trust, has the sole voting and dispositive power over the shares held on behalf of the Burwell Mountain Trust, a non-grantor, fully discretionary dynasty trust duly organized under Wyoming law of which Felipe Dutra and his descendants are eligible beneficiaries. Burwell Mountain PTC LLC is an independent trustee over which Mr. Dutra has no control. The business address of each is 270 W. Pearl, Suite 103, Jackson, WY 83001. Burwell Mountain PTC LLC, as trustee of the Burwell Mountain Trust, pledged substantially all of the reported securities held by it pursuant to a loan agreement with customary default provisions. In the event of a default under the loan agreement, following such securities respective lock-up periods, the secured parties may foreclose upon any and all securities pledged to them.
6.Reflects securities held directly by Annapurna Investment Fund Ltd consisting of (i) 5,328,927 Class A ordinary shares and (ii) 1,333,333 Class A ordinary shares issuable upon exercise of warrants. Antonio Carlos de Freitas Valle may be deemed to have sole voting and dispositive power over these securities via his interest in Annapurna Investment Fund Ltd according to the information provided to the Company via written correspondence on March 10, 2025. The business address of Annapurna Investment Fund Ltd is Bahamas Financial Centre, 4th Floor, Shirley and Charlotte Street, P.O. Box CB-13515, Nassau, The Bahamas.
7.This information is based on a Schedule 13G filed with the SEC on February 1, 2024 by Santa Venerina Inv. & Arbitrage Ltd, pursuant to which Santa Venerina Inv. & Arbitrage Ltd holds 10,000,000 Class A ordinary shares. The business address of Santa Venerina Inv. & Arbitrage Ltd. is East Bay Street, P.O. Box N-7757, Nassau, Bahamas.
8.Main Post Growth Capital, LLC is the general partner of Main Post Growth Capital, L.P. R. Sean Honey and Jeff Mills may be deemed to have voting and dispositive power over these securities via their interest in Main Post Growth Capital, LLC. The business address of Main Post Growth Capital, L.P. is One Embarcadero Center, Suite 3500, San Francisco, CA 94111.
9.Waldencast Ventures, LP holds (i) 2,848,334 Class A ordinary shares, (ii) 1,977,779 Class A ordinary shares issuable upon exercise of the Private Placement Warrants and (iii) 333,334 Class A ordinary shares issuable upon exercise of the Working Capital Loan warrants. Mr. Brousset is the chief executive officer of Waldencast Management, LLC, the general partner of Waldencast Ventures, LP. As such, Mr. Brousset may be deemed to beneficially own the shares held by Waldencast Ventures, LP. Mr. Brousset also holds (i) 50,000 Class A ordinary shares and (ii) 2,766,666 stock options that are exercisable within 60 days of the record date for Class A ordinary shares, subject to a per share exercise price of $10.70 and an expiration date of August 12, 2028.
10.Ms. Sebti holds (i) 20,000 Class A ordinary shares and (ii) 1,066,666 stock options that are exercisable within 60 days of the record date for Class A ordinary shares, subject to a per share exercise price of $10.70 and an expiration date of August 12, 2028.
84

11.Ms. Sarah Brown was part of the Board and has resigned as a director following her initial mandate.
12.Effective January 31, 2024, Philippe Gautier resigned as Chief Financial Officer, Chief Operating Officer and the principal financial officer of the Company. Mr. Gautier holds 3,379 Class A ordinary shares. Effective April 1, 2024 Manuel Manfredi was appointed Chief Financial Officer and principal financial officer of the Company.
13.Class B ordinary shares are non-economic voting shares and may be exchanged, together with an equal amount of Waldencast LP Units, for Class A ordinary shares.
14.Includes both Class A ordinary shares and Class B ordinary shares.
Based on a review of the information provided to us by our transfer agent, as of February 28, 2025, there were 49 registered holders of our Class A ordinary shares, 16 of which are United States registered holders (including Cede & Co., the nominee of the Depository Trust Company), holding approximately 37.13% of our outstanding Class A ordinary shares; and there were 7 registered holders of our Class B ordinary shares, 6 of which are United States registered holders, holding approximately 73.83% of our outstanding Class B ordinary shares. The number of record holders in the United States is not representative of the number of beneficial holders nor is it representative of where such beneficial holders reside since many of these ordinary shares are held by brokers or other nominees.
B.Related Party Transactions
Waldencast
Forward Purchase Agreements
In connection with our IPO, on February 22, 2021, we, the Sponsor and Zeno entered into a Forward Purchase Agreement (the “Sponsor FPA”), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor’s rights and benefits under the Forward Purchase Agreement, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Class A ordinary shares and 5,333,333 warrants for an aggregate commitment amount of $160.0 million in connection with the closing of our initial business combination. In addition, we and Beauty Ventures entered into a Forward Purchase Agreement on March 1, 2021 (the “Third-Party FPA”, and together with the Sponsor FPA, the “FPAs”) pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and up to 5,766,666 warrants for an aggregate commitment amount of $173.0 million, in connection with the closing of our initial business combination. Members of our Sponsor or their affiliates will begin to receive a twenty percent (20%) performance fee allocation on the return of the forward purchase securities in excess of the hurdle rate, calculated on the total return generated from forward purchase securities (whether by dividend, transfer or increase in value as measured from date of issuance), when the return of such securities (less the expenses of Beauty Ventures) underlying the Third-Party FPA exceeds a hurdle rate of five percent (5%) accrued annually until the fifth anniversary of the issuance of such securities. In the event of a transfer and subsequent sale of any forward purchase securities prior to such fifth anniversary, the performance fee for the period between such transfer and such fifth anniversary will be calculated based on the proceeds generated by such sale. The FPA investments were consummated substantially concurrently with the consummation of the Business Combination.
The foregoing description of the FPAs and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, copies of which are attached as Exhibits 4.7, 4.8 and 4.9 to this Report and the terms of which are incorporated by reference herein.
Private Placement Warrants
Simultaneously with the consummation of our IPO, the Sponsor purchased 5,933,333 private placement warrants at a purchase price of $1.50 per private placement warrant, or $8.9 million in the aggregate. Each private placement warrant entitles the holder to purchase one Class A ordinary share for $11.50 per share. The private placement warrants may not be redeemed by us so long as they are held by the Sponsor or its permitted transferees. If the private placement warrants are held by holders other than the Sponsor or its permitted transferees, the private placement warrants will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the Units that were sold as part of our IPO. The Sponsor, or its permitted transferees, has the option to exercise the private placement warrants on a cashless basis.
The private placement warrants are identical to the warrants included in the Units sold in our IPO, except that the private placement warrants: (i) are not redeemable by us, (ii) may be exercised for cash or on a cashless basis so long as they are
85

held by the Sponsor or any of its permitted transferees and (iii) are entitled to registration rights (including the Class A ordinary shares issuable upon exercise of the private placement warrants). Additionally, the purchasers have agreed not to transfer, assign or sell any of the private placement warrants, including our Class A ordinary shares issuable upon exercise of the private placement warrants (except to certain permitted transferees), until 30 days after the completion of our initial business combination.
In connection with the Business Combination, each of the 5,933,333 private placement warrants converted automatically into a warrant to acquire one Class A ordinary share. The foregoing description of the private placement Warrant Agreement is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 2.3 and Exhibit 2.4 to this Report and the terms of which are incorporated by reference herein.
Registration Rights
The holders of the sponsor shares and private placement warrants, (and any Class A ordinary shares issuable upon (i) the exercise of the private placement warrants and (ii) the conversion of the sponsor shares) are entitled to registration rights pursuant to a registration rights agreement dated March 15, 2021 (the “Legacy Registration Rights Agreement”) requiring us to register such securities for resale (in the case of the sponsor shares, only after conversion to our Class A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses incurred in connection with the filing of any such registration statements.
We, the Sponsor, the members of the Sponsor and certain of our shareholders, Obagi Medical and Milk Makeup and certain of their respective affiliates entered into an amended and restated registration rights agreement, dated July 27, 2022 (the “Registration Rights Agreement”), pursuant to which we agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain of our Class A ordinary shares and our other securities that are held by the parties thereto from time to time, subject to the restrictions on transfer therein. The Registration Rights Agreement amended and restated the Legacy Registration Rights Agreement and terminates with respect to any party thereto, on the date that such party no longer holds any registrable securities (as defined therein).
The foregoing description of the Registration Rights Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.4 to this Report and the terms of which are incorporated by reference herein.
In connection with the PIPE Investments and the 2023 PIPE Investment, we agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain of our Class A ordinary shares and our other securities that are held by the parties thereto from time to time, subject to the restrictions on transfer therein (the “PIPE Registration Rights”). The PIPE Registration Rights terminate with respect to any party thereto, on the date that such party no longer holds any registrable securities.
In June 2024, we filed a registration statement on Form F-3, which succeeded the prior registration statement on Form F-1 filed in August 2022, to register up to 131,442,733 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the founder shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,103,225 Class A ordinary shares issuable in exchange for 21,103,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 8,848,070 Class A ordinary shares issued in the PIPE Investments; (vii) 32,809,200 Class A ordinary shares issued pursuant to the FPAs; (viii) 17,869,732 Class A ordinary shares issuable in respect of the private placement warrants, and (ix) 13,930,000 Class A ordinary shares issued in the 2023 PIPE Investment, pursuant to the Registration Rights Agreement or the PIPE Subscription Agreements, as applicable.
Waiver and Agreement
In connection with the consummation of the Business Combination, we waived those certain provisions as contemplated by the Letter Agreement and certain other agreements related thereto (collectively, the “Waiver”), with respect to any
86

securities held by an Insider (as defined in the Letter Agreement) as of the closing the Business Combination (the “Lock-Up Securities”) that would disallow a pledge by such Insider of the Lock-Up Securities in a transaction for the purpose of financing such Insider’s payment obligations owed in connection with the closing of the Business Combination.
In connection with such Waiver, we entered into that certain Waiver and Agreement, dated as of July 25, 2022, by and between us and Burwell (the “Waiver and Agreement”), to permit a pledge by Burwell of its Lock-Up Securities to be used as a portion of the collateral under a loan to finance Burwell’s payment obligations under the Sponsor FPA in connection with the closing of the Business Combination. Pursuant to the terms of the Waiver and Agreement, in the event of a foreclosure, any such lenders or a collateral agents will be required to execute a joinder to the Letter Agreement pursuant to which they will be bound by the transfer restrictions of the Lock-Up Securities (including the foreclosure of or other exercise of remedies under any such loan documentation) in the Letter Agreement for the duration of such agreement. We also agreed to provide any such lender or collateral agent with customary registration rights in the event of default, foreclosure or other exercise of remedies following the respective Lock-Up Periods (as defined in the Letter Agreement).
The foregoing description of the Waiver and Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.12 to this Report and the terms of which are incorporated by reference herein.
Indemnification Agreements
We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from indemnitee’s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company’s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. The foregoing description of the indemnification agreements and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of the form of indemnification agreement is attached as Exhibit 4.6 to this Report and the terms of which are incorporated by reference herein.
Director Interests
Pursuant to Article 75 of the Jersey Companies Law and the Constitutional Document, any director of the Company who has, directly or indirectly, an interest in a transaction entered into or proposed to be entered into by the Company or by a subsidiary of the Company which to a material extent conflicts or may conflict with the interests of the Company and of which the director is aware, is required to disclose to the Company the nature and extent of the director’s interest.
Mr. Dutra and his descendants are eligible beneficiaries of Burwell Mountain Trust and should be regarded as interested accordingly in any transaction involving Burwell and its affiliates;
In February 2021, the Sponsor transferred 20,000 Class B ordinary shares to each of the Company’s then-serving independent directors, Ms. Sarah Brown, Ms. Juliette Hickman, Ms. Lindsay Pattison and Mr. Zack Werner (the “Investor Directors”). Investor Directors and Mr. Chatterley each owns 20,000 Class A ordinary shares and should be regarded as interested accordingly in any transaction involving such Class A ordinary shares;
Simon Dai was nominated for appointment to our Board by Cedarwalk, pursuant to the Investor Rights Agreement, and should be regarded as interested accordingly in any transaction involving Cedarwalk and its affiliates;
Mr. Brousset is the chief executive officer of Waldencast Management, LLC, the general partner of Waldencast Ventures. Waldencast Ventures holds (a) 2,848,334 Class A ordinary shares; (b) 1,977,779 Class A ordinary shares issuable upon exercise of the Private Placement Warrants; and (c) 333,334 Class A ordinary shares issuable upon exercise of the Working Capital Loan warrants. Mr. Brousset should be regarded as interested accordingly in any transaction involving such Class A ordinary shares, Waldencast Ventures and its affiliates; and
Mr. Souza is the controlling shareholder of Zeno Equity Partners LLP, the investment manager of Zeno Investment Master Fund. Zeno Investment Master Fund holds (a) 14,522,933 Class A ordinary shares; and (b) 5,766,666 Class A ordinary shares issuable upon exercise of the Private Placement Warrants. Mr. Souza should be
87

regarded as interested accordingly in any transaction involving such Class A ordinary shares, Zeno Investment Master Fund and its affiliates.
As a matter of Jersey law, each director of the Company is under a duty to act honestly and in good faith with a view to acting in the best interests of the Company, regardless of any other directorship such director may hold. Each director is responsible for advising the Board in advance of any potential conflicts of interest.
2023 PIPE Transaction
In September 2023, we entered into the 2023 Subscription Agreements with the 2023 PIPE Investors, pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment was anchored by a $50 million investment by a Beauty Ventures stakeholder. The remainder of the 2023 PIPE Investors were certain existing shareholders, certain members of the Sponsor, Mr. Brousset and Ms. Sebti. The 2023 Subscription Agreements relating to approximately $68 million of proceeds was consummated in September 2023, with the closings of 2023 Subscription Agreements relating to the remaining approximately $2 million consummated in November 2023 (the “Closing Date”).
The 2023 Subscription Agreements provide for certain registration rights pursuant to which Waldencast is required to, as soon as practicable but no later than 60 days following the SEC notice that the post-effective amendment filed in connection with the Company’s Registration Statement on Form F-1, has been declared effective, submit to or file with the SEC a registration statement registering the resale of such shares. Additionally, Waldencast is required to use its commercially reasonable efforts to have the registration statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) the 90th calendar day following the filing date thereof if the SEC notifies us that it will review the registration statement and (ii) the 10th business day after the date we are notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be “reviewed” or will not be subject to further review. We must use commercially reasonable efforts to keep the registration statement effective until the earliest of: (i) the date the 2023 PIPE Investors no longer hold any registrable shares, (ii) the date all registrable shares held by the 2023 PIPE Investors may be sold without restriction under Rule 144 under the Securities Act and (iii) two years from the date of effectiveness of the registration statement.
The foregoing description of the 2023 Subscription Agreements and the transactions contemplated thereby is not complete and is subject to, and qualified in its entirety by, the full text of the form of 2023 Subscription Agreement, the form of which is attached as Exhibit 4.14 to this Report on Form 20-F and incorporated by reference herein.
Obagi Medical
Obagi China Distribution
As a condition under the Obagi Merger Agreement, prior to the Closing Date, Obagi Holdco distributed to Obagi and then Obagi distributed to Cedarwalk all of the issued and outstanding shares of capital stock of Obagi Hong Kong and certain related assets pursuant to distribution agreements in the Obagi China Distribution (“Obagi China Distribution”). Prior to the closing of the Business Combination, the Obagi China Business had been conducted through Obagi Hong Kong and its subsidiaries. The following agreements were entered into in connection with the closing of the Business Combination: (a) that certain Transition Services Agreement, dated as of July 27, 2022, by and among Obagi, certain of Obagi’s affiliates and Obagi Hong Kong, pursuant to which Obagi and certain of its affiliates will provide transition services to Obagi Hong Kong (the “Transition Services Agreement”), (b) that certain Intellectual Property License Agreement, dated as of July 27, 2022, by and among Obagi and Obagi Hong Kong, pursuant to which Obagi will exclusively license intellectual property relating to the Obagi brand to Obagi Hong Kong with respect to the China Region (the “IP License Agreement”), and (c) that certain Supply Agreement, dated as of July 27, 2022, by and between Obagi and Obagi Hong Kong, pursuant to which Obagi will supply products to Obagi Hong Kong for distribution and sale in the China Region.
In connection with the consummation of the Business Combination, we entered into the Investor Rights Agreement (together with the Transition Services Agreement, the IP License Agreement, and the Supply Agreement, collectively, the “Obagi China Related Party Agreements”).
88

IP License Agreement
Under the IP License Agreement, Obagi Medical will exclusively license intellectual property relating to the Obagi Medical brand to Obagi Hong Kong with respect to the China Region, and Obagi Medical will retain the rights to such intellectual property to conduct the Obagi Medical-branded business worldwide except for the China Region. The license from Obagi to Obagi Hong Kong will include future intellectual property of Obagi Medical relating to the Obagi Medical brand in the worldwide business, including, but not limited to: (i) trademarks; (ii) domain names; (iii) patents; (iv) trade secrets and know-how; (v) copyrights; and (vi) product specifications and formulas.
The license will be perpetual, irrevocable, non-transferable and sublicensable, subject to: (x) a limited right of Obagi to terminate for an uncured material breach by Obagi Hong Kong that materially and adversely affects Obagi Medical or the Obagi Medical brand, in which case Obagi Medical will purchase Obagi Hong Kong at a discount to fair market value based on an independent valuation procedure; (y) the right of either party to transfer the IP License Agreement without consent of the other party to an affiliate or to a successor in interest in connection with any merger, business combination or other change of control transaction, or sale of a product or service line; and (z) a right of Obagi Hong Kong to sublicense to affiliates, Approved CMOs (as defined in the Supply Agreement) and other approved third parties. Upon the termination of the IP License Agreement, at the written request of Obagi Medical, Obagi Hong Kong shall promptly cease, and shall cause its sublicensees to promptly cease, all use of the Licensed IP Rights (as defined in the IP License Agreement), subject to a non-exclusive right to use the Licensed IP Rights for a period of up to nine complete calendar months following the effective date of termination, in a manner consistent with past practice and in compliance with the terms and conditions of the IP License Agreement, to sell off all inventory of China Products (as defined in the Intellectual Property License Agreement) to consumers in the China Region (and subject to the terms relating to royalties in the IP License Agreement).
Under the IP License Agreement, Obagi Hong Kong is required to pay Obagi Medical a royalty of 5.5% of gross sales of licensed products, subject to certain deductions. Obagi Hong Kong paid royalty fees of $0.1 million, $0.3 million, and $0.2 million during the year ended December 31, 2024, the year ended December 31, 2023, and during the period from July 28, 2022 to December 31, 2022, respectively.
Obagi Supply Agreement
Pursuant to the Supply Agreement, Obagi Medical will supply, or cause to be supplied through certain CMOs, products to Obagi Hong Kong and its affiliates, and Obagi Hong Kong may purchase such products for distribution and sale in the China Region. The parties operated under an interim supply agreement, which terminated in July 2023. However, the parties continued to operate under the interim supply agreement terms until December 2024, at which point the remaining related party liability was amortized and released. The term of the Obagi Supply Agreement is perpetual, subject to termination for uncured material breach or termination in the event that the Intellectual Property License Agreement is terminated.
Investor Rights Agreement
Pursuant to the Investor Rights Agreement, Cedarwalk has the right to nominate one director for election or appointment to the Board for so long as Cedarwalk owns 5% of the then-outstanding common stock of Waldencast, and such appointee was initially Simon Dai. Upon termination of the Supply Agreement:
Obagi Hong Kong will promptly refrain from using the Product Information File, the Specifications and the Confidential Information of Obagi Medical (each as defined in the Supply Agreement);
Obagi Hong Kong will return to Obagi Medical all documents relating to the Product Information File, Specifications and Confidential Information of Obagi Cosmeceuticals. The relevant costs will be borne by the party who is responsible for the termination or the non-renewal of the Supply Agreement; and
Unless the Supply Agreement is terminated by Obagi Hong Kong due to Obagi Medical’s breach of its obligations related to the quality of the products, Obagi Cosmeceuticals will complete the manufacturing of all products covered by firm orders and deliver them to the applicable recipient.
The foregoing description of the Investor Rights Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.10 to this Report and the terms of which are incorporated by reference herein.
89

Milk
Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA, on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. Milk also receives certain services from an employee of Milk Studios. During the years ended December 31, 2024, December 31, 2023, and the period from July 28, 2022 to December 31, 2022 the Company incurred administrative fees of $0.3 million, $0.3 million, and $0.1, million, respectively, in connection with the sublease and services, which is recorded in SG&A expenses in the consolidated statements of operations and comprehensive loss
One of the co-founders of Milk Makeup and a shareholder of the Company, is party to an influencer agreement with Milk Makeup, pursuant to which such co-founder provides certain brand services to Milk Makeup. Milk Makeup incurred $0.1 million in fees pursuant to this agreement during the both year ended December 31, 2024, and the year ended December 31, 2023.
C.Interests of Experts and Counsel
Not applicable.
90

ITEM 8. FINANCIAL INFORMATION

Waldencast plc
Index to Consolidated Financial Statements

F-1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of Waldencast plc
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Waldencast plc and subsidiaries (the 'Company") as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, shareholders' equity, and cash flows, for the years ended December 31, 2024 and December 31, 2023 and periods from July 28, 2022 through December 31, 2022 and January 1, 2022 through July 27, 2022 (Predecessor), and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and December 31, 2023, and the results of its operations and its cash flows for each of the years ended December 31, 2024 and December 31, 2023 and periods from July 28, 2022 through December 31, 2022 and January 1, 2022 through July 27, 2022 (Predecessor) in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Deloitte & Touche LLP
Costa Mesa, California
March 20, 2025

We have served as the Company’s auditor since 2018.




F-2

WALDENCAST PLC
CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars, except share and per share data)
December 31, 2024December 31, 2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$14,802 $21,089 
Restricted cash1,500 1,487 
Accounts receivable, net25,484 21,330 
Related party accounts receivable792 1,101 
Inventories53,104 55,684 
Prepaid expenses7,513 5,277 
Other current assets427 1,359 
Total current assets103,622 107,327 
Property and equipment, net5,831 5,931 
Intangible assets, net526,438 582,863 
Goodwill329,589 334,620 
Right-of-use asset, net9,839 11,589 
Other non-current assets541 380 
TOTAL ASSETS$975,860 $1,042,710 
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable$25,087 $28,069 
Related party accounts payable (Note 16) 18 
Current portion of lease liabilities2,766 2,400 
Current portion of long-term debt29,479 8,529 
Other current liabilities
19,560 23,698 
Total current liabilities76,892 62,714 
Long-term debt, net137,137 151,264 
Derivative warrant liabilities5,021 28,647 
Long-term lease liabilities12,724 15,531 
Deferred income tax liabilities14,044 15,229 
Other non-current liabilities105 52 
TOTAL LIABILITIES245,923 273,437 
COMMITMENTS AND CONTINGENCIES (NOTE 17)
SHAREHOLDERS’ EQUITY:
Preferred shares, 25,000,000 shares authorized, $0.0001 par value, none issued and outstanding
— — 
Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 112,026,440 and 101,228,857 outstanding as of December 31, 2024 and December 31, 2023, respectively
11 9 
Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized; and 10,666,528 and 20,847,553 outstanding as of December 31, 2024 and December 31, 2023, respectively
1 2 
Additional paid-in capital951,260 871,527 
Retained earnings(289,204)(246,761)
Accumulated other comprehensive income (loss)251 (151)
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY662,319 624,626 
Noncontrolling interest67,618 144,647 
TOTAL SHAREHOLDERS' EQUITY729,937 769,273 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$975,860 $1,042,710 
F-3
See accompanying notes to consolidated financial statements.

WALDENCAST PLC
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands of U.S. dollars, except share and per share data)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Successor (Waldencast)Predecessor (Obagi)
Net revenue
$273,868 $218,138 $92,373 $73,760 
Cost of goods sold
82,124 76,561 60,657 30,868 
Gross profit191,744 141,577 31,716 42,892 
Selling, general and administrative245,297 223,508 90,722 58,155 
Loss on impairment of goodwill5,031  68,715  
Total operating expenses250,328 223,508 159,437 58,155 
Operating loss(58,584)(81,931)(127,721)(15,263)
Interest expense, net17,155 18,906 6,230 6,652 
Change in fair value of derivative warrant liabilities (Note 9)(23,627)10,337 (6,793) 
Other (income) expense, net(3,574)1,769 (798)(971)
Total other expenses (income), net(10,046)31,012 (1,361)5,681 
Loss before income taxes(48,538)(112,943)(126,360)(20,944)
Income tax expense (benefit)
110 (6,975)(5,803)113 
Net loss(48,648)(105,968)(120,557)(21,057)
Net loss attributable to noncontrolling interests(6,205)(15,987)(24,990) 
Net loss attributable to Class A shareholders$(42,443)$(89,981)$(95,567)$(21,057)
Net loss per share attributable to Class A shareholders (Note 14):
Basic and Diluted$(0.39)$(0.99)$(1.11)$(2.63)
Shares used in computing net loss per share (Note 14):
Basic and Diluted109,295,74291,158,50086,460,5608,000,002
Net loss$(48,648)$(105,968)$(120,557)$(21,057)
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax
450 (147)(36)96 
Comprehensive loss(48,198)(106,115)(120,593)(20,961)
Comprehensive loss attributable to noncontrolling interests(6,148)(16,012)(24,997) 
Comprehensive loss attributable to Class A shareholders
$(42,050)$(90,103)$(95,596)$(20,961)
F-4
See accompanying notes to consolidated financial statements.

WALDENCAST PLC
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands of U.S. dollars, except share data)
Shareholders' Equity
Obagi Global Holdings Limited
Class A Ordinary SharesAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other Comprehensive
 Loss
Total Shareholders’ Equity
PredecessorSharesAmount
BALANCE—January 1, 2022
8,000,0024,000 100,113 (64,849)(25)39,239 
Net loss— — (21,057)— (21,057)
Foreign currency translation adjustment— — — 96 96 
Distribution of Obagi China Business— (13,113)(188)(71)(13,372)
BALANCE—July 27, 20228,000,002$4,000 $87,000 $(86,094)$ $4,906 
Shareholders' Equity
Waldencast plc
 Class A Ordinary SharesClass B Ordinary SharesAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other Comprehensive
 Loss
Noncontrolling InterestTotal Shareholders’ Equity
SuccessorSharesAmountSharesAmount
BALANCE—July 28, 20228,645,000$1 $ $174 $(61,213)$ $ $(61,038)
Issuance of Class A ordinary shares upon release of Trust proceeds4,478,054— — — 44,882 — — — 44,882 
Issuance of common shares in connection with the FPA investment 33,300,0003 — — 332,997 — — — 333,000 
Issuance of common shares in connection with the PIPE investment 11,800,0001 — — 117,999 — — — 118,000 
Issuance of common shares in connection with the Obagi and Milk Business Combination 28,237,5063 21,104,2252 292,250 — — 185,656 477,911 
Net loss— — — — — (95,567)— (24,990)(120,557)
Stock-based compensation— — — — 7,736 — — — 7,736 
Foreign currency translation adjustment— — — — — — (29)(7)(36)
BALANCE—December 31, 202286,460,560$8 21,104,225$2 $796,038 $(156,780)$(29)$160,659 $799,898 
Issuance of common shares in connection with the PIPE investment14,000,0001 — — 69,999 — — — 70,000 
Fees paid in connection with the PIPE— — — (1,068)— — — (1,068)
Class B to Class A shares256,672— (256,672)— — — — — — 
Net loss— — — — (89,981)— (15,987)(105,968)
Stock-based compensation511,625— — — 9,235 — — — 9,235 
RSU taxes paid on behalf of employees— — — (1,473)— — — (1,473)
Distribution to pay withholding taxes— — — (1,204)— — — (1,204)
Foreign currency translation adjustment— — — — — (122)(25)(147)
BALANCE—December 31, 2023
101,228,857$9 20,847,553$2 $871,527 $(246,761)$(151)$144,647 $769,273 
Class B to Class A shares10,181,025$(10,181,025)(1)70,872 — — (70,872)— 
Net loss— — — — (42,443)— (6,205)(48,648)
Stock-based compensation616,558$— — 9,391 — — — 9,392 
RSU taxes paid on behalf of employees— — — (530)— — — (530)
Foreign currency translation adjustment— — — — — 402 48 450 
BALANCE—December 31, 2024
112,026,440$11 10,666,528$1 $951,260 $(289,204)$251 $67,618 $729,937 
F-5
See accompanying notes to consolidated financial statements.

WALDENCAST PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Successor (Waldencast)Predecessor (Obagi)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$(48,648)$(105,968)$(120,557)$(21,057)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation9,392 9,235 7,736  
Depreciation and amortization60,015 60,498 26,982 8,190 
Non-cash lease expense1,986 1,721 740  
Provision for doubtful accounts
(996)   
Change in fair value of derivative warrant liabilities(23,627)10,337 (6,793) 
Non-cash loss from change in fair value on interest rate collar 106 592  
Amortization of debt issuance costs1,712 1,575 677 767 
Amortization and release of related party liability
(5,856)(4,058)(12,186) 
Deferred income taxes(1,185)(7,021)(5,823)90 
Loss on impairment of goodwill5,031  68,715  
Loss on impairment of right of use assets 3,643   
Loss (gain) on disposal of equipment112 62 (2)35 
Changes in operating assets and liabilities, net of impact of business combinations:
Accounts receivable(3,158)(2,071)(204)3,524 
Related party accounts receivable309 (816)265  
Inventories2,580 (1,300)6,382 (13,008)
Prepaid expenses(2,236)996 (213)658 
Other current assets and other assets(377)138 (250)(352)
Accounts payable(2,982)4,382 (1,021)9,635 
Related party accounts payable(18)(354)43  
Operating lease liabilities(2,677)(2,560)(724) 
Other current liabilities and other liabilities1,803 1,680 (39,336)1,481 
Net cash used in operating activities
(8,820)(29,775)(74,977)(10,037)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditure on intangible assets(304)(455)(247)(248)
Capital expenditure on property and equipment(2,708)(1,591)(1,340)(661)
Proceeds from trust account  44,883  
Acquisition of Obagi Business Combinations, net of cash acquired  (465,010) 
Acquisition of Milk Business Combinations, net of cash acquired  (122,653) 
Cash received for interest rate collar premium92 52   
Net cash used in investing activities(2,920)(1,994)(544,367)(909)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from PIPE investments 70,000 118,000  
Payment of PIPE transaction costs (1,068)  
Proceeds from FPA investments  333,000  
Proceeds from term loan  175,000  
Repayment of term loan(8,750)(8,777)(4,348)(1,375)
Proceeds from revolving credit facility15,000 35,000 14,117 6,000 
Repayment of revolving credit facility (49,117)  
F-6
See accompanying notes to consolidated financial statements.

Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Successor (Waldencast)Predecessor (Obagi)
Proceeds from note payable1,632 2,420   
Repayment of note payable(1,770)(1,452)  
Payment of debt issuance costs  (6,304)(742)
RSU taxes paid on behalf of employees(530)(1,473)  
Distribution to pay withholding taxes (1,204)  
Net cash provided by financing activities5,582 44,329 629,465 3,883 
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH(6,158)12,560 10,121 (7,063)
Effect of foreign exchange rates on cash and cash equivalents(116)(147)(36)96 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period22,576 10,163 78 13,444 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period$16,302 $22,576 $10,163 $6,477 
SUPPLEMENTAL CASH FLOW DATA – CASH PAID:
Income taxes$ $ $152 $3 
Interest15,125 17,331 5,550 5,053 
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capital expenditures in accounts payable and accruals$146 $318 $406 $43 
Obagi China Distribution to shareholder   13,113 
Issuance of ordinary shares for Obagi Business Combinations  277,824  
Issuance of ordinary shares for Milk Business Combinations  200,087  
Conversion of promissory note to warrants  650  
F-7
See accompanying notes to consolidated financial statements.

Waldencast plc
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In U.S. dollars, except share and per share data)
1.ORGANIZATION AND DESCRIPTION OF BUSINESS
Successor
Waldencast plc (“Waldencast” or the “Company”), formerly known as Waldencast Acquisition Corp., is a Bailiwick of Jersey (“Jersey”) company. Waldencast was originally incorporated on December 8, 2020 as a Cayman Islands exempted company and a blank check company solely for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March 18, 2021, Waldencast consummated an initial public offering of 34,500,000 units (the “IPO”), with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant (“Public Warrant”) to acquire one Class A ordinary share (together, a “Unit”), at $10.00 per Unit.
In connection with the Business Combination (as defined below), on July 26, 2022, Waldencast obtained shareholder approval to change its jurisdiction of incorporation. Pursuant to the Cayman Companies Act (the “Cayman Act”) and the Companies (Jersey) Law 1991, as amended (the “Jersey Companies Law”), Waldencast effected a deregistration under the Cayman Act and a domestication under Part 18C of the Jersey Companies Law. This was accomplished by filing a memorandum and articles of association with the Registrar of Companies in Jersey (the “Domestication”). Upon the effective time of the Domestication, Waldencast Acquisition Corp. was renamed Waldencast.
On July 27, 2022 (the “Closing Date”), Waldencast acquired (the “Business Combination”) Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, “Obagi”) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively “Milk”), as more fully described in “Note 3. Business Combinations.” Following the closing of the Business Combination, the Company conducts its business through the following operating and reportable segments: (i) Obagi Medical and (ii) Milk Makeup.
Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, over-the-counter and prescription products.
Milk Makeup develops and sells cosmetic, skin care and other beauty products. The brand creates vegan, cruelty-free, clean formulas from its Milk headquarters in downtown New York City. Milk’s products are offered through its U.S. website, www.milkmakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.
As a result of the Business Combination, Waldencast is organized as an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP (“Waldencast Partners LP”), a Cayman Islands exempted limited partnership and indirect subsidiary of Waldencast, which is an entity that is classified as a partnership for U.S. federal income tax purposes.
Predecessor
Obagi Global Holdings Limited is a holding company incorporated that conducts all operations through its wholly-owned subsidiaries. On July 15, 2021, ZhongHua Finance Acquisition Fund I, L.P., Obagi’s sole shareholder, transferred its 4,000,000 ordinary shares to its affiliate, Cedarwalk Skincare Ltd. (“Cedarwalk”), which became the new sole shareholder of Obagi. This transfer between affiliates did not result in any change of control.
Immediately prior to the closing of the Business Combination, Obagi carved out and distributed all of the outstanding shares of its subsidiary, Obagi Hong Kong Limited (“Obagi Hong Kong” or “Obagi HK”) to its shareholder, Cedarwalk (the “Obagi China Distribution”). All sales of Obagi products in the People’s Republic of China, inclusive of the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the “China Region”) prior to the Business Combination had been conducted through the Obagi China Business (the “Obagi China Business”), which were not acquired by Waldencast in the Business Combination.
F-8

Unless the context requires otherwise, the “Company,” “we,” or “our” refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.
Basis of Presentation
Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”).
In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the “Successor”), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the “Predecessor”). Under the acquisition method of accounting, Waldencast’s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.
This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the relevant financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the “Successor Period”) are presented on a measurement basis different from those for the period prior to the Closing Date (the “Predecessor Period(s)”). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Periods, which include Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022, the year ended December 31, 2023, and the year ended December 31, 2024, are presented on a different basis of accounting and are therefore, not comparable.
Certain prior year amounts in the consolidated financial statements and notes have been reclassified to conform to current year presentation. These reclassifications had no effect on net income or loss. These include reclassifying research and development costs into selling, general and administrative costs and reclassifying gondolas into furniture and fixtures.
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation—The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.
Emerging Growth Company—Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, will adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates—The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial
F-9

statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, goodwill valuation, inventory valuation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company’s consolidated balance sheets and consolidated statements of operations and comprehensive loss.
Concentrations of Credit Risk—Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.
The Company’s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailer located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions, monitoring payment frequency, and requiring customer advance payments in certain circumstances. The Company generally does not require collateral.
As of December 31, 2024 and 2023, one U.S. customer accounted for 33% and 27% of accounts receivable, respectively.
During the year ended December 31, 2024, the Company purchased approximately 15% and 12% of inventory from two vendors, respectively. During the year ended December 31, 2023 the Company purchased approximately 17% of inventory from one vendor.
As of December 31, 2024, no vendor exceeded 10% of accounts payable. As of December 31, 2023, one vendor accounted for 18% of accounts payable.
Cash and Cash Equivalents—The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.
Restricted Cash—The Company’s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December 31, 2024, the Company’s cash and cash equivalents, and restricted cash balance was $14.8 million and $1.5 million respectively. Restricted cash is composed of $0.7 million held as collateral for corporate credit cards and $0.8 million held as a lease deposit through the end of the lease in November 2030. As of December 31, 2023 the Company’s cash and cash equivalents, and restricted cash balance was $21.1 million and $1.5 million respectively.
Inventories—The Company’s products are produced by third-party contract manufacturers (“CMOs”). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (“FIFO”) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional products are charged to cost of goods sold at the time the product is shipped to the Company’s customer.
The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (“FOB”) shipping point or FOB destination point.
The Company evaluates the carrying value of inventories on a regular basis and determines the need, if any, to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. It accounts for losses that may occur when the inventory cannot be sold at its full cost. If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory
F-10

to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). Each period, Management will evaluate whether any additional write downs are required (generally, by stock keeping unit (“SKU”) and/or lot). Specific write downs may relate to known matters, such as quality concerns or a discontinued product.
Sales Returns
Certain arrangements may give the Company’s customers the right to return products. In addition, when customer arrangements do not give the Company’s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, Guarantees and the Company accrues for replacement costs.
Derivatives—The Company accounts for derivative instruments in accordance with ASC 815, Derivatives and Hedging (“ASC 815”), which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements.
The Company has used interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See “Note 9. Financial Instruments” for further discussion of the interest rate collar.
Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815.
Warrant Liabilities
The Company accounts for Public Warrants and Private Placement Warrants (each as defined in “Note 9. Financial Instruments”) as liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company’s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See “Note 9. Financial Instruments” for further discussion of the warrants, including the FPA Warrants (as defined therein).
Fair Value Measurement—The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
F-11

The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management’s judgment and conditions that existed at each reporting date. See “Note 10. Fair Value Measurements” for further details.
The fair values of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company’s term loan, which approximate current market rates.
Capitalized Software and Website Development Costs—The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (“CCA”) implementation costs, and (iii) other software-related costs (e.g., website development costs).
For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use.
For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.
Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.
Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Prepaid Expenses—At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.
Prepaid Inventory
Prepayments are required to begin production of inventory at certain of the Company’s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.
Prepaid Marketing and Advertising
The Company generally expenses the costs of advertising and marketing as incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.
Property and Equipment, Net—Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation.
F-12

Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company’s assets are as follows:
ESTIMATED USEFUL LIVES
Computer hardware and software3 years
Furniture and fixtures
3 - 5 years
Machinery and equipment
3 - 5 years
Leasehold improvementsLesser of useful life or term of lease
Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Intangible Assets, Net—Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, and formulations. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset.
Impairment of Long-Lived Assets—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss.
Business Combinations—When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.
Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company’s consolidated statements of operations and comprehensive loss.
Goodwill—Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1st and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions.
Debt Issuance Costs—The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.
F-13

Accounts Receivable, Net—Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers. Payment terms are generally short-term in nature and are determined based on the financial stability of the customer.
The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i) customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii) formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer’s remittance advice or to the customer’s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.
Revenue Recognition—The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.
Product Sales
The Company’s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (“DTC”) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.
At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.
The Company has determined that each of its products is distinct and represents a separate performance obligation. The Company does not have any contracts that contain multiple performance obligations. The transaction price is equal to the consideration the Company expects to be entitled to. When measuring revenue and determining the consideration the Company expects to be entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer.
The Company’s distributors charge us fees for certain services rendered by them, including packing and shipping, marketing and advertising the Company’s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are not distinct from the distributors’ purchase of products.
F-14

Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.
The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and when assumption of the risks and rewards occur. For distributors (other than the “Physician Channel Provider”) and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company’s designated warehouse/distribution center by the customer’s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer.
Obagi’s operations in the U.S. heavily depend on a single distributor, referred to as the Physician Channel Provider, which manages sales to healthcare professionals in the physician-dispensed channel as well as retail and spa customers. For DTC sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician.
Promotional Products
When the Company provides promotional products (e.g., samples and testers) alongside a related saleable product, their cost is recognized in cost of sales at the same time the related product’s revenue is recognized.
Royalties
The Company generates royalty revenue from products in China by Obagi Hong Kong and in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi Medical brand name in the Japanese retail skincare channels. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. The Company recognizes revenue for the sales-based royalty at the later of when the local operators make sales of the products or when the purchase obligation has been satisfied.
Costs to Obtain a Contract with a Customer
The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. There were no total capitalizable costs to obtain a contract during the periods presented.
Other
The Company’s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company’s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) for ASC 340-40-25-4 related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.
Cost of Goods Sold—Cost of goods sold consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, freight and inventory inspection costs, depreciation and amortization of product-related intangible asset and supply agreements, and amortization of the inventory fair value step-up related to the Business Combination.
F-15

Distribution—Costs related to shipping, handling, warehousing and distribution for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, were $8.7 million, $6.6 million, and $2.0 million, respectively. These costs include costs that are incurred in order to get the product from the distribution centers to the end consumer and are included within selling, general and administrative expense (“SG&A”). The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&A expenses. Amounts billed to customers for shipping and handling are included in revenue. In the Predecessor period, the Company only included shipping and handling costs in SG&A expense. The costs related to shipping and handling for the period from January 1, 2022 to July 27, 2022 (Predecessor Period) were $0.6 million.
Advertising—Advertising costs are expensed in the period in which they are incurred. Total advertising costs, included in SG&A expense on the consolidated statements of operations and comprehensive loss, were $43.5 million, $16.3 million, $11.7 million, and $6.8 million for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period), respectively.
Research and Development—Research and development costs are included in SG&A expense on the consolidated statements of operations and comprehensive loss. All periods presented reflect this classification.
Stock-Based Compensation—The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards.
Replacement Options
On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested options granted under those plans (“Replacement Options”). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple.
Founder Awards
The Company estimated the fair value and derived service period of the stock options issued to founders (“Founder Awards”) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option’s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.
Restricted Stock
The fair value of restricted stock is equal to the price of the Company’s ordinary shares on the grant date.
The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.
The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award’s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition is deemed probable.
Income Taxes—The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.
F-16

The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $22.5 million was recorded as of December 31, 2024 and $19.8 million was recorded as of December 31, 2023.
The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority’s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December 31, 2024 and December 31, 2023, the Company had no uncertain positions in the consolidated financial statements.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no amounts accrued for interest and penalties as of December 31, 2024, December 31, 2023, or December 31, 2022.
Net Loss Per Share—Basic net loss per share attributable to shareholders of ordinary shares is computed by dividing the Company’s net loss attributable to holders of ordinary shares by the weighted-average number of ordinary shares outstanding during the period. Diluted net income per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net loss per share that is not attributable to the Company is reflected in net loss attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss.
Noncontrolling Interests—Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder’s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder’s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.
Segments—An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Company has two operating and reportable segments: Obagi Medical and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company’s CODM is its Chief Executive Officer.
Commitments and Contingencies—In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Recently Adopted Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The guidance expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for
F-17

other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company adopted this accounting standard in the fourth quarter of 2024, which resulted in expanded disclosures within our notes to the consolidated financial statements. There was no other impact on our consolidated financial statements. See “Note 18. Segment Reporting” for additional detail.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree’s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2023 for an EGC company, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company adopted this accounting standard as of January 1, 2024, with no material impact on its consolidated financial statements and related disclosures. Future acquisitions will be evaluated under this guidance.
Recently Issued Accounting Standards, Not Yet Adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): Reporting Comprehensive Income – Expense Disaggregation Disclosures. The guidance will require disaggregated disclosures and of certain cost and expense categories presented on the face of the income statement. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.
3.BUSINESS COMBINATIONS
On July 27, 2022, Waldencast consummated its initial business combination with (i) Obagi, pursuant to an Agreement and Plan of Merger dated November 15, 2021, by and among Waldencast, Obagi Merger Sub, Inc., a Cayman Islands exempted company limited by shares and an indirect wholly-owned subsidiary of Waldencast (“Merger Sub”), and Obagi (the “Obagi Merger Agreement”), and (ii), Milk, pursuant to an Equity Purchase Agreement dated November 15, 2021, by and among Waldencast, Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey (“Holdco Purchaser”) and a subsidiary of Waldencast, Waldencast Partners LP together with Holdco Purchaser, (the “Purchasers”), certain members of Milk (the “Milk Members”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members (the “Equityholder Representative”) (the “Milk Equity Purchase Agreement” and together with the Obagi Merger Agreement, the “Transaction Agreements”).
Pursuant to the Obagi Merger Agreement, at the effective time of the Obagi Merger (the “Obagi Merger Effective Time”) Merger Sub merged with and into Obagi (the “Obagi Merger”) and the separate corporate existence of Merger Sub ceased, with Obagi surviving as an indirect subsidiary of the Company. At the Obagi Merger Effective Time, all outstanding ordinary shares of Obagi, $0.50 par value (“Obagi common shares”) were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $345.4 million.
F-18

Pursuant to the Milk Equity Purchase Agreement, at the effective time of the Milk Transaction (the “Milk Purchase Effective Time”) the Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 limited partnership units in Waldencast Partners LP (“Waldencast LP Units”) (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $121.6 million (the “Milk Transaction”). Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, and, if such option is exercised, exchangeable at the option of Waldencast into one Waldencast Class A ordinary share or cash, in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement. Upon consummation of the Business Combination Waldencast became organized in an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP, which is an indirect subsidiary of Waldencast.
In the Business Combination, Waldencast was deemed to be the accounting acquirer and continues as the SEC registrant. Obagi and Milk were deemed to be the accounting acquirees, however Obagi is considered the predecessor entity for purposes of financial reporting. Waldencast was determined to be the accounting acquirer based on evaluation of the following factors:
The owners of Waldencast have the largest voting interest in the combined company;
The original owner of Waldencast, Waldencast Long-Term Capital LLC (the “Sponsor”), and its affiliates nominated the majority of the initial members who will serve on the Board (the former owner of Obagi nominated one director, and Milk nominated no directors); and
Waldencast’s existing management holds executive management roles for the post-combination company, whilst Obagi and Milk management team members report into the current Waldencast executive team.
Immediately prior to the Obagi Merger Effective Time, Obagi carved out and distributed the Obagi China Business to Cedarwalk pursuant to the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned 24.5% of the fully diluted Waldencast Class A ordinary shares as of the Obagi Merger Effective Time. Prior to the Obagi China Distribution, the pre-tax losses for the Obagi China Business were $8.0 million for the period from January 1, 2022 to July 27, 2022 (Predecessor Period).
See “Note 16. Related Party Transactions” for more information on ongoing transactions with the Obagi China Business following the close of the Obagi Merger.
F-19

Obagi and Milk Purchase Price Allocation:
(In thousands)ObagiMilk Total
Total Purchase Price:
Cash consideration$345,398 $121,629 $467,027 
Equity consideration277,824 200,087 477,911 
Cash repayment of debt136,112 3,935 140,047 
Related party liability22,100  22,100 
Total purchase consideration$781,434 $325,651 $1,107,085 
Fair value of assets acquired:
Cash and cash equivalents$15,850 $2,092 $17,942 
Restricted cash650 819 1,469 
Account receivable, net15,214 3,866 19,080 
Related party receivable327 199 526 
Inventories31,026 30,945 61,971 
Prepaid expenses4,307 520 4,827 
Other current assets359  359 
Property and equipment1,245 8,436 9,681 
Intangible assets505,300 157,500 662,800 
Right-of-use assets4,811 8,232 13,043 
Other assets227  227 
Total identifiable assets acquired$579,316 $212,609 $791,925 
Liabilities assumed:
Accounts payable and accrued expenses18,699 6,442 25,141 
Other current liabilities12,912 5,483 18,395 
Lease liabilities6,461 10,105 16,566 
Deferred income tax liabilities28,073  28,073 
Total liabilities assumed:$66,145 $22,030 $88,175 
Net assets acquired513,171 190,579 703,750 
Purchase consideration781,434 325,651 1,107,085 
Goodwill $268,263 $135,072 $403,335 
Goodwill recognized for these acquisitions is attributable to improving the product offerings, expanding into additional markets and the expected cash flows resulting from these efforts, and assembled workforce. Goodwill recognized is not expected to be deductible for local tax purposes. During the period from July 28, 2022 to December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Medical reporting unit. During the year ended December 31, 2024, the Company recorded an additional non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit. See “Note 5. Goodwill” for additional details.
See “Note 18. Segment Reporting” for amounts related to revenue and earnings associated with Obagi Medical and Milk Makeup subsequent to the acquisition date.
Related Party Liability
The Company recognized a liability with respect to a related party supply contract executed on the Closing Date between Obagi and Obagi Hong Kong. The fair value of the related party liability was determined using the present value of after-tax cash flows related to unfavorable discounts provided to the Obagi China Business included in the Supply Agreement (the “Supply Agreement” as further detailed in “Note 16. Related Party Transactions”). As of the Obagi Merger Effective Time, the Company recognized a related party liability of $22.1 million. During the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, the Company amortized $2.3 million, $4.1 million, and $12.2 million, respectively, of the related party liability into the related party revenue recognized on the sale of products to the Obagi China Business. During the year ended
F-20

December 31, 2024, the Company recorded $3.4 million in Other income due to the termination of an interim supply agreement and the associated release of the remaining related party liability. The parties operated under this interim supply agreement, which terminated in July 2023, until December 2024, at which point the remaining related party liability was amortized and released. As a result, the Company did not have a remaining related party liability as of December 31, 2024. The Company had a related party liability of $5.9 million, included in Other current liabilities, as of December 31, 2023.
Intangible Assets
Fair Value
ObagiMilkTotalWeighted-
Average
Useful Life
(In thousands) 
Trademarks and trade name$414,000 $145,000 $559,000 14 years
Customer/distributor relationships25,000 11,000 36,000 11 years
Tretinoin distribution and supply agreement38,900  38,900 5 years
Formulations27,400 1,500 28,900 8 years
Total Intangible Assets$505,300 $157,500 $662,800 
The intangible assets acquired in connection with the Business Combination are classified as Level 3 in the fair value hierarchy. The estimate of the fair values of the acquired amortizable intangible assets were determined using a multi-period excess earnings income approach by discounting the incremental after-tax cash flows over multiple periods. Significant estimates used in the determination include estimating future cash flows over multiple periods, terminal value, and discounting such cash flows at a rate of return that reflects the relative risk of the cash flows.
Transaction Costs
In connection with the Business Combination, Waldencast incurred transactions costs of $9.4 million which were incurred during the period from July 28, 2022 to December 31, 2022. Transaction costs consisted of advisory, legal, accounting and management fees, which are included in SG&A expenses on the consolidated statements of operations and comprehensive loss.
Unaudited ASC 805 Pro Forma
The following unaudited pro forma combined financial information presents the Company’s results as though the Business Combination had occurred on January 1, 2021, for the year ended December 31, 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.
Year ended
December 31, 2022
(In thousands)(Unaudited)
Pro forma net revenue$200,547 
Pro forma net loss(86,930)
Less: Pro forma net loss attributable to noncontrolling interest(25,140)
Pro forma net loss attributable to Waldencast plc$(61,790)
These unaudited pro forma results include adjustments such as inventory step-up, amortization of acquired intangible assets, and interest expense on debt financing in connection with the Business Combination. Material, nonrecurring pro forma adjustments directly attributable to the Business Combination include: 
• Cost of goods sold related to acquired inventory step-up of $10.0 million was removed from net income for the year ended December 31, 2022; and
F-21

Transaction related costs of $66.1 million were removed from net income for the year ended December 31, 2022.
The unaudited consolidated pro forma financial information was prepared in accordance with accounting standards and is not necessarily indicative of the results of operations that would have occurred if the Business Combination had been completed on the date indicated, nor is it indicative of the future operating results of the Company. 
The unaudited pro forma results do not reflect events that either have occurred or may occur after the Business Combination, including, but not limited to, the anticipated realization of operating synergies in subsequent periods. They also do not give effect to certain charges that the Company expects to incur in connection with these acquisitions, including, but not limited to, additional professional fees and employee integration. 
SA Distributor Transaction
In March 2023, as part of our strategy to internalize distribution channels in key markets, certain of Obagi's subsidiaries entered into and consummated a Purchase Agreement (the “Vietnam Purchase Agreement” with Obagi Vietnam and the Company’s Southeast Asia Distributor (“SA Distributor”), pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam, from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, an indirect subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve months ending December 31, 2026, subject to setoff for any owed obligations. The acquisition was determined to be an asset acquisition with the primary asset being the recovery of $1.6 million of inventory held by the SA Distributor. No fair value was allocated to the earnout liability as the Company concluded the earnout projections would not be achieved. In June 2024, Obagi entered into a Settlement and Release Agreement with the SA Distributor, which, among other things, extinguished the SA Distributor’s right to receive an earnout and the SA Distributor’s 40% interest in the outstanding equity of Obagi Blue Sea Holding, LLC.
4.REVENUE
The Company disaggregates its revenue from customers by sales channel, as well as by revenue source and geographic region, based on the location of the end customer, as it believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.
Revenue by Sales Channel
The Company’s revenue is primarily generated from product sales. Direct sales revenue listed in the table below includes (i) sales to physicians through the Physician Channel Provider, (ii) DTC sales via the Company’s e-commerce platforms, and (iii) sales directly to retailers. Distributors revenue includes products sold through distributors other than the Physician Channel Provider.
Total revenue by sales channel was as follows for the periods indicated:
Year ended December 31, 2024
(In thousands)Obagi MedicalMilk
Makeup
Total
Revenue by Sales Channel
Direct sales$103,168 $120,362 $223,530 
Distributors41,630 4,209 45,839 
Net product sales$144,798 $124,571 $269,369 
Royalties4,468 31 4,499 
Net revenue$149,266 $124,602 $273,868 

F-22

Year ended December 31, 2023
(In thousands)Obagi MedicalMilk
Makeup
Total
Revenue by Sales Channel
Direct sales$72,446 $97,222 $169,668 
Distributors40,203 3,245 43,448 
Net product sales$112,649 $100,467 $213,116 
Royalties5,002 20 5,022 
Net revenue$117,651 $100,487 $218,138 
Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)Obagi MedicalMilk
Makeup
TotalTotal
Revenue by Sales Channel
Direct sales$30,276 $30,192 $60,468 $39,649 
Distributors28,826 1,091 29,917 31,080 
Net product sales$59,102 $31,283 $90,385 $70,729 
Royalties1,988  1,988 3,031 
Net revenue$61,090 $31,283 $92,373 $73,760 

For the year ended December 31, 2024, three customers accounted for 18%, 17%, and 10% of the Company’s revenue, respectively. For the year ended December 31, 2023, two customers accounted for 28% and 20% of the Company’s revenue, respectively. During the period from July 28, 2022 to December 31, 2022, three customers accounted for 29%, 18%, and 16% of the Company’s revenue, respectively. During the period from January 1, 2022 to July 27, 2022, two customers accounted for 44% and 20% of the Company’s revenue, respectively.
The Physician Channel Provider is an authorized wholesale distributor and service provider for the Company in the U.S. Revenue from sales to physicians and e-commerce customers made through this provider are considered direct sales revenue. The Physician Channel Provider is also a distributor of the Company’s products to other channels, such as the spa channel, and the related sales are considered distributor revenue.
Revenue by Geographic Region
Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Revenue by Geographic Region 
North America$202,261 $154,357 $56,630 $44,443 
Rest of the World67,108 58,759 33,755 26,286 
Net product sales$269,369 $213,116 $90,385 $70,729 
Royalties4,499 5,022 1,988 3,031 
Net revenue$273,868 $218,138 $92,373 $73,760 

F-23

During the years ended December 31, 2024, and 2023, only one country, the United States, accounted for more than 10% of the Company’s total revenues, with net product sales amounting to $192.6 million and $145.3 million, respectively.
During the period from July 28, 2022 to December 31, 2022, the two countries that accounted for more than 10% of the Company’s total revenues were the United States and China, respectively, with net product sales amounting to $54.3 million and $17.0 million, respectively.
During the period from January 1, 2022 to July 27, 2022, (Predecessor Period) the two countries that accounted for more than 10% of the Company’s total revenues were the United States and Vietnam, with net product sales amounting to $43.8 million and $14.9 million, respectively.
5.GOODWILL
The Company allocated goodwill acquired in the Obagi Merger to its Obagi Medical reporting unit and goodwill acquired in the Milk Transaction to its Milk Makeup reporting unit. The fair value of each reporting unit was determined as of the Closing Date as part of the Business Combination (see “Note 3. Business Combinations”). The following table presents changes in goodwill by reportable segment:
(In thousands)Obagi MedicalMilk MakeupTotal Goodwill
Balance as of December 31, 2022
$199,548 $135,072 $334,620 
Balance as of December 31, 2023
$199,548 $135,072 $334,620 
Impairment loss(5,031) $(5,031)
Balance as of December 31, 2024
$194,517 $135,072 $329,589 
The Company evaluates goodwill for impairment on an annual basis on October 1st and at an interim date if indicators of a potential impairment exist. The goodwill impairment test is conducted at the reporting unit level. The fair value of the Company’s reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the Company’s most recent projected long-term financial forecasts for revenue, earnings, capital expenditures, and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the respective reporting unit. Under the guideline public company method, fair value is estimated using market multiples of various financial metrics observed for the reporting unit’s comparable public companies.
Immediately after the Business Combination (see “Note 3. Business Combinations”), the Company concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Medical reporting unit was less than its carrying amount. Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Medical reporting unit. The annual impairment test performed for fiscal 2022 did not indicate a further impairment of goodwill at the time it was performed.
The annual impairment test performed for fiscal 2023 did not indicate an impairment of goodwill at the time it was performed.
The Company performed its annual goodwill impairment analysis using the qualitative approach on October 1, 2024, and the analysis concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Medical reporting unit was less than its carrying amount. Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the year ended December 31, 2024, the Company recorded a non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit.
F-24

The Company performed a qualitative review of the Milk Makeup reporting unit on October 1, 2024, which did not indicate that the fair value of the reporting unit was less than the carrying value. On that basis, management concluded that there was no change in the fair value. As a result, the goodwill balance for the Milk Makeup reporting unit has not changed.
Changes in market conditions, laws and regulations, and key assumptions made in future qualitative or quantitative assessments, such as expected cash flows, competitive factors, discount rates, and value indications from market transactions, could negatively impact the results of future impairment testing and could result in the recognition of additional future impairment charges.
6.INTANGIBLE ASSETS—NET
Intangible assets, net consisted of the following as of December 31, 2024:
(In thousands)Weighted
Average Useful
Lives (Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Trademark and trade name14$559,875 $(102,169)$457,706 
Customer/distributor relationships1136,000 (6,449)29,551 
Tretinoin distribution and supply agreement
538,900 (18,885)20,015 
Formulations828,900 (9,943)18,957 
Patents20227 (18)209 
Total$663,902 $(137,464)$526,438 
Intangible assets, net consisted of the following as of December 31, 2023:
(In thousands)Weighted
Average Useful
Lives (Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Trademark and trade name14$559,644 $(59,989)$499,655 
Customer/distributor relationships1136,000 (4,532)31,468 
Tretinoin distribution and supply agreement538,900 (11,105)27,795 
Formulations828,900 (5,101)23,799 
Patents20154 (8)146 
Total$663,598 $(80,735)$582,863 
Due to the non-cash goodwill impairment charge within the Obagi Medical reporting unit during the year ended December 31, 2024, the Company also performed a quantitative analysis on Obagi Medical's definite lived intangibles. The Company concluded there was no impairment to these assets.
Amortization expense for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) was $56.7 million, $56.7 million, $24.0 million, and $7.7 million, respectively.
F-25

Expected amortization for each of the years between 2025 through 2029, and thereafter are as follows:
(In thousands)
Years ending December 31,
2025$56,737 
202656,737 
202753,496 
202848,957 
202948,957 
Thereafter261,554 
$526,438 
7.DEBT
(In thousands)Maturity Date
As of December 31, 2024
As of December 31, 2023
2022 Term LoanJuly 2026$153,125 $161,875 
Note PayableMay 2024830 968 
2022 Revolving Credit FacilityJuly 202615,000  
Unamortized debt issuance costs(2,339)(3,050)
Net carrying amount$166,616 $159,793 
Less: Current portion of long-term debt(29,479)(8,529)
Total long-term portion$137,137 $151,264 
Note Payable — Directors and Officers (“D&O”) Insurance
In July 2024, the Company entered into an agreement with a financing company for $1.6 million to finance its D&O insurance policy. The terms of the agreement stipulated equal monthly payments of principal and interest payments of $0.2 million over a ten-month period, ending in May 2025. Interest is accrued on this loan at an annual rate of 8.25%.
In August 2023, the Company entered into an agreement with a financing company for $2.4 million to finance its D&O insurance policy. The terms of the agreement stipulated equal monthly payments of principal and interest payments of $0.2 million over a ten-month period, ending in May 2024, which had been fully repaid as of December 31, 2024. Interest was accrued on this loan at an annual rate of 8.2%.
2022 Credit Agreement
In June 2022, Waldencast Finco Limited, a wholly-owned subsidiary of the Company (the “2022 Credit Agreement Borrower”), together with Waldencast and certain of its subsidiaries as guarantors (the “2022 Credit Agreement Parent Guarantor”), entered into the 2022 Credit Agreement with the 2022 Credit Agreement Lenders and JPMorgan, as administrative agent for the 2022 Credit Agreement Lenders (the “2022 Credit Agreement Lenders”). The 2022 Credit Agreement provides the Company with access to a term loan of $175.0 million (the “2022 Term Loan”) and a revolving credit capacity with a current borrowing capacity of up to $45.0 million (the “2022 Revolving Credit Facility”), of which up to $7.5 million may be available, at 2022 Credit Agreement Borrower’s option, to be drawn in form of letters of credit (“2022 Letter of Credit”). The 2022 Credit Agreement is secured by the assets of the Company. The 2022 Credit Agreement restricts the Company’s ability to make certain distributions or dividends, subject to a number of enumerated exceptions.
The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. Borrowings under the 2022 Credit Agreement may accrue interest at a rate per annum equal to, at the 2022 Credit Agreement Borrower’s election, either alternate base rate plus an applicable margin of 2.5% per annum or a term benchmark rate plus an applicable margin of 3.5% per annum. As of December 31, 2024, borrowings under the 2022 Credit Agreement consisted entirely of term benchmark borrowings at a borrowing rate of 7.9% per annum.
F-26

In connection with the issuance of the 2022 Credit Agreement, the Company incurred $6.3 million of debt issuance costs. As of December 31, 2024, the weighted average interest rate was 8.7% for the 2022 Term Loan and 8.7% for the 2022 Revolving Credit Facility. The current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $15.3 million and $15.0 million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and the 2022 Revolving Credit Facility was $1.2 million and $0.5 million, respectively. The accrued interest was $1.4 million as of December 31, 2024. Unamortized debt issuance costs on the 2022 Letter of Credit is $0.1 million, which is recorded in other current assets in the consolidated balance sheets.
Scheduled maturities under the Company’s 2022 Credit Agreement and the Note Payable as of December 31, 2024 are as follows:
(In thousands)
Year Ending December 31,
2025$31,142 
2026137,813 
2027 
2028 
2029 
Total unpaid principal$168,955 
Waiver and Consent and Amendment to the 2022 Credit Agreement
On April 26, 2024, the 2022 Credit Agreement Borrower, 2022 Credit Agreement Parent Guarantor, JPMorgan and the required lenders entered into an amendment (the “Third Amendment”) to the 2022 Credit Agreement. Among other things, the Third Amendment: (i) waived certain historical breaches of the financial covenant, (ii) modified the existing financial covenants, (iii) reduced the revolving commitments of the lenders by $5.0 million in the aggregate to $45.0 million, (iv) lowered the existing minimum liquidity covenant to $10.0 million and (v) extended the Covenant Relief Period until December 31, 2024.
8.LEASES
The Company has operating leases for real estate properties for office and warehouse spaces with initial terms between approximately 1 and 11 years. Some of the Company’s lease contracts include options to extend the leases for up to 5 years. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.
The Company determines if a contract contains a lease at inception of the arrangement based on whether the Company has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether the Company has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset that the Company does not own. Right of use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of any changes in market conditions but generally, these termination options are not exercised and not considered in the determination of the lease term. Lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. ROU assets are recognized on the balance sheet based on the lease liability adjusted for any initial direct costs, lease incentives received, and prepaid rent. The Company may elect to apply the short-term lease exception for leases with a term of 12 months or less. These leases will be not be recognized as an ROU asset or lease liability. The short-term lease payments will be expensed on a straight-line basis over the lease term.
The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate (“IBR”), because the interest rate implicit in most of the Company’s leases is not readily determinable. The IBR is a hypothetical rate based on the Company’s understanding of what its credit rating would be, and resulting interest the Company would pay, to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Lease payments may be fixed or variable, however, only fixed payments or in-substance fixed payments are included in the Company’s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligation for those payments is incurred. The Company has elected not
F-27

to separate non-lease components from lease components and accounts for them as a single lease component. The Company has also elected the short-term lease recognition exemption for all leases that qualify.
The Company historically accounted for leases in accordance with ASC 840, Leases, under which operating leases were not recorded on the balance sheet. Adoption of ASC 842, Leases (“ASC 842”) was not required in interim periods preceding December 31, 2022. Upon consummation of the Business Combination, Obagi and Milk adopted ASC 842 as a matter of policy alignment. The period from January 1, 2022 to July 27, 2022 (Predecessor Period) does not reflect the impact of ASC 842 adoption, as the Company did not adopt the standard as of an interim 2022 period.
The Company’s lease expenses of $3.7 million and $3.5 million during the year ended December 31, 2024 and year ended December 31, 2023, respectively, were composed of operating lease costs. The Company does not have any finance leases, short-term lease costs or variable lease costs.
Supplemental cash flow information related to the Company’s operating leases was as follows:
(In thousands)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Cash paid for amounts included in the measurement of operating lease liabilities$3,826 $3,309 $1,166 
Right-of-use assets obtained in exchange for new operating lease liabilities$131 $446 $4,081 

Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Weighted-average remaining lease term6.056.927.75
Weighted-average discount rate5.9%5.9%5.9%
Reconciliation of the undiscounted future minimum lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2024 was as follows:
(In thousands)
Amount
2025$3,797 
20262,899 
20272,452 
20282,504 
20292,548 
Thereafter4,173 
Total future minimum lease payments$18,373 
Less: Imputed interest
2,883 
Total reported lease liability$15,490 
Texas Leases
In December 2021 and July 2022, Obagi entered into a lease for a warehouse and office space, respectively, in Texas as part of their plans to relocate headquarters from California. The warehouse and office space leases will expire in 2032 and 2033, respectively.
The warehouse space was never made operational and in 2023, the Company permanently decided not to use the warehouse with no intention to occupy or utilize the space in the future, and actively began marketing the space for sublease. The Company entered into a sublease for the warehouse space that will run through February 2032 with
F-28

annual rent of $0.3 million. The sublease does not contain a provision for early termination or extension at the end of the lease. As a result, the Company recorded an impairment charge of $0.8 million during the year ended December 31, 2023 which was the excess of the carrying value of the associated lease right-of-use asset over its fair value.
In September 2023, Obagi vacated the Texas office space and relocated its headquarters back to California, permanently deciding to not use the office with no intention to occupy or utilize the space in the future, and actively began marketing the space for sublease. The Company has entered into a sublease for the office space that will run through December 2025 with annual rent of $0.4 million. The sublease does not contain a provision for early termination or extension at the end of the lease. As a result, the Company recorded an impairment charge of $2.7 million during the year ended December 31, 2023 which was the excess of the carrying value of the associated office lease right-of-use asset over its fair value.
The Company estimated the fair values using discounted cash flows from the estimated net sublease rental income as of the date the decision to sublease was made. The impairment charges are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.
Disclosures Related to Periods Prior to the Adoption of ASC 842
Prior to the Obagi China Distribution, the Company leased office space under three non-cancelable operating leases expiring between September 2023 and February 2032. Rent expense related to the Company’s operating leases was $0.9 million for the period from January 1, 2022 to July 27, 2022 (Predecessor Period).
9.FINANCIAL INSTRUMENTS
Interest Rate Collar
To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, the Company entered into an interest rate collar with Wells Fargo Bank, N.A. (“Wells Fargo”) in October 2022 for a notional value of $160.0 million and a fixed cash payment of $0.8 million. Under the terms of the interest rate collar, the Company was required to pay Wells Fargo if the monthly SOFR-based interest fell below the defined interest rate floor of 2.55%; conversely, the Company was entitled to receive payment from Wells Fargo if the monthly SOFR-based interest rate rose above the defined interest rate cap of 5.25%. Settlement in cash occurred monthly, if contractually required, until termination of the agreement, which occurred in October 2024. As of December 31, 2024, the Company no longer had an interest rate collar.
This derivative instrument has not been designated for hedge accounting, therefore the change in fair value is recognized in current period earnings. The fair value of these contracts, included in other non-current assets was zero and $0.1 million as of December 31, 2024 and December 31, 2023, respectively. The non-cash gain from the change in fair value was $0.1 million during the year ended December 31, 2024, recognized in other expenses, net. The non-cash losses from the change in fair value during the year ended December 31, 2023 and from July 28, 2022 to December 31, 2022 were $0.1 million and $0.6 million, respectively, and are recognized in other expenses, net. Receipts of $0.1 million were exchanged on the interest rate collar contract during each year ended December 31, 2024 and year ended December 31, 2023. No payments or receipts were exchanged on the interest rate collar contract during the period from July 28, 2022 to December 31, 2022 aside from the initial fixed cash payment of $0.8 million.
Warrant Liabilities
Pursuant to Waldencast’s IPO, the Company issued 11,499,950 Public Warrants to third-party investors. Simultaneously with the closing of the IPO, Waldencast completed the private sale of 5,933,333 warrants (the “Sponsor Warrants”) to the Sponsor. Also, in connection with the IPO, on February 22, 2021, Waldencast, the Sponsor and Zeno Investment Master Fund (f/k/a Dynamo Master Fund, a member of the Sponsor (“Zeno”), entered into a Forward Purchase Agreement (the “Sponsor FPA”), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell Mountain Trust (“Burwell”) on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor’s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Waldencast Class A ordinary shares and 5,333,333 warrants (the “Sponsor FPA Warrants”) in connection with the closing of the Business Combination. In addition, Waldencast and Beauty Ventures LLC (“Beauty Ventures”) entered into a Forward Purchase Agreement on March 1, 2021 (the “Third-Party FPA”, and
F-29

together with the Sponsor FPA, the “FPAs”), pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and 5,766,666 warrants (the “Third-Party FPA Warrants” and together with the Sponsor FPA Warrants, the “FPA Warrants”) for an aggregate commitment amount of $173.0 million, in connection with the closing of Waldencast’s initial business combination. Finally, in connection with the Business Combination, Waldencast issued 1,000,000 warrants to settle $1.5 million working capital loans with its Sponsor, the terms of which are identical to the Sponsor FPA Warrants (the “Sponsor Loan Warrants”). The Sponsor Loan Warrants and Third-Party FPA Warrants are collectively referred to as the “Private Placement Warrants.
As of December 31, 2024, all of the above-noted warrants, totaling 29,533,282, remained issued and outstanding. The Company recognized a gain of $23.6 million, a loss of $10.3 million, and a gain of $6.8 million from the change in fair value of the Public Warrants and Private Placement Warrants in the Company’s consolidated statements of operations and comprehensive loss during the year ended December 31, 2024, during the year ended December 31, 2023, and for the period from July 28, 2022 to December 31, 2022, respectively.
Following the Domestication, Public Warrants and Private Placement Warrants each entitle the holder to purchase one share of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued and only whole warrants can trade. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire June 27, 2027 or earlier upon redemption or liquidation.
The Company may redeem the Public Warrants:
in whole and not in part;
upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption, based on the redemption date and the “fair market value” of the Class A ordinary shares;
at a price of $0.01 per warrant if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted);
at a price of $0.01 per warrant if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and
if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.
The exercise price and number of Class A ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants.
The terms of the Third-Party FPA Warrants are identical to the Public Warrants. The Sponsor Loan Warrants and Sponsor FPA Warrants are also identical to the Public Warrants, except that they and the Class A ordinary shares issuable upon the exercise of such warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Loan Warrants and Sponsor FPA Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees, thereafter they will be redeemable by the Company and exercisable by such holders on the same basis as Public Warrants.
F-30

10.FAIR VALUE MEASUREMENTS
The following tables present information by year about the Company’s financial instruments that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:
As of December 31, 2024
(In thousands)TotalQuoted Prices in Active MarketSignificant Other Observable InputsSignificant Other Unobservable Inputs
(Level 1)(Level 2)(Level 3)
Liabilities:
Derivative warrant liabilities - Public$1,983 $1,983 $ $ 
Derivative warrant liabilities - Private$3,038 $ $3,038 $ 
As of December 31, 2023
(In thousands)TotalQuoted Prices in Active MarketSignificant Other Observable InputsSignificant Other Unobservable Inputs
(Level 1)(Level 2)(Level 3)
Assets:
Interest rate collar$61 $ $61 $ 
Liabilities:
Derivative warrant liabilities - Public$11,155 $11,155 $ $ 
Derivative warrant liabilities - Private$17,492 $ $17,492 $ 
Private derivative warrants are classified as Level 2 financial instruments. The fair value of the Level 2 Private Placement Warrant liabilities has been measured based on the fair value of Public Warrant liabilities. The interest rate collar has been measured at net present value by projecting future cash flows and discounting the future amounts to a present value using market-based observable inputs including interest rate curves and credit spreads.
For goodwill (see “Note 5. Goodwill”), fair value assessments of the reporting units and the reporting units’ net assets performed for goodwill impairment tests are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.
The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Except for the initial valuation of long-lived assets in connection with the Business Combination (see “Note 3. Business Combinations”) and impairment of goodwill discussed above, no long-lived assets were remeasured at fair value on a nonrecurring basis during the periods presented.
11.SUPPLEMENTAL BALANCE SHEET DISCLOSURES
Accounts Receivable, Net
As of December 31, 2024, accounts receivable, net consisted of accounts receivable of $25.6 million, less allowance for doubtful accounts of $0.1 million. As of December 31, 2023, accounts receivable, net consisted of accounts receivable of $22.9 million, less allowance for doubtful accounts of $1.6 million.
F-31

The change in the allowance for doubtful accounts were as follows:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Balance at beginning of period$1,552 $994 $1,061 $671 
Provision (recovery) for bad debts
(996)558 (67)390 
Write-off of uncollectible accounts, net(448)   
Balance at end of period$108 $1,552 $994 $1,061 
Inventories
The components of inventories were as follows:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Work in process$8,354 $10,336 
Finished goods44,750 45,348 
Total inventories$53,104 $55,684 
Property and Equipment, Net
Property and equipment, net consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Computer hardware, software and equipment$742 $689 
Furniture and fixture9,848 7,611 
Machinery and equipment598 812 
Internally developed software1,739 854 
Leasehold improvements2,100 2,070 
Total property and equipment$15,027 $12,036 
Less accumulated depreciation(9,196)(6,105)
Property and equipment, net$5,831 $5,931 
Depreciation expense for property and equipment for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022 were $3.3 million, $3.8 million, and $2.9 million, respectively. Depreciation expense for property and equipment for the period from January 1, 2022 to July 27, 2022 (Predecessor Period) was $0.5 million.
Depreciation expense pertains to property and equipment utilized as part of the Company’s SG&A activities and therefore has not been allocated to cost of goods sold.
F-32

Other Current Liabilities
The major components of other current liabilities consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Accrued salaries and related expenses$9,155 $8,702 
Accrued sales returns and damages2,723 2,527 
Accrued interest1,424 1,357 
Accrued distribution fees 590 
Related party liability 5,856 
Accrued professional services3,832 2,901 
Other2,426 1,765 
Total$19,560 $23,698 
There was no related party liability as of December 31, 2024 due to the change in contract terms, which resulted in a release of the liability. The related party liability of $5.9 million as of December 31, 2023 reflects the remaining unamortized fair value of the related party inventory contract executed on the acquisition date between Obagi and the Obagi China Business (see “Note 3. Business Combinations”).
12.STOCK-BASED COMPENSATION
Incentive Award Plan
The Company’s 2022 Incentive Award Plan (the “2022 Plan”) provides for incentives to be provided to selected officers, employees, non-employee directors and consultants of the Company in the form of options, stock appreciation rights, restricted stock, restricted stock units, stock bonuses or other stock-based awards granted under the 2022 Plan. The 2022 Plan became effective on July 27, 2022 in connection with the closing of the Business Combination.
The notional maximum number of ordinary shares authorized under the 2022 Plan for the fiscal year ended December 31, 2024 was 23,042,449 (the “Share Reserve”). The Share Reserve automatically increases on January 1st of each calendar year by 3% of the total ordinary shares then issued and outstanding, or such lesser amount as determined by the Board. All shares reserved for issuance under the 2022 Plan may be granted as incentive stock options. As of December 31, 2024, taking into account previous grants and forfeitures, the Company had 5,533,142 ordinary shares remaining available for future issuances under the 2022 Plan.
In 2024, the Company granted an aggregate of 3,828,878 Restricted Stock Unit (“RSU”) incentive awards to employees and non employees of the Company, generally vesting over one to three years. Some portion vested immediately with the balance vesting annually. Of these awards 312,830 were granted to the Founders,
Also in 2024, the Company granted an aggregate of 319,471 RSUs to directors, typically vesting immediately or over one to three years.
In August 2022, the Company approved incentive awards to employees of Waldencast, Milk, and Obagi. The long-term incentive awards (the “LTI Awards”) are restricted stock units that vest based on both a service condition and meeting either a net sales or EBITDA target in calendar year 2022. These LTI Awards were granted to employees in November 2022. The performance targets for the LTI Awards were met for Milk in 2022. The Company granted LTI Awards will vest one-third each year beginning on February 15, 2023, subject to continued service through such dates. In May 2023, the Board approved a modification to the LTI Awards by waiving the performance conditions for most Obagi and Waldencast employees totaling 137,537 RSUs. The conditions were not waived for the former Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast, resulting in forfeiture of 360,000 RSUs. Based on the financial statements prepared by the Company for the period ended December 31, 2022, the Board certified that the applicable performance goals were not met and, accordingly, that the
F-33

2022 RSUs granted to the Company’s founders would not vest. No additional grants of RSUs were made for the year ended December 31, 2024 or for the year ended December 31, 2023.
In November 2022, the Company approved a one-time stock grant for certain Milk employees that were not eligible to participate in the LTI award program. A total of 10,000 awards were approved under this program. These awards are service-based restricted stock units that will cliff vest three years from the grant date, subject to continued employment with the Company.
Strategic Growth Incentive
In 2024, the Company granted an aggregate of 2,557,119 strategic growth incentive 2027 awards in performance vested share units to certain Company employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the Company’s Net Revenue and earnings before interest, taxes, depreciation, and amortizations (“EBITDA”) targets for the year ended December 31, 2027. These awards had a grant date fair value per share ranging between $2.88 and $6.48. Some of the awards require a one-year post vesting holding period once the shares have been awarded.
In 2023, the Company granted an aggregate of 2,290,000 strategic growth incentive 2025 awards in performance vested share units to certain Company employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the Company’s net revenue and EBITDA targets for the year ended December 31, 2025. These awards had a grant date fair value per share of $8.88 and require a one-year post vesting holding period once the shares have been awarded.
Restricted stock activity for the year ended December 31, 2024 was as follows:
SharesWeighted Average
Grant Date Fair Value
per Share
Outstanding as of December 31, 2023
2,296,831 $8.72 
Granted6,705,468 3.69 
Vested(567,745)5.84 
Forfeited(851,298)8.87 
Outstanding as of December 31, 2024
7,583,255 $4.61 
Business Combination
On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested awards granted under those plans. The Company assumed 5,906,300 stock options and 1,776,827 restricted stock units as replacement awards pursuant to the Obagi Merger Agreement, as well as 237,724 stock options and 2,808,131 share appreciation rights as replacement awards pursuant to the Milk Merger Agreement. The total post-combination incremental stock-based compensation was $18.3 million, which is expected to be recognized over the remaining requisite service periods, where $47.7 million represents the fair value of the equity awards as part of the equity purchase consideration. The awards that were replaced had been contingent on a performance condition and as such, the Company is required to use an attribution model in which compensation cost for each vesting tranche is recognized as if each vesting tranche were a separate award.
Founder Awards
In August 2022 the Company granted a total of 11,500,000 stock options to the two founders of Waldencast that vest based on service over the six-year period from August 2022 through August 2028. The options were granted with four vesting tranches, each tranche with a different exercise price, subject to their continued employment with the Company. Additionally, the Company granted 692,000 founders service-based restricted stock units that cliff vest in August 2025, subject to their continued employment with the Company.
F-34

Stock option activity for the year ended December 31, 2024 was as follows:
Number of
Common
Stock
Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life (in years)
Aggregate
intrinsic
Value (in
thousands)
Balance as of December 31, 2023
18,915,358 $9.10 7.3$47,792 
Granted  — — 
Exercised(150,000)0.68 — — 
Forfeited(1,628,000)5.73 — — 
Balance as of December 31, 2024
17,137,35810.48 6.41,156 
Exercisable as of December 31, 2024
9,168,9757.31 5.01,156 
Vested and expected to vest as of December 31, 2024
17,137,358$10.48 6.4$1,156 
The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for Replacement Options based on the following weighted-average assumptions:
Period from July 28, 2022 to December 31, 2022
Founder Awards
Replacement Options
Risk-free interest rate (1)
2.87% - 2.92%
 2.79% - 2.80%
Expected term (years) (2)
4.7 - 9.9
N/A
Exercise multiple (3)
N/A2.30 
Expected stock price volatility (4)
39.77% - 44.76%
50.00 %
Dividend yield (5)
N/AN/A
(1)The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.
(2)The expected term for Founder Awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.
(3)The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.
(4)For Founder Awards, the expected stock price volatility is the median historical volatility of Waldencast’s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for Replacement Options, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.
(5)Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.
Stock-compensation expense for the years ended December 31, 2024 and 2023, and the period from July 28, 2022 to December 31, 2022, was $9.4 million, $9.2 million, and $7.7 million, respectively. The unrecognized compensation cost as of December 31, 2024 for stock options and restricted stock was $16.1 million and $13.0 million, respectively. These costs are expected to be recognized over a weighted-average service period of 3.5 and 2.3 years for stock options and restricted stock, respectively.
Predecessor Incentive Plan
In January 2021, the Predecessor established a Stock Incentive Plan (the “Predecessor Incentive Plan”), under which stock options, stock awards, and restricted stock units (“Predecessor Restricted Stock”) of the Company could be granted to eligible employees, directors, and consultants. Under the Predecessor Incentive Plan, the Company was authorized to issue of a maximum number of 1,500,000 shares of Obagi common stock. Incentive stock options were
F-35

required to have an exercise price at or above the fair market value of the stock on the date of the grant. The Company’s stock options and Predecessor Restricted Stock granted during the period from January 1, 2022 to July 27, 2022 (Predecessor Period) had service-based and performance-based vesting conditions.
The options vested over five years, with 25% of options vesting in four equal quarterly installments at the end of each three-month period through the first anniversary of the grant, and the remaining 75% vesting in a series of five equal annual installments over the five-year period measured from the grant date. The Predecessor Restricted Stock vested in five equal annual installments at the end of each year, over the five-year period from the grant date. Award holders had a ten-year period to exercise the options before they expire. Notwithstanding achievement of the service-based condition, the options and the Predecessor Restricted Stock did not vest or become exercisable until a qualifying transaction was consummated prior to the expiration date. A qualifying transaction consisted of either a change in control event or an underwritten initial public offering by the Company of its equity securities on a U.S. or foreign exchange, which occurred upon Waldencast’s acquisition of Obagi.
13. SHAREHOLDERS’ EQUITY
Share Capital
Under the Company’s Memorandum of Association (the “Constitutional Document”), its authorized share capital consists of 1,000,000,000 Class A ordinary shares, 100,000,000 Class B ordinary shares and 25,000,000 Preferred Shares, each having a par value of $0.0001. As of December 31, 2024, there were 112,026,440 and 10,666,528 Class A and Class B ordinary shares, respectively, issued and outstanding. The Company did not have any Preferred Shares issued and outstanding as of December 31, 2024.
Each Class A ordinary share is entitled to one vote per share. The Company can, at the discretion of its Board, declare dividends and distributions out of the funds of the Company lawfully available therefor. In the event of a voluntary or involuntary liquidation or wind-up, assets available for distribution among the holders of Class A ordinary shares will be distributed on a pro rata basis.
Each Class B ordinary share is entitled to one vote per share and will vote together with holders of Class A ordinary shares as a single class. Class B ordinary shares are non-economic shares that are not entitled to dividends. Upon a liquidation, dissolution or winding up of the Company, the holders of Class B ordinary shares will not be entitled to receive any assets of the Company, except to the extent of the par value of their shares, pro rata with the distributions that are shared with the Class A ordinary shares.
As outlined in “Note 3. Business Combinations,” Class B ordinary shares were issued by the Company to the Milk Members in connection with the Business Combination, giving rise to noncontrolling interest in the Company’s controlled subsidiary, Waldencast Partners LP. As such, the Constitutional Document prohibits issuances of additional shares of Class B ordinary shares, unless issued to a noncontrolling interest in connection with the Company’s Up-C structure. Class B ordinary shares are convertible into Class A ordinary shares on a one-to-one basis at the option of the holder. If such option is exercised, the exchanged Class B ordinary shares will automatically be surrendered and retired for no consideration. If the Company issues or redeems Class B ordinary shares, Waldencast Partners LP is obligated to issue or redeem a corresponding number of Waldencast LP partnership units, such that the number of issued and outstanding partnership units at any time will correspond and be equivalent to the then number of issued and outstanding Class B ordinary shares.
F-36

14. NET LOSS PER SHARE
The Company uses the weighted average ownership percentages during the period to calculate the net loss per share attributable to public shareholders and the noncontrolling interest holders. The following table sets forth the computation of basic and diluted net loss using the treasury stock method:
(In thousands, except for share and per share amounts)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Numerator:
Net loss$(48,648)$(105,968)$(120,557)$(21,057)
Net loss attributable to noncontrolling interest(6,205)(15,987)(24,990) 
Net loss attributed to Class A shareholders - basic and diluted EPS(42,443)(89,981)(95,567)(21,057)
Denominator:
Weighted-average basic shares outstanding109,295,74291,158,50086,460,5608,000,002
Effect of dilutive securities    
Weighted-average diluted shares109,295,74291,158,50086,460,5608,000,002
Basic and diluted net loss per share$(0.39)$(0.99)$(1.11)$(2.63)
The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Warrants29,533,28229,533,28229,533,282
Stock options17,137,35818,915,35820,452,155774,800
Restricted stock7,583,2552,296,8312,802,419234,842
Total54,253,89550,745,47152,787,8561,009,642
15. INCOME TAX BENEFIT
The Company, incorporated in the Bailiwick of Jersey migrated its place of residence on October 29, 2024. It was tax resident in the Bailiwick of Jersey prior to this date, resident in the United Kingdom in the period thereafter, and subject to taxation in the U.S. and various states jurisdictions throughout. ASC Topic 740, Income Taxes (“ASC 740”) indicates that the federal statutory income tax rate of a foreign reporting entity be used when preparing the rate reconciliation disclosure. As such, the Company and its wholly-owned subsidiaries use the statutory income tax rate in the Bailiwick of Jersey and the Cayman Islands of 0% through October 29, 2024, and the statutory income tax rate in the United Kingdom for the period thereafter of 25.0%.
F-37

The Company’s consolidated pretax loss for the periods presented were generated by domestic and foreign operations as follows:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)
Successor (Waldencast)
Predecessor (Obagi)
Loss before income taxes:
United States$2,684 $(82,868)$(125,281)$(17,676)
Foreign(51,222)(30,075)(1,079)(3,268)
Total$(48,538)$(112,943)$(126,360)$(20,944)
The provision for income taxes for the periods presented consisted of the following:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Current provision (benefit):
Federal$784 $12 $ $ 
State268 32 20 19 
Foreign243 2  4 
1,295 46 20 23 
Deferred (income) expense:
Federal(144)(7,927)(4,557)38 
State(976)906 (1,266)52 
Foreign(66)   
(1,185)(7,021)(5,823)90 
Net income tax (benefit) provision$110 $(6,975)$(5,803)$113 
F-38

The components of income tax expense related to the following:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate
4.3 % % % %
U.S./foreign tax rate differential10.0 %15.9 %20.7 %17.7 %
State income tax benefit, net of federal benefit1.7 %2.1 %2.4 %1.4 %
Permanent Items3.5 %(0.1)%0.2 %(0.1)%
Noncontrolling interest(0.9 %)(1.8 %)(1.1 %)0.0 %
Change in valuation allowance(5.6 %)(10.4 %)(6.1 %)(16.9 %)
Transaction bonuses % % %8.6 %
Transaction costs % % %(11.3)%
True-Ups(12.2)% % % %
Equity Compensation0.5 %0.5 % % %
Withholding tax(1.6)% % % %
Goodwill impairment % %(11.4)% %
Total income tax (benefit) expense (0.2)%6.2 %4.6 %(0.6)%
As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2024, a valuation allowance of $22.5 million has been provided for predominantly on the deferred tax assets related to the Company’s investment in Waldencast Partners LP. If or when recognized, the tax benefits related to any reversal of valuation allowance will be accounted for as a reduction of income tax expense.
Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.
F-39

The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December 31, 2024 and December 31, 2023 are presented below:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Deferred tax assets:
Accrued interest to foreign related parties$2,388 $2,771 
Lease liability1,763 2,222 
Formation costs1,205 1,421 
Net operating losses19,016 20,669 
Inventory reserve3,217 2,134 
Fixed asset basis10  
Accrued compensation864 1,112 
R&D tax credits457 482 
Non-deductible interest carryover3,790 5,077 
Below market contract 1,469 
Capitalized research2,256 2,811 
Investment in Waldencast LP13,147 9,059 
Other temporary differences 962 
Total deferred tax assets48,113 50,189 
Deferred tax liabilities:
Goodwill(1,658)(1,016)
Fixed asset basis (92)
Lease asset(778)(1,015)
Intangibles(37,035)(43,543)
Other temporary differences(215) 
Total deferred tax liabilities(39,685)(45,666)
Net deferred tax (liabilities) assets8,427 4,523 
Less: valuation allowance(22,471)(19,752)
Net deferred tax liabilities$(14,044)$(15,229)
Net operating losses and tax credit carryforwards as of December 31, 2024 and December 31, 2023 were as follows:
As of December 31, 2024
As of December 31, 2023
(In thousands)AmountExpiration YearAmountExpiration Year
Net operating losses, federal$42,539 Do not expire$75,142 Do Not Expire
Net operating losses, state25,383 2039 - 204464,984 2039 - 2043
Tax Credits, federal387 2039 - 2042387 2039 - 2041
Tax Credits, state88 Do not expire121 Do Not Expire
Net operating losses, Hong Kong N/A375 Do Not Expire
Net operating losses, Vietnam N/A1,929 2028
Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “IRC”) annual use of the Company’s net operating losses (“NOLs”) and research and development (“R&D”) credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50.0% occurs within a three-year period. The Company has not undergone an analysis to determine whether this limitation would apply to the utilization of the NOL carryforward. However, as the federal NOLs do not expire, the Company does not believe that any potential limitations to federal or state NOLs, or federal credit carryforwards, if applicable, would be material to the financial statements.
F-40

The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations and comprehensive loss. There were no such unrecognized tax benefits as of December 31, 2024 or December 31, 2023. The Company does not expect material changes to its unrecognized tax benefits for the twelve month period following the reporting date.
As of December 31, 2024, there were no active taxing authority examinations in any of the Company's major tax jurisdictions other than in relation to Obagi Cosmeceuticals LLC for the 2021 tax year. There have been no findings or adjustments related to this open tax examination. The Company remains subject to examination for federal and state income tax purposes for the tax years ending 2020 through 2024.
16. RELATED PARTY TRANSACTIONS
Waldencast
2023 Subscription Agreement with PIPE Investors
In September 2023, the Company entered into subscription agreements (the “2023 Subscription Agreements”) with certain investors (collectively, the “2023 PIPE Investors”), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares (the “PIPE Shares”), in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million (the “2023 PIPE Investment”). The 2023 Subscription Agreements relating to approximately $68.0 million of proceeds were consummated in September 2023, with the remaining approximately $2.0 million of proceeds related to the closing of the 2023 Subscription Agreements in November 2023, following receipt of regulatory approvals (the “2023 PIPE Closings” and the date on which such Closing occurred, the “PIPE Closing Date”). No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment.
In connection with the 2023 PIPE Investment, we agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain of our Class A ordinary shares that are held by the parties thereto from time to time, subject to the restrictions on transfer therein (the “2023 PIPE Registration Rights”). The 2023 PIPE Registration Rights terminate with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein).
Indemnification Agreements
The Company has entered into indemnification agreements with each of its directors and executive officers. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from an indemnitee’s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company’s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. During the year ended December 31, 2024, the total expense related to the indemnification agreements was $4.6 million.
Prior to the Business Combination
Registration Rights
In August 2022, the Company filed a registration statement on Form F-1 to register up to 121,120,063 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the sponsor shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of
F-41

the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,104,225 Class A ordinary shares issuable in exchange for 21,104,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 11,800,000 Class A ordinary shares issued in the PIPE investments; (vii) 33,300,000 Class A ordinary shares issued pursuant to the FPAs; and (viii) 18,033,332 Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement.
Transactions with Cedarwalk in Connection with the Business Combination
In connection with the Obagi China Distribution, the Company entered into an Intellectual Property License Agreement (the “IP License Agreement”), a Global Supply Services Agreement (the “Supply Agreement”), and a Transition Services Agreement (the “Transition Services Agreement”) with Obagi Hong Kong, which is owned by Cedarwalk, the former owner of Obagi and a beneficial holder of 24.5% of the Company’s fully diluted Class A ordinary shares as of the closing of the Business Combination.
Under the IP License Agreement, the Company exclusively licenses intellectual property relating to the Obagi brand to the Obagi China Business, and the Company retains the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The Obagi China Business pays the Company a royalty on gross sales of licensed products. The IP License Agreement is perpetual subject to certain conditions. During the year ended December 31, 2024, net revenue generated from related party royalties was $0.1 million. During the year ended December 31, 2023, net revenue generated from related party royalties was $0.3 million. During the period from July 28, 2022 to December 31, 2022, net revenue generated from related party royalties was $0.2 million.
Under the Supply Agreement, the Company supplies or causes to be supplied through certain Obagi CMOs products for distribution and sale in the China Region by the Obagi China Business. The parties operated under an interim supply agreement, which terminated in July 2023. However, the parties continued to operate under the interim supply agreement terms until December 2024, at which point the remaining related party liability was released as the Company had fulfilled its contractual obligations related to pricing. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products until the Obagi China Business has been added as a party to Obagi’s CMO agreements, at which time it will then order directly from the CMOs. During the year ended December 31, 2024, net revenue generated from supplying products to the Obagi China Business was $2.8 million and the related cost of goods sold was $0.8 million. During the year ended December 31, 2023, net revenue generated from supplying products to the Obagi China Business was $5.6 million and the related cost of goods sold was $1.7 million. During the period from July 28, 2022 to December 31, 2022, net revenue generated from supplying products to the Obagi China Business was $17.0 million and the related cost of goods sold was $5.1 million.
As of December 31, 2024, the Company had $0.8 million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. As of December 31, 2023, the Company had $1.1 million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet.
Under the Transition Services Agreement, the Company provided Obagi Hong Kong and its affiliates certain transition services to enable them to conduct the Obagi China Business as a going concern in the China Region. The transition services were provided for an initial term of up to twelve (12) months, with an option for Obagi China Business to extend the service period for up to an additional twelve (12) months solely as to certain R&D services. Obagi Hong Kong did not elect to extend the services and as a result the Transition Services Agreement expired on July 27, 2023. Services under the agreement were to be charged at the reasonable, fully-loaded costs of providing the services, but such services were to be provided at no charge for a certain period of time or up to a specified dollar value of services (the “Threshold Amount”). The Company determined that the Threshold Amount may be applied towards a combination of the Company’s services or inventory purchases made by the Obagi China Business under the Supply Agreement. Due to the fact that the Threshold Amount had not been reached at the time of expiration, the Company received no fees from the Obagi China Business during the year ended December 31, 2024 or the year ended December 31, 2023.
Milk
Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. Milk also receives certain services
F-42

from an employee of Milk Studios. During the year ended December 31, 2024 and the year ended December 31, 2023, the Company incurred administrative fees of $0.3 million in connection with the sublease and services, which is recorded in SG&A expenses in the consolidated statements of operations and comprehensive loss. During the period from July 28, 2022 to December 31, 2022, the Company incurred administrative fees of $0.1 million, which is recorded in SG&A expenses in the consolidated statements of operations and comprehensive loss.
One of the cofounders of Milk Makeup and a shareholder of the Company is party to an influencer agreement with Milk Makeup pursuant to which the shareholder provides certain brand services to Milk Makeup. Milk incurred $0.1 million in fees pursuant to this agreement during the year ended December 31, 2024 and the year ended December 31, 2023.
17. COMMITMENTS AND CONTINGENCIES
Purchase Commitments
Purchase commitments represent unconditional purchase obligations to purchase goods or services, primarily inventory, that are enforceable and legally binding on the Company and specify all significant terms, including fixed or minimum quantities to be purchased, price provisions, and the approximate timing of the transaction.
The Company had previously entered into a certain development and production agreement with a third-party vendor in which the Company was committed to purchase from the vendor certain units of Skintrinsiq devices totaling $5.7 million. As of December 31, 2024, the Company did not have any associated future minimum payments due to the vendor ceasing all its operations.
Legal Proceedings
Except for the SEC investigation described below, the Company is not involved in any material litigation nor, to management’s knowledge, was any material litigation threatened against the Company, which if adversely determined could have a material adverse impact on the Company.
SEC Investigation
The Audit and Governance Committee of the Board, engaged in a review of certain accounting practices applied to the Company’s financial statements for the Predecessor Periods and Successor Period through December 31, 2022. The Company proactively and voluntarily self-reported the review to the SEC. In connection with this matter, the Company received a document subpoena from the SEC in September 2023. Although the Company is fully cooperating with the SEC’s investigation and continues to respond to requests related to this matter, it cannot predict when the SEC will complete its investigation or its outcome and potential impact such outcome may have on the Company’s business. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company could have a material adverse effect on its business, financial condition and results of operations.
18. SEGMENT REPORTING
The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. Prior to the consummation of the Business Combination, the Predecessor operated its business and reported its results through a single operating and reportable segment. Following the Business Combination, the Company determined that it has two operating and reportable segments: Obagi Medical and Milk Makeup. See. “Note 3, Business Combinations.” Each segment represents a business unit that focuses on distinct products, markets, and customers.
Obagi Medical - this segment consists of the business of Obagi. Obagi’s business activities include developing, marketing, and selling skin health products. These assets and activities are conducted by Obagi Global Holdings Limited and its wholly-owned subsidiaries.
F-43

Milk Makeup - this segment consists of the business of Milk. Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Milk generates revenue from the sale of cosmetics to retailers, including off-price retailers, and sales DTC via its website.
The accounting policies of the segments are the same as those described in “Note 2, Summary of Significant Accounting Policies.”
The Company's chief operating decision maker (“CODM”) is its Chief Executive Officer, who utilizes adjusted gross profit as the financial measure for assessing the performance of each segment. The CODM evaluates each segment's performance by comparing the current period's adjusted gross margin to those of prior periods and allocates resources based on the adjusted gross margin.
The following table includes segment revenue and significant segments expenses:
Year ended December 31, 2024Year ended December 31, 2023
(In thousands)Obagi MedicalMilk MakeupTotalObagi MedicalMilk MakeupTotal
Net revenue
$149,266 $124,602 $273,868 $117,651 $100,487 $218,138 
Adjusted cost of goods sold(1)
(30,697)(39,618)(33,922)(33,801)
Adjusted gross profit
$118,569 $84,984 $203,553 $83,729 $66,686 $150,415 
(1) Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.
Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)Obagi MedicalMilk MakeupTotal
Obagi Medical
Net revenue
$61,090 $31,283 $92,373 $73,760 
Adjusted cost of goods sold(1)
(45,611)(12,408)30,868 
Adjusted gross profit
$15,479 $18,875 $34,354 $42,892 
(1) Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold. The period from January 1, 2022 to July 27, 2022 did have any adjustments to cost of goods sold.
F-44

The following table reconciles total consolidated adjusted gross profit to consolidated net loss before and after income taxes:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Adjusted gross profit(1)
$203,553 $150,415 $34,354 $42,892 
Amortization of the fair value of the related party liability(2)
(2,260)(4,058)(12,186) 
Discontinued product write-off(3)
2,864    
Amortization of the inventory fair value adjustment(4)
 1,691 10,035  
Amortization impact of intangible assets(5)
11,205 11,205 4,789  
Selling, general and administrative245,297 223,508 90,722 58,155 
Loss on impairment of goodwill5,031  68,715  
Interest expense, net17,155 18,906 6,230 6,652 
Change in fair value of derivative warrant liabilities (23,627)10,337 (6,793) 
Other expenses (income), net(3,574)1,769 (798)(971)
Loss before income taxes$(48,538)$(112,943)$(126,360)$(20,944)
(1) The period from January 1, 2022 to July 27, 2022 did not have any adjustments to cost of goods sold.
(2) Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.
(3) Relates to the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated.
(4) Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.
(5) The Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.
The Company does not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented. All of the Company’s and the Predecessor’s long-lived assets are located in the U.S.
19. EMPLOYEE BENEFIT PLAN
The Company sponsors a Section 401(k) retirement plan and pension plans for employees in the U.S. and the United Kingdom. During the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) the Company’s contributions to the plan were $1.3 million, $1.2 million, $0.3 million, and $0.4 million, respectively.
20. SUBSEQUENT EVENTS
On March 12, 2025, the Company canceled 11,500,000 of founder stock options and concurrently granted 5,730,000 replacement stock options. These new options vest in three equal annual tranches on each grant date anniversary. The founders have five years to exercise each tranche after it vests. The stock options are subject to continued employment with the Company.
2025 Credit Agreement
On March 18, 2025, the Company entered into a credit agreement (the “2025 Credit Agreement”) with TCW Asset Management Company, LLC and the 2025 Credit Agreement lenders. The 2025 Credit Agreement provides for a five-year secured first lien (i) term loan facility in an aggregate principal amount of $175.0 million (the “Term Loans”) and (ii) revolving loan facility in an aggregate principal amount of up to $30.0 million.
The proceeds of the initial borrowings under the 2025 Credit Agreement were used to (i) repay and terminate the 2022 Credit Agreement, (ii) pay fees and expenses relating to the 2025 Credit Agreement and (iii) fund working capital and for general corporate purposes.
F-45

As of the issuance date of these financial statements, the 2025 Term Loans’ outstanding balance is $175.0 million. The 2025 revolving loan facility has $15.0 million drawn with $15.0 million remaining available. The 2022 Credit Agreement including its revolving line of credit has been fully extinguished.
21. CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)
The parent company financial statements for Waldencast plc should be read in conjunction with the Company’s Consolidated Financial Statements and the accompanying notes thereto. For purposes of this condensed financial information, the Company’s wholly owned and majority owned subsidiaries are recorded based upon its proportionate share of its subsidiaries’ net assets (similar to presenting them on the equity method). Waldencast has no material operations of its own and conducts substantially all of its activities through its wholly owned subsidiaries. Waldencast has no significant assets or liabilities other than derivative warrant liabilities, note payable, and cash, most expenditures paid by Waldencast are allocated to its subsidiaries. Waldencast Finco Limited, a wholly-owned indirect subsidiary of Waldencast, is the borrower under the 2022 Credit Agreement. The terms and conditions of the 2022 Credit Agreement (see “Note 7. Debt” for definition) limit the ability of Waldencast’s wholly owned subsidiaries to make certain distributions or dividends, subject to a number of enumerated exceptions. Due to the aforementioned restrictions, substantially all of the Successor period net assets of Waldencast’s subsidiaries are restricted. Since the restricted net assets of consolidated subsidiaries exceed 25% of the consolidated net assets of the Company and its subsidiaries, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X. This information should be read in conjunction with the accompanying Consolidated Financial Statements.
F-46

The following condensed financial statements have been presented on a “parent-only” basis. Under a parent-only presentation, Waldencast’s investment in its subsidiaries is presented under the equity method of accounting.
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED BALANCE SHEETS
(In thousands of U.S. dollars, except share and per share data)
As of December 31, 2024As of December 31, 2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$472 $419 
Intercompany receivable37,431 51,964 
Total current assets37,903 52,383 
Investment in subsidiary697,885 745,537 
TOTAL ASSETS$735,788 $797,920 
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Note payable
$830 $ 
Derivative warrant liabilities5,021 28,647 
TOTAL LIABILITIES5,851 28,647 
SHAREHOLDERS’ EQUITY:
Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 112,026,440 and 101,228,857 outstanding as of December 31, 2024 and December 31, 2023, respectively
11 9 
Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized; and 10,666,528 and 20,847,553 outstanding as of December 31, 2024 and December 31, 2023, respectively
1 2 
Additional paid-in capital951,260 871,527 
Accumulated deficit(289,204)(246,761)
Accumulated other comprehensive income (loss)
251 (151)
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY662,319 624,626 
Noncontrolling Interest67,618 144,647 
TOTAL SHAREHOLDERS’ EQUITY729,937 769,273 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$735,788 $797,920 

F-47

WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars, except share and per share data)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Net revenue$ $ $ 
Selling, general and administrative18,393 1,259  
Total operating loss(18,393)(1,259) 
Other expense (income):
Interest expense (income), net
24 (14)19 
Change in fair value of derivative warrant liabilities(23,627)10,337 6,793 
Income (loss) before income taxes
5,209 (11,582)6,812 
Income tax benefit   
Income (loss) before equity in undistributed earnings of subsidiaries
5,209 (11,582)6,812 
Equity in undistributed earnings of subsidiaries(47,652)(78,399)(102,379)
Net loss(42,443)(89,981)(95,567)
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax
393 (122)(29)
Comprehensive loss$(42,050)$(90,103)$(95,596)
F-48

WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED STATEMENTS OF CASH FLOW
(In thousands of U.S. dollars)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(42,443)$(89,981)$(95,567)
Adjustments to reconcile net loss to net cash
Cash (used in) provided by operating activities:
Equity in income of subsidiaries47,652 78,399 102,379 
Change in fair value of derivative warrant liabilities(23,627)10,337 (6,793)
Net cash (used in) provided by operating activities
(18,417)(1,245)19 
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from trust  6,400 
Net cash provided by investing activities  6,400 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from PIPE investments 70,000  
Payment of PIPE transaction costs (1,069) 
Proceeds from note payable
1,632   
Repayment of note payable
(1,770)  
Tax refund (withholding)558 (1,204) 
Transfers from subsidiaries32,750 30,575 6,000 
Transfers to subsidiaries (66,250)(300)
Expenses paid on behalf of subsidiaries(14,700)(33,603)(8,982)
Net cash provided by (used in) financing activities
18,470 (1,551)(3,282)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH53 (2,796)3,137 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period419 3,215 78 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period
$472 $419 $3,215 
F-49

ITEM 9. THE OFFER AND LISTING
A.Offer and Listing Details
Nasdaq Listing of Waldencast Plc Class A Ordinary Shares and Waldencast Plc Warrants
Waldencast Class A ordinary shares and Waldencast Warrants are listed on Nasdaq under the symbols “WALD” and “WALDW,” respectively. Holders of Waldencast Class A ordinary shares and Waldencast Warrants should obtain current market quotations for their securities.
B.Plan of Distribution
Not applicable.
C.Markets
Waldencast Class A ordinary shares and Waldencast Warrants are listed on Nasdaq under the symbols “WALD” and “WALDW,” respectively.
D.Selling Shareholders
Not applicable.
E.Dilution
Not applicable.
F.Expenses of the Issue
Not applicable.
ITEM 10. ADDITIONAL INFORMATION
A.Share Capital
Not applicable.
B.Memorandum and Articles of Association
Save as updated by this Report, the information set forth in our Registration Statement on Form F-1 (File No. 333-267053), as amended, initially filed with the SEC on August 24, 2022, under the heading “Description of Share Capital” is incorporated herein by reference.
C.Material Contracts
Material Contracts Relating to Waldencast Plc’s Operations
2022 Credit Facility
In June 2022, we entered into the 2022 Credit Agreement by and among the 2022 Credit Agreement Borrower, the 2022 Credit Agreement Parent Guarantor, the 2022 Credit Agreement Lenders and the 2022 Credit Agreement Administrative Agent. The 2022 Credit Agreement provides us with access to the 2022 Term Loan of $175.0 million, the Revolving Credit Facility with a current borrowing capacity of up to $45.0 million, of which an aggregate principal amount of up to $7.5 million may be available, at the 2022 Credit Agreement Borrower’s option to be drawn in the form of letters credit (collectively, the “2022 Credit Facilities”).
In May 2023, the 2022 Credit Agreement Borrower entered into a waiver and consent agreement with JPMorgan and the required 2022 Credit Agreement Lenders to, among other things, waive certain defaults or events of default that had or
91

would have resulted from the failure to deliver certain financial information and related reports. In June 2023, the 2022 Credit Agreement Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required 2022 Credit Agreement Lenders, pursuant to which they agreed to, among other things, (a) continue to waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports and (b) suspend the testing of certain financial covenants in the 2022 Credit Agreement.
In August 2023, the 2022 Credit Agreement Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required 2022 Credit Agreement Lenders, pursuant to which they agreed to, among other things, (i) waive any default or event of default that has or would result from the failure to deliver certain financial information and (ii) suspend the testing of certain financial covenants set forth in the 2022 Credit Agreement. Such waiver would remain in effect until September 15, 2023.
In September 2023, the 2022 Credit Agreement Borrower and the 2022 Credit Agreement Parent Guarantor entered into the second amendment and waiver to the 2022 Credit Agreement (the “Second Amendment”) with JPMorgan and the required 2022 Credit Agreement Lenders, pursuant to which they agreed to (i) waive any default or event of default that has or would result from (a) the failure to deliver certain financial information and related reports, (b) any inaccuracy or misrepresentation in certain historical financial statements previously delivered to JPMorgan and (c) certain historical breaches of the financial covenants and (ii) amend the 2022 Credit Agreement to, among other things, modify the existing financial covenant tests. The 2022 Credit Agreement Borrower subsequently delivered all of the outstanding financial information and related reports referred to above. The Second Amendment also (i) included additional restrictions on the 2022 Credit Agreement Borrower’s, the 2022 Credit Agreement Parent Guarantor and certain of their subsidiaries’ ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $15.0 million, which is certified on a monthly basis, and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the 2022 Credit Agreement Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Second Amendment (the period until such date, the “Covenant Relief Period”).
On April 26, 2024, the 2022 Credit Agreement Borrower, 2022 Credit Agreement Parent Guarantor, JPMorgan and the required 2022 Credit Agreement Lenders entered into an amendment (the “Third Amendment”) to the 2022 Credit Agreement. Among other things, the Third Amendment: (i) waived certain historical breaches of the financial covenant, (ii) modified the existing financial covenants, (iii) reduced the revolving commitments of the lenders by $5.0 million in the aggregate to $45.0 million, (iv) lowered the existing minimum liquidity covenant to $10.0 million and (v) extended the Covenant Relief Period until the earlier of December 31, 2024, or such earlier time that the 2022 Credit Agreement Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Second Amendment. The foregoing descriptions of the 2022 Credit Agreement (as amended by the Third Amendment) and the Third Amendment are qualified in its entirety by reference to the full and complete terms thereof and are attached as Exhibit 4.17 to this Report and is incorporated herein by reference. As of the date of the issuance of these financial statements and after giving effect to the Third Amendment, the Company was in compliance with all financial covenants.
The 2022 Credit Agreement restricts our ability to make certain distributions or dividends, subject to a number of enumerated exceptions. The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. Borrowings under the 2002 Term Loan were used, among other things, to repay outstanding amounts under, and terminate, the existing credit facilities of Obagi and Milk in connection with the closing of the Business Combination.
Borrowings under the 2022 Credit Facilities will accrue interest at a rate per annum equal to, at 2022 Credit Agreement Borrower’s option, either an alternative base rate plus an applicable margin of 2.5% per annum or a term benchmark rate plus an applicable margin of 3.50% per annum. Borrowings under the 2022 Revolving Credit Facility may be prepaid without premium or penalty, subject to applicable notice requirements and the payment of customary “breakage” costs.
Obligations under the 2022 Credit Agreement are (i) guaranteed by certain existing and future subsidiaries of the Company and (ii) secured by a first priority lien on substantially all of the assets of the 2022 Credit Agreement Parent Guarantor, the 2022 Credit Agreement Borrower and the subsidiary guarantors, in the case of each of clauses (i) and (ii) above, subject to customary exceptions and limitations.
The 2022 Credit Agreement contains customary representations and warranties, affirmative covenants and events of default and also contains customary negative covenants including, among other things, limitations on the ability of 2022 Credit Agreement, the 2022 Credit Agreement Borrower and certain of their subsidiaries to incur indebtedness, create liens, make
92

investments, enter into mergers, consolidations and other similar transactions, dispose of assets, declare dividends, enter into certain transactions with their affiliates and enter into sale and leaseback transactions. Further, the Waivers described above, the Second Amendment and the Third Amendment (i) provided additional restrictions on the 2022 Credit Agreement Borrower’s, the 2022 Credit Agreement Parent Guarantor’s and certain of their subsidiaries’ ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $10 million, which is certified on a monthly basis and (iii) introduced additional financial reporting obligations, in each case until the earlier of December 31, 2024 or such earlier time that the 2022 Credit Agreement Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Second Amendment. Additionally, the 2022 Credit Agreement requires the 2022 Credit Agreement Parent Guarantor, the 2022 Credit Agreement Borrower and certain of their subsidiaries to comply with specified financial covenants, including maintaining (i) a maximum Total Leverage Ratio of (a) during the Covenant Relief Period, 8.00 to 1.00, which steps down over time to 4.00 to 1.00 and (b) upon and after the termination of the Covenant Relief Period, 3.75 to 1.00 and (ii) a minimum Interest Coverage Ratio of (a) during the Covenant Relief Period, 1.25 to 1.00, which steps up over time to 2.50 to 1.00, and (b) upon and after the termination of the Covenant Relief Period, 3.00 to 1.00 (each, as defined in the 2022 Credit Agreement). The foregoing descriptions of the 2022 Credit Agreement, the First Amendment, the Second Amendment, the Third Amendment and the Waivers are qualified in its entirety by reference to the full and complete terms thereof and are attached as Exhibit 4.11, Exhibit 4.12, Exhibit 4.13, and Exhibit 4.17, respectively, to this Report and is incorporated herein by reference.
Contracts Material to Our Obagi Medical and Milk Makeup Businesses
Information relating to agreements that are material to our Obagi Medical business and Milk Makeup business can be found in “Item 4. Information on the Company—4.B. Business Overview” of this Report.
Material Contracts with Directors, Executive Officers, Major Shareholders and Related Parties
The information relating to material agreements with our directors and executive officers, major shareholders and related parties can be found in “Item 7 Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” of this Report.
Material Contracts Relating to the Business Combination
Contracts Entered Into Prior to the Business Combination
PIPE Subscriptions
Concurrently with the execution of the Transaction Agreements, we entered into subscription agreements, executed on or prior to November 14, 2021 (the “Initial Subscription Agreements”), pursuant to which the investors (the “Initial PIPE Investors”) agreed to purchase, in the aggregate, 10,500,000 Class A ordinary shares at $10.00 per share for an aggregate commitment amount of $105.0 million. The Transaction Agreements provided that we could enter into additional subscription agreements with investors to participate in the purchase of our shares after November 15, 2021 but prior to the Closing Date. On June 14, 2022, we entered into subscription agreements (the “June 2022 Subscription Agreements”) with additional investors on the same terms as the Initial PIPE Investors, pursuant to which such investors agreed to acquire an aggregate of 800,000 shares of Class A ordinary shares for an aggregate purchase price equal to $8.0 million. On July 15, 2022, we entered additional subscription agreements (together with the Initial Subscription Agreements and the June 2022 Subscription Agreements, the “deSPAC Subscription Agreements”) on the same terms as the Initial PIPE Investors, pursuant to which such investors subscribed for 500,000 Class A ordinary shares for an aggregate purchase price equal to $5.0 million (collectively, the “PIPE Investments”). The foregoing description of the deSPAC Subscription Agreements and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.3 to this Report and the terms of which are incorporated by reference herein.
FPAs and Agreements with the Sponsor and its Affiliates
Information relating to material agreements with related parties entered into prior to and in contemplation of the Business Combination can be found in “Item 7 Major Shareholders and Related Party Transactions—7.B. Related Party Transactions.”
93

Transaction Agreements
The following summary describes the material provisions of the Obagi Merger Agreement and the Milk Purchase Agreement but does not purport to describe all of the terms of such agreements and is qualified in its entirety by reference to the complete text of the Obagi Merger Agreement and Milk Purchase Agreement, copies of which are attached as Exhibits 4.1 and 4.2, respectively, of this Report.
Obagi Merger Agreement
On November 15, 2022, we entered into the Obagi Merger Agreement pursuant to which Merger Sub merged with and into Obagi, with Obagi as the surviving corporation and an indirect subsidiary of Waldencast as of the Closing Date (the “Obagi Merger”). At the effective time of the Obagi Merger, all outstanding ordinary shares of Obagi common stock were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $317.5 million. At the effective time of the Obagi Merger, all options to purchase Obagi common stock granted under the 2021 Obagi Stock Incentive Plan (“Obagi Options”) were converted into options to purchase Waldencast Class A ordinary shares, subject to substantially the same terms and conditions as were in effect with respect to such Obagi Option immediately prior to the Obagi Merger Effective Time. Each Obagi Option to purchase one share of Obagi common stock converted into the right to purchase 7.62 Waldencast Class A ordinary shares. Similarly, all restricted stock units issued in respect of Obagi common stock granted (“Obagi RSUs”) were converted into restricted stock units with respect to Waldencast Class A ordinary shares, subject to substantially the same terms and conditions as were in effect with respect to such Obagi RSU immediately prior to the effective time. Each Obagi RSU with respect to one share of Obagi common stock converted into an RSU with respect to 7.62 Waldencast Class A ordinary shares.
As a condition to the merger, immediately prior to the closing, Obagi effected the Obagi China Distribution. For a description of that transaction as well as the agreement related thereto, see “Item 7. Major Shareholders and Related Party Transactions—7.B. Related Party Transactions” in this Report.
The Obagi Merger Agreement contains certain post-closing covenants of Waldencast, pursuant to which the Company agreed:
as soon as practicable following the date that is 60 days after the Closing Date and subject to applicable securities laws, file an effective registration statement on Form S-8 (or other applicable form) with respect to Waldencast’s Class A ordinary shares issuable under the 2022 Plan and use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards granted pursuant to the 2022 Plan remain outstanding;
for a period of twelve (12) months following the Closing Date, provide, or cause its affiliates to provide, each Obagi employee continuing employment with Waldencast or Obagi with (i) an annual base salary or hourly wage rate, as applicable, that is no less favorable than the annual base salary or hourly wage rate, as applicable, provided to such employee immediately prior to the Closing Date, (ii) target cash incentive opportunity that is no less favorable than the target cash incentive opportunity provided to such employee immediately prior to the Closing Date and (iii) health, retirement, welfare and other employee and fringe benefits that are no less favorable, in the aggregate, than those provided to such employee immediately prior to the Closing Date;
for the purposes of determining eligibility, vesting, participation and benefits accrual under Waldencast and its affiliate’s’ plans and programs providing employee benefits, credit each Obagi employee continuing employment with Waldencast or Obagi with his or her years of service with Obagi prior to the Closing Date to the same extent as such employee was (or would have been) entitled prior to the Closing Date;
cause (i) each Obagi employee continuing employment with Waldencast or Obagi to be immediately eligible to participate in any and all Waldencast benefit plans; (ii) all pre-existing condition exclusions and actively-at-work requirements of such Waldencast benefit plan to be waived for such employee and his or her covered dependents; and (iii) any co-payments, deductibles and other eligible expenses incurred by such employee to be credited for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee and his or her covered dependents for the applicable plan year of each comparable Waldencast benefit plan;
indemnify and hold harmless each present and former director and officer of Obagi and Waldencast and each of their respective subsidiaries against any costs, expenses, judgments, fines, losses, claims, damages or liabilities incurred in connection with any legal proceeding arising out of or pertaining to matters existing or occurring at or prior to the Closing Date to the fullest extent that would have been permitted under applicable law and the applicable governing documents to indemnify such person;
94

maintain for a period of not less than six years from the Closing Date provisions in its governing documents and those of its subsidiaries concerning the indemnification and exoneration (including provisions relating to expense advancement) of its and its subsidiaries’ former and current officers, directors and employees, no less favorable to those persons than the provisions of the governing documents of Obagi, Waldencast or their respective subsidiaries, as applicable, in each case, as of the date of the Obagi Merger Agreement and (ii) not amend, repeal or otherwise modify such provisions in any respect that would adversely affect the rights of those persons thereunder; and
for a period of six years from the Closing Date, maintain in effect directors’ and officers’ liability, employment practices liability and fiduciary liability insurance covering those persons who are currently covered by Waldencast’s, Obagi’s or their respective subsidiaries’ directors’ and officers’ liability, employment practices liability and fiduciary liability insurance policies on terms not less favorable to the insureds than the terms of such current insurance coverage.
Milk Purchase Agreement
On November 15, 2022, we also entered into the Milk Purchase Agreement pursuant to which the Waldencast Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 Waldencast LP Units (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $112.5 million (the “Milk Transaction”). Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, and, if such option is exercised, exchangeable at the option of Waldencast into one Waldencast Class A ordinary share or cash, in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement. Upon consummation of the Business Combination Waldencast became organized in an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast LP, which is an indirect subsidiary of Waldencast. We, in turn, hold our interests in Obagi and Milk through Waldencast LP and Holdco 1.
At the Milk Purchase Effective Time (the “Milk Closing”), all options to purchase Milk common stock (“Milk Options”) were converted into options to purchase Waldencast Class A ordinary shares, subject to substantially the same terms and conditions as were in effect with respect to such Milk Option immediately prior to the Milk Transaction effective time. Each Milk Option to purchase one Milk common unit converted into an option to purchase 1.47 Waldencast Class A ordinary shares. Similarly, all unit appreciation rights issued in respect of Milk common stock (“Milk UARs”) were converted into SARs with respect to Waldencast Class A ordinary shares, subject to substantially the same terms and conditions as are in effect with respect to such Milk UAR immediately prior to the effective time. Each Milk UAR with respect to one Milk common unit converted into a SAR with respect to 1.47 Waldencast Class A ordinary shares.
The Milk Purchase Agreement contains certain post-closing covenants of Waldencast, pursuant to which the Company agreed:
as soon as practicable following the date that is 60 days after the Closing Date and subject to applicable securities laws, file an effective registration statement on Form S-8 (or other applicable form) with respect to Waldencast’s Class A ordinary shares issuable under the Waldencast 2022 Plan and use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards granted pursuant to the 2022 Plan remain outstanding;
for a period of twelve (12) months following the Closing Date, provide, or cause its affiliates to provide, each Milk employee continuing employment with Waldencast or Milk with (i) an annual base salary or hourly wage rate, as applicable, that is no less favorable than the annual base salary or hourly wage rate, as applicable, provided to such employee immediately prior to the Closing Date, (ii) target cash incentive opportunity that is no less favorable than the target cash incentive opportunity provided to such employee immediately prior to the Closing Date and (iii) health, retirement, welfare and other employee and fringe benefits that are no less favorable, in the aggregate, than those provided to such employee immediately prior to the Closing Date;
for the purposes of determining eligibility, vesting, participation and benefit accrual under Waldencast and its affiliate’s’ plans and programs providing employee benefits, credit each Milk employee continuing employment with Waldencast or Milk with his or her years of service with Milk prior to the Closing Date to the same extent as such employee was (or would have been) entitled prior to the Closing Date;
cause (i) each Milk employee continuing employment with Waldencast or Milk to be immediately eligible to participate in any and all Waldencast benefit plans; (ii) all pre-existing condition exclusions and actively-at-work requirements of such Waldencast benefit plan to be waived for such employee and his or her covered dependents; and (iii) any co-payments, deductibles and other eligible expenses incurred by such employee to be credited for
95

purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee and his or her covered dependents for the applicable plan year of each comparable Waldencast benefit plan;
indemnify and hold harmless each present and former director and officer of Milk and Waldencast and each of their respective subsidiaries against any costs, expenses, judgments, fines, losses, claims, damages or liabilities incurred in connection with any legal proceeding arising out of or pertaining to matters existing or occurring at or prior to the Closing Date to the fullest extent that would have been permitted under applicable law and the applicable governing documents to indemnify such person;
maintain for a period of not less than six years from the Closing Date provisions in its governing documents and those of its subsidiaries concerning the indemnification and exoneration (including provisions relating to expense advancement) of its and its subsidiaries’ former and current officers, directors and employees, no less favorable to those persons than the provisions of the governing documents of Milk, Waldencast or their respective subsidiaries, as applicable, in each case, as of the date of the Milk Purchase Agreement and (ii) not amend, repeal or otherwise modify such provisions in any respect that would adversely affect the rights of those persons thereunder; and
for a period of six years from the Closing Date, maintain in effect directors’ and officers’ liability, employment practices liability and fiduciary liability insurance covering those persons who are currently covered by Waldencast’s, Milk’s or their respective subsidiaries’ directors’ and officers’ liability, employment practices liability and fiduciary liability insurance policies on terms not less favorable to the insureds than the terms of such current insurance coverage.
Related Agreements
Amended and Restated Exempted Limited Partnership Agreement
Effective as of immediately before the consummation of the Milk Transaction, the initial exempted limited partnership agreement of Waldencast LP was amended and restated in its entirety to provide that each Waldencast LP Unit will have identical economic rights and Holdco 1 was admitted as the general partner of Waldencast LP. The Waldencast LP Units have no voting rights. The Amended and Restated Waldencast Partners LP Agreement prohibits transfers of Waldencast LP Units held by the Milk Members and will require the prior consent of Holdco 1 for such transfers, subject to certain exceptions set forth in the Amended and Restated Waldencast Partners LP Agreement.
Following the expiration of any applicable lock-up period, each holder of the Waldencast LP Unit (other than Holdco 1) is entitled at any time, to cause Waldencast LP to redeem (each, a “Unit Redemption”), all or a portion of its Waldencast LP Units, in which case, we may at our option, acquire such Waldencast LP Units in exchange for cash or new Waldencast Class A ordinary shares on a one-for-one basis. In connection with any Unit Redemption, a number of Waldencast Class B ordinary shares equal to the number of redeemed Waldencast LP Units will be surrendered and canceled. Once the Milk Members have caused Unit Redemptions to have occurred that cause the aggregate Waldencast LP Units held by the Milk Members to be equal to or less than 20% of the total Waldencast LP Units held by the Milk Members as of the Closing Date of the Milk Transaction, Waldencast LP will have the right to acquire all or a portion of the remaining Waldencast LP Units that remain outstanding in exchange for cash or Waldencast Class A ordinary shares on a one-for-one basis, at Waldencast LP’s sole discretion, subject to certain limitations set forth in the Amended and Restated Waldencast Partners LP Agreement.
Under the terms of the Amended and Restated Waldencast Partners LP Agreement, Waldencast LP is obligated to make pro rata tax distributions to holders of Waldencast LP Units at certain assumed tax rates unless such distribution would not be permitted under applicable law.
D.Exchange Controls
There are no governmental laws, decrees, regulations or other legislation in Jersey that may affect the import or export of capital, including the availability of cash and cash equivalents for use by the Company, or that may affect the remittance of dividends, interest, or other payments by the Company to non-resident holders of its ordinary shares. There is no limitation imposed by the laws of Jersey or in the Company’s articles of association on the right of non-residents to hold or vote shares.
96

E.Taxation
U.S. Federal Income Tax Considerations 
The following is a discussion of U.S. federal income tax considerations generally applicable to the ownership and disposition of Class A ordinary shares by U.S. Holders. This discussion addresses only those holders of Class A ordinary shares that hold their ordinary shares as capital assets (generally, property held for investment) and assumes that any distributions made (or deemed made) by us and any consideration received (or deemed received) by a holder in consideration for the sale or other disposition of Class A ordinary shares will be in U.S. dollars. This discussion does not discuss all aspects of U.S. federal income taxation that may be relevant to holders in light of their particular circumstances or status including:
the Sponsor or Waldencast’s officers or directors;
financial institutions or financial services entities;
broker-dealers;
taxpayers that are subject to the mark-to-market accounting rules;
tax-exempt entities;
governments or agencies or instrumentalities thereof;
insurance companies;
regulated investment companies or real estate investment trusts;
expatriates or former long-term residents of the U.S.;
persons that actually or constructively own five percent or more of our voting shares or five percent or more of the total value of any class of our shares;
persons that acquired our ordinary shares pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation or in connection with the performance of services;
persons that hold our ordinary shares as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction; or
persons whose functional currency is not the U.S. dollar.
This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date of this Report. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S. federal taxes other than those pertaining to U.S. federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S. state or local or non-U.S. taxation.
We have not and do not intend to seek any rulings from the IRS regarding any of the U.S. federal income tax considerations described herein. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.
This discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our ordinary shares through such entities. If a partnership (or any entity or arrangement so characterized for U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of such partnership and a person treated as a partner of such partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships holding any of our ordinary shares and persons that are treated as partners of such partnerships should consult their tax advisors as to the particular U.S. federal income tax consequences of the ownership and disposition of Class A ordinary shares.
EACH HOLDER SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES OF THE OWNERSHIP AND DISPOSITION OF CLASS A ORDINARY SHARES, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX LAWS.
As used herein, a “U.S. Holder” is a beneficial owner of Class A ordinary shares who or that is, for U.S. federal income tax purposes:
1.an individual citizen or resident of the U.S.;
97

2.a corporation (or other entity that is treated as a corporation for U.S. federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the U.S. or any state thereof or the District of Columbia;
3.an estate whose income is subject to U.S. federal income tax regardless of its source; or
4.a trust if (i) a U.S. court can exercise primary supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of the trust or (ii) it has a valid election in place to be treated as a U.S. person.
Tax Residence of Waldencast Plc for U.S. Federal Income Tax Purposes
A corporation is generally considered for U.S. federal income tax purposes to be a tax resident in the jurisdiction of its organization or incorporation. Section 7874 of the Code provides an exception to this general rule, under which a non-U.S. incorporated entity may, in certain circumstances, be treated as a U.S. corporation for U.S. federal income tax purposes. These rules are complex and there is limited guidance regarding their application.
Based on the rules currently in effect, we do not expect to be treated as a U.S. corporation for U.S. federal income tax purposes by virtue of Section 7874 of the Code as a result of the Business Combination. Nevertheless, because the rules and exceptions under Section 7874 of the Code are complex, subject to factual and legal uncertainties, and may change in the future (possibly with retroactive effect), there can be no assurance that we will not be treated as a U.S. corporation for U.S. federal income tax purposes. In addition, it is possible that a future acquisition of the stock or assets of a U.S. corporation could result in our being treated as a U.S. corporation at the time of the Business Combination.
If we were to be treated as a U.S. corporation for U.S. federal income tax purposes, we could be subject to liability for additional U.S. income taxes, and the gross amount of any dividend payments to our non-U.S. shareholders could be subject to 30% U.S. withholding tax, depending on the application of any income tax treaty that might apply to reduce the withholding tax. If Holdco 1 were to be disregarded, or we were otherwise to be treated as a direct partner in Waldencast LP, dividend payments by us could be treated as wholly or partially U.S.-source for foreign tax credit and other U.S. federal income tax purposes even if we are treated as a non-U.S. corporation under Section 7874 of the Code.
The remainder of this discussion assumes that Waldencast will not be treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code.
U.S. Federal Income Tax Considerations of Owning Class A Ordinary Shares
Taxation of Dividends and Other Distributions on Class A Ordinary Shares
Subject to the PFIC rules discussed below, any distribution of cash or other property to a U.S. Holder of Class A ordinary shares, will generally be treated as a dividend for U.S. federal income tax purposes to the extent the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Such dividends will be taxable to a corporate U.S. Holder at regular rates and will not be eligible for the dividends-received deduction generally allowed to domestic corporations in respect of dividends received from other domestic corporations.
Distributions in excess of such earnings and profits will generally be applied against and reduce the U.S. Holder’s basis in its Class A ordinary shares (but not below zero) and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of such Class A ordinary shares. We may not determine our earnings and profits on the basis of U.S. federal income tax principles, however, in which case any distribution paid by us will be treated as a dividend.
With respect to non-corporate U.S. Holders, dividends will generally be taxed at preferential long-term capital gains rates only if (i) Class A ordinary shares are readily tradable on an established securities market in the U.S. or (ii) we are eligible for the benefits of an applicable income tax treaty, in each case provided that we are is not treated as a PFIC in the taxable year in which the dividend was paid or in any previous year and certain holding period or other requirements are met. If our Class A ordinary shares are delisted from Nasdaq and are not otherwise readily tradable on an established securities market in the U.S., and provided that we remain ineligible for the benefits of an applicable tax treaty with the U.S., dividends received on our Class A ordinary shares would generally not be eligible to be taxed at preferential rates. U.S. Holders should consult their tax advisors regarding the availability of the lower rate for any dividends paid with respect to Class A ordinary shares.
98

Taxation on the Disposition of Class A Ordinary Shares
Subject to the PFIC rules discussed below, upon a sale or other taxable disposition of Class A ordinary shares, a U.S. Holder will generally recognize capital gain or loss. The amount of gain or loss recognized will generally be equal to the difference between (i) the sum of the amount of cash and the fair market value of any property received in such disposition and (ii) the U.S. Holder’s adjusted tax basis in such ordinary shares.
Under tax law currently in effect, long-term capital gains recognized by non-corporate U.S. Holders are generally subject to U.S. federal income tax at a reduced rate of tax. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder’s holding period for the ordinary shares exceeds one year. The deductibility of capital losses is subject to various limitations.
PFIC Considerations
Definition of a PFIC
A foreign (i.e., non-U.S.) corporation will be a PFIC for U.S. federal income tax purposes if at least 75% of its gross income in a taxable year of the foreign corporation, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income. Alternatively, a foreign corporation will be a PFIC if at least 50% of its assets in a taxable year of the foreign corporation, ordinarily determined based on fair market value and averaged quarterly over the year, including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than certain rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets.
Pursuant to a start-up exception, a corporation will not be a PFIC for the first taxable year the corporation has gross income, if (1) no predecessor of the foreign corporation was a PFIC; (2) the corporation satisfies the IRS that it will not be a PFIC for either of the first two taxable years following the start-up year; and (3) the corporation is not in fact a PFIC for either of those years.
PFIC Status of Waldencast
Although a foreign corporation’s PFIC determination will be made annually, absent certain elections described below, a determination that Waldencast Acquisition Corp., our predecessor (“WAC”) was or Waldencast is a PFIC will continue to apply to subsequent years in which a U.S. Holder continues to hold shares in such entity (including a successor entity), whether or not such entity is a PFIC in those subsequent years. Because, following the Domestication, Waldencast is treated as the successor to WAC for U.S. federal income tax purposes, any Class A ordinary shares treated as received in exchange for WAC Class A ordinary shares in the Domestication may, in the absence of certain elections described below, be treated as stock of a PFIC if WAC or Waldencast was treated as a PFIC during the holding period of a U.S. Holder.
Although WAC likely met the PFIC income or asset tests for the Start-Up Year, the start-up exception is expected to apply to prevent such entity from being treated as a PFIC for the taxable year ending on December 31, 2021 (the “Start-Up Year”) provided that the combined company did not meet either test in the two subsequent taxable years. Based on the timing of the Business Combination and the assets and income of the combined company, we do not believe we met either test for our taxable year ended December 31, 2022, December 31, 2023 or December 31, 2024, and do not expect to meet either test in the foreseeable future. However, because PFIC status is an annual factual determination, we may become a PFIC in future if the composition of our income or assets, or the market price of our Class A ordinary shares, were to change. Accordingly, there can be no assurance with respect to the PFIC status of Waldencast for the current taxable year or any future taxable year.
Application of PFIC Rules to Ordinary Shares
If (i) WAC or Waldencast is determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder and (ii) the U.S. Holder did not make a timely and effective QEF Election (as defined below) for the first year in its holding period in which WAC or Waldencast (as the case may be) was or is a PFIC (such taxable year as it relates to each U.S. Holder, the “First PFIC Holding Year”), a QEF Election along with a purging
99

election, or a “mark-to-market” election, each as described below under “QEF Election, Mark-to-Market Election and Purging Election,” then such holder will generally be subject to special rules (the “Default PFIC Regime”) with respect to:
any gain recognized by the U.S. Holder on the sale or other disposition of its ordinary shares; and
any “excess distribution” made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of its ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter, such U.S. Holder’s holding period for such ordinary shares).
Under the Default PFIC Regime:
the U.S. Holder’s gain or excess distribution will be allocated ratably over the U.S. Holder’s holding period for its ordinary shares (taking into account the relevant holding period of the WAC Class A ordinary share treated as exchanged therefor);
the amount of gain allocated to the U.S. Holder’s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder’s holding period before the first day of the first taxable year in which WAC was or Waldencast is a PFIC, will be taxed as ordinary income;
the amount of gain allocated to other taxable years (or portions thereof) of the U.S. Holder and included in such U.S. Holder’s holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and
an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder in respect of the tax attributable to each such other taxable year of such U.S. Holder.
A U.S. Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder may be required to file an IRS Form 8621 (whether or not the U.S. Holder makes one or more of the elections described below with respect to such shares) with such U.S. Holder’s U.S. federal income tax return and provide such other information as may be required by the U.S. Treasury Department.
QEF Election, Mark-to-Market Election and Purging Election
In general, if WAC or Waldencast is determined to be a PFIC, a U.S. Holder may avoid the Default PFIC Regime with respect to its ordinary shares by making a timely and effective “qualified electing fund” (“QEF”) election under Section 1295 of the Code (a “QEF Election”) for such holder’s First PFIC Holding Year. In order to comply with the requirements of a QEF Election with respect to Class A ordinary shares, a U.S. Holder must receive a PFIC Annual Information Statement from us. If we determine we are a PFIC for any taxable year, we may endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC Annual Information Statement, in order to enable the U.S. Holder to make and maintain a QEF Election. However, there is no assurance that we will so endeavor, or that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided. U.S. Holders are urged to consult their tax advisors with respect to any QEF Election previously made with respect to Waldencast shares.
Alternatively, if a U.S. Holder, at the close of its taxable year, owns (or is deemed to own) shares in a PFIC that are treated as marketable shares, the U.S. Holder may make a mark-to-market election with respect to such shares for such taxable year. If the U.S. Holder makes a valid mark-to-market election for such holder’s First PFIC Holding Year, such holder will generally not be subject to the Default PFIC Regime in respect of its ordinary shares as long as such shares continue to be treated as marketable shares. Instead, the U.S. Holder will generally include as ordinary income for each year in its holding period that Waldencast or WAC is treated as a PFIC the excess, if any, of the fair market value of its ordinary shares at the end of its taxable year over the adjusted basis in its ordinary shares. The U.S. Holder also will be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted basis of its Class A ordinary shares over the fair market value of its ordinary shares at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder’s basis in its ordinary shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of the ordinary shares in a taxable year in which WAC was or Waldencast is treated as a PFIC will be treated as ordinary income. Special tax rules may also apply if a U.S. Holder makes a mark-to-market election for a taxable year after such holder’s First PFIC Holding Year.
The mark-to-market election is available only for “marketable stock,” which generally includes stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission, including Nasdaq. If our Class A ordinary shares are delisted from Nasdaq (and are not otherwise regularly traded on another national
100

securities exchange that is registered with the SEC), our Class A ordinary shares would generally not be treated as “marketable stock” for such purposes, and a U.S. Holder would not be eligible to make a mark-to-market election with respect to our Class A ordinary shares. Any mark-to-market election that is otherwise in effect with respect to our Class A ordinary shares at the time that they are delisted would generally terminate automatically, effective as of the beginning of the U.S. Holder’s taxable year in which the delisting occurs. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election in respect of WAC Class A ordinary shares or the Class A ordinary shares under their particular circumstances, as well as regarding any mark-to-market elections previously made with respect to WAC Class A ordinary shares or our Class A ordinary shares.
Class A ordinary shares treated as stock of a PFIC under the Default PFIC Regime (including Class A ordinary shares treated as received in exchange for WAC Class A ordinary shares that were so treated at the time of the Domestication) will continue to be treated as stock of a PFIC, including in taxable years in which we cease to be a PFIC, unless the applicable U.S. Holder makes a “purging election” with respect to such shares. Under one type of purging election, the U.S. Holder will be deemed to have sold such shares at their fair market value on the last day of the last year in which WAC or Waldencast, as applicable, is treated as a PFIC, and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of this election, the U.S. Holder will have additional basis (to the extent of any gain recognized in the deemed sale) and, solely for purposes of the PFIC rules, a new holding period in such holder’s Class A ordinary shares. U.S. Holders should consult their tax advisors regarding the application of the purging elections rules to their particular circumstances.
If we are a PFIC and, at any time, have foreign subsidiary that is a PFIC, U.S. Holders would be deemed to own a portion of the shares of such lower-tier PFIC, and could incur liability for the deferred tax and interest charge described above if we receive a distribution from, or disposes of all or part of our interest in, the lower-tier PFIC or the U.S. Holders otherwise were deemed to have disposed of an interest in the lower-tier PFIC. A mark-to-market election would not be available with respect to such lower-tier PFIC. U.S. Holders should consult their own tax advisors regarding the tax issues raised by lower-tier PFICs.
The rules dealing with PFICs and with the QEF and mark-to-market elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders of Class A ordinary shares should consult their own tax advisors concerning the application of the PFIC rules to Class A ordinary shares under their particular circumstances.
THE RULES DEALING WITH PFICS ARE COMPLEX AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES, INCLUDING, WITHOUT LIMITATION, WHETHER A QEF ELECTION, A MARK-TO-MARKET ELECTION OR ANY OTHER ELECTION IS AVAILABLE AND THE CONSEQUENCES TO THEM OF ANY SUCH ELECTION, AND THE IMPACT OF ANY PROPOSED OR FINAL PFIC TREASURY REGULATIONS.
Jersey Tax Considerations, for the period through October 29, 2024 and United Kingdom Tax Considerations for the period thereafter
This summary of both Jersey and UK taxation issues can only provide a general overview of this area and it is not a description of all the tax considerations that may be relevant to a decision to invest in our Class A ordinary shares. The following summary of the anticipated treatment of Waldencast and holders of Class A ordinary shares (other than residents of Jersey and/or the United Kingdom) is based on Jersey and United Kingdom taxation law and practice as it is understood to apply at the date of this document and may be subject to any changes after such date. It does not constitute legal or tax advice and does not address all aspects of relevant tax law and practice (including such tax law and practice as it may apply to land or buildings). Legal advice should be taken with regard to individual circumstances. Prospective investors in our Class A ordinary shares should consult their professional advisers on the implications of acquiring, buying, selling or otherwise disposing of Waldencast common stock under the laws of any jurisdiction in which they may be liable to taxation.
Shareholders should note that tax law and interpretation can change and that, in particular, the levels and basis of, and reliefs from, taxation may change and may alter the benefits of investment in our Class A ordinary shares.
Any person who is in any doubt about their tax position should consult their own professional adviser.
101

The following considerations apply for the period through October 29, 2024, prior to the Company’s migration of tax residency in United Kingdom
Company Residence
Under the Income Tax (Jersey) Law 1961 (as amended) (“Tax Law”), a company shall be regarded as resident in Jersey if it is incorporated under the Jersey Companies Law unless:
its business is centrally managed and controlled outside Jersey in a country or territory where the highest rate at which any company may be charged to tax on any part of its income is 10% or higher; and
the company is resident for tax purposes in that country or territory.
We were resident for tax purposes in Jersey and subject to tax in Jersey for the period to 29 October 2024, the point at which the Company migrated its tax residency to the United Kingdom.
Summary
Under current Jersey law, there are no capital gains, capital transfer, gift, wealth or inheritance taxes, or any death or estate duties. No capital or stamp duty is levied in Jersey on the issue, conversion, redemption, or transfer of ordinary shares. On the death of an individual holder of ordinary shares (whether or not such individual was domiciled in Jersey), duty at rates of up to 0.75% of the value of the relevant ordinary shares may be payable on the registration of any Jersey probate or letters of administration which may be required in order to transfer, convert, redeem, or make payments in respect of, ordinary shares held by a deceased individual sole shareholder, subject to a cap of £100,000.
Income Tax
The general rate of income tax under the Tax Law on the profits of companies regarded as resident in Jersey or having a permanent establishment in Jersey is 0% (“zero tax rating”), though certain exceptions from zero tax rating might apply.
Withholding Tax
For so long as we are subject to a zero tax rating, or are deemed to be resident for tax purposes in Jersey, no withholding in respect of Jersey taxation will be required on payments in respect of our Class A ordinary shares to any holder of our Class A ordinary shares not resident in Jersey.
Stamp Duty
In Jersey, no stamp duty is levied on the issue or transfer of our Class A ordinary shares except that stamp duty is payable on Jersey grants of probate and letters of administration, which will generally be required to transfer ordinary shares on the death of a holder of such ordinary shares if such holder was entered as the holder of the shares on the register maintained in Jersey. In the case of a grant of probate or letters of administration, stamp duty is levied according to the size of the estate (wherever situated in respect of a holder of ordinary shares domiciled in Jersey, or situated in Jersey in respect of a holder of ordinary shares domiciled outside Jersey) and is payable on a sliding scale at a rate of up to 0.75% on the value of an estate up to a maximum stamp duty charge of £100,000. The rules for joint holders through a nominee are different and advice relating to this form of holding should be obtained from a professional adviser.
Jersey does not otherwise levy taxes upon capital, inheritances, capital gains or gifts nor are there otherwise estate duties.
Goods and Services Tax
Pursuant to the Goods and Services Tax (Jersey) Law 2007 (“GST Law”), a tax rate which is currently 5% applies to the supply of goods and services (“GST”), unless the supply is regarded as exempt or zero rated, or the relevant supplier or recipient of such goods and services is registered as an “international services entity.”
A company must register for GST if its turnover is greater than £300,000 in any 12-month period, and will then need to charge GST to its customers. Companies can also choose to register voluntarily.
102

A company may apply to be registered as an International Services Entity (“ISE”) if it mainly serves non-Jersey residents. By virtue of a company being an ISE, it will not have to register for GST, will not charge GST on its supplies, and will not be charged GST on its purchases.
We will be an ISE within the meaning of the GST Law, as we satisfy the requirements of the Goods and Services Tax (International Services Entities) (Jersey) Regulations 2008, as amended. As long as we continue to be such an entity, a supply of goods or of a service made by or to us shall not be a taxable supply for the purposes of the GST Law.
Substance Legislation
With effect from January 1, 2019, Jersey has implemented legislation to meet EU demands for companies to have substance in certain circumstances. Broadly, part of the legislation is intended to apply to holding companies managed and controlled in Jersey.
The following select considerations apply from October 29, 2024, when the Company became a tax resident in the United Kingdom
Company residence
The Company migrated its place of tax residence to the United Kingdom on October 29, 2024 on occasion of it being centrally managed and controlled in the United Kingdom from this time.
Corporation Tax
The headline rate of Corporation Tax in the United Kingdom is 25%.
Withholding Tax
Dividends received from subsidiaries are exempt from UK Corporation Tax, provided certain conditions are met, whilst dividends paid by the company to shareholders are generally not subject to UK withholding tax. Withholding tax can also apply in interest, royalty and other scenarios to the extent that double tax treaties do not shield exposure.
Stamp Duty and Capital Gains Taxes
Since the Company is not incorporated in the UK, transfers of shares executed outside the UK should generally not attract UK Stamp Duty unless settled electronically.
Capital Gains Tax positions will depend on specific circumstances.
Value Added Tax
The buying and selling of shares is generally treated as an exempt supply for UK VAT purposes, but depending on circumstances the VAT on associated costs may not be recoverable.
F.Dividends and Paying Agents
Not applicable.
G.Statement by Experts
Not applicable.
H.Documents on Display
The Company is subject to certain of the informational filing requirements of the Exchange Act. Since the Company is a “foreign private issuer,” the Company is exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions contained in Section 16 of the Exchange Act, with respect to their
103

purchase and sale of our shares. In addition, the Company is not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC an Annual Report on Form 20-F containing financial statements audited by an independent accounting firm. The Company may, but is not required, to furnish to the SEC, on Form 6-K, unaudited financial information after each of our first three fiscal quarters. Information filed with or furnished to the SEC by us will be available on our website. The SEC also maintains a website at http://www.sec.gov that contains reports and other information that we file with or furnish electronically with the SEC. You may read and copy any report or document we file, including the exhibits, at the SEC’s public reference room located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room.
I.Subsidiary Information
Not applicable.
J.Annual Reports to Security Holders
Not applicable.
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is exposed to certain market risks in the ordinary course of its business, including fluctuations in interest rates, foreign exchange and inflation. Currently, these risks are not material to the Company’s financial condition or results of operations, but they may be in the future.
Further information regarding quantitative and qualitative disclosure about market risk is included in “Item 4. Information on the Company—B. Business Overview” of this Report.
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
Warrants
As of December 31, 2024, there were 11,663,550 warrants outstanding that had been issued in our initial public offering (the “Public Warrants”). The Public Warrants entitle the holder to purchase one Waldencast Class A ordinary share at an exercise price of $11.50 per share. The Public Warrants will expire on July 27, 2027 (i.e., five years after the completion of the Business Combination), at 5:00 p.m., New York City time, or earlier upon redemption or liquidation in accordance with their terms. As of December 31, 2024, there were also 17,869,732 private placement warrants held by Beauty Ventures, Burwell as trustee of Burwell, and Zeno Investment Master Fund. The private placements warrants are identical to the Public Warrants in all material respects.
PART II
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
None/not applicable.
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
None/not applicable.
ITEM 15. CONTROLS AND PROCEDURES
A. Disclosure Controls and Procedures
Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act,are required to be designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms
104

of the SEC, and that information relating to the Company is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2024 (the end of the period covered by this Report). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of December 31, 2024 were not effective because of material weaknesses in internal control over financial reporting as described below.
B. Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our management evaluated the effectiveness of our internal control over financial reporting based on criteria established in the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, our management has concluded that our internal control over financial reporting was ineffective as of December 31, 2024, due to the material weaknesses described below.
Material Weaknesses
A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
As previously reported in the Company’s 2023 Annual Report on Form 20-F as filed with the SEC on April 30, 2024, management of the Company had identified material weaknesses primarily related to controls around the accounting process. Based upon the current year evaluation by our Chief Executive Officer and Chief Financial Officer, we have concluded that we continue to have material weaknesses in each of the components of the COSO framework. The identified material weaknesses related to the lack of a formal and documented risk assessment process by the Company; that not all control activities, including the delegation of authority control, have been implemented or are operating effectively; and insufficient monitoring of the control environment.
Remediation Plan and Status
Management has been actively engaged in ongoing remediation efforts to address the material weaknesses. We have been making enhancements to our control environment throughout 2024 and to date by improving oversight, communication of expectations, emphasizing the importance of internal controls and creating a more robust internal control environment. We plan to continue improving the operating effectiveness of our internal controls over financial reporting and the timeliness of those procedures during the calendar year-ended December 31, 2025. Management’s ongoing commitment to organizational improvements and remediation efforts included the following actions:
a.hired additional qualified accounting, finance, tax and legal personnel, to provide additional capacity and expertise to enhance our accounting and review procedures;
b.hired new seasoned executive leadership, including a new Group Chief Financial Officer and a Global Head of Tax;
c.appointed an additional Board director with expertise in accounting standards, policies and procedures;
d.implemented controls in our journal entry process, including proper segregation of duties and automated controls requiring appropriate approvals before an entry is recorded;
e.implemented a contract review control which focuses on identifying and evaluating key provisions that could impact revenue recognition;
f.prepared accounting manuals and policies designed to create a clear understanding and expectation on compliance with GAAP;
g.created a robust review process of monthly financial statements where multiple levels of management are involved in reviewing the financial statement fluctuation analysis and balance sheet reconciliations;
h.enhanced the process and documentation for controls including the implementation of an internal control software system and engaged a third-party internal control specialist to improve the documentation of our Information Technology process;
105

i.completed a company risk assessment process after year-end to appropriately identify risks to the Company and appropriate monitoring of those risks; and
While we have made significant progress towards the remediation of the material weaknesses noted above, management has concluded that the material weaknesses were not fully remediated as of December 31, 2024. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
Notwithstanding the identified material weaknesses, management has concluded that the consolidated financial statements included in this Report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. generally accepted accounting principles (U.S. GAAP).
C. Attestation Report of the Registered Public Accounting Firm
Because we are an “emerging growth company” under the JOBS Act, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting for so long as we are an emerging growth company.
D. Changes in Internal Control over Financial Reporting
Other than as described above and under “Remediation Plan and Status,” there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal year-ended December 31, 2024, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM 16. [RESERVED]
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
Our Board has determined that each of the members of the Audit and Governance Committee qualifies as independent under the Nasdaq rules applicable to members of our Board generally and under the Nasdaq rules and Exchange Act Rule 10A-3 specific to audit committee members and that each of the members of the Audit and Governance Committee meets the requirements for financial sophistication under the applicable Nasdaq rules. In addition, our Board has determined that Juliette Hickman and Kelly Brookie qualify as “audit committee financial experts,” as such term is defined in Item 407(d)(5) of Regulation S-K.
ITEM 16B. CODE OF ETHICS
We have a code of ethics and business conduct that applies to all of our directors, officers and employees, and is intended to meet the definition of “code of ethics” under Item 16B of Form 20-F. Our code of ethics is filed as Exhibit 11.2 to this Report and is available on our website, www.waldencast.com. The information on or available through our website is not deemed incorporated in this Report and does not form part of this Report. We intend to make any legally required disclosures regarding amendments to, or waivers of, the provisions of its code of ethics on our website rather than by filing a Current Report on Form 6-K.
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Since the Successor Period (July 28, 2022 to December 31, 2024), Deloitte & Touche LLP (“Deloitte”) has served as the Company’s independent registered public accounting firm. For the Predecessor Periods, Deloitte served as Obagi’s
106

independent registered public accounting firm. The following table sets out the aggregate fees for professional audit services and other services rendered by Deloitte for each of the periods presented.
Successor
(Waldencast)
Predecessor
(Obagi)
(In thousands)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Audit fees1
$3,766 $2,866 $950 $513 
Audit-related fees90 — 380 1,089 
Tax fees2
321 459 179 136 
Total fees$4,177 $3,325 $1,509 $1,738 
1.Audit fees consist of professional services provided in connection with the audit of our annual financial statements and other audit or interim review services provided in connection with regulatory filings or engagements.
2.Tax fees consist of fees for professional services for tax compliance, tax advice, and tax audits.
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
None/not applicable.
ITEM 16E. ISSUER PURCHASES OF EQUITY SECURITIES
None/not applicable.
ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANTS
None/not applicable.
ITEM 16G. CORPORATE GOVERNANCE
As a foreign private issuer, we are not subject to all of the corporate governance requirements applicable to public companies organized within the U.S. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act (including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer and the other two most highly compensated executive officers on an individual, rather than an aggregate, basis). In addition, our officers and directors are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we submit quarterly interim consolidated financial data to the SEC under cover of the SEC’s Form 6-K, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and are not required to file quarterly reports on Form 10-Q or current reports on Form 6-K under the Exchange Act. We also are exempt from the requirements to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. In addition, as a foreign private issuer, we are exempt from the provisions of Regulation FD, which prohibits issuers from making selective disclosure of material nonpublic information.
We were incorporated under the laws of Jersey and our corporate governance practices are governed by applicable Jersey law, including the provisions of the Jersey Companies Law, and the Constitutional Document. In addition, because our securities are listed on Nasdaq, we are subject to Nasdaq’s corporate governance listing standards.
Rule 5615(a)(3) of the Rules permits a foreign private issuer like us to follow home country practices in lieu of certain requirements of Listing Rule 5600, provided that such foreign private issuer discloses in its annual report filed with the SEC each requirement of Rule 5600 that it does not follow and describes the home country practice followed in lieu of such requirement.
107

We currently follow our home country practice in lieu of the requirements of the 5600 Series of the Rules to be exempt from the requirements as follows: (i) Rule 5620(a) of the Rules which provides that (with certain exceptions not relevant to the conclusions expressed herein) each company listing common stock or voting preferred stock, and their equivalents, shall hold an annual meeting of shareholders no later than one year after the end of the company’s fiscal year-end; (ii) Rule 5635(c) of the Rules which sets forth the circumstances under which shareholder approval is required prior to an issuance of securities of the Company in connection with equity-based compensation of officers, directors, employees or consultants; (iii) Rule 5635(d) of the Rules which sets forth the circumstances under which shareholder approval is required prior to an issuance of securities, other than in a public offering, equal to 20% or more of the voting power outstanding at a price less than the lower of: (x) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the signing of the binding agreement; or (y) the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement; and (iv) Rule 5250(b)(3) of the Rules which requires disclosure of third-party director and nominee compensation.
If we choose to follow additional home country practice in the future, our shareholders may be afforded less protection than they would otherwise enjoy under the Nasdaq corporate governance requirements applicable to U.S. domestic issuers. See “Item 3. Key Information—Risk Factors—Risks Related to our Organization and Corporate Structure—As a public limited company incorporated under the laws of Jersey, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to securityholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.
ITEM 16H. MINE SAFETY DISCLOSURES
None/not applicable.
ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
None/not applicable.
ITEM 16J. INSIDER TRADING POLICY
We have adopted an Insider Trading Policy, as amended on October 29, 2024, that applies to all directors, officers and employees of Waldencast and (a) their spouses, minor children, adult family members sharing the same house, and (b) any other person or entity over whom a person subject to the policy has substantial influence or control when it relates to decisions to purchase or sell securities. The Insider Trading Policy, which applies to any purchases and sales of our securities (including ordinary shares, warrants, shares issued under stock options, RSUs or other equity awards, and if we ever issue them preferred shares, bonds or debt securities or convertible debentures and warrants) is designed to promote compliance with applicable insider trading laws, rules and regulations, and the Nasdaq listing standards. The foregoing description of the Insider Trading Policy, as amended is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is filed as Exhibit 11.1 to this Report and the terms of which are incorporated by reference herein.
ITEM 16K. CYBERSECURITY
Risk Management and Strategy
We regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and review our cybersecurity policies, processes, and practices. To help protect our information systems from cybersecurity threats, we use a suite of security and business continuity tools that are designed to help us proactively identify, monitor, escalate, investigate, resolve, and recover from security incidents in a timely manner. Our cybersecurity training and testing program helps ensure awareness and knowledge of cybersecurity best practices purvey all departments. Our information technology department, in connection with management and legal, assesses risks based on probability and potential impact to key business systems and processes. With over 21 years of experience, our recently appointed Chief Technology Officer (“CTO”) has expertise in managing information security, developing cybersecurity strategies and internal awareness programs, implementing effective cybersecurity programs, and executing business continuity and incident response plans, including regular disaster recovery testing, who leads the assessment and management of such risks.
108

We take a risk-based approach to cybersecurity and have implemented cybersecurity policies and practices throughout our operations that are designed to address cybersecurity threats and incidents.

Refer to the risk factor captioned “We are dependent on information technology systems and infrastructure; if we, or the third parties we rely on, fail to protect sensitive information of our consumers and information technology systems against security breaches, it could damage our reputation and brand and substantially harm our business.” in Part I, “Item 3.D. Risk Factors” for additional description of cybersecurity risks and potential related impacts on the Company.
Governance
Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year.
PART III
ITEM 17. FINANCIAL STATEMENTS
See “Item 18. Financial Statements.”
ITEM 18. FINANCIAL STATEMENTS
The consolidated financial statements and the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.
ITEM 19. EXHIBITS
EXHIBIT INDEX 
EXHIBIT
NUMBER
DESCRIPTION
1.1
1.2*
2.1+
2.3
2.4
4.1
109

4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
110

4.14
4.16
4.17
4.18*†
8.1*
11.1*
Insider Trading Policy, as amended October. 29, 2024.
11.2*
12.1*
12.2*
13.1**
13.2**
15.1*
97.1
101.INS*
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
111

101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File (embedded as Inline XBRL and contained in Exhibit 101).
*Filed herewith.
**    Furnished herewith. This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
+Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K on the basis that the Company customarily and actually treats that information as private or confidential and the omitted information is not material.
†    Pursuant to Item 601(b)(2) of Regulation S-K, certain schedules and exhibits have been omitted. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
112

SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.
WALDENCAST PLC
March 20, 2025By:/s/ Manuel Manfredi
Name: Manuel Manfredi
Title: Chief Financial Officer and Principal Financial Officer
113
EX-1.2 2 wald-20241231x20fxexhibit12.htm EX-1.2 Document
Exhibit 1.2
WALDENCAST PARTNERS LP
AMENDED AND RESTATED EXEMPTED LIMITED PARTNERSHIP AGREEMENT
Dated as of July 27, 2022

THE UNITS REPRESENTED BY THIS AMENDED AND RESTATED EXEMPTED LIMITED PARTNERSHIP AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TIME WITHOUT EFFECTIVE REGISTRATION UNDER SUCH ACT AND LAWS OR EXEMPTION THEREFROM, AND COMPLIANCE WITH THE OTHER SUBSTANTIAL RESTRICTIONS ON TRANSFERABILITY SET FORTH HEREIN.
SUCH UNITS MAY ALSO BE SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER, VESTING PROVISIONS, REPURCHASE OPTIONS, OFFSET RIGHTS AND FORFEITURE PROVISIONS SET FORTH HEREIN AND/OR IN A SEPARATE AGREEMENT WITH THE HOLDER OF SUCH UNITS. A COPY OF SUCH AGREEMENT(S) MAY BE OBTAINED BY THE HOLDER OF SUCH UNITS UPON WRITTEN REQUEST AND WITHOUT CHARGE.
WALDENCAST PARTNERS LP
AMENDED AND RESTATED EXEMPTED LIMITED PARTNERSHIP AGREEMENT
This Amended and Restated Exempted Limited Partnership Agreement (this “Agreement”) of Waldencast Partners LP, a Cayman Islands exempted limited partnership (the “Partnership”), dated July 27, 2022 (the “Effective Date”), is entered into by and among Waldencast Cayman LLC, a Cayman Islands limited liability company, as General Partner (“DRE Partner”), Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey, as Limited Partner (“Holdco 1”), Waldencast plc., a public limited company incorporated under the laws of Jersey (formerly known as Waldencast Acquisition Corp., a Cayman Islands exempted company, prior to its migration from the Cayman Islands to Jersey) (“PubCo”) and the other persons who execute a counterpart of, and are admitted to the Partnership in accordance with, this Agreement as Limited Partners. Capitalized terms used herein without definition shall have the meanings assigned to such terms in Article I.
WHEREAS, the Partnership is an exempted limited partnership that was formed pursuant to an Initial Exempted Limited Partnership Agreement of the Partnership, dated November 5, 2021, between Holdco 1, as general partner of the Partnership, and Pubco, as initial limited partner of the Partnership (the “Prior Agreement”) and registered pursuant to the statement under section 9 of the Cayman Act filed with the Registrar of Exempted Limited Partnerships of the Cayman Islands on November 5, 2021;
WHEREAS, prior to the execution of this Agreement, Pubco transferred and assigned the entirety of the limited partnership interest it held in the Partnership to the DRE Partner in accordance with the terms of the Prior Agreement (the "PubCo Contribution");
WHEREAS, prior to the execution of this Agreement, and following the PubCo Contribution, pursuant to a deed of transfer and adherence between Holdco 1 and the DRE Partner, and with simultaneous effect (i) Holdco 1 transferred the entirety of the general partnership interest it held in the Partnership to the DRE Partner and withdrew as general partner of the Partnership and the DRE Partner was appointed as general partner of the Partnership, and (ii) the DRE Partner transferred and assigned the entirety of the limited partnership interest it held in the Partnership to Holdco 1, as a result of which the DRE Partner became the sole general partner of the Partnership and Holdco 1 became the sole limited partner of the Partnership in accordance with the terms of the Prior Agreement (the "Partner Transfer");



Exhibit 1.2
WHEREAS, in connection with the transactions described herein, the DRE Partner and Holdco 1 desire to amend and restate the Prior Agreement in its entirety as set forth herein effective upon the execution of this Agreement, at which time the Prior Agreement will be superseded and replaced entirely by this Agreement;
WHEREAS, prior to the consummation of the Milk Transaction (as defined below), the General Partner shall declare and pay a Distribution in accordance with this Agreement of certain distribution proceeds received by the Partnership from Waldencast Finco Limited, a limited company incorporated under the laws of Jersey, to Holdco 1 as the sole Limited Partner;
WHEREAS, upon the terms and subject to the conditions of the Merger Agreement, dated November 15, 2021, by and among PubCo, Obagi Merger Sub, Inc. a Cayman Islands exempted company limited by shares (“Obagi Merger Sub”) and Obagi Global Holdings Limited, a Cayman Islands exempted company limited by shares (“Obagi”), immediately prior to the consummation of the Milk Transaction (as defined below), Obagi Merger Sub shall merge with and into Obagi (the “Obagi Merger”), pursuant to which the separate corporate existence of Obagi Merger Sub will cease and Obagi will survive the Obagi Merger as a direct wholly owned subsidiary of Obagi Holdco 2 Limited, a limited company incorporated under the laws of Jersey (“Obagi Holdco 2”), and an indirect wholly owned subsidiary of Holdco 1;
WHEREAS, upon the terms and subject to the conditions of the Equity Purchase Agreement (the “Milk Equity Purchase Agreement”), dated November 15, 2021, by and among PubCo, Holdco 1, the Partnership, Milk Makeup LLC, a Delaware limited liability company (“Milk”), the members of Milk listed therein (the “Milk Members”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney-in-fact of the Milk Members, the Partnership and Holdco 1 (the Partnership and Holdco 1 together, the “Purchasers”) shall acquire from the Milk Members and the Milk Members shall sell to the Purchasers all of the issued and outstanding membership interests of Milk held by them, which represent 100% of the issued and outstanding membership interests of Milk, in exchange for cash, limited partnership interests in the Partnership and Class B ordinary shares (the “Milk Transaction” and, together with the Obagi Merger, the “Transactions”);
WHEREAS, at the Effective Time, pursuant to a contribution agreement, (a) Holdco 1 will contribute its equity interest in Milk to the Partnership in exchange for limited partnership units of the Partnership and (b) Holdco 1 will contribute its equity interest in Obagi Holdco 2 to the Partnership in exchange for limited partnership units in Partnership (the "Holdco 1 Contribution");
WHEREAS, for U.S. federal income tax purposes (and for purposes of any applicable state or local income tax that follows the U.S. federal income tax treatment), the Partners intend that the Partnership be treated as the continuation of Milk as a tax partnership under Section 708(a) of the Code; and
NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree to amend and restate the Prior Agreement to read in its entirety as follows:
ARTICLE I
DEFINITIONS
1.1 Certain Definitions. The following definitions shall be applied to the terms used in this Agreement for all purposes, unless otherwise clearly indicated to the contrary.
Additional Partner” means a Person admitted to the Partnership as a Partner pursuant to Section 10.2.
Adjusted Capital Account Balance” means, with respect to each Partner, the balance in such Partner’s Capital Account adjusted (i) by taking into account the adjustments, allocations and distributions described in Treasury Regulations Sections 1.704-1(b)(2)(ii)(d)(4), (5) and (6); and (ii) by adding to such balance such Partner’s share of Partnership Minimum Gain and Partner Nonrecourse Debt Minimum Gain, determined pursuant to Treasury Regulations Sections 1.704-2(g)(1) and 1.704-2(i)(5), and any amounts such Partner is obligated to contribute or



Exhibit 1.2
deemed obligated to contribute pursuant to any provision of this Agreement or by Applicable Law. The foregoing definition of Adjusted Capital Account Balance is intended to comply with the provisions of Treasury Regulations Section 1.704-1(b)(2)(ii)(d) and shall be interpreted consistently therewith.
Admission Date” has the meaning set forth in Section 9.4(b).
Affiliate” of any Person means any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, where “control” means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, its capacity as a general partner or otherwise. For purposes of this Agreement, no Partner shall be deemed to be an Affiliate of any other Partner solely by reason of being a Partner.
Agreement” has the meaning set forth in the Recitals to this Agreement.
Applicable Law” means, with respect to any Person, any federal, state or local law (statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling, or other similar requirement enacted, adopted, promulgated, or applied by a governmental authority that is binding upon or applicable to such Person or its assets, as amended unless expressly otherwise specified herein.
Base Rate” means, on any date, a variable rate per annum equal to the rate of interest most recently published by The Wall Street Journal as the “prime rate” at large U.S. money center banks.
Board” means the board of directors of PubCo, as constituted at any given time.
Book Value” means, with respect to any Property (other than money) treated as being held by the Partnership for U.S. federal income tax purposes (including Property held by an entity disregarded as being separate from the Partnership for federal income tax purposes), such Property’s adjusted basis for federal income tax purposes, except as follows:
(i) The initial Book Value of any such Property contributed by a Partner to the Partnership will be the gross Fair Market Value of such Property on the date of contribution, as reasonably determined by the General Partner.
(ii) The Book Values of each such item of Property will be adjusted to equal their respective gross Fair Market Values (taking Section 7701(g) of the Code into account), at the time of any Revaluation pursuant to Section 3.10(d); provided that if any Noncompensatory Option with respect to Units or other Equity Securities of the Partnership is outstanding, then Book Values will also be adjusted in accordance with Treasury Regulations Sections 1.704-1(b)(2)(iv)(h)(2).
(iii) The Book Value of any such Property distributed to any Partner will be adjusted to equal the gross Fair Market Value (taking Section 7701(g) of the Code into account) of such Property on the date of distribution.
(iv) The Book Values of such Properties will be increased (or decreased) to reflect any adjustments to the adjusted basis of such Properties pursuant to Code Section 734(b) or Code Section 743(b), but only to the extent that such adjustments are taken into account in determining Capital Accounts pursuant to Treasury Regulations Section 1.704- 1(b)(2)(iv)(m) and paragraph (vi) of the definition of “Net Profit” or “Net Loss” or Section 4.3(h); provided, however, that Book Values will not be adjusted pursuant to this paragraph (iv) to the extent that an adjustment pursuant to paragraph (ii) is required in connection with a transaction that would otherwise result in an adjustment pursuant to this paragraph (iv).
(v) If the Book Value of any such Property has been determined or adjusted pursuant to paragraph (i), (ii) or (iii), then such Book Value will thereafter be adjusted by the Depreciation taken into account with respect to such asset, for purposes of computing Net Profit or Net Loss.
Business Day” means any day, other than a Saturday, Sunday or any other day on which commercial banks located in the State of New York are authorized or obligated by law or executive order to close.



Exhibit 1.2
Business Opportunities Exempt Party” has the meaning set forth in Section 6.7.
Capital Account” has the meaning set forth in Section 3.10(a).
Capital Contribution” means any cash, cash equivalents, or the Fair Market Value of other property which a Partner contributes to the Partnership pursuant to Section 3.1.
Capital Stock” shall mean any and all shares, interests, participations or other equivalents (however designated) of capital stock of a corporation, any and all shares of a company, any and all equivalent ownership interests in a Person (other than a corporation or a company) including, without limitation, partnership or membership interests (including any components thereof such as capital accounts, priority returns or the like) in a limited partnership or limited liability company and any and all warrants, rights or options to purchase any of the foregoing.
Cash Exchange Class A 5-Day VWAP” means the arithmetic average of the VWAP for each of the five (5) consecutive Trading Days ending on the Trading Day immediately prior to the Redemption Notice Date.
Cash Exchange Payment” means with respect to a particular Exchange for which PubCo has elected to make a Cash Exchange Payment in accordance with Section 12.1(d):
(i) if the Class A ordinary shares are then traded on a National Securities Exchange or automated or electronic quotation system, an amount of cash equal to the product of (x) the number of Class A ordinary shares that would have been received by the Redeeming Partner in the Exchange for that portion of the Common Units subject to the Exchange set forth in the Redemption Notice if PubCo had paid the Stock Exchange Payment with respect to such number of Common Units, and (y) the Cash Exchange Class A 5-Day VWAP; or
(ii) if the Class A ordinary shares are not then traded on a National Securities Exchange or automated or electronic quotation system, as applicable, an amount of cash equal to the product of (x) the number of Class A ordinary shares that would have been received by the Redeeming Partner in the Exchange for that portion of the Common Units subject to the Exchange set forth in the Redemption Notice if PubCo had paid the Stock Exchange Payment with respect to such number of Common Units, for which PubCo has elected to make a Cash Exchange Payment and (y) the Fair Market Value of one (1) Class A ordinary share.
For the avoidance of doubt, the Cash Exchange Payment may be made by PubCo, Waldencast Limited Partner or the Partnership.
Cayman Act” means the Exempted Limited Partnership Act (As Revised) of the Cayman Islands, as it may be amended from time to time, and any successor to the Cayman Act.
Certificate” has the meaning set forth in Section 2.1.
Change of Control” means the occurrence of any transaction or series of related transactions in which: (a) any Person or any group of Persons (other than PubCo) acting together that would constitute a “group” for purposes of Section 13(d) of the Exchange Act, is or becomes the beneficial owner, directly or indirectly, of securities of PubCo or the Partnership representing more than 50% of the combined voting power of PubCo or more than 50% of the value of the Partnership, as applicable, then outstanding voting securities (excluding a transaction or series of related transactions described in clause (b) that would not constitute a Change of Control), (b) the consummation of a merger or consolidation of PubCo or the Partnership with any other Person, and, immediately after the consummation of such merger or consolidation, the outstanding voting securities of PubCo or the Partnership, as applicable, immediately prior to such merger or consolidation do not continue to represent or are not converted into more than 50% of the combined voting power of the then outstanding voting securities of the Person resulting from such merger or consolidation or, if PubCo or the Partnership, as applicable (or its successor), is a Subsidiary of such Person, the ultimate parent thereof, or (c) there is consummated an agreement or series of related agreements for the sale or transfer, directly or indirectly, by PubCo of all or substantially all of PubCo’s assets (including the Equity Securities or assets of the Partnership).



Exhibit 1.2
Class A ordinary shares” means, as applicable, (a) the Class A ordinary shares, par value $0.0001 per share, of PubCo or (b) following any consolidation, merger, reclassification or other similar event involving PubCo, any shares or other securities of PubCo or any other Person that become payable in consideration for the Class A ordinary shares
or into which the Class A ordinary shares are exchanged or converted as a result of such consolidation, merger, reclassification or other similar event.
Class B ordinary shares” means, as applicable, (a) the Class B ordinary shares, par value $0.0001 per share, of PubCo or (b) following any consolidation, merger, reclassification or other similar event involving PubCo, any shares or other securities of PubCo or any other Person that become payable in consideration for the Class B ordinary shares or into which the Class B ordinary shares are exchanged or converted as a result of such consolidation, merger, reclassification or other similar event.
Closing” means the closing of the transactions contemplated by the Milk Equity Purchase Agreement. “COC Exchange” has the meaning set forth in Section 12.3.
COC Exchange Date” has the meaning set forth in Section 12.3.
COC Exchanging Partner” has the meaning set forth in Section 12.3.
COC Notice” has the meaning set forth in Section 12.3.
Code” means the United States Internal Revenue Code of 1986, as amended from time to time.
Common Unit Percentage Interest” means, with respect to any Partner, the quotient obtained by dividing the aggregate number of Common Units then owned by such Partner by the aggregate number of Common Units then owned by all Partners.
Common Units” means the common limited partnership interests described in Section 3.1(b) and having the rights and preferences specified herein.
Confidential Information” has the meaning set forth in Section 7.7(b).
Contribution Register” has the meaning set forth in Section 3.1(a)(ii).
Convertible Securities” means any securities directly or indirectly convertible into or exercisable or exchangeable for Units, other than Options.
Covered Transaction” means any Liquidity Event or any other sale, redemption or Transfer of Units.
Depreciation” means, for each Fiscal Year, an amount equal to the depreciation, amortization, or other cost recovery deduction allowable with respect to an asset for such Fiscal Year, except that if the Book Value of an asset differs from its adjusted basis for federal income tax purposes at the beginning of such Fiscal Year, then Depreciation will be, subject to Treasury Regulations Section 1.704-3(d)(2), an amount that bears the same ratio to such beginning Book Value as the federal income tax depreciation, amortization, or other cost recovery deduction for such Fiscal Year bears to such beginning adjusted tax basis; provided that if the adjusted basis for federal income tax purposes of an asset at the beginning of such Fiscal Year is zero, then Depreciation will be determined with reference to such beginning Book Value using any reasonable method selected by the General Partner.
Designated Individual” has the meaning set forth in Section 8.3.
Direct Exchange” has the meaning set forth in Section 12.2(a).
Disputing Partner” has the meaning set forth in Section 14.2.



Exhibit 1.2
Distribution” means each distribution made by the Partnership to a Partner, whether in cash, property or securities of the Partnership and whether by liquidating distribution or otherwise; provided that none of the following shall be a Distribution: (a) any redemption or repurchase by the Partnership of any securities, or (b) any recapitalization or
exchange of securities of the Partnership, or any subdivision (by Unit split or otherwise) or any combination (by reverse Unit split or otherwise) of any outstanding Units.
Distributive Share” has the meaning set forth in Section 4.1(b).
DRE Partner” has the meaning set forth in the Recitals to this Agreement.
Effective Date” has the meaning set forth in the Recitals to this Agreement.
Effective Time” means immediately following the consummation of the Milk Transaction.
Encumbrance” means any mortgage, hypothecation, claim, lien, encumbrance, conditional sales or other title retention agreement, right of first refusal, preemptive right, pledge, option, charge, security interest or other similar interest, easement, judgment or imperfection of title of any nature whatsoever.
Equity Securities” means (i) Units or other equity interests in the Partnership (including other classes or groups thereof having such relative rights, powers and duties as may from time to time be established by the General Partner, including rights, powers and/or duties senior to existing classes and groups of Units and other equity interests in the Partnership) or equity interests in any other specified Person, (ii) Convertible Securities or other obligations, evidences of Indebtedness or other securities or interests convertible or exchangeable into other equity interests in the Partnership or any other specified Person and (iii) Options or warrants, or other rights to purchase or otherwise acquire other equity interests in the Partnership or any other specified Person.
ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
Event of Withdrawal” means the death, retirement, resignation, expulsion, bankruptcy or dissolution of a Partner or the occurrence of any other event that terminates the partner status of a Partner in the Partnership.
Exchange” means (a) a Redemption by the Partnership of Common Units held by a Partner for the Cash Exchange Payment or Stock Exchange Payment (together with the redemption and subsequent cancellation by PubCo of the same number of outstanding Class B ordinary shares held by such Partner for no additional consideration) or (b) the direct purchase by Waldencast Limited Partner of Common Units and Class B ordinary shares held by a Partner for the Cash Exchange Payment or Stock Exchange Payment in accordance with a Direct Exchange, in each case in accordance with Article XII.
Exchange Act” means the Securities Exchange Act of 1934, as amended, and applicable rules and regulations thereunder, and any successor to such statute, rules or regulations. Any reference herein to a specific section, rule or regulation of the Exchange Act shall be deemed to include any corresponding provisions of future law.
Exchange Blackout Period” means the period of time commencing on (x) the date of payment of a distribution by the Partnership indirectly to PubCo (or the record date for such distribution, if earlier than the date of payment of such distribution) (such date, the “Start Date”) for the first distribution under Section 4.1 after the date of this Agreement and thereafter for each first distribution under Section 4.1 following the end of each immediately preceding Exchange Blackout Period (in respect of the four (4) distribution dates in a calendar year) and ending on (but including) (y) the PubCo Record Date for the PubCo dividend immediately following such distribution; provided that in no event shall such period of time exceed twenty (20) calendar days following the Start Date. For the avoidance of doubt, no more than four (4) Exchange Blackout Periods can begin in any calendar year.
Exchange Date” means the COC Exchange Date or Redemption Date, as applicable.
Exchange Election Notice” has the meaning set forth in Section 12.2(b).



Exhibit 1.2
Exchange Rate” means, at any time, the number of Class A ordinary shares for which one Common Unit is entitled to be Exchanged at such time pursuant to this Agreement. On the date of this Agreement, the Exchange Rate shall be one for one, subject to adjustment pursuant to Section 12.5.
Exempt Pledge” means a pledge, charge, mortgage, assignment by way of security, or other grant of encumbrance, by a Partner of Common Units held by such Partner as security for a bona fide margin loan or other customary lending arrangement with one or more banks or financial institutions (the “Lenders”) that meets the following conditions: (a) such pledging, charging, mortgaging, assigning by way of security, or other granting of encumbrance Partner shall have complied with all applicable policies of PubCo and the Partnership, including any securities trading, insider trading and pledging policies, in entering into such pledge charge, mortgage, assignment by way of security, or other grant of encumbrance, (or otherwise entered into such pledge charge, mortgage, assignment by way of security, or other grant of encumbrance, pursuant to a valid waiver of any of such policies in accordance with the applicable terms thereof), (b) the documentation of such bona fide margin loan or other customary arrangement shall be in a form reasonably acceptable to the General Partner, and (c) it is established to the reasonable satisfaction of the General Partner that, based upon the terms and conditions of such bona fide margin loan or other customary arrangement and any related agreements, (i) the Lender(s) will not be considered to be the “tax owner” of such Common Units for United States federal income tax purposes and (ii) such bona fide margin loan or other customary arrangement shall not create adverse tax consequences for the Partnership or any Partner. For the avoidance of doubt, the exercise by a Lender of its rights to acquire or Transfer any Common Units subject to such pledge charge, mortgage, assignment by way of security, or other grant of encumbrance, shall not be an Exempt Pledge.
Exempt Transfer” has the meaning set forth in Section 9.1(b).
Fair Market Value” means, with respect to any asset or equity interest, its fair market value determined according to Article XIV.
Family Group” means a Partner’s spouse, parents, siblings and descendants (whether by birth or adoption) and any trust or other estate planning vehicle established solely for the benefit of such Partner and/or such Partner’s spouse and/or such Partner’s descendants (by birth or adoption), parents, siblings or dependents, or any charitable trust the grantor of which is such Partner and/or member of such Partner’s Family Group.
Fiscal Year” means the Partnership’s annual accounting period established pursuant to Section 7.3.
Forward Purchase Transaction” means the transactions pursuant to (a) the Forward Purchase Agreement dated March 2, 2021, by and between PubCo and Beauty Ventures LLC pursuant to which, among other things, Beauty Ventures LLC agreed to acquire units of PubCo, and (b) the Forward Purchase Agreement dated February 22, 2021, by and among PubCo, the Sponsor and Dynamo Master Fund (a member of the Sponsor) (“February FPA”), as amended by the assignment and assumption agreement dated December 20, 2021, by and between the Sponsor and Burwell Mountain Trust (a member of the Sponsor), pursuant to which, among other things, the Sponsor assigned, and Burwell Mountain Trust assumed, all of the Sponsor’s rights and benefits as purchaser under the February FPA, including the right to purchase units of PubCo subscribed for by the Sponsor.
General Partner” means the DRE Partner, or any successor General Partner admitted to the Partnership in accordance with the terms of this Agreement and the Cayman Act, in its capacity as the general partner of the Partnership.
Governmental Entity” means the United States of America or any other nation, any state or other political subdivision thereof, or any entity exercising executive, legislative, judicial, regulatory or administrative functions of government.
Holdco 1” has the meaning set forth in the Recitals to this Agreement.
Holdco 1 Contribution” has the meaning set forth in the Recitals to this Agreement.



Exhibit 1.2
Imputed Underpayment Amount” means (a) any “imputed underpayment” within the meaning of Section 6225 of the Code (or any corresponding or similar provision of state, local or foreign tax law) paid (or payable) by the Partnership as a result of any adjustment by the IRS with respect to any Partnership item of income, gain, loss, deduction, or credit of the Partnership (including, without limitation, any “partnership-related item” within the meaning of Section 6241(2) of the Code (or any corresponding or similar provision of state, local or foreign tax law)),
including any interest, penalties or additions to tax with respect to any such adjustment, (b) any amount not described in clause (a) (including any interest, penalties or additions to tax with respect to such amounts) paid (or payable) by the Partnership as a result of the application of Sections 6221-6241 of the Code (or any corresponding or similar provision of state, local or foreign tax law), and/or (c) any amount paid (or payable) by any entity treated as a partnership for U.S. federal income tax purposes in which the Partnership holds (or has held) a direct or indirect interest other than through entities treated as corporations for U.S. federal income tax purposes if the Partnership bears the economic burden of such amounts, whether by law or agreement, as a result of the application of Sections 6221- 6241 of the Code (including, for the avoidance of doubt, Section 6226(b) of the Code (or any corresponding or similar provision of state, local or foreign tax law)), including any interest, penalties or additions to tax with respect to such amounts.
Indebtedness” means (a) all indebtedness for borrowed money (including capitalized lease obligations, sale leaseback transactions or other similar transactions, however evidenced), (b) any other indebtedness that is evidenced by a note, bond, debenture, draft or similar instrument, and (c) notes payable.
Indemnified Person” has the meaning set forth in Section 6.4(a).
IRS” means the United States Internal Revenue Service.
Limited Partner” means a Limited Partner identified on the Schedule of Partners as of the Effective Time, or an Additional Partner or a Substituted Partner who is admitted as a Limited Partner in accordance with the terms of this Agreement and the Cayman Act for so long as such Person continues to hold an economic interest in any of the Units.
Liquid Securities” has the meaning set forth in Section 12.3.
Liquidity Event” means, whether occurring through one transaction or a series of related transactions, any liquidation, dissolution or winding up, voluntary or involuntary, of the Partnership.
Mark-to-Market Gain” means any net gain recognized for Capital Account purposes upon an adjustment to the Book Value of any Property pursuant to the definition of Book Value and/or a Revaluation.
Milk” has the meaning set forth in the Recitals to this Agreement.
Milk Equity Purchase Agreement” has the meaning set forth in the Recitals to this Agreement. “Milk Lock-Up Agreements” has the meaning set forth in Section 12.1(a).
Milk Members” has the meaning set forth in the Recitals to this Agreement.
Milk Partners” means the Partners set forth on Schedule I who were equityholders of Milk as of immediately prior to the consummation of the Milk Transaction.
Milk Transaction” has the meaning set forth in the Recitals to this Agreement.
Minimum Exchange Amount” means a number of Common Units held by a Redeeming Partner equal to the lesser of (x) 1,000 Common Units and (y) all of the Common Units then held by the applicable Redeeming Partner.
National Securities Exchange” means a securities exchange registered with the Securities and Exchange Commission under Section 6 of the Exchange Act.



Exhibit 1.2
Net Profit” or “Net Loss” means, for each Fiscal Year or other applicable period, an amount equal to the Partnership’s taxable income or loss for such Fiscal Year (or other period), determined in accordance with Section 703(a) of the Code (for this purpose, all items of income, gain, loss, or deduction required to be stated separately pursuant to Section 703(a)(1) of the Code will be included in taxable income or loss), with the following adjustments (without duplication):
(i) any income of the Partnership that is exempt from U.S. federal income tax and not otherwise taken into account in computing Net Profit or Net Loss pursuant to this definition will be added to such taxable income or loss;
(ii) any expenditures of the Partnership described in Section 705(a)(2)(B) of the Code or treated as such pursuant to Treasury Regulations Section 1.704-1(b)(2)(iv)(i), and not otherwise taken into account in computing Net Profit or Net Loss pursuant to this definition will be subtracted from such taxable income (or added to such taxable loss), notwithstanding that such items are not deductible for U.S. federal income tax purposes;
(iii) in the event the Book Value of any Partnership asset is adjusted pursuant to paragraphs (ii) or (iii) of the definition of “Book Value,” the amount of such adjustment will be treated as an item of gain (if the adjustment increases the Book Value of the asset) or an item of loss (if the adjustment decreases the Book Value of the asset) from the disposition of such asset, and will be taken into account, immediately prior to the event giving rise to such adjustment, for purposes of computing Net Profit or Net Loss;
(iv) gain or loss resulting from any disposition of Property with respect to which gain or loss is recognized for federal income tax purposes will be computed by reference to the Book Value of the Property disposed of, notwithstanding that the adjusted tax basis of such Property differs from its Book Value;
(v) in lieu of the depreciation, amortization, and other cost recovery deductions taken into account in computing such taxable income or loss, there will be taken into account Depreciation for such Fiscal Year, computed in accordance with the definition of “Depreciation”;
(vi) to the extent an adjustment to the adjusted tax basis of any Property pursuant to Section 734(b) or 743(b) of the Code is required, pursuant to Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(4), to be taken into account in determining Capital Accounts as a result of a Distribution other than in liquidation of a Partner’s partnership interest in the Partnership, the amount of such adjustment will be treated as an item of gain (if the adjustment increases the Property’s basis) or loss (if the adjustment decreases such basis) from the disposition of such Property, and will be taken into account in computing Net Profit or Net Loss; and
(vii) notwithstanding any other provision of this definition, any items that are specially allocated pursuant to Section 4.3(a) to (g) will not be taken into account in computing Net Profit or Net Loss. Instead, the amounts of the items of Partnership income, gain, loss, or deduction available to be specially allocated pursuant to Section 4.3(a) to (g) will be determined by applying rules analogous to those set forth in paragraphs (i) through (vi) above.
Non-PubCo Partner” means any Partner that is not a PubCo Partner.
Noncompensatory Option” means a non-compensatory option within the meaning of Treasury Regulations Section 1.721-2(f) that is issued by the Partnership.
Nonrecourse Deductions” has the meaning set forth in Treasury Regulations Section 1.704-2(b)(1). The amount of Nonrecourse Deductions of the Partnership for a Fiscal Year equals the net increase, if any, in the amount of Partnership Minimum Gain of the Partnership during that fiscal year, determined according to the provisions of Treasury Regulations Section 1.704-2(c).
Obagi” has the meaning set forth in the Recitals to this Agreement.
Obagi Holdco 2” has the meaning set forth in the Recitals to this Agreement.
Obagi Merger” has the meaning set forth in the Recitals to this Agreement.



Exhibit 1.2
Obagi Merger Sub” has the meaning set forth in the Recitals to this Agreement.
Option” means any right, option or warrant to subscribe for, purchase or otherwise acquire any Units.
Partner” means each of the Persons from time to time admitted to the Partnership as a partner (general partner or limited partner) of the Partnership and listed as a Partner in the books and records of the Partnership, each in its capacity as a partner (general partner or limited partner) of the Partnership.
Partner Nonrecourse Debt Minimum Gain” has the meaning ascribed to the term “partner nonrecourse debt minimum gain” in Treasury Regulations Sections 1.704-2(i)(2) and 1.704-2(i)(3).
Partner Nonrecourse Deductions” has the meaning ascribed to the term “partner nonrecourse deductions” set forth in Treasury Regulations Sections 1.704-2(i)(1) and 1.704-2(i)(2).
Partnership” has the meaning set forth in the Recitals to this Agreement.
Partnership Indemnitees” has the meaning set forth in Section 6.4(e).
Partnership Indemnitors” has the meaning set forth in Section 6.4(e).
Partnership Minimum Gain” has the meaning ascribed to the term “partnership minimum gain” set forth in Treasury Regulations Sections 1.704-2(b)(2) and 1.704-2(d).
Partnership Representative” has the meaning set forth in Section 8.3.
Party” or “Parties” means a party or parties (as applicable) to this Agreement.
Pass-Through Entity” means a partnership, Subchapter S corporation, trust, grantor trust, or any other pass-through entity or flow-through entity for U.S. federal income tax purposes.
Pass-Through Partner” means a Partner that is a Pass-Through Entity.
Permitted Transferee” means any transferee in an Exempt Transfer.
Person” means an individual or a corporation, company, partnership, limited liability company, trust, unincorporated organization, association or other entity.
PFIC” has the meaning set forth in Section 7.6.
PIPE Investment” means the purchase of Class A ordinary shares pursuant to the subscription agreements, entered into on or prior to the date of this Agreement (as assigned or amended from time to time in accordance with their terms and this Agreement after the date of this Agreement).
Prior Agreement” has the meaning set forth in the Recitals to this Agreement.
Property” means an interest of any kind in any real, personal or intellectual (or mixed) property, including cash, and any improvements thereto, and shall include both tangible and intangible property.
PubCo” means Waldencast plc., a public limited company incorporated under the laws of Jersey, and its successors. “PubCo Contribution” has the meaning set forth in the Recitals to this Agreement.
PubCo Memorandum and Articles of Association” means the Amended and Restated Memorandum and Articles of Association of PubCo.
PubCo Partner” means (a) PubCo (if PubCo were to become a Partner of the Partnership), (b) Holdco 1, (c) DRE Partner and (d) any Subsidiary of PubCo or Holdco 1 (other than the Partnership and its Subsidiaries) that is or becomes a Partner.



Exhibit 1.2
PubCo Record Date” means the record date determined by the Board for the declaration of a dividend payable on the outstanding Class A ordinary shares.
Purchasers” has the meaning set forth in the Recitals to this Agreement.
Recitals” means the Recitals to this Agreement.
Redeemed Units” means with respect to any Redemption, the Common Units being redeemed or exchanged pursuant to a relevant Redemption Notice; provided that such amount of Common Units shall in no event be less than the Minimum Exchange Amount.
Redeeming Partner” has the meaning set forth in Section 12.1(b).
Redemption” has the meaning set forth in Section 12.1(a).
Redemption Date” means the date that is not less than five (5) Business Days nor more than ten (10) Business Days after the Redemption Notice Date (unless and to the extent that the General Partner in its sole discretion agrees in writing to waive such time periods); provided, however, that if the Redemption Date for any Redemption with respect to which PubCo elects to make a Stock Exchange Payment would otherwise fall within any Exchange Blackout Period, then the Redemption Date shall occur on the next Business Day following the end of such Exchange Blackout Period; and provided further, that to the extent a Redemption is made in connection with a Redeeming Partner’s proper exercise of its rights to participate in a Piggyback Registration pursuant to Section 2.2 of the Registration Rights Agreement, the Redemption Date shall be the date on which the offering with respect to such Piggyback Registration is completed.
Redemption Notice” has the meaning set forth in Section 12.1(b).
Redemption Notice Date” means, with respect to any Redemption Notice, the date such Redemption Notice is given to the Partnership in accordance with Section 12.1.
Redemption Right” has the meaning set forth in Section 12.1(a).
Register” has the meaning set forth in Section 3.1(a)(iii).
Registration Rights Agreement” means the Amended and Restated Registration Rights Agreement, dated as of or about the date hereof, by and among PubCo and the parties listed thereto, as may be amended from time to time.
Revaluation” has the meaning set forth in Section 3.10(d).
Reviewed Year” has the meaning set forth in Section 8.3.
Schedule of Partners” has the meaning set forth in Section 3.1(a)(i).
Section 704(c) Property” has the meaning ascribed to such term in Treasury Regulations Section 1.704–3(a)(3) and shall include assets treated as Section 704(c) property by virtue of revaluations of Partnership assets as permitted by Treasury Regulations Section 1.704–1(b)(2)(iv)(f).
Securities Act” means the Securities Act of 1933, as amended, and applicable rules and regulations thereunder, and any successor to such statute, rules or regulations. Any reference herein to a specific section, rule or regulation of the Securities Act shall be deemed to include any corresponding provisions of future law.
Securities and Exchange Commission” means the United States Securities and Exchange Commission, including any governmental body or agency succeeding to the functions thereof.
Security Interests Register” has the meaning set forth in Section 3.1(a)(iii).



Exhibit 1.2
Similar Law” means any law or regulation that could cause the underlying assets of the Partnership to be treated as assets of a Partner by virtue of its partnership interest in the Partnership and thereby subject the Partnership and the General Partner (or other persons responsible for the investment and operation of the Partnership’s assets) to laws or regulations that are similar to the fiduciary responsibility or prohibited transaction provisions contained in Title I of ERISA or Section 4975 of the Code.
Sponsor” means Waldencast Long-Term Capital LLC, a Cayman Islands limited liability company.
Stock Exchange Payment” means, with respect to any Exchange of Common Units for which a Stock Exchange Payment is elected by PubCo, a number of Class A ordinary shares equal to the number of Common Units so exchanged multiplied by the Exchange Rate.
Subsidiary” means, with respect to any Person, any corporation, company, limited liability company, partnership, association or business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a company, a majority of the total voting power of shares entitled (without regard to the occurrence of any contingency) to vote in the election of directors thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (iii) if a limited liability company, partnership, association or other business entity (other than a corporation), a majority of partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity (other than a corporation) if such Person or Persons shall be allocated a majority of limited liability company, partnership, association or other business entity gains or losses or shall be or control any managing director or general partner of such limited liability company, partnership, association or other business entity. For purposes hereof, references to a “Subsidiary” of the Partnership shall be given effect only at such times that the Partnership has one or more Subsidiaries, and, unless otherwise indicated, the term “Subsidiary” refers to a Subsidiary of the Partnership.
Substituted Partner” means a Person that is admitted as a Partner to the Partnership pursuant to Section 10.1 in connection with the Transfer of then-existing Units to such Person.
Tax Distributions” has the meaning set forth in Section 4.1(d)(i).
Taxable Year” means the Partnership’s accounting period for federal income tax purposes determined pursuant to Section 8.2.
Trading Day” means a day on which the principal U.S. securities exchange on which the Class A ordinary shares are listed or admitted to trading is open for the transaction of business (unless such trading shall have been suspended for the entire day).
Transactions” has the meaning set forth in the Recitals to this Agreement.
Transfer” has the meaning set forth in Section 9.1(a).
Transferee” means a Person to whom any Units have been Transferred in accordance with the terms of this Agreement but who has not become a Partner pursuant to Sections 10.2 and 10.3.
Transferor” has the meaning set forth in Section 9.1(b).
Transferor’s Owner” has the meaning set forth in Section 9.1(c)(i).
Treasury Regulations” means the income tax regulations promulgated under the Code, as amended.



Exhibit 1.2
Trust Account” means the trust account holding of the cash proceeds of PubCo’s initial public offering and private placements of its securities that was established for the benefit of PubCo, certain public shareholders, and the underwriters of the initial public offering of PubCo.
Unit” means, collectively, the Common Units and such other units of the Partnership as may be authorized, designated or issued, as determined by the General Partner from time to time after the date hereof.
VWAP” means the daily per share volume-weighted average price of the Class A ordinary shares on the Nasdaq Stock Market or such other principal United States securities exchange on which the Class A ordinary shares are listed, quoted or admitted to trading, as displayed under the heading Bloomberg VWAP on the Bloomberg page designated for the Class A ordinary shares (or its equivalent successor if such page is not available) in respect of the period from the open of trading on such Trading Day until the close of trading on such Trading Day (or if such volume-weighted average price is unavailable, (a) the per share volume-weighted average price of a Class A ordinary shares on such Trading Day (determined without regard to afterhours trading or any other trading outside the regular trading session or trading hours), or (b) if such determination is not feasible, the market price per Class A ordinary share, in either case as determined by a nationally recognized independent investment banking firm retained in good faith for this purpose by PubCo); provided, however, that if at any time for purposes of the Cash Exchange Class A 5-Day VWAP, Class A ordinary shares are not then listed, quoted or traded on a principal United States securities exchange or automated or electronic quotation system, then the VWAP shall mean the per share Fair Market Value of one (1) Class A ordinary share (or such other Equity Security into which the Class A ordinary share was converted or exchanged).
Waldencast Limited Partner” means Holdco 1, or its successor or assignee.
Withholding Payment” has the meaning set forth in Section 4.5(b).
1.2 Interpretive Provisions. For all purposes of this Agreement, except as otherwise provided in this Agreement or unless the context otherwise requires:
(a) The singular includes the plural and the plural includes the singular.
(b) A reference to the masculine gender shall be deemed to be a reference to the feminine gender and vice versa. (c) The words “or,” “either,” and “any” are not exclusive.
(d) A reference to a Person includes its permitted successors and permitted assigns.
(e) The words “include,” “includes” and “including” are not limiting and shall be deemed to be followed by the words “without limitation.”
(f) The words “shall” and “will” have the same meaning hereunder.
(g) The headings of particular provisions of this Agreement are inserted for convenience only and will not be construed as a part of this Agreement or serve as a limitation or expansion on the scope of any term or provision of this Agreement.
(h) A reference in a document to an Article, Section, Exhibit, Schedule, Annex or Appendix is to the Article, Section, Exhibit, Schedule, Annex or Appendix of such document unless otherwise indicated. Exhibits, Schedules, Annexes or Appendices to any document shall be deemed incorporated by reference in such document.
(i) References to any document, instrument or agreement (i) shall include all exhibits, schedules and other attachments thereto, (ii) shall include all documents, instruments or agreements issued or executed in replacement thereof, and (iii) shall mean such document, instrument or agreement, or replacement or predecessor thereto, as amended, modified and supplemented from time to time and in effect at any given time.
(j) References to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder.



Exhibit 1.2
(k) The words “hereof,” “herein” and “hereunder” and words of similar import when used in any document shall refer to such document as a whole and not to any particular provision of such document.
(l) This Agreement is the result of negotiations among, and has been reviewed by, the Partners with the advice of counsel to the extent deemed necessary by any Partner. Accordingly, this Agreement shall be deemed to be the product of all of the Partners, and no ambiguity shall be construed in favor of or against any Partner.
(m) All accounting terms not specifically defined in this Agreement shall be construed in accordance with generally accepted accounting principles in the United States of America, consistently applied.
(n) All references to currency, monetary values and dollars set forth in this Agreement shall mean United States (U.S.) dollars and all payments under this Agreement shall be made in United States dollars.
(o) The term “day” shall mean calendar day.
(p) Whenever an event or action is to be performed by a particular date or a period ends on a particular date, and the date in question falls on a day which is not a Business Day, the event or action shall be performed, or the period shall end, on the next succeeding Business Day.
(q) All references in this Agreement to any law shall be to such law as amended, supplemented, modified and replaced from time to time, and all rules and regulations promulgated thereunder.
(r) Wherever required by the context, references to a Fiscal Year shall refer to a portion thereof.
(s) Wherever a conflict exists between this Agreement and any other agreement, this Agreement shall control but solely to the extent of such conflict.
ARTICLE II
ORGANIZATIONAL MATTERS
2.1 Formation of Partnership. The Partnership was formed on November 5, 2021, pursuant to the Prior Agreement and registered pursuant to the statement under section 9 of the Cayman Act filed with the Registrar of Exempted Limited Partnerships of the Cayman Islands on November 5, 2021 (the "Certificate").
2.2 Limited Partnership Agreement. The Partners hereby execute this Agreement for the purpose of establishing and continuing the affairs of the Partnership and the conduct of its business in accordance with the provisions of the Cayman Act. The Partners hereby agree that during the term of the Partnership set forth in Section 2.8, the rights and obligations of the Partners with respect to the Partnership will be determined in accordance with the terms and conditions set forth in this Agreement and the Cayman Act. On any matter upon which this Agreement is silent, the Cayman Act shall control. No provision of this Agreement shall be in violation of the Cayman Act and to the extent any provision of this Agreement is in violation of the Cayman Act, such provision shall be void and of no effect to the extent of such violation without affecting the validity of the other provisions of this Agreement; provided, however, that where the Cayman Act provides that a provision of the Cayman Act shall apply “unless otherwise provided in a limited partnership agreement” or words of similar effect, the provisions of this Agreement shall in each instance control.
2.3 Name. The name of the Partnership continued hereby shall be “Waldencast Partners LP”. The General Partner in its sole discretion may change the name of the Partnership at any time and from time to time in accordance with the Cayman Act. Notification of any such change shall be given to all of the Partners. The Partnership’s business may be conducted under its name and/or any other name or names deemed advisable by the General Partner.
2.4 Admission of Partners in connection with Milk Transaction. The Milk Partners shall be admitted as Limited Partners in accordance with the terms of the Milk Transaction on the Effective Date upon such Milk Partners' execution of a counterpart of this Agreement. The General Partner shall enter the names of the Milk Partners



Exhibit 1.2
admitted in accordance with this Section 2.4 on the Register. Following the Effective Date, Persons subsequently admitted as Partners shall be admitted as provided herein.
2.5 General Powers; Purpose. The Partnership shall have authority to engage in any lawful business, purpose or activity permitted for exempted limited partnerships under the Cayman Act. The Partnership and the General Partner on its own behalf and/or on behalf of the Partnership shall possess and may exercise all of the powers and privileges granted by the Cayman Act or by any other law or by this Agreement, together with any powers incidental thereto, and may take any other action not prohibited under the Cayman Act or other Applicable Law, including such powers or privileges as are necessary or convenient to the conduct, promotion or attainment of the business, purposes or activities of the Partnership, except that the Partnership shall not undertake business with the public in the Cayman Islands other than so far as may be necessary or advisable for carrying on the business of the Partnership exterior to the Cayman Islands. Pubco shall not, and shall not cause nor permit any of its Subsidiaries to, directly or indirectly, take any actions that would cause the economic benefits and burdens of the business and operations of PubCo and/or its Subsidiaries to not be vested in the Partnership and its Subsidiaries. Subject to the immediately prior sentence, PubCo will be permitted to, and will be permitted to cause any of its Subsidiaries to, take actions in connection with (a) the ownership, acquisition and disposition of Common Units and other Equity Securities, (b) the management of the business and affairs of the Partnership and its Subsidiaries, (c) the operation of Pubco as a reporting company with class (or classes) of securities registered under Section 12 of the Exchange Act and listed on a securities exchange, (d) the offering, sale, syndication, private placement or public offering of Equity Securities or Indebtedness, in each case, subject to the terms of this Agreement, (e) financing or refinancing of any type related to the Partnership, its Subsidiaries or their assets or activities, in each case, subject to the terms of this Agreement and (f) such activities as are incidental to the foregoing; provided, further, that, Pubco may, in its sole and absolute discretion, from time to time hold or acquire assets in its own name or otherwise other than through the Partnership and its Subsidiaries so long as Pubco takes all necessary measures to ensure that the economic benefits and burdens of such assets are otherwise vested in the Partnership or its Subsidiaries, through assignment, mortgage loan or otherwise. Nothing contained herein shall be deemed to prohibit Pubco and its Subsidiaries from executing any guarantee of indebtedness of the Partnership or its Subsidiaries.
2.6 Partnership Action. Subject to compliance by the General Partner with the provisions of this Agreement and except as prohibited by Applicable Law, (i) the Partnership may, upon approval by the General Partner, enter into and perform any and all documents, agreements and instruments, all without any further act, vote or approval of any other Partner, and (ii) the General Partner may authorize any Person (including any Partner or its or their officers) to enter into and perform any documents on behalf of the Partnership.
2.7 Principal Office; Registered Office. The principal office of the Partnership shall be at 10 Bank Street, Suite 560, White Plains, NY 10606, or such other place as the General Partner may from time to time designate. The Partnership may maintain offices at such other place or places as the General Partner deems advisable. Notification of any such change shall be given to all of the Partners. The address of the registered office of the Partnership in Cayman Islands shall be at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, and the registered agent for service of process on the Partnership in Cayman Islands at such registered office shall be Maples Corporate Services Limited.
2.8 Term. The term of the Partnership commenced upon registration of the Partnership by the Registrar of Exempted Limited Partnerships of the Cayman Islands and shall continue in existence until dissolution thereof in accordance with the provisions of Article XIII.
2.9 Tax Treatment. The Partners intend that the Partnership shall be treated as a partnership that is a continuation (within the meaning of Section 708 of the Code) of Milk as a tax partnership for U.S. federal and applicable state or local income tax purposes. Each Partner and the Partnership shall file all tax returns and shall otherwise take all tax and financial reporting positions in a manner consistent with and actions necessary to obtain such treatment.
2.10 Foreign Qualification. The General Partner shall cause to be taken all actions as may be reasonably necessary to perfect and maintain the status of the Partnership as an exempted limited partnership or similar type of entity under the laws of the Cayman Islands or any other jurisdictions in which the Partnership engages in business.



Exhibit 1.2
2.11 Partnership Status. The Partners intend that the Partnership not be a joint venture, and that no Partner be a joint venturer of any other Partner by virtue of this Agreement for any purpose, and neither this Agreement nor any other document entered into by the Partners relating to the subject matter hereof shall be construed to suggest otherwise.
2.12 General Partner Activities. The General Partner shall devote such time and attention to the affairs of the Partnership as it deems necessary. Each Partner agrees that the General Partner and any member, manager or officer of the General Partner, may engage in or possess an interest in other business ventures or commercial dealings of every kind and description, independently or with others. The Partners expressly agree that neither the Partnership nor the Limited Partners shall have any rights in or to such other activities, or any profits derived therefrom. In particular, the General Partner may establish additional partnerships in the future, which may require the General Partner to allocate their time between partnerships.
2.13 Representations and Warranties by the Partners.
(a) Each Partner that is a natural person (including each Additional Partner or Substituted Partner as a condition to becoming an Additional Partner or a Substituted Partner) represents and warrants to, and covenants with, each other Partner that, as of the date upon which such Partner becomes a Partner (i) the consummation of the transactions contemplated by this Agreement to be performed by such Partner will not result in a breach or violation of, or a default under, any material agreement by which such Partner or any of such Partner’s property is bound, or any statute, regulation, order or other law to which such Partner is subject and (ii) this Agreement is binding upon, and enforceable against, such Partner in accordance with its terms.
(b) Each Partner that is not a natural person (including each Additional Partner or Substituted Partner as a condition to becoming an Additional Partner or a Substituted Partner) represents and warrants to, and covenants with, each other Partner that, as of the date upon which such Partner becomes a Partner (i) all transactions contemplated by this Agreement to be performed by it have been duly authorized by all necessary action, including that of its general partner(s), managing member(s), manager(s), member(s), committee(s), trustee(s), beneficiaries, directors, officers and/or shareholder(s) (as the case may be) as required, (ii) the consummation of such transactions shall not result in a breach or violation of, or a default under, its partnership or operating agreement, trust agreement, charter or bylaws (as the case may be), any material agreement by which such Partner or any of such Partner’s properties or any of its partners, members, beneficiaries, trustees or stockholders (as the case may be) is or are bound, or any statute, regulation, order or other law to which such Partner or any of its partners, members, trustees, beneficiaries or stockholders (as the case may be) is or are subject, and (iii) this Agreement is binding upon, and enforceable against, such Partner in accordance with its terms.
(c) PubCo represents and warrants to, and covenants with, each Partner that (i) all transactions contemplated by this Agreement to be performed by it have been duly authorized by all necessary action, including that of its directors and/or shareholders as required, (ii) the consummation of such transactions shall not result in a breach or violation of, or a default under, its charter or bylaws, any material agreement by which PubCo is bound, or any statute, regulation, order or other law to which PubCo is subject, and (iii) this Agreement is binding upon, and enforceable against, PubCo in accordance with its terms.
(d) Each Partner (including each Additional Partner or Substituted Partner as a condition to becoming an Additional Partner or Substituted Partner) represents and warrants that as of the date upon which such Partner becomes a Partner, it is an “accredited investor” as defined in Rule 501 promulgated under the Securities Act and represents, warrants and agrees that, as of the date upon which such Partner becomes a Partner, it has acquired and continues to hold its interest in the Partnership for its own account for investment purposes only and not for the purpose of, or with a view toward, the resale or distribution of all or any part thereof, and not with a view toward selling or otherwise distributing such interest or any part thereof at any particular time or under any predetermined circumstances. Each Partner further represents and warrants that, as of the date upon which such Partner becomes a Partner, it is a sophisticated investor, able and accustomed to handling sophisticated financial matters for itself, and
that it has a sufficiently high net worth that it does not anticipate a need for the funds that it has invested in the Partnership in what it understands to be a speculative and illiquid investment.



Exhibit 1.2
(e) The representations and warranties contained in Sections 2.13(a), (b), (c) and (d) shall survive the execution and delivery of this Agreement by each Partner (and, in the case of an Additional Partner or a Substituted Partner, the admission of such Additional Partner or Substituted Partner as a Limited Partner in the Partnership) and the termination, liquidation and dissolution of the Partnership.
(f) Each Partner (including each Additional Partner or Substituted Partner as a condition to becoming an Additional Partner or Substituted Partner) hereby acknowledges that, as of the date upon which such Partner becomes a Partner, no representations as to potential profit, cash flows, funds from operations or yield, if any, in respect of the Partnership or any Affiliate of PubCo have been made by any Partner or any employee or representative or Affiliate of any Partner, and that projections and any other information, including financial and descriptive information and documentation, that may have been in any manner submitted to such Partner shall not constitute any representation or warranty of any kind or nature, express or implied.
(g) Notwithstanding the foregoing, the General Partner may permit the modification of any of the representations and warranties contained in Sections 2.13(a), (b), (c) and (d) as applicable to any Partner (including any Additional Partner or Substituted Partner or any transferee of either, but excluding any Affiliate of PubCo) provided that such representations and warranties, as modified, shall be set forth in a separate writing addressed to the Partnership and the General Partner.
(h) Each Partner hereby represents and warrants and covenants to the Partnership and each other Partner as follows as of the date upon which such Partner becomes a Partner:
(i) Such Partner maintains its domicile or principal place of business at the address shown, and tax residence in the jurisdiction shown, on the Schedule of Partners with respect to such Partner, and such Partner is not merely transient or temporarily resident at such address.
(ii) Such Partner is aware that its partnership interest in the Partnership involve a substantial degree of risk of loss of such Partner’s entire investment and that there is no assurance of any income from such Partner’s investment.
(iii) As of the date upon which a Partner becomes a Partner, such Partner shall represent and warrant to the Partnership and each other Partner as to the total number of “partners” in the Partnership for purposes of Treasury Regulations Section 1.7704-1(h)(l)(ii) that such Partner represents. For purposes of this calculation, any entity that is a direct or indirect Partner in the Partnership that is a Pass-Through Entity, fifty percent (50%) or more of the asset value of which consists of Units, in each case, shall be treated as representing a number of “partners” in the Partnership for purposes of Treasury Regulations Section 1.7704-1(h)(l)(ii) equal to the number of beneficial owners (within the meaning of Treasury Regulations Section 1.7704-1(h)(3)) of such entity.
(iv) Such Partner has not obtained, nor will such Partner transfer or assign (other than pursuant to an Exchange), any of its Units (or any interest therein) or cause any of its Units (or any interest therein) to be marketed on or through an “established securities market” within the meaning of Section 7704(b)(1) of the Code, or a “secondary market,” or the substantial equivalent thereof, within the meaning of Section 7704(b)(2) of the Code, including an over-the counter market or an interdealer quotation system that regularly disseminates firm buy or sell quotations.
ARTICLE III
CAPITALIZATION; CAPITAL CONTRIBUTIONS
3.1 Capitalization.
(a) Each Partner shall hold Units, and the relative rights, privileges, preferences and obligations with respect to each Partner’s Units shall be determined under this Agreement and the Cayman Act based upon the number and the class of Units held by such Partner. The number and the class of Units held by each Partner shall be set forth in the books
and records of the Partnership. The Partnership shall maintain (as updated and amended from time to time in accordance with the terms of this Agreement and current as of the date set forth therein):



Exhibit 1.2
(i) a schedule which shall include: (1) the name and address of each Partner; (2) the date upon which a Person became a Partner; and (3) (if applicable), the date upon which such Person ceased to be a Partner in accordance with section 29 of the Cayman Act (the “Schedule of Partners”);
(ii) a schedule which shall include: (1) the aggregate number of and type of Units issued and outstanding held by each Partner; and (2) the amount and date of each Partner’s Capital Contributions with respect to such Partner’s Units, the Fair Market Value of any property other than cash contributed by each Partner with respect to such Partner’s Units (including, if applicable, a description and the amount of any liability assumed by the Partnership or to which contributed property is subject) and the amount and date of any repayment representing a return of the whole or any part of the contribution of any Partner in accordance with section 30 of the Cayman Act (the “Contribution Register”); and
(iii) a register of security interests of Units in accordance with section 31 of the Cayman Act (the “Security Interests Register” and, together with the Schedule of Partners and the Contribution Register, the “Register”).
The Schedule of Partners following the Holdco 1 Contribution, the consummation of the Milk Transaction and the redemption contemplated by Section 3.1(d) shall be as set out in Schedule I.
(b) Common Units. The Partnership shall, as of the Effective Date, have one authorized type of Units: Common Units. The Common Units shall have all the rights, privileges and obligations as are specifically provided for in this Agreement for Common Units, and as may otherwise be generally applicable to all classes of Units, unless such application is specifically limited to one or more other classes of Units.
(c) The Limited Partners shall have no right to vote on any matter, except as may be required under the Cayman Act. Any such vote shall be at a meeting of the Partners entitled to vote or in writing as provided herein.
(d) Immediately following the Effective Time, the Partnership redeemed for no consideration the limited partnership interest in the Partnership held by Holdco 1 as of the execution of this Agreement (such limited partnership interest being the limited partnership interest contributed by PubCo to the DRE Partner pursuant to the PubCo Contribution and then transferred to Holdco 1 by the DRE Partner as part of the Partner Transfer). For the avoidance of doubt, the redemption contemplated by this Section 3.1(d) shall not affect the limited partnership interest received by Holdco 1 pursuant to the Holdco 1 Contribution.
(e) Subject to the provisions of this Agreement, the General Partner in its sole discretion may establish and issue, from time to time in accordance with such procedures as the General Partner shall determine from time to time, additional Units, in one or more classes or series of Units, or other Partnership securities, at such prices, and with such designations, preferences and relative, participating, optional or other special rights, powers and duties (which may be senior to existing Units, classes and series of Units or other Partnership securities), as shall be determined by the General Partner without the approval of any Partner or any other Person who may acquire an interest in any of the Units, including (i) the right of such Units to share in profits and losses or items thereof; (ii) the right of such Units to share in Distributions; (iii) the rights of such Units upon winding up and subsequent dissolution of the Partnership; (iv) whether, and the terms and conditions upon which, the Partnership may or shall be required to redeem such Units (including sinking fund provisions); (v) whether such Units are issued with the privilege of conversion or exchange and, if so, the terms and conditions of such conversion or exchange; (vi) the terms and conditions upon which such Units will be issued, evidenced by certificates and assigned or transferred; (vii) the method for determining the Common Unit Percentage Interest, as to such Units; (viii) the terms and conditions of the issuance of such Units (including, without limitation, the amount and form of consideration, if any, to be received by the Partnership in respect thereof, the General Partner being expressly authorized, in its sole discretion, to cause the Partnership to issue such Units for less than Fair Market Value); and (ix) the right, if any, of the holder of such Units to vote on Partnership matters, including matters relating to the relative designations, preferences, rights, powers and duties of such Units.
(f) Subject to the provisions of this Agreement, the General Partner in its sole discretion, without the approval of any Partner or any other Person, is authorized (i) to issue (1) Units or other Partnership securities; (2) obligations, evidences of indebtedness or other securities or interests convertible or exchangeable into Units or other Partnership securities; or (3) warrants, options or other rights to purchase or otherwise acquire Units or other Partnership



Exhibit 1.2
securities, of any newly established class or any existing class to Partners or other Persons who may acquire an interest in the Partnership; (ii) to amend this Agreement and the Register to reflect the creation of any such new class, the issuance of Units or other Partnership securities of such class, and the admission of any Person as a Partner which has received Units or other Partnership securities; and (iii) to effect the combination, subdivision and/or reclassification of outstanding Units as may be necessary or appropriate to give economic effect to equity investments in the Partnership by the General Partner that are not accompanied by the issuance by the Partnership to the General Partner of additional Units and to update the books and records of the Partnership, including the Register, accordingly.
(g) All Units of a particular class shall have identical rights in all respects as all other Units of such class, except in each case as otherwise specified in this Agreement.
(h) The Partnership shall not, and the General Partner shall not cause the Partnership to, issue any Units if such issuance would result in the Partnership having more than ninety-five (95) partners, within the meaning of Treasury Regulations Section 1.7704-1(h) (determined taking into account the rules of Treasury Regulations Section 1.7704- 1(h)(3)); provided that, for such purposes, the Partnership and the General Partner shall be entitled to assume that each person who is a Partner immediately prior to the Effective Date is treated as a single partner within the meaning of Treasury Regulations Section 1.7704-1(h) (determined taking into account the rules of Treasury Regulations Section 1.7704-1(h)(3)), unless otherwise required by Applicable Law.
(i) All Units issued hereunder shall be uncertificated unless otherwise determined by the General Partner.
(j) Each Partner who is issued Units by the Partnership pursuant to the authority of the General Partner pursuant to Section 5.1 shall make the Capital Contributions to the Partnership determined by the General Partner pursuant to the authority of the General Partner pursuant to Section 5.1 in exchange for such Units.
(k) Each Limited Partner, to the extent having the right to consent thereto, by executing this Agreement, or a counterpart of this Agreement, hereby confirms, ratifies and approves the transactions contemplated by this Agreement and the other agreements and transactions referred to herein.
(l) For purposes of this Agreement, Units held by the Partnership or any of its Subsidiaries shall be deemed not to be outstanding.
(m) The Partnership may issue fractional Units, and all Units shall be rounded to the fourth decimal place. 3.2 New PubCo Issuances.
(a) Subject to Article XII and Section 3.2(b), if, at any time after the Effective Time, PubCo issues Class A ordinary shares or any other Equity Security of PubCo (other than Class B ordinary shares) or Holdco 1 issues Equity Securities, to any person other than Pubco or any of its Subsidiaries, (i) the Partnership shall concurrently issue to the Waldencast Limited Partner (1) an equal number of Common Units (if PubCo issues Class A ordinary shares) or (2) an equal number of such other Equity Securities of the Partnership corresponding to the Equity Securities issued by PubCo (if PubCo issues Equity Securities of PubCo other than Class A ordinary shares) or by Holdco 1 (if Holdco 1 issues Equity Securities), as applicable, and with the same rights to dividends and distributions (including distributions upon liquidation) and other economic rights as those of such Equity Securities of PubCo or its Subsidiary, as applicable, so issued and (ii) PubCo or Holdco 1, as applicable, shall concurrently contribute to the Partnership (indirectly through Holdco 1 and in exchange for shares in Waldencast Limited Partner, if applicable) the net proceeds or other property received by PubCo or Holdco 1, as applicable, if any, for such Class A ordinary shares or other Equity Security of PubCo or Holdco 1.
(b) Notwithstanding anything to the contrary contained in Section 3.2(a) or Section 3.2(c), this Section 3.2 shall not apply to (x) the issuance and distribution to holders of Class A ordinary shares of rights to purchase Equity Securities
of PubCo under a “poison pill” or similar shareholder rights plan (and upon exchange of Common Units for Class A ordinary shares, such Class A ordinary shares will be issued together with corresponding rights to purchase Equity Securities of PubCo under such plan) or (y) the issuance under PubCo’s employee benefit plans of any warrants, options, stock appreciation right, restricted stock, restricted stock units, performance based award or other rights to



Exhibit 1.2
acquire Equity Securities of PubCo or rights or property that may be converted into or settled in Equity Securities of PubCo, but shall in each of the foregoing cases apply to the issuance of Equity Securities of PubCo in connection with the exercise or settlement of such warrants, options, stock appreciation right, restricted stock units, performance based awards or the vesting of restricted stock (including as set forth in clause (c) below, as applicable) which shall be undertaken so as to comply with the provisions of Treasury Regulations Section 1.1032-3 and deemed to occur for U.S. federal (and applicable state and local) income tax purposes as provided therein.
(c) In the event any outstanding Equity Security of PubCo or Holdco1 is exercised or otherwise converted and, as a result, any Class A ordinary shares or other Equity Securities of PubCo or Holdco 1 are issued, (x) the corresponding Equity Security outstanding at the Partnership, if any, shall be similarly exercised or otherwise converted, if applicable, (y) an equivalent number of Common Units or equivalent Equity Securities of the Partnership shall be issued to PubCo or Holdco 1 (indirectly through the Waldencast Limited Partner, if applicable), as applicable, as required by the first sentence of Section 3.2(a), and (z) PubCo or Holdco 1, as applicable, shall concurrently contribute to the Partnership (indirectly through the Waldencast Limited Partner and in exchange for shares in the Waldencast Limited Partner, if applicable) the net proceeds received by PubCo or Holdco 1 from any such exercise or conversion; provided that if any such Class A ordinary shares or other Equity Securities of PubCo or Holdco 1 so issued are subject to vesting or forfeiture provisions, then the Common Units or Equity Securities of the Partnership, as applicable, issued by the Partnership to the Waldencast Limited Partner in connection therewith will be subject to vesting or forfeiture on the same basis as the corresponding Class A ordinary shares or Equity Securities of PubCo or Holdco 1, as applicable. If any such Class A ordinary shares or other Equity Securities of PubCo or Holdco 1 vest or are forfeited, then a corresponding number of the Common Units or Equity Securities of the Partnership, as applicable, issued by the Partnership therewith will automatically vest or be forfeited. Any cash or property held by PubCo, the General Partner, or the Partnership or on each other’s behalf in respect of dividends paid on restricted Class A ordinary shares or other Equity Securities of PubCo or Holdco 1 that fails to vest will be returned to the Partnership upon the forfeiture of such restricted Class A ordinary shares or other Equity Securities of PubCo or Holdco 1.
(d) If at any time PubCo issues one or more Class A ordinary shares in connection with the exercise of a PubCo warrant:
(i) PubCo shall, as soon as practicable after such exercise, make a capital contribution to the Waldencast Limited Partner in an amount equal to the exercise price paid to PubCo in connection with the exercise of the warrant, in exchange for shares in the Waldencast Limited Partner.
(ii) Immediately after the capital contribution described in Section 3.2(d)(i), the Waldencast Limited Partner shall make a capital contribution to the Partnership in an amount equal to the exercise price described in Section 3.2(d)(i).
(iii) Notwithstanding the amount of the capital contribution actually made pursuant to Section 3.2(d)(ii), the Waldencast Limited Partner will be deemed to have contributed to the Partnership as a Capital Contribution, in lieu of the capital contribution actually made and in consideration for additional Units, an amount equal to product of (A) the value of a Class A ordinary share as of the date of such exercise multiplied by (B) the number of Class A ordinary shares then being issued by PubCo in connection with the exercise of such warrant. The provisions of this Section 3.2(d)(iii) will be accounted for by the Partnership using principles applicable to Noncompensatory Options (including as provided for in Section 4.3(g)).
(iv) The Waldencast Limited Partner will receive in exchange for the Capital Contribution (as deemed made under Section 3.2(d)(iii)) a number of Units equal to the number of Class A ordinary shares issued upon exercise of such warrant.
(e) Notwithstanding anything in this Agreement to the contrary, PubCo shall have the right to elect to cause the Waldencast Limited Partner to (i) purchase from the Partnership additional Units for cash at a price determined in accordance with the method prescribed in this Agreement for Cash Exchange Payments, and in connection therewith (ii) effect a share split or share dividend to reflect its additional interest in the Partnership such that the actions described in this Section 3.2(e) taken together do not alter the relationship between the number of issued and outstanding PubCo shares and the number of Units held by the Waldencast Limited Partner. For the avoidance of



Exhibit 1.2
doubt, actions undertaken pursuant to this Section 3.2(e) shall not give rise to an adjustment to the Exchange Rate under Section 12.5 or otherwise.
3.3 PubCo Indebtedness Issuance. If at any time PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) issues Indebtedness, PubCo or such Subsidiary shall transfer to the Partnership (indirectly through the Waldencast Limited Partner and in exchange for shares in the Waldencast Limited Partner) the net proceeds received by PubCo or such Subsidiary, as applicable, in exchange for such Indebtedness in a manner that directly or indirectly burdens the Partnership with the repayment of the Indebtedness; provided that if PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) is unable to transfer to the Partnership (indirectly through the Waldencast Limited Partner) the net proceeds received by PubCo or such Subsidiary, as applicable, in exchange for such Indebtedness on an equivalent basis because of restrictions in any debt instrument of PubCo, the General Partner, the Partnership or any of their Subsidiaries then, notwithstanding Section 3.2, the General Partner may in good faith implement an economically equivalent alternative arrangement in connection with the transfer of net proceeds to the Partnership using non-participating preferred Equity Securities of the Partnership; provided that such alternative arrangement shall not have any non de minimis adverse tax consequences to any Partner.
3.4 New Partnership Issuances. Except pursuant to Article XII, (a) the Partnership may not issue any additional Units to PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) unless (i) substantially simultaneously therewith PubCo or such Subsidiary issues or transfers an equal number of newly issued Class A ordinary shares (or relevant Equity Security of PubCo or such Subsidiary) to another Person or Persons, and (ii) such issuance is in accordance with Section 3.2, and (b) the Partnership may not issue any other Equity Securities of the Partnership to PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) unless (i) substantially simultaneously therewith PubCo or such Subsidiary issues or transfers an equal number of newly issued Equity Securities of PubCo or such Subsidiary with substantially the same rights to dividends and distributions (including distributions upon liquidation) and other economic rights as those of such Equity Securities of the Partnership to another Person or Persons, and (ii) such issuance is in accordance with Section 3.2.
3.5 Repurchases and Redemptions.
(a) Neither PubCo nor any of its Subsidiaries (other than the Partnership and its Subsidiaries) may redeem, repurchase or otherwise acquire (A) Class A ordinary shares pursuant to a Board approved repurchase plan or program (or otherwise in connection with a transaction approved by the Board) unless substantially simultaneously therewith the Partnership redeems, repurchases or otherwise acquires from PubCo or such Subsidiary an equal number of Common Units for the same price per security, if any, or (B) any other Equity Securities of PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) pursuant to a Board approved repurchase plan or program (or otherwise in connection with a transaction approved by the Board) unless substantially simultaneously therewith the Partnership redeems, repurchases or otherwise acquires from PubCo or such Subsidiary an equal number of the corresponding class or series of Equity Securities of the Partnership with substantially the same rights to dividends and distributions (including distributions upon liquidation) and other economic rights as those of such Equity Securities of PubCo or such Subsidiary for the same price per security, if any.
(b) The Partnership may not redeem, repurchase or otherwise acquire (x) any Common Units from PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) unless substantially simultaneously PubCo or such Subsidiary redeems, repurchases or otherwise acquires pursuant to a Board approved repurchase plan or program (or otherwise in connection with a transaction approved by the Board) an equal number of Class A ordinary shares for the same price per security from holders thereof or (y) any other Equity Securities of the Partnership from PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) unless substantially simultaneously PubCo or such Subsidiary redeems, repurchases or otherwise acquires pursuant to a Board approved repurchase plan or program (or otherwise in connection with a transaction approved by the Board) an equal number of Equity Securities of PubCo (or such Subsidiary) of a corresponding class or series with substantially the same rights to dividends and distributions (including distributions upon liquidation) and other economic rights as those of such Equity Securities of PubCo or such Subsidiary for the same price per security from holders thereof.
(c) Notwithstanding the foregoing clauses (a) and (b) of this Section 3.5, to the extent that any consideration payable by PubCo in connection with the redemption, repurchase or acquisition of any Class A ordinary shares or other Equity Securities of PubCo or any of its Subsidiaries (other than the Partnership and its Subsidiaries) consists (in



Exhibit 1.2
whole or in part) of Class A ordinary shares or such other Equity Securities of PubCo (including in connection with the cashless exercise of an option or warrant (or other convertible right or security)) other than under PubCo’s employee benefit plans for which there are no corresponding Common Units or other Equity Securities of the Partnership, the redemption, repurchase or acquisition of the corresponding Common Units or other Equity Securities of the Partnership shall be effectuated in an equivalent manner.
3.6 Equity Subdivisions and Combinations.
(a) The Partnership shall not in any manner effect any subdivision (by any equity split, equity distribution, reclassification, recapitalization or otherwise) or combination (by reverse equity split, reclassification, recapitalization or otherwise) of the outstanding Units or other Equity Securities of the Partnership unless accompanied by an identical subdivision or combination, as applicable, of the outstanding Class A ordinary shares or other related class or series of Equity Security of PubCo, with corresponding changes made with respect to any other exchangeable or convertible Equity Securities of the Partnership and PubCo.
(b) Except in accordance with Section 12.5, PubCo shall not in any manner effect any subdivision (by any equity split, equity distribution, reclassification, recapitalization or otherwise) or combination (by reverse equity split, reclassification, recapitalization or otherwise) of the outstanding Class A ordinary shares or any other class or series of Equity Security of PubCo, unless accompanied by an identical subdivision or combination, as applicable, of the outstanding Units or other related class or series of Equity Security of the Partnership, with corresponding changes made with respect to any applicable exchangeable or convertible Equity Securities of the Partnership and PubCo.
3.7 General Authority. For the avoidance of doubt, but subject to Sections 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6, the Partnership and the General Partner shall be permitted to undertake all actions, including any issuance, redemption, reclassification, distribution, division or recapitalization, with respect to the Units to maintain at all times a one-to one ratio between (i) the number of Common Units owned by PubCo, directly or indirectly, and the number of outstanding Class A ordinary shares, and (ii) the number of outstanding Class B ordinary shares held by any Person (other than PubCo) and the number of Common Units held by such Person disregarding, for purposes of maintaining the one-to-one ratios in clause (i), (A) options, rights or securities of PubCo issued under any plan involving the issuance of any Equity Securities of PubCo that are convertible into or exercisable or exchangeable for Class A ordinary shares, (B) treasury shares, or (C) preferred shares or other debt or equity securities (including warrants, options or rights) issued by PubCo that are convertible into or exercisable or exchangeable for Class A ordinary shares (but in each case prior to such conversion or exchange).
3.8 Specific Authority. For the avoidance of doubt, if at any time the General Partner determines that:
(a) any debt instrument of PubCo, the General Partner, the Partnership, or any of their Subsidiaries does not permit PubCo, the Waldencast Limited Partner, the General Partner or the Partnership to comply with Sections 3.2, 3.3, 3.4 or 3.5 in connection with the issuance, exercise, conversion, redemption or repurchase of any Class A ordinary shares or other Equity Securities of PubCo or any of its Subsidiaries, or any Units or Equity Securities of the Partnership; or
(b) compliance by PubCo, the General Partner, the Partnership or any of their Subsidiaries with any of the provisions of Sections 3.2, 3.3, 3.4 or 3.5 would give rise to a material tax liability or tax consequence for PubCo, the Waldencast Limited Partner, the General Partner, the Partnership or any of their Subsidiaries, then the General Partner may in good faith implement an economically equivalent alternative arrangement without complying with such provisions; provided that such alternative arrangement shall not have any non-de-minimis adverse tax consequences to any Partner.
3.9 Capital Contributions. From and after the Effective Date, no Partner shall have any obligation to the Partnership, to any other Partner, or to any creditor of the Partnership to make any further Capital Contribution, except as expressly provided herein.
3.10 Capital Accounts.



Exhibit 1.2
(a) Maintenance of Capital Accounts. The Partnership shall establish and maintain a separate capital account (each, a “Capital Account”) for each Limited Partner on the books of the Partnership consistent with the following provisions:
(i) Each Limited Partner listed on the Schedule of Partners has a Capital Account balance as of the date hereof equal to such Limited Partner’s Capital Account balance as of the Effective Time, as set forth on the Schedule of Partners. The General Partner shall amend the Schedule of Partners as of the Effective Date and from time to time to reflect adjustments to the Limited Partners’ Capital Accounts made in accordance with Sections 3.10(a)(ii), (a)(iii), (a)(iv), (e), and otherwise.
(ii) To each Limited Partner’s Capital Account there will be credited: (A) such Limited Partner’s Capital Contributions, (B) such Limited Partner’s Distributive Share of Net Profit and any item in the nature of income or gain that is allocated pursuant to Section 4.2, and (C) the amount of any Partnership liabilities assumed by such Limited Partner or that are secured by any Property distributed to such Limited Partner.
(iii) To each Limited Partner’s Capital Account there will be debited: (A) the amount of money and the Book Value of any Property distributed to such Limited Partner pursuant to any provision of this Agreement, (B) such Limited Partner’s Distributive Share of Net Loss and any items in the nature of expenses or losses that are allocated to such Limited Partner pursuant to Section 4.2, and (C) the amount of any liabilities of such Limited Partner assumed by the Partnership or that are secured by any Property contributed by such Limited Partner to the Partnership.
(iv) In determining the amount of any liability for purposes of paragraphs (ii) and (iii) above, there will be taken into account Section 752(c) of the Code and any other applicable provisions of the Code and the Treasury Regulations.
(v) For purposes of applying the rules of this Section 3.10, at the time the General Partner contributes any portion of the net proceeds of the Transactions, the PIPE Investment or the Forward Purchase Transaction to the Partnership, to the extent permitted by Applicable Law, (A) the General Partner will be treated as making a Capital Contribution to the Partnership in an amount equal to the applicable portion of the gross proceeds received by PubCo pursuant to the Transactions (including the Trust Account), the PIPE Investment and the Forward Purchase Transaction and (B) the Partnership will be treated as having paid the fees, costs, and expenses accrued with respect to the Transactions, the PIPE Investment and the Forward Purchase Transaction (as applicable) out of the proceeds received in accordance therewith.
The foregoing provisions and the other provisions of this Agreement relating to the maintenance of Capital Accounts are intended to comply with Treasury Regulations Sections 1.704-1 and 1.704-2, and will be interpreted and applied in a manner consistent therewith. In the event that the General Partner reasonably determines based on the advice of a tax return preparer or tax counsel of recognized national standing that it is necessary to modify the manner in which the Capital Accounts or any debits or credits thereto are maintained (including debits or credits relating to liabilities that are secured by contributed or distributed Property or that are assumed by the Partnership or the Limited Partners), the General Partner may make such modification so long as such modification will not have any non-de-minimis adverse tax consequences to the Limited Partners or non-de-minimis adverse effect on the Limited Partners’ economic entitlements under this agreement (including the amounts distributed to any Limited Partner pursuant to Article XIII upon the dissolution of the Partnership). The General Partner also shall (i) make any adjustments that are necessary or appropriate to maintain equality between Capital Accounts of the Limited Partners and the amount of capital reflected on the Partnership’s balance sheet, as computed for book purposes, in accordance with Treasury Regulations Section 1.704-1(b)(2)(iv)(g) while taking into consideration the principles applicable to Noncompensatory Options, and (ii) make any appropriate modifications in the event unanticipated events might otherwise cause this Agreement not to comply with Treasury Regulations Sections 1.704-1 or 1.704-2.
(b) No Right of Partition. No Limited Partner shall have the right to seek or obtain partition by court decree or operation of law of any property of the Partnership or any of its Subsidiaries or the right to own or use particular or individual assets of the Partnership or any of its Subsidiaries, or, except as expressly contemplated by this Agreement, be entitled to Distributions of specific assets of the Partnership or any of its Subsidiaries.



Exhibit 1.2
(c) Succession to Capital Accounts. In the event any Person becomes a Substitute Partner in accordance with the provisions of this Agreement, such Substitute Partner will succeed to the Capital Account of the former Limited Partner to the extent such Capital Account relates to the Units Transferred.
(d) Adjustments of Capital Accounts. The Partnership shall revalue the Capital Accounts of the Limited Partners in accordance with Treasury Regulations Section 1.704-1(b)(2)(iv)(f) (a “Revaluation”) at the following times:
(i) immediately prior to a Capital Contribution of more than a de minimis amount of money or other Property to the Partnership by a new or existing Limited Partner as consideration for one or more Units;
(ii) immediately prior to a Distribution by the Partnership to a Limited Partner of more than a de minimis amount of property of the Partnership in respect of one or more Units;
(iii) upon the issuance by the Partnership of Units as consideration for the provision of services to or for the benefit of the Partnership or a subsidiary of the Partnership by an existing Limited Partner or a new Limited Partner acting in a “partner” capacity or “in anticipation of becoming a partner” (as described in Treasury Regulations Section 1.704- 1(b)(2)(iv)(f)(5)(iii));
(iv) upon the liquidation of the Partnership within the meaning of Treasury Regulations Section 1.704-1(b)(2)(ii)(g);
(v) immediately prior to the issuance by the partnership of a Noncompensatory Option (other than an option for a de minimis partnership interest);
(vi) upon the acquisition of an interest in the Partnership upon the exercise of a Noncompensatory Option in accordance with Treasury Regulations Section 1.704-1(b)(2)(iv)(s) (in which case the adjustments will occur as of immediately after such exercise);
(vii) upon the purchase of a Unit by the Waldencast Limited Partner pursuant to Section 3.2(d) in connection with the exercise of a corresponding PubCo warrant for a Class A ordinary share in accordance with principles similar to those set forth in Treasury Regulations Section 1.704-1(b)(2)(iv)(s) (in which case the adjustments will occur as of immediately after such purchase or issuance); and
(viii) at such other times as the General Partner reasonably determines in good faith to be necessary or advisable in order to comply with Treasury Regulations Sections 1.704-1(b) and 1.704-2; provided, however, that (I) adjustments described above other than in clause (iv) above will be made only if the General Partner reasonably determines that such adjustments are necessary or appropriate to reflect the relative economic interest of the Limited Partners and (II) so long as any Noncompensatory Option is outstanding, the adjustment of Book Values will take into account Treasury Regulations Section 1.704-1(b)(2)(iv)(h)(2).
(e) No Limited Partner shall be entitled to withdraw capital or receive Distributions except as specifically provided herein. A Limited Partner shall have no obligation to the Partnership, to any other Limited Partner or to any creditor of the Partnership to restore any negative balance in the Capital Account of such Limited Partner. Except as expressly provided elsewhere herein, no interest will be paid on the balance in any Limited Partner’s Capital Account.
(f) Whenever it is necessary for purposes of this Agreement to determine a Limited Partner’s Capital Account on a per Unit basis, such amount will be determined by dividing the Capital Account of such Limited Partner attributable to the applicable class of Units held of record by such Limited Partner by the number of Units of such class held of record by such Limited Partner.
(g) Notwithstanding anything to the contrary in this Article III but subject to the application of this Section 3.10, it is intended that each Limited Partner’s Capital Account per Unit amount be equal to each of the other Limited Partners’ Capital Account per Unit amount. If at any time there is a difference between a Limited Partner’s Capital Account per Unit amount and the other Limited Partners’ Capital Accounts per Unit amount, then the Partnership shall make



Exhibit 1.2
appropriate adjustments with respect to the Limited Partners’ Capital Accounts to eliminate or minimize such difference.
3.11 Negative Capital Accounts. No Partner shall be required to pay to any other Partner or the Partnership any deficit or negative balance which may exist from time to time in such Partner’s Capital Account (including upon and after dissolution of the Partnership).
3.12 No Withdrawal. No Person shall be entitled to withdraw any part of such Person’s Capital Contribution or Capital Account or to receive any Distribution from the Partnership, except as expressly provided herein.
3.13 Loans From Partners. Loans by Partners to the Partnership shall not be considered Capital Contributions. If any Partner shall advance funds to the Partnership in excess of the amounts required hereunder to be contributed by such Partner to the capital of the Partnership, the making of such advances shall not result in any increase in the amount of the Capital Account of such Partner. The amount of any such advances shall be a debt of the Partnership to such Partner and shall be payable or collectible in accordance with the terms and conditions upon which such advances are made.

ARTICLE IV
DISTRIBUTIONS AND ALLOCATIONS
4.1 Distributions.
(a) Distributions Generally. The General Partner may, subject to (i) any restrictions contained in the financing agreements to which the Partnership or any of its Subsidiaries is a party, (ii) having immediately available cash for Distribution, and (iii) any other restrictions set forth in this Agreement, make Distributions at any time and from time to time. Notwithstanding any other provision of this Agreement to the contrary, no Distribution, Tax Distribution or other payment in respect of Units shall be required to be made to any Partner if, and to the extent that, such Distribution, Tax Distribution or other payment in respect of Units would not be permitted under the Cayman Act or other Applicable Law or applicable financing agreement.
(b) Operating Distributions. All Distributions by the Partnership other than those made in connection with a Liquidity Event pursuant to Section 4.1(c), shall be made or allocated to holders of Common Units pro rata based on each such holder’s Common Unit Percentage Interest (such allocation being the holder’s “Distributive Share”).
(c) Distributions in Connection with a Liquidity Event. Subject to Section 4.1(d) with respect to Tax Distributions, all Distributions by the Partnership, and all proceeds (whether received by the Partnership or directly by the Partners) in connection with any Liquidity Event, shall be made or allocated among the holders of Common Units pro rata based on each such holder’s Common Unit Percentage Interest (such allocation being the holder’s Distributive Share).
(d) Tax Distributions.
(i) On or before March 31 of each Taxable Year (or the corresponding date of any Taxable Year that is not the calendar year), the Partnership shall make Distributions (“Tax Distributions”) among the holders of Common Units on a pro rata basis so that each holder receives an amount of cash that is no less than: (a) the highest applicable federal, state and non-U.S. individual or corporate marginal tax rate pertaining to the type of income being taxed on any Partner (i.e., the same rate shall be applied to each Partner) multiplied by the excess of: (i) the net taxable income and gain allocated to such person for federal income tax purposes in the Partnership income tax return filed or to be filed with respect to such immediately preceding Taxable Year (including any forward and reverse Section 704(c) amounts but ignoring adjustments pursuant to Section 743 of the Code) and any inclusions by such person under Section 1293 of the Code with respect to any entity in which the Partnership directly or indirectly holds an interest, over (ii) any net losses, deductions and credits allocated to such person from the Partnership for federal income tax purposes in prior Taxable Years to the extent such items have not been previously taken into account in calculating Tax Distributions and are reasonably expected to be of a character that would permit such loss, deduction or credit to be deductible against the income applicable to the Taxable Year in question, minus (b) any prior



Exhibit 1.2
discretionary Distributions or Tax Distributions made or deemed made to such person with respect to such immediately preceding Taxable Year, including any Distributions made prior to March 31 of the current Taxable Year. The Partnership shall also make such Distributions on an estimated basis five days before each due date for the payment of estimated federal income taxes
by an individual, and if such estimated distributions exceed the actual amount of Tax Distributions required on March 31, such Partner receiving excess Distributions shall promptly repay such excess to the Partnership, net of any taxes payable with respect to such amount. Any Tax Distributions shall be treated in all respects as advances of amounts otherwise distributable pursuant to this Agreement.
(ii) If the amount of any Tax Distribution is reduced as a result of any prior Distribution taken into account under clause (b) of Section 4.1(d)(i), the amount of such prior Distribution shall be treated as a Tax Distribution for purposes of this Article IV and not a Distribution under Section 4.1(b) and (c) regardless of whether such Distribution was labeled as such.
(iii) Notwithstanding anything to the contrary herein, no Tax Distributions will be required to be made with respect to items arising with respect to any Covered Transaction, although any unpaid Tax Distributions with respect to any Taxable Year, or portion thereof, ending before a Covered Transaction shall continue to be required to be paid prior to any Distributions being made under Sections 4.1(b) and (c).
(iv) The General Partner will undertake commercially reasonable efforts (1) to prevent any restrictions in financing agreements to which the Partnership or any of its subsidiaries that are Pass-Through Entities will become party after the Effective Date and (2) to permit such entities to make Tax Distributions as provided herein. As of the Effective Time, the Partnership and its subsidiaries that are Pass-Through Entities will not be subject to restrictions contained in financing agreements regarding distributions.
(e) Each Distribution pursuant to Sections 4.1(b) and (c) and each Distribution pursuant to Section 4.1(d) shall be made to the Persons shown on the Partnership’s books and records as Partners as of the date of such Distribution; provided, however, that any Transferor and Transferee of Units may mutually agree as to which of them should receive payment of any Distribution under Section 4.1(d).
(f) For purposes of this Section 4.1, any non-cash Partnership assets distributed in kind to any Partners shall be valued at their Fair Market Value in accordance with Article XIV. If cash and property in kind are to be distributed simultaneously, then the Partnership shall distribute such cash and property in kind in the same proportion to each Limited Partner entitled to participate in such Distribution.
(g) Assignment. Each Limited Partner and its Permitted Transferees shall have the right to assign to any Transferee of Units, pursuant to a Transfer made in compliance with this Agreement, the right to receive any portion of the amounts distributable or otherwise payable to such Limited Partner pursuant to Section 4.1(b).
4.2 Allocations of Net Profit and Net Loss. Except as otherwise provided in this Agreement, including after giving effect to Section 4.3, Net Profits and Net Losses (and, to the extent necessary, individual items of income, gain or loss or deduction of the Partnership) shall be allocated among the Partners in a manner such that, after such allocations have been made, the sum of (i) the balance of each Partner’s Capital Account (which may be a positive, negative or zero balance) (ii) such Partner’s share of Partnership Minimum Gain (as determined according to Treasury Regulations Section 1.704-2(g)) and (iii) such Partner’s Partner Nonrecourse Debt Minimum Gain (as defined in Treasury Regulations Section 1.704-2(i)(3)) will equal the amount that would be distributed to such Partner, determined as if (a) the Partnership were to sell all of its assets for their then Book Values; and (b) the net proceeds thereof were distributed to the Partners pursuant to the terms of this Agreement (after the payment of all actual Indebtedness of the Partnership, and any other liabilities related to the Partnership’s assets, limited, in the case of nonrecourse liabilities, to the Book Value of the collateral securing or otherwise available to satisfy such liabilities). Notwithstanding the foregoing, the General Partner may adjust the allocations to the Partners pursuant to this Article in its discretion so as to conform as nearly as practicable with the related distributions and expected distributions pursuant to this Agreement, and the General Partner may take into account whatever facts and circumstances the General Partner determines are relevant in exercising such discretion (including unrealized gains or losses or expected accruals of preferred return).



Exhibit 1.2
4.3 Special Allocations. Notwithstanding any other provision in this Article IV:
(a) Minimum Gain Chargeback. If there is a net decrease in Partnership Minimum Gain or Partner Nonrecourse Debt Minimum Gain (determined in accordance with the principles of Treasury Regulations Sections 1.704-2(d) and 1.704-
2(i)) during any Taxable Year, the Partners shall be specially allocated items of Partnership income and gain for such year (and, if necessary, subsequent years) in an amount equal to their respective shares of such net decrease during such year, determined pursuant to Treasury Regulations Sections 1.704-2(g) and 1.704-2(i)(5). The items to be so allocated shall be determined in accordance with Treasury Regulations Section 1.704-2(f). This Section 4.3(a) is intended to comply with the minimum gain chargeback requirements in such Treasury Regulations Sections and shall be interpreted consistently therewith; including that no chargeback shall be required to the extent of the exceptions provided in Treasury Regulations Sections 1.704-2(f) and 1.704-2(i)(4).
(b) Qualified Income Offset. If any Partner unexpectedly receives any adjustments, allocations, or distributions described in Treasury Regulations Section 1.704-1(b)(2)(ii)(d)(4), (5) or (6), items of Partnership income and gain shall be specially allocated to such Partner in an amount and manner sufficient to eliminate the deficit balance in such Partner’s Adjusted Capital Account Balance created by such adjustments, allocations or distributions as promptly as possible; provided that an allocation pursuant to this Section 4.3(b) shall be made only to the extent that a Partner would have a deficit Adjusted Capital Account Balance in excess of such sum after all other allocations provided for in this Article IV have been tentatively made as if this Section 4.3(b) were not in this Agreement. This Section 4.3(b) is intended to comply with the “qualified income offset” requirement of the Code and shall be interpreted consistently therewith.
(c) Gross Income Allocation. If any Partner has a deficit Capital Account at the end of any taxable year which is in excess of the sum of (i) the amount such Partner is obligated to restore, if any, pursuant to any provision of this Agreement, and (ii) the amount such Partner is deemed to be obligated to restore pursuant to the penultimate sentences of Treasury Regulations Sections 1.704-2(g)(1) and 1.704-2(i)(5), each such Partner shall be specially allocated items of Partnership income and gain in the amount of such excess as quickly as possible; provided that an allocation pursuant to this Section 4.3(c) shall be made only if and to the extent that a Partner would have a deficit Capital Account in excess of such sum after all other allocations provided for in this Article IV have been tentatively made as if Section 4.3(b) and this Section 4.3(c) were not in this Agreement.
(d) Nonrecourse Deductions. Nonrecourse Deductions shall be allocated to the Partners holding Common Units in accordance with their respective Common Unit Percentage Interest.
(e) Partner Nonrecourse Deductions. Partner Nonrecourse Deductions for any taxable period shall be allocated to the Partner who bears the economic risk of loss with respect to the liability to which such Partner Nonrecourse Deductions are attributable in accordance with Treasury Regulations Section 1.704-2(j).
(f) Ameliorative Allocations. Any special allocations of income or gain pursuant to Sections 4.3(a) or 4.3(c) hereof shall be taken into account in computing subsequent allocations pursuant to Section 4.2 and this Section 4.3(f), so that the net amount of any items so allocated and all other items allocated to each Partner shall, to the extent possible, be equal to the net amount that would have been allocated to each Partner if such allocations pursuant to Sections 4.3(b) or 4.3(c) had not occurred.
(g) Noncompensatory Options and Similar Interests. Upon the exercise of a Noncompensatory Option or the purchase of a Unit by Holdco 1 pursuant to Section 3.2(d) in connection with the exercise of a corresponding PubCo warrant for a Class A ordinary share, the Partnership shall comply with the allocation provisions set forth in Treasury Regulations Sections 1.704-1(b)(2)(iv)(s) and 1.704-1(b)(4)(x) (including making any required “corrective” allocations in accordance with the Treasury Regulations), in each case in the manner determined by the General Partner in its sole discretion. The Partnership shall also comply with the provisions set forth in Treasury Regulations Section 1.704-1(b)(2)(iv)(h)(2) in the manner determined by the General Partner in its sole discretion. To the maximum extent possible, allocations pursuant to this Section 4.3(g) will be made with Mark-to-Market Gain. This Section 4.3(g) is intended to comply with Section 1.704-1(b)(2)(iv)(s)(4).



Exhibit 1.2
(h) Section 754 Adjustments. To the extent an adjustment to the adjusted tax basis of any Partnership asset pursuant to Sections 734(b) or 743(b) of the Code is required pursuant to Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(4) to be taken into account in determining Capital Accounts as a result of a distribution other than in liquidation of a Partner’s interest in the Partnership or as a result of a Transfer of a Partner’s interest in the Partnership, as the case may be, the amount of such adjustment will be treated as an item of gain (if the adjustment increases the basis of such asset) or loss (if the adjustment decreases the basis of such asset) from the disposition of the asset and will be taken
into account for purposes of computing Net Profit or Net Loss. To the extent an adjustment to the adjusted tax basis of any Partnership asset pursuant to Sections 734(b) or 743(b) of the Code is required, pursuant to Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(2) or Section 1.704-1(b)(2)(iv)(m)(4), to be taken into account in determining Capital Accounts as the result of a distribution to a Partner in complete liquidation of such Partner’s interest in the Partnership, the amount of such adjustment to Capital Accounts will be treated as an item of gain (if the adjustment increases the basis of the asset) or loss (if the adjustment decreases such basis) and such gain or loss will be specially allocated to such Partners in accordance with their interests in the Partnership in the event Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(2) applies, or to the Partner to whom such distribution was made in the event Treasury Regulations Section 1.704-1(b)(2)(iv)(m)(4) applies.
4.4 Tax Allocations.
(a) Except as provided in Sections 4.4(b), (c) and (d), Net Profits and Net Losses (and, to the extent necessary, items of income, gains, losses, deductions and credits) of the Partnership will be allocated, for U.S. federal, state and local income tax purposes, among the holders of Units in accordance with the allocation of such income, gains, losses, deductions and credits among the holders of Units for book purposes. Notwithstanding the foregoing, the General Partner will have the power to make such allocations for U.S. federal, state, and local income tax purposes as the General Partner reasonably determines may be necessary to maintain “substantial economic effect” or to ensure that such allocations are in accordance with each “partner’s interest in the partnership,” in each case within the meaning of Code Section 704(b) and the Treasury Regulations promulgated thereunder. Such allocations shall be made in accordance with the method chosen by the General Partner under Treasury Regulations Section 1.704-3 and shall be subject to Section 4.4(b).
(b) Income, gain, loss and deduction with respect to any Section 704(c) Property shall, solely for U.S. federal, state and local income tax purposes, be allocated among the Partners so as to take account of any variation between the adjusted basis of such property to the Partnership for U.S. federal income tax purposes and its Book Value pursuant to the “traditional method” within the meaning of Treasury Regulations Section 1.704-3(b), unless otherwise determined by the General Partner; provided that the General Partner shall not elect to use any method other than the “traditional method” with respect to assets held directly or indirectly by the Partnership that were, immediately prior to the Effective Date, held by Milk and the subsidiaries of Milk. Any elections or decisions relating to allocations under this Section 4.4(b) shall be determined by the General Partner.
(c) Allocations of tax credits, tax credit recapture, and any items related thereto shall be allocated to the holders of Units according to their interests in such items as determined by the General Partner taking into account the principles of Treasury Regulations Section 1.704-1(b)(4)(ii).
(d) Allocations pursuant to this Section 4.4 are solely for purposes of federal, state and local taxes and shall not affect, or in any way be taken into account in computing, any holder’s Capital Account or share of book income, gain, loss or deduction, Distributions or other Partnership items pursuant to any provision of this Agreement.
(e) The Limited Partners acknowledge and are aware of the income tax consequences of the allocations made pursuant to this Section 4.4 and, except as may otherwise be required by Applicable Law or regulatory requirements, hereby agree to be bound by the provisions of this Section 4.4 in reporting their shares of Partnership income, gain, loss, deduction and credit for federal, state and local income tax purposes.
4.5 Withholding Taxes.



Exhibit 1.2
(a) If requested by the General Partner, each Limited Partner shall, if able to do so, deliver to the Partnership: (A) any certificate or form (e.g., an IRS W-9) that the Partnership may reasonably request with respect to any U.S. federal, state, local, non-U.S. or other laws; and/or (B) any other form or instrument reasonably requested by the Partnership relating to any Limited Partner’s status under such law. In the event that a Limited Partner fails or is unable to deliver to the Partnership a certificate or form described in clause (C) of this clause (a), the Partnership may withhold amounts from such Limited Partner in accordance with Section 4.5(b).
(b) The Partnership shall withhold taxes from distributions to, and allocations among, the Partners to the extent required by Applicable Law (including backup withholding and any tax payment made by the Partnership pursuant to Section 6225 of the Code that is attributable to such Limited Partner). Except as otherwise provided in this Section 4.5, any amount so withheld by the Partnership with regard to a Partner shall be treated for purposes of this Agreement as an amount distributed to such Partner pursuant to Section 4.1(b) or Section 4.1(c), as appropriate (a “Withholding Payment”). An amount shall be considered withheld by the Partnership if, and at the time, remitted to a Governmental Entity without regard to whether such remittance occurs at the same time as the distribution or allocation to which it relates; provided, however, that an amount withheld from a specific distribution or designated by the General Partner as withheld from a specific allocation shall be treated as if distributed at the time such distribution or allocation occurs.
(c) Each Partner hereby agrees to indemnify the Partnership and the other Partners for any liability they may incur for failure to properly withhold taxes in respect of such Partner. Moreover, each Partner hereby agrees that neither the Partnership nor any other Partner shall be liable to such Partner for any excess taxes withheld in respect of such Partner’s Units and that, in the event of over-withholding, a Partner’s sole recourse shall be to apply for a refund from the appropriate governmental authority.
(d) If it is anticipated that at the due date of the Partnership’s withholding obligation the Partner’s share of cash distributions or other amounts due is less than the amount of the Withholding Payment, the Partner with respect to which the withholding obligation applies shall pay to the Partnership the amount of such shortfall within thirty (30) days after notice by the Partnership. If a Partner fails to make the required payment when due hereunder, and the Partnership nevertheless pays the withholding, in addition to the Partnership’s remedies for breach of this Agreement, the amount paid shall be deemed a recourse loan from the Partnership to such Partner bearing interest at an interest rate per annum equal to the Base Rate plus 3.0%, and the Partnership shall apply all distributions or payments that would otherwise be made to such Partner toward payment of the loan and interest, which payments or distributions shall be applied first to interest and then to principal until the loan is repaid in full. In the event that the distributions or proceeds to the Partnership or any Subsidiary of the Partnership are reduced on account of taxes withheld at the source or any taxes are otherwise required to be paid by the Partnership and such taxes are imposed on or with respect to one or more, but not all of the Partners in the Partnership, or all of the Partners in the Partnership at different tax rates, the amount of the reduction shall be borne by the relevant Partners and treated as if it were paid by the Partnership as a Withholding Payment with respect to such Partners pursuant to Section 4.5(a). Taxes imposed on the Partnership where the rate of tax varies depending on characteristics of the Partners shall be treated as taxes imposed on or with respect to the Partners for purposes of Section 4.5(a). In addition, if the Partnership is obligated to pay any taxes (including penalties, interest and any addition to tax) to any Governmental Entity that is specifically attributable to a Partner or a former Partner, including, without limitation, on account of Sections 864 or 1446 of the Code, then (x) such Partner or former Partner shall indemnify the Partnership in full for the entire amount paid or payable, (y) the General Partner may offset future distributions from such Partner or former Partner pursuant to Section 4.1 to which such Person is otherwise entitled under this Agreement against such Partner or former Partner’s obligation to indemnify the Partnership under this Section 4.5(d) and (z) such amounts shall be treated as a Withholding Payment pursuant to Section 4.5(a) with respect to such Partner or former Partner.
(e) If the Partnership incurs an Imputed Underpayment Amount, the General Partner shall determine in its discretion the portion of such Imputed Underpayment Amount attributable to each Partner or former Partner and such attributable amount shall be treated as a Withholding Payment pursuant to Section 4.5(a). The portion of the Imputed Underpayment Amount that the General Partner attributes to a former Partner of the Partnership shall be treated as a Withholding Payment with respect to both such former Partner and such former Partner’s transferee(s) or assignee(s), as applicable, and the General Partner may in its discretion exercise the Partnership’s rights pursuant to this Section 4.5 in respect of either or both of the former Partner and its transferee or assignee.



Exhibit 1.2
(f) A Partner’s obligations under this Section 4.5 shall survive the dissolution and winding up of the Partnership and any transfer, assignment or liquidation of such Partner’s interest in the Partnership.
4.6 Allocations Upon Final Liquidation. With respect to the fiscal year in which the final liquidation of the Partnership occurs in accordance with Section 13.2, and notwithstanding any other provision of Sections 4.2, 4.3 or 4.4 hereof, items of Partnership income, gain, loss and deduction shall be specially allocated to the Partners in such amounts and priorities as are necessary so that the positive capital accounts of the Partners shall, as closely as possible, equal the amounts that will be distributed to the Partners pursuant to Section 13.2.
ARTICLE V
MANAGEMENT
5.1 Authority of General Partner. Except for situations in which the approval of one or more of the Partners is specifically required by the express terms of this Agreement, and subject to the provisions of this Article V, (i) all management powers over the business and affairs of the Partnership shall be exclusively vested in the General Partner, (ii) the General Partner shall conduct, direct and exercise full control over all activities of the Partnership, and (iii) the General Partner shall have the sole power to bind or take any action on behalf of the Partnership, or to exercise any rights and powers (including, without limitation, the rights and powers to take certain actions, give or withhold certain consents or approvals, or make certain determinations, opinions, judgments or other decisions) granted to the Partnership under this Agreement or any other agreement, instrument or other document to which the Partnership is a party. Each Partner agrees that, except as otherwise expressly provided herein and to the fullest extent permitted by Applicable Law, any action of or relating to the Partnership by the General Partner as provided herein shall bind each Partner in its capacity as Partner. Without limiting the generality of the foregoing, but subject to any situations in which the approval of the Partners is specifically required by this Agreement, (x) the General Partner shall have discretion in determining whether to issue Equity Securities of the Partnership, the number of Equity Securities of the Partnership to be issued at any particular time, the purchase price for any Equity Securities of the Partnership issued, and all other terms and conditions governing the issuance of Equity Securities of the Partnership and (y) the General Partner may enter into, approve, and consummate any Liquidity Event or other extraordinary or business combination or divestiture transaction, and execute and deliver on behalf of the Partnership or the Partners any agreement, document and instrument in connection therewith (including amendments, if any, to this Agreement or adoptions of new constituent documents) without the approval or consent of any Partner. The General Partner is hereby authorized to execute, deliver and file all statements (including in respect of any changes to the details contained in the Certificate) and certificates (and any amendments and/or restatements thereof) required or permitted by the Cayman Act to be filed with the Registrar of Exempted Limited Partnerships of the Cayman Islands. The General Partner is hereby authorized to execute, deliver and file any other certificates (and any amendments and/or restatements thereof) necessary for the Partnership to qualify to do business in a jurisdiction in which the Partnership may wish to conduct business. Notwithstanding any other provision of this Agreement to the contrary, without the consent of any Partner or other Person being required, the Partnership is hereby authorized to execute, deliver and perform, and the General Partner or any officer on behalf of the Partnership, is hereby authorized to execute and deliver any amendment and any agreement, document or other instrument contemplated thereby or related thereto. The General Partner or any officer is hereby authorized to enter into the documents described in the preceding sentence on behalf of the Partnership, but such authorization shall not be deemed a restriction on the power of the General Partner or any officer to enter into other documents on behalf of the Partnership. The General Partner or any officer is hereby authorized to employ, on behalf of the Partnership, such Persons (including advisers, attorneys and accountants) as they deem advisable for the conduct of the business of the Partnership, on such terms and for such compensation as the General Partner or any officer shall determine. The General Partner is hereby authorized to borrow money or otherwise incur Indebtedness on behalf of the Partnership and may grant security over the assets of the Partnership to secure the obligations of the Partnership or any of its Subsidiaries or of PubCo or any of its Subsidiaries (other than the Partnership or any of its Subsidiaries) in connection with any borrowings of, or other Indebtedness incurred by, any of them. The General Partner may enter into any side letter arrangements on such terms as the General Partner may determine, in its absolute discretion, with any Limited Partner and without the consent or approval of any other Limited Partner.



Exhibit 1.2
5.2 Actions of the General Partner. Any decision, action, approval or consent required or permitted to be taken by the General Partner (or by any Person or Persons to whom authority and duties have been delegated pursuant to Section 5.4(a)) in accordance with this Article V shall be taken from outside the United Kingdom and any decision, action, approval or consent required or permitted taken by the General Partner (or by any Person or Persons to whom authority and duties have been delegated pursuant to Section 5.4(a)) from inside the United Kingdom shall be void and nonbinding on the General Partner or the Partnership. Unless otherwise provided in this Agreement, any decision, action, approval or consent required or permitted to be taken by the General Partner may be taken by the General Partner through any Person or Persons to whom authority and duties have been delegated pursuant to Section 5.4(a). The General Partner shall not cease to be a General Partner of the Partnership as a result of the delegation of any duties hereunder. No Person or Persons to whom authority and duties have been delegated pursuant to Section 5.4(a) shall be considered a General Partner of the Partnership, as a result of the performance of its duties hereunder or otherwise.
5.3 Compensation; Expenses.
(a) The General Partner shall not be entitled to any compensation for services rendered to the Partnership in its capacity as General Partner. The General Partner’s interest in its capacity as such shall be a non-economic interest in the Partnership, which does not entitle the General Partner, solely in its capacity as such, to any Units, Distributions or Tax Distributions.
(b) The Partnership shall pay, or cause to be paid, all costs, fees, operating expenses and other expenses of the Partnership (including the costs, fees and expenses of attorneys, accountants or other professionals) incurred in pursuing and conducting, or otherwise related to, the activities of the Partnership.
(c) The Partnership shall, subject to paragraph (e) below, bear and/or reimburse the General Partner for (i) any costs, fees or expenses incurred by the General Partner in connection with serving as the General Partner, (ii) operating, administrative and other similar costs incurred by the General Partner in connection with operating the Partnership’s business, and payments of any legal, tax, accounting and other professional fees and expenses, (iii) any judgments, settlements, penalties, fines or other costs and expenses in respect of any claims against, or any litigation or proceedings involving the General Partner in connection with operating the Partnership’s business, (iv) fees and expenses (other than any underwriters’ discounts and commissions that are economically recovered by the General Partner as a result of the Partnership acquiring Common Units with the net proceeds of the transactions in which any such underwriters’ discounts and commissions were incurred) related to any securities offering, investment or acquisition transaction (whether or not successful) authorized by the General Partner in connection with operating the Partnership’s business, (v) other fees and expenses in connection with the maintenance of the existence of the General Partner (but, for the avoidance of doubt, excluding any tax liabilities of the General Partner), and (vi) all other expenses allocable to the Partnership or otherwise incurred by the General Partner in connection with operating the Partnership’s business; in each case including any irrecoverable value added tax or sales tax incurred thereon;
(d) subject to paragraph (e) below, bear and/or reimburse the PubCo or the Waldencast Limited Partner for (i) any costs, fees or expenses incurred by the PubCo or Waldencast Limited Partner in fulfilling its obligations under this Agreement, including payments of any legal, tax, accounting and other professional fees and expenses, (ii) any judgments, settlements, penalties, fines or other costs and expenses in respect of any claims against, or any litigation or proceedings involving PubCo or Waldencast Limited Partner in connection with its obligations under this Agreement; in each case including any irrecoverable value added tax or sales tax incurred thereon;
(e) amounts so borne or reimbursed by the Partnership under this Section 5.3 shall not be used to pay or facilitate dividends or distributions on the securities of PubCo and must be used solely for one of the express purposes set forth under Sections 5.3(b) to 5.3(d). To the extent practicable, expenses incurred by the General Partner on behalf of or for the benefit of the Partnership shall be billed directly to and paid by the Partnership and, if and to the extent any reimbursements to the General Partner, PubCo or the Waldencast Limited Partner or any of their Affiliates by the Partnership pursuant to this Sections 5.3(b) to 5.3(e) constitute gross income to such Person (as opposed to the repayment of advances made by such Person on behalf of the Partnership), such amounts shall be treated as “guaranteed payments” within the meaning of Section 707(c) of the Code and shall not be treated as distributions for



Exhibit 1.2
purposes of computing the Partners’ Capital Account. Reimbursements pursuant to this Sections 5.3(b) to 5.3(e) shall be in addition to any reimbursement to the General Partner, PubCo or the Waldencast Limited Partner as a result of indemnification pursuant to Section 6.4.
5.4 Delegation of Authority.
(a) The General Partner may, from time to time, delegate to one or more Persons, including any manager, officer or director of the General Partner, or to any other Person, such authority and duties as the General Partner may deem advisable; provided that any such Person shall exercise such authority subject to the same duties and obligations to which the General Partner would have otherwise been subject pursuant to the terms of this Agreement.
(b) The General Partner may assign titles (including, without limitation, executive chairman, non-executive chairman, chief executive officer, chief financial officer, president, vice president, secretary, assistant secretary, treasurer or assistant treasurer) and delegate certain authority and duties to such Persons on behalf of the Partnership. If an officer is also an officer of the General Partner, then Section 5.6(b)(i) shall apply to such officer in the same manner as it
applies to the General Partner. Any number of titles may be held by the same officer or other individual. The salaries or other compensation, if any, of the Person or Persons to whom authority and duties have been delegated pursuant to Section 5.4(a) shall be fixed from time to time by the General Partner. Any delegation pursuant to this Section 5.4 may be revoked at any time by the General Partner. Any executive officer may resign at any time by giving written notice to the General Partner, and such resignation shall take effect at the date of the receipt of that notice or any later time specified in that notice; provided that, unless otherwise specified in that notice, the acceptance of the resignation will not be necessary to make it effective. Any such resignation will be without prejudice to the rights, if any, of the General Partner, the Partnership or such executive officer under this Agreement. A vacancy in any office because of death, resignation, removal, or otherwise may be filled by the General Partner.
5.5 Reliance by Third Parties. Notwithstanding any other provision of this Agreement to the contrary, any Person dealing with the Partnership shall be entitled to rely exclusively on the representations of the General Partner as to its power and authority to enter into arrangements and shall be entitled to deal with the General Partner as if it were the sole party in interest therein, both legally and beneficially. In no event shall any Person dealing with the General Partner or the General Partner’s representative with respect to any business or property of the Partnership be obligated to ascertain that the terms of this Agreement have been complied with, or be obligated to inquire into the necessity or expedience of any act or action of the General Partner or the General Partner’s representative and every contract or other document executed by the General Partner or the General Partner’s representative with respect to any business or property of the Partnership shall be conclusive evidence in favor of any and every Person relying thereon or claiming thereunder that (a) at the time of the execution and/or delivery thereof this Agreement was in full force and effect, (b) such instrument or document was duly executed in accordance with the terms of this Agreement and is binding upon the Partnership and (c) the General Partner or the General Partner’s representative was duly authorized and empowered to execute and deliver any and every such instrument or document for and on behalf of the Partnership.
5.6 Limitation of Liability.
(a) To the maximum extent permitted by Applicable Law, and except as otherwise provided herein or in any agreement entered into by such Person and the Partnership, none of the General Partner or any manager, officer, director, principal, member, employee, agent or Affiliate of the General Partner shall be liable to the Partnership or to any Partner for any act or omission performed or omitted by the General Partner in its capacity as the General Partner pursuant to authority granted to such Person by this Agreement; provided that, except as otherwise provided herein, such limitation of liability shall not apply to the extent the act or omission was attributable to such Person’s gross negligence, willful misconduct or knowing violation of law, or for any present or future breaches of any representations, warranties or covenants by such Person or its Affiliates contained herein. The General Partner may exercise any of the powers granted to it by this Agreement and perform any of the duties imposed upon it hereunder either directly or by or through its agents, and none of the General Partner or any manager, officer, director, principal, member, employee, agent or Affiliate of the General Partner shall be responsible for any misconduct or negligence on the part of any such agent appointed by the General Partner (so long as such agent was selected in



Exhibit 1.2
good faith and with reasonable care). The General Partner shall be entitled to rely upon the advice of legal counsel, independent public accountants and other experts, including financial advisors, and any act of or failure to act by the General Partner in good faith reliance on such advice shall in no event subject the General Partner to liability to the Partnership or any Partner.
(b) Notwithstanding the provisions of Section 6.1:
(i) the General Partner shall be subject to all of the duties and obligations of a general partner specified in this Agreement and the Cayman Act. The Parties acknowledge that the General Partner will take action through its managers, who will owe certain duties to the General Partner. In the event of a conflict between the interests of the General Partner and the interests of the Partners, such other Partners agree that the managers of the General Partner shall discharge their duties to such other Partners by acting in the interests of the General Partner’s member;
(ii) to the extent that, at Law or in equity, any Subsidiary of the Partnership or any manager, director (or equivalent), officer, employee or agent of any Subsidiary of the Partnership has duties (including fiduciary duties) to the Partnership, to a Partner (other than the General Partner) or to any Person who acquires Units, all such duties (including fiduciary duties) are hereby limited solely to those expressly set forth in this Agreement (if any), to the fullest extent permitted by applicable law; and
(iii) the limitation of duties (including fiduciary duties) to the Partnership, each Partner (other than the General Partner) and any Person who acquires Units set forth in this Section 5.6(b) shall be deemed to be approved by the Partnership, each Partner (other than the General Partner) and any Person who acquires Units.
5.7 Resignation or Termination of General Partner. The DRE Partner shall not, by any means, resign as, cease to be or be replaced as General Partner except in compliance with this Section 5.7. No termination or replacement of the DRE Partner, as General Partner shall be effective without the prior written consent of PubCo and unless proper provision is made, in compliance with this Agreement and the Cayman Act, so that the obligations of the DRE Partner and any new General Partner and the rights of all Partners under this Agreement and Applicable Law remain in full force and effect. No appointment of a Person other than the DRE Partner as general partner of the Partnership shall be effective unless the new General Partner executes a joinder to this Agreement and agrees to be bound by the terms and conditions in this Agreement and a statement pursuant to section 10 of the Cayman Act is filed with the Registrar of Exempted Limited Partnerships in the Cayman Islands in respect of such change of General Partner.
5.8 Affiliate Transactions. The Partnership shall conduct, and shall cause each of its Subsidiaries to conduct, all transactions with its Affiliates (other than Subsidiaries of the Partnership), current or former officers or directors, or any members of their respective immediate families on terms that are fair and reasonable and no less favorable to the Partnership or such Subsidiary than it would obtain in a comparable arm’s-length transaction with a Person that is not an Affiliate, current or former officer or director, or member of their respective immediate families, and in compliance with all Applicable Law.

ARTICLE VI
RIGHTS AND OBLIGATIONS OF PARTNERS
6.1 Limitation of Liability.
(a) The debts, obligations and liabilities of the Partnership, whether arising in contract, tort or otherwise, shall be satisfied out of the assets of the Partnership. In the event that the assets of the Partnership are inadequate to satisfy such debts, obligations and liabilities, the General Partner shall be liable for the same in accordance with the Cayman Act. Save as provided in sections 20(1) and 34(1) of the Cayman Act, no Limited Partner shall be obligated personally for any such debts, obligations or liabilities solely by reason of being a Limited Partner.
(b) Except as provided in this Agreement or in the Cayman Act, this Agreement is not intended to, and does not, create or impose any duty (including any fiduciary duty) on any of the Partners (other than the General Partner) hereto or on their respective Affiliates. Further, notwithstanding any other provision of this Agreement or any duty



Exhibit 1.2
otherwise existing at law or in equity, the Parties hereto agree that no Partner (other than the General Partner) shall, to the fullest
extent permitted by Applicable Law, have duties (including fiduciary duties) to any other Partner or to the Partnership, and in doing so, recognize, acknowledge and agree that their duties and obligations to one another and to the Partnership are only as expressly set forth in this Agreement; provided, however, that each Partner and the General Partner shall have the duty to act in accordance with the implied contractual covenant of good faith and fair dealing.
(c) To the extent that, at law or in equity, any Partner (other than the General Partner) has duties (including fiduciary duties) and liabilities relating thereto to the Partnership, to another Partner or to another Person who is a Party to or is otherwise bound by this Agreement, the Partners (other than the General Partner) acting under this Agreement will not be liable to the Partnership, to any such other Partner or to any such other Person who is a party to or is otherwise bound by this Agreement, for their good faith reliance on the provisions of this Agreement. The provisions of this Agreement, to the extent that they restrict or eliminate the duties and liabilities relating thereto of any Partner (other than the General Partner) otherwise existing at law or in equity, are agreed by the Partners to replace to that extent such other duties and liabilities of the Partners relating thereto (including, without limitation, the General Partner).
(d) Under the Cayman Act, a Partner may, under certain circumstances, be required to return amounts previously distributed to such Partner. It is the intent of the Partners that no Distribution to any Partner pursuant to Section 4.1 shall be deemed to constitute money or other property paid or distributed in violation of the Cayman Act, and the Partner receiving such Distribution shall not be required to return to any Person any such money or property, except
as otherwise expressly set forth herein or the Cayman Act. If, however, it is required pursuant to the Cayman Act or any court of competent jurisdiction holds that, notwithstanding the provisions of this Agreement, any Partner is obligated to make any such payment, such obligation shall be the obligation of such Partner and not of the other Partners.
6.2 Lack of Authority. No Partner (other than the General Partner) in its capacity as such (other than in its capacity as a Person delegated authority pursuant to Section 5.4) has the authority or power to act for or on behalf of the Partnership, to do any act that would be binding on the Partnership, to make any expenditures on behalf of the Partnership or to otherwise take part in the conduct of the business of the Partnership. The Partners hereby consent to the exercise by the General Partner of the powers conferred on it by law and this Agreement.
6.3 Performance of Duties; Conflicts of Interest. To the extent that this Agreement or the Cayman Act creates or imposes any duties on the Partners:
(a) In performing its, his or her duties, each of the Partners shall be entitled to rely in good faith on the provisions of this Agreement and on information, opinions, reports or statements (including financial statements and information, opinions, reports or statements as to the value or amount of the assets, liabilities, profits or losses of the Partnership and its Subsidiaries), of the following other Persons or groups: (i) one or more officers or employees of such Partner or the Partnership or any of its Subsidiaries, (ii) any attorney, accountant, financial advisor, consultant or other Person employed or engaged by such Partner or the Partnership or any of its Subsidiaries, or (iii) any other Person who has been selected with reasonable care by or on behalf of such Partner or the Partnership or any of its Subsidiaries, in each case, as to matters which such relying Person reasonably believes to be within such other Person’s professional or expert competence.
(b) On any matter involving a conflict of interest not provided for elsewhere in this Agreement, each Partner shall be guided by its reasonable judgment as to the best interests of the Partnership and its Subsidiaries and shall take such actions as are determined by such Person to be necessary or appropriate to ameliorate such conflict of interest.
6.4 Indemnification.
(a) Subject to the other provisions of this Agreement, the Partnership shall indemnify and hold harmless any Person (each an “Indemnified Person”) to the fullest extent permitted under the Cayman Act, as the same now exists or may hereafter be amended, substituted or replaced (but, in the case of any such amendment, substitution or replacement only to the extent that such amendment, substitution or replacement permits the Partnership to provide



Exhibit 1.2
broader indemnification rights than the Partnership is providing immediately prior to such amendment, substitution or replacement), against all expenses, liabilities and losses (including attorneys’ fees, judgments, fines, excise taxes or penalties, as reasonably required) reasonably incurred or suffered by such Person (or one or more of such Person’s Affiliates) by reason of the fact that such Person is or was a Partner (or Affiliate of a Partner) or is or was serving as the General Partner, any additional or substitute General Partner, any Person or Persons to whom authority and duties have been delegated pursuant to Section 5.4(a), Partnership Representative, employee or other agent of the Partnership, or is or was serving at the request of the Partnership as a manager, officer, director, principal, member, employee or agent of another corporation, partnership, joint venture, limited liability company, trust or other enterprise (including any manager, officer, director, principal, member, employee or agent of the General Partner or any additional or substitute General Partner); provided that (unless the General Partner otherwise consents) no Indemnified Person shall be indemnified for any expenses, liabilities and losses suffered that are attributable to such Indemnified Person’s or its Affiliates’ gross negligence, willful misconduct or knowing violation of law. Expenses, including reasonable attorneys’ fees, incurred by any such Indemnified Person in defending a proceeding related to any such indemnifiable matter shall be paid by the Partnership in advance of the final disposition of such proceeding, including any appeal therefrom, upon receipt of an undertaking by or on behalf of such Indemnified Person to repay such amounts if it shall ultimately be determined that such Indemnified Person is not entitled to be indemnified by the Partnership.
(b) The right to indemnification and the advancement of expenses conferred in this Section 6.4 shall not be exclusive of any other right which any Person may have or hereafter acquire under any statute, agreement, by-law, determination of the General Partner or otherwise.
(c) The Partnership will maintain directors’ and officers’ liability insurance, at its expense, for the benefit of the General Partner, the managers and officers of the General Partner and any other Persons to whom the General Partner has delegated its authority pursuant to Section 5.4.
(d) Notwithstanding anything contained herein to the contrary (including in this Section 6.4), any indemnity by the Partnership relating to the matters covered in this Section 6.4 shall be provided out of and to the extent of Partnership assets only, and, to the maximum extent permitted by Applicable Law, no Partner (unless such Partner otherwise agrees in writing or is found in a final decision by a court of competent jurisdiction to have personal liability on account thereof) shall have personal liability on account thereof or shall be required to make additional Capital Contributions or otherwise provide funding to help satisfy such indemnity of the Partnership.
(e) The Partnership hereby acknowledges that certain of its Partners (the “Partnership Indemnitees”) may have rights to indemnification, advancement of expenses and/or insurance in connection with their involvement with the Partnership provided by other Persons (collectively, the “Partnership Indemnitors”). The Partnership hereby agrees that, with respect to matters for which a Fund Indemnitee is entitled to indemnification, advancement of expenses and/or insurance pursuant to this Section 6.4, (i) the Partnership is and shall be the indemnitor of first resort (i.e., its obligations to the Fund Indemnitee are primary, and any obligation of the Partnership Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by the Partnership Indemnitees are secondary), and (ii) the Partnership irrevocably waives, relinquishes and releases the Partnership Indemnitors from any and all claims against the Partnership Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof to the fullest extent permitted by law. The Partnership further agrees that no advancement or payment by the Partnership Indemnitors on behalf of the Partnership Indemnitees with respect to any claim for which the Partnership Indemnitees have sought indemnification from the Partnership shall affect the foregoing, and the Partnership Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of the Partnership Indemnitees against the Partnership.
(f) If this Section 6.4 or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Partnership shall nevertheless indemnify and hold harmless each Indemnified Person pursuant to this Section 6.4 to the fullest extent permitted by any applicable portion of this Section 6.4 that shall not have been invalidated and to the fullest extent permitted by Applicable Law.
6.5 Voting Rights. To the maximum extent permitted by Applicable Law, all of the Units issued hereunder (i) shall be deemed to be non-voting Units, (ii) have no voting power and (iii) do not entitle any holder thereof to any right to vote upon or approve any action to be taken by the Partnership.



Exhibit 1.2
6.6 Outside Activities. Each Partner acknowledges and agrees that the Partnership may, or may cause one of its Subsidiaries to, enter into one or more agreements or other transactions with the General Partner or one or more of its Affiliates, relating to the provision of various commercial services, financial and advisory services, indemnification or expense reimbursement obligations, registration rights or any other matters, in each case on such terms and conditions as determined by the General Partner in good faith and subject to this Agreement.
6.7 Investment Opportunities. To the fullest extent permitted by Applicable Law, the doctrine of corporate opportunity, or any analogous doctrine, shall not apply to (a) any Partner (other than PubCo or any of its Subsidiaries, in which case solely acting in their capacity as such), (b) any of the Partners’ respective Affiliates (other than the Partnership, the General Partner or any of their respective Subsidiaries), (c) each Person that was a Partner immediately prior to the Effective Date or any of its respective Affiliates (including its respective investors and equityholders and any associated Persons or investment funds or any of their respective portfolio companies or investments) or (d) any of the respective officers, managers, directors, agents, shareholders, members, and partners of any of the foregoing (each, a “Business Opportunities Exempt Party”). The Partnership and each of the Partners, on its own behalf and on behalf of their respective Affiliates and equityholders, hereby renounce any interest or expectancy of the Partnership in, or in being offered an opportunity to participate in, business opportunities that are from time to time presented to any Business Opportunities Exempt Party and irrevocably waive any right to require any Business Opportunity Exempt Party to act in a manner inconsistent with the provisions of this Section 6.7. No Business Opportunities Exempt Party who acquires knowledge of a potential transaction, agreement, arrangement or other matter that may be an opportunity for PubCo, the Partnership or any of their respective Subsidiaries, Affiliates or equityholders shall have any duty to communicate or offer such
opportunity to the Partnership, and none of PubCo, the Partnership or any of their respective Subsidiaries, Affiliates or equityholders will acquire or be entitled to any interest or participation in any such transaction, agreement, arrangement or other matter or opportunity as a result of participation therein by a Business Opportunity Exempt Party. This Section 6.7 shall not apply to, and no interest or expectancy of the Partnership is renounced with respect to, any opportunity offered to any director of PubCo if such opportunity is expressly offered or presented to, or acquired or developed by, such Person solely in his or her capacity as a director or officer of the Partnership or General Partner. No amendment or repeal of this Section 6.7 shall apply to, or have any effect on, the liability or alleged liability of any Business Opportunities Exempt Party for or with respect to any opportunity of which any such Business Opportunities Exempt Party becomes aware prior to such amendment or repeal. Any Person purchasing or otherwise acquiring any interest in any Units shall be deemed to have had notice of and consented to the provisions of this Section 6.7. Neither the amendment or repeal of this Section 6.7, nor the adoption of any provision of this Agreement inconsistent with this Section 6.7, shall eliminate or reduce the effect of this Section 6.7 in respect of any business opportunity first identified, any other matter occurring, or any cause of action that, but for this Section 6.7, would have accrued or arisen, prior to such amendment, repeal or adoption. No action or inaction by any Business Opportunities Exempt Party in a manner consistent with this Section 6.7 shall be deemed to be a violation of any fiduciary or other duty owed to any Person.
6.8 Pre-emptive Rights. No Non-PubCo Partner shall have any preemptive, preferential or other similar right with respect to: (a) additional Capital Contributions; (b) issuances or sales by the Partnership of any class or series of Units or other Equity Securities of the Partnership, whether unissued or hereafter created; (c) issuances of any obligations, evidences of indebtedness or other securities of the Partnership convertible into or exchangeable for, or carrying or accompanied by any rights to receive, purchase or subscribe to, any Units; (d) issuances of any right of subscription to or right to receive, or any warrant or option for the purchase of, any Units; or (e) issuances or sales of any other securities that may be issued or sold by the Partnership.



Exhibit 1.2
ARTICLE VII
BOOKS, RECORDS, ACCOUNTING AND REPORTS
7.1 Records. The Partnership shall keep, or cause to be kept, appropriate books and records with respect to the Partnership’s business, including:
(a) the Register, which shall be:
(i) kept in the Cayman Islands and maintained in accordance with Section 3.1(a); and
(ii) kept confidential, but will be available for inspection upon the written request of a Partner to the Partnership, at the Partnership’s principal location and with the consent of the General Partner (which consent shall not be unreasonably withheld, conditioned or delayed in response to any request by a Partner) at such reasonable times as may be designated by the General Partner; provided that, notwithstanding anything to the contrary contained herein or in the Cayman Act, neither the General Partner nor the Partnership shall be required to disclose to any Non-PubCo Partner an unredacted Register, or any other information showing the identity of the other Non-PubCo Partners or the number and class of Units owned by another Non-PubCo Partner. For each Non-PubCo Partner, the Partnership shall provide such Partner, upon request, a redacted copy of the Register revealing only such Partner’s Units, the total number of issued and outstanding Units, and such Partner’s Common Unit Percentage Interest; provided, further, that the General Partner may close the Register for any time or times not exceeding in the aggregate thirty (30) days in each calendar year; and
(b) all books and records necessary to provide any information, lists and copies of documents required to be provided pursuant to (i) Section 7.4 or (ii) any Applicable Law.
7.2 Accounting. All matters concerning (i) the determination of the relative amount of allocations and distributions among the Partners pursuant to Article III and Article IV and (ii) accounting procedures and determinations, and other determinations not specifically and expressly provided for by the terms of this Agreement, shall be determined by the General Partner in accordance with Applicable Law, this Agreement and with accounting methods followed for U.S. federal income tax or other applicable purposes. In making these decisions, the General Partner may rely upon the advice of the Partnership’s independent accountants. The General Partner’s determination shall be final and conclusive as to all of the Partners, absent manifest clerical error.
7.3 Fiscal Year. The Fiscal Year of the Partnership shall be used for financial reporting and shall be its Taxable Year.
7.4 Reports. In the event that neither PubCo nor the Partnership is required to file an annual report on SEC Form 20- F or an annual report on SEC Form 10-K or a quarterly report on SEC Form 10-Q or any other filing document, the Partnership shall use commercially reasonable efforts to deliver or cause to be delivered, as soon as practicable following the completion of each Taxable Year, but in all events within ninety (90) days after the end of each Taxable Year, to each Person who was a holder of Units at any time during such Taxable Year, all information from the Partnership necessary for the preparation of such Person’s federal and state corporate or income tax returns. Except as set forth herein or in any separate written agreement between the Partnership and any Partner, no Partner shall have the right to any other information from the Partnership, except as may be required by any non-waivable provision of law.
7.5 Transmission of Communications. Each Person that owns or controls Units on behalf of, or for the benefit of, another Person or Persons shall be responsible for conveying any report, notice or other communication received from the Partnership to such other Person or Persons.
7.6 PFIC Information. The General Partner shall (a) (i) to the extent PubCo or the Partnership undertakes an analysis of the status of PubCo, Holdco 1, or any direct or indirect Subsidiary of the Partnership as a “passive foreign investment company” (“PFIC”), undertake commercially reasonable efforts to cause the Partnership to provide information regarding such analysis with respect to any direct or indirect Subsidiaries of the Partnership to the Partners, and (ii) to the extent neither PubCo nor the Partnership undertakes an analysis of the status of PubCo,



Exhibit 1.2
Holdco 1, or any direct or indirect subsidiary of the Partnership as a PFIC, at the sole cost and expense of any specific Partners, cooperate with such Partners and their advisors to permit them to undertake such an analysis with respect to any direct or indirect Subsidiary of the Partnership, and (b) (i) if PubCo or the Partnership prepares the information necessary to permit shareholders of PubCo to make a “qualified electing fund” election within the meaning of Section 1295 of the Code with respect to PubCo or any Subsidiary of PubCo, provide information to the Partners to make such an election with respect to any direct or indirect Subsidiary of the Partnership that is a PFIC, and (ii) if neither PubCo nor the Partnership prepares the information necessary to permit shareholders of PubCo to make a “qualified electing fund” election within the meaning of Section 1295 of the Code with respect to PubCo or any Subsidiary of PubCo, at the sole cost and expense of any requesting Partners, cooperate with such Partners and their advisors to permit them to prepare such information with respect to any direct or indirect Subsidiary of the Partnership that is a PFIC; provided, however, that if either clause (a)(ii) or (b)(ii) above applies, then the analysis and information undertaken or obtained shall be for the sole and exclusive benefit of the requesting Partners.
7.7 Confidentiality.
(a) The General Partner may keep confidential from the Partners, for such period of time as the General Partner determines in its sole discretion, (i) any information that the General Partner reasonably believes to be competitively sensitive or in the nature of trade secrets or (ii) other information, the disclosure of which the General Partner believes is not in the best interests of the Partnership or could damage the Partnership or its business, or that the Partnership is required by law or by agreement with any third party to keep confidential, including, without limitation, information as to the Units held by any other Partner, as set out in the Register or otherwise, and any privileged information of PubCo, the Partnership or any of their Subsidiaries. With respect to any schedules, annexes or exhibits to this Agreement, to the fullest extent permitted by law, each Partner (other than the General Partner) shall only be entitled to receive and review any such schedules, annexes and exhibits relating to such Partner and shall not be entitled to receive or review any schedules, annexes or exhibits relating to any other Partner (other than the General Partner).
(b) Each Partner agrees, for so long as such Partner owns any Units and for a period of two (2) years following the date upon which such Partner ceases to own any Units, to keep confidential, any non-public information provided to such Partner by the Partnership (“Confidential Information”); provided, however, that nothing herein will limit the disclosure of any Confidential Information (i) to the extent required by law, statute, rule, regulation, judicial process, subpoena or court order or required by any governmental agency or other regulatory authority; (ii) that is in the public
domain or becomes generally available to the public, in each case, other than as a result of a disclosure by the Parties in violation of this Agreement; or (iii) that relates solely to such Partner’s investment in the Partnership, to a Partner’s advisors, representatives, partners and Affiliates; provided that such advisors, representatives, partners and Affiliates shall have been advised of this Agreement and shall have expressly agreed to be bound by the confidentiality provisions hereof, or shall otherwise be bound by comparable obligations of confidentiality, and the applicable Partner shall be responsible for any breach of or failure to comply with this Agreement by any of its advisors, representatives, partners and Affiliates, and such Partner agrees, at its sole expense, to take reasonable measures (including but not limited to court proceedings) to restrain its advisors, representatives, partners and Affiliates from prohibited or unauthorized disclosure or use of any Confidential Information.
ARTICLE VIII
TAX MATTERS
8.1 Tax Returns.
(a) The Partnership shall arrange for the preparation and timely filing (taking into account all extensions validly obtained) of all tax returns (including tax reporting and information returns) required to be filed by the Partnership and its Subsidiaries. Except as otherwise provided in this Agreement or under the Milk Equity Purchase Agreement, the General Partner shall determine the accounting methods and conventions under the tax laws of the United States, the several states and other relevant jurisdictions as to the treatment of items of income, gain, deduction, loss and credit or any other method or procedure related to the preparation of such tax returns. The Partnership and the



Exhibit 1.2
General Partner shall have full power and authority: (i) without consultation with any of the Non-Pubco Partners but after delivering written notice to the relevant Non-Pubco Partners, to disclose to any governmental authorities in connection with the Partnership such information about the identity of the Partners and their respective Common Unit Percentage Interest as any such authorities may require the Partnership or the General Partner to disclose (and each Partner hereby waives all rights it may have under section 7.7 of this Agreement, applicable bank secrecy, data protection or similar rules, legislation or regulations that would otherwise prohibit, limit or otherwise restrict any such disclosure); and (ii) to obtain such information (including, for the avoidance of doubt, any reference or identification number(s)) from Partners as the Partnership or the General Partner may reasonably require to enable the Partnership and its Subsidiaries to determine the applicability of any relevant tax treaty, directive or legislation or properly and promptly to prepare and file any tax elections, tax returns and other disclosures. Each Partner will, upon request, take commercially reasonable efforts to promptly procure and supply to the Partnership all information requested by the Partnership or General Partner pursuant to (ii) above and each Partner hereby agrees to indemnify the Partnership and the other Partners for any taxes imposed by a governmental authority that they incur pursuant to applicable law and that would not have arisen but for the indemnifying Partner's failure to procure and supply any such timely requested information.
(b) Upon request of any Partner, the Partnership shall furnish to such Partner a copy of any tax return (including tax reporting and information returns) filed by or with respect to the Partnership or any of its Subsidiaries. The Partnership will also supply each Partner with any information regarding the determination of the tax consequences of the Partner’s ownership interest in the Partnership, the receipt by any Partner of any distributions from the Partnership, and the disposition by a Partner of its interest in the Partnership, including providing the Partner with a calculation of the income, gain, loss, deduction and credit of the Partnership for all relevant periods. Each Partner agrees in respect of any year in which such Partner had an investment in the Partnership that, unless otherwise agreed by the General Partner or as required by law, such Partner shall not: (i) treat, on its individual tax returns, any item of income, gain, loss, deduction or credit relating to such investment in a manner inconsistent with the treatment of such item by the Partnership, as reflected on the Schedule K-1 or other information statement furnished by the Partnership to such Partner; or (ii) file any claim for refund relating to any such item based on, or which would result in, any such inconsistent treatment.
8.2 Tax Elections. The Taxable Year of the Partnership shall be the calendar year unless otherwise required by the Code or applicable tax laws. If not yet made, the Partnership shall make, and shall cause any Subsidiary of the Partnership that is treated as a partnership for U.S. federal income tax purposes to make, a timely election under Section 754 of the Code (and applicable corresponding elections under state and local law) effective with respect to the taxable year of the Partnership that includes the Closing. The General Partner shall not take any action to revoke such elections. Subject to Section 8.3 and the Milk Equity Purchase Agreement, the General Partner shall determine
whether to make or revoke any other available election or decision relating to tax matters pursuant to the Code, including, for the avoidance of doubt, regarding the tax classification of entities and methods of accounting for items of income, gain, deduction, loss and credit; provided that no election to change the classification of the Partnership as a partnership for U.S. federal and applicable state and local income tax purposes shall be made. Each Partner will upon request supply any information necessary to give proper effect to any such election described in this Section 8.2.
8.3 Tax Controversies. The General Partner shall be the “partnership representative” of the Partnership (the “Partnership Representative”) for purposes of Section 6223 of the Code (and any applicable state, local, and non U.S. law). The Partnership Representative shall comply with the rules set forth in the Revised Partnership Audit Procedures. The Partnership Representative may be removed, and a new Partnership Representative appointed, by the General Partner in accordance with the Code and the Treasury Regulations. The Partnership Representative shall be permitted to appoint any “designated individual” (or similar person) (a “Designated Individual”) permitted under Treasury Regulations Section 301.6223-1 or any successor regulations or similar provisions of tax law. If the Partnership Representative appoints a Designated Individual pursuant to Section 6223 of the Code and the Treasury Regulations thereunder (or similar provisions of state, local or other tax laws), such Designated Individual shall be subject to this Agreement in the same manner as the Partnership Representative (and references to the Partnership Representative shall include any such Designated Individual, unless the context otherwise requires, or shall mean solely the Designated Individual, as needed to comply with Applicable Law). Except as otherwise provided in the Milk Equity Purchase Agreement, the Partnership Representative shall have the power to manage and represent the



Exhibit 1.2
Partnership in any administrative proceeding of the IRS, and shall be indemnified by the Partnership for all costs and expenses relating to serving in its capacity as the Partnership Representative. Each Partner hereby agrees: (a) to take such actions as may be required to effect the General Partner’s designation as the Partnership Representative, and (b) to cooperate to provide any information as may be reasonably requested by the Partnership Representative in order to carry out the duties of the Partnership Representative under the Code. In connection with any audit or examination of the Partnership or Milk, the Partnership Representative (or other applicable partnership representative) shall reasonably determine the portion of any Imputed Underpayment Amount attributable to each Partner or former Partner, and shall use reasonable best efforts to (i) make the election described in Section 6226 of the Code with respect to such Imputed Underpayment Amount or (ii) otherwise ensure that no Partner is allocated or becomes liable for taxes (including penalties or interest) attributable to other Partners or to a taxable year (or portion thereof) occurring prior to such Partner’s admission to the Partnership. Notwithstanding any other provision of this Agreement, the Partnership Representative (or other applicable partnership representative) shall, and is authorized by the Partners to, ensure that the tax and economic consequences of any Imputed Underpayment Amount with respect to any taxable year of the Partnership or Milk prior to the taxable year of the Partnership that includes the Effective Date (and any associated interest and penalties) are borne in the aggregate by former members of Milk. A Partner’s obligation to comply with this Section 8.3 shall survive the transfer, assignment or liquidation of such Partner’s partnership interest in the Partnership. Notwithstanding the foregoing, the Partnership Representative shall be subject to the control of the General Partner pursuant to Section 8.2 and shall not settle or otherwise compromise any issue in any such examination, audit or other proceeding without first obtaining the approval of the General Partner.
The provisions of this Section 8.3, including the obligations of a Limited Partner, will survive a Limited Partner’s sale or other disposition of its interests in the Partnership and the termination, dissolution, liquidation, or winding up of the Partnership.
8.4 Tax Treatment.
(a) The Partnership, the General Partner, Holdco 1, and PubCo shall take, and shall hereby be permitted to take, all reasonable steps to ensure (as far as is legally possible) that any disposal of Common Units or other Units by Holdco 1 or PubCo, to the extent such disposal is within the charge to UK corporation tax on chargeable gains, is treated as an exempt disposal of the Partnership's assets pursuant to the substantial shareholding exemption in Schedule 7AC to the Taxation of Chargeable Gains Act 1992.
(b) Notwithstanding anything herein to the contrary, to the extent Section 8.6 of the Milk Equity Purchase Agreement explicitly sets forth rights and obligations with respect to Tax matters, it shall govern with respect to those matters.
ARTICLE IX
RESTRICTIONS ON TRANSFER OF UNITS
9.1 Transfers of Units.
(a) Except as otherwise agreed to in writing between the General Partner and the applicable Partner and reflected in the books and records of the Partnership, or as otherwise provided in this Article IX, no holder of Units may sell, transfer, assign, pledge, encumber, distribute, contribute or otherwise dispose of (whether directly or indirectly (including, for the avoidance of doubt, by Transfer or issuance of any Capital Stock of any Partner that is not a natural person), whether with or without consideration and whether voluntarily or involuntarily or by operation of law) any interest (legal or beneficial) in any Units (a “Transfer”), except Exchanges pursuant to and in accordance with Article XII or Transfers pursuant to and in accordance with Section 9.1(b). Notwithstanding anything herein to the contrary, a Partner may pledge, charge, mortgage, assign by way of security, or other grant encumbrance over,



Exhibit 1.2
its Units to secure obligations of PubCo, the Partnership or its subsidiaries, and the secured party upon foreclosure or applicable enforcement proceedings or any Transferee may be admitted as a Partner.
(b) Subject to Section 9.6 and Section 9.7, the restrictions contained in Section 9.1(a) shall not apply to any Transfer of Units by any Partner (the “Transferor”) (i) to its Affiliates, (ii) to its direct or indirect partners, members, shareholders, or other equity holders, whether as a distribution, a liquidating distribution or otherwise, (iii) to a trust solely for the benefit of such Partner and such Partner’s Family Group (or a re-Transfer of such Units by such trust back to such Partner upon the revocation of any such trust) or pursuant to the Applicable Law of descent or distribution among such Partner’s Family Group for estate planning purposes, or (iv) to the Partnership (each of clauses (i)-(iv), an “Exempt Transfer”); provided that, in respect of any Exempt Transfer pursuant to clauses (i)-(iii), (x) the restrictions contained in this Article IX (other than in Section 9.1(a)) shall apply to an Exempt Transfer, (y) the restrictions contained in this Agreement will continue to apply to the Units after any Exempt Transfer, and each Transferee shall agree in writing, prior to and as a condition precedent to the effectiveness of such Exempt Transfer, to be bound by the provisions of this Agreement, without modification or condition, subject only to the consummation of such Exempt Transfer, and (z) each Transferee must certify to the Partnership that it is an “accredited investor” as defined in Rule 501 of Regulation D promulgated pursuant to Section 4(2) of the Securities Act, unless, in the reasonable judgment of the General Partner, another exemption from the registration requirements of the Securities Act is available. Upon an Exempt Transfer of Units, the Transferor Partner will deliver written notice to the Partnership, which notice will disclose in reasonable detail the identity of the Transferee(s) and shall include original counterparts of this Agreement in a form acceptable to the General Partner. Notwithstanding the foregoing, no party hereto shall avoid the provisions of this Agreement by making one or more Exempt Transfers to one or more Transferees and then disposing of all or any portion of such party’s interest in such Transferee if such disposition would result in such Transferee ceasing to be a Permitted Transferee. Notwithstanding anything to the contrary in Section 9.1(a), any Partner shall be permitted to make an Exempt Pledge; provided, however, that, for the avoidance of doubt, any exercise by a Lender of its rights to acquire or Transfer any Units subject to an Exempt Pledge shall constitute a Transfer of Units subject to the restrictions contained in this Article IX and shall not be an Exempt Transfer.
(c) Notwithstanding anything in this Agreement to the contrary, as a condition to any Transfer:
(i) if the Transferor who proposes to Transfer such Units or, if such Transferor is a disregarded entity for U.S. federal income tax purposes, the first direct or indirect beneficial owner of such Transferor that is not a disregarded entity (the “Transferor’s Owner”) is a “United States person,” as defined in Section 7701(a)(30) of the Code, then such Transferor (or Transferor’s Owner, if applicable) shall complete and provide, to both the Transferee and the Partnership, a duly executed affidavit, in the form provided to such Transferor by the Partnership, certifying, under penalty of perjury, that the Transferor (or Transferor’s Owner, if applicable) is not a foreign person, nonresident alien, foreign corporation, foreign partnership, foreign trust, or foreign estate (as such terms are defined under the Code and the applicable Treasury Regulations), and including the Transferor’s (or Transferor’s Owner’s, if applicable) United States taxpayer identification number, or
(ii) if the Transferor who proposes to Transfer such Units (or if such Transferor is a disregarded entity for U.S. federal income tax purposes, the Transferor’s Owner) is not a “United States person,” as defined in Section 7701(a)(30) of the Code, then such Transferor and Transferee shall jointly provide to the Partnership written proof, reasonably satisfactory to the General Partner, that any applicable withholding tax that may be imposed on such Transfer (including pursuant to Sections 864 and 1446 of the Code), and any related tax returns or forms that are required to be filed, have been, or will be, timely paid and filed, as applicable.
(d) Notwithstanding anything in this Agreement to the contrary, the Transferor and Transferee shall (as between them) bear their own expenses in connection with the consummation of any Transfer and shall bear any transfer taxes, stamp taxes or duties, or other similar taxes in connection with, or arising by reason of, any Transfer.
(e) Except as otherwise expressly provided herein, it shall be a condition precedent to any Transfer of any Unit by a Partner other than the PubCo Partners that, concurrently with such Transfer, such Transferor shall also Transfer to the Transferee (i) an equal number of Class B ordinary shares and (ii) the Capital Account of the Transferor, to the extent such Capital Account relates to the Units subject to such Transfer.



Exhibit 1.2
(f) Upon the reasonable request of any Partner, the Partnership will make available information necessary to comply with Rule 144, all to the extent required from time to time to enable such Partner or its prospective transferees to Transfer the Units without registration under the Securities Act, within the limitations of the exemption provided by Rule 144 of the Securities Act.
9.2 Restricted Units Legend.
(a) The Units have not been registered under the Securities Act and, therefore, in addition to the other restrictions on Transfer contained in this Agreement, cannot be sold unless subsequently registered under the Securities Act or an exemption from such registration is then available. To the extent such Units have been certificated, each certificate evidencing Units, and each certificate issued in exchange for or upon the Transfer of any Units (if such securities remain Units as defined herein after such Transfer), shall be stamped or otherwise imprinted with a legend in substantially the following form:
THE UNITS REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE ASSIGNED EXCEPT (1) PURSUANT TO A REGISTRATION STATEMENT WITH RESPECT TO SUCH SECURITIES WHICH IS EFFECTIVE UNDER THE SECURITIES ACT, (2) PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT RELATING TO THE DISPOSITION OF SECURITIES OR (3) IN ACCORDANCE WITH APPLICABLE STATE SECURITIES OR BLUE SKY LAWS.
THE UNITS REPRESENTED BY THIS CERTIFICATE ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER SPECIFIED IN THE AMENDED AND RESTATED EXEMPTED LIMITED PARTNERSHIP AGREEMENT OF WALDENCAST PARTNERS LP (THE “ISSUER”), DATED JULY 27, 2022, AS SUCH AGREEMENT MAY BE AMENDED, MODIFIED OR RESTATED FROM TIME TO TIME, AND THE ISSUER RESERVES THE RIGHT TO REFUSE THE TRANSFER OF SUCH SECURITIES UNTIL SUCH TRANSFER RESTRICTIONS HAVE BEEN FULFILLED. A COPY OF SUCH AMENDED AND RESTATED LIMITED PARTNERSHIP AGREEMENT SHALL BE FURNISHED BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST AND WITHOUT CHARGE.
The Partnership will imprint such legend on certificates (if any) evidencing Units. The legend set forth above will be removed from the certificates (if any) evidencing any units which cease to be Units in accordance with the definition thereof.
9.3 Notice of Transfer. In connection with the Transfer of any Units, the Transferor shall deliver written notice to the Partnership describing in reasonable detail the Transfer or proposed Transfer, which shall, if so requested by the General Partner, be accompanied by (a) an opinion of counsel who (to the General Partner’s reasonable satisfaction) is knowledgeable in securities law matters on such matters as are customary and appropriate in transactions of this type, including that such Transfer of Units may be effected without registration of such Units under the Securities Act and will not otherwise result in a violation of any Applicable Law, obtained at the sole expense of the Transferor and in form and substance reasonably satisfactory to the General Partner, or (b) such other evidence reasonably satisfactory to the General Partner to the effect that such Transfer of Units may be effected without registration of such Units under the Securities Act and without violating any Applicable Law. In addition, if the Transferor delivers to the Partnership an opinion of counsel that no subsequent Transfer of such Units shall require registration under the Securities Act, promptly upon such contemplated Transfer, the Partnership shall deliver new certificates for such securities (if then certificated) which do not bear the Securities Act legend set forth in Section 9.2(a). If the Partnership is not required to deliver new certificates for such Units not bearing such legend, the Transferor shall not affect any Transfer of the same until the prospective Transferee has confirmed to the Partnership in writing its agreement to be bound by the conditions contained in this Agreement.



Exhibit 1.2
9.4 Transferee’s Rights.
(a) Subject to Section 9.4(b), a Transfer of Units in a manner in accordance with this Agreement shall be effective as of the date of Transfer, and compliance with the conditions to such Transfer and such Transfer shall be shown on the books and records of the Partnership. Income, loss and other Partnership items shall be allocated between the Transferor and the Transferee according to Section 706 of the Code, as determined by the General Partner. Distributions made before the effective date of such Transfer shall be paid to the Transferor, and Distributions made after such date shall be paid to the Transferee.
(b) Unless and until the Transferee becomes a Substituted Partner or Additional Partner pursuant to Article X (the “Admission Date”), the Transferee shall not be entitled to any of the rights granted to a Partner hereunder or under Applicable Law, other than the rights granted specifically to Transferees pursuant to this Agreement; provided that without relieving the Transferring Partner from any such limitations or obligations as more fully described in Section 9.5, such Transferee shall be bound by any limitations and obligations of a Partner contained herein that a Partner would be bound by on account of such Units (including the obligation to make Capital Contributions on account of such Units).
9.5 Transferor’s Rights and Obligations.
(a) Subject to Section 9.5(b), the Transferor shall cease to be a Partner with respect to such Units or such other interest and shall no longer have any rights or privileges, or, except as set forth in this Section 9.5, duties, liabilities or obligations, of a Partner with respect to such Units or such other interest (it being understood, however, that the applicable provisions of Sections 5.5, 6.4 and 6.5 shall continue to inure to such Person’s benefit). If the Transferor shall Transfer all (but not less than all) of such Transferor’s Units (and any other interests in the Partnership) in accordance with the terms of this Agreement, then the Transferor shall thereupon cease to be a Partner of the Partnership.
(b) Unless and until the applicable Admission Date, (i) such Transferor shall retain all of the duties, liabilities and obligations of a Partner with respect to such Units or other interest, including, without limitation, the obligation (together with its Transferee pursuant to Section 9.4(b)) to make and return Capital Contributions on account of such Units or other interest pursuant to the terms of this Agreement, and (ii) the General Partner may reinstate all or any portion of the rights and privileges of such Transferor with respect to such Units or other interest for any period of time prior to the Admission Date. Nothing contained herein shall relieve the Transferor from any liability of such Transferor to the Partnership with respect to such Units that may exist on the Admission Date, or that is otherwise specified in the Cayman Act and incorporated into this Agreement, or from any liability to the Partnership or any other Person for any materially false statement made by such Partner (in its capacity as such) or for any present or future breaches of any representations, warranties or covenants by such Transferor (in its capacity as such) contained herein or in the other agreements with the Partnership.
9.6 Encumbrances. No Partner, Transferor or Transferee may create an Encumbrance with respect to all or any portion of its Units (or any beneficial interest therein) other than Encumbrances that run in favor of such Partner, Transferor or Transferee (as applicable), unless the General Partner consents in writing thereto, which consent may be given or withheld, or made subject to such conditions, as are determined by the General Partner, in the General Partner’s sole discretion. Consent of the General Partner shall be withheld until the holder of the Encumbrance acknowledges the
terms and conditions of this Agreement. Any purported Encumbrance that is not in accordance with this Agreement shall be, to the fullest extent permitted by law, null and void.
9.7 Further Restrictions.
(a) Notwithstanding any contrary provision in this Agreement, in no event may any Transfer (including an Exempt Transfer or an Exempt Pledge) of a Unit be made if the General Partner determines that:
(i) such Transfer is being made to a Person lacking the legal right, power or capacity to own such Unit;



Exhibit 1.2
(ii) such Transfer would require the registration of such transferred Unit, or of any class of Unit, pursuant to any applicable U.S. federal or state securities laws (including, without limitation, the Securities Act or the Exchange Act) or other non-U.S. securities laws, or would constitute a non-exempt distribution pursuant to applicable provincial or state securities laws;
(iii) such Transfer would cause (A) all or any portion of the assets of the Partnership to (1) constitute “plan assets” (under ERISA, the Code or any applicable Similar Law) of any existing or contemplated Partner, or (2) be subject to the provisions of ERISA, Section 4975 of the Code or any applicable Similar Law, or (B) the General Partner to become a fiduciary with respect to any existing or contemplated Partner, pursuant to ERISA, any applicable Similar Law, or otherwise;
(iv) the legal and/or tax opinions and written instruments (including, without limitation, copies of any instruments of Transfer and such Transferee’s consent to be bound by this Agreement as a Transferee) requested by the General Partner and received by the Partnership are not in a form satisfactory to the General Partner, as determined in the General Partner’s sole discretion;
(v) such Transfer would, as determined by the General Partner in its sole discretion , (A) pose a material risk that the Partnership would be treated as a “publicly traded partnership” within the meaning of Section 7704 of the Code and the regulations promulgated thereunder, or (B) result in the Partnership having more than ninety-five (95) partners or, in the case of an Exempt Transfer, ninety (90) partners, in each case within the meaning of Treasury Regulations Section 1.7704-1(h)(1) (determined pursuant to the rules in Treasury Regulations Section 1.7704-1(h)(3)).
(b) In addition, notwithstanding any contrary provision in this Agreement, to the extent that the General Partner shall determine, in good faith, that additional restrictions on Transfers are necessary so that the Partnership is not treated as a “publicly traded partnership” under Section 7704 of the Code, the General Partner may impose such additional restrictions on Transfers.
(c) Notwithstanding any contrary provision in this Agreement, in no event may any Transfer of a Unit be made by any Partner unless such Partner or the prospective Transferee(s) of such Units shall have reimbursed the Partnership for all reasonable and documented out-of-pocket expenses (including attorneys’ fees and expenses) incurred and paid by the Partnership in connection with implementing such Transfer or proposed Transfer, whether or not consummated (other than Exchanges pursuant to Article XII or any Transfer to the Partnership). In addition, the Transferor hereby indemnifies and holds harmless the General Partner and the Partnership from and against any losses, claims, damages, or liabilities, arising out of, or based upon, or in connection with such Transfer, to which the General Partner, the Partnership or any of their Affiliates may become subject.
9.8 Counterparts; Joinder. Prior to Transferring any Units (other than Exchanges pursuant to Article XII or any Transfer to the Partnership), and as a condition precedent to the effectiveness of any such Transfer, the transferring holder of Units will cause the prospective transferee(s) of such Units to execute and deliver to the Partnership such instruments as the General Partner deems necessary or desirable, in its reasonable discretion, to effectuate such Transfer, including counterparts of this Agreement and any other agreements relating to such Units, or executed joinders to such agreements, in each case, in a form acceptable to the General Partner. Notwithstanding anything herein to the contrary, to the fullest extent permitted by law, any Person who acquires in any manner whatsoever any Units, irrespective of whether such Person has accepted and adopted in writing the terms and conditions of this Agreement, shall be deemed by the acceptance of the benefits of the acquisition thereof to have agreed to be subject
to and bound by all of the terms and conditions of this Agreement to which any predecessor in such Units was subject or by which such predecessor was bound.
9.9 Ineffective Transfer. Any Transfer or attempted Transfer of any Units in violation of any provision of this Agreement shall, to the fullest extent permitted by law, be null and void ab initio, and the General Partner will not record such Transfer on the books of the Partnership or treat any purported Transferee of such Units as the owner of such Units for any purpose.
9.10 Pass-Through Partners Liquidating or Entering into Certain Transactions.



Exhibit 1.2
(a) If a Pass-Through Partner enters (or intends to enter) into a liquidation or other transaction that could result in an increase in the number of Partners of the Partnership for purposes of the private placement safe harbor in Treasury Regulations Section 1.7704-1(h) (regardless of whether the transaction could result in the number of Partners exceeding 100 for purposes of such safe harbor), then such Pass-Through Partner shall notify the General Partner in writing of such liquidation or other transaction at least twenty (20) days prior to engaging in such transaction.
(b) If a Pass-Through Partner becomes aware that a direct or indirect beneficial owner of such Pass-Through Partner enters (or intends to enter) into a liquidation or other transaction that could result in an increase in the number of Partners of the Partnership for purposes of the private placement safe harbor in Treasury Regulations Section 1.7704- 1(h) (regardless of whether the transaction could result in the number of partners exceeding 100 for purposes of such safe harbor), then such Pass-Through Partner shall take commercially reasonable efforts to notify the General Partner in writing of such liquidation or other transaction at least twenty (20) days prior to the engagement of such direct or
indirect beneficial owner in such transaction.
(c) On the occurrence of any liquidation of a Pass-Through Partner (or the receipt of notice of such a liquidation) that could result in the number of Partners of the Partnership exceeding ninety-five (95) Partners for purposes of the private placement safe harbor in Treasury Regulations Section 1.7704-1(h), the General Partner shall have the right to place customary restrictions on the transfer and exchange rights of Partners, in addition to those described in this Agreement, as necessary to prevent interests in the Partnership from being treated as “readily tradable on a secondary market or the substantial equivalent thereof” within the meaning of Section 7704 of the Code.
ARTICLE X
ADMISSION OF PARTNERS
10.1 Substituted Partners. Subject to the provisions of Article IX hereof, in connection with the permitted Transfer of any Units of a Partner, the Transferee shall become a Substituted Partner on the effective date of such Transfer, which effective date shall not be earlier than the date of compliance with the conditions to such Transfer, and such admission shall be shown on the books and records of the Partnership.
10.2 Additional Partners. Subject to the provisions of Article IX hereof, a Person may be admitted to the Partnership as an Additional Partner only upon furnishing to the Partnership (a) counterparts of this Agreement, or an executed joinder to this Agreement in a form acceptable to the General Partner, and (b) such other documents or instruments as may be necessary or appropriate to effect such Person’s admission as a Partner (including entering into such documents as the General Partner may deem appropriate). Such admission shall become effective on the date on which the General Partner determines that such conditions have been satisfied and when any such admission is shown on the books and records of the Partnership.
10.3 Additional General Partner. No Person may be admitted to the Partnership as an additional General Partner or substitute General Partner without the prior written consent of each incumbent General Partner, which consent may be given, withheld or made subject to such conditions as are determined by each incumbent General Partner, in each case in the sole discretion of each incumbent General Partner. A General Partner will not be entitled to resign as a General Partner of the Partnership unless another General Partner shall have been admitted hereunder (and shall not have previously resigned or been removed) and the requirements of Section 5.6 have been satisfied. Any additional
General Partner or substitute General Partner admitted as a General Partner of the Partnership pursuant to this Section 10.3 is hereby authorized to, and shall, continue the Partnership without dissolution.
ARTICLE XI
WITHDRAWAL AND RESIGNATION OF PARTNERS
No Partner shall have the power or right to withdraw or otherwise resign as a Partner from the Partnership prior to the winding up and dissolution of the Partnership pursuant to Article XIII without the prior written consent of the General Partner, except as otherwise expressly permitted by this Agreement. Any Partner, however, that attempts to withdraw or otherwise resign as a Partner from the Partnership without the prior written consent of the General



Exhibit 1.2
Partner or otherwise as expressly permitted by this Agreement upon or following the winding up and dissolution of the Partnership pursuant to Article XIII, but prior to receipt by such Partner of the full amount of distributions from the Partnership to which such Partner is entitled pursuant to Article XIII, shall be liable to the Partnership for all damages (including all lost profits and special, indirect and consequential damages) directly or indirectly caused by the withdrawal or resignation of such Partner, and such Partner shall be entitled to receive the Fair Market Value of such Partner’s interest in the Partnership as of the date of its resignation (or, if less, the amount that such Partner would have received on account of such interest had such Partner not resigned or otherwise withdrew from the Partnership), as conclusively determined by the General Partner, on the sixth-month anniversary date (or such earlier date determined by the General Partner) following the completion of the distribution of Partnership assets to all other Partners, as provided in Article XIII.
ARTICLE XII
REDEMPTION RIGHTS AND EXCHANGES
12.1 Redemption Right of a Limited Partner.
(a) Upon the terms and subject to the conditions set forth in this Article XII, and further subject to (i) the conditions set forth in any other agreement between such Limited Partner and the Partnership, PubCo or any of their Affiliates; (ii) the availability of an exemption from the registration requirements of the Securities Act or other Applicable Law or a registration statement then in effect with respect to such Limited Partner; and (iii) a Direct Exchange pursuant to Section 12.2, each Limited Partner (collectively with such Limited Partner’s Affiliates and Permitted Transferees), other than the PubCo Partners, shall have the right (a “Redemption Right”) to cause the Partnership to redeem all or a portion of its Units (subject to having the equivalent number of Class B ordinary shares redeemed by the PubCo for no additional consideration) (a “Redemption”); provided that, absent a waiver from the General Partner, a Redemption shall be for a number of Common Units at least equal to or exceeding the Minimum Exchange Amount, at any time and from time to time, except: (x) prior to the expiration or termination of any contractual lock-up period relating to the shares of PubCo that is applicable to such Limited Partner (including, in respect of the Milk Partners, the expiration or termination of the Lock-Up Period set out in the Lock-Up Agreements entered into by PubCo and Milk with each such Milk Partner (the “Milk Lock-Up Agreements”)); (y) to the extent inconsistent with any insider trading policy of the Partnership, any law or regulation relating to insider trading, or any other public stock restrictions, or (z) as otherwise provided in Section 12.1(g). Each Limited Partner exercising the Redemption Right hereby agrees to comply with each covenant and other provision in the PubCo Memorandum and Articles of Association with respect to Class A ordinary shares received in any Redemption involving a Stock Exchange Payment.
(b) A Limited Partner desiring to exercise the Redemption Right (the “Redeeming Partner”) shall exercise such right by giving written notice in the form set forth on Exhibit A to this Agreement to the General Partner with a copy to PubCo (the “Redemption Notice”). The Redemption Notice shall include all information required to be included therein, including the number of Redeemed Units and the Redemption Date.
(c) On the Redemption Date (to be effective immediately prior to the close of business on the Redemption Date), (i) the Redeeming Partner shall transfer the Redeemed Units to the Partnership, free and clear of all liens, and, if the Redeemed Units are certificated, the certificate relating to such Redeemed Units, (ii) upon the Partnership’s receipt of the Redeemed Units and, if applicable, the related certificates, the Partnership shall or shall direct PubCo to (1) provide to the Redeeming Partner the consideration the Redeeming Partner is entitled to receive under Section 12.1(d) (in the form of a Stock Exchange Payment or a Cash Exchange Payment) and (2) cancel the corresponding Class B ordinary shares, (iii) upon receipt of the Redeemed Units and, if applicable, the related certificates, the Partnership shall (x) cancel the Redeemed Units and update the Register accordingly, (y) if the Common Units are certificated, issue to the Redeeming Partner a certificate for a number of Common Units equal to the difference (if any) between the number of Units evidenced by the certificate transferred by the Redeeming Partner pursuant to clause (i) of this Section 12.1(c) and the Redeemed Units (i.e., the number of Units the Redeeming Partner will hold, if any, after the Redemption Date), and (z) issue to the Waldencast Limited Partner in exchange for the consideration provided by PubCo pursuant to Section 12.1(c)(ii) a number of Common Units equal to the number of Redeemed Units transferred by the Redeeming Partner.



Exhibit 1.2
(d) In exercising the Redemption Right, a Redeeming Partner will be entitled to receive either a Cash Exchange Payment or a Share Exchange Payment, calculated by reference to the Exchange Rate, at the sole discretion of PubCo; provided, that, if a Redeeming Partner or any of such Redeeming Partner’s Affiliates is an officer or director of PubCo or has other decision making authority with respect to PubCo, such Redeeming Partner or Affiliate shall not participate in the decision by PubCo as to whether PubCo selects the Cash Exchange Payment or the Stock Exchange Payment. Within five (5) Business Days of the Redemption Notice Date, PubCo shall give written notice to the Partnership and to the Redeeming Partner of PubCo’s intended settlement method.
(e) If a Redeeming Partner causes the Partnership to redeem Redeemed Units, and the Redemption Date occurs subsequent to the record date for any Distribution with respect to the Redeemed Units but prior to the date of such Distribution, the Redeeming Partner will be entitled to receive such Distribution with respect to the Redeemed Units on the date that it is made, and, solely for purposes of such Distribution, such Redeemed Units will be included in the numerator of such Redeeming Partner’s Common Unit Percentage Interest and in the denominator of each Limited Partner’s Common Unit Percentage Interest, notwithstanding that the Redeeming Partner transferred the Redeemed Units to the Partnership prior to the date of the Distributions.
(f) In the event that a Redemption Right is being exercised pursuant to Section 12.1 in order to participate in a Registration (as such term is defined in the Registration Rights Agreement) (i) the Redemption Notice Date shall be prior to the expiration of the time period in which a holder of securities is required to notify PubCo that it wishes to participate in such Registration in accordance with Section 2.1 of the Registration Rights Agreement; and (ii) the General Partner and the Partnership will cooperate in good faith with such Redeeming Partner to exercise such Redemption in a manner which preserves such Redeeming Partner’s rights under the Registration Rights Agreement.
(g) PubCo, the Partnership and each Exchanging Partner shall bear their own expenses in connection with the consummation of any Exchange, whether or not any such Exchange is ultimately consummated, except that the Exchanging Partner shall bear any transfer taxes, stamp taxes or duties, or other similar taxes (irrespective of to which party such taxes or duties arise) in connection with, or arising by reason of, any Exchange.
(h) In connection with any Redemption described in this Section 12.1, Waldencast Limited Partner will issue shares to PubCo in exchange for the consideration provided by PubCo, if any, for which Waldencast Limited Partner received the Common Units described in Section 12.1(c)(iii)(z).
12.2 Exchange Right of the PubCo
(a) Notwithstanding anything to the contrary in this Article XII, PubCo may, in its sole and absolute discretion, elect to effect on the Redemption Date the Redemption of Redeemed Units for the Stock Exchange Payment or Cash Exchange Payment, as the case may be, through a direct exchange of such Redeemed Units and such consideration between the Redeeming Partner and PubCo (a “Direct Exchange”). Upon a Direct Exchange pursuant to this Section 12.2, the Waldencast Limited Partner shall ultimately acquire the Redeemed Units and will be treated for all purposes of this Agreement as the owner of such Units upon the actions set out in Section 12.2(c) occurring or being deemed to occur contemporaneously on the Redemption Date. For the avoidance of doubt, where the Waldencast Limited Partner ultimately acquires any Redeemed Units in accordance with this Section 12.2 each of the actions set out in Section 12.2(c) shall be deemed to have occurred on the Redemption Date.
(b) PubCo may, at any time prior to a Redemption Date, deliver written notice (an “Exchange Election Notice”) to the Partnership and the Redeeming Partner setting forth its election to exercise its right to consummate a Direct Exchange; provided that such election does not prejudice the ability of the Parties to consummate a Redemption or Direct Exchange on the Redemption Date. An Exchange Election Notice may be revoked by PubCo at any time, provided that any such revocation does not prejudice the ability of the Parties to consummate a Redemption or Direct Exchange on the Redemption Date. The right to consummate a Direct Exchange in all events will be exercisable for all the Redeemed Units that would have otherwise been subject to a Redemption. Except as otherwise provided by this Section 12.2, a Direct Exchange will be consummated pursuant to the same timeframe and in the same manner as the relevant Redemption would have been consummated if PubCo had not delivered an Exchange Election Notice.



Exhibit 1.2
(c) If PubCo elects to effect a Direct Exchange, (i) the Redeeming Partner will transfer to PubCo the number of Redeemed Units specified in the Redemption Notice in exchange for the consideration the Redeeming Partner is entitled to receive under Section 12.1(d) (in the form of a Stock Exchange Payment or a Cash Exchange Payment), (ii) in exchange for shares in the Waldencast Limited Partner, PubCo will immediately contribute to the Waldencast Limited Partner the Redeemed Units described in clause (i) and the Waldencast Limited Partner shall automatically be admitted as a Partner of the Partnership in respect of the number of Redeemed Units so transferred and contributed as described in clauses (i) and (ii); and (iii) PubCo will cancel the redeemed Class B ordinary shares as described in Section 12.1(a).
12.3 COC Exchange Right. In the event of a Change of Control, the General Partner may elect, pursuant to a written notice given to the Partners (other than the PubCo Partners) (each, a “COC Exchanging Partner”) at least thirty (30) days prior to the consummation of a Change of Control (a “COC Notice”), to require each such Partner to effect an exchange with respect to any portion of such Partner’s Common Units (together with the redemption and subsequent cancellation of the corresponding number of outstanding Class B ordinary shares held by such Partner for nil consideration) (a “COC Exchange”), which shall be effective immediately prior to the consummation of the Change of Control (but such COC Exchange shall be conditioned on the consummation of such Change of Control, and shall not be effective if such Change of Control is not consummated) (the “COC Exchange Date”). Each COC Exchange shall take the form of a Redemption by the Partnership or a Direct Exchange, in each case for either (i) the Stock Exchange Payment with respect to the Common Units subject to the COC Exchange or (ii) the Cash Exchange Payment, so long as in each case each such Partner receives the identical consideration or the identical right to elect the form of consideration, in each case on a per Unit basis, that the holder of a Class A ordinary share would receive in connection with such Change of Control. Notwithstanding anything in this Section 12.4 to the contrary, the General Partner cannot elect to require any COC Exchanging Partner to effect a COC Exchange unless such Partner receives, pursuant to such COC Exchange (including in connection with the consummation of such Change of Control), (x) consideration consisting entirely of (A) cash, (B) Equity Securities of a Person that (I) are listed on a National Securities Exchange within sixty (60) days of the consummation of such Change of Control and (II) can be resold without registration or within sixty (60) days of the consummation of such Change of Control are registered for resale on a shelf registration statement under the Securities Act (the Equity Securities referred to in this clause (B), the “Liquid Securities”), or (C) a combination of cash and Liquid Securities, or (y) consideration that includes cash and Liquid Securities, where the sum of such cash plus the Fair Market Value of such Liquid Securities is at least equal to the income taxes incurred by such Partner in connection with such COC Exchange (including in connection with the consummation of such Change of Control), determined on a “with and without” basis.
12.4 Limitations on Exchanges; Effect of Redemption or Exchange; Call Right.
(a) This Agreement shall continue notwithstanding the consummation of an Exchange, and all governance or other rights set forth herein will be exercised by the remaining Limited Partners and the Redeeming Partner (to the extent of such Redeeming Partner’s remaining interest in the Partnership). No Exchange shall relieve such Redeeming Partner of any prior breach of this Agreement.
(b) Notwithstanding anything to the contrary herein, the General Partner may impose such restrictions on an Exchange as PubCo or the General Partner may determine to be necessary or advisable so that the Partnership is not treated as a “publicly traded partnership” under Section 7704 of the Code. Notwithstanding anything to the contrary herein, no Exchange shall be permitted (and, if attempted, shall, to the fullest extent permitted by law, be void ab initio) if, in the good faith determination of PubCo or the General Partner, such an Exchange would pose a material risk that the Partnership would be a “publicly traded partnership” under Section 7704 of the Code. If at any time the General Partner determines that, as a result of a change in law after the Effective Date, compliance by PubCo, PubCo’s Subsidiaries or the Partnership with any of the provisions of this Article XII would give rise to a material tax liability or tax consequence for PubCo, PubCo’s Subsidiaries or the Partnership, then the General Partner may, in good faith, implement an alternative arrangement without complying with such provisions that is economically equivalent (on an after tax basis and ignoring any de minimis variation) to PubCo, PubCo’s Subsidiaries, the Partnership, and each of the Partners vis-à-vis compliance with such provisions..
(c) For the avoidance of doubt, and notwithstanding anything to the contrary herein, a Partner shall not be entitled to effect an Exchange to the extent PubCo or the Partnership determines that such Exchange (i) would be prohibited by



Exhibit 1.2
law or regulation (including, without limitation, the unavailability of any requisite registration statement filed under the Securities Act or any exemption from the registration requirements thereunder) or (ii) would not be permitted under any other agreements with PubCo or its subsidiaries to which such Partner may be party (including, without limitation, this Agreement) or any written policies of PubCo related to unlawful or inappropriate trading applicable to its directors, officers or other personnel.
(d) Once the Partners have caused Exchanges to have occurred that cause the aggregate Common Units held by the Milk Partners to be equal to or less than 20% of the total Common Units held by the Milk Partners as of the Effective Time, the Partnership shall have the right to acquire all or a portion of the remaining Common Units that remain outstanding in exchange for cash or Class A ordinary shares on a one-for-one basis, at the Partnership’s sole discretion, provided that the Partnership shall not exercise its right to effect a compulsory redemption and Exchange during the Lock-Up Period in accordance with the Milk Lock-Up Agreements; provided further that the Partnership shall provide the Milk Partners ten (10) Business Days prior notice of its intention to exercise such right and to provide each Milk Partner the option, at their sole discretion, to exchange their Common Units for Class A ordinary shares on a one-for one basis. For the avoidance of doubt, the Class A ordinary shares to be received in exchange for the Common Units shall be subject to the lock-up requirements set forth in the Milk Lock-Up Agreements.
12.5 Adjustments.
(a) The Exchange Rate shall be adjusted accordingly if there is: (i) any subdivision (by any unit split, unit distribution, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse unit split, reclassification, reorganization, recapitalization or otherwise) of the applicable Units that is not accompanied by a substantively identical subdivision or combination of the Class A ordinary shares; or (ii) any subdivision (by any share split, share dividend or distribution, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse share split, reclassification, reorganization, recapitalization or otherwise) of the Class A ordinary shares that is not accompanied by a substantively identical subdivision or combination of Class B ordinary shares or the applicable Units, in each case, to the extent necessary to maintain the economic equivalency in the value transferred for Exchange and the value received, as determined by PubCo in its sole discretion; provided, however, that no adjustment to the Exchange Rate will be made solely as a result of a share dividend by PubCo that is effected to maintain the relationship between the outstanding Class A ordinary shares and Common Units. If there is any reclassification, reorganization, recapitalization or other similar transaction in which the Class A ordinary shares are converted or changed into another security or other property, then, and in each such event, provision shall be made so that the Redeeming Partner shall receive upon the Exchange the amount of such security or other property that such Redeeming Partner would have received if such Exchange had occurred immediately prior to the effective date of such reclassification, reorganization, recapitalization or other similar transaction, and had such Redeeming Partner thereafter, during the period from the date of such event to and including the Exchange Date, retained such security or other property receivable by such Redeeming Partner as aforesaid during such period, giving application to all adjustments called for during such period under this Section 12.5(a) with respect to the rights of the Redeeming Partner. Except as may be required in the immediately preceding sentences, no adjustments in respect of distributions shall be made upon the Exchange of any Unit. This Agreement shall apply to, and all references to “Units” shall be deemed to include, any security or other property of PubCo or the Partnership which may be issued in respect of, in exchange for or in substitution of Class B ordinary shares or Common Units, as applicable, by reason of share or unit split, reverse share or unit split, share or unit dividend or distribution, combination, reclassification, reorganization, recapitalization, merger, exchange (other than an Exchange) or other transaction, mutatis mutandis.
(b) This Agreement shall apply to the Units held by the Partners and their Permitted Transferees as of the date hereof, as well as any Units hereafter acquired by a Partner and his or her or its Permitted Transferees.
12.6 Reservation of Class A ordinary shares.
(a) PubCo shall at all times reserve and keep available out of its authorized but unissued Class A ordinary shares, solely for the purpose of issuance upon an Exchange, such number of Class A ordinary shares as shall be deliverable upon any such Exchange; provided that nothing contained herein shall be construed to preclude PubCo or the Partnership from satisfying its obligations in respect of the Exchange of the Units by delivery of Class A ordinary shares which are held in the treasury of PubCo or are held by the Partnership or any of their Subsidiaries or by



Exhibit 1.2
delivery of purchased Class A ordinary shares (which may or may not be held in the treasury of PubCo or held by any subsidiary thereof). PubCo and the Partnership covenant that all Class A ordinary shares issued upon an Exchange will, upon issuance, have been duly authorized and validly issued and will be fully paid and non-assessable.
(b) PubCo and the Partnership covenant and agree that, to the extent that a registration statement under the Securities Act is effective and available for Class A ordinary shares to be delivered with respect to any Exchange, shares that have been registered under the Securities Act shall be delivered in respect of such Exchange. In the event that any Exchange in accordance with this Agreement is to be effected at a time when any required registration has not become effective or otherwise is unavailable, upon the request and with the reasonable cooperation of the Partner requesting such Exchange, PubCo and the Partnership shall use commercially reasonable efforts to promptly facilitate such Exchange pursuant to any reasonably available exemption from such registration requirements. PubCo and the Partnership shall use commercially reasonable efforts to list the Class A ordinary shares required to be delivered upon Exchange prior to such delivery upon each national securities exchange or inter-dealer quotation system upon which the outstanding Class A ordinary shares may be listed or traded at the time of such delivery.
(c) PubCo shall use its reasonable best efforts to take all reasonable steps as may be required to cause to qualify for exemption under Rule 16b-3(d) or (e), as applicable, under the Exchange Act, and to be exempt for purposes of Section 16(b) under the Exchange Act, any acquisitions from, or dispositions to, PubCo, of Equity Securities of PubCo (including derivative securities with respect thereto) and any securities that may be deemed to be Equity Securities or derivative securities of PubCo for such purposes that result from the transactions contemplated by this Agreement, by each executive officer (including the chief accounting officer) or director of PubCo.
12.7 Restrictions. Any restrictions on transfer of Common Units under any agreements with PubCo or any of its subsidiaries (other than this Agreement) to which a Redeeming Partner may be party shall apply, mutatis mutandis, to any Class A ordinary shares and Class B ordinary shares.
12.8 Distribution Rights. No Exchange shall impair the right of the Redeeming Partner to receive any distributions payable on the Common Units redeemed pursuant to such Exchange in respect of a record date that occurs prior to the Exchange Date for such Exchange. No Redeeming Partner, or a Person designated by a Redeeming Partner to receive Class A ordinary shares, shall be entitled to receive, with respect to such record date, distributions or dividends both on Common Units redeemed by the Partnership from such Redeeming Partner and on Class A ordinary shares received by such Redeeming Partner, or other Person so designated, if applicable, in such Exchange.
12.9 Tax Treatment; Tax Withholding.
(a) As required by the Code and the Treasury Regulations, the parties shall report (i) any Direct Exchange consummated hereunder as a taxable sale of Common Units and Class B ordinary shares by a Partner to PubCo in a transaction governed by Section 741 of the Code, and (ii) any Exchange other than a Direct Exchange in which the consideration is contributed (or deemed contributed) to the Partnership by PubCo as a disguised sale of Common Units in a transaction governed by Section 707 of the Code and a taxable sale of Class B ordinary shares by the Redeeming Partner to PubCo, and no party shall take a contrary position on any income tax return, amendment thereof or communication with a taxing authority, unless an alternate position is permitted under the Code and Treasury Regulations and PubCo and the Redeeming Partner consent in writing.
(b) Notwithstanding any other provision in this Agreement (and without limiting Section 4.5 or Section 9.1(c)), PubCo, the Partnership and their agents and affiliates shall have the right to deduct and withhold taxes (including Class A ordinary shares with a fair market value determined in the sole discretion of PubCo equal to the amount of such taxes) from any payments to be made pursuant to the transactions contemplated by this Agreement if, in their opinion, such withholding is required by law, and shall be provided with any necessary tax forms, including Form W-9 or the appropriate series of Form W-8, as applicable, and any similar information; provided that (i) PubCo may, in its sole discretion, allow a Redeeming Partner to pay such taxes owed on the Exchange of Units and Class B ordinary shares for Class A ordinary shares, in cash, in lieu of PubCo withholding or deducting such taxes, and (ii) PubCo will notify the Redeeming Partner at least five (5) Business Days prior to any required deduction or withholding (other than withholding on amounts properly treated as compensation for tax purposes or subject to



Exhibit 1.2
withholding under Section 1446(f)) and shall reasonably cooperate with the Redeeming Partner to reduce or eliminate any such withholding prior to any remittance to a governmental authority. To the extent that any of the aforementioned amounts are so withheld, such withheld amounts shall be treated for all purposes of this Agreement as having been delivered and paid to the recipient of the payments in respect of which such deduction and withholding was made. To the extent that any payment pursuant to this Agreement is not reduced by such deductions or withholdings, such recipient shall indemnify the applicable withholding agent for any amounts imposed by any taxing authority together with any costs and expenses related thereto.
(c) In connection with any Redemption Notice or COC Notice, the Redeeming Partner shall deliver to PubCo or the Partnership, as applicable, a certificate, dated as of the Exchange Date and sworn under penalties of perjury, in a form reasonably acceptable to PubCo or the Partnership, as applicable, certifying such Redeeming Partner’s taxpayer identification number and that such Redeeming Partner is a not a “foreign person,” for purposes of Section 1445 and Section 1446(f) of the Code (which certificate may be an Internal Revenue Service Form W-9 if then sufficient for such purposes under Applicable Law or written evidence that all required withholding under Section 1446(f) of the Code will have been done and duly remitted to the applicable taxing authority). In the event that a Limited Partner fails or is unable to deliver to the Partnership such a certificate, the Partnership may withhold amounts from such Limited Partner in accordance with Section 4.5(b) to the extent required under Applicable Law.
Section 12.10 The provisions of this Article XII will be interpreted and applied in a manner consistent with the corresponding provisions of the PubCo Memorandum and Articles of Association.
ARTICLE XIII
WINDING UP AND DISSOLUTION
13.1 Dissolution. The Partnership shall not be dissolved by the admission of Additional Partners or Substituted Partners or the attempted withdrawal or resignation of a Partner. The Partnership shall be wound up and subsequently dissolved upon:
(a) the entry of a decree of judicial dissolution of the Partnership under the Cayman Act;
(b) at any time there are less than two Partners (being one general partner and one limited partner), unless the Partnership is continued in accordance with the Cayman Act;
(c) the sale of all or substantially all of the assets of the Partnership;
(d) the determination of the General Partner to wind up and dissolve the Partnership; or
(e) any event which makes it unlawful for the business of the Partnership to be carried on by the General Partner.
The Partners hereby agree that the Partnership shall not wind up and dissolve prior to the occurrence of one of the events specified in the first sentence of this Section 13.1. In the event of a winding up and dissolution pursuant to Section 13.1(d), the relative economic rights of each class of Units immediately prior to such winding up and dissolution shall be preserved to the greatest extent practicable with respect to distributions made to Partners pursuant to Section 13.2 in connection with such winding up and dissolution, taking into consideration tax and other legal constraints that may adversely affect one or more Partners and subject to compliance with Applicable Law, unless, with respect to any class of Units, holders of at least ninety percent (90%) of the Units of such class not held by the General Partner consent in writing to a treatment other than as described above. Further, if a winding up and dissolution pursuant to Section 13.1(d) or Section 13.1(e) would have a material adverse effect on any Partner, the winding up and dissolution of the Partnership shall require the prior consent of such Partner, which consent shall not be unreasonably withheld, delayed or conditioned.
Except as otherwise set forth in this Article XIII, the Partnership is intended to have perpetual existence. An Event of Withdrawal shall not, in and of itself, cause a winding up and dissolution of the Partnership, and the Partnership shall continue in existence subject to the terms and conditions of this Agreement.



Exhibit 1.2
13.2 Winding Up and Termination. On winding up and dissolution of the Partnership, the General Partner shall act as liquidating trustee or may appoint one or more Persons as liquidator or liquidating trustee (or, if there is no General Partner, such liquidating trustee may be designated by the Partners). The liquidator or liquidating trustee shall proceed diligently to wind up the affairs of the Partnership and make final distributions as provided herein and in the Cayman Act; provided that the winding up of the Partnership shall not commence until notice of winding up has been filed with the Registrar of Exempted Limited Partnerships in the Cayman Islands, unless the General Partner or liquidator resolves or determines otherwise. The costs of winding up shall be borne as a Partnership expense. Until final distribution, the liquidating trustee shall continue to operate the Partnership properties with all of the power and authority of the General Partner. The following steps are to be accomplished by the liquidator or liquidating trustee in the following order:
(a) as promptly as possible after commencement of winding up, and again after completion of the dissolution, the liquidator or liquidating trustee shall cause a proper accounting to be made by a recognized firm of certified public accountants of the Partnership’s assets, liabilities and operations through the last day of the calendar month in which the winding up occurs or the dissolution occurs;
(b) the liquidator or liquidating trustee shall pay, satisfy or discharge from Partnership funds all of the debts, liabilities and obligations of the Partnership (including, without limitation, all expenses incurred in winding up) or otherwise make adequate provision for payment and discharge thereof (including, without limitation, the establishment of a cash fund for contingent, conditional or unmatured liabilities in such amount and for such term as the liquidating trustee may reasonably determine); and
(c) all remaining assets of the Partnership shall be distributed to the Partners in accordance with Section 4.1(c) by the end of the Taxable Year of the Partnership during which the winding up of the Partnership occurs (or, if later, by ninety (90) days after the date of the winding up).
The distribution of cash and/or property to Partners in accordance with the provisions of this Section 13.2 and Section 13.3 constitutes a complete return to the Partners of their Capital Contributions and a complete distribution to the Partners of their interest in the Partnership and all the Partnership’s property. To the extent that a Partner returns funds to the Partnership, it has no claim against any other Partner for those funds.
13.3 Deferment; Distribution in Kind. Notwithstanding the provisions of Section 13.2, but subject to the order of priorities set forth therein, if upon winding up of the Partnership the liquidator or liquidating trustee determines that an immediate sale of part or all of the Partnership’s assets would be impractical or would cause undue loss (or would otherwise not be beneficial) to the Partners, the liquidator or liquidating trustee may, in its sole discretion, defer for a reasonable time the winding up of any assets, except those necessary to satisfy Partnership liabilities (other than loans to the Partnership by Partners) and reserves. Subject to the order of priorities set forth in Section 13.2, the liquidator or liquidating trustee may, in its sole discretion, distribute to the Partners, in lieu of cash, either (i) all or any portion of such remaining Partnership assets in-kind in accordance with the provisions of Section 13.2(c), (ii) as tenants in common and in accordance with the provisions of Section 13.2(c), undivided interests in all or any portion of such Partnership assets, or (iii) a combination of the foregoing. Any such distributions in kind shall be subject to (x) such conditions relating to the disposition and management of such assets as the liquidator or liquidating trustee deems reasonable and equitable and (y) the terms and conditions of any agreements governing such assets (or the operation or the holders thereof) at such time. Any Partnership assets distributed in kind will first be written up or down to their Fair Market Value, thus creating profit or loss (if any), which shall be allocated in accordance with Section 4.2. The liquidator or liquidating trustee shall determine the Fair Market Value of any property distributed in accordance with the valuation procedures set forth in Article XIV.
13.4 Cancellation of Certificate. On completion of the winding up of the Partnership’s affairs and distribution of Partnership assets as provided herein, the Partnership is terminated (and the Partnership shall not be terminated prior to such time), and the General Partner (or such other Person or Persons as the Cayman Act may require or permit) shall file a notice of dissolution with the Registrar of Exempted Limited Partnerships in the Cayman Islands, cancel any other filings made pursuant to this Agreement that are or should be canceled and take such other actions as may be necessary to terminate the Partnership. The Partnership shall be deemed to continue in existence for all purposes of this Agreement until it is terminated pursuant to this Section 13.4.



Exhibit 1.2
13.5 Reasonable Time for Winding Up. A reasonable time shall be allowed for the orderly winding up of the business and affairs of the Partnership and the liquidation of its assets pursuant to Sections 13.2 and 13.3 in order to minimize any losses otherwise attendant upon such winding up.
13.6 Return of Capital. The liquidator or liquidating trustee shall not be personally liable for the return of Capital Contributions or any portion thereof to the Partners (it being understood that any such return shall be made solely from Partnership assets).
ARTICLE XIV
VALUATION
14.1 Value. “Fair Market Value” of any asset, property or equity interest means the amount which a seller of such asset, property or equity interest would receive in a sale of such asset, property or equity interest in an arm’s-length transaction with an unaffiliated third party, consummated on a date determined by the General Partner (which may be the date on which the event occurred which necessitated the determination of the Fair Market Value) (and after giving effect to any transfer taxes payable in connection with such sale). Notwithstanding the foregoing, in making the determination of Fair Market Value as described in Section 14.2, the General Partner, the Disputing Partner (defined below) and any investment banking firm (as described below) shall not give effect or take into account any “minority discount” or “liquidity discount” (or any similar discount arising out of the fact that the Units are restricted or are not registered with the Securities and Exchange Commission, publicly traded or listed on a securities exchange), but shall value the Partnership and its Subsidiaries and their respective businesses in their entirety on an enterprise basis, using any variety of industry recognized valuation techniques commonly used to value businesses.
14.2 Determination and Dispute. Fair Market Value shall be determined by the General Partner (or, if pursuant to Section 13.3, the liquidating trustee) in its good faith judgment in such manner as it deems reasonable and using all factors, information and data deemed to be pertinent. Notwithstanding the foregoing, the General Partner may, in its own discretion, or will at the request of any Partner or Partners that hold at least 5% of the total number of Common Units on issue (a “Disputing Partner”), cause the Partnership to retain a financial advisory, valuation or investment banking firm of recognized national standing, reasonably acceptable to such Disputing Partner, to advise upon the determination of the Fair Market Value of such Units, assets or consideration; provided that any such determination shall ultimately be made by the General Partner.
ARTICLE XV
GENERAL PROVISIONS
15.1 Power of Attorney.
(a) Each holder of Units hereby constitutes and appoints the General Partner and the liquidator or liquidating trustee, as applicable, with full power of substitution, as his, her or its true and lawful agent and attorney-in-fact, with full power and authority in his, her or its name, place and stead, to:
(i) execute, swear to, acknowledge, deliver, file and record in the appropriate public offices: (A) this Agreement and all certificates and other instruments and all amendments thereof which the General Partner deems appropriate or necessary to form, qualify, or continue the qualification of, the Partnership as an exempted limited partnership (or a partnership in which the limited partners have limited liability) in the Cayman Islands and in all other jurisdictions in
which the Partnership may conduct business or own property; (B) all instruments which the General Partner deems appropriate or necessary to reflect any amendment, change, modification or restatement of this Agreement in accordance with its terms; (C) all conveyances and other instruments or documents which the General Partner or the liquidating trustee, as applicable, deems appropriate or necessary to reflect the winding up and dissolution of the Partnership pursuant to the terms of this Agreement; and (D) all instruments relating to the admission, withdrawal or substitution of any Partner pursuant to Article X or Article XI; and



Exhibit 1.2
(ii) sign, execute, swear to and acknowledge all ballots, consents, approvals, waivers, certificates and other instruments appropriate or necessary, in the reasonable judgment of the General Partner, to evidence, confirm or ratify any vote, consent, approval, agreement or other action which is made or given by such holder of Units hereunder or is consistent with the terms of this Agreement and/or appropriate or necessary (and not inconsistent with the terms of this Agreement), in the reasonable judgment of the General Partner, to effectuate the terms of this Agreement.
(b) For the avoidance of doubt, the foregoing power of attorney does not include the power or authority to vote any Units held by any Partner on any matter on which the Partners have a right to vote, either at a meeting or by any written consent, either as contemplated by Section 6.5 or otherwise under this Agreement.
(c) The foregoing power of attorney is irrevocable and coupled with an interest, and shall survive the death, disability, incapacity, dissolution, bankruptcy, insolvency or termination of any Partner and the Transfer of all or any portion of his, her or its Units and shall extend to such Partner’s heirs, successors, assigns and personal representatives.
15.2 Amendments.
(a) The General Partner (pursuant to its power of attorney from the holders of Units as provided in Section 15.1 or otherwise), without the consent of any holder of Units, may amend any provision of this Agreement, and execute, swear to, acknowledge, deliver, file and record whatever documents may be required in connection therewith, to reflect:
(i) a change in the name of the Partnership or the location of the principal place of business of the Partnership; (ii) admission, substitution, removal or withdrawal of Partners or Transferees in accordance with this Agreement;
(iii) a change that does not adversely affect any holder of Units in any material respect in its capacity as an owner of Units and is necessary or desirable to satisfy any requirements, conditions or guidelines contained in any opinion, directive, order, ruling or regulation of any United States federal or state agency or judicial authority or contained in any United States federal or state statute;
(iv) as contemplated by Section 3.1(e); or
(v) as contemplated by Section 3.6.
(b) Except as provided in Section 15.2(a), this Agreement may not be amended or modified except with the consent of the General Partner and, so long as the holders of the Common Units have an ownership percentage of at least 10% of the total issued and outstanding Common Units, the consent or approval of the holders of a majority of the Common Units, in writing, to a treatment other than as described above. Notwithstanding the preceding sentence, (i) no consent or approval shall be required for the Partnership to admit a Permitted Transferee as a Partner following an Exempt Transfer completed in compliance with this Agreement, and (ii) if the holders of the Common Units have an ownership percentage of less than 10% of the total issued and outstanding Common Units, the holders of a majority of the Common Units must also consent to or approve any amendments or modifications to Article IV, Section 9.1, Article XII, Section 13.2, this Section 15.2 or related definitions, or any other amendments or modifications that affect the rights granted to the such holders in such sections in any material respect, including, without limitation, changes to the number of Class A ordinary shares issued upon an Exchange, either through an amendment to the definition of “Exchange Rate” or otherwise, or that otherwise increase the obligations of or decrease the benefits to the applicable holders. Notwithstanding the foregoing, any amendment which would materially and adversely affect the rights or duties of a Partner on a discriminatory and non-pro rata basis shall require the consent of such Partner, other than
those actions set forth in Section 15.2(a) above. In addition, the amendment of any specific approval, consent, voting right, or transfer rights of a specified Partner shall require the approval of such Partner; provided that such Partner holds the number of Units, as applicable, required to exercise such rights. Any amendment or modification effected in accordance with this Section 15.2(b) shall be effective, in accordance with its terms, with respect to the rights and



Exhibit 1.2
obligations of, and binding upon, all Partners. For the avoidance of doubt, without any action or requirement of consent by any Partner, the Partnership shall update the books and records of the Partnership to remove a Partner’s name therefrom once such Partner no longer holds any Equity Securities of the Partnership, following which such Person shall cease to be a “Partner” or have any rights or obligations under this Agreement.
15.3 Title to Partnership Assets. Any rights or property of every description of the Partnership that is conveyed to or vested in or held on behalf of the General Partner or in the name of the Partnership shall be held or deemed to be held by the General Partner upon trust as an asset of the Partnership in accordance with the terms of this Agreement. No holder of Units, individually or collectively, shall have any ownership interests in any assets of the Partnership or any portion thereof.
15.4 Addresses and Notices. Any notice provided for in this Agreement will be in writing and will be either personally delivered or received by certified mail, return receipt requested, sent by reputable overnight courier service (charges prepaid), or electronic mail to the Partnership at the address set forth below and to any other recipient and to any holder of Units at such address as indicated by the Partnership’s records, or at such address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder when delivered personally, three days after deposit in the U.S. mail and one day after deposit with a reputable overnight courier service and, on the day sent, if sent by electronic mail if confirmation of receipt is received. The Partnership’s address is:
To the Partnership, PubCo or the General Partner:
Waldencast Partners LP
10 Bank Street, Suite 560
White Plains, NY 10606
Attention: Michel Brousset
Email: michel@waldencast.com
with a copy (which shall not constitute notice) to:
Skadden, Arps, Slate, Meagher & Flom LLP
One Manhattan West
New York, New York 10001
Attention: Paul T. Schnell
Maxim Mayer-Cesiano
Email: paul.schnell@skadden.com
maxim.mayercesiano@skadden.com
To any Milk Partner:
To the address or email set forth opposite such Milk Partner’s name on Schedule I
with a copy (which shall not constitute notice) to:
Goodwin Procter LLP
601 Marshall Street
Redwood City, California 94063
Attention: Daniel J. Espinoza
Email: despinoza@goodwinlaw.com
15.5 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their heirs, executors, administrators, successors, legal representatives and permitted assigns. Except as otherwise provided in this Agreement, no Partner may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of the General Partner.



Exhibit 1.2
15.6 Waiver. No failure by any party to insist upon the strict performance of any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute a waiver of any such breach or any other covenant, duty, agreement or condition.
15.7 Counterparts. This Agreement may be executed in separate counterparts, each of which will be an original, and all of which together shall constitute one and the same agreement binding on all the parties hereto.
15.8 Applicable Law; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the laws of the Cayman Islands, without giving effect to any choice of law or conflict of law rules or provisions (whether of the Cayman Islands or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the Cayman Islands. Any dispute relating hereto shall be heard in the state or federal courts of the state of New York, and the parties agree to exclusive jurisdiction and venue therein and waive, to the fullest extent permitted by law, any objection based on venue or forum non conveniens with respect to any action instituted therein. The Parties hereto consent to service being made through the notice procedures set forth in Section 15.4 and irrevocably submit to the jurisdiction of the aforesaid courts. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
15.9 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any Applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision, or the effectiveness or validity of any provision, in any other jurisdiction, and this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.
15.10 Further Action. The Parties shall use commercially reasonable efforts to execute and deliver all documents, provide all information and take or refrain from taking such actions as may be necessary or appropriate to achieve the purposes of this Agreement.
15.11 Offset. Whenever the Partnership is to pay any sum to any holder of Units or any Affiliate or related person thereof, any undisputed amounts that such holder of Units or such Affiliate or related person owes to the Partnership (such lack of dispute to be evidenced by written confirmation of such by such holder of Units or related person thereof) may be deducted from that sum before payment.
15.12 Entire Agreement. This Agreement, and those documents expressly referred to herein (including the Registration Rights Agreement), embody the complete agreement and understanding among the Parties and supersede and preempt any prior understandings, agreements or representations by or among the Parties, written or oral (including the Prior Agreement), which may have related to the subject matter hereof in any way.
15.13 Remedies. Each holder of Units shall have all rights and remedies set forth in this Agreement and all rights and remedies which such Person has been granted at any time under any other agreement or contract and all of the rights which such Person has under any Applicable Law. Any Person having any rights under any provision of this Agreement or any other agreements contemplated hereby shall be entitled to seek to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law.
15.14 Descriptive Headings; Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. Whenever required by the context, any pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns and verbs shall include the plural and vice versa. The use of the word “including” in this Agreement shall be by way of example rather than by limitation. Reference to any agreement, document or instrument means such agreement, document or instrument as amended or otherwise modified from time to time in accordance with the terms thereof, and if applicable hereof. The use of the words “or,” “either” and “any” shall not be exclusive. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity



Exhibit 1.2
or question of intent or interpretation arises, to the fullest extent permitted by law, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Wherever a conflict exists between this Agreement and any other agreement, this Agreement shall control but solely to the extent of such conflict.
15.15 Spousal Consent. Each Partner who is married severally represents that true and complete copies of this Agreement and all documents to be executed by such Partner hereunder have been furnished to his or her spouse, represents and warrants to the Partnership and to the other Partners that such spouse has read this Agreement and all related documents applicable to such Partner, is familiar with each of their terms, and has agreed to be bound to the obligations of such Partner hereunder and thereunder and has executed the form of spousal consent set forth in Exhibit B to this Agreement.
15.16 Third-Party Rights. A person who is not a party to this Agreement may not, in its own right or otherwise, enforce any term of this Agreement, except that, each Indemnified Person may in its own right enforce Section 6.4 of this Agreement, subject to and in accordance with the provisions of the Contracts (Rights of Third Parties) Act (As Revised) of the Cayman Islands, as amended, modified, re-enacted or replaced. Notwithstanding any other term of this Agreement, the consent of any person who is not a party to this Agreement (including, without limitation, any Indemnified Person) is not required for any amendment to, or variation, release, rescission or termination of, this Agreement.
* * * * *






Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
WALDENCAST CAYMAN LLC, as General Partner
By:     /s/ Michel Brousset    
Name: Michel Brousset
Title: Manager
EXECUTED AND\ DELIVERED AS A DEED BY:
WALDENCAST PLC
By:     /s/ Michel Brousset    
Name: Michel Brousset
Title: Chief Executive Officer


Exhibit 1.2

EXECUTED AND DELIVERED AS A DEED BY:

OBAGI HOLDCO 1 LIMITED, as Limited Partner


By:     /s/ Robert Lucas            
Name: Robert Lucas
Title: Director







Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
ACG DAIRY LLC
By: Alliance Consumer Growth, LLC, its Manager
By:         
Name:
Title:

in the presence of:
image_0.jpg
Witness Name:
Witness Address:



Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
[PARTNER]
By:     Amorepacific Group    image_1a.jpg
Name: Seung-hwan Kim
Title: President

in the presence of:
                
Witness Name:
Witness Address



Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
[PARTNER]
By: /s/ Dianna Ruth            
Name: Dianna Ruth
Title:

in the presence of:
/s/ Tim Coolican            
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road



Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
[PARTNER]
By: /s/ Erez Shternlict
Name: Erez Shternlicht
Title: Member

in the presence of:
    /s/ Tim Coolican        
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road





Exhibit 1.2
image_2.jpgIN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
GEORGIE GREVILLE JASPER
By: /s/ Georgia Greville Jasper    
Name:
Title:

in the presence of:
    /s/ Tim Coolican        
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road






Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
Main Post Growth Capital, L.P.
By: /s/ Josh D. McDowell        
Name: Josh D. McDowell
Title: Partner

in the presence of:

                    
Witness Name:
Witness Address:








Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
MAZDACK RASSI
By: /s/ Mazdack Rassi        
Name:
Title:

in the presence of:
    /s/ Tim Coolican        
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road




Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
Moishe Mana
By: /s/ Bruce D. Fischman        
Name: Bruce D. Fischman
Title: Attorney-in-fact

in the presence of:
    /s/ Tim Coolican        
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road





Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
SCOTT SASSA
By: /s/ Scott Sassa        
Name:
Title:

in the presence of:
    /s/ Tim Coolican    
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road






Exhibit 1.2
IN WITNESS WHEREOF, the undersigned have executed and delivered this Amended and Restated Limited Partnership Agreement as a deed on the date first above written.
EXECUTED AND DELIVERED AS A DEED BY:
SUZANNA ROBERTS RASSI
By: /s/ Suzanna Roberts Rassi        
Name:
Title:
in the presence of:
    /s/ Tim Coolican        
Witness Name: Tim Coolican
Witness Address: 29 Edgewood Road




Exhibit 1.2


SCHEDULE I 
PARTNERS; PARTNERSHIP INTERESTS; ADDRESSES




Exhibit 1.2
SCHEDULE OF PARTNERS 

Name of Partner Address of Partner 
Nature of Interest in  
Partnership 
Date of Admission Date Ceased to be a Partner 
Waldencast Cayman LLC 
PO Box 309, Ugland House  Grand Cayman  
KY1-1104  
Cayman Islands
General Partner 25 July 2022 
Obagi Holdco 1 Limited 
2nd Floor, Sir Walter Raleigh  House  
48-50 Esplanade  
St Helier, JE2 3QB  
Jersey
Limited Partner 25 July 2022 
ACG Dairy LLC 
410 Park Avenue, Suite 600  New York  
NY, 10022  
United States
Limited Partner 27 July 2022 
AmorePacific Group 
100, Hangang-daero  
Yongsan-gu  
Seoul  
Republic of Korea
Limited Partner 27 July 2022 
Dianna Ruth 
272 Sycamore Ave Shrewsbury  NJ, 7702  
USA
Limited Partner 27 July 2022 
Erez Shternlicht 
7146 La Presa Drive  
Los Angeles  
CA, 90068  
USA
Limited Partner 27 July 2022 
Georgia Greville Jasper 
138 Broadway, #6D  
New York  
NY, 11211  
USA
Limited Partner 27 July 2022 
Main Post Growth Capital, L.P. 
One Embarcadero Center, Suite  3500  
San Francisco  
CA, 94111  
USA
Limited Partner 27 July 2022 
Mazdack Rassi 
17 Vyl Atwood Road  
Stone Ridge  
NY, 12484  
USA
Limited Partner 27 July 2022 
Moishe Mana 
16722 Senterra Drive  
Delray Beach
FL, 33484  
USA
Limited Partner 27 July 2022 



Exhibit 1.2
Scott Sassa 

2392 Century Hill  
Los Angeles  
CA,  
90067  
USA
Limited Partner 27 July 2022 
Suzanna Roberts Rassi 
17 Vyl Atwood Road  
Stone Ridge  
NY, 12484  
USA
Limited Partner 27 July 2022 
Scott M. Sassa Extra-Crummey  Trust dated August 25, 2014 
2392 Century Hill  
Los Angeles  
CA,  
90067  
USA
Limited Partner 
30 December 2022 (with  
economic effect on 27 July 2022) 







Exhibit 1.2
EXHIBIT A 
FORM OF 
ELECTION OF EXCHANGE 
Reference is hereby made to the Amended and Restated Limited Partnership Agreement of Waldencast Partners LP,  a Cayman Islands exempted limited partnership (the “Partnership”), dated July 27, 2022 (as amended from time to  time, the “Agreement”), among Waldencast Cayman LLC, a limited company incorporated under the laws of the  Cayman Islands, as General Partner ("DRE Partner"), Obagi Holdco 1 Limited, a limited company incorporated  under the laws of Jersey, as Limited Partner (“Holdco 1”), Waldencast plc., a public limited company incorporated  under the laws of Jersey (formerly known as Waldencast Acquisition Corp., a Cayman Islands exempted company,  prior to its migration from the Cayman Islands to Jersey) ("PubCo") and the Partners from time to time party thereto  (each, a “Holder”). Capitalized terms used but not defined herein shall have the meanings given to them in the  Agreement. 
The undersigned Holder hereby transfers to PubCo the number of Common Units plus Class B ordinary shares set  forth below (together, the “Exchanged Interests”) in Exchange for the Cash Exchange Payment or Stock Exchange  Payment, as set forth in the Agreement. 
Legal Name of Holder: 
Address: 
Number of Exchanged Interests to be Exchanged: 
The undersigned hereby represents and warrants that: (i) the undersigned has full legal capacity to execute and deliver  this Election of Exchange and to perform the undersigned’s obligations hereunder; (ii) this Election of Exchange has  been duly executed and delivered by the undersigned and is the legal, valid and binding obligation of the undersigned,  enforceable against it in accordance with the terms hereof or of the Agreement, as the case may be, subject to  applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and the availability of  equitable remedies; (iii) the Exchanged Interests subject to this Election of Exchange are being transferred to PubCo  (or the Partnership, if applicable) free and clear of any pledge, lien, security interest, encumbrance, equities or claim;  and (iv) no consent, approval, authorization, order, registration or qualification of any third party, or with any court  or governmental agency or body having jurisdiction over the undersigned or the Exchanged Interests subject to this  Election of Exchange, is required to be obtained by the undersigned for the transfer of such Exchanged Interests to  PubCo. 
The undersigned hereby irrevocably constitutes and appoints any officer of PubCo or of the General Partner as the  attorney of the undersigned, with full power of substitution and resubstitution in the premises, to do any and all  things and to take any and all actions that may be necessary to transfer to PubCo (or the Partnership, if applicable)  the Exchanged Interests subject to this Election of Exchange and to deliver to the undersigned the Stock Exchange  Payment or Cash Exchange Payment to be delivered in exchange therefor.
IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Election of Exchange to be  executed and delivered by the undersigned or by its duly authorized attorney. 



Exhibit 1.2
Name: 
Dated:
EXHIBIT B 
FORM OF  
SPOUSAL CONSENT 
I acknowledge that I have read the Amended and Restated Exempted Limited Partnership Agreement (the  “Agreement”) of Waldencast Partners LP (the “Partnership”), dated on July 27, 2022, and that I know its contents.  I am aware that by its provisions, my spouse agrees to sell, convert, dispose of, or otherwise transfer his or her interest  in the Partnership, including any property or other interest that I have or acquire therein, under certain circumstances.  I hereby consent to such sale, conversion, disposition or other transfer; and approve of the provisions of the Agreement  and any action hereafter taken by my spouse thereunder with respect to his or her interest, and I agree to be bound  thereby. 
I further agree that in the event of my death or a dissolution of marriage or legal separation, my spouse shall  have the absolute right to have my interest, if any, in the Partnership set apart to him or her, whether through a will, a  trust, a property settlement agreement or by decree of court, or otherwise, and that if he or she be required by the terms  of such will, trust, settlement or decree, or otherwise, to compensate me for said interest, that the price shall be an  amount equal to its appraised value as determined by a reputable accounting firm, investment bank or other qualified  appraiser selected by me and my spouse (or if we cannot agree on an appraiser within five (5) Business Days, such  appraiser as is selected by the Partnership), payable in cash or on such other terms as may be agreed upon by me and  my spouse. 
This consent, including its existence, validity, construction, and operating effect, and the rights of each of the  parties hereto, shall be governed by and construed in accordance with the laws of the [ ]* without regard to  otherwise governing principles of choice of law or conflicts of law. 
Dated: 
Name: 
* Insert jurisdiction of residence of Partner and Spouse.



EX-4.18 3 exhibit418-tcw_waldencastx.htm EX-4.18 Document
Exhibit 4.18



Execution Version

CREDIT AGREEMENT
dated as of
March 18, 2025
among
WALDENCAST PLC,
as Parent Guarantor,

MILK MAKEUP LLC and OBAGI COSMECEUTICALS LLC,
as Borrowers,

The Lenders Party Hereto

TCW ASSET MANAGEMENT COMPANY LLC,
as Administrative Agent
and
TCW ASSET MANAGEMENT COMPANY LLC,
as Sole Bookrunner and Lead Arranger









FOR U.S. FEDERAL INCOME TAX PURPOSES, THE LOANS UNDER THIS AGREEMENT HAVE BEEN ISSUED WITH “ORIGINAL ISSUE DISCOUNT” (WITHIN THE MEANING OF SECTION 1272 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED). UPON WRITTEN REQUEST, THE ADMINISTRATIVE BORROWER WILL PROMPTLY MAKE AVAILABLE TO ANY LENDER THE FOLLOWING INFORMATION WITH RESPECT TO ANY LOAN HEREUNDER: (1) THE ISSUE PRICE AND DATE OF THE LOAN, (2) THE AMOUNT OF ORIGINAL ISSUE DISCOUNT ON THE LOAN AND (3) THE YIELD TO MATURITY OF THE LOAN. LENDERS SHOULD CONTACT MICHEL BROUSSET AND MANUEL MANFREDI OF THE ADMINISTRATIVE BORROWER AT C/O WALDENCAST, 10 BANK STREET, SUITE 560, WHITE PLAINS, NEW YORK 10606.



Table of Contents
Page
i
        

Table of Contents
(continued)
Page
ii


Table of Contents
(continued)
Page
iii


Table of Contents
(continued)
Page

iv


Table of Contents
(continued)
Page



SCHEDULES:
Schedule 1.01 – Expenses, Charges or Losses in respect of Clean Team Agreement Related Matters
Schedule 2.01A – Commitments
Schedule 3.01 – Guarantors
Schedule 3.15 – Subsidiaries; Equity Interests
Schedule 3.18 – Compliance with Laws
Schedule 3.28 – Permits, Etc.
Schedule 3.29 – Health Care
Schedule 5.07 – Compliance with Laws
Schedule 5.17 – Health Care
Schedule 5.11(a) – Agreed Security Principles
Schedule 5.11(b) – Mortgaged Property
Schedule 5.15 – Post-Closing Obligations
Schedule 6.01 – Existing Liens
Schedule 6.02 – Existing Investments
Schedule 6.03 – Existing Indebtedness
Schedule 6.08 – Transactions with Affiliates
EXHIBITS:
Exhibit A – Form of Assignment and Assumption
Exhibit B-1 – Form of U.S. Tax Certificate (Foreign Lenders That Are Not Partnerships)
Exhibit B-2 – Form of U.S. Tax Certificate (Foreign Participants That Are Not Partnerships)
Exhibit B-3 – Form of U.S. Tax Certificate (Foreign Participants That Are Partnerships)
Exhibit B-4 – Form of U.S. Tax Certificate (Foreign Lenders That Are Partnerships)
Exhibit C-1 – Form of Borrowing Request
Exhibit C-2 – Form of Interest Election Request
Exhibit D-1 – Form of Revolving Loan Note
Exhibit D-2 – Form of Term Loan Note
Exhibit E – Form of Compliance Certificate
Exhibit F – [Reserved]
Exhibit G – [Reserved]
Exhibit H – Form of Solvency Certificate
v



CREDIT AGREEMENT (this “Agreement”) dated as of March 18, 2025, among WALDENCAST PLC, a public limited company incorporated in Jersey (the “Parent Guarantor” or “Waldencast”), MILK MAKEUP LLC, a Delaware limited liability company (“Milk Makeup”), and OBAGI COSMECEUTICALS LLC, a Delaware limited liability company (“Obagi Cosmeceuticals”, and collectively with Milk Makeup, the “Borrowers”, and each, a “Borrower”), the LENDERS from time to time party hereto, and TCW ASSET MANAGEMENT COMPANY LLC (“TCW”), as Administrative Agent.
WHEREAS, the Borrowers have requested that the Lenders extend credit in the form of (a) Term Loans to the Borrowers on the Closing Date, in an aggregate principal amount of $175,000,000 and (b) Revolving Loans made available to the Borrowers at any time and from time to time on and after the Closing Date and prior to the Maturity Date in an aggregate principal amount at any time outstanding not in excess of $30,000,000;
WHEREAS, the Borrowers shall use the proceeds of the Term Loans, together with certain proceeds of Revolving Loans, to (i) consummate the Refinancing, (ii) pay the fees and expenses in connection with the consummation of the foregoing, and (iii) fund working capital and for general corporate purposes; and
WHEREAS, the Lenders are willing to make available to the Borrowers the term loan and revolving credit described herein, in each case, upon the terms and subject to the conditions set forth herein;
NOW, THEREFORE, in consideration of the premises and the covenants and agreements contained herein, the parties hereto agree as follows:
Article I

Definitions
Section 1.01.Defined Terms. As used in this Agreement, the following terms have the meanings specified below:
ABR” when used in reference to any Loan or Borrowing, refers to such Loan, or the Loans comprising such Borrowing, bearing interest at a rate determined by reference to the Alternate Base Rate.
ABR Term SOFR Determination Day” has the meaning specified in the definition of “Term SOFR”.
ABL Facility” has the meaning assigned to such term in Section 1.15.
ABL Lender” has the meaning assigned to such term in Section 1.15.
Adjusted Term SOFR Rate” means, for any Interest Period, an interest rate per annum equal to (a) the Term SOFR Rate for such Interest Period, plus (b) (i) 0.11448% (11.48 basis points) for an Interest Period of one-month’s duration or (ii) 0.26161% (26.161 basis points) for an Interest Period of three-months’ duration.
Administrative Agent” means TCW Asset Management Company LLC, in its capacity as administrative agent for the Lenders hereunder.




Administrative Borrower” means Obagi Cosmeceuticals LLC.
Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent.
Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial Institution.
Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. Notwithstanding anything herein to the contrary, in no event shall the Administrative Agent or any Lender be considered an “Affiliate” of any Loan Party.
Agent-Related Person” has the meaning assigned to such term in Section 9.03(d).
Agreed Security Principles” means the provisions set forth on Schedule 5.11(a).
Agreement” has the meaning assigned to such term in the introductory paragraph.
Alternate Base Rate” means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) Federal Funds Effective Rate plus 0.50% per annum and (c) the Adjusted Term SOFR Rate for a one month Interest Period (based on the Term SOFR Rate determined under clause (b) of such definition) plus 1%. Any change in the Alternate Base Rate due to a change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted Term SOFR Rate shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted Term SOFR Rate, respectively. If the Alternate Base Rate is being used as an alternate rate of interest pursuant to Section 2.14 (only until the Benchmark Replacement has been determined pursuant to Section 2.14(b)), then the Alternate Base Rate shall be the greater of clauses (a) and (b) above and shall be determined without reference to clause (c) above. Notwithstanding the foregoing, the Alternate Base Rate as determined pursuant to the foregoing would be less than 3.0%, such rate shall be deemed to be 3.0 % for purposes of this Agreement.
Ancillary Document” has the meaning assigned to such term in Section 9.06.
Anti-Corruption Laws” means any laws, rules and regulations of any jurisdiction applicable to the Parent Guarantor, any Borrower or any Subsidiary concerning or relating to bribery or corruption of public officials, including the U.S. Foreign Corrupt Practices Act of 1977, as amended.
Anti-Money Laundering Laws” has the meaning assigned to such term in Section 3.24.
Applicable Parties” has the meaning assigned to such term in Section 8.03(c).
Applicable Percentage” means, with respect to any Lender, (a) with respect to Revolving Loans, the percentage equal to a fraction the numerator of which is such Lender’s Revolving Commitment and the denominator of which is the aggregate Revolving Commitments of all Revolving Lenders (if the Revolving Commitments have terminated or expired, the Applicable Percentages shall be determined based upon the Revolving Commitments most recently in effect, giving effect to any assignments); provided that, in the case of Section 2.21 when a Defaulting Lender shall exist, any such Defaulting Lender’s Revolving Commitment shall be disregarded in the calculation and (b) with respect to the Term Loans, (x) prior to the initial funding hereunder on the Closing Date, a percentage equal to a fraction the numerator of which is such Lender’s Term Loan Commitment and the denominator of which
2



is the aggregate Term Loan Commitments of all Term Lenders (if the Term Loan Commitments have terminated or expired prior to the Closing Date, the Applicable Percentages shall be determined based upon the Term Loan Commitments most recently in effect, giving effect to any assignments) and (y), thereafter, a percentage equal to a fraction the numerator of which is such Lender’s outstanding principal amount of the Term Loans and the denominator of which is the aggregate outstanding principal amount of the Term Loans of all Term Lenders.
Applicable Premium” means:
(a)    with respect to the Term Loans, in the event that an Applicable Premium Trigger Event occurs on or prior to the fourth anniversary of the Closing Date:
(i)    if such Applicable Premium Trigger Event occurs on or prior to the first anniversary of the Closing Date (the “First Period”), an amount equal to 5.00% of the aggregate amount of all Term Loans so prepaid, repaid, replaced or accelerated;
(ii)    if such Applicable Premium Trigger Event occurs after the First Period but on or prior to the second anniversary of the Closing Date (the “Second Period”), an amount equal to 3.00% of the aggregate amount of all Term Loans so prepaid, repaid, replaced or accelerated;
(iii)    if such Applicable Premium Trigger Event occurs after the Second Period but on or prior to the third anniversary of the Closing Date (the “Third Period”), an amount equal to 2.00% of the aggregate amount of all Term Loans so prepaid, repaid or accelerated; and
(iv)    if such Applicable Premium Trigger Event occurs after the Third Period but on or prior to the fourth anniversary of the Closing Date (the “Fourth Period”), an amount equal to 1.00% of the aggregate amount of all Term Loans so prepaid, repaid, replaced or accelerated;
(b)    with respect to the Revolving Commitments, in the event that an Applicable Premium Trigger Event occurs on or prior to the fourth anniversary of the Closing Date:
(i)    if such Applicable Premium Trigger Event occurs during the First Period, an amount equal to 5.00% of the Revolving Commitments so terminated or reduced;
(ii)    if such Applicable Premium Trigger Event occurs during the Second Period, an amount equal to 3.00% of the Revolving Commitments so terminated or reduced;
(iii)    if such Applicable Premium Trigger Event occurs during the Third Period, an amount equal to 2.00% of the Revolving Commitments so terminated or reduced; and
(iv)    if such Applicable Premium Trigger Event occurs during the Fourth Period, an amount equal to 1.00% of the Revolving Commitments so terminated or reduced;
provided that, (i) the Applicable Premium payable pursuant to clause (a) above shall be reduced to (x) 0.00% for any voluntary prepayments of the Term Loans pursuant to Section 2.11(a) with the proceeds of the public issuance of Equity Interests of Waldencast (to the extent received within the twelve month period prior to the prepayment) and any mandatory prepayments of the Term Loans pursuant to Section 2.11(d) with the proceeds of Project Romania, up to $35,000,000 in the aggregate for all such voluntary and mandatory prepayments and (y) by 50% for any voluntary prepayments of the Term Loans pursuant to Section 2.11(a) with the proceeds of the public issuance of Equity Interests of Waldencast (to the extent received within the twelve month period prior to the prepayment) and any mandatory prepayments of the Term Loans pursuant to Section 2.11(d) with the proceeds of Project Romania, in excess of $35,000,000 but up to $50,000,000 in the aggregate for all such voluntary and mandatory prepayments (and there shall be no reduction for any such voluntary prepayments or
3



mandatory prepayments in excess of $50,000,000 in the aggregate), (ii) the Applicable Premium payable pursuant to clause (b) above shall be reduced by 50% for any permanent termination of the Revolving Commitments in connection with the transactions contemplated by Section 1.15 if (and solely if) Consolidated EBITDA of the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis (calculated as of the end of the most recent fiscal quarter ended prior to such permanent termination of the Revolving Commitments in connection with the transactions contemplated by Section 1.15 for which quarterly financial statements and a Compliance Certificate are received by the Administrative Agent (for distribution to the Lenders) in accordance with Sections 5.01(b) and 5.02(a), respectively) exceeds $45,000,000 for each of such fiscal quarter and the immediately preceding fiscal quarter and (iii) the Applicable Premium payable pursuant to clauses (a) and (b) above shall be reduced by 50% for any voluntary prepayments of the Term Loan pursuant to Section 2.11(a) and/or any permanent termination of the Revolving Commitments pursuant to Section 2.09(b) after following, and as a result of, the procedure set out at Section 2.17(g).
Applicable Premium Trigger Event” means:
(a)    any permanent termination or reduction of the Revolving Commitments (including pursuant to Section 2.09, Section 7.02 and any permanent termination of the Revolving Commitments in connection with the incurrence of an ABL Facility pursuant to Section 1.15);
(b)    any payment by any Loan Party of all, or any part, of the principal balance of any Term Loan for any reason (including any (i) voluntary prepayments, (ii) replacement of Non-Consenting Lenders pursuant to Section 9.02(e) and (iii) any mandatory prepayments, but excluding (1) any amortization payments made pursuant to Section 2.10(a), (2) any prepayments made pursuant to Section 2.11(c) and (3) the first $10,000,000 of any prepayments made pursuant to Section 2.11(d) with the proceeds of Extraordinary Receipts (other than proceeds of Project Romania) in the aggregate) whether before or after (i) the occurrence of an Event of Default, or (ii) the commencement of any proceeding under any Debtor Relief Law, and notwithstanding any acceleration (for any reason) of the Obligations; or
(c)    the acceleration of the Loans for any reason, including, without limitation, acceleration in accordance with Section 7.02, including as a result of the commencement of any proceeding under any Debtor Relief Law;
in each case subject to the proviso in the definition of “Applicable Premium”.
Applicable Rate” means, for any day, with respect to any ABR Loan or Term Benchmark Loan, or with respect to the commitment fees payable hereunder, as the case may be:
(a)     From the Closing Date until the date that is 2 Business Days after the date on which the Loan Parties are required to deliver to the Administrative Agent (for distribution to the Lenders) the quarterly financial statements and a Compliance Certificate for the fiscal quarter ending September 30, 2025 in accordance with Sections 5.01(b) and 5.02(a), respectively (the “Initial Applicable Margin Period”), the relevant Applicable Rate shall be set at Level I in the table below.
(b)    After the Initial Applicable Margin Period, the relevant Applicable Margin shall be set at the respective level indicated below based upon the Total Leverage Ratio set forth opposite thereto, which ratio shall be calculated as of the end of the most recent fiscal quarter for which quarterly
4



financial statements and a Compliance Certificate are received by the Administrative Agent (for distribution to the Lenders) in accordance with Sections 5.01(b) and 5.02(a), respectively:
LevelTotal Leverage RatioABR LoansTerm Benchmark LoansCommitment Fee Rate
Revolving LoansTerm LoanRevolving LoansTerm LoanRevolving Loans
IGreater than or equal to 4.50 to 1:006.50%6.50%7.50%7.50%0.75%
IILess than 4.50 to 1:00 and equal to or greater than 4.00 to 1:006.25%6.25%7.25%7.25%0.75%
IIILess than 4.00 to 1:00 and equal to or greater than 3.50 to 1:006.00%6.00%7.00%7.00%0.75%
IVLess than 3.50 to 1:00 and equal to or greater than 3.00 to 1:005.75%5.75%6.75%6.75%0.75%
VLess than 3.00 to 1:00 and equal to or greater than 2.50 to 1:005.50%5.50%6.50%6.50%0.75%
VILess than 2.50 to 1:005.25%5.25%6.25%6.25%0.75%

(c)    Subject to clause (d) below, the adjustment of the Applicable Rate (if any) pursuant to clause (b) above resulting from a change in the Total Leverage Ratio will become effective as of the second Business Day immediately after the date on which the Loan Parties are required to deliver to the Administrative Agents (for distribution to the Lenders) the quarterly financial statements and a Compliance Certificate in accordance with Sections 5.01(b) and 5.02(a), respectively.
(d)    Notwithstanding the foregoing:
(i)    the Applicable Margin shall be set at Level I in the table above (A) upon the occurrence and during the continuation of an Event of Default or (B) if for any period, the Administrative Agent does not receive the quarterly financial statements and Compliance Certificate in accordance with Sections 5.01(b) and 5.02(a), respectively, for such period commencing on the date such quarterly financial statements and Compliance Certificate were required to be delivered to the Administrative Agent through the date on which such quarterly financial statements and Compliance Certificate are actually delivered to the Administrative Agent; and
5



(ii)    in the event that the Total Leverage Ratio set forth in any Compliance Certificate delivered to the Administrative Agent described in clause (c) above is inaccurate (regardless of whether this Agreement or any Commitments are in effect when such inaccuracy is discovered), and as a result thereof the Lenders received interest or fees for any period based on an Applicable Rate that is less than that which would have been applicable had the Total Leverage Ratio been accurately determined, then the Applicable Rate for such fiscal period shall be adjusted retroactively (to the effective date of the determination of the Applicable Rate that was based upon the delivery of such inaccurate Compliance Certificate) to reflect the correct Applicable Rate, and the Borrowers shall promptly make payments in the amount of the shortfall to the Administrative Agent and the Lenders.
(e)    In addition to the foregoing, the Administrative Borrower may elect to pay up to 3.00% (which may be elected in 1.00% increments) of the Applicable Rate accrued on the Revolving Loans and Term Loans in kind (the “PIK Option”) by adding such accrued interest to the outstanding principal amount of the Revolving Loans and the Term Loans, as applicable, on the applicable Interest Payment Date, subject to an increase to the Applicable Rate calculated in accordance with the table above of 0.50% per annum for each 1.00% of cash interest that is elected to be paid in kind pursuant to the PIK Option. The Administrative Borrower shall elect the PIK Option in the applicable Borrowing Request delivered pursuant to Section 2.03 or the applicable Interest Election Request delivered pursuant to Section 2.08. For the avoidance of any doubt, an example of the PIK Option applied to Level I of the pricing grid set forth above is as follows:
Cash Portion of Applicable RatePIK Portion of Applicable RateTotal Applicable Rate
6.0%3.0%9.0%
6.5%2.0%8.5%
7.0%1.0%8.0%
7.5%0.0%7.5%

Approved Electronic Platform” has the meaning assigned to such term in Section 8.03(a).
Approved Fund” has the meaning assigned to such term in Section 9.04(b).
Arranger” means TCW Asset Management Company LLC in its capacity as a bookrunner and lead arranger hereunder.
Assignment and Assumption” means an assignment and assumption agreement entered into by a Lender and an assignee (with the consent of any party whose consent is required by Section 9.04), and accepted by the Administrative Agent, in the form of Exhibit A or any other form (including electronic records generated by the use of an electronic platform) approved by the Administrative Agent.
ASU” has the meaning assigned to such term in Section 1.04(d).
Attributable Indebtedness” means, on any date, in respect of any Capital Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP.
6



Availability Period” means the period from and including the Closing Date to but excluding the earlier of the Maturity Date and the date of termination of the Revolving Commitments.
Available Amount” means, as at any date of determination, an amount equal to (a) an amount, which shall not be less than zero, equal to the Retained Excess Cash Flow Amount (commencing with the fiscal year ending December 31, 2025), plus (b) Retained Declined Proceeds, plus (c) solely to the extent such amounts have not otherwise reduced outstanding Investments or increased Investment basket capacity, returns received in cash or Cash Equivalents (including net cash proceeds of Dispositions of Investment made using the Available Amount) by the Parent Guarantor, the Borrowers or the Subsidiaries on Investments made by such Person using the Available Amount (up to the original amount of such Investment made using the Available Amount), minus (d) any portion of such amount utilized by the Parent Guarantor, the Borrowers and the Subsidiaries on or prior to such date of determination to make (1) Investments pursuant to Section 6.02(c)(iv)(C)(2), (2) Investments pursuant to Section 6.02(o)(2), (3) Restricted Payments pursuant to Section 6.06(e)(2) or Section 6.06(f), or (4) prepayments, redemptions, purchases, defeasances or other payments of Junior Indebtedness pursuant to Section 6.14(c)(2).
Available Revolving Commitment” means, at any time with respect to any Lender, the Revolving Commitment of such Lender then in effect minus the Revolving Credit Exposure of such Lender at such time.
Available Tenor” means, as of any date of determination and with respect to the then-current Benchmark, as applicable, if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to Section 2.14(d).
Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.
Bail-In Legislation” means, (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).
Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy”, as now and hereafter in effect, or any successor statute.
Bankruptcy Event” means, with respect to any Person, such Person becomes the subject of a voluntary or involuntary bankruptcy or insolvency proceeding, or has had a receiver, conservator, trustee, administrator, custodian, assignee for the benefit of creditors or similar Person charged with the reorganization or liquidation of its business appointed for it, or, in the good faith determination of the Administrative Agent, has taken any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any such proceeding or appointment or has had any order for relief in such proceeding entered in respect thereof; provided that, a Bankruptcy Event shall not result solely by virtue of any ownership interest, or the acquisition of any ownership interest, in such Person by a Governmental
7



Authority or instrumentality thereof, unless such ownership interest results in or provides such Person with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permits such Person (or such Governmental Authority or instrumentality) to reject, repudiate, disavow or disaffirm any contracts or agreements made by such Person.
Benchmark” means, initially, the Term SOFR Rate; provided that if a Benchmark Transition Event has occurred with respect to the Term SOFR Rate or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to Section 2.14(a).
Benchmark Replacement” means, with respect to any Benchmark Transition Event: the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Administrative Borrower giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated credit facilities at such time and (b) the related Benchmark Replacement Adjustment; provided that, if such Benchmark Replacement as so determined would be less than the Floor, such Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.
Benchmark Replacement Adjustment” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Administrative Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time.
Benchmark Replacement Conforming Changes” means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of “Alternate Base Rate,” the definition of “Business Day,” the definition of “U.S. Government Securities Business Day,” the definition of “Interest Period” or any similar or analogous definition (or the addition of a concept of “interest period”), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of Section 2.16 and other technical, administrative or operational matters) that the Administrative Agent decides, in consultation with the Borrowers, may be appropriate to reflect the adoption and implementation of any such Benchmark or to permit the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of any such Benchmark exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).
8



Benchmark Replacement Date” means the earliest to occur of the following events with respect to the then-current Benchmark:
(a)     in the case of clause (a) or (b) of the definition of “Benchmark Transition Event,” the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof); or
            (b)    in the case of clause (c) of the definition of “Benchmark Transition Event,” the first date on which such Benchmark (or the published component used in the calculation thereof) has been or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) have been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; provided that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.
For the avoidance of doubt, if such Benchmark is a term rate, the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (a) or (b) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).
Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then-current Benchmark:
(a)    a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof);
(b)    a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component thereof), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component thereof) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component thereof), which states that the administrator of such Benchmark (or such component thereof) has ceased or will cease to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide such Benchmark (or such component thereof) or, if such Benchmark is a term rate, any Available Tenor of such Benchmark (or such component thereof); or
9



(c)    a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such Benchmark (or such component thereof) or, if such Benchmark is a term rate, all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.
For the avoidance of doubt, if such Benchmark is a term rate, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).
        “Benchmark Transition Start Date” means, in the case of a Benchmark Transition Event, the earlier of (a) the applicable Benchmark Replacement Date and (b) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication).
Benchmark Unavailability Period” means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.14 and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.14.
Beneficial Ownership Certification” means a certification or register regarding beneficial ownership or control as required by the Beneficial Ownership Regulation.
Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230, the Beneficial Ownership Transparency Act, 2023 of the Cayman Islands together with the Beneficial Ownership Transparency Regulations, 2024 of the Cayman Islands (as applicable).
Benefit Plan” means any of (a) an “employee benefit plan” (as defined in ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in and subject to Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such “employee benefit plan” or “plan”.
BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.
Borrower” and “Borrowers” each have the meaning assigned to such term in the introductory paragraph.
Borrower Materials” has the meaning assigned to such term in Section 5.02.
Borrower Notice” has the meaning assigned to such term in Section 5.11(b).
Borrowing” means (a) Revolving Loans of the same Type, made, converted or continued on the same date and, in the case of Term Benchmark Loans, as to which a single Interest
10



Period is in effect or (b) a Term Loan of the same Type, made, converted or continued on the same date and, in the case of Term Benchmark Loans, as to which a single Interest Period is in effect.
Borrowing Request” means a request by the Administrative Borrower for a Borrowing in accordance with Section 2.03, which shall be substantially in the form attached hereto as Exhibit C-1 or any other form approved by the Administrative Agent.
Business Day” means any day (other than a Saturday or a Sunday) on which banks are open for business in New York City.
Capital Expenditures” means, with respect to any Person for any period, the sum of (a) the aggregate of all expenditures (whether paid in cash or accrued as liabilities) by such Person and its Subsidiaries during such period that in accordance with GAAP are or are required to be included as capital expenditures on the consolidated statement of cash flows for such period, or in “property, plant and equipment” or in a similar fixed asset account on its balance sheet, including all Capital Lease Obligations, obligations under synthetic leases and capitalized software costs that are paid or due and payable during such period and (b) to the extent not covered by clause (a) above, the aggregate of all expenditures (whether paid in cash or accrued as liabilities) by such Person and its Subsidiaries during such period to acquire by purchase or otherwise the business or fixed assets of, or the Equity Interests of, any other Person.
Capital Lease” means, with respect to any Person, any capital lease or financing lease that (subject to Section 1.04) is required by GAAP to be accounted for as a capital lease or financing lease.
Capital Lease Obligations” of any Person means the obligations of such Person to pay rent or other amounts under any lease, which obligations are required to be classified and accounted for as Capital Leases or financing leases on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP, in each case subject to Section 1.04.
Captive Insurance Subsidiary” means any Subsidiary that is subject to regulation as an insurance company.
Cash Equivalents” means any of the following types of Investments, to the extent owned by the Parent Guarantor, any Borrower or any Subsidiary:
(i)readily marketable obligations issued or directly and fully guaranteed or insured by the United States of America or any agency or instrumentality thereof having maturities of not more than 360 days from the date of acquisition thereof; provided that, the full faith and credit of the United States of America is pledged in support thereof;
(ii)time deposits with, or insured certificates of deposit or bankers’ acceptances of, any commercial bank that (i) (A) is a Lender or (B) is organized under the laws of the United States of America, any state or province thereof or the District of Columbia or is the principal banking subsidiary of a bank holding company organized under the laws of the United States of America, any state thereof or the District of Columbia, and is a member of the Federal Reserve System that has combined capital and surplus of at least $500,000,000, in each case with maturities of not more than 365 days from the date of acquisition thereof;
11



(iii)commercial paper maturing no more than 365 days from the time of the acquisition thereof, and having, at the time of acquisition thereof, a rating of A-2 or better from S&P or P-2 or better from Moody’s (or, if at any time neither Moody’s nor S&P shall be rating such obligations, an equivalent rating from another rating agency);
(iv)Investments, classified in accordance with GAAP as current assets of the Parent Guarantor, any Borrower or any of the Subsidiaries, in money market investment programs registered under the Investment Company Act of 1940, which are administered by financial institutions that have the highest rating obtainable from either Moody’s or S&P, and the portfolios of which are limited solely to Investments of the character, quality and maturity described in clauses (a), (b) and (c) of this definition;
(v)fully collateralized repurchase agreements with a term of not more than thirty (30) days for securities described in clause (a) of this definition and entered into with a financial institution satisfying the requirements in clause (b) of this definition; and
(vi)instruments equivalent to those referred to in clauses (a) to (e) in this definition denominated in any foreign currency comparable in credit quality and tenor to those referred to above and commonly used by corporations for cash management purposes in any jurisdiction outside the United States to the extent reasonably required in connection with any business conducted by any Loan Party or any Subsidiary organized in such jurisdiction.
Casualty Proceeds” has the meaning assigned to such term in the definition of Extraordinary Receipts.
Cayman Companies Act” has the meaning assigned to such term in Section 8.10(a)(i)(x).
Cayman Islands Collateral Agreements” means (i) (a) a Cayman Islands law governed fixed and floating security agreement to be granted by Waldencast Cayman LLC in its personal capacity and as general partner of Waldencast Partners LP in favor of the Administrative Agent (the “Cayman Islands Waldencast Cayman LLC Fixed and Floating Security Agreement”), (b) a Cayman Islands law governed fixed and floating security agreement to be granted by Obagi Global Holdings Limited in favor of the Administrative Agent (the “Cayman Islands Obagi Global Holdings Limited Fixed and Floating Security Agreement”), and (c) a Cayman Islands law governed fixed and floating security agreement to be granted by Obagi Holdings Company Limited in favor of the Administrative Agent (the “Cayman Islands Obagi Holdings Company Limited Fixed and Floating Security Agreement”),; and (ii) (a) a Cayman Islands law governed equitable share mortgage over the shares in Obagi Global Holdings Limited to be granted by Obagi Holdco 2 Limited in favor of the Administrative Agent (the “Cayman Islands Obagi Holdco 2 Limited Equitable Share Mortgage”); (b) a Cayman Islands law governed equitable share mortgage over the shares in Obagi Holdings Company Limited to be granted by Obagi Global Holdings Limited in favor of the Administrative Agent (the “Cayman Islands Obagi Global Holdings Ltd. Equitable Share Mortgage”), (c) a Cayman Islands law governed security deed over the interests in Waldencast Cayman LLC to be granted by Obagi Holdco 1 Limited in favor of the Administrative Agent (the “Cayman Islands Waldencast Cayman LLC Security over Interests”) and (d) a Cayman Islands law governed charge over the limited partnership interests of Waldencast Partners LP to be granted by Obagi Holdco 1 Limited in favor of the Administrative Agent (the “Cayman Islands Waldencast Partners LP Charge over Interests”).
Cayman Islands Obagi Global Holdings Limited Fixed and Floating Security Agreement” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
12



Cayman Islands Obagi Global Holdings Limited Equitable Share Mortgage” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
Cayman Islands Obagi Holdco 2 Limited Equitable Share Mortgage” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
Cayman Islands Obagi Holdings Company Limited Fixed and Floating Security Agreement” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
Cayman Islands Waldencast Cayman LLC Fixed and Floating Security Agreement” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
Cayman Islands Waldencast Cayman LLC Security over Interests” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
Cayman Islands Waldencast Partners LP Charge over Interests” has the meaning assigned to such term in the definition of “Cayman Islands Collateral Agreements”.
Cayman LLC Act” has the meaning assigned to such term in Section 8.10(a)(i)(x).
Change in Law” means the occurrence after the date hereof of (a) the adoption of or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) compliance by any Lender (or, for purposes of Section 2.15(b), by any lending office of such Lender or by such Lender’s holding company, if any) with any request, rule, guideline or directive (whether or not having the force of law) of any Governmental Authority made or issued after the Closing Date; provided that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith or in the implementation thereof and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall, in each case, be deemed to be a “Change in Law,” regardless of the date enacted, adopted, issued or implemented.
Change of Control” means the occurrence of any of the following:
(i)any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of the Parent Guarantor or its Subsidiaries and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, except that a person or group shall be deemed to have “beneficial ownership” of all securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an “option right”)), directly or indirectly, of 40% or more of the equity securities of Waldencast entitled to vote for members of the board of directors or equivalent governing body of Waldencast on a fully-diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right);
(ii)a “Change of Control,” “Change in Control” or similar event shall occur under any Indebtedness of the Parent Guarantor, any Borrower or any Subsidiary with an aggregate principal amount in excess of the Threshold Amount (to the extent that the occurrence of such event permits the
13



holders of Indebtedness thereunder to accelerate the maturity thereof or to resell such other Indebtedness to the Parent Guarantor, any Borrower or any Subsidiary, or requires the Parent Guarantor, any Borrower or any Subsidiary to repay, or offer to repurchase, such Indebtedness prior to the stated maturity thereof);
(iii)the Parent Guarantor ceases to directly or indirectly own and control 100% of the Equity Interests of each Borrower and each Loan Party that is a parent entity of any Borrower (other than, to the extent attributable, directly or directly, to, any Equity Interests of Waldencast Partners LP that are not directly or indirectly owned by Parent Guarantor on the Closing Date until such time as such Equity Interests are redeemed by the holders thereof); provided that, this clause (c) shall not prevent any transaction permitted under Section 6.04 involving any Loan Party that is a parent entity of any Borrower merging with a Borrower or another Loan Party that is a parent entity of a Borrower.
Charges” has the meaning assigned to such term in Section 9.16
Class”, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are Revolving Loans or Term Loans.
Clean Team Agreement Related Matters” means any investigations, shareholder litigation, derivative actions or other claims arising out of the primary matter covered by the “Clean Team Material” as defined in the Clean Team Agreement, dated as of February 26, 2025, by and between the Parent Guarantor and TCW Asset Management Company LLC.
Closing Date” means the date on which the conditions precedent specified in Section 4.01 are satisfied (or waived in accordance with Section 9.02).
Code” means the Internal Revenue Code of 1986, as amended.
Collateral” means all of the “Collateral” and “Mortgaged Property” referred to in the Collateral Documents and all of the other property provided as collateral security under the terms of the Collateral Documents; provided that, the Collateral shall exclude the Excluded Assets.
Collateral Agreements” means, collectively, the U.S. Collateral Agreement, the Jersey Collateral Agreements, the Cayman Islands Collateral Agreements and the English Collateral Agreements.
Collateral Documents” means, collectively, the Collateral Agreements, the Mortgages, each of the mortgages, landlord waivers, collateral access agreements, Control Agreements, collateral assignments, registration pages, irrevocable proxies, supplements to all of the foregoing, security agreements, pledge agreements, control agreements (if any) or other similar agreements delivered to the Administrative Agent pursuant to Section 4.01, 5.11 or 5.14 and each of the other agreements, instruments or documents that creates or purports to create a Lien in favor of the Administrative Agent for the benefit of the Secured Parties.
Commitment” means, (a) the Revolving Commitments and the Term Loan Commitments and (b) with respect to each Lender, the sum of such Lender’s Revolving Commitment and Term Loan Commitment. The initial amount of each Lender’s Commitment is set forth on Schedule 2.01A, or in the Assignment and Assumption or other documentation contemplated hereby pursuant to which such Lender shall have assumed its Revolving Commitment or Term Loan Commitment pursuant to the terms hereof, as applicable.
14



Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.), as amended from time to time, and any successor statute.
Communications” means, collectively, any notice, demand, communication, information, document or other material provided by or on behalf of any Loan Party pursuant to any Loan Document or the transactions contemplated therein which is distributed by the Administrative Agent or any Lender by means of electronic communications pursuant to Section 8.03, including through an Approved Electronic Platform.
Compliance Certificate” means a certificate substantially in the form of Exhibit E.
Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.
Consolidated EBITDA” means, at any date of determination, an amount equal to Consolidated Net Income of the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis for the most recently completed Measurement Period, plus (i) the following, without duplication, and, except with respect to clause (o) below, to the extent deducted in calculating such Consolidated Net Income:
(i)Consolidated Interest Expense, plus
(ii)the provision for federal, state, local and foreign income and franchise taxes payable (calculated net of federal, state, local and foreign income tax credits) and other taxes (including, without duplication, any Permitted Tax Distributions), interest and penalties included under GAAP in income tax expense, plus
(iii)depreciation and amortization expenses (including amortization of goodwill and other intangibles but excluding amortization of prepaid cash expenses that were paid in a prior period), plus
(iv)other non-recurring expenses, write-offs, write-downs or impairment charges which do not represent a cash item in such period (or in any future period) (excluding any such non-cash expense to the extent that it represents an accrual of or reserve for cash expenses in any future period or amortization of a prepaid cash expense that was paid in a prior period and any non-cash charge, expense or loss relating to write-offs, write-downs or reserves with respect to accounts receivable or inventory), plus
(v)non-cash charges or expenses related to stock-based compensation and other non-cash charges or non-cash losses (including, extraordinary, unusual or non-recurring non-cash losses) incurred or recognized, plus
(vi)cash or non-cash charges constituting fees and expenses incurred in connection with the Transactions; provided that, the aggregate amount of cash charges, fees and expenses (which shall not include any original issue discount on the Loans and Commitments) added-back pursuant to this clause (f) shall not exceed $7,000,000, plus
(vii)losses relating to hedging transactions and mark-to-market of Indebtedness denominated in foreign currencies resulting from the application of FASB ASC 830 or any similar accounting standard, plus
(viii)any expenses or charges related to any issuance of Equity Interests or debt securities, Investment, acquisition, Disposition, recapitalization or the incurrence, modification or repayment of Indebtedness permitted to be incurred by this Agreement (including a refinancing thereof) (whether or not
15



successful), including any amendment or other modification of the Obligations or other Indebtedness; provided that, the aggregate amount of expenses or charges added-back pursuant to this clause (h) in connection with unsuccessful transactions in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to the first proviso set forth in clause (i) below for such period, 2.5% of Consolidated EBITDA for such period prior to giving effect to any amounts added back pursuant to this proviso in this clause (h) or the first proviso set forth in clause (i) below; provided that, in no event shall the cap set forth in this clause (h) require the re-calculation of the Consolidated EBITDA of any prior period, plus
(ix)one-time deal advisory, financing, legal, accounting, and consulting cash expenses incurred by the Parent Guarantor, the Borrowers and the Subsidiaries in connection with Permitted Acquisitions not constituting the consideration for any such Permitted Acquisition; provided that, the aggregate amount of expenses added-back pursuant to this clause (i) in connection with unsuccessful transactions in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to the first proviso set forth in clause (h) above for such period, 2.5% of Consolidated EBITDA for such period prior to giving effect to any amounts added back pursuant to this proviso in this clause (i) or the first proviso set forth in clause (h) above; provided that, in no event shall the cap set forth in this clause (i) require the re-calculation of the Consolidated EBITDA of any prior period, plus
(x)non-cash losses and expenses resulting from fair value accounting (as permitted by Accounting Standard Codification Topic No. 825-10-25 – Fair Value Option or any similar accounting standard), plus
(xi)restructuring charges or reserves or integration costs or other business optimization expenses, including in connection with (x) the Transactions or any Permitted Acquisition or (y) the consolidation or closing of facilities during such Measurement Period; provided that, (A) the aggregate amount of charges, reserves, costs or expenses added-back pursuant to this clause (k) in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to clause (l) below for such period, 12.5% of Consolidated EBITDA (or starting with the fiscal quarter ending June 30, 2026, and thereafter, 10% of Consolidated EBITDA) for such period prior to giving effect to this clause (k) and clause (l), and (B) the aggregate amount of charges, reserves, costs or expenses added-back pursuant to this clause (k) in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to clauses (l) and (iii) below for such period, 17.5% of Consolidated EBITDA (or starting with the fiscal quarter ending June 30, 2026, and thereafter, 15% of Consolidated EBITDA) for such period prior to giving effect to this clause (k) or clauses (l) and (iii) below, plus
(xii)extraordinary, unusual or non-recurring cash charges and cash losses incurred or recognized (including costs and payments, in connection with actual or prospective litigation, legal settlements, fines, judgments or orders); provided that, (x) the aggregate amount of charges and losses added-back pursuant to this clause (l) in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to clause (k) above for such period, 12.5% of Consolidated EBITDA (or starting with the fiscal quarter ending June 30 30, 2026, and thereafter, 10% of Consolidated EBITDA) for such period prior to giving effect to this clause (l) and clause (k), and (y) the aggregate amount of charges, reserves, costs or expenses added-back pursuant to this clause (l) in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to clause (k) above and clause (iii) below for such period, 17.5% of Consolidated EBITDA (or starting with the fiscal quarter ending June 30, 2026, and thereafter, 15% of Consolidated EBITDA) for such period prior to giving effect to this clause (l) or clause (k) above and clause (iii) below, plus
(xiii)the amount of any minority interest expense consisting of Subsidiary income attributable to minority interests of third parties in any non-wholly owned Subsidiary (and not added back in such period to Consolidated Net Income), plus
16



(xiv)earn-out and contingent consideration obligations (including to the extent accounted for as bonuses, compensation or otherwise) and adjustments thereof and purchase price adjustments, in each case incurred in connection with acquisitions permitted hereunder, plus
(xv)cash receipts (or any netting arrangements resulting in reduced cash expenditures) not included in Consolidated EBITDA or Consolidated Net Income in any period to the extent non-cash gains relating to such receipts were deducted in the calculation of Consolidated EBITDA (pursuant to paragraph (ii) below) or Consolidated Net Income, for any previous period and not added back, plus
(xvi)to the extent covered by insurance and actually reimbursed, or, so long as the Administrative Borrower has made a determination that there exists reasonable evidence that such amount will in fact be reimbursed by the insurer and only to the extent that such amount is in fact reimbursed within 365 days of the date of such determination (with a deduction in the applicable future period for any amount so added back to the extent not so reimbursed within such 365 days), expenses, charges or losses with respect to liability or casualty events or business interruption, plus
(xvii)any expenses, charges or losses that are covered by indemnification or other reimbursement provisions in connection with any Investment, Permitted Acquisition or any sale, conveyance, transfer or other disposition of assets permitted under this Agreement, to the extent actually reimbursed, or, so long as the Administrative Borrower has made a determination that a reasonable basis exists for indemnification or reimbursement and only to the extent that such amount is in fact indemnified or reimbursed within 365 days of such determination (with a deduction in the applicable future period for any amount so added back to the extent not so indemnified or reimbursed within such 365 day period); plus
(xviii)any expenses, charges or losses in respect of the Clean Team Agreement Related Matters in the amounts and for each of the four consecutive fiscal quarter periods specified in Schedule 1.01 (provided, that (i) to the extent such scheduled amounts exceed the amounts actually deducted in the calculation of Consolidated Net Income in respect of such scheduled amounts, the addbacks pursuant to this clause (r) shall not exceed such amounts actually deducted in the calculation of Consolidated Net Income and (ii) in no event shall any addbacks pursuant to this clause (r) apply to any four consecutive fiscal quarter period ending after March 31, 2026); plus
(xix)any penalty payments made in respect of the Clean Team Agreement Related Matters;
and (ii) minus, without duplication,
(i)gains included in Consolidated EBITDA for such Measurement Period in respect of hedging transactions and mark-to-market of Indebtedness denominated in foreign currencies resulting from the application of FASB ASC 830 or any similar accounting standard;
(ii)non-cash gains included in Consolidated Net Income for such Measurement Period (excluding any such non-cash gain to the extent it represents the reversal of an accrual or a reserve for a potential cash gain in any prior period);
(iii)the amount of any minority interest income consisting of Subsidiary losses attributable to minority interests of third parties in any non-wholly owned Subsidiary (and not deducted in calculating Consolidated Net Income for such Measurement Period); and
(iv)extraordinary, unusual or non-recurring cash gains and income.
If there has occurred a Permitted Acquisition or other Investment in the nature of an acquisition permitted by this Agreement during the applicable Measurement Period, or for purposes of calculating pro forma
17



Total Leverage Ratio or pro forma Fixed Charge Coverage Ratio after the applicable Measurement Period but on or prior to the Ratio Calculation Date in accordance with Section 1.12(b), Consolidated EBITDA shall be calculated on a Pro Forma Basis. Calculating Consolidated EBITDA on a “Pro Forma Basis” shall mean giving effect to any such Permitted Acquisition or other Investment in the nature of an acquisition, and any Indebtedness incurred or assumed in connection therewith, as follows:
(i)any Indebtedness incurred or assumed in connection with such Permitted Acquisition or other permitted Investment in the nature of an acquisition was incurred or assumed on the first day of the applicable Measurement Period and remained outstanding,
(ii)the rate on such Indebtedness shall be calculated as if the rate in effect on the date of such Permitted Acquisition or other permitted Investment in the nature of an acquisition had been the applicable rate for the entire period (taking into account any interest rate Swap Contracts applicable to such Indebtedness), and
(iii)all income, depreciation, amortization, taxes, and expense associated with the assets or entity acquired in connection with such Permitted Acquisition or other permitted Investment in the nature of an acquisition for the applicable period shall be calculated on a pro forma basis after giving effect to cost savings, operating expense reductions, other operating improvements and acquisition synergies (including custodial and interchange synergies) that are reasonably identifiable and projected by the Administrative Borrower in good faith to be realized within twelve (12) months after such Permitted Acquisition or other permitted Investment in the nature of an acquisition (calculated on a pro forma basis as though such items had been realized on the first day of such period) as a result of actions taken by the Parent Guarantor, any Borrower or any Subsidiary in connection with such Permitted Acquisition or other such permitted Investment and net of (x) the amount of actual benefits realized during such period from such actions that are otherwise included in the calculation of Consolidated EBITDA in each case from and after the first day of such Measurement Period and (y) the amount of all income, depreciation, amortization, taxes and expenses associated with any assets or entity acquired in connection with such Permitted Acquisition or other such permitted Investment that the Administrative Borrower reasonably anticipates will be divested;
provided that:
(A)    the aggregate amount of cost savings, operating expense reductions, other operating improvements and acquisition synergies added-back in connection with Permitted Acquisitions or such other permitted Investments pursuant to this clause (iii) in any four consecutive fiscal quarter period shall not exceed, together with amounts added back pursuant to clause (k) and clause (l) above for such period, 17.5% of Consolidated EBITDA (or starting with the fiscal quarter ending June 30, 2026, and thereafter, 15% of Consolidated EBITDA) for such period prior to giving effect to this clause (iii), clause (k) and clause (l) above; and
(B)    at the time any such calculation pursuant to this clause (iii) is made, the Administrative Borrower shall deliver to the Administrative Agent a certificate signed by a Responsible Officer (which may be the Compliance Certificate) setting forth reasonably detailed calculations in respect of the matters referred to in this clause (iii), as well as the relevant factual support in respect thereof.
Notwithstanding anything herein to the contrary, the total amount of Consolidated EBITDA attributable to any Subsidiary formed or organized under the laws of Thailand or Vietnam (or any political sub-division of Thailand or Vietnam, as applicable) shall not exceed $4,000,000 in any four consecutive fiscal quarter period.

18



Consolidated First Lien Debt” means, as of any date of determination, without duplication, the aggregate principal amount of Consolidated Funded Indebtedness outstanding on such date that is secured by a Lien on any asset or property of Parent Guarantor, any Borrower or any Subsidiary (including purchase money Indebtedness and Attributable Indebtedness in respect of Capital Leases) that is senior or pari passu to the Liens securing the Obligations.
Consolidated Funded Indebtedness” means, as of any date of determination, for the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis, the sum, without duplication of (if and to the extent the same would constitute indebtedness or a liability in accordance with GAAP), (i) the outstanding principal amount of all obligations, whether current or long-term, for borrowed money and all obligations evidenced by bonds, debentures, notes (including seller notes), loan agreements or other similar instruments, (ii) all purchase money Indebtedness, (iii) obligations in respect of drawn letters of credit, bankers acceptances or similar instruments to the extent not reimbursed within one (1) Business Day (provided that, cash collateralized amounts under drawn letters of credit, bankers acceptances and similar instruments shall not be counted as Consolidated Funded Indebtedness), (iv) Attributable Indebtedness in respect of Capital Leases, (v) obligations in respect of trade accounts and accrued expenses past due for more than sixty (60) days after the date on which such trade accounts or accrued expenses are due and payable (other than any such trade account or accrued expense that is (x) being contested by a Loan Party in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP in an aggregate amount for all such contested trade accounts and accrued expenses not to exceed $3,000,000 at any time, (y) an intercompany trade account or accrued expense among the Parent Guarantor, any Borrowers and any Subsidiaries or (z) accrued expenses covered in full by the Loan Parties’ director’s and officer’s insurance policy) and earn-outs, hold-backs and other deferred payment of consideration in Permitted Acquisitions to the extent not required to be reflected as liabilities on the balance sheet of the Parent Guarantor, the Borrowers and the Subsidiaries, and (vi) all Guarantees with respect to outstanding Indebtedness of the types specified in clauses (i) through (v) above of Persons other than the Parent Guarantor, any Borrower or any Subsidiary. Consolidated Funded Indebtedness shall not include any financing arrangement in effect on the Closing Date (or any amendment, restatement, amendment and restatement, refinancing or replacement of such financing arrangement for another customary arrangement for the financing of insurance premiums from time to time) in respect of Parent Guarantor’s director’s and officer’s insurance policy to the extent that the payments in respect thereof are payable to the provider of such insurance policy over not more than a twelve (12) month period (the “D&O Financing”).
Consolidated Interest Expense” means, with reference to any period, the interest expense (including interest expense attributable to Capital Lease Obligations that is treated as interest in accordance with GAAP) of the Parent Guarantor, the Borrowers and the Subsidiaries calculated on a consolidated basis for such period with respect to all outstanding Indebtedness of the Parent Guarantor, the Borrowers and the Subsidiaries allocable to such period in accordance with GAAP (including all commissions, discounts and other fees and charges owed with respect to letters of credit and bankers’ acceptance financing and net costs under interest rate Swap Contracts to the extent such net costs are allocable to such period in accordance with GAAP).
Consolidated Net Income” means, at any date of determination, the net income (or loss) of the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis for the most recently completed Measurement Period taken as a single accounting period determined in conformity with GAAP; provided that, Consolidated Net Income shall exclude, without duplication, (a) [reserved], (b) the net income (to the extent positive) of any Subsidiary that is not a Loan Party during such Measurement Period to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary of such income is not permitted by operation of the terms of its Organization Documents or
19



any agreement, instrument or Law applicable to such Subsidiary during such Measurement Period, except that the amount of dividends or distributions or other payments that are actually paid to the Parent Guarantor, a Borrower or a Subsidiary that is a Loan Party (or, if not a Loan Party, to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary of such income is not so prohibited) for such Measurement Period shall be included in determining Consolidated Net Income, (c) any income (or loss) for such Measurement Period of any Person if such Person is not a Subsidiary, except that the Parent Guarantor’s or Borrowers’ equity in the net income of any such Person for such Measurement Period shall be included in Consolidated Net Income up to the aggregate amount of cash actually distributed by such Person during such Measurement Period to the Parent Guarantor, a Borrower or a Subsidiary as a dividend or other distribution (and in the case of a dividend or other distribution to a Subsidiary, such Subsidiary is not precluded from further distributing such amount to the Parent Guarantor, a Borrower or a Subsidiary as described in clause (b) of this proviso), (d) any cancellation of debt income arising from any early extinguishment of Indebtedness, hedging agreements or other similar instruments, (e) the effects of purchase accounting adjustments (including the effects of such adjustments pushed down to the Parent Guarantor, the Borrowers and the Subsidiaries) in component amounts required or permitted by GAAP resulting from the application of purchase accounting in relation to any consummated acquisition or the amortization or write-off of any amounts thereof, net of taxes, (f) any net after-tax gains or losses on disposal of disposed, abandoned, transferred, closed, or discontinued operations (and facilities, plants or distribution centers that have been closed, or temporarily shut down or idled) (excluding held-for-sale discontinued operations until actually disposed of) and (g) any after-tax effect of gains or losses (less all fees and expenses relating thereto) attributable to asset dispositions or abandonments other than in the ordinary course of business, as determined in good faith by the board of directors (or analogous governing body) of the Parent Guarantor, any Borrower or any Subsidiary.
Consolidated Total Assets” means, on any date of determination, the total assets of the Parent Guarantor, the Borrowers and the Subsidiaries, determined in accordance with GAAP as shown on the most recent consolidated balance sheet of the Parent Guarantor delivered pursuant to Section 5.01(a) or (b) on or prior to such date (or, prior to the time any such statements are first required to be so delivered pursuant to Section 5.01(a) or (b), the financial statements delivered pursuant to Section 4.01) in each case after giving pro forma effect to acquisitions or dispositions of Persons, divisions or lines of business that had occurred on or after such balance sheet date and on or prior to such date of determination.
Contractual Obligation” means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.
Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. The terms “Controlling” and “Controlled” have meanings correlative thereto.
Control Agreement” means, with respect to any deposit account, any securities account or any commodity account, an account control agreement, in form and substance satisfactory to the Administrative Agent, among the Administrative Agent, the financial institution or other Person at which such account is maintained and the Loan Party maintaining such account, effective to grant “control” (within the meaning of Articles 8 and 9 under the applicable UCC) over such account to the Administrative Agent.
20



Corresponding Tenor with respect to any Available Tenor means, as applicable, either a tenor (including overnight) or an interest payment period having approximately the same length (disregarding Business Day adjustment) as such Available Tenor.
Covenant Transaction” has the meaning assigned to such term in Section 1.12(d).
Covered Entity” means any of the following:
(i)a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii)a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or
(iii)a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).
Credit Exposure” means, as to any Lender at any time, the sum of (a) such Lender’s Revolving Credit Exposure at such time, plus (b) an amount equal to the aggregate principal amount of its Term Loans outstanding at such time.
Credit Party” means the Administrative Agent or any Lender.

Debtor Relief Laws” means the Bankruptcy Code, all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States, the Companies (Jersey) Law 1991, the Bankruptcy (Désastre) (Jersey) Law 1990, the English Insolvency Act 1986, Part 26 and Part 26A of the UK Companies Act 2006 and the UK Corporate Insolvency and Governance Act 2020 or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.
Default” means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default.
Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
Defaulting Lender” means any Lender that (a) has failed, within two (2) Business Days of the date required to be funded or paid, to (i) fund any portion of its Loans or (ii) pay over to any Credit Party any other amount required to be paid by it hereunder, unless, in the case of clause (i) above, such Lender notifies the Administrative Agent in writing that such failure is the result of such Lender’s good faith determination that a condition precedent to funding (specifically identified and including the particular default, if any) has not been satisfied, (b) has notified the Administrative Borrower or any Credit Party in writing, or has made a public statement to the effect, that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement indicates that such position is based on such Lender’s good faith determination that a condition precedent (specifically identified and including the particular default, if any) to funding a Loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to extend credit, (c) has failed, within three (3) Business Days after request by a Credit Party, acting in good faith, to provide a certification in writing from an authorized officer of such Lender that it will comply with its
21



obligations (and is financially able to meet such obligations as of the date of certification) to fund prospective Loans under this Agreement, provided that, such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon such Credit Party’s receipt of such certification in form and substance satisfactory to it and the Administrative Agent, or (d) has become the subject of (i) a Bankruptcy Event or (ii) a Bail-In Action.
Discharge Date” has the meaning assigned to such term in Section 8.10(a)(i)(x).
Disposition” or “Dispose” means the sale, transfer, license, lease or other disposition (including any Sale and Leaseback Transaction) of any property by any Person, including (x) any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith and (y) any issuance of Equity Interests by any Subsidiary of such Person (other than directors’ qualifying shares). Notwithstanding anything herein to the contrary, any issuance of Equity Interests by the Parent Guarantor shall not be a Disposition. Notwithstanding anything herein to the contrary, the transactions contemplated pursuant to the Intercompany Distribution Agreements shall not be deemed to be Dispositions.
Disqualified Equity Interests” means any Equity Interests that, by their terms (or by the terms of any security or other Equity Interest into which they are convertible or for which they are exchangeable) or upon the happening of any event or condition, (a) mature or are mandatorily redeemable (other than solely for Qualified Equity Interests), pursuant to a sinking fund obligation or otherwise (except as a result of a change of control or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitments), (b) are redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests) (except as a result of a change of control or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitments), in whole or in part, (c) provide for the mandatory scheduled payment of dividends in cash or (d) are or become convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case prior to the date that is one hundred and eighty (180) days after the Latest Maturity Date in effect at the time of issuance of such Equity Interests; provided that, only the portion of Equity Interests which so mature or are mandatorily redeemable, are redeemable at the option of the holder thereof, provide for the mandatory scheduled payment of dividends or which are or become convertible as described above shall be deemed to be Disqualified Equity Interests; provided further, however, that that any Equity Interests that would not constitute Disqualified Equity Interests but for provisions thereof giving holders thereof (or the holders of any security into or for which such Equity Interests is convertible, exchangeable or exercisable) the right to require the issuer thereof to redeem such Equity Interests upon the occurrence of any change of control, any offering of Equity Interests or any Disposition occurring prior to the date that is one hundred and eighty (180) days after the Latest Maturity Date in effect at the time of issuance of such Equity Interests shall not constitute Disqualified Equity Interests if such Equity Interests provide that the issuer thereof will not redeem any such Equity Interests pursuant to such provisions prior to the repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitments; and provided further, however, that notwithstanding the foregoing, (i) if such Equity Interests are issued pursuant to any plan for the benefit of directors, officers, employees, members of management, managers or consultants or by any such plan to such directors, officers, employees, members of management, managers or consultants, in each case in the ordinary course of business of the Parent Guarantor, any Borrower or any Subsidiary, such Equity Interests shall not constitute Disqualified Equity Interests solely because they may be required to be
22



repurchased by the issuer thereof in order to satisfy applicable statutory or regulatory obligations, and (ii) no Equity Interests held by any future, present or former employee, director, officer, manager, member of management or consultant (or their respective Affiliates or Immediate Family Members) of the Parent Guarantor, any Borrower or any Subsidiary shall be considered Disqualified Equity Interests because such stock is redeemable or subject to repurchase pursuant to any management equity subscription agreement, stock option, stock appreciation right or other stock award agreement, stock ownership plan, put agreement, stockholder agreement or similar agreement that may be in effect from time to time.
Disqualified Institution” means (a) Persons that are specifically identified by the Administrative Borrower to the Administrative Agent in writing prior to the Closing Date, (b) any Person that is reasonably determined by the Administrative Borrower after the Closing Date to be a competitor of the Parent Guarantor, the Borrowers or the Subsidiaries and which is specifically identified in a written supplement to the list of “Disqualified Institutions”, which supplement shall become effective three (3) Business Days after delivery thereof to the Administrative Agent in accordance with Section 9.01 and (c) in the case of the foregoing clauses (a) and (b), any of such entities’ Affiliates to the extent such Affiliates (x) are clearly identifiable as Affiliates of such Persons based solely on the similarity of such Affiliates’ and such Persons’ names and (y) are not bona fide debt investment funds. It is understood and agreed that (i) any supplement to the list of Persons that are Disqualified Institutions contemplated by the foregoing clause (b) shall not apply retroactively to disqualify any Persons that have previously acquired an assignment or participation interest in the Loans (but solely with respect to such Loans), (ii) the Administrative Agent shall have no responsibility or liability to determine or monitor whether any Lender or potential Lender is a Disqualified Institution, (iii) the Administrative Borrower’s failure to deliver such list (or supplement thereto) in accordance with Section 9.01 shall render such list (or supplement) not received and not effective and (iv) “Disqualified Institution” shall exclude any Person that the Administrative Borrower has designated as no longer being a “Disqualified Institution” by written notice delivered to the Administrative Agent from time to time in accordance with Section 9.01.
Dollar Equivalent” means, at any time, (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in any other currency, the equivalent amount thereof in Dollars as determined by the Administrative Agent at such time on the basis of the Spot Rate for the purchase of Dollars with such other currency.
D&O Financing” has the meaning assigned to such term in the definition of “Consolidated Funded Indebtedness”.
Dollars”, “dollars” or “$” refers to lawful money of the United States of America.
Domestic Subsidiary” means a Subsidiary organized under the laws of a jurisdiction located in the United States of America.
DQ List” has the meaning assigned to such term in Section 9.04(e)(iv).
ECP” means an “eligible contract participant” as defined in Section 1(a)(18) of the Commodity Exchange Act or any regulations promulgated thereunder and the applicable rules issued by the Commodity Futures Trading Commission and/or the SEC.
EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member
23



Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.
EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.
EEA Resolution Authority” means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
Electronic Signature” means an electronic sound, symbol, or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record. “Environmental Claim” means any written notice, claim, demand, action, litigation, toxic tort, proceeding, demand, request for information, complaint, citation, summons, investigation, notice of non-compliance or violation, cause of action, consent order, consent decree, investigation, or other proceeding by any Governmental Authority or any other Person, arising out of, based on or pursuant to any Environmental Law or related in any way to any actual, alleged or threatened Environmental Liability.
English Debenture” means the English law governed debenture entered in to between Milk Makeup UK Limited, Waldencast UK Operations Limited and the Administrative Agent on or around the date of this Agreement.
English Loan Party” means any Loan Party incorporated in England and Wales.
English Collateral Agreements” means (a) the English Debenture, and (b) any English law governed security documents securing Obligations that are entered into after the date of this Agreement.
Environmental Laws” means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, agreements or governmental restrictions relating to human health and safety (as it pertains to exposure to hazardous materials), pollution, the protection of the environment or the release of any materials into the environment, including those related to hazardous materials, substances or wastes and air emissions and water discharges.
Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), obligation, responsibility or cost directly or indirectly resulting from or based upon (a) any violation of, or liability under, any Environmental Law, (b) the generation, use, handling, transportation, storage, distribution, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment, (e) natural resource damage or (f) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.
Environmental Permit” means any permit, approval, identification number, license or other authorization issued pursuant to or required under any Environmental Law.
Equity Interests” means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit
24



interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination; provided that, any interests evidenced by instruments of Indebtedness convertible into or exchangeable for Equity Interests shall not be deemed to be Equity Interests unless and until such interests are so converted or exchanged.
ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder.
ERISA Affiliate” means any trade or business (whether or not incorporated) that, together with any Loan Party, is treated as a single employer under Section 414(b) or (c) of the Code or Section 4001(a)(14) of ERISA (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code).
ERISA Event” means the occurrence of any of the following (a) a “Reportable Event” with respect to a Pension Plan; (b) the filing pursuant to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Pension Plan; (c) the withdrawal of any Loan Party or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which such entity was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (d) a complete or partial withdrawal by any Loan Party or any ERISA Affiliate from a Multiemployer Plan or notification concerning the imposition upon any Loan Party or any ERISA Affiliate of any liability with respect to such withdrawal, or a determination that a Multiemployer Plan is or is expected to be insolvent or in critical status within the meaning of Title IV of ERISA; (e) the filing of a notice of intent to terminate a Pension Plan, or the treatment of a Pension Plan amendment as a termination, under Section 4041 or 4041A of ERISA; (f) the institution by the PBGC of proceedings to terminate a Pension Plan; (g) any event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan; (h) the determination that the adjusted funding target attainment percentage (as defined in Section 436(j)(2) of the Code) of any Pension Plan is both less than 80% and such Pension Plan is more than $20,000,000 underfunded on an adjusted funding target attainment percentage basis; (i) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Loan Party or any ERISA Affiliate; (j) the failure to satisfy the Pension Funding Rules with respect to any Pension Plan, whether or not waived; or (k) a Foreign Plan Event.
Erroneous Payment” has the meaning assigned to such term in Section 8.06.
EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.
Event of Default” has the meaning assigned to such term in Section 7.01.
Evidence of Flood Insurance” has the meaning assigned to such term in Section 5.11(b)(vii).
25



Excess Cash Flow” means, with respect to any Person for any period, (a) (i) Consolidated EBITDA of such Person and its Subsidiaries for such period plus (ii) the excess, if any, of Working Capital at the beginning of such period over Working Capital at the end of such period, less (b) the sum of, without duplication, (i) all cash principal payments (excluding any principal payments made pursuant to Sections 2.11(a), 2.11(c) and 2.11(d) (but including, in the case of Section 2.11(d), any amounts that increased Consolidated EBITDA) on the Loans made during such period (but, in the case of the Revolving Loans, only to the extent that the Revolving Commitment is permanently reduced by the amount of such payments), and all cash principal payments on Indebtedness (other than Indebtedness incurred under this Agreement) of such Person or any of its Subsidiaries during such period (other than payments made using the Available Amount) to the extent such other Indebtedness was permitted to be incurred, and such payments are permitted to be made, under this Agreement (but, in the case of revolving loans, only to the extent that the revolving commitment in respect thereof is permanently reduced by the amount of such payments) (except to the extent financed through the incurrence of Indebtedness or through proceeds of Equity Interests), (ii) all Consolidated Interest Expense to the extent paid or payable in cash during such period, (iii) the cash portion of Capital Expenditures made by such Person and its Subsidiaries during such period to the extent permitted to be made under this Agreement (excluding Capital Expenditures to the extent financed through the incurrence of Indebtedness or through proceeds of Equity Interests), (iv) all scheduled loan servicing fees and other similar fees in respect of Indebtedness of such Person or any of its Subsidiaries paid in cash during such period, to the extent such Indebtedness is permitted to be incurred, and such payments are permitted to be made, under this Agreement, (v) all taxes paid in cash by such Person and its Subsidiaries for such period (including Permitted Tax Distributions), (vi) all cash expenses, cash charges, cash losses and other cash items that were added back in the determination of Consolidated EBITDA for such period, (vii) the excess, if any, of Working Capital at the end of such period over Working Capital at the beginning of such period, (viii) the aggregate amount of consideration paid by such Person and its Subsidiaries in cash during such period (or, at the option of the Administrative Borrower, committed to be paid in cash within the period of four consecutive fiscal quarters of such Person following the end of such period (provided that if not so paid within such period, such amounts shall be included in Excess Cash Flow in the next period)) with respect to Permitted Acquisitions, Investments, Restricted Payments to the extent such Permitted Acquisitions, Investments or Restricted Payments are permitted to be made under this Agreement (except to the extent financed through the incurrence of Indebtedness or through proceeds of Equity Interests or made using the Available Amount), (ix) the aggregate consideration required to be paid in cash by such Person and its Subsidiaries pursuant to binding contracts, commitments or purchase orders entered into prior to or during such period relating to Permitted Acquisitions or Capital Expenditures to the extent expected to be consummated or made, in each case, during the period of four consecutive fiscal quarters of such Person following the end of such period (provided that if not so paid within such period, such amounts shall be included in Excess Cash Flow in the next period) (except to the extent financed through the incurrence of Indebtedness or through proceeds of Equity Interests or made using the Available Amount) and (x) an amount equal to the amount of all non cash credits included in arriving at Consolidated EBITDA.
Excess Cash Flow Period” means the Fiscal Year of Parent Guarantor, the Borrowers and each Subsidiary ended on December 31, 2025 and each Fiscal Year thereafter.
Excluded Accounts” means, collectively, deposit accounts, to the extent exclusively constituting (a) payroll and other employee wage and benefit accounts, (b) tax accounts, including sales tax accounts, (c) petty cash accounts funded in the ordinary course of business with a balance not
26



exceeding $250,000 for all such accounts in the aggregate, (d) escrow, fiduciary or trust accounts (including the escrow account holding $5,000,000 of proceeds of Project Romania, as required by the terms of Project Romania and the escrow account holding penalty payments in respect of the Clean Team Agreement Related Matters), (e) [reserved], (f) deposit accounts (i) that are zero balance accounts or (ii) the balances of which are transferred automatically on a daily basis to deposit accounts that are not Excluded Accounts, (g) accounts holding cash to secure letter of credit reimbursement obligations, bankers acceptances and similar instruments to the extent such secured letters of credit, acceptances and instruments are permitted, and such cash collateral is permitted, by this Agreement and (h) the funds or other property held in or maintained in any such account identified in clauses (a) through (g).
Excluded Assets” means:
(i)any fee-owned real property that is not a Material Real Estate Asset and all leasehold or subleasehold interests in real property;
(ii)any motor vehicles, aircraft and other assets subject to certificates of title (other than to the extent the security interest in such certificates of title may be perfected by the filing of UCC financing statements or a financing statement on the register of security interests created under Part 8 of the Security Interests (Jersey) Law 2012) (the “SIR”);
(iii)assets in respect of which pledges and security interests are prohibited by applicable U.S. law, rule or regulation or agreements with any United States Governmental Authority (other than to the extent that such prohibition would be rendered ineffective pursuant to Section 9-406, 9-407, 9-408, 9-409 or other applicable provisions of the UCC of any applicable jurisdiction or any other applicable law); provided that, immediately upon the ineffectiveness, lapse or termination of any such prohibitions, such assets shall automatically cease to constitute “Excluded Assets”;
(iv)Equity Interests in any Person other than wholly-owned Subsidiaries (other than a Loan Party) to the extent not permitted by terms in such Person’s organizational or joint venture documents (unless any such restriction would be rendered ineffective pursuant to Section 9-406, 9-407, 9-408, 9-409 or other applicable provisions of the UCC of any applicable jurisdiction or any other applicable law);
(v)any lease, license or other agreement or any property subject to a purchase money security interest or similar arrangement, in each case to the extent permitted under this Agreement, to the extent that a grant of a security interest therein would violate or invalidate such lease, license or agreement or purchase money arrangement or create a right of termination in favor of any other party thereto (other than a Loan Party) (other than (i) proceeds and receivables thereof, the assignment of which is expressly deemed effective under the UCC notwithstanding such prohibition, (ii) to the extent that any such term has been waived or (iii) to the extent any such term would be rendered ineffective pursuant to Section 9-406, 9-407, 9-408, 9-409 or other applicable provisions of the UCC of any applicable jurisdiction or any other applicable law); provided that, immediately upon the ineffectiveness, lapse or termination of any such express term, such assets shall automatically cease to constitute “Excluded Assets”;
(vi)Excluded Accounts (other than pursuant to clause (c) of such definition);
(vii)[reserved];
(viii)any “intent-to-use” application for registration of a trademark filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, to the extent, if any, that and solely during the period, if any, in which, the grant of a
27



security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law;
(ix)[reserved];
(x)Equity Interests in any (w) Immaterial Subsidiary (other than to the extent the security interest in such Equity Interests may be perfected by the filing of a UCC financing statement), (x) not-for-profit Subsidiary, (y) Captive Insurance Subsidiary, or (z) Subsidiary if the granting of a security interest in such Equity Interests (i) is prohibited or restricted by any applicable Law or any Contractual Obligation (limited, in the case of a Contractual Obligation, to such Contractual Obligations in place on the Closing Date or on the date such Subsidiary was acquired by the Parent Guarantor, any Borrower or any Subsidiary and that was not entered into in contemplation thereof) from providing a Guarantee of the Obligations, (ii) would require a governmental consent, approval, license or authorization (including any regulatory consent, approval, license or authorization) in order to provide such security interest (other than any such consent, approval, license or authorization that has been obtained);
(xi)any assets to the extent a security interest in such assets would result in material adverse Tax consequences (as reasonably determined by the Administrative Agent in consultation with the Administrative Borrower); and
(xii)Specified Assets.
provided that, “Excluded Assets” shall not include any proceeds, products, substitutions or replacements of Excluded Assets (unless such proceeds, products, substitutions or replacements would otherwise constitute Excluded Assets).
Excluded Subsidiary” means:
(i)[reserved],
(ii)any Immaterial Subsidiary,
(iii)[reserved],
(iv)any not-for-profit Subsidiary,
(v)any Captive Insurance Subsidiary,
(vi)any Subsidiary (i) that is prohibited or restricted by any applicable Law or any Contractual Obligation (limited, in the case of a Contractual Obligation, to such Contractual Obligations in place on the Closing Date or on the date such Subsidiary was acquired by the Parent Guarantor, any Borrower or any Subsidiary and that was not entered into in contemplation thereof) from providing a Guarantee of the Obligations (provided that this exclusion shall not apply to documentation governing assumed Indebtedness), (ii) that would require a governmental consent, approval, license or authorization (including any regulatory consent, approval, license or authorization) in order to provide a Guarantee of the Obligations (other than any such consent, approval, license or authorization that has been obtained) (iii) if the provision of a Guarantee of the Obligations by such Subsidiary would result in adverse tax consequences to the Borrowers, as reasonably determined by the Administrative Borrower in consultation with the Administrative Agent or (iv) any Foreign Subsidiary excluded in accordance with the Agreed Security Principles,
(vii)[reserved], or
28



(viii)any other Subsidiary with respect to which, in the reasonable judgment of the Administrative Agent in consultation with the Administrative Borrower, the burden or cost of providing a Guarantee of the Obligations outweighs the benefits afforded thereby.
Notwithstanding the foregoing, in no event shall any Borrower or any parent company of any Borrower (other than any parent company of the Parent Guarantor) be an “Excluded Subsidiary”.
Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, any U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Administrative Borrower under Section 2.19(b)) or (ii) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2.17, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender acquired the applicable interest in a Loan or Commitment or to such Lender immediately before it changed its lending office, (c) Taxes attributable to such Recipient’s failure to comply with Sections 2.17(f) and (d) any withholding Taxes imposed under FATCA.
Existing Credit Agreement Refinancing” means the repayment in full of all principal, interest, fees and other amounts due or outstanding under the Existing Credit Agreement, the termination of all commitments under the Existing Credit Agreement and the termination and release of all guarantees and security in support of the Existing Credit Agreement.
Existing Credit Agreement” means that certain Credit Agreement, dated as of June 24, 2022, by and among WALDENCAST PARTNERS LP, as parent guarantor, WALDENCAST FINCO LIMITED, as borrower, the lenders from time to time party thereto and JPMORGAN CHASE BANK, N.A., as administrative agent, as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the Closing Date.
(ix)    “Extraordinary Receipt” means the receipt by the Parent Guarantor, any Borrower or any Subsidiary of any cash not in the ordinary course of business (and not consisting of proceeds described in clause (a) of the definition of Prepayment Event), limited solely to the following, without duplication: (a) as a result of proceeds of insurance that results from a casualty or similar event (other than proceeds of business interruption insurance to the extent such proceeds constitute compensation for lost earnings or the proceeds of director’s and officer’s liability insurance (including proceeds paid as a reimbursement for costs and expenses)) and condemnation awards (and payments in lieu thereof), excluding cash receipts from proceeds of insurance or condemnation awards (or payments in lieu thereof) to the extent that such proceeds or awards are received by any Person in respect of any third party claim against, or liability of, such Person and applied to pay (or to reimburse such Person for its prior payment of) such claim or liability and the costs and expenses of such Person with respect thereto (collectively, “Casualty Proceeds”), (b) foreign, United States, state or local tax refunds, (c) pension plan reversions, (d) proceeds of insurance (other than to the extent such insurance proceeds are (i) covered in clause (a) above (and other than proceeds of business interruption insurance to the extent such proceeds constitute compensation for lost earnings or the proceeds of director’s and officer’s liability insurance (including proceeds paid as a reimbursement for costs and expenses)), (ii) immediately payable to a
29



Person that is not Parent Guarantor or any of its Subsidiaries in accordance with applicable law or with Contractual Obligations entered into in the ordinary course of business or (iii) received by Parent Guarantor or any of its Subsidiaries as reimbursement for any out-of-pocket costs incurred or made by such Person prior to the receipt thereof directly related to the event resulting from the payment of such proceeds), (e) judgments, proceeds of settlements (which shall not include proceeds from Project Romania) or other consideration of any kind in connection with any cause of action (other than to the extent such judgments, proceeds of settlements or other consideration of any kind are received as reimbursement for any losses, costs, expenses or charges directly related to the event resulting from the payment of such proceeds)), (f) indemnity payments (other than to the extent such indemnity payments are (i) immediately payable to a Person that is not an Affiliate of Parent Guarantor or any of its Subsidiaries, or (ii) received by Parent Guarantor or any of its Subsidiaries as reimbursement for any costs previously incurred or any payment previously made by such Person), (g) proceeds of Project Romania and (h) any purchase price adjustment received in connection with any purchase agreement.
(x)    “Facility” means the Term Facility or a Revolving Facility, as the context may require.
FATCA” means Sections 1471 through 1474 of the Code, as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.
Federal Funds Effective Rate” means, for each day, the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by the Administrative Agent from three federal funds brokers of recognized standing selected by it; provided that, if the Federal Funds Effective Rate as so determined would be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.
Federal Reserve Board” means the Board of Governors of the Federal Reserve System of the United States of America.
Fee Letter” means that certain Fee Letter, dated as of the Closing Date, by and among the Administrative Agent and the Borrowers.
Financial Officer” means the chief financial officer, principal accounting officer, treasurer or controller (or, in the case of the Parent Guarantor, the sole manager of its general partner) of any Borrower or the Parent Guarantor (as the context may require).
Financials” means the annual or quarterly financial statements, and accompanying certificates and other documents, of the Parent Guarantor, the Borrowers and the Subsidiaries required to be delivered pursuant to Section 5.01(a) or 5.01(b).
Fiscal Year” means the fiscal year of the Parent Guarantor, the Borrowers and the Subsidiaries ending on December 31 of each calendar year.
Fixed Amounts” has the meaning assigned to such term in Section 1.12(f).
30



Fixed Charge Coverage Ratio” means, with respect to any Person for any period, the ratio of (a) the result of (i) Consolidated EBITDA of such Person and its Subsidiaries for such period minus (ii) Capital Expenditures made by such Person and its Subsidiaries during such period that (x) are not financed with the proceeds of any sale or issuance of Equity Interests of, or equity contributions to Parent Guarantor and (y) are not reimbursed by a third person (excluding any Loan Party or any of its Subsidiaries), to (b) the sum of (i) all principal of Indebtedness (other than (x) any intercompany Indebtedness or (y) the D&O Financing) of such Person and its Subsidiaries scheduled to be paid or prepaid in cash during such period to the extent there is an equivalent permanent reduction in the commitments thereunder (excluding the payment of any long-term Indebtedness at maturity) plus (ii) Consolidated Interest Expense of such Person and its Subsidiaries for such period, excluding (x) any prepayment premium or make-whole and (y) any non-cash interest expense plus (iii) income taxes paid or payable by such Person and its Subsidiaries during such period (net of cash tax refunds received by such Person and its Subsidiaries during such period) plus (iv) cash dividends or distributions paid, or the purchase, redemption or other acquisition or retirement for value (including in connection with any merger or consolidation), by such Person or any of its Subsidiaries, in respect of the Equity Interests of such Person or any of its Subsidiaries (other than dividends or distributions paid (x) by a Loan Party to any other Loan Party or (y) pursuant to Section 6.06(g) if already included in clause (b)(iii) above) during such period.
Notwithstanding anything to the contrary contained herein, causes (b)(i) and (b)(ii) above shall be calculated: (a) in the case of the Measurement Period ending March 31, 2025, (i) in the case of clause (b)(i), (x) with respect to the principal of Indebtedness under this Agreement, calculating the amortization of the principal of such Indebtedness that would have occurred had the Closing Date been the first day of such Measurement Period, and (y) with respect to the principal of all other Indebtedness (excluding, for the avoidance of doubt, Indebtedness paid in full on the Closing Date), the actual amortization of the principal of all such Indebtedness during such Measurement Period, and (y) in the case of clause (b)(ii), (x) with respect to the Consolidated Interest Expense incurred under this Agreement, calculating such Consolidated Interest Expense that would have been incurred had the Closing Date been the first day of such Measurement Period and the interest rate hereunder for such Measurement Period been the interest rate in effect on the Closing Date, and (y) with respect to the Consolidated Interest Expense in respect of all other Indebtedness (excluding, for the avoidance of doubt, Indebtedness paid in full on the Closing Date), the actual Consolidated Interest Expense in respect of all such Indebtedness for such Measurement Period, (b) in the case of the Measurement Period ending June 30, 2025, by multiplying the amount of such clauses for the fiscal quarter ending June 30, 2025 by four (4), (c) in the case of the Measurement Period ending September 30, 2025, by multiplying the amount of such clauses for the fiscal quarter ending September 30, 2025 and June 30, 2025 by two (2), and (d) in the case of the Measurement Period ending December 31, 2025, by multiplying the amount of such clauses for the fiscal quarter ending December 31, 2025, September 30, 2025 and June 30, 2025 by four-thirds (4/3). For purpose of determining the amount of principal allocated to scheduled payments under Capital Leases under this definition, interest in respect of any Capital Lease of any Person shall be deemed to accrue at an interest rate reasonably determined by such Person to be the rate of interest implicit in such Capital Lease in accordance with GAAP.
Flood Determination Form” has the meaning assigned to such term in Section 5.11(b).
Flood Laws” means (i) the National Flood Insurance Act of 1968, (ii) the Flood Disaster Protection Act of 1973, (iii) the National Flood Insurance Reform Act of 1994, (iv) the Flood Insurance Reform Act of 2004 and (v) the Biggert –Waters Flood Insurance Reform Act of 2012, in each case,
31



together with all regulations promulgated thereunder, as such statutes or regulations may be amended or modified from time to time.
Floor” means 2.00%.
Foreign Lender” means, if any Borrower is a U.S. Person, a Lender that is not a U.S. Person.
Foreign Perfection Requirements” means, with respect to any jurisdiction outside of the United States, the making or procuring of any registrations, filings, endorsements, or stampings, in each case as required by local Laws, notations in stock registries (or equivalent), notarisations, legalisation, notices and other actions and steps required by Law to be made in any such jurisdiction in order to perfect the security created or purported to be created pursuant to the Collateral Documents or in order to achieve the relevant priority for such Collateral.
Foreign Plan” means each employee benefit plan, fund or arrangement (within the meaning of Section 3(3) of ERISA, whether or not subject to ERISA) or other similar program that is not subject to U.S. law and is maintained or contributed to (or required to be contributed to) by any Loan Party for the benefit of its employees working outside of the U.S.
Foreign Plan Event” means with respect to any Foreign Plan, (a) the failure to make or, if applicable, accrue in accordance with normal accounting practices, any employer or employee contributions required by applicable law or by the terms of such Foreign Plan; (b) the failure to register or loss of good standing with applicable regulatory authorities of any such Foreign Plan required to be registered; or (c) the failure of any Foreign Plan to comply with any material provisions of applicable law and regulations or with the material terms of such Foreign Plan.
Foreign Subsidiary” means any Subsidiary which is not a Domestic Subsidiary.
GAAP” means generally accepted accounting principles in the United States of America as in effect from time to time or, in relation to any English Loan Party, generally accepted accounting principles in the United Kingdom including IFRS.
Governmental Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including the National Association of Insurance Commissioners and any supra-national bodies such as the European Union or the European Central Bank).
Guarantee” means, as to any Person, without duplication, (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other monetary obligation payable or performable by another Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other monetary obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other monetary obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other monetary
32



obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other monetary obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness or other monetary obligation of any other Person, whether or not such Indebtedness or other monetary obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien); provided that, the term “Guarantee” shall not include endorsements for collection or deposit, in either case in the ordinary course of business, or customary and reasonable indemnity obligations in effect on the Closing Date entered into in connection with any acquisition or disposition of assets permitted under this Agreement (other than such obligations with respect to Indebtedness). The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term “Guarantee” as a verb has a corresponding meaning.
Guarantee Agreement” means the Guarantee Agreement, to be dated as of the Closing Date, among the Guarantors party thereto and the Administrative Agent.
Guarantor” means, collectively, (a) the Parent Guarantor (b) each existing and future direct or indirect Subsidiary (other than any Excluded Subsidiary) and (c) each Borrower (other than with respect to its own obligations). The Guarantors that are expected to be existing on the Closing Date are listed on Schedule 3.01.
Hazardous Materials” means all explosive or radioactive substances or wastes, contaminants, pollutants or any other hazardous or toxic substances, wastes or materials regulated under or defined in any Environmental Law, including petroleum, its derivatives or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, and infectious or medical wastes.
Health Care Claim” means any action, suit, complaint, summons, citation, notice, warning letter, untitled letter, directive, order, writ, injunction, seizure, decree, claim, litigation, investigation, judicial or administrative proceeding, judgment, letter or other communication, from any Person or Governmental Authority relating to or arising out of or asserting, in writing, any alleged or actual violation of, non-compliance with, or liability under, any Health Care Law.
Health Care Law” means (a) Laws regulating the research, procurement, development, clinical and non-clinical evaluation or investigation, testing, product approval or clearance, import, export, production, manufacturing, current good manufacturing practices, analysis, use, disposal, processing, transportation, handling, storage, packaging, recall, licensing, labeling, promotion, recordkeeping and reporting requirements, distribution, marketing, advertising, reimbursement, offer for sale, sale, and introduction or delivery for introduction into interstate commerce of any product, including the Food, Drug, and Cosmetic Act, as amended, other applicable Laws enforced by the U.S. Food and Drug Administration, U.S. Federal Trade Commission, the U.S. Customs and Border Protection, state boards of pharmacy and health, and similar foreign, federal, state, and local Governmental Authorities, and all similar applicable laws and orders in each jurisdiction where any Borrower’s products are developed, manufactured, offered for sale or sold; (b) all healthcare Laws applicable to Parent Guarantor or its Subsidiaries; (c) all applicable Laws regulating patient referrals and payments to and interactions with health care professionals and (d) all applicable privacy Laws.
33



Health Care Liability” means all liabilities (contingent or otherwise), monetary obligations, losses (including monies paid in settlement), damages, costs and expenses (including all reasonable fees, costs, client charges and expenses of counsel, experts and consultants), fines, penalties, sanctions and interest arising directly as a result of, from or based upon (a) any Health Care Claim, or (b) any actual, alleged or threatened, in writing, violation of or non-compliance with any Health Care Law or Health Care Permit.
Health Care Permit” means all necessary approvals, clearances, permits, licenses, registrations, listings or authorizations of any Governmental Authority, necessary for the research, development, investigation, testing, production, manufacture, disposal, processing, prescription, dispensing, handling, packaging, labeling, promotion, distribution, advertising, use, storage, import, export, transport, marketing, promotion, offer for sale, sale, introduction into interstate commerce, and delivery for introduction into interstate commerce of any product in a given country or regulatory jurisdiction.
Hemp Claim” means any action, suit, complaint, summons, citation, notice, letter of admonition, warning letter, untitled letter, directive, order, writ, injunction, seizure, decree, claim, litigation, investigation, judicial or administrative proceeding, judgment, letter or other communication, from any Person or Governmental Authority relating to or arising out of or asserting, in writing, any alleged or actual violation of, non-compliance with, or liability under, any Hemp Laws.
Hemp Laws” means any state or foreign Laws regulating the research, development, creation, investigation, testing, import, export, production, manufacturing, use, disposal, processing, transportation, handling, storage, possession, packaging, licensing, prescribing, dispensing, labeling, promotion, distribution, marketing, advertising, offer for sale, sale, and introduction or delivery for introduction into interstate commerce of (i) hemp (as defined in 7 U.S.C. § 1639o(1) or any similar applicable foreign, federal, state or local Law), or (ii) any hemp derivatives or extracts, including in each jurisdiction where any Borrower’s products hemp or any derivatives or extracts thereof are offered for sale or sold.
Historical Annual Financial Statements” means (i) the draft audited consolidated balance sheets and statements of operations, and member’s equity and cash flows of Parent Guarantor and its Subsidiaries (including all notes thereto) as of and for the year ended December 31, 2024 and (ii) the audited consolidated balance sheets and statements of operations, and member’s equity and cash flows of Parent Guarantor and its Subsidiaries (including all notes thereto) as of and for the years ended December 31, 2023 and December 31, 2022, together with the auditor’s reports thereon.
Immaterial Subsidiary” means as of any date, any Subsidiary (other than the Borrowers or any direct or indirect parent entity of any Borrower that is a Subsidiary) that, as of the last date of the most recent fiscal quarter of the Borrowers for which financial statements have been delivered, accounts for less than 5.0% of the Consolidated Total Assets of the Parent Guarantor, the Borrowers and the Subsidiaries and less than 5.0% of the Consolidated EBITDA of the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis, in each case, as measured as of the last day of the most recent fiscal quarter of the Borrowers for which financial statements have been delivered; provided that, if, as of the last date of the most recent fiscal quarter of the Borrowers for which financial statements have been delivered, the aggregate amount of Consolidated Total Assets or Consolidated EBITDA attributable to all Subsidiaries that are Immaterial Subsidiaries exceeds 10.0% of the Consolidated Total Assets or Consolidated EBITDA, respectively, of the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis, then a sufficient number of Subsidiaries shall be designated by the Administrative Borrower (or, in the event the Administrative Borrower has failed to do so within fifteen (15) days, the
34



Administrative Agent) to eliminate such excess, and such designated Subsidiaries shall no longer constitute Immaterial Subsidiaries under this Agreement.
Immediate Family Member” means, with respect to any individual, such individual’s child, stepchild, grandchild or more remote descendant, parent, stepparent, grandparent, spouse, former spouse, domestic partner, former domestic partner, sibling, mother-in-law, father-in-law, son-in-law and daughter-in-law (including adoptive relationships), any trust, partnership or other bona fide estate-planning vehicle the only beneficiaries of which are any of the foregoing individuals, such individual’s estate (or an executor or administrator acting on its behalf), heirs or legatees or any private foundation or fund that is controlled by any of the foregoing individuals or any donor-advised fund of which any such individual is the donor.
Incurrence-Based Amounts” has the meaning assigned to such term in Section 1.12(f).
Indebtedness” means, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP:
(i)all obligations of such Person for borrowed money and all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments;
(ii)the maximum amount (after giving effect to any prior drawings or reductions which may have been reimbursed) of all outstanding direct or contingent obligations of such Person arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments;
(iii)net obligations of such Person under any Swap Contract;
(iv)all obligations of such Person to pay the deferred purchase price of property or services (other than (i) trade accounts and accrued expenses payable in the ordinary course of business and not past due for more than sixty (60) days after the date on which such trade accounts or accrued expenses are due and payable, (ii) accruals for payroll and other liabilities accrued in the ordinary course of business and (iii) earn-outs, hold-backs and other deferred payment of consideration in Permitted Acquisitions to the extent not required to be reflected as liabilities on the balance sheet of the Parent Guarantor, the Borrowers and the Subsidiaries in accordance with GAAP);
(v)Indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse; provided that, the amount of such Indebtedness shall be the lesser of (i) the fair market value of such property as determined by such Person in good faith on the applicable date of determination and (ii) the amount of such Indebtedness of other Persons;
(vi)Capital Lease Obligations;
(vii)all obligations of such Person in respect of Disqualified Equity Interests valued, in the case of a redeemable preferred interest that is a Disqualified Equity Interest, at the greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends; and
(viii)to the extent not otherwise included above, all Guarantees of such Person in respect of any of the foregoing.
35



For all purposes hereof, the Indebtedness of any Person shall include the Indebtedness of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person is a general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of any net obligation under any Swap Contract on any date shall be deemed to be the Swap Termination Value thereof as of such date. The amount of any Capital Lease as of any date shall be deemed to be the amount of Attributable Indebtedness in respect thereof as of such date. Notwithstanding anything herein to the contrary, the transactions contemplated pursuant to the Intercompany Distribution Agreements shall not be deemed to be Indebtedness.
Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a) hereof, Other Taxes.
Indemnitee” has the meaning assigned to such term in Section 9.03(c).
Ineligible Institution” has the meaning assigned to such term in Section 9.04(b).
Information” has the meaning assigned to such term in Section 9.12
Intercompany Distribution Agreement” means each of the Intercompany Limited Risk Distribution Agreements that the Borrowers and any Subsidiary enter into from time to time, in each case, in the form in effect on the Closing Date or as amended or otherwise modified in any manner that is not adverse in any material respect to the Loan Parties taken as a whole.
Interest Election Request” means a request by the Administrative Borrower to convert or continue a Borrowing in accordance with Section 2.08, which shall be substantially in the form attached hereto as Exhibit C-2 or any other form approved by the Administrative Agent.
Interest Payment Date” means (a) with respect to any ABR Loan, the last Business Day of each March, June, September and December and the Maturity Date and (b) with respect to any Term Benchmark Loan, the last day of each Interest Period applicable to the Borrowing of which such Loan is a part and the Maturity Date.
Interest Period” means with respect to any Term Benchmark Borrowing, the period commencing on the date of such Borrowing and ending on the numerically corresponding day in the calendar month that is one (1) or three (3) months thereafter (in each case, subject to the availability for the Benchmark applicable to the relevant Loan or Commitment), as the Administrative Borrower may elect; provided that, (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, (ii) any Interest Period that commences on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period and (iii) no tenor that has been removed from this definition pursuant to Section 2.14(d) shall be available for specification in such Borrowing Request or Interest Election Request. For purposes hereof, the date of a Borrowing initially shall be the date on which such Borrowing is made and thereafter shall be the effective date of the most recent conversion or continuation of such Borrowing.
Investment” means, as to any Person, any direct or indirect acquisition or investment by such Person by means of (a) the purchase or other acquisition of Equity Interests or debt or other
36



securities of another Person, (b) a loan, advance, extension of credit (including extended account receivable terms), or capital contribution to, Guarantee or assumption of Indebtedness of, or purchase or other acquisition of any other Indebtedness or interest in, another Person or (c) the purchase or other acquisition (in one transaction or a series of transactions) of all or substantially all of the assets or business of, or a line of business, division or a separate operation of, another Person. For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment, less any cash repayments thereof, returns thereon (whether as a principal payment, distribution, dividend, redemption or sale but not in excess of the amount of the relevant initial Investment) and liabilities expressly assumed by another person in connection with the sale of such investment. Notwithstanding anything herein to the contrary, the transactions contemplated pursuant to the Intercompany Distribution Agreements shall not be deemed to be Investment.
IP Rights” has the meaning assigned to such term in Section 3.20.
IRS” means the United States Internal Revenue Service.
Jersey Collateral Agreement” means each of:
(a)    the Jersey law governed security interest agreement over all Jersey situs intangible movable assets of Waldencast Finco Limited entered into between Waldencast Finco Limited (as grantor) and the Administrative Agent (as secured party) (the “Jersey Waldencast Finco Limited Security Interest Agreement”);
(b)    the Jersey law governed security interest agreement over all Jersey situs intangible moveable assets of Obagi Holdco 2 Limited entered into between Obagi Holdco 2 Limited (as grantor) and the Administrative Agent (as secured party) (the “Jersey Obagi Holdco 2 Limited Security Interest Agreement”); and
(c)    the Jersey law governed security interest agreement over all Jersey situs intangible moveable assets of Waldencast Partners LP entered into between Waldencast Partners LP (as grantor) and the Administrative Agent (as secured party) (the “Jersey Waldencast Partners LP Security Interest Agreement”);
(d)    the Jersey law governed security interest agreement over all Jersey situs intangible moveable assets of the Parent Guarantor entered into between the Parent Guarantor (as grantor) and the Administrative Agent (as secured party) (the “Jersey Waldencast PLC Security Interest Agreement”);
(e)    the Jersey law governed security interest agreement over all Jersey situs intangible moveable assets of Obagi Holdco 1 Limited entered into between Obagi Holdco 1 Limited (as grantor) and the Administrative Agent (as secured party) (the “Jersey Obagi Holdco 1 Limited Security Interest Agreement”);
(f)     the Jersey law governed security interest agreement over all Jersey situs intangible moveable assets of Obagi Cosmeceuticals LLC between Obagi Cosmeceuticals LLC (as grantor) and the Administrative Agent (as secured party) (the “Jersey Obagi Cosmeceuticals LLC Security Interest Agreement”); and
37



(g)     any other Jersey law governed Collateral Document that is entered into after the date of this Agreement.
Jersey Loan Party” means any Loan Party incorporated in Jersey.
Jersey Obagi Cosmeceuticals LLC Limited Security Interest Agreement” has the meaning assigned to such term in the definition of “Jersey Collateral Agreement”.
Jersey Obagi Holdco 1 Limited Security Interest Agreement”) has the meaning assigned to such term in the definition of “Jersey Collateral Agreement”.
Jersey Obagi Holdco 2 Limited Security Interest Agreement” has the meaning assigned to such term in the definition of “Jersey Collateral Agreement”.
Jersey Waldencast Finco Limited Security Interest Agreement” has the meaning assigned to such term in the definition of “Jersey Collateral Agreement”.
Jersey Waldencast Partners LP Security Interest Agreement” has the meaning assigned to such term in the definition of “Jersey Collateral Agreement”.
Jersey Waldencast PLC Security Interest Agreement” has the meaning assigned to such term in the definition of “Jersey Collateral Agreement”.
Junior Indebtedness” has the meaning assigned to such term in Section 6.14.
Latest Maturity Date” means, at any date of determination, the latest Maturity Date applicable to any Loan or Commitment hereunder at such time, in each case as extended in accordance with this Agreement from time to time.
Laws” means, collectively, all international, foreign, Federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.
LCA Election” means the Administrative Borrower’s election to treat a specified Investment in the nature of an acquisition (including a Permitted Acquisition) as a Limited Condition Acquisition by giving written notice of such election to the Administrative Agent at any time prior to the closing of such Limited Condition Acquisition.
LCA Test Date” has the meaning assigned to such term in Section 1.12(c).
Lender Parent” means, with respect to any Lender, any Person as to which such Lender is, directly or indirectly, a subsidiary.
Lender-Related Person” has the meaning assigned to such term in Section 9.03(b).
38



Lenders” means the Persons listed on Schedule 2.01A and any other Person that shall have become a Lender hereunder pursuant to an Assignment and Assumption or otherwise, other than any such Person that ceases to be a party hereto pursuant to an Assignment and Assumption or otherwise.
Liabilities” means any losses, claims (including intraparty claims), demands, damages or liabilities of any kind.
Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing); provided that, in no event shall an operating lease be deemed to constitute a Lien.
Limited Condition Acquisition” means any Permitted Acquisition or other Investment in the nature of an acquisition, by the Parent Guarantor, any Borrower or any Subsidiary whose consummation is not, by the terms of the applicable purchase, sale, joint venture, merger or any other definitive agreement with respect to such Permitted Acquisition or other Investment, conditioned on the availability of, or on obtaining, third party financing; provided that such Permitted Acquisition or other Investment in the nature of an acquisition shall be consummated within 90 days of the LCA Test Date or such Permitted Acquisition or other Investment shall no longer constitute a “Limited Condition Acquisition”.
Liquidity” means, as of any date of determination, the sum of (i) unused Revolving Commitments at such time (provided that if such unused Revolving Commitments are not available to be drawn because the borrowing conditions set forth in Section 4.02 have not been met, unused Revolving Commitments shall be deemed to be $0), plus (ii) the aggregate amount of unrestricted cash and Cash Equivalents of any Loan Party that is subject to a perfected first lien security interest in favor of the Administrative Agent pursuant to a Control Agreement (or other applicable method for any non U.S. account) as of such time (provided that for the first sixty (60) days after the Closing Date (or such longer period as may be extended by the Administrative Agent in its reasonable discretion), a Control Agreement shall not be required for such unrestricted cash and Cash Equivalents to be included pursuant to this clause (ii)), minus (iii) trade accounts and accrued expenses of any Loan Party past due for more than sixty (60) days after the date on which such trade accounts or accrued expenses are due and payable (other than any such trade account or accrued expense that is (x) being contested by a Loan Party in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP in an aggregate amount for all such contested trade accounts and accrued expenses not to exceed $3,000,000 at any time, (y) an intercompany trade account or accrued expense among the Parent Guarantor, any Borrower or any Subsidiary or (z) accrued expenses covered in full by the Loan Parties’ director’s and officer’s insurance policy). For purposes of determining Liquidity, Revolving Commitments shall be deemed to be used at any date of determination to the extent of the outstanding Revolving Loans at such time.
Loan Documents” means this Agreement, any Notes, the Collateral Documents, the Guarantee Agreement, the Fee Letter, any joinder agreement and any other agreement or instrument designated by any Loan Party and the Administrative Agent as a “Loan Document” by its terms.
Loan Parties” means, collectively, the Parent Guarantor, the Borrowers and the Guarantors.
39



Loans” means the loans (including any Revolving Loans or Term Loans) made by the Lenders to the Borrowers (or any Borrower) pursuant to this Agreement.
Material Adverse Effect” means (a) a material adverse change in, or a material adverse effect upon, the results of operations, business, properties, liabilities (actual or contingent) or financial condition of the Parent Guarantor, the Borrowers and the Subsidiaries taken as a whole; (b) a material impairment of the rights and remedies of the Administrative Agent or any Lender under any Loan Document; or (c) a material adverse effect upon the legality, validity, binding effect or enforceability against any Loan Party of any Loan Document to which it is a party.
Material Real Estate Asset” means any fee-owned real property with a fair market value, as reasonably determined by the Administrative Borrower (acting in good faith), in excess of $4,000,000.
Material Subsidiary” means any Subsidiary that is not an Immaterial Subsidiary.
Maturity Date” means the date that is five years from the Closing Date; provided that, if such date is not a Business Day, the Maturity Date shall be the next preceding Business Day.
Maximum Rate” has the meaning assigned to such term in Section 9.16.
Maximum Total Leverage Ratio” has the meaning assigned to such term in Section 6.11(a)(ii).
Measurement Period” means, at any date of determination, the most recently completed four fiscal quarters of the Parent Guarantor in respect of which Financials have been delivered or were required to be delivered to the Administrative Agent pursuant to Section 5.01(a) or (b), as applicable, for each fiscal quarter or fiscal year in such period (or, prior to the time any such statements are first required to be so delivered, the four fiscal quarters of the Borrowers ending December 31, 2024).
Minimum Liquidity Covenant” has the meaning assigned to such term in Section 6.11(c).
MIRE Event” means, if there are any Mortgaged Properties at such time, any increase in the amount, extension of the maturity or renewal of any of the Commitments or Loans (other than (i) any conversion or continuation of any Borrowing from one Type into another Type or (ii) the making of any Revolving Loan).
MNPI” has the meaning assigned to such term in Section 5.02.
Monthly Financial Statements” means unaudited balance sheets and related statements of operations and cash flows (prepared on a consolidated basis) of Parent Guarantor and its Subsidiaries for the calendar month ending on January 31, 2025.
Moody’s” means Moody’s Investors Service, Inc.
Mortgage” has the meaning assigned to such term in Section 5.11(b).
Mortgage Policies” has the meaning assigned to such term in Section 5.11(b).
40



Mortgaged Property” means the Material Real Estate Assets listed on Schedule 5.11(b) and any real property which becomes subject to a Mortgage pursuant to Section 5.11(b).
Multiemployer Plan” means an employee benefit plan defined in Section 4001(a)(3) of ERISA to which any Loan Party or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years has made or been obligated to make contributions.
Net Cash Proceeds” means with respect to any Disposition by the Parent Guarantor, any Borrower or any Subsidiary, or any Extraordinary Receipt received by or paid to or for the account of the Parent Guarantor, any Borrower or any Subsidiary, in each case, after the Closing Date, the excess, if any, of (i) the sum of cash and Cash Equivalents actually received in connection with such transaction (including any cash or Cash Equivalents received by way of deferred payment pursuant to, or by monetization of, a note receivable or otherwise, but only as and when so received) over (ii) the sum of (A) the principal amount of any Indebtedness that is secured by the applicable asset and that is required to be repaid in connection with such transaction (other than Indebtedness under the Loan Documents or Indebtedness that is secured by a Lien that ranks pari passu with or junior to the Liens securing the Obligations), (B) the selling costs and out-of-pocket expenses incurred (or reasonably expected to be incurred) by the Parent Guarantor, such Borrower or such Subsidiary in connection with such transaction, (C) taxes reasonably estimated to be actually payable within one year of the date of the relevant transaction, including any taxes payable as a result of any gain recognized in connection therewith; provided that, if the amount of any estimated taxes pursuant to subclause (C) exceeds the amount of taxes actually required to be paid in cash in respect of such transaction, the aggregate amount of such excess shall be a reduction of the Taxes previously taken into account under subclause (C) for purposes of redetermining Net Cash Proceeds, (D) any reserve for adjustment in respect of the sale price of such asset or assets established in accordance with GAAP (until released from such reserve in accordance with GAAP or otherwise) and (E) cash escrows (until released from escrow to the Parent Guarantor, any Borrower or any Subsidiary) from the sale price for such Disposition. Notwithstanding anything to contrary, for purposes of calculating any mandatory prepayment required hereunder with respect to any Prepayment Event described under clause (c) of such definition, the amounts that may be reduced from the calculation of Net Cash Proceeds pursuant to this definition (other than pursuant to clauses (C) above) shall not exceed 2.00% of the cash proceeds of such applicable mandatory prepayment.
NFIP” has the meaning assigned to such term in Section 5.11(b).
Non-Consenting Lender” has the meaning assigned to such term in Section 9.02(e).
Notes” has the meaning assigned to such term in Section 2.10(e).
NYFRB” means the Federal Reserve Bank of New York.
NYFRB Rate” means, for any day, the greater of (a) the Federal Funds Effective Rate in effect on such day and (b) the Overnight Bank Funding Rate in effect on such day (or for any day that is not a Business Day, for the immediately preceding Business Day); provided that, if none of such rates are published for any day that is a Business Day, the term “NYFRB Rate” means the rate for a federal funds transaction quoted at 11:00 a.m., New York City time, on such day received by the Administrative Agent from a federal funds broker of recognized standing selected by it; provided further that, if any of the aforesaid rates as so determined would be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.
41



NYFRB’s Website” means the website of the NYFRB at http://www.newyorkfed.org, or any successor source.
Obagi” means Obagi Global Holdings Limited, a Cayman Islands exempted company limited by shares.
Obligations” means all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan Party arising under any Loan Document or otherwise with respect to any Loan, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding.
OFAC” means the U.S. Department of the Treasury’s Office of Foreign Assets Control.
Organization Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to any limited liability company, the certificate or articles of formation or organization or certificate of registration and operating agreement or limited liability company agreement; and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation and registration or organization with the applicable Governmental Authority in the jurisdiction of its incorporation, association, organization, formation or registration and, if applicable, any certificate or articles of formation or organization of such entity.
Original Jurisdiction” means, in relation to each of the Parent Guarantor, the other Guarantors and the Borrowers, the jurisdiction under whose laws the Parent Guarantor, each other Guarantor and each Borrower (as relevant) is incorporated or formed and registered as at the date of this Agreement.
Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).
Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than any assignment made pursuant to Section 2.19(b)).
Overnight Bank Funding Rate” means, for any day, the rate comprised of both overnight federal funds and overnight eurodollar transactions denominated in Dollars by U.S.-managed banking offices of depository institutions (as such composite rate shall be determined by the NYFRB as set forth on the NYFRB’s Website from time to time) and published on the next succeeding Business Day by the NYFRB as an overnight bank funding rate.
42



Participant” has the meaning assigned to such term in Section 9.04(c).
Participant Register” has the meaning assigned to such term in Section 9.04(c).
Patriot Act” means the USA PATRIOT Act of 2001.
Payment” has the meaning assigned to such term in Section 8.06(c).
Payment Notice” has the meaning assigned to such term in Section 8.06(c).
PBGC” means the Pension Benefit Guaranty Corporation.
Pension Act” means the Pension Protection Act of 2006.
Pension Funding Rules” means the rules of the Code and ERISA regarding minimum required contributions (including any installment payment thereof) to Pension Plans and set forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.
Pension Plan” means any employee pension benefit plan (excluding Multiemployer Plans) that is maintained or is contributed to (or required to be contributed to) by any Loan Party or any ERISA Affiliate or during the preceding five plan years was required to be contributed to by any Loan Party or any ERISA Affiliate and is either covered by Title IV of ERISA or is subject to the Pension Funding Rules.
Periodic Term SOFR Determination Day” has the meaning assigned to it under the definition of “Term SOFR Rate”.
Permitted Acquisition” means any acquisition by the Parent Guarantor, any Borrower or any Subsidiary in the form of acquisitions of (i) at least 50% of the Equity Interests in or (ii) all or substantially all of the assets, business or a line of business, division or a separate operation (whether by the acquisition of Equity Interests, assets or any combination thereof) of, any other Person, if:
(i)the acquired entity, assets or operations shall be in the Permitted Business;
(ii)the pro forma Total Leverage Ratio is less than 4.50:1.00;
(iii)pro forma Liquidity is greater than $20,000,000;
(iv)no Event of Default shall have occurred and be continuing or result therefrom;
(v)the Administrative Borrower shall have furnished to the Administrative Agent at least ten (10) Business Days prior to the consummation of such acquisition (or such shorter time as may be agreed to by the Administrative Agent in its reasonable discretion) (i) an executed term sheet and/or commitment letter setting forth in reasonable detail the terms and conditions of such acquisition (in each case, if any) and, at the request of the Administrative Agent, such other available information and documents that the Administrative Agent may request, including, without limitation, executed counterparts of the respective agreements, instruments or other documents pursuant to which such acquisition is to be consummated (including, without limitation, any related management, non-compete, employment, option or other material agreements), any schedules to such agreements, instruments or other documents and all other material ancillary agreements, instruments or other documents to be executed or delivered in connection therewith, (ii) pro forma financial statements of the Parent Guarantor and its Subsidiaries after the consummation of such acquisition, (iii) any financial statements and due diligence materials of the target
43



Person or target assets that may be available to the Loan Parties, (iv) to the extent the total cash and non-cash consideration for such acquisition equals or exceeds $20,000,000, a quality of earnings report with respect to such target Person or target assets, and (v) a certificate of a Financial Officer of Parent Guarantor, demonstrating on compliance with the conditions set forth in clauses (b), (c), (d), (f) and (g);
(vi)the assets being acquired or the Person whose Equity Interests are being acquired did not have negative Consolidated EBITDA during the 12-consecutive-month period most recently concluded prior to the date of the proposed acquisition;
(vii)such acquisition shall be consensual and shall have been approved by the board of directors of the Person whose Equity Interests or assets are proposed to be acquired and shall not have been preceded by an unsolicited tender offer for such Equity Interests by, or proxy contest initiated by, Parent Guarantor or any of its Subsidiaries; and
(viii)(i) the assets being acquired will be acquired by a Loan Party and (ii) the Person whose Equity Interests are being acquired shall become a Loan Party in accordance with the terms of this Agreement and the assets being acquired shall be acquired by a Loan Party.
(ix)Notwithstanding anything to the contrary, the Specified Acquisition (to the extent consummated on the terms previously disclosed to the Administrative Agent prior to the Closing Date or terms otherwise reasonably acceptable to the Administrative Agent) shall be deemed to be a Permitted Acquisition so long as the Borrowers comply with Section 5.11 with respect to such acquisition.
Permitted Business” means the lines of business in which the Parent Guarantor, the Borrowers and the Subsidiaries and their respective Subsidiaries, are engaged on the Closing Date or a line of business reasonably related, complementary, synergistic or ancillary thereto or reasonable extensions thereof.
Permitted Liens” means any Liens permitted under Section 6.01.
Permitted Prior Liens” has the meaning assigned to such term in Section 3.22.
Permitted Refinancing Indebtedness” means any Indebtedness issued in exchange for, or the net proceeds of which are used to extend, refinance, renew, replace, defease or refund (collectively, to “Refinance”), the Indebtedness being Refinanced (or previous refinancings thereof constituting Permitted Refinancing Indebtedness) (and, in the case of revolving Indebtedness being Refinanced, to effect a corresponding reduction in the commitments with respect to such revolving Indebtedness being Refinanced); provided that, with respect to any Indebtedness being Refinanced: (a) the principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness does not exceed the principal amount (or accreted value, if applicable) of the Indebtedness so Refinanced (plus unpaid accrued interest and premium (including tender premiums) thereon and underwriting discounts, defeasance costs, fees, commissions and expenses, plus an amount equal to any existing commitment unutilized thereunder (the “Refinancing Excess Amounts”)), (b) except with respect to Section 6.03(e), such Permitted Refinancing Indebtedness (x) has a final maturity date equal to or later than the earlier of (i) the final maturity date of the Indebtedness being Refinanced and (ii) the Latest Maturity Date then in effect and (y) has a Weighted Average Life to Maturity greater than or equal to the shorter of (i) the remaining Weighted Average Life to Maturity of the Indebtedness being Refinanced and (ii) the remaining Weighted Average Life to Maturity of each Facility hereunder, (c) if the Indebtedness being Refinanced is subordinated in right of payment to the Obligations under this Agreement, such Permitted Refinancing Indebtedness shall be subordinated in right of payment to such Obligations on terms in the aggregate not materially less favorable to the Lenders as those contained in the documentation governing
44



the Indebtedness being Refinanced (as determined by the Administrative Borrower in good faith), (d) if the Indebtedness being Refinanced was unsecured, such Permitted Refinancing Indebtedness shall also be unsecured (unless such Permitted Refinancing Indebtedness could otherwise be secured pursuant to Section 6.01, which shall cause a reduction in capacity under the applicable basket of Section 6.01 that was relied upon), (e) no Permitted Refinancing Indebtedness shall have obligors that are not (or would not have been) obligated with respect to the Indebtedness being Refinanced (except that a Loan Party may be added as an additional obligor if such Loan Party would have otherwise been permitted to incur or Guarantee such Indebtedness pursuant to Section 6.03, which shall cause a reduction in capacity under the applicable basket of Section 6.03 that was relied upon) and (f) if the Indebtedness being Refinanced is secured, (x) such Permitted Refinancing Indebtedness may be secured (including by any Collateral pursuant to after-acquired property clauses to the extent any such Collateral secured (or would have secured) the Indebtedness being Refinanced) to the extent, and with no greater lien priority, than the Indebtedness being Refinanced (unless such Permitted Refinancing Indebtedness could otherwise be secured pursuant to Section 6.01, which shall cause a reduction in capacity under the applicable basket of Section 6.01 that was relied upon) and (y) the holders of such Permitted Refinancing Indebtedness or a representative thereof shall be or become a party to an intercreditor agreement reasonably satisfactory to the Administrative Agent (if such Indebtedness is secured by any or all of the Collateral).
Permitted Tax Distributions” means, for any taxable period in which Waldencast Partners LP is treated as a partnership or disregarded entity for U.S. federal income tax purposes, distributions by Waldencast Partners LP to any direct or indirect beneficial owners of Waldencast Partners LP in an amount reasonably determined by Waldencast Partners LP not to exceed in any such taxable period the product of (a) the highest combined U.S. federal, state, and non-U.S. individual or corporate marginal tax rate (whichever is higher) pertaining to the type of income being taxed that is applicable to any partner of Waldencast Partners LP and (b) the estimated aggregate combined U.S. federal, state, local and non-U.S. taxable income and gain allocated to the partners or other beneficial owners of Waldencast Partners LP, directly or indirectly, by Waldencast Partners LP for the relevant taxable period (including any section 704(c) amounts), reduced by any net losses, deductions and credits allocated to such persons, directly or indirectly, by Waldencast Partners LP in prior taxable periods to the extent such items have not been previously taken into account in calculating Permitted Tax Distributions and are expected to be of a character that would permit such loss, deduction or credit to be deductible against income in the current taxable period, and calculated by disregarding the effect of any special basis adjustments under Code section 743 (assuming also that each such beneficial owner elects to carry forward such items and that such beneficial owner’s only income, gain, deductions, losses and similar items are those allocated to such beneficial owner by Waldencast Partners LP for purposes of such carry forward).
Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.
PIK Option” has the meaning assigned to such term in the definition of “Applicable Rate.”
Plan Asset Regulations” means 29 CFR § 2510.3-101 et seq., as modified by Section 3(42) of ERISA, as amended from time to time.
Platform” has the meaning assigned to such term in Section 5.02.
45



Post-Default Rate” means a rate of interest per annum equal to the rate of interest otherwise in effect from time to time pursuant to the terms of this Agreement plus 2.00%, or, if a rate of interest is not otherwise in effect, interest at the highest rate specified herein for any Loan then outstanding prior to an Event of Default plus 2.00%, in each case, to the fullest extent permitted by the applicable Laws.
Prepayment Event” means:
(i)any Disposition (including pursuant to a Sale and Leaseback Transaction) of any property or asset of the Parent Guarantor, any Borrower or any Subsidiary made pursuant to Section 6.05(j), which results in the realization by such Person of Net Cash Proceeds in excess of an aggregate amount of $3,500,000 per Fiscal Year;
(ii)the receipt by the Parent Guarantor, any Borrower or any Subsidiary of any Extraordinary Receipt (other than in respect of Project Romania), which results in the receipt by such Person of Net Cash Proceeds in excess of an aggregate amount of $3,500,000 per Fiscal Year;
(iii)the receipt by the Parent Guarantor, any Borrower or any Subsidiary of any Extraordinary Receipt in respect of Project Romania; or
(iv)the incurrence by the Parent Guarantor, any Borrower or any Subsidiary of any Indebtedness (other than Loans), other than Indebtedness permitted under Section 6.03 or permitted by the Required Lenders pursuant to Section 9.02.
Prime Rate” means the rate last quoted by The Wall Street Journal as the “Prime Rate” in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the “bank prime loan” rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent) or any similar release by the Federal Reserve Board (as determined by the Administrative Agent). Each change in the Prime Rate shall be effective from and including the date such change is publicly announced or quoted as being effective.
Proceeding” means any claim, litigation, investigation, action, suit, arbitration or administrative, judicial or regulatory action or proceeding in any jurisdiction.
Project Romania” means that certain contemplated arrangement identified as “Project Romania” and disclosed to the Administrative Agent in writing prior to the Closing Date.
PTE” means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.
Public Lender” has the meaning assigned to such term in Section 5.02.
Qualified Equity Interests” means any Equity Interests that are not Disqualified Equity Interests.
Ratio Calculation Date” has the meaning assigned to such term in Section 1.12(b)(i).
Recipient” means (a) the Administrative Agent and (b) any Lender, as applicable, in each case including an assignee or a Participant.
46



Reference Time” with respect to any setting of the then-current Benchmark means (1) if such Benchmark is the Term SOFR Rate, 5:00 a.m. (Chicago time) on the day that is two (2) Business Days preceding the date of such setting or (2) if such Benchmark is not the Term SOFR Rate, the time determined by the Administrative Agent in its reasonable discretion.
Refinance” has the meaning assigned to such term in the definition of the term “Permitted Refinancing Indebtedness,” “Refinancing” and “Refinanced” shall have a meaning correlative thereto.
Refinancing Excess Amounts” has the meaning assigned to such term in the definition of the term “Permitted Refinancing Indebtedness.
Register” has the meaning assigned to such term in Section 9.04(b).
Register of Mortgages and Charges” has the meaning assigned to such term in Section 8.10(a)(i)(x).
Regulation U” means Regulation U of the Federal Reserve Board, as in effect from time to time and all official rulings and interpretations thereunder or thereof.
Related Parties” means, with respect to any Person, such Person’s Affiliates and the direct and indirect equityholders, partners, directors, officers, employees, agents, consultants, trustees, controlling persons, administrators, managers, advisors and other representatives of such Person and of such Person’s Affiliates.
Relevant Governmental Body” means, the Federal Reserve Board and/or the NYFRB, the Term SOFR Administrator, as applicable, or a committee officially endorsed or convened by the Federal Reserve Board and/or the NYFRB or, in each case, any successor thereto.

Reportable Event” means any of the events set forth in Section 4043(c) of ERISA, other than events for which the 30 day notice period has been waived.
Required Lenders” means Lenders having Credit Exposures, Unfunded Revolving Commitments and Term Loan Commitments representing more than 50% of the sum of the total Credit Exposures plus Unfunded Revolving Commitments plus Term Loan Commitments at such time; provided that, for the purpose of determining the Required Lenders needed for any waiver, amendment, modification or consent of or under this Agreement or any other Loan Document, any Lender that is a Defaulting Lender shall be disregarded, together with its Credit Exposures, Unfunded Revolving Commitments and Term Loan Commitments.
Required Revolving Lenders” means Revolving Lenders having Revolving Credit Exposures and Unfunded Revolving Commitments representing more than 50% of the sum of the Total Revolving Credit Exposure and Unfunded Revolving Commitments at such time; provided that, for the purpose of determining the Required Revolving Lenders needed for any waiver, amendment, modification or consent of or under this Agreement or any other Loan Document, any Revolving Lender that is a Defaulting Lender shall be disregarded, together with its Credit Exposures and Unfunded Revolving Commitments.
47



Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.
Responsible Officer” means the chief executive officer, president, director, chief financial officer, director of corporate finance, treasurer, assistant treasurer or controller (or, in the case of the Parent Guarantor, the sole manager of its general partner) of a Loan Party, and including solely for purposes of Section 4.01, the secretary or assistant secretary of a Loan Party. Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party.
Restricted Payment” means any dividend or other distribution (whether in cash, securities or other property) with respect to any capital stock or other Equity Interest of any Person or any of its Subsidiaries, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, defeasance, acquisition, cancellation or termination of any such capital stock or other Equity Interest, or on account of any return of capital to any Person’s equity holders, partners or members (or the equivalent of any thereof) or any option, warrant or other right to acquire any such dividend or other distribution or payment.
Retained Excess Cash Flow Amount” means, at any date, an amount, not less than zero, determined on a cumulative basis equal to the amount of Excess Cash Flow for all completed Excess Cash Flow Periods (commencing with the Excess Cash Flow Period ending December 31, 2025) that was not required to be applied to prepay the Loans in accordance with Section 2.11(c) (without giving effect to any deductions to Excess Cash Flow as set forth in Section 2.11(c)).
Retained Declined Proceeds” has the meaning assigned to such term in Section 2.11(g).
Revolving Commitment” means, with respect to each Lender, the amount set forth on Schedule 2.01A opposite such Lender’s name under the heading “Revolving Commitment”, or in the Assignment and Assumption or other documentation or record (as such term is defined in Section 9-102(a)(70) of the New York Uniform Commercial Code) contemplated hereby pursuant to which such Lender shall have assumed its Revolving Commitment, as applicable, and giving effect to (a) any reduction in such amount from time to time pursuant to Section 2.09 and (b) any reduction or increase in such amount from time to time pursuant to assignments by or to such Lender pursuant to Section 9.04; provided that, at no time shall the Revolving Credit Exposure of any Lender exceed its Revolving Commitment. The initial aggregate amount of the Revolving Commitments on the Closing Date is $30,000,000.
Revolving Credit Exposure” means, with respect to any Lender at any time, the outstanding principal amount of such Lender’s Revolving Loans at such time.
Revolving Facility” means, at any time, the aggregate amount of the Revolving Lenders’ Revolving Commitments at such time and Borrowings thereunder.
Revolving Lender” means, as of any date of determination, each Lender that has a Revolving Commitment or, if the Revolving Commitments have terminated or expired, a Lender with Revolving Credit Exposure.
Revolving Loan” means a Loan made by a Revolving Lender pursuant to Section 2.01(a).
48



S&P” means Standard & Poor’s Rating Services, a Standard & Poor’s Financial Services LLC business.
Sale and Leaseback Transaction” means any sale or other transfer of any property or asset by any Person with the intent to lease such property or asset as lessee (or otherwise use such property or asset through the lease of an Affiliate as lessee).
Sanctioned Country” means, at any time, a country, territory, or region that is the subject of Sanctions (at the time of this Agreement, the so - called Donetsk People’s Republic, the so- called Luhansk People’s Republic, and the Crimea regions of Ukraine, and Cuba, Iran, North Korea and Syria).
Sanctioned Person” means (a) any Person listed in any Sanctions-related list of designated Persons maintained by OFAC, the U.S. Department of State, the United Nations Security Council, the European Union, any European Union member state, His Majesty’s Treasury of the United Kingdom or the Government of Canada or any other relevant sanctions authority with jurisdiction over any party to this Agreement, (b) any Person located, organized or ordinarily resident in a Sanctioned Country or (c) any Person 50% or more owned or controlled by any such Person or Persons described in the foregoing clauses (a) or (b).
Sanctions” means all economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, the United Nations Security Council, the European Union, any European Union member state, His Majesty’s Treasury of the United Kingdom or the Government of Canada or any other relevant sanctions authority with jurisdiction over any party to this Agreement.
SEC” means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.
Secured Parties” means, collectively, the Administrative Agent, the Lenders, each co-agent or sub-agent appointed by the Administrative Agent from time to time pursuant to Section 9.04, and the other Persons the Obligations owing to which are or are purported to be secured by the Collateral under the terms of the Collateral Documents.
SIR” has the meaning assigned to such term in the definition of “Excluded Assets”.
SOFR” means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.
SOFR Administrator” means the NYFRB (or a successor administrator of the secured overnight financing rate).
SOFR Administrator’s Website” means the NYFRB’s Website, currently at http://www.newyorkfed.org, or any successor source for the secured overnight financing rate identified as such by the SOFR Administrator from time to time.
Solvency Certificate” means a certificate substantially in the form attached hereto as Exhibit H.
49



Solvent” means, with respect to the Parent Guarantor, the Borrowers and the Subsidiaries on any date of determination, that on such date (a) the sum of the liabilities of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, does not exceed either the present fair saleable value or fair value of the assets of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole; (b) the capital of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, is not unreasonably small in relation to the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, contemplated through the maturity of the credit facilities evidenced by this Agreement, (c) the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, do not intend to incur, or believe that they will incur, debts including current obligations beyond their ability to pay such debts as they mature in the ordinary course of business and (d) or (in relation to any English Loan Party), by reason of actual financial difficulties, it has not commenced negotiations with one or more of its groups of creditors or class of creditors generally (other than the Administrative Agent and the Lenders in their capacity as such) with a view to rescheduling any of its indebtedness. For the purposes hereof, the amount of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability (irrespective of whether such contingent liabilities meet the criteria for accrual under Statement of Financial Accounting Standard No. 5).
Specified Acquisition” means the contemplated acquisition identified as the “Specified Acquisition” and disclosed to the Administrative Agent in writing prior to the Closing Date.
Specified Assets” means, collectively, (a) letter of credit rights (other than to the extent the security interest in such letter of credit rights may be perfected by the filing of UCC financing statements) with a value of less than $2,500,000, (b) commercial tort claims with a value of less than $2,500,000 and (c) such assets as to which the Administrative Agent and the Administrative Borrower reasonably agree that the cost of obtaining such a security interest therein or perfection thereof are excessive in relation to the benefit to the Secured Parties of the security to be afforded thereby.
Specified Material Contract” means the To Know-How and Trademark License Agreement, dated as of September 13, 2022, by and between Obagi Cosmeceuticals and Rohto Pharmaceutical Co LTD., a Japanese company established and existing under the laws of Japan, as amended by Amendment No. 1 dated June 1, 2024, Amendment No. 2 dated December 4, 2028, Amendment No 3. dated September 27, 2011, Amendment No. 4 dated June 9, 2016, Amendment No. 5 dated January 12, 2018, Amendment No. 6 dated April 5, 2019 and Amendment No. 7 dated December 10, 2019, or any successor contract described in Section 6.19.
Spot Rate” for a currency means the rate determined by the Administrative Agent to be the rate quoted by the Person acting in such capacity as the spot rate for the purchase by such Person of such currency with another currency through its principal foreign exchange trading office at approximately 11:00 a.m. on the date two (2) Business Days prior to the date as of which the foreign exchange computation is made; provided that, the Administrative Agent may obtain such spot rate from another financial institution designated by the Administrative Agent if the Person acting in such capacity does not have as of the date of determination a spot buying rate for any such currency.
Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability company or other business entity of which a majority of the Equity Interests having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person. Unless otherwise specified, all references herein to a “Subsidiary” or to
50



“Subsidiaries” shall refer to a Subsidiary or Subsidiaries of the Parent Guarantor. In respect of a Jersey Loan Party, a Subsidiary shall include a “subsidiary” within the meaning of Articles 2 and 2A of the Companies (Jersey) Law 1991. In respect of an English Loan Party, a Subsidiary shall include a “subsidiary” within the meaning of section 1159 of the Companies Act 2006.
Swap Contract” means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other similar master agreement relating to a transaction described in clause (a), including any such obligations or liabilities under any master agreement.
Swap Termination Value” means, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender).
Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.
TCW” has the meaning assigned to such term in the preamble hereto.
Term Benchmark” when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Adjusted Term SOFR Rate.
Term Facility” means, at any time, (a) prior to the funding of the Term Loans on the Closing Date, the aggregate amount of the Term Loan Commitments at such time and (b) thereafter, the aggregate principal amount of the Term Loans of all Term Lenders outstanding at such time.
Term Lender” means, as of any date of determination, each Lender having a Term Loan Commitment or that holds Term Loans.
Term Loan Commitment” means (a) with respect to any Term Lender, the amount set forth on Schedule 2.01A opposite such Lender’s name under the heading “Term Loan Commitment”, or in the Assignment and Assumption or other documentation or record (as such term is defined in Section 9-102(a)(70) of the New York Uniform Commercial Code) contemplated hereby pursuant to which such Lender shall have assumed its Term Loan Commitment, as applicable, and giving effect to
51



(i) any reduction in such amount from time to time pursuant to Section 2.09 and (ii) any reduction or increase in such amount from time to time pursuant to assignments by or to such Lender pursuant to Section 9.04 and (b) as to all Term Lenders, the aggregate commitments of all Term Lenders to make Term Loans. The initial aggregate amount of the Term Loan Commitments on the Closing Date is $175,000,000.
Term Loans” means the term loans made by the Term Lenders to the Borrowers (or any Borrower) pursuant to Section 2.01(b).
Term SOFR Administrator” means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Administrative Agent in its reasonable discretion).
Term SOFR Rate” means (a) for any calculation with respect to a Term Benchmark Borrowing, the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the “Periodic Term SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day, and
(b)    for any calculation with respect to an ABR Loan on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such day, the “ABR Term SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator; provided, however, that if as of 5:00 p.m. (New York City time) on any ABR Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such ABR SOFR Determination Day;
provided that, if the Term SOFR Rate as so determined pursuant to clause (a) or (b) above would be less than the Floor, such rate shall be deemed to be equal to the Floor for the purposes of this Agreement.
Term SOFR Reference Rate” means the forward-looking term rate based on SOFR.
Termination Date” has the meaning assigned to it in Section 9.14(c).
Threshold Amount” means $5,000,000.
52



Total Leverage Ratio” means, with respect to any Measurement Period, the ratio of (a) Consolidated Funded Indebtedness as of the last day of such Measurement Period to (b) Consolidated EBITDA for the most recently completed Measurement Period, in each case, for the Parent Guarantor, the Borrowers and the Subsidiaries.
Total Revolving Credit Exposure” means, at any time, the outstanding principal amount of the Revolving Loans at such time.
Trade Date” has the meaning assigned to such term in Section 9.04(e).
Transactions” means, collectively, (a) the Existing Credit Agreement Refinancing, (b) the entering into by the Borrowers and the other Loan Parties of the Loan Documents to which they are or are intended to be a party, (c) the initial Borrowing on the Closing Date and (d) the payment of the fees and expenses incurred in connection with the consummation of the foregoing.
Type”, when used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans comprising such Borrowing, is determined by reference to the Adjusted Term SOFR Rate or the Alternate Base Rate.
UCC” means the Uniform Commercial Code as in effect from time to time in the State of New York; provided that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, “UCC” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.
UK Anti-Money Laundering and Anti-Terrorism Legislation” means the Bribery Act 2010 (UK), the Terrorism Act 2000 (UK), the Proceeds of Crime Act 2002 (UK) and any similar English legislation, together with all rules, regulations and interpretations thereunder or related thereto.
UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
UK Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.
Unadjusted Benchmark Replacement means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.
Unfunded Revolving Commitment” means, with respect to each Lender, the Revolving Commitment of such Lender less its Revolving Credit Exposure.
United Kingdom” or “UK” means the United Kingdom of Great Britain and Northern Ireland.
United States” or “U.S.” mean the United States of America.
53



Unliquidated Obligations” means, at any time, any Obligations (or portion thereof) that are contingent in nature or unliquidated at such time, including any Obligation that is: (i) any obligation (including any guarantee) that is contingent in nature at such time; or (ii) an obligation to provide collateral to secure the foregoing type of obligations.
U.S. Collateral Agreement” means the Collateral Agreement, to be dated as of the Closing Date, among the Grantors (as defined therein) party thereto and the Administrative Agent.
U.S. Government Securities Business Day” means any day except for (i) a Saturday, (ii) a Sunday or (iii) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.
U.S. Person” means a “United States person” within the meaning of Section 7701(a)(30) of the Code.
U.S. Tax Compliance Certificate” has the meaning assigned to such term in Section 2.17(f)(ii)(B)(3).
Waldencast LPA” means the Amended and Restated Exempted Limited Partnership Agreement for Waldencast Partners LP, dated as of July 27, 2022.
Weighted Average Life to Maturity” means, when applied to any Indebtedness at any date, the number of years obtained by dividing: (i) the sum of the products obtained by multiplying (a) the amount of each then remaining scheduled installment, sinking fund, serial maturity or other required scheduled payments of principal, including payment at final scheduled maturity, in respect thereof, by (b) the number of years (calculated to the nearest one-twelfth) that will elapse between such date and the making of such payment by (ii) the then outstanding principal amount of such Indebtedness; provided that, for purposes of determining the Weighted Average Life to Maturity of any Indebtedness that is being modified, refinanced, refunded, renewed, replaced or extended (the “Applicable Indebtedness”), the effect of any prepayments made on such Applicable Indebtedness prior to the date of the applicable modification, refinancing, refunding, renewal, replacement or extension shall be disregarded.
Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.
Working Capital” means, at any date of determination thereof, (a) the sum of all amounts (other than cash and Cash Equivalents) that would, in conformity with GAAP, be set forth opposite the caption “total current assets” (or any like caption) on a consolidated balance sheet of any Person and its Subsidiaries, including (i) the unpaid face amount of all accounts of such Person and its Subsidiaries as at such date of determination and (ii) the aggregate amount of prepaid expenses and other current assets of such Person and its Subsidiaries as at such date of determination, minus (b) the sum of
54



all amounts that would, in conformity with GAAP, be set forth opposite the caption “total current liabilities” (or any like caption) on a consolidated balance sheet of such Person and its Subsidiaries, including (i) the unpaid amount of all accounts payable of such Person and its Subsidiaries as at such date of determination and (ii) the aggregate amount of all accrued expenses of such Person and its Subsidiaries as at such date of determination (other than the current portion of long-term debt and all accrued interest and taxes).
Section 1.02.Classification of Loans and Borrowings. For purposes of this Agreement, Loans may be classified and referred to by Class (e.g., a “Revolving Loan”) or by Type (e.g., a “Term Benchmark Loan”) or by Class and Type (e.g., a “Term Benchmark Revolving Loan”). Borrowings also may be classified and referred to by Class (e.g., a “Revolving Borrowing”) or by Type (e.g., a “Term Benchmark Borrowing”) or by Class and Type (e.g., a “Term Benchmark Revolving Borrowing”).
Section 1.03.Terms Generally. With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan Document:
(a)The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including any Organization Document and any Loan Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, restated, amended and restated, supplemented, extended, renewed, replaced, refinanced or otherwise modified (subject to any restrictions on such amendments, restatements, amendments and restatements, supplements, extensions, renewals, replacements, refinancings or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such Person’s successors and permitted assigns, (iii) the words “herein,” “hereof” and “hereunder,” and words of similar import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, the Loan Document in which such references appear, (v) any reference in any Loan Document to any law (including by succession of comparable successor laws) shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such law and any reference to any law or regulation in any Loan Document shall, unless otherwise specified, refer to such law or regulation as consolidated, amended, replaced, supplemented or interpreted from time to time, and (vi) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights.
(b)In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including;” the words “to” and “until” each mean “to but excluding” and the word “through” means “to and including.”
(c)Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document.
(d)Any reference herein to a merger, transfer, consolidation, amalgamation, assignment, sale, disposition or transfer, or similar term, shall be deemed to apply to a division of or by a Person, or an allocation of assets to a series of a Person (or the unwinding of such a division or allocation), as if it were a merger, transfer, consolidation, amalgamation, assignment, sale, disposition or transfer, or similar term, as applicable, to, of or with a separate Person. Any division of a Person shall constitute a separate Person hereunder (and each division of any Person that is a Subsidiary, joint venture or any other like term shall also constitute such a Person or entity).
Section 1.04.Accounting Terms; Changes in GAAP; Rounding.
55



(a)Subject to Section 1.04(b), all accounting terms not specifically or completely defined herein shall be construed in conformity with GAAP, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with GAAP, applied on a consistent basis, as in effect from time to time.
(b)If at any time any change in GAAP or the application thereof would affect the computation or interpretation of any financial ratio, basket, requirement or other provision set forth in any Loan Document, and either the Administrative Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Administrative Borrower shall negotiate in good faith to amend such ratio, basket, requirement or other provision to preserve the original intent thereof in light of such change in GAAP or the application thereof (subject to the consent of the Required Lenders; such consent not to be unreasonably withheld, conditioned or delayed); provided that, until so amended, such ratio, basket, requirement or other provision shall continue to be computed or interpreted in accordance with GAAP or the application thereof prior to such change therein.
(c)Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made, without giving effect to (i) any election under Financial Accounting Standards Board Accounting Standards Codification 825 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any Indebtedness or other liabilities of the Parent Guarantor, any Borrower or any Subsidiary at “fair value”, as defined therein and (ii) any treatment of Indebtedness under Accounting Standards Codification 470-20 or 2015-03 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any such Indebtedness in a reduced or bifurcated manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal amount thereof.
(d)Notwithstanding the foregoing, with respect to the accounting for leases as either operating leases or capital leases and the impact of such accounting in accordance with FASB ASC 842 on the definitions and covenants herein, GAAP as in effect on December 31, 2018 shall be applied.
(e)Any financial ratios required to be maintained or complied with by the Parent Guarantor or any Borrower pursuant to this Agreement (or required to be satisfied in order for a specific action to be permitted under this Agreement) shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).
Section 1.05.Times of Day. Unless otherwise specified, all references herein to times of day shall be references to Eastern Time (daylight or standard, as applicable).
Section 1.06.Interest Rates; Benchmark Notification. The interest rate on a Loan denominated in dollars may be derived from an interest rate benchmark that may be discontinued or is, or may in the future become, the subject of regulatory reform. Upon the occurrence of a Benchmark Transition Event, Section 2.14 provides a mechanism for determining an alternative rate of interest. Administrative Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Alternate Base Rate, the Term SOFR Rate or Adjusted Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Alternate Base Rate, the Term SOFR Rate, Adjusted Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Benchmark Replacement Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in transactions that affect the calculation of the Alternate Base Rate, the Term SOFR Rate, Adjusted Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to any Borrower. The Administrative Agent may select information sources or services in its reasonable
56



discretion to ascertain the Alternate Base Rate, the Term SOFR Rate, Adjusted Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to any Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.
Section 1.07.Currency Equivalents Generally; Change of Currency. For purposes of this Agreement and the other Loan Documents (other than Articles 2, 8 and 9 hereof), where the permissibility of a transaction or determinations of required actions or circumstances depend upon compliance with, or are determined by reference to, amounts stated in Dollars, such amounts shall be deemed to refer to Dollars or Dollar Equivalents and any requisite currency translation shall be based on the Spot Rate in effect on the Business Day of such transaction or determination. Notwithstanding the foregoing, for purposes of determining compliance with Sections 6.01, 6.02 and 6.03 with respect to any amount of Liens, Indebtedness or Investment in currencies other than Dollars, no Default shall be deemed to have occurred solely as a result of changes in rates of exchange occurring after the time such Lien is created, Indebtedness is incurred or Investment is made. Each provision of this Agreement shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify with the Administrative Borrower’s consent (not to be unreasonably withheld) to appropriately reflect a change in currency of any country and any relevant market conventions or practices relating to such change in currency.
Section 1.08.Timing of Payment and Performance. When the payment of any obligation or the performance of any covenant, duty or obligation is stated to be due or performance required on a day which is not a Business Day, the date of such payment (other than as described in the definition of Interest Period) or performance shall extend to the immediately succeeding Business Day.
Section 1.09.Jersey Terms. In each Loan Document, where it relates to a person (i) incorporated, (ii) established, (iii) constituted, (iv) formed, (v) which carries on, or has carried on, business, or (vi) that owns immovable property, in each case, in Jersey, a reference to:
(a)a “composition, compromise, assignment or arrangement with any creditor”, “winding-up”, “administration”, “insolvency”, “insolvent”, “bankruptcy”, “liquidation” or “dissolution” includes, without limitation, “bankruptcy” (as that term is interpreted pursuant to Article 8 of the Interpretation (Jersey) Law 1954), a compromise or arrangement of the type referred to in Article 125 of the Companies (Jersey) Law 1991, any procedure or process referred to in Part 21 of the Companies (Jersey) Law 1991, and any other similar proceedings affecting the rights of creditors generally under Jersey law, and shall be construed so as to include any equivalent or analogous proceedings;
(b)a “liquidator”, “receiver”, “administrative receiver”, “administrator” or the like includes, without limitation, the Viscount of the Royal Court of Jersey, Autorisés, any provisional liquidator or liquidator appointed pursuant to Part 21 of the Companies (Jersey) Law 1991, or any other person performing the same function of each of the foregoing;
(c)a “security interest”, “security”, “encumbrance”, “lien” or the like includes, without limitation, any hypothèque, whether conventional, judicial or arising by operation of law and any security interest created pursuant to the Security Interests (Jersey) Law 1983 or Security Interests (Jersey) Law 2012 and any related legislation; and
(d)any equivalent or analogous procedure or step being taken in connection with insolvency includes any corporate action, legal proceedings or other formal procedure or step being taken in connection with an application for a declaration of en désastre being made in respect of any such entity or any of its assets (or the making of such declaration) or the service of a statutory demand pursuant to Section 21 of the Companies (Jersey) Law 2991 in respect of such entity.
Section 1.10.[Reserved].
57



Section 1.11.Divisions. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized and acquired on the first date of its existence by the holders of its Equity Interests at such time.
Section 1.12.Certain Calculations.
(a)All pro forma calculations permitted or required to be made by the Parent Guarantor, any Borrower or any Subsidiary pursuant to this Agreement shall include only those adjustments that have been prepared in good faith based upon reasonably detailed written assumptions believed by the Borrowers at the time of preparation to be reasonable and which are reasonably foreseeable. Any ratio calculated hereunder that includes Consolidated EBITDA shall look to Consolidated EBITDA for the most recently completed Measurement Period.
(b)The pro forma Total Leverage Ratio, pro forma Fixed Charge Coverage Ratio and pro forma Consolidated EBITDA shall be calculated as follows:
(i)in the event that the Parent Guarantor, any Borrower or any Subsidiary incurs, assumes, guarantees, redeems, retires or extinguishes any Indebtedness subsequent to the last day of the Measurement Period for which such pro forma ratio is being calculated but on or prior to the date of the event for which the calculation of such pro forma ratio is being made (a “Ratio Calculation Date”), then such pro forma ratio shall be calculated as if such incurrence, assumption, guarantee, redemption, retirement or extinguishment of Indebtedness (and all other incurrences, assumptions, guarantees, redemptions, retirements or extinguishments of Indebtedness consummated since the last day of the applicable Measurement Period but on or prior to the Ratio Calculation Date) had occurred at the last day of the applicable Measurement Period; provided that, (i) in the case of any incurrence of Indebtedness or establishment of any revolving credit or delayed draw commitments, a borrowing of the maximum amount of Indebtedness available under such revolving credit or delayed draw commitments shall be assumed and (ii) the pro forma Consolidated Interest Expense for the applicable Measurement Period shall be calculated assuming such Indebtedness had been outstanding or repaid, as the case may be, since the first day and through the end of the applicable Measurement Period (taking into account any interest rate Swap Contracts applicable to such Indebtedness);
(ii)in the event that any Permitted Acquisitions or other permitted Investments in the nature of an acquisition are made subsequent to the last day of the applicable Measurement Period for which such pro forma ratio is being calculated but on or prior to the Ratio Calculation Date, then Consolidated EBITDA shall be (x) increased by an amount equal to the Consolidated EBITDA attributable to the property or Investment that is the subject of such Permitted Acquisition or other permitted Investment in the nature of an acquisition, in each case assuming such Permitted Acquisition or other permitted Investment had been made on the first day of the applicable Measurement Period and (y) otherwise calculated as set forth in the third paragraph of the definition of “Consolidated EBITDA” on a Pro Forma Basis; and
(iii)in the event that Dispositions are made subsequent to the last day of the applicable Measurement Period for which such pro forma ratio is being calculated but on or prior to the relevant Ratio Calculation Date, then Consolidated EBITDA shall be reduced by an amount equal to the Consolidated EBITDA (if positive) attributable to the property that is the subject of such Disposition or increased by an amount equal to the Consolidated EBITDA (if negative) attributable thereto, in each case assuming such Disposition had been made on the first day of the applicable Measurement Period; provided that, notwithstanding anything herein to the contrary, no such events or transactions occurring subsequent to the last day of the applicable Measurement Period for which such pro forma ratio is being calculated but on or prior to the Ratio Calculation Date shall be taken into account for purposes of any calculation of Total Leverage Ratio, Fixed Charge Coverage Ratio and Consolidated EBITDA for purposes of (i) actual compliance with the
58



financial covenants set forth in Section 6.11, (ii) the determination of Excess Cash Flow and (iii) the determination of the Applicable Rate.
(c)Notwithstanding anything to the contrary in this Agreement, solely for the purpose of (A) measuring the relevant financial ratios and basket availability or pro forma compliance with any covenant with respect to the incurrence of any Indebtedness or Liens or the making of any Investments (including the determination of whether an acquisition is a Permitted Acquisition) or Dispositions or (B) other than in connection with the incurrence of any Revolving Loans, determining compliance with representations and warranties or the occurrence of any Default or Event of Default (other than any Event of Default pursuant to Section 7.01(a), (f) or (g)), in each case, in connection with any action being taken in connection with a Limited Condition Acquisition (including any incurrence or assumption of Indebtedness and the use of proceeds thereof, the incurrence or assumption of any Liens, the making of any Investments or Restricted Payments or the repayment of any Indebtedness for which an irrevocable notice of prepayment or redemption is required), if the Administrative Borrower has made an LCA Election with respect to such Limited Condition Acquisition, the date of determination of whether any such action is permitted hereunder shall be deemed to be the date on which the definitive agreements for such Limited Condition Acquisition are entered into (the “LCA Test Date”), and if, after giving effect on a Pro Forma Basis to the Limited Condition Acquisition and the other transactions to be entered into in connection therewith (including any incurrence or assumption of Indebtedness and the use of proceeds thereof, the incurrence or assumption of any Liens, the making of any Investments or Restricted Payments or the repayment of any Indebtedness for which an irrevocable notice of prepayment or redemption is required) as if they had occurred at the beginning of the most recently completed Measurement Period ending prior to the LCA Test Date, the Borrowers could have taken such action on the relevant LCA Test Date in compliance with such financial ratio or basket, such financial ratio or basket shall be deemed to have been complied with. If the Administrative Borrower has made an LCA Election for any Limited Condition Acquisition, then in connection with any subsequent calculation of any financial ratio or basket availability on or following the relevant LCA Test Date and prior to the earlier of (x) the date on which such Limited Condition Acquisition is consummated or (y) the date that the definitive agreement for such Limited Condition Acquisition is terminated or expires without consummation of such Limited Condition Acquisition, any such financial ratio or basket availability shall be calculated (and tested) (A) on a Pro Forma Basis assuming such Limited Condition Acquisition and other transactions in connection therewith (including any incurrence or assumption of Indebtedness and the use of proceeds thereof, the incurrence or assumption of any Liens, the making of any Investments or Restricted Payments or the repayment of any Indebtedness for which an irrevocable notice of prepayment or redemption is required) have been consummated until such time as the applicable Limited Condition Acquisition has actually closed or the definitive agreement with respect thereto has been terminated and (B) solely with respect to (i) the making of any Restricted Payments or (ii) payments of Junior Indebtedness, on a standalone basis without giving effect to such Limited Condition Acquisition and the other transactions in connection therewith; provided that, notwithstanding anything herein to the contrary, no Limited Condition Acquisition shall be taken into account for purposes of any calculation of (i) actual compliance with the financial covenants set forth in Section 6.11, (ii) the determination of Excess Cash Flow and (iii) the determination of the Applicable Rate.
(d)For purposes of determining compliance with Sections 6.01, 6.02, 6.03, 6.06 and 6.14, with respect to any grant of any Lien, the making of any Investment or Restricted Payment, the incurrence of any Indebtedness or the prepayment, redemption, purchase, defeasement or satisfaction of Junior Indebtedness (each, a “Covenant Transaction”) in reliance on a “basket” that makes reference to a percentage of Consolidated EBITDA or Consolidated Total Assets, no Default or Event of Default shall be deemed to have occurred solely as a result of changes in the amount of Consolidated EBITDA or Consolidated Total Assets, as applicable, occurring after the time such Covenant Transaction is incurred, granted or made in reliance on such provision.
(e)For purposes of calculating any ratio test utilized in any debt incurrence test, such ratio shall be calculated after giving effect to any such incurrence on a pro forma basis, and, in each case, with respect to any revolving credit commitments being established utilizing a debt incurrence test, assuming a borrowing of the maximum amount of such revolving credit commitment (but no other previously established revolving commitment).
59



(f)Notwithstanding anything to the contrary herein, with respect to any amounts incurred or transactions entered into (or consummated) in reliance on a provision of this Agreement that does not require compliance with a financial ratio or test (any such amounts, which shall not include incurrence of Revolving Loans, the “Fixed Amounts”) substantially concurrently with any amounts incurred or transactions entered into (or consummated) in reliance on a provision of this Agreement that requires compliance with a financial ratio or test (including any Total Leverage Ratio test and any Fixed Charge Coverage Ratio test) (any such amounts, the “Incurrence-Based Amounts”), it is understood and agreed that the Fixed Amounts shall be disregarded in the calculation of the financial ratio or test applicable to any substantially concurrent utilization of the Incurrence-Based Amounts.
Section 1.13.Basket Amounts and Application of Multiple Relevant Provisions. Notwithstanding anything to the contrary, (a) unless specifically stated otherwise herein, any dollar, number, percentage or other amount available under any carve-out, basket, exclusion or exception to any affirmative, negative or other covenant in this Agreement or the other Loan Documents may be accumulated, added, combined, aggregated or used together by any Loan Party and the Subsidiaries without limitation for any purpose not prohibited hereby, and (b) any action or event permitted by this Agreement or the other Loan Documents need not be permitted solely by reference to one provision permitting such action or event but may be permitted in part by one such provision and in part by one or more other provisions of this Agreement and the other Loan Documents.
Section 1.14.Cashless Roll. Notwithstanding anything to the contrary, if agreed by the Administrative Agent and the Administrative Borrower, any Lender may exchange, continue or rollover all of its Loans in connection with any refinancing, extension, loan modification or similar transaction permitted by the terms of this Agreement, pursuant to a cashless settlement mechanism approved by the Administrative Borrower, the Administrative Agent and such Lender.
Section 1.15.Revolving Commitments Refinancing. The parties hereto agree that the Loan Parties may elect to refinance the Revolving Commitments (and the Revolving Loans outstanding thereunder) after the Closing Date with an asset based revolving credit facility (the “ABL Facility”) provided by a commercial bank reasonably acceptable to the Administrative Agent (as used herein, an “ABL Lender”) subject to (i) a cap on the commitments under such asset based revolving credit facility in an aggregate principal amount not to exceed $30,000,000 (which, for the avoidance of doubt, shall replace, and terminate, in full the Revolving Commitments under this Agreement), (ii) the negotiation, execution and delivery of an intercreditor agreement, in form and substance reasonably satisfactory to the Administrative Agent, providing for, among other things, the ABL Lender to have a first lien on “ABL Priority Collateral” and the Administrative Agent to have a first lien on “Term Priority Collateral” (as such terms shall be defined therein), (iii) an increase in the pricing at each level in the table set forth in the definition of “Applicable Rate” of 0.25% per annum, (iv) the negotiation of a cross-default to the ABL Facility that is reasonably acceptable to the Administrative Agent, and (iv) the absence of any Event of Default occurring and continuing under this Agreement. The terms and conditions of the ABL Facility shall be agreed by the Borrowers and the ABL Lender. The Administrative Agent shall (and is authorized by the Lenders to) enter into any amendments to this Agreement and/or the other Loan Documents and enter into the applicable intercreditor agreement to effectuate the transactions contemplated by this Section 1.15.

Article II

The Credits
Section 2.01.Commitments. Subject to the terms and conditions set forth herein, (a) each Revolving Lender (severally and not jointly) agrees to make Revolving Loans to the Borrowers (or any Borrower) in Dollars from time to time during the Availability Period in an aggregate principal amount that will not result in (i) the amount of such Lender’s Revolving Credit Exposure exceeding such Lender’s Revolving Commitment or (ii) the Total Revolving Credit Exposure exceeding the aggregate Revolving Commitments, and (b) each Term Lender with a Term Loan Commitment (severally and not jointly) agrees to make a Term Loan to the Borrowers (or any Borrower) in Dollars on the Closing Date,
60



in an amount equal to such Lender’s Term Loan Commitment. Within the foregoing limits and subject to the terms and conditions set forth herein, the Borrowers may borrow, prepay and reborrow Revolving Loans. Amounts repaid or prepaid in respect of Term Loans may not be reborrowed.
Section 2.02.Loans and Borrowings.
(a)Each Loan shall be made as part of a Borrowing consisting of Loans of the same Class and Type made by the applicable Lenders ratably in accordance with their respective Commitments of the applicable Class. The failure of any Lender to make any Loan required to be made by it shall not relieve any other Lender of its obligations hereunder; provided that, the Commitments of the Lenders are several and no Lender shall be responsible for any other Lender’s failure to make Loans as required. The Term Loans shall amortize as set forth in Section 2.10.
(b)Subject to Section 2.14, each Revolving Borrowing and Term Loan Borrowing shall be comprised entirely of ABR Loans or Term Benchmark Loans as the Administrative Borrower may request in accordance herewith. Each Lender at its option may make any Loan by causing any domestic or foreign branch or Affiliate of such Lender to make such Loan (and in the case of an Affiliate, the provisions of Sections 2.14, 2.15, 2.16 and 2.17 shall apply to such Affiliate to the same extent as to such Lender); provided that, any exercise of such option shall not affect the obligation of the Borrowers to repay such Loan in accordance with the terms of this Agreement or result in any increased cost to any Borrower.
(c)At the commencement of each Interest Period for any Term Benchmark Revolving Borrowing, such Borrowing shall be in an aggregate amount that is an integral multiple of $500,000 and not less than $1,000,000. At the time that each ABR Revolving Borrowing is made, such Borrowing shall be in an aggregate amount that is an integral multiple of $500,000 and not less than $1,000,000; provided that, an ABR Revolving Borrowing may be in an aggregate amount that is equal to the entire unused balance of the aggregate Revolving Commitments. Borrowings of more than one Type and Class may be outstanding at the same time; provided that, there shall not at any time be more than a total of ten (10) Term Benchmark Borrowings outstanding.
(d)Notwithstanding any other provision of this Agreement, the Borrowers shall not be entitled to request, or to elect to convert or continue, any Borrowing if the Interest Period requested with respect thereto would end after the Maturity Date.
(e)Notwithstanding anything to the contrary in this Agreement, the Administrative Borrower shall be the entity that (i) requests and receives the Term Loans and each Revolving Loan under this Agreement, and (ii) makes payments of principal and interest in respect of the Term Loans and each Revolving Loan under this Agreement, including, for the avoidance of doubt, any prepayment contemplated by this Agreement.
Section 2.03.Requests for Borrowings. To request a Borrowing, the Administrative Borrower shall notify the Administrative Agent of such request by irrevocable written notice (via a written Borrowing Request signed by a Responsible Officer of the Administrative Borrower) (a) in the case of a Term Benchmark Borrowing, not later than 11:00 a.m., New York City time, three (3) Business Days (or, in the case of a Term Benchmark Borrowing to be made on the Closing Date, one (1) Business Day) before the date of the proposed Borrowing or (b) in the case of an ABR Borrowing, not later than 11:00 a.m., New York City time, one (1) Business Day before the date of the proposed Borrowing; provided that with respect to any Borrowing of Revolving Loans, the Administrative Borrower shall notify the Administrative Agent of such request by irrevocable written notice (via a written Borrowing Request signed by a Responsible Officer of the Administrative Borrower), not later than 11:00 a.m., New York City time, five (5) Business Days (or, in the case of a Revolving Borrowing to be made on the Closing Date, one (1) Business Day) before the date of the proposed Borrowing. Each such Borrowing Request shall specify the following information in compliance with Section 2.02:
(i)the aggregate principal amount of the requested Borrowing;
(ii)the date of such Borrowing, which shall be a Business Day;
61



(iii)whether such Borrowing is to be an ABR Borrowing or a Term Benchmark Borrowing and whether such Borrowing is a Revolving Borrowing or a Term Loan Borrowing;
(iv)in the case of a Term Benchmark Borrowing, the initial Interest Period to be applicable thereto, which shall be a period contemplated by the definition of the term “Interest Period”;
(v)whether the Administrative Borrower has elected the PIK Option; and
(vi)the location and number of the Administrative Borrower’s account to which funds are to be disbursed, which shall comply with the requirements of Section 2.07.
If no election as to the Type of Borrowing is specified, then the requested Borrowing shall be an ABR Borrowing. If no Interest Period is specified with respect to any requested Term Benchmark Borrowing, then the Administrative Borrower shall be deemed to have selected an Interest Period of one month’s duration. Promptly following receipt of a Borrowing Request in accordance with this Section, the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender’s Loan to be made as part of the requested Borrowing.
Section 2.04.[Reserved].
Section 2.05.[Reserved].
Section 2.06.[Reserved].
Section 2.07.Funding of Borrowings.
(a)Each Lender shall make each Loan to be made by it hereunder on the proposed date thereof solely by wire transfer of immediately available funds by 2:00 noon, New York City time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the Lenders; provided that, Term Loans shall be made as provided in Section 2.01(b). The Administrative Agent will make such Loans available to the Administrative Borrower by promptly crediting the funds so received in the aforesaid account of the Administrative Agent to an account of the Administrative Borrower designated by the Administrative Borrower in the applicable Borrowing Request.
(b)Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing (or in the case of an ABR Borrowing, prior to 12:00 noon, New York City time, on the date of such Borrowing) that such Lender will not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with paragraph (a) of this Section and may, in reliance upon such assumption, make available to the Administrative Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Borrowers severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day from and including the date such amount is made available to each of the applicable Borrowers to but excluding the date of payment to the Administrative Agent, at (i) in the case of such Lender, the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation or (ii) in the case of the Borrowers, the interest rate applicable to ABR Loans. If such Lender pays such amount to the Administrative Agent, then such amount shall constitute such Lender’s Loan included in such Borrowing.
Section 2.08.Interest Elections.
(a)Each Borrowing initially shall be of the Type specified in the applicable Borrowing Request and, in the case of a Term Benchmark Borrowing, shall have an initial Interest Period as specified in such Borrowing Request. Thereafter, the Administrative Borrower may elect to convert
62



such Borrowing to a different Type or to continue such Borrowing and, in the case of a Term Benchmark Borrowing, may elect Interest Periods therefor, all as provided in this Section. The Administrative Borrower may elect different options with respect to different portions of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the Loans comprising such Borrowing, and the Loans comprising each such portion shall be considered a separate Borrowing.
(b)To make an election pursuant to this Section, the Administrative Borrower shall notify the Administrative Agent of such election (by irrevocable written notice via an Interest Election Request signed by a Responsible Officer of the Administrative Borrower) by the time that a Borrowing Request would be required under Section 2.03 if the Administrative Borrower were requesting a Borrowing of the Type resulting from such election to be made on the effective date of such election. Notwithstanding any contrary provision herein, this Section shall not be construed to permit any Borrower to (i) elect an Interest Period for Term Benchmark Loans that does not comply with Section 2.02(d) or (ii) convert any Borrowing to a Borrowing of a Type not available under such Borrowing.
(c)Each Interest Election Request shall specify the following information in compliance with Section 2.02:
(i)the Borrowing to which such Interest Election Request applies and, if different options are being elected with respect to different portions thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and (iv) below shall be specified for each resulting Borrowing);
(ii)the effective date of the election made pursuant to such Interest Election Request, which shall be a Business Day;
(iii)whether the resulting Borrowing is to be an ABR Borrowing or a Term Benchmark Borrowing;
(iv)whether the Administrative Borrower has elected the PIK Option; and
(v)if the resulting Borrowing is a Term Benchmark Borrowing, the Interest Period to be applicable thereto after giving effect to such election, which Interest Period shall be a period contemplated by the definition of the term “Interest Period”.
If any such Interest Election Request requests a Term Benchmark Borrowing but does not specify an Interest Period, then the Administrative Borrower shall be deemed to have selected an Interest Period of one month’s duration.
(d)Promptly following receipt of an Interest Election Request, the Administrative Agent shall advise each Lender of the details thereof and of such Lender’s portion of each resulting Borrowing.
(e)If the Administrative Borrower fails to deliver a timely Interest Election Request with respect to a Term Benchmark Borrowing prior to the end of the Interest Period applicable thereto, then, unless such Borrowing is repaid as provided herein, at the end of such Interest Period such Borrowing shall be converted to an ABR Borrowing. Notwithstanding any contrary provision hereof, if an Event of Default has occurred and is continuing and the Administrative Agent, at the request of the Required Lenders, so notifies the Administrative Borrower, then, so long as an Event of Default is continuing (i) no outstanding Borrowing may be converted to or continued as a Term Benchmark Borrowing and (ii) unless repaid, each Term Benchmark Borrowing shall be converted to an ABR Borrowing at the end of the Interest Period applicable thereto.
Section 2.09.Termination and Reduction of Commitments.
63



(a) Unless previously terminated, (i) any unfunded Term Loan Commitments shall terminate on the Closing Date after the funding of Term Loans on such date and (ii) all Revolving Commitments shall terminate on the Maturity Date.
(a)The Administrative Borrower may at any time terminate, or from time to time reduce, the Revolving Commitments; provided that, (i) each reduction of the Revolving Commitments shall be in an amount that is an integral multiple of $2,500,000 and not less than $2,500,000 and (ii) the Administrative Borrower shall not terminate or reduce the Revolving Commitments if, after giving effect to any concurrent prepayment of the Loans in accordance with Section 2.11, (A) the amount of any Revolving Lender’s Revolving Credit Exposure would exceed its Revolving Commitment or (B) the Total Revolving Credit Exposure would exceed the aggregate Revolving Commitments.
(b)The Administrative Borrower shall notify the Administrative Agent of any election to terminate or reduce the Commitments under paragraph (b) of this Section at least three (3) Business Days prior to the effective date of such termination or reduction, specifying such election and the effective date thereof. Promptly following receipt of any notice, the Administrative Agent shall advise the Lenders of the contents thereof. Each notice delivered by the Administrative Borrower pursuant to this Section shall be irrevocable; provided that, a notice of termination of the Commitments delivered by the Administrative Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities or other transactions specified therein, in which case such notice may be revoked by the Administrative Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Any termination or reduction of the Commitments shall be permanent. Each reduction of the Revolving Commitments shall be made ratably among the Revolving Lenders in accordance with their respective Revolving Commitments.
Section 2.10.Repayment and Amortization of Loans; Evidence of Debt.
(a)The Borrowers hereby unconditionally promises to pay to the Administrative Agent for the account of each Revolving Lender the then unpaid principal amount of each Revolving Loan (including any interest that has been paid in kind and added to the principal amount of the Revolving Loans pursuant to Section 2.13(f)) on the Maturity Date. The Borrowers shall repay Term Loans on each date set forth below in an amount equal to (x) the original aggregate principal amount of Term Loans funded on the Closing Date multiplied by (y) the percentage set forth opposite such date (as adjusted from time to time pursuant to Section 2.11(a) and Section 2.11(f), and if such date is not a Business Day, on the last Business Day of the fiscal quarter represented by such date):
64



DateAmount
June 30, 20250.25%
September 30, 20250.25%
December 31, 20250.25%
March 31, 20260.25%
June 30, 20261.25%
September 30, 20261.25%
December 31, 20261.25%
March 31, 20271.25%
June 30, 20271.25%
September 30, 20271.25%
December 31, 20271.25%
March 31, 20281.25%
June 30, 20281.25%
September 30, 20281.25%
December 31, 20281.25%
March 31, 20291.25%
June 30, 20291.25%
September 30, 20291.25%
December 31, 20291.25%
March 31, 20301.25%

To the extent not previously repaid, all unpaid Term Loans (including any interest that has been paid in kind and added to the principal amount of the Term Loans pursuant to Section 2.13(f)) shall be paid in full in Dollars by the Borrowers on the Maturity Date.
(b)Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the indebtedness of the Borrowers to such Lender resulting from each Loan made by such Lender, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder.
(c)The Administrative Agent shall maintain accounts in which it shall record (i) the amount of each Loan made hereunder, the Class and Type thereof and the Interest Period applicable thereto, (ii) the amount of any principal or interest due and payable or to become due and payable from the Borrowers to each Lender hereunder and (iii) the amount of any sum received by the Administrative Agent hereunder for the account of the Lenders and each Lender’s share thereof.
(d)The entries made in the accounts maintained pursuant to paragraph (b) or (c) of this Section shall be prima facie evidence of the existence and amounts of the obligations recorded therein; provided that, the failure of any Lender or the Administrative Agent to maintain such accounts or any error therein shall not in any manner affect the Obligations (including the obligation of the Borrowers to repay the Loans in accordance with the terms of this Agreement).
(e)Any Lender may request that Loans made by it be evidenced by a promissory note. In such event, the Borrowers shall prepare, execute and deliver to such Lender a promissory note payable to such Lender (or, if requested by such Lender, to such Lender and its registered assigns) in the form attached hereto as Exhibit D-1 or Exhibit D-2, as applicable, or otherwise as approved by the Administrative Agent (such notes, collectively, the “Notes”). Thereafter, the Loans evidenced by such promissory note and interest thereon shall at all times (including after assignment pursuant to Section 9.04) be represented by one or more promissory notes in such form.
65



Section 2.11.Prepayment of Loans.
(a)The Borrowers shall have the right at any time and from time to time to prepay any Borrowing in whole or in part, without penalty or premium (other than break funding payments required by Section 2.16 and payments required by Section 2.12(e)) subject to prior notice in accordance with the provisions of this Section 2.11(a). The Administrative Borrower shall notify the Administrative Agent by written notice of any prepayment hereunder (i) in the case of prepayment of a Term Benchmark Borrowing, not later than 11:00 a.m., New York City time, three (3) Business Days before the date of prepayment, (ii) in the case of prepayment of an ABR Borrowing, not later than 11:00 a.m., New York City time one (1) Business Day before the date of prepayment. Each such notice shall be irrevocable and shall specify the prepayment date and the principal amount of each Borrowing or portion thereof to be prepaid; provided that, if a notice of prepayment is given in connection with a notice of termination of the Commitments that is conditional upon the effectiveness of other transactions, then such notice of prepayment may be revoked by the Administrative Borrower if such condition is not satisfied. Promptly following receipt of any such notice relating to a Borrowing, the Administrative Agent shall advise the Lenders of the contents thereof. Each partial prepayment of any Borrowing shall be in an amount that would be permitted in the case of an advance of a Borrowing of the same Type as provided in Section 2.02. Each prepayment of a Revolving Borrowing shall be applied ratably to the Revolving Loans included in the prepaid Revolving Borrowing and each voluntary prepayment of a Term Loan Borrowing shall be applied ratably to the Term Loans included in the prepaid Term Loan Borrowing in such order of application as directed by the Administrative Borrower, and each mandatory prepayment of a Term Loan Borrowing shall be applied in accordance with Section 2.11(f). Prepayments shall be accompanied by (i) accrued interest to the extent required by Section 2.13 and (ii) any break funding payments required by Section 2.16.
(b)If at any time the Total Revolving Credit Exposures exceed the aggregate Revolving Commitments, the Borrowers shall immediately repay Borrowings in an aggregate principal amount sufficient to cause the aggregate principal amount of the Total Revolving Credit Exposures to be less than or equal to the aggregate Revolving Commitments.
(c)Within five (5) Business Days following the delivery to the Administrative Agent (for distribution to the Lenders) of audited annual financial statements pursuant to Section 5.01(a), commencing with the delivery to the Administrative Agent of the financial statements for the Fiscal Year ending December 31, 2025 or, if such financial statements are not delivered to the Administrative Agent, within five (5) Business Days following the date on which such statements are required to be delivered pursuant to Section 5.01(a), the Borrowers shall prepay the Obligations as set forth in Section 2.11(f) below in an aggregate amount equal to the result of (to the extent positive) (1) 50% of the Excess Cash Flow of the Parent Guarantor and its Subsidiaries for such Fiscal Year (provided that, with respect to the Fiscal Year ending December 31, 2025, such period shall be calculated from the Closing Date until December 31, 2025) minus (2) the aggregate principal amount of all payments made by the Borrowers pursuant to Section 2.11(a) for such Fiscal Year (in the case of payments of Revolving Loans made by the Borrowers pursuant to Section 2.11(a), only to the extent that the Revolving Commitment is permanently reduced by the amount of such payments) (and only to the extent that any such payment was not made with the proceeds of Equity Interests or other long-term Indebtedness (other than revolving Indebtedness)).
(d)In the event and on each occasion that any Net Cash Proceeds are received by or on behalf of the Parent Guarantor, any Borrower or any Subsidiary in respect of any Prepayment Event, the Borrowers shall, within five (5) Business Days after such Net Cash Proceeds are received, prepay the Obligations as set forth in Section 2.11(e) below in an aggregate amount equal to 100% of such Net Cash Proceeds; provided that, (i) in the case of any event described in clause (a) or (b) of the definition of the term “Prepayment Event”, such required prepayment shall only be required to be made for amounts in excess of $3,500,000 per Fiscal Year and (ii) in the case of any event described in clause (c) of the definition of the term “Prepayment Event”, (1) for the first $5,000,000 of Net Cash Proceeds received in respect of Project Romania, the Borrowers shall prepay in an aggregate amount equal to 50% of such Net Cash Proceeds (and then retain any remaining amounts), (2) for the second $5,000,000 of Net Cash Proceeds received in respect of Project Romania, the Borrowers shall prepay in an aggregate amount equal to 50% of such Net Cash Proceeds (and then retain any remaining amounts), (3) for the next
66



$20,000,000 of Net Cash Proceeds received in respect of Project Romania, the Borrowers shall first prepay in an aggregate amount equal to $15,000,000 of such Net Cash Proceeds (and then retain any remaining amounts), and (4) for Net Cash Proceeds received in respect of Project Romania thereafter the Borrowers shall repay in an aggregate amount equal to 66.67% of such cash proceeds (and then retain any remaining amounts) (and concurrently with any such prepayment resulting from an event described in clause (c) of the definition of the term “Prepayment Event”, the Administrative Borrower will deliver to the Administrative Agent a reasonably detailed reconciliation of any amounts deducted in the calculation of the Net Cash Proceeds thereof); provided further that, so long as no Event of Default has occurred and is continuing, such prepayment shall not be required to the extent that any Borrower reinvests such Net Cash Proceeds (limited to Net Cash Proceeds representing (i) a Prepayment Event pursuant to clause (a) of such definition or (ii) Casualty Proceeds) in assets of a kind then used or usable in the business of the Parent Guarantor, the Borrowers and the Subsidiaries within 180 days after the date of receipt of such Net Cash Proceeds, or enters into a binding commitment thereof within said 180-day period and subsequently makes such reinvestment within 180 days after the end of such 180-day period; provided that, the Administrative Borrower notifies the Administrative Agent within five (5) Business Days following receipt by the Parent Guarantor, any Borrower or any Subsidiary of such Net Cash Proceeds of the Borrowers’ (or any Borrower’s) intent to reinvest such Net Cash Proceeds. Notwithstanding anything to the contrary contained herein, the Borrowers may retain any Net Cash Proceeds of Project Romania that is not required to be repaid pursuant to this Section 2.11(d) (such Net Cash Proceeds, excluding $5,000,000 of such Net Cash Proceeds required to be deposited into escrow in accordance with the terms of Project Romania, the “Retained Project Romania Proceeds”).
(e)All such amounts pursuant to Sections 2.11(c) and 2.11(d) shall be applied to prepay the outstanding Term Loans in the inverse order of maturity. Once the outstanding Term Loans are repaid in full then all such amounts shall be applied to prepay the outstanding Revolving Loans (if any).
(f)Each prepayment of Term Loans pursuant to Sections 2.11(c) and 2.11(d) shall be allocated ratably to the Term Lenders, and shall be subject to break funding payments required by Section 2.16 and payments (if any) required by Section 2.12(e).
(g)Each Term Lender may reject all (or any portion) of its pro rata share of any mandatory prepayment (such declined amounts, the “Declined Proceeds”) of Term Loans required to be made pursuant to clause (c) or (d) of this Section 2.11 by providing written notice to the Administrative Agent by 5:00 p.m. New York City time, one (1) Business Day prior to the date of such prepayment. If any Lender shall fail to notify the Administrative Agent within the time frame set forth above of its intent to reject its pro rata share of such mandatory prepayment, such Lender shall be deemed to have accepted its pro rata share of such mandatory prepayment. Any Declined Proceeds remaining thereafter shall (i) unless the Administrative Agent otherwise agrees, be offered on a pro rata basis to the Term Lenders that did not reject their pro rata share of such mandatory prepayment and (ii) if rejected by such Term Lenders, be retained by the Borrowers (“Retained Declined Proceeds”).
Section 2.12.Fees.
(a)The Borrowers agree to pay to the Administrative Agent for the account of each Revolving Lender a commitment fee, which shall accrue at the “Commitment Fee Rate” specified in the definition of Applicable Rate on the average daily amount of the Available Revolving Commitment of such Lender during the period from and including the Closing Date to but excluding the date on which such Revolving Commitment terminates. Commitment fees accrued through and including the last Business Day of March, June, September and December of each year shall be payable in arrears on the last Business Day of March, June, September and December of each year and on the date on which the Revolving Commitments terminate, commencing on the first such date to occur after the date hereof; provided that, any commitment fees accruing after the date on which the Revolving Commitments terminate shall be payable on demand. All commitment fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day and the last day of each period but excluding the date on which the Revolving Commitments terminate).
(b)[Reserved].
67



(c)The Borrowers agree to pay to the Administrative Agent, for its own account, fees payable in the amounts and at the times separately agreed upon between the Borrowers and the Administrative Agent.
(d)All fees payable hereunder shall be paid on the dates due, in Dollars and immediately available funds, to the Administrative Agent for distribution, in the case of commitment fees, to the applicable Lenders. Fees paid shall not be refundable under any circumstances.
(e)Upon the occurrence of an Applicable Premium Trigger Event, the Borrowers shall pay to the Administrative Agent, for the account of the Lenders in accordance with their Applicable Percentage, the Applicable Premium. Any Applicable Premium payable in accordance with this clause (e) shall be presumed to be the liquidated damages sustained by the Lenders as the result of the occurrence of the Applicable Premium Trigger Event and the Borrowers agree that it is reasonable under the circumstances currently existing. THE BORROWERS EXPRESSLY WAIVE THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE FOREGOING APPLICABLE PREMIUM IN CONNECTION WITH ANY ACCELERATION. The Borrowers expressly agree (to the fullest extent that they may lawfully do so) that: (i) the Applicable Premium is reasonable and is the product of an arm's length transaction between sophisticated business people, ably represented by counsel; (ii) the Applicable Premium shall be payable notwithstanding the then prevailing market rates at the time payment is made; (iii) there has been a course of conduct between the Lenders and the Borrowers giving specific consideration in this transaction for such agreement to pay the Applicable Premium; (iv) the Loan Parties shall be estopped hereafter from claiming differently than as agreed to in this paragraph; (v) their agreement to pay the Applicable Premium is a material inducement to Lenders to provide the Commitments and make the Loans; and (vi) the Applicable Premium represents a good faith, reasonable estimate and calculation of the lost profits or damages of the Administrative Agent and the Lenders and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Administrative Agent and the Lenders or profits lost by the Administrative Agent and the Lenders as a result of such Applicable Premium Trigger Event. Nothing contained in this clause (vii) shall permit any prepayment of the Loans or reduction of the Commitments not otherwise permitted by the terms of this Agreement or any other Loan Document.
Section 2.13.Interest.
(a)The Loans comprising each ABR Borrowing shall bear interest at the Alternate Base Rate plus the Applicable Rate.
(b)The Loans comprising each Term Benchmark Borrowing shall bear interest at the Adjusted Term SOFR Rate for the Interest Period in effect for such Borrowing plus the Applicable Rate.
(c)[Reserved].
(d)To the extent permitted by law and notwithstanding anything to the contrary in this Section 2.13, upon the occurrence and during the continuance of an Event of Default, at the election of the Administrative Agent or Required Lenders (and automatically upon the occurrence and during the continuance of any Event of Default pursuant to Section 7.01(a) or Section 7.01(f)), the principal of, and all accrued and unpaid interest on, all Loans, fees, indemnities, or any other Obligations of the Loan Parties under this Agreement and the other Loan Documents, shall bear interest, from the date such Event of Default occurred until the date such Event of Default is cured or waived in writing in accordance herewith, at a rate per annum equal to the Post-Default Rate.
(e)Accrued interest on each Loan shall be payable in cash (other than as set forth in clause (f) below) in arrears on each Interest Payment Date for such Loan and, in the case of Revolving Loans, upon termination of the Revolving Commitments; provided that, (i) interest accrued pursuant to paragraph (d) of this Section shall be payable on demand, (ii) in the event of any repayment or prepayment of any Loan (other than a prepayment of an ABR Revolving Loan prior to the end of the Availability Period), accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or prepayment and (iii) in the event of any conversion of any Term Benchmark
68



Loan prior to the end of the current Interest Period therefor, accrued interest on such Loan shall be payable on the effective date of such conversion.
(f)On each Interest Payment Date in respect of which the PIK Option applies, to the extent elected by the Administrative Borrower, an amount of accrued and unpaid interest may be paid in kind by adding such accrued and unpaid interest to the principal amount of the Revolving Loans and the Term Loans, as applicable, in accordance with the terms set forth in the definition of “Applicable Rate”. Any interest to be so paid-in-kind pursuant to this clause (f) shall be capitalized on such Interest Payment Date and added to the then-outstanding principal amount of such Revolving Loans and Term Loans, as applicable, and, thereafter, shall bear interest as provided hereunder as if it had originally been part of the outstanding principal of such Revolving Loans and Term Loans.
(g)All interest hereunder shall be computed on the basis of a year of 360 days, except that interest computed by reference to the Alternate Base Rate at times when the Alternate Base Rate is based on the Prime Rate shall be computed on the basis of a year of 365 days (or 366 days in a leap year), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding principal amount of such Loan as of the applicable date of determination. The applicable Alternate Base Rate, Adjusted Term SOFR Rate or Term SOFR Rate shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest error.
(h)Notwithstanding anything herein to the contrary, interest that has been paid in kind and added to the principal amount of the Revolving Loans shall not constitute outstanding Revolving Loans for purposes of (i) determining Unfunded Revolving Commitments or Available Revolving Commitments (including for the calculation of commitment fees pursuant to Section 2.12(a)) and (ii) determining whether the amount of any Lender’s (or the Lenders’) Revolving Credit Exposure exceeds such Lender’s (or the Lenders’) Revolving Commitment (including for purposes of Section 2.01, 2.09 and 2.11).
Section 2.14.Benchmark Replacement Setting.
(a)Benchmark Replacement. Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark Transition Event, the Administrative Agent and the Administrative Borrower may amend this Agreement to replace the then-current Benchmark with a Benchmark Replacement. Any such amendment with respect to a Benchmark Transition Event will become effective at 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the Administrative Agent has posted such proposed amendment to all affected Lenders and the Administrative Borrower so long as the Administrative Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Required Lenders. No replacement of a Benchmark with a Benchmark Replacement pursuant to this Section 2.14(a) will occur prior to the applicable Benchmark Transition Start Date.
(b)Benchmark Replacement Conforming Changes. In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.
(c)Notices; Standards for Decisions and Determinations. The Administrative Agent will promptly notify the Administrative Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Benchmark Replacement Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Administrative Agent will notify the Administrative Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to Section 2.14(d) and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.14, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an
69



event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 2.14.
(d)Unavailability of Tenor of Benchmark. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.
(e)Benchmark Unavailability Period. Upon the Administrative Borrower’s receipt of notice of the commencement of a Benchmark Unavailability Period, the Administrative Borrower may revoke any pending request for a Term Benchmark Borrowing of, conversion to or continuation of Term Benchmark Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrowers will be deemed to have converted any such request into a request for a Borrowing of or conversion to ABR Loans. During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of the Alternate Base Rate based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of the Alternate Base Rate.
Section 2.15.Increased Costs.
(a)If any Change in Law shall:
(i)impose, modify or deem applicable any reserve, special deposit, liquidity or similar requirement (including any compulsory loan requirement, insurance charge or other assessment) against assets of, deposits with or for the account of, or credit extended by, any Lender (except any such reserve requirement reflected in the Adjusted Term SOFR Rate);
(ii)impose on any Lender or the applicable offshore interbank market any other condition, cost or expense (other than Taxes) affecting this Agreement or Loans made by such Lender; or
(iii)subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto;
and the result of any of the foregoing shall be to increase the cost to such Lender or such other Recipient of making, continuing, converting or maintaining any Loan (or of maintaining its obligation to make any such Loan) or to reduce the amount of any sum received or receivable by such Lender or such other Recipient hereunder (whether of principal, interest or otherwise), then, upon request of such Lender or such other Recipient, the Borrowers will pay to such Lender or such other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender or such other Recipient, as the case may be, for such additional costs incurred or reduction suffered.
70



(b)If any Lender determines that any Change in Law regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender’s capital or on the capital of such Lender’s holding company, if any, as a consequence of this Agreement or the Loans made by such Lender, to a level below that which such Lender or such Lender’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s policies and the policies of such Lender’s holding company with respect to capital adequacy and liquidity), then from time to time the Borrowers will pay to such Lender such additional amount or amounts as will compensate such Lender or such Lender’s holding company for any such reduction suffered as reasonably determined by the Administrative Agent or such Lender (which determination shall be made in good faith (and not on an arbitrary or capricious basis) and generally consistent with similarly situated customers of the Administrative Agent or such Lender, as applicable, under agreements having provisions similar to this Section 2.15, after consideration of such factors as the Administrative Agent or such Lender, as applicable, then reasonably determines to be relevant).
(c)A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section shall be delivered to the Administrative Borrower and shall be conclusive absent manifest error. The Borrowers shall pay such Lender, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof.
(d)Failure or delay on the part of any Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender’s right to demand such compensation; provided that, the Borrowers shall not be required to compensate a Lender pursuant to this Section for any increased costs or reductions incurred more than 180 days prior to the date that such Lender, as the case may be, notifies the Administrative Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s intention to claim compensation therefor; provided further that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof.
Section 2.16.Break Funding Payments. In the event of (a) the payment of any principal of any Term Benchmark Loan other than on the last day of an Interest Period applicable thereto (including as a result of an Event of Default or as a result of any prepayment pursuant to Section 2.11), (b) the conversion of any Term Benchmark Loan other than on the last day of the Interest Period applicable thereto, (c) the failure to borrow, convert, continue or prepay any Term Benchmark Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice may be revoked under Section 2.11(a) and is revoked in accordance therewith) or (d) the assignment of any Term Benchmark Loan other than on the last day of the Interest Period applicable thereto as a result of a request by the Administrative Borrower pursuant to Section 2.19 or 9.02(e), then, in any such event, the Borrowers shall compensate each Lender for the loss, cost and expense attributable to such event. Such loss, cost or expense to any Lender shall be deemed to include an amount determined by such Lender to be the excess, if any, of (i) the amount of interest which would have accrued on the principal amount of such Loan had such event not occurred, at the Adjusted Term SOFR Rate that would have been applicable to such Loan, for the period from the date of such event to the last day of the then current Interest Period therefor (or, in the case of a failure to borrow, convert or continue, for the period that would have been the Interest Period for such Loan), over (ii) the amount of interest which would accrue on such principal amount for such period at the interest rate which such Lender would bid were it to bid, at the commencement of such period, for deposits in Dollars of a comparable amount and period from other banks in the applicable offshore interbank market. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive pursuant to this Section shall be delivered to the Administrative Borrower and shall be conclusive absent manifest error. The Borrowers shall pay such Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof.
Section 2.17.Taxes.
(a)Payments Free of Taxes. Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as reasonably determined by a potential withholding agent) requires the deduction or withholding of any Tax from any such payment by
71



a withholding agent, then the applicable withholding agent shall make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the applicable Loan Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2.17) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.
(b)Payment of Other Taxes by the Administrative Borrower. The Administrative Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for, Other Taxes.
(c)Evidence of Payments. As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority pursuant to this Section 2.17, such Loan Party shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.
(d)Indemnification by the Loan Parties. The Loan Parties shall jointly and severally indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 2.17) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Administrative Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.
(e)Indemnification by the Lenders. Each Lender shall severally indemnify the Administrative Agent, within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that any Loan Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan Parties to do so), (ii) any Taxes attributable to such Lender’s failure to comply with the provisions of Section 9.04(c) relating to the maintenance of a Participant Register and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to setoff and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this paragraph (e).
(f)Exemption from Withholding.
(i)Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Administrative Borrower and the Administrative Agent, at the time or times reasonably requested by the Administrative Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Administrative Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Administrative Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Administrative Borrower or the Administrative Agent as will enable the Administrative Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set
72



forth in either (i) Section 2.17(f)(ii)(A), (ii)(B) or (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender. Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Administrative Borrower and the Administrative Agent in writing of its legal inability to do so.
(ii)Without limiting the generality of the foregoing, in the event that the Administrative Borrower is a U.S. Person:
(A)any Lender that is a U.S. Person shall deliver to the Administrative Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Administrative Borrower or the Administrative Agent), an executed copy of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;
(B)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Administrative Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Administrative Borrower or the Administrative Agent), whichever of the following is applicable:
(1)in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, an executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;
(2)in the case of a Foreign Lender claiming that its extension of credit will generate U.S. effectively connected income, an executed copy of IRS Form W-8ECI;
(3)in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit B-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Administrative Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) an executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E; or
(4)to the extent a Foreign Lender is not the beneficial owner, an executed copy of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN or IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit B-2 or Exhibit B-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that, if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance
73



Certificate substantially in the form of Exhibit B-4 on behalf of each such direct and indirect partner;
(C)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Administrative Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Administrative Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Administrative Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and
(D)if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Administrative Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Administrative Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Administrative Borrower or the Administrative Agent as may be necessary for the Administrative Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the Closing Date.
(g)UK Tax Deduction. If any United Kingdom taxes are required, in the opinion of the relevant Borrower acting reasonably and in good faith, and based on written advice from an appropriately qualified UK tax advisor (a “UK Tax Advisor”) (such advice to be shared with the Lenders and the Administrative Agent on request), to be deducted or withheld from (i) a payment of interest by such Borrower or (ii) any payment in respect of a Guarantee, in each case under any Loan Document (a “UK Tax Deduction”), and such UK Tax Deduction is both (A) as a result of the identity or residence of any of the Loan Parties and/or any of the parties who grant Collateral under the Collateral Agreements and/or any of the parties who provide a Guarantee under the Guarantee Agreements, and (B) an Indemnified Tax, (an “Indemnified UK Tax Deduction”) the relevant Borrower, the Lenders and the Administrative Agent, in each case acting reasonably, shall negotiate in good faith to restructure the Loan Parties and/or the Collateral under this Agreement and/or the Collateral Agreements and/or the Guarantee Agreements (as required) and/or take any other reasonable actions either such that no Indemnified UK Tax Deduction is required or such that full relief or exemption from any obligation to make a UK Tax Deduction may be obtained (in the opinion of the relevant Borrower acting reasonably and in good faith, based on written advice from a UK Tax Advisor (such advice to be shared with the Lenders and the Administrative Agent on written request)). If an amendment or other modification to any Loan Document is required pursuant to this Section 2.17(g), the Lenders authorize the Administrative Agent to, and the Administrative Agent shall, enter into such amendments or modifications. If no agreement after such negotiation is reached by the end of three (3) months (or such longer period as may be agreed acting reasonably and in good faith and provided that such initial negotiation period shall (absent prior written agreement of the Administrative Agent in its discretion) be in no event shorter than three (3) months unless agreement on terms is reached) following the due date of the first payment giving rise to an Indemnified UK Tax Deduction, the Borrower may promptly (but in any event within ten (10) Business Days) give the Administrative Agent notice of its intention to prepay the Loans under Section 2.11(a), and its intention to terminate the outstanding Revolving Commitments under 2.09(b), and promptly thereafter so prepay the Loans and terminate the Revolving Commitments. Without prejudice to the rights of either party pursuant to this Section 2.17(g), as soon as practically possible after the relevant Borrower identifies
74



that a UK Tax Deduction may be required, the Borrower shall notify the Administration Agent of the same such that the parties may promptly commence discussions as contemplated by this Section 2.17(g).
(h)Survival. Each party’s obligations under this Section 2.17 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.
(i)Defined Terms. For purposes of this Section 2.17, the term “applicable law” includes FATCA.
Section 2.18.Payments Generally; Allocations of Proceeds; Pro Rata Treatment; Sharing of Setoffs.
(a)The Borrowers shall make each payment or prepayment required to be made by it hereunder (whether of principal, interest, fees, or of amounts payable under Section 2.15, 2.16 or 2.17, or otherwise) in Dollars prior to 12:00 noon, New York City time on the date when due or the date fixed for any prepayment hereunder, in immediately available funds, without setoff, recoupment or counterclaim. Any amounts received after such time on any date may, in the discretion of the Administrative Agent, be deemed to have been received on the next succeeding Business Day for purposes of calculating interest thereon. All such payments shall be made to the Administrative Agent, except that payments pursuant to Sections 2.15, 2.16, 2.17, 9.02(e) and 9.03 shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following receipt thereof. If any payment under this Agreement shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be payable for the period of such extension. All payments hereunder shall be made in Dollars.
(b)At any time that payments are not required to be applied in the manner required by Section 7.03, if at any time insufficient funds are received by and available to the Administrative Agent to pay fully all amounts of principal, interest and fees then due hereunder, such funds shall be applied (i) first, towards payment of interest and fees then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of interest and fees then due to such parties, and (ii) second, towards payment of principal then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of principal then due to such parties.
(c)At the election of the Administrative Agent, all payments of principal, interest, fees, premiums, reimbursable expenses (including all reimbursement for fees and expenses pursuant to Section 9.03), and other sums payable under the Loan Documents, may be paid from the proceeds of Borrowings made hereunder whether made following a request by the Administrative Borrower pursuant to Section 2.03 or a deemed request as provided in this Section or may be deducted from any deposit account of any Borrower maintained with the Administrative Agent (if any). The Borrowers hereby irrevocably authorizes the Administrative Agent to make a Borrowing for the purpose of paying each payment of principal, interest and fees as it becomes due hereunder or any other amount due under the Loan Documents and agrees that all such amounts charged shall constitute Loans and that all such Borrowings shall be deemed to have been requested pursuant to Section 2.03 or 2.05, as applicable.
(d)If, except as expressly provided herein, any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of its Loans resulting in such Lender receiving payment of a greater proportion of the aggregate amount of its Loans and accrued interest thereon than the proportion received by any other similarly situated Lender, then the Lender receiving such greater proportion shall purchase (for cash at face value) participations in the Loans of other Lenders to the extent necessary so that the benefit of all such payments shall be shared by all such Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans; provided that, (i) if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest, and (ii) the provisions of this paragraph shall not be construed to apply to any payment made by any Borrower pursuant to and in accordance with
75



the express terms of this Agreement or any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans to any assignee or participant, other than to the Parent Guarantor, any Borrower, any Subsidiary or any Affiliate thereof (which assignments and participations shall not be permitted). Each Borrower consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against any Borrower rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Borrower in the amount of such participation.
(e)Unless the Administrative Agent shall have received, prior to any date on which any payment is due to the Administrative Agent for the account of the relevant Lenders pursuant to the terms of this Agreement or any other Loan Document (including any date that is fixed for prepayment by notice from the Administrative Borrower to the Administrative Agent pursuant to Section 2.11(a)), notice from the Administrative Borrower that the Borrowers will not make such payment or prepayment, the Administrative Agent may assume that the Borrowers have made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the relevant Lenders the amount due. In such event, if the Borrowers have not in fact made such payment, then each of the relevant Lenders severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.
Section 2.19.Mitigation Obligations; Replacement of Lenders.
(a)If any Lender requests compensation under Section 2.15, or if any Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.17, then such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or Affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 2.15 or 2.17, as the case may be, in the future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. Each Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.
(b)If (i) any Lender requests compensation under Section 2.15, (ii) any Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.17 or (iii) any Lender becomes a Defaulting Lender, then the Administrative Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in Section 9.04), all its interests, rights (other than its existing rights to payments pursuant to Section 2.15 or 2.17) and obligations under this Agreement and the other Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that, (i) the Administrative Borrower shall have received the prior written consent of the Administrative Agent, which consent shall not unreasonably be withheld, (ii) such Lender shall have received payment of an amount equal to the outstanding principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder, from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrowers (in the case of all other amounts) and (iii) in the case of any such assignment resulting from a claim for compensation under Section 2.15 or payments required to be made pursuant to Section 2.17, such assignment will result in a reduction in such compensation or payments. A Lender shall not be required to make any such assignment and delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Administrative Borrower to require such assignment and delegation cease to apply. Each party hereto agrees that (i) an assignment required pursuant to this paragraph may be effected pursuant to an Assignment and Assumption executed by the Administrative Borrower, the Administrative Agent and the assignee (or, to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to an Approved
76



Electronic Platform as to which the Administrative Agent and such parties are participants), and (ii) the Lender required to make such assignment need not be a party thereto in order for such assignment to be effective and shall be deemed to have consented to and be bound by the terms thereof; provided that, following the effectiveness of any such assignment, the other parties to such assignment agree to execute and deliver such documents necessary to evidence such assignment as reasonably requested by the applicable Lender, provided that, any such documents shall be without recourse to or warranty by the parties thereto.
Section 2.20.[Reserved].
Section 2.21.Defaulting Lenders. Notwithstanding any provision of this Agreement to the contrary, if any Lender becomes a Defaulting Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender:
(a)fees shall cease to accrue on the unfunded portion of the Revolving Commitment of such Defaulting Lender pursuant to Section 2.12(a);
(b)any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 7.03 or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to Section 9.08 shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder; second, [reserved]; third, [reserved]; fourth, as the Administrative Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Administrative Borrower, to be held in a deposit account and released pro rata in order to satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Agreement, in accordance with this Section; sixth, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement or under any other Loan Document; seventh, so long as no Default or Event of Default exists, to the payment of any amounts owing to any Borrower as a result of any judgment of a court of competent jurisdiction obtained by any Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement or under any other Loan Document; and eighth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that, if (x) such payment is a payment of the principal amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share, and (y) such Loans were made at a time when the conditions set forth in Section 4.02 were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of such Defaulting Lender until such time as all Loans are held by the Lenders pro rata in accordance with the Revolving Commitments without giving effect to clause (d) below. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post cash collateral pursuant to this Section shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto; and
(c)the Revolving Commitment and Revolving Credit Exposure of such Defaulting Lender shall not be included in determining whether the Required Lenders or the Required Revolving Lenders have taken or may take any action hereunder (including any consent to any amendment, waiver or other modification pursuant to Section 9.02); provided further that, any amendment, waiver or other modification requiring the consent of all Lenders or all Lenders directly affected thereby shall not, except as otherwise provided in Section 9.02, require the consent of such Defaulting Lender in accordance with the terms hereof.
In the event that the Administrative Agent and the Administrative Borrower agree that a Defaulting Lender has adequately remedied all matters that caused such Lender to be a Defaulting Lender, then on such date such Lender shall purchase at par such of the Loans of the other Lenders as the
77



Administrative Agent shall determine may be necessary in order for such Lender to hold such Loans in accordance with its Applicable Percentage.
Section 2.22.Administrative Borrower; Joint and Several Liability of the Borrowers.
(a)Each Borrower hereby irrevocably appoints Obagi Cosmeceuticals as the borrowing agent and attorney-in-fact for the Borrowers (the “Administrative Borrower”) which appointment shall remain in full force and effect unless and until the Administrative Agent shall have received prior written notice signed by all of the Borrowers that such appointment has been revoked and that another Borrower has been appointed as Administrative Borrower. Each Borrower hereby irrevocably appoints and authorizes the Administrative Borrower (i) to provide to the Administrative Agent and receive from the Administrative Agent all notices with respect to Loans obtained for the benefit of any Borrower and all other notices and instructions under this Agreement; (ii) to request and receive the Term Loans and each Revolving Loan under this Agreement; (iii) to make payments of principal and interest in respect of the Term Loans and each Revolving Loan under this Agreement (including, for the avoidance of doubt, any prepayment made under this Agreement); and (iv) to take such action as the Administrative Borrower deems appropriate on its behalf to obtain Loans and to exercise such other powers as are reasonably incidental thereto to carry out the purposes of this Agreement. It is understood that the handling of the Loans and Collateral of the Borrowers in a combined fashion, as more fully set forth herein, is done solely as an accommodation to the Borrowers in order to utilize the collective borrowing powers of the Borrowers in the most efficient and economical manner and at their request, and that neither the Administrative Agent nor the Lenders shall incur liability to the Borrowers as a result hereof. Each Borrower expects to derive benefit, directly or indirectly, from the handling of the Loans and the Collateral in a combined fashion since the successful operation of each Borrower is dependent on the continued successful performance of the integrated group.
(b)Each Borrower hereby accepts joint and several liability hereunder and under the other Loan Documents in consideration of the financial accommodations to be provided by the Administrative Agent and the Lenders under this Agreement and the other Loan Documents, for the mutual benefit, directly and indirectly, of each of the Borrowers and in consideration of the undertakings of the other Borrowers to accept joint and several liability for the Obligations. Each of the Borrowers, jointly and severally, hereby irrevocably and unconditionally accepts, not merely as a surety, but also as a co-debtor, joint and several liability with the other Borrowers, with respect to the payment and performance of all of the Obligations (including, without limitation, any Obligations arising under this Section 2.22), it being the intention of the parties hereto that all of the Obligations shall be the joint and several obligations of each of the Borrowers without preferences or distinction among them. If and to the extent that any of the Borrowers shall fail to make any payment with respect to any of the Obligations as and when due or to perform any of the Obligations in accordance with the terms thereof, then in each such event, the other Borrowers will make such payment with respect to, or perform, such Obligation. Subject to the terms and conditions hereof, the Obligations of each of the Borrowers under the provisions of this Section 2.22 constitute the absolute and unconditional, full recourse Obligations of each of the Borrowers, enforceable against each such Person to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of this Agreement, the other Loan Documents or any other circumstances whatsoever.
(c)The provisions of this Section 2.22 may be enforced without requirement on the part of the Administrative Agent, the Lenders or such successors or assigns first to marshal any of its or their claims or to exercise any of its or their rights against any of the other Borrowers or to exhaust any remedies available to it or them against any of the other Borrowers or to resort to any other source or means of obtaining payment of any of the Obligations hereunder or to elect any other remedy. The provisions of this Section 2.22 shall remain in effect until all of the Obligations shall have been paid in full or otherwise fully satisfied (other than contingent indemnification obligations as to which no claim has been asserted).
(d)Each of the Borrowers hereby agrees that it will not enforce any of its rights of contribution or subrogation against the other Borrowers with respect to any liability incurred by it hereunder or under any of the other Loan Documents, any payments made by it to the Administrative Agent or the Lenders with respect to any of the Obligations or any Collateral, until such time as all of the
78



Obligations have been paid in full in cash. Any claim which any Borrower may have against any other Borrower with respect to any payments to the Administrative Agent or the Lenders hereunder or under any other Loan Documents are hereby expressly made subordinate and junior in right of payment, without limitation as to any increases in the Obligations arising hereunder or thereunder, to the prior payment in full in cash of the Obligations.
Article III

Representations and Warranties
Each of the Parent Guarantor and each Borrower represents and warrants to the Lenders that:
Section 3.01.Organization; Powers; Subsidiaries. Each Loan Party and each Subsidiary (other than any Immaterial Subsidiary) thereof (a) is duly incorporated, organized, formed or registered, validly existing and, as applicable, in good standing under the Laws of the jurisdiction of its incorporation, association, organization, formation or registration (to the extent that such concept exists in such jurisdiction); (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own or lease its assets and carry on its business as currently conducted and (ii) in the case of each Loan Party, execute, deliver and perform its obligations under the Loan Documents to which it is a party; and (c) is duly qualified and is licensed and, as applicable, in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license, except in each case referred to in clauses (a) (other than with respect to the Loan Parties), (b)(i) or (c), to the extent that failure to do so would not reasonably be expected to have a Material Adverse Effect.
Section 3.02.Authorization; No Contravention. The execution, delivery and performance by each Loan Party of each Loan Document to which such Person is party (a) have been duly authorized by all necessary corporate or other organizational action, and (b) do not (i) contravene the terms of any of such Person’s Organization Documents, (ii) conflict with or result in any breach or contravention of, or the creation of any Lien (other than as permitted under Section 6.01) under, or require any payment to be made under (x) any material contract to which such Person is a party or affecting such Person or the properties of such Person or any Subsidiary or (y) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject or (iii) violate any Law, except in each case referred to in clauses (ii) or (iii), to the extent that such conflict, breach, contravention, Lien, payment or violation would not reasonably be expected to have a Material Adverse Effect.
Section 3.03.Governmental Approvals; Other Consents. No material approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with (a) the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document, or for the consummation of the Transactions, (b) the grant by any Loan Party of the Liens granted by it pursuant to the Collateral Documents or (c) the perfection or maintenance of the Liens created under the Collateral Documents (including the priority thereof), subject to the Foreign Perfection Requirements and except in each case for (x) filings and actions completed on or prior to the Closing Date and as contemplated hereby and by the Collateral Documents necessary to perfect or maintain the Liens on the Collateral granted by the Loan Parties in favor of the Administrative Agent for the benefit of the Secured Parties (including, without limitation, UCC financing statements, filings in the United States Patent and Trademark Office and the United States Copyright Office and Mortgages (if any)), (y) payment of Cayman Islands stamp duty in the event that any Loan Document is executed in, or brought into, the Cayman Islands and (z) (i) approvals, consents, exemptions, authorizations, actions, notices, filings and (ii) to the extent necessary, clearances, registrations and listings, in each case, which have been duly obtained, taken, given or made and are in full force and effect or which would not reasonably be expected to have a Material Adverse Effect
Section 3.04.Binding Effect. This Agreement has been, and each other Loan Document, when delivered hereunder, will have been, duly executed and delivered by each Loan Party
79



that is party thereto. This Agreement constitutes, and each other Loan Document when so delivered will constitute, a legal, valid and binding obligation of such Loan Party, enforceable against each Loan Party that is party thereto in accordance with its terms, in each case subject to the Foreign Perfection Requirements (solely in the case of any Foreign Loan Party) and except to the extent that the enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights and by equitable principles (regardless of whether enforcement is sought in equity or at law).
Section 3.05.Financial Condition; No Material Adverse Change.
(a)The Historical Annual Financial Statements: (A) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein and (B) fairly present, in all material respects, the financial condition of Parent Guarantor and its Subsidiaries as of the date thereof and the applicable results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein.
(b)The Monthly Financial Statements: (A) were each prepared in accordance with GAAP consistently applied throughout the period covered thereby, subject only to normal year-end audit adjustments and the absence of footnotes, except as otherwise expressly noted therein, and (B) fairly present, in all material respects, the financial condition of Parent Guarantor and its Subsidiaries as of the date hereof and their results of operations for the period covered hereby.
(c)Since December 31, 2023, there has been no event or circumstance, either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect.
Section 3.06.Litigation. There are no actions, suits, proceedings, claims or disputes pending or, to the knowledge of the Parent Guarantor or any Borrower, threatened, at law, in equity, in arbitration or by or before any Governmental Authority, by or against the Parent Guarantor, any Borrower or any Subsidiary or against any of their properties or revenues that are reasonably likely to be adversely determined and, if so determined, would reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.
Section 3.07.No Default. Each of the Parent Guarantor, each Borrower and each Subsidiary is in compliance with all indentures, agreements and other instruments binding upon it or its property, except where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. No Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Agreement or any other Loan Document.
Section 3.08.Ownership of Property; Liens. Each of the Parent Guarantor, each Borrower and each Subsidiary has good record and marketable title in fee simple to, or valid leasehold interests in, all real property necessary or used in the ordinary conduct of its business, including the Mortgaged Property, except for such defects in title that do not materially interfere with its ability to conduct its business as currently conducted or to utilize such assets for their intended purposes and Liens permitted under Section 6.01 and except where the failure to have such title or other interest would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
Section 3.09.Environmental.
(a)Each of the Loan Parties and the Subsidiaries is and has been in compliance with all Environmental Laws and has received and maintained in full force and effect all Environmental Permits required for its current operations, except where non-compliance would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(b)No Environmental Claim is pending or, to the Loan Parties’ knowledge, proposed, threatened or anticipated, with respect to or in connection with any Loan Party or the Subsidiaries or any real properties now or previously owned, leased or operated by any Loan Party or the
80



Subsidiaries except as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(c)To the Loan Parties’ knowledge, there are no Environmental Liabilities of any Subsidiary of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, and there are no facts, conditions, situations or set of circumstances which could reasonably be expected to result in or be the basis for any such Environmental Liability, except, in each case, as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(d)Neither the Parent Guarantor, nor any Borrower nor any Subsidiary has assumed or retained any Environmental Liability of any other Person, except as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
This Section 3.09 contains the sole and exclusive representations and warranties of the Loan Parties with respect to environmental matters.
Section 3.10.Insurance. The properties of the Parent Guarantor, the Borrowers and the Subsidiaries are insured with financially sound and reputable insurance companies that are not Affiliates of any Borrower, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where the Parent Guarantor, the applicable Borrower or the applicable Subsidiary operates.
Section 3.11.Taxes.
(a)The Parent Guarantor, the Borrowers and the Subsidiaries have filed all Federal, state and other material tax returns and reports required to be filed, and have paid all Federal, state and other material taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income, business, franchise or assets otherwise due and payable, except (x) those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP or (y) to the extent that failure to do so would not reasonably be expected to result in a Material Adverse Effect.
(b)As at the date of this Agreement, and by reference only to the facts pertaining to its first signature, each Borrower is not required to make any deduction for or on account of United Kingdom tax from any payment it may make under any Loan Document to a Lender.
Section 3.12.[Reserved].
(a)
Section 3.13.[Reserved].
Section 3.14.ERISA Compliance; Labor Matters.
(a)No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events for which liability is reasonably expected to occur, would reasonably be expected to result in a Material Adverse Effect. The present value of all accumulated benefit obligations under each Pension Plan (based on the assumptions used for purposes of FASB Accounting Standards Codification 715 or subsequent recodification thereof, as applicable) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair market value of the assets of such Pension Plan, and the present value of all accumulated benefit obligations of all underfunded Pension Plans (based on the assumptions used for purposes of FASB Accounting Standards Codification 715 or subsequent recodification thereof, as applicable) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair market value of the assets of all such underfunded Pension Plans, except to the extent that such excess would not reasonably be expected to have a Material Adverse Effect.
81



(b)There are no strikes, or other labor disputes pending or threatened against the Parent Guarantor, any Borrower or any Subsidiary, the hours worked and payments made to employees of the Parent Guarantor, the Borrowers and the Subsidiaries have not been in material violation of the Fair Labor Standards Act or any other applicable law dealing with such matters and all payments due from the Parent Guarantor, any Borrower or any Subsidiary or for which any claim may be made against the Parent Guarantor, any Borrower or any Subsidiary, on account of wages and employee health and welfare insurance and other benefits have been paid or accrued as a liability on the books of the Parent Guarantor, such Borrower or such Subsidiary to the extent required by GAAP. Except as would not reasonably be expected to result in a Material Adverse Effect, the consummation of the Transactions will not give rise to a right of termination or right of renegotiation on the part of any union under any material collective bargaining agreement to which the Parent Guarantor, any Borrower or any Subsidiary (or any predecessor) is a party or by which the Parent Guarantor, any Borrower or any Subsidiary (or any predecessor) is bound.
Section 3.15.Subsidiaries; Equity Interests. As of the Closing Date, (x) the Parent Guarantor has no Subsidiaries other than those specifically disclosed in Part (a) of Schedule 3.15, and (y) all of the outstanding Equity Interests in such Subsidiaries have been validly issued, are fully paid and nonassessable and are owned by the Parent Guarantor or the Subsidiaries in the amounts specified on Part (a) of Schedule 3.15 free and clear of all Liens except those created under the Collateral Documents and Permitted Prior Liens. As of the Closing Date, (x) the Parent Guarantor has no equity investments in an individual amount in excess of $500,000 (valued at the time of such initial investment) in any other Person other than (i) those specifically disclosed in Part (b) of Schedule 3.15 and (ii) investments in Subsidiaries and (y) with respect to any English Loan Party whose shares are subject to Liens under the relevant Loan Documents, its shares are fully paid and not subject to any option to purchase or similar rights that prejudice such Liens and its constitutional documents do not restrict or inhibit any transfer of those shares on creation or enforcement of such Liens in a manner which is materially adverse to the interests of the Lenders (other than to the extent such restrictions or inhibitions are required by applicable law). There are no agreements in force which provide for the issue or allotment of, or grant any person the right to call for the issue or allotment of, any share or loan capital of any English Loan Party (including any option or right of pre-emption or conversion) other than as required under applicable law or as permitted by this Agreement.
Section 3.16.Margin Regulations; Investment Company Act.
(a)No Borrower is engaged, principally or as one of its important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the Federal Reserve Board), nor extending credit for the purpose of purchasing or carrying margin stock and no proceeds of any Borrowings will be used for any purpose that violates Regulation U issued by the Federal Reserve Board.
(b)None of any Borrower, the Parent Guarantor, any Person Controlling the Parent Guarantor, any Borrower or any Subsidiary is or is required to be registered as an “investment company” under the Investment Company Act of 1940.
Section 3.17.Disclosure. No report, financial statement, certificate or other written information (other than projected financial information and information of a general economic or industry nature) furnished in writing by or on behalf of any Loan Party to the Administrative Agent or any Lender in connection with the Transactions or delivered hereunder or under any other Loan Document (in each case, taken as a whole and as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein (when taken as a whole), in the light of the circumstances under which they were made, not materially misleading; provided that, with respect to projected financial information, each Borrower represents only that such information was prepared in good faith based upon assumptions believed by it to be reasonable at the time made and at the time delivered to the Administrative Agent or any Lender, it being recognized by the Administrative Agent and the Lenders that such financial information as it relates to future events is not to be viewed as fact and that actual results during the period or periods covered by such financial information may vary from the projected results set forth therein and that such variations may be material.
82



As of the Closing Date, as applicable, all of the information included in the Beneficial Ownership Certification is true and correct in all material respects.
Section 3.18.Compliance with Laws. Except as set forth on Schedule 3.18, each Loan Party and each Subsidiary thereof is in compliance in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its properties (including the Patriot Act), except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
Section 3.19.Use of Proceeds. The proceeds of the Loans have been (and will be) used in accordance with Section 5.10 and Section 6.10.
Section 3.20.Intellectual Property; Licenses. The Parent Guarantor, the Borrowers and the Subsidiaries own or possess the right to use all of the trademarks, service marks, trade names, trade dress, logos, domain names and all good will associated therewith, copyrights, patents, patent rights, trade secrets, know-how, franchises, licenses, and other intellectual property rights (collectively, “IP Rights”) that are reasonably necessary for the operation of their respective businesses as currently conducted, without conflict with the rights of any other Person, except where the failure to own or possess the right to use any such IP Rights would not reasonably be expected to have a Material Adverse Effect. Except as would not reasonably be expected to have a Material Adverse Effect, the Parent Guarantor, the Borrowers and the Subsidiaries hold all right, title and interest in and to such IP Rights free and clear of any Lien (other than Liens permitted by Section 6.01). No slogan or other advertising device, product, process, method, substance, part or other material or activity now employed by the Parent Guarantor, any Borrower or any Subsidiary infringes upon, misappropriates or otherwise violates any rights held by any other Person, except where such infringement, misappropriation or other violation would not reasonably be expected to have a Material Adverse Effect.
Section 3.21.Solvency. As of the Closing Date, immediately after giving effect to the consummation of the Transactions to be consummated on such date, the Parent Guarantor, the Borrowers and the Subsidiaries are, on a consolidated basis, Solvent.
Section 3.22.Collateral Documents. Subject to the Foreign Perfection Requirements (solely in the case of any Foreign Loan Party) and except to the extent that the enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights and by equitable principles (regardless of whether enforcement is sought in equity or at law), the provisions of the applicable Collateral Documents will, upon execution and delivery thereof, be effective to create in favor of the Administrative Agent, for the benefit of the Secured Parties, a legal, valid and enforceable first priority Lien (subject, in the case of any Collateral other than Collateral consisting of Equity Interests, to Permitted Liens and, in the case of Collateral consisting of Equity Interests, to non-consensual Liens permitted by Section 6.01 (collectively, such Liens, “Permitted Prior Liens”)) on all right, title and interest of the respective Loan Parties in the Collateral described therein and proceeds thereof.
Section 3.23.Senior Debt. The Obligations constitute “Senior Indebtedness” (or any comparable term) or “Senior Secured Financing” (or any comparable term) under, and as defined in, the documentation governing, any Indebtedness that is subordinated to the Obligations expressly by its terms.
Section 3.24.Anti-Terrorism; Anti-Money Laundering; Etc.
(a)The Parent Guarantor and the Borrowers have implemented and maintain in effect policies and procedures reasonably designed to ensure compliance in all material respects by the Parent Guarantor, the Borrowers, the Subsidiaries and their respective directors, officers, and employees with Anti-Corruption Laws and applicable Sanctions, and the Parent Guarantor, the Borrowers, the Subsidiaries and, to each of the Parent Guarantor’s and each Borrower’s knowledge, its and the Subsidiaries’ respective officers and directors, are in compliance with Anti-Corruption Laws and Anti-Money Laundering Laws in all material respects and applicable Sanctions in all material respects and are
83



not knowingly engaged in any activity that would reasonably be expected to result in any Borrower being designated as a Sanctioned Person.
(b)No Loan Party nor any of the Subsidiaries or, to their knowledge, any of their Related Parties (i) is an “enemy” or an “ally of the enemy” within the meaning of Section 2 of the Trading with the Enemy Act of the United States (50 U.S.C. App. §§ 1 et seq.), (ii) is in violation of (A) the Trading with the Enemy Act, (B) any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V) or any enabling legislation or executive order relating thereto, or (C) the UK Anti-Money Laundering and Anti-Terrorism Legislation and any other applicable laws relating to terrorism financing or money laundering of jurisdictions where each Borrower and each Subsidiary is formed or organized or conducts business (collectively, the “Anti-Money Laundering Laws”), in each case in any material respect or (iii) is a Sanctioned Person.
(c)No part of the proceeds of any Loan will be unlawfully used directly or, to the knowledge of the Parent Guarantor or any Borrower, indirectly to fund any operations in, finance any investments or activities in or make any payments to, a Sanctioned Person or a Sanctioned Country, or in any other manner that will result in any violation by any Person that is a party to this Agreement (including any Lender or Arranger or the Administrative Agent) of any applicable Anti-Money Laundering Laws, Sanctions or Hemp Laws.
Section 3.25.Anti-Corruption Laws. No part of the proceeds of the Loans will be used, directly or, to the knowledge of the Parent Guarantor or any Borrower, indirectly, for any payments to any governmental official, governmental employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity on behalf of a Governmental Authority, in order to obtain, retain or direct business or obtain any improper advantage, in violation of Anti-Corruption Laws.
Section 3.26.Affected Financial Institution. No Loan Party is an Affected Financial Institution.
Section 3.27.[Reserved].
Section 3.28.Permits, Etc. Except as set forth on Schedule 3.28, each Loan Party and each Subsidiary has, and is in compliance with, all permits, licenses, authorizations, approvals, entitlements and accreditations, including Environmental Permits and Health Care Permits, required for such Person lawfully to own, lease, manage or operate, or to acquire, each business and property currently owned, leased, managed or operated, or to be acquired, by such Person, except to the extent that failure to have or be in compliance therewith would not reasonably be expected to have a Material Adverse Effect. No condition exists or event has occurred which, in itself or with the giving of notice or lapse of time or both, would result in the suspension, revocation, cancellation, material impairment, forfeiture or non-renewal of any such permit, license, authorization, approval, entitlement or accreditation, including any such Environmental Permit or Health Care Permit, and, to the knowledge of the Loan Party, there is no claim that any of the foregoing is not in full force and effect.
Section 3.29.Health Care.
(a)    Except as set forth on Schedule 3.29, (i) each of the Loan Parties and the Subsidiaries is in compliance with all Health Care Laws and (ii) there are no pending or, to the knowledge of the Parent Guarantor or any Borrower, threatened Health Care Claims against, or Health Care Liability of, any Loan Party or Subsidiary or, to the knowledge of the Parent Guarantor or any Borrower, any respective predecessor in interest, except, in each case with respect to (i) and (ii), where such non-compliance with a Health Care Law or such Health Care Claim, as the case may be, would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Loan Parties have made available to the Administrative Agent and the Lenders true and complete copies of documents pertaining to all material inspections, investigations, enforcement actions or similar material actions by a
84



Governmental Authority related to Health Care Laws in the possession or control of any Loan Party or any Subsidiary with respect to the operations and business of the Loan Parties and the Subsidiaries.
    (b)    Except as set forth on Schedule 3.29, each of the Loan Parties and the Subsidiaries is in material compliance with all Hemp Laws. There are no pending or, to the knowledge of the Parent Guarantor or any Borrower, threatened material Hemp Claims against any Loan Party or Subsidiary or, to the knowledge of the Parent Guarantor or any Borrower, any respective predecessor in interest. The Loan Parties have made available to the Administrative Agent and the Lenders true and complete copies of documents pertaining to all material inspections, investigations, enforcement actions or similar material actions by a Governmental Authority related to Hemp Laws in the possession or control of any Loan Party or any Subsidiary as of the Closing Date with respect to the operations and business of the Loan Parties and the Subsidiaries.

Article IV

Conditions
Section 4.01.Closing Date. The obligations of the Lenders to make Loans shall not become effective until the date on which each of the following conditions is satisfied (or waived in accordance with Section 9.02):
(a)Since December 31, 2023, there shall not have occurred a Material Adverse Effect that is continuing.
(b)The Administrative Agent shall have received, in form and substance reasonably satisfactory to the Administrative Agent:
(i)from each party hereto a counterpart of this Agreement signed on behalf of such party (which, subject to Section 9.06, may include any Electronic Signatures transmitted by telecopy, emailed pdf, or any other electronic means that reproduces an image of an actual executed signature page);
(ii)the Collateral Documents and the Guarantee Agreement, duly executed by each party thereto, together with:
(A)subject to the terms of the Collateral Agreements, the certificates (if any) representing the shares, membership interests, shares of capital stock or other Equity Interests (in each case, to the extent certificated) required to be pledged by any Loan Party (including the Parent Guarantor and each Borrower) pursuant to the Collateral Agreements, together with an undated transfer form or stock power for each such certificate executed in blank by a duly authorized officer of the pledgor thereof,
(B)each promissory note (if any) required to be pledged by any Loan Party (including the Parent Guarantor and each Borrower) pursuant to the Collateral Agreements, endorsed in blank (or accompanied by an executed transfer form in blank) by the pledgor thereof,
(C)one or more intellectual property security agreements, duly executed and delivered by each Loan Party required to be party thereto pursuant to the Collateral Agreements,
(D)UCC-1 financing statements with respect to each Loan Party, in proper form for filing with the applicable Governmental Authority, and
85



(iii)other than in respect of the English Loan Parties, a certificate of each Loan Party as of the Closing Date, dated as of the Closing Date and executed by a secretary, assistant secretary or other Responsible Officer thereof, which shall:
(A)certify that:
(1)attached thereto is a true and complete copy of the certificate or articles of incorporation, formation, registration or organization (including all amendments thereto) of such Loan Party (and in relation to any Jersey Loan Party, a copy of all consents to issue shares issued to it under the Control of Borrowing (Jersey) Order 1958 and all other Jersey regulatory approvals, authorizations, consents, licenses, permits or registrations issued to it (if any)) that is, where customary or available in the applicable jurisdiction, certified as of a recent date by the relevant authority of its jurisdiction of incorporation, association, organization, formation or registration,
(2)such certificate or articles of incorporation, formation or organization of such Loan Party attached thereto have not been amended (except as attached thereto) since the date reflected thereon and are in full force and effect,
(3)attached thereto is a true and correct copy of the by-laws or operating, management, partnership or similar agreement of such Loan Party, together with all amendments thereto as of the Closing Date and such by-laws or operating, management, partnership or similar agreements are or is in full force and effect and
(4)attached thereto is a true and complete copy of the resolutions or written consent, as applicable, of its board of directors, board of managers, sole member, general partner, shareholders or other applicable governing body authorizing the execution, delivery and performance of the Loan Documents, which resolutions or consent have not been modified, rescinded or amended (other than as attached thereto) and are in full force and effect, and
(B)identify by name and title and bear the signatures of the officers, managers, directors or authorized signatories of such Loan Party authorized to sign the Loan Documents to which such Loan Party is a party on the Closing Date
(iv)other than in respect of the English Loan Parties, a good standing (or equivalent) certificate as of a recent date for such Loan Party from the relevant authority of its jurisdiction of incorporation, association, organization, formation or registration (to the extent applicable); and
(v)an intercompany note signed by Parent Guarantor and each of its Subsidiaries and an allonge to the intercompany note signed by each Loan Party.
(c)The Administrative Agent shall have received a written opinion (addressed to the Administrative Agent and the Lenders and dated the Closing Date) of (i) Skadden, Arps, Slate, Meagher & Flom LLP, United States counsel to the Loan Parties, (ii) Stuarts Humphries, Cayman Islands counsel to the Lenders, (iii) Walkers (Jersey) LLP, Jersey counsel to the Administrative Agent and the Lenders, and (iv) Proskauer Rose LLP, UK counsel to the Administrative Agent and the Lenders, each in form and substance reasonably satisfactory to the Administrative Agent. The Borrowers hereby request each such counsel to deliver such opinions.
(d)The Administrative Agent shall have received a Solvency Certificate, dated the Closing Date and signed by a Financial Officer of the Parent Guarantor.
86



(e)The Administrative Agent shall have received a Borrowing Request as required by Section 2.03.
(f)(i) The representations and warranties contained in Article III shall be true and correct in all material respects (provided that, any representation and warranty that is qualified by Material Adverse Effect or other materiality qualifier shall be true and correct in all respects) as of such date except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (or, in the case of any representation or warranty qualified by Material Adverse Effect or other materiality qualifier, in all respects) as of such earlier date and (ii) no Default or Event of Default shall have occurred and be continuing as of such date.
(g)The Administrative Agent shall have received a certificate, dated the Closing Date and signed by a Responsible Officer of the Administrative Borrower, certifying as to the conditions set forth in clauses 4.01(a), (f) and (o).
(h)The Administrative Agent shall have received information necessary to perform customary UCC lien searches with respect to the Loan Parties prior to the Closing Date.
(i)The Administrative Agent shall have received (i) the Historical Annual Financial Statements, (ii) the Monthly Financial Statements (including, for the avoidance of doubt, for the calendar month ending on January 31, 2025) and (iii) a report of key performance indicators (consistent with those key performance indicators required by Section 5.01(b)) for the period commencing January 1, 2025 through February 28, 2025, setting forth on a weekly basis in comparative form to the budget for such period, in form and substance reasonably acceptable to the Administrative Agent. The Administrative Agent acknowledges receipt of the items required by this clause (i).
(j)The Existing Credit Agreement Refinancing shall have occurred or will occur on the Closing Date.
(k)(i) The Administrative Agent shall have received, at least three (3) Business Days prior to the Closing Date, all documentation and other information regarding the Guarantors requested in connection with applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act, to the extent requested in writing at least ten (10) Business Days prior to the Closing Date and (ii) to the extent any Guarantor qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, at least three (3) Business Days prior to the Closing Date, any Lender that has requested, in a written notice to the Administrative Borrower at least three (3) Business Days prior to the Closing Date, a Beneficial Ownership Certification in relation to such Guarantor shall have received such Beneficial Ownership Certification (provided that, upon the execution and delivery by such Lender of its signature page to this Agreement, the condition set forth in this clause (k) shall be deemed to be satisfied).
(l)The Administrative Agent shall have received all fees and other amounts due and payable on or prior to the Closing Date, including, to the extent invoiced at least two (2) Business Days prior to the Closing Date, reimbursement or payment of all reasonable and documented out-of-pocket expenses required to be reimbursed or paid by any Loan Party under any Loan Document.
(m)To the extent requested at least three (3) Business Days prior to the Closing Date, a Note executed by the Borrowers in favor of each Lender which has requested a Note pursuant to Section 2.10(e) shall have been received by each such Lender.
(n)[Reserved].
(o)There shall exist no claim, action, suit, investigation, litigation or proceeding (including, without limitation, shareholder or derivative litigation) pending or threatened in any court or before any arbitrator or Governmental Authority which relates to the Loans or which, in the opinion of the Administrative Agent, is reasonably likely to be adversely determined, and that, if adversely determined, would reasonably be expected to have a Material Adverse Effect.
87



(p)[Reserved].
(q)The Administrative Agent shall have received:
(i)duly completed grantor consent forms signed by the relevant grantor and any individual named therein as the contact for service for the applicable grantor consenting to the inclusion of their name and contact details in a financing statement on the SIR against the relevant grantor in respect of the security interest to be created pursuant to each Jersey Collateral Agreement,
(ii)a search on the SIR made against each grantor on the Closing Date showing that no financing statement have been registered against it (other than in favor of the Administrative Agent),
(iii) a verification statement issued by the Registrar of the SIR indicating that a financing statement has been successfully registered in respect of each grantor under each Jersey Collateral Agreement,
(iv) a copy of each duly executed notice and acknowledgement required to be given in connection with each Jersey Collateral Agreement,
(v)in relation to Waldencast Partners LP, a Jersey process agent letter in respect of the Jersey Waldencast Partners LP Security Interest Agreement,
(vi)in relation to Obagi Cosmeceuticals LLC, a Jersey process agent letter in respect of the Jersey Obagi Cosmeceuticals LLC Security Interest Agreement; and
(vii)in relation to Obagi Holdco 1 Limited, a copy of a special resolution amending its articles of association to permit the taking and enforcement of security without, inter alia, a right for directors to refuse, in their discretion, to register a transfer of shares and an extract of its register of members including an annotation identifying the shares over which security has been granted, duly authorized by an authorized signatory of that company as at the date of the relevant Jersey Collateral Agreement.
(r)In relation to each English Loan Party, the Administrative Agent shall have received:

(i)a copy of the memorandum of association, articles of association, certificate of incorporation and certificate of change of name (if applicable) of each English Loan Party;
(ii)a copy of a resolution of the board or, if applicable, a committee of the board of directors of each English Loan Party:
(A)approving the terms of, and the transactions contemplated by, the Loan Documents to which it is a party and resolving that it execute, deliver and perform the Loan Documents to which it is a party;
(B)authorising a specified person or persons to execute the Loan Documents to which it is a party on its behalf; and
(C)authorising a specified person or persons, on its behalf, to sign and/or despatch all documents and notices to be signed and/or despatched by it under or in connection with the Loan Documents to which it is a party;
(iii)a specimen of the signature of each person authorised by the resolution referred to in paragraph (b) above in relation to the Loan Documents and related documents;
88



(iv)a copy of a resolution signed by all the holders of the issued shares in each English Loan Party, approving the terms of, and the transactions contemplated by, the Loan Documents to which the English Loan Party is a party;
(v)a certificate of each English Loan Party (signed by a director) confirming that:
(A)borrowing or guaranteeing or securing, as appropriate, the Commitments would not cause any borrowing, guarantee, security or similar limit binding on that English Loan Party to be exceeded; and
(B)each copy document relating to it specified in this section 4.01 is correct, complete and in full force and effect and has not been amended or superseded as at a date no earlier than the date of this Agreement; and
(vi)agreed form of all notices required to be sent under the English Collateral Agreements executed by the relevant English Loan Party subject to English Collateral Agreements.
(vii)Without limiting the generality of the provisions in Section 9.04, for purposes of determining compliance with the conditions specified in this Section 4.01, each Lender that has signed this Agreement (and each such Lender’s Affiliates, successors and/or assigns) shall conclusively be deemed to (i) have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.
Section 4.02.Each Borrowing. After the Closing Date, the obligation of each Lender to make a Loan on the occasion of any Borrowing is subject to the satisfaction of the following conditions:
(a)The representations and warranties of the Parent Guarantor and the Borrowers set forth in this Agreement shall be true and correct in all material respects (provided that, any representation and warranty that is qualified by Material Adverse Effect or other materiality qualifier shall be true and correct in all respects) on and as of the date of such Borrowing except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (provided that, any representation and warranty that is qualified by Material Adverse Effect or other materiality qualifier shall be true and correct in all respects) as of such earlier date.
(b)At the time of and immediately after giving effect to such Borrowing, no Default or Event of Default shall have occurred and be continuing.
Each Borrowing shall be deemed to constitute a representation and warranty by the Borrowers on the date thereof as to the matters specified in paragraphs (a) and (b) of this Section.
Article V

Affirmative Covenants
From and after the Closing Date, so long as any Lender shall have any Commitment hereunder, any Loan or other Obligation (other than contingent indemnification obligations as to which no claim has been asserted) hereunder shall remain unpaid or unsatisfied, the Parent Guarantor and each Borrower shall, and shall (except in the case of the covenants set forth in Sections 5.01, 5.02, 5.03 and 5.13) cause each Subsidiary to:
89



Section 5.01.Financial Statements. Deliver to the Administrative Agent for prompt distribution to each Lender:
(a)within one hundred twenty (120) days after the end of each Fiscal Year (commencing with the Fiscal Year ending December 31, 2024), (i) a consolidated balance sheet of the Parent Guarantor, the Borrowers and the Subsidiaries as at the end of such Fiscal Year, and the related consolidated statement of income or operations, changes in equity holders’ equity, and cash flows for such Fiscal Year, setting forth in each case in comparative form the figures for the previous Fiscal Year and the annual budget for such Fiscal Year, all in reasonable detail and prepared in accordance with GAAP, audited and accompanied by a report and opinion of an independent certified public accountant of nationally recognized standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception or explanatory paragraph (other than a “going concern” qualification or exception or explanatory paragraph resulting solely from an upcoming maturity date under any Indebtedness occurring within one year from the time such opinion is delivered or any actual or anticipated breach of the financial covenants set forth in Section 6.11) or any qualification or exception or explanatory paragraph as to the scope of such audit and (ii) unaudited consolidating balance sheets of the Parent Guarantor, the Borrowers and the Subsidiaries as at the end of such Fiscal Year, and the related unaudited consolidating statements of income or operations, changes in equity holders’ equity, and cash flows for such Fiscal Year, all in reasonable detail, certified by a Responsible Officer of the Administrative Borrower as fairly presenting, in all material respects, the financial condition, results of operations, equity holders’ equity and cash flows of the Parent Guarantor, the Borrowers and the Subsidiaries in accordance with GAAP, subject only to the absence of footnotes;
(b)(x) in connection with each of the fiscal quarters of each Fiscal Year (commencing with the fiscal quarter ending March 31, 2025), within forty-five (45) days after the end of each such fiscal quarter, (i) unaudited consolidated and consolidating balance sheets of the Parent Guarantor, the Borrowers and the Subsidiaries as at the end of such fiscal quarter, the related unaudited consolidated and consolidating statements of income or operations for such fiscal quarter and for the portion of the Fiscal Year then ended, and the related consolidated and consolidating statements of changes in equity holders’ equity, and cash flows for the portion of the Fiscal Year then ended, setting forth in each case in comparative form, as applicable, the figures for the corresponding fiscal quarter of the previous Fiscal Year and the corresponding portion of the previous Fiscal Year and the annual budget for such periods, all in reasonable detail, certified by a Responsible Officer of the Administrative Borrower as fairly presenting, in all material respects, the financial condition, results of operations, equity holders’ equity and cash flows of the Parent Guarantor, the Borrowers and the Subsidiaries in accordance with GAAP, subject only to normal year-end audit adjustments and the absence of footnotes and (ii) a key performance indicator reporting package for such fiscal quarter covering (1) TTM EBITDA build from Reported to Adjusted, (2) Obagi net accounts for DTP, (3) Milk Sell-In & Sell Out Analysis (for Sephora and Ulta), (4) Milk EOM Recap file that has productivity and rankings (for Sephora and Ulta), (5) AP Aging, (6) AR Aging and (7) Inventory Aging, (8) Sephora/Milk OTB Reporting (Inventory DOH included) and (9) Kline and similar industry reports, in each case (I) in a form consistent with the files delivered to the Administrative Agent prior to the Closing Date and (II) and solely if provided by an unaffiliated third party, to the extent available to the Parent Guarantor or any Borrower;
(c)not later than forty-five (45) days after the end of each Fiscal Year (commencing with the Fiscal Year ending December 31, 2025), an annual budget of the Parent Guarantor, the Borrowers and the Subsidiaries on a consolidated basis (but prepared on a segment level basis with channel level detail) consisting of consolidated balance sheets and statements of income or operations and cash flows of the Parent Guarantor, the Borrowers and the Subsidiaries on a quarterly basis for the then-current Fiscal Year, in each case, including the segment level and channel level detail (including the Fiscal Year in which the Latest Maturity Date occurs, if such Fiscal Year is the then-current Fiscal Year); and
(d)within forty-five (45) days after the end of each calendar month (commencing with the calendar month ending March 31, 2025), or within thirty (30) days after the end of each calendar month ending on and following July 31, 2025, of the Parent Guarantor, unaudited balance sheets of the Parent Guarantor, the Borrowers and the Subsidiaries as at the end of such calendar month and the related
90



unaudited statements of income or operations for such calendar month and for the portion of the Fiscal Year then ended, and the related statements of changes in equity holders’ equity, and cash flows for the portion of the Fiscal Year then ended, in a form consistent with “7.4.8 January 2025 Reporting Package – Group” delivered to the Administrative Agent prior to the Closing Date and certified by a Responsible Officer the Administrative Borrower as fairly presenting, in all material respects, the financial condition, results of operations, equity holders’ equity and cash flows of the Parent Guarantor, the Borrowers and the Subsidiaries in accordance with GAAP, subject only to normal year-end audit adjustments and the absence of footnotes.
Section 5.02.Certificates; Other Information. Deliver to the Administrative Agent for prompt distribution to each Lender:
(a)(i) concurrently with the delivery of the financial statements referred to in Sections 5.01(a) and (b), a duly completed Compliance Certificate signed by a Responsible Officer of the Administrative Borrower in connection with the testing of the financial covenants set forth in Section 6.11(a) and 6.11(b) (which shall include a calculation of Excess Cash Flow in connection with each delivery of the financial statements referred to in Sections 5.01(a)) and (ii) on the last day of each calendar month (commencing with the calendar month ending March 31, 2025) in connection with the testing of the covenant set forth in Section 6.11(c), a certificate signed by a Responsible Officer of the Administrative Borrower certifying that (1) at no point during such reporting period was the Minimum Liquidity Covenant breached and (2) the Liquidity as of the end of the last day of such month;
(b)promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the equity holders of any Borrower or the Parent Guarantor, and copies of all annual, regular, periodic and special reports and registration statements which any Borrower or the Parent Guarantor may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, whether or not otherwise required to be delivered to the Administrative Agent pursuant hereto; provided that, to the extent any such documents are filed with the SEC, such documents shall be deemed delivered pursuant to this Section 5.02(b) at the time of and so long as the Administrative Borrower notifies the Administrative Agent in writing (by facsimile or electronic mail) of the filing with the SEC of any such documents;
(c)promptly following any request therefor, information regarding the business, financial or corporate affairs of the Parent Guarantor, any Borrower or any Subsidiary, or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender may reasonably request;
(d)concurrently with the delivery of the financial statements referred to in Sections 5.01(a) and (b), a customary summary management discussion and analysis report, describing the material operations and financial conditions of the Parent Guarantor (or any direct or indirect parent thereof), the Borrowers and the Subsidiaries for the fiscal quarter and portion of the fiscal year then ended (or for the fiscal year then ended in the case of financial statements delivered pursuant to Section 5.01(a));
(e)concurrently with the delivery of the financial statements referred to in Sections 5.01(a) and (b), all material documents and material written information furnished to such Governmental Authority in connection with any investigation of any Loan Party other than routine inquiries by such Governmental Authority;
(f)concurrently with the delivery of the financial statements referred to in Sections 5.01(a) and (b), copies of all final financial reports (including, without limitation, management letters), if any, submitted to any Loan Party by its auditors in connection with any annual or interim audit of the books thereof; and
(g)promptly after a Responsible Officer of the Parent Guarantor or any Borrower or Subsidiary has obtained actual knowledge of the occurrence of a material development or change in circumstance in the Clean Team Agreement Related Matters, information related to such development or change and copies of any related documents, including subpoenas, notices, administrative orders, settlement offers, demand letters, notices of suit or proceeding, complaints or pleadings;
91



provided that, in the case of clauses (c), (d), (e), (f) and (g) above, (1) the Parent Guarantor, the Borrowers and the Subsidiaries shall not be required to provide any information that is subject to attorney-client or similar privilege or constitutes attorney work product; provided, in each case, that the Administrative Borrower shall have notified the Administrative Agent or the applicable Lender that such document, information or other matter is being withheld on the basis of the foregoing and (2) to the extent any such information can not be provided in written form but can be discussed on a call, the Parent Guarantor, the Borrowers and the Subsidiaries (as applicable) shall provide such information to the Administrative Agent and the Lenders on a call or during a meeting held pursuant to Section 5.13.
Documents required to be delivered pursuant to Sections 5.01(a), (b), (d) or (e) or Sections 5.02(b) or (d) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (1) on which the Parent Guarantor or any Borrower posts such documents, or provides a link thereto at www.waldencast.com or any successor website identified in writing by Parent Guarantor or the Administrative Borrower to the Administrative Agent from time to time, (2) on which such documents are posted on the Borrowers’ behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent) or (3) on which such documents are filed for public availability on the SEC’s Electronic Data Gathering and Retrieval System.
Each of the Parent Guarantor and each Borrower hereby acknowledges that (a) the Administrative Agent and/or the Arranger will make available to the Lenders materials and/or information provided by or on behalf of any Borrower hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks, SyndTrak or another similar electronic system (the “Platform”) and (b) certain of the Lenders (each, a “Public Lender”) may have personnel who do not wish to receive material non-public information within the meaning of United States federal securities laws (“MNPI”) with respect to the Parent Guarantor, the Borrowers or the Subsidiaries, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons’ securities. Each of the Parent Guarantor and each Borrower hereby agrees that (w) all Borrower Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof; (x) by marking Borrower Materials “PUBLIC,” the Borrowers shall be deemed to have authorized the Administrative Agent, the Arranger and the Lenders to treat such Borrower Materials as not containing any MNPI with respect to the Parent Guarantor, the Borrowers or the Subsidiaries, or their respective securities (provided that, to the extent such Borrower Materials constitute Information, they shall be treated as set forth in Section 9.12); (y) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Side Information” (and the Administrative Agent agrees that only Borrower Materials marked “PUBLIC” will be made available on such portion of the Platform); and (z) the Administrative Agent and the Arranger shall be entitled to treat any Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform that is not designated “Public Side Information.” Notwithstanding the foregoing, the Borrowers shall be under no obligation to mark any Borrower Materials “PUBLIC.”
Section 5.03.Notices of Material Events. Promptly notify the Administrative Agent (for distribution to each Lender) after a Responsible Officer of the Parent Guarantor or any Borrower has obtained actual knowledge of the occurrence of:
(a)any Default or Event of Default;
(b)any ERISA Event that, alone or together with any other ERISA Events that have occurred, would reasonably be expected to result in a Material Adverse Effect;
92



(c)any suit or proceeding before any court or other Governmental Authority or other regulatory body or any arbitrator (or any development in any such suit or proceeding) which could reasonably be expected to have a Material Adverse Effect; or
(d)any other matter that has resulted, or would reasonably be expected to result in, a Material Adverse Effect.
Each notice pursuant to this Section 5.03 shall be accompanied by a statement of a Responsible Officer of the Administrative Borrower setting forth reasonable details of the occurrence referred to therein and stating what action the Borrowers have (or any Borrower has) taken and proposes to take with respect thereto.
Section 5.04.Preservation of Existence, Etc. (a) Preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its incorporation, association, organization, formation or registration except, solely in the case of a Subsidiary other than any Borrower, to the extent that failure to do so would not reasonably be expected to result in a Material Adverse Effect; provided that, the foregoing shall not prohibit any a transaction permitted by Section 6.04; (b) take all action to maintain all rights, privileges, permits, and licenses reasonably necessary in the normal conduct of its business, except to the extent that failure to do so would not reasonably be expected to have a Material Adverse Effect; (c) except as otherwise determined in the Administrative Borrower’s reasonable business judgment, preserve, maintain, renew and keep in full force and effect all of its registered patents, trademarks, trade names, trade dress and service marks, the failure of which to so preserve, maintain, renew or keep in full force and effect would reasonably be expected to have a Material Adverse Effect; and (d) pay and discharge as the same shall become due and payable all Federal, state and other material tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, except to the extent (i) the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Parent Guarantor, such Borrower or such Subsidiary or (ii) failure to do so could not reasonably be expected to result in a Material Adverse Effect.
Section 5.05.Maintenance of Properties. Maintain, preserve and protect all of its properties and equipment necessary in the operation of its business in good working order and condition, ordinary wear and tear excepted, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect.
Section 5.06.Maintenance of Insurance.
(a)Maintain with insurance companies that each Borrower believes (in the good faith judgment of its management) are financially sound and reputable (that are not Affiliates of any Borrower) insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts (after giving effect to any self-insurance reasonable and customary for similarly situated persons engaged in the same or similar businesses as the Parent Guarantor, the Borrowers and the Subsidiaries) as are customarily carried under similar circumstances by such other Persons, and within 45 days after the Closing Date (or such later date as the Administrative Agent may agree in its sole discretion), providing for not less than thirty (30) days’ prior notice (or ten (10) days in the case of non-payment) to the Administrative Agent of termination, lapse or cancellation of such insurance, which insurance (except as to Excluded Subsidiaries) within 45 days after the Closing Date (or such later date as the Administrative Agent may agree in its sole discretion), shall name the Administrative Agent as lender loss payee (in the case of casualty insurance) or additional insured (in the case of liability insurance); provided, however, if any insurance proceeds are paid on the account of a casualty to assets or properties of any Loan Party that do not constitute Collateral and at such time no Event of Default shall have occurred and is continuing, then the Administrative Agent shall take such actions, including endorsement, to cause any such insurance proceeds to be promptly remitted to the Administrative Borrower to be used by any Borrower or such Loan Party in any manner not prohibited by this Agreement.
93



(b)Notwithstanding anything herein to the contrary, with respect to each Mortgaged Property (if any), if at any time the area in which the buildings and other improvements (as described in the applicable Mortgage) is designated a “flood hazard area” in any Flood Insurance Rate Map published by the Federal Emergency Management Agency (or any successor agency), obtain flood insurance in such total amount as the Administrative Agent may from time to time reasonably require, and otherwise to ensure compliance with the NFIP as set forth in the Flood Laws. Following the Closing Date, the Administrative Borrower shall deliver to the Administrative Agent annual renewals of each earthquake insurance policy, each flood insurance policy or annual renewals of each force-placed flood insurance policy, as applicable. In connection with any MIRE Event, the Administrative Borrower shall provide to the Administrative Agent not later than thirty (30) days prior to the closing of such MIRE Event (and authorize the Administrative Agent to provide to the Lenders) for each Mortgaged Property (if any) a Flood Determination Form, Borrower Notice and Evidence of Flood Insurance, as applicable.
Section 5.07.Compliance with Laws.
(a)Except as set forth on Schedule 5.07, comply with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which (i) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted; or (ii) the failure to comply therewith would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Maintain in effect and enforce policies and procedures reasonably designed to ensure compliance in all material respects by the Parent Guarantor, the Borrowers and the Subsidiaries and their respective directors, officers, and employees with Anti-Corruption Laws and applicable Sanctions.
(b)Maintain, and cause each of its Subsidiaries to maintain, policies and procedures reasonably designed to promote compliance by each Loan Party, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws.
(c)Comply, and cause each of its Subsidiaries to comply, in connection with this Agreement, in all material respects with all applicable Anti-Corruption Laws, Anti-Money Laundering Laws and Sanctions.
(d)Not engage, or permit any director, officer, employee or any Person acting on behalf of any Loan Party to engage, in any activity that would breach, in any material respect, any Anti-Corruption Law.
(e)Promptly notify the Administrative Agent of any action, suit or investigations by any court or Governmental Authority in relation to an alleged breach any Anti-Corruption Law.
(f)Not directly or knowingly indirectly use, lend or contribute the proceeds of any Loan for any purpose that would breach Anti-Corruption Law.
Section 5.08.Books and Records. Maintain proper books of record and account, in which full, true and correct (in all material respects) entries in conformity with GAAP consistently applied shall be made of all material financial transactions, and if and to the extent required by GAAP, matters involving the assets and business of the Parent Guarantor, such Borrower or such Subsidiary, as the case may be (it being understood and agreed that certain Foreign Subsidiaries maintain individual books and records in conformity with generally accepted accounting principles in their respective jurisdictions of incorporation, association, organization, formation or registration and that such maintenance shall not constitute a breach of the representations, warranties and covenants hereunder).
Section 5.09.Inspection Rights. Permit representatives and independent contractors of the Administrative Agent to visit and inspect any of its properties, to examine its corporate, financial and operating records, and to make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants (subject to such accountants’ customary policies and procedures), at such reasonable times during normal business hours and as often as may be reasonably desired (with the Borrowers being required to pay all reasonable and documented out-of-pocket expenses for one such visit in each Fiscal Year) by the Administrative Agent, upon
94



reasonable advance notice to the Administrative Borrower; provided that, when an Event of Default exists the Administrative Agent or any Lender (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of the Borrowers at any time during normal business hours and upon reasonable advance notice, and without limitation as to frequency. The Administrative Agent shall give the Administrative Borrower reasonable opportunity to participate in any discussions with independent public accountants. Notwithstanding the foregoing, no Borrower nor any Subsidiary will be required to disclose, permit the inspection, examination or making copies or abstracts of, or discuss, any document, information or other matter (i) that constitutes non-financial trade secrets or non-financial proprietary information, (ii) in respect of which disclosure to the Administrative Agent or any Lender (or their respective representatives or contractors) is prohibited by applicable Law or any binding agreement (to the extent such binding agreement was not created in contemplation of such Loan Party’s or Subsidiary’s obligations under this Agreement) or (iii) that is subject to attorney-client or similar privilege or constitutes attorney work product; provided, in each case, that the Administrative Borrower shall have notified the Administrative Agent that such document, information or other matter is being withheld on the basis of the foregoing.
Section 5.10.Use of Proceeds. Use the proceeds of (a) the Term Loans and the Revolving Loans to consummate the Existing Credit Agreement Refinancing and to pay the fees and expenses incurred in connection with the Transactions and (b) the Revolving Loans for working capital and general corporate purposes of the Parent Guarantor, the Borrowers and the Subsidiaries, including for the financing of acquisitions and Investments, and any other purpose not in contravention of any Law or of any Loan Document; provided that, $15,000,000 of Revolving Loans (but not more than such amount) will be available and made on the Closing Date.
Section 5.11.Covenant to Guarantee Obligations and Give Security.
(a)Subject to the Agreed Security Principles and the Foreign Perfection Requirements, upon the formation or acquisition by any Loan Party of any new direct or indirect Subsidiary (other than any Excluded Subsidiary), or upon a Subsidiary ceasing to be an Excluded Subsidiary, the Parent Guarantor and each Borrower shall, at the Borrowers’ expense:
(i)Within forty-five (45) days (as such time may be extended by the Administrative Agent in its reasonable discretion) following the creation or acquisition of such Subsidiary or following such Subsidiary ceasing to be an Excluded Subsidiary, cause such Subsidiary to (A) become a Guarantor and provide the Administrative Agent, for the benefit of the Secured Parties, a Lien on its assets to secure the Obligations by executing and delivering to the Administrative Agent a joinder to the applicable Collateral Agreement, the Guarantee Agreement and/or such other documents as the Administrative Agent shall deem appropriate for such purpose and (B) deliver to the Administrative Agent such other customary documentation reasonably requested by the Administrative Agent including opinions of counsel to such Person (which shall cover, among other things, the legality, validity, binding effect and enforceability of the documentation referred to in this clause (i)), all in form, content and scope reasonably satisfactory to the Administrative Agent;
(ii)within forty-five (45) days (as such time may be extended by the Administrative Agent in its reasonable discretion) after such formation or acquisition or after such Subsidiary ceases to be an Excluded Subsidiary, if requested in writing by the Administrative Agent or if the Administrative Agent is directed in writing by the Required Lenders to request, furnish to the Administrative Agent a description of the owned real property of such Subsidiary, in detail reasonably satisfactory to the Administrative Agent;
(iii)within forty-five (45) days (as such time may be extended by the Administrative Agent in its reasonable discretion) after such formation or acquisition or after such Subsidiary ceases to be an Excluded Subsidiary, cause each direct and indirect parent (to the extent such parent is a Loan Party) of such Subsidiary to pledge its interests in such Subsidiary to the Administrative Agent, for the benefit of the Secured Parties, to secure such parent’s Obligations (if it has not already done so) and to deliver to the Administrative Agent all
95



certificated Equity Interests of such Subsidiary (if any) together with transfer powers in respect thereof endorsed in blank, and cause such Subsidiary:
(A)to duly execute and deliver to the Administrative Agent, for the benefit of the Secured Parties, any additional collateral and security agreements or supplements thereto, as reasonably specified by and in form and substance reasonably satisfactory to the Administrative Agent, to secure payment of all the Obligations of such Subsidiary, and constituting Liens on the personal property (other than Excluded Assets) of such Subsidiary; and
(B)to take whatever action (including the recording of mortgages, the filing of Uniform Commercial Code financing statements, the giving of notices and the endorsement of notices on title documents) may be necessary or advisable in the reasonable opinion of the Administrative Agent to vest in the Administrative Agent (or in any representative of the Administrative Agent designated by it) valid and subsisting first priority perfected Liens on properties purported to be subject to the Collateral Documents and other agreements delivered pursuant to this Section 5.11, subject to Permitted Prior Liens; and
(iv)within forty-five (45) days (as such time may be extended by the Administrative Agent in its reasonable discretion) after such formation or acquisition or after such Subsidiary ceases to be an Excluded Subsidiary, deliver to the Administrative Agent, upon the request of the Administrative Agent, a signed copy of an opinion, addressed to the Administrative Agent and the other Secured Parties, of counsel for the Loan Parties as to such matters as the Administrative Agent may reasonably request.
Notwithstanding any of the foregoing to the contrary, the Collateral shall be subject to the limitations and exclusions set forth in the applicable Collateral Documents and it is understood and agreed that:
(i)[reserved];
(ii)no action shall be required to perfect any Lien with respect to (A) any vehicle or other asset subject to a certificate of title, (B) [reserved] (C) the capital stock or other Equity Interests of any Immaterial Subsidiary or (D) the capital stock or other Equity Interests of any Person that is not a Subsidiary which, if a Subsidiary, would constitute an Immaterial Subsidiary, in each case, except to the extent that a security interest therein is perfected by filing a UCC financing statement or a financing statement on the SIR (or equivalent) (which shall be the only required perfection action);
(iii)no Loan Party shall be required to perfect a security interest in any asset to the extent perfection of a security interest in such asset would be prohibited under any applicable Law;
(iv)the Administrative Agent shall not require the taking of a Lien on, or require the perfection of any Lien granted in, those assets as to which the cost of obtaining or perfecting such Lien (including any Tax or expenses relating to such Lien) is excessive in relation to the benefit to the Lenders of the security afforded thereby as reasonably determined by the Administrative Agent in consultation with the Administrative Borrower;
(v)no actions shall be required with respect to assets requiring perfection through control agreements or perfection by “control” (other than Control Agreements in accordance with the terms of this Agreement, in respect of Indebtedness for borrowed money owing to the Loan Parties evidenced by promissory notes in an aggregate principal amount in excess of $2,500,000 and certificated Equity Interests of each Borrower and such other Persons as are required to be pledged pursuant to the Collateral Agreements);
96



(vi)the Loan Parties shall not have any obligation to perfect any security interest or Lien, or record any notice thereof, in any IP Rights included in the Collateral in any jurisdiction other than (A) the United States of America and (B) the jurisdiction of incorporation, association, organization, formation or registration of an applicable Loan Party, in each case, subject to the Agreed Security Principles; and
(vii)the creation and perfection of any security interest by Foreign Subsidiaries shall be subject to the Agreed Security Principles and the Foreign Perfection Requirements.
(b)With respect to any Material Real Estate Assets owned by a Loan Party on the Closing Date or acquired by a Loan Party thereafter, and all Material Real Estate Assets owned by any Subsidiary that becomes a Loan Party pursuant to Section 5.11(a) above, within ninety (90) days (as such time may be extended by the Administrative Agent in its reasonable discretion) (and, in the case of clause (vii) below, within the time period set forth therein) after (i) the Closing Date, in the case of Material Real Estate Assets owned by the Loan Parties on the Closing Date and (ii) the date such Material Real Estate Assets is acquired (or such Subsidiary is formed or acquired or ceases to be an Excluded Subsidiary, as the case may be) in such other cases, the Parent Guarantor and each Borrower shall, or shall cause the applicable Loan Party to, at its expense, provide to the Administrative Agent, or, with respect to clause (vii), as applicable, acknowledge receipt of, as applicable (in each case, subject to the Agreed Security Principles and the Foreign Perfection Requirements):
(i)deeds of trust, trust deeds, deeds to secure debt or mortgages made by the Loan Parties in favor of the Administrative Agent for the benefit of the Secured Parties (collectively, with each other mortgage or similar document delivered pursuant to this Section 5.11, the “Mortgages”), each in form and substance reasonably satisfactory to the Administrative Agent and covering the Material Real Estate Assets then owned by the applicable Loan Party, together with any other Material Real Estate Asset acquired by any Loan Party, in each case duly executed by the appropriate Loan Party;
(ii)a description of the owned property so acquired in detail reasonably satisfactory to the Administrative Agent;
(iii)evidence that counterparts of the Mortgages have been duly executed, acknowledged and delivered and are in form suitable for filing or recording in all filing or recording offices that the Administrative Agent may deem necessary or desirable in order to create a valid first and subsisting Lien on the property described therein subject to Permitted Prior Liens in favor of the Administrative Agent for the benefit of the Secured Parties and that all filing, documentary, stamp, intangible and recording taxes and fees have been paid;
(iv)fully paid American Land Title Association Lender’s Extended Coverage title insurance policies (the “Mortgage Policies”), with endorsements and in amounts reasonably acceptable to the Administrative Agent, issued, coinsured and reinsured by title insurers acceptable to the Administrative Agent, insuring the Mortgages to be valid first and subsisting Liens on the property described therein, subject only to Permitted Prior Liens;
(v)American Land Title Association/National Society of Professional Surveyors surveys of any Material Real Estate Assets that are reasonably acceptable to Administrative Agent and are of a form, scope and substance sufficient to cause all standard survey exceptions from the corresponding Mortgage Policy to be removed and the survey related endorsements issued, for which all necessary fees (where applicable) have been paid and, in each case, certified to the Administrative Agent, the applicable Loan Party, and the issuer of the Mortgage Policies in a manner reasonably satisfactory to the Administrative Agent by a land surveyor duly registered and licensed in the States in which the property described in such surveys is located, or in lieu thereof, an existing survey, together with a no change affidavit sufficient for the title insurance company to remove the standard survey exception from the applicable Mortgaged Policy and issue the survey related endorsements to the applicable Mortgage Policy;
97



(vi)without limiting clause (vii) below, evidence of the insurance required by the terms of the Mortgages;
(vii)at least forty (40) days (as such time period may be reduced by the Administrative Agent in its reasonable discretion) prior to the end of the ninety (90) day period referred to in the lead in to this clause (b), the following documents: (A) a completed “life of loan” Federal Emergency Management Agency Standard Flood Hazard Determination form (a “Flood Determination Form”), (B) if any improvement(s) to the applicable improved real property is located in a special flood hazard area, a notification thereof to the Administrative Borrower from Administrative Agent (“Borrower Notice”) and (if applicable) notification to the Administrative Borrower that flood insurance coverage under the National Flood Insurance Program (“NFIP”) is not available because the community does not participate in the NFIP, (C) documentation evidencing the Administrative Borrower’s receipt of the Borrower Notice (e.g., countersigned Borrower Notice, return receipt of certified U.S. Mail, or overnight delivery), and (D) if the Borrower Notice is required to be given and flood insurance is available in the community in which the applicable real property is located, a copy of one of the following: the flood insurance policy, the Borrowers’ application for a flood insurance policy plus proof of premium payment, a declaration page confirming that flood insurance has been provided as a separate policy or within the property insurance program for the applicable real property, or such other evidence of flood insurance reasonably satisfactory to the Administrative Agent (any of the foregoing being “Evidence of Flood Insurance”); and
(viii)such customary legal opinions and other customary documents (including a certificate from the Administrative Borrower certifying that all conditions and requirements in clause (vii) above have been satisfied) as the Administrative Agent may reasonably request with respect to such Mortgage or Mortgaged Property.
(c)With respect to any location leased by a Loan Party on the Closing Date or leased by a Loan Party thereafter (or leased by any Subsidiary that becomes a Loan Party pursuant to Section 5.11(a) above) (including, without limitation, any premises of a bailee, warehouseman or similar party), within sixty (60) days of the Closing Date or such later date (as such time may be extended by the Administrative Agent in its reasonable discretion), use commercially reasonable efforts to obtain a written subordination or waiver or collateral access agreement, as the case may be, in form and substance satisfactory to the Administrative Agent, with respect to each location where any Collateral with a book value in excess of $4,000,000 (when aggregated with all other Collateral at the same location) is stored or maintained; provided that such subordination or waiver or collateral access agreement shall not be required with respect to any such location if such subordination or waiver or collateral access agreement will not be obtained after the Loan Parties have used commercially reasonable efforts to obtain the same.
(d)With respect to any deposit account, securities account or commodity account of a Loan Party that is a Domestic Subsidiary on the Closing Date or opened, established or acquired by a Loan Party that is a Domestic Subsidiary thereafter (including any such account of any Domestic Subsidiary that becomes a Loan Party pursuant to Section 5.11(a) above), within sixty (60) days of the Closing Date or such later date (as such time may be extended by the Administrative Agent in its reasonable discretion), deliver to the Administrative Agent a Control Agreement with respect to each such account (other than Excluded Accounts). The Loan Parties that are Domestic Subsidiaries shall not maintain cash, Cash Equivalents or other amounts in any deposit account, securities account or commodity account, unless the Administrative Agent shall have received a Control Agreement in respect of each such account (other than Excluded Accounts, and subject to the time period to obtain a Control Agreement noted above).
Section 5.12.Compliance with Environmental Laws. Comply, and cause all lessees and other Persons operating or occupying its properties to comply with all applicable Environmental Laws and Environmental Permits, except where the failure to so comply would not reasonably be likely to have a Material Adverse Effect; and, if ordered to do so by a Governmental Authority or otherwise required pursuant to any Environmental Law, conduct any investigation, study, sampling and testing, and undertake any cleanup, removal, remedial or other action necessary to address all Hazardous Materials from any of its properties, in accordance with the requirements of all Environmental Laws; provided that,
98



neither the Parent Guarantor, any Borrower nor any Subsidiary shall be required to undertake any such ordered or required cleanup, removal, remedial or other action to the extent that its obligation to do so is being contested in good faith and by proper proceedings and appropriate reserves are being maintained with respect to such circumstances in accordance with GAAP.
Section 5.13.Lender Meetings. Participate in quarterly meetings (which may be virtual) with the Administrative Agent and the Lenders, such meetings to be held at such time as may be agreed to by the Borrowers and the Administrative Agent within a reasonable period of time following such request, with such meetings including members of senior management of each Borrower as such Borrower deems appropriate, to discuss the state of each Borrower’s business, including recent performance, operational activities, current business and market conditions and material performance changes; provided that, (i) so long as no Event of Default has occurred and is continuing, in no event shall more than one such meeting be required in any fiscal quarter, (ii) at the election of the Administrative Agent, at least one such meeting shall be conducted by a physical in-person meeting in each Fiscal Year, and (iii) at the election of the Administrative Agent, the requirements set forth in this Section 5.13 may be satisfied with a public earnings call for the applicable period.
Section 5.14.Further Assurances. Promptly upon request by the Administrative Agent, or any Lender through the Administrative Agent, (a) correct any material defect or error that may be discovered in any Loan Document or in the execution, acknowledgment, filing or recordation thereof, and (b) do, execute, acknowledge, deliver, record, re-record, file, re-file, register and re-register any and all such further acts, deeds, certificates, assurances and other instruments as the Administrative Agent, or any Lender through the Administrative Agent, may reasonably require from time to time (in each case, subject to the Agreed Security Principles) in order to (i) carry out more effectively the purposes of the Loan Documents, (ii) to the fullest extent permitted by applicable law, subject any Loan Party’s properties, assets, rights or interests to the Liens now or hereafter intended to be covered by any of the Collateral Documents or Section 5.11 or 5.15, (iii) perfect and maintain the validity, effectiveness and priority of any of the Collateral Documents and any of the Liens intended to be created thereunder and (iv) subject to the limitations set forth in Section 5.11, assure, convey, grant, assign, transfer, preserve, protect and confirm more effectively unto the Secured Parties the rights granted or now or hereafter intended to be granted to the Secured Parties under any Loan Document or under any other instrument executed in connection with any Loan Document to which any Loan Party or any Subsidiary is or is to be a party, and cause each Subsidiary to do so.
Section 5.15.Post-Closing Obligations. Each of the Loan Parties shall satisfy the requirements set forth on Schedule 5.15 on or before the date specified for such requirement in such Schedule or such later date to be determined by the Administrative Agent in its sole discretion. So long as the applicable Loan Parties shall have complied with the immediately preceding sentence, the representations and warranties contained in this Agreement and the other Loan Documents in respect of any action described on Schedule 5.15 shall not be deemed violated solely due to the fact that any such action was not taken as of the Closing Date (so long as any such representation and warranty with respect to any such action shall be true and correct in all material respects as of the date such action is taken (or was required to be taken as set forth in Schedule 5.15 (or such later time as the Administrative Agent may have agreed to in its sole discretion)).
Section 5.16.[Reserved].
Section 5.17.Health Care.
(a)Except as set forth on Schedule 5.17, obtain, maintain and preserve, and cause each of the Subsidiaries to obtain, maintain and preserve, and take all necessary action to timely renew, all Health Care Permits that are necessary for the conduct of its business, and comply, and cause each of the Subsidiaries to be in compliance with all Health Care Laws and Health Care Permits, except where the failure to do so could not reasonably be expected to result in a Material Adverse Effect; and
(b)Provide the Administrative Agent with written notice within ten (10) Business Days of a Health Care Claim or Health Care Liability that could reasonably be expected to result in a
99



Material Adverse Effect; and provide such non-privileged reports, documents and information as the Administrative Agent may reasonably request from time to time with respect to any of the foregoing.


(a)
(b)
(c)Comply, and cause each of the Subsidiaries to be in material compliance with all Hemp Laws; and
(c)Provide the Administrative Agent with written notice within ten (10) Business Days of a material Hemp Claim; and provide such non-privileged reports, documents and information as the Administrative Agent may reasonably request from time to time with respect to any of the foregoing.
Article VI

Negative Covenants
From and after the Closing Date, so long as any Lender shall have any Commitment hereunder, any Loan or other Obligation (other than contingent indemnification obligations as to which no claim has been asserted) hereunder shall remain unpaid or unsatisfied, each of the Parent Guarantor and each Borrower shall not, nor shall it permit any Subsidiary to, directly or indirectly:
Section 6.01.Liens. Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, other than the following:
(a)Liens created pursuant to any Loan Document;
(b)Liens existing on the Closing Date and, to the extent securing an aggregate amount greater than $500,000, as set forth on Schedule 6.01, and any modifications, replacements, renewals, refinancings or extensions thereof; provided that, (i) the Lien does not extend to any additional property other than (A) after-acquired property that is affixed or incorporated into the property covered by such Lien and (B) proceeds and products thereof, and (ii) the modification, replacement, renewal, refinancing or extension of the obligations secured or benefited thereby, to the extent constituting Indebtedness, is permitted by Section 6.03(b);
(c)Liens for Taxes which are not yet due or are not overdue for period of more than sixty (60) days or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP or the equivalent accounting principles in the relevant local jurisdiction;
(d)Liens imposed by applicable Law, such as carriers’, warehousemen’s, landlords’, mechanics’, materialmen’s, repairmen’s or other like Liens granted or arising in the ordinary course of business, which secure amounts not overdue for a period of more than sixty (60) days or if more than sixty (60) days overdue, are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are (if applicable) maintained on the books of the applicable Person in accordance with GAAP or the equivalent accounting principles in the relevant local jurisdiction;
(e)(i) pledges or deposits in the ordinary course of business in connection with workers’ compensation, health, disability or employee benefits, unemployment insurance and other social security laws or similar legislation or regulation or other insurance-related obligations (including, in
100



respect of deductibles, self-insured retention amounts and premiums and adjustments thereto) other than any Lien imposed by ERISA, (ii) pledges and deposits in the ordinary course of business securing liability for reimbursement of or indemnification obligations to (including obligations in respect of letters of credit or bank guarantees for the benefit of) insurance carriers providing property, casualty or liability insurance to the Parent Guarantor, any Borrower or any Subsidiary and (ii) liens on cash collateral to secure reimbursement obligations under letters of credit provided to support any of the obligations described in the preceding clauses (i) and (ii);
(f)deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness for borrowed money), statutory obligations, surety, stay, customs and appeal bonds, performance bonds and other obligations of a like nature (including those to secure health, safety and environmental obligations) incurred in the ordinary course of business or consistent with past practice;
(g)easements, rights-of-way, covenants, conditions, restrictions (including zoning restrictions), encroachments, protrusions and other similar Liens and minor title defects affecting real property which, in the aggregate, do not materially interfere with the ordinary conduct of the business of the applicable Person, and matters that are disclosed in any Mortgage Policies reasonably acceptable to the Administrative Agent;
(h)Liens securing judgments or orders for the payment of money not constituting an Event of Default under Section 7.01(h) or securing appeal or other surety bonds related to such judgments;
(i)(i) Liens securing Indebtedness permitted under Section 6.03(e); provided that, (A) such Liens do not at any time encumber any property (except for replacements, additions and accessions to such property) other than the property financed by such Indebtedness and (B) the Indebtedness secured thereby does not exceed the cost or fair market value of the property, whichever is lower, being acquired on the date of acquisition, improvements thereto and related expenses; provided that, individual financings of equipment provided by one lender may be cross collateralized to other financings of equipment provided by such lender on customary terms; and (ii) Liens securing Indebtedness permitted under Section 6.03(t); provided that, (w) such Liens existed on the property or asset prior to the acquisition thereof by the Parent Guarantor, any Borrower or any Subsidiary or existed on the property or asset of any Person that becomes a Subsidiary in connection with a Permitted Acquisition, (x) such Lien is not created in connection with such acquisition or such Person becoming a Subsidiary, as the case may be and (y) such Lien shall not encumber any other property or assets of the Parent Guarantor, any Borrower or any Subsidiary (other than any Person acquired by the Parent Guarantor, any Borrower or any Subsidiary as a result of a Permitted Acquisition and any Subsidiary of such acquired Person) as of the date of such Permitted Acquisition;
(j)(x) precautionary filings in respect of operating leases and (y) leases, licenses, subleases, cross-licenses or sublicenses granted to others in the ordinary course of business which do not (i) interfere in any material respect with the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole or (ii) secure any Indebtedness;
(k)other Liens in an aggregate principal amount and other obligations in an amount which does not exceed $5,000,000 in the aggregate;
(l)Liens on property of Foreign Subsidiaries that are Subsidiaries securing Indebtedness of such Foreign Subsidiaries permitted by Section 6.03(g);
(m)Liens in favor of custom and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods;
(n)Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person’s obligations in respect of letters of credit and bankers’ acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;
101



(o)Liens arising out of conditional sale, consignment, title retention or similar arrangements for the sale of goods entered into by the Parent Guarantor, any Borrower or any Subsidiary in the ordinary course of business;
(p)Liens (i) of a collection bank arising under Section 4-210 of the UCC on items in the course of collection; (ii) attaching to commodity trading accounts or other commodity brokerage accounts incurred in the ordinary course of business; and (iii) in favor of banking institutions arising as a matter of Law or under customary general terms and conditions encumbering deposits or other funds maintained with a financial institution (including the right of set-off) and which are within the general parameters customary in the banking industry or arising pursuant to such banking institution’s general terms and conditions;
(q)deposits made in the ordinary course of business to secure liability to insurance carriers;
(r)Liens in respect of overdraft facilities, automatic clearinghouse arrangements, employee credit card programs, corporate cards and purchasing cards, and other business cash management arrangements, and incentive, supplier finance or similar programs, in each case, incurred in the ordinary course of business of the Parent Guarantor, any Borrower or any Subsidiary;
(s)Liens that are customary contractual rights of setoff (i) relating to the establishment of depository relations with banks or other financial institutions not given in connection with the incurrence of Indebtedness; (ii) relating to pooled deposit or sweep accounts of the Parent Guarantor, any Borrower or any Subsidiary to permit satisfaction of overdraft or similar obligations incurred in the ordinary course of business of the Parent Guarantor, any Borrower or any Subsidiary; or (iii) relating to purchase orders and other agreements entered into with customers of the Parent Guarantor, any Borrower or any Subsidiary in the ordinary course of business;
(t)(i) zoning, entitlements, environmental or conservation restrictions, licenses and permits (including building licenses and permits) and other land use and environmental regulations by Governmental Authorities with which the normal operation of the business complies except for such non-compliance that does not materially interfere with the ordinary conduct of the business of the Parent Guarantor, any Borrower or any Subsidiary; and (ii) any zoning or similar law or right reserved to or vested in any Governmental Authority to control or regulate the use of any real property that does not materially interfere with the ordinary conduct of the business of the Parent Guarantor, any Borrower or any Subsidiary;
(u)Liens (i) (1) on advances of cash or Cash Equivalents in favor of the seller of any property to be acquired in any Investment permitted pursuant to Section 6.02 (other than Section 6.02(g)) to be applied against the purchase price for such Investment and (2) consisting of any agreement to dispose of any property in a Disposition permitted pursuant to Section 6.05 (other than Section 6.05(g)), in each case solely to the extent such Investment or Disposition, as the case may be, would have been permitted on the date of the creation of such Lien or on the date of any contract for such Investment or Disposition and (ii) on any cash earnest money deposits made by the Parent Guarantor, any Borrower or any Subsidiary in connection with any letter of intent or purchase agreement permitted hereunder;
(v)Liens consisting of non-exclusive licensing or sublicensing agreements for the use of IP Rights entered into in the ordinary course of business;
(w)Following the Closing Date, Liens on the assets of a Subsidiary that exist at the time such Subsidiary first becomes a Subsidiary or such assets were first acquired by such Subsidiary, so long as (i) such Liens were not entered into in contemplation of such Person becoming a Subsidiary or assets being acquired and (ii) such Liens are not securing Indebtedness;
(x)Liens on cash incurred with respect to any letters of credit permitted by Section 6.03(q); and
102



(y)Liens on Equity Interests in joint ventures (i) securing obligations of such joint ventures or (ii) pursuant to the relevant joint venture agreement or arrangement;
(z)Liens on cash in an escrow account holding up to $5,000,000 of proceeds of Project Romania, as required by the terms of the agreements governing Project Romania; and
(aa)Liens on cash in an escrow account holding penalty payments in respect of the Clean Team Agreement Related Matters.
For purposes of determining compliance with this Section 6.01, (A) a Lien securing an item of Indebtedness need not be permitted solely by reference to one category of Permitted Liens described in Sections 6.01(b) through (y) but may be permitted in part under any combination thereof and (B) in the event that a Lien securing an item of Indebtedness (or any portion thereof) meets the criteria of one or more of the categories of permitted Liens described in Sections 6.01(b) through (y), the Administrative Borrower shall, in its sole discretion, classify or reclassify, or later divide, classify or reclassify, such Lien securing such item of Indebtedness (or any portion thereof) in any manner that complies with this Section 6.01 and will only be required to include the amount and type of such Lien or such item of Indebtedness secured by such Lien in one of the categories of such Lien securing such item of Indebtedness permitted in this Section 6.01. In addition, with respect to any Lien securing Indebtedness that was permitted to be secured at the time of incurrence thereof, additional Indebtedness resulting solely from the accrual of interest, accretion of accreted value, the payment of interest in the form of additional Indebtedness or in the form of common stock of the Parent Guarantor, or the amortization of original issue discount, the accretion of original issue discount or liquidation preference and increases in the amount of Indebtedness outstanding solely as a result of fluctuations in the exchange rate of currencies, in each case with respect to such permitted secured Indebtedness, shall also be permitted to be secured by such Lien.
Section 6.02.Investments. Make any Investments, except:
(a)Investments held by the Parent Guarantor, any Borrower or any Subsidiary in the form of cash and Cash Equivalents;
(b)advances to officers, directors, employees and consultants of the Parent Guarantor, the Borrowers and Subsidiaries (i) in an aggregate amount not to exceed $1,500,000 at any time outstanding, for travel, entertainment, relocation and analogous ordinary business purposes; (ii) in connection with such Person’s purchase of Equity Interests of the Parent Guarantor, provided that, no cash is actually advanced pursuant to this clause (ii) unless immediately used for such purchase; and (iii) to fund U.K. tax obligations of such officers, directors, employees and consultants (in an amount not to exceed such U.K. tax obligations) pursuant to the compensation arrangements of such officer, director, employee of or consultant to the Parent Guarantor, any Borrower or any Subsidiary to enable such Person to pay such U.K. tax obligation;
(c)Investments (i) existing or contractually committed on the Closing Date as set forth on Schedule 6.02; (ii) in Loan Parties (including those formed or acquired after the Closing Date so long as the Parent Guarantor, the Borrowers and the Subsidiaries comply with the applicable provisions of Section 5.11, provided that, notwithstanding anything to the contrary in this Agreement or any other Loan Document, the Lien of the Administrative Agent for the benefit of the Secured Parties shall not attach to any such Investment in the form of an intercompany loan and any intercompany note evidencing such loan shall not be required to be delivered to the Administrative Agent if any such note is subsequently reasonably promptly contributed to a Subsidiary that is not a Loan Party pursuant to Section 6.02(c)(iv)); (iii) by Subsidiaries that are not Loan Parties in Subsidiaries that are not Loan Parties; (iv) by any Borrower or any other Loan Party in Subsidiaries that are not Loan Parties; provided that, in the case of this clause (iv), (A) no Event of Default shall have occurred and be continuing, (B) the Parent Guarantor, the Borrowers and the Subsidiaries comply with the applicable provisions of Section 5.11, (C) the
103



aggregate amount of all such Investments outstanding at any time (determined without regard to any write-downs or write-offs of such Investments) shall not exceed $6,000,000 plus (2) so long as the pro forma Total Leverage Ratio is less than 4.25:1.00 and pro forma Liquidity is greater than $20,000,000, an amount not to exceed the Available Amount at the time of the making of such Investment; provided further that, this clause (C) shall not apply to any such Investment that is in the form of an equity contribution or intercompany loan if, reasonably promptly following receipt of such equity contribution or intercompany loan, the proceeds of such equity contribution or intercompany loan shall be used by such Subsidiaries that are not Loan Parties (or Subsidiaries thereof) to consummate a Permitted Acquisition (and any such Investment described in this proviso shall not utilize the basket set forth in this clause (C), and (D) any such Investments in the form of intercompany loans shall be evidenced by notes that have been pledged (individually or pursuant to a global note) to the Administrative Agent in form and substance reasonably satisfactory to the Administrative Agent for the benefit of the Secured Parties unless (x) such pledge would result in material adverse tax consequences to the Parent Guarantor, the Borrowers and the Subsidiaries as reasonably determined by the Administrative Agent in consultation with Administrative Borrower or (y) reasonably promptly following the making of such intercompany loan the holder of such note representing such loan contributes such note as an equity contribution to any Subsidiary that is not a Loan Party that will reasonably promptly following receipt of such equity contribution consummate (or cause one or more of its Subsidiaries to consummate) a Permitted Acquisition, in which case and in each such case, notwithstanding anything to the contrary in this Agreement or any other Loan Document, the Lien of the Administrative Agent for the benefit of the Secured Parties shall not attach to any such note, and any such note shall not be required to be delivered to the Administrative Agent;
(d)Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant of trade credit in the ordinary course of business, and Investments received in satisfaction or partial satisfaction thereof from financially troubled account debtors to the extent reasonably necessary in order to prevent or limit loss;
(e)any Investments in the form of Permitted Acquisitions;
(f)Guarantees permitted by Section 6.03 or of obligations that do not constitute Indebtedness in the ordinary course of business or consistent with past practice;
(g)to the extent constituting Investments, transactions expressly permitted under Sections 6.01 (other than Section 6.01(u)), 6.04 (other than Section 6.04(c)), 6.06(d) and 6.14;
(h)Investments existing on, or made pursuant to legally binding written commitments in existence on, the Closing Date as set forth on Schedule 6.02, and any modification, replacement, renewal or extension thereof; provided that, the amount of the original Investment is not increased except by the terms of such Investment or as otherwise permitted by this Section 6.02;
(i)promissory notes and other non-cash consideration received in connection with Dispositions permitted by Section 6.05;
(j)Investments (including debt obligations and Equity Interests) received in connection with the bankruptcy or reorganization of suppliers and customers and in settlement of delinquent obligations of, and other disputes with, customers and suppliers arising in the ordinary course of business and upon the foreclosure with respect to any secured Investment or other transfer of title with respect to any secured Investment;
(k)Investments to the extent that payment for such Investments is made solely by the issuance of Qualified Equity Interests of the Parent Guarantor to the seller of such Investments;
(l)Subsidiaries may be established or created (but not capitalized) if the Parent Guarantor, the Borrowers and such Subsidiary comply with the requirements of Section 5.11, if applicable; provided that, in each case, to the extent such new Subsidiary is created solely for the purpose of consummating a transaction pursuant to an acquisition permitted by this Section 6.02, and such new Subsidiary at no time holds any assets or liabilities other than any merger or acquisition consideration
104



contributed to it contemporaneously with the closing of such transactions, such new Subsidiary shall not be required to take the actions set forth in Section 5.11, as applicable, until the applicable acquisition is consummated (at which time the surviving entity of the applicable transaction shall be required to so comply in accordance with the provisions thereof);
(m)(i) Investments (other than Investments in the form of Subsidiaries) held by any Subsidiary acquired after the Closing Date, or of any Person acquired by, or merged into or consolidated or amalgamated with the Parent Guarantor, any Borrower or any Subsidiary after the Closing Date, in each case, as part of a Permitted Acquisition to the extent that such Investments were not made in contemplation of or in connection with such acquisition, merger, amalgamation or consolidation and were in existence on the date of the relevant acquisition, merger, amalgamation or consolidation and (ii) any modification, replacement, renewal or extension of any Investment permitted under clause (i) of this Section 6.02(m) so long as no such modification, replacement, renewal or extension thereof increases the amount of such Investment except as otherwise permitted by this Section 6.02;
(n)Swap Contracts to the extent permitted pursuant to Section 6.03(d);
(o)so long as no Event of Default has occurred and is continuing or would be caused thereby, other Investments; provided that, in no event shall the aggregate amount of Investments outstanding at any time pursuant to this Section 6.02(o) during the term of this Agreement (net of any returns of capital on such Investments) exceed the sum of (1) $6,000,000 plus (2) so long as the pro forma Total Leverage Ratio is less than 4.25:1.00 and pro forma Liquidity is greater than $20,000,000, an amount not to exceed the Available Amount at the time of the making of such Investment;
(p)extensions of credit, loans or other advances that are made to Persons treated as partners of Waldencast Partners LP for U.S. federal income tax purposes other than Parent Guarantor or its Subsidiary (such partners, “Non-Waldencast Partners,” and such extensions of credit, loans or other advances, “WPLP Loans”) to the extent (A) such WPLP Loans to each Non-Waldencast Partner are made in lieu of Permitted Tax Distributions by Waldencast Partners LP in amounts to each Non-Waldencast Partner that do not exceed the amounts otherwise distributable to such partner as Permitted Tax Distributions, and (B) in connection with any transaction in which such Non-Waldencast Partner disposes of any portion of its equity in Waldencast Partners LP (including pursuant to a redemption of such equity), such Non-Waldencast Partner is required to repay a proportionate amount of any WPLP Loans made to such partner pursuant to this Section 6.02(p);
(q)Investments consisting of the non-exclusive licensing or sublicensing of IP Rights in the ordinary course of business;
(r)Investments consisting of the non-exclusive licensing or sublicensing of IP Rights pursuant to joint marketing arrangements with other Persons in the ordinary course of business; and
(s)unlimited Investments shall be permitted so long as (i) no Event of Default shall exist before or after giving effect to such Investment and (ii) the pro forma Total Leverage Ratio would be less than 2.75:1.00; provided that, Investments by Loan Parties in Subsidiaries that are not Loan Parties made pursuant to this clause (s) shall not exceed $10,000,000 at any time outstanding.
Notwithstanding anything to the contrary in Article VI,
(1)    the Parent Guarantor and the Borrowers will not, and will not permit any Subsidiary to, sell, lease, convey, assign, transfer or otherwise dispose (including pursuant to an exclusive license) of intellectual property that is material to the operation of the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, to any Affiliate of any Borrower who is not a Loan Party, other than (x) non-exclusive licenses, sublicenses or cross-licenses of intellectual property in the ordinary course of business and which do not materially interfere with the business of the Parent
105



Guarantor, the Borrowers and the Subsidiaries, taken as a whole and (y) any such disposition from a Subsidiary that is not a Loan Party to a Subsidiary that is not a Loan Party; and
(2) the aggregate amount of all Investments made by Loan Parties in Subsidiaries formed or organized under the laws of Thailand or Vietnam (or any political sub-division of Thailand or Vietnam, as applicable) shall not exceed (x) in the case of Section 6.02(c), $4,000,000 at any time outstanding, and (y) in all cases, $10,000,000 at any time outstanding after the Closing Date.
Section 6.03.Indebtedness. Create, incur, assume or suffer to exist any Indebtedness, except:
(a)Indebtedness under the Loan Documents;
(b)Indebtedness outstanding on the Closing Date as set forth on Schedule 6.03, and any Permitted Refinancing Indebtedness in respect thereof;
(c)(i) Guarantees by any Borrower or any Guarantor in respect of Indebtedness otherwise permitted hereunder of any Borrower or any Guarantor; (ii) Guarantees by any Subsidiary that is not a Loan Party in respect of Indebtedness otherwise permitted hereunder of the Parent Guarantor, any Borrower or any Subsidiary; and (iii) Guarantees by any Borrower or any Guarantor in respect of Indebtedness otherwise permitted hereunder of Subsidiaries that are not Loan Parties to the extent such Guarantee constitutes an Investment permitted by Sections 6.02(c)(i) or 6.02(o);
(d)obligations (contingent or otherwise) of the Parent Guarantor, any Borrower or any Subsidiary existing or hereafter arising under any Swap Contract; provided that, (i) such obligations are (or were) entered into by such Person in the ordinary course of business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person, or changes in the value of securities issued by such Person, and not for purposes of speculation; and (ii) such Swap Contract does not contain any provision exonerating the non-defaulting party from its obligation to make payments on outstanding transactions to the defaulting party (other than pursuant to customary netting or set-off provisions);
(e)(1) Indebtedness of the Parent Guarantor, the Borrowers or any Subsidiary in respect of Capital Leases and purchase money obligations for fixed or capital assets, which may be secured by Liens under and within the applicable limitations set forth in Section 6.01(i); provided that, the aggregate amount of all such Indebtedness at any one time outstanding pursuant to this clause (e) (when aggregated with the aggregate principal amount of Permitted Refinancing Indebtedness (other than any Refinancing Excess Amounts) Incurred pursuant to subclause (2) below in respect of such Indebtedness then outstanding) shall not exceed $2,500,000 and (2) Permitted Refinancing Indebtedness in respect of any Indebtedness incurred under the foregoing;
(f)Indebtedness of the Parent Guarantor, any Borrower or any Subsidiary owing to the Parent Guarantor, any Borrower or any Subsidiary to the extent constituting an Investment permitted by Section 6.02(c);
(g)Indebtedness incurred by a Subsidiary that is not organized under the laws of any political subdivision of the United States, which, when aggregated with the principal amount of all other Indebtedness incurred pursuant to this clause (g) and then outstanding, does not exceed $5,000,000;
(h)intercompany trade payables and accrued expenses among the Parent Guarantor, any Borrower or any Subsidiary solely to the extent permitted by Section 6.02;
(i)other Indebtedness of the Parent Guarantor, the Borrowers and the Subsidiaries in an aggregate principal amount at any one time outstanding not to exceed $5,000,000;
(j)[reserved];
106



(k)Indebtedness of the Parent Guarantor, any Borrower or any Subsidiary consisting of obligations to pay insurance premiums or take-or-pay obligations contained in supply arrangements incurred in the ordinary course of business;
(l)Indebtedness consisting of obligations of the Parent Guarantor, the Borrowers or the Subsidiaries under deferred consideration or other similar arrangements (including earn-outs, indemnifications, incentive non-competes and other contingent obligations and agreements consisting of the adjustment of purchase price or similar adjustments, but not seller notes) incurred by such Person in connection with any Permitted Acquisition or Disposition permitted by Section 6.05 or any other Investment permitted under Section 6.02; provided that, (i) the aggregate principal amount of all such Indebtedness of Subsidiaries that are not Loan Parties shall not exceed $5,000,000 in the aggregate at any time outstanding, (ii) the aggregate principal amount of all such Indebtedness in the form of earn-outs and similar arrangements (calculated as the maximum amount reasonably expected to be payable in respect thereof) shall not exceed $5,000,000 at any one time outstanding, provided that any such Indebtedness with respect to the Specified Acquisition (to the extent on the terms previously disclosed to the Administrative Agent in writing prior to the Closing Date or terms otherwise reasonably acceptable to the Administrative Agent) shall not count against such cap and (iii) earn-outs and similar arrangements shall be required to be subordinated to the Obligations on terms and pursuant to documentation that is reasonably acceptable to the Administrative Agent (other than in the case of the Specified Acquisition, unless such earn-out provides for cash payments by Parent Guarantor or any of its Subsidiaries); provided further that this Section 6.03(l) shall not restrict earnouts that are payable solely in the form of Qualified Equity Interests of the Parent Guarantor;
(m)Indebtedness incurred by the Parent Guarantor, any Borrower or any Subsidiary in respect of bank guarantees, warehouse receipts or similar instruments (other than letters of credit) issued or created in the ordinary course of business or consistent with past practice, including in respect of workers compensation claims, health, disability or other employee benefits or property, casualty or liability insurance or self-insurance, or other Indebtedness with respect to reimbursement type obligations (other than obligations in respect of letters of credit) regarding workers compensation claims;
(n)obligations in respect of performance, bid, appeal and surety bonds and performance and completion guarantees and similar obligations provided by the Parent Guarantor, any Borrower or any Subsidiary in the ordinary course of business or consistent with past practice;
(o)Indebtedness arising from the honoring by a bank or other financial institution of a check, draft or similar instrument inadvertently (except in the case of daylight overdrafts) drawn against insufficient funds in the ordinary course of business; provided that, such Indebtedness is extinguished within five (5) Business Days of incurrence;
(p)Indebtedness in respect of overdraft facilities, automatic clearinghouse arrangements, employee credit card programs, corporate cards and purchasing cards, and other business cash management arrangements in the ordinary course of business, and incentive, supplier finance or similar programs;
(q)Indebtedness incurred with respect to any letters of credit issued for the account of the Parent Guarantor, any Borrower or any Subsidiary in an aggregate principal amount at any one time outstanding not to exceed $5,000,000;
(r)Indebtedness representing deferred compensation to employees of the Parent Guarantor, any Borrower or any Subsidiary incurred in the ordinary course of business;
(s)[reserved];
(t)(x) Indebtedness assumed in connection with a Permitted Acquisition; provided that, (i) such Indebtedness existed prior to the consummation of such Permitted Acquisition, (ii) such Indebtedness is not created in contemplation of such Permitted Acquisition, (iii) such Indebtedness is solely the obligation of such Person, and not of the Parent Guarantor, any Borrower or any Subsidiary (other than any Person acquired by the Parent Guarantor, any Borrower or any Subsidiary as a result of
107



such Permitted Acquisition and any Subsidiary of such acquired Person as of the date of such Permitted Acquisition), (iv) the Borrowers are in pro forma compliance with the financial covenants set forth in Section 6.11 and (v) to the extent such Indebtedness represents Indebtedness for borrowed money, the aggregate amount of such Indebtedness (when aggregated with the aggregate principal amount of Permitted Refinancing Indebtedness (other than any Refinancing Excess Amounts) Incurred pursuant to subclause (y) below in respect of such Indebtedness then outstanding) shall not exceed $4,000,000 at any one time outstanding and (y) Permitted Refinancing Indebtedness in respect thereof; and
(u)unsecured Indebtedness in respect of obligations to pay the deferred purchase price of goods or services or progress payments in connection with such goods and services; provided that, such obligations are incurred in connection with open accounts extended by suppliers on customary trade terms in the ordinary course of business and not in connection with the borrowing of money or hedging obligations.
Any such Indebtedness for borrowed money pursuant to this Section 6.03 (including any Permitted Refinancing Indebtedness in respect thereof), to the extent owed by a Loan Party to a Subsidiary that is not a Loan Party, shall be unsecured and subordinated to the payment of the Obligations in a manner reasonably satisfactory to the Administrative Agent, to the extent such Indebtedness is not otherwise subject to the Intercompany Note.
The accrual of interest, the accretion of accreted value, the payment of interest in the form of additional Indebtedness, the payment of dividends on Disqualified Equity Interests in the form of additional shares of Disqualified Equity Interests, accretion or amortization of original issue discount or liquidation preferences and increases in the amount of Indebtedness outstanding solely as a result of fluctuations in the exchange rate or currencies will not be deemed to be an incurrence of Indebtedness for purposes of this Section 6.03. The principal amount of any non-interest bearing Indebtedness or other discount security constituting Indebtedness at any date shall be the principal amount thereof that would be shown on a consolidated balance sheet of Holdings dated such date prepared in accordance with GAAP.
Further, for purposes of determining compliance with this Section 6.03, (A) Indebtedness need not be permitted solely by reference to one category of permitted Indebtedness described in Sections 6.03(b) through (u) but may be permitted in part under any combination thereof and (B) in the event that an item of Indebtedness (or any portion thereof) meets the criteria of one or more of the categories of permitted Indebtedness described in Sections 6.03(b) through (u), the Administrative Borrower shall, in its sole discretion, classify or reclassify, or later divide, classify or reclassify, such item of Indebtedness (or any portion thereof) in any manner that complies with this Section 6.03 and will only be required to include the amount and type of such item of Indebtedness (or any portion thereof) in one of the categories of Indebtedness permitted in this Section 6.03; provided that,, notwithstanding the foregoing, (i) all Indebtedness outstanding on the Closing Date and set forth on Schedule 6.03 shall at all times be deemed to have been incurred and to exist pursuant to Section 6.03(b) and (ii) all obligations under Swap Contracts shall at all times be deemed to have been incurred and to exist pursuant to Section 6.03(d).
Section 6.04.Fundamental Changes. Merge, dissolve, liquidate, consolidate with or into another Person, take any action for its registration by way of continuation under the laws of a jurisdiction outside of its Original Jurisdiction or Dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person, except that, so long as no Event of Default exists or would result therefrom:
(a)any Subsidiary (other than any Borrower) may merge with (i) any Borrower; provided that, a Borrower shall be the continuing or surviving Person and (ii) any other Subsidiary (other than any Borrower); provided that, (A) [reserved], (B) when any Guarantor is merging with another Subsidiary, the continuing or surviving Person shall be a Guarantor, and (C) if as a result thereof, either the Parent Guarantor or any Borrower owns, directly or indirectly, less of such Subsidiary’s equity
108



interests than it did prior to the merger, such merger shall also constitute a Disposition subject to Section 6.05 (and must be permitted by any clause thereof other than Section 6.05(g));
(b)a merger, dissolution, liquidation, consolidation or Disposition (i) of any Immaterial Subsidiary or (ii) the purpose of which is to effect a Disposition permitted pursuant to Section 6.05 (other than Section 6.05(g));
(c)the Parent Guarantor, any Borrower or any Subsidiary may consummate any Permitted Acquisition or any other Investment permitted by Section 6.02; provided that, (i) in any such transaction involving any Borrower, such Borrower shall be the continuing or surviving Person; (ii) in any such transaction involving the Parent Guarantor, the Parent Guarantor shall be the continuing or surviving person; and (iii) in any such transaction involving a Guarantor, the continuing or surviving Person shall be a Guarantor;
(d)any Subsidiary (other than any Borrower) may Dispose of all or substantially all of its assets (upon voluntary liquidation, dissolution or otherwise) (i) to a Borrower or to a Guarantor; or (ii) if the transferor is not a Guarantor, to any other Subsidiary; provided in each case that (A) if the transferor in such a transaction is a wholly-owned Subsidiary, then the transferee must either be a Borrower or a wholly-owned Subsidiary and (B) to the extent that the transferee is not a Borrower or a wholly-owned Subsidiary (based on the percentage of such transferee which is not owned directly or indirectly by a Borrower), the Disposition shall constitute a Disposition subject to Section 6.05 and shall be permitted under this Section 6.04 so long as it is permitted by any clause of Section 6.05 other than Section 6.05(g);
(e)any Subsidiary (other than any Borrower) may liquidate or dissolve or change in legal form if the Administrative Borrower determines in good faith that such liquidation or dissolution or change in legal form is in the best interests of the Borrowers and is not materially disadvantageous to the Lenders (it being understood that in the case of any change in legal form, a Subsidiary that is a Guarantor will remain a Guarantor);
(f)the Parent Guarantor may merge or consolidate with any other Person; provided that the Parent Guarantor shall be the continuing or surviving corporation;
(g)any Guarantor (other than Parent Guarantor) may take any action to form, register or domicile under the laws of a jurisdiction outside of its Original Jurisdiction, if such Guarantor remains as a Guarantor under this Agreement in accordance with Section 5.11 (provided that, such new jurisdiction shall be a jurisdiction located in the United States of America or another jurisdiction in which one or more of the existing Loan Parties is organized or formed); and
(h)any Subsidiary that is not a Loan Party may take any action to form, register or domicile under the laws of a jurisdiction outside of its Original Jurisdiction;
Notwithstanding anything to the contrary in Article VI, the Parent Guarantor and the Borrowers will not, and will not permit any Subsidiary to, sell, lease, convey, assign, transfer or otherwise dispose (including pursuant to an exclusive license) of intellectual property that is material to the operation of the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, to any Affiliate of any Borrower who is not a Loan Party, other than (x) non-exclusive licenses, sublicenses or cross-licenses of intellectual property in the ordinary course of business and which do not materially interfere with the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole and (y) any such disposition from a Subsidiary that is not a Loan Party to a Subsidiary that is not a Loan Party.
Section 6.05.Dispositions. Make any Disposition or enter into any agreement to make any Disposition except:
109



(a)Dispositions of obsolete or worn out property, whether now owned or hereafter acquired in the ordinary course of business and Dispositions of property no longer used or useful in the conduct of the business of the Parent Guarantor, the Borrowers and the Subsidiaries (including, in the Administrative Borrower’s reasonable business judgment, allowing any registrations or any applications for registration of any IP Rights to lapse or go abandoned);
(b)Dispositions of inventory and goods held for sale in the ordinary course of business;
(c)Dispositions of property to the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such Disposition are reasonably promptly applied to the purchase price of such replacement property;
(d)Dispositions of property by any Borrower to any Subsidiary, or by any Subsidiary to any Borrower or to a Subsidiary; provided that, if the transferor of such property is a Borrower or a Guarantor, the transferee thereof must either be a Borrower or a Guarantor or such Disposition must otherwise constitute an Investment permitted by Section 6.02;
(e)Dispositions of accounts receivable for purposes of collection;
(f)Dispositions of investment securities and Cash Equivalents in the ordinary course of business;
(g)(A) Dispositions permitted by Section 6.04 (other than Section 6.04(a)(ii)(C), Section 6.04(b) or Section 6.04(d)(ii)(B)); (B) Dispositions that constitute Investments permitted by Section 6.02 (other than Section 6.02(g)); (C) Dispositions that constitute Restricted Payments permitted by Section 6.06 (other than Section 6.06(o)) and (D) Dispositions that constitute Liens permitted by Section 6.01 (other than Section 6.01(u));
(h)Dispositions consisting of non-exclusive licenses or sublicenses of IP Rights in the ordinary course of business;
(i)Dispositions of property subject to or resulting from casualty losses and (ii) transfers of condemned property as a result of the exercise of “eminent domain” or other similar policies to the respective Governmental Authority or agency that has condemned the same (whether by deed in lieu of condemnation or otherwise), and transfers of property that have been subject to a casualty to the respective insurer of such real property as part of an insurance settlement;
(j)Dispositions by the Parent Guarantor, the Borrowers and the Subsidiaries of property not otherwise permitted under this Section 6.05; provided that, (i) at the time of such Disposition and after giving effect thereto, no Event of Default shall exist or would result from such Disposition, (ii) the consideration received for such property shall be in an amount at least equal to the fair market value thereof, (iii) no less than 75% of such consideration shall have been paid in cash or Cash Equivalents and (iv) the aggregate fair market value of the assets so Disposed pursuant to this clause (j) shall not exceed 10.0% of Consolidated Total Assets in any Fiscal Year;
(k) Dispositions by the Parent Guarantor, the Borrowers and the Subsidiaries of non-core assets and property acquired after the Closing Date in connection with a Permitted Acquisition; provided that, (i) the Borrowers dispose of any such assets within 270 days following the closing of such Permitted Acquisition and (ii) the fair market value of the assets to be divested in connection with such Permitted Acquisition does not exceed an amount equal to 20% of the total cash and non-cash consideration for such Permitted Acquisition;
(l)leases, licenses, easements, subleases, sublicenses or other similar agreements with respect to real or personal property (which shall be non-exclusive with respect to intellectual property and IP Rights) granted to others in the ordinary course of business which do not interfere in any material respect with the business of the Parent Guarantor, any Borrower or any Subsidiary;
110



(m)the issuance of (x) Qualified Equity Interests by a Subsidiary (other than any Borrower) to the Parent Guarantor or to another Subsidiary (and each other equity holder on a no greater than pro rata basis) and (y) Qualified Equity Interests by any Borrower to the Parent Guarantor;
(n)Dispositions of Investments in joint ventures to the extent required by, or made pursuant to, buy/sell arrangements between the joint venture parties set forth in the joint venture agreement or similar binding agreements entered into with respect to such Investment in such joint venture;
(o)Repurchases of Equity Interests deemed to occur upon the exercise of stock options, warrants or other convertible securities if such Equity Interests represent (i) a portion of the exercise price thereof or (ii) withholding incurred in connection with such exercise; and
(p)Dispositions of any assets having a fair market value in an aggregate amount not to exceed $1,000,000 in the aggregate in any Fiscal Year.
Notwithstanding anything to the contrary in Article VI, the Parent Guarantor and the Borrowers will not, and will not permit any Subsidiary to, sell, lease, convey, assign, transfer or otherwise dispose (including pursuant to an exclusive license) of intellectual property that is material to the operation of the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, to any Affiliate of any Borrower who is not a Loan Party, other (x) non-exclusive licenses, sublicenses or cross-licenses of intellectual property in the ordinary course of business and which do not materially interfere with the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole and (y) any such disposition from a Subsidiary that is not a Loan Party to a Subsidiary that is not a Loan Party.
Section 6.06.Restricted Payments. Declare or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or otherwise) to do so, except that:
(a)each Subsidiary may make Restricted Payments to any Borrower, the Parent Guarantor and any other Person (including any other Subsidiary) that owns an Equity Interest in such Subsidiary ratably according to their respective holdings of the type of Equity Interest in respect of which such Restricted Payment is being made;
(b)the Parent Guarantor and each Subsidiary may declare and make dividend payments or other distributions payable solely in Qualified Equity Interests of such Person, in the case of a Subsidiary, ratably to each Person that owns an Equity Interest in such Subsidiary of the class of Equity Interest in respect of which the Restricted Payment is being made;
(c)the Parent Guarantor and each Subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it (in the case of a Subsidiary, ratably from each Person that owns the class of Equity Interest being repurchased, redeemed or acquired) with the proceeds received from the substantially concurrent issue (in the case of a Subsidiary, ratably to each Person that owns an Equity Interest in such Subsidiary) of new shares of its Qualified Equity Interests;
(d)the Parent Guarantor, each Borrower and each Subsidiary may make Restricted Payments pursuant to and in accordance with their stock option, stock purchase and other benefit plans of general application to management, directors or other employees of the Parent Guarantor (or any direct or indirect parent thereof, to the extent attributable to the Parent Guarantor, the Borrowers and the Subsidiaries), the Borrowers and the Subsidiaries, as adopted or implemented in the ordinary course of business in an aggregate amount not to exceed $2,250,000 in any Fiscal Year;
(e)so long as no Default shall have occurred and be continuing at the time of any action described in this clause (e) or would result therefrom, the Parent Guarantor may (i) declare and make cash dividends to its equity holders in respect of Qualified Equity Interests and (ii) purchase, redeem or otherwise acquire for cash Qualified Equity Interests issued by it in an aggregate amount with
111



respect to clauses (i) and (ii) collectively from and after the Closing Date not to exceed the sum of (1) $5,000,000 plus (2), so long as the pro forma Total Leverage Ratio is less than 3.75:1.00 and pro forma Liquidity is greater than $15,000,000, an amount not to exceed the Available Amount at the time of the making of such dividend, purchase, redemption or acquisition; provided that, in the case of each of clauses (i) and (ii) above, the Borrowers are in pro forma compliance with the financial covenants set forth in Section 6.11;
(f)on and after the Closing Date, so long as no Default shall have occurred and be continuing at the time of any action described in this clause (f) or would result therefrom, the pro forma Total Leverage Ratio is less than 3.75:1.00 and pro forma Liquidity is greater than $15,000,000, the Parent Guarantor may declare and make cash dividends to its equity holders in respect of Disqualified Equity Interests in an amount not to exceed the Available Amount at the time of the making of such dividend;
(g)Waldencast Partners LP may make Permitted Tax Distributions (which shall only be made if WPLP Loans (as defined in Section 6.02(p)) are not made pursuant to Section 6.02(p) for such period), provided that, to the extent Permitted Tax Distributions are made to Parent Guarantor or its Subsidiary (either entity, to the extent such entity is a partner of Waldencast Partners LP for U.S. federal income tax purposes, the “Public Partner”), any amounts of such distributions in excess of the amounts required to discharge Public Partner’s tax liabilities (including any reasonably necessary related costs or expenses) shall not be permitted to be further distributed out in any form by the Public Partner to (i) the Parent Guarantor (if the Public Partner is a Subsidiary of the Parent Guarantor) or (ii) any beneficial owner other than another Loan Party (other than the Parent Guarantor);
(h)non-cash repurchases of Equity Interests of the Parent Guarantor (or any direct or indirect parent thereof) deemed to occur (i) upon the non-cash exercise of stock options and warrants or similar equity incentive awards, and (ii) in connection with the withholding of a portion of the Equity Interests granted or awarded to a director or an employee to pay for the taxes payable by such director or employee upon such grant or award shall be permitted;
(i)the Parent Guarantor, any Borrower or any Subsidiary may (i) pay cash in lieu of fractional shares in connection with any dividend, split or combination thereof or any Permitted Acquisition and (ii) honor any conversion request by a holder of convertible Indebtedness and make cash payments in lieu of fractional shares in connection with any such conversion;
(j)the payment of dividends and distributions within forty five (45) days after the date of declaration thereof, if at the date of declaration of such payment, such payment would have complied with the other provisions of this Section 6.06 shall be permitted (provided that such dividend or distribution will reduce the capacity of the applicable other provision of this Section 6.06);
(k)the purchase, redemption, acquisition, cancellation or other retirement for a nominal value per right of any rights granted to all holders of common stock of the Parent Guarantor, any Borrower or any Subsidiary pursuant to any shareholders’ rights plan adopted for the purpose of protecting shareholders from unfair takeover tactics shall be permitted; provided that, any such purchase, redemption, acquisition, cancellation or other retirement of such rights is not for the purpose of evading the limitations of this covenant (all as determined in good faith by a Responsible Officer that is a senior financial officer of the Administrative Borrower);
(l)unlimited Restricted Payments shall be permitted so long as (i) no Default shall exist before or after giving effect to such Restricted Payment and (ii) the pro forma Total Leverage Ratio would be less than 2.25:1.00;
(m)any Cash Exchange Payment (as defined in the Waldencast LPA) made in accordance with Article XII of the Waldencast LPA; provided that, if any such Cash Exchange Payment is made at any time that any Event of Default pursuant to Section 7.01(a), (b) (solely related to a breach of Section 6.11 or Sections 5.01 or 5.02(a) (solely to the extent such reporting is needed to determine if a breach of Section 6.11 has occurred)), (f) or (g), (i) the Borrowers shall have received cash proceeds within 30 days of such payment from the issuance of Qualified Equity Interests of the Parent Guarantor
112



issued on or after the date of such Cash Exchange Payment in the amount thereof (to the extent not otherwise applied or applied to increase any basket capacity) or (ii) such Cash Exchange Payment shall have been permitted under another clause of this Section 6.06 (and such Cash Exchange Payment shall cause a deduction in such other clause of this Section 6.06);
(n)the Parent Guarantor, the Borrowers and the Subsidiaries may make distributions to any direct or indirect parent thereof the proceeds of which shall be used (i) [reserved]; (ii) to pay any costs and expenses incurred by Waldencast as a public company for, among other things, directors’ and officers’ liability insurance, director fees, public filings, compliance with regulatory requirements, and additional internal and external accounting and legal and administrative resources (in each case, attributable to the ownership or operations of the Parent Guarantor, the Borrowers and the Subsidiaries) or (iii) to pay such parent’s operating costs and expenses incurred in the ordinary course of business and other corporate overhead costs and expenses (including administrative, legal, accounting and similar expenses provided by third parties), which are reasonable and customary and incurred in the ordinary course of business and attributable to the ownership or operations of the Parent Guarantor, the Borrowers and the Subsidiaries, and any reasonable and indemnification claims made by directors or officers of such parent (in each case, attributable to the ownership or operations of the Parent Guarantor, the Borrowers and the Subsidiaries); and
(o)to the extent constituting Restricted Payments, the Parent Guarantor, the Borrowers and the Subsidiaries may enter into transactions expressly permitted by Section 6.04 and Section 6.05 (other than pursuant to Section 6.05(f), (g) or (k)).
Notwithstanding anything to the contrary in Article VI, the Parent Guarantor and the Borrowers will not, and will not permit any Subsidiary to, sell, lease, convey, assign, transfer or otherwise dispose (including pursuant to an exclusive license) of intellectual property that is material to the operation of the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole, to any Affiliate of any Borrower who is not a Loan Party, other (x) non-exclusive licenses, sublicenses or cross-licenses of intellectual property in the ordinary course of business and which do not materially interfere with the business of the Parent Guarantor, the Borrowers and the Subsidiaries, taken as a whole and (y) any such disposition from a Subsidiary that is not a Loan Party to a Subsidiary that is not a Loan Party.
Section 6.07.Change in Nature of Business. Engage in any material line of business substantially different from the Permitted Business.
Section 6.08.Transactions with Affiliates. Enter into any transaction of any kind with any Affiliate of any Borrower, whether or not in the ordinary course of business, other than on fair and reasonable terms not materially less favorable to the Parent Guarantor, such Borrower or such Subsidiary than would be obtainable by the Parent Guarantor, such Borrower or such Subsidiary at the time in a comparable arm’s length transaction with a Person other than an Affiliate (and the Administrative Borrower shall disclose to the Administrative Agent, within ten (10) days of entering into such transaction, any such transaction, to the extent such transaction (x) involves aggregate payments or consideration in excess of $1,000,000 for any individual transaction or series of related transactions and (y) is required to be disclosed as a “related party transaction” under Item 404 of Regulation S-K under the Securities Act or Item 7.B of Form 20-F, as applicable), provided that, the foregoing restriction on transactions shall not apply to:
(a)transactions among the Parent Guarantor, the Borrowers and the Subsidiaries or any entity that becomes a Subsidiary as a result of such transactions;
(b)the payment of reasonable fees, expenses and compensation (including equity compensation) to and insurance provided on behalf of current, former and future officers and directors of the Parent Guarantor (or any direct or indirect parent thereof), any Borrower or any Subsidiary and indemnification agreements entered into by the Parent Guarantor (or any direct or indirect parent thereof), any Borrower or any Subsidiary, limited, solely with respect to any such officers and directors that are, or are Affiliated with, a direct or indirect holder of Equity Interests of Parent Guarantor (excluding (i) any
113



such officers and directors in place on the Closing Date or (ii) any officers involved in day to day management of the business of the Parent Guarantor, the Borrowers and the Subsidiaries) in an aggregate amount not to exceed $3,000,000 in any Fiscal Year;
(c)employment and severance arrangements between the Parent Guarantor (or any direct or indirect parent thereof), the Borrowers and the Subsidiaries and their respective current, former and future officers and employees and transactions pursuant to stock option plans and other employee benefit plans and arrangements in the ordinary course of business;
(d)transactions pursuant to agreements in existence on the Closing Date and set forth on Schedule 6.08 or any amendment thereto to the extent such an amendment is not adverse to the Parent Guarantor, the Borrowers and the Subsidiaries or the Lenders in any material respect;
(e)Restricted Payments made pursuant to Section 6.06;
(f) Project Romania;
(g)[reserved];
(h)[reserved];
(i)the payment of customary fees and reasonable out of pocket costs to, and indemnities provided on behalf of, directors, officers, employees and consultants of the Parent Guarantor, the Borrowers and the Subsidiaries (or any direct or indirect parent of the Parent Guarantor) in the ordinary course of business to the extent attributable to the ownership or operation of the Parent Guarantor, the Borrowers and the Subsidiaries;
(j)transactions with customers, clients, joint venture partners, suppliers or purchasers or sellers of goods or services, in each case in the ordinary course of business and otherwise in compliance with the terms of this Agreement which are fair to the Parent Guarantor, the Borrowers and the Subsidiaries, in the reasonable determination of the senior management of the Administrative Borrower; and
(k)payments to or from, and transactions with, joint ventures (to the extent any such joint venture is only an Affiliate as a result of Investments by the Parent Guarantor, the Borrowers and the Subsidiaries in such joint venture) to the extent otherwise constituting an Investment permitted under Section 6.02 or Restricted Payment permitted under Section 6.06.
Section 6.09.Restrictive Agreements. Enter into any Contractual Obligation (other than this Agreement or any other Loan Document) that limits the ability (i) of any Subsidiary to make Restricted Payments to any Borrower or any Guarantor or to otherwise transfer property to any Borrower or any Guarantor, (ii) of the Parent Guarantor or any Subsidiary to Guarantee the Indebtedness of the Borrowers hereunder or (iii) of the Parent Guarantor, any Borrower or any Subsidiary to create, incur, assume or suffer to exist Liens on property of such Person to secure the Obligations; provided that, clauses (i) and (iii) shall not prohibit any negative pledge or similar provision, or restriction on transfer of property, incurred or provided in favor of any holder of Indebtedness permitted under Section 6.03(e) solely to the extent any such negative pledge relates to the property financed by or the subject of such Indebtedness or any other property securing any other Indebtedness permitted under Section 6.03(e). Notwithstanding the foregoing, this Section 6.09 will not restrict or prohibit:
(A)to the extent constituting a limitation described in Section 6.09(i), restrictions imposed pursuant to an agreement that has been entered into in connection with a transaction permitted pursuant to Section 6.05 with respect to the property that is subject to that transaction;
(B)(x) restrictions imposed by any agreement relating to Indebtedness permitted pursuant to Section 6.03 (to the extent such restriction is
114



customary in agreements governing Indebtedness of such type and is no more restrictive, taken as a whole, to the Parent Guarantor, the Borrowers and the Subsidiaries than the covenants contained in this Agreement) and (y) customary restrictions and conditions contained in the document relating to any consensual Lien, so long as (i) such Lien is permitted by Section 6.01 and such restrictions or conditions relate only to the specific asset(s) subject to such Lien and (ii) such restrictions and conditions are not created for the purpose of avoiding the restrictions imposed by this Section 6.09;
(C)provisions restricting subletting, transfer or assignment of Contractual Obligations (including the granting of any Lien);
(D)[reserved];
(E)to the extent constituting a limitation described in Section 6.09(i), provisions with respect to the disposition or distribution of assets or property in joint venture agreements and other similar agreements entered into by the Parent Guarantor, the Borrowers and the Subsidiaries in the ordinary course of business;
(F)to the extent constituting a limitation described in Section 6.09(i), restrictions on cash or other deposits or net worth imposed by customers on the Parent Guarantor, the Borrowers and the Subsidiaries under contracts entered into in the ordinary course of business;
(G)to the extent constituting a limitation described in Section 6.09(i), encumbrances or restrictions arising or agreed to in the ordinary course of business, not relating to any Indebtedness, and that do not, individually or in the aggregate, detract from the value of property or assets of the Parent Guarantor, any Borrower or any Subsidiary in any manner material to the Parent Guarantor, any Borrower or any Subsidiary;
(H)to the extent constituting a limitation described in Section 6.09(i), encumbrances or restrictions existing under, by reason of or with respect to customary provisions contained in leases or non-exclusive licenses of IP Rights and other agreements, in each case, entered into by the Parent Guarantor, any Borrower or any Subsidiary in the ordinary course of business; or
(I)following the Closing Date, restrictions and conditions were binding on a Subsidiary or its assets at the time such Subsidiary first becomes a Subsidiary or such assets were first acquired by such Subsidiary, so long as such Contractual Obligations were not entered into in contemplation of such Person becoming a Subsidiary or assets being acquired;
(J)provisions in agreements or instruments which prohibit the payment of dividends or the making of other distributions with respect to any class of Equity Interests of a Person other than on a pro rata basis; and
(K)restrictions or conditions imposed by any agreement relating to secured Indebtedness permitted by this Agreement if such restrictions or conditions apply only to the property or assets securing such Indebtedness or the Persons obligated thereon.
Section 6.10.Use of Proceeds. Request any Borrowing, use, or allow any Subsidiary to use, the proceeds of any Borrowing, directly or, to the knowledge of the Parent Guarantor or any Borrower, indirectly (a) in furtherance of an offer, payment, promise to pay or authorization of the payment or giving of money, or anything else of value to any Person in violation of Anti-Corruption Laws, (b) for the purpose of funding, financing or facilitating any activities, business or transaction of, or with, any Sanctioned Person or in any Sanctioned Country or in any other manner that would result in a violation of Sanctions by any Person that is a party to this Agreement, or (c) to purchase or carry margin
115



stock (within the meaning of Regulation U) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose.
Section 6.11.Financial Covenants.
(a)Maximum Total Leverage Ratio. Permit, with respect to any Measurement Period ending on or after March 31, 2025, the Total Leverage Ratio as of the last day of any Measurement Period to be greater than the amount set forth in the table below:
Measurement Period ending
Total Leverage Ratio
March 31, 2025
5.75 to 1.00
June 30, 2025
5.50 to 1.00
September 30, 2025
5.25 to 1.00
December 31, 2025
5.00 to 1.00
March 31, 2026
4.75 to 1.00
June 30, 2026
4.35 to 1.00
September 30, 2026
4.00 to 1.00
December 31, 2026
3.75 to 1.00
March 31, 2027
3.35 to 1.00
June 30, 2027
3.30 to 1.00
September 30, 2027
2.75 to 1.00
December 31, 2027 and each fiscal quarter ending thereafter
1.50to 1.00

(b)Minimum Fixed Charge Coverage Ratio. Permit, with respect to any Measurement Period ending on or after March 31, 2025, the Fixed Charge Coverage Ratio of Parent Guarantor and its Subsidiaries as of the last day of any Measurement Period to be less than the amount set forth in the table below:
116



Measurement Period ending
Fixed Charge Coverage Ratio
March 31, 2025
1.15 to 1.00
June 30, 2025
1.15 to 1.00
September 30, 2025
1.25 to 1.00
December 31, 2025
1.30 to 1.00
March 31, 2026
1.35 to 1.00
June 30, 2026
1.40 to 1.00
September 30, 2026
1.45 to 1.00
December 31, 2026
1.50 to 1.00
March 31, 2027
1.50 to 1.00
June 30, 2027
1.50 to 1.00
September 30, 2027
1.50 to 1.00
December 31, 2027 and each fiscal quarter ending thereafter
1.50 to 1.00
(c)
(d)Minimum Liquidity. Permit Liquidity to be less than $12,500,000 for any period of three (3) consecutive Business Days (the “Minimum Liquidity Covenant”).
Section 6.12.Amendments to Organization Documents. Amend any of its Organization Documents in a manner materially adverse to the Lenders (in their capacities as such); provided that, any amendment of any such Organization Documents to confirm “blocker” treatment for UK tax purposes shall not be deemed to be materially adverse to the Lenders.
Section 6.13.Fiscal Year. Make any change in its (a) accounting policies or financial reporting practices, except as required by GAAP, or (b) Fiscal Year; provided that, the Parent Guarantor may, upon written notice to the Administrative Agent, change the Fiscal Year to any other fiscal year reasonably acceptable to the Administrative Agent, in which case, the Parent Guarantor, the Borrowers and the Administrative Agent will, and are hereby authorized by the Lenders to, make any amendments and/or adjustments to this Agreement that are necessary to reflect such change in fiscal year.
Section 6.14.Prepayments of Indebtedness. Prepay, redeem, purchase, defease or otherwise satisfy prior to the scheduled maturity thereof in any manner, or make any payment in violation of any subordination terms of, any Indebtedness that is (x) subordinated in right of payment to the Obligations expressly by its terms, (y) unsecured or (z) secured on a junior lien basis to any Liens securing the Obligations (collectively, the “Junior Indebtedness”), except, in each case, so long as no Event of Default has occurred and is continuing or would be caused thereby, for (a) the Refinancing thereof with the proceeds of any Permitted Refinancing Indebtedness permitted by Section 6.03, (b) the prepayment of Indebtedness of the Parent Guarantor, any Borrower or any Subsidiary owed to the Parent Guarantor, any Borrower or any Subsidiary to the extent not prohibited by the subordination provisions
117



applicable thereto (without duplication of, or giving effect to, the clauses of this Section), (c) prepayments, redemptions, purchases or other payments made to satisfy Junior Indebtedness (not in violation of any subordination terms in respect thereof) in an amount not to exceed, so long as the pro forma Total Leverage Ratio is less than 3.75:1.00 and pro forma Liquidity is greater than $15,000,000, an amount not to exceed the Available Amount at the time of the making of such prepayment, redemption, repurchase or other payment, (d) unlimited prepayments, redemptions, purchases or other payments made to satisfy Junior Indebtedness (not in violation of any subordination terms in respect thereof) shall be permitted so long as the pro forma Total Leverage Ratio would be less than 2.25:1.00, (e) payments of regularly scheduled interest and fees due under any document, agreement or instrument evidencing any Junior Indebtedness or entered into in connection with any Junior Indebtedness, other non-principal payments thereunder, any mandatory prepayments of principal, interest and fees thereunder, scheduled payments thereon necessary to avoid the Junior Indebtedness from constituting “applicable high yield discount obligations” within the meaning of Section 163(i)(1) of the Code and principal on the scheduled maturity date of any Junior Indebtedness (or within ninety (90) days thereof), in each case to the extent not expressly prohibited by the subordination provisions applicable thereto, if any, and (f) the conversion or exchange of any Junior Indebtedness to Equity Interests (other than Disqualified Equity Interests) of the Parent Guarantor or any of its direct or indirect parents.
Section 6.15.Sale and Leaseback Transactions. Enter into any Sale and Leaseback Transaction in which any Loan Party is the seller or the lessee unless the disposition of assets is permitted under Section 6.05 and the incurrence of indebtedness is permitted by Section 6.03.
Section 6.16.Amendments to Indebtedness. Amend, modify, or change in any manner any term or condition of any Junior Indebtedness, in each case, in a manner materially adverse to the Lenders.
Section 6.17.Parent Guarantor. With respect to Parent Guarantor, engage in any material business activities; provided that the following shall be permitted in any event: (i) its ownership of its Subsidiaries and activities incidental thereto, (ii) maintenance of its legal existence (including the ability to incur fees, costs and expenses relating to such maintenance), (iii) any offering or any other issuance or sale of its Equity Interests, (iv) the receipt and payment of dividends and making contributions to the capital of its Subsidiaries, (v) participating in tax, accounting and other administrative matters as a member of the consolidated group of Parent Guarantor, the Borrowers and the Subsidiaries, (vi) holding any cash or Cash Equivalents, (vii) providing indemnification to officers and directors, (viii) the performance of its obligations with respect to the Loan Documents and any other Indebtedness, (ix) liabilities and activities to comply with applicable Law, (x) the maintenance and administration of equity option and ownership plans, (xi) the Parent Guarantor may consolidate or merge with or into any other Person or Dispose of all or substantially all of its assets to any other Person in accordance with Section 6.04 hereof, (xii) issuances of guarantees (A) of Indebtedness of the Borrowers and the other Loan Parties, to the extent such Indebtedness is otherwise permitted by this Agreement and (B) of Contractual Obligations of a Subsidiary of the Parent Guarantor entered into in the ordinary course of business and not constituting Indebtedness, (xiii) entering into and maintaining any customary insurance or casualty policies on behalf of itself and/or the consolidated group of the Parent Guarantor and the Borrowers, (xiv) maintain the D&O Financing and (xv) any activities incidental to the foregoing. Notwithstanding anything herein to the contrary, Parent Guarantor shall not directly hold the equity interests of any Person other than a Loan Party.
Section 6.18.No Excess Cash. Permit any Subsidiary formed or organized under the laws of Thailand or Vietnam (or any political sub-division of Thailand or Vietnam, as applicable) to maintain a balance of cash and Cash Equivalents (in the aggregate for all of the checking, savings and other accounts of all such Subsidiaries), at the close of business on the last Business Day of any month, in excess of $2,500,000 for any month in the Fiscal Year ended December 31, 2025, $3,000,000 for any month in the Fiscal Year ended December 31, 2026, $3,500,000 for any month in the Fiscal Year ended December 31, 2027, and $4,000,000 for any month in the Fiscal Year ended December 31, 2028 and thereafter.
Section 6.19.Specified Material Contract. Terminate the Specified Material Contract, unless the Parent Guarantor, any Borrower or any Subsidiary enters into another contract with a new
118



distributor covering a reasonably similar geographic area, and with substantially equivalent terms, as the Specified Material Contract within six (6) months after the termination of the Specified Material Contract.
Article VII

Events of Default
Section 7.01.Events of Default. Each of the following shall constitute an Event of Default (each, an “Event of Default”):
(a)Non-Payment. The Parent Guarantor, any Borrower or any other Loan Party fails to pay (i) when and as required to be paid herein, any amount of principal of any Loan, or (ii) within three (3) Business Days after the same becomes due, any interest on any Loan or any fee due hereunder, or (iii) within three (3) Business Days after the same becomes due, any other amount payable hereunder or under any other Loan Document; or
(b)Specific Covenants. (i) The Parent Guarantor or any Borrower fails to perform or observe any term, covenant or agreement contained in any of Sections 5.03(a), 5.04, 5.10, 5.11, 5.13 or Article 6 (other than the disclosure required by the lead-in to Section 6.08) or (ii) the Parent Guarantor or any Borrower fails to perform or observe any term, covenant or agreement contained in Sections 5.01 or 5.02(a) and such failure continues for ten (10) days; or
(c)Other Defaults. Any Loan Party fails to perform or observe any other covenant or agreement (not specified in subsection (a) or (b) above) contained in any Loan Document on its part to be performed or observed and such failure continues until the earlier of (i) thirty (30) days after the Administrative Agent provides written notice to the Administrative Borrower of such failure or (ii) thirty (30) days after any Loan Party has knowledge of such failure; or
(d)Representation and Warranties. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Parent Guarantor, any Borrower or any other Loan Party herein, in any other Loan Document, or in any document delivered in connection herewith or therewith shall be incorrect in any material respect when made or deemed made; or
(e)Cross-Default. (i) The Parent Guarantor, any Borrower or any Subsidiary (A) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Guarantee (other than Indebtedness under the Loan Documents and Indebtedness under Swap Contracts) having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than the Threshold Amount or (B) fails to observe or perform any other agreement or condition relating to any such Indebtedness or Guarantee or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, in each case after any applicable grace, cure or notice period, the effect of which default or other event is to cause, or to permit the holder or holders of such Indebtedness or the beneficiary or beneficiaries of such Guarantee (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Indebtedness to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded (provided that, this clause (B) shall not apply to secured Indebtedness that becomes due as a result of the sale, transfer or other disposition (including as a result of a casualty or condemnation event) of the property or assets securing such Indebtedness (to the extent such sale, transfer or other disposition is not prohibited under this Agreement) or (ii) there occurs under any Swap Contract an Early Termination Date (as defined, or as such comparable term may be used and defined, in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which the Parent Guarantor, any Borrower or any Subsidiary is the Defaulting Party (as defined, or as such comparable term may be used and defined, in such Swap Contract) or (B) any Termination Event (as defined, or as such comparable term may be used and defined, in such Swap Contract) under such Swap Contract as to which the Parent Guarantor, any Borrower or any Subsidiary is an Affected Party (as defined, or as such comparable term may be used and defined, in such
119



Swap Contract) and, in either event, the Swap Termination Value owed by the Parent Guarantor, such Borrower or such Subsidiary as a result thereof is greater than the Threshold Amount; or
(f)Insolvency Proceedings, Etc. Any Loan Party or any Subsidiary institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for sixty (60) days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undismissed or unstayed for sixty (60) days, or an order for relief is entered in any such proceeding; or
(g)Inability to Pay Debts; Attachment; Strike-Off. (i) The Parent Guarantor, any Borrower or any Subsidiary becomes unable or admits in writing its inability or fails generally to pay its debts as they become due (including, in respect of the Parent Guarantor and any such Subsidiary incorporated under the laws of the Cayman Islands, if it is or becomes unable to pay its debts within the meaning of Section 93 of the Companies Act (as amended) of the Cayman Islands), (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of the Parent Guarantor, any Borrower or any Subsidiary (and is not released, vacated or fully bonded within sixty (60) days after its issue or levy or (iii) in respect of any of the Parent Guarantor or any Subsidiary incorporated under the laws of the Cayman Islands, action is being or is taken by the Registrar of Companies of the Cayman Islands or any other person to dissolve such Subsidiary or to strike such Subsidiary off the Cayman Islands register of companies; or
(h)Judgments. There is entered against the Parent Guarantor, any Borrower or any Subsidiary one or more final judgments, orders or settlements requiring the payment of money in an aggregate amount (as to all such judgments, orders or settlements) exceeding the Threshold Amount (to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage) and (i) enforcement proceedings are commenced by any creditor upon such judgment, order or settlement, or (ii) there is a period of sixty (60) consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect; or
(i)ERISA. (i) An ERISA Event occurs that alone or together with any other ERISA Events that have occurred would reasonably be expected to result in a Material Adverse Effect, or (ii) the Parent Guarantor, any Borrower or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount that could reasonably be expected to have a Material Adverse Effect; or
(j)Invalidity of Loan Documents. Any material provision of any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder including the release or termination thereof by the Required Lenders or satisfaction in full of all the Obligations, ceases to be in full force and effect; or any Loan Party contests in any manner the validity or enforceability of any material provision of any Loan Document; or any Loan Party denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind any material provision of any Loan Document; or
(k)Change of Control. There occurs any Change of Control; or
(l)Collateral Documents. (i) Any Collateral Document after delivery thereof pursuant to Article 4 or Section 5.11 shall for any reason (other than pursuant to the terms hereof) cease to create a valid and perfected first priority Lien (subject to Permitted Prior Liens and any exceptions on the Mortgage Policies issued in connection with the Mortgaged Properties reasonably acceptable to the Administrative Agent) on the Collateral purported to be covered thereby, subject to Liens permitted under Section 6.01 (except to the extent that any such perfection or priority results from (A) the Administrative Agent no longer having possession of certificates actually delivered to it representing securities or negotiable instruments pledged under the Collateral Documents or (B) the UCC filing having lapsed
120



because a UCC continuation statement was not filed in a timely manner) or (ii) subject to the Agreed Security Principles and the Foreign Perfection Requirements, any Lien created or purported to be created by the Collateral Documents shall cease to have the lien priority established or purported to be established by any applicable intercreditor agreement (other than in accordance with its terms); or
(m)Clean Team Agreement Related Matters. The Clean Team Agreement Related Matter results in one or more penalty payments payable by the Parent Guarantor, the Borrowers or the Subsidiaries, in an aggregate amount in excess of $15,000,000 in cash; provided that (i) such event shall not result in an Event of Default until the date that one or more penalty payments have become due and payable and are, in the aggregate, in excess of $15,000,000, (ii) for purposes of determining whether penalty payments exceed $15,000,000 in cash, the actual penalty payments shall be decreased on a dollar-for dollar basis by any Retained Project Romania Proceeds up to $5,000,000 applied to pay such penalty and (iii) for purposes of determining whether penalty payments exceed $15,000,000 in cash, the actual penalty payments shall be decreased on a dollar-for dollar basis by any cash proceeds from the issuance of Qualified Equity Interests of the Parent Guarantor received after the Closing Date (to the extent not otherwise applied or applied to increase any basket capacity) and applied to pay such penalty; or
(n)Loss of License. The loss, suspension or revocation of, or failure to renew, any license or permit now held or hereafter acquired by any Loan Party or any of its Subsidiaries, if such loss, suspension, revocation or failure to renew could reasonably be expected to have a Material Adverse Effect; or
(o)Indictment of Loan Party. The indictment of any Loan Party under any criminal statute, or commencement of criminal or civil proceedings against any Loan Party, pursuant to which statute or proceedings the penalties or remedies sought include forfeiture to any Governmental Authority of any material portion of the property of any Loan Party.
Section 7.02.Remedies Upon an Event of Default. If an Event of Default occurs (other than an event described in Section 7.01(f)), and at any time thereafter during the continuance of such Event of Default, the Administrative Agent may, and shall at the request of the Required Lenders, by notice to the Administrative Borrower, take any or all of the following actions, at the same or different times:
(a)terminate the Commitments, and thereupon the Commitments shall terminate immediately;
(b)declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations accrued hereunder and under any other Loan Document, shall become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrowers and the other Loan Parties; and
(c)exercise on behalf of itself, the Lenders all rights and remedies available to it and the Lenders under the Loan Documents and applicable law.
If an Event of Default described in Section 7.01(f) occurs, the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations accrued hereunder and under any other Loan Document, shall automatically become due and payable, in each case, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Borrower and the Parent Guarantor.
In addition to any other rights and remedies granted to the Administrative Agent and the Lenders in the Loan Documents, the Administrative Agent on behalf of the Lenders may exercise all rights and remedies of a secured party under the UCC or any other applicable law. Without limiting the generality of the foregoing, the Administrative Agent, without demand of performance or other demand,
121



presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Loan Party or any other Person (all and each of which demands, defenses, advertisements and notices are hereby waived by each of the Parent Guarantor and each Borrower, in each case, on behalf of itself and the Subsidiaries), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, or consent to the use by any Loan Party of any cash collateral arising in respect of the Collateral on such terms as the Administrative Agent deems reasonable, and/or may forthwith sell, lease, assign give an option or options to purchase or otherwise dispose of and deliver, or acquire by credit bid on behalf of the Secured Parties, the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of the Administrative Agent or any Lender or elsewhere, upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery, all without assumption of any credit risk. The Administrative Agent or any Lender shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Loan Party, which right or equity is hereby waived and released by each of the Parent Guarantor and each Borrower, in each case, on behalf of itself and the Subsidiaries. Each of the Parent Guarantor and each Borrower further agrees on behalf of itself and the Subsidiaries, at the Administrative Agent’s request, to assemble the Collateral and make it available to the Administrative Agent at places which the Administrative Agent shall reasonably select, whether at the premises of any Borrower, another Loan Party or elsewhere. The Administrative Agent shall apply the net proceeds of any action taken by it pursuant to this Article VII, after deducting all reasonable costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any other way relating to the Collateral or the rights of the Administrative Agent and the Lenders hereunder, including reasonable attorneys’ fees and disbursements, to the payment in whole or in part of the Obligations, in such order as the Administrative Agent may elect, and only after such application and after the payment by the Administrative Agent of any other amount required by any provision of law, including Section 9-615(a)(3) of the New York Uniform Commercial Code, need the Administrative Agent account for the surplus, if any, to any Loan Party. To the extent permitted by applicable law, each of the Parent Guarantor and each Borrower, in each case, on behalf of itself and the Subsidiaries waives all Liabilities it may acquire against the Administrative Agent or any Lender arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) days before such sale or other disposition.
Section 7.03.Application of Payments. Notwithstanding anything herein to the contrary, following the occurrence and during the continuance of an Event of Default, and notice thereof to the Administrative Agent by the Administrative Borrower or the Required Lenders, all payments received on account of the Obligations shall, subject to Section 2.21, be applied by the Administrative Agent as follows:
(i)first, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts or reimbursements payable to the Administrative Agent (including fees and disbursements and other charges of counsel to the Administrative Agent payable under Section 9.03 and amounts pursuant to Section 2.12(c) payable to the Administrative Agent in its capacity as such);
(ii)second, to payment of that portion of the Obligations constituting fees, expenses, indemnities and other amounts (other than principal and interest) payable to the Lenders and the other Secured Parties (including fees and disbursements and other charges of counsel to the Lenders payable under Section 9.03) arising under the Loan Documents, ratably among them in proportion to the respective amounts described in this clause (ii) payable to them;
122



(iii)third, to payment of that portion of the Obligations constituting interest on the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause (iii) payable to them;
(iv)fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans ratably among the Lenders in proportion to the respective amounts described in this clause (iv) payable to them;
(v)fifth, to the payment in full of all other Obligations, in each case ratably among the Administrative Agent, the Lenders and the other Secured Parties based upon the respective aggregate amounts of all such Obligations owing to them in accordance with the respective amounts thereof then due and payable; and
(vi)finally, the balance, if any, after all Obligations have been indefeasibly paid in full, to the Administrative Borrower or as otherwise required by law.
Article VIII

The Administrative Agent
Section 8.01.Authorization and Action.
(a)Each Lender hereby irrevocably appoints the entity named as Administrative Agent in the heading of this Agreement and its successors and assigns to serve as the administrative agent and collateral agent under the Loan Documents and each Lender authorizes the Administrative Agent to take such actions as agent on its behalf and to exercise such powers under this Agreement and the other Loan Documents as are delegated to the Administrative Agent under such agreements and to exercise such powers as are reasonably incidental thereto. Further, each of the Lenders, on behalf of itself and any of its Affiliates that are Secured Parties, hereby irrevocably empower and authorize TCW Asset Management Company LLC (in its capacity as Administrative Agent) to execute and deliver the Collateral Documents and the Guarantee Agreement and all related documents or instruments as shall be necessary or appropriate to effect the purposes of the Collateral Documents and the Guarantee Agreement. In addition, to the extent required under the laws of any jurisdiction other than within the United States, each Lender hereby grants to the Administrative Agent any required powers of attorney to execute and enforce any Collateral Document governed by the laws of such jurisdiction on such Lender’s behalf. Without limiting the foregoing, each Lender hereby authorizes the Administrative Agent to execute and deliver, and to perform its obligations under, each of the Loan Documents to which the Administrative Agent is a party, and to exercise all rights, powers and remedies that the Administrative Agent may have under such Loan Documents.
(b)As to any matters not expressly provided for herein and in the other Loan Documents (including enforcement or collection), the Administrative Agent shall not be required to exercise any discretion or take any action, but shall be required to act or to refrain from acting (and shall be fully protected in so acting or refraining from acting) upon the written instructions of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, pursuant to the terms in the Loan Documents), and, unless and until revoked in writing, such instructions shall be binding upon each Lender; provided that, the Administrative Agent shall not be required to take any action that (i) the Administrative Agent in good faith believes exposes it to liability unless the Administrative Agent receives an indemnification and is exculpated in a manner satisfactory to it from the Lenders with respect to such action or (ii) is contrary to this Agreement or any other Loan Document or applicable law, including any action that may be in violation of the automatic stay under any requirement of law relating to bankruptcy, insolvency or reorganization or relief of debtors or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any requirement of law relating to bankruptcy, insolvency or reorganization or relief of debtors; provided further that, the Administrative Agent may seek clarification or direction from the Required Lenders prior to the exercise of any such instructed action and may refrain from acting until such clarification or direction has been provided. Except as expressly set forth in the Loan Documents, the Administrative Agent shall not have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the
123



Parent Guarantor, any Borrower, any Subsidiary or any Affiliate of any of the foregoing that is communicated to or obtained by the Person serving as Administrative Agent or any of its Affiliates in any capacity. Nothing in this Agreement shall require the Administrative Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it shall have reasonable grounds for believing that repayment of such funds or adequate indemnity against such risk or liability is not reasonably assured to it.
(c)In performing its functions and duties hereunder and under the other Loan Documents, the Administrative Agent is acting solely on behalf of the Lenders (except in limited circumstances expressly provided for herein relating to the maintenance of the Register), and its duties are entirely mechanical and administrative in nature. Without limiting the generality of the foregoing:
(i)the Administrative Agent does not assume and shall not be deemed to have assumed any obligation or duty or any other relationship as the agent, fiduciary or trustee of or for any Lender or any other Secured Party other than as expressly set forth herein and in the other Loan Documents, regardless of whether a Default or an Event of Default has occurred and is continuing (and it is understood and agreed that the use of the term “agent” (or any similar term) herein or in any other Loan Document with reference to the Administrative Agent is not intended to connote any fiduciary duty or other implied (or express) obligations arising under agency doctrine of any applicable law, and that such term is used as a matter of market custom and is intended to create or reflect only an administrative relationship between contracting parties); additionally, each Lender agrees that it will not assert any claim against the Administrative Agent based on an alleged breach of fiduciary duty by the Administrative Agent in connection with this Agreement and/or the transactions contemplated hereby;
(ii)where the Administrative Agent is required or deemed to act as a trustee in respect of any Collateral over which a security interest has been created pursuant to a Loan Document expressed to be governed by the laws of any jurisdiction other than the United States of America, or is required or deemed to hold any Collateral “on trust” pursuant to the foregoing, the obligations and liabilities of the Administrative Agent to the Secured Parties in its capacity as trustee shall be excluded to the fullest extent permitted by applicable law; and
(iii)nothing in this Agreement or any Loan Document shall require the Administrative Agent to account to any Lender for any sum or the profit element of any sum received by the Administrative Agent for its own account.
(d)The Administrative Agent may perform any of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any of their respective duties and exercise their respective rights and powers through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities pursuant to this Agreement. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agent.
(e)The Arranger shall not have obligations or duties whatsoever in such capacity under this Agreement or any other Loan Document and shall incur no liability hereunder or thereunder in such capacity, but all such persons shall have the benefit of the indemnities provided for hereunder.
(f)In case of the pendency of any proceeding with respect to any Loan Party under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on any Loan Party) shall be entitled and empowered (but not obligated) by intervention in such proceeding or otherwise:
124



(i)to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim under Sections 2.12, 2.13, 2.15, 2.17 and 9.03) allowed in such judicial proceeding; and
(ii)to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;
and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such proceeding is hereby authorized by each Lender and each other Secured Party to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders or the other Secured Parties, to pay to the Administrative Agent any amount due to it, in its capacity as the Administrative Agent, under the Loan Documents (including under Section 9.03). Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.
(g)[reserved.]
(h)The provisions of this Article VIII are solely for the benefit of the Administrative Agent and the Lenders, and, except solely to the extent of the Administrative Borrower’s (or Borrowers’) rights to consent pursuant to and subject to the conditions set forth in this Article VIII, none of the Parent Guarantor, any Borrower or any Subsidiary, or any of their respective Affiliates, shall have any rights as a third party beneficiary under any such provisions (other than Section 8.06). Each Secured Party, whether or not a party hereto, will be deemed, by its acceptance of the benefits of the Collateral and of the Guarantees of the Obligations provided under the Loan Documents, to have agreed to the provisions of this Article VIII.
Section 8.02.Administrative Agent’s Reliance, Limitation of Liability, Etc.
(a)Neither the Administrative Agent nor any of its Related Parties shall be (i) liable for any action taken or omitted to be taken by such party, the Administrative Agent or any of its Related Parties under or in connection with this Agreement or the other Loan Documents (x) with the consent of or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in the Loan Documents) or (y) in the absence of its own gross negligence or willful misconduct (such absence to be presumed unless otherwise determined by a court of competent jurisdiction by a final and non-appealable judgment) or (ii) responsible in any manner to any of the Lenders for any recitals, statements, representations or warranties made by any Loan Party or any officer thereof contained in this Agreement or any other Loan Document or in any certificate, report, statement or other document referred to or provided for in, or received by the Administrative Agent under or in connection with, this Agreement or any other Loan Document or for the value, validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Loan Document (including in connection with the Administrative Agent’s reliance on any Electronic Signature transmitted by emailed pdf, or any other electronic means that reproduces an image of an actual executed signature page) or for any failure of any Loan Party to perform its obligations hereunder or thereunder.
(b)The Administrative Agent shall be deemed not to have knowledge of any (i) notice of any of the events or circumstances set forth or described in Section 5.03 or 5.17 unless and until written notice thereof stating that it is a “notice under Section 5.03” or a “notice under Section 5.17”, respectively, in respect of this Agreement and identifying the specific clause under said Section is given to the Administrative Agent by the Administrative Borrower or (ii) notice of any Default or Event of Default unless and until written notice thereof (stating that it is a “notice of Default” or a “notice of an Event of Default”) is given to the Administrative Agent by the Administrative Borrower or a Lender.
125



Further, the Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with any Loan Document, (ii) the contents of any certificate, report or other document delivered thereunder or in connection therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth in any Loan Document or the occurrence of any Default or Event of Default, (iv) the sufficiency, validity, enforceability, effectiveness or genuineness of any Loan Document or any other agreement, instrument or document, (v) the satisfaction of any condition set forth in Article IV or elsewhere in any Loan Document, other than to confirm receipt of items (which on their face purport to be such items) expressly required to be delivered to the Administrative Agent or satisfaction of any condition that expressly refers to the matters described therein being acceptable or satisfactory to the Administrative Agent or (vi) the creation, perfection or priority of Liens on the Collateral or the existence of the Collateral. Notwithstanding anything herein to the contrary, the Administrative Agent shall not be liable for, or be responsible for any Liabilities, costs or expenses suffered by the Parent Guarantor, any Borrower, any Subsidiary, any Lender as a result of, any determination of the Credit Exposure, any of the component amounts thereof or any portion thereof attributable to each Lender or any Dollar amount thereof.
(c)Without limiting the foregoing, the Administrative Agent (i) may treat the payee of any promissory note as its holder until such promissory note has been assigned in accordance with Section 9.04, (ii) may rely on the Register to the extent set forth in Section 9.04(b), (iii) may consult with legal counsel (including counsel to the Borrowers), independent public accountants and other experts selected by it, and shall not be liable for any action taken or omitted to be taken in good faith by it in accordance with the advice of such counsel, accountants or experts, (iv) makes no warranty or representation to any Lender and shall not be responsible to any Lender for any statements, warranties or representations made by or on behalf of any Loan Party in connection with this Agreement or any other Loan Document, (v) in determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received notice to the contrary from such Lender sufficiently in advance of the making of such Loan and (vi) shall be entitled to rely on, and shall incur no liability under or in respect of this Agreement or any other Loan Document by acting upon, any notice, consent, certificate or other instrument or writing (which writing may be a fax, any electronic message, Internet or intranet website posting or other distribution) or any statement made to it orally or by telephone and believed by it to be genuine and signed or sent or otherwise authenticated by the proper party or parties (whether or not such Person in fact meets the requirements set forth in the Loan Documents for being the maker thereof).
Section 8.03.Posting of Communications.
(a)Each of the Parent Guarantor and each Borrower agrees that the Administrative Agent may, but shall not be obligated to, make any Communications available to the Lenders by posting the Communications on IntraLinks™, DebtDomain, SyndTrak, ClearPar or any other electronic platform chosen by the Administrative Agent to be its electronic transmission system (the “Approved Electronic Platform”).
(b)Although the Approved Electronic Platform and its primary web portal are secured with generally-applicable security procedures and policies implemented or modified by the Administrative Agent from time to time (including, as of the Closing Date, a user ID/password authorization system) and the Approved Electronic Platform is secured through a per-deal authorization method whereby each user may access the Approved Electronic Platform only on a deal-by-deal basis, each of the Lenders, the Parent Guarantor and each Borrower acknowledges and agrees that the distribution of material through an electronic medium is not necessarily secure, that the Administrative Agent is not responsible for approving or vetting the representatives or contacts of any Lender that are added to the Approved Electronic Platform, and that there may be confidentiality and other risks associated with such distribution. Each of the Lenders the Parent Guarantor and each Borrower hereby approves distribution of the Communications through the Approved Electronic Platform and understands and assumes the risks of such distribution.
(c)THE APPROVED ELECTRONIC PLATFORM AND THE COMMUNICATIONS ARE PROVIDED “AS IS” AND “AS AVAILABLE”. THE APPLICABLE
126



PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE COMMUNICATIONS, OR THE ADEQUACY OF THE APPROVED ELECTRONIC PLATFORM AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS OR OMISSIONS IN THE APPROVED ELECTRONIC PLATFORM AND THE COMMUNICATIONS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE APPLICABLE PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE APPROVED ELECTRONIC PLATFORM. IN NO EVENT SHALL THE ADMINISTRATIVE AGENT, THE ARRANGER, OR ANY OF THEIR RESPECTIVE RELATED PARTIES (COLLECTIVELY, “APPLICABLE PARTIES”) HAVE ANY LIABILITY TO ANY LOAN PARTY, ANY LENDER OR ANY OTHER PERSON OR ENTITY FOR DAMAGES OF ANY KIND, INCLUDING DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF ANY LOAN PARTY’S OR THE ADMINISTRATIVE AGENT’S TRANSMISSION OF COMMUNICATIONS THROUGH THE INTERNET OR THE APPROVED ELECTRONIC PLATFORM.
(d)Each Lender agrees that notice to it (as provided in the next sentence) specifying that Communications have been posted to the Approved Electronic Platform shall constitute effective delivery of the Communications to such Lender for purposes of the Loan Documents. Each Lender agrees (i) to notify the Administrative Agent in writing (which could be in the form of electronic communication) from time to time of such Lender’s email address to which the foregoing notice may be sent by electronic transmission and (ii) that the foregoing notice may be sent to such email address.
(e)Each of the Lenders the Parent Guarantor and each Borrower agrees that the Administrative Agent may, but (except as may be required by applicable law) shall not be obligated to, store the Communications on the Approved Electronic Platform in accordance with the Administrative Agent’s generally applicable document retention procedures and policies.
(f)Nothing herein shall prejudice the right of the Administrative Agent or any Lender to give any notice or other communication pursuant to any Loan Document in any other manner specified in such Loan Document.
Section 8.04.The Administrative Agent Individually. With respect to its Commitments and Loans, the Person serving as the Administrative Agent shall have and may exercise the same rights and powers hereunder and is subject to the same obligations and liabilities as and to the extent set forth herein for any other Lender. The terms “Lenders”, “Required Lenders”, “Required Revolving Lenders” and any similar terms shall, unless the context clearly otherwise indicates, include the Administrative Agent in its individual capacity as a Lender, or as one of the Required Lenders or Required Revolving Lenders, as applicable. The Person serving as the Administrative Agent and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of banking, trust or other business with, the Parent Guarantor, the Borrower, any Subsidiary or any Affiliate of any of the foregoing as if such Person was not acting as the Administrative Agent and without any duty to account therefor to the Lenders.
Section 8.05.Successor Administrative Agent.
(a)The Administrative Agent may resign at any time by giving thirty (30) days’ prior written notice thereof to the Lenders and the Borrower, whether or not a successor Administrative Agent has been appointed. Upon any such resignation, the Required Lenders shall have the right, in consultation with the Administrative Borrower (unless an Event of Default has occurred and is continuing), to appoint a successor Administrative Agent. If no successor Administrative Agent shall have been so appointed by the Required Lenders, and shall have accepted such appointment, within thirty (30) days after the retiring Administrative Agent’s giving of notice of resignation, then the retiring Administrative Agent may, on behalf of the Lenders and in consultation with the Borrowers (unless an Event of Default has occurred and is continuing), appoint a successor Administrative Agent. In either
127



case, such appointment shall be subject to the prior written approval of the Administrative Borrower (which approval may not be unreasonably withheld and shall not be required while an Event of Default has occurred and is continuing). Upon the acceptance of any appointment as Administrative Agent by a successor Administrative Agent, such successor Administrative Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the retiring Administrative Agent. Upon the acceptance of appointment as Administrative Agent by a successor Administrative Agent, the retiring Administrative Agent shall be discharged from its duties and obligations under this Agreement and the other Loan Documents. Prior to any retiring Administrative Agent’s resignation hereunder as Administrative Agent, the retiring Administrative Agent shall take such action as may be reasonably necessary to assign to the successor Administrative Agent its rights as Administrative Agent under the Loan Documents.
(b)Notwithstanding paragraph (a) of this Section, in the event no successor Administrative Agent shall have been so appointed and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its intent to resign, the retiring Administrative Agent may give notice of the effectiveness of its resignation to the Lenders and the Administrative Borrower, whereupon, on the date of effectiveness of such resignation stated in such notice, (i) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents; provided that, solely for purposes of maintaining any security interest granted to the Administrative Agent under any Collateral Document for the benefit of the Secured Parties, the retiring Administrative Agent shall continue to be vested with such security interest as collateral agent for the benefit of the Secured Parties, and continue to be entitled to the rights set forth in such Collateral Document and Loan Document, and, in the case of any Collateral in the possession of the Administrative Agent, shall continue to hold such Collateral, in each case until such time as a successor Administrative Agent is appointed and accepts such appointment in accordance with this Section (it being understood and agreed that the retiring Administrative Agent shall have no duty or obligation to take any further action under any Collateral Document, including any action required to maintain the perfection of any such security interest) and (ii) the Required Lenders shall succeed to and become vested with all the rights, powers, privileges and duties of the retiring Administrative Agent; provided that, (A) all payments required to be made hereunder or under any other Loan Document to the Administrative Agent for the account of any Person other than the Administrative Agent shall be made directly to such Person and (B) all notices and other communications required or contemplated to be given or made to the Administrative Agent shall directly be given or made to each Lender. Following the effectiveness of the Administrative Agent’s resignation from its capacity as such, the provisions of this Article VIII and Section 9.03, as well as any exculpatory, reimbursement and indemnification provisions set forth in any other Loan Document, shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent and in respect of the matters referred to in the proviso under clause (i) above. Notwithstanding anything herein to the contrary, any retiring Administrative Agent shall continue to be subject to Section 9.12.
Section 8.06.Acknowledgements of Lenders.
(a)Each Lender represents and warrants that (i) the Loan Documents set forth the terms of a commercial lending facility, (ii) it is engaged in making, acquiring or holding commercial loans and in providing other facilities set forth herein as may be applicable to such Lender in each case in the ordinary course of business, and not for the purpose of purchasing, acquiring or holding any other type of financial instrument (and each Lender agrees not to assert a claim in contravention of the foregoing), (iii) it has, independently and without reliance upon the Administrative Agent, the Arranger or any other Lender or any of the Related Parties of any of the foregoing, and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement as a Lender, and to make, acquire or hold Loans hereunder and (iv) it is sophisticated with respect to decisions to make, acquire and/or hold commercial loans and to provide other facilities set forth herein, as may be applicable to such Lender, and either it, or the Person exercising discretion in making its decision to make, acquire and/or hold such commercial loans or to provide such other facilities, is experienced in making, acquiring or holding such commercial loans or providing such other facilities. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent, the Arranger or any other Lender, or any of the Related Parties of any of the foregoing, and based
128



on such documents and information (which may contain material, non-public information within the meaning of the United States securities laws concerning any Borrower and its Affiliates) as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.
(b)Each Lender, by delivering its signature page to this Agreement on the Closing Date, or delivering its signature page to an Assignment and Assumption or any other Loan Document pursuant to which it shall become a Lender hereunder, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be delivered to, or be approved by or satisfactory to, the Administrative Agent or the Lenders on the Closing Date.
(c)(i) Each Lender hereby agrees that (x) if the Administrative Agent notifies such Lender that the Administrative Agent has determined in its sole discretion that any funds received by such Lender from the Administrative Agent or any of its Affiliates (whether as a payment, prepayment or repayment of principal, interest, fees or otherwise; individually and collectively, a “Payment”) were erroneously transmitted to such Lender (whether or not known to such Lender), and demands the return of such Payment (or a portion thereof), such Lender shall promptly, but in no event later than one (1) Business Day thereafter, return to the Administrative Agent the amount of any such Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect, and (y) to the extent permitted by applicable law, such Lender shall not assert, and hereby waives, as to the Administrative Agent, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Payments received, including any defense based on “discharge for value” or any similar doctrine. A notice of the Administrative Agent to any Lender under this Section 8.06(c) shall be conclusive, absent manifest error.
(i)Each Lender hereby further agrees that if it receives a Payment from the Administrative Agent or any of its Affiliates (x) that is in a different amount than, or on a different date from, that specified in a notice of payment sent by the Administrative Agent (or any of its Affiliates) with respect to such Payment (a “Payment Notice”) or (y) that was not preceded or accompanied by a Payment Notice, it shall be on notice, in each such case, that an error has been made with respect to such Payment. Each Lender agrees that, in each such case, or if it otherwise becomes aware a Payment (or portion thereof) may have been sent in error, such Lender shall promptly notify the Administrative Agent of such occurrence and, upon demand from the Administrative Agent, it shall promptly, but in no event later than one (1) Business Day thereafter, return to the Administrative Agent the amount of any such Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid to the Administrative Agent at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect.
(ii)In the event any such erroneous Payment contemplated by this Section 8.06 (an “Erroneous Payment”) (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor by the Administrative Agent in accordance with the preceding clauses, from any Lender that has received such Erroneous Payment (or portion thereof) (or from any recipient who received such Erroneous Payment (or portion thereof) on its respective behalf) (such unrecovered amount, an “Erroneous Payment Return Deficiency”), upon the Administrative Agent’s request to such Lender at any time, (i) such Lender shall be deemed to have assigned its Loans (but not its Commitments) of the relevant class with respect to which such Erroneous Payment was made in an amount equal to the Erroneous Payment Return Deficiency (such assignment of the Loans (but not Commitments), the “Erroneous Payment Deficiency Assignment”) at par plus any accrued and unpaid interest (with the assignment fee to be waived by the Administrative Agent in such instance), and is hereby (together with the
129



Administrative Borrower) deemed to execute and deliver an Assignment and Assumption with respect to such Erroneous Payment Deficiency Assignment, and such Lender shall deliver any Notes evidencing such Loans to the Administrative Borrower or the Administrative Agent, (ii) the Administrative Agent as the assignee Lender shall be deemed to acquire the Erroneous Payment Deficiency Assignment and (iii) upon such deemed acquisition, the Administrative Agent as the assignee Lender shall become a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning Lender shall cease to be a Lender hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this Agreement and its applicable Commitments which shall survive as to such assigning Lender. For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender and such Commitments shall remain available in accordance with the terms of this Agreement.
(iii)Each Lender hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender under any Loan Document with respect to any payment of principal, interest, fees or other amounts, against any amount that the Administrative Agent has demanded to be returned under the preceding clauses.
(iv)Each Borrower and each other Loan Party hereby agrees that (x) in the event an Erroneous Payment (or portion thereof) are not recovered from any Lender that has received such Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights of such Lender with respect to such amount and (y) an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations (or any other Obligations) owed by any Borrower or any other Loan Party, except, in each case of this clause (y), to the extent such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrowers or any other Loan Party for the purpose of making such Erroneous Payment.
(v)To the extent permitted by applicable law, no Lender shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including, without limitation, any defense based on “discharge for value” or any similar doctrine
(vi)Each party’s obligations under this Section 8.06(c) shall survive the resignation or replacement of the Administrative Agent or any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Commitments or the repayment, satisfaction or discharge of all Obligations under any Loan Document.
Section 8.07.Collateral Matters.
(a)Except with respect to the exercise of setoff rights in accordance with Section 9.08 or with respect to a Secured Party’s right to file a proof of claim in an insolvency proceeding, no Secured Party shall have any right individually to realize upon any of the Collateral or to enforce any Guarantee of the Obligations, it being understood and agreed that all powers, rights and remedies under the Loan Documents may be exercised solely by the Administrative Agent on behalf of the Secured Parties in accordance with the terms thereof. In its capacity, the Administrative Agent is a “representative” of the Secured Parties within the meaning of the term “secured party” as defined in the UCC. In the event that any Collateral is hereafter pledged by any Person as collateral security for the Obligations, the Administrative Agent is hereby authorized, and hereby granted a power of attorney, to execute and deliver on behalf of the Secured Parties any Loan Documents necessary or appropriate to grant and perfect a Lien on such Collateral in favor of the Administrative Agent on behalf of the Secured Parties. The Lenders hereby authorize the Administrative Agent, at its option and in its discretion, to release any Lien granted to or held by the Administrative Agent upon any Collateral (i) as described in Section 9.02(d); (ii) as permitted by, but only in accordance with, the terms of the applicable Loan Document (as in effect on the Closing Date or as amended or otherwise modified in accordance with Section 9.02); or (iii) if approved, authorized or ratified in writing by the Required Lenders, unless such
130



release is required to be approved by all of the Lenders hereunder. Upon request by the Administrative Agent at any time, the Lenders will confirm in writing the Administrative Agent’s authority to release particular types or items of Collateral pursuant hereto. Upon any sale or transfer to any Person that is not a Loan Party of assets constituting Collateral which is permitted pursuant to the terms of any Loan Document, or consented to in writing by the Required Lenders or all of the Lenders, as applicable, and upon at least five (5) Business Days’ prior written request by the Administrative Borrower to the Administrative Agent, the Administrative Agent shall (and is hereby irrevocably authorized by the Lenders to) execute such documents as may be necessary to evidence the release of the Liens granted to the Administrative Agent for the benefit of the Secured Parties herein or pursuant hereto upon the Collateral that was sold or transferred; provided that, (i) the Administrative Agent shall not be required to execute any such document on terms which, in the Administrative Agent’s reasonable opinion, would expose the Administrative Agent to liability or create any obligation or entail any consequence other than the release of such Liens without recourse or warranty, and (ii) such release shall not in any manner discharge, affect or impair the Obligations or any Liens upon (or obligations of the Loan Parties in respect of) all interests retained by any Loan Party, including the proceeds of the sale, all of which shall continue to constitute part of the Collateral. Any execution and delivery by the Administrative Agent of documents in connection with any such release shall be without recourse to or warranty by the Administrative Agent.
(b)[Reserved].
(c)The Secured Parties irrevocably authorize the Administrative Agent, at its option and in its discretion, to (i) subordinate any Lien on any property granted to or held by the Administrative Agent under any Loan Document to the holder of any Lien on such property that is permitted by Section 1.15 or Sections 6.01 (f), (i), (n) and (x) and (ii) execute any intercreditor agreements and/or subordination agreements with any holder of any Indebtedness or Liens permitted by this Agreement to the extent such intercreditor agreement and/or subordination agreement is required. The Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon or any certificate prepared by any Loan Party in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders or any other Secured Party for any failure to monitor or maintain any portion of the Collateral.
Section 8.08.Credit Bidding. The Secured Parties hereby irrevocably authorize the Administrative Agent, at the direction of the Required Lenders, to credit bid all or any portion of the Obligations (including by accepting some or all of the Collateral in satisfaction of some or all of the Obligations pursuant to a deed in lieu of foreclosure or otherwise) and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (a) at any sale thereof conducted under the provisions of the Bankruptcy Code, including under Sections 363, 1123 or 1129 of the Bankruptcy Code, or any similar laws in any other jurisdictions to which a Loan Party is subject, or (b) at any other sale, foreclosure or acceptance of collateral in lieu of debt conducted by (or with the consent or at the direction of) the Administrative Agent (whether by judicial action or otherwise) in accordance with any applicable law. In connection with any such credit bid and purchase, the Obligations owed to the Secured Parties shall be entitled to be, and shall be, credit bid by the Administrative Agent at the direction of the Required Lenders on a ratable basis (with Obligations with respect to contingent or unliquidated claims receiving contingent interests in the acquired assets on a ratable basis that shall vest upon the liquidation of such claims in an amount proportional to the liquidated portion of the contingent claim amount used in allocating the contingent interests) for the asset or assets so purchased (or for the equity interests or debt instruments of the acquisition vehicle or vehicles that are issued in connection with such purchase). In connection with any such bid, (i) the Administrative Agent shall be authorized to form one or more acquisition vehicles and to assign any successful credit bid to such acquisition vehicle or vehicles, (ii) each of the Secured Parties’ ratable interests in the Obligations which were credit bid shall be deemed without any further action under this Agreement to be assigned to such vehicle or vehicles for the purpose of closing such sale, (iii) the Administrative Agent shall be authorized to adopt documents providing for the governance of the acquisition vehicle or vehicles (provided that, any actions by the Administrative Agent with respect to such acquisition vehicle or vehicles, including any disposition of the assets or equity interests thereof, shall be governed, directly or indirectly, by, and the governing documents shall provide for, control by the vote of the Required Lenders or their permitted assignees under the terms of this Agreement or the governing documents of the
131



applicable acquisition vehicle or vehicles, as the case may be, irrespective of the termination of this Agreement and without giving effect to the limitations on actions by the Required Lenders contained in Section 9.02 of this Agreement), (iv) the Administrative Agent on behalf of such acquisition vehicle or vehicles shall be authorized to issue to each of the Secured Parties, ratably on account of the relevant Obligations which were credit bid, interests, whether as equity, partnership interests, limited partnership interests or membership interests, in any such acquisition vehicle and/or debt instruments issued by such acquisition vehicle, all without the need for any Secured Party or acquisition vehicle to take any further action, and (v) to the extent that Obligations that are assigned to an acquisition vehicle are not used to acquire Collateral for any reason (as a result of another bid being higher or better, because the amount of Obligations assigned to the acquisition vehicle exceeds the amount of Obligations credit bid by the acquisition vehicle or otherwise), such Obligations shall automatically be reassigned to the Secured Parties pro rata with their original interest in such Obligations and the equity interests and/or debt instruments issued by any acquisition vehicle on account of such Obligations shall automatically be cancelled, without the need for any Secured Party or any acquisition vehicle to take any further action. Notwithstanding that the ratable portion of the Obligations of each Secured Party are deemed assigned to the acquisition vehicle or vehicles as set forth in clause (ii) above, each Secured Party shall execute such documents and provide such information regarding the Secured Party (and/or any designee of the Secured Party which will receive interests in or debt instruments issued by such acquisition vehicle) as the Administrative Agent may reasonably request in connection with the formation of any acquisition vehicle, the formulation or submission of any credit bid or the consummation of the transactions contemplated by such credit bid.
Section 8.09.[Reserved].
Section 8.10.Certain Foreign Pledge Matters.
(a) Cayman Islands:

(i)    In respect of any Loan Party incorporated under the laws of the Cayman Islands as an exempted company or formed and registered as a limited liability company, forthwith following execution of the relevant Collateral Documents, each such Loan Party shall:

(x)    until the full and final unconditional discharge and release of the security granted or otherwise constituted pursuant to the relevant Collateral Documents (the “Discharge Date”), keep and maintain a register of mortgages and charges (the “Register of Mortgages and Charges”), at the relevant Loan Party’s registered office in the Cayman Islands, in accordance with Section 54 of the Cayman Companies Act (as Revised) (the “Cayman Companies Act”) and Section 62 of the Cayman Limited Liability Companies Act (as Revised) (the “Cayman LLC Act”) (as applicable);

(y)    until the Discharge Date, enter into the Register of Mortgages and Charges (and maintain therein) appropriate particulars of the Collateral Documents (which particulars shall include all particulars required to be kept in such Register of Mortgages and Charges pursuant to the provisions of Section 54 of the Cayman Companies Act and Section 62 of the Cayman LLC Act (as applicable)), such particulars to be in a form and substance being satisfactory to the Administrative Agent; and

(z)    provide a copy of the Register of Mortgages and Charges (containing all such particulars as referred to foregoing) to the Administrative Agent (such copy of the Register of Mortgages and Charges being certified, by a director or manager of each relevant Loan Party (as applicable), as a “true, accurate and complete copy of the original”).

132



(ii)    In respect of any Loan Party incorporated under the laws of the Cayman Islands as (i) an exempted company and whose shares are secured by way of any of the Collateral Agreements or (ii) a limited liability company and whose interests are secured by way of any of the Collateral Agreements, forthwith following execution of the relevant Collateral Agreements, each such Loan Party shall:
    
(x)    until the Discharge Date, enter and maintain a notation in such Loan Party’s register of members or register of managers (as applicable) recording appropriate particulars of the security granted or otherwise constituted by the relevant Collateral Agreements; and
(y)    provide a copy of the register of members or the register of managers (as applicable) (containing all such particulars as referred to foregoing) to the Administrative Agent (such copy of the register of members or register of managers (as applicable) being certified, by a director or manager (as applicable) of each relevant Loan Party, as a “true, accurate and complete copy of the original”).

(b) Jersey: In respect of any Jersey Loan Party and whose shares are secured by way of any of the Collateral Agreements, forthwith following execution of the relevant collateral Agreement, each Jersey Loan Party shall:

    (a)    until the Discharge Date, enter and maintain a notation in such Jersey Loan Party’s register of members recording appropriate particulars of the security granted or otherwise constituted by the relevant Jersey Collateral Agreement; and

    (b)    provide a copy of the register of members (containing all such particulars as referred to foregoing) to the Administrative Agent (such copy of the register of members being certificated, by a director of each relevant Jersey Loan Party, as a “true, accurate and complete copy of the original”).


Article IX

Miscellaneous
Section 9.01.Notices.
(a)Except in the case of notices and other communications expressly permitted to be given by telephone (and subject to paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by e-mail, as follows:
(i)if to any Borrower or the Administrative Borrower, to it at c/o Waldencast, 10 Bank Street, Suite 560, White Plains, New York 10606, Attention of Michel Brousset (E-mail michel@waldencast.com) and Manuel Manfredi (E-mail manuel@waldencast.com);
(ii)if to the Parent Guarantor, to it at c/o Waldencast, 10 Bank Street, Suite 560, White Plains, New York 10606, Attention of Michel Brousset (E-mail michel@waldencast.com) and Manuel Manfredi (E-mail manuel@waldencast.com);
(iii)if to the Administrative Agent, to TCW Asset Management Company LLC, 1251 Avenue of the Americas, Suite 4700, New York, NY 10020, Attention of Benjamin McArthur (E-mail: Ben.McArthur@tcw.com and TCW@alterdomus.com) (with a copy (which shall not constitute notice) to Proskauer Rose LLP, One International Place, Boston, MA 02110-2600, Attention of Michelle L. Iodice (Email: miodice@proskauer.com)); and
133



(iv)if to any other Lender, to it at its address (or email) set forth in its Administrative Questionnaire.
Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient). Notices delivered through Approved Electronic Platforms, to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b).
(b)Notices and other communications to any Loan Party or the Lenders hereunder may be delivered or furnished by using Approved Electronic Platforms pursuant to procedures approved by the Administrative Agent; provided that, the foregoing shall not apply to notices pursuant to Article II unless otherwise agreed by the Administrative Agent and the applicable Lender. The Administrative Agent or the Borrowers (or Administrative Borrower) may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that, approval of such procedures may be limited to particular notices or communications.
(c)Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address as described in the foregoing clause (i), of notification that such notice or communication is available and identifying the website address therefor; provided that, for both clauses (i) and (ii) above, if such notice, email or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient.
(d)Any party hereto may change its address or email for notices and other communications hereunder by notice to the other parties hereto.
Section 9.02.Waivers; Amendments.
(a)No failure or delay by the Administrative Agent or any Lender in exercising any right or power hereunder or under any other Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Administrative Agent and the Lenders hereunder and under the other Loan Documents are cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provision of this Agreement or consent to any departure by the Parent Guarantor or any Borrower therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) of this Section, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan shall not be construed as a waiver of any Default, regardless of whether the Administrative Agent or any Lender may have had notice or knowledge of such Default at the time.
(b)Except as provided in Section 1.15, Section 2.14(b), Section 2.14(c), Section 2.17(g) and Section 9.02(d) below, neither this Agreement nor any other Loan Document nor any provision hereof or thereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by, in the case of this Agreement, the Parent Guarantor, the Borrowers and the Required Lenders (or the Administrative Agent with the consent of the Required Lenders) and, in the case of any other Loan Document, the applicable Loan Parties party to such Loan Document and the Required Lenders (or the Administrative Agent with the consent of the Required Lenders); provided that, no such agreement shall (i) increase the Commitment of any Lender without the written consent of such Lender (but not the consent of the Required Lenders) (it being understood that no amendment, modification, termination, waiver or consent with respect to any condition precedent, covenant or Default
134



shall constitute an increase in the Commitment of any Lender), (ii) reduce or forgive the principal amount of any Loan or reduce the rate of interest thereon, or reduce or forgive any interest, fees or other amounts payable hereunder, without the written consent of each Lender directly and adversely affected thereby (but not the consent of the Required Lenders) (except that (A) any amendment or modification of the financial covenants in this Agreement (or defined terms used in the financial covenants in this Agreement) or (B) the waiver or reduction of the Borrowers obligation to pay interest or fees at the applicable Default Rate set forth in Section 2.13(f) shall not constitute a reduction in the rate of interest or fees for purposes of this clause (ii)), (iii) postpone the scheduled date of payment of the principal amount of any Loan, or any interest thereon, or any fees payable hereunder, or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date of expiration of any Commitment, without the written consent of each Lender directly affected thereby (but not the consent of the Required Lenders) (other than any reduction of the amount of, or any extension of the payment date for, the mandatory prepayments required under Section 2.11 or the waiver or reduction of the Borrowers obligation to pay interest or fees at the applicable Default Rate set forth in Section 2.13(f), in each case which shall only require the approval of the Required Lenders), (iv) change Section 2.09(c) or 2.18(b) or (d) in a manner that would alter the ratable reduction of Commitments or the pro rata sharing of payments required thereby, without the written consent of each Lender, (v) change the payment waterfall provisions of Section 2.21(b) or 7.03 without the written consent of each Lender, (vi) waive any condition set forth in Section 4.02 in respect of the making of a Revolving Loan without the written consent of the Required Revolving Lenders (provided further that, notwithstanding anything to the contrary herein, any waiver of the conditions set forth in Section 4.02 in respect of the making of Revolving Loans shall only require the consent of the Required Revolving Lenders), (vii) [reserved], (viii) change any of the provisions of this Section or the definition of “Required Lenders”, “Required Revolving Lenders” or any other provision hereof specifying the number or percentage of Lenders required to waive, amend or modify any rights hereunder or make any determination or grant any consent hereunder, without the written consent of each Lender, (ix) (1) release any Borrower from its obligations under Article X or under the Collateral Documents or (2) release all or substantially all of the Guarantors from their obligations under the Collateral Documents and the Guarantee Agreement, in each case, without the written consent of each Lender, (x) except as provided in clause (d) of this Section or in any Collateral Document (as in effect on the Closing Date or as modified with the consent of all Lenders), release all or substantially all of the Collateral, without the written consent of each Lender, or (xi) except as provided in clause (d) of this Section or in any Collateral Document (as in effect on the Closing Date or as modified with the consent of all Lenders), subordinate the (x) Lien securing the Obligations under the Loan Documents or (y) the Obligations under the Loan Documents in right of payment, in each case, to the obligations under any Indebtedness, without the written consent of each Lender; provided further that, (A) no such agreement shall amend, modify or otherwise affect the rights or duties of the Administrative Agent hereunder without the prior written consent of the Administrative Agent (it being understood that any change to Section 2.21 shall require the consent of the Administrative Agent) and (B) any amendment or waiver that by its terms affects the rights or duties of Lenders holding Loans or Commitments of a particular Class (but not the Lenders holding Loans or Commitments of any other Class) that is adverse to such Class will require only the requisite percentage in interest of the affected Class or Lenders that would be required to consent thereto if such Class of Lenders were the only Class of Lenders. Notwithstanding the foregoing, no consent with respect to any amendment, waiver or other modification of this Agreement or any other Loan Document shall be required of any Defaulting Lender, except with respect to any amendment, waiver or other modification referred to in clause (i), (ii) or (iii) of the first proviso of this paragraph and then only in the event such Defaulting Lender shall be directly and adversely affected by such amendment, waiver or other modification.
(c)Notwithstanding the foregoing, this Agreement and any other Loan Document may be amended (or amended and restated) with the written consent of the Required Lenders, the Administrative Agent and the Borrowers (x) to add one or more credit facilities to this Agreement and to permit extensions of credit from time to time outstanding thereunder and the accrued interest and fees in respect thereof to share ratably in the benefits of this Agreement and the other Loan Documents with the Revolving Loans, the initial Term Loans and the accrued interest and fees in respect thereof and (y) to include appropriately the Lenders holding such credit facilities in any determination of the Required Lenders and Lenders.
(d)
135



(1)    The Liens granted to the Administrative Agent by the Loan Parties on any Collateral shall automatically terminate and be released and the Administrative Agent is hereby authorize to release such Liens (i) upon the Termination Date, (ii) on Collateral constituting property being sold or disposed of to any Person (other than to a Loan Party) in compliance with the terms of this Agreement, (iii) on Collateral constituting property leased to the Parent Guarantor, any Borrower or any Subsidiary under a lease which has expired or been terminated in a transaction permitted under this Agreement, (iv) as required to effect any sale or other disposition of such Collateral in connection with any exercise of remedies of the Administrative Agent and the Lenders pursuant to Article VII or (v) on assets that constitute Excluded Assets. Any such release shall not in any manner discharge, affect, or impair the Obligations or any Liens (other than those expressly being released) upon (or obligations of the Loan Parties in respect of) all interests retained by the Loan Parties, including the proceeds of any sale, all of which shall continue to constitute part of the Collateral.
(2)    Each of the Lenders, on behalf of itself and any of its Affiliates that are Secured Parties, irrevocably authorizes the Administrative Agent to (i) subordinate any Lien on any assets granted to or held by the Administrative Agent under any Loan Document to the holder of any Lien on such property that is permitted by Section 1.15 or Sections 6.01 (f), (i), (n) and (x) and (ii) execute any intercreditor agreements and/or subordination agreements with any holder of any Indebtedness or Liens permitted by this Agreement to the extent such intercreditor agreement and/or subordination agreement is required. In each case as specified in this Section 9.02(d), the Administrative Agent will (and each Lender irrevocably authorizes the Administrative Agent to), at the Borrowers’ expense, execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of such item of Collateral from the assignment and security interest granted under the Collateral Documents or to subordinate its interest in such item, or to evidence the release of such Guarantor from its obligations under the Guarantee Agreement, in each case in accordance with the terms of the Loan Documents and this Section 9.02; provided that, if requested by the Administrative Agent, the Administrative Borrower has delivered a certificate, executed by a Responsible Officer of the Administrative Borrower on or prior to the date any such action is requested to be taken by the Administrative Agent, certifying that the applicable transaction is permitted under the Loan Documents and such release or subordination is permitted pursuant to this Section 9.02(d) (and the Lenders hereby authorize the Administrative Agent to rely upon such certificate in performing its obligations under this Section 9.02(d)).
(e)If, in connection with any proposed amendment, waiver or consent requiring the consent of “each Lender” or “each Lender directly affected thereby,” the consent of the Required Lenders is obtained, but the consent of other necessary Lenders (other than any Affiliate or Approved Fund of the Administrative Agent) is not obtained (any such Lender whose consent is necessary but not obtained being referred to herein as a “Non-Consenting Lender”), then the Administrative Borrower may elect to replace a Non-Consenting Lender as a Lender party to this Agreement, provided that, concurrently with such replacement, (i) another bank or other entity which is reasonably satisfactory to the Administrative Borrower and the Administrative Agent shall agree, as of such date, to purchase for cash the Loans and other Obligations due to the Non-Consenting Lender pursuant to an Assignment and Assumption and to become a Lender for all purposes under this Agreement and to assume all obligations of the Non-Consenting Lender to be terminated as of such date and to comply with the requirements of clause (b) of Section 9.04, (ii) the Borrowers shall pay to such Non-Consenting Lender in same day funds on the day of such replacement (1) all interest, fees, Applicable Premium (if any), and other amounts then accrued but unpaid to such Non-Consenting Lender by the Borrowers hereunder to and including the date of termination, including payments due to such Non-Consenting Lender under Sections 2.15 and 2.17, and (2) an amount, if any, equal to the payment which would have been due to such Lender on the day of such replacement under Section 2.16 had the Loans of such Non-Consenting Lender been prepaid on such date rather than sold to the replacement Lender and (iii) such Non-Consenting Lender shall have received the outstanding principal amount of its Loans. Each party hereto agrees that (i) an assignment required pursuant to this paragraph may be effected pursuant to an Assignment and Assumption executed by the Administrative Borrower, the Administrative Agent and the assignee (or, to the extent applicable, an
136



agreement incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and such parties are participants), and (ii) the Lender required to make such assignment need not be a party thereto in order for such assignment to be effective and shall be deemed to have consented to and be bound by the terms thereof; provided that, following the effectiveness of any such assignment, the other parties to such assignment agree to execute and deliver such documents necessary to evidence such assignment as reasonably requested by the applicable Lender, provided that, any such documents shall be without recourse to or warranty by the parties thereto.
(f)Notwithstanding anything herein to the contrary, if the Administrative Agent and the Borrowers acting together identify any ambiguity, omission, mistake, typographical error or other defect in any provision of this Agreement or any other Loan Document, then the Administrative Agent and the Borrowers shall be permitted to amend, modify or supplement such provision to cure such ambiguity, omission, mistake, typographical error or other defect, and such amendment shall become effective without any further action or consent of any other party to this Agreement.
(g)Notwithstanding anything to the contrary, the Administrative Agent and the Borrowers shall be permitted to amend, modify or supplement this Agreement to give effect to a change in the Parent Guarantor’s fiscal year pursuant to Section 6.13 without any further action or consent of any other party to this Agreement.
(h)Notwithstanding anything herein to the contrary, guarantees, collateral security documents and related documents entered into in connection with this Agreement and the other Loan Documents may be in a form reasonably determined by the Administrative Agent and may be, together with this Agreement, amended, supplemented and waived with the consent of the Administrative Agent at the request of the Borrowers without the need to obtain the consent of any other Lender if such amendment, supplement or waiver is delivered in order (i) to comply with local Law or advice of local counsel, (ii) to cause such guarantee, collateral security document or other document to be consistent with this Agreement and the other Loan Documents, or (iii) to effect the granting, perfection, protection, expansion or enhancement of any security interest in any Collateral or additional property to become Collateral for the benefit of the Secured Parties.
Section 9.03.Expenses; Limitation of Liability; Indemnity Etc.
(a)Expenses. Each Borrower shall pay (i) all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent and its Affiliates and the Arranger (which shall be limited, in the case of legal fees and expenses, to the reasonable and documented fees, disbursements and other charges of a single firm as primary counsel, along with such special regulatory counsel as may reasonably be required by the Administrative Agent, and a single firm of local counsel in each applicable jurisdiction), in connection with the syndication and distribution (including via the Internet or through a service such as Intralinks and any virtual data room fees) of the credit facilities provided for herein, the preparation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) the fees and expenses of any UK tax consultant or advisor engaged in order for the Administrative Agent to negotiate a restructuring pursuant to Section 2.17(g), in an aggregate amount not to exceed $20,000), and (iii) all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent or any Lender (which shall be limited, in the case of legal fees and expenses, to the reasonable and documented fees, disbursements and other charges of a single firm as primary counsel, along with such special regulatory counsel as may reasonably be required by the Administrative Agent, and a single firm of local counsel in each applicable jurisdiction, for all such parties taken as a whole, and, in the event of an actual or reasonably perceived conflict of interest (as reasonably determined by the Administrative Agent), one additional firm of primary counsel, one special regulatory counsel and one additional local counsel in each applicable jurisdiction, in each case, for each group of similarly affected persons) in connection with the enforcement or protection of its rights in connection with this Agreement and any other Loan Document, including its rights under this Section, or in connection with the Loans made hereunder, including all such out-of-pocket expenses (subject to the foregoing limitations with respect to legal fees and expenses) incurred during any workout, restructuring or negotiations in respect of such Loans.
137



(b)Limitation of Liability. To the extent permitted by applicable law (i) no Borrower nor any other Loan Party shall assert, and each Borrower and each other Loan Party hereby waives, any claim against the Administrative Agent, the Arranger, any Lender, and any Related Party of any of the foregoing Persons (each such Person being called a “Lender-Related Person”) for any Liabilities arising from the use by others of information or other materials (including any personal data) obtained through telecommunications, electronic or other information transmission systems (including the Internet), and (ii) no party hereto shall assert, and each such party hereby waives, any Liabilities against any other party hereto, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document, or any agreement or instrument contemplated hereby or thereby, the Transactions, any Loan or the use of the proceeds thereof; provided that, nothing in this Section 9.03(b) shall relieve the Parent Guarantor, any Borrower or any other Loan Party of any obligation it may have to indemnify an Indemnitee, as provided in Section 9.03(c), against any special, indirect, consequential or punitive damages asserted against such Indemnitee by a third party.
(c)Indemnity. Each Borrower shall indemnify the Administrative Agent, the Arranger, each Lender, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all Liabilities and related expenses (which shall be limited, in the case of legal fees and expenses, to the reasonable and documented fees, disbursements and other charges of a single firm of primary counsel, along with such special regulatory counsel as may reasonably be required by the Administrative Agent, and a single firm of local counsel in each applicable jurisdiction for all Indemnitees taken as whole, and, in the event of an actual or reasonably perceived conflict of interest (as reasonably determined by the applicable Indemnitees), one additional firm of primary counsel, one special regulatory counsel and one additional local counsel in each applicable jurisdiction, in each case to each group of similarly affected Indemnitees) incurred by or asserted against any Indemnitee arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document, or any agreement or instrument contemplated hereby or thereby, (ii) the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the Transactions or any other transactions contemplated hereby, (iii) any action taken in connection with this Agreement, including the payment of principal, interest and fees, (iv) any Loan or the use of the proceeds therefrom, (v) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by the Parent Guarantor, any Borrower or any of the Subsidiaries, or any Environmental Liability related in any way to the Parent Guarantor, any Borrower or any of the Subsidiaries, or (vi) any actual or prospective Proceeding in any jurisdiction relating to any of the foregoing (including in relation to enforcing the terms of the limitation of liability and indemnification referred to above), whether or not such Proceeding is brought by the Parent Guarantor, any Borrower or any other Loan Party or its or their respective equity holders, Affiliates, creditors or any other third Person and whether based on contract, tort or any other theory and regardless of whether any Indemnitee is a party thereto; provided that, such indemnity shall not, as to any Indemnitee, be available to the extent that such Liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from (i) the willful misconduct, bad faith or gross negligence of such Indemnitee or any of its Controlled Related Parties, (ii) a breach by such Indemnitee or any of its Controlled Related Parties of its obligations under this Agreement or the other Loan Documents (including a breach of funding obligations) (that is not responsive to a material breach by any Loan Party) or (iii) any dispute solely among Indemnitees (not arising from any act or omission of the Parent Guarantor, any Borrower or any of its Affiliates) other than claims against an Indemnitee acting in its capacity as, or in fulfilling its role as, the Administrative Agent or an Arranger or any other similar capacity under this Agreement or the other Loan Documents. As used above, a “Controlled Related Party” of an Indemnitee means (1) any Controlling Person or Controlled Affiliate of such Indemnitee, (2) the respective directors, officers, or employees of such Indemnitee or any of its Controlling Persons or Controlled Affiliates and (3) the respective agents or representatives of such Indemnitee or any of its Controlling Persons or Controlled Affiliates, in the case of this clause (3), acting at the instructions of such Indemnitee, Controlling Person or Controlled Affiliate; provided that, each reference to a Controlling Person, Controlled Affiliate, director, officer or employee in this sentence pertains to a Controlling Person, Controlled Affiliate, director, officer or employee involved in the arrangement, negotiation or syndication of the credit facilities evidenced by this Agreement. This Section 9.03(c) shall not apply with respect to Taxes other than any Taxes that represent losses, claims or damages arising from any non-Tax claim.
138



(d)Lender Reimbursement. To the extent that the Borrowers fail (or any Borrower fails) to pay any amount required to be paid by it under clause (a) or (c) of this Section 9.03, each Lender severally agrees to pay to the Administrative Agent and each Related Party of any of the foregoing Persons (each, an “Agent-Related Person”), as the case may be, such Lender’s Applicable Percentage (determined as of the time that the applicable payment is sought) of such unpaid amount (it being understood that any Borrower’s failure to pay any such amount shall not relieve the Borrowers of any default in the payment thereof); provided that, the unreimbursed expense or Liability or related expense, as the case may be, was incurred by or asserted against such Agent-Related Person in its capacity as such.
(e)Payments. All amounts due under this Section 9.03 shall be payable not later than fifteen (15) days after written demand therefor; provided that, with respect to such amount due under clause (c) of this Section 9.03, such Indemnitee shall promptly refund such amount to the extent there is a final non-appealable judgment of a court of competent jurisdiction that such Indemnitee was not entitled to indemnification rights with respect to such payment.
Section 9.04.Successors and Assigns.
(a)The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that (i) the Borrowers may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of each Lender (and any attempted assignment or transfer by any Borrower without such consent shall be null and void) and (ii) no Lender may assign or otherwise transfer its rights or obligations hereunder except in accordance with this Section. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants (to the extent provided in paragraph (c) of this Section) and, to the extent expressly contemplated hereby, Indemnitees, Lender-Related Persons and the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.
(b)(i) Subject to the conditions set forth in paragraph (b)(ii) below, any Lender may assign to one or more Persons (other than an Ineligible Institution) all or a portion of its rights and obligations under this Agreement (including all or a portion of its Revolving Commitments and the Loans at the time owing to it) with the prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) of:
(A)the Administrative Borrower (provided that, the Administrative Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received notice thereof); provided further that, no consent of the Administrative Borrower shall be required (i) for an assignment to a Lender, an Affiliate of a Lender, an Approved Fund, (ii) other than with respect to any proposed assignment to any Person that is a Disqualified Institution, if an Event of Default has occurred and is continuing, any other assignee or (iii) with respect to any proposed assignment to any Person that is a Disqualified Institution, if an Event of Default pursuant to Section 7.01(a), (f) or (g) has occurred and is continuing; and
(B)the Administrative Agent; provided that, no consent of the Administrative Agent shall be required for an assignment to a Lender, an Affiliate of a Lender or an Approved Fund.
(viii)Assignments shall be subject to the following additional conditions:
(A)except in the case of an assignment to a Lender or an Affiliate of a Lender or an Approved Fund or an assignment of the entire remaining amount of the assigning Lender’s Commitment or Loans of any Class, the amount of the Commitment or Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent) shall not be less than $5,000,000 (in the case of Revolving
139



Commitments and Revolving Loans) or $1,000,000 (in the case of a Term Loan) unless each of the Administrative Borrower and the Administrative Agent otherwise consent; provided that, no such consent of the Administrative Borrower shall be required if an Event of Default has occurred and is continuing;
(B)each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement, provided that, this clause shall not be construed to prohibit the assignment of a proportionate part of all the assigning Lender’s rights and obligations in respect of one Class of Commitments or Loans;
(C)the parties to each assignment shall execute and deliver to the Administrative Agent (x) an Assignment and Assumption or (y) to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and the parties to the Assignment and Assumption are participants, together with a processing and recordation fee of $3,500, such fee to be paid by either the assigning Lender or the assignee Lender or shared between such Lenders; and
(D)the assignee, if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire in which the assignee designates one or more credit contacts to whom all syndicate-level information (which may contain material non-public information about any Borrower and its Affiliates and their Related Parties or their respective securities) will be made available and who may receive such information in accordance with the assignee’s compliance procedures and applicable laws, including federal and state securities laws.
(iii) The assignee, to the extent such assignee is not an existing Lender, shall deliver to the Administrative Borrower a copy of the executed Assignment and Assumption or agreement incorporating an Assignment and Assumption by reference (as applicable) as soon as reasonably practicable following the execution of such relevant Assignment and Assumption or agreement.
For the purposes of this Section 9.04(b), the terms “Approved Fund” and “Ineligible Institution” have the following meanings:
Approved Fund” means any Person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.
Ineligible Institution” means (a) a natural person, (b) a Defaulting Lender or its Lender Parent, (c) a company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person or relative(s) thereof, (d) the Parent Guarantor, any Borrower or any of their respective Subsidiaries or Affiliates or (e) a Disqualified Institution (unless an Event of Default pursuant to Section 7.01(a), (f) or (g) has occurred and is continuing at the time of such assignment or participation).
(i)    Subject to acceptance and recording thereof pursuant to clause (b)(iv) of this Section, from and after the effective date specified in each Assignment and Assumption the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue
140



to be entitled to the benefits of Sections 2.15, 2.16, 2.17 and 9.03 with respect to facts and circumstances occurring prior to the effective date of such Assignment and Assumption). Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 9.04 shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with clause (c) of this Section.
(ii)    The Administrative Agent, acting for this purpose as an agent of the Borrowers, shall maintain at one of its offices a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amount (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive (absent manifest error), and the Borrowers, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrowers and any Lender, at any reasonable time and from time to time upon reasonable prior notice.
(iii)    Upon its receipt of (x) a duly completed Assignment and Assumption executed by an assigning Lender and an assignee or (y) to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to an Approved Electronic Platform as to which the Administrative Agent and the parties to the Assignment and Assumption are participants, the assignee’s completed Administrative Questionnaire (unless the assignee shall already be a Lender hereunder), the processing and recordation fee referred to in clause (b) of this Section and any written consent to such assignment required by clause (b) of this Section, the Administrative Agent shall accept such Assignment and Assumption and record the information contained therein in the Register; provided that, if either the assigning Lender or the assignee shall have failed to make any payment required to be made by it pursuant to Section 2.07(b), 2.18(e) or 9.03(d), the Administrative Agent shall have no obligation to accept such Assignment and Assumption and record the information therein in the Register unless and until such payment shall have been made in full, together with all accrued interest thereon. No assignment shall be effective for purposes of this Agreement unless it has been recorded in the Register as provided in this paragraph.
(c)Any Lender may, without the consent of, or notice to, any Borrower or the Administrative Agent, sell participations to one or more banks or other entities (a “Participant”), other than an Ineligible Institution, in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitments and/or the Loans owing to it); provided that, (A) such Lender’s obligations under this Agreement shall remain unchanged; (B) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations; and (C) the Borrowers, the Administrative Agent and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that, such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in the first proviso to Section 9.02(b) that affects such Participant. Each Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.15, 2.16 and 2.17 (subject to the requirements and limitations therein, including the requirements under Section 2.17(f) (it being understood that the documentation required under Section 2.17(f) shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that, such Participant (A) agrees to be subject to the provisions of Sections 2.18 and 2.19 as if it were an assignee under paragraph (b) of this Section; and (B) shall not be entitled to receive any greater payment under Section 2.15 or 2.17, with respect to any participation, than
141



its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation. Each Lender that sells a participation agrees, at the Borrowers’ request and expense, to use reasonable efforts to cooperate with the Borrowers to effectuate the provisions of Section 2.19(b) with respect to any Participant. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 9.08 as though it were a Lender; provided that, such Participant agrees to be subject to Section 2.18(d) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that, no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any Commitments, Loans or its other obligations under any Loan Document) to any Person except that the Participant Register shall be available for inspection by the Administrative Borrower upon reasonable request to the extent that such disclosure is necessary to establish that such Commitment, Loan, or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations or Section 1.163-5(b) of the Proposed United States Treasury Regulations (or, in each case, any amended or successor version). The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. Notwithstanding anything herein to the contrary, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.
(d)Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section shall not apply to any such pledge or assignment of a security interest; provided that, no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.
(e)Disqualified Institutions.
(i)So long as no Event of Default pursuant to Section 7.01(a), (f) or (g) has occurred and is continuing, no assignment or participation shall be made to any Person that was a Disqualified Institution as of the date (the “Trade Date”) on which the assigning Lender entered into a binding agreement to sell and assign or grant a participation in all or a portion of its rights and obligations under this Agreement to such Person (unless the Administrative Borrower has consented to such assignment or participation in writing in its sole and absolute discretion, in which case such Person will not be considered a Disqualified Institution for the purpose of such assignment or participation (it being understood and agreed, for the avoidance of doubt, that no such consent by the Administrative Borrower for any assignment to, or participation of, any Person that was a Disqualified Institution as of the Trade Date shall be required if an Event of Default pursuant to Section 7.01(a), (f) or (g) has occurred and is continuing as of the Trade Date)). Notwithstanding anything herein to the contrary, no assignee or Participant shall retroactively be disqualified from becoming a Lender or Participant due to being a Disqualified Institution. Any assignment or participation in violation of this clause (e)(i) shall not be void, but the other provisions of this clause (e) shall apply.
(ii)If any assignment or participation is made to any Disqualified Institution in violation of clause (i) above, the Administrative Borrower may, at its sole expense and effort, upon notice to the applicable Disqualified Institution and the Administrative Agent, require such Disqualified Institution to assign, without recourse (in accordance with and subject to the restrictions contained in this Section 9.04), all of its interest, rights and obligations under this Agreement to one or more Persons (other than an Ineligible Institution) at the lesser of (x) the principal amount thereof and (y) the amount that such Disqualified Institution paid to acquire such interests, rights and obligations in each case plus accrued interest, accrued fees and all other amounts (other than principal amounts) payable to it hereunder.
142



(iii)Notwithstanding anything to the contrary contained in this Agreement, Disqualified Institutions to whom an assignment or participation is made in violation of clause (i) above (A) will not have the right to (x) receive information, reports or other materials provided to Lenders by the Borrowers, the Administrative Agent or any other Lender, (y) attend or participate in meetings attended by the Lenders and the Administrative Agent, or (z) access any electronic site established for the Lenders or confidential communications from counsel to or financial advisors of the Administrative Agent or the Lenders and (B) (x) for purposes of any consent to any amendment, waiver or modification of, or any action under, and for the purpose of any direction to the Administrative Agent or any Lender to undertake any action (or refrain from taking any action) under this Agreement or any other Loan Document, such Disqualified Institution will be deemed to have consented in the same proportion as the Lenders that are not Disqualified Institutions to whom an assignment or participation is made in violation of clause (i) consented to such matter and (y) for purposes of voting on any plan of reorganization, such Disqualified Institution party hereto hereby agrees (1) not to vote on such plan of reorganization (and such Disqualified Institution shall be deemed to have voted in the same proportion as the Lenders that are not Disqualified Institutions to whom an assignment or participation is made in violation of clause (i)), (2) if such Disqualified Institution does vote on such plan of reorganization notwithstanding the restriction in the foregoing clause (1), such vote will be deemed not to be in good faith and shall be “designated” pursuant to Section 1126(e) of the Bankruptcy Code (or any similar provision in any other applicable laws), and such vote shall not be counted in determining whether the applicable class has accepted or rejected such plan of reorganization in accordance with Section 1126(c) of the Bankruptcy Code (or any similar provision in any other applicable laws) and (3) not to contest any request by any party for a determination by the bankruptcy court (or other applicable court of competent jurisdiction) effectuating the foregoing clause (2).
(iv)The Administrative Agent shall have the right, and the Borrowers hereby expressly authorizes the Administrative Agent, to (A) post the list of Disqualified Institutions provided by the Administrative Borrower and any updates thereto from time to time (collectively, the “DQ List”) on an Approved Electronic Platform, including that portion of such Platform that is designated for “public side” Lenders and/or (B) provide the DQ List to each Lender or potential Lender requesting the same.
(v)The Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor or enforce, compliance with the provisions hereof relating to Disqualified Institutions. Without limiting the generality of the foregoing, the Administrative Agent shall not (x) be obligated to ascertain, monitor or inquire as to whether any other Lender or Participant or prospective Lender or Participant is a Disqualified Institution or (y) have any liability with respect to or arising out of any assignment or participation of Loans, or disclosure of confidential information, by any other Person to any Disqualified Institution.
Section 9.05.Survival. All covenants, agreements, representations and warranties made by the Loan Parties in the Loan Documents and in the certificates or other instruments delivered in connection with or pursuant to this Agreement or any other Loan Document shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of the Loan Documents and the making of any Loans, regardless of any investigation made by any such other party or on its behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default or incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other amount payable under this Agreement or any other Loan Document is outstanding and unpaid and so long as the Commitments have not expired or terminated. The provisions of Sections 2.15, 2.16, 2.17 and 9.03 and Article VIII shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans, the expiration or termination of the Commitments or the termination of this Agreement or any other Loan Document or any provision hereof or thereof.
143



Section 9.06.Counterparts; Integration; Effectiveness; Electronic Execution. This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement, the other Loan Documents and any separate letter agreements with respect to fees payable to the Administrative Agent (including for the benefit of the Lenders) constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof which, when taken together, bear the signatures of each of the other parties hereto, and thereafter shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. Delivery of an executed counterpart of a signature page of (x) this Agreement, (y) any other Loan Document and/or (z) any document, amendment, approval, consent, information, notice (including any notice delivered pursuant to Section 9.01), certificate, request, statement, disclosure or authorization related to this Agreement, any other Loan Document and/or the transactions contemplated hereby and/or thereby (each an “Ancillary Document”) that is an Electronic Signature transmitted by emailed pdf, or any other electronic means that reproduces an image of an actual executed signature page shall be effective as delivery of a manually executed counterpart of this Agreement, such other Loan Document or such Ancillary Document, as applicable. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Agreement, any other Loan Document and/or any Ancillary Document shall be deemed to include Electronic Signatures, deliveries or the keeping of records in any electronic form (including deliveries by emailed pdf, or any other electronic means that reproduces an image of an actual executed signature page), each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be; provided that, nothing herein shall require the Administrative Agent to accept Electronic Signatures in any form or format without its prior written consent and pursuant to procedures approved by it; provided further that, without limiting the foregoing, (i) to the extent the Administrative Agent has agreed to accept any Electronic Signature, the Administrative Agent and each of the Lenders shall be entitled to rely on such Electronic Signature purportedly given by or on behalf of the Parent Guarantor, any Borrower or any other Loan Party without further verification thereof and without any obligation to review the appearance or form of any such Electronic Signature and (ii) upon the request of the Administrative Agent, any Electronic Signature shall be promptly followed by a manually executed counterpart. Without limiting the generality of the foregoing, each Borrower and each other Loan Party hereby (i) agrees that, for all purposes, including in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Administrative Agent, the Lenders, the Borrowers and the other Loan Parties, Electronic Signatures transmitted by emailed pdf, or any other electronic means that reproduces an image of an actual executed signature page and/or any electronic images of this Agreement, any other Loan Document and/or any Ancillary Document shall have the same legal effect, validity and enforceability as any paper original, (ii) agrees that the Administrative Agent and each of the Lenders may, at its option, create one or more copies of this Agreement, any other Loan Document and/or any Ancillary Document in the form of an imaged electronic record in any format, which shall be deemed created in the ordinary course of such Person’s business, and destroy the original paper document (and all such electronic records shall be considered an original for all purposes and shall have the same legal effect, validity and enforceability as a paper record), (iii) waives any argument, defense or right to contest the legal effect, validity or enforceability of this Agreement, any other Loan Document and/or any Ancillary Document based solely on the lack of paper original copies of this Agreement, such other Loan Document and/or such Ancillary Document, respectively, including with respect to any signature pages thereto and (iv) waives any claim against any Lender-Related Person for any Liabilities arising solely from the Administrative Agent’s and/or any Lender’s reliance on or use of Electronic Signatures and/or transmissions by emailed pdf, or any other electronic means that reproduces an image of an actual executed signature page, including any Liabilities arising as a result of the failure of any Borrower and/or any other Loan Party to use any available security measures in connection with the execution, delivery or transmission of any Electronic Signature.
Section 9.07.Severability. Any provision of any Loan Document held to be invalid, illegal or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of
144



the remaining provisions thereof; and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction.
Section 9.08.Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to setoff and apply any and all deposits (general or special, time or demand, provisional or final) at any time held, and other obligations at any time owing, by such Lender or any such Affiliate, to or for the credit or the account of the Borrowers against any and all of the obligations of the Borrowers now or hereafter existing under this Agreement or any other Loan Document to such Lender or its Affiliates, irrespective of whether or not such Lender or Affiliate shall have made any demand under this Agreement or any other Loan Document and although such obligations of the Borrowers may be contingent or unmatured or are owed to a branch office or Affiliate of such Lender different from the branch office or Affiliate holding such deposit or obligated on such indebtedness; provided that, in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so setoff shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.21 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender or their respective Affiliates may have. Each Lender agrees to notify the Administrative Borrower and the Administrative Agent promptly after any such setoff and application; provided that, the failure to give such notice shall not affect the validity of such setoff and application.
Section 9.09.Governing Law; Jurisdiction; Consent to Service of Process.
(a)THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN ANY SUCH OTHER LOAN DOCUMENT) SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.
(b)Each of the Lenders and the Administrative Agent hereby irrevocably and unconditionally agrees that, notwithstanding the governing law provisions of any applicable Loan Document, any claims brought against the Administrative Agent by any Secured Party relating to this Agreement, any other Loan Document, the Collateral or the consummation or administration of the transactions contemplated hereby or thereby shall be construed in accordance with and governed by the law of the State of New York.
(c)Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the United States District Court for the Southern District of New York sitting in the Borough of Manhattan (or if such court lacks subject matter jurisdiction, the Supreme Court of the State of New York sitting in the Borough of Manhattan), and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or any other Loan Document or the transactions relating hereto or thereto, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may (and any such claims, cross-claims or third party claims brought against the Administrative Agent or any of its Related Parties may only) be heard and determined in such Federal (to the extent permitted by law) or New York State court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or in any other Loan Document shall affect any right that the Administrative Agent or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Loan Document against any Loan Party or its properties in the courts of any jurisdiction.
(d)Each of the parties hereto hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or any other
145



Loan Document in any court referred to in paragraph (c) of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.
(e)Each of the parties hereto hereby irrevocably consents to service of process in the manner provided for notices in Section 9.01. Nothing in this Agreement or any other Loan Document will affect the right of any party to this Agreement to serve process in any other manner permitted by law.
Section 9.10.WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.
Section 9.11.Headings. Article and Section headings and the Table of Contents used herein are for convenience of reference only, are not part of this Agreement and shall not affect the construction of, or be taken into consideration in interpreting, this Agreement.
Section 9.12.Confidentiality. Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its and its Affiliates’ directors, officers, employees and agents, including accountants, legal counsel and other advisors and financing sources (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any Governmental Authority (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process; provided that, the Administrative Agent or such Lender, as applicable, shall, to the extent practicable and permitted by applicable Law and except with respect to any audit or examination conducted by bank accountants or any Governmental Authority exercising examination or regulatory authority, promptly inform the Administrative Borrower of such disclosure, (d) to any other party to this Agreement, (e) in connection with the exercise of any remedies under this Agreement or any other Loan Document or any suit, action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (1) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement (it being understood that the DQ List may be disclosed to any assignee or Participant, or prospective assignee or Participants, in reliance on this clause (f)) or (2) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to any Borrower and its obligations, (g) on a confidential basis to (1) any rating agency in connection with rating the Parent Guarantor, the Borrowers or the Subsidiaries or the credit facilities provided for herein or (2) on a confidential basis, the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of identification numbers with respect to the credit facilities provided for herein, (h) with the written consent of the Administrative Borrower or (i) to the extent such Information (1) becomes publicly available other than as a result of a breach of this Section or (2) becomes available to the Administrative Agent or any Lender on a nonconfidential basis from a source other than the Borrowers. For the purposes of this Section, “Information” means all information received from the Loan Parties relating to the Borrowers or its business, other than any such information that is available to the Administrative Agent or any Lender on a nonconfidential basis prior to disclosure by any Loan Party or any Subsidiary thereof (other than as a result of a breach of this Section 9.12) and other than information pertaining to this Agreement routinely provided by arrangers to data service providers, including league table providers, that serve the lending industry; provided that, in the case of information received from the Borrowers after the date hereof, such information is clearly identified at the time of
146



delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.
EACH LENDER ACKNOWLEDGES THAT INFORMATION AS DEFINED IN THE IMMEDIATELY PRECEDING PARAGRAPH FURNISHED TO IT PURSUANT TO THIS AGREEMENT MAY INCLUDE MATERIAL NON-PUBLIC INFORMATION CONCERNING ANY BORROWER AND ITS RELATED PARTIES OR THEIR RESPECTIVE SECURITIES, AND CONFIRMS THAT IT HAS DEVELOPED COMPLIANCE PROCEDURES REGARDING THE USE OF MATERIAL NON-PUBLIC INFORMATION AND THAT IT WILL HANDLE SUCH MATERIAL NON-PUBLIC INFORMATION IN ACCORDANCE WITH THOSE PROCEDURES AND APPLICABLE LAW, INCLUDING FEDERAL AND STATE SECURITIES LAWS.
ALL INFORMATION, INCLUDING REQUESTS FOR WAIVERS AND AMENDMENTS, FURNISHED BY THE BORROWERS OR THE ADMINISTRATIVE AGENT PURSUANT TO, OR IN THE COURSE OF ADMINISTERING, THIS AGREEMENT WILL BE SYNDICATE-LEVEL INFORMATION, WHICH MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION ABOUT THE BORROWERS, THE OTHER LOAN PARTIES AND THEIR RELATED PARTIES OR THEIR RESPECTIVE SECURITIES. ACCORDINGLY, EACH LENDER REPRESENTS TO THE BORROWERS AND THE ADMINISTRATIVE AGENT THAT IT HAS IDENTIFIED IN ITS ADMINISTRATIVE QUESTIONNAIRE A CREDIT CONTACT WHO MAY RECEIVE INFORMATION THAT MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION IN ACCORDANCE WITH ITS COMPLIANCE PROCEDURES AND APPLICABLE LAW.
Section 9.13.USA PATRIOT Act. Each Lender that is subject to the requirements of the Patriot Act and the requirements of the Beneficial Ownership Regulation hereby notifies the Administrative Borrower and each other Loan Party that, pursuant to the requirements of the Patriot Act and the Beneficial Ownership Regulation, it is required to obtain, verify and record information that identifies such Borrower or such Loan Party, which information includes the name, address and tax identification number of such Borrower and such Loan Party and other information that will allow such Lender to identify such Borrower and such Loan Party in accordance with the Patriot Act and the Beneficial Ownership Regulation and other applicable “know your customer” and anti-money laundering rules and regulations.
Section 9.14.Releases of Guarantors.
(a)A Guarantor (but not any Borrower) shall automatically be released from its obligations under the Guarantee Agreement and the Collateral Documents upon the consummation of any transaction permitted by this Agreement as a result of which such Guarantor ceases to be a Subsidiary; provided that, if so required by this Agreement, the Required Lenders shall have consented to such transaction and the terms of such consent shall not have provided otherwise. In connection with any release permitted pursuant to this Section 9.14, the Administrative Agent will (and each Lender irrevocably authorizes the Administrative Agent to), at the Borrowers’ expense, execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of such release of such Guarantor from its obligations under the Guarantee Agreement, in each case in accordance with the terms of the Loan Documents and this Section 9.14; provided that, if requested by the Administrative Agent, the Administrative Borrower has delivered a certificate, executed by a Responsible Officer of the Administrative Borrower on or prior to the date any such action is requested to be taken by the Administrative Agent, certifying that the applicable transaction is permitted under the Loan Documents (and the Lenders hereby authorize the Administrative Agent to rely upon such certificate in performing its obligations under this Section 9.14).
147



(b)Further, the Administrative Agent may (and is hereby irrevocably authorized by each Lender to), upon the request of the Administrative Borrower, release any Guarantor (other than any direct or indirect parent entity of any Borrower, and not any Borrower, provided that, this parenthetical shall not prevent any transaction permitted under Section 6.04 involving any direct or indirect parent entity of any Borrower merging with a Borrower or another Loan Party that is a parent entity of a Borrower) from its obligations under the Guarantee Agreement and the Collateral Documents if (i) such Guarantor becomes an Excluded Subsidiary or is otherwise not required pursuant to the terms of this Agreement to be a Guarantor or (ii) such release is approved, authorized or ratified by the requisite Lenders pursuant to Section 9.02.
(c)At such time as the principal and interest on the Loans, the fees, expenses and other amounts payable under the Loan Documents and the other Obligations (other than Unliquidated Obligations for which no claim has been made and other Obligations expressly stated to survive such payment and termination) shall have been paid in full in cash, the Commitments shall have been terminated (the “Termination Date”), the Collateral Documents and all obligations (other than those expressly stated to survive such termination) of each Guarantor thereunder shall automatically terminate, all without delivery of any instrument or performance of any act by any Person.
Notwithstanding anything to the contrary in this Agreement, upon a Subsidiary ceasing to be a Subsidiary (including by way of liquidation or dissolution) in a transaction permitted by this Agreement, such Subsidiary shall be automatically released and relieved of any obligations under this Agreement, the Guarantee Agreement, the Collateral Documents and all other Loan Documents, all Liens granted by such Subsidiary in its assets to the Administrative Agent shall be automatically released, all pledges to the Administrative Agent of Equity Interests in any such Subsidiary shall be automatically released, and the Administrative Agent is authorized to, and shall promptly, deliver to the Administrative Borrower any acknowledgement confirming such releases and all necessary releases and terminations, in each case as the Administrative Borrower may reasonably request to evidence such release and at Borrowers’ expense. To the extent any Loan Document conflicts or is inconsistent with the terms of this Section, this Section shall govern and control in all respects.
Section 9.15.Appointment for Perfection. Each Lender hereby appoints each other Lender as its agent for the purpose of perfecting Liens, for the benefit of the Administrative Agent and the Secured Parties, in assets which, in accordance with Article 9 of the UCC or any other applicable law can be perfected only by possession or control. Should any Lender (other than the Administrative Agent) obtain possession or control of any such Collateral, such Lender shall notify the Administrative Agent thereof, and, promptly upon the Administrative Agent’s request therefor shall deliver such Collateral to the Administrative Agent or otherwise deal with such Collateral in accordance with the Administrative Agent’s instructions.
Section 9.16.Interest Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts which are treated as interest on such Loan under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received or reserved by the Lender holding such Loan in accordance with applicable law, the rate of interest payable in respect of such Loan hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of such Loan but were not payable as a result of the operation of this Section shall be cumulated and the interest and Charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the NYFRB Rate to the date of repayment, shall have been received by such Lender.
Section 9.17.No Fiduciary Duty, etc.
(a)Each of the Parent Guarantor and each Borrower acknowledges and agrees, and acknowledges the Subsidiaries’ understanding, that no Credit Party will have any obligations except those
148



obligations expressly set forth herein and in the other Loan Documents and each Credit Party is acting solely in the capacity of an arm’s length contractual counterparty to the Parent Guarantor and the Borrowers with respect to the Loan Documents and the transactions contemplated herein and therein and not as a financial advisor or a fiduciary to, or an agent of, the Parent Guarantor, the Borrowers or any other person. Each of the Parent Guarantor and the Borrowers agree that it will not assert any claim against any Credit Party based on an alleged breach of fiduciary duty by such Credit Party in connection with this Agreement and the transactions contemplated hereby. Additionally, each of the Parent Guarantor and each Borrower acknowledges and agrees that no Credit Party is advising the Parent Guarantor or the Borrowers as to any legal, tax, investment, accounting, regulatory or any other matters in any jurisdiction. Each of the Parent Guarantor and each Borrower shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated herein or in the other Loan Documents, and the Credit Parties shall have no responsibility or liability to the Parent Guarantor or any Borrower with respect thereto.
(b)Each of the Parent Guarantor and each Borrower further acknowledges and agrees, and acknowledges the Subsidiaries’ understanding, that each Credit Party, together with its Affiliates, is a full service securities or banking firm engaged in securities trading and brokerage activities as well as providing investment banking and other financial services. In the ordinary course of business, any Credit Party may provide investment banking and other financial services to, and/or acquire, hold or sell, for its own accounts and the accounts of customers, equity, debt and other securities and financial instruments (including bank loans and other obligations) of, the Parent Guarantor, the Borrowers, the Subsidiaries and other companies with which the Parent Guarantor, any Borrower or any of the Subsidiaries may have commercial or other relationships. With respect to any securities and/or financial instruments so held by any Credit Party or any of its customers, all rights in respect of such securities and financial instruments, including any voting rights, will be exercised by the holder of the rights, in its sole discretion.
(c)In addition, each of the Parent Guarantor and each Borrower acknowledges and agrees, and acknowledges the Subsidiaries’ understanding, that each Credit Party and its Affiliates may be providing debt financing, equity capital or other services (including financial advisory services) to other companies in respect of which the Parent Guarantor, any Borrower or any of the Subsidiaries may have conflicting interests regarding the transactions described herein and otherwise. No Credit Party will use confidential information obtained from the Borrowers by virtue of the transactions contemplated by the Loan Documents or its other relationships with the Borrowers in connection with the performance by such Credit Party of services for other companies, and no Credit Party will furnish any such information to other companies. Each of the Parent Guarantor and each Borrower also acknowledges that no Credit Party has any obligation to use in connection with the transactions contemplated by the Loan Documents, or to furnish to the Parent Guarantor, any Borrower or any of the Subsidiaries, confidential information obtained from other companies.
Section 9.18.Acknowledgement and Consent to Bail-In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
(b)the effects of any Bail-In Action on any such liability, including, if applicable:
(i)a reduction in full or in part or cancellation of any such liability;
(ii)a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent entity, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other
149



instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or
(iii)the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.
Section 9.19.AHYDO Savings Clause. Notwithstanding anything herein to the contrary, if (1) the Loans remain outstanding after the fifth anniversary of the initial issuance thereof and (2) the aggregate amount of the accrued but unpaid interest on the Loans (including any amounts treated as interest for U.S. federal income tax purposes, such as “original issue discount”) as of any Testing Date occurring after such fifth anniversary exceeds an amount equal to the Maximum Accrual, then all such accrued but unpaid interest on the Loans (including any amounts treated as interest for U.S. federal income tax purposes, such as “original issue discount”) as of such time in excess of an amount equal to the Maximum Accrual shall be paid in cash by the Borrowers to the holders thereof on such Testing Date, it being the intent of the parties hereto that the deductibility of interest under the Loans shall not be limited or deferred by reason of Section 163(i) of the Code. For these purposes, the “Maximum Accrual” is an amount equal to the product of such Loans’ issue price (as defined in Sections 1273(b) and 1274(a) of the Code) and their yield to maturity, and a “Testing Date” is any Interest Payment Date and the date on which any “accrual period” (within the meaning of Section 1272(a)(5) of the Code) closes. Any accrued interest which for any reason has not theretofore been paid shall be paid when otherwise due or in full on the date on which the final principal payment on a Loan is made.
Section 9.20.Borrower for Tax Purposes. Each of the Parties to this Agreement hereby agree that Obagi Cosmeceuticals LLC is intended and expected to be the Borrower for U.S. federal income tax purposes. Accordingly, the Parties agree (i) that payments of interest under this Agreement are treated for U.S. federal income tax as received from sources within the United States and (ii) not to take any position to the contrary for U.S. federal income tax purposes.
Section 9.21.Appointment of Administrative Agent as Security Trustee
(a)For the purposes of any Liens or Collateral created under the English Collateral Agreements, the following additional provisions shall apply. It is intended that the agreement set forth in this Article 10 take effect as a deed notwithstanding the fact that a party (other than any English Loan Party) may only execute this Agreement under hand.
(b)In this Article 9.17, the following expressions have the following meanings:
Appointee” means any receiver, administrator or other insolvency officer appointed in respect of any Loan Party or its assets.

Charged Property” means the assets of the Loan Parties subject to a security interest under the English Collateral Agreements.
Delegate” means any delegate, agent, attorney or co-trustee appointed by the Administrative Agent (in its capacity as security trustee).
(c) The Secured Parties appoint the Administrative Agent to hold the security interests constituted by the English Collateral Agreements on trust for the Secured Parties on the terms of the Loan Documents and the Administrative Agent accepts that appointment. The Administrative Agent, its subsidiaries and associated companies may each retain for its own account and benefit any fee, remuneration and profits paid to it in connection with (i) its activities under the Loan Documents; and (ii) its engagement in any kind of banking or other business with any Loan Party.
(d)Nothing in this Agreement constitutes the Administrative Agent as a trustee or fiduciary of, nor shall the Administrative Agent have any duty or responsibility to, any Loan Party. The Administrative Agent shall have no duties or obligations to any other person except for those which are expressly specified in the Loan Documents or mandatorily required by applicable law.
150



(e)The Administrative Agent may appoint one or more Delegates on such terms (which may include the power to sub-delegate) and subject to such conditions as it thinks fit, to exercise and perform all or any of the duties, rights, powers and discretions vested in it by the English Collateral Agreements and shall not be obliged to supervise any Delegate or be responsible to any person for any loss incurred by reason of any act, omission, misconduct or default on the part of any Delegate.
(f)The Administrative Agent may (whether for the purpose of complying with any law or regulation of any overseas jurisdiction, or for any other reason) appoint (and subsequently remove) any person to act jointly with the Administrative Agent either as a separate trustee or as a co-trustee on such terms and subject to such conditions as the Administrative Agent thinks fit and with such of the duties, rights, powers and discretions vested in the Administrative Agent by the English Collateral Agreements as may be conferred by the instrument of appointment of that person.
(g)The Administrative Agent shall notify the Secured Parties of the appointment of each Appointee (other than a Delegate). Subject to Section 9.03 of this Agreement, the Administrative Agent may pay reasonable remuneration to any Delegate or Appointee, together with any costs and expenses (including legal fees) reasonably incurred by the Delegate or Appointee in connection with its appointment. All such remuneration, costs and expenses shall be treated, for the purposes of this Agreement, as paid or incurred by the Administrative Agent.
(h)Each Delegate and each Appointee shall have every benefit, right, power and discretion and the benefit of every exculpation (together “Rights”) of the Administrative Agent (in its capacity as security trustee) under the English Collateral Agreements, and each reference to the Administrative Agent (where the context requires that such reference is to the Administrative Agent in its capacity as security trustee) in the provisions of the English Collateral Agreements which confer Rights shall be deemed to include a reference to each Delegate and each Appointee.
Each Secured Party confirms its approval of the English Collateral Agreements and authorizes and instructs the Administrative Agent: (i) to execute and deliver the English Collateral Agreements; (ii) to exercise the rights, powers and discretions given to the Administrative Agent (in its capacity as security trustee) under or in connection with the English Collateral Agreements together with any other incidental rights, powers and discretions; and (iii) to give any authorizations and confirmations to be given by the Administrative Agent (in its capacity as security trustee) on behalf of the Secured Parties under the English Collateral Agreements.

(i)The Administrative Agent may accept without inquiry the title (if any) which any person may have to the Charged Property. Each other Secured Party confirms that it does not wish to be registered as a joint proprietor of any security interest constituted by an English Collateral Agreement and accordingly authorizes: (a) the Administrative Agent to hold such security interest in its sole name (or in the name of any Delegate) as trustee for the Secured Parties; and (b) the Land Registry (or other relevant registry) to register the Administrative Agent (or any Delegate or Appointee) as a sole proprietor of such security interest.
(j)Except to the extent that an English Collateral Agreement otherwise requires, any moneys which the Administrative Agent receives under or pursuant to an English Collateral Agreement may be: (a) invested in any investments which the Administrative Agent selects and which are authorized by applicable law; or (b) placed on deposit at any bank or institution (including the Administrative Agent) on terms that the Administrative Agent thinks fit, in each case in the name or under the control of the Administrative Agent, and the Administrative Agent shall hold those moneys, together with any accrued income (net of any applicable Tax) to the order of the Lenders, and shall pay them to the Lenders on demand.
On a disposal of any of the Charged Property which is permitted under the Loan Documents, the Administrative Agent shall (at the cost of the Loan Parties) execute any release of the English Collateral Agreements or other claim over that Charged Property and issue any certificates of non-crystallisation of
151



floating charges that may be required or take any other action that the Administrative Agent considers desirable.
(k) The Administrative Agent shall not be liable for (i) any defect in or failure of the title (if any) which any person may have to any assets over which security is intended to be created by an English Collateral Agreement; (ii) any loss resulting from the investment or deposit at any bank of moneys which it invests or deposits in a manner permitted by an English Collateral Agreement; (iii) the exercise of, or the failure to exercise, any right, power or discretion given to it by or in connection with any Loan Document or any other agreement, arrangement or document entered into, or executed in anticipation of, under or in connection with, any Loan Document; or (iv) any shortfall which arises on enforcing an English Collateral Agreement.
The Administrative Agent shall not be obligated to (i) obtain any authorization or environmental permit in respect of any of the Charged Property or an English Collateral Agreement; (ii) hold in its own possession an English Collateral Agreement, title deed or other document relating to the Charged Property or an English Collateral Agreement; (iii) perfect, protect, register, make any filing or give any notice in respect of an English Collateral Agreement (or the order of ranking of an English Collateral Agreement), unless that failure arises directly from its own gross negligence or willful misconduct; or (iv) require any further assurances in relation to an English Collateral Agreement.
(l) In respect of any English Collateral Agreement, the Administrative Agent shall not be obligated to: (i) insure, or require any other person to insure, the Charged Property; or (ii) make any enquiry or conduct any investigation into the legality, validity, effectiveness, adequacy or enforceability of any insurance existing over such Charged Property.
In respect of any English Collateral Agreement, the Administrative Agent shall not have any obligation or duty to any person for any loss suffered as a result of: (i) the lack or inadequacy of any insurance; or (ii) the failure of the Administrative Agent to notify the insurers of any material fact relating to the risk assumed by them, or of any other information of any kind, unless Required Lenders have requested it to do so in writing and the Administrative Agent has failed to do so within fourteen (14) days after receipt of that request.
(m)Every appointment of a successor Administrative Agent under an English Collateral Agreement shall be by deed. Section 1 of the Trustee Act 2000 (UK) shall not apply to the duty of the Administrative Agent in relation to the trusts constituted by this Agreement.
(n)In the case of any conflict between the provisions of this Agreement and those of the Trustee Act 1925 (UK) or the Trustee Act 2000 (UK), the provisions of this Agreement shall prevail to the extent allowed by law and shall constitute a restriction or exclusion for the purposes of the Trustee Act 2000 (U.K.).
The perpetuity period under the rule against perpetuities if applicable to this Agreement and any English Collateral Agreement shall be 80 years from the Closing Date.
(o) This section 9.21 shall be governed by English law.
[Signature Pages Follow]

152



IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective authorized officers as of the day and year first above written.
WALDENCAST PLC, as the Parent Guarantor


By    /s/ Hind Sebti    
Name: Hind Sebti
Title: Director

Signature Page to Credit Agreement



MILK MAKEUP LLC, as a Borrower
By        /s/ Tim Coolican    
Name: Tim Coolican
Title: Director and Chief Executive Officer
OBAGI COSMECEUTICALS LLC, as a Borrower
By            
Name: Arash Khazei
Title: President

Signature Page to Credit Agreement



MILK MAKEUP LLC, as a Borrower
By            
Name: Tim Coolican
Title: Director and Chief Executive Officer
OBAGI COSMECEUTICALS LLC, as a Borrower
By        /s/ Arash Khazei    
Name: Arash Khazei
Title: President

2
2516344.01C-NYCSR03A        MSW - Draft March 17, 2025 - 6:10 PM



TCW ASSET MANAGEMENT COMPANY LLC, as Administrative Agent
By    /s/ Suzanne Grosso    
Name: Suzzane Grosso
Title: Managing Director

Signature Page to Credit Agreement




TCW DL VIII FINANCING LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Advisor

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
TCW WV FINANCING LLC, as a Lender

By: TCW Asset Management Company LLC,
its Investment Advisor

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
TCW SKYLINE LENDING LP, as a Lender

By: TCW Asset Management Company LLC its Investment Manager

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
Signature Page to Credit Agreement




TCW BRAZOS FUND LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Advisor

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
TCW DIRECT LENDING STRUCTURED SOLUTIONS 2019 LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Manager

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
TCW STAR DIRECT LENDING LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Advisor

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director





TCW DIRECT LENDING STRUCTURED SOLUTIONS 2022 LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Manager

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director

TCW DIRECT LENDING PRIVATE FUND VIII LP, as a Lender

By: TCW Asset Management Company LLC, its Investment Advisor

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
CCLF HOLDINGS (D41) LLC, as a Lender
By            
Name:
Title:

        


CCLF HOLDINGS (D41) LLC, as a Lender
By    /s/ Stephen Nesbitt    
Name: Stephen Nesbitt
Title: President

        


TCW SPIRIT DIRECT LENDING LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Advisor

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director

TMD- DL HOLDINGS LLC, as a Lender

By: TCW Asset Management Company LLC, its Investment Manager and Attorney-in-Fact

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
SAFETY NATIONAL CASUALTY CORPORATION, as a Lender

By: TCW Asset Management Company LLC,its Investment Manager and Attorney-in-Fact

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director

        


RELIANCE STANDARD LIFE INSURANCE COMPANY, as a Lender

By: TCW Asset Management Company LLC, its Investment Manager and Attorney-in-Fact

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director

PHILADELPHIA INDEMNITY INSURANCE COMPANY, as a Lender

By: TCW Asset Management Company LLC, its Investment Manager and Attorney-in-Fact

By    /s/ Suzanne Grosso    
Name: Suzanne Grozzo
Title: Managing Director
        


Schedules and Exhibits
SCHEDULES
Schedule 1.01 – Expenses, Charges or Losses in respect of Clean Team Agreement Related Matters
Schedule 2.01A – Commitments
Schedule 3.01 – Guarantors
Schedule 3.15 – Subsidiaries; Equity Interests
Schedule 3.18 – Compliance with Laws
Schedule 3.28 – Permits, Etc.
Schedule 3.29 – Health Care
Schedule 5.07 – Compliance with Laws
Schedule 5.17 – Health Care
Schedule 5.11(a) – Agreed Security Principles
Schedule 5.11(b) – Mortgaged Property
Schedule 5.15 – Post-Closing Obligations
Schedule 6.01 – Existing Liens
Schedule 6.02 – Existing Investments
Schedule 6.03 – Existing Indebtedness
Schedule 6.08 – Transactions with Affiliates

EXHIBITS
Exhibit A – Form of Assignment and Assumption
Exhibit B-1 – Form of U.S. Tax Certificate (Foreign Lenders That Are Not Partnerships)
Exhibit B-2 – Form of U.S. Tax Certificate (Foreign Participants That Are Not Partnerships)
Exhibit B-3 – Form of U.S. Tax Certificate (Foreign Participants That Are Partnerships)
Exhibit B-4 – Form of U.S. Tax Certificate (Foreign Lenders That Are Partnerships)
Exhibit C-1 – Form of Borrowing Request
Exhibit C-2 – Form of Interest Election Request
Exhibit D-1 – Form of Revolving Loan Note
Exhibit D-2 – Form of Term Loan Note
Exhibit E – Form of Compliance Certificate
Exhibit F – [Reserved]
Exhibit G – [Reserved]
Exhibit H – Form of Solvency Certificate


†    Pursuant to Item 601(b)(2) of Regulation S-K, certain schedules and exhibits have been omitted. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
        
EX-8.1 4 wald-20241231xexhibit81.htm EX-8.1 Document

Exhibit 8.1

Waldencast plc
List of Subsidiaries


Name of SubsidiaryJurisdiction of Formation
Waldencast Vietnam LimitedVietnam
Milk Makeup LLCU.S., Delaware
Milk Makeup Europe, S.L.Barcelona
Milk Makeup UK LimitedEngland & Wales
Obagi AsiaPac LimitedHong Kong
Obagi Blue Sea Holding, LLCCayman Islands
Obagi Cosmeceuticals LLCU.S., Delaware
Obagi Global Holdings LimitedCayman Islands
Obagi Holdco 1 LimitedJersey
Obagi Holdco 2 LimitedJersey
Obagi Holdings Company LimitedCayman Islands
Obagi Netherlands B.V.Netherlands
Obagi Viet Nam Import Export Trading MTV Company LimitedVietnam
Waldencast Cayman LLCCayman Islands
Waldencast Finco LimitedJersey
Waldencast Malaysia SDN. BHD.Malaysia
Waldencast Partners LPCayman Islands
Waldencast Singapore Pte. Ltd.Singapore
Waldencast (Thailand) Co., Ltd.Thailand
Waldencast UK Operations LimitedEngland & Wales

EX-11.1 5 exhibit111-2024_insidertra.htm EX-11.1 Document
Exhibit 11.1
WALDENCAST PLC INSIDER TRADING POLICY

Adopted on September 16, 2022
(As amended on October 29, 2024)
As a director, officer or employee of Waldencast plc or one of its subsidiaries (together, “we,” “us,” “Waldencast” or the “Company”), you will probably become aware of material information about our business or other companies that we do business with or are interested in acquiring (“other entities”) that is not available to the investing public (“material nonpublic information”). You have a legal and ethical obligation to maintain the confidentiality of material nonpublic information. In addition, it is illegal and a violation of Company policy to purchase or sell any securities of the Company (including selling shares issued under stock options, restricted stock units (“RSUs”) or other equity awards) or in any other entities while you are in possession of material nonpublic information about the Company or those other entities. The Company’s Board of Directors (the “Board”) has adopted this Insider Trading Policy (this “Policy”) to ensure compliance with the law and to avoid even the appearance of improper conduct by anyone associated with Waldencast. We have all worked hard to establish the Company’s reputation for integrity and ethical conduct, and we are all responsible for preserving and enhancing this reputation.

I.WHO IS COVERED BY THE POLICY
This Policy applies to all Waldencast directors, officers and employees, wherever located and whether they work on a full- or part-time basis, and (a) their spouses, minor children, adult family members sharing the same house, and (b) any other person or entity over whom a person subject to the Policy has substantial influence or control when it relates to decisions to purchase or sell securities (collectively, “Related Insiders”). This Policy also applies to any trust or other estate in which you have a substantial beneficial interest or for which you serve as trustee or in a similar fiduciary capacity. We may also determine that the Policy should apply to other people, such as contractors or consultants who have access to material nonpublic information about the Company.

II.TRANSACTIONS COVERED BY THE POLICY
This Policy applies to purchases and sales of securities, including Waldencast ordinary shares, warrants, shares issued under stock options, RSUs or other equity awards, and if we ever issue them preferred shares, bonds or debt securities or convertible debentures and warrants (“Waldencast Securities”). The Policy also applies to purchases and sales of derivative securities, such as exchange-traded put or call options or swaps relating to Waldencast Securities, as well as securities of other entities, to the extent you become aware of material nonpublic information about the other entities by virtue of your employment at or service with Waldencast. The Policy does not apply, however, to trading in funds that may hold Waldencast Securities, such as exchange-traded funds or mutual funds.
If you are a director, officer or an employee that we identify as having regular access to material nonpublic information about our business, then there are additional restrictions that apply to you that are set forth in the Addendum to Insider Trading Policy that is attached to this Policy (the “Addendum”). We will notify you if the Addendum applies to you. The Addendum contains restrictions about trading in our securities during “blackout periods” and requires pre-clearance for transactions in Waldencast Securities.



Exhibit 11.1
III.INDIVIDUAL RESPONSIBILITY
You are responsible for complying with this Policy and ensuring that your Related Insiders also comply with the Policy. As a result, you should make sure that your family and others that live in your home are aware that they need to confer with you before they trade in any Waldencast Securities. You should treat all transactions by your Related Insiders as if they were your own transactions for purposes of this Policy and U.S. securities laws. In all cases, the responsibility for determining whether someone has material nonpublic information rests with that individual. Any action taken by the Company or any other employee pursuant to this Policy does not in any way constitute legal advice or insulate you or your Related Insiders from liability under applicable securities laws.

IV.WHAT IS CONSIDERED MATERIAL NONPUBLIC INFORMATION

What Does Material Mean?
You may wonder what is considered “material” information under the Policy? Under our policies and U.S. securities law, information is material if:

there is a substantial likelihood that a reasonable investor would consider the information important in determining whether to purchase or sell a security; or

the information, if made public, likely would affect the market price of a company’s securities.
Information may be material even if it relates to future, speculative or contingent events and even if it is significant only when considered in combination with already publicly available information. Material information can be positive or negative. Information can be material even with respect to companies that are not publicly traded, such as those with outstanding bonds.
Whether information is considered material depends on the facts and circumstances of each situation. It is impossible to list all the information that could be considered material, but some of the more common examples include:
earnings announcements or guidance on future earnings, or changes to previously released announcements or guidance;
other unpublished financial results;
development of a significant new product, process, or service, or new significant contracts or customers;
the loss of a significant contract or customer;
expansion or shrinking of our operations or major business disruptions;
changes in our management team or the Board;
a cybersecurity incident or risk that may negatively impact our business, reputation or share value;
pending or threatened significant litigation or government action, or the resolution of any of these types of matters;
a pending or proposed merger, acquisition, tender offer, joint venture, restructuring or change in assets;
changes in analyst recommendations or debt ratings;
events related to Waldencast Securities (e.g., stock splits, dividends, changes to the rights of security holders, an offering of additional securities, stock repurchases);
significant changes in the Company’s pricing or cost structure;


Exhibit 11.1
extraordinary borrowing or other financing transactions out of the ordinary course of business;
write-downs and additions to reserves for bad debts;
liquidity problems or impending bankruptcy; and
changes in auditors or auditor notification that the Company may no longer rely on an audit report.
What Does Nonpublic Mean?
What is “Nonpublic” information? Information is considered to be nonpublic unless and until it has been fully disclosed to the public and sufficient time has passed for the stock market to digest the information.
It is important to note that information is not necessarily public just because it has been discussed in the press or on social media, which will sometimes report rumors. You should presume that information is nonpublic until it has been officially released by the Company in at least one of the following ways:
publicly available filings with the U.S. Securities and Exchange Commission (the “SEC”) or securities regulatory authorities; or
issuance of press releases via major newswire.
You may not attempt to “beat the market” by trading simultaneously with, or shortly after, the official release of material information. Although there is no fixed period for how long it takes the market to absorb information, as a general rule a person who has material nonpublic information should not engage in any trading activities for one (1) full trading day following its official release.

What if I have questions about Information?
If the SEC decides to investigate a transaction, they are likely to view it after-the-fact with the benefit of hindsight. As a result, before engaging in any transaction you should carefully consider how the transaction may be construed in the bright light of hindsight. If you have any questions or uncertainties about this Policy, the Addendum or whether information you may have may be considered Material or Nonpublic, please ask a member of Waldencast management or the Company’s legal department (“Legal”). Please note, however, that neither the Company nor Legal can provide legal advice to you on a specific proposed transaction (Legal represents the Company not directors, officers or employees, so you may want to talk to your own legal advisor) and asking the Company or Legal will not insulate you from liability under applicable securities laws.

V.“TIPPING” MATERIAL NONPUBLIC INFORMATION IS PROHIBITED
In addition to trading while in possession of material nonpublic information, it is also illegal and a violation of this Policy to give that information to another person (“tipping”) if you know or have reason to believe that the person will misuse the information by trading in securities or will pass it on to others who will trade on it. This applies regardless of whether the “tippee” is related to you or is an entity, such as a trust or a corporation, and regardless of whether you receive any monetary benefit from the tippee.

VI.GIFTS OF SECURITIES
True or “bona fide” gifts of Waldencast Securities are not subject to this Policy, unless (a) you have a reason to believe that the recipient intends to sell the securities while you are aware of material nonpublic information, or (b) you are subject to the Addendum (in which case you will have to have the gift pre-cleared). Gifts of securities may include gifts to trusts for estate planning purposes, as well as donations to a charitable organization. Whether a gift is “bona fide” may depend on various circumstances surrounding the gift. For example, a gift may not be considered bona fide if you receive a monetary benefit such as a tax deduction by donating shares to a charity before you believe the share price will drop because of material nonpublic


Exhibit 11.1
information you have. Accordingly, you are encouraged to consult Company management or Legal when contemplating a gift.

VII.PROHIBITED TRANSACTIONS

A.Short Sales. You may not engage in short sales of Waldencast Securities. A short sale is a sale of securities when you (i) do not own the securities sold or (ii) do own the securities sold, but do not deliver them within 20 days or place them in the mail within five days of the sale. Short sales may reduce your incentive to seek to improve the Company’s performance and often have the potential to signal to the market that you lack confidence in the Company’s prospects.

B.Margin Accounts and Pledges. Because a margin sale or foreclosure sale may occur at a time when you are aware of material nonpublic information (or for those subject to the Addendum in a blackout period) you may not hold Waldencast Securities in a margin account or otherwise pledge them as collateral for a loan without prior approval in writing from the Company. You will need to get written approval from either Company management or Legal. However, if you are an executive officer or director, you will need to obtain written approval from the Board.

C.Hedging Transactions. You may not engage (directly or indirectly) in hedging transactions, or otherwise engage in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Waldencast Securities. Hedging transactions include (but are not limited to) collars, equity swaps, exchange funds and prepaid variable forward sale contracts. Hedging transactions may allow you to continue to own Waldencast Securities, but without the full risks and rewards of ownership. This may lead you to no longer having the same objectives as the Company’s other shareholders.

VIII.SAFEGUARDING CONFIDENTIAL INFORMATION
If material information about Waldencast has not been disclosed to the general public, you must keep that information in strict confidence and discuss it only with authorized persons and other employees who have a “need to know” the information for a legitimate business purpose. You are required to use the utmost care in protecting the Company’s confidential information. You should follow the guidelines below to help prevent the misuse of our confidential information:

Avoid discussing confidential information with colleagues in places where you may be overheard by people who do not have a valid need to know that information, such as on elevators, in lobbies, common areas, restaurants and on airplanes.

Be very careful when discussing confidential information on speaker phones or on cell phones in locations where you may be overheard. Do not discuss such information with relatives or social acquaintances.

Do not give your computer IDs and passwords to any other person. Password protect your computers and log off when they are not in use.

Always put confidential documents away when you are not using them and, based upon the sensitivity of the material, keep them in a locked desk or office. Do not leave documents containing confidential information where they may be seen by people who do not have a need to know the content of the documents.

Be aware that the Internet and other external electronic mail carriers are not secure environments for the transmission of confidential information. If available, use Company-authorized encryption software to protect confidential electronic communications.

Comply with the specific terms of any confidentiality agreements of which you are aware.


Exhibit 11.1

Upon termination of your employment, you must return to the Company all physical (including electronic) copies of confidential information as well as all other material in any physical or electronic form that is based on or derived from such information, without retaining any copies.

You may not bring the confidential information of any former employer to the Company.

IX.RESPONDING TO REQUESTS FOR INFORMATION
People may ask you questions about various activities of the Company. Questions can come from the media, securities analysts and others asking about our business, rumors about us, trading activity, current and future prospects and plans for the Company, whether we are acquiring or selling companies and other similar important information. Do not attempt to handle these inquiries without prior authorization from Waldencast management. Only Waldencast management or our investor relations or public relations employees or agencies are specifically authorized to answer questions about or disclose information about the Company.

Refer questions or requests for information from the financial community, such as securities analysts, brokers or investors, to the Company’s Chief Executive Officer or Chief Financial Officer.

Refer requests for information about the Company from the media or press to Waldencast management.

Refer requests for information from the SEC or other regulators to Waldencast management or Legal.

Please see our Corporate Disclosure Policy for additional guidelines.

X.REPORTING VIOLATIONS/SEEKING ADVICE
If you suspect someone has violated this Policy, you should report it to Company management or Legal through the reporting procedures set forth in our Code of Ethics and Business Conduct. In addition, if you receive:

material nonpublic information that you are not authorized to receive or that you do not need to know to perform your employment responsibilities; or

confidential information and are unsure if it is within the definition of material nonpublic information or whether its release might be contrary to a fiduciary or other duty or obligation, you should not share it with anyone. Consulting your colleagues can have the effect of making the problem worse. Containment of the information is critical until you have talked to Company management or Legal about the situation.

XI.POST-TERMINATION TRANSACTIONS
This Policy and the Addendum continue to apply to transactions in Waldencast Securities even after you are no longer employed by the Company, or if you are a director after your service on the Board ends. If you have material nonpublic information when your employment/service with the Company ends, you may not trade in Waldencast Securities until that information has become public or is no longer material. Questions or concerns on whether any continuing nonpublic information remains material should be directed to Company management or Legal. If you are subject to the Addendum, the Policy will cease to apply to your transactions in Waldencast Securities upon the expiration of any blackout period or other Company-imposed trading restrictions applicable at the time your employment/service ended.



Exhibit 11.1
XII.PENALTIES FOR VIOLATIONS OF THE INSIDER TRADING POLICY AND LAWS
The personal consequences to you of illegal insider trading can be severe. Any person who “willfully” violates any provision of U.S. securities laws may be fined up to $5 million ($25 million for entities) and/or imprisoned for up to twenty years.
In addition, U.S. law empowers the government to seek significant civil penalties against anyone found liable of insider trading, including as tippers or tippees. The amount of a penalty could total three times the profits made or losses avoided. All those who violate U.S. insider trading laws, including tippers and tippees could be subject to the maximum penalty. The maximum penalty may be assessed even against tippers for the profits made or losses avoided by all people you gave the information to or anyone they then passed the information on to. In addition, civil penalties of the greater of $2 million or three times the profits made or losses avoided can be imposed on any person who “controls” a person who engages in illegal insider trading.
Subject to applicable law, Company employees who violate this Policy may also be subject to discipline by the Company, up to and including termination of employment. Needless to say, a violation of law, or even a governmental or regulatory investigation that does not result in prosecution, can tarnish your reputation and irreparably damage your career.
If you are located or engaged in dealings outside the U.S., you should be aware that laws regarding insider trading and similar offenses differ from country to country. You must abide by the laws in the country where you are located in addition to the U.S. securities laws. If a local law conflicts with this Policy, you should consult Company management or Legal.


Exhibit 11.1
WALDENCAST PLC

ADDENDUM TO
INSIDER TRADING POLICY

INTRODUCTION
This Addendum explains requirements and procedures that apply to all directors and officers of Waldencast plc or one of its subsidiaries (together, “we,” “us,” or the “Company”), as well as designated Company employees who have access to material nonpublic information about the Company (collectively, “Covered Persons”), and is in addition to and supplements the Company’s Insider Trading Policy (the “Policy”). Please note that this Addendum applies to all Waldencast Securities that you hold or may acquire in the future during your employment with the Company. Any capitalized terms used in this Addendum but not defined in it, have the meanings given to them in the Policy.
Please read this Addendum carefully. When you have completed your review, please sign the attached acknowledgment form and return it to Legal.

PRE-CLEARANCE PROCEDURES
As a Covered Person, you and your Related Insiders may not engage in any transaction involving Waldencast Securities (including the exercise of stock options or warrants, sales of shares issued under stock options, RSUs or other equity awards, gifts of shares, loans using Waldencast Securities as collateral, contributions of shares to a trust, or any other transfers) without first obtaining pre-clearance of the transaction from Legal. Each proposed transaction will be evaluated to determine if it raises insider trading concerns or other concerns under applicable laws and regulations. Any advice you receive from Legal will relate solely to the restraints imposed by law and will not constitute advice regarding the investment aspects of any transaction.
If requested and provided within a trading window, clearance will be valid until the end of the relevant trading window, provided that it may be earlier revoked by Legal. If clearance is denied, the fact of such denial must be kept confidential by you.
When a request for pre-clearance is made, you should carefully consider whether you may be aware of any material nonpublic information about the Company and should fully describe your circumstances to Legal. You should also be prepared to comply with applicable securities laws at the time of any sale.

BLACKOUT PERIODS
As a Covered Person, you and your Related Insiders are subject to the following blackout periods, during which you/they may not trade in Waldencast Securities (except by means of pre-arranged 10b5-1 Plans established in compliance with this Addendum). Remember to cancel any “limit” orders or other pending trading orders you have in place during a blackout period (unless the orders were made pursuant to your 10b5-1 Plan).
Quarterly Blackout. Because the announcement of the Company’s quarterly financial results will almost always have the potential to have a material effect on the market for the Company’s securities, all Covered Persons are prohibited from trading in the Company’s securities during the period (i) beginning on the fifteenth (15th) day of the third month of the quarter (March 15, June 15, September 15 and December 15 each year) and (ii) ending after the first full trading day following the release of the Company’s earnings for that quarter. For example, if we issue an earnings release on a Wednesday, you may not trade in Waldencast Securities until open of markets on Friday.
Interim Earnings Guidance Blackout. The Company may on occasion issue interim earnings guidance or other potentially material information by means of a press release, SEC filing on Form 6-K or Form 8-K, as applicable, or other means designed to achieve public dissemination of the information. You should expect that


Exhibit 11.1
trading will be blacked out while the Company is in the process of assembling the information to be released until after the first full trading day following the release of the information.
Event Specific Blackout. From time to time, an event may occur that is material to the Company and is known by only a few directors, officers or employees. The existence of an event-specific blackout will not be announced generally, but you will be informed if you are subject to the event specific blackout. If you are informed that the Company has implemented a special blackout, you may not disclose the fact that trading has been suspended to anyone, including other Company employees (who may themselves not be subject to the special blackout), family members (other than those subject to this Policy who would be prohibited from trading because you are), friends or brokers. You should treat the imposition of a special blackout period as material nonpublic information.
NOTE: Even if a blackout period is not in effect, at no time may you trade in Waldencast Securities if you have material nonpublic information about the Company. The failure of the Company to notify you of an event specific blackout will not relieve you of the obligation not to trade while in possession of material nonpublic information.

RULE 10B5-1 TRADING PLANS
SEC Rule 10b5-1 provides an affirmative defense against insider trading liability. This does not protect you from having any transactions you engage in investigated by the SEC, but can provide a defense for you if you are subject to an investigation. You can rely on this defense and trade in Waldencast Securities, regardless of whether you have material nonpublic information about the Company, if your trade is made under a written trading plan adopted by you in good faith when you were not aware of any material nonpublic information and that plan complies with the requirements of Rule 10b5-1 (a “10b5-1 Plan”). Our shareholder services provider, Fidelity, our your own personal broker can help you with creating a 10b5-1 Plan.
If you want to enter into a 10b5-1 Plan, you must submit a copy of your proposed 10b5-1 Plan to Company management or Legal for approval at least five (5) business days before you want to adopt the 10b5-1 Plan. You may not adopt a 10b5-1 Plan during a blackout period or when you are aware of material nonpublic information about the Company.
Once the 10b5-1 Plan is adopted, you must not exercise any subsequent influence or control over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. Trades should happen automatically under the 10b5-1 Plan according to the provisions of the plan. You may amend, replace, or terminate your 10b5-1 Plan only during periods when trading is permitted in accordance with this Policy, and you must submit any proposed amendment, replacement or termination of your 10b5-1 Plan to Company management or Legal for approval at least five (5) business days prior to adoption. You should understand that frequent changes or terminations of a 10b5-1 Plan may call into question whether you entered into the plan in good faith (and therefore may jeopardize your ability to use the affirmative defense against insider trading allegations).

ACKNOWLEDGEMENT
All directors, officers and other employees subject to the procedures set forth in this Addendum must acknowledge their understanding of, and intent to comply with, the Policy and this Addendum on the form attached to this Addendum.



Exhibit 11.1

INSIDER TRADING POLICY ADDENDUM ACKNOWLEDGMENT FORM

I have read and understand the Company’s Insider Trading Policy and the Addendum attached to it (together, the “Insider Trading Policy”). I agree to comply fully with all policies and procedures contained in the Insider Trading Policy for as long as I am subject to the Insider Trading Policy. If I am an employee of Waldencast plc, I acknowledge that the Insider Trading Policy is a statement of policies and procedures and does not, in any way, constitute an employment contract or an assurance of continued employment.




                             ___________________________________________image_1.jpg
Printed Name


                             __________________________________________________image_1.jpg
Signature


                             __________________________________________________image_1.jpg
Date

EX-11.2 6 exhibit112-codeofethicsand.htm EX-11.2 Document
Exhibit 11.2


WALDENCAST PLC
CODE OF ETHICS AND BUSINESS CONDUCT
(Amended as of March 12, 2025)

1.Introduction
Waldencast plc and its subsidiaries (together, “we,” “us,” “Waldencast” or the “Company”) are committed to conducting all business affairs in an honest, fair, ethical and legal manner. As a representative of Waldencast you are expected to conduct yourself in a similar manner. This Code of Ethics and Business Conduct (the “Code”) sets forth the guidelines for conducting our business consistent with the highest standards of business ethics and the law. The Code applies to all directors, officers and employees of Waldencast, wherever they are located and whether they work for the Company on a full- or part-time basis.
Purpose
The purpose of this Code is to:
promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
promote full, fair, accurate, timely and understandable disclosure in reports and documents that we file with the Securities and Exchange Commission (the “SEC”), as well as in other public communications that we make or that are made on our behalf;
ensure that we comply with all laws, rules and regulations that apply to our business (the “Law”); and
require prompt internal reporting of violations of, and accountability for complying with, this Code.
This Code is just one element of our overall effort to ensure lawful and ethical conduct in all aspects of our business. This Code is not intended to be a comprehensive document that addresses every situation that you may face. In fact, there are many policies and procedures not covered by this Code, such as those covered in your employee handbook or other similar guidelines. These and similar policies, while not a part of the Code, provide additional guidance on acceptable standards of conduct while working for Waldencast. This Code does not take the place of or modify other more detailed written policies. Instead, it establishes key standards and general guidelines that the Company expects you to follow.
Seeking Help and Information
If you are faced with a difficult business decision that is not addressed by this Code, you should ask yourself the following questions:
Am I absolutely certain that my decision is legal and in compliance with Company policy?
Is it honest and fair?
Is it in the best interests of the Company?
Would I feel comfortable if my actions were in the news or posted on social media or in a viral video?
If your answer to any of these questions is “no,” then don’t do it. If you aren’t sure about the answer to any of these questions or still feel uncomfortable about a situation, please talk to your supervisor. If your supervisor can’t answer your question, or if you are not comfortable discussing the situation with your supervisor or with their answer, you should contact Company leadership or the General Counsel or another member of the legal department (legal@waldencast.com) (“Legal”).


Exhibit 11.2
2.Honest, Ethical and Fair Conduct
Essential Principles
All directors, officers and employees owe a duty to the Company to act with integrity.
Integrity requires, among other things, being honest and fair at all times; deceit and dishonesty will not be tolerated. You should never put your own personal gain or advantage above what is right or in the best interests of the Company.
We expect you to:
act with integrity, including being honest and candid while still maintaining the confidentiality of Company trade secrets and confidential information, except as permitted in the Legally Protected Communications section;
comply with the Law;
follow the requirements of accounting and auditing standards that apply to us, as well as Company policies to maintain accurate and complete financial records and other business-related information;
adhere to a high standard of business ethics and not seek competitive advantage through unlawful or unethical business practices;
deal fairly with our customers, suppliers, competitors, employees and independent contractors;
not take advantage of anyone through manipulation, concealment, abuse of confidential information, misrepresentations or other similar actions; and
protect the Company’s assets and make sure they are used properly.
Avoiding Conflicts of Interest
A conflict of interest may occur when you, or one of your family members, has a private interest that interferes, or appears to interfere, with the interests of the Company. In that situation, your loyalties may be divided, which could make it difficult for you to perform your work objectively and effectively and to act in the best interests of the Company. Accordingly, conflicts of interest are prohibited unless: 1) they are allowed under guidelines or resolutions approved by the Company’s Board of Directors (the “Board”) or the appropriate Board committee or 2) as disclosed in our public filings with the SEC.
The following are just a few examples of situations that could lead to a conflict of interest:
owning a significant amount of stock in any other company Waldencast is interested in acquiring (“target company”) or in one of our suppliers or customers;
a consulting or employment relationship with any target company or supplier, customer or competitor of Waldencast;
receiving money, gifts (other than nominal, inexpensive, ones) or excessive entertainment from any person or company that we do business with or with whom we have prospective business;
being in the position of supervising, reviewing or having any influence on the job evaluation, pay or benefit of any close relative or yours;
selling anything to, or buying anything from, the Company, except on the same terms and conditions as given to other directors, officers or employees in similar positions (or, in the absence of any comparable deal, on the same terms and conditions as a third party would buy or sell a similar item in an arm’s-length transaction);


Exhibit 11.2
any other financial transaction, arrangement or relationship (including any debt or guarantee of a debt or obligation) involving the Company; and
any other circumstance, event, relationship or situation in which your personal interest interferes — or even appears to interfere — with the interests of the Company.
Evaluating whether a conflict of interest exists can be difficult and may involve a number of considerations. You should seek guidance from your supervisor, Company leadership or Legal when you have any questions or doubts. You must fully disclose any situation that reasonably could be expected to give rise to or be perceived as a conflict of interest to your supervisor, Company leadership or Legal, who will work with you to determine whether a conflict of interest exists and, if so, how best to address it.
Dealing with Corporate Opportunities
If, through the use of Company property or because of your position with the Company, you discover or are presented with a business opportunity that is related to our business, you should immediately disclose it to your supervisor, Company leadership or Legal. That person will discuss the opportunity with the appropriate members of management to determine whether the situation is a corporate opportunity and, if so, whether the Company would like to pursue it. If you are an officer or member of the Board and want to pursue a business opportunity that is related to the Company’s business, you must first fully present the opportunity to the Board. If the Company decides not to pursue the opportunity, then you may pursue it on the same terms and conditions as originally proposed, provided that your conduct is consistent with the other guidelines set forth in this Code.
Civic and Political contributions
Any contribution to, advocacy for, or endorsement by the Company or any brand of the Company of any civic, social welfare, or non-profit organizations, community initiative, political party, or candidate must receive prior written approval by the CEO of such entity and/or brand. Any contribution to, advocacy for or endorsement on behalf of a brand in excess of USD 100,000 must receive the prior written approval of the CEO of Waldencast plc in addition to the prior written approval by the CEO of such brand. Any contribution to, advocacy for or endorsement on behalf of Waldencast plc in excess of USD 100,000 must receive the prior written approval of the Audit Committee of the Board of Directors of Waldencast plc in addition to the prior written approval by the CEO of Waldencast plc. Corporate funds or assets should not be used without prior approval as set forth above for any such purposes, including, but not limited to, in-kind contributions (such as purchasing tickets to fund-raising events), donations of money, products or services, lobbying, or campaign contributions. This policy applies at the local, state, federal, and international levels.
While the Company encourages employees and directors to engage personally in their communities, social causes and participate in the political process, corporate resources, including financial contributions, facilities, communication tools, or other assets, must not be used for these activities. Directors, officers and employees of Waldencast must ensure their personal views and actions are clearly identified as their own and do not imply endorsement by the Company or any of the brands.
In addition, individuals are free to engage in local political activities or to run for office but must be clear that they are not representing the Company or any of the brands in any way and personal political activities must be kept separate from their work for Waldencast/any of the brands.
Neither the Company nor any of the brands will provide reimbursement to employees or directors for contributions made to any type of cause in any form. In alignment with its ethical standards, the Company and the brands are committed to transparency and compliance with all Laws governing all types of contributions, ensuring that its operations reflect integrity and impartiality.
If you have any question regarding any contemplated civic or political contribution, please contact Legal.


Exhibit 11.2
3.Corporate Records and Disclosures
Corporate & Financial Records
Accurate and reliable records are essential to our business. Our records form the basis for our financial reports and other public disclosures and are the source of critical data that guides management’s decision-making and strategic planning. Our records include sales information and the recording of revenue, employee records, payroll, timecards, expense reports, accounting and financial data, electronic data files, e-mails, research and development records, manufacturing records, distribution information and all other records that we normally keep.
Employees responsible for financial records or who prepare other company records and reports are obligated, ethically and legally, to assure that those documents are accurate, complete, safeguarded against loss or destruction, retained for specified periods as may be established by the Company or otherwise required by Law, and maintained in confidence. There is no valid reason for making or allowing others to make false or misleading entries in our records. All employees responsible for keeping the books and records must communicate candidly with, and provide full and accurate information to, upper management, independent accountants and auditors and, if appropriate, internal and outside legal counsel.
Public Disclosures
As a public company, we are subject to various securities Laws and reporting obligations. These Laws and our policies require timely disclosure of accurate and complete information about our business, financial condition and results of operations in documents we file with the SEC and in other public communications that we make. Inaccurate, incomplete or late reporting can result in serious damage to and legal liability for us. To make sure we comply with the SEC’s disclosure standards, we expect you to:
not misrepresent, or encourage or authorize others to misrepresent, facts about the Company to others, including our independent accountants and auditors, governmental regulators, governmental officials, the SEC, Nasdaq and other self- regulating organizations; and
properly review and critically analyze proposed disclosures for accuracy and completeness.
It is important to note that the SEC regards misrepresentations to include both misstating material information as well as failing to disclose all material information required to make a disclosure complete and accurate. Information is considered material if a reasonable investor would consider it important in deciding whether to buy, sell or hold our stock.
All employees involved in the reporting of the Company’s financial results of operations, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) and each subsidiary of the Company (or persons performing similar functions), should understand and know all disclosure requirements that apply to the Company as well as the business and financial operations of the Company. However, all employees have an obligation to abide by the Law and this Code and must not participate in or tolerate improper financial practices or reporting.
If you are a director you should promptly bring to the attention of the Chairperson of the Audit Committee of the Board, and if you are an officer or employee you should promptly bring to the attention of Legal or your supervisor, any information you may have about: 1) significant deficiencies in our internal and/or disclosure controls that could impact our ability to accurately record, process, summarize and report financial data or 2) any fraud that involves management or other employees who have a significant role in our financial reporting, disclosures or internal controls. If you would prefer to submit your report anonymously, you can use our whistleblower hotline: https://www.whistleblowerservices.com/WALD.
Some examples of matters that should be reported include:
financial results that seem inconsistent with our business transactions;
inaccurate records, such as overstated expense reports or erroneous invoices;


Exhibit 11.2
transactions that don’t seem to have a genuine business purpose;
incidents or concerns about employee theft; and
requests to circumvent ordinary review and approval procedures.
4.Compliance
We have an obligation to comply with all Laws. It’s your personal responsibility to learn about, understand and adhere to the standards and restrictions imposed by any Laws that apply to you in your position with the Company. If you are not sure about a Law or how it applies to you, you should contact Legal for clarification.
5.Insider Information and Securities Trading
Under the Law, you are not allowed to purchase or sell Waldencast securities or securities of any other company if you possess material nonpublic information about Waldencast or the other company. It is also against the Law and Company policy to give material nonpublic information to another person (commonly referred to as “tipping”) if you know or have reason to believe that the person will misuse the information by trading in securities or passing such information to others who will trade. For example, using material nonpublic information to buy or sell Waldencast stock, warrants or options in Waldencast securities, or the securities of any company supplier, customer, competitor, potential business partner or target company is prohibited. The consequences of insider trading violations can be severe. These rules also apply to the use of material nonpublic information about other companies (including, for example, our customers, competitors, potential business partners and target companies). In addition to applying to you, these rules apply to your spouse, children, parents and siblings, as well as any other family members living in your home. You should familiarize yourself with the Company’s Insider Trading Policy.
6.Economic Sanctions and Embargos
    The Company is committed to compliance with applicable economic or financial sanctions and trade embargoes, including applicable economic or financial sanctions and trade embargoes imposed by the United States, the United Kingdom, the European Union, any EU Member State, or the United Nations Security Council (collectively, “Economic Sanctions and Embargoes”).
Consistent with applicable law, the Company will not conduct transactions, directly or indirectly, with any person that is the subject or target of U.S., UK, EU, or UN sanctions or with any person that is located, organized, or resident in Cuba, Iran, North Korea, Syria, the Crimea, so-called Donetsk People’s Republic, or so-called Luhansk People’s Republic regions of Ukraine, or the non-government controlled areas of the Kherson or Zaporizhzhia oblasts of Ukraine.1
Company employees must immediately notify Legal of any possible violations of these restrictions or of Economic Sanctions and Embargoes or report the possible violations via the Company’s whistleblower hotline, which is available at https://www.whistleblowerservices.com/WALD.
    All Company employees are required to comply with these requirements and with Economic Sanctions and Embargoes. Failure to do so may result in disciplinary action, including termination of employment by the Company, and for violations of Economic Sanctions and Embargoes, civil and/or criminal penalties.
7.Improper Influence on Audits
You cannot take any action to coerce, manipulate, mislead or fraudulently influence any accountants we use to perform an audit or review of our financial statements or take any action that you know or should know could result in rendering our financial statements materially misleading. If you believe such improper influence is being exerted,
1     Certain jurisdictions have adopted so-called “blocking statutes” that prohibit adherence to certain sanctions. If you encounter such a conflict, or if a local law conflicts with a requirement set forth in this Code of Conduct, you should consult with your local head of legal or head of compliance to determine the appropriate course of action.


Exhibit 11.2
you should report it to your supervisor, or if that is impractical under the circumstances, to any of the Company’s directors or Legal.
8.Anti-Corruption Laws
Waldencast complies with the anti-corruption Laws of all countries where we do business, including the U.S. Foreign Corrupt Practices Act of 1977 (“FCPA”) and the U.K. Bribery Act 2010 (the “UKBA”). You cannot take any action (or use or authorize a distributor or third party to take any action) that would reasonably result in the violation of these anti-corruption Laws, including the FCPA or UKBA. Examples of third parties include people or companies we hire or engage to help sell or distribute our products outside of the U.S. or to register or get approval for, or make filings or submissions related to, our products in a foreign country. In particular, we strictly prohibit giving, requesting, promising or offering (or authorizing anyone to give, request, promise or offer) anything of value (such as money, any advantage, benefits, gifts), either directly or indirectly, to a government official, to influence them to get or retain business or to get or retain a business advantage. An offer or a promise of a bribe, even if the government official rejects it or if it fails to result in the desired outcome, is prohibited.
Key Terms
Anything of value means, broadly construed, anything that has value to the recipient. This includes cash, gifts, job offers, meals, entertainment, travel, services, and contributions to a political party or charity. Anything of value can include things provided to family members or close associates of government officials (for example, providing an internship to a child of a government official is something of value to that official) or entities connected to government officials (for example, making a contribution to a charity closely associated with a government official is providing something of value to the official). There is no minimum threshold in determining value – whether the amount involves only a small or a much greater amount, both are serious.
Bribery is giving, promising, receiving, or soliciting anything of value with the intent to influence a business action or decision or gain other unlawful advantage.
Corruption is the abuse of power for private gain.
Facilitation payments, also known as grease payments, are payments of small amounts made to secure or expedite the performance of routine, non-discretionary government action by clerical-level foreign government officials. Examples of facilitation payments include obtaining routine permits to do business, processing visas and work orders, obtaining mail or telephone services, or expediting shipments through customs (assuming all legal requirements for obtaining these have been satisfied).
A government official is any official or employee of a government agency at any level (such as legislators, tax authorities, police officials, judges, etc.); employees of state-owned/controlled enterprises (e.g., state-owned universities, hospitals, or infrastructure organizations); political parties and officials of political parties; employees of public international organizations (e.g., the United Nations or the World Bank); other people who act in an official capacity on behalf of any of the above; and candidates for public office.
Unlawful advantage, by way of example, is inducing a foreign government official to:
oInfluence the award of a government contract;
oPrevent some governmental action, such as the imposition of a tax or fine;
oObtain confidential information about business opportunities, bids, or the activities of competitors;
oObtain a permit or license, other than to cover appropriate application fees;
oInfluence the rate of taxes that would be levied on the Company’s business; or


Exhibit 11.2
oObtain relief or exemption from government controls, inspections, or regulations of any kind, or expediting shipments through customs (assuming all legal requirements for obtaining these have been satisfied).
Bribes, Kickbacks, or Other Corrupt Payments Prohibited
In doing business anywhere in the world, neither the Company nor Company personnel shall offer, pay, promise, solicit, or receive (or authorize anyone to offer, pay, promise, solicit, or receive) any bribe, kickback, or other illicit payment or benefit in violation of the FCPA, the UKBA, or the anti-corruption laws of any other country in which the Company does business.
Public Bribery
This policy prohibits the offering, promising, or giving (or authorizing anyone to offer, promise, or give) anything of value, directly or indirectly, to a foreign government official to obtain or retain business or to gain an improper business advantage. This policy prohibits an offer or promise of a bribe, even if the foreign government official rejects the offer, or it fails to bring about the desired outcome. No funds or assets of the Company shall be paid, loaned, or otherwise disbursed as bribes, kickbacks, or other payments designed to influence or compromise the conduct of the recipient; and no Company personnel shall accept any funds or other assets (including those provided as preferential treatment to the employee for fulfilling his or her responsibilities), for assisting in obtaining business or for securing special concessions for the Company.
    Company personnel must understand whether any person they interact with is a foreign government official or whether any entity is a government, governmental entity, state-owned or controlled enterprise, or other entity that could be construed as such. Accordingly, consult with Legal if you are unsure. Or, when in doubt, treat all individuals (regardless of title or rank) who work for or represent these or similar agencies or companies as foreign government officials.
    It is permissible, in relation to Company business with a foreign government official, to incur expenses in connection with the legitimate promotion or demonstration of the Company’s services and products. Such expenses are discussed more fully below.
Commercial Bribery
This policy strictly prohibits the Company or Company personnel from offering, promising, or giving (or authorizing anyone to offer, promise, or give) anything of value to a private person, directly or indirectly, with the intention of inducing a person to improperly perform a relevant function or activity (such as their work) or to reward a person for having improperly performed a relevant function or activity. This policy prohibits an offer or promise of a bribe, even if the private person rejects the offer, or it fails to bring about the desired outcome.
It is permissible, in relation to Company business with private persons, to incur reasonable, proportionate, and good faith expenses in connection with the promotion of the Company’s services and products and in the provision of corporate hospitality. Such expenses are discussed more fully below.
Passive Bribery
This policy prohibits receiving or accepting a bribe, kickback, or similar unlawful payment.
Corrupt Payments Through Third Parties Are Prohibited
This policy prohibits the offer, promise, or payment (or authorizing the offer, promise, or payment) of any bribe, kickback, or other corrupt payment that may be carried out through the Company’s representatives, consultants, brokers, contractors, suppliers, distributors, joint ventures, or affiliates, or any other intermediary or agent acting on behalf of the Company (collectively, “Company third parties”).
It is unlawful to make a payment to a third party while knowing that all or a portion of the payment will go directly or indirectly to a foreign government official. If Company personnel have reason to believe that a Company


Exhibit 11.2
third party may be making illegal payments or if circumstances are such that Company personnel should have known that the Company third party was acting improperly, then such Company personnel could be deemed to have “knowledge” and be liable for the Company third party’s violations.
Third-Party Management
This policy provides for strict due diligence on any third party who may have any contact with a foreign government official on behalf of the Company. The purpose of due diligence is to ensure, to the extent possible, that the Company retains only reputable, honest, and qualified third parties. Please contact Legal for further detail and guidance on the due diligence process if required.
Diligence should be enhanced if there are red flags of improper activity, such as the following:
Unusual or excessive payment requests, such as requests for over-invoicing or up-front payments;
Unusual commissions or mid-stream compensation payments;
Requests for payments in a different country, to a third party, to a bank account outside of the country in which the third party operates, or in cash or other untraceable funds;
A close relationship between the third party and a foreign government official or commercial counterparty;
Any refusal or hesitancy by the third party to promise in writing to abide by the Company’s policies and governing law;
Charges against the third party for violation of local or foreign laws, or regulations concerning the award of government or other contracts;
A demand or strong suggestion by a foreign government official or commercial counterparty that a particular third party should be retained;
Reliance by the third party on government or business contacts as opposed to knowledgeable staff and investment of time to promote the Company’s interests; or
The third party expresses a desire to keep his representation of the Company or the terms of his retention secret.
All business relationships with third parties who will or may act on behalf of the Company must be documented in written contracts. These contracts must include provisions to mitigate against the risk of illicit payments. These provisions may include: (a) anti-corruption representations, warranties, and covenants relating to compliance with anti-corruption laws, including the FCPA and the UKBA; (b) rights to conduct audits of books and records of the third party to ensure compliance with these representations, warranties, and covenants; and (c) rights to terminate the contract as a result of any violation of anti-corruption laws or the anti-corruption representations, warranties, and covenants in the agreement. It is the responsibility of the person initiating a third-party relationship on behalf of the Company to monitor that relationship to determine whether the conduct of the third party is consistent with this Policy and applicable anti-corruption laws.
Gifts, Meals, and Entertainment
Although business meals and entertainment, and business gifts may be common practice, certain benefits to foreign government officials and commercial counterparties may violate governing laws, rules, and regulations. Providing meals and entertainment or making gifts with the intention or appearance of improperly influencing a foreign government official or a private party in order to obtain a business advantage for the Company, or for any other corrupt purpose, is strictly prohibited.


Exhibit 11.2
Gifts
Gifts to persons other than foreign government officials should generally be limited to $50 or less per occasion, not to exceed $200 per calendar year from one source. Extravagant or cash gifts, including gift cards, are prohibited. Company personnel and third parties should not provide gifts in a circumstance where the recipient is prohibited by their employer’s policy from receiving it.
Other than as approved in writing by the General Counsel of the Company, gifts to foreign government officials are not permitted under any circumstance. Any items provided to foreign government officials should generally be limited to logo gifts (e.g., hats, t-shirts, pens), and every effort should be made to ensure that the gift’s symbolic value outweighs its monetary value.
Meals and Entertainment
Lavish meals and entertainment are prohibited. Company personnel and third parties should not provide meals and entertainment in a circumstance where the recipient is prohibited by their employer’s policy from receiving it.
Meals and entertainment with foreign government officials are only permitted with the prior written approval of the General Counsel of the Company and where the expense is in connection with the promotion, demonstration, or explanation of the Company’s products or services, or in connection with the execution or performance of a contract. Such expenses must be reasonable in value. The Company may not provide meals or entertainment to spouses or relatives of foreign government officials.
All gift, meal, and entertainment expenses must be accurately and fully documented in writing and reflected in the Company’s books and records.
Travel
Under this policy, things of value also include travel expenses, such as travel to inspect the Company’s offices or facilities or to a seminar or promotional event sponsored by the Company. Paying for or reimbursing travel expenses with the intention of improperly influencing a foreign government official or private party in order to obtain a business advantage for the Company, or for any other corrupt purpose, is strictly prohibited.
Extravagant travel or paying for expenses associated with layovers or side trips that do not have a direct business purpose is prohibited. Company personnel should not provide travel in a circumstance where the recipient is prohibited by their employer’s policy from receiving it.
The issue of travel expenses can raise complicated compliance questions and accordingly all travel expenses for government officials must be approved in advance by Legal.
Facilitation Payments
Facilitation payments are strictly prohibited.
Civic and Political Contributions
The Company will not directly or indirectly reimburse or otherwise compensate any Company personnel for political contributions or political participation. No contribution may be made with the expectation of favorable treatment in return by a government official, agency, or by a person or other company who requests such contributions.
Charitable donations on behalf of the Company or its subsidiaries may raise anti-corruption issues and implicate anti-corruption laws, particularly where a donation is to a charity with which a foreign government official is associated. Charitable donations must not be made to gain or retain a business advantage.
Please see the Civic and Political contributions section of this Code for additional information.


Exhibit 11.2
Sponsorships
Sponsorships are contributions in money or in kind towards an event organized by a third party in return for the opportunity to advertise. Sponsorships are not considered donations if the Company receives advertising. For example, the Company may sponsor an event and advertise its brand by displaying its logo, receiving recognition in the event’s promotional materials or speeches opening or closing the event, participating as a speaker in a discussion panel, or purchasing tickets to the event.
All sponsoring contributions must be transparent, pursuant to a written agreement, for legitimate business purposes, and commensurate with the consideration offered by the event host
Books and Records
The FCPA requires that an issuer of securities on a U.S. exchange maintain complete books, records, and accounts that, in reasonable detail, accurately and fairly reflect all transactions, including all expenses, disbursements, receipts, and the disposition of assets.
Company personnel are required to completely and accurately record all transactions involving foreign government officials (regardless of the amount involved) so that the purpose and amount of such payments are clear. Making false, misleading, or artificial entries or failure to make complete and accurate entries in the Company’s books and records is a violation of this policy. Please see the Corporate Records and Disclosures section of this Code for additional information.
Commercial Transactions Involving Government Officials
From time to time, the Company may engage in commercial transactions with Government Officials in their capacity as individuals, as opposed to their capacity as representatives of their government, political party, state-owned commercial venture, or public international organization. Because of the sensitivities presented by such arrangements, any such transaction must be approved, in advance and in writing, by Legal.
Similarly, when engaging in government contracting or transactions with state-owned or controlled enterprises, no payments or any other benefits that flow directly or indirectly to a foreign government official may be provided. For example, a foreign government official shall not be provided a commission for services or any other payment or benefit in connection with a government contract, tender, or bid – regardless of whether such a payment or benefit is customary in the country in question.
Hiring a Current or Former Government Official
From time to time, because of specific experience or expertise in a market, the Company may seek to employ, either as an employee or consultant, a former government official. Because of the sensitivities presented by such arrangements, any such agreement or discussions regarding a potential agreement, either as an employment or consulting relationship, must be approved in advance, by Legal.
The retention of current government officials, either as employees or consultants, is likely to present significant concerns under anti-corruption laws and this policy. Before entering into any discussions with any current government official concerning any employment, internship, consulting, or similar relationship, you must obtain approval in advance and in writing from Legal.
Transactional Due Diligence
In considering and executing acquisitions, investments, joint ventures, and other business combinations or transactions, the Company will apply a risk-based approach to ensure that there is appropriate due diligence of the potential target or partner concerning compliance with anti-corruption laws, and that there are appropriate legal protections for these issues for the Company in the transactional documents. Accordingly, Legal should be consulted early in the transactional process regarding an appropriate due diligence work plan, and appropriate representations, warranties, and covenants, as needed.


Exhibit 11.2
Penalties and Discipline
Penalties for violating the FCPA or the UKBA are severe, including significant fines for companies and both fines (not reimbursable by companies) and imprisonment for individuals. Therefore, all Company employees are required to comply with the FCPA, the UKBA, other applicable anti-corruption laws, and the Company’s policies that are designed to protect the Company and its employees from potential liabilities and penalties. Failure to follow the Company’s policy may result in disciplinary action by the Company, up to and including termination of employment.
Policy Distribution and Certification
A copy of this policy will be distributed to all Company personnel and will be available from the Human Resources Department of the Company. All Company personnel must review this policy and certify periodically (as required by the Company), in writing or via an online system, as the Company may determine from time to time.
Training
All Company personnel who interact with government entities as part of their ordinary course duties shall undergo periodic training concerning the requirements of this policy.
Reporting and Non-Retaliation
Company personnel and third parties acting on behalf of the Company who know of or suspect a violation of this policy or any applicable anti-bribery laws must report the violation immediately through the procedures set out in the Waldencast plc Code of Conduct. The Company has zero tolerance for retaliation against anyone who makes a good-faith report of suspected violations. In addition, no Company personnel or third parties acting on behalf of the Company will be penalized for any delay or loss of business resulting from a refusal to pay a bribe.
Company personnel and third parties should report any actual, attempted, or contemplated bribery, kickback or fraud to one of the Company’s Senior Management or via the whistleblower hotline at: https://www.whistleblowerservices.com/ WALD.
Nothing in this policy prohibits, restricts, or limits the Legally Protected Communications section contained in this Code.
Guidance
The policy cannot and is not intended to cover every aspect of governing anti-corruption laws or provide answers to all questions that might arise. Accordingly, if any questions arise about this policy or any anti-bribery or anti-corruption laws, please contact Legal.
Administration and Review
The General Counsel is primarily responsible for the oversight and enforcement of this policy. The Audit Committee will review, on a regular basis, the implementation and effectiveness of the Company’s anti-bribery and anti-corruption compliance program.
9.Anti-Money Laundering
    Money laundering involves acts designed to conceal or disguise the true origins of criminally derived proceeds, so that the unlawful proceeds appear to have been derived from legitimate origins or to constitute legitimate assets, or other financial transactions involving the proceeds of crime or that promote illegal activity.
The Company strictly prohibits any involvement in money laundering. As such, Company employees must refuse to engage in any transaction that the employee knows or suspects involves the proceeds of crime or that promotes illegal activity.
Company employees must remain alert to “red flags” for money laundering, including, but not limited to:


Exhibit 11.2
Payments in non-invoice currencies;
Substantial payments in cash or cash equivalents, when such forms of payment are not common in the business;
Payments to or from an account that is not the normal business relationship account or to or from a third party that has no identifiable relationship to the transaction;
Payments to or from an account in a jurisdiction other than where the counterparty conducts business or in a place that is not logical for its business, especially an offshore jurisdiction;
Requests for overpayments or split payments to several bank account; or
Requests for a transaction to be processed in such a manner so as to avoid any of the Company’s normal documentation requirements.
Company employees must immediately consult with Legal should they observe any of these or other red flags for money laundering.
Company employees must immediately notify Legal and their head of department of any suspected money laundering activity or report the conduct via the Company’s whistleblower hotline, which is available at https://www.whistleblowerservices.com/WALD.
10.Fair and Open Competition
Relationships with Customers, Suppliers & Competitors
Waldencast is a determined but fair competitor. You are required to deal fairly with customers, suppliers, competitors, other third parties and, of course, with fellow employees.
Customers - Our success depends upon our ability to form and maintain lasting customer relationships. We are committed to dealing with all customers fairly, honestly and with integrity. When dealing with customers, you should always remember that the information we provide to them should be current, accurate and truthful to the best of your knowledge; you should never deliberately misrepresent information to a customer. Any promises or arrangements about discounts, credits, rebates or other price adjustments must be promptly communicated to sales and finance management personnel. You should never provide gifts, entertainment or other benefits to a customer that could be viewed as an inducement or reward for their purchase decisions.
Suppliers - Our relationships with suppliers are based on price, quality of service and reputation. Payments to suppliers should fairly reflect the services or products being provided. You should not accept or solicit any personal benefit from a supplier or potential supplier that might compromise your objective assessment of that supplier’s products or prices.
Competitors - Waldencast competes vigorously, but fairly. You should avoid any actions that could be viewed as being anti-competitive, monopolistic or in violation of federal or state anti-trust Laws (discussed below). You should not obtain or give competitive information to others by unethical or illegal means. You also should not make false or misleading statements about a competitor.


Exhibit 11.2
Anti-Trust Laws
Our policy is to always compete fairly and legitimately and to comply with all anti-trust and trade regulation Laws. The purpose of these Laws is to promote vigorous, free and open competition in the marketplace. Anti-trust Laws are complex, and compliance can vary depending on the circumstance, but, in general, you should not:
participate in meetings, conversations, or exchanges of information with competitors that discuss pricing, production, employee compensation, marketing and product development, or suggested list prices for retailers or our other customers;
agree (whether verbally or in writing) to set prices or wages, divide or allocate markets or territories, rig bids, limit production or restrict the supply of products, or limit competition in any other way;
require a customer to purchase a product that it does not want as a condition to the sale of a different product that the customer does wish to purchase;
allow new recruits to share confidential information about competitors for whom they used to work;
induce customers or suppliers to breach contracts with competitors;
establish exclusive arrangements without prior legal advice; or
collect competitive information through illegal means and/or by failing to identify yourself clearly as a Company director, officer or employee when collecting such information.
11.Compliance with Laws that Apply to Cosmetics and Drugs
The development, testing, manufacture, promotion and sale of prescription and over-the- counter drugs and cosmetic products are highly regulated. The Food & Drug Administration (“FDA”) regulates these activities in the U.S. and other government agencies, such as the Federal Trade Commission, regulate ads and promotional materials on drugs and cosmetics. There are also federal statutes, such as the Public Health Service Act, Administrative Procedure Act, Federal Trade Commission Act, Fair Packaging and Labeling Act, Prescription Drug Marketing Act, Homeland Security Act and federal anti-kickback and false claim Laws, that may apply to our products or operations. Several states have Laws that apply to the marketing or promotion of drugs as well. You are expected to understand and comply with the Laws that apply to your job. If you have any questions, please contact your supervisor, Company leadership or Legal.
12.Violations, Reporting and Accountability
Violation of this Code will not be tolerated and could result in disciplinary action, up to and including termination of your employment. Any action the Company takes would be in addition to any civil or criminal liability that you may face.
The Board is responsible for applying this Code to specific situations that are presented to it and has the authority to interpret this Code in any particular situation. If you are a director you are required to promptly notify the Chairperson of the Board (or Lead Independent Director, if you are the Chairperson), and if you are an officer or employee you are required to promptly notify your supervisor, the CEO or Legal, if you are aware of any existing or potential violation of this Code. If you would prefer to submit your report anonymously, you can use our whistleblower hotline: https://www.whistleblowerservices.com/WALD. Failure to do so is, in and of itself, a violation of this Code.
Specifically, you must:
promptly notify the Chairperson of the Board or your supervisor, the CEO or Legal of any existing or potential violation of this Code; and
not retaliate against any other person for reports of potential violations that are made in good faith.


Exhibit 11.2
We will follow the following procedures in investigating and enforcing this Code:
the Board will take all appropriate action to investigate any potential or actual violations reported to it;
upon determination by the Board that a violation has occurred, the Board (by majority decision) will take or authorize disciplinary or preventive action as it deems appropriate, after consulting with Legal or outside legal counsel, up to and including termination of employment, and in the event of criminal or other serious violations of Law, notification of appropriate law enforcement authorities; and
we will take appropriate steps to maintain the confidentiality of your identity to the extent that we can, consistent with our obligations to investigate and remedy the matter and, if appropriate, to report the matter to government officials.
If you report a violation or potential violation of the Code, no employee, officer or director of Waldencast is allowed to retaliate against you; they cannot, fire, demote, threaten, harass or, in any manner, discriminate against you because you reported the violation or potential violation.
13.Legally Protected Communications
Nothing in this Code, however, prohibits, restricts or limits you from (i) initiating communications directly with, responding to any inquiry from, volunteering information to, or providing testimony before any law enforcement agency, the SEC, the Equal Employment Opportunity Commission (“EEOC”), a Federal, State or local commission on human rights, or any self-regulatory organization, or otherwise initiating with, or participating in any manner with, an investigation conducted by such government agency, in each case, regarding possible violations of law, without advance notice to the Company; (ii) recovering an SEC whistleblower award as provided under Section 21F of the Securities Exchange Act of 1934; or (iii) disclosing any information (including, without limitation, confidential information) to a court or other administrative or legislative body in response to a subpoena, court order or written request directed to you in your individual capacity and, with respect to any subpoena, court order or written request on behalf of any non-governmental person, use commercially reasonable efforts to cooperate with any effort by the Company to seek to challenge the subpoena, court order or written request on behalf of any non-governmental person or obtain a protective order limiting its disclosure, or other appropriate remedy.
Nothing contained in this Code restricts or limits your (i) right to discuss your employment or report possible violations of law or regulation with the EEOC, the United States Department of Labor, the National Labor Relations Board, the SEC, or other federal government agency or similar state or local agency without notice to the Company, (ii) exercise of any rights afforded to you under the National Labor Relations Act, including but not limited to the right to discuss the terms and conditions of your employment with others, to the extent expressly permitted by Section 7 of the National Labor Relations Act, or (iii) right to make disclosures that are protected under applicable provisions of law or regulation, including but not limited to “whistleblower” statutes or other similar provisions that protect such disclosures. 
    You shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of any confidential information that is a trade secret that is made: (i) confidentially to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 
14.Other Policies and Procedures
Any other policy or procedure Waldencast adopted prior to the date of this Code, or that it adopts after the date of this Code, is a separate requirement and remains in full force and effect.
15.Inquiries
If you have questions about the Code or whether it applies to particular people or situations, you should contact Legal.


Exhibit 11.2
16.Waivers and Amendments
Any waiver from a provision of this Code for a director or officer may be made only by the Board. Any waivers, or amendments to the Code, must be disclosed in accordance with applicable Nasdaq standards and SEC rules and regulations.
You should note that we do not intend to grant or to permit waivers from the requirements of this Code as a general rule. The Company expects full compliance with the Code.


Exhibit 11.2
PROVISIONS FOR
CHIEF EXECUTIVE OFFICER AND SENIOR FINANCIAL OFFICERS
The CEO and all senior financial officers, including the CFO and principal accounting officer, are bound by the provisions below relating to ethical conduct, conflicts of interest, and compliance with the Law. In addition to this Code, the CEO and senior financial officers are subject to the following additional specific policies:
A.Act with honesty and integrity, avoiding actual or apparent conflicts between personal, private interests and the interests of the Company, including receiving improper personal benefits as a result of their position.
B.Disclose to the CEO, if applicable, and the Board any material transaction or relationship that reasonably could be expected to give rise to a conflict of interest.
C.Perform responsibilities with a view to causing periodic reports and documents filed with or submitted to the SEC and all other public communications made by the Company to contain information that is accurate, complete, fair, objective, relevant, timely and understandable, including full review of all annual and quarterly reports.
D.Comply with laws, rules and regulations of federal, state and local governments applicable to the Company and with the rules and regulations of private and public regulatory agencies having jurisdiction over the Company.
E.Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting or omitting material facts or allowing independent judgment to be compromised or subordinated.
F.Respect the confidentiality of information acquired in the course of performance of his or her responsibilities except when authorized, as permitted in the Legally Protected Communications section, or otherwise legally obligated to disclose any such information; not use confidential information acquired in the course of performing his or her responsibilities for personal advantage.
G.Share knowledge and maintain skills important and relevant to the needs of the Company, its shareholders and other constituencies and the general public.
H.Proactively promote ethical behavior among subordinates and peers in his or her work environment and community.
I.Use and control all corporate assets and resources employed by or entrusted to him or her in a responsible manner.
J.Not use corporate information, corporate assets, corporate opportunities or his or her position with the Company for personal gain; not compete directly or indirectly with the Company.
K.Comply in all respects with this Code.
L.Advance the Company’s legitimate interests when the opportunity arises.
The Board will investigate any reported violations and will oversee an appropriate response, including corrective action and preventative measures. Any officer who violates this Code will face appropriate, case-specific disciplinary action, which may include demotion or discharge.
Any request for a waiver of any provision of this Code must be in writing and addressed to the Chairperson of the Board. Any waiver of this Code will be disclosed as provided in Section 13 of this Code.
It is the policy of the Company that each officer covered by this Code shall acknowledge and certify to the foregoing annually and file a copy of such certification with the Chairperson of the Board.


Exhibit 11.2
CERTIFICATION
I have read and understand the Code. I hereby certify that I am in compliance with the foregoing Code and I will comply with this Code in the future. I understand that any violation of this Code will subject me to appropriate disciplinary action, which may include demotion or termination of my employment.
Dated:


Signature:    
Name:
Title:

EX-12.1 7 wald-20241231x20fxex121.htm EX-12.1 Document
Exhibit 12.1
Certification

I, Michel Brousset, certify that:
1.I have reviewed this annual report on Form 20–F of Waldencast plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.    The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the company and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    c)    Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    d)    Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
5.    The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors:
    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

March 20, 2025By:/s/ Michel Brousset
Name: Michel Brousset
Title: Chief Executive Officer

EX-12.2 8 wald-20241231x20fxex122.htm EX-12.2 Document
Exhibit 12.2
Certification

I, Manuel Manfredi, certify that:
1.I have reviewed this annual report on Form 20–F of Waldencast plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.    The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [language omitted in accordance with Exchange Act Rule 13a-14(a)] for the company and have:

    a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    c)    Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    d)    Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
5.    The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors:
    a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
    b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

March 20, 2025By:/s/ Manuel Manfredi
Name: Manuel Manfredi
Title: Chief Financial Officer and Principal Financial Officer

EX-13.1 9 wald-20241231x20fxex131.htm EX-13.1 Document
Exhibit 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350

In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by Waldencast plc (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)    the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 20, 2025By:/s/ Michel Brousset
Name: Michel Brousset
Title: Chief Executive Officer

EX-13.2 10 wald-20241231x20fxex132.htm EX-13.2 Document
Exhibit 13.2
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350

In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by Waldencast plc (the “Company”), the undersigned, as the Chief Financial Officer and Chief Operating Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)    the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
(2)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 20, 2025By:/s/ Manuel Manfredi
Name: Manuel Manfredi
Title: Chief Financial Officer and Principal Financial Officer

EX-15.1 11 wald-20241231x20fxex151.htm EX-15.1 Document
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-280502 on Form F-3 and Registration Statement No. 333-268108 on Form S-8 of our report dated March 20, 2025, relating to the financial statements of Waldencast plc appearing in this Annual Report on Form 20-F for the year ended December 31, 2024.


/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California
March 20, 2025

EX-101.SCH 12 wald-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - GOODWILL link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - INTANGIBLE ASSETS—NET link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - INCOME TAX BENEFIT link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - BUSINESS COMBINATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - INTANGIBLE ASSETS—NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - INCOME TAX BENEFIT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - REVENUE - Revenue by Sales Channel (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - REVENUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - REVENUE - Revenue by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - GOODWILL - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - GOODWILL - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - INTANGIBLE ASSETS—NET - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - INTANGIBLE ASSETS—NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - INTANGIBLE ASSETS—NET - Expected Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - DEBT - Summary of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - DEBT - Summary of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - DEBT - Scheduled Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - SHAREHOLDERS’ EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - INCOME TAX BENEFIT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - RELATED PARTY TRANSACTIONS - Subscription Agreement with PIPE Investors (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - RELATED PARTY TRANSACTIONS - Indemnification Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - RELATED PARTY TRANSACTIONS - Registration Rights (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - RELATED PARTY TRANSACTIONS - Transactions with Cedarwalk in Connection with the Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - RELATED PARTY TRANSACTIONS - MILK (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - SEGMENT REPORTING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - SEGMENT REPORTING - Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - SEGMENT REPORTING - Reconciliation Of Consolidated Adjusted Gross Profit To Consolidated Net Loss Before And After Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 wald-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 14 wald-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 wald-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Transfers to subsidiaries Payments of Distributions to Affiliates Vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to reconcile net loss to net cash Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Non-deductible interest carryover Deferred Tax Asset, Interest Carryforward RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Other income Other Nonoperating Income Cover [Abstract] Maximum allocated target share units, percent Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Operating Lease Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Inventory reserve Deferred Tax Assets, Inventory Customer Two Customer Two [Member] Customer Two Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Condensed Income Statements, Captions [Line Items] Condensed Income Statements, Captions [Line Items] Trading Symbol Trading Symbol Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Alternate Base Rate Alternate Base Rate [Member] Alternate Base Rate Non-NEOs Non-NEOs [Member] Private Placement Warrants Private Placement Warrants [Member] Private Placement Warrants Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Allowance for doubtful accounts Balance at beginning of period Balance at end of period Accounts Receivable, Allowance for Credit Loss, Current VIET NAM VIET NAM Distributors Sales Channel, Through Intermediary [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Change in fair value of derivative warrant liabilities Change in fair value of derivative warrant liabilities Increase (Decrease) in Derivative Assets and Liabilities Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Income (loss) before equity in undistributed earnings of subsidiaries Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Related party receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party Payments on interest rate collar contracts Payments for Derivative Instrument, Financing Activities Interest expense (income), net Interest Income (Expense), Operating Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Segments Segment Reporting, Policy [Policy Text Block] Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] Price per unit (in dollars per share) Sale of Stock, Price Per Share UNITED STATES UNITED STATES Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other non-current assets Other Assets, Noncurrent Leases [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] R&D tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Obagi China Distribution to shareholder Distribution To Shareholder For Disposition Of Business Distribution To Shareholder For Disposition Of Business Supplier [Domain] Supplier [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Secured Debt Secured Debt [Member] Prepaid expenses Prepaid Expense, Current Indemnification agreements payments Indemnification Agreements Payments Indemnification Agreements Payments Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] True-Ups Effective Income Tax Rate Reconciliation, True-Ups, Percent Effective Income Tax Rate Reconciliation, True-Ups, Percent Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Administrative expenses Administrative Fees Expense Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjusted gross profit Adjusted Gross Profit Loss Adjusted Gross Profit Loss Insider Trading Policies and Procedures [Line Items] Supply Commitment [Axis] Supply Commitment [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Issuance of common shares in connection with the PIPE investment (in shares) Stock Issued During Period, Shares, Subscription Agreements Stock Issued During Period, Shares, Subscription Agreements Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Company Selected Measure Amount Company Selected Measure Amount Payment of debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Anniversary period, annual increase in shares issued under plan Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period (Level 3) Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Stock Options Activity Schedule of Stock Options Roll Forward [Table Text Block] Obagi and Milk Business Combinations Obagi and Milk Business Combinations [Member] Obagi and Milk Business Combinations Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Asset Acquisition [Axis] Asset Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] Accounts and Financing Receivables [Table] Accounts and Financing Receivables [Table] Goodwill Beginning balance Ending balance Goodwill Distribution to pay withholding taxes Tax refund (withholding) Payment, Tax Withholding, Share-Based Payment Arrangement Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Receipts exchanged on interest rate collar contracts Proceeds from Derivative Instrument, Financing Activities Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Stock options Share-Based Payment Arrangement, Option [Member] Depreciation expense Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Document Registration Statement Document Registration Statement Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Number of tranches Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches Comprehensive loss attributable to Class A shareholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Obagi Global Holdings Limited Obagi Cosmeceuticals Obagi Cosmeceuticals LLC [Member] Obagi Cosmeceuticals LLC Repayment of revolving credit facility Repayments of Lines of Credit Award Type [Axis] Award Type [Axis] Net deferred tax liabilities Deferred Tax Liabilities, Net Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Repayment of term loan Repayments of Debt ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag TOTAL LIABILITIES Liabilities Noncontrolling interest Noncontrolling Interest Equity, Attributable to Noncontrolling Interest Common shares, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Weighted- Average Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Sponsor Warrants Sponsor Warrants [Member] Sponsor Warrants Number of shares called by each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Current portion of lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Subsequent Event [Line Items] Subsequent Event [Line Items] Total property and equipment Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Sponsor Sponsor [Member] Sponsor Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted-average diluted shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Predecessor Incentive Plan Predecessor Incentive Plan [Member] Predecessor Incentive Plan MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts Payable Accounts Payable [Member] TOTAL CONTROLLING SHAREHOLDERS’ EQUITY Equity, Attributable to Parent Total deferred tax assets Deferred Tax Assets, Gross Contact Personnel Name Contact Personnel Name Proceeds from term loan Proceeds from Issuance of Debt FINANCIAL INSTRUMENTS Financial Instruments Disclosure [Text Block] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Internal-Use Software and Website Development Costs Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Related party accounts payable Increase (Decrease) in Accounts Payable, Related Parties Category of Item Purchased [Axis] Category of Item Purchased [Axis] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Company 401(k) retirement plan contributions Defined Contribution Plan, Cost Net product sales Product [Member] Accrued interest Debt Instrument, Increase, Accrued Interest Maximum number of shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four Transaction costs Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Accrued sales returns and damages Accrued Sales Returns And Damages, Current Accrued Sales Returns And Damages, Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Variable Rate Component Three Variable Rate Component Three [Member] Variable Rate Component Three Nonrelated Party Nonrelated Party [Member] Transition services, initial term Transition Services Agreement Period Transition Services Agreement Period Exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Accounts payable Increase (Decrease) in Accounts Payable, Excluding Related Parties Increase (Decrease) in Accounts Payable, Excluding Related Parties Skintrinsiq Devices Skintrinsiq Devices [Member] Skintrinsiq Devices Schedule of Expected Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Subsequent Event [Table] Subsequent Event [Table] Parent Company Parent Company [Member] Maximum Maximum [Member] Financial designation, predecessor and successor [Fixed List] Financial Designation, Predecessor and Successor [Fixed List] Condensed Statements of Cash Flow Condensed Cash Flow Statement [Table Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net Carrying Amount Finite-Lived Intangible Assets, Net Furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Schedule of Valuation Assumptions, Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes Pre-tax losses Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Grantee Status [Domain] Grantee Status [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Rest of the World Rest of the World [Member] Rest of the World Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Loss on impairment of goodwill Loss on impairment of goodwill Impairment loss Goodwill, Impairment Loss Accrued distribution fees Accrued Distribution Fees, Current Accrued Distribution Fees, Current Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Public Warrants Public Warrants [Member] Public Warrants Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Customer/distributor relationships Customer/distributor relationships Customer Relationships [Member] Forecast Forecast [Member] Diluted (in dollars per share) Diluted net loss per share (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition and Distribution Revenue from Contract with Customer [Policy Text Block] Issuance of Class A ordinary shares upon release of Trust proceeds Stock Issued During Period, Value, Trust Proceeds Stock Issued During Period, Value, Trust Proceeds State State and Local Jurisdiction [Member] United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Other expense (income): Other Income, Nonoperating [Abstract] Current provision (benefit), total Current Income Tax Expense (Benefit) Number of shares in each IPO unit (in shares) Stockholders' Equity, Number Of Shares In Each Unit Stockholders' Equity, Number Of Shares In Each Unit Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Ownership [Axis] Ownership [Axis] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Retirement Benefits [Abstract] Change in fair value of derivative warrant liabilities (Note 9) Change in fair value of derivative warrant liabilities Fair Value Adjustment of Warrants Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Preferred shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Other temporary differences Deferred Tax Liabilities, Other Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Percent of award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Loss from change in fair value on derivative instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income tax expense (benefit) Net income tax (benefit) provision Income tax benefit Income Tax Expense (Benefit) Derivative Assets Derivative Asset Number of nominated directors Number of Nominated Directors Number of Nominated Directors Compensation cost, weighted average service period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net revenue Net revenue Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Capital expenditure on intangible assets Payments to Acquire Intangible Assets Derivative warrant liabilities - Private Private Derivative Warrant Liabilities [Member] Private Derivative Warrant Liabilities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Interest rate floor (percent) Derivative, Floor Interest Rate Proceeds from PIPE investments Proceeds from Issuance of Private Placement Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] All Adjustments to Compensation All Adjustments to Compensation [Member] Additional paid-in capital Additional Paid in Capital Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Investor Directors Investor Directors [Member] Investor Directors Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Number of non-cancelable operating leases Number of Operating Leases Number of Operating Leases Document Shell Company Report Document Shell Company Report Scenario [Domain] Scenario [Domain] Condensed Statements of Operations Condensed Income Statement [Table Text Block] Restricted cash Restricted Cash Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Amortization impact of intangible assets Amortization of Intangible Assets, Adjustment Amortization of Intangible Assets, Adjustment Expenses paid on behalf of subsidiaries Payments Of Expenses On Behalf Of Subsidiaries Payments Of Expenses On Behalf Of Subsidiaries Financial Instruments [Domain] Financial Instruments [Domain] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Vesting [Domain] Vesting [Domain] Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Interest rate cap (percent) Derivative, Cap Interest Rate LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent RSU taxes paid on behalf of employees Payment, Share-Based Payment Arrangement, Restricted Stock Taxes For Employees Payment, Share-Based Payment Arrangement, Restricted Stock Taxes For Employees Restatement Determination Date Restatement Determination Date Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Monthly principal and interest payments Debt Instrument, Periodic Payment Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Hong Kong Inland Revenue, Hong Kong [Member] CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) Condensed Financial Information of Parent Company Only Disclosure [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Right-of-use asset, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Condensed Financial Information Disclosure [Abstract] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] NET LOSS PER SHARE Earnings Per Share [Text Block] Number of quarterly installments Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments Subsequent Event Subsequent Event [Member] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Warrant exercise period Class of Warrant or Right, Exercise Period After Completion of Business Combination Class of Warrant or Right, Exercise Period After Completion of Business Combination Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Document Accounting Standard Document Accounting Standard Minimum liquidity covenant Line of Credit, Covenant Terms, Minimum Liquidity Line of Credit, Covenant Terms, Minimum Liquidity Proceeds from revolving credit facility Proceeds from Lines of Credit Trademarks and trade name Trademark and trade name Trademarks and Trade Names [Member] PEO PEO [Member] Name Trading Arrangement, Individual Name Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Equity Compensation Effective Income Tax Rate Reconciliation, Equity Compensation, Percent Effective Income Tax Rate Reconciliation, Equity Compensation, Percent Operating lease remaining term Lessee, Operating Lease, Remaining Lease Term Cash received for interest rate collar premium Proceeds from Derivative Instrument, Investing Activities Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Share-Based Payment Arrangement, Tranche Three Share-Based Payment Arrangement, Tranche Three [Member] Transaction costs Effective Income Tax Rate Reconciliation, Transaction Costs, Percent Effective Income Tax Rate Reconciliation, Transaction Costs, Percent Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Customer Three Customer Three [Member] Customer Three Local Phone Number Local Phone Number Liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Valuation allowance Less: valuation allowance Deferred Tax Assets, Valuation Allowance Net carrying amount Debt, Long-Term and Short-Term, Combined Amount Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Weighted Average Remaining Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities, net of impact of business combinations: Increase (Decrease) in Operating Capital [Abstract] Decrease in revolving commitments Line of Credit Facility, Increase (Decrease), Net PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Accrued interest Interest Payable, Current Entity Ex Transition Period Entity Ex Transition Period Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Debt Disclosure [Abstract] Ordinary Shares Common Stock [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Line of Credit Line of Credit [Member] Milk Milk Transaction Milk Transaction [Member] Milk Transaction Segment Reporting [Abstract] Fees paid in connection with the PIPE Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Intangible Assets, Net Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Unrecognized tax benefits, accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount SHAREHOLDERS’ EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Replacement Options Replacement Awards [Member] Replacement Awards Financial Instrument [Axis] Financial Instrument [Axis] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Current portion of long-term debt Less: Current portion of long-term debt Long-Term Debt, Current Maturities Gain (loss) from change in fair value of warrants Change in fair value of derivative warrant liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Class B Ordinary Shares Common Class B [Member] Title Trading Arrangement, Individual Title Formation costs Deferred Tax Assets, Formation Costs Deferred Tax Assets, Formation Costs Consolidated Entities [Axis] Consolidated Entities [Axis] Schedule of Consolidated Pretax Income (Loss) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Geographic Concentration Risk Geographic Concentration Risk [Member] Uncertain tax positions Unrecognized tax benefits Unrecognized Tax Benefits Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Milk  Milk Makeup Milk Makeup [Member] Milk Makeup City Area Code City Area Code Equity in undistributed earnings of subsidiaries Equity in income of subsidiaries Income (Loss) from Subsidiaries, Net of Tax CURRENT LIABILITIES: Liabilities, Current [Abstract] Auditor Location Auditor Location Office Office Building [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Influencer fees Influencer Fees Expense Influencer Fees Expense Remaining balance Line of Credit Facility, Remaining Borrowing Capacity Document Information [Line Items] Document Information [Line Items] Long-term debt, net Total long-term portion Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Weighted Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Net loss per share attributable to Class A shareholders (Note 14): Earnings Per Share [Abstract] Warrant redemption, trading period Class of Warrant or Right, Redemption, Trading Period Class of Warrant or Right, Redemption, Trading Period SHAREHOLDERS’ EQUITY: SHAREHOLDERS’ EQUITY: Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Share-Based Payment Arrangement, Founder Share-Based Payment Arrangement, Founder [Member] Share-Based Payment Arrangement, Founder Class of Stock [Domain] Class of Stock [Domain] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories Increase (Decrease) in Inventories SUPPLEMENTAL CASH FLOW DATA – CASH PAID: Supplemental Cash Flow Elements [Abstract] Schedule of Debt Schedule of Debt [Table Text Block] 2026 Long-Term Debt, Maturity, Year Two Applicable Rate Applicable Rate [Member] Applicable Rate Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total reported lease liability Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Amendment Flag Amendment Flag Loss (gain) on disposal of equipment Gain (Loss) on Disposition of Property Plant Equipment Account receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Machinery and equipment Machinery and Equipment [Member] Subsequent Events [Abstract] Unamortized debt issuance costs Unamortized debt issuance costs Debt Issuance Costs, Net Issued (in shares) Issued (in shares) Sale of Stock, Number of Shares Issued in Transaction DEBT Debt Disclosure [Text Block] Condensed Income Statement [Table] Condensed Income Statement [Table] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Exercise multiple Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple Stock conversion ratio (in shares) Common Stock, Convertible, Conversion Ratio Common Stock, Convertible, Conversion Ratio Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt Debt Instrument, Face Amount Condensed Cash Flow Statements, Captions [Line Items] Condensed Cash Flow Statements, Captions [Line Items] Derivative warrant liabilities Derivative Liability, Noncurrent Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising expense Advertising Expense Note Payable Notes Payable, Other Payables [Member] Long-Term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Grantee Status [Axis] Grantee Status [Axis] Vendor One Vendor One [Member] Vendor One Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Beauty Ventures LLC Beauty Ventures LLC [Member] Beauty Ventures LLC Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Current provision (benefit): Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Lease liability Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Aggregate intrinsic Value (in thousands) Share-Based Compensation By Share-Based Payment Award, Aggregate Intrinsic Value [Abstract] Share-Based Compensation By Share-Based Payment Award, Aggregate Intrinsic Value Estimated useful life (in years) ESTIMATED USEFUL LIVES Property, Plant and Equipment, Useful Life Number of Common Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Warrant redemption period Class of Warrant or Right, Redemption Period Class of Warrant or Right, Redemption Period Lender Concentration Risk Lender Concentration Risk [Member] Amortization Amortization Net loss attributed to Class A shareholders - basic EPS Net Income (Loss) Available to Common Stockholders, Basic Post vesting holding period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Permanent Items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] TOTAL ASSETS Assets Cost of goods sold Cost of Goods and Services Sold Stock Growth Incentive 2027 Awards (SGI Awards) Stock Growth Incentive 2027 Awards (SGI Awards) [Member] Stock Growth Incentive 2027 Awards (SGI Awards) Advertising Advertising Cost [Policy Text Block] Capital expenditure on property and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Percentage increase in shares available for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount COMMITMENTS AND CONTINGENCIES (NOTE 17) Commitments and Contingencies Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Stock-based compensation (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number Schedule of Components of Income Tax Expense Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Related Party Transaction [Table] Related Party Transaction [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Variable Rate Component One Variable Rate Component One [Member] Variable Rate Component One 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Annual sublease rent Operating Leases, Income Statement, Annual Expected Sublease Revenue Operating Leases, Income Statement, Annual Expected Sublease Revenue 2025 Long-Term Debt, Maturity, Year One Transaction bonuses Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent Fair value of assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Revenue by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Summary of Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Net loss attributable to Class A shareholders Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Inventory Purchases Inventory Purchases [Member] Inventory Purchases Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Consolidated Entities [Domain] Consolidated Entities [Domain] Transition services, optional extension term Transition Services Agreement, Extension Period Transition Services Agreement, Extension Period Issuance of common shares in connection with the PIPE investment Stock Issued During Period, Value, Subscription Agreements Stock Issued During Period, Value, Subscription Agreements Noncontrolling Interest Noncontrolling Interest [Member] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Federal Current Federal Tax Expense (Benefit) Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Lease liabilities Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Noncontrolling interest Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Net loss attributable to noncontrolling interests Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Forward Purchase Agreement Forward Purchase Agreement [Member] Forward Purchase Agreement Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] TOTAL SHAREHOLDERS' EQUITY Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment North America North America [Member] Accrued professional services Accrued Professional Fees, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Other Current Liabilities Other Current Liabilities [Table Text Block] Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Private Placement Private Placement [Member] Fair value of derivative asset Derivative Asset, Noncurrent Share-Based Payment Arrangement Board Of Directors Share-Based Payment Arrangement Board Of Directors [Member] Share-Based Payment Arrangement Board Of Directors Condensed Balance Sheet Statements, Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Asset acquisition, inventory Asset Acquisition, Inventory Asset Acquisition, Inventory Work in process Inventory, Work in Process, Gross Statistical Measurement [Domain] Statistical Measurement [Domain] Prepaid expenses Increase (Decrease) in Prepaid Expense Schedule of Supplemental Cash Flow and Other Information Related to Leases Lease, Cost [Table Text Block] Other current liabilities Related party liability Total Other Liabilities, Current Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Tax credits Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Share-Based Payment Arrangement, Employees And Non Employees Share-Based Payment Arrangement, Employees And Non Employees [Member] Share-Based Payment Arrangement, Employees And Non Employees Class A Ordinary Shares Common Class A [Member] Shares exchanged (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Pay vs Performance Disclosure [Line Items] Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Derivative [Table] Derivative [Table] Aaron Chatterley Aaron Chatterley [Member] Aaron Chatterley Operating lease liabilities Increase (Decrease) in Operating Lease Liability Deferred (income) expense: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] TEXAS TEXAS Payment of PIPE transaction costs Payments for Repurchase of Private Placement Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Burwell and Zeno Burwell Mountain Trust and Zeno Investment Master Fund [Member] Burwell Mountain Trust and Zeno Investment Master Fund Goodwill [Line Items] Goodwill [Line Items] LEASES Lessee, Operating Leases [Text Block] Common shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease costs Operating Lease, Cost Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2022 Incentive Award Plan 2022 Incentive Award Plan [Member] 2022 Incentive Award Plan Long-term lease liabilities Operating Lease, Liability, Noncurrent Rent expense Operating Leases, Rent Expense Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Long-Term Incentive Awards Long-Term Incentive Awards [Member] Long-Term Incentive Awards Capitalized Software and Website Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Foreign Deferred Foreign Income Tax Expense (Benefit) Fixed asset basis Deferred Tax Assets, Property, Plant and Equipment, Net Of Federal And State Impacts Deferred Tax Assets, Property, Plant and Equipment, Net Of Federal And State Impacts Patents Patents [Member] Consideration received Sale of Stock, Consideration Received on Transaction Shares used in computing net loss per share (Note 14): Earnings Per Share Reconciliation [Abstract] Plan Name [Axis] Plan Name [Axis] Proceeds from Notes Payable Proceeds From Note Payable, Adjusted Proceeds From Note Payable, Adjusted Vietnam General Department Of Taxation, Vietnam [Member] General Department Of Taxation, Vietnam Equity Components [Axis] Equity Components [Axis] Interest rate collar Interest Rate Collar [Member] Interest Rate Collar Warehouse Warehouse [Member] Other current assets Other Assets, Current Research and Development Research and Development Expense, Policy [Policy Text Block] Accounts Receivable, Net Accounts Receivable [Policy Text Block] Pro forma net loss Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] SGI Awards Stock Growth Incentive Awards (SGI Awards) [Member] Stock Growth Incentive Awards (SGI Awards) Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Equity consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Obagi Vietnam Import Export Trading MTV Company Limited Obagi Vietnam Import Export Trading MTV Company Limited [Member] Obagi Vietnam Import Export Trading MTV Company Limited Geographical [Axis] Geographical [Axis] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Discontinued product write-off Gain (Loss) on Disposition of Business Total Purchase Price: Business Combination, Consideration Transferred [Abstract] Founder Awards Founder Awards [Member] Founder Awards Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Change in Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets EMPLOYEE BENEFIT PLAN Compensation and Employee Benefit Plans [Text Block] Non-cash lease expense Operating Lease, Expense Cost of Goods Sold Cost of Goods and Service [Policy Text Block] CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Term Loan Facility 2025 Term Loan [Member] 2025 Term Loan Interest rate Debt, Weighted Average Interest Rate Computer hardware and software Computer hardware, software and equipment Computer Hardware, Software And Equipment [Member] Computer Hardware, Software And Equipment Foreign Current Foreign Tax Expense (Benefit) CURRENT ASSETS: Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Audit Information [Abstract] Audit Information Preferred shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share Warrants Warrant [Member] Debt instrument, rate Debt Instrument, Basis Spread on Variable Rate Restricted cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Direct sales Sales Channel, Directly to Consumer [Member] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] State Current State and Local Tax Expense (Benefit) Short-term debt Short-Term Debt Withholding tax Effective Income Tax Rate Reconciliation, Withholding Tax, Percent Effective Income Tax Rate Reconciliation, Withholding Tax, Percent Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Common shares issued (in shares) Common Stock, Shares, Issued Entity [Domain] Entity [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Concentration risk, percentage Concentration Risk, Percentage 2022 Credit Agreement 2022 Credit Agreement [Member] 2022 Credit Agreement Derivative Liabilities Derivative Liability Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Proceeds from trust account Proceeds from trust Proceeds From Trust Account Proceeds From Trust Account Common shares authorized (in shares) Common Stock, Shares Authorized Acquisition of Business Combinations, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Derivative notional value Derivative Liability, Notional Amount Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Prepaid expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Supply Commitment Supply Commitment [Member] Entity Voluntary Filers Entity Voluntary Filers Related Party Related Party [Member] Lease Deposits Lease Deposits [Member] Lease Deposits Interest expense, net Interest Expense, Nonoperating Proceeds from FPA investments Proceeds From Forward Purchase Agreements Proceeds From Forward Purchase Agreements Deferred income taxes Deferred (income) expense, total Deferred Income Tax Expense (Benefit) Accrued salaries and related expenses Accrued Salaries, Current Unaudited Pro Forma Consolidated Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Entity Address, Country Entity Address, Country Write-off of uncollectible accounts, net Accounts Receivable, Allowance for Credit Loss, Writeoff Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Other current liabilities and other liabilities Increase (Decrease) in Other Operating Liabilities Outstanding borrowings as of closing date Long-Term Debt Obagi Obagi Medical Obagi Skincare [Member] Obagi Skincare Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Accounts receivable, before allowance for doubtful accounts Accounts Receivable, before Allowance for Credit Loss, Current Stock Growth Incentive 2025 Awards (SGI Awards) Stock Growth Incentive 2025 Awards (SGI Awards) [Member] Stock Growth Incentive 2025 Awards (SGI Awards) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Amortization of the fair value of the related party liability Amortization Of The Fair Value Of The Related Party Liability Amortization Of The Fair Value Of The Related Party Liability Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Document Annual Report Document Annual Report Intercompany receivable Intercompany Receivables Intercompany Receivables Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Warrant redemption, period between end of trading and notice of redemption Class of Warrant or Right, Period Between End of Trading and Notice of Redemption Class of Warrant or Right, Period Between End of Trading and Notice of Redemption Condensed Balance Sheets Condensed Balance Sheet [Table Text Block] Awards with modified performance conditions in period (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Modified In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Modified In Period Accounting Policies [Abstract] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Leasehold improvements Leasehold Improvements [Member] Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] BUSINESS COMBINATIONS Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Period after which production costs will be expensed for advertising that has not yet occurred Recognition Period for Deferred Advertising Costs, Maximum Recognition Period for Deferred Advertising Costs, Maximum PEO Name PEO Name Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Initial commitment amount of purchase commitments Long-Term Purchase Commitment, Amount Country Region Country Region Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Supplier Concentration Risk Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Weighted Average Useful Lives (Years) Finite-Lived Intangible Asset, Useful Life Total identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Additional Paid-In Capital Additional Paid-in Capital [Member] GOODWILL Goodwill Disclosure [Text Block] Note payable Notes Payable Class of Stock [Line Items] Class of Stock [Line Items] Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards, Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Number of operating segments Number of Operating Segments Repayment of note payable Repayments of Notes Payable, Adjusted Repayments of Notes Payable, Adjusted Income taxes Income Taxes Paid Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Amortization and release of related party liability Amortization Of Related Party Liability Amortization Of Related Party Liability CHINA CHINA Debt issuance cost, current Debt Issuance Costs, Current, Net Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Equity outstanding percentage Equity Outstanding Percentage Equity Outstanding Percentage Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Below market contract Deferred Tax Assets, Below Market Lease Contract Deferred Tax Assets, Below Market Lease Contract Annual interest rate Debt Instrument, Interest Rate, Stated Percentage Goodwill impairment Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Schedule of Long Term and Short Term Debt Instruments [Table] Schedule of Long Term and Short Term Debt Instruments [Table] Schedule of Long Term and Short Term Debt Instruments Equity instruments assumed in business combination (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period Net loss attributed to Class A shareholders - diluted EPS Net Income (Loss) Available to Common Stockholders, Diluted Capitalized research Deferred Tax Asset, In-Process Research and Development Total other expenses (income), net Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Number of founders Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals Auditor Firm ID Auditor Firm ID Adjusted cost of goods sold Total Gross Margin Adjustments Total Gross Margin Adjustments Total income tax (benefit) expense Effective Income Tax Rate Reconciliation, Percent Total operating loss Operating Income (Loss) Corporate Credit Cards Corporate Credit Cards [Member] Corporate Credit Cards Variable Rate [Domain] Variable Rate [Domain] Number of reportable segments Number of Reportable Segments TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity SUBSEQUENT EVENTS Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Loss on impairment of right of use assets Operating Lease, Impairment Loss Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] ORGANIZATION AND DESCRIPTION OF BUSINESS Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Proceeds from note payable Proceeds from Notes Payable Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Distribution to pay withholding taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Related party liability from merger Related party liability Business Combination, Consideration Transferred, Liabilities Incurred Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Total inventories Inventory, Net Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Operating lease extension term Lessee, Operating Lease, Extension Term Lessee, Operating Lease, Extension Term Formulations Formulations Formulations [Member] Formulations Summary of Net Operating Losses and Tax Credit Carryforwards Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block] Summary of Operating Loss Carryforwards and Tax Credit Carryforwards Estimated Useful Lives of Assets Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] IPO IPO [Member] Total purchase consideration Purchase consideration Business Combination, Consideration Transferred RSU taxes paid on behalf of employees Share-Based Payment Arrangement, Decrease For Tax Withholding, Employee Restricted Stock Units Share-Based Payment Arrangement, Decrease For Tax Withholding, Employee Restricted Stock Units Derivatives Derivatives, Policy [Policy Text Block] Internally developed software Software Development [Member] Condensed Cash Flow Statement [Table] Condensed Cash Flow Statement [Table] Schedule of Intangible Assets Acquired in Business Combination Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Minimum Minimum [Member] Royalties Royalty [Member] Adoption Date Trading Arrangement Adoption Date Related Party Transactions [Abstract] UNITED KINGDOM UNITED KINGDOM Number of annual installments Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments Obagi Obagi Merger Obagi Merger [Member] Obagi Merger Cedarwalk Cedarwalk [Member] Cedarwalk Provision for doubtful accounts Provision (recovery) for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Pro forma net revenue Business Acquisition, Pro Forma Revenue Income tax rate Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt Total unpaid principal Long-Term Debt, Gross Related party accounts receivable Increase (Decrease) in Accounts Receivable, Related Parties Exercise Price Award Exercise Price Summary of Deferred Tax Assets and Deferred Tax Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Bailiwick of Jersey and the Cayman Islands Bailiwick of Jersey and the Cayman Islands [Member] Bailiwick of Jersey and the Cayman Islands Arrangement Duration Trading Arrangement Duration Net operating losses Operating Loss Carryforwards Federal Domestic Tax Jurisdiction [Member] Stock options assumed in business combination (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period Customer One Customer One [Member] Customer One Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt term Debt Instrument, Term 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Obagi China Business Obagi China Business [Member] Obagi China Business All Individuals All Individuals [Member] Schedule of Long Term and Short Term Debt Instruments [Line Items] Schedule of Long Term and Short Term Debt Instruments [Line Items] Schedule of Long Term and Short Term Debt Instruments Accrued interest to foreign related parties Deferred Tax Assets, Accrued Interest to Foreign Related Parties Deferred Tax Assets, Accrued Interest to Foreign Related Parties Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Other (income) expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Restricted stock, unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Address Type [Domain] Address Type [Domain] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Related Party [Domain] Related and Nonrelated Parties [Domain] Long-Term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Supplier [Axis] Supplier [Axis] Total liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Deferred income tax liabilities Deferred Income Tax Liabilities, Net Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Net deferred tax (liabilities) assets Deferred Tax Assets, Net, Before Valuation Allowance Deferred Tax Assets, Net, Before Valuation Allowance U.S./foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Stock compensation expense APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Other current assets and other assets Increase (Decrease) in Other Operating Assets Real Estate [Domain] Real Estate [Domain] Federal Deferred Federal Income Tax Expense (Benefit) Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] 2022 Term Loan 2022 Term Loan [Member] 2022 Term Loan Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Measure: Measure [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Preferred shares authorized (in shares) Preferred Stock, Shares Authorized Stock registered (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Related party liability Related party liability Other Sundry Liabilities, Current Amortization of the inventory fair value adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Business Contact Business Contact [Member] 2029 Long-Term Debt, Maturity, Year Five One-Tim Stock Grant One-Tim Stock Grant [Member] One-Tim Stock Grant Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Vendor Two Vendor Two [Member] Vendor Two Expected stock price volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Equity Component [Domain] Equity Component [Domain] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Shipping and handling costs Shipping And Handling Costs Shipping And Handling Costs Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Warrant redemption, number of trading days at or above trigger price Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price Issuance of Class A ordinary shares upon release of Trust proceeds (in shares) Stock Issued During Period, Shares, Trust Proceeds Stock Issued During Period, Shares, Trust Proceeds Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Distribution of Obagi China Business Distribution of Business Distribution of Business Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities 2022 Revolving Credit Facility 2022 Revolving Credit Facility [Member] 2022 Revolving Credit Facility D&O Insurance Note Payable, Directors And Officers Insurance [Member] Note Payable, Directors And Officers Insurance (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other comprehensive income (loss) — foreign currency translation adjustments, net of tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accrued compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Total current assets Assets, Current Statement of Cash Flows [Abstract] Conversion of promissory note to warrants Debt Conversion, Converted Instrument, Amount Issuance of common shares in connection with the FPA investment (in shares) Stock Issued During Period, Shares, Foreign Purchase Agreements Stock Issued During Period, Shares, Foreign Purchase Agreements Fixed asset basis Deferred Tax Liabilities, Property, Plant and Equipment, Net Of Federal And State Impacts Deferred Tax Liabilities, Property, Plant and Equipment, Net Of Federal And State Impacts 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Intangible assets Total Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer INCOME TAX BENEFIT Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Revenue by Sales Channel Revenue from External Customers by Products and Services [Table Text Block] Right-of-use assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred Issuance Costs Debt, Policy [Policy Text Block] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Credit Facility [Axis] Credit Facility [Axis] Non-cash loss from change in fair value on interest rate collar Non-Cash Loss From Change In Fair Value On Interest Rate Collar Non-Cash Loss From Change In Fair Value On Interest Rate Collar Entity Registrant Name Entity Registrant Name Cash consideration Payments to Acquire Businesses, Gross Cash (used in) provided by operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Gross profit Gross Profit Prepaid Expenses Prepaid Expenses [Policy Text Block] Prepaid Expenses INTANGIBLE ASSETS—NET Intangible Assets Disclosure [Text Block] State Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value (Level 2) Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Incremental stock based compensation expense Share-Based Payment Arrangement, Business Combination, Incremental Cost Share-Based Payment Arrangement, Business Combination, Incremental Cost Waldencast plc Waldencast plc [Member] Waldencast plc Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common shares Successor ordinary shares Common Stock, Value, Issued Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Share-Based Payment Arrangement [Abstract] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Issuance of common shares in connection with the Obagi and Milk Business Combination Issuance of ordinary shares for Business Combinations Stock Issued During Period, Value, Acquisitions Issuance of common shares in connection with the Obagi and Milk Business Combination (in shares) Stock Issued During Period, Shares, Acquisitions State income tax benefit, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Other temporary differences Deferred Tax Assets, Other Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Derivative warrant liabilities - Public Public Derivative Warrant Liabilities [Member] Public Derivative Warrant Liabilities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Finished goods Inventory, Finished Goods, Gross Tretinoin distribution and supply agreement Tretinoin distribution and supply agreement Tretinoin Distribution and Supply Agreement [Member] Tretinoin Distribution and Supply Agreement Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total deferred tax liabilities Deferred Tax Liabilities, Gross Basic (in dollars per share) Basic net loss per share (in dollars per share) Earnings Per Share, Basic Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Investment in Waldencast LP Deferred Tax Assets, Investments Ownership [Domain] Ownership [Domain] Capital expenditures in accounts payable and accruals Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Goodwill [Table] Goodwill [Table] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Intangibles Deferred Tax Liabilities, Intangible Assets Total current liabilities Liabilities, Current Stock options, unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Repayment of note payable Repayments of Notes Payable Pro forma net loss attributable to Waldencast plc Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Business Combinations Business Combinations Policy [Policy Text Block] Warrant redemption price (in dollars per share) Class of Warrant or Right, Redemption Price Per Share Class of Warrant or Right, Redemption Price Per Share Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Expected stock price volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights STOCK BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Warrant redemption, stock price trigger (in dollars per share) Class of Warrant or Right, Redemption, Stock Price Trigger Class of Warrant or Right, Redemption, Stock Price Trigger Entity Address, City or Town Entity Address, City or Town Goodwill Deferred Tax Liabilities, Goodwill Exercise term, percent Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent Shares exchanged Stock Issued During Period, Value, Conversion of Convertible Securities Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in shares) Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Foreign Tax Jurisdiction Foreign Tax Jurisdiction [Member] Lease asset Deferred Tax Liabilities, Leasing Arrangements Fair value of equity awards in business combination Equity Issued in Business Combination, Fair Value Disclosure REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Investment in subsidiary Investment in Subsidiary Investment in Subsidiary Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Common stock, voting rights Common Stock, Voting Rights SUPPLEMENTAL BALANCE SHEET DISCLOSURES Supplemental Balance Sheet Disclosures [Text Block] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Less: Pro forma net loss attributable to noncontrolling interest Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest Document Transition Report Document Transition Report Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Ownership interest in fully diluted Class A ordinary shares (percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Amortization of debt issuance costs Amortization of Debt Issuance Costs Transfers from subsidiaries Proceeds from Contributions from Affiliates Asset Acquisition [Domain] Asset Acquisition [Domain] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Depreciation and amortization Depreciation, Depletion and Amortization, Operating Activities Depreciation, Depletion and Amortization, Operating Activities Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Cash repayment of debt Business Combination, Consideration Transferred, Cash Repayments of Debt Business Combination, Consideration Transferred, Cash Repayments of Debt Restricted stock Restricted Stock Units (RSUs) [Member] Noncontrolling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Issuance of common shares in connection with the FPA investment Stock Issued During Period, Value, Foreign Purchase Agreements Stock Issued During Period, Value, Foreign Purchase Agreements Interest Rate Collar, Initial Fixed Payment Interest Rate Collar, Initial Fixed Payment [Member] Interest Rate Collar, Initial Fixed Payment Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Customer payment period Customer Payment Period Customer Payment Period Schedule of Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 16 wald-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 17 image_0.jpg begin 644 image_0.jpg MB5!.1PT*&@H -24A$4@ !6, !" 8 "[4+R& "7!(67, $SE M !,Y0%USO"5 (4E$051XVNW#L0T C H/[_M#[@Z @)5:.JJJJJZMO3 5 F*45^] "4_9 $E%3D2N0F"" end GRAPHIC 18 image_1.jpg begin 644 image_1.jpg MB5!.1PT*&@H -24A$4@ 8 &" 8 #@S.]( "7!(67, $SE M !,Y0%USO"5 #$E$051XVF-@&(P "6 &-R,$A $E%3D2N0F"" end GRAPHIC 19 image_1a.jpg begin 644 image_1a.jpg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image_2.jpg begin 644 image_2.jpg MB5!.1PT*&@H -24A$4@ 5@ /" 8 "AD->[ "7!(67, $SE M !,Y0%USO"5 *TE$051XVNW!,0$ #"H/5/[6T'H ? S@!0KP !?9[+%@ !)14Y$KD)@@@$! end XML 22 R1.htm IDEA: XBRL DOCUMENT v3.25.1
COVER
12 Months Ended
Dec. 31, 2024
shares
Document Information [Line Items]  
Document Type 20-F
Document Registration Statement false
Document Annual Report true
Current Fiscal Year End Date --12-31
Document Period End Date Dec. 31, 2024
Document Transition Report false
Document Shell Company Report false
Entity File Number 001-40207
Entity Registrant Name Waldencast plc
Entity Address, Address Line One 81 Fulham Road
Entity Address, City or Town London
Entity Address, Postal Zip Code SW3 6RD
Entity Address, Country GB
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company true
Entity Ex Transition Period false
ICFR Auditor Attestation Flag false
Document Financial Statement Error Correction [Flag] false
Document Accounting Standard U.S. GAAP
Entity Shell Company false
Entity Central Index Key 0001840199
Amendment Flag false
Document Fiscal Period Focus FY
Document Fiscal Year Focus 2024
Entity Incorporation, State or Country Code X0
Class A Ordinary Shares  
Document Information [Line Items]  
Title of 12(b) Security Class A ordinary shares, par value $0.0001 per share
Trading Symbol WALD
Security Exchange Name NASDAQ
Entity Common Stock, Shares Outstanding 112,026,440
Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
Trading Symbol WALDW
Security Exchange Name NASDAQ
Class B Ordinary Shares  
Document Information [Line Items]  
Entity Common Stock, Shares Outstanding 10,666,528
Business Contact  
Document Information [Line Items]  
Entity Address, Address Line One 81 Fulham Road
Entity Address, City or Town London
Entity Address, Postal Zip Code SW3 6RD
Entity Address, Country GB
Contact Personnel Name Michel Brousset
Country Region 44
City Area Code (0)20
Local Phone Number 3196 0264
XML 23 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Audit Information
12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Firm ID 34
Auditor Name Deloitte & Touche LLP
Auditor Location Costa Mesa, California
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 14,802 $ 21,089
Restricted cash 1,500 1,487
Inventories 53,104 55,684
Prepaid expenses 7,513 5,277
Other current assets 427 1,359
Total current assets 103,622 107,327
Property and equipment, net 5,831 5,931
Intangible assets, net 526,438 582,863
Goodwill 329,589 334,620
Right-of-use asset, net 9,839 11,589
Other non-current assets 541 380
TOTAL ASSETS 975,860 1,042,710
CURRENT LIABILITIES:    
Current portion of lease liabilities 2,766 2,400
Current portion of long-term debt 29,479 8,529
Other current liabilities 19,560 23,698
Total current liabilities 76,892 62,714
Long-term debt, net 137,137 151,264
Derivative warrant liabilities 5,021 28,647
Long-term lease liabilities 12,724 15,531
Deferred income tax liabilities 14,044 15,229
Other non-current liabilities 105 52
TOTAL LIABILITIES 245,923 273,437
COMMITMENTS AND CONTINGENCIES (NOTE 17)
SHAREHOLDERS’ EQUITY:    
Additional paid-in capital 951,260 871,527
Retained earnings (289,204) (246,761)
Accumulated other comprehensive income (loss) 251 (151)
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY 662,319 624,626
Noncontrolling interest 67,618 144,647
TOTAL SHAREHOLDERS' EQUITY 729,937 769,273
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 975,860 1,042,710
Nonrelated Party    
CURRENT ASSETS:    
Accounts receivable, net 25,484 21,330
CURRENT LIABILITIES:    
Accounts payable 25,087 28,069
Related Party    
CURRENT ASSETS:    
Accounts receivable, net 792 1,101
CURRENT LIABILITIES:    
Accounts payable 0 18
Other current liabilities   5,900
Class A Ordinary Shares    
SHAREHOLDERS’ EQUITY:    
Common shares 11 9
Class B Ordinary Shares    
SHAREHOLDERS’ EQUITY:    
Common shares $ 1 $ 2
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Preferred shares authorized (in shares) 25,000,000 25,000,000
Preferred shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred shares issued (in shares) 0 0
Preferred shares outstanding (in shares) 0 0
Class A Ordinary Shares    
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Common shares authorized (in shares) 1,000,000,000 1,000,000,000
Common shares outstanding (in shares)   101,228,857
Class B Ordinary Shares    
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Common shares authorized (in shares) 100,000,000 100,000,000
Common shares outstanding (in shares)   20,847,553
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]        
Net revenue $ 92,373 $ 73,760 $ 273,868 $ 218,138
Cost of goods sold 60,657   82,124 76,561
Gross profit 31,716   191,744 141,577
Selling, general and administrative 90,722 58,155 245,297 223,508
Loss on impairment of goodwill 68,715 0 5,031 0
Total operating expenses 159,437 58,155 250,328 223,508
Total operating loss (127,721) (15,263) (58,584) (81,931)
Interest expense, net 6,230 6,652 17,155 18,906
Change in fair value of derivative warrant liabilities (Note 9) (6,793) 0 (23,627) 10,337
Other (income) expense, net (798) (971) (3,574) 1,769
Total other expenses (income), net (1,361) 5,681 (10,046) 31,012
Loss before income taxes (126,360) (20,944) (48,538) (112,943)
Income tax expense (benefit) (5,803) 113 110 (6,975)
Net loss (120,557) (21,057) (48,648) (105,968)
Net loss attributable to noncontrolling interests (24,990) 0 (6,205) (15,987)
Net loss attributable to Class A shareholders $ (95,567) $ (21,057) $ (42,443) $ (89,981)
Net loss per share attributable to Class A shareholders (Note 14):        
Basic (in dollars per share) $ (1.11) $ (2.63) $ (0.39) $ (0.99)
Diluted (in dollars per share) $ (1.11) $ (2.63) $ (0.39) $ (0.99)
Shares used in computing net loss per share (Note 14):        
Basic (in shares) 86,460,560 8,000,002 109,295,742 91,158,500
Diluted (in shares) 86,460,560 8,000,002 109,295,742 91,158,500
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax $ (36) $ 96 $ 450 $ (147)
Comprehensive loss (120,593) (20,961) (48,198) (106,115)
Comprehensive loss attributable to noncontrolling interests (24,997) 0 (6,148) (16,012)
Comprehensive loss attributable to Class A shareholders $ (95,596) $ (20,961) $ (42,050) $ (90,103)
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Waldencast plc
Obagi Global Holdings Limited
Class A Ordinary Shares
Class B Ordinary Shares
Ordinary Shares
Obagi Global Holdings Limited
Ordinary Shares
Class A Ordinary Shares
Waldencast plc
Ordinary Shares
Class B Ordinary Shares
Waldencast plc
Additional Paid-In Capital
Waldencast plc
Additional Paid-In Capital
Obagi Global Holdings Limited
Accumulated Deficit
Waldencast plc
Accumulated Deficit
Obagi Global Holdings Limited
Accumulated Other Comprehensive Loss
Waldencast plc
Accumulated Other Comprehensive Loss
Obagi Global Holdings Limited
Noncontrolling Interest
Waldencast plc
Beginning balance (in shares) at Dec. 31, 2021           8,000,002,000                  
Beginning balance at Dec. 31, 2021     $ 39,239     $ 4,000       $ 100,113   $ (64,849)   $ (25)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Net loss $ (21,057)   (21,057)                 (21,057)      
Stock-based compensation                 $ 7,736            
Foreign currency translation adjustment 96   96                     96  
Distribution of Obagi China Business     (13,372)             (13,113)   (188)   (71)  
Ending balance (in shares) at Jul. 27, 2022           8,000,002,000 8,645,000 0              
Ending balance at Jul. 27, 2022   $ (61,038) $ 4,906     $ 4,000 $ 1 $ 0 174 $ 87,000 $ (61,213) $ (86,094) $ 0 $ 0 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of Class A ordinary shares upon release of Trust proceeds (in shares)             4,478,054                
Issuance of Class A ordinary shares upon release of Trust proceeds   44,882             44,882            
Issuance of common shares in connection with the FPA investment (in shares)             33,300,000                
Issuance of common shares in connection with the FPA investment   333,000         $ 3   332,997            
Issuance of common shares in connection with the PIPE investment (in shares)             11,800,000                
Issuance of common shares in connection with the PIPE investment   118,000         $ 1   117,999            
Issuance of common shares in connection with the Obagi and Milk Business Combination (in shares)             28,237,506 21,104,225              
Issuance of common shares in connection with the Obagi and Milk Business Combination   477,911         $ 3 $ 2 292,250           185,656
Net loss (120,557) (120,557)                 (95,567)       (24,990)
Stock-based compensation   7,736                          
Foreign currency translation adjustment   (36)                     (29)   (7)
Ending balance (in shares) at Dec. 31, 2022             86,460,560 21,104,225              
Ending balance at Dec. 31, 2022   799,898         $ 8 $ 2 796,038   (156,780)   (29)   160,659
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of common shares in connection with the PIPE investment (in shares)             14,000,000                
Issuance of common shares in connection with the PIPE investment   70,000         $ 1   69,999            
Fees paid in connection with the PIPE   (1,068)             (1,068)            
Shares exchanged (in shares)             256,672 256,672              
Net loss (105,968) (105,968)                 (89,981)       (15,987)
Stock-based compensation (in shares)             511,625                
Stock-based compensation   9,235             9,235            
RSU taxes paid on behalf of employees   (1,473)             (1,473)            
Distribution to pay withholding taxes   (1,204)             (1,204)            
Foreign currency translation adjustment (147) (147)                     (122)   (25)
Ending balance (in shares) at Dec. 31, 2023       101,228,857 20,847,553   101,228,857 20,847,553              
Ending balance at Dec. 31, 2023 769,273 769,273         $ 9 $ 2 871,527   (246,761)   (151)   144,647
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Shares exchanged (in shares)             10,181,025 10,181,025              
Net loss (48,648) (48,648)                 (42,443)       (6,205)
Stock-based compensation (in shares)             616,558                
Stock-based compensation   9,392             9,391            
RSU taxes paid on behalf of employees   (530)             (530)            
Foreign currency translation adjustment 450 450                     402   48
Ending balance (in shares) at Dec. 31, 2024             112,026,440 10,666,528              
Ending balance at Dec. 31, 2024 $ 729,937 $ 729,937         $ 11 $ 1 $ 951,260   $ (289,204)   $ 251   $ 67,618
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $ (120,557) $ (21,057) $ (48,648) $ (105,968)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation 7,736 0 9,392 9,235
Depreciation and amortization 26,982 8,190 60,015 60,498
Non-cash lease expense 740 0 1,986 1,721
Provision for doubtful accounts 0 0 (996) 0
Change in fair value of derivative warrant liabilities (6,793) 0 (23,627) 10,337
Non-cash loss from change in fair value on interest rate collar 592 0 0 106
Amortization of debt issuance costs 677 767 1,712 1,575
Amortization and release of related party liability (12,186) 0 (5,856) (4,058)
Deferred income taxes (5,823) 90 (1,185) (7,021)
Loss on impairment of goodwill 68,715 0 5,031 0
Loss on impairment of right of use assets 0 0 0 3,643
Loss (gain) on disposal of equipment (2) 35 112 62
Changes in operating assets and liabilities, net of impact of business combinations:        
Accounts receivable (204) 3,524 (3,158) (2,071)
Related party accounts receivable 265 0 309 (816)
Inventories 6,382 (13,008) 2,580 (1,300)
Prepaid expenses (213) 658 (2,236) 996
Other current assets and other assets (250) (352) (377) 138
Accounts payable (1,021) 9,635 (2,982) 4,382
Related party accounts payable 43 0 (18) (354)
Operating lease liabilities (724) 0 (2,677) (2,560)
Other current liabilities and other liabilities (39,336) 1,481 1,803 1,680
Net cash used in operating activities (74,977) (10,037) (8,820) (29,775)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Capital expenditure on intangible assets (247) (248) (304) (455)
Capital expenditure on property and equipment (1,340) (661) (2,708) (1,591)
Proceeds from trust account 44,883 0 0 0
Cash received for interest rate collar premium 0 0 92 52
Net cash used in investing activities (544,367) (909) (2,920) (1,994)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from PIPE investments 118,000 0 0 70,000
Payment of PIPE transaction costs 0 0 0 (1,068)
Proceeds from FPA investments 333,000 0 0 0
Proceeds from term loan 175,000 0 0 0
Repayment of term loan (4,348) (1,375) (8,750) (8,777)
Proceeds from revolving credit facility 14,117 6,000 15,000 35,000
Repayment of revolving credit facility 0 0 0 (49,117)
Proceeds from note payable 0 0 1,632 2,420
Repayment of note payable 0 0 (1,770) (1,452)
Payment of debt issuance costs (6,304) (742) 0 0
RSU taxes paid on behalf of employees 0 0 (530) (1,473)
Distribution to pay withholding taxes 0 0 0 (1,204)
Net cash provided by financing activities 629,465 3,883 5,582 44,329
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 10,121 (7,063) (6,158) 12,560
Effect of foreign exchange rates on cash and cash equivalents (36) 96 (116) (147)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period 78 13,444 22,576 10,163
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period 10,163 6,477 16,302 22,576
SUPPLEMENTAL CASH FLOW DATA – CASH PAID:        
Income taxes 152 3 0 0
Interest 5,550 5,053 15,125 17,331
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Capital expenditures in accounts payable and accruals 406 43 146 318
Obagi China Distribution to shareholder 0 13,113 0 0
Conversion of promissory note to warrants 650 0 0 0
Obagi        
CASH FLOWS FROM INVESTING ACTIVITIES:        
Acquisition of Business Combinations, net of cash acquired (465,010) 0 0 0
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Issuance of ordinary shares for Business Combinations 277,824 0 0 0
Milk        
CASH FLOWS FROM INVESTING ACTIVITIES:        
Acquisition of Business Combinations, net of cash acquired (122,653) 0 0 0
NON-CASH INVESTING AND FINANCING ACTIVITIES:        
Issuance of ordinary shares for Business Combinations $ 200,087 $ 0 $ 0 $ 0
XML 29 R8.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION AND DESCRIPTION OF BUSINESS
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS ORGANIZATION AND DESCRIPTION OF BUSINESS
Successor
Waldencast plc (“Waldencast” or the “Company”), formerly known as Waldencast Acquisition Corp., is a Bailiwick of Jersey (“Jersey”) company. Waldencast was originally incorporated on December 8, 2020 as a Cayman Islands exempted company and a blank check company solely for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March 18, 2021, Waldencast consummated an initial public offering of 34,500,000 units (the “IPO”), with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant (“Public Warrant”) to acquire one Class A ordinary share (together, a “Unit”), at $10.00 per Unit.
In connection with the Business Combination (as defined below), on July 26, 2022, Waldencast obtained shareholder approval to change its jurisdiction of incorporation. Pursuant to the Cayman Companies Act (the “Cayman Act”) and the Companies (Jersey) Law 1991, as amended (the “Jersey Companies Law”), Waldencast effected a deregistration under the Cayman Act and a domestication under Part 18C of the Jersey Companies Law. This was accomplished by filing a memorandum and articles of association with the Registrar of Companies in Jersey (the “Domestication”). Upon the effective time of the Domestication, Waldencast Acquisition Corp. was renamed Waldencast.
On July 27, 2022 (the “Closing Date”), Waldencast acquired (the “Business Combination”) Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, “Obagi”) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively “Milk”), as more fully described in “Note 3. Business Combinations.” Following the closing of the Business Combination, the Company conducts its business through the following operating and reportable segments: (i) Obagi Medical and (ii) Milk Makeup.
Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, over-the-counter and prescription products.
Milk Makeup develops and sells cosmetic, skin care and other beauty products. The brand creates vegan, cruelty-free, clean formulas from its Milk headquarters in downtown New York City. Milk’s products are offered through its U.S. website, www.milkmakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.
As a result of the Business Combination, Waldencast is organized as an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP (“Waldencast Partners LP”), a Cayman Islands exempted limited partnership and indirect subsidiary of Waldencast, which is an entity that is classified as a partnership for U.S. federal income tax purposes.
Predecessor
Obagi Global Holdings Limited is a holding company incorporated that conducts all operations through its wholly-owned subsidiaries. On July 15, 2021, ZhongHua Finance Acquisition Fund I, L.P., Obagi’s sole shareholder, transferred its 4,000,000 ordinary shares to its affiliate, Cedarwalk Skincare Ltd. (“Cedarwalk”), which became the new sole shareholder of Obagi. This transfer between affiliates did not result in any change of control.
Immediately prior to the closing of the Business Combination, Obagi carved out and distributed all of the outstanding shares of its subsidiary, Obagi Hong Kong Limited (“Obagi Hong Kong” or “Obagi HK”) to its shareholder, Cedarwalk (the “Obagi China Distribution”). All sales of Obagi products in the People’s Republic of China, inclusive of the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the “China Region”) prior to the Business Combination had been conducted through the Obagi China Business (the “Obagi China Business”), which were not acquired by Waldencast in the Business Combination.
Unless the context requires otherwise, the “Company,” “we,” or “our” refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.
Basis of Presentation
Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”).
In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the “Successor”), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the “Predecessor”). Under the acquisition method of accounting, Waldencast’s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.
This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the relevant financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the “Successor Period”) are presented on a measurement basis different from those for the period prior to the Closing Date (the “Predecessor Period(s)”). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Periods, which include Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022, the year ended December 31, 2023, and the year ended December 31, 2024, are presented on a different basis of accounting and are therefore, not comparable.
Certain prior year amounts in the consolidated financial statements and notes have been reclassified to conform to current year presentation. These reclassifications had no effect on net income or loss. These include reclassifying research and development costs into selling, general and administrative costs and reclassifying gondolas into furniture and fixtures.
XML 30 R9.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation—The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.
Emerging Growth Company—Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, will adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates—The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial
statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, goodwill valuation, inventory valuation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company’s consolidated balance sheets and consolidated statements of operations and comprehensive loss.
Concentrations of Credit Risk—Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.
The Company’s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailer located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions, monitoring payment frequency, and requiring customer advance payments in certain circumstances. The Company generally does not require collateral.
As of December 31, 2024 and 2023, one U.S. customer accounted for 33% and 27% of accounts receivable, respectively.
During the year ended December 31, 2024, the Company purchased approximately 15% and 12% of inventory from two vendors, respectively. During the year ended December 31, 2023 the Company purchased approximately 17% of inventory from one vendor.
As of December 31, 2024, no vendor exceeded 10% of accounts payable. As of December 31, 2023, one vendor accounted for 18% of accounts payable.
Cash and Cash Equivalents—The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.
Restricted Cash—The Company’s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December 31, 2024, the Company’s cash and cash equivalents, and restricted cash balance was $14.8 million and $1.5 million respectively. Restricted cash is composed of $0.7 million held as collateral for corporate credit cards and $0.8 million held as a lease deposit through the end of the lease in November 2030. As of December 31, 2023 the Company’s cash and cash equivalents, and restricted cash balance was $21.1 million and $1.5 million respectively.
Inventories—The Company’s products are produced by third-party contract manufacturers (“CMOs”). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (“FIFO”) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional products are charged to cost of goods sold at the time the product is shipped to the Company’s customer.
The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (“FOB”) shipping point or FOB destination point.
The Company evaluates the carrying value of inventories on a regular basis and determines the need, if any, to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. It accounts for losses that may occur when the inventory cannot be sold at its full cost. If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory
to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). Each period, Management will evaluate whether any additional write downs are required (generally, by stock keeping unit (“SKU”) and/or lot). Specific write downs may relate to known matters, such as quality concerns or a discontinued product.
Sales Returns
Certain arrangements may give the Company’s customers the right to return products. In addition, when customer arrangements do not give the Company’s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, Guarantees and the Company accrues for replacement costs.
Derivatives—The Company accounts for derivative instruments in accordance with ASC 815, Derivatives and Hedging (“ASC 815”), which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements.
The Company has used interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See “Note 9. Financial Instruments” for further discussion of the interest rate collar.
Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815.
Warrant Liabilities
The Company accounts for Public Warrants and Private Placement Warrants (each as defined in “Note 9. Financial Instruments”) as liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company’s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See “Note 9. Financial Instruments” for further discussion of the warrants, including the FPA Warrants (as defined therein).
Fair Value Measurement—The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management’s judgment and conditions that existed at each reporting date. See “Note 10. Fair Value Measurements” for further details.
The fair values of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company’s term loan, which approximate current market rates.
Capitalized Software and Website Development Costs—The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (“CCA”) implementation costs, and (iii) other software-related costs (e.g., website development costs).
For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use.
For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.
Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.
Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Prepaid Expenses—At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.
Prepaid Inventory
Prepayments are required to begin production of inventory at certain of the Company’s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.
Prepaid Marketing and Advertising
The Company generally expenses the costs of advertising and marketing as incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.
Property and Equipment, Net—Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation.
Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company’s assets are as follows:
ESTIMATED USEFUL LIVES
Computer hardware and software3 years
Furniture and fixtures
3 - 5 years
Machinery and equipment
3 - 5 years
Leasehold improvementsLesser of useful life or term of lease
Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Intangible Assets, Net—Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, and formulations. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset.
Impairment of Long-Lived Assets—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss.
Business Combinations—When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.
Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company’s consolidated statements of operations and comprehensive loss.
Goodwill—Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1st and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions.
Debt Issuance Costs—The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.
Accounts Receivable, Net—Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers. Payment terms are generally short-term in nature and are determined based on the financial stability of the customer.
The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i) customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii) formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer’s remittance advice or to the customer’s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.
Revenue Recognition—The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.
Product Sales
The Company’s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (“DTC”) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.
At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.
The Company has determined that each of its products is distinct and represents a separate performance obligation. The Company does not have any contracts that contain multiple performance obligations. The transaction price is equal to the consideration the Company expects to be entitled to. When measuring revenue and determining the consideration the Company expects to be entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer.
The Company’s distributors charge us fees for certain services rendered by them, including packing and shipping, marketing and advertising the Company’s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are not distinct from the distributors’ purchase of products.
Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.
The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and when assumption of the risks and rewards occur. For distributors (other than the “Physician Channel Provider”) and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company’s designated warehouse/distribution center by the customer’s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer.
Obagi’s operations in the U.S. heavily depend on a single distributor, referred to as the Physician Channel Provider, which manages sales to healthcare professionals in the physician-dispensed channel as well as retail and spa customers. For DTC sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician.
Promotional Products
When the Company provides promotional products (e.g., samples and testers) alongside a related saleable product, their cost is recognized in cost of sales at the same time the related product’s revenue is recognized.
Royalties
The Company generates royalty revenue from products in China by Obagi Hong Kong and in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi Medical brand name in the Japanese retail skincare channels. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. The Company recognizes revenue for the sales-based royalty at the later of when the local operators make sales of the products or when the purchase obligation has been satisfied.
Costs to Obtain a Contract with a Customer
The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. There were no total capitalizable costs to obtain a contract during the periods presented.
Other
The Company’s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company’s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) for ASC 340-40-25-4 related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.
Cost of Goods Sold—Cost of goods sold consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, freight and inventory inspection costs, depreciation and amortization of product-related intangible asset and supply agreements, and amortization of the inventory fair value step-up related to the Business Combination.
Distribution—Costs related to shipping, handling, warehousing and distribution for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, were $8.7 million, $6.6 million, and $2.0 million, respectively. These costs include costs that are incurred in order to get the product from the distribution centers to the end consumer and are included within selling, general and administrative expense (“SG&A”). The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&A expenses. Amounts billed to customers for shipping and handling are included in revenue. In the Predecessor period, the Company only included shipping and handling costs in SG&A expense. The costs related to shipping and handling for the period from January 1, 2022 to July 27, 2022 (Predecessor Period) were $0.6 million.
Advertising—Advertising costs are expensed in the period in which they are incurred. Total advertising costs, included in SG&A expense on the consolidated statements of operations and comprehensive loss, were $43.5 million, $16.3 million, $11.7 million, and $6.8 million for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period), respectively.
Research and Development—Research and development costs are included in SG&A expense on the consolidated statements of operations and comprehensive loss. All periods presented reflect this classification.
Stock-Based Compensation—The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards.
Replacement Options
On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested options granted under those plans (“Replacement Options”). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple.
Founder Awards
The Company estimated the fair value and derived service period of the stock options issued to founders (“Founder Awards”) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option’s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.
Restricted Stock
The fair value of restricted stock is equal to the price of the Company’s ordinary shares on the grant date.
The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.
The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award’s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition is deemed probable.
Income Taxes—The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.
The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $22.5 million was recorded as of December 31, 2024 and $19.8 million was recorded as of December 31, 2023.
The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority’s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December 31, 2024 and December 31, 2023, the Company had no uncertain positions in the consolidated financial statements.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no amounts accrued for interest and penalties as of December 31, 2024, December 31, 2023, or December 31, 2022.
Net Loss Per Share—Basic net loss per share attributable to shareholders of ordinary shares is computed by dividing the Company’s net loss attributable to holders of ordinary shares by the weighted-average number of ordinary shares outstanding during the period. Diluted net income per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net loss per share that is not attributable to the Company is reflected in net loss attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss.
Noncontrolling Interests—Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder’s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder’s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.
Segments—An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Company has two operating and reportable segments: Obagi Medical and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company’s CODM is its Chief Executive Officer.
Commitments and Contingencies—In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Recently Adopted Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The guidance expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for
other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company adopted this accounting standard in the fourth quarter of 2024, which resulted in expanded disclosures within our notes to the consolidated financial statements. There was no other impact on our consolidated financial statements. See “Note 18. Segment Reporting” for additional detail.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree’s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2023 for an EGC company, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company adopted this accounting standard as of January 1, 2024, with no material impact on its consolidated financial statements and related disclosures. Future acquisitions will be evaluated under this guidance.
Recently Issued Accounting Standards, Not Yet Adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): Reporting Comprehensive Income – Expense Disaggregation Disclosures. The guidance will require disaggregated disclosures and of certain cost and expense categories presented on the face of the income statement. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.
XML 31 R10.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS
12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
BUSINESS COMBINATIONS BUSINESS COMBINATIONS
On July 27, 2022, Waldencast consummated its initial business combination with (i) Obagi, pursuant to an Agreement and Plan of Merger dated November 15, 2021, by and among Waldencast, Obagi Merger Sub, Inc., a Cayman Islands exempted company limited by shares and an indirect wholly-owned subsidiary of Waldencast (“Merger Sub”), and Obagi (the “Obagi Merger Agreement”), and (ii), Milk, pursuant to an Equity Purchase Agreement dated November 15, 2021, by and among Waldencast, Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey (“Holdco Purchaser”) and a subsidiary of Waldencast, Waldencast Partners LP together with Holdco Purchaser, (the “Purchasers”), certain members of Milk (the “Milk Members”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members (the “Equityholder Representative”) (the “Milk Equity Purchase Agreement” and together with the Obagi Merger Agreement, the “Transaction Agreements”).
Pursuant to the Obagi Merger Agreement, at the effective time of the Obagi Merger (the “Obagi Merger Effective Time”) Merger Sub merged with and into Obagi (the “Obagi Merger”) and the separate corporate existence of Merger Sub ceased, with Obagi surviving as an indirect subsidiary of the Company. At the Obagi Merger Effective Time, all outstanding ordinary shares of Obagi, $0.50 par value (“Obagi common shares”) were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $345.4 million.
Pursuant to the Milk Equity Purchase Agreement, at the effective time of the Milk Transaction (the “Milk Purchase Effective Time”) the Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 limited partnership units in Waldencast Partners LP (“Waldencast LP Units”) (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $121.6 million (the “Milk Transaction”). Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, and, if such option is exercised, exchangeable at the option of Waldencast into one Waldencast Class A ordinary share or cash, in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement. Upon consummation of the Business Combination Waldencast became organized in an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP, which is an indirect subsidiary of Waldencast.
In the Business Combination, Waldencast was deemed to be the accounting acquirer and continues as the SEC registrant. Obagi and Milk were deemed to be the accounting acquirees, however Obagi is considered the predecessor entity for purposes of financial reporting. Waldencast was determined to be the accounting acquirer based on evaluation of the following factors:
The owners of Waldencast have the largest voting interest in the combined company;
The original owner of Waldencast, Waldencast Long-Term Capital LLC (the “Sponsor”), and its affiliates nominated the majority of the initial members who will serve on the Board (the former owner of Obagi nominated one director, and Milk nominated no directors); and
Waldencast’s existing management holds executive management roles for the post-combination company, whilst Obagi and Milk management team members report into the current Waldencast executive team.
Immediately prior to the Obagi Merger Effective Time, Obagi carved out and distributed the Obagi China Business to Cedarwalk pursuant to the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned 24.5% of the fully diluted Waldencast Class A ordinary shares as of the Obagi Merger Effective Time. Prior to the Obagi China Distribution, the pre-tax losses for the Obagi China Business were $8.0 million for the period from January 1, 2022 to July 27, 2022 (Predecessor Period).
See “Note 16. Related Party Transactions” for more information on ongoing transactions with the Obagi China Business following the close of the Obagi Merger.
Obagi and Milk Purchase Price Allocation:
(In thousands)ObagiMilk Total
Total Purchase Price:
Cash consideration$345,398 $121,629 $467,027 
Equity consideration277,824 200,087 477,911 
Cash repayment of debt136,112 3,935 140,047 
Related party liability22,100 — 22,100 
Total purchase consideration$781,434 $325,651 $1,107,085 
Fair value of assets acquired:
Cash and cash equivalents$15,850 $2,092 $17,942 
Restricted cash650 819 1,469 
Account receivable, net15,214 3,866 19,080 
Related party receivable327 199 526 
Inventories31,026 30,945 61,971 
Prepaid expenses4,307 520 4,827 
Other current assets359 — 359 
Property and equipment1,245 8,436 9,681 
Intangible assets505,300 157,500 662,800 
Right-of-use assets4,811 8,232 13,043 
Other assets227 — 227 
Total identifiable assets acquired$579,316 $212,609 $791,925 
Liabilities assumed:
Accounts payable and accrued expenses18,699 6,442 25,141 
Other current liabilities12,912 5,483 18,395 
Lease liabilities6,461 10,105 16,566 
Deferred income tax liabilities28,073 — 28,073 
Total liabilities assumed:$66,145 $22,030 $88,175 
Net assets acquired513,171 190,579 703,750 
Purchase consideration781,434 325,651 1,107,085 
Goodwill $268,263 $135,072 $403,335 
Goodwill recognized for these acquisitions is attributable to improving the product offerings, expanding into additional markets and the expected cash flows resulting from these efforts, and assembled workforce. Goodwill recognized is not expected to be deductible for local tax purposes. During the period from July 28, 2022 to December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Medical reporting unit. During the year ended December 31, 2024, the Company recorded an additional non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit. See “Note 5. Goodwill” for additional details.
See “Note 18. Segment Reporting” for amounts related to revenue and earnings associated with Obagi Medical and Milk Makeup subsequent to the acquisition date.
Related Party Liability
The Company recognized a liability with respect to a related party supply contract executed on the Closing Date between Obagi and Obagi Hong Kong. The fair value of the related party liability was determined using the present value of after-tax cash flows related to unfavorable discounts provided to the Obagi China Business included in the Supply Agreement (the “Supply Agreement” as further detailed in “Note 16. Related Party Transactions”). As of the Obagi Merger Effective Time, the Company recognized a related party liability of $22.1 million. During the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, the Company amortized $2.3 million, $4.1 million, and $12.2 million, respectively, of the related party liability into the related party revenue recognized on the sale of products to the Obagi China Business. During the year ended
December 31, 2024, the Company recorded $3.4 million in Other income due to the termination of an interim supply agreement and the associated release of the remaining related party liability. The parties operated under this interim supply agreement, which terminated in July 2023, until December 2024, at which point the remaining related party liability was amortized and released. As a result, the Company did not have a remaining related party liability as of December 31, 2024. The Company had a related party liability of $5.9 million, included in Other current liabilities, as of December 31, 2023.
Intangible Assets
Fair Value
ObagiMilkTotalWeighted-
Average
Useful Life
(In thousands) 
Trademarks and trade name$414,000 $145,000 $559,000 14 years
Customer/distributor relationships25,000 11,000 36,000 11 years
Tretinoin distribution and supply agreement38,900 — 38,900 5 years
Formulations27,400 1,500 28,900 8 years
Total Intangible Assets$505,300 $157,500 $662,800 
The intangible assets acquired in connection with the Business Combination are classified as Level 3 in the fair value hierarchy. The estimate of the fair values of the acquired amortizable intangible assets were determined using a multi-period excess earnings income approach by discounting the incremental after-tax cash flows over multiple periods. Significant estimates used in the determination include estimating future cash flows over multiple periods, terminal value, and discounting such cash flows at a rate of return that reflects the relative risk of the cash flows.
Transaction Costs
In connection with the Business Combination, Waldencast incurred transactions costs of $9.4 million which were incurred during the period from July 28, 2022 to December 31, 2022. Transaction costs consisted of advisory, legal, accounting and management fees, which are included in SG&A expenses on the consolidated statements of operations and comprehensive loss.
Unaudited ASC 805 Pro Forma
The following unaudited pro forma combined financial information presents the Company’s results as though the Business Combination had occurred on January 1, 2021, for the year ended December 31, 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.
Year ended
December 31, 2022
(In thousands)(Unaudited)
Pro forma net revenue$200,547 
Pro forma net loss(86,930)
Less: Pro forma net loss attributable to noncontrolling interest(25,140)
Pro forma net loss attributable to Waldencast plc$(61,790)
These unaudited pro forma results include adjustments such as inventory step-up, amortization of acquired intangible assets, and interest expense on debt financing in connection with the Business Combination. Material, nonrecurring pro forma adjustments directly attributable to the Business Combination include: 
• Cost of goods sold related to acquired inventory step-up of $10.0 million was removed from net income for the year ended December 31, 2022; and
Transaction related costs of $66.1 million were removed from net income for the year ended December 31, 2022.
The unaudited consolidated pro forma financial information was prepared in accordance with accounting standards and is not necessarily indicative of the results of operations that would have occurred if the Business Combination had been completed on the date indicated, nor is it indicative of the future operating results of the Company. 
The unaudited pro forma results do not reflect events that either have occurred or may occur after the Business Combination, including, but not limited to, the anticipated realization of operating synergies in subsequent periods. They also do not give effect to certain charges that the Company expects to incur in connection with these acquisitions, including, but not limited to, additional professional fees and employee integration. 
SA Distributor Transaction
In March 2023, as part of our strategy to internalize distribution channels in key markets, certain of Obagi's subsidiaries entered into and consummated a Purchase Agreement (the “Vietnam Purchase Agreement” with Obagi Vietnam and the Company’s Southeast Asia Distributor (“SA Distributor”), pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam, from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, an indirect subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve months ending December 31, 2026, subject to setoff for any owed obligations. The acquisition was determined to be an asset acquisition with the primary asset being the recovery of $1.6 million of inventory held by the SA Distributor. No fair value was allocated to the earnout liability as the Company concluded the earnout projections would not be achieved. In June 2024, Obagi entered into a Settlement and Release Agreement with the SA Distributor, which, among other things, extinguished the SA Distributor’s right to receive an earnout and the SA Distributor’s 40% interest in the outstanding equity of Obagi Blue Sea Holding, LLC.
XML 32 R11.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company disaggregates its revenue from customers by sales channel, as well as by revenue source and geographic region, based on the location of the end customer, as it believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.
Revenue by Sales Channel
The Company’s revenue is primarily generated from product sales. Direct sales revenue listed in the table below includes (i) sales to physicians through the Physician Channel Provider, (ii) DTC sales via the Company’s e-commerce platforms, and (iii) sales directly to retailers. Distributors revenue includes products sold through distributors other than the Physician Channel Provider.
Total revenue by sales channel was as follows for the periods indicated:
Year ended December 31, 2024
(In thousands)Obagi MedicalMilk
Makeup
Total
Revenue by Sales Channel
Direct sales$103,168 $120,362 $223,530 
Distributors41,630 4,209 45,839 
Net product sales$144,798 $124,571 $269,369 
Royalties4,468 31 4,499 
Net revenue$149,266 $124,602 $273,868 
Year ended December 31, 2023
(In thousands)Obagi MedicalMilk
Makeup
Total
Revenue by Sales Channel
Direct sales$72,446 $97,222 $169,668 
Distributors40,203 3,245 43,448 
Net product sales$112,649 $100,467 $213,116 
Royalties5,002 20 5,022 
Net revenue$117,651 $100,487 $218,138 
Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)Obagi MedicalMilk
Makeup
TotalTotal
Revenue by Sales Channel
Direct sales$30,276 $30,192 $60,468 $39,649 
Distributors28,826 1,091 29,917 31,080 
Net product sales$59,102 $31,283 $90,385 $70,729 
Royalties1,988 — 1,988 3,031 
Net revenue$61,090 $31,283 $92,373 $73,760 

For the year ended December 31, 2024, three customers accounted for 18%, 17%, and 10% of the Company’s revenue, respectively. For the year ended December 31, 2023, two customers accounted for 28% and 20% of the Company’s revenue, respectively. During the period from July 28, 2022 to December 31, 2022, three customers accounted for 29%, 18%, and 16% of the Company’s revenue, respectively. During the period from January 1, 2022 to July 27, 2022, two customers accounted for 44% and 20% of the Company’s revenue, respectively.
The Physician Channel Provider is an authorized wholesale distributor and service provider for the Company in the U.S. Revenue from sales to physicians and e-commerce customers made through this provider are considered direct sales revenue. The Physician Channel Provider is also a distributor of the Company’s products to other channels, such as the spa channel, and the related sales are considered distributor revenue.
Revenue by Geographic Region
Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Revenue by Geographic Region 
North America$202,261 $154,357 $56,630 $44,443 
Rest of the World67,108 58,759 33,755 26,286 
Net product sales$269,369 $213,116 $90,385 $70,729 
Royalties4,499 5,022 1,988 3,031 
Net revenue$273,868 $218,138 $92,373 $73,760 
During the years ended December 31, 2024, and 2023, only one country, the United States, accounted for more than 10% of the Company’s total revenues, with net product sales amounting to $192.6 million and $145.3 million, respectively.
During the period from July 28, 2022 to December 31, 2022, the two countries that accounted for more than 10% of the Company’s total revenues were the United States and China, respectively, with net product sales amounting to $54.3 million and $17.0 million, respectively.
During the period from January 1, 2022 to July 27, 2022, (Predecessor Period) the two countries that accounted for more than 10% of the Company’s total revenues were the United States and Vietnam, with net product sales amounting to $43.8 million and $14.9 million, respectively.
XML 33 R12.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL GOODWILL
The Company allocated goodwill acquired in the Obagi Merger to its Obagi Medical reporting unit and goodwill acquired in the Milk Transaction to its Milk Makeup reporting unit. The fair value of each reporting unit was determined as of the Closing Date as part of the Business Combination (see “Note 3. Business Combinations”). The following table presents changes in goodwill by reportable segment:
(In thousands)Obagi MedicalMilk MakeupTotal Goodwill
Balance as of December 31, 2022
$199,548 $135,072 $334,620 
Balance as of December 31, 2023
$199,548 $135,072 $334,620 
Impairment loss(5,031)— $(5,031)
Balance as of December 31, 2024
$194,517 $135,072 $329,589 
The Company evaluates goodwill for impairment on an annual basis on October 1st and at an interim date if indicators of a potential impairment exist. The goodwill impairment test is conducted at the reporting unit level. The fair value of the Company’s reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the Company’s most recent projected long-term financial forecasts for revenue, earnings, capital expenditures, and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the respective reporting unit. Under the guideline public company method, fair value is estimated using market multiples of various financial metrics observed for the reporting unit’s comparable public companies.
Immediately after the Business Combination (see “Note 3. Business Combinations”), the Company concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Medical reporting unit was less than its carrying amount. Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Medical reporting unit. The annual impairment test performed for fiscal 2022 did not indicate a further impairment of goodwill at the time it was performed.
The annual impairment test performed for fiscal 2023 did not indicate an impairment of goodwill at the time it was performed.
The Company performed its annual goodwill impairment analysis using the qualitative approach on October 1, 2024, and the analysis concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Medical reporting unit was less than its carrying amount. Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the year ended December 31, 2024, the Company recorded a non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit.
The Company performed a qualitative review of the Milk Makeup reporting unit on October 1, 2024, which did not indicate that the fair value of the reporting unit was less than the carrying value. On that basis, management concluded that there was no change in the fair value. As a result, the goodwill balance for the Milk Makeup reporting unit has not changed.
Changes in market conditions, laws and regulations, and key assumptions made in future qualitative or quantitative assessments, such as expected cash flows, competitive factors, discount rates, and value indications from market transactions, could negatively impact the results of future impairment testing and could result in the recognition of additional future impairment charges.
XML 34 R13.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS—NET
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS—NET INTANGIBLE ASSETS—NET
Intangible assets, net consisted of the following as of December 31, 2024:
(In thousands)Weighted
Average Useful
Lives (Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Trademark and trade name14$559,875 $(102,169)$457,706 
Customer/distributor relationships1136,000 (6,449)29,551 
Tretinoin distribution and supply agreement
538,900 (18,885)20,015 
Formulations828,900 (9,943)18,957 
Patents20227 (18)209 
Total$663,902 $(137,464)$526,438 
Intangible assets, net consisted of the following as of December 31, 2023:
(In thousands)Weighted
Average Useful
Lives (Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Trademark and trade name14$559,644 $(59,989)$499,655 
Customer/distributor relationships1136,000 (4,532)31,468 
Tretinoin distribution and supply agreement538,900 (11,105)27,795 
Formulations828,900 (5,101)23,799 
Patents20154 (8)146 
Total$663,598 $(80,735)$582,863 
Due to the non-cash goodwill impairment charge within the Obagi Medical reporting unit during the year ended December 31, 2024, the Company also performed a quantitative analysis on Obagi Medical's definite lived intangibles. The Company concluded there was no impairment to these assets.
Amortization expense for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) was $56.7 million, $56.7 million, $24.0 million, and $7.7 million, respectively.
Expected amortization for each of the years between 2025 through 2029, and thereafter are as follows:
(In thousands)
Years ending December 31,
2025$56,737 
202656,737 
202753,496 
202848,957 
202948,957 
Thereafter261,554 
$526,438 
XML 35 R14.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT
12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
(In thousands)Maturity Date
As of December 31, 2024
As of December 31, 2023
2022 Term LoanJuly 2026$153,125 $161,875 
Note PayableMay 2024830 968 
2022 Revolving Credit FacilityJuly 202615,000 — 
Unamortized debt issuance costs(2,339)(3,050)
Net carrying amount$166,616 $159,793 
Less: Current portion of long-term debt(29,479)(8,529)
Total long-term portion$137,137 $151,264 
Note Payable — Directors and Officers (“D&O”) Insurance
In July 2024, the Company entered into an agreement with a financing company for $1.6 million to finance its D&O insurance policy. The terms of the agreement stipulated equal monthly payments of principal and interest payments of $0.2 million over a ten-month period, ending in May 2025. Interest is accrued on this loan at an annual rate of 8.25%.
In August 2023, the Company entered into an agreement with a financing company for $2.4 million to finance its D&O insurance policy. The terms of the agreement stipulated equal monthly payments of principal and interest payments of $0.2 million over a ten-month period, ending in May 2024, which had been fully repaid as of December 31, 2024. Interest was accrued on this loan at an annual rate of 8.2%.
2022 Credit Agreement
In June 2022, Waldencast Finco Limited, a wholly-owned subsidiary of the Company (the “2022 Credit Agreement Borrower”), together with Waldencast and certain of its subsidiaries as guarantors (the “2022 Credit Agreement Parent Guarantor”), entered into the 2022 Credit Agreement with the 2022 Credit Agreement Lenders and JPMorgan, as administrative agent for the 2022 Credit Agreement Lenders (the “2022 Credit Agreement Lenders”). The 2022 Credit Agreement provides the Company with access to a term loan of $175.0 million (the “2022 Term Loan”) and a revolving credit capacity with a current borrowing capacity of up to $45.0 million (the “2022 Revolving Credit Facility”), of which up to $7.5 million may be available, at 2022 Credit Agreement Borrower’s option, to be drawn in form of letters of credit (“2022 Letter of Credit”). The 2022 Credit Agreement is secured by the assets of the Company. The 2022 Credit Agreement restricts the Company’s ability to make certain distributions or dividends, subject to a number of enumerated exceptions.
The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. Borrowings under the 2022 Credit Agreement may accrue interest at a rate per annum equal to, at the 2022 Credit Agreement Borrower’s election, either alternate base rate plus an applicable margin of 2.5% per annum or a term benchmark rate plus an applicable margin of 3.5% per annum. As of December 31, 2024, borrowings under the 2022 Credit Agreement consisted entirely of term benchmark borrowings at a borrowing rate of 7.9% per annum.
In connection with the issuance of the 2022 Credit Agreement, the Company incurred $6.3 million of debt issuance costs. As of December 31, 2024, the weighted average interest rate was 8.7% for the 2022 Term Loan and 8.7% for the 2022 Revolving Credit Facility. The current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $15.3 million and $15.0 million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and the 2022 Revolving Credit Facility was $1.2 million and $0.5 million, respectively. The accrued interest was $1.4 million as of December 31, 2024. Unamortized debt issuance costs on the 2022 Letter of Credit is $0.1 million, which is recorded in other current assets in the consolidated balance sheets.
Scheduled maturities under the Company’s 2022 Credit Agreement and the Note Payable as of December 31, 2024 are as follows:
(In thousands)
Year Ending December 31,
2025$31,142 
2026137,813 
2027— 
2028— 
2029— 
Total unpaid principal$168,955 
Waiver and Consent and Amendment to the 2022 Credit Agreement
On April 26, 2024, the 2022 Credit Agreement Borrower, 2022 Credit Agreement Parent Guarantor, JPMorgan and the required lenders entered into an amendment (the “Third Amendment”) to the 2022 Credit Agreement. Among other things, the Third Amendment: (i) waived certain historical breaches of the financial covenant, (ii) modified the existing financial covenants, (iii) reduced the revolving commitments of the lenders by $5.0 million in the aggregate to $45.0 million, (iv) lowered the existing minimum liquidity covenant to $10.0 million and (v) extended the Covenant Relief Period until December 31, 2024.
XML 36 R15.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES
12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
LEASES LEASES
The Company has operating leases for real estate properties for office and warehouse spaces with initial terms between approximately 1 and 11 years. Some of the Company’s lease contracts include options to extend the leases for up to 5 years. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.
The Company determines if a contract contains a lease at inception of the arrangement based on whether the Company has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether the Company has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset that the Company does not own. Right of use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of any changes in market conditions but generally, these termination options are not exercised and not considered in the determination of the lease term. Lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. ROU assets are recognized on the balance sheet based on the lease liability adjusted for any initial direct costs, lease incentives received, and prepaid rent. The Company may elect to apply the short-term lease exception for leases with a term of 12 months or less. These leases will be not be recognized as an ROU asset or lease liability. The short-term lease payments will be expensed on a straight-line basis over the lease term.
The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate (“IBR”), because the interest rate implicit in most of the Company’s leases is not readily determinable. The IBR is a hypothetical rate based on the Company’s understanding of what its credit rating would be, and resulting interest the Company would pay, to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Lease payments may be fixed or variable, however, only fixed payments or in-substance fixed payments are included in the Company’s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligation for those payments is incurred. The Company has elected not
to separate non-lease components from lease components and accounts for them as a single lease component. The Company has also elected the short-term lease recognition exemption for all leases that qualify.
The Company historically accounted for leases in accordance with ASC 840, Leases, under which operating leases were not recorded on the balance sheet. Adoption of ASC 842, Leases (“ASC 842”) was not required in interim periods preceding December 31, 2022. Upon consummation of the Business Combination, Obagi and Milk adopted ASC 842 as a matter of policy alignment. The period from January 1, 2022 to July 27, 2022 (Predecessor Period) does not reflect the impact of ASC 842 adoption, as the Company did not adopt the standard as of an interim 2022 period.
The Company’s lease expenses of $3.7 million and $3.5 million during the year ended December 31, 2024 and year ended December 31, 2023, respectively, were composed of operating lease costs. The Company does not have any finance leases, short-term lease costs or variable lease costs.
Supplemental cash flow information related to the Company’s operating leases was as follows:
(In thousands)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Cash paid for amounts included in the measurement of operating lease liabilities$3,826 $3,309 $1,166 
Right-of-use assets obtained in exchange for new operating lease liabilities$131 $446 $4,081 

Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Weighted-average remaining lease term6.056.927.75
Weighted-average discount rate5.9%5.9%5.9%
Reconciliation of the undiscounted future minimum lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2024 was as follows:
(In thousands)
Amount
2025$3,797 
20262,899 
20272,452 
20282,504 
20292,548 
Thereafter4,173 
Total future minimum lease payments$18,373 
Less: Imputed interest
2,883 
Total reported lease liability$15,490 
Texas Leases
In December 2021 and July 2022, Obagi entered into a lease for a warehouse and office space, respectively, in Texas as part of their plans to relocate headquarters from California. The warehouse and office space leases will expire in 2032 and 2033, respectively.
The warehouse space was never made operational and in 2023, the Company permanently decided not to use the warehouse with no intention to occupy or utilize the space in the future, and actively began marketing the space for sublease. The Company entered into a sublease for the warehouse space that will run through February 2032 with
annual rent of $0.3 million. The sublease does not contain a provision for early termination or extension at the end of the lease. As a result, the Company recorded an impairment charge of $0.8 million during the year ended December 31, 2023 which was the excess of the carrying value of the associated lease right-of-use asset over its fair value.
In September 2023, Obagi vacated the Texas office space and relocated its headquarters back to California, permanently deciding to not use the office with no intention to occupy or utilize the space in the future, and actively began marketing the space for sublease. The Company has entered into a sublease for the office space that will run through December 2025 with annual rent of $0.4 million. The sublease does not contain a provision for early termination or extension at the end of the lease. As a result, the Company recorded an impairment charge of $2.7 million during the year ended December 31, 2023 which was the excess of the carrying value of the associated office lease right-of-use asset over its fair value.
The Company estimated the fair values using discounted cash flows from the estimated net sublease rental income as of the date the decision to sublease was made. The impairment charges are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.
Disclosures Related to Periods Prior to the Adoption of ASC 842
Prior to the Obagi China Distribution, the Company leased office space under three non-cancelable operating leases expiring between September 2023 and February 2032. Rent expense related to the Company’s operating leases was $0.9 million for the period from January 1, 2022 to July 27, 2022 (Predecessor Period).
XML 37 R16.htm IDEA: XBRL DOCUMENT v3.25.1
FINANCIAL INSTRUMENTS
12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
Interest Rate Collar
To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, the Company entered into an interest rate collar with Wells Fargo Bank, N.A. (“Wells Fargo”) in October 2022 for a notional value of $160.0 million and a fixed cash payment of $0.8 million. Under the terms of the interest rate collar, the Company was required to pay Wells Fargo if the monthly SOFR-based interest fell below the defined interest rate floor of 2.55%; conversely, the Company was entitled to receive payment from Wells Fargo if the monthly SOFR-based interest rate rose above the defined interest rate cap of 5.25%. Settlement in cash occurred monthly, if contractually required, until termination of the agreement, which occurred in October 2024. As of December 31, 2024, the Company no longer had an interest rate collar.
This derivative instrument has not been designated for hedge accounting, therefore the change in fair value is recognized in current period earnings. The fair value of these contracts, included in other non-current assets was zero and $0.1 million as of December 31, 2024 and December 31, 2023, respectively. The non-cash gain from the change in fair value was $0.1 million during the year ended December 31, 2024, recognized in other expenses, net. The non-cash losses from the change in fair value during the year ended December 31, 2023 and from July 28, 2022 to December 31, 2022 were $0.1 million and $0.6 million, respectively, and are recognized in other expenses, net. Receipts of $0.1 million were exchanged on the interest rate collar contract during each year ended December 31, 2024 and year ended December 31, 2023. No payments or receipts were exchanged on the interest rate collar contract during the period from July 28, 2022 to December 31, 2022 aside from the initial fixed cash payment of $0.8 million.
Warrant Liabilities
Pursuant to Waldencast’s IPO, the Company issued 11,499,950 Public Warrants to third-party investors. Simultaneously with the closing of the IPO, Waldencast completed the private sale of 5,933,333 warrants (the “Sponsor Warrants”) to the Sponsor. Also, in connection with the IPO, on February 22, 2021, Waldencast, the Sponsor and Zeno Investment Master Fund (f/k/a Dynamo Master Fund, a member of the Sponsor (“Zeno”), entered into a Forward Purchase Agreement (the “Sponsor FPA”), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell Mountain Trust (“Burwell”) on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor’s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Waldencast Class A ordinary shares and 5,333,333 warrants (the “Sponsor FPA Warrants”) in connection with the closing of the Business Combination. In addition, Waldencast and Beauty Ventures LLC (“Beauty Ventures”) entered into a Forward Purchase Agreement on March 1, 2021 (the “Third-Party FPA”, and
together with the Sponsor FPA, the “FPAs”), pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and 5,766,666 warrants (the “Third-Party FPA Warrants” and together with the Sponsor FPA Warrants, the “FPA Warrants”) for an aggregate commitment amount of $173.0 million, in connection with the closing of Waldencast’s initial business combination. Finally, in connection with the Business Combination, Waldencast issued 1,000,000 warrants to settle $1.5 million working capital loans with its Sponsor, the terms of which are identical to the Sponsor FPA Warrants (the “Sponsor Loan Warrants”). The Sponsor Loan Warrants and Third-Party FPA Warrants are collectively referred to as the “Private Placement Warrants.
As of December 31, 2024, all of the above-noted warrants, totaling 29,533,282, remained issued and outstanding. The Company recognized a gain of $23.6 million, a loss of $10.3 million, and a gain of $6.8 million from the change in fair value of the Public Warrants and Private Placement Warrants in the Company’s consolidated statements of operations and comprehensive loss during the year ended December 31, 2024, during the year ended December 31, 2023, and for the period from July 28, 2022 to December 31, 2022, respectively.
Following the Domestication, Public Warrants and Private Placement Warrants each entitle the holder to purchase one share of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued and only whole warrants can trade. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire June 27, 2027 or earlier upon redemption or liquidation.
The Company may redeem the Public Warrants:
in whole and not in part;
upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption, based on the redemption date and the “fair market value” of the Class A ordinary shares;
at a price of $0.01 per warrant if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted);
at a price of $0.01 per warrant if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and
if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.
The exercise price and number of Class A ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants.
The terms of the Third-Party FPA Warrants are identical to the Public Warrants. The Sponsor Loan Warrants and Sponsor FPA Warrants are also identical to the Public Warrants, except that they and the Class A ordinary shares issuable upon the exercise of such warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Loan Warrants and Sponsor FPA Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees, thereafter they will be redeemable by the Company and exercisable by such holders on the same basis as Public Warrants.
XML 38 R17.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The following tables present information by year about the Company’s financial instruments that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:
As of December 31, 2024
(In thousands)TotalQuoted Prices in Active MarketSignificant Other Observable InputsSignificant Other Unobservable Inputs
(Level 1)(Level 2)(Level 3)
Liabilities:
Derivative warrant liabilities - Public$1,983 $1,983 $— $— 
Derivative warrant liabilities - Private$3,038 $— $3,038 $— 
As of December 31, 2023
(In thousands)TotalQuoted Prices in Active MarketSignificant Other Observable InputsSignificant Other Unobservable Inputs
(Level 1)(Level 2)(Level 3)
Assets:
Interest rate collar$61 $— $61 $— 
Liabilities:
Derivative warrant liabilities - Public$11,155 $11,155 $— $— 
Derivative warrant liabilities - Private$17,492 $— $17,492 $— 
Private derivative warrants are classified as Level 2 financial instruments. The fair value of the Level 2 Private Placement Warrant liabilities has been measured based on the fair value of Public Warrant liabilities. The interest rate collar has been measured at net present value by projecting future cash flows and discounting the future amounts to a present value using market-based observable inputs including interest rate curves and credit spreads.
For goodwill (see “Note 5. Goodwill”), fair value assessments of the reporting units and the reporting units’ net assets performed for goodwill impairment tests are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.
The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Except for the initial valuation of long-lived assets in connection with the Business Combination (see “Note 3. Business Combinations”) and impairment of goodwill discussed above, no long-lived assets were remeasured at fair value on a nonrecurring basis during the periods presented.
XML 39 R18.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL BALANCE SHEET DISCLOSURES SUPPLEMENTAL BALANCE SHEET DISCLOSURES
Accounts Receivable, Net
As of December 31, 2024, accounts receivable, net consisted of accounts receivable of $25.6 million, less allowance for doubtful accounts of $0.1 million. As of December 31, 2023, accounts receivable, net consisted of accounts receivable of $22.9 million, less allowance for doubtful accounts of $1.6 million.
The change in the allowance for doubtful accounts were as follows:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Balance at beginning of period$1,552 $994 $1,061 $671 
Provision (recovery) for bad debts
(996)558 (67)390 
Write-off of uncollectible accounts, net(448)— — — 
Balance at end of period$108 $1,552 $994 $1,061 
Inventories
The components of inventories were as follows:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Work in process$8,354 $10,336 
Finished goods44,750 45,348 
Total inventories$53,104 $55,684 
Property and Equipment, Net
Property and equipment, net consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Computer hardware, software and equipment$742 $689 
Furniture and fixture9,848 7,611 
Machinery and equipment598 812 
Internally developed software1,739 854 
Leasehold improvements2,100 2,070 
Total property and equipment$15,027 $12,036 
Less accumulated depreciation(9,196)(6,105)
Property and equipment, net$5,831 $5,931 
Depreciation expense for property and equipment for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022 were $3.3 million, $3.8 million, and $2.9 million, respectively. Depreciation expense for property and equipment for the period from January 1, 2022 to July 27, 2022 (Predecessor Period) was $0.5 million.
Depreciation expense pertains to property and equipment utilized as part of the Company’s SG&A activities and therefore has not been allocated to cost of goods sold.
Other Current Liabilities
The major components of other current liabilities consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Accrued salaries and related expenses$9,155 $8,702 
Accrued sales returns and damages2,723 2,527 
Accrued interest1,424 1,357 
Accrued distribution fees— 590 
Related party liability— 5,856 
Accrued professional services3,832 2,901 
Other2,426 1,765 
Total$19,560 $23,698 
There was no related party liability as of December 31, 2024 due to the change in contract terms, which resulted in a release of the liability. The related party liability of $5.9 million as of December 31, 2023 reflects the remaining unamortized fair value of the related party inventory contract executed on the acquisition date between Obagi and the Obagi China Business (see “Note 3. Business Combinations”).
XML 40 R19.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK BASED COMPENSATION STOCK-BASED COMPENSATION
Incentive Award Plan
The Company’s 2022 Incentive Award Plan (the “2022 Plan”) provides for incentives to be provided to selected officers, employees, non-employee directors and consultants of the Company in the form of options, stock appreciation rights, restricted stock, restricted stock units, stock bonuses or other stock-based awards granted under the 2022 Plan. The 2022 Plan became effective on July 27, 2022 in connection with the closing of the Business Combination.
The notional maximum number of ordinary shares authorized under the 2022 Plan for the fiscal year ended December 31, 2024 was 23,042,449 (the “Share Reserve”). The Share Reserve automatically increases on January 1st of each calendar year by 3% of the total ordinary shares then issued and outstanding, or such lesser amount as determined by the Board. All shares reserved for issuance under the 2022 Plan may be granted as incentive stock options. As of December 31, 2024, taking into account previous grants and forfeitures, the Company had 5,533,142 ordinary shares remaining available for future issuances under the 2022 Plan.
In 2024, the Company granted an aggregate of 3,828,878 Restricted Stock Unit (“RSU”) incentive awards to employees and non employees of the Company, generally vesting over one to three years. Some portion vested immediately with the balance vesting annually. Of these awards 312,830 were granted to the Founders,
Also in 2024, the Company granted an aggregate of 319,471 RSUs to directors, typically vesting immediately or over one to three years.
In August 2022, the Company approved incentive awards to employees of Waldencast, Milk, and Obagi. The long-term incentive awards (the “LTI Awards”) are restricted stock units that vest based on both a service condition and meeting either a net sales or EBITDA target in calendar year 2022. These LTI Awards were granted to employees in November 2022. The performance targets for the LTI Awards were met for Milk in 2022. The Company granted LTI Awards will vest one-third each year beginning on February 15, 2023, subject to continued service through such dates. In May 2023, the Board approved a modification to the LTI Awards by waiving the performance conditions for most Obagi and Waldencast employees totaling 137,537 RSUs. The conditions were not waived for the former Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast, resulting in forfeiture of 360,000 RSUs. Based on the financial statements prepared by the Company for the period ended December 31, 2022, the Board certified that the applicable performance goals were not met and, accordingly, that the
2022 RSUs granted to the Company’s founders would not vest. No additional grants of RSUs were made for the year ended December 31, 2024 or for the year ended December 31, 2023.
In November 2022, the Company approved a one-time stock grant for certain Milk employees that were not eligible to participate in the LTI award program. A total of 10,000 awards were approved under this program. These awards are service-based restricted stock units that will cliff vest three years from the grant date, subject to continued employment with the Company.
Strategic Growth Incentive
In 2024, the Company granted an aggregate of 2,557,119 strategic growth incentive 2027 awards in performance vested share units to certain Company employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the Company’s Net Revenue and earnings before interest, taxes, depreciation, and amortizations (“EBITDA”) targets for the year ended December 31, 2027. These awards had a grant date fair value per share ranging between $2.88 and $6.48. Some of the awards require a one-year post vesting holding period once the shares have been awarded.
In 2023, the Company granted an aggregate of 2,290,000 strategic growth incentive 2025 awards in performance vested share units to certain Company employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the Company’s net revenue and EBITDA targets for the year ended December 31, 2025. These awards had a grant date fair value per share of $8.88 and require a one-year post vesting holding period once the shares have been awarded.
Restricted stock activity for the year ended December 31, 2024 was as follows:
SharesWeighted Average
Grant Date Fair Value
per Share
Outstanding as of December 31, 2023
2,296,831 $8.72 
Granted6,705,468 3.69 
Vested(567,745)5.84 
Forfeited(851,298)8.87 
Outstanding as of December 31, 2024
7,583,255 $4.61 
Business Combination
On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested awards granted under those plans. The Company assumed 5,906,300 stock options and 1,776,827 restricted stock units as replacement awards pursuant to the Obagi Merger Agreement, as well as 237,724 stock options and 2,808,131 share appreciation rights as replacement awards pursuant to the Milk Merger Agreement. The total post-combination incremental stock-based compensation was $18.3 million, which is expected to be recognized over the remaining requisite service periods, where $47.7 million represents the fair value of the equity awards as part of the equity purchase consideration. The awards that were replaced had been contingent on a performance condition and as such, the Company is required to use an attribution model in which compensation cost for each vesting tranche is recognized as if each vesting tranche were a separate award.
Founder Awards
In August 2022 the Company granted a total of 11,500,000 stock options to the two founders of Waldencast that vest based on service over the six-year period from August 2022 through August 2028. The options were granted with four vesting tranches, each tranche with a different exercise price, subject to their continued employment with the Company. Additionally, the Company granted 692,000 founders service-based restricted stock units that cliff vest in August 2025, subject to their continued employment with the Company.
Stock option activity for the year ended December 31, 2024 was as follows:
Number of
Common
Stock
Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life (in years)
Aggregate
intrinsic
Value (in
thousands)
Balance as of December 31, 2023
18,915,358 $9.10 7.3$47,792 
Granted— — — — 
Exercised(150,000)0.68 — — 
Forfeited(1,628,000)5.73 — — 
Balance as of December 31, 2024
17,137,35810.48 6.41,156 
Exercisable as of December 31, 2024
9,168,9757.31 5.01,156 
Vested and expected to vest as of December 31, 2024
17,137,358$10.48 6.4$1,156 
The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for Replacement Options based on the following weighted-average assumptions:
Period from July 28, 2022 to December 31, 2022
Founder Awards
Replacement Options
Risk-free interest rate (1)
2.87% - 2.92%
 2.79% - 2.80%
Expected term (years) (2)
4.7 - 9.9
N/A
Exercise multiple (3)
N/A2.30 
Expected stock price volatility (4)
39.77% - 44.76%
50.00 %
Dividend yield (5)
N/AN/A
(1)The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.
(2)The expected term for Founder Awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.
(3)The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.
(4)For Founder Awards, the expected stock price volatility is the median historical volatility of Waldencast’s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for Replacement Options, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.
(5)Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.
Stock-compensation expense for the years ended December 31, 2024 and 2023, and the period from July 28, 2022 to December 31, 2022, was $9.4 million, $9.2 million, and $7.7 million, respectively. The unrecognized compensation cost as of December 31, 2024 for stock options and restricted stock was $16.1 million and $13.0 million, respectively. These costs are expected to be recognized over a weighted-average service period of 3.5 and 2.3 years for stock options and restricted stock, respectively.
Predecessor Incentive Plan
In January 2021, the Predecessor established a Stock Incentive Plan (the “Predecessor Incentive Plan”), under which stock options, stock awards, and restricted stock units (“Predecessor Restricted Stock”) of the Company could be granted to eligible employees, directors, and consultants. Under the Predecessor Incentive Plan, the Company was authorized to issue of a maximum number of 1,500,000 shares of Obagi common stock. Incentive stock options were
required to have an exercise price at or above the fair market value of the stock on the date of the grant. The Company’s stock options and Predecessor Restricted Stock granted during the period from January 1, 2022 to July 27, 2022 (Predecessor Period) had service-based and performance-based vesting conditions.
The options vested over five years, with 25% of options vesting in four equal quarterly installments at the end of each three-month period through the first anniversary of the grant, and the remaining 75% vesting in a series of five equal annual installments over the five-year period measured from the grant date. The Predecessor Restricted Stock vested in five equal annual installments at the end of each year, over the five-year period from the grant date. Award holders had a ten-year period to exercise the options before they expire. Notwithstanding achievement of the service-based condition, the options and the Predecessor Restricted Stock did not vest or become exercisable until a qualifying transaction was consummated prior to the expiration date. A qualifying transaction consisted of either a change in control event or an underwritten initial public offering by the Company of its equity securities on a U.S. or foreign exchange, which occurred upon Waldencast’s acquisition of Obagi.
XML 41 R20.htm IDEA: XBRL DOCUMENT v3.25.1
SHAREHOLDERS’ EQUITY
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
SHAREHOLDERS’ EQUITY SHAREHOLDERS’ EQUITY
Share Capital
Under the Company’s Memorandum of Association (the “Constitutional Document”), its authorized share capital consists of 1,000,000,000 Class A ordinary shares, 100,000,000 Class B ordinary shares and 25,000,000 Preferred Shares, each having a par value of $0.0001. As of December 31, 2024, there were 112,026,440 and 10,666,528 Class A and Class B ordinary shares, respectively, issued and outstanding. The Company did not have any Preferred Shares issued and outstanding as of December 31, 2024.
Each Class A ordinary share is entitled to one vote per share. The Company can, at the discretion of its Board, declare dividends and distributions out of the funds of the Company lawfully available therefor. In the event of a voluntary or involuntary liquidation or wind-up, assets available for distribution among the holders of Class A ordinary shares will be distributed on a pro rata basis.
Each Class B ordinary share is entitled to one vote per share and will vote together with holders of Class A ordinary shares as a single class. Class B ordinary shares are non-economic shares that are not entitled to dividends. Upon a liquidation, dissolution or winding up of the Company, the holders of Class B ordinary shares will not be entitled to receive any assets of the Company, except to the extent of the par value of their shares, pro rata with the distributions that are shared with the Class A ordinary shares.
As outlined in “Note 3. Business Combinations,” Class B ordinary shares were issued by the Company to the Milk Members in connection with the Business Combination, giving rise to noncontrolling interest in the Company’s controlled subsidiary, Waldencast Partners LP. As such, the Constitutional Document prohibits issuances of additional shares of Class B ordinary shares, unless issued to a noncontrolling interest in connection with the Company’s Up-C structure. Class B ordinary shares are convertible into Class A ordinary shares on a one-to-one basis at the option of the holder. If such option is exercised, the exchanged Class B ordinary shares will automatically be surrendered and retired for no consideration. If the Company issues or redeems Class B ordinary shares, Waldencast Partners LP is obligated to issue or redeem a corresponding number of Waldencast LP partnership units, such that the number of issued and outstanding partnership units at any time will correspond and be equivalent to the then number of issued and outstanding Class B ordinary shares.
XML 42 R21.htm IDEA: XBRL DOCUMENT v3.25.1
NET LOSS PER SHARE
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
The Company uses the weighted average ownership percentages during the period to calculate the net loss per share attributable to public shareholders and the noncontrolling interest holders. The following table sets forth the computation of basic and diluted net loss using the treasury stock method:
(In thousands, except for share and per share amounts)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Numerator:
Net loss$(48,648)$(105,968)$(120,557)$(21,057)
Net loss attributable to noncontrolling interest(6,205)(15,987)(24,990)— 
Net loss attributed to Class A shareholders - basic and diluted EPS(42,443)(89,981)(95,567)(21,057)
Denominator:
Weighted-average basic shares outstanding109,295,74291,158,50086,460,5608,000,002
Effect of dilutive securities— — — — 
Weighted-average diluted shares109,295,74291,158,50086,460,5608,000,002
Basic and diluted net loss per share$(0.39)$(0.99)$(1.11)$(2.63)
The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Warrants29,533,28229,533,28229,533,282
Stock options17,137,35818,915,35820,452,155774,800
Restricted stock7,583,2552,296,8312,802,419234,842
Total54,253,89550,745,47152,787,8561,009,642
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAX BENEFIT INCOME TAX BENEFIT
The Company, incorporated in the Bailiwick of Jersey migrated its place of residence on October 29, 2024. It was tax resident in the Bailiwick of Jersey prior to this date, resident in the United Kingdom in the period thereafter, and subject to taxation in the U.S. and various states jurisdictions throughout. ASC Topic 740, Income Taxes (“ASC 740”) indicates that the federal statutory income tax rate of a foreign reporting entity be used when preparing the rate reconciliation disclosure. As such, the Company and its wholly-owned subsidiaries use the statutory income tax rate in the Bailiwick of Jersey and the Cayman Islands of 0% through October 29, 2024, and the statutory income tax rate in the United Kingdom for the period thereafter of 25.0%.
The Company’s consolidated pretax loss for the periods presented were generated by domestic and foreign operations as follows:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)
Successor (Waldencast)
Predecessor (Obagi)
Loss before income taxes:
United States$2,684 $(82,868)$(125,281)$(17,676)
Foreign(51,222)(30,075)(1,079)(3,268)
Total$(48,538)$(112,943)$(126,360)$(20,944)
The provision for income taxes for the periods presented consisted of the following:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Current provision (benefit):
Federal$784 $12 $— $— 
State268 32 20 19 
Foreign243 — 
1,295 46 20 23 
Deferred (income) expense:
Federal(144)(7,927)(4,557)38 
State(976)906 (1,266)52 
Foreign(66)— — — 
(1,185)(7,021)(5,823)90 
Net income tax (benefit) provision$110 $(6,975)$(5,803)$113 
The components of income tax expense related to the following:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate
4.3 %— %— %— %
U.S./foreign tax rate differential10.0 %15.9 %20.7 %17.7 %
State income tax benefit, net of federal benefit1.7 %2.1 %2.4 %1.4 %
Permanent Items3.5 %(0.1)%0.2 %(0.1)%
Noncontrolling interest(0.9 %)(1.8 %)(1.1 %)0.0 %
Change in valuation allowance(5.6 %)(10.4 %)(6.1 %)(16.9 %)
Transaction bonuses— %— %— %8.6 %
Transaction costs— %— %— %(11.3)%
True-Ups(12.2)%— %— %— %
Equity Compensation0.5 %0.5 %— %— %
Withholding tax(1.6)%— %— %— %
Goodwill impairment— %— %(11.4)%— %
Total income tax (benefit) expense (0.2)%6.2 %4.6 %(0.6)%
As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2024, a valuation allowance of $22.5 million has been provided for predominantly on the deferred tax assets related to the Company’s investment in Waldencast Partners LP. If or when recognized, the tax benefits related to any reversal of valuation allowance will be accounted for as a reduction of income tax expense.
Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.
The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December 31, 2024 and December 31, 2023 are presented below:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Deferred tax assets:
Accrued interest to foreign related parties$2,388 $2,771 
Lease liability1,763 2,222 
Formation costs1,205 1,421 
Net operating losses19,016 20,669 
Inventory reserve3,217 2,134 
Fixed asset basis10 — 
Accrued compensation864 1,112 
R&D tax credits457 482 
Non-deductible interest carryover3,790 5,077 
Below market contract— 1,469 
Capitalized research2,256 2,811 
Investment in Waldencast LP13,147 9,059 
Other temporary differences— 962 
Total deferred tax assets48,113 50,189 
Deferred tax liabilities:
Goodwill(1,658)(1,016)
Fixed asset basis— (92)
Lease asset(778)(1,015)
Intangibles(37,035)(43,543)
Other temporary differences(215)— 
Total deferred tax liabilities(39,685)(45,666)
Net deferred tax (liabilities) assets8,427 4,523 
Less: valuation allowance(22,471)(19,752)
Net deferred tax liabilities$(14,044)$(15,229)
Net operating losses and tax credit carryforwards as of December 31, 2024 and December 31, 2023 were as follows:
As of December 31, 2024
As of December 31, 2023
(In thousands)AmountExpiration YearAmountExpiration Year
Net operating losses, federal$42,539 Do not expire$75,142 Do Not Expire
Net operating losses, state25,383 2039 - 204464,984 2039 - 2043
Tax Credits, federal387 2039 - 2042387 2039 - 2041
Tax Credits, state88 Do not expire121 Do Not Expire
Net operating losses, Hong Kong— N/A375 Do Not Expire
Net operating losses, Vietnam— N/A1,929 2028
Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “IRC”) annual use of the Company’s net operating losses (“NOLs”) and research and development (“R&D”) credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50.0% occurs within a three-year period. The Company has not undergone an analysis to determine whether this limitation would apply to the utilization of the NOL carryforward. However, as the federal NOLs do not expire, the Company does not believe that any potential limitations to federal or state NOLs, or federal credit carryforwards, if applicable, would be material to the financial statements.
The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations and comprehensive loss. There were no such unrecognized tax benefits as of December 31, 2024 or December 31, 2023. The Company does not expect material changes to its unrecognized tax benefits for the twelve month period following the reporting date.
As of December 31, 2024, there were no active taxing authority examinations in any of the Company's major tax jurisdictions other than in relation to Obagi Cosmeceuticals LLC for the 2021 tax year. There have been no findings or adjustments related to this open tax examination. The Company remains subject to examination for federal and state income tax purposes for the tax years ending 2020 through 2024.
XML 44 R23.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Dec. 31, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
Waldencast
2023 Subscription Agreement with PIPE Investors
In September 2023, the Company entered into subscription agreements (the “2023 Subscription Agreements”) with certain investors (collectively, the “2023 PIPE Investors”), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares (the “PIPE Shares”), in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million (the “2023 PIPE Investment”). The 2023 Subscription Agreements relating to approximately $68.0 million of proceeds were consummated in September 2023, with the remaining approximately $2.0 million of proceeds related to the closing of the 2023 Subscription Agreements in November 2023, following receipt of regulatory approvals (the “2023 PIPE Closings” and the date on which such Closing occurred, the “PIPE Closing Date”). No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment.
In connection with the 2023 PIPE Investment, we agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain of our Class A ordinary shares that are held by the parties thereto from time to time, subject to the restrictions on transfer therein (the “2023 PIPE Registration Rights”). The 2023 PIPE Registration Rights terminate with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein).
Indemnification Agreements
The Company has entered into indemnification agreements with each of its directors and executive officers. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from an indemnitee’s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company’s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. During the year ended December 31, 2024, the total expense related to the indemnification agreements was $4.6 million.
Prior to the Business Combination
Registration Rights
In August 2022, the Company filed a registration statement on Form F-1 to register up to 121,120,063 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the sponsor shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of
the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,104,225 Class A ordinary shares issuable in exchange for 21,104,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 11,800,000 Class A ordinary shares issued in the PIPE investments; (vii) 33,300,000 Class A ordinary shares issued pursuant to the FPAs; and (viii) 18,033,332 Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement.
Transactions with Cedarwalk in Connection with the Business Combination
In connection with the Obagi China Distribution, the Company entered into an Intellectual Property License Agreement (the “IP License Agreement”), a Global Supply Services Agreement (the “Supply Agreement”), and a Transition Services Agreement (the “Transition Services Agreement”) with Obagi Hong Kong, which is owned by Cedarwalk, the former owner of Obagi and a beneficial holder of 24.5% of the Company’s fully diluted Class A ordinary shares as of the closing of the Business Combination.
Under the IP License Agreement, the Company exclusively licenses intellectual property relating to the Obagi brand to the Obagi China Business, and the Company retains the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The Obagi China Business pays the Company a royalty on gross sales of licensed products. The IP License Agreement is perpetual subject to certain conditions. During the year ended December 31, 2024, net revenue generated from related party royalties was $0.1 million. During the year ended December 31, 2023, net revenue generated from related party royalties was $0.3 million. During the period from July 28, 2022 to December 31, 2022, net revenue generated from related party royalties was $0.2 million.
Under the Supply Agreement, the Company supplies or causes to be supplied through certain Obagi CMOs products for distribution and sale in the China Region by the Obagi China Business. The parties operated under an interim supply agreement, which terminated in July 2023. However, the parties continued to operate under the interim supply agreement terms until December 2024, at which point the remaining related party liability was released as the Company had fulfilled its contractual obligations related to pricing. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products until the Obagi China Business has been added as a party to Obagi’s CMO agreements, at which time it will then order directly from the CMOs. During the year ended December 31, 2024, net revenue generated from supplying products to the Obagi China Business was $2.8 million and the related cost of goods sold was $0.8 million. During the year ended December 31, 2023, net revenue generated from supplying products to the Obagi China Business was $5.6 million and the related cost of goods sold was $1.7 million. During the period from July 28, 2022 to December 31, 2022, net revenue generated from supplying products to the Obagi China Business was $17.0 million and the related cost of goods sold was $5.1 million.
As of December 31, 2024, the Company had $0.8 million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. As of December 31, 2023, the Company had $1.1 million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet.
Under the Transition Services Agreement, the Company provided Obagi Hong Kong and its affiliates certain transition services to enable them to conduct the Obagi China Business as a going concern in the China Region. The transition services were provided for an initial term of up to twelve (12) months, with an option for Obagi China Business to extend the service period for up to an additional twelve (12) months solely as to certain R&D services. Obagi Hong Kong did not elect to extend the services and as a result the Transition Services Agreement expired on July 27, 2023. Services under the agreement were to be charged at the reasonable, fully-loaded costs of providing the services, but such services were to be provided at no charge for a certain period of time or up to a specified dollar value of services (the “Threshold Amount”). The Company determined that the Threshold Amount may be applied towards a combination of the Company’s services or inventory purchases made by the Obagi China Business under the Supply Agreement. Due to the fact that the Threshold Amount had not been reached at the time of expiration, the Company received no fees from the Obagi China Business during the year ended December 31, 2024 or the year ended December 31, 2023.
Milk
Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. Milk also receives certain services
from an employee of Milk Studios. During the year ended December 31, 2024 and the year ended December 31, 2023, the Company incurred administrative fees of $0.3 million in connection with the sublease and services, which is recorded in SG&A expenses in the consolidated statements of operations and comprehensive loss. During the period from July 28, 2022 to December 31, 2022, the Company incurred administrative fees of $0.1 million, which is recorded in SG&A expenses in the consolidated statements of operations and comprehensive loss.
One of the cofounders of Milk Makeup and a shareholder of the Company is party to an influencer agreement with Milk Makeup pursuant to which the shareholder provides certain brand services to Milk Makeup. Milk incurred $0.1 million in fees pursuant to this agreement during the year ended December 31, 2024 and the year ended December 31, 2023.
XML 45 R24.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Purchase Commitments
Purchase commitments represent unconditional purchase obligations to purchase goods or services, primarily inventory, that are enforceable and legally binding on the Company and specify all significant terms, including fixed or minimum quantities to be purchased, price provisions, and the approximate timing of the transaction.
The Company had previously entered into a certain development and production agreement with a third-party vendor in which the Company was committed to purchase from the vendor certain units of Skintrinsiq devices totaling $5.7 million. As of December 31, 2024, the Company did not have any associated future minimum payments due to the vendor ceasing all its operations.
Legal Proceedings
Except for the SEC investigation described below, the Company is not involved in any material litigation nor, to management’s knowledge, was any material litigation threatened against the Company, which if adversely determined could have a material adverse impact on the Company.
SEC Investigation
The Audit and Governance Committee of the Board, engaged in a review of certain accounting practices applied to the Company’s financial statements for the Predecessor Periods and Successor Period through December 31, 2022. The Company proactively and voluntarily self-reported the review to the SEC. In connection with this matter, the Company received a document subpoena from the SEC in September 2023. Although the Company is fully cooperating with the SEC’s investigation and continues to respond to requests related to this matter, it cannot predict when the SEC will complete its investigation or its outcome and potential impact such outcome may have on the Company’s business. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company could have a material adverse effect on its business, financial condition and results of operations.
XML 46 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. Prior to the consummation of the Business Combination, the Predecessor operated its business and reported its results through a single operating and reportable segment. Following the Business Combination, the Company determined that it has two operating and reportable segments: Obagi Medical and Milk Makeup. See. “Note 3, Business Combinations.” Each segment represents a business unit that focuses on distinct products, markets, and customers.
Obagi Medical - this segment consists of the business of Obagi. Obagi’s business activities include developing, marketing, and selling skin health products. These assets and activities are conducted by Obagi Global Holdings Limited and its wholly-owned subsidiaries.
Milk Makeup - this segment consists of the business of Milk. Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Milk generates revenue from the sale of cosmetics to retailers, including off-price retailers, and sales DTC via its website.
The accounting policies of the segments are the same as those described in “Note 2, Summary of Significant Accounting Policies.”
The Company's chief operating decision maker (“CODM”) is its Chief Executive Officer, who utilizes adjusted gross profit as the financial measure for assessing the performance of each segment. The CODM evaluates each segment's performance by comparing the current period's adjusted gross margin to those of prior periods and allocates resources based on the adjusted gross margin.
The following table includes segment revenue and significant segments expenses:
Year ended December 31, 2024Year ended December 31, 2023
(In thousands)Obagi MedicalMilk MakeupTotalObagi MedicalMilk MakeupTotal
Net revenue
$149,266 $124,602 $273,868 $117,651 $100,487 $218,138 
Adjusted cost of goods sold(1)
(30,697)(39,618)(33,922)(33,801)
Adjusted gross profit
$118,569 $84,984 $203,553 $83,729 $66,686 $150,415 
(1) Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.
Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)Obagi MedicalMilk MakeupTotal
Obagi Medical
Net revenue
$61,090 $31,283 $92,373 $73,760 
Adjusted cost of goods sold(1)
(45,611)(12,408)30,868 
Adjusted gross profit
$15,479 $18,875 $34,354 $42,892 
(1) Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold. The period from January 1, 2022 to July 27, 2022 did have any adjustments to cost of goods sold.
The following table reconciles total consolidated adjusted gross profit to consolidated net loss before and after income taxes:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Adjusted gross profit(1)
$203,553 $150,415 $34,354 $42,892 
Amortization of the fair value of the related party liability(2)
(2,260)(4,058)(12,186)— 
Discontinued product write-off(3)
2,864 — — — 
Amortization of the inventory fair value adjustment(4)
— 1,691 10,035 — 
Amortization impact of intangible assets(5)
11,205 11,205 4,789 — 
Selling, general and administrative245,297 223,508 90,722 58,155 
Loss on impairment of goodwill5,031 — 68,715 — 
Interest expense, net17,155 18,906 6,230 6,652 
Change in fair value of derivative warrant liabilities (23,627)10,337 (6,793)— 
Other expenses (income), net(3,574)1,769 (798)(971)
Loss before income taxes$(48,538)$(112,943)$(126,360)$(20,944)
(1) The period from January 1, 2022 to July 27, 2022 did not have any adjustments to cost of goods sold.
(2) Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.
(3) Relates to the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated.
(4) Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.
(5) The Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.
The Company does not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented. All of the Company’s and the Predecessor’s long-lived assets are located in the U.S.
XML 47 R26.htm IDEA: XBRL DOCUMENT v3.25.1
EMPLOYEE BENEFIT PLAN
12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLAN
The Company sponsors a Section 401(k) retirement plan and pension plans for employees in the U.S. and the United Kingdom. During the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) the Company’s contributions to the plan were $1.3 million, $1.2 million, $0.3 million, and $0.4 million, respectively.
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
On March 12, 2025, the Company canceled 11,500,000 of founder stock options and concurrently granted 5,730,000 replacement stock options. These new options vest in three equal annual tranches on each grant date anniversary. The founders have five years to exercise each tranche after it vests. The stock options are subject to continued employment with the Company.
2025 Credit Agreement
On March 18, 2025, the Company entered into a credit agreement (the “2025 Credit Agreement”) with TCW Asset Management Company, LLC and the 2025 Credit Agreement lenders. The 2025 Credit Agreement provides for a five-year secured first lien (i) term loan facility in an aggregate principal amount of $175.0 million (the “Term Loans”) and (ii) revolving loan facility in an aggregate principal amount of up to $30.0 million.
The proceeds of the initial borrowings under the 2025 Credit Agreement were used to (i) repay and terminate the 2022 Credit Agreement, (ii) pay fees and expenses relating to the 2025 Credit Agreement and (iii) fund working capital and for general corporate purposes.
As of the issuance date of these financial statements, the 2025 Term Loans’ outstanding balance is $175.0 million. The 2025 revolving loan facility has $15.0 million drawn with $15.0 million remaining available. The 2022 Credit Agreement including its revolving line of credit has been fully extinguished.
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)
12 Months Ended
Dec. 31, 2024
Condensed Financial Information Disclosure [Abstract]  
CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)
The parent company financial statements for Waldencast plc should be read in conjunction with the Company’s Consolidated Financial Statements and the accompanying notes thereto. For purposes of this condensed financial information, the Company’s wholly owned and majority owned subsidiaries are recorded based upon its proportionate share of its subsidiaries’ net assets (similar to presenting them on the equity method). Waldencast has no material operations of its own and conducts substantially all of its activities through its wholly owned subsidiaries. Waldencast has no significant assets or liabilities other than derivative warrant liabilities, note payable, and cash, most expenditures paid by Waldencast are allocated to its subsidiaries. Waldencast Finco Limited, a wholly-owned indirect subsidiary of Waldencast, is the borrower under the 2022 Credit Agreement. The terms and conditions of the 2022 Credit Agreement (see “Note 7. Debt” for definition) limit the ability of Waldencast’s wholly owned subsidiaries to make certain distributions or dividends, subject to a number of enumerated exceptions. Due to the aforementioned restrictions, substantially all of the Successor period net assets of Waldencast’s subsidiaries are restricted. Since the restricted net assets of consolidated subsidiaries exceed 25% of the consolidated net assets of the Company and its subsidiaries, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X. This information should be read in conjunction with the accompanying Consolidated Financial Statements.
The following condensed financial statements have been presented on a “parent-only” basis. Under a parent-only presentation, Waldencast’s investment in its subsidiaries is presented under the equity method of accounting.
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED BALANCE SHEETS
(In thousands of U.S. dollars, except share and per share data)
As of December 31, 2024As of December 31, 2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$472 $419 
Intercompany receivable37,431 51,964 
Total current assets37,903 52,383 
Investment in subsidiary697,885 745,537 
TOTAL ASSETS$735,788 $797,920 
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Note payable
$830 $— 
Derivative warrant liabilities5,021 28,647 
TOTAL LIABILITIES5,851 28,647 
SHAREHOLDERS’ EQUITY:
Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 112,026,440 and 101,228,857 outstanding as of December 31, 2024 and December 31, 2023, respectively
11 
Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized; and 10,666,528 and 20,847,553 outstanding as of December 31, 2024 and December 31, 2023, respectively
Additional paid-in capital951,260 871,527 
Accumulated deficit(289,204)(246,761)
Accumulated other comprehensive income (loss)
251 (151)
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY662,319 624,626 
Noncontrolling Interest67,618 144,647 
TOTAL SHAREHOLDERS’ EQUITY729,937 769,273 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$735,788 $797,920 
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars, except share and per share data)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Net revenue$— $— $— 
Selling, general and administrative18,393 1,259 — 
Total operating loss(18,393)(1,259)— 
Other expense (income):
Interest expense (income), net
24 (14)19 
Change in fair value of derivative warrant liabilities(23,627)10,337 6,793 
Income (loss) before income taxes
5,209 (11,582)6,812 
Income tax benefit— — — 
Income (loss) before equity in undistributed earnings of subsidiaries
5,209 (11,582)6,812 
Equity in undistributed earnings of subsidiaries(47,652)(78,399)(102,379)
Net loss(42,443)(89,981)(95,567)
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax
393 (122)(29)
Comprehensive loss$(42,050)$(90,103)$(95,596)
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED STATEMENTS OF CASH FLOW
(In thousands of U.S. dollars)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(42,443)$(89,981)$(95,567)
Adjustments to reconcile net loss to net cash
Cash (used in) provided by operating activities:
Equity in income of subsidiaries47,652 78,399 102,379 
Change in fair value of derivative warrant liabilities(23,627)10,337 (6,793)
Net cash (used in) provided by operating activities
(18,417)(1,245)19 
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from trust— — 6,400 
Net cash provided by investing activities  6,400 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from PIPE investments— 70,000 — 
Payment of PIPE transaction costs— (1,069)— 
Proceeds from note payable
1,632 — — 
Repayment of note payable
(1,770)— — 
Tax refund (withholding)558 (1,204)— 
Transfers from subsidiaries32,750 30,575 6,000 
Transfers to subsidiaries— (66,250)(300)
Expenses paid on behalf of subsidiaries(14,700)(33,603)(8,982)
Net cash provided by (used in) financing activities
18,470 (1,551)(3,282)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH53 (2,796)3,137 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period419 3,215 78 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period
$472 $419 $3,215 
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure        
Net Income (Loss) $ (95,567) $ (21,057) $ (42,443) $ (89,981)
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
We regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and review our cybersecurity policies, processes, and practices. To help protect our information systems from cybersecurity threats, we use a suite of security and business continuity tools that are designed to help us proactively identify, monitor, escalate, investigate, resolve, and recover from security incidents in a timely manner. Our cybersecurity training and testing program helps ensure awareness and knowledge of cybersecurity best practices purvey all departments. Our information technology department, in connection with management and legal, assesses risks based on probability and potential impact to key business systems and processes. With over 21 years of experience, our recently appointed Chief Technology Officer (“CTO”) has expertise in managing information security, developing cybersecurity strategies and internal awareness programs, implementing effective cybersecurity programs, and executing business continuity and incident response plans, including regular disaster recovery testing, who leads the assessment and management of such risks.
We take a risk-based approach to cybersecurity and have implemented cybersecurity policies and practices throughout our operations that are designed to address cybersecurity threats and incidents.

Refer to the risk factor captioned “We are dependent on information technology systems and infrastructure; if we, or the third parties we rely on, fail to protect sensitive information of our consumers and information technology systems against security breaches, it could damage our reputation and brand and substantially harm our business.” in Part I, “Item 3.D. Risk Factors” for additional description of cybersecurity risks and potential related impacts on the Company.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] We regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and review our cybersecurity policies, processes, and practices. To help protect our information systems from cybersecurity threats, we use a suite of security and business continuity tools that are designed to help us proactively identify, monitor, escalate, investigate, resolve, and recover from security incidents in a timely manner.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block] Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year
Cybersecurity Risk Role of Management [Text Block] Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] With over 21 years of experience, our recently appointed Chief Technology Officer (“CTO”) has expertise in managing information security, developing cybersecurity strategies and internal awareness programs, implementing effective cybersecurity programs, and executing business continuity and incident response plans, including regular disaster recovery testing, who leads the assessment and management of such risks.
We take a risk-based approach to cybersecurity and have implemented cybersecurity policies and practices throughout our operations that are designed to address cybersecurity threats and incidents.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”).
In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the “Successor”), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the “Predecessor”). Under the acquisition method of accounting, Waldencast’s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.
This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the relevant financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the “Successor Period”) are presented on a measurement basis different from those for the period prior to the Closing Date (the “Predecessor Period(s)”). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Periods, which include Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022, the year ended December 31, 2023, and the year ended December 31, 2024, are presented on a different basis of accounting and are therefore, not comparable.
Principles of Consolidation
Principles of Consolidation—The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.
Use of Estimates
Use of Estimates—The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial
statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, goodwill valuation, inventory valuation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company’s consolidated balance sheets and consolidated statements of operations and comprehensive loss.
Concentrations of Credit Risk
Concentrations of Credit Risk—Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.
The Company’s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailer located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions, monitoring payment frequency, and requiring customer advance payments in certain circumstances. The Company generally does not require collateral.
As of December 31, 2024 and 2023, one U.S. customer accounted for 33% and 27% of accounts receivable, respectively.
During the year ended December 31, 2024, the Company purchased approximately 15% and 12% of inventory from two vendors, respectively. During the year ended December 31, 2023 the Company purchased approximately 17% of inventory from one vendor.
As of December 31, 2024, no vendor exceeded 10% of accounts payable. As of December 31, 2023, one vendor accounted for 18% of accounts payable.
Cash and Cash Equivalents
Cash and Cash Equivalents—The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.
Restricted Cash
Restricted Cash—The Company’s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December 31, 2024, the Company’s cash and cash equivalents, and restricted cash balance was $14.8 million and $1.5 million respectively. Restricted cash is composed of $0.7 million held as collateral for corporate credit cards and $0.8 million held as a lease deposit through the end of the lease in November 2030. As of December 31, 2023 the Company’s cash and cash equivalents, and restricted cash balance was $21.1 million and $1.5 million respectively.
Inventories
Inventories—The Company’s products are produced by third-party contract manufacturers (“CMOs”). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (“FIFO”) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional products are charged to cost of goods sold at the time the product is shipped to the Company’s customer.
The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (“FOB”) shipping point or FOB destination point.
The Company evaluates the carrying value of inventories on a regular basis and determines the need, if any, to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. It accounts for losses that may occur when the inventory cannot be sold at its full cost. If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory
to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). Each period, Management will evaluate whether any additional write downs are required (generally, by stock keeping unit (“SKU”) and/or lot). Specific write downs may relate to known matters, such as quality concerns or a discontinued product.
Sales Returns
Certain arrangements may give the Company’s customers the right to return products. In addition, when customer arrangements do not give the Company’s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, Guarantees and the Company accrues for replacement costs.
Derivatives
Derivatives—The Company accounts for derivative instruments in accordance with ASC 815, Derivatives and Hedging (“ASC 815”), which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements.
The Company has used interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See “Note 9. Financial Instruments” for further discussion of the interest rate collar.
Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815.
Warrant Liabilities
The Company accounts for Public Warrants and Private Placement Warrants (each as defined in “Note 9. Financial Instruments”) as liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company’s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See “Note 9. Financial Instruments” for further discussion of the warrants, including the FPA Warrants (as defined therein).
Fair Value Measurement
Fair Value Measurement—The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management’s judgment and conditions that existed at each reporting date. See “Note 10. Fair Value Measurements” for further details.
The fair values of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company’s term loan, which approximate current market rates.
Capitalized Software and Website Development Costs
Capitalized Software and Website Development Costs—The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (“CCA”) implementation costs, and (iii) other software-related costs (e.g., website development costs).
For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use.
For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.
Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.
Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Prepaid Expenses
Prepaid Expenses—At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.
Prepaid Inventory
Prepayments are required to begin production of inventory at certain of the Company’s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.
Prepaid Marketing and Advertising
The Company generally expenses the costs of advertising and marketing as incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.
Property and Equipment, Net
Property and Equipment, Net—Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation.
Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company’s assets are as follows:
ESTIMATED USEFUL LIVES
Computer hardware and software3 years
Furniture and fixtures
3 - 5 years
Machinery and equipment
3 - 5 years
Leasehold improvementsLesser of useful life or term of lease
Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Intangible Assets, Net Intangible Assets, Net—Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, and formulations. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss.
Business Combinations
Business Combinations—When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.
Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company’s consolidated statements of operations and comprehensive loss.
Goodwill Goodwill—Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1st and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions.
Deferred Issuance Costs
Debt Issuance Costs—The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.
Accounts Receivable, Net
Accounts Receivable, Net—Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers. Payment terms are generally short-term in nature and are determined based on the financial stability of the customer.
The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i) customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii) formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer’s remittance advice or to the customer’s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.
Revenue Recognition and Distribution
Revenue Recognition—The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.
Product Sales
The Company’s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (“DTC”) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.
At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.
The Company has determined that each of its products is distinct and represents a separate performance obligation. The Company does not have any contracts that contain multiple performance obligations. The transaction price is equal to the consideration the Company expects to be entitled to. When measuring revenue and determining the consideration the Company expects to be entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer.
The Company’s distributors charge us fees for certain services rendered by them, including packing and shipping, marketing and advertising the Company’s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are not distinct from the distributors’ purchase of products.
Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.
The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and when assumption of the risks and rewards occur. For distributors (other than the “Physician Channel Provider”) and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company’s designated warehouse/distribution center by the customer’s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer.
Obagi’s operations in the U.S. heavily depend on a single distributor, referred to as the Physician Channel Provider, which manages sales to healthcare professionals in the physician-dispensed channel as well as retail and spa customers. For DTC sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician.
Promotional Products
When the Company provides promotional products (e.g., samples and testers) alongside a related saleable product, their cost is recognized in cost of sales at the same time the related product’s revenue is recognized.
Royalties
The Company generates royalty revenue from products in China by Obagi Hong Kong and in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi Medical brand name in the Japanese retail skincare channels. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. The Company recognizes revenue for the sales-based royalty at the later of when the local operators make sales of the products or when the purchase obligation has been satisfied.
Costs to Obtain a Contract with a Customer
The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. There were no total capitalizable costs to obtain a contract during the periods presented.
Other
The Company’s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company’s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) for ASC 340-40-25-4 related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.Distribution—Costs related to shipping, handling, warehousing and distribution for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, were $8.7 million, $6.6 million, and $2.0 million, respectively. These costs include costs that are incurred in order to get the product from the distribution centers to the end consumer and are included within selling, general and administrative expense (“SG&A”). The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&A expenses. Amounts billed to customers for shipping and handling are included in revenue. In the Predecessor period, the Company only included shipping and handling costs in SG&A expense.
Cost of Goods Sold
Cost of Goods Sold—Cost of goods sold consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, freight and inventory inspection costs, depreciation and amortization of product-related intangible asset and supply agreements, and amortization of the inventory fair value step-up related to the Business Combination.
Advertising Advertising—Advertising costs are expensed in the period in which they are incurred.
Research and Development
Research and Development—Research and development costs are included in SG&A expense on the consolidated statements of operations and comprehensive loss. All periods presented reflect this classification.
Stock-Based Compensation
Stock-Based Compensation—The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards.
Replacement Options
On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested options granted under those plans (“Replacement Options”). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple.
Founder Awards
The Company estimated the fair value and derived service period of the stock options issued to founders (“Founder Awards”) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option’s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.
Restricted Stock
The fair value of restricted stock is equal to the price of the Company’s ordinary shares on the grant date.
The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.
The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award’s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition is deemed probable.
Income Taxes
Income Taxes—The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.
The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $22.5 million was recorded as of December 31, 2024 and $19.8 million was recorded as of December 31, 2023.
The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority’s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December 31, 2024 and December 31, 2023, the Company had no uncertain positions in the consolidated financial statements.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.
Net Loss Per Share Net Loss Per Share—Basic net loss per share attributable to shareholders of ordinary shares is computed by dividing the Company’s net loss attributable to holders of ordinary shares by the weighted-average number of ordinary shares outstanding during the period. Diluted net income per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net loss per share that is not attributable to the Company is reflected in net loss attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss.
Noncontrolling Interests
Noncontrolling Interests—Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder’s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder’s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.
Segments
Segments—An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company’s chief operating decision maker (“CODM”) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Company has two operating and reportable segments: Obagi Medical and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company’s CODM is its Chief Executive Officer.
Commitments and Contingencies
Commitments and Contingencies—In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards, Not Yet Adopted
Recently Adopted Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The guidance expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for
other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company adopted this accounting standard in the fourth quarter of 2024, which resulted in expanded disclosures within our notes to the consolidated financial statements. There was no other impact on our consolidated financial statements. See “Note 18. Segment Reporting” for additional detail.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree’s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2023 for an EGC company, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company adopted this accounting standard as of January 1, 2024, with no material impact on its consolidated financial statements and related disclosures. Future acquisitions will be evaluated under this guidance.
Recently Issued Accounting Standards, Not Yet Adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): Reporting Comprehensive Income – Expense Disaggregation Disclosures. The guidance will require disaggregated disclosures and of certain cost and expense categories presented on the face of the income statement. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Estimated Useful Lives of Assets The estimated useful lives of the Company’s assets are as follows:
ESTIMATED USEFUL LIVES
Computer hardware and software3 years
Furniture and fixtures
3 - 5 years
Machinery and equipment
3 - 5 years
Leasehold improvementsLesser of useful life or term of lease
Property and equipment, net consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Computer hardware, software and equipment$742 $689 
Furniture and fixture9,848 7,611 
Machinery and equipment598 812 
Internally developed software1,739 854 
Leasehold improvements2,100 2,070 
Total property and equipment$15,027 $12,036 
Less accumulated depreciation(9,196)(6,105)
Property and equipment, net$5,831 $5,931 
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS (Tables)
12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Summary of Purchase Price Allocation
Obagi and Milk Purchase Price Allocation:
(In thousands)ObagiMilk Total
Total Purchase Price:
Cash consideration$345,398 $121,629 $467,027 
Equity consideration277,824 200,087 477,911 
Cash repayment of debt136,112 3,935 140,047 
Related party liability22,100 — 22,100 
Total purchase consideration$781,434 $325,651 $1,107,085 
Fair value of assets acquired:
Cash and cash equivalents$15,850 $2,092 $17,942 
Restricted cash650 819 1,469 
Account receivable, net15,214 3,866 19,080 
Related party receivable327 199 526 
Inventories31,026 30,945 61,971 
Prepaid expenses4,307 520 4,827 
Other current assets359 — 359 
Property and equipment1,245 8,436 9,681 
Intangible assets505,300 157,500 662,800 
Right-of-use assets4,811 8,232 13,043 
Other assets227 — 227 
Total identifiable assets acquired$579,316 $212,609 $791,925 
Liabilities assumed:
Accounts payable and accrued expenses18,699 6,442 25,141 
Other current liabilities12,912 5,483 18,395 
Lease liabilities6,461 10,105 16,566 
Deferred income tax liabilities28,073 — 28,073 
Total liabilities assumed:$66,145 $22,030 $88,175 
Net assets acquired513,171 190,579 703,750 
Purchase consideration781,434 325,651 1,107,085 
Goodwill $268,263 $135,072 $403,335 
Schedule of Intangible Assets Acquired in Business Combination
Intangible Assets
Fair Value
ObagiMilkTotalWeighted-
Average
Useful Life
(In thousands) 
Trademarks and trade name$414,000 $145,000 $559,000 14 years
Customer/distributor relationships25,000 11,000 36,000 11 years
Tretinoin distribution and supply agreement38,900 — 38,900 5 years
Formulations27,400 1,500 28,900 8 years
Total Intangible Assets$505,300 $157,500 $662,800 
Unaudited Pro Forma Consolidated Financial Information
The following unaudited pro forma combined financial information presents the Company’s results as though the Business Combination had occurred on January 1, 2021, for the year ended December 31, 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.
Year ended
December 31, 2022
(In thousands)(Unaudited)
Pro forma net revenue$200,547 
Pro forma net loss(86,930)
Less: Pro forma net loss attributable to noncontrolling interest(25,140)
Pro forma net loss attributable to Waldencast plc$(61,790)
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue by Sales Channel
Total revenue by sales channel was as follows for the periods indicated:
Year ended December 31, 2024
(In thousands)Obagi MedicalMilk
Makeup
Total
Revenue by Sales Channel
Direct sales$103,168 $120,362 $223,530 
Distributors41,630 4,209 45,839 
Net product sales$144,798 $124,571 $269,369 
Royalties4,468 31 4,499 
Net revenue$149,266 $124,602 $273,868 
Year ended December 31, 2023
(In thousands)Obagi MedicalMilk
Makeup
Total
Revenue by Sales Channel
Direct sales$72,446 $97,222 $169,668 
Distributors40,203 3,245 43,448 
Net product sales$112,649 $100,467 $213,116 
Royalties5,002 20 5,022 
Net revenue$117,651 $100,487 $218,138 
Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)Obagi MedicalMilk
Makeup
TotalTotal
Revenue by Sales Channel
Direct sales$30,276 $30,192 $60,468 $39,649 
Distributors28,826 1,091 29,917 31,080 
Net product sales$59,102 $31,283 $90,385 $70,729 
Royalties1,988 — 1,988 3,031 
Net revenue$61,090 $31,283 $92,373 $73,760 
Revenue by Geographic Region
Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Revenue by Geographic Region 
North America$202,261 $154,357 $56,630 $44,443 
Rest of the World67,108 58,759 33,755 26,286 
Net product sales$269,369 $213,116 $90,385 $70,729 
Royalties4,499 5,022 1,988 3,031 
Net revenue$273,868 $218,138 $92,373 $73,760 
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL (Tables)
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill The following table presents changes in goodwill by reportable segment:
(In thousands)Obagi MedicalMilk MakeupTotal Goodwill
Balance as of December 31, 2022
$199,548 $135,072 $334,620 
Balance as of December 31, 2023
$199,548 $135,072 $334,620 
Impairment loss(5,031)— $(5,031)
Balance as of December 31, 2024
$194,517 $135,072 $329,589 
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS—NET (Tables)
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net consisted of the following as of December 31, 2024:
(In thousands)Weighted
Average Useful
Lives (Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Trademark and trade name14$559,875 $(102,169)$457,706 
Customer/distributor relationships1136,000 (6,449)29,551 
Tretinoin distribution and supply agreement
538,900 (18,885)20,015 
Formulations828,900 (9,943)18,957 
Patents20227 (18)209 
Total$663,902 $(137,464)$526,438 
Intangible assets, net consisted of the following as of December 31, 2023:
(In thousands)Weighted
Average Useful
Lives (Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Trademark and trade name14$559,644 $(59,989)$499,655 
Customer/distributor relationships1136,000 (4,532)31,468 
Tretinoin distribution and supply agreement538,900 (11,105)27,795 
Formulations828,900 (5,101)23,799 
Patents20154 (8)146 
Total$663,598 $(80,735)$582,863 
Due to the non-cash goodwill impairment charge within the Obagi Medical reporting unit during the year ended December 31, 2024, the Company also performed a quantitative analysis on Obagi Medical's definite lived intangibles. The Company concluded there was no impairment to these assets.
Schedule of Expected Amortization Expense
Expected amortization for each of the years between 2025 through 2029, and thereafter are as follows:
(In thousands)
Years ending December 31,
2025$56,737 
202656,737 
202753,496 
202848,957 
202948,957 
Thereafter261,554 
$526,438 
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT (Tables)
12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
(In thousands)Maturity Date
As of December 31, 2024
As of December 31, 2023
2022 Term LoanJuly 2026$153,125 $161,875 
Note PayableMay 2024830 968 
2022 Revolving Credit FacilityJuly 202615,000 — 
Unamortized debt issuance costs(2,339)(3,050)
Net carrying amount$166,616 $159,793 
Less: Current portion of long-term debt(29,479)(8,529)
Total long-term portion$137,137 $151,264 
Schedule of Maturities of Long-Term Debt
Scheduled maturities under the Company’s 2022 Credit Agreement and the Note Payable as of December 31, 2024 are as follows:
(In thousands)
Year Ending December 31,
2025$31,142 
2026137,813 
2027— 
2028— 
2029— 
Total unpaid principal$168,955 
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES (Tables)
12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Schedule of Supplemental Cash Flow and Other Information Related to Leases
Supplemental cash flow information related to the Company’s operating leases was as follows:
(In thousands)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Cash paid for amounts included in the measurement of operating lease liabilities$3,826 $3,309 $1,166 
Right-of-use assets obtained in exchange for new operating lease liabilities$131 $446 $4,081 

Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Weighted-average remaining lease term6.056.927.75
Weighted-average discount rate5.9%5.9%5.9%
Operating Lease Maturity
Reconciliation of the undiscounted future minimum lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2024 was as follows:
(In thousands)
Amount
2025$3,797 
20262,899 
20272,452 
20282,504 
20292,548 
Thereafter4,173 
Total future minimum lease payments$18,373 
Less: Imputed interest
2,883 
Total reported lease liability$15,490 
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS (Tables)
12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present information by year about the Company’s financial instruments that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:
As of December 31, 2024
(In thousands)TotalQuoted Prices in Active MarketSignificant Other Observable InputsSignificant Other Unobservable Inputs
(Level 1)(Level 2)(Level 3)
Liabilities:
Derivative warrant liabilities - Public$1,983 $1,983 $— $— 
Derivative warrant liabilities - Private$3,038 $— $3,038 $— 
As of December 31, 2023
(In thousands)TotalQuoted Prices in Active MarketSignificant Other Observable InputsSignificant Other Unobservable Inputs
(Level 1)(Level 2)(Level 3)
Assets:
Interest rate collar$61 $— $61 $— 
Liabilities:
Derivative warrant liabilities - Public$11,155 $11,155 $— $— 
Derivative warrant liabilities - Private$17,492 $— $17,492 $— 
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Change in Allowance for Doubtful Accounts
The change in the allowance for doubtful accounts were as follows:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Balance at beginning of period$1,552 $994 $1,061 $671 
Provision (recovery) for bad debts
(996)558 (67)390 
Write-off of uncollectible accounts, net(448)— — — 
Balance at end of period$108 $1,552 $994 $1,061 
Schedule of Inventory
The components of inventories were as follows:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Work in process$8,354 $10,336 
Finished goods44,750 45,348 
Total inventories$53,104 $55,684 
Property and Equipment, Net The estimated useful lives of the Company’s assets are as follows:
ESTIMATED USEFUL LIVES
Computer hardware and software3 years
Furniture and fixtures
3 - 5 years
Machinery and equipment
3 - 5 years
Leasehold improvementsLesser of useful life or term of lease
Property and equipment, net consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Computer hardware, software and equipment$742 $689 
Furniture and fixture9,848 7,611 
Machinery and equipment598 812 
Internally developed software1,739 854 
Leasehold improvements2,100 2,070 
Total property and equipment$15,027 $12,036 
Less accumulated depreciation(9,196)(6,105)
Property and equipment, net$5,831 $5,931 
Other Current Liabilities
The major components of other current liabilities consisted of the following:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Accrued salaries and related expenses$9,155 $8,702 
Accrued sales returns and damages2,723 2,527 
Accrued interest1,424 1,357 
Accrued distribution fees— 590 
Related party liability— 5,856 
Accrued professional services3,832 2,901 
Other2,426 1,765 
Total$19,560 $23,698 
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Options Activity
Restricted stock activity for the year ended December 31, 2024 was as follows:
SharesWeighted Average
Grant Date Fair Value
per Share
Outstanding as of December 31, 2023
2,296,831 $8.72 
Granted6,705,468 3.69 
Vested(567,745)5.84 
Forfeited(851,298)8.87 
Outstanding as of December 31, 2024
7,583,255 $4.61 
Schedule of Valuation Assumptions, Stock Options
Stock option activity for the year ended December 31, 2024 was as follows:
Number of
Common
Stock
Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life (in years)
Aggregate
intrinsic
Value (in
thousands)
Balance as of December 31, 2023
18,915,358 $9.10 7.3$47,792 
Granted— — — — 
Exercised(150,000)0.68 — — 
Forfeited(1,628,000)5.73 — — 
Balance as of December 31, 2024
17,137,35810.48 6.41,156 
Exercisable as of December 31, 2024
9,168,9757.31 5.01,156 
Vested and expected to vest as of December 31, 2024
17,137,358$10.48 6.4$1,156 
Schedule of Restricted Stock Activity
The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for Replacement Options based on the following weighted-average assumptions:
Period from July 28, 2022 to December 31, 2022
Founder Awards
Replacement Options
Risk-free interest rate (1)
2.87% - 2.92%
 2.79% - 2.80%
Expected term (years) (2)
4.7 - 9.9
N/A
Exercise multiple (3)
N/A2.30 
Expected stock price volatility (4)
39.77% - 44.76%
50.00 %
Dividend yield (5)
N/AN/A
(1)The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.
(2)The expected term for Founder Awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.
(3)The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.
(4)For Founder Awards, the expected stock price volatility is the median historical volatility of Waldencast’s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for Replacement Options, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.
(5)Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.25.1
NET LOSS PER SHARE (Tables)
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The following table sets forth the computation of basic and diluted net loss using the treasury stock method:
(In thousands, except for share and per share amounts)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Numerator:
Net loss$(48,648)$(105,968)$(120,557)$(21,057)
Net loss attributable to noncontrolling interest(6,205)(15,987)(24,990)— 
Net loss attributed to Class A shareholders - basic and diluted EPS(42,443)(89,981)(95,567)(21,057)
Denominator:
Weighted-average basic shares outstanding109,295,74291,158,50086,460,5608,000,002
Effect of dilutive securities— — — — 
Weighted-average diluted shares109,295,74291,158,50086,460,5608,000,002
Basic and diluted net loss per share$(0.39)$(0.99)$(1.11)$(2.63)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Warrants29,533,28229,533,28229,533,282
Stock options17,137,35818,915,35820,452,155774,800
Restricted stock7,583,2552,296,8312,802,419234,842
Total54,253,89550,745,47152,787,8561,009,642
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Consolidated Pretax Income (Loss)
The Company’s consolidated pretax loss for the periods presented were generated by domestic and foreign operations as follows:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)
Successor (Waldencast)
Predecessor (Obagi)
Loss before income taxes:
United States$2,684 $(82,868)$(125,281)$(17,676)
Foreign(51,222)(30,075)(1,079)(3,268)
Total$(48,538)$(112,943)$(126,360)$(20,944)
Schedule of Provision for Income Taxes
The provision for income taxes for the periods presented consisted of the following:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Current provision (benefit):
Federal$784 $12 $— $— 
State268 32 20 19 
Foreign243 — 
1,295 46 20 23 
Deferred (income) expense:
Federal(144)(7,927)(4,557)38 
State(976)906 (1,266)52 
Foreign(66)— — — 
(1,185)(7,021)(5,823)90 
Net income tax (benefit) provision$110 $(6,975)$(5,803)$113 
Schedule of Components of Income Tax Expense
The components of income tax expense related to the following:
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate
4.3 %— %— %— %
U.S./foreign tax rate differential10.0 %15.9 %20.7 %17.7 %
State income tax benefit, net of federal benefit1.7 %2.1 %2.4 %1.4 %
Permanent Items3.5 %(0.1)%0.2 %(0.1)%
Noncontrolling interest(0.9 %)(1.8 %)(1.1 %)0.0 %
Change in valuation allowance(5.6 %)(10.4 %)(6.1 %)(16.9 %)
Transaction bonuses— %— %— %8.6 %
Transaction costs— %— %— %(11.3)%
True-Ups(12.2)%— %— %— %
Equity Compensation0.5 %0.5 %— %— %
Withholding tax(1.6)%— %— %— %
Goodwill impairment— %— %(11.4)%— %
Total income tax (benefit) expense (0.2)%6.2 %4.6 %(0.6)%
Summary of Deferred Tax Assets and Deferred Tax Liabilities
The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December 31, 2024 and December 31, 2023 are presented below:
(In thousands)
As of December 31, 2024
As of December 31, 2023
Deferred tax assets:
Accrued interest to foreign related parties$2,388 $2,771 
Lease liability1,763 2,222 
Formation costs1,205 1,421 
Net operating losses19,016 20,669 
Inventory reserve3,217 2,134 
Fixed asset basis10 — 
Accrued compensation864 1,112 
R&D tax credits457 482 
Non-deductible interest carryover3,790 5,077 
Below market contract— 1,469 
Capitalized research2,256 2,811 
Investment in Waldencast LP13,147 9,059 
Other temporary differences— 962 
Total deferred tax assets48,113 50,189 
Deferred tax liabilities:
Goodwill(1,658)(1,016)
Fixed asset basis— (92)
Lease asset(778)(1,015)
Intangibles(37,035)(43,543)
Other temporary differences(215)— 
Total deferred tax liabilities(39,685)(45,666)
Net deferred tax (liabilities) assets8,427 4,523 
Less: valuation allowance(22,471)(19,752)
Net deferred tax liabilities$(14,044)$(15,229)
Summary of Net Operating Losses and Tax Credit Carryforwards
Net operating losses and tax credit carryforwards as of December 31, 2024 and December 31, 2023 were as follows:
As of December 31, 2024
As of December 31, 2023
(In thousands)AmountExpiration YearAmountExpiration Year
Net operating losses, federal$42,539 Do not expire$75,142 Do Not Expire
Net operating losses, state25,383 2039 - 204464,984 2039 - 2043
Tax Credits, federal387 2039 - 2042387 2039 - 2041
Tax Credits, state88 Do not expire121 Do Not Expire
Net operating losses, Hong Kong— N/A375 Do Not Expire
Net operating losses, Vietnam— N/A1,929 2028
XML 66 R45.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit
The following table includes segment revenue and significant segments expenses:
Year ended December 31, 2024Year ended December 31, 2023
(In thousands)Obagi MedicalMilk MakeupTotalObagi MedicalMilk MakeupTotal
Net revenue
$149,266 $124,602 $273,868 $117,651 $100,487 $218,138 
Adjusted cost of goods sold(1)
(30,697)(39,618)(33,922)(33,801)
Adjusted gross profit
$118,569 $84,984 $203,553 $83,729 $66,686 $150,415 
(1) Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.
Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
(In thousands)Obagi MedicalMilk MakeupTotal
Obagi Medical
Net revenue
$61,090 $31,283 $92,373 $73,760 
Adjusted cost of goods sold(1)
(45,611)(12,408)30,868 
Adjusted gross profit
$15,479 $18,875 $34,354 $42,892 
(1) Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold. The period from January 1, 2022 to July 27, 2022 did have any adjustments to cost of goods sold.
The following table reconciles total consolidated adjusted gross profit to consolidated net loss before and after income taxes:
(In thousands)Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022Period from January 1, 2022 to July 27, 2022
Adjusted gross profit(1)
$203,553 $150,415 $34,354 $42,892 
Amortization of the fair value of the related party liability(2)
(2,260)(4,058)(12,186)— 
Discontinued product write-off(3)
2,864 — — — 
Amortization of the inventory fair value adjustment(4)
— 1,691 10,035 — 
Amortization impact of intangible assets(5)
11,205 11,205 4,789 — 
Selling, general and administrative245,297 223,508 90,722 58,155 
Loss on impairment of goodwill5,031 — 68,715 — 
Interest expense, net17,155 18,906 6,230 6,652 
Change in fair value of derivative warrant liabilities (23,627)10,337 (6,793)— 
Other expenses (income), net(3,574)1,769 (798)(971)
Loss before income taxes$(48,538)$(112,943)$(126,360)$(20,944)
(1) The period from January 1, 2022 to July 27, 2022 did not have any adjustments to cost of goods sold.
(2) Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.
(3) Relates to the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated.
(4) Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.
(5) The Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.
XML 67 R46.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)
12 Months Ended
Dec. 31, 2024
Condensed Financial Information Disclosure [Abstract]  
Condensed Balance Sheets
The following condensed financial statements have been presented on a “parent-only” basis. Under a parent-only presentation, Waldencast’s investment in its subsidiaries is presented under the equity method of accounting.
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED BALANCE SHEETS
(In thousands of U.S. dollars, except share and per share data)
As of December 31, 2024As of December 31, 2023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$472 $419 
Intercompany receivable37,431 51,964 
Total current assets37,903 52,383 
Investment in subsidiary697,885 745,537 
TOTAL ASSETS$735,788 $797,920 
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Note payable
$830 $— 
Derivative warrant liabilities5,021 28,647 
TOTAL LIABILITIES5,851 28,647 
SHAREHOLDERS’ EQUITY:
Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 112,026,440 and 101,228,857 outstanding as of December 31, 2024 and December 31, 2023, respectively
11 
Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized; and 10,666,528 and 20,847,553 outstanding as of December 31, 2024 and December 31, 2023, respectively
Additional paid-in capital951,260 871,527 
Accumulated deficit(289,204)(246,761)
Accumulated other comprehensive income (loss)
251 (151)
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY662,319 624,626 
Noncontrolling Interest67,618 144,647 
TOTAL SHAREHOLDERS’ EQUITY729,937 769,273 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$735,788 $797,920 
Condensed Statements of Operations
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars, except share and per share data)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
Net revenue$— $— $— 
Selling, general and administrative18,393 1,259 — 
Total operating loss(18,393)(1,259)— 
Other expense (income):
Interest expense (income), net
24 (14)19 
Change in fair value of derivative warrant liabilities(23,627)10,337 6,793 
Income (loss) before income taxes
5,209 (11,582)6,812 
Income tax benefit— — — 
Income (loss) before equity in undistributed earnings of subsidiaries
5,209 (11,582)6,812 
Equity in undistributed earnings of subsidiaries(47,652)(78,399)(102,379)
Net loss(42,443)(89,981)(95,567)
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax
393 (122)(29)
Comprehensive loss$(42,050)$(90,103)$(95,596)
Condensed Statements of Cash Flow
WALDENCAST PLC
(PARENT COMPANY ONLY)
CONDENSED STATEMENTS OF CASH FLOW
(In thousands of U.S. dollars)
Year ended December 31, 2024Year ended December 31, 2023Period from July 28, 2022 to December 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(42,443)$(89,981)$(95,567)
Adjustments to reconcile net loss to net cash
Cash (used in) provided by operating activities:
Equity in income of subsidiaries47,652 78,399 102,379 
Change in fair value of derivative warrant liabilities(23,627)10,337 (6,793)
Net cash (used in) provided by operating activities
(18,417)(1,245)19 
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from trust— — 6,400 
Net cash provided by investing activities  6,400 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from PIPE investments— 70,000 — 
Payment of PIPE transaction costs— (1,069)— 
Proceeds from note payable
1,632 — — 
Repayment of note payable
(1,770)— — 
Tax refund (withholding)558 (1,204)— 
Transfers from subsidiaries32,750 30,575 6,000 
Transfers to subsidiaries— (66,250)(300)
Expenses paid on behalf of subsidiaries(14,700)(33,603)(8,982)
Net cash provided by (used in) financing activities
18,470 (1,551)(3,282)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH53 (2,796)3,137 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period419 3,215 78 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period
$472 $419 $3,215 
XML 68 R47.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) - $ / shares
1 Months Ended 5 Months Ended
Mar. 18, 2021
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2024
Jul. 15, 2021
Class of Stock [Line Items]          
Financial designation, predecessor and successor [Fixed List]     Successor    
Number of shares called by each warrant (in shares)       1  
Common shares issued (in shares)         4,000,000
IPO          
Class of Stock [Line Items]          
Issued (in shares) 34,500,000        
Price per unit (in dollars per share) $ 10.00        
Class A Ordinary Shares          
Class of Stock [Line Items]          
Issued (in shares)   14,000,000      
Price per unit (in dollars per share)   $ 5.00      
Ordinary Shares | Class A Ordinary Shares | IPO          
Class of Stock [Line Items]          
Number of shares in each IPO unit (in shares) 1        
Number of shares called by each warrant (in shares) 1        
Warrants | IPO          
Class of Stock [Line Items]          
Number of shares in each IPO unit (in shares) 0.3333        
XML 69 R48.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
5 Months Ended 7 Months Ended 12 Months Ended
Jul. 27, 2022
segment
Dec. 31, 2022
USD ($)
Jul. 27, 2022
USD ($)
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Aug. 31, 2022
Concentration Risk [Line Items]            
Restricted cash       $ 1,500,000 $ 1,487,000  
Period after which production costs will be expensed for advertising that has not yet occurred       12 months    
Shipping and handling costs   $ 2,000,000.0 $ 600,000 $ 8,700,000 6,600,000  
Advertising expense   11,700,000 $ 6,800,000 43,500,000 16,300,000  
Valuation allowance       22,471,000 19,752,000  
Uncertain tax positions       0 0  
Unrecognized tax benefits, accrued interest and penalties   $ 0   $ 0 $ 0  
Number of reportable segments | segment 1     2    
Number of operating segments | segment 1     2    
Corporate Credit Cards            
Concentration Risk [Line Items]            
Restricted cash       $ 700,000    
Lease Deposits            
Concentration Risk [Line Items]            
Restricted cash       $ 800,000    
Maximum            
Concentration Risk [Line Items]            
Customer payment period       90 days    
Minimum            
Concentration Risk [Line Items]            
Customer payment period       30 days    
Internal-Use Software and Website Development Costs | Maximum            
Concentration Risk [Line Items]            
Estimated useful life (in years)       3 years    
Founder Awards            
Concentration Risk [Line Items]            
Percent of award vesting period           50.00%
Inventory Purchases | Supplier Concentration Risk | Vendor One            
Concentration Risk [Line Items]            
Concentration risk, percentage       15.00% 17.00%  
Inventory Purchases | Supplier Concentration Risk | Vendor Two            
Concentration Risk [Line Items]            
Concentration risk, percentage       12.00%    
Accounts Payable | Lender Concentration Risk | Vendor One            
Concentration Risk [Line Items]            
Concentration risk, percentage         18.00%  
Customer One | Accounts Receivable | Customer Concentration Risk            
Concentration Risk [Line Items]            
Concentration risk, percentage       33.00% 27.00%  
XML 70 R49.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)
Dec. 31, 2024
Computer hardware and software  
Property, Plant and Equipment [Line Items]  
ESTIMATED USEFUL LIVES 3 years
Furniture and fixtures | Minimum  
Property, Plant and Equipment [Line Items]  
ESTIMATED USEFUL LIVES 3 years
Furniture and fixtures | Maximum  
Property, Plant and Equipment [Line Items]  
ESTIMATED USEFUL LIVES 5 years
Machinery and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
ESTIMATED USEFUL LIVES 3 years
Machinery and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
ESTIMATED USEFUL LIVES 5 years
XML 71 R50.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS - Narrative (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 5 Months Ended 7 Months Ended 12 Months Ended
Jul. 28, 2022
USD ($)
director
$ / shares
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Jul. 27, 2022
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]                
Pre-tax losses     $ 126,360 $ 126,360 $ 20,944 $ 48,538 $ 112,943  
Loss on impairment of goodwill     68,715   0 5,031 0  
Net revenue     92,373 92,373 73,760 273,868 218,138  
Related party liability           19,560 23,698  
Cost of goods sold     60,657     82,124 76,561  
Tretinoin distribution and supply agreement                
Business Acquisition [Line Items]                
Other income           $ 3,400    
Obagi Vietnam Import Export Trading MTV Company Limited                
Business Acquisition [Line Items]                
Equity outstanding percentage   40.00%            
Asset acquisition, inventory   $ 1,600            
Related Party                
Business Acquisition [Line Items]                
Related party liability             $ 5,900  
Obagi China Business | Related Party                
Business Acquisition [Line Items]                
Pre-tax losses         8,000      
Class A Ordinary Shares                
Business Acquisition [Line Items]                
Common shares, par value (in dollars per share) | $ / shares           $ 0.0001 $ 0.0001  
Stock conversion ratio (in shares) | shares 1              
Class B Ordinary Shares                
Business Acquisition [Line Items]                
Common shares, par value (in dollars per share) | $ / shares           $ 0.0001 $ 0.0001  
Waldencast plc | Class A Ordinary Shares | Obagi China Business | Related Party | Cedarwalk                
Business Acquisition [Line Items]                
Ownership interest in fully diluted Class A ordinary shares (percent) 24.50%              
Obagi and Milk Business Combinations                
Business Acquisition [Line Items]                
Transaction costs       9,400       $ 66,100
Cost of goods sold               10,000
Obagi and Milk Business Combinations | Related Party                
Business Acquisition [Line Items]                
Related party liability from merger $ 22,100              
Net revenue       12,200   $ 2,300 $ 4,100  
Obagi Merger                
Business Acquisition [Line Items]                
Common shares, par value (in dollars per share) | $ / shares $ 0.50              
Shares exchanged $ 345,400              
Number of nominated directors | director 1              
Obagi Merger | Class A Ordinary Shares                
Business Acquisition [Line Items]                
Shares exchanged (in shares) | shares 28,237,506              
Milk Transaction                
Business Acquisition [Line Items]                
Shares exchanged $ 121,600              
Number of nominated directors | director 0              
Milk Transaction | Class B Ordinary Shares                
Business Acquisition [Line Items]                
Shares exchanged (in shares) | shares 21,104,225              
Obagi                
Business Acquisition [Line Items]                
Loss on impairment of goodwill       $ 68,700   5,000   $ 68,700
Net revenue     $ 61,090   $ 73,760 $ 149,266 $ 117,651  
Obagi | Obagi and Milk Business Combinations | Related Party                
Business Acquisition [Line Items]                
Related party liability from merger $ 22,100              
XML 72 R51.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Jul. 28, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Liabilities assumed:        
Goodwill   $ 329,589 $ 334,620 $ 334,620
Obagi and Milk Business Combinations        
Total Purchase Price:        
Cash consideration $ 467,027      
Equity consideration 477,911      
Cash repayment of debt 140,047      
Total purchase consideration 1,107,085      
Fair value of assets acquired:        
Cash and cash equivalents 17,942      
Restricted cash 1,469      
Account receivable, net 19,080      
Related party receivable 526      
Inventories 61,971      
Prepaid expenses 4,827      
Other current assets 359      
Property and equipment 9,681      
Intangible assets 662,800      
Right-of-use assets 13,043      
Other assets 227      
Total identifiable assets acquired 791,925      
Liabilities assumed:        
Accounts payable and accrued expenses 25,141      
Other current liabilities 18,395      
Lease liabilities 16,566      
Deferred income tax liabilities 28,073      
Total liabilities assumed: 88,175      
Net assets acquired 703,750      
Purchase consideration 1,107,085      
Goodwill 403,335      
Obagi and Milk Business Combinations | Related Party        
Total Purchase Price:        
Related party liability 22,100      
Obagi        
Liabilities assumed:        
Goodwill   194,517 199,548 199,548
Obagi | Obagi and Milk Business Combinations        
Total Purchase Price:        
Cash consideration 345,398      
Equity consideration 277,824      
Cash repayment of debt 136,112      
Total purchase consideration 781,434      
Fair value of assets acquired:        
Cash and cash equivalents 15,850      
Restricted cash 650      
Account receivable, net 15,214      
Related party receivable 327      
Inventories 31,026      
Prepaid expenses 4,307      
Other current assets 359      
Property and equipment 1,245      
Intangible assets 505,300      
Right-of-use assets 4,811      
Other assets 227      
Total identifiable assets acquired 579,316      
Liabilities assumed:        
Accounts payable and accrued expenses 18,699      
Other current liabilities 12,912      
Lease liabilities 6,461      
Deferred income tax liabilities 28,073      
Total liabilities assumed: 66,145      
Net assets acquired 513,171      
Purchase consideration 781,434      
Goodwill 268,263      
Obagi | Obagi and Milk Business Combinations | Related Party        
Total Purchase Price:        
Related party liability 22,100      
Milk         
Liabilities assumed:        
Goodwill   $ 135,072 $ 135,072 $ 135,072
Milk  | Obagi and Milk Business Combinations        
Total Purchase Price:        
Cash consideration 121,629      
Equity consideration 200,087      
Cash repayment of debt 3,935      
Total purchase consideration 325,651      
Fair value of assets acquired:        
Cash and cash equivalents 2,092      
Restricted cash 819      
Account receivable, net 3,866      
Related party receivable 199      
Inventories 30,945      
Prepaid expenses 520      
Other current assets 0      
Property and equipment 8,436      
Intangible assets 157,500      
Right-of-use assets 8,232      
Other assets 0      
Total identifiable assets acquired 212,609      
Liabilities assumed:        
Accounts payable and accrued expenses 6,442      
Other current liabilities 5,483      
Lease liabilities 10,105      
Deferred income tax liabilities 0      
Total liabilities assumed: 22,030      
Net assets acquired 190,579      
Purchase consideration 325,651      
Goodwill 135,072      
Milk  | Obagi and Milk Business Combinations | Related Party        
Total Purchase Price:        
Related party liability $ 0      
XML 73 R52.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details) - Obagi and Milk Business Combinations
$ in Thousands
Jul. 28, 2022
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 662,800
Obagi  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets 505,300
Milk   
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets 157,500
Trademarks and trade name  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 559,000
Weighted- Average Useful Life 14 years
Trademarks and trade name | Obagi  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 414,000
Trademarks and trade name | Milk   
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets 145,000
Customer/distributor relationships  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 36,000
Weighted- Average Useful Life 11 years
Customer/distributor relationships | Obagi  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 25,000
Customer/distributor relationships | Milk   
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets 11,000
Tretinoin distribution and supply agreement  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 38,900
Weighted- Average Useful Life 5 years
Tretinoin distribution and supply agreement | Obagi  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 38,900
Tretinoin distribution and supply agreement | Milk   
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets 0
Formulations  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 28,900
Weighted- Average Useful Life 8 years
Formulations | Obagi  
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 27,400
Formulations | Milk   
Acquired Finite-Lived Intangible Assets [Line Items]  
Total Intangible Assets $ 1,500
XML 74 R53.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details) - Obagi and Milk Business Combinations
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]  
Pro forma net revenue $ 200,547
Pro forma net loss (86,930)
Less: Pro forma net loss attributable to noncontrolling interest (25,140)
Pro forma net loss attributable to Waldencast plc $ (61,790)
XML 75 R54.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE - Revenue by Sales Channel (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]          
Net revenue $ 92,373 $ 92,373 $ 73,760 $ 273,868 $ 218,138
Obagi Medical          
Disaggregation of Revenue [Line Items]          
Net revenue 61,090   73,760 149,266 117,651
Milk Makeup          
Disaggregation of Revenue [Line Items]          
Net revenue 31,283     124,602 100,487
Net product sales          
Disaggregation of Revenue [Line Items]          
Net revenue 90,385 90,385 70,729 269,369 213,116
Net product sales | Obagi Medical          
Disaggregation of Revenue [Line Items]          
Net revenue 59,102     144,798 112,649
Net product sales | Milk Makeup          
Disaggregation of Revenue [Line Items]          
Net revenue 31,283     124,571 100,467
Net product sales | Direct sales          
Disaggregation of Revenue [Line Items]          
Net revenue 60,468   39,649 223,530 169,668
Net product sales | Direct sales | Obagi Medical          
Disaggregation of Revenue [Line Items]          
Net revenue 30,276     103,168 72,446
Net product sales | Direct sales | Milk Makeup          
Disaggregation of Revenue [Line Items]          
Net revenue 30,192     120,362 97,222
Net product sales | Distributors          
Disaggregation of Revenue [Line Items]          
Net revenue 29,917   31,080 45,839 43,448
Net product sales | Distributors | Obagi Medical          
Disaggregation of Revenue [Line Items]          
Net revenue 28,826     41,630 40,203
Net product sales | Distributors | Milk Makeup          
Disaggregation of Revenue [Line Items]          
Net revenue 1,091     4,209 3,245
Royalties          
Disaggregation of Revenue [Line Items]          
Net revenue 1,988 $ 1,988 $ 3,031 4,499 5,022
Royalties | Obagi Medical          
Disaggregation of Revenue [Line Items]          
Net revenue 1,988     4,468 5,002
Royalties | Milk Makeup          
Disaggregation of Revenue [Line Items]          
Net revenue $ 0     $ 31 $ 20
XML 76 R55.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 5 Months Ended 7 Months Ended 12 Months Ended
Jul. 31, 2024
Aug. 31, 2023
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]              
Net revenue     $ 92,373 $ 92,373 $ 73,760 $ 273,868 $ 218,138
D&O Insurance | Note Payable              
Disaggregation of Revenue [Line Items]              
Monthly principal and interest payments $ 200 $ 200          
Net product sales              
Disaggregation of Revenue [Line Items]              
Net revenue     $ 90,385 90,385 70,729 269,369 213,116
UNITED STATES | Net product sales              
Disaggregation of Revenue [Line Items]              
Net revenue       54,300 43,800 $ 192,600 $ 145,300
CHINA | Net product sales              
Disaggregation of Revenue [Line Items]              
Net revenue       $ 17,000      
VIET NAM | Net product sales              
Disaggregation of Revenue [Line Items]              
Net revenue         $ 14,900    
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer One              
Disaggregation of Revenue [Line Items]              
Concentration risk, percentage       29.00% 44.00% 18.00% 28.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer Two              
Disaggregation of Revenue [Line Items]              
Concentration risk, percentage       18.00% 20.00% 17.00% 20.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer Three              
Disaggregation of Revenue [Line Items]              
Concentration risk, percentage       16.00%   10.00%  
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | UNITED STATES              
Disaggregation of Revenue [Line Items]              
Concentration risk, percentage       10.00% 10.00% 10.00%  
XML 77 R56.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUE - Revenue by Geographic Region (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]          
Net revenue $ 92,373 $ 92,373 $ 73,760 $ 273,868 $ 218,138
Net product sales          
Disaggregation of Revenue [Line Items]          
Net revenue 90,385 90,385 70,729 269,369 213,116
Net product sales | North America          
Disaggregation of Revenue [Line Items]          
Net revenue   56,630 44,443 202,261 154,357
Net product sales | Rest of the World          
Disaggregation of Revenue [Line Items]          
Net revenue   33,755 26,286 67,108 58,759
Royalties          
Disaggregation of Revenue [Line Items]          
Net revenue $ 1,988 $ 1,988 $ 3,031 $ 4,499 $ 5,022
XML 78 R57.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Goodwill [Roll Forward]            
Beginning balance       $ 334,620 $ 334,620  
Impairment loss   $ (68,715) $ 0 (5,031) 0  
Ending balance $ 334,620 334,620   329,589 334,620 $ 334,620
Obagi            
Goodwill [Roll Forward]            
Beginning balance       199,548 199,548  
Impairment loss (68,700)     (5,000)   (68,700)
Ending balance 199,548 199,548   194,517 199,548 199,548
Milk Makeup            
Goodwill [Roll Forward]            
Beginning balance       135,072 135,072  
Impairment loss       0    
Ending balance $ 135,072 $ 135,072   $ 135,072 $ 135,072 $ 135,072
XML 79 R58.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL - Narrative (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Goodwill [Line Items]            
Loss on impairment of goodwill $ 68,715   $ 0 $ 5,031 $ 0  
Obagi            
Goodwill [Line Items]            
Loss on impairment of goodwill   $ 68,700   $ 5,000   $ 68,700
XML 80 R59.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS—NET - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 663,902 $ 663,598
Accumulated Amortization (137,464) (80,735)
Net Carrying Amount $ 526,438 $ 582,863
Trademark and trade name    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Lives (Years) 14 years 14 years
Gross Carrying Amount $ 559,875 $ 559,644
Accumulated Amortization (102,169) (59,989)
Net Carrying Amount $ 457,706 $ 499,655
Customer/distributor relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Lives (Years) 11 years 11 years
Gross Carrying Amount $ 36,000 $ 36,000
Accumulated Amortization (6,449) (4,532)
Net Carrying Amount $ 29,551 $ 31,468
Tretinoin distribution and supply agreement    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Lives (Years) 5 years 5 years
Gross Carrying Amount $ 38,900 $ 38,900
Accumulated Amortization (18,885) (11,105)
Net Carrying Amount $ 20,015 $ 27,795
Formulations    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Lives (Years) 8 years 8 years
Gross Carrying Amount $ 28,900 $ 28,900
Accumulated Amortization (9,943) (5,101)
Net Carrying Amount $ 18,957 $ 23,799
Patents    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Useful Lives (Years) 20 years 20 years
Gross Carrying Amount $ 227 $ 154
Accumulated Amortization (18) (8)
Net Carrying Amount $ 209 $ 146
XML 81 R60.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS—NET - Narrative (Details) - USD ($)
$ in Millions
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization $ 24.0 $ 7.7 $ 56.7 $ 56.7
XML 82 R61.htm IDEA: XBRL DOCUMENT v3.25.1
INTANGIBLE ASSETS—NET - Expected Amortization (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2025 $ 56,737  
2026 56,737  
2027 53,496  
2028 48,957  
2029 48,957  
Thereafter 261,554  
Net Carrying Amount $ 526,438 $ 582,863
XML 83 R62.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT - Summary of Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Jun. 30, 2022
Schedule of Long Term and Short Term Debt Instruments [Line Items]      
Unamortized debt issuance costs $ (2,339) $ (3,050) $ (6,300)
Net carrying amount 166,616 159,793  
Less: Current portion of long-term debt (29,479) (8,529)  
Total long-term portion 137,137 151,264  
2022 Term Loan      
Schedule of Long Term and Short Term Debt Instruments [Line Items]      
Less: Current portion of long-term debt (15,300)    
2022 Revolving Credit Facility      
Schedule of Long Term and Short Term Debt Instruments [Line Items]      
Less: Current portion of long-term debt (15,000)    
Note Payable | D&O Insurance      
Schedule of Long Term and Short Term Debt Instruments [Line Items]      
Short-term debt 830 968  
Line of Credit | 2022 Term Loan | Secured Debt      
Schedule of Long Term and Short Term Debt Instruments [Line Items]      
Long-term debt 153,125 161,875  
Line of Credit | 2022 Revolving Credit Facility | Revolving Credit Facility      
Schedule of Long Term and Short Term Debt Instruments [Line Items]      
Long-term debt $ 15,000 $ 0  
XML 84 R63.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Apr. 26, 2024
Jun. 30, 2022
Jul. 31, 2024
Aug. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Unamortized debt issuance costs   $ 6,300,000     $ 2,339,000 $ 3,050,000
Current portion of long-term debt         29,479,000 $ 8,529,000
Accrued interest         1,400,000  
2022 Term Loan            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Current portion of long-term debt         15,300,000  
Debt issuance cost, current         $ 1,200,000  
2022 Term Loan | Line of Credit            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Interest rate         8.70%  
2022 Term Loan | Line of Credit | Variable Rate Component One | Alternate Base Rate            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Debt instrument, rate   2.50%     7.90%  
2022 Term Loan | Line of Credit | Variable Rate Component Three | Applicable Rate            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Debt instrument, rate   3.50%        
2022 Revolving Credit Facility            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Current portion of long-term debt         $ 15,000,000.0  
Debt issuance cost, current         500,000  
Secured Debt | 2022 Term Loan | Line of Credit            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Debt   $ 7,500,000     $ 100,000  
Maximum borrowing capacity   $ 175,000,000.0        
Revolving Credit Facility | 2022 Term Loan | Line of Credit            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Debt term   4 years        
Revolving Credit Facility | 2022 Revolving Credit Facility | Line of Credit            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Maximum borrowing capacity $ 45,000,000.0 $ 45,000,000.0        
Interest rate         8.70%  
Decrease in revolving commitments 5,000,000.0          
Minimum liquidity covenant $ 10,000,000.0          
Note Payable | D&O Insurance            
Schedule of Long Term and Short Term Debt Instruments [Line Items]            
Debt     $ 1,600,000 $ 2,400,000    
Monthly principal and interest payments     $ 200,000 $ 200,000    
Debt term     10 months 10 months    
Annual interest rate     8.25% 8.20%    
XML 85 R64.htm IDEA: XBRL DOCUMENT v3.25.1
DEBT - Scheduled Maturities (Details) - 2022 Credit Agreement
$ in Thousands
Dec. 31, 2024
USD ($)
Debt Instrument [Line Items]  
2025 $ 31,142
2026 137,813
2027 0
2028 0
2029 0
Total unpaid principal $ 168,955
XML 86 R65.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES - Narrative (Details)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Jul. 27, 2022
USD ($)
operatingLease
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Lessee, Lease, Description [Line Items]          
Operating lease extension term       5 years  
Operating lease costs       $ 3,700 $ 3,500
Loss on impairment of right of use assets $ 0   $ 0 0 3,643
Number of non-cancelable operating leases | operatingLease     3    
Rent expense     $ 900    
Cash paid for amounts included in the measurement of operating lease liabilities   $ 1,166   3,826 3,309
Right-of-use assets obtained in exchange for new operating lease liabilities   $ 4,081   131 $ 446
TEXAS | Warehouse          
Lessee, Lease, Description [Line Items]          
Loss on impairment of right of use assets       800  
TEXAS | Office          
Lessee, Lease, Description [Line Items]          
Loss on impairment of right of use assets       2,700  
Annual sublease rent       $ 400  
Minimum          
Lessee, Lease, Description [Line Items]          
Operating lease remaining term       1 year  
Maximum          
Lessee, Lease, Description [Line Items]          
Operating lease remaining term       11 years  
XML 87 R66.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
5 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Leases [Abstract]      
Cash paid for amounts included in the measurement of operating lease liabilities $ 1,166 $ 3,826 $ 3,309
Right-of-use assets obtained in exchange for new operating lease liabilities $ 4,081 $ 131 $ 446
Weighted-average remaining lease term 7 years 9 months 6 years 18 days 6 years 11 months 1 day
Weighted-average discount rate 5.90% 5.90% 5.90%
XML 88 R67.htm IDEA: XBRL DOCUMENT v3.25.1
LEASES - Operating Lease Maturity Schedule (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Leases [Abstract]  
2025 $ 3,797
2026 2,899
2027 2,452
2028 2,504
2029 2,548
Thereafter 4,173
Total future minimum lease payments 18,373
Less: Imputed interest 2,883
Total reported lease liability $ 15,490
XML 89 R68.htm IDEA: XBRL DOCUMENT v3.25.1
FINANCIAL INSTRUMENTS (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 5 Months Ended 12 Months Ended
Jul. 28, 2022
Dec. 20, 2021
Mar. 18, 2021
Mar. 01, 2021
Nov. 30, 2023
Sep. 30, 2023
Nov. 30, 2023
Dec. 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Derivative [Line Items]                    
Warrants outstanding (in shares)                 29,533,282  
Gain (loss) from change in fair value of warrants               $ (6.8) $ (23.6) $ 10.3
Number of shares called by each warrant (in shares)                 1  
Exercise price of warrants (in dollars per share)                 $ 11.50  
Beauty Ventures LLC                    
Derivative [Line Items]                    
Consideration received       $ 173.0            
Class A Ordinary Shares                    
Derivative [Line Items]                    
Issued (in shares)           14,000,000        
Consideration received         $ 2.0 $ 68.0 $ 70.0      
Class A Ordinary Shares | Burwell and Zeno                    
Derivative [Line Items]                    
Issued (in shares)   16,000,000                
Class A Ordinary Shares | Beauty Ventures LLC                    
Derivative [Line Items]                    
Issued (in shares)       17,300,000            
Public Warrants                    
Derivative [Line Items]                    
Issued (in shares)     11,499,950              
Warrant exercise period                 30 days  
Warrant redemption period                 30 days  
Warrant redemption, number of trading days at or above trigger price                 20 days  
Warrant redemption, trading period                 30 days  
Warrant redemption, period between end of trading and notice of redemption                 3 days  
Warrant redemption, stock price trigger (in dollars per share)                 $ 18.00  
Public Warrants | Share-Based Payment Arrangement, Tranche One                    
Derivative [Line Items]                    
Warrant redemption price (in dollars per share)                 0.01  
Warrant redemption, stock price trigger (in dollars per share)                 18.00  
Public Warrants | Share-Based Payment Arrangement, Tranche Two                    
Derivative [Line Items]                    
Warrant redemption price (in dollars per share)                 0.01  
Warrant redemption, stock price trigger (in dollars per share)                 $ 10.00  
Sponsor Warrants                    
Derivative [Line Items]                    
Issued (in shares) 1,000,000   5,933,333              
Consideration received $ 1.5                  
Sponsor Warrants | Burwell and Zeno                    
Derivative [Line Items]                    
Issued (in shares)   5,333,333                
Sponsor Warrants | Beauty Ventures LLC                    
Derivative [Line Items]                    
Issued (in shares)       5,766,666            
Private Placement Warrants                    
Derivative [Line Items]                    
Warrant exercise period                 30 days  
Interest rate collar                    
Derivative [Line Items]                    
Derivative notional value                 $ 160.0  
Payments on interest rate collar contracts               0.0    
Interest rate floor (percent)                 2.55%  
Interest rate cap (percent)                 5.25%  
Fair value of derivative asset                 $ 0.0 0.1
Loss from change in fair value on derivative instruments               0.6 (0.1) $ 0.1
Receipts exchanged on interest rate collar contracts               0.0 0.1  
Interest Rate Collar, Initial Fixed Payment                    
Derivative [Line Items]                    
Payments on interest rate collar contracts               $ 0.8 $ 0.8  
XML 90 R69.htm IDEA: XBRL DOCUMENT v3.25.1
FAIR VALUE MEASUREMENTS (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Derivative warrant liabilities - Public    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities $ 1,983 $ 11,155
Derivative warrant liabilities - Private    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities 3,038 17,492
Interest rate collar    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Assets   61
(Level 1) | Derivative warrant liabilities - Public    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities 1,983 11,155
(Level 1) | Derivative warrant liabilities - Private    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities 0 0
(Level 1) | Interest rate collar    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Assets   0
(Level 2) | Derivative warrant liabilities - Public    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities 0 0
(Level 2) | Derivative warrant liabilities - Private    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities 3,038 17,492
(Level 2) | Interest rate collar    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Assets   61
(Level 3) | Derivative warrant liabilities - Public    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities 0 0
(Level 3) | Derivative warrant liabilities - Private    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liabilities $ 0 0
(Level 3) | Interest rate collar    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Assets   $ 0
XML 91 R70.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Related Party Transaction [Line Items]        
Accounts receivable, before allowance for doubtful accounts     $ 25,600 $ 22,900
Allowance for doubtful accounts     100 1,600
Depreciation expense $ 2,900 $ 500 3,300 3,800
Related Party        
Related Party Transaction [Line Items]        
Related party liability     $ 0 $ 5,856
XML 92 R71.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]          
Balance at beginning of period       $ 1,600  
Provision (recovery) for bad debts $ 0   $ 0 (996) $ 0
Balance at end of period       100 1,600
Waldencast plc          
Accounts Receivable, Allowance for Credit Loss [Roll Forward]          
Balance at beginning of period   $ 1,061 671 1,552 994
Provision (recovery) for bad debts   (67) 390 (996) 558
Write-off of uncollectible accounts, net   0 0 (448) 0
Balance at end of period $ 994 $ 994 $ 1,061 $ 108 $ 1,552
XML 93 R72.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Work in process $ 8,354 $ 10,336
Finished goods 44,750 45,348
Total inventories $ 53,104 $ 55,684
XML 94 R73.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 15,027 $ 12,036
Less accumulated depreciation (9,196) (6,105)
Property and equipment, net 5,831 5,931
Computer hardware, software and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 742 689
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment 9,848 7,611
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 598 812
Internally developed software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 1,739 854
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 2,100 $ 2,070
XML 95 R74.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Related Party Transaction [Line Items]    
Accrued salaries and related expenses $ 9,155 $ 8,702
Accrued sales returns and damages 2,723 2,527
Accrued interest 1,424 1,357
Accrued distribution fees 0 590
Accrued professional services 3,832 2,901
Total 19,560 23,698
Related Party    
Related Party Transaction [Line Items]    
Related party liability 0 5,856
Total   5,900
Nonrelated Party    
Related Party Transaction [Line Items]    
Related party liability $ 2,426 $ 1,765
XML 96 R75.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Narrative (Details)
$ / shares in Units, $ in Millions
1 Months Ended 5 Months Ended 12 Months Ended
Aug. 12, 2022
individual
tranche
shares
Jul. 27, 2022
USD ($)
shares
Aug. 31, 2024
$ / shares
Apr. 30, 2024
$ / shares
May 31, 2023
shares
Jan. 31, 2023
shares
Nov. 30, 2022
shares
Aug. 31, 2022
Dec. 31, 2021
Jan. 31, 2021
installment
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Maximum allocated target share units, percent           200.00%              
Granted (in dollars per share) | $ / shares       $ 6.48                  
Number of founders | individual 2                        
Stock options, unrecognized compensation cost | $                       $ 16.1  
Waldencast plc                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       0  
Additional Paid-In Capital | Waldencast plc                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Stock compensation expense | $                     $ 7.7 $ 9.4 $ 9.2
Obagi Merger                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Stock options assumed in business combination (in shares)   5,906,300                      
Milk Transaction                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Stock options assumed in business combination (in shares)   237,724                      
Obagi and Milk Business Combinations                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Incremental stock based compensation expense | $   $ 18.3                      
Fair value of equity awards in business combination | $   $ 47.7                      
Share-Based Payment Arrangement, Founder                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares) 11,500,000                        
Number of tranches | tranche 4                        
Predecessor Incentive Plan                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Maximum number of shares available for issuance (in shares)                   1,500,000      
Employee Stock | 2022 Incentive Award Plan                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Maximum number of shares available for issuance (in shares)                       23,042,449  
Anniversary period, annual increase in shares issued under plan                       10 years  
Percentage increase in shares available for issuance                       3.00%  
Shares reserved for future issuance (in shares)                       5,533,142  
Restricted stock                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Restricted stock, unrecognized compensation cost | $                       $ 13.0  
Compensation cost, weighted average service period                       2 years 3 months 18 days  
Restricted stock | Waldencast plc                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       6,705,468  
Forfeited (in shares)                       851,298  
Granted (in dollars per share) | $ / shares                       $ 3.69  
Restricted stock | Obagi Merger                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Equity instruments assumed in business combination (in shares)   1,776,827                      
Restricted stock | Share-Based Payment Arrangement, Founder                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares) 692,000                        
Restricted stock | Long-Term Incentive Awards                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       0 0
Awards with modified performance conditions in period (in shares)         137,537                
Forfeited (in shares)         360,000                
Vesting percentage             33.00%            
Restricted stock | Long-Term Incentive Awards | Share-Based Payment Arrangement, Employees And Non Employees                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       3,828,878  
Restricted stock | Long-Term Incentive Awards | Share-Based Payment Arrangement, Founder                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       312,830  
Restricted stock | Long-Term Incentive Awards | Share-Based Payment Arrangement Board Of Directors                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       319,471  
Restricted stock | One-Tim Stock Grant                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Maximum number of shares available for issuance (in shares)             10,000            
Award vesting period             3 years            
Restricted stock | Predecessor Incentive Plan                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Award vesting period                   5 years      
Number of annual installments | installment                   5      
Award expiration period                   10 years      
Stock Growth Incentive 2027 Awards (SGI Awards)                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)                       2,557,119  
Maximum allocated target share units, percent     200.00%                    
Granted (in dollars per share) | $ / shares     $ 2.88                    
SGI Awards                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Post vesting holding period                       1 year  
Stock Growth Incentive 2025 Awards (SGI Awards)                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Granted (in shares)           2,290,000              
Granted (in dollars per share) | $ / shares                         $ 8.88
Post vesting holding period                         1 year
Stock Appreciation Rights (SARs) | Milk Transaction                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Equity instruments assumed in business combination (in shares)   2,808,131                      
Stock options                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Compensation cost, weighted average service period                       3 years 6 months  
Stock options | Share-Based Payment Arrangement, Founder                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Award vesting period               6 years          
Stock options | Predecessor Incentive Plan                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Award vesting period                   5 years      
Stock options | Predecessor Incentive Plan | Share-Based Payment Arrangement, Tranche One                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Award vesting period                 3 months        
Vesting percentage                   25.00%      
Number of quarterly installments | installment                   4      
Stock options | Predecessor Incentive Plan | Share-Based Payment Arrangement, Tranche Two                          
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                          
Award vesting period                 5 years        
Vesting percentage                   75.00%      
Number of annual installments | installment                   5      
XML 97 R76.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Stock Option Activity (Details) - Waldencast plc - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Number of Common Stock Options    
Beginning balance (in shares) 18,915,358  
Granted (in shares) 0  
Exercised (in shares) (150,000)  
Forfeited (in shares) (1,628,000)  
Ending balance (in shares) 17,137,358 18,915,358
Exercisable (in shares) 9,168,975  
Vested and expected to vest (in shares) 17,137,358  
Weighted Average Exercise Price    
Beginning balance (in dollars per share) $ 9.10  
Granted (in dollars per share) 0  
Exercised (in dollars per share) 0.68  
Forfeited (in dollars per share) 5.73  
Ending balance (in dollars per share) 10.48 $ 9.10
Exercisable (in dollars per share) 7.31  
Vested and expected to vest (in dollars per share) $ 10.48  
Weighted Average Remaining Contractual Life (in years)    
Outstanding (in years) 6 years 4 months 24 days 7 years 3 months 18 days
Exercisable (in years) 5 years  
Vested and expected to vest (in years) 6 years 4 months 24 days  
Aggregate intrinsic Value (in thousands)    
Outstanding $ 1,156 $ 47,792
Exercisable 1,156  
Vested and expected to vest $ 1,156  
XML 98 R77.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details) - USD ($)
5 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise multiple   230.00%
Exercise term, percent   50.00%
Dividend yield   $ 0
Minimum    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise multiple   200.00%
Maximum    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise multiple   250.00%
Founder Awards    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate, minimum 2.87%  
Risk-free interest rate, maximum 2.92%  
Expected stock price volatility, minimum 39.77%  
Expected stock price volatility, maximum 44.76%  
Founder Awards | Minimum    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected term 4 years 8 months 12 days  
Founder Awards | Maximum    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected term 9 years 10 months 24 days  
Replacement Options    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate, minimum 2.79%  
Risk-free interest rate, maximum 2.80%  
Exercise multiple 230.00%  
Expected stock price volatility 50.00%  
XML 99 R78.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) - $ / shares
1 Months Ended 12 Months Ended
Apr. 30, 2024
Dec. 31, 2024
Weighted Average Grant Date Fair Value per Share    
Granted (in dollars per share) $ 6.48  
Restricted stock | Waldencast plc    
Shares    
Outstanding, beginning balance (in shares)   2,296,831
Granted (in shares)   6,705,468
Vested (in shares)   (567,745)
Forfeited (in shares)   (851,298)
Outstanding, ending balance (in shares)   7,583,255
Weighted Average Grant Date Fair Value per Share    
Outstanding beginning balance (in dollars per share)   $ 8.72
Granted (in dollars per share)   3.69
Vested (in dollars per share)   5.84
Forfeited (in dollars per share)   8.87
Outstanding ending balance (in dollars per share)   $ 4.61
XML 100 R79.htm IDEA: XBRL DOCUMENT v3.25.1
SHAREHOLDERS’ EQUITY (Details) - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jul. 27, 2022
Class of Stock [Line Items]        
Preferred shares authorized (in shares) 25,000,000 25,000,000    
Preferred shares, par value (in dollars per share) $ 0.0001 $ 0.0001    
Preferred shares outstanding (in shares) 0 0    
Preferred shares issued (in shares) 0 0    
Class A Ordinary Shares        
Class of Stock [Line Items]        
Common shares authorized (in shares) 1,000,000,000 1,000,000,000    
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001    
Common shares outstanding (in shares)   101,228,857    
Common stock, voting rights one      
Class A Ordinary Shares | Ordinary Shares | Waldencast plc        
Class of Stock [Line Items]        
Common shares outstanding (in shares) 112,026,440 101,228,857 86,460,560 8,645,000
Class B Ordinary Shares        
Class of Stock [Line Items]        
Common shares authorized (in shares) 100,000,000 100,000,000    
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001    
Common shares outstanding (in shares)   20,847,553    
Class B Ordinary Shares | Ordinary Shares | Waldencast plc        
Class of Stock [Line Items]        
Common shares outstanding (in shares) 10,666,528 20,847,553 21,104,225 0
XML 101 R80.htm IDEA: XBRL DOCUMENT v3.25.1
NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details) - USD ($)
$ / shares in Units, $ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Numerator:          
Net loss $ (120,557) $ (120,557) $ (21,057) $ (48,648) $ (105,968)
Net loss attributable to noncontrolling interest $ (24,990) (24,990) 0 (6,205) (15,987)
Net loss attributed to Class A shareholders - basic EPS   (95,567) (21,057) (42,443) (89,981)
Net loss attributed to Class A shareholders - diluted EPS   $ (95,567) $ (21,057) $ (42,443) $ (89,981)
Denominator:          
Weighted-average basic shares outstanding (in shares) 86,460,560 86,460,560 8,000,002 109,295,742 91,158,500
Effect of dilutive securities (in shares)   0 0 0 0
Weighted-average diluted shares (in shares) 86,460,560 86,460,560 8,000,002 109,295,742 91,158,500
Basic net loss per share (in dollars per share) $ (1.11) $ (1.11) $ (2.63) $ (0.39) $ (0.99)
Diluted net loss per share (in dollars per share) $ (1.11) $ (1.11) $ (2.63) $ (0.39) $ (0.99)
XML 102 R81.htm IDEA: XBRL DOCUMENT v3.25.1
NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 52,787,856 1,009,642 54,253,895 50,745,471
Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 29,533,282 0 29,533,282 29,533,282
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 20,452,155 774,800 17,137,358 18,915,358
Restricted stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 2,802,419 234,842 7,583,255 2,296,831
XML 103 R82.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT - Narrative (Details) - USD ($)
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]        
Income tax rate 0.00% 0.00% 4.30% 0.00%
U.S./foreign tax rate differential 20.70% 17.70% 10.00% 15.90%
Valuation allowance     $ 22,471,000 $ 19,752,000
Unrecognized tax benefits     $ 0 $ 0
Bailiwick of Jersey and the Cayman Islands        
Effective Income Tax Rate Reconciliation [Line Items]        
Income tax rate     0.00%  
UNITED KINGDOM        
Effective Income Tax Rate Reconciliation [Line Items]        
Income tax rate     25.00%  
XML 104 R83.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]          
United States   $ (125,281) $ (17,676) $ 2,684 $ (82,868)
Foreign   (1,079) (3,268) (51,222) (30,075)
Loss before income taxes $ (126,360) $ (126,360) $ (20,944) $ (48,538) $ (112,943)
XML 105 R84.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Current provision (benefit):          
Federal   $ 0 $ 0 $ 784 $ 12
State   20 19 268 32
Foreign   0 4 243 2
Current provision (benefit), total   20 23 1,295 46
Deferred (income) expense:          
Federal   (4,557) 38 (144) (7,927)
State   (1,266) 52 (976) 906
Foreign   0 0 (66) 0
Deferred (income) expense, total $ (5,823) (5,823) 90 (1,185) (7,021)
Net income tax (benefit) provision $ (5,803) $ (5,803) $ 113 $ 110 $ (6,975)
XML 106 R85.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]        
Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate 0.00% 0.00% 4.30% 0.00%
U.S./foreign tax rate differential 20.70% 17.70% 10.00% 15.90%
State income tax benefit, net of federal benefit 2.40% 1.40% 1.70% 2.10%
Permanent Items 0.20% (0.10%) 3.50% (0.10%)
Noncontrolling interest (1.10%) (0.00%) (0.90%) (1.80%)
Change in valuation allowance (6.10%) (16.90%) (5.60%) (10.40%)
Transaction bonuses 0.00% 8.60% 0.00% 0.00%
Transaction costs 0.00% (11.30%) 0.00% 0.00%
True-Ups 0.00% 0.00% (12.20%) 0.00%
Equity Compensation 0.00% 0.00% 0.50% 0.50%
Withholding tax 0 0 (0.016) 0
Goodwill impairment (11.40%) 0.00% 0.00% 0.00%
Total income tax (benefit) expense 4.60% (0.60%) (0.20%) 6.20%
XML 107 R86.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Accrued interest to foreign related parties $ 2,388 $ 2,771
Lease liability 1,763 2,222
Formation costs 1,205 1,421
Net operating losses 19,016 20,669
Inventory reserve 3,217 2,134
Fixed asset basis 10 0
Accrued compensation 864 1,112
R&D tax credits 457 482
Non-deductible interest carryover 3,790 5,077
Below market contract 0 1,469
Capitalized research 2,256 2,811
Investment in Waldencast LP 13,147 9,059
Other temporary differences 0 962
Total deferred tax assets 48,113 50,189
Deferred tax liabilities:    
Goodwill (1,658) (1,016)
Fixed asset basis 0 (92)
Lease asset (778) (1,015)
Intangibles (37,035) (43,543)
Other temporary differences (215) 0
Total deferred tax liabilities (39,685) (45,666)
Net deferred tax (liabilities) assets 8,427 4,523
Less: valuation allowance (22,471) (19,752)
Net deferred tax liabilities $ (14,044) $ (15,229)
XML 108 R87.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Federal    
Operating Loss Carryforwards [Line Items]    
Net operating losses $ 42,539 $ 75,142
Tax credits 387 387
State    
Operating Loss Carryforwards [Line Items]    
Net operating losses 25,383 64,984
Tax credits 88 121
Foreign Tax Jurisdiction | Hong Kong    
Operating Loss Carryforwards [Line Items]    
Net operating losses 0 375
Foreign Tax Jurisdiction | Vietnam    
Operating Loss Carryforwards [Line Items]    
Net operating losses $ 0 $ 1,929
XML 109 R88.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS - Subscription Agreement with PIPE Investors (Details) - Class A Ordinary Shares - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended
Nov. 30, 2023
Sep. 30, 2023
Nov. 30, 2023
Related Party Transaction [Line Items]      
Issued (in shares)   14,000,000  
Price per unit (in dollars per share)   $ 5.00  
Consideration received $ 2.0 $ 68.0 $ 70.0
XML 110 R89.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS - Indemnification Agreements (Details) - USD ($)
$ in Millions
12 Months Ended
Mar. 18, 2021
Dec. 31, 2024
Related Party    
Related Party Transaction [Line Items]    
Indemnification agreements payments   $ 4.6
Private Placement Warrants    
Related Party Transaction [Line Items]    
Warrant exercise period   30 days
Private Placement Warrants | Related Party    
Related Party Transaction [Line Items]    
Warrant exercise period 30 days  
XML 111 R90.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS - Registration Rights (Details) - Related Party
1 Months Ended
Aug. 31, 2022
shares
Class A Ordinary Shares  
Related Party Transaction [Line Items]  
Stock registered (in shares) 121,120,063
Class A Ordinary Shares | Private Placement Warrants  
Related Party Transaction [Line Items]  
Stock registered (in shares) 18,033,332
Class A Ordinary Shares | Forward Purchase Agreement  
Related Party Transaction [Line Items]  
Stock registered (in shares) 33,300,000
Class A Ordinary Shares | Private Placement  
Related Party Transaction [Line Items]  
Stock registered (in shares) 11,800,000
Class A Ordinary Shares | Obagi Merger  
Related Party Transaction [Line Items]  
Stock registered (in shares) 28,237,506
Class A Ordinary Shares | Milk Transaction  
Related Party Transaction [Line Items]  
Stock registered (in shares) 21,104,225
Class A Ordinary Shares | Sponsor  
Related Party Transaction [Line Items]  
Stock registered (in shares) 8,545,000
Class A Ordinary Shares | Investor Directors  
Related Party Transaction [Line Items]  
Stock registered (in shares) 80,000
Class A Ordinary Shares | Aaron Chatterley  
Related Party Transaction [Line Items]  
Stock registered (in shares) 20,000
Class B Ordinary Shares | Milk Transaction  
Related Party Transaction [Line Items]  
Stock registered (in shares) 21,104,225
XML 112 R91.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS - Transactions with Cedarwalk in Connection with the Business Combination (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Jul. 28, 2022
Related Party Transaction [Line Items]            
Net revenue $ 92,373 $ 92,373 $ 73,760 $ 273,868 $ 218,138  
Cost of goods sold 60,657     82,124 76,561  
Net product sales            
Related Party Transaction [Line Items]            
Net revenue $ 90,385 $ 90,385 $ 70,729 269,369 213,116  
Related Party            
Related Party Transaction [Line Items]            
Accounts receivable, net       792 1,101  
Cedarwalk | Waldencast plc | Related Party | Class A Ordinary Shares | Obagi China Business            
Related Party Transaction [Line Items]            
Ownership interest in fully diluted Class A ordinary shares (percent)           24.50%
Obagi China Business | Related Party            
Related Party Transaction [Line Items]            
Accounts receivable, net       800 1,100  
Transition services, initial term   12 months        
Transition services, optional extension term   12 months        
Obagi China Business | Related Party | Supply Commitment            
Related Party Transaction [Line Items]            
Net revenue   $ 17,000   2,800 5,600  
Cost of goods sold   5,100   800 1,700  
Obagi China Business | Related Party | Net product sales            
Related Party Transaction [Line Items]            
Net revenue   $ 200   $ 100 $ 300  
XML 113 R92.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS - MILK (Details) - Related Party - Milk Makeup - USD ($)
$ in Millions
5 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2024
Related Party Transaction [Line Items]    
Administrative expenses $ 0.1 $ 0.3
Influencer fees   $ 0.1
XML 114 R93.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
Skintrinsiq Devices  
Long-Term Purchase Commitment [Line Items]  
Initial commitment amount of purchase commitments $ 5.7
XML 115 R94.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING - Narrative (Details) - segment
12 Months Ended
Jul. 27, 2022
Dec. 31, 2024
Segment Reporting [Abstract]    
Number of operating segments 1 2
Number of reportable segments 1 2
XML 116 R95.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING - Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]          
Net revenue $ 92,373 $ 92,373 $ 73,760 $ 273,868 $ 218,138
Adjusted gross profit 34,354     203,553 150,415
Obagi          
Segment Reporting Information [Line Items]          
Net revenue 61,090   73,760 149,266 117,651
Adjusted cost of goods sold (45,611)   30,868 30,697 33,922
Adjusted gross profit 15,479   $ 42,892 118,569 83,729
Milk Makeup          
Segment Reporting Information [Line Items]          
Net revenue 31,283     124,602 100,487
Adjusted cost of goods sold (12,408)     39,618 33,801
Adjusted gross profit $ 18,875     $ 84,984 $ 66,686
XML 117 R96.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING - Reconciliation Of Consolidated Adjusted Gross Profit To Consolidated Net Loss Before And After Income Taxes (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting [Abstract]          
Adjusted gross profit $ 34,354     $ 203,553 $ 150,415
Amortization of the fair value of the related party liability   $ (12,186) $ 0 (2,260) (4,058)
Discontinued product write-off   0 0 2,864 0
Amortization of the inventory fair value adjustment   10,035 0 0 1,691
Amortization impact of intangible assets   4,789 0 11,205 11,205
Selling, general and administrative 90,722   58,155 245,297 223,508
Loss on impairment of goodwill 68,715   0 5,031 0
Interest expense, net 6,230   6,652 17,155 18,906
Change in fair value of derivative warrant liabilities (6,793)   0 (23,627) 10,337
Other (income) expense, net (798)   (971) (3,574) 1,769
Loss before income taxes $ (126,360) $ (126,360) $ (20,944) $ (48,538) $ (112,943)
XML 118 R97.htm IDEA: XBRL DOCUMENT v3.25.1
EMPLOYEE BENEFIT PLAN (Details) - USD ($)
$ in Millions
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Retirement Benefits [Abstract]        
Company 401(k) retirement plan contributions $ 0.3 $ 0.4 $ 1.3 $ 1.2
XML 119 R98.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS (Details) - USD ($)
$ in Millions
Mar. 18, 2025
Mar. 11, 2025
Mar. 12, 2027
Mar. 12, 2026
Mar. 12, 2025
Subsequent Event | Line of Credit | Secured Debt | 2025 Term Loan Facility          
Subsequent Event [Line Items]          
Debt term 5 years        
Maximum borrowing capacity $ 175.0        
Outstanding borrowings as of closing date 175.0        
Subsequent Event | Line of Credit | Revolving Credit Facility | 2025 Term Loan Facility          
Subsequent Event [Line Items]          
Maximum borrowing capacity 30.0        
Debt 15.0        
Remaining balance $ 15.0        
Subsequent Event | Stock options | Forecast          
Subsequent Event [Line Items]          
Number of shares available for grant (in shares)   11,500,000      
Award vesting period   5 years      
Share-Based Payment Arrangement, Tranche One | Subsequent Event | Stock options | Forecast          
Subsequent Event [Line Items]          
Vested and expected to vest (in shares)         5,730,000
Share-Based Payment Arrangement, Tranche Two | Stock options | Forecast          
Subsequent Event [Line Items]          
Vested and expected to vest (in shares)       5,730,000  
Share-Based Payment Arrangement, Tranche Three | Stock options | Forecast          
Subsequent Event [Line Items]          
Vested and expected to vest (in shares)     5,730,000    
XML 120 R99.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details) - USD ($)
$ / shares in Units, $ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:      
Cash and cash equivalents $ 14,802 $ 21,089  
Total current assets 103,622 107,327  
TOTAL ASSETS 975,860 1,042,710  
CURRENT LIABILITIES:      
Note payable 830 0  
Derivative warrant liabilities 5,021 28,647  
TOTAL LIABILITIES 245,923 273,437  
SHAREHOLDERS’ EQUITY:      
Additional paid-in capital 951,260 871,527  
Retained Earnings (Accumulated Deficit) (289,204) (246,761)  
Accumulated Other Comprehensive Income (Loss), Net of Tax 251 (151)  
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY 662,319 624,626  
Noncontrolling Interest 67,618 144,647  
TOTAL SHAREHOLDERS' EQUITY 729,937 769,273  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 975,860 $ 1,042,710  
Class A Ordinary Shares      
SHAREHOLDERS’ EQUITY:      
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001  
Common shares authorized (in shares) 1,000,000,000 1,000,000,000  
Common shares outstanding (in shares)   101,228,857  
Successor ordinary shares $ 11 $ 9  
Class B Ordinary Shares      
SHAREHOLDERS’ EQUITY:      
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001  
Common shares authorized (in shares) 100,000,000 100,000,000  
Common shares outstanding (in shares)   20,847,553  
Successor ordinary shares $ 1 $ 2  
Parent Company      
CURRENT ASSETS:      
Cash and cash equivalents 472 419  
Intercompany receivable 37,431 51,964  
Total current assets 37,903 52,383  
Investment in subsidiary 697,885 745,537  
TOTAL ASSETS 735,788 797,920  
CURRENT LIABILITIES:      
Derivative warrant liabilities 5,021 28,647  
TOTAL LIABILITIES 5,851 28,647  
SHAREHOLDERS’ EQUITY:      
Additional paid-in capital 951,260 871,527  
Retained Earnings (Accumulated Deficit) (289,204) (246,761)  
Accumulated Other Comprehensive Income (Loss), Net of Tax 251 (151)  
TOTAL CONTROLLING SHAREHOLDERS’ EQUITY 662,319 624,626  
Noncontrolling Interest 67,618 144,647  
TOTAL SHAREHOLDERS' EQUITY 729,937 769,273  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 735,788 $ 797,920  
Parent Company | Class A Ordinary Shares      
SHAREHOLDERS’ EQUITY:      
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001  
Common shares authorized (in shares) 1,000,000,000 1,000,000,000  
Common shares outstanding (in shares) 112,026,440 101,228,857  
Successor ordinary shares $ 11 $ 9  
Parent Company | Class B Ordinary Shares      
SHAREHOLDERS’ EQUITY:      
Common shares, par value (in dollars per share) $ 0.0001 $ 0.0001  
Common shares authorized (in shares) 100,000,000 100,000,000  
Common shares outstanding (in shares) 10,666,528   20,847,553
Successor ordinary shares $ 1 $ 2  
XML 121 R100.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
Condensed Income Statements, Captions [Line Items]          
Net revenue $ 92,373 $ 92,373 $ 73,760 $ 273,868 $ 218,138
Selling, general and administrative 90,722   58,155 245,297 223,508
Total operating loss (127,721)   (15,263) (58,584) (81,931)
Other expense (income):          
Change in fair value of derivative warrant liabilities   6,800   $ 23,600 (10,300)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]       Change in fair value of derivative warrant liabilities  
Loss before income taxes (126,360) (126,360) (20,944) $ (48,538) (112,943)
Income tax benefit 5,803 $ 5,803 (113) (110) 6,975
Net loss attributable to Class A shareholders (95,567)   (21,057) (42,443) (89,981)
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax (36)   96 450 (147)
Comprehensive loss attributable to Class A shareholders (95,596)   $ (20,961) (42,050) (90,103)
Parent Company          
Condensed Income Statements, Captions [Line Items]          
Net revenue 0     0 0
Selling, general and administrative 0     18,393 1,259
Total operating loss 0     (18,393) (1,259)
Other expense (income):          
Interest expense (income), net 19     24 (14)
Change in fair value of derivative warrant liabilities 6,793     (23,627) 10,337
Loss before income taxes 6,812     5,209 (11,582)
Income tax benefit 0     0 0
Income (loss) before equity in undistributed earnings of subsidiaries 6,812     5,209 (11,582)
Equity in undistributed earnings of subsidiaries (102,379)     (47,652) (78,399)
Net loss attributable to Class A shareholders (95,567)     (42,443) (89,981)
Other comprehensive income (loss) — foreign currency translation adjustments, net of tax (29)     393 (122)
Comprehensive loss attributable to Class A shareholders $ (95,596)     $ (42,050) $ (90,103)
XML 122 R101.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details) - USD ($)
$ in Thousands
5 Months Ended 7 Months Ended 12 Months Ended
Dec. 31, 2022
Jul. 27, 2022
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net Income (Loss) $ (95,567) $ (21,057) $ (42,443) $ (89,981)
Cash (used in) provided by operating activities:        
Change in fair value of derivative warrant liabilities (6,793) 0 (23,627) 10,337
Net cash used in operating activities (74,977) (10,037) (8,820) (29,775)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Proceeds from trust 44,883 0 0 0
Net cash used in investing activities (544,367) (909) (2,920) (1,994)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from PIPE investments 118,000 0 0 70,000
Payment of PIPE transaction costs 0 0 0 (1,068)
Proceeds from Notes Payable 0   1,632 0
Repayment of note payable 0   (1,770) 0
Tax refund (withholding) 0 0 0 (1,204)
Net cash provided by financing activities 629,465 3,883 5,582 44,329
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 10,121 (7,063) (6,158) 12,560
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period 78 13,444 22,576 10,163
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period 10,163 $ 6,477 16,302 22,576
Parent Company        
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net Income (Loss) (95,567)   (42,443) (89,981)
Cash (used in) provided by operating activities:        
Equity in income of subsidiaries 102,379   47,652 78,399
Change in fair value of derivative warrant liabilities (6,793)   (23,627) 10,337
Net cash used in operating activities 19   (18,417) (1,245)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Proceeds from trust 6,400   0 0
Net cash used in investing activities 6,400   0 0
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from PIPE investments 0   0 70,000
Payment of PIPE transaction costs 0   0 (1,069)
Tax refund (withholding) 0   558 (1,204)
Transfers from subsidiaries 6,000   32,750 30,575
Transfers to subsidiaries (300)   0 (66,250)
Expenses paid on behalf of subsidiaries (8,982)   (14,700) (33,603)
Net cash provided by financing activities (3,282)   18,470 (1,551)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 3,137   53 (2,796)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period 78   419 3,215
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period $ 3,215   $ 472 $ 419
EXCEL 123 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 125 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 127 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 450 539 1 false 129 0 false 10 false false R1.htm 0000001 - Document - COVER Sheet http://www.waldencast.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.waldencast.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 9952151 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 5 false false R6.htm 9952154 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 9952158 - Disclosure - BUSINESS COMBINATIONS Sheet http://www.waldencast.com/role/BUSINESSCOMBINATIONS BUSINESS COMBINATIONS Notes 10 false false R11.htm 9952159 - Disclosure - REVENUE Sheet http://www.waldencast.com/role/REVENUE REVENUE Notes 11 false false R12.htm 9952160 - Disclosure - GOODWILL Sheet http://www.waldencast.com/role/GOODWILL GOODWILL Notes 12 false false R13.htm 9952161 - Disclosure - INTANGIBLE ASSETS???NET Sheet http://www.waldencast.com/role/INTANGIBLEASSETSNET INTANGIBLE ASSETS???NET Notes 13 false false R14.htm 9952162 - Disclosure - DEBT Sheet http://www.waldencast.com/role/DEBT DEBT Notes 14 false false R15.htm 9952163 - Disclosure - LEASES Sheet http://www.waldencast.com/role/LEASES LEASES Notes 15 false false R16.htm 9952164 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://www.waldencast.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 16 false false R17.htm 9952165 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 17 false false R18.htm 9952166 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES SUPPLEMENTAL BALANCE SHEET DISCLOSURES Notes 18 false false R19.htm 9952167 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.waldencast.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 19 false false R20.htm 9952168 - Disclosure - SHAREHOLDERS??? EQUITY Sheet http://www.waldencast.com/role/SHAREHOLDERSEQUITY SHAREHOLDERS??? EQUITY Notes 20 false false R21.htm 9952169 - Disclosure - NET LOSS PER SHARE Sheet http://www.waldencast.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 21 false false R22.htm 9952170 - Disclosure - INCOME TAX BENEFIT Sheet http://www.waldencast.com/role/INCOMETAXBENEFIT INCOME TAX BENEFIT Notes 22 false false R23.htm 9952171 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 23 false false R24.htm 9952172 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 9952173 - Disclosure - SEGMENT REPORTING Sheet http://www.waldencast.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 25 false false R26.htm 9952174 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 26 false false R27.htm 9952175 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.waldencast.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 27 false false R28.htm 9952176 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) Sheet http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) Notes 28 false false R29.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 29 false false R30.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 30 false false R31.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 31 false false R32.htm 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 32 false false R33.htm 9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 33 false false R34.htm 9955513 - Disclosure - BUSINESS COMBINATIONS (Tables) Sheet http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables BUSINESS COMBINATIONS (Tables) Tables http://www.waldencast.com/role/BUSINESSCOMBINATIONS 34 false false R35.htm 9955514 - Disclosure - REVENUE (Tables) Sheet http://www.waldencast.com/role/REVENUETables REVENUE (Tables) Tables http://www.waldencast.com/role/REVENUE 35 false false R36.htm 9955515 - Disclosure - GOODWILL (Tables) Sheet http://www.waldencast.com/role/GOODWILLTables GOODWILL (Tables) Tables http://www.waldencast.com/role/GOODWILL 36 false false R37.htm 9955516 - Disclosure - INTANGIBLE ASSETS???NET (Tables) Sheet http://www.waldencast.com/role/INTANGIBLEASSETSNETTables INTANGIBLE ASSETS???NET (Tables) Tables http://www.waldencast.com/role/INTANGIBLEASSETSNET 37 false false R38.htm 9955517 - Disclosure - DEBT (Tables) Sheet http://www.waldencast.com/role/DEBTTables DEBT (Tables) Tables http://www.waldencast.com/role/DEBT 38 false false R39.htm 9955518 - Disclosure - LEASES (Tables) Sheet http://www.waldencast.com/role/LEASESTables LEASES (Tables) Tables http://www.waldencast.com/role/LEASES 39 false false R40.htm 9955519 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS 40 false false R41.htm 9955520 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables) Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables) Tables http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES 41 false false R42.htm 9955521 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.waldencast.com/role/STOCKBASEDCOMPENSATION 42 false false R43.htm 9955522 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.waldencast.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.waldencast.com/role/NETLOSSPERSHARE 43 false false R44.htm 9955523 - Disclosure - INCOME TAX BENEFIT (Tables) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITTables INCOME TAX BENEFIT (Tables) Tables http://www.waldencast.com/role/INCOMETAXBENEFIT 44 false false R45.htm 9955524 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://www.waldencast.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://www.waldencast.com/role/SEGMENTREPORTING 45 false false R46.htm 9955525 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables) Sheet http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables) Tables http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY 46 false false R47.htm 9955526 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Sheet http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Details http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS 47 false false R48.htm 9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 48 false false R49.htm 9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details) Sheet http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details) Details 49 false false R50.htm 9955529 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details) Sheet http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails BUSINESS COMBINATIONS - Narrative (Details) Details 50 false false R51.htm 9955530 - Disclosure - BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details) Sheet http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details) Details 51 false false R52.htm 9955531 - Disclosure - BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details) Sheet http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details) Details 52 false false R53.htm 9955532 - Disclosure - BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details) Sheet http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details) Details 53 false false R54.htm 9955533 - Disclosure - REVENUE - Revenue by Sales Channel (Details) Sheet http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails REVENUE - Revenue by Sales Channel (Details) Details 54 false false R55.htm 9955534 - Disclosure - REVENUE - Narrative (Details) Sheet http://www.waldencast.com/role/REVENUENarrativeDetails REVENUE - Narrative (Details) Details 55 false false R56.htm 9955535 - Disclosure - REVENUE - Revenue by Geographic Region (Details) Sheet http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails REVENUE - Revenue by Geographic Region (Details) Details 56 false false R57.htm 9955536 - Disclosure - GOODWILL - Schedule of Goodwill (Details) Sheet http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails GOODWILL - Schedule of Goodwill (Details) Details 57 false false R58.htm 9955537 - Disclosure - GOODWILL - Narrative (Details) Sheet http://www.waldencast.com/role/GOODWILLNarrativeDetails GOODWILL - Narrative (Details) Details 58 false false R59.htm 9955538 - Disclosure - INTANGIBLE ASSETS???NET - Schedule of Intangible Assets (Details) Sheet http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails INTANGIBLE ASSETS???NET - Schedule of Intangible Assets (Details) Details 59 false false R60.htm 9955539 - Disclosure - INTANGIBLE ASSETS???NET - Narrative (Details) Sheet http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails INTANGIBLE ASSETS???NET - Narrative (Details) Details 60 false false R61.htm 9955540 - Disclosure - INTANGIBLE ASSETS???NET - Expected Amortization (Details) Sheet http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails INTANGIBLE ASSETS???NET - Expected Amortization (Details) Details 61 false false R62.htm 9955541 - Disclosure - DEBT - Summary of Debt (Details) Sheet http://www.waldencast.com/role/DEBTSummaryofDebtDetails DEBT - Summary of Debt (Details) Details 62 false false R63.htm 9955542 - Disclosure - DEBT - Narrative (Details) Sheet http://www.waldencast.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 63 false false R64.htm 9955543 - Disclosure - DEBT - Scheduled Maturities (Details) Sheet http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails DEBT - Scheduled Maturities (Details) Details 64 false false R65.htm 9955544 - Disclosure - LEASES - Narrative (Details) Sheet http://www.waldencast.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 65 false false R66.htm 9955545 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 66 false false R67.htm 9955546 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details) Sheet http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails LEASES - Operating Lease Maturity Schedule (Details) Details 67 false false R68.htm 9955547 - Disclosure - FINANCIAL INSTRUMENTS (Details) Sheet http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails FINANCIAL INSTRUMENTS (Details) Details http://www.waldencast.com/role/FINANCIALINSTRUMENTS 68 false false R69.htm 9955548 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables 69 false false R70.htm 9955549 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details) Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details) Details 70 false false R71.htm 9955550 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details) Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details) Details 71 false false R72.htm 9955551 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details) Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details) Details 72 false false R73.htm 9955552 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details) Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details) Details 73 false false R74.htm 9955553 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details) Sheet http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details) Details 74 false false R75.htm 9955554 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 75 false false R76.htm 9955555 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details) Sheet http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails STOCK-BASED COMPENSATION - Stock Option Activity (Details) Details 76 false false R77.htm 9955556 - Disclosure - STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details) Sheet http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details) Details 77 false false R78.htm 9955557 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) Sheet http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) Details 78 false false R79.htm 9955558 - Disclosure - SHAREHOLDERS??? EQUITY (Details) Sheet http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails SHAREHOLDERS??? EQUITY (Details) Details http://www.waldencast.com/role/SHAREHOLDERSEQUITY 79 false false R80.htm 9955559 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details) Sheet http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details) Details 80 false false R81.htm 9955560 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 81 false false R82.htm 9955561 - Disclosure - INCOME TAX BENEFIT - Narrative (Details) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails INCOME TAX BENEFIT - Narrative (Details) Details 82 false false R83.htm 9955562 - Disclosure - INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details) Details 83 false false R84.htm 9955563 - Disclosure - INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details) Details 84 false false R85.htm 9955564 - Disclosure - INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details) Details 85 false false R86.htm 9955565 - Disclosure - INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details) Details 86 false false R87.htm 9955566 - Disclosure - INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details) Sheet http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details) Details 87 false false R88.htm 9955567 - Disclosure - RELATED PARTY TRANSACTIONS - Subscription Agreement with PIPE Investors (Details) Sheet http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails RELATED PARTY TRANSACTIONS - Subscription Agreement with PIPE Investors (Details) Details 88 false false R89.htm 9955568 - Disclosure - RELATED PARTY TRANSACTIONS - Indemnification Agreements (Details) Sheet http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails RELATED PARTY TRANSACTIONS - Indemnification Agreements (Details) Details 89 false false R90.htm 9955569 - Disclosure - RELATED PARTY TRANSACTIONS - Registration Rights (Details) Sheet http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails RELATED PARTY TRANSACTIONS - Registration Rights (Details) Details 90 false false R91.htm 9955570 - Disclosure - RELATED PARTY TRANSACTIONS - Transactions with Cedarwalk in Connection with the Business Combination (Details) Sheet http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails RELATED PARTY TRANSACTIONS - Transactions with Cedarwalk in Connection with the Business Combination (Details) Details 91 false false R92.htm 9955571 - Disclosure - RELATED PARTY TRANSACTIONS - MILK (Details) Sheet http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails RELATED PARTY TRANSACTIONS - MILK (Details) Details 92 false false R93.htm 9955572 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES 93 false false R94.htm 9955573 - Disclosure - SEGMENT REPORTING - Narrative (Details) Sheet http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails SEGMENT REPORTING - Narrative (Details) Details 94 false false R95.htm 9955574 - Disclosure - SEGMENT REPORTING - Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit (Details) Sheet http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails SEGMENT REPORTING - Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit (Details) Details 95 false false R96.htm 9955575 - Disclosure - SEGMENT REPORTING - Reconciliation Of Consolidated Adjusted Gross Profit To Consolidated Net Loss Before And After Income Taxes (Details) Sheet http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails SEGMENT REPORTING - Reconciliation Of Consolidated Adjusted Gross Profit To Consolidated Net Loss Before And After Income Taxes (Details) Details 96 false false R97.htm 9955576 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) Sheet http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails EMPLOYEE BENEFIT PLAN (Details) Details http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN 97 false false R98.htm 9955577 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.waldencast.com/role/SUBSEQUENTEVENTS 98 false false R99.htm 9955578 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details) Sheet http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details) Details http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables 99 false false R100.htm 9955579 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details) Sheet http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details) Details http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables 100 false false R101.htm 9955580 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details) Sheet http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details) Details http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables 101 false false All Reports Book All Reports wald-20241231.htm wald-20241231.xsd wald-20241231_cal.xml wald-20241231_def.xml wald-20241231_lab.xml wald-20241231_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 130 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "wald-20241231.htm": { "nsprefix": "wald", "nsuri": "http://www.waldencast.com/20241231", "dts": { "inline": { "local": [ "wald-20241231.htm" ] }, "schema": { "local": [ "wald-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "wald-20241231_cal.xml" ] }, "definitionLink": { "local": [ "wald-20241231_def.xml" ] }, "labelLink": { "local": [ "wald-20241231_lab.xml" ] }, "presentationLink": { "local": [ "wald-20241231_pre.xml" ] } }, "keyStandard": 455, "keyCustom": 84, "axisStandard": 44, "axisCustom": 1, "memberStandard": 64, "memberCustom": 59, "hidden": { "total": 14, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 4, "http://www.waldencast.com/20241231": 5 }, "contextCount": 450, "entityCount": 1, "segmentCount": 129, "elementCount": 970, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1502, "http://xbrl.sec.gov/dei/2024": 50, "http://xbrl.sec.gov/cyd/2024": 15, "http://fasb.org/srt/2024": 3, "http://xbrl.sec.gov/ecd/2024": 2 }, "report": { "R1": { "role": "http://www.waldencast.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.waldencast.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R4": { "role": "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R6": { "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R8": { "role": "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS", "longName": "9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONS", "longName": "9952158 - Disclosure - BUSINESS COMBINATIONS", "shortName": "BUSINESS COMBINATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.waldencast.com/role/REVENUE", "longName": "9952159 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.waldencast.com/role/GOODWILL", "longName": "9952160 - Disclosure - GOODWILL", "shortName": "GOODWILL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNET", "longName": "9952161 - Disclosure - INTANGIBLE ASSETS\u2014NET", "shortName": "INTANGIBLE ASSETS\u2014NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.waldencast.com/role/DEBT", "longName": "9952162 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.waldencast.com/role/LEASES", "longName": "9952163 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.waldencast.com/role/FINANCIALINSTRUMENTS", "longName": "9952164 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952165 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES", "longName": "9952166 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATION", "longName": "9952167 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.waldencast.com/role/SHAREHOLDERSEQUITY", "longName": "9952168 - Disclosure - SHAREHOLDERS\u2019 EQUITY", "shortName": "SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.waldencast.com/role/NETLOSSPERSHARE", "longName": "9952169 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFIT", "longName": "9952170 - Disclosure - INCOME TAX BENEFIT", "shortName": "INCOME TAX BENEFIT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952171 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952172 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.waldencast.com/role/SEGMENTREPORTING", "longName": "9952173 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN", "longName": "9952174 - Disclosure - EMPLOYEE BENEFIT PLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.waldencast.com/role/SUBSEQUENTEVENTS", "longName": "9952175 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY", "longName": "9952176 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)", "shortName": "CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables", "longName": "9955513 - Disclosure - BUSINESS COMBINATIONS (Tables)", "shortName": "BUSINESS COMBINATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.waldencast.com/role/REVENUETables", "longName": "9955514 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.waldencast.com/role/GOODWILLTables", "longName": "9955515 - Disclosure - GOODWILL (Tables)", "shortName": "GOODWILL (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETTables", "longName": "9955516 - Disclosure - INTANGIBLE ASSETS\u2014NET (Tables)", "shortName": "INTANGIBLE ASSETS\u2014NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.waldencast.com/role/DEBTTables", "longName": "9955517 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.waldencast.com/role/LEASESTables", "longName": "9955518 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9955519 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables", "longName": "9955520 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9955521 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.waldencast.com/role/NETLOSSPERSHARETables", "longName": "9955522 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITTables", "longName": "9955523 - Disclosure - INCOME TAX BENEFIT (Tables)", "shortName": "INCOME TAX BENEFIT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.waldencast.com/role/SEGMENTREPORTINGTables", "longName": "9955524 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables", "longName": "9955525 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)", "shortName": "CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "longName": "9955526 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wald:RecognitionPeriodForDeferredAdvertisingCostsMaximum", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "wald:PrepaidExpensesPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R49": { "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "longName": "9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-113", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "longName": "9955529 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details)", "shortName": "BUSINESS COMBINATIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "us-gaap:OtherNonoperatingIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R51": { "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "longName": "9955530 - Disclosure - BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)", "shortName": "BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R52": { "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "longName": "9955531 - Disclosure - BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)", "shortName": "BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-138", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-147", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R53": { "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails", "longName": "9955532 - Disclosure - BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)", "shortName": "BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-162", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-162", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails", "longName": "9955533 - Disclosure - REVENUE - Revenue by Sales Channel (Details)", "shortName": "REVENUE - Revenue by Sales Channel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R55": { "role": "http://www.waldencast.com/role/REVENUENarrativeDetails", "longName": "9955534 - Disclosure - REVENUE - Narrative (Details)", "shortName": "REVENUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R56": { "role": "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "longName": "9955535 - Disclosure - REVENUE - Revenue by Geographic Region (Details)", "shortName": "REVENUE - Revenue by Geographic Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R57": { "role": "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails", "longName": "9955536 - Disclosure - GOODWILL - Schedule of Goodwill (Details)", "shortName": "GOODWILL - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-176", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R58": { "role": "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "longName": "9955537 - Disclosure - GOODWILL - Narrative (Details)", "shortName": "GOODWILL - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails", "longName": "9955538 - Disclosure - INTANGIBLE ASSETS\u2014NET - Schedule of Intangible Assets (Details)", "shortName": "INTANGIBLE ASSETS\u2014NET - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails", "longName": "9955539 - Disclosure - INTANGIBLE ASSETS\u2014NET - Narrative (Details)", "shortName": "INTANGIBLE ASSETS\u2014NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails", "longName": "9955540 - Disclosure - INTANGIBLE ASSETS\u2014NET - Expected Amortization (Details)", "shortName": "INTANGIBLE ASSETS\u2014NET - Expected Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "longName": "9955541 - Disclosure - DEBT - Summary of Debt (Details)", "shortName": "DEBT - Summary of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R63": { "role": "http://www.waldencast.com/role/DEBTNarrativeDetails", "longName": "9955542 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-271", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtInstrumentIncreaseAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R64": { "role": "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails", "longName": "9955543 - Disclosure - DEBT - Scheduled Maturities (Details)", "shortName": "DEBT - Scheduled Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-275", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-275", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.waldencast.com/role/LEASESNarrativeDetails", "longName": "9955544 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-7", "name": "wald:LesseeOperatingLeaseExtensionTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "wald:LesseeOperatingLeaseExtensionTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails", "longName": "9955545 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-93", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R67": { "role": "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails", "longName": "9955546 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details)", "shortName": "LEASES - Operating Lease Maturity Schedule (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "longName": "9955547 - Disclosure - FINANCIAL INSTRUMENTS (Details)", "shortName": "FINANCIAL INSTRUMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails", "longName": "9955548 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-302", "name": "us-gaap:DerivativeLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-302", "name": "us-gaap:DerivativeLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "longName": "9955549 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails", "longName": "9955550 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-321", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R72": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails", "longName": "9955551 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryWorkInProcess", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:InventoryWorkInProcess", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails", "longName": "9955552 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails", "longName": "9955553 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)", "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9955554 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-347", "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-347", "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails", "longName": "9955555 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R77": { "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "longName": "9955556 - Disclosure - STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)", "shortName": "STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-97", "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "longName": "9955557 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-344", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-349", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R79": { "role": "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails", "longName": "9955558 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details)", "shortName": "SHAREHOLDERS\u2019 EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R80": { "role": "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails", "longName": "9955559 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)", "shortName": "NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R81": { "role": "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9955560 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "longName": "9955561 - Disclosure - INCOME TAX BENEFIT - Narrative (Details)", "shortName": "INCOME TAX BENEFIT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-394", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R83": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails", "longName": "9955562 - Disclosure - INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)", "shortName": "INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails", "longName": "9955563 - Disclosure - INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)", "shortName": "INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails", "longName": "9955564 - Disclosure - INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)", "shortName": "INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R86": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails", "longName": "9955565 - Disclosure - INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)", "shortName": "INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-7", "name": "wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails", "longName": "9955566 - Disclosure - INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)", "shortName": "INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-396", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-396", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails", "longName": "9955567 - Disclosure - RELATED PARTY TRANSACTIONS - Subscription Agreement with PIPE Investors (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Subscription Agreement with PIPE Investors (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-404", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": null }, "R89": { "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "longName": "9955568 - Disclosure - RELATED PARTY TRANSACTIONS - Indemnification Agreements (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Indemnification Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-409", "name": "wald:IndemnificationAgreementsPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-409", "name": "wald:IndemnificationAgreementsPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "longName": "9955569 - Disclosure - RELATED PARTY TRANSACTIONS - Registration Rights (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Registration Rights (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-410", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-410", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "longName": "9955570 - Disclosure - RELATED PARTY TRANSACTIONS - Transactions with Cedarwalk in Connection with the Business Combination (Details)", "shortName": "RELATED PARTY TRANSACTIONS - Transactions with Cedarwalk in Connection with the Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-426", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R92": { "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "longName": "9955571 - Disclosure - RELATED PARTY TRANSACTIONS - MILK (Details)", "shortName": "RELATED PARTY TRANSACTIONS - MILK (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-430", "name": "us-gaap:AdministrativeFeesExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-430", "name": "us-gaap:AdministrativeFeesExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9955572 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-431", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-431", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails", "longName": "9955573 - Disclosure - SEGMENT REPORTING - Narrative (Details)", "shortName": "SEGMENT REPORTING - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": null }, "R95": { "role": "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails", "longName": "9955574 - Disclosure - SEGMENT REPORTING - Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit (Details)", "shortName": "SEGMENT REPORTING - Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "wald:TotalGrossMarginAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R96": { "role": "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails", "longName": "9955575 - Disclosure - SEGMENT REPORTING - Reconciliation Of Consolidated Adjusted Gross Profit To Consolidated Net Loss Before And After Income Taxes (Details)", "shortName": "SEGMENT REPORTING - Reconciliation Of Consolidated Adjusted Gross Profit To Consolidated Net Loss Before And After Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-18", "name": "wald:AdjustedGrossProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "wald:AmortizationOfTheFairValueOfTheRelatedPartyLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R97": { "role": "http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails", "longName": "9955576 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)", "shortName": "EMPLOYEE BENEFIT PLAN (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails", "longName": "9955577 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-438", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-438", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "longName": "9955578 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)", "shortName": "CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:NotesPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R100": { "role": "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "longName": "9955579 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)", "shortName": "CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-448", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } }, "R101": { "role": "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "longName": "9955580 - Disclosure - CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)", "shortName": "CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-18", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-18", "name": "wald:ProceedsFromNotePayableAdjusted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wald-20241231.htm", "unique": true } } }, "tag": { "wald_A2022CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "A2022CreditAgreementMember", "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Credit Agreement", "label": "2022 Credit Agreement [Member]", "documentation": "2022 Credit Agreement" } } }, "auth_ref": [] }, "wald_A2022IncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "A2022IncentiveAwardPlanMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Incentive Award Plan", "label": "2022 Incentive Award Plan [Member]", "documentation": "2022 Incentive Award Plan" } } }, "auth_ref": [] }, "wald_A2022RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "A2022RevolvingCreditFacilityMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Revolving Credit Facility", "label": "2022 Revolving Credit Facility [Member]", "documentation": "2022 Revolving Credit Facility" } } }, "auth_ref": [] }, "wald_A2022TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "A2022TermLoanMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Term Loan", "label": "2022 Term Loan [Member]", "documentation": "2022 Term Loan" } } }, "auth_ref": [] }, "wald_A2025TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "A2025TermLoanMember", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025 Term Loan Facility", "label": "2025 Term Loan [Member]", "documentation": "2025 Term Loan" } } }, "auth_ref": [] }, "wald_AaronChatterleyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AaronChatterleyMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aaron Chatterley", "label": "Aaron Chatterley [Member]", "documentation": "Aaron Chatterley" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r394", "r1313" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r104", "r1099" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r106" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Allowance for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1320" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, before allowance for doubtful accounts", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r265", "r394", "r1033" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1310" ] }, "wald_AccruedDistributionFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AccruedDistributionFeesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued distribution fees", "label": "Accrued Distribution Fees, Current", "documentation": "Accrued Distribution Fees, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r107" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries and related expenses", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r107", "r1035" ] }, "wald_AccruedSalesReturnsAndDamagesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AccruedSalesReturnsAndDamagesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued sales returns and damages", "label": "Accrued Sales Returns And Damages, Current", "documentation": "Accrued Sales Returns And Damages, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r51", "r255", "r846" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "verboseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r20", "r21", "r129", "r266", "r840", "r883", "r884" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r14", "r21", "r688", "r691", "r745", "r879", "r880", "r1279", "r1280", "r1281", "r1297", "r1298", "r1299", "r1301" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r463", "r464", "r465", "r467", "r1027" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Useful Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r465", "r1027" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1179" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r120", "r1099", "r1478" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r900", "r1297", "r1298", "r1299", "r1301", "r1406", "r1480" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1192" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1192" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1192" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1192" ] }, "wald_AdjustedGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AdjustedGrossProfitLoss", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted gross profit", "label": "Adjusted Gross Profit Loss", "documentation": "Adjusted Gross Profit Loss" } } }, "auth_ref": [] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r10" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distribution to pay withholding taxes", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock compensation expense", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r63", "r64", "r582" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fees paid in connection with the PIPE", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r15", "r161" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "terseLabel": "Adjustments to reconcile net loss to net cash", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdministrativeFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdministrativeFeesExpense", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administrative expenses", "label": "Administrative Fees Expense", "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost." } } }, "auth_ref": [ "r98", "r950", "r1479" ] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r201" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r623", "r1082" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1237" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1150", "r1161", "r1171", "r1204" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1153", "r1164", "r1174", "r1207" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1238" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1192" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1199" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1199", "r1208", "r1212", "r1220" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1218" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r267", "r395", "r429" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-off of uncollectible accounts, net", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r433" ] }, "wald_AlternateBaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AlternateBaseRateMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alternate Base Rate", "label": "Alternate Base Rate [Member]", "documentation": "Alternate Base Rate" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r138", "r525", "r1286", "r1426" ] }, "wald_AmortizationOfIntangibleAssetsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AmortizationOfIntangibleAssetsAdjustment", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization impact of intangible assets", "label": "Amortization of Intangible Assets, Adjustment", "documentation": "Amortization of Intangible Assets, Adjustment" } } }, "auth_ref": [] }, "wald_AmortizationOfRelatedPartyLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AmortizationOfRelatedPartyLiability", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization and release of related party liability", "label": "Amortization Of Related Party Liability", "documentation": "Amortization Of Related Party Liability" } } }, "auth_ref": [] }, "wald_AmortizationOfTheFairValueOfTheRelatedPartyLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AmortizationOfTheFairValueOfTheRelatedPartyLiability", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "netLabel": "Amortization of the fair value of the related party liability", "label": "Amortization Of The Fair Value Of The Related Party Liability", "documentation": "Amortization Of The Fair Value Of The Related Party Liability" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r342" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r33" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r33" ] }, "wald_ApplicableRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ApplicableRateMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable Rate", "label": "Applicable Rate [Member]", "documentation": "Applicable Rate" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r463", "r464", "r465", "r466", "r467", "r1402" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r463", "r464", "r465", "r466", "r467", "r1402" ] }, "wald_AssetAcquisitionInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AssetAcquisitionInventory", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, inventory", "label": "Asset Acquisition, Inventory", "documentation": "Asset Acquisition, Inventory" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r181", "r193", "r259", "r303", "r347", "r355", "r380", "r384", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r680", "r685", "r718", "r835", "r943", "r1050", "r1051", "r1099", "r1128", "r1356", "r1357", "r1434" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r250", "r272", "r303", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r680", "r685", "r718", "r1099", "r1356", "r1357", "r1434" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "wald_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.waldencast.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1133", "r1134", "r1157" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.waldencast.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1133", "r1134", "r1157" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.waldencast.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1133", "r1134", "r1157" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1215" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1216" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1211" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1211" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1211" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1211" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1211" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1211" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r610", "r611", "r612", "r613" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1214" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1213" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1212" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1212" ] }, "wald_BailiwickOfJerseyAndTheCaymanIslandsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BailiwickOfJerseyAndTheCaymanIslandsMember", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bailiwick of Jersey and the Cayman Islands", "label": "Bailiwick of Jersey and the Cayman Islands [Member]", "documentation": "Bailiwick of Jersey and the Cayman Islands" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "wald_BeautyVenturesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BeautyVenturesLLCMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beauty Ventures LLC", "label": "Beauty Ventures LLC [Member]", "documentation": "Beauty Ventures LLC" } } }, "auth_ref": [] }, "wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BurwellMountainTrustAndZenoInvestmentMasterFundMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Burwell and Zeno", "label": "Burwell Mountain Trust and Zeno Investment Master Fund [Member]", "documentation": "Burwell Mountain Trust and Zeno Investment Master Fund" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r463", "r464", "r465", "r466", "r467", "r673", "r1076", "r1077" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r66", "r67", "r463", "r464", "r465", "r466", "r467", "r673", "r1076", "r1077" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r673" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Pro Forma Consolidated Financial Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1250", "r1251" ] }, "wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails": { "parentTag": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Pro forma net loss attributable to noncontrolling interest", "label": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest", "documentation": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest" } } }, "auth_ref": [] }, "wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BusinessAcquisitionProFormaNetIncomeLossAttributableToParent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails": { "parentTag": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma net loss attributable to Waldencast plc", "label": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent", "documentation": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Pro forma net loss", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r671", "r672" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma net revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r671", "r672" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r65" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total purchase consideration", "terseLabel": "Purchase consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r13" ] }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredAbstract", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Purchase Price:", "label": "Business Combination, Consideration Transferred [Abstract]" } } }, "auth_ref": [] }, "wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash repayment of debt", "label": "Business Combination, Consideration Transferred, Cash Repayments of Debt", "documentation": "Business Combination, Consideration Transferred, Cash Repayments of Debt" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity consideration", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r2", "r3" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Related party liability from merger", "terseLabel": "Related party liability", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r2", "r3", "r73", "r676" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS COMBINATIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r168", "r674" ] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of the inventory fair value adjustment", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r70" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of assets acquired:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Account receivable, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "verboseLabel": "Total Intangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r68", "r69" ] }, "wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities assumed:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities assumed:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r68", "r69" ] }, "wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r169", "r170", "r171", "r172" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r1134", "r1157" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CHINA", "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures in accounts payable and accruals", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r253", "r1031" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r28" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r28", "r180" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r143", "r299" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r143" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "wald_CedarwalkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CedarwalkMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cedarwalk", "label": "Cedarwalk [Member]", "documentation": "Cedarwalk" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1190" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1187" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1185" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/COVER", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r212", "r262", "r263", "r264", "r303", "r331", "r332", "r339", "r341", "r349", "r350", "r426", "r494", "r496", "r497", "r498", "r501", "r502", "r533", "r534", "r537", "r540", "r547", "r718", "r889", "r890", "r891", "r892", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r931", "r952", "r974", "r1003", "r1004", "r1005", "r1006", "r1007", "r1243", "r1289", "r1302" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r262", "r263", "r264", "r349", "r533", "r534", "r535", "r537", "r540", "r545", "r547", "r889", "r890", "r891", "r892", "r1065", "r1243", "r1289" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise period", "label": "Class of Warrant or Right, Exercise Period After Completion of Business Combination", "documentation": "Class of Warrant or Right, Exercise Period After Completion of Business Combination" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of warrants (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r548" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares called by each warrant (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption, period between end of trading and notice of redemption", "label": "Class of Warrant or Right, Period Between End of Trading and Notice of Redemption", "documentation": "Class of Warrant or Right, Period Between End of Trading and Notice of Redemption" } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption, number of trading days at or above trigger price", "label": "Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price", "documentation": "Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price" } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightRedemptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightRedemptionPeriod", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption period", "label": "Class of Warrant or Right, Redemption Period", "documentation": "Class of Warrant or Right, Redemption Period" } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightRedemptionPricePerShare", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption price (in dollars per share)", "label": "Class of Warrant or Right, Redemption Price Per Share", "documentation": "Class of Warrant or Right, Redemption Price Per Share" } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightRedemptionStockPriceTrigger", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption, stock price trigger (in dollars per share)", "label": "Class of Warrant or Right, Redemption, Stock Price Trigger", "documentation": "Class of Warrant or Right, Redemption, Stock Price Trigger" } } }, "auth_ref": [] }, "wald_ClassOfWarrantOrRightRedemptionTradingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ClassOfWarrantOrRightRedemptionTradingPeriod", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption, trading period", "label": "Class of Warrant or Right, Redemption, Trading Period", "documentation": "Class of Warrant or Right, Redemption, Trading Period" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1191" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1191" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 17)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r113", "r185", "r838", "r930" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r155", "r486", "r487", "r1012", "r1345", "r1350" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r52", "r1013" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/COVER", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Ordinary Shares", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1480" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/COVER", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Ordinary Shares", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1480" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r118" ] }, "wald_CommonStockConvertibleConversionRatio": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CommonStockConvertibleConversionRatio", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock conversion ratio (in shares)", "label": "Common Stock, Convertible, Conversion Ratio", "documentation": "Common Stock, Convertible, Conversion Ratio" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1118", "r1119", "r1120", "r1122", "r1123", "r1124", "r1125", "r1297", "r1298", "r1301", "r1406", "r1476", "r1480" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r118" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r118", "r931" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r118" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r118", "r931", "r949", "r1480", "r1481" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares", "netLabel": "Successor ordinary shares", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r118", "r839", "r1099" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [ "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, voting rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r57" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1196" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1195" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1197" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1194" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFIT PLAN", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r162", "r163", "r164", "r165" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Class A shareholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r22", "r276", "r278", "r285", "r830", "r854", "r856" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r8", "r78", "r82", "r276", "r278", "r284", "r829", "r854", "r855" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r82", "r176", "r276", "r278", "r283", "r828", "r854" ] }, "wald_ComputerHardwareSoftwareAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ComputerHardwareSoftwareAndEquipmentMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer hardware and software", "terseLabel": "Computer hardware, software and equipment", "label": "Computer Hardware, Software And Equipment [Member]", "documentation": "Computer Hardware, Software And Equipment" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r36", "r38", "r96", "r97", "r392", "r1011" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r36", "r38", "r96", "r97", "r392", "r886", "r1011" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r36", "r38", "r96", "r97", "r392", "r1011", "r1249" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r102", "r204" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r36", "r38", "r96", "r97", "r392" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r35", "r36", "r38", "r39", "r96", "r179", "r1011" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r36", "r38", "r96", "r97", "r392", "r1011" ] }, "srt_CondensedBalanceSheetStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedBalanceSheetStatementTable", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Balance Sheet Statement [Table]", "label": "Condensed Balance Sheet Statement [Table]", "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r213", "r311", "r1245" ] }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]", "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r311", "r1245" ] }, "srt_CondensedCashFlowStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedCashFlowStatementTable", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Cash Flow Statement [Table]", "label": "Condensed Cash Flow Statement [Table]", "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r213", "r311", "r1245" ] }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedCashFlowStatementsCaptionsLineItems", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]", "label": "Condensed Cash Flow Statements, Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r311", "r1245" ] }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY" ], "lang": { "en-us": { "role": { "terseLabel": "CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)", "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document." } } }, "auth_ref": [ "r311", "r1245" ] }, "srt_CondensedIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedIncomeStatementTable", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Income Statement [Table]", "label": "Condensed Income Statement [Table]", "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r213", "r311", "r1245" ] }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedIncomeStatementsCaptionsLineItems", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Income Statements, Captions [Line Items]", "label": "Condensed Income Statements, Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r311", "r1245" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r213", "r233", "r311", "r680", "r681", "r685", "r686", "r754", "r1018", "r1271", "r1272", "r1273", "r1355", "r1358", "r1359" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r213", "r233", "r311", "r680", "r681", "r685", "r686", "r754", "r1018", "r1271", "r1272", "r1273", "r1355", "r1358", "r1359" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r79", "r1040" ] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r200" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelAxis", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Sales Channel [Axis]", "label": "Contract with Customer, Sales Channel [Axis]", "documentation": "Information by sales channel for delivery of good or service in contract with customer." } } }, "auth_ref": [ "r1072", "r1362" ] }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelDomain", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Sales Channel [Domain]", "label": "Contract with Customer, Sales Channel [Domain]", "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary." } } }, "auth_ref": [ "r1072", "r1362" ] }, "wald_CorporateCreditCardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CorporateCreditCardsMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Credit Cards", "label": "Corporate Credit Cards [Member]", "documentation": "Corporate Credit Cards" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r132", "r133", "r792" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods Sold", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1255" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r240", "r241", "r308", "r309", "r507", "r535", "r752", "r774", "r834", "r1036", "r1038" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r493", "r1353" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r493", "r1353", "r1354" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1254", "r1292", "r1401" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1254", "r1292" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current provision (benefit), total", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r657", "r1292" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current provision (benefit):", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1254", "r1292", "r1401" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r150", "r392" ] }, "wald_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CustomerOneMember", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]", "documentation": "Customer One" } } }, "auth_ref": [] }, "wald_CustomerPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CustomerPaymentPeriod", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer payment period", "label": "Customer Payment Period", "documentation": "Customer Payment Period" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Customer/distributor relationships", "terseLabel": "Customer/distributor relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r72", "r1332", "r1333", "r1334", "r1335", "r1337", "r1339", "r1342", "r1343" ] }, "wald_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CustomerThreeMember", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Three", "label": "Customer Three [Member]", "documentation": "Customer Three" } } }, "auth_ref": [] }, "wald_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "CustomerTwoMember", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer Two" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1142", "r1231" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1142", "r1231" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1144", "r1233" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1144", "r1233" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1146", "r1235" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1144", "r1233" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1137", "r1226" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1138", "r1227" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1138", "r1227" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1136", "r1225" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1136", "r1225" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1136", "r1225" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1139", "r1228" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1141", "r1230" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1141", "r1230" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1142", "r1231" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1145", "r1234" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1143", "r1232" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1140", "r1229" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of promissory note to warrants", "label": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r30", "r32" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r156", "r301", "r479", "r480", "r481", "r482", "r483", "r492", "r493", "r503", "r509", "r510", "r511", "r512", "r513", "r514", "r519", "r526", "r527", "r529", "r727" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r18", "r106", "r107", "r182", "r184", "r311", "r504", "r505", "r506", "r507", "r508", "r510", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r1060", "r1061", "r1062", "r1063", "r1064", "r1097", "r1290", "r1346", "r1347", "r1348", "r1425", "r1427" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTSummaryofDebtDetails": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "totalLabel": "Total unpaid principal", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r18", "r184", "r530" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r504", "r727", "r728", "r1061", "r1062", "r1097" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r1290" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r109", "r505" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r311", "r504", "r505", "r506", "r507", "r508", "r510", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r1060", "r1061", "r1062", "r1063", "r1064", "r1097", "r1290", "r1425", "r1427" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r18", "r311", "r504", "r505", "r506", "r507", "r508", "r510", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r1060", "r1061", "r1062", "r1063", "r1064", "r1097", "r1290", "r1346", "r1347", "r1348", "r1425", "r1427" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly principal and interest payments", "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r18", "r101" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r18", "r57", "r60", "r100", "r159", "r160", "r311", "r504", "r505", "r506", "r507", "r508", "r510", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r1060", "r1061", "r1062", "r1063", "r1064", "r1097", "r1290", "r1425", "r1427" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTSummaryofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.waldencast.com/role/DEBTSummaryofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net carrying amount", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Issuance Costs", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1292", "r1400", "r1401" ] }, "us-gaap_DeferredFinanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsCurrentNet", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance cost, current", "label": "Debt Issuance Costs, Current, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1424", "r1425", "r1427" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/DEBTSummaryofDebtDetails": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "terseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1361", "r1424", "r1425", "r1427" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1292", "r1400" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "totalLabel": "Deferred (income) expense, total", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r10", "r209", "r1292" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred (income) expense:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r114", "r115", "r183", "r649" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r629", "r630", "r836" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1292", "r1400", "r1401" ] }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible interest carryover", "label": "Deferred Tax Asset, Interest Carryforward", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": [ "r1398" ] }, "wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxAssetsAccruedInterestToForeignRelatedParties", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest to foreign related parties", "label": "Deferred Tax Assets, Accrued Interest to Foreign Related Parties", "documentation": "Deferred Tax Assets, Accrued Interest to Foreign Related Parties" } } }, "auth_ref": [] }, "wald_DeferredTaxAssetsBelowMarketLeaseContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxAssetsBelowMarketLeaseContract", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market contract", "label": "Deferred Tax Assets, Below Market Lease Contract", "documentation": "Deferred Tax Assets, Below Market Lease Contract" } } }, "auth_ref": [] }, "wald_DeferredTaxAssetsFormationCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxAssetsFormationCosts", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Formation costs", "label": "Deferred Tax Assets, Formation Costs", "documentation": "Deferred Tax Assets, Formation Costs" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r650" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory reserve", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxAssetsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInvestments", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Waldencast LP", "label": "Deferred Tax Assets, Investments", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)." } } }, "auth_ref": [ "r1398" ] }, "wald_DeferredTaxAssetsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxAssetsLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Deferred Tax Assets, Lease Liabilities", "documentation": "Deferred Tax Assets, Lease Liabilities" } } }, "auth_ref": [] }, "wald_DeferredTaxAssetsNetBeforeValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxAssetsNetBeforeValuationAllowance", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax (liabilities) assets", "label": "Deferred Tax Assets, Net, Before Valuation Allowance", "documentation": "Deferred Tax Assets, Net, Before Valuation Allowance" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other temporary differences", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1398" ] }, "wald_DeferredTaxAssetsPropertyPlantAndEquipmentNetOfFederalAndStateImpacts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentNetOfFederalAndStateImpacts", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed asset basis", "label": "Deferred Tax Assets, Property, Plant and Equipment, Net Of Federal And State Impacts", "documentation": "Deferred Tax Assets, Property, Plant and Equipment, Net Of Federal And State Impacts" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D tax credits", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "negatedTerseLabel": "Less: valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r651" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred tax liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1394" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill", "label": "Deferred Tax Liabilities, Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": [ "r74", "r75", "r1398" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intangibles", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lease asset", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r1398" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other temporary differences", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1398" ] }, "wald_DeferredTaxLiabilitiesPropertyPlantAndEquipmentNetOfFederalAndStateImpacts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipmentNetOfFederalAndStateImpacts", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fixed asset basis", "label": "Deferred Tax Liabilities, Property, Plant and Equipment, Net Of Federal And State Impacts", "documentation": "Deferred Tax Liabilities, Property, Plant and Equipment, Net Of Federal And State Impacts" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company 401(k) retirement plan contributions", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r577" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r50" ] }, "wald_DepreciationDepletionAndAmortizationOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DepreciationDepletionAndAmortizationOperatingActivities", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Operating Activities", "documentation": "Depreciation, Depletion and Amortization, Operating Activities" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r273", "r274", "r699", "r700", "r709", "r717", "r912", "r913", "r914", "r915", "r916", "r918", "r919", "r920", "r921", "r922", "r937", "r938", "r989", "r994", "r996", "r997", "r999", "r1000", "r1038", "r1087", "r1090", "r1120", "r1410", "r1411", "r1412", "r1477" ] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of derivative asset", "label": "Derivative Asset, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r273" ] }, "us-gaap_DerivativeCapInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCapInterestRate", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap (percent)", "label": "Derivative, Cap Interest Rate", "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r920", "r922", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r944", "r945", "r946", "r947", "r962", "r963", "r964", "r965", "r968", "r969", "r970", "r971", "r989", "r991", "r996", "r999", "r1118", "r1120", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1420", "r1421" ] }, "us-gaap_DerivativeFloorInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFloorInterestRate", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate floor (percent)", "label": "Derivative, Floor Interest Rate", "documentation": "Floor rate on an interest rate derivative such as an interest rate floor or collar. If market rates falls below the floor rate, a payment or receipt is triggered on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r87", "r89", "r91", "r178", "r920", "r922", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r944", "r945", "r946", "r947", "r962", "r963", "r964", "r965", "r968", "r969", "r970", "r971", "r989", "r991", "r996", "r999", "r1038", "r1118", "r1120", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1420", "r1421" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from change in fair value on derivative instruments", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r90", "r1253" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r273", "r274", "r699", "r700", "r709", "r717", "r912", "r913", "r914", "r915", "r918", "r919", "r920", "r921", "r922", "r944", "r946", "r947", "r991", "r992", "r994", "r996", "r997", "r999", "r1000", "r1038", "r1410", "r1411", "r1412", "r1477" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities", "label": "Derivative Liability, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r273" ] }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotionalAmount", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative notional value", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": [ "r990", "r993", "r995", "r998", "r1403", "r1404", "r1405" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r693" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r16", "r83", "r84", "r85", "r86", "r88", "r89", "r92", "r94", "r95", "r693" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r16", "r83", "r84", "r86", "r93", "r310", "r325" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r567", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r567", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r580", "r584", "r614", "r615", "r617", "r1079" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "wald_DistributionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DistributionOfBusiness", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distribution of Obagi China Business", "label": "Distribution of Business", "documentation": "Distribution of Business" } } }, "auth_ref": [] }, "wald_DistributionToShareholderForDispositionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "DistributionToShareholderForDispositionOfBusiness", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Obagi China Distribution to shareholder", "label": "Distribution To Shareholder For Disposition Of Business", "documentation": "Distribution To Shareholder For Disposition Of Business" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r1134" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1133", "r1134", "r1157" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1133", "r1134", "r1157", "r1200" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r1129" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r1134" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1178" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r633" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1189" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to Class A shareholders (Note 14):", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "terseLabel": "Basic net loss per share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r286", "r317", "r318", "r319", "r320", "r321", "r322", "r328", "r331", "r339", "r340", "r341", "r346", "r669", "r678", "r696", "r697", "r831", "r857", "r1042" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "terseLabel": "Diluted net loss per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r286", "r317", "r318", "r319", "r320", "r321", "r322", "r331", "r339", "r340", "r341", "r346", "r669", "r678", "r696", "r697", "r831", "r857", "r1042" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r33", "r34", "r343" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in computing net loss per share (Note 14):", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r327", "r342", "r344", "r345" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r719" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total income tax (benefit) expense", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r633", "r1084" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax rate", "verboseLabel": "Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r305", "r633", "r660", "r1084" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r638", "r1084", "r1293", "r1392" ] }, "wald_EffectiveIncomeTaxRateReconciliationEquityCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationEquityCompensationPercent", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Compensation", "label": "Effective Income Tax Rate Reconciliation, Equity Compensation, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Equity Compensation, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S./foreign tax rate differential", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r634", "r637", "r1084", "r1293", "r1392" ] }, "wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation [Line Items]", "label": "Effective Income Tax Rate Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r633", "r634", "r1084" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Noncontrolling interest", "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes." } } }, "auth_ref": [ "r1293", "r1392", "r1393" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent Items", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r639", "r640", "r1293", "r1392" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income tax benefit, net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r636", "r1084", "r1293", "r1392" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation [Table]", "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r633", "r634", "r1084" ] }, "wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction bonuses", "label": "Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent" } } }, "auth_ref": [] }, "wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationTransactionCostsPercent", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent" } } }, "auth_ref": [] }, "wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationTrueUpsPercent", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "True-Ups", "label": "Effective Income Tax Rate Reconciliation, True-Ups, Percent", "documentation": "Effective Income Tax Rate Reconciliation, True-Ups, Percent" } } }, "auth_ref": [] }, "wald_EffectiveIncomeTaxRateReconciliationWithholdingTaxPercent": { "xbrltype": "pureItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxPercent", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax", "label": "Effective Income Tax Rate Reconciliation, Withholding Tax, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Withholding Tax, Percent" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost, weighted average service period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r616" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock, unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1390" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options, unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1390" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1131" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1131" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1242" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1131" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1240" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1131" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1131" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1241" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1183" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1236" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1236" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1236" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY:", "verboseLabel": "SHAREHOLDERS\u2019 EQUITY:", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r246", "r280", "r281", "r282", "r312", "r313", "r314", "r316", "r321", "r323", "r325", "r348", "r427", "r428", "r477", "r549", "r658", "r659", "r666", "r667", "r668", "r670", "r677", "r678", "r687", "r688", "r689", "r690", "r691", "r692", "r695", "r720", "r721", "r722", "r723", "r724", "r725", "r729", "r732", "r745", "r852", "r879", "r880", "r881", "r900", "r974" ] }, "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of equity awards in business combination", "label": "Equity Issued in Business Combination, Fair Value Disclosure", "documentation": "Fair value of equity issued in a business combination." } } }, "auth_ref": [ "r699", "r700" ] }, "wald_EquityOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "EquityOutstandingPercentage", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity outstanding percentage", "label": "Equity Outstanding Percentage", "documentation": "Equity Outstanding Percentage" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1193" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1150", "r1161", "r1171", "r1204" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1147", "r1158", "r1168", "r1201" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1199" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of derivative warrant liabilities (Note 9)", "terseLabel": "Change in fair value of derivative warrant liabilities", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r10" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r699", "r700", "r709", "r1087" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r699", "r700", "r709", "r1087" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r517", "r570", "r571", "r572", "r573", "r574", "r575", "r698", "r700", "r701", "r702", "r703", "r708", "r709", "r711", "r761", "r762", "r763", "r1061", "r1062", "r1073", "r1074", "r1075", "r1087", "r1090" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r705", "r706", "r707", "r708", "r711", "r712", "r713", "r714", "r715", "r825", "r1087", "r1091" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r517", "r570", "r575", "r700", "r709", "r761", "r1073", "r1074", "r1075", "r1087" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r517", "r570", "r575", "r700", "r701", "r709", "r762", "r1061", "r1062", "r1073", "r1074", "r1075", "r1087" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r517", "r570", "r571", "r572", "r573", "r574", "r575", "r700", "r701", "r702", "r703", "r709", "r763", "r1061", "r1062", "r1073", "r1074", "r1075", "r1087", "r1090" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain (loss) from change in fair value of warrants", "terseLabel": "Change in fair value of derivative warrant liabilities", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r704", "r710" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r517", "r570", "r571", "r572", "r573", "r574", "r575", "r698", "r700", "r701", "r702", "r703", "r708", "r709", "r711", "r761", "r762", "r763", "r1061", "r1062", "r1073", "r1074", "r1075", "r1087", "r1090" ] }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)." } } }, "auth_ref": [ "r704", "r710" ] }, "us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList": { "xbrltype": "financialDesignationType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialDesignationPredecessorAndSuccessorFixedList", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial designation, predecessor and successor [Fixed List]", "label": "Financial Designation, Predecessor and Successor [Fixed List]", "documentation": "Indicates designation of financial information when substantially all business or separately identifiable line of business transfers from one entity to another entity. Acceptable values are \"Predecessor\" and \"Successor\"." } } }, "auth_ref": [ "r198" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r528", "r545", "r693", "r716", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r853", "r1057", "r1087", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1100", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1315", "r1316", "r1317", "r1318", "r1407", "r1410", "r1411", "r1412", "r1419", "r1422" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Useful Lives (Years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r257", "r445", "r468", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "documentation": "Disclosure of information about finite-lived intangible asset acquired in business combination." } } }, "auth_ref": [ "r49" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1340", "r1489" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r469", "r1027", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r469", "r1027", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r469", "r1027", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r469", "r1027", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r469", "r1027", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r462", "r463", "r464", "r465", "r467", "r468", "r470", "r471", "r793", "r794", "r1027" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r445", "r468", "r794", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462", "r468", "r470", "r471", "r474", "r793", "r1027", "r1059" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r462", "r463", "r464", "r465", "r467", "r468", "r470", "r471", "r1027" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r793", "r1339" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Jurisdiction", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r633", "r634" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1208" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1208" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1208" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1208" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1208" ] }, "wald_FormulationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "FormulationsMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Formulations", "terseLabel": "Formulations", "label": "Formulations [Member]", "documentation": "Formulations" } } }, "auth_ref": [] }, "wald_ForwardPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ForwardPurchaseAgreementMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Purchase Agreement", "label": "Forward Purchase Agreement [Member]", "documentation": "Forward Purchase Agreement" } } }, "auth_ref": [] }, "wald_FounderAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "FounderAwardsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Founder Awards", "label": "Founder Awards [Member]", "documentation": "Founder Awards" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1188" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED KINGDOM", "label": "UNITED KINGDOM" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued product write-off", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r684", "r1286" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss (gain) on disposal of equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r10" ] }, "wald_GeneralDepartmentOfTaxationVietnamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "GeneralDepartmentOfTaxationVietnamMember", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vietnam", "label": "General Department Of Taxation, Vietnam [Member]", "documentation": "General Department Of Taxation, Vietnam" } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r37", "r1011" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r256", "r447", "r826", "r1051", "r1058", "r1088", "r1099", "r1322", "r1329" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r446", "r460", "r1058" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r461", "r473", "r476" ] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/GOODWILL" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r446", "r449", "r459", "r1058" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on impairment of goodwill", "verboseLabel": "Loss on impairment of goodwill", "negatedLabel": "Impairment loss", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r10", "r448", "r454", "r460", "r1058", "r1088" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r1058" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Axis]", "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r581", "r583", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r610", "r611", "r612", "r613" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Domain]", "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r581", "r583", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r610", "r611", "r612", "r613" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r130", "r134", "r192", "r303", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r718", "r1044", "r1050", "r1304", "r1306", "r1307", "r1308", "r1309", "r1356" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1133", "r1134", "r1157" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r154" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r304", "r632" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "negatedLabel": "Pre-tax losses", "terseLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r131", "r188", "r192", "r832", "r848", "r1044", "r1050", "r1304", "r1306", "r1307", "r1308", "r1309" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r304", "r632" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before equity in undistributed earnings of subsidiaries", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r176", "r192", "r303", "r315", "r321", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r669", "r678", "r697", "r718", "r848", "r1044", "r1304", "r1306", "r1307", "r1308", "r1309", "r1356" ] }, "us-gaap_IncomeLossFromSubsidiariesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromSubsidiariesNetOfTax", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in undistributed earnings of subsidiaries", "negatedTerseLabel": "Equity in income of subsidiaries", "label": "Income (Loss) from Subsidiaries, Net of Tax", "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r298", "r633", "r634", "r645", "r654", "r1084", "r1397" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r298", "r633", "r634", "r645", "r654", "r1084", "r1397" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Axis]", "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r645", "r1397" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority, Name [Domain]", "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r645", "r1397" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFIT" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAX BENEFIT", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r305", "r625", "r633", "r641", "r642", "r643", "r647", "r653", "r661", "r663", "r664", "r665", "r894", "r1084" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense (benefit)", "totalLabel": "Net income tax (benefit) provision", "negatedNetLabel": "Income tax benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r197", "r210", "r324", "r325", "r347", "r363", "r384", "r631", "r633", "r662", "r858", "r1084" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r279", "r627", "r628", "r647", "r648", "r652", "r656", "r888" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r29", "r145", "r1287", "r1395", "r1396" ] }, "wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "IncreaseDecreaseInAccountsPayableExcludingRelatedParties", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Excluding Related Parties", "documentation": "Increase (Decrease) in Accounts Payable, Excluding Related Parties" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Related party accounts payable", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Related party accounts receivable", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDerivativeAssetsAndLiabilities", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivative warrant liabilities", "negatedTerseLabel": "Change in fair value of derivative warrant liabilities", "label": "Increase (Decrease) in Derivative Assets and Liabilities", "documentation": "The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [ "r1285" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of impact of business combinations:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1252", "r1285" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current assets and other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities and other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "wald_IndemnificationAgreementsPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "IndemnificationAgreementsPayments", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification agreements payments", "label": "Indemnification Agreements Payments", "documentation": "Indemnification Agreements Payments" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1199", "r1208", "r1212", "r1220" ] }, "wald_InfluencerFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "InfluencerFeesExpense", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Influencer fees", "label": "Influencer Fees Expense", "documentation": "Influencer Fees Expense" } } }, "auth_ref": [] }, "us-gaap_InlandRevenueHongKongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InlandRevenueHongKongMember", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hong Kong", "label": "Inland Revenue, Hong Kong [Member]", "documentation": "Designated tax department of the government of Hong Kong." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1218" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1135", "r1224" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1135", "r1224" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1135", "r1224" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNET" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS\u2014NET", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r461", "r472", "r475", "r1026", "r1027" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r462", "r1339", "r1341" ] }, "wald_IntercompanyReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "IntercompanyReceivables", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany receivable", "label": "Intercompany Receivables", "documentation": "Intercompany Receivables" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r359", "r1282" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense (income), net", "label": "Interest Income (Expense), Operating", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": [ "r827", "r1306" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r293", "r296", "r297" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r107" ] }, "wald_InterestRateCollarInitialFixedPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "InterestRateCollarInitialFixedPaymentMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Collar, Initial Fixed Payment", "label": "Interest Rate Collar, Initial Fixed Payment [Member]", "documentation": "Interest Rate Collar, Initial Fixed Payment" } } }, "auth_ref": [] }, "wald_InterestRateCollarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "InterestRateCollarMember", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate collar", "label": "Interest Rate Collar [Member]", "documentation": "Interest Rate Collar" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1277" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r269", "r1032", "r1099" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r199", "r252", "r268", "r440", "r441", "r442", "r791", "r1041" ] }, "wald_InventoryPurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "InventoryPurchasesMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory Purchases", "label": "Inventory Purchases [Member]", "documentation": "Inventory Purchases" } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1278" ] }, "wald_InvestmentInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "InvestmentInSubsidiary", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in subsidiary", "label": "Investment in Subsidiary", "documentation": "Investment in Subsidiary" } } }, "auth_ref": [] }, "wald_InvestorDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "InvestorDirectorsMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investor Directors", "label": "Investor Directors [Member]", "documentation": "Investor Directors" } } }, "auth_ref": [] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Leases, Rent Expense", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.waldencast.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow and Other Information Related to Leases", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1431" ] }, "wald_LeaseDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "LeaseDepositsMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Deposits", "label": "Lease Deposits [Member]", "documentation": "Lease Deposits" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r153", "r743" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LenderConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LenderConcentrationRiskMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Concentration Risk", "label": "Lender Concentration Risk [Member]", "documentation": "Reflects the percentage that borrowings or credit lines from one or more lenders is to a specified benchmark, such as total debt, segment debt. Risk is the materially adverse effects from loss of financing arrangements with a particular lender." } } }, "auth_ref": [ "r150" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r736", "r744" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r736", "r744" ] }, "wald_LesseeOperatingLeaseExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "LesseeOperatingLeaseExtensionTerm", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease extension term", "label": "Lessee, Operating Lease, Extension Term", "documentation": "Lessee, Operating Lease, Extension Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.waldencast.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1432" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r742" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease remaining term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r744", "r1430" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.waldencast.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r731" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r18", "r106", "r107", "r108", "r111", "r112", "r113", "r116", "r303", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r681", "r685", "r686", "r718", "r929", "r1043", "r1128", "r1356", "r1434", "r1435" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r124", "r187", "r843", "r1099", "r1291", "r1319", "r1423" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r108", "r251", "r303", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r681", "r685", "r686", "r718", "r1099", "r1356", "r1434", "r1435" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "wald_LineOfCreditCovenantTermsMinimumLiquidity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "LineOfCreditCovenantTermsMinimumLiquidity", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum liquidity covenant", "label": "Line of Credit, Covenant Terms, Minimum Liquidity", "documentation": "Line of Credit, Covenant Terms, Minimum Liquidity" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in revolving commitments", "label": "Line of Credit Facility, Increase (Decrease), Net", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": [ "r1290" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r105", "r110" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining balance", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r105", "r110", "r493" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding borrowings as of closing date", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r18", "r184", "r516", "r531", "r1061", "r1062", "r1097", "r1444" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTSummaryofDebtDetails_1": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 2.0 }, "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedTerseLabel": "Less: Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r260" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r311", "r521" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r311", "r521" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r311", "r521" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r311", "r521" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r311", "r521" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTSummaryofDebtDetails_1": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net", "verboseLabel": "Total long-term portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r261" ] }, "wald_LongTermIncentiveAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "LongTermIncentiveAwardsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Incentive Awards", "label": "Long-Term Incentive Awards [Member]", "documentation": "Long-Term Incentive Awards" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial commitment amount of purchase commitments", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Category of Item Purchased [Axis]", "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Purchase Commitment [Line Items]", "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Purchase Commitment [Table]", "label": "Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about long-term purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes short-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r18", "r1346", "r1347", "r1348" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r18", "r54", "r1346", "r1347", "r1348" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r392", "r1068", "r1110", "r1115", "r1362", "r1447", "r1448", "r1449", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r214", "r216", "r218", "r219", "r221", "r244", "r245", "r488", "r489", "r490", "r491", "r578", "r622", "r703", "r790", "r877", "r878", "r885", "r921", "r922", "r982", "r984", "r986", "r987", "r1001", "r1024", "r1025", "r1056", "r1065", "r1078", "r1090", "r1091", "r1095", "r1096", "r1111", "r1360", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1191" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1191" ] }, "wald_MilkMakeupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "MilkMakeupMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Milk", "terseLabel": "Milk Makeup", "label": "Milk Makeup [Member]", "documentation": "Milk Makeup" } } }, "auth_ref": [] }, "wald_MilkTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "MilkTransactionMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Milk", "terseLabel": "Milk Transaction", "label": "Milk Transaction [Member]", "documentation": "Milk Transaction" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r214", "r216", "r218", "r219", "r221", "r244", "r245", "r488", "r489", "r490", "r491", "r578", "r622", "r703", "r790", "r877", "r878", "r885", "r921", "r922", "r982", "r984", "r986", "r987", "r1001", "r1024", "r1025", "r1056", "r1065", "r1078", "r1090", "r1091", "r1095", "r1111", "r1360", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "verboseLabel": "Noncontrolling Interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r123", "r186", "r303", "r426", "r494", "r496", "r497", "r498", "r501", "r502", "r718", "r842", "r933" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest in fully diluted Class A ordinary shares (percent)", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1211" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]", "documentation": "Information by type of real estate property." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r1010", "r1014", "r1015", "r1016", "r1017", "r1019", "r1020", "r1021", "r1022", "r1023" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]", "documentation": "Land and any structures permanently fixed to it." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r1014", "r1015", "r1016", "r1017", "r1019", "r1020", "r1021", "r1022", "r1023" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1219" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r392", "r1068", "r1110", "r1115", "r1362", "r1447", "r1448", "r1449", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1192" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r295" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r295" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r143", "r144", "r146" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash (used in) provided by operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Class A shareholders", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r135", "r146", "r189", "r249", "r275", "r277", "r282", "r303", "r315", "r317", "r318", "r319", "r320", "r321", "r324", "r325", "r337", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r669", "r678", "r697", "r718", "r851", "r951", "r972", "r973", "r1126", "r1356" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss attributable to noncontrolling interests", "terseLabel": "Net loss attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r81", "r177", "r275", "r277", "r321", "r324", "r325", "r850", "r1281" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributed to Class A shareholders - basic EPS", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r289", "r317", "r318", "r319", "r320", "r328", "r329", "r338", "r341", "r678" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributed to Class A shareholders - diluted EPS", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r289", "r330", "r333", "r334", "r335", "r336", "r338", "r341" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards, Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "wald_NonCashLossFromChangeInFairValueOnInterestRateCollar": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "NonCashLossFromChangeInFairValueOnInterestRateCollar", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash loss from change in fair value on interest rate collar", "label": "Non-Cash Loss From Change In Fair Value On Interest Rate Collar", "documentation": "Non-Cash Loss From Change In Fair Value On Interest Rate Collar" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1191" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1154", "r1165", "r1175", "r1199", "r1208" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1182" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1181" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1199" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1219" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1219" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r76", "r549", "r1297", "r1298", "r1299", "r1301", "r1480" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expenses (income), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r137" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r1294", "r1295" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r17" ] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NorthAmericaMember", "presentation": [ "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North America", "label": "North America [Member]", "documentation": "Continent of North America." } } }, "auth_ref": [ "r1265", "r1266", "r1267", "r1268", "r1482", "r1483", "r1484", "r1485" ] }, "wald_NotePayableDirectorsAndOfficersInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "NotePayableDirectorsAndOfficersInsuranceMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "D&O Insurance", "label": "Note Payable, Directors And Officers Insurance [Member]", "documentation": "Note Payable, Directors And Officers Insurance" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r18", "r184", "r1444", "r1445" ] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note Payable", "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "wald_NumberOfNominatedDirectors": { "xbrltype": "integerItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "NumberOfNominatedDirectors", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of nominated directors", "label": "Number of Nominated Directors", "documentation": "Number of Nominated Directors" } } }, "auth_ref": [] }, "wald_NumberOfOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "NumberOfOperatingLeases", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of non-cancelable operating leases", "label": "Number of Operating Leases", "documentation": "Number of Operating Leases" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1051", "r1305" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1045", "r1055", "r1305" ] }, "wald_ObagiAndMilkBusinessCombinationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ObagiAndMilkBusinessCombinationsMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obagi and Milk Business Combinations", "label": "Obagi and Milk Business Combinations [Member]", "documentation": "Obagi and Milk Business Combinations" } } }, "auth_ref": [] }, "wald_ObagiChinaBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ObagiChinaBusinessMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obagi China Business", "label": "Obagi China Business [Member]", "documentation": "Obagi China Business" } } }, "auth_ref": [] }, "wald_ObagiCosmeceuticalsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ObagiCosmeceuticalsLLCMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Obagi Global Holdings Limited", "terseLabel": "Obagi Cosmeceuticals", "label": "Obagi Cosmeceuticals LLC [Member]", "documentation": "Obagi Cosmeceuticals LLC" } } }, "auth_ref": [] }, "wald_ObagiMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ObagiMergerMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Obagi", "terseLabel": "Obagi Merger", "label": "Obagi Merger [Member]", "documentation": "Obagi Merger" } } }, "auth_ref": [] }, "wald_ObagiSkincareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ObagiSkincareMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Obagi", "terseLabel": "Obagi Medical", "label": "Obagi Skincare [Member]", "documentation": "Obagi Skincare" } } }, "auth_ref": [] }, "wald_ObagiVietnamImportExportTradingMTVCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ObagiVietnamImportExportTradingMTVCompanyLimitedMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obagi Vietnam Import Export Trading MTV Company Limited", "label": "Obagi Vietnam Import Export Trading MTV Company Limited [Member]", "documentation": "Obagi Vietnam Import Export Trading MTV Company Limited" } } }, "auth_ref": [] }, "srt_OfficeBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OfficeBuildingMember", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office", "label": "Office Building [Member]", "documentation": "Building designed primarily for the conduct of business, for example, but not limited to, administration, clerical services, and consultation." } } }, "auth_ref": [ "r1269", "r1270", "r1486", "r1487" ] }, "wald_OneTimStockGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "OneTimStockGrantMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One-Tim Stock Grant", "label": "One-Tim Stock Grant [Member]", "documentation": "One-Tim Stock Grant" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r192", "r1044", "r1304", "r1306", "r1307", "r1308", "r1309" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r737", "r1098" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1429" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on impairment of right of use assets", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1428" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total reported lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r734" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r734" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r734" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r735", "r738" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r733" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r741", "r1098" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r740", "r1098" ] }, "wald_OperatingLeasesIncomeStatementAnnualExpectedSubleaseRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "OperatingLeasesIncomeStatementAnnualExpectedSubleaseRevenue", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual sublease rent", "label": "Operating Leases, Income Statement, Annual Expected Sublease Revenue", "documentation": "Operating Leases, Income Statement, Annual Expected Sublease Revenue" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r655" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Line Items]", "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r655" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r655" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r147", "r148", "r149", "r175" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r271", "r1099" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r258" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) \u2014 foreign currency translation adjustments, net of tax", "verboseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6", "r852" ] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeDisclosureNonoperatingAbstract", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense (income):", "label": "Other Income, Nonoperating [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "verboseLabel": "Related party liability", "totalLabel": "Total", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r107", "r1099" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r112" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r288" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r139" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1191" ] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Related party liability", "terseLabel": "Related party liability", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r53", "r107" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1152", "r1163", "r1173", "r1206" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1155", "r1166", "r1176", "r1209" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1155", "r1166", "r1176", "r1209" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parent Company", "label": "Parent Company [Member]", "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary." } } }, "auth_ref": [ "r213", "r311" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r174", "r1332", "r1333", "r1334", "r1335", "r1337", "r1339", "r1342", "r1343" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1180" ] }, "wald_PaymentShareBasedPaymentArrangementRestrictedStockTaxesForEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PaymentShareBasedPaymentArrangementRestrictedStockTaxesForEmployees", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "RSU taxes paid on behalf of employees", "label": "Payment, Share-Based Payment Arrangement, Restricted Stock Taxes For Employees", "documentation": "Payment, Share-Based Payment Arrangement, Restricted Stock Taxes For Employees" } } }, "auth_ref": [] }, "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForDerivativeInstrumentFinancingActivities", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments on interest rate collar contracts", "label": "Payments for Derivative Instrument, Financing Activities", "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [ "r292", "r1039" ] }, "us-gaap_PaymentsForRepurchaseOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfPrivatePlacement", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of PIPE transaction costs", "label": "Payments for Repurchase of Private Placement", "documentation": "The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r141" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDistributionsToAffiliates", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transfers to subsidiaries", "label": "Payments of Distributions to Affiliates", "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership." } } }, "auth_ref": [ "r141" ] }, "wald_PaymentsOfExpensesOnBehalfOfSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PaymentsOfExpensesOnBehalfOfSubsidiaries", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expenses paid on behalf of subsidiaries", "label": "Payments Of Expenses On Behalf Of Subsidiaries", "documentation": "Payments Of Expenses On Behalf Of Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Distribution to pay withholding taxes", "negatedTerseLabel": "Tax refund (withholding)", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r291" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r23", "r675" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Business Combinations, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditure on intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r140" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditure on property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r140" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1190" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1190" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1182" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1199" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1192" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1181" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1183" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1239" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1182" ] }, "wald_PredecessorIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PredecessorIncentivePlanMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Predecessor Incentive Plan", "label": "Predecessor Incentive Plan [Member]", "documentation": "Predecessor Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r117", "r533" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r117", "r931" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r117", "r533" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r117", "r931", "r949", "r1480", "r1481" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r270", "r443", "r444", "r1034" ] }, "wald_PrepaidExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PrepaidExpensesPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Prepaid Expenses [Policy Text Block]", "documentation": "Prepaid Expenses" } } }, "auth_ref": [] }, "wald_PrivateDerivativeWarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PrivateDerivativeWarrantLiabilitiesMember", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities - Private", "label": "Private Derivative Warrant Liabilities [Member]", "documentation": "Private Derivative Warrant Liabilities" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "wald_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants", "label": "Private Placement Warrants [Member]", "documentation": "Private Placement Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromContributionsFromAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromContributionsFromAffiliates", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfers from subsidiaries", "label": "Proceeds from Contributions from Affiliates", "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDerivativeInstrumentFinancingActivities", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts exchanged on interest rate collar contracts", "label": "Proceeds from Derivative Instrument, Financing Activities", "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [ "r290", "r1039" ] }, "us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDerivativeInstrumentInvestingActivities", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received for interest rate collar premium", "label": "Proceeds from Derivative Instrument, Investing Activities", "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments." } } }, "auth_ref": [ "r1247" ] }, "wald_ProceedsFromForwardPurchaseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ProceedsFromForwardPurchaseAgreements", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from FPA investments", "label": "Proceeds From Forward Purchase Agreements", "documentation": "Proceeds From Forward Purchase Agreements" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loan", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1283" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from PIPE investments", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from revolving credit facility", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r25", "r1290" ] }, "wald_ProceedsFromNotePayableAdjusted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ProceedsFromNotePayableAdjusted", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from Notes Payable", "label": "Proceeds From Note Payable, Adjusted", "documentation": "Proceeds From Note Payable, Adjusted" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from note payable", "label": "Proceeds from Notes Payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r25" ] }, "wald_ProceedsFromTrustAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ProceedsFromTrustAccount", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from trust account", "verboseLabel": "Proceeds from trust", "label": "Proceeds From Trust Account", "documentation": "Proceeds From Trust Account" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net product sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1066" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r242", "r388", "r792", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r1029", "r1066", "r1109", "r1111", "r1112", "r1116", "r1117", "r1274", "r1351", "r1352", "r1362", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r242", "r388", "r792", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r1029", "r1066", "r1109", "r1111", "r1112", "r1116", "r1117", "r1274", "r1351", "r1352", "r1362", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r249", "r275", "r277", "r294", "r303", "r315", "r321", "r324", "r325", "r426", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r669", "r678", "r679", "r682", "r683", "r697", "r718", "r832", "r849", "r899", "r951", "r972", "r973", "r1085", "r1086", "r1127", "r1281", "r1356" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11", "r743" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r153", "r254", "r847" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r743" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r743", "r833", "r847", "r1099" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r11", "r205", "r208", "r845" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Lives of Assets", "verboseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r153", "r743" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated useful life (in years)", "terseLabel": "ESTIMATED\u00a0USEFUL\u00a0LIVES", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for doubtful accounts", "terseLabel": "Provision (recovery) for bad debts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r287", "r432" ] }, "wald_PublicDerivativeWarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PublicDerivativeWarrantLiabilitiesMember", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities - Public", "label": "Public Derivative Warrant Liabilities [Member]", "documentation": "Public Derivative Warrant Liabilities" } } }, "auth_ref": [] }, "wald_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "PublicWarrantsMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Warrants", "label": "Public Warrants [Member]", "documentation": "Public Warrants" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1180" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1180" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r214", "r216", "r218", "r219", "r221", "r244", "r245", "r488", "r489", "r490", "r491", "r569", "r578", "r610", "r611", "r612", "r622", "r703", "r764", "r773", "r790", "r877", "r878", "r885", "r921", "r922", "r982", "r984", "r986", "r987", "r1001", "r1024", "r1025", "r1056", "r1065", "r1078", "r1090", "r1091", "r1095", "r1096", "r1111", "r1120", "r1349", "r1360", "r1411", "r1437", "r1438", "r1439", "r1440", "r1441" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r214", "r216", "r218", "r219", "r221", "r244", "r245", "r488", "r489", "r490", "r491", "r569", "r578", "r610", "r611", "r612", "r622", "r703", "r764", "r773", "r790", "r877", "r878", "r885", "r921", "r922", "r982", "r984", "r986", "r987", "r1001", "r1024", "r1025", "r1056", "r1065", "r1078", "r1090", "r1091", "r1095", "r1096", "r1111", "r1120", "r1349", "r1360", "r1411", "r1437", "r1438", "r1439", "r1440", "r1441" ] }, "wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "RecognitionPeriodForDeferredAdvertisingCostsMaximum", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period after which production costs will be expensed for advertising that has not yet occurred", "label": "Recognition Period for Deferred Advertising Costs, Maximum", "documentation": "Recognition Period for Deferred Advertising Costs, Maximum" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Segment Net Revenue To Segment Adjusted Gross Profit", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r46", "r47" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1147", "r1158", "r1168", "r1201" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r393", "r576", "r749", "r750", "r837", "r844", "r924", "r925", "r926", "r927", "r928", "r948", "r950", "r981" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r306", "r307", "r749", "r750", "r751", "r752", "r837", "r844", "r924", "r925", "r926", "r927", "r928", "r948", "r950", "r981" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r393", "r955", "r956", "r959" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r393", "r576", "r749", "r750", "r837", "r844", "r924", "r925", "r926", "r927", "r928", "r948", "r950", "r981", "r1433" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r746", "r747", "r748", "r750", "r753", "r895", "r896", "r897", "r957", "r958", "r959", "r978", "r980" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of term loan", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1284" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of revolving credit facility", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r142", "r1290" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of note payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r142" ] }, "wald_RepaymentsOfNotesPayableAdjusted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "RepaymentsOfNotesPayableAdjusted", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of note payable", "label": "Repayments of Notes Payable, Adjusted", "documentation": "Repayments of Notes Payable, Adjusted" } } }, "auth_ref": [] }, "wald_ReplacementAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ReplacementAwardsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Replacement Options", "label": "Replacement Awards [Member]", "documentation": "Replacement Awards" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r240", "r241", "r308", "r309", "r507", "r535", "r752", "r774", "r834", "r1037", "r1038" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r624" ] }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Software and Website Development Costs", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination." } } }, "auth_ref": [ "r1344", "r1391", "r1488" ] }, "wald_RestOfTheWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "RestOfTheWorldMember", "presentation": [ "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rest of the World", "label": "Rest of the World [Member]", "documentation": "Rest of the World" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1148", "r1159", "r1169", "r1202" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1149", "r1160", "r1170", "r1203" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1156", "r1167", "r1177", "r1210" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1276", "r1288", "r1442", "r1446" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash and Cash Equivalents [Axis]", "label": "Restricted Cash and Cash Equivalents [Axis]", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": [ "r103" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r253" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "verboseLabel": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r121", "r161", "r841", "r882", "r884", "r893", "r932", "r1099" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r246", "r312", "r313", "r314", "r316", "r321", "r323", "r325", "r427", "r428", "r477", "r658", "r659", "r666", "r667", "r668", "r670", "r677", "r678", "r687", "r689", "r690", "r692", "r695", "r729", "r732", "r879", "r881", "r900", "r1480" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenue", "verboseLabel": "Net revenue", "netLabel": "Net revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r190", "r191", "r347", "r356", "r357", "r378", "r384", "r388", "r390", "r392", "r566", "r567", "r792" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r392", "r1248" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition and Distribution", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r211", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r1028" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.waldencast.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r211", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r568" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.waldencast.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by Geographic Region", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r151" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r739", "r1098" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [ "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalties", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r1363" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1219" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1219" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration received", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued (in shares)", "verboseLabel": "Issued (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per unit (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesChannelDirectlyToConsumerMember", "presentation": [ "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Direct sales", "label": "Sales Channel, Directly to Consumer [Member]", "documentation": "Contract with customer in which good or service is transferred directly to consumer." } } }, "auth_ref": [ "r1072" ] }, "us-gaap_SalesChannelThroughIntermediaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesChannelThroughIntermediaryMember", "presentation": [ "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Distributors", "label": "Sales Channel, Through Intermediary [Member]", "documentation": "Contract with customer in which good or service is transferred through intermediary." } } }, "auth_ref": [ "r1072" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r579", "r1263", "r1300" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r243", "r326", "r579", "r1244", "r1300" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts and Financing Receivables [Table]", "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r119", "r125", "r394", "r1313" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r66", "r67", "r673" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1399" ] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Balance Sheets", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1264", "r1296" ] }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Statements of Cash Flow", "label": "Condensed Cash Flow Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1264", "r1296" ] }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Statements of Operations", "label": "Condensed Income Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r1264", "r1296" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.waldencast.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Deferred Tax Assets and Deferred Tax Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1394" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1303" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r635", "r1084", "r1392" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.waldencast.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by Sales Channel", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1408", "r1409" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets Acquired in Business Combination", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r462", "r468", "r470", "r471", "r474", "r793", "r1027", "r1059" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1059", "r1338" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r1058" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.waldencast.com/role/GOODWILLTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1058", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Consolidated Pretax Income (Loss)", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1292" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r126", "r127", "r128" ] }, "wald_ScheduleOfLongTermAndShortTermDebtInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ScheduleOfLongTermAndShortTermDebtInstrumentsLineItems", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long Term and Short Term Debt Instruments [Line Items]", "label": "Schedule of Long Term and Short Term Debt Instruments [Line Items]", "documentation": "Schedule of Long Term and Short Term Debt Instruments" } } }, "auth_ref": [] }, "wald_ScheduleOfLongTermAndShortTermDebtInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ScheduleOfLongTermAndShortTermDebtInstrumentsTable", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long Term and Short Term Debt Instruments [Table]", "label": "Schedule of Long Term and Short Term Debt Instruments [Table]", "documentation": "Schedule of Long Term and Short Term Debt Instruments" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.waldencast.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-Term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11", "r743" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Purchase Price Allocation", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSIndemnificationAgreementsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r98", "r99", "r955", "r956", "r959" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r581", "r583", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r610", "r611", "r612", "r613" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Valuation Assumptions, Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r167" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r55", "r56", "r57", "r58", "r59", "r60", "r157", "r159", "r160", "r161", "r262", "r263", "r264", "r349", "r533", "r534", "r535", "r537", "r540", "r545", "r547", "r889", "r890", "r891", "r892", "r1065", "r1243", "r1289" ] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Options Activity", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r1059", "r1340" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1130" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1132" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r190", "r191", "r192", "r193", "r347", "r352", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r392", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r474", "r484", "r485", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r1047", "r1050", "r1051", "r1058", "r1114", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r215", "r217", "r220", "r222", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r390", "r391", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r914", "r917", "r919", "r983", "r985", "r988", "r1002", "r1010", "r1014", "r1015", "r1016", "r1017", "r1019", "r1020", "r1021", "r1022", "r1023", "r1030", "r1067", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1113", "r1120", "r1362", "r1447", "r1448", "r1449", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r193", "r347", "r351", "r352", "r353", "r354", "r355", "r367", "r369", "r370", "r382", "r383", "r384", "r385", "r386", "r388", "r389", "r392", "r1045", "r1048", "r1049", "r1050", "r1052", "r1054", "r1055" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r387", "r390", "r1046", "r1047", "r1053" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationOfConsolidatedAdjustedGrossProfitToConsolidatedNetLossBeforeAndAfterIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "netLabel": "Selling, general and administrative", "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r136" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1079" ] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent" } } }, "auth_ref": [] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches" } } }, "auth_ref": [] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity instruments assumed in business combination (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in shares)", "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r602" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r602" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r600" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r600" ] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum allocated target share units, percent", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent" } } }, "auth_ref": [] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards with modified performance conditions in period (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Modified In Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Modified In Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r597", "r598" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding beginning balance (in dollars per share)", "periodEndLabel": "Outstanding ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r597", "r598" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post vesting holding period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r166" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r601" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r601" ] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise multiple", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple" } } }, "auth_ref": [] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise term, percent", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r610" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term." } } }, "auth_ref": [ "r611" ] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anniversary period, annual increase in shares issued under plan", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r581", "r583", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r610", "r611", "r612", "r613" ] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of annual installments", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments" } } }, "auth_ref": [] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of quarterly installments", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares available for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1081" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options assumed in business combination (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r595" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r593" ] }, "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals": { "xbrltype": "integerItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of founders", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r589", "r590" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r589", "r590" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r606" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r606" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r606" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r605" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r605" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r605" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage increase in shares available for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r610", "r611", "r612", "r613" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r594" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r595" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r593" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "wald_ShareBasedCompensationByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedCompensationByShareBasedPaymentAwardAggregateIntrinsicValueAbstract", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic Value (in thousands)", "label": "Share-Based Compensation By Share-Based Payment Award, Aggregate Intrinsic Value [Abstract]", "documentation": "Share-Based Compensation By Share-Based Payment Award, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r580", "r588", "r607", "r608", "r609", "r610", "r613", "r618", "r619", "r620", "r621" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "wald_ShareBasedPaymentArrangementBoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedPaymentArrangementBoardOfDirectorsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement Board Of Directors", "label": "Share-Based Payment Arrangement Board Of Directors [Member]", "documentation": "Share-Based Payment Arrangement Board Of Directors" } } }, "auth_ref": [] }, "wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedPaymentArrangementBusinessCombinationIncrementalCost", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental stock based compensation expense", "label": "Share-Based Payment Arrangement, Business Combination, Incremental Cost", "documentation": "Share-Based Payment Arrangement, Business Combination, Incremental Cost" } } }, "auth_ref": [] }, "wald_ShareBasedPaymentArrangementDecreaseForTaxWithholdingEmployeeRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedPaymentArrangementDecreaseForTaxWithholdingEmployeeRestrictedStockUnits", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "RSU taxes paid on behalf of employees", "label": "Share-Based Payment Arrangement, Decrease For Tax Withholding, Employee Restricted Stock Units", "documentation": "Share-Based Payment Arrangement, Decrease For Tax Withholding, Employee Restricted Stock Units" } } }, "auth_ref": [] }, "wald_ShareBasedPaymentArrangementEmployeesAndNonEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedPaymentArrangementEmployeesAndNonEmployeesMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Employees And Non Employees", "label": "Share-Based Payment Arrangement, Employees And Non Employees [Member]", "documentation": "Share-Based Payment Arrangement, Employees And Non Employees" } } }, "auth_ref": [] }, "wald_ShareBasedPaymentArrangementFounderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShareBasedPaymentArrangementFounderMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Founder", "label": "Share-Based Payment Arrangement, Founder [Member]", "documentation": "Share-Based Payment Arrangement, Founder" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1364" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1080" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r609" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r62" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r166" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r605" ] }, "wald_ShippingAndHandlingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "ShippingAndHandlingCosts", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and handling costs", "label": "Shipping And Handling Costs", "documentation": "Shipping And Handling Costs" } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/DEBTSummaryofDebtDetails": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/DEBTSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term debt", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r104", "r182", "r1099", "r1443" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r106", "r1346", "r1347", "r1348" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails", "http://www.waldencast.com/role/DEBTSummaryofDebtDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r104", "r1346", "r1347", "r1348" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r147", "r300" ] }, "wald_SkintrinsiqDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "SkintrinsiqDevicesMember", "presentation": [ "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Skintrinsiq Devices", "label": "Skintrinsiq Devices [Member]", "documentation": "Skintrinsiq Devices" } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-Use Software and Website Development Costs", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internally developed software", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "wald_SponsorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "SponsorMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sponsor", "label": "Sponsor [Member]", "documentation": "Sponsor" } } }, "auth_ref": [] }, "wald_SponsorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "SponsorWarrantsMember", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sponsor Warrants", "label": "Sponsor Warrants [Member]", "documentation": "Sponsor Warrants" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r633" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails", "http://www.waldencast.com/role/GOODWILLNarrativeDetails", "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSMILKDetails", "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails", "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r190", "r191", "r192", "r193", "r248", "r347", "r352", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r378", "r379", "r380", "r381", "r382", "r384", "r385", "r386", "r392", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r474", "r478", "r484", "r485", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r1047", "r1050", "r1051", "r1058", "r1114", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/COVER", "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSSubscriptionAgreementwithPIPEInvestorsDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r212", "r262", "r263", "r264", "r303", "r331", "r332", "r339", "r341", "r349", "r350", "r426", "r494", "r496", "r497", "r498", "r501", "r502", "r533", "r534", "r537", "r540", "r547", "r718", "r889", "r890", "r891", "r892", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r931", "r952", "r974", "r1003", "r1004", "r1005", "r1006", "r1007", "r1243", "r1289", "r1302" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r118", "r122", "r123", "r246", "r280", "r281", "r282", "r312", "r313", "r314", "r316", "r321", "r323", "r325", "r348", "r427", "r428", "r477", "r549", "r658", "r659", "r666", "r667", "r668", "r670", "r677", "r678", "r687", "r688", "r689", "r690", "r691", "r692", "r695", "r720", "r721", "r722", "r723", "r724", "r725", "r729", "r732", "r745", "r852", "r879", "r880", "r881", "r900", "r974" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "http://www.waldencast.com/role/LEASESNarrativeDetails", "http://www.waldencast.com/role/REVENUENarrativeDetails", "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r215", "r217", "r220", "r222", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r390", "r391", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r914", "r917", "r919", "r983", "r985", "r988", "r1002", "r1010", "r1014", "r1015", "r1016", "r1017", "r1019", "r1020", "r1021", "r1022", "r1023", "r1030", "r1067", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1113", "r1120", "r1362", "r1447", "r1448", "r1449", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r312", "r313", "r314", "r348", "r732", "r792", "r887", "r911", "r923", "r924", "r925", "r926", "r927", "r928", "r931", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r944", "r945", "r946", "r947", "r948", "r950", "r953", "r954", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r974", "r1121" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r243", "r326", "r579", "r1244", "r1246", "r1300" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r312", "r313", "r314", "r348", "r393", "r732", "r792", "r887", "r911", "r923", "r924", "r925", "r926", "r927", "r928", "r931", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r944", "r945", "r946", "r947", "r948", "r950", "r953", "r954", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r974", "r1121" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1151", "r1162", "r1172", "r1205" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "wald_StockGrowthIncentive2025AwardsSGIAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockGrowthIncentive2025AwardsSGIAwardsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Growth Incentive 2025 Awards (SGI Awards)", "label": "Stock Growth Incentive 2025 Awards (SGI Awards) [Member]", "documentation": "Stock Growth Incentive 2025 Awards (SGI Awards)" } } }, "auth_ref": [] }, "wald_StockGrowthIncentive2027AwardsSGIAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockGrowthIncentive2027AwardsSGIAwardsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Growth Incentive 2027 Awards (SGI Awards)", "label": "Stock Growth Incentive 2027 Awards (SGI Awards) [Member]", "documentation": "Stock Growth Incentive 2027 Awards (SGI Awards)" } } }, "auth_ref": [] }, "wald_StockGrowthIncentiveAwardsSGIAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockGrowthIncentiveAwardsSGIAwardsMember", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SGI Awards", "label": "Stock Growth Incentive Awards (SGI Awards) [Member]", "documentation": "Stock Growth Incentive Awards (SGI Awards)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with the Obagi and Milk Business Combination (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r117", "r118", "r161" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares exchanged (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r15", "r57", "r118", "r122", "r161", "r520" ] }, "wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockIssuedDuringPeriodSharesForeignPurchaseAgreements", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with the FPA investment (in shares)", "label": "Stock Issued During Period, Shares, Foreign Purchase Agreements", "documentation": "Stock Issued During Period, Shares, Foreign Purchase Agreements" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock registered (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r117", "r118", "r161", "r889", "r974", "r1004" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r117", "r118", "r161", "r594" ] }, "wald_StockIssuedDuringPeriodSharesSubscriptionAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockIssuedDuringPeriodSharesSubscriptionAgreements", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with the PIPE investment (in shares)", "label": "Stock Issued During Period, Shares, Subscription Agreements", "documentation": "Stock Issued During Period, Shares, Subscription Agreements" } } }, "auth_ref": [] }, "wald_StockIssuedDuringPeriodSharesTrustProceeds": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockIssuedDuringPeriodSharesTrustProceeds", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A ordinary shares upon release of Trust proceeds (in shares)", "label": "Stock Issued During Period, Shares, Trust Proceeds", "documentation": "Stock Issued During Period, Shares, Trust Proceeds" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with the Obagi and Milk Business Combination", "verboseLabel": "Issuance of ordinary shares for Business Combinations", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r15", "r118", "r122", "r123", "r161" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares exchanged", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r15", "r118", "r122", "r123", "r161" ] }, "wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockIssuedDuringPeriodValueForeignPurchaseAgreements", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with the FPA investment", "label": "Stock Issued During Period, Value, Foreign Purchase Agreements", "documentation": "Stock Issued During Period, Value, Foreign Purchase Agreements" } } }, "auth_ref": [] }, "wald_StockIssuedDuringPeriodValueSubscriptionAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockIssuedDuringPeriodValueSubscriptionAgreements", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares in connection with the PIPE investment", "label": "Stock Issued During Period, Value, Subscription Agreements", "documentation": "Stock Issued During Period, Value, Subscription Agreements" } } }, "auth_ref": [] }, "wald_StockIssuedDuringPeriodValueTrustProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockIssuedDuringPeriodValueTrustProceeds", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A ordinary shares upon release of Trust proceeds", "label": "Stock Issued During Period, Value, Trust Proceeds", "documentation": "Stock Issued During Period, Value, Trust Proceeds" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CONTROLLING SHAREHOLDERS\u2019 EQUITY", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r118", "r122", "r123", "r152", "r933", "r949", "r975", "r976", "r1099", "r1128", "r1291", "r1319", "r1423", "r1480" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/CONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails", "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL SHAREHOLDERS' EQUITY", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r76", "r77", "r80", "r246", "r247", "r281", "r312", "r313", "r314", "r316", "r321", "r323", "r427", "r428", "r477", "r549", "r658", "r659", "r666", "r667", "r668", "r670", "r677", "r678", "r687", "r688", "r689", "r690", "r691", "r692", "r695", "r720", "r721", "r725", "r730", "r745", "r880", "r881", "r898", "r933", "r949", "r975", "r976", "r1008", "r1127", "r1291", "r1319", "r1423", "r1480" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.waldencast.com/role/SHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r158", "r302", "r532", "r534", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r546", "r549", "r694", "r977", "r979", "r1009" ] }, "wald_StockholdersEquityNumberOfSharesInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "StockholdersEquityNumberOfSharesInEachUnit", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares in each IPO unit (in shares)", "label": "Stockholders' Equity, Number Of Shares In Each Unit", "documentation": "Stockholders' Equity, Number Of Shares In Each Unit" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r726", "r756" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r726", "r756" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r726", "r756" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r726", "r756" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r726", "r756" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.waldencast.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r755", "r757" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Operating Losses and Tax Credit Carryforwards", "label": "Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block]", "documentation": "Summary of Operating Loss Carryforwards and Tax Credit Carryforwards" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r1275" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW DATA \u2013 CASH PAID:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r150" ] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentArrangementMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment Arrangement [Domain]", "label": "Supply Commitment Arrangement [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r113", "r185" ] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentAxis", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment [Axis]", "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer." } } }, "auth_ref": [ "r113", "r185" ] }, "us-gaap_SupplyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentMember", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supply Commitment", "label": "Supply Commitment [Member]", "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments." } } }, "auth_ref": [ "r113", "r185" ] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "TX", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TEXAS", "label": "TEXAS" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1198" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credits", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r655" ] }, "wald_TotalGrossMarginAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "TotalGrossMarginAdjustments", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentNetRevenueToSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted cost of goods sold", "label": "Total Gross Margin Adjustments", "documentation": "Total Gross Margin Adjustments" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1190" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1197" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Net", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r194", "r195", "r196", "r1311", "r1312", "r1314" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trademarks and trade name", "terseLabel": "Trademark and trade name", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r71", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1339", "r1341", "r1342", "r1343" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1218" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1220" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.waldencast.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSRegistrationRightsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r528", "r545", "r693", "r716", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r853", "r1087", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1100", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1315", "r1316", "r1317", "r1318", "r1407", "r1410", "r1411", "r1412", "r1419", "r1422" ] }, "wald_TransitionServicesAgreementExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "TransitionServicesAgreementExtensionPeriod", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition services, optional extension term", "label": "Transition Services Agreement, Extension Period", "documentation": "Transition Services Agreement, Extension Period" } } }, "auth_ref": [] }, "wald_TransitionServicesAgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "TransitionServicesAgreementPeriod", "presentation": [ "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition services, initial term", "label": "Transition Services Agreement Period", "documentation": "Transition Services Agreement Period" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1221" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1222" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1222" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1220" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1220" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1223" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1221" ] }, "wald_TretinoinDistributionAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "TretinoinDistributionAndSupplyAgreementMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails", "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tretinoin distribution and supply agreement", "verboseLabel": "Tretinoin distribution and supply agreement", "label": "Tretinoin Distribution and Supply Agreement [Member]", "documentation": "Tretinoin Distribution and Supply Agreement" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1217" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails", "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Uncertain tax positions", "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r626", "r646", "r1083" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, accrued interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r644", "r1083" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r40", "r41", "r42", "r202", "r203", "r206", "r207" ] }, "country_VN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "VN", "presentation": [ "http://www.waldencast.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VIET NAM", "label": "VIET NAM" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "wald_VariableRateComponentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "VariableRateComponentAxis", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Axis]", "label": "Variable Rate Component [Axis]", "documentation": "Variable Rate Component" } } }, "auth_ref": [] }, "wald_VariableRateComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "VariableRateComponentDomain", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component [Domain]", "label": "Variable Rate Component [Domain]", "documentation": "Variable Rate Component [Domain]" } } }, "auth_ref": [] }, "wald_VariableRateComponentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "VariableRateComponentOneMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component One", "label": "Variable Rate Component One [Member]", "documentation": "Variable Rate Component One" } } }, "auth_ref": [] }, "wald_VariableRateComponentThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "VariableRateComponentThreeMember", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Component Three", "label": "Variable Rate Component Three [Member]", "documentation": "Variable Rate Component Three" } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.waldencast.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "wald_VendorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "VendorOneMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vendor One", "label": "Vendor One [Member]", "documentation": "Vendor One" } } }, "auth_ref": [] }, "wald_VendorTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "VendorTwoMember", "presentation": [ "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vendor Two", "label": "Vendor Two [Member]", "documentation": "Vendor Two" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1186" ] }, "wald_WaldencastPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.waldencast.com/20241231", "localname": "WaldencastPlcMember", "presentation": [ "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSTransactionswithCedarwalkinConnectionwiththeBusinessCombinationDetails", "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails", "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Waldencast plc", "label": "Waldencast plc [Member]", "documentation": "Waldencast plc" } } }, "auth_ref": [] }, "srt_WarehouseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WarehouseMember", "presentation": [ "http://www.waldencast.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warehouse", "label": "Warehouse [Member]", "documentation": "Facility designed for the storage of goods or equipment." } } }, "auth_ref": [ "r1269", "r1270", "r1486", "r1487" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.waldencast.com/role/COVER", "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share", "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r1118", "r1119", "r1122", "r1123", "r1124", "r1125" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1303" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average diluted shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r330", "r341" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted-average basic shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r328", "r341" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1184" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-9" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "27", "SubTopic": "10", "Topic": "852", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-23" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1243": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1244": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1245": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11" }, "r1246": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/730/tableOfContent" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 131 0001840199-25-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001840199-25-000025-xbrl.zip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�T;B?SBPET9GLBEG+F]H0Q F+Q1B .R=Y7:__\%JP'7@-23N ?#Z MS$7)_8$DNZQQOV@PLY2.%]05E5_\NA-ZCH[X-K/H-^K#.WGY_'NOWD,V1\8A M= T8:YEN@G:C@8[)-B-(?P).EYV^UC@U=IMIY4,1A@M8_K!LV QZ#(2"_[R7 M9"D2XDC?KS/#"67P8<%2T4VB*ICT])*DOAT,053 [=5ZUH2J.M /(?^L$88- MG_CSO?/)VX0GT[,)G2S/CIN\LZU[]FS'WE"%B(N]*"&+.Q]+M*F#4[6_,8OJ M3/I&>$%6Z2H7M"H=Z(6CPQIJ(3C@Y?1T>LOIQB.&I0SM"3._?D24+ZX3B?@V MN3^)\_@8XJM,HH%-N1Q"S]KK9#][3YHQUY,N^.5C(^IYD7T?6J*C$>J]7Z7/ M[N$J[7&$P&7 "%^Q>ZJ.+D=Y1PI4SL=YF51+ A%Z6D'W.UY'^"LDCIPT MTF5I2:$"]5D0/^,U4?R9[GAJX=I+GXS7?*UC/X\]]3EU":85V7.TL!:]Y\IK M&BVUGEV>N67.5=$'A^??'YJB23B,-5#$2-6AS#_#W$5 M$1Q9S[4O@'%-UF9).%7R/S6LB8["S=<(U3EDB'9#DAPMZR.'>=!V/7;Z5(#P6U.#T*N]N %L%XJ%]7;N ; MN&OAFLC?[\G]=^HGH2JFJED&1PYEM[!']/U'N'0*)N.TVB#Y6DXI\5_2Y!RM MY%__\O3['Z*?6Z=^WZ\U%1;\_ M2ZYAAJ,W=0ZCZUZ#1QX+T^(_D_PC/HC+?-$H),O5^NHN,Q)+3^SE#-53ZX_) M%A/U99W*X_WC\RY*V^C.D*8,7C>T[^":SKGBC)(I!A;CQRH>-?]>5LVAL&<= M+:>TG6\/0D;V1A' BLZ\IQ /;$U>0,Y$)X;,ZK<0U-0^'8;?][=78/[NH O, M$]ZLZ90VZ^?L55]O>2<6-ZD]W =VY#0IEA7$_N3X\=/]C?!@B-6.5M-9Q\^/ M']-$H+_V@2)&01B;!MBK!*EXJ=T5NY 2T9.*7%_GFS>RWN=I-Q,^*/-Q1(*' M2SJFDD9;H^WM[=VO72?4O[;P5E>"G!QJF^HH(F/LJ]^L;AZNCG(F0;>3:!WA M!Z//W#"!>%4ZI)&[I$I7S'F*^,\$-AO\Q#*PF?8"$A4*W.B:,H>WF-RRZI54 M;$TP]0[*_-[!O,:CTV4._9TQI+Y;CG)SIB6N M_9(.1C[C?#J6XC/=T\5G>*5]\*9^@5)/K"#(&UD,7HY9>V8]CP721>7)MH9Y MPA[HHP1E+E9":53.#N60N;CG2RH80,CO9V=1CFJR-9B8 MQ47:!=YV>!M(A=9AJ,UB/)37/QW@I6NZO-7K/V*>MNCO\.&R(@KRTZ) K+V/ M6=\[I'7LB-VB7V!P%W"X]GW,0+.\JG%R669++1$NR^W<*!XO, N_3$B+!5:4 MLM 4T?\D,!98>M+@_=PQHB$W&IZR)3>0?H23VU8AD;MLD5"1Z$BTAG$&!.V- MV:*1;]A(07WRYVC"YK.9&S)\-RNIQ N/3(!T':L,%6EP4(LZ^BF=5_0'9*'% MO\1H):FWS#'^)-%5FGY$'C44DE>JO41>'^U#V43S[?*<;:PC]81Q[- EG2S0 MH;J)T(89@0:29@O'Q%/S"MJXJDL&KSZ<.>KIY1, 5]G!^ I_3'/'O_XD>MIG M1-5JNJG?I:9IHL?-(PI;Q!_B+_J*FX=BJS].Y\WI4:WQX.YL"*AE#YNZ(98M MV%E/9]&/RIST*KD>.7*9OCH4)D9KP8&&]0.0W[%R77HN.5EK IOC4K"KA5A' MAD9Y'(DH6:&YB*Y+6%7L1+# )BJO<9VKR1YUQ+>J;2YU,*-89CF'.6W:P%,V MK'\6AHC!$+$(0ZZJFS3P7HY.'N\\9X;,-"RZ0HSG2WH:F-4L,RA/G\,LYDRE M?-V9 (\3_C$M4M'S^.U*$6#OW+-_X1OW6C\4.U\DYB5R&.DJ54):W7\X>-VS M+QE-_\/ZC#JNI18VFPXY/]5]/@Q]9(-;7]\[6WOU2X6:'LI;7TUG+"A'[,. 4?-GQ]6MIZ2NDJ<67^3$&@S"W M\JV+;"T]A/\86'\I2*J:SE-1'[ZH> M'?O^3,,"-'AMY8M/$6$.(TK%.#BB0LE5G-,SQ%F9UX M@(-74?$Y@;%, I5; YS8#$&A!4C6GZ&G@SK&NIU)^>39QY1U@%"*ARM,\/,R M17JDC&1\& B%=4%L".S]R$T2[#=P_3\@6ARBY<4#HF4_AFXS/4-WN*?*OZ8W MV;>);+Z,S&'J /H)UJN(MDE;Y9;1N61ZM#D,TY*UJ5L'#1?G!E3/DMVJ64.- M1M(5EA5.\@:&"&X$ET]@ZV'"RQ6H3!]<. ;AZ6<7>LA+-(<^_LW[YP60N]3=9M;'.^5T@_*X;X@EV09A!,4(@C0NH^^Z@LX MS2:_RB>TS)5Z-)&RN7W[+#0A2X#>E[[ZOAZS^H)!C93)!;>X;VG9:!%[AHC\ M3.^ O ]A[Y0+5X=;BKM O >+A9KE$IJ=8%ER(NM&RW*X:V9"#6B:ZC(\ M-?1B0AI$J>JP]*RKWZ\U*V8RF>>PZ8N^PMZW^[HG]+;5E6V5Q_Z9Y#!+"\QH MOA4&B0C[H!)]890)035?\G?!Q6K2/L="/MU_.''\N,\2\)O[ M>YDO%V5T$OV,*4[*\'D6,X;%,WY=>#B85H,4E(EBQA,VF=YT@8.BIC,NE2;Y MR.+/RT"0#)'AND@DT1ISG!+!6TUP)!4^$P5$\]NF+6>>Z1Y>"F& 29I(6[F)OL1S4CF"& D#1X[< MX5Q1L%:^>W'\W7/=6K*/'O$YLA_AXFI?V^A)>QN]D(Z<-^$N(E^G0R'!8N2W M2R$-GXM]K^ASQ.<>W[$9_=KXDBDFGY* FPD,10G[>KE=MRQ@/&0:XS9E;<#P MP6FA\ ,+"+U9((821T3$Z"D\G!??78.W4HNY?VMC0HO#IVS\T6F.3.6;8_JM MBDMGAK(K(50X@NK2UF=7EKQH[$7?"9WP!-[J!+F#F4Y5CWH5BM%*:,H>A@JH M8DHW76]8*74NQ\ 095366)8HAK#"HKET^9BLT;C<$:A9_K3=+_YEPE&36B$3 MI"L3WXT2KXFVDJ;TFFJ!%]"_Z.W("[W%PD"'$QG]2-KLRV.G2;W-"8J)[/PV MX_#-Q(XF#M[.7__R[,4/A ZI-TFSN B@]!R"<**M5L JUZMZOLHA@J.*YC)/ M.^5V.TNP5M$Z=:Z 1T#KJ2ZK2Q>?+5TZ/X+ZTB7_B@HE M295 5+FYB([FLRB90_C9!L/W+ L^9OB <@MR_'SX]H WWQ\L\.;^[>@)Y=0U MJ3K@YYM>^9P%I!UWKC0]S!UW,Z>RDOKS_75[QWRVE"J\D10O:J MV/2\HR-+QJ"!X0Q?_RI#\"5'#0_1X->,!N>.*@HN+P&$FY:[* M3951*P!A,RC(%P4RPL@BA?6".IDPN^LN'?L+QSZ3;$C>"8X2(1B3PC(6U#'/_J5^.ZE=I!PY: H'>L/(7O"DH+MQ;MU MO'G_3H3I1 S>P<#I7XI,+O>=:;C8 F$0Y-$W!ZL-Z)6?['0BN%[4VO8'KXV0QI:P9NZ-$L*GQ1R5 M0@;G[DEWTKO.K_V-N>NWZM E)SJ5VR)'2,IM:JH*9"/2?=N$'C1LHHM68K8E M!,[2NK]6E$-)EC!CB"UJAAQ(YX79-D^.IW(&GCP[?N*$A?JW^VNO^ U?VROS M*>S31O7[@MY?ZL";YZ[%,&SPA=6W3CYB%QR=N +>+A>+1%L%,"#PM+3H)?KS MF#*(NE5,@7$%YS-_WMOP6T>#TUVN1\ET'#7#,WP#L^@ <;?+Y/AN\"[-A3\L M/H?']8&]Y ;VDHDRVZJVH%L[&IDQ;XTS"OMBO'U8B]_.6AR@"3X0!^AH/J43 MA;/!IX*9A1NQ'P#!UQH\>8P%$#A*_L9Y1K4!R0 IZ]6//H%X%^S-7_B2]Q3' MA\YA'ST4AB1-UB ((QG=LQAP+M:)F5Z0%3^SDN\<_@!/# M'''S&?]",V[BC'_NI(_62^]N'[WHW4?*./^_D]E-WQ^_?#$>1%#I%/Z'@3;Q M&%YBAAXV"KSZ^L\Q;U][*_R$H2^Y$@-!2EU&J!M&N6%/_&>, _[6ERTB%]S' MGIO*G36_^6C'-HVR/3EG=JYENBY\KZ*/CVK91NQJ*(.+!\\G-4Q!DRYG?@@R MS"I=)[#-M@4Q:5''H4M=Q,.>=^JMA%Z*BZM\556&;C'UO=,RSUB28Y[D5)RI+]*T&4HEQ2TO53-+H5"H:QV3 M\5/$8(;GL46*#@Q&8LA(N&=EG1IQ>D+#F#T824]XJ5HI.XE^T>\Y_9.6E!.\K]*KW,RFT=O 5]RH15"]KT M^.&,@"M B$I'^GK:'\[/<6>ZNV2M#.YEYZ;^#+% M[X@6 ;&A>J8V8ME8IL@>AW,MP" B:@%G:4&7V4*PPN^AH*F7#,ZB/"^X?U U MBV]-YN]EUSMC//X^S4B?G%;4/SH*5[?P+_F,%?$*C2E!JSJ M)^:%I#U$RGG8*[IH<'W33Q"=91LV*)5*"?.&T3-SW*ME4_7=\"(I2T9E9E66#@MDW(.+OE\LUP2SGT:?9('.,,TZTYO^%<* MOZANUR_$I>5T@6*UKVCKKA^M;-)\Y:I-=EX,>=^P,*OS7 M-?CV.:=4&XGQ?\GRC^ R MYOFC-P7XUT^__X%^BG[;-M$IA"G7*%5VA%]YGVXNRBJAI_L];TCJ\9EE;"&UHC1U]!S^]XY]X M6E_,P/?&TABZJ?JI[V=Z*0+:T9!^^_"C3 M-G?_2J]_^+B0QF)NFB[Z<1?_ M0U#4,QFP#Z\*YK&ZEC=%^D3&AAR]F0GY)PDH=O3G4IH*Z^2/Y91N$"=Z\X9' M*F%*MHI<&9RI:."<4/ A@1:K)3<&M<4VDDNP"3:D[&3:)5;0K71(/M5B2CX5 MN5083!,\FR/<6_@U=Y;%0K>*F9+,^?(E5I:4#EL9,3(B\VWC,Q'TJ3H]7S-A MV66:R\?H =!%*.!7_ <^R6:ZR:A_9C62=)-TQT1V>+?0\8K&=Q*/Z#>B6 M/**2/5PWB NM26D+H(6S0V/MF1:C?=!Y[PX(1,V%"$QN$'_"&0VR+I2ZJ(G= MI!VT8H9B;/"SSZ(UF+!Y6$[)/)S8-/.,!3H^C](IJ;WB8=WG8]]OGH(UAIY.[QY*/%JB??EXV^LQ+NG M#C>_]F\3V/''\[/A[I\5,0LS>U7\KX12-Z>2'Z&]5 MN=UHE> NO/$= NJ':/K.HND#@:T:B,:]ZMOQZJJ27X]^HXK<&R\E_(#8F-QJ MFR!B W/N6++E0"*_]NZH4Y[M5#C-Z=/B4>I"]PQ(%]D96X(S9[YIUJQHR_[R M.8G1 5(OC+,D2+U-Q3;"8JT^!OU[/HN.A)OX@A.\E+;"^#K)%R(>C;=Y_8GH MO\_0LO\$EGVP3G-GS?A2UCZZ$L&B7^#2Z^TZ^CF#0WJ)Q[2"FJ7V M+T45S.=2).\^Y_N-))IIOPBZ,/%-7M0_H8THU J4I.N2 ^R MD09#VB*2=>.5$>,9]8E:K'NVI0=M"]*'I*O6ZVWA9&2HETS2O8$3&#:G,B%A MO]_'M3L=(]H<'B)ZFZA6#Q_AQ8NX)DRR.;)YRI$+4]VY[!2K;5-+*FJ7<8 ; M?,V5!-+;#/@SZ-?.!+Q_?2:HG #VN&+F):EN;[*ZO#N\W37$$)%NKC[/*1PW,.JW:&C;I]^W$2G M9O\]AJWR37'-)MW0DE9<:5H&FR)N?ZS=4^57L963LUU-[KA_0E25W18WTXDR M=D0BI\,*M]W@7L$T=<6(PR,XB%?)@FIPM/O3'$93E6#DP"A@$< Y+GG@2* A M$"L7/OGMR%,G?O!-KX+ESCV?W^6V6-) QU=3H5XR)CA<'*+:3W M"@\K ]N51S^H=3?!TLB?&$LNX&W 4U1H6M;T7WBD1 364,9F6]?:B)HH9D)] MNF5:+ZILKHO=)?A:9#-\P#\61+$#FDV1Z:?GWAC_;<*?K;*=,GJ9G>W!A MK8RM?.(ZS-C2>%H7:7^DU977^U[ZSR3;W(2!YT%MK'1*&^M/WE8-_ D/ZXM MEDGT3,=!56X;A 5E!48 N%7FUV.W/*08>S6=E?E<9)S^M*491L!XP=Q<5F-= M#[R(50N-.?]$-,@<$JS(5\]81J:XIB()J<B*M+K1XL\$W=8NXLV57:9Y>EYRLEI9;>KW7>BJ[+Z MJ U4'+[I^=]N&Z [CY5@##N85&.6H\EMPN*Y7LB &STHKH2!0)M@/$,B,"W2 M7*3Y4I$BW!SA")"KE D=',2AO^1E;[6 &$5>C6N$DBH2IHL(.XKM)O@YK'EQ MCE;;3A;$'/;9*^,HZ!15+G==%IVQCE6)]?H\P[4?'DZF8$<@DDM3*H[1'-K4 MZ#1WOT_8GCS=IQDX_I.2Q%\[\/*"8(-(A)Y\>9C;BCFQ17B(*CI*Z3^=3U*E M%_\.'\.J5G /7XEEMA@D.5UA$=A]).YC[B2K0X2 AN[$<'*BD2YMG]*-N1$( MG;&@'51Y8XGI<0NB*AK,XD?.?9$9CJZNKHZODAQ>)9C,YA@B?KVL$VJ(KE+8 MY#"B#%^X(P/5RO3\NG=D8V9W%))*S#!83<=/P7^Y7=?-1$^5'Y_;3YXS4HKP M9D53;K>)WF"B +M^.3L(XX5_RP/Z)*1C;[0\]VJ3>H?-#),T8PA-9,0,:V&G M%69'8VH66CYB&5R=4IQ=^3#EQ,K*"]KTW8=7X=/Q^6#4 TNE,-$2XZPR5EDI M%!?@]#E>>RS!JZ1)HK\E."(]>MZE#9CW2R2CNX:)7O])P/.O;3U>&WJ.'6@U M<@YIA(G]!DDXSU/L7^,BCP?TV[CL1YYFJ8,=%+L^6D[ MG7'/%6ZEMT!MGF;T""87WS4)J\3:-3)-'1PW?"4&WQ<#(JT6Z9.9X62CO=&R M=7>4^"+>H&7Y&4PMV-_WU\7R0Y5\9+O*CJ ZNP;$4]/>BH[PHI-^+V_SI,%% M.(FW(94I@ALC=:YB5F0/'>$>CCU!VD1GE*TT#WH2TXH^#IUHK.2,K=57%^#0 ME!1<7*%^&E@K42?R!96B+![)D6,-E6N6A8^F22'(]-\+:N,C@M,Z6J5+TF*K M/1HU3Z[@#4[ZS?WRZ]LWDWAA5/N4UK@A!HMV#"=GD@WA8OVE7 K?KGDC(?VNX#C:N@9(N.\I\3*,A@-N?1X>[LF8O@=K'>+UQ00T&.Z,#_ M>R2Y$H?N43O\QQ5=I9IEZ1F>2(8B/WO":H"X4'%[WO76R*J!S;$O69@;3-04 M9&&>]$&VAUZE4;0PO93TA@*YGI1MQQC)Y\OCDR<"BSNZ%HF*@;T^MC$IQD29 M286E]!B#BZK&.$ 31F/4F;#W>8W+,/*G>]6@TWK0FC/J) M;_E,%(!TGP,;4X@^K?\I/+5)=/3O\; GW-#NO6$&HC M;T>SJ8A@D(<@V'7E''7*'@Z]&$U/XWUV?DG'>O=?RP8-C*,I;AV, P:2H[&B MM*IZ)*-7?1R:C^#9]?:' 5HR0-:G]ZD%_%>/GG'B5:1.M&>N_K<*N**:QG R MB;GF1AJ_9W<"V;H]2.NAX?QK IGQY8SH:1T25G>"_; X^Z_?O7E_*A./QP]B MOI$:G;A5SCD=[-"L'#*9K\C9& B>Q1 4;/.E;;?!P_83^JE\V#(I"E/(#$CM MW=! \.T!^YY\8\"^R>S;Z;7S<46L#9&%38;.'NW31;FM3#/Z0.^%:5;'MG$B M7IV7RVNG=%#-,SRD;3.3P0WC]M6Z?WH=7 MO.[Q:&V3#>7=LL(QL1(.B&+=A:"E;,1(._6HQZ.&X#OYF/)EP # X9IRF@QK MBF'*BXO]AT<7]NP^Q8IOD=*NNC3$1$3?MTCCZ'6SV&^\^/5C%+KB?V5P%&:+ M'8:T1](+]Z929'8IX)+<=YE18AG/W]466]_*:L&].R);C'UI>7H.]C?5-TM_ M/B]+(V*U%;P@D@Y[EL$_ME56+[.%K@V\%O)9.'@+Q$]M(9=6DC*5IYVSIG%J!E=MR5619(LZ)SRG,G]UA M^+&'/3WQ++H2GP384(_&A2%>9/.,$ZI)A-"F6LX4G[R&,[ E@_7XF23(YWRD M,+?1PJ63/BT.I(X]1K>.Y=HUUP!A>Z<%GD1F(10I@J)PDU\G9Q=B'@X/F0>V/&RM$!PP ?2G]+*XIF5RXO& .:8J'1POF9GRP-_FON[P9*C4L9_"(7$Y% MQ/(%."RI\I 0F9CZ>\0!O-SR*. K] KP3S\QO"!F_R\H1 M5OC#?C?+8:R)"=;9U KQZ9KIVXXT(R5UG!"A-D_S+,4#^DCLCCGYU854"^1Y M5&:"^Q-JZ MB?*R)J]GF:P37^$%V[BL'6581@$IW 4]%/D>=I(PU,\B")UK9)H$?;"@5+[- M]4:&DPF$)5FSJML1U[#/(60!XRRNJ7#+U&F^>N0?UOCM9+X=O=G*WQOG-FNV MA!'9W&ZTK++RN>UU,Y)H@9=GIW"15%5&FHD=7IEAP6PR,O?9 M\[9Z3:#M<*2.'2MR47?2& L@HD )GT0 4&Q)*G/N-:Q2M(FS6'H7)(U*RS'' M%40)B+:HCN(^67Q"DL X)NQH/#I1Z9U6>H.PR,DU[XZQAB-2UP:&&6QJ+RX7SU'/GB$^[W^Q$IZK7>XMQF71 $NS6'8%N:P:"71 M%H;I@RL>M286_KM-\N;:/SGK:"_9U4ERMZ_;W]3PRGZUW 0A>4 DN M'><2X"D7R%QANX$[$\:(14?#5*4>R7A#EQY"U6K54KSN1GIF%J4RN48AMBI( M2&D "1/AF).&/=%O#V7P] %E\( .DLIP&TX*6PK/B_-(JH:R9=&@5,3@V_;/ MR)O\I:P:]D@D(H?3E.VI$.UQDIB[;"\HZ92$FH@DH4LY)9\JR]9HIH4W$'O] MA<'5.SZ&&D&',$/[9V"UKA5KE:-C>Y'\.ZF6- !%U(HA^8G^[F*DZ!V>@;\D M&^YI)9I+24M);B]ZO4XK,**+:_B8(Q@\Y=]H"=4W-2?T!U3S(VABQ./QUE/= MR*;$?!\[DS>>P9WFY3;_<5:EL9]22B_C2Z,#LY>*^=>?WKSM@-SIJ6F\6$8Z MCGYR%--M3R(>+V73:;/<02C(Z3$4Z562>YV&%&S_Q;^V>%Z9@Z>$50!KDS[1 MGE?^(\-=^J])>>1'FSQ98!=S[]=;HN3'L$YZF2!_>?/N-9_4NTR$,E6,341+ MF+8C !DHI"WD3:CSZ(?#Z'[7&#-\/\.K$O8'S\ASOFF[PW[CA?(J-4XN+!@4 M=G>/ST!F6I>O\5:2H&?:D'T;BP"237MRG9-)9RUB@)7A()!UD(NFUBRO] M*0 K]CWJ'VWAK,6E*V2=AOY7CANG48D6CE '9'F(28=Y0I'(@R*,/[;%PA.O MP[*C%B-SJ%/^AU'*80K= MGZ/2 Q[/P[EZ5\4@4BLI_V*-HN!"*YV$FH.C!US"@(/2._M=/*"NCS&DK#E< M[MN! TI^&79),@5_65&^CD!VDG]*83#E=:J-OZ<0)C\Z@QML-_3"_7+U:_!] M(HOT0,Z?*48AOG[&LJB88$BETQKW??#@DONVBQ)Q$V02K$A8?=R"YU$+< MO>?NJ\RO,%I'YRRX-;38#F5-30\_3^[*]:X+:B&?[M4WM'FD87U@"0*X'5Z- M1]\[C_FWOY3(+?AS0BX6'BW.^!R/K*I_9[6 MG@DN:5"NE)M]0QXDF^HMW5TDS2#<$Y(%YI.=M25CG](,EQ;+*O4LI4-9']/3 M7MFYHU5>.:?-8]S,G65Q1Q!J'E1B2S;;"1HJN+3C@ MMVSR']_?I_S'CZ3BPOR$B&.<".1,XF 1F8%%5M'HV/OD0F7L V'$S2(X=ZLZ M(!5IE1T-.34SY,\@)XD](\3^HZ7R^$TL8%+_ 0FNH.<#YLJU0Q';A^0"W,6] M@(_!C$N EK&B90A8=6RK8$?QIK&TL>&H+LO\4A/14G\-,"*#4H4W04F=\"!5 MDX5HZBAK)!% *Z-N, / CCXXB(S6=]QP/Y45O+,B=#9-9X>&ZO+N&#M#2ZMO MMN&XP:H#SO*",7SZ?DG(&ES(1;;)4\4EA*&*[?B@.;F+=@\.BK1.O39@,]\D M8.K;B=HV>2552F#)@E6:,"^4('N+@_EXC7;')SD[E*2?,8(O[Y,1?%/PDH*A MOZ/>C#T3C[#;;E?2I4-E+=--2B]:JI<4J@\T6[K:QV569XU<@&N<0D 7XM ( M")%^2M8D2M?47B/5:J=2W8UAO+!%96_':N"(C564F(04V#E5]BA<]] M1>C3692,M5CU?IIP8),@T2A^;C 79F=(>7OYV[3IC@Q]OD!#W!\5(>4!:P-Y MF%GL<"P&Z];0*A!6=>G.<0;[ IQD>19\6XBY2FJUOZVT#H%^7 +:9PK91 =: M 0A8PHZB$'&G/,;(YKQM'I6K1YMR\3%M*+5*C44K8KH5= RO#N7\_XD%-O\O M3:K9&(=RS+T:#P@4AT!Y]HTA4/[\>::'M(M]>4DGLZ 9QY%8#XV1.S5&7EU0 M/WP7F4<=N3NK5BM4A$^FT&]KGVPL,-QWL#&'[K+L)4Q5T7BQ:OIW4UHQ )T; M[3)9L\&UY8&^H0RGP%17I,I=+*Z/HP_CH,1S_,48B,(,H=P@V]ZVR#CGAISW MT7I!U)TE,X=W:$]@W (>8FY DDWXB4SYU'% MXE X9QL?D&COEP:6\>8MML(MY M)F@W)ZQYU,,5VOW4E=*^"ADHAVD-YH=#U+9/ ;L>W4!(U/_6\3'6KEG?UAMF M4B36MW8 LD9?6;WHX-)D)X_O4X3X>ZV=F93VW&]\^'O=3<*J?,8'L,&T3SVP MX%VJV23^/14&BWJ[QM05?8)85/ #9V#3LR90YA4+*2(F$G/0TM1JL LJLD+P M^KWU1AB;R8M%*CG0-\(5L39Q&^@BV62-1)V2+/)AJ:::1Q)B-X,M;%? 2BBK M_5-CFF\!IQU'(WR%-XZ-78).ST2EN6^TIV)'JP0]*2L&+_@MIES8SQA,[/3+%,UPA;\ M>WC9N9.3^V1[SR1CBL9'-G::1K\9%P/?WM_P*'[///+7>[7/A[%:)@C@?.]= M1'+#N#BA[QP.9U1&BPVB\^]U^BU@1B'P-@2@R%#Y[+OT/ MV!?D^R15#P:CN.6XLIUVKEI"1=^_"C>S+2X4\/6L>8WW0@8:_]WV'W=;K8Q7 M:W\7OG-T.E/2H:2UD%W3QF 26CVV.?B&JZQ11Y"L K9R)%+92**?(9B,2IX> MJ:EB$8 ^2-^Q1PKB)S_!GQKU?*6]1QYSN,,G^J/,..(MV\U=&HG D%:<=2>DZP&^O]%KJI9(3_N-LI]XE,PA?(-'A\#)J=6DQ MHGQ\L:KC76[@KU+%Q715G>8MX2+4@R2E1GHV+*."=P\>'7Y9["P"TWE"B4,P M0]#K)?QW2?_2Q$<7!.XT'7GMM!_*LXY2$1H[D4GG'K-.6 K*\XCW\3KFQ(E( M=]2+M;S"YV\9TFAHWDE(P 3/6V*D3S;L1^ M[ZPPP7X(" M 2;P#QOVV/MR\_*G#"6F?<0QZW/(,!/'TB_,5?)C-0E M_*WKA$VS&?.P8PXFR>%%+-%50+Q!.7.HCUWZI>%H?0 8.(#!\X,&&.QB3O<$ M.4#L8[8"-QY/O==@)^ >N.V7,_N=(WCH1 -(4-7I#%_Q4#/D%\>>_>9EX8. MUWF>%!]MLT_K-E\6LK^8> +J=#+GU9/'QR^>X42@V=KF&AJF-C"\&RM+71>> M FH1DB?5FNIRM=N:(;X08\J/#C>2[:/+PH)J0N:V MW=TF>S((49A"H]LQ=9_+IMJN5,>E##Y$Z;6FX9D9SKI]-J?F#M]3BN;[CDG' M?GRPN^3'Z>R2D^.GSV67L'[&!:Q=W!K"@W[DPWU&2B^(SI5J;&LAWU 6;0C( MG;XU+=2S@!5(?R%S<"<>' &* _%RU!;F]'.Q"B0D:O;)B!8']G MS8S3'FYW2WE7=(N16P6MR(:SXABMZ:8S#&^4(ZJ\5&L=9M]-,NN5STDYEB-C MH<1 (M'C#9(S)R>QO! ;:>CVY6( M)(\QMA$QS2QM^8MR(Z4BM0TQGNPH'3#(&1BJ_O)&ZK@()D&J7H4+%3/A1BVU M>87[B6[BV^KF;0]$[ZJ'!ZZ+(NV0P;7,FVO[:EE #P)5' PL,89B=FC&^JL MH>',*/ ?[L!Z*-#]R06ZO_[EY_G#P.<+IO 1-S!>ENH]N'P8= M,.S#<(T>"WQM)D( FH:,9TE<'9QWW9 MMI&QZ!];&S8[K"N4^ !5\Y$SLSY?GD[V_C^P17W_ MYATYR[@6P-DE4'%0(9QS49=4[-V*V7@@"*^JV:UUFN_9CI[.EG99?]C2!DXS MOJU[EI12CM#^#9>A>;U$8]W[988"TK>%G""U\'K&J],= I3]@2^4"08=-\ ; MF#F.U@RM@88;2^C%"]8CYNYN_YG6 M%#XYS0%TO2@&TN"!DA3??D3'M"WT7) M 0"SW;),C;NH(F/HDB;9@;?YD'S"CSJL--874WXM[C GQ79#>$9 \5R0$ [(O5.#W<%MD0GM$.5[ M*EE8X\>1G25A,#DLBW%9Y'4ODF/%-U5LA^Q%'\YY/XN8#.*6U]4U$H1&%R M+JXM(*)J)/;PP_.(2KOMC%D_A*R^P8?Y]NJDWWWS==+I&,WI^)^!7Q$8">]/ ML/ ;9HEI/G:YAGA:) W;BASJZR'= DL.)3>L@6Y[1(%ZL=T7M M'WYF_W)*T=B+X\??ZVYP0'#"7'=\Y.Z2A\.TEP=J*%?ZY;T:A])6,T&>XG^V M'464?-!$T#M$7;YFO=]348*ZDL@A"=IBNIUSKEI3]7R>["*=KM)#"0MGM[N& MG 24>N+V@1 V%SA/G4HC-LPF\Q+IQ:6X!>%10NJ1UHYWFN'-$]KU=.F1@N#RI MA)S'7[-&Q\A=$-ZHJ\))M)DWFI&/OTZ7P?K!AO]=BGI=?KN9R_I(^P)>Y;;= M4Z7R 3 2JU74"$0^'&!O)T, @6_(\TV M#5%H!!\C%L3/.8YW-QP)_B;VX)&,&[ M2TIBFGWSJBNT5]8(2=/,1$[JSN!_CM.R4EC7F.5OD%LJ.&0&0H@0-NOI%88O M'CH:0<=N&)$$"$X[#MD?X?AP&M2_^RO[SEYX!?[W3> MKZO]:3XV$K:N+4:42&SFBAC.7'(R9IZ"R0BV;.#X+"T&6W["?*H:.*2N)^N" MYY:B2BN#/16.Z+X_,;&HZ(N/ JBHTS; BA*/IV)%28F)W#EBV((HA>&9C,=L M@32U3;EAAA]>\EXC4@OJ-^$D[_0T=YS(?JIBWR:+7C=8XO4V<).>94JKX MN6R23W(=X@WRKQ8EB ]\'TZH<*0I4&1,OV;Y9TD9(AD_O)T/!(0^]3E!J3&Z M3J_7&O\B+4N%+AQCIUO:DN0#WAO7+'HK8YZ&B\;>L@>K*_>S5*6"6B[3IJNN MW'!TF=7U%FWGHE1=<=Z@^A/Z0?Y%$FITUROC%YSWYZPW1^DW&+KZ9DOG0U:" M\HSBP@_6ADS(A&C6\ :[0=P5OR;2R/0>?IURU_;;JERE1%E*,+/J,KU&!O.: M_N5@;>-1!)Y$53J\#08C%?P6 428K8$9&L(@J-[BL9])P\;_9^]-F]M&LBS0 MOX+HJ3=!1L :2[;LJJYX$Z&VJWH\XZKVU-+]YB-()"F408 -$)+9O_[=+3-O M8B$I>1%$,V)ZRI)(((',O'F7<\\16?@<\7CP.519YI$*#HYJ[ZQ73/"0"I,W M):.-0^NRE1U1F158SM2E5^1R5) U:;CM[:8E0CP"H5"ARCD:=)9.;G&CJ$AJ MVCI>(YMO5&D@*5[OAJ+'NT(T.WX:8]7VWIQ%);-E]>SO$V!2WCCG.>+%PNX@ MUZ.N&I M77-T<. ,[5UK7;Z:UOH]H0Q"E,'+$\I@-,?C>"+=H&7*<843DVE/A<5E'[O6,*8-AZ^7@>^1PC'$);AM-GO>7"Z56YQ0^TF;^445# MZMIT<&?LL^2ET*I:VOMV6*N0$ROATU%RZ78]SJ;2<^OXW5P?+)5VN(6"Q40- M'AL2TN79@M9M#DZ!10'^:%+"K_P SN$2^?#!D2M@H5)>_XI_\ZL]T7[,L]IST M\H$VQY)WAMB+(Q8!E#JC![_FB0.7.HG)ZQ$T).-)F)J1$MI"P4K\+F M9 ;A^I+2\]@!^GAK<4<3<[8\BVVN7MJ;6Q^*X2*;IBKTM7R(^?O9KR3MR# * M4HG%-V+3]LB"2ZOW]=12S[7'D-5MA#3JJ#!>K;UF$5[B7JH%O[CW&02$R@0. M6;Z8CC[NY48&*]<^+(!F#S?XJ$,HC"KF>GSVE4)JVBB<=)G)?SQCL26>ZO,1UT(<7-'B[ M]-F00\0?WCJKP;3#1:J$0"J%@Z-V.1WB$[I4I6)Y^\)Y.+T'(4<'&<@H2P6C M4JD_,3/' IF>CV9%6B6"/L0T^0MXY&!VX'!\],"G/3J:(++J4Y\6_3Q5&R3N MT;=C2CHZ9$5F)XEFX%P90\K&!CY>FU52!")=1%KJX,MU]@$3%"]LGD0.IO:+ MH 5-_2\,(_Y,Z.L8=>W)'V0VL7RK/VBP<9:3X=SB"X^+%,>HUUHW,P(SN(Z8 MVX38@TB)S//TS:E=,/&MC%U 2.A/6@+1MD=)*BO:/[:RZJ"!CZ@3FR-Z>8ANPQ(+:MMK@)@WU MV"(OF7:_5ZOZMG;VO6('2Z-?3[;XJ-N2?)#HRT5SN86C+_34V$4([O:P=^P*F=S@=?:3DXIV^?0L(FW8P#PX*$-W"L+&5&M$\1BYCJ-7 M\/^IYYRI;VI%:R00(2L0>\]%#<=DD:/9&WQ%2AV3DCZ$:>AY;6$G_QU?6FQ/ M2-VSHNLK^J#NWAN[_%-9CT_-YLZ90$2V/8E$EL4V\L/>A5%:H^P[H M1N&O&>Y6.^8M=NXHMP..N,@/U_X^Q&G$Y#@NBIPA7>%[P_@Y;G+W$*NK%,PA M/.\/)(SCDAQ$&D;091%ZIKO0.?17RN'*^*X:"!JH>1/(&\C J'!A3<]($<442 AOWB@3B)6FU<(KC(6Z3(#D@E-C= M"0\J^)]IY=,5_XRL!34MT>-@AJ- D5A,G&3 M^D2.T3"YO&4A_EV L-)YU:XGM)S,H\07]2F'_KSI/*OFS8JS M+KW<5'^]NGIW).&W\A>?/29_D?M.HI^,P;/^@9W#=V'Q_9^P]Q]-"E#8B[ M4N>]-Y;0/-%!LD141'R[TG PNK%3<:,G"L?I,PPKLYH)(6%MBHRR?P[_U:5$ MDPC?_0+[Z&J]N4E=!*/W1D)1;@1H7\E!&69-G2%)G-9TQ^A4N$&1SZA M((X M[X1C0>-UD[$K1P+V"#J7ZX@P>/7>;-JU'T>5JRXLN._Z,QJDX52\PX-V;N=.70EO;!9O?;VMLSFQ M?#UAA1OW%=ND\2,/Z_],(NPXU,U[MX%U8I 6*SV\R7&N4'UB/2C(1(RL*]S: M$LJZ 8]F#C-5%63_YM06VP5]L$4]PL33\\?D2/S85.2D7M4")7EH7Z(J5^L- M^ ZD+&+K^SL2V@07(DH+(RA,)FL=_CQFX:D737(J[JQ*S4($ZPV?H!Z0!U)4,R8%O2\,I?"_]V5OF@:\ WC0SI,*JT_-AD]( M5L$F>AZ&L[$DN"O/!'-?R\$HM\7N<5RSGG5=^G%G 6EZCJD].^*0DL4Y;#J/ MQ@3%,*],CTGKS=+I6FY?ZAF&U8)_]34N_!R5A=ACMLM8X!*VX-0GO%)6W1H6 M_A+^>QG+J>O9/U-?A\$K>FUQ]S:=T^A4MJ3&MFL0M%;]9RQ_0_A,1!TA7=&6 MHQ[]@IOI+F&:X,Q7%OQ<5KRAY"NU,1().OT:#I_8:54B>QE'V,1CMK%O0D"5 MW=74%#*.-HL$.20\MY9PO:SV3J;]Z,!%/5U_QUKY/[5WLZ?_88[S0EZ,8QL* MK^4HX,-%''43+1DO6\=1QU@8752@S1R*\U)&Y/BR#9>/R4EX5]:;)[8DK40K M']95^($8TY1!#AF+V3'=[O+T82I^G5^;M,F-,W"7$:-=9F912B6)B1N=2.C" MUN/55;VR='"]GLH]K_W#108P1UB709G^+/K5QX5#3>C^15!%B^I?SDNG;LH5 M)2HW:)76F :@? !**AK* O![\RJ+-K2_A:,2C Y>'V--3B3:F,E7ET.AMO# M;)6]R2/AG>%[S]7.1?XK-1S*(%@TC4!-?T^ CM0U3VO4L,\,13@B]:H_) 8]Z!KH;=I0* M\J@?#]83Z?BD[[D$='LHM&2/7_SA*1[RH,NHX'43"Q38_HBYT_ MG49_L<6QUP+G38*%\RI/LA7&%\$2RY)9EF<6N,PKYK#5<@+;.+#-=R>PS9C6=>[3_=3/#?=%8N^?W M4P8IV+HZ/+^[+RV_VI3K+WZK.[??JIM_Z76G_*ZC?]39U_.HX^M?[6+=]SN1 M+GG3[TVNUA[.3-<]$B=N?)/WN7PX-\$TF>3%?3TGWDZ_[M,MLI>]B^P*P840 MQ/[]S6C6VO.S%]_MSKG0P0S_^QE[A'$VD1"\2&#VO\S._XROX_P2)N5'[OC0 MG;VAKE8K?2ZU?U60X/[K%4315"YPA=O8UQ$=@MJ7G(*&.(:Z2:$D-:O"TWEY M5'4H4UV0:A1$8([5!NOJU09Y)WSMF(=9&4QR1$U!-,%4,G5@IS@X$PX5RD)[ M$Q,$G7_,+#R@0UQ0@KW(L#J0;[G4;W]B1J7C.#YL0O7%V=/SQY10)0C" _?C M$>"!@+Q-Q6B%E30*0S1&L!9B8HZ:OXUBF(TSX,@C&HE[:/81!L?7.)+@CGH@1Y@QY)ASK M^8 29-SJ_N$^S^2.') ?X!+?O#HN@M>@P; M^*UW@"@ZL\Z3N1'X'E4CDIS^MK M&4<_AP4P>N)2YNRPEAM-C#3>. ;%EK(Y'7C.'#$2NWOY'"F>!$L:X+2W\+IQD"MC!>DE_ABL1?X5=\QYUO6NJPY53J MF@>US.K>6-TWFV8PIS"#^=8W)!''0Y*:?S9!)VV8:<%EB;NW,KJQ5OP I!-S M("Z%TF.:C*'>VDA*W<91V%@^&'S M1-;W")FR!(R^PN: -L#_+0/\<7'6U%^0>89C30]H"HOWCTG)!QXG]9];&>R: MS.;J-Y*)#+X(1C?)*O4KGSQ!:A-!S2M@>0)K1'KJR/P2TUN%B[^I6 K=(RMX MBXEDLJ50:F_7Y- -F^W\.U\Q'L>&;C/&GS;X9]W@9DP;G/8W^FQKZKVJ6;>4 M8!'U ;NFKW".[=(/AO_D^L&X;I=HRY,#.WD/EFC75:73;5EP@T$3F*MATS3&M>4WQOQWM, MI_)B/*?RY=E3>A%NI_G9ISE17".XV3)L9-Y4X/"1$UDE![5$G3J@ MG3#C59F"LUH8).Q&%BA&[# 3:Z3Q6.-+S.;FF!;XWM, LCB!6 ME#L8_]6;BB."0-7A7V7!+#_^S["433&ORF1^+;? QN6JJ5MZ$=9;Y-"1VKLS M+%VS,BMS)5"Z$5UA/5TG1H M?SJ:W/H@[O@F(E5Z%C*^XB M([;W8L)M<&2I\]PHCVEQC$?S!AR %\]L7-Y:(,$![O/^P2Q'E/4WTQZIA9B* M*ZX.4EL[)?W#!+$#L]D@@YNH?HBEFT@+$/OONJQHJSGB#I!2@G7;Z4[V&M,V MC,)=G(LFJD@3/*8MUN!7@C_8"HH4372Y:6[X][!!:@H#%DE6618W5KX0X^K= M>S+F!FGA2?KM%E%:G)QS=2C)AZ5"0$>_Y^@]U@J;M<^O$2V-2&U_P#S(B1GN MP$HBHL%@+ V*C:IJ]8+RB6LRA6ZTLRU1K^6,OQ,R(SC]ZUI%47!W)HNG57C( M-;EOG"^*49G3EB(E9H^,I>#MWCMU,SVMB,-JR[>![2(XBM^4OI1<,=@KU$M6 M>]46>"TIQ9T#=BKM[KFY,#Y(BKPEI:'I8GK89Z3QM+* M4\G0M2C*_9(N-5&?4H\A1:.][]PA:_3L+]2+)1XB&M*TS61A/]=[X6-RG?X8 MH>OT84K)JX0XZJBSFECIVBE#K^ @V1*[T/G'.(*XB0YM8C&SOZ23Y8G]$^^J MF?M1L571VCTH5_'LX)M9"B,0L(#%T(HI7:*Q,4,INQ/LLG7^"-V M@84N\C>73O&MG<0XIOG-QS._UD*]M;E^?U8NHA_+"KY8M-KO;'XGU(7J=33M MF=-[H3Z<&+N@RZ/*Y:_&,]M/S\[5;*/D8W*#29:%!!,2(%)#0I2(B@X)PQ9_JHQ)791MD.,>6U0*S->5E==-XCFQ>%0&IX:AA-OXRI/W>*@[%$<)6I04&JLA M.6&6Q*CKAE%4-L)P]-9>.E!'$[ N%\D&NY3=ZCS!XE:"JV]&X8/S0AAJ:.5Q:#S]3:Y M]9S2/AF\- 6#=# I;'FQ;4W$)L?P<@[0X9YPT6!]K2U5E=CD-.F#N'&%& GA MT6:9GT$:,MVU W#%-7#6>B;-8+QHP2(XP&,/J!9?'Z:1 HHE['\"U4C' M'/U!P@UVU@GLA[^,55;)K1<")BH]K_"N3/F"3G)V0TH5"%QQM3:C_0T_EE#= MXD[PK?N5%(YI*=?C6QR5OZ8L>!$+.A:>0\ZN^#H(G^$8S=V#ZAO MI$9T4E9?VQR'6#>,%/FS>,#2B8G'D3Y6^XY/SGLN4:!C,#W"BT^0E9UD-[LQ M>ICKLLR-PT33^KXU9JU\F7M6O?#:S)G"9"R)$_OR5D'MIC#L_S([2.H#[3GK;7PD"5&R!4+;>V88W\:EU:!P.;)^308T?MM80=>P3\* MBE:W4'' PX&&-!)R7;.*;ERW(GYW0 V> CTP^V6N6K X-]CPYL0OAYC:T;R= M(S$5S7A,13<',3F?8AHA26\XZ8RY W0Q849>X7]_<+VC8?6$LE,FSSDP#Y"* M(KLT#T4^WQ2X8%>A5ID.:U4]["(*4"?Z+Y/E=&KOL&:IF629H)<1)+RQ0CLW MW@"HN].6NYC:Q@/:<2(.XU1E6/ 66[$Z3T=TV*_ICPQ0V?LTEX-/33>@9X+#6$/L!0'-T2O3>1X!$#G1]G"T1)W\0*@YA4#S$JJP[@LO!^ M9._;#4?F[9NP@M':0LU.9)=D%'48,G]$6K-/0XR++ESIV3.X>RX,>)?V /1PGLH*^@=69LHE\/LS;OH%XYL @_W MZW)-;\_TA48?1FN-"*2 %[ )\* MI-F"NSOSJ6YL26QZ\2?'M(X_C&<=AU;+]@>[0+^/%+FG#W@0_?//Z7[9E:^P MVGYQJK8_S,[;CGCG84"RP7#"JA*#R?VC!.,;(8BEJ:1%WEG'5M,S]\^%GQ>< M+1=9M1,?D.($7U*^8QG4[O=@9A[7.OC7F-9!KP%&?"UR)I2W#A1U77)^JEGC M%"I\+4L(0KJ#:+F#O=BXIVX)W:5WEZ*07DO&P M$I]_>_;=Q1T7P=H41!@B0,UVA8^]40/?_\TD*R4K^XNT#/[$+=Y?2&CT&Q9Q 4!EUIMM]5PD9#+=U<4#OPP2>2H$"PK[KR-%H9LY%< M39518I5*2@659HFOSB9D^$UD/%'KCWH7<1^Y0"@9$ ]H[,;(.U/7L(8Y?VQ_ MBHF"A^6FL4G4#']0=:P%P-F[O3C7@U,4G$C;^&S_CO7*B)PLS^$=L\*=5C#F MJ@:GPU4CQV:[-IU$V/"8;1=T0' +XZ59[9O-.[V18/'V/^09?,-U@<>]T4AX MM^ &]"Y1V]G?B?.K]KETQ$V)-%>CW3B>7D\H'%R;V_OH 7G3LZ ,0Y@K+$1+ M9@Y=N9A^:6S8S#^@^C9VB\=M"@;[+;M+D?6&OC8P%**X"CY)Z+8"T=#S]\-U M"@NY7N&*_)<+ZF$RP>YC@1M1VK1C%LN:R2D1.;6U"2OR]#\ANM*[Y;DLF]H7>!S\P$8["CXV1-/0:N3R.*I%-^LGSUA0Y$1ZO5B9%&F[X8E-+ M4QQ[)3)C[6X#;(N#EQ']?O8_9]$F^=";$KSC%ID$K=WAZJ;K]=UL&K63BYJ: M.>P :HW+#TM!BYFXU0_KWORG./:"B.A:[83@;P\^#K_F8\ESC4_50A_(:%F] M^%.EH;Q$/+\*D1VA+M3C%'2Z>$@[%1X7)'0&FVK#AUR+)Q4='1$[<&7;7K5* M74R^+TL()SVV'H"GJ"G)RM?6J@59@LNS\_/3X73 X;3!%^L":C"3&]LOQ^8: MMYWU<>%\N@JJ0(Y]*5#&XVGE--*B+Q/'"KQ=6FR>? F6[?+SK$_5 M* 5UK"Z46V8)#04.RHLB]5:9#4V539K)('0Q84(#5?B]^FV#XKG M+0L8^TEV,YVZ70[;?+8=X/S 2P<&(!MB!VE_TE[^AJ[>=P2KU<+#OMNU/_-F MH2O^.=O @3T_8/N%1 YXQY)6MX6K 1'/T)4M\@(C_\ O.'PB");B51$]/[NXI.3P^1EFE)BY M1[[]EDHL)!-2MR1O+Y[:>8D'8WER96Z2+"=#>"4UPK @AO]>)>\%Q-Q:$(^! M6?:DX]IY-8NF0M_L0=\,\X4'7L(K;5[PA-X.^?_6,^[& 8:3F)>A]R)KV.9WV1KST-UZ*5CN\4=&.M.7Y=W,#.< .S@MG?[[P@Q:'U4, ;< M+%4N\)Q,-(S!L?L[@H9 &6_@^:B1#]\D9^S4_VZ* M^WK:=\/.Y'9>5.W?E$1T_+HP]I)7I/J#2&,*DZ:.]SO?2K^,UWV/EGDY2^AA MS'1WL%?PP/ ),,@C5C.]H%QC=5EM=U[IP-!8$L2.HYD?2/J@I!X.@W(TKDD* M1PH*W20?N"$6HU"IF-S;C4X"B0_E6T@Y;>A5V2RN+TH,X740K;J=[MF9/6=2 M=QOAAQ HQPU2/BJOS!I[35DFTL?_/A"OU8<1;=!O5,0R'1*N,P8%83H?;W#4 M%L:M/J>]U$)8(=(IM %ZZT^'"W] M5']T NBHP-$CU G69T/86N>$T'5#BAP?(@#&D"MFS:!]=D,^+ZPG/B[4[RPK ME4-S$>,VK36600NNOU/T%U>9'C;?A<_0D'FC(N@F*8[JWUO0)HW%\8Z@8U25 M2!B>.DPP(I3*RIEW::U5!JLT9WKE^!1L/5!GH3S28,\"?"OYT,?>3Z9 MRT=>P,E,Q\J+L_/GQ[0D1JB>IXVTQR<4A)HF.@<=.^9F20?S+&.W&!.IL)0$ MON L/0O[$ 68) J. L[PD.5W/%'9F4M=/88L MY@@*?"%.GX\S ?_KTCP'P!;AGUJVJG;/80^U"@HSI"+8S)_ M(]2'Q Q%5M>8O^(8R;.?$>,8BXC#3DHM8YD.;]HH5,6;L\?'NCRF>1VA>%4( MO7-X+_16 [\6I[N-#9[NG..-\#Q7S7HSEU:YLEHFA6HMLJRM@CIUQ(R2;8+3 M3YC]N(43GHG@,RU8JV:/12XK2MOA&.+6)=7M)*P_P!4G;K]UZ>(R@[K'3=7M M%Z(,DFL2TK9,_#AT%A><@61V_,.N<%2II!&J7^DM$#K^%,S91KP>"C 4+F'G MSS?ZXM>Q_2T19M?_;6 B%DC>=BBTW@["<\ZU;WM,-G&$:XKUDS7!Q_YE("3+#N\J:?,ZM;%)DGMV2/D>2!)"#1V"Z>2^'HI/4T3@ M/0R$$" $G5ZUFW+;WFNETKGM1A11N*S"K%JP80NW GDYD%NST\@MR^Q-5L0 MZ&QC2>; GA2F;&IM'.>2+;%'I$['Q;W[9;"NAXJDTM#.;F6 5>BQNE@,=E8W MCB 0SO(VFE3OK*Q6956 D6_EC6G+O$8$$9'*3J4.1(U2)_/*LF7"2]9MX;NKG\],+KP%$9>#F2L M*8<5LGO<\XY+[M@JK2Y-AZ62^3'V"9C'RO:R3JA2R/5 MQ,..7NV>-W'DZ7?-;,H*Z*6E%H$I@F&Q>1.YKGY/!#:8AJ\6PI)QSURKHOX( M\XGM?*"D#;_FG. (Y49_O4W6T:N2^S/;L?-.KG!?0IVD1W7^C%"\,=RNG8:; M:]Q4NM.&'17IM*$N $(58@-.0B!4VKQT?-!!-I27^$POX-2J]>E#85@7#/QA MGY)L<4^SR2$])AU>@^X14DZCE,FY; W(G3<>'3@IS,9K=FR:2N!6=__?8=Y9E^/_OU+%J8E*0NP6;9SO_1_O8-4A'OM!W[&\XFG+J\2V87KC?I1D0#&*[%\I?@O"09=GI@EA ME;_!-GJ-V&W!U)-*U\!6S*S=WGM/C0)4QMU^VPKUKI+%F M;^U3A-'9(H?FIQL,#%N$@&JG!"34I-)&("T(<*F!%Z0*R&$G#6P(B, #E0B^ MV#3>.:"L#K);$%@F6[@<*A3QT%K=L#!FM3"LX0W>Z9"#PI)+Z^E155M'*!L\ M#-PG@/Z!NCB! ,[7I7DS0D7ASS"G>INR' ',TGO#I37-'D;6C@]8ZV#=0:7] M2-;$^*1YFX(Z2$S8\N)J%IHB/9 =&N8$84VDF5E08ULE2>6E5$P6"\W:V]; M(VZ\_8&>RW3X<._B[*4/]WC9!+%['#P?^ [W(]#I0HB#]MA>KH5S%U(.44L^ M?B[_\TM8WC_?H F=I&[CPW+-4=ZK(2MDH:F&6FA_5P[T#DVFYDCJGX6S"9^.UUF3,B!-_+ MU6*1Y9D2A'1%+OA<7WMOK$-Q;,_N._P,%:=G3E68\$1E73_QOQEZ,0?B%=G5 MEP!DMZSMP!L\03\\]./R!/WX$H;N(SSX]E"!?;MRLUXFSRY)9OSVS4FO OZW-\SLRF2 ME9)&0>S:'/N@F]D3I.JP]>R>;[4@.3T>$]KC%C%=$/S/IW'TS?-]3E7L%AKF M@^ .>"U8CP?X8P- B.-3A'CVN!0A?&_NPTI"O*+*0,RZ,^1Q-2O#AA4!#J$#[S3JOK,<[_X1/LO M1K@UVO)12E!/-XL>R62/CQ8>\T&*BV& 6=A'OJ'@8;A2>F!C.(6\B]O!7?O* MBB.].YY#7,J/&=E]$)=M78@O]18/3';U]%NX$2K6#*+;ZD4M^D;1NL5U/<4' M$IC),>W.$5(PZ2;,"4/&EKKA$1?*]+XK.-" P#7&KK/MV_2JE@$(\01 >X0 M--*P)@$8W6]<,:<=(JNGK(ID8>J6!%,0[0>DQ'IZM5AC)M]&8%'HIDBYE]7O MD=:P+N>91[RK'JI8$WB@FZZH8+CIBC#U+EM'J'UJ?';$6[#XLWFV3C:*S9,? MA+[*6H6NA$5ZD%0R)SU+#K-16['[933V:&@7+>%;M.1-KF1L7$&$6P_U]HG2 MTM26N@A%J#@*MRTCL"?+@A*P@MW#Y&;*11I*^-)91YD6A OXZ42#O\(&&Z=- MC%&\/:^879X.@?E%@78T>S00IOU?ES5 ?C M^"C=$'0:NDV'U29Z]065*_9*L*]ON6."H*=6N6T%&W,;&%"T XOL@[0KRU>M MD>+Z@+0V*Y%2EERVARL;0"O*ZKO0J+*;[&N3(S*K;'HZDA_AD;PK#RP%=K6^ M)=N)Q+.=C.=@21M.]Y&L4!H?JDU>VL/_C#!^2^ M%'QUC7M5NA_T6.MF9D=Z,85=DI>WK>W8?0\;?!SU\'U%^PLO!XGG,%S[;HD' MU\L5_%D>P.>D$"2Q+.%"QV3J1T@5>9B=WQ/J"(_U_14-A[@*]X?/0?1\3&ME MA*22_7L6\S%#.:1==;-.?4R7Q_"#OQ<$O_H53FICCWS\SX#)[3.T:+QLDU?? MV >-^W)JB[9%6#IS 8:UAY>V9G9,BV^$])4!)3Y35T,PANX<>Y+)?%XU1-"W M9@@*K *)\NYLD80A9:@?M,_Z'-/LCY"]KV<3?P1@JJ-\W;$=NSS"ECYV: ". M!7@_0J:_?_^W[\Z_1[&+ZL:D\,.S[W=ONJ\0Z/7B*P-ZC6:[C)(5\!-X]F$S M1, 3SXKC65$W%3'TK"NSRIH5I8$0VO:DK)[@)_27)"LKDA$-B6(%S1#.,_NZ M6F)&R"$8+)_A97!X:K!S"'-(D)J%H1D/F=MD9E4X'A?Z#1ID!"X3QR]XCR:D_M55OQ99;&);^?M:@I(4EY E=G593/ C MYHQWLJ-VGX/16*I%X<4D&N)I$$BURD)]/9']O$)P2T5)O(>1.%0NVL&JT^_E MGK*/AQ0$]VG0O! M/I7SF#^ V2 ^9*MF96^F:HT8R\TW3K=*XKT>&%-?HO*R#6;M<^;'RATP"KE/ M7GI>S%!-?)OXF8P[_,!$P8$$8QA%"\J-B?-1KBEC2L0TJY$,<9\H?4%*%)27 MKS+/-!R YO#7S,OOT#ZZ?CU'G*GM5A^ZDUY0K$B5+,%QJ3=6.VZMP$D'+/M> MKD,L734S=G$V_LG_IH_70IY%BF4N6Y4*7%/*TY)SN_-S!G6&CN;YP)S&5KZ1 M^^#EZ6U;(5?NB$_?5,9(!;)UO=Z="/Z8@9834I(,5B7L%NV&5$J4?HJ7#G<;1 M+5SONFSH."%ITUI[^G@X5$V7(34WX%!7BE9G:@%0BH7]$PBJ4; C,5'X(+=E M]1Y'0.%/4?.),<^3; 4/=6V2''4FX/QEE-C6AU[(.5INC1,HK34V+$83#_N! MOV Q9CHA0-"=?/'$_2;VE][I3%0F6\WP!; Z]G9M@N!,OUW]^_"I>]X[NK<5 MRUD-OY)CVK$CI-PDVFWMDF M)TQ+-IV@",)!',VOS?P]&,LJ66SZC3_\D[3*<=+!@9@(\6_+M4Z3;8X/$)7P M4;I:/<6KWA8NSD"KN5AD\XRD6QI<]X?2PHS3.QQ1?J8GD8&:B!A7-JR0(KC! M!09*D\MI]!>[JU\G6V$W(&>C.*Y]/$+.RATX,K=YHD4R=PCWI$$P-5A8.-#! MP8 M>!,)WZE=W=BW@6-1#I.T=>P4O\0J!?6"AZ)3X'9%I.;O3!9CM6<&K[N M%/?SS;0-]64-*\^12DG!+-2/\]F=.<2/\._-[A[ \W.N]-ZTF=R[IL0Y=W7X M>_3^9SS*E!L=AQO4NE=])$UFVT_99-;A,.L-:"R-V?V9;XZ(0;D9CR=F ^>F M\%K@PTF<+J94FN>-76X!MFX1+:[===KDUA4QXUF\W4XARMCCW6W1S] ;?U,.#E0*)8M!H] MMR9B6#*Y MJ4_G*D8DF7]#O_($?",GW5B]3J'CX[%22>:6SMO6G%IFU):KH[ MU5KNP5,:>_B4-RE<%>RBIZS:O?@2?POKC0GF9E%%0R&E,.]2+Y(Y.-O;75BI M7IGMOA#%X\Y@@'\HA-P;WR9X9@"519XT^"QXATUB2X):E_ M$12U$%ZE7C? '"CQ:RL07.0-EK5@ZC M2,A 6^WJ#*1-U],Q*&?1;T/=N; +$)?O9GW&]9K6D]JZK'N%PB6T#7O%^Q@= M*))PQJ.W2U@L%AL?IY]07Y>W!2ZB)%04GB4YA1/UM6%YO_\J9RBL*)L'ERK&"'-X]":J:GG53;CF>F0\#V;S#"L MK,IF>1V!4TU-&\(SXR^(428J/7L6-WC$&1Y$6AQ8J5O1YB-9$ %51]G&K#J; MR?-&5_I*TV@%RXW1\C!V8L,G&U/0)EZ1H,A"$ ;T C*>A$_R"N*^$]$EI&AW MD0@G L1P:FBCLF&,$515U[!>F47,_D1(L)S4)=ED#W^0=M3=7I;0?LE)3R^< M5Z"I=ZT_+RY1%OFV#=9FK\AHFTRMQ81.6]QSF#2!?1,77"%8=_UC?] 0!@S! MV$,8LE5QC+8D4&()J&8XH\U4\7<@Z958*CAGKY,;Q%F: MPD=4M+PL8?9N#>K9U+/B$>>%\GJEE2N4NOX,PXE$#?OXR."?/R8R^!_AWPEU MAN31*R9C?%A.^)],M30$,(;# 2$MUOUE:1[K6TG*H&**S*30BFBLE4%65-0@ M%R(*"SM7SB3X)3@$MPD=_:+_S;_NH9Z)_@ 'LDXSOAAN<#!0MA7E;]9S_^_@ M0[;#DCZ'25D:H!AQK53)%,0)II?$FFMV2-F@)!V'9F7#PC;T2[X_<]SY6Q3E M+<3/!2/&%9.LY,\I+\WW7"0WI2.#MJ].$(BL];5'2YTV=^TUTR6:H",+L9,G M>O[/R;NXIV!H7:XI^:,KW%:\:>C44A]X#/G,4_M4Y]4\?(8W:;GU-F@6<^HT M+ZL;%BVTE3OG>KBF\D.6\6F9GI;I_7 G5].HBZN**=;F8FFH!U"3L:2^'V91 M:*_1^)!5[G9$$H(S8.V_@F!N$>3?),B#TS>3U=\C="B!H<=VW")GA2/VIC/= M_A2SI*>--+52PK<7YR^_=^+6)_R'QW]\>\)_?(D=F;FD.K>1;V -M_!?Y*U4 MDLWA'VP,FH-/ZB4S8 MI(A-50.G2F$QP\ZV:NI4>%($0 2;89)PZA3I7FBRG M1\4=.D+9H\0M 0X$&TX/JE*(C@9[*&U(&46X@U=.5E7CBBHED^QU$I@I/"-P M@8@L)P-<.;MR+)>!'W/T*VA\6DKWPD9BH.2@IV8W?](>1J2]I)^?Z46=J.$_ M VI9*@1T&NG435;PT1J'=?QH"&LU1 \6\T! MS]Z^_3T\XZ/JP5K34^YVM(_)SQZ?^-.=#A97RL/U:"M\ M7@8.=W%NEA"G$+^BQS!V=-MY'OC]&J <4EEGT2=&>.CXMVB".32D6D%$<[#JE MY2J;9[GY-+"-& \=K<],Z$*TI#77:_ROE4-S9:F_^\"[%AATB:V!DR"Q(8F" M MYY,%(5( >_S\NYIO\+!(_PL:[ T&3SA+-3_'J#[R,=+OF(/4!0)S\<<$9G MM=)D0H%%>/\FG1Y;,]P(]8L&E-:[4NL/M%.^H%?]&=\_X3Q_;H$\X44BFY=3 MJ,.CHQ(ZG2O8%W-XAW]_,Y!IL_I!WD^TC1*Q!PSC)'*(TQ6WBXGO'^NWX E2 MD>,&&X 1W[Q$9)O$>T$F!;U.RMBH9BQ=G4A0RAC^4*,##:<^*EY-;0--GAML M_,B]C+-=;*YL(B\"_^P:5LA%=N2%]Q=78K!>P>85PV#C_$:GA0)]W!+7?'!^*]?$P@7I6<>6CTKCV)=+X(=A@! M.RQ6=^O%4IQ2>OL[#$/=#2#]"B$JWWUE$)6Q6(81PG_UIF=F!.RFXMS:;5F1 M&Z?HMP^$AQ]ZQK7O[L[(@G.Y<,FFYIO ?Q=-[A)<99$V\\VG="&4VQ/;VPQD M#1W\S35TJR'\T:3+%75NPW'-5 !HEG33@%.M%WEX_MV"PD356F"1)^^B7W 6 M*0V8)^N:)F<)-G &SP%16'I4V>D1XHC:RS0KL(>AE)(-[%S MN!>N\A?1K4/.5,MRN//6+W;>^L6DG IOQ.L]=WZ;F8%9P9/G?.=M MSB?-J%;=7S$1#+"ND/C"=KEJBSB.@W)3S3.>=$RQ73S]WB T#UY0 M6B)\@GYY_GU7IWU=YAGQR4ET+,R0N/C^BH(]A7"37#6;Z[(2O<%D:8JY5*,@ ME%:#Q$O4R)\75%,:F8&HX2A$D.LS6:34S+@F/;.'R/?.X.<^@?DH,,AVR MWNW;Q#Y)20=Z:J$:'&Y*-C1,6CBA$.4THQ)YLD"' 8S\6289@UNJ]V3 9 MJ^13@_W%/;= M\]@;,V?#+GA3DZ6FO4P&ARGA84[PA]!0.7-Y@.33 M(]_Q^?C<,D(_UK&"[.$O1(P3(U'Y>PO(%\86#F74IQF>4&,K]SQKCWS"Z#UW M-H8!,S2T[/S9[;%"PGZ$Z&V1XSQ_PZ+!E"?[4'=D>)E M]W%^*7I3?2FT,=0:S7\2.J_K,L<0DYCHP2-?DOJ=W!&%KN!P0_WR.JNG#B2\ MYP%:A?"^81Z3^UN,9]4-X11T+0'.@S]*.!XBC"";RB?2!"?C.,EG#%I8H62. M"HAB.## YC]_^3VV'83ZTS.SN372(Q_&ZTTY?Q^5:UK(<71+BVVC'#=J=H&5A;5Q58:U/7F=NSH%/4[$.,[\=E:: MD5:.VDT 7;C0KEF/8ZM! ML3QLB]MK5!NJN($>UN8P S-+Y+9''_/'T$DB]@^O(#YACHJE^,N*)PV6*NRX MN@S4&4[B"I\3ODFA=8L:E!H5^U!5+=SWCI.S3?C2EL]LQ_E3-DM(]8V'7,L# M=K&0&BA&^-A^P#P4_I3/*HU*N+8Z=#8G+KI4/3=0XKN2&L4[=E\#VDZF-L(8 M\YA2 B/L:QI<8'WK-A6+1?S7N(:M[J57/]:JB3"OLT: EK84>R M2%6#2$FFS6@5]$_898JN>>*^=.?5;M704/_MT/6+7_B:EN_X>KSNM'IMX@'9 M3##-$ 8&4C3M$6Q%'56"GF:8'CAD+9+SV+\:=RXR7C:52Y&D=JC<_^J5EYQK M[/K(/#H#[TWHM8!J%5P"EE+=B##L84_R<;N*(B=D)?+2ML@#,[SUCRK[-L)& MM?[HB6;818Q#VV?0:0GCYU[A678;=-HNEI]<$R-^LY0.IL(L8*^M\X33-N#( M0CB=ZU9IIGLH$LXP6]>YK-0!9%;KO-P:,Q@V.H5,_K+VNC$OS&UL!3)X+GKJPWKL#\MF7<07ERZ;=<28I/&U M=X7*>"%LC]!ME >W0IBS@("PA1A4Q%V!TFX 53/389F]@7@#=S_FQ3ON'Z%= MO/8YPA@V=5A!K%N>TPZWS\)\&,IZV&E-G=DXBAW7#0[P@>U 5NH$5O!@A?.O M#*SP0!)&JCS)&[06545!O-E&SAMCW4J/ N[@^D*;SCX@Z4)/SJ?1-Y>N8+'. M&[C-Q320Y11ODOC^$H&IOC4WNZ([^Z2;*M(8I;GOYJ M[:16AG!W#W 8C)TP?YROYN&1^JVPB9$SB_[=F\Q*%!YN^7@,OO.[A37B VW!>V MY8..XZ=P&E]G]3]W^'?%YSI)CFE/C;#]_A\)3'8QQQ8A+) 6./%OW_ED@P?, M_Y9\P$6@$LH!NKHL4(O$,"8M6T3_> >7P<(K?"Y!3!&84]Y$FK=DLL8V],I( M!3J$L[4_J;J>X V4*3A/XSPA1]34%B9-=LTFS@+- 'RE#[J*%D)C5H7K!CZ7 M(98AO!'#K.A/3*>SYL6%VWM@R>'D_G[VZUFT,"FEFK("3F48#HS4\JJPC9.F MY''._3M";-@G>\C)ES;M*1>OV3;7RK[JR<^8I-7C.^S''>04R]99#2X]RE^$ M#^EX&'&JP(N:93EC_5KU4,6G5AB\&94X,82'Z\_+FDM7YL.:T"VZG2]0'^+N MHD53A34NS,PU&YL[(_T7V^ 5C!:_;]NGNNE(H8=J?866<+=2U94ZL'!$' +G M4,F!1([.*@H X_R#@K!H/'GOQ8_I)!PACX9K':OVP&,_.I4][2!L<3TZE*T; MR"#&SU(AJH6^[;P$VP:% MSXSWX*=)7!& >Y%< 0#_N$YH6[+CEWPPOB(]<^ O_V7W37HO]&>ZI[MCCS#9 M496N1LA-YQNFG9:W(.Q851UE@(J4\V=<72WO*YI5JB-,WK+^TFF7" M^Z'0X,,ZOVX/7)>%?) QZC6WUO^SH?HOMOG8SIM%@&)_ XMB!E=U^$D?2SGL MQ7T>SG;6RU".R7TZYB=IG M(5+!_'*4'2Q(HIN46+?O8XYZTL()]4^26J#4!>>G3.HM-GL+%&G4%EO?2T;R MHD_!,=0N"B-N4==S[\%JT*7-7.2WDG4R)_8>\16Y)HQ;I#6JX4$=EX#=3IJ% MAX,9].7@8YV!CV$NP5?(\Y ^"3Z^@:.8%N&"Z$N+6-,0?O4Q'"D/6A1G J1,T1SU M3Q*U!,(D)-RV2*4FLM?X4X>CK:_L\!();)-I'"%S\$1@\S9?2=D.Q-9P[=F7 M*L[/%64HZX(=S'"H&2-)%7I-D)[^7Q M7A7L"""110X4B>,WV52"E4;<4FG2;B50[Y0JQ>#M_+2,5DQQV((*^7- MDAH;WVU4[8L(.T;285YLT9+:^H)@%5IA>,3\X.B+[+W'G"Z0@!5"I2]1'J9O M[;W#454L1D@EQ-*% ME-"P&U(U)-CD /4W<%SF?F?KE5M/V.R_&2T,%IWEAMC?3Q=NH\4JLVS@8"JI MG$GU4B&W([@23)VD@:FO'O_!CVI_8#$1KI*FX.POY1-)&#/"BRPA?N:Z*H/> MYA1+][5"4,6QOL[6%$-;*H2/:M^WALG/G7@$%3%;2PU8[@4/LVM6#R0HL$PR M$--79)XA/KHV2=IW;5UL#EY#CZ;M/2 -<]6XCC/MJV6'MDYRA>L MF*[G05;CL>G6CY H*G1LG"8(;J">;$H_ /'@ \EX56&BC4DD@(+M"9:O1A&^ M 0V2YW11K?<<@"E<:->"E%U"B!1C@$1V[?UT>F((.C$$G1B"3@Q!QW"<*#OW M\C$Q!+WB&!26Y\\)T4[":OJ+K*R'I0KZH5@FRRYG,WXTV#9ASW^:+7";Z(R9 M1Z?8!SN^-??M8UISOVEW@[/TUE(_^)IS/A'EL/U [1'R/BM2CR0:/&&\9'Q9 M"0GY/OL?:[PJVEJLB:,U5B$$)J;K]ME U:I%<@-O>F=O/EES7>YO\\'0G5T1 MK)QMDJRP>,%[7E+WG>!.YB0"#S2I5BZ*S4VQQ'--O7"OT8 L' &65[WWB3W6 M!@J^DB5!*'6.'HZ\G=:GKY:$!I(3\Z=1EXLE59J936VI4(U7U]N"W M/14'_7SH9&3%39G?H'Z8:\[6K$*AJ$* &5=@;$: M&JZ:HK>@/?*S$'Y.DA+\VE+V$*01P%YDS0>]OY05*N.AK+\_^@E_[$5'E%T^?_,B$$ [W=.I$.: 3 MY9JH LRR9((=CA]I113A_'O M&>SC:750M'0'V];HJ%0F1THYIT"PZDCGC+?+B5**$\Y(^$F(+7U(+MT&^L]3 M3T!DU0^="8(OSPQL[04! ID(*R;\BS >+1KQ^"7/R(!JOJ_J/SM5];^$@[%K'R#50YX@1J7H\ 8$+7ON^^(( M4QT'O&Z"X5#1U-*=?'YE?Y-A3,9_7&% -FDI>]9;_!N'E^;=(F-ZZGYUOKPB1PR73E M5C3F';JI!Z(+L9^S>?@46^ ^BLXQDCZ MZ:P)"9]$GM'M>3&1ZC8A[4?8O?P M/6%'-2DCY$^*WE4ER=S3#;+DJ-[W"+EU!N!O1_+"1TCA,(0W/)(W/E)& )5' M\F"XA74N56H)Z5FP]Q*<2L0[$X0/ 2(J[4*)]]Z,D8)SQLZ9C5N>+!8HFGR3 M%,,=!PU$<;(*M"I(?->H$4ZSS,&R'6% M-POZ0-U0;P#C+&V3+/^$Z"D!76)'JORNNH'U7Q,3IH->W@E42S KXJ/H$E]R M5=76VJVK4X9E[X.MP6L.2(3#.KJK7J15LT=1 ,<8.A[]6>G+0OM M-TP @87Q*27;=@>.YB[$]]33"[SC*R^.#Q+TW6."!-G98C"&S9*,"@STJD08 M+\,Z_Z:$YP(:NE_,&_R3*9%1O8AIRVQ2#%1W!$@6PWH/UT^Q= MVS+H?E,Y"+ '[.ZY1,P9^Z&*8+>P!Q>4/QNFL FHG.0ZWE1@UHJWI.MXN2]G M"9+*$V%OS+TAA'QN5H;!28@-Y P_D@J\!2\!;9]_$:$*%Z5D$9_"S^ G/:R6 M?Z;525?\<[8!.S,_8+V> #'[ #%"5\[Y+\59GFGF2QCO=3838'V!U2$T2>O< MI$NCF?\OO0-0LNZ=JU%?M>I;+R(1?272%TSVYZ7PL.MLS T>5R><]0 MXZ2WT]T=^NV'8127BX[<'F!*%6[ZD.1NWK*5%$02'S>V=68I_5* I%T,16IXHKLO 9BSP-U+(=H$GZF $#U*1? MG[M2Z)<=B$BPE6S/@]T_]'>$Q&K(Y!TSE(]J-?YE/*OQ_.S9);X(A-WV+J,9 M]T;[Y<,P&>[C&K!= ^3IS]J1E]"-^$,"%L4)L^,Q.\^/&K-SR)9](!2/3R!G M ?1NB9W?!2[^MN?.R%%4/*8T,FE_K$KJTW8AW$!/WKVS!HZCVPO#8%-EX@FA M=-PU=8!V_W3!CI?,-=,$="YEHE2BM, ""'UM#2$#1H 8.\1M\C)Z-_@7?"]# MW;/GD>,!"4;%>'\[*/;..#$CKP[/&,1)8D1C-A,D;/?GBK^U8SSKWJ+UX%8' M@@.F7MY&<$TSYWD-FV44M8#KL!5]L]^!0?U52_'L]46W?Z$U2Y']44_#"> M*3@_^^[E)XYHU,;M"R5T\W6;)AJW(9X$M82WKM$\3.^K4]V#"6T:XXYH^T-S M_)\<@/BH5NR/XUFQ%V>7GWK%ADY+P32&CC@X-;1>:4T6!CG52;S/.PNN3&M1 MC_=:8YPTFLO!57>"^T,6X-&NO[^.9_U]AAR0*< [GQ$:O&[E7M&ES0A"6XII M$_:__;W7G"X,W7T=^DC)%;,WS,X1JW[;?,N0%:[DV*Z"&$OLN#P]%0'3N:NL ML#AC9A=^9D_%PR%N"]0\:G.NW/5R1VZ:_^OKW1I4\\*KDNV,T18S&B1B(9>V M^^ ^6C!+$R40RQI>\ERZ$JQKOH%WP#VOGP3D<(J(D/]$'V;XB#_(^R.MIE M_F8\R]R"H1=EGI>W-I8,E61W)2END?1HEG']!_M# UTXEDD4"ZK))MI$%(NL MJ@=:HRUMA5R%;L@?)Z$$(<5L73#(_3"IZT 43=?#XZ6G +%!.&4H32.E9QHI MVX!PJ#+*F:$_R@"/VY_Y[_&LYN=GSUOIEC!O2FX +.:&?V0$GZLIM]"[7@I) M$F]>DE>9XG]:!J7A]Y"NT@U$&HDDV"5,A9?2\,WZ-:0/\SG@5D M3_T=J=^#"E*,2TF'"E,V*^O!2-EB;\Z9V3]TRKG'376%_5XD@/!MU71Q-H(L M25V9LC@ZC-WYT\>$L?N=G:!W0B3]L."Z7T3^S_MRE*1N:B%/0&>A!]M%?Y>5 MZ>BP6]?@Q@&*R5S9Z7U1W@J&9S>(S1-XV0X$N!#J2"!0AR5PK?H"6E,$E,5> M3@Y&M[7:FDH+VW,J46M+11D:0QKQ9,Z\VH+^)UN85"2@B<;H M5)]7]?G+HZ[/CZ8:S_W_$TM#AQZA20JQ#XI"[?>I@'HI:9!B 3?--@[E6_YR?,?[^6,Z MWG]T4GBO+$KB08_XXU@-HZ./V[4$?DH^9*MFU:MN][#NGI#PQKU![$\FJ1M1 MFX3/964:&9?O<9I!/R5@P*)GYW%T\?3BDKW 7AF_Q.72ZFR.Q]TSA;SN'H(*)>P)SD"?KVOS9_N-[ MK/GFR?;/64%ODK[T?;AI+N&UDTSV/,GE+G1#_K,_.,^>\N&Y@6-QD]H[RY_/ MZ$__L4F[?WO^[=EWWP[_^>G9^>#?]ESVVXO#+OL?-&0>-KR9>IT4_^^?GOVI M]?)H7SP]@]>!X/Q:EK]ORG7OGV5?_?EB_2$Z#^T/7K+S;LOUG^Z4$+DX M>_E2_8ZD4^TOQ^!MT"0,;KN6!R53=?]9X,<_3=/]IFF7,55O$G6,67 M3T^K^&%6\:]FO3&K&3CMIZ7\29;RQR96 (I/ M+LX'$8J?>U[/SRZ?/A"X[Z(#4P4+(#W-@1%HP53^@S!M/:BY\&+?[MH^/5CO M1XLQ'9U@[4Z0:580R/3'[ .V<5S#FS8$.1X+UO3S0$UW/&ZO2BNQXVWJEHC@ MW:&I.2F8?#);?/*"55\0A6/W,T\H8H?Q30=<'J?P,4G*GY^,\5@\Y--2_LBE?#+((_&03ROYXU;RJ2=Z%![R M"7#S]_@$GZBYSXNB@ M'W)RZ)6=?S\]$E9HQ1%^\9@XPJ]6^-?CLI&2-/V=(?+].YB1I886[6A+6 MX]K-)#25&E:>?,B986V/Q*X?V[9 _/\#4X0:@F6QR*J5M9BSO)R_-Y48@VB# MK-MT-33&O_]/M$D^6#$!F)MKF%$23@,;GJ)PAVV)V#O?9W<2L'P49N;98S(S M/[++_W\FJ1[6FOR4O#>LDP;'_]*@U4";@GH^R7R.K308BZS!R9]GK&2Y<"H* ME5F7%?\=9?VR.:K@F ]S".O1=%3&:P/^]>KJ'6O*S*:1>OB393G(LO3J,:V2 M;1PU:UC]MQ5JFA5H"F 2[%:_2E?@Z=2;BCJ7HJLEZ?K(/'/#EIL'V_W%"D,2 MD&[Q#ZR "C$0BAWAU%(OS_IP%=^8?,NF9M01Z7_SM;E-$/ M-^+MOC:+!&7HKK&'=RX26-3DRZK86=%DK*W%JG7@I\Z3IK;JES.8*?1RP?5@ MT6Z2N?[\"S>T$N ]M3K[5N>7G9?Q:%N=QZS3AT*YV9Q=1=RV ML'Y)M*]L-E':T-^T-J9H?)K%@ID(V&;/EY_FW4-W1SH*5?GIU?'N1?=RP^5O6>/#O[MH?F -PO MP\[* T;K?_K/B9E&VLFO2/*S M_2.\B9*+S3#ED8N'G:F(C<+9K^5/)OL1(. M#U3I(T.J\^0]X!?Z%E>)=5J\#]VOQ/4#/DXAH1.Y* -?C64M%V7Q!%Q\N,T: M5HY[*%I]--C8NO5I B["5N\4\KCM=^.>)]97\6\FO F,,PAPDYLR8TO0]\"+ MJEQ1V6>3;1I*^HA+K4S]-Z]E$#EF& 3-N8N\V8> 5&UN=U5O^S@0V]R&"8[4].AUQ;ZX]*O8%%OWG+R+_7](WZ^!(@ MEX\I ?)KDO,>>8M)A5DR?Q_]YG7('S@)\@,N,[:5K'.^:ZP^A4C1?@E+]QT) ME6=\[L)9E'.<1$Q1L/0-6G@Y9@U:'WNZT7:!OV-%3,=_?![XJ7YZZ9*0HM\L M(O:!RG/6'T+B]Y\=W^I_\9A6?UBY'4LN1>JU<;0J4YADBG9\\MCG[>B?Z(K2 M!THPK-IC[74CPJ3,G?H?+1K ;G;*%,M$KUA>7M', M(G_0:M\09N Q%/0>\G5S-AVWXJ+,\_(6G=^>.%/>M,'<*H6+$;C#Y'V5M[## MZ^ML;=VQD#X1BV1N,O DPT@&0U/G:4XRN-(JP9@!4Z3&7B0L@;K9E.X/ V!_ M*4;=I3!!S79FL,?E;8%LX9/G_+X)'6! MF>@JFS5<*1"S.$_6&;ZDGE<*M[G!F!.C80@[Z,$P>$D^Q+I"CG?@\2=A"1,V MRX8JG#7:9X8 BY^-T12B9ZF8LJS*9MW'DSE4*FT/$E[J=9FG-FB%4^$:7^$K M_"^^NQMXEY1D@8]F4XY'4GZ:U*P*B DD)[=!ND[XR=Z,??RRDJ]FDB$W%64^ MU I2H5Z'6I0.'_3C//HEL3 F>FWAV3;)/DRC/.-%U[.P"3FS6L,!QZ&VCZC> M)K67.5U!S0V?KH9754E))YY%M\'6>8)YJ,D'>>2^"KR>1"J]&:2+ MHT&5RMWE9WP'%^9@[C4YJ!S+P=['I0[3N8'+RK&=N\4HSFO?A=!*P!*L4GI MNJER2)]'',72$Z#UD(U%V8,E/P3F"B97TZ$B1W?5\?V=1TYK+PR+:&0QV*!D2*;+!##E]"VMM-^NL1)2T.?^GIE-D:PH9TB0BA)/ M)(3\@,5^@BY&+4=)S[=B.O;=X33%7>%V8Q+-DMR>GW1V8G7?B[R@ MBWSD2%YR.O:;YQ\[FF^M;9:&KN.S4]\])COU*SBEG +_R4:RUMUX8*/U&QHM M!%>QAS\\SEAG.^^,)B$7IK8.#%N*N5Q9'.JH@(U:%\0)D(VJAS]>RYW7WN_<\E_.NO^LGOZ8CMS!Z7B@8B36363?MO.P M+@. *:,NNG6"-1<"4HT:4MP>]QCPQ+MU=Q[5/IPD8^I"WQN7%T_><5K\8;?= M;P<[JZTT(P3N$%M3$G0-\2?60FZO#>=K=:<9=S^NDRR5-)1MRF0HTD*CAQ8. M6\"-:9C;<\@DV^<>]K;[\[].5B@F-2]7#"_C^S@<5EEXX((\T0*NB#@T!$]\-8+'L?O(T'OZD7:S/Q7+(KJR/9F8]**DZQVZ=^/W(=B%)J,[COC7%0AI@\>'PJ^KI+\V.HF<#-79G3H_]J!N%= MGCU]!B8VCN ?S_'_GS^E_W].__\97D[<4VG>"%!N@@#"A%93F: /E>%"2?J$ M,]2J6O+MU%F!71BX3_\"[)/CLY[CY^"_%]1_"\:-\G5X*WP0::*!^<8\%#9\ M3LZ?3E$CKSZR/3P?TQ[>LX7_1@M/W*R'QAJ%:+E]:]1F?OK6**'G:Q?38C , M8;7&Z.(:E8[N9 ;7F'8W=G#.X*F(!4VLI=N3FL6;IKX6.U/><*40+O MGVOI$]JS&3[QY)EL"'5H]O84"Q:D/JQWVKLGBW!DWF3TWKZ%7L3.N/=%>9N; ME'&\^EI'MH4?%4W3+P9AW%CK=#" ?R056O[,C&!+5\'PXNB6Q[:%\P6[-!QR M XNJ\!EC 3 +3&51JPS\10A"Z$S^\AVF!G3#MNS MP5Y595T_&4$N8MC%W5LU09R,.U$[+?:TZ## F\"_: ?,MCV]*;%W1W7S'%)K MY*:2_9T:[/J) UJ J6Y1D^"UW9'T5POJ"=SAX%.^V-V#QNKYY*^WR=KEL>LI M'&$WC/90]6@?5$L,JJ"#<)4JN<7]O1+8#[Y8UVG(7^"[^R_9WW):#HM4F)># M=Y8A#$U%LW#5&?D;:/FV18J&$'[BCT9D)9=D#0E3M"HKXR.$WR#:K@EP(NV. M>);_14VQ]93@]]9_4M&V;AWS>&V-?73L3\/3Q-\-?2;5AQ8X9+XI+?;,!V6E M;FD1GH&=-IP(Q'[\%F9<^2@*/[>$B39PL(AW(VX1

K'S/@O MZM4/CQ7!6ZSE)2=+\3_]>4=?Z1E%M?-F4_5,CH= NI?AHO*VLH7;Y7'/0['O MRYN@F0MY"2*BH0O.CAP/$ICSTZ"+CUY'=K($: QF!/_B#9#Q9"XZX@$N&$E M@OWH=N&V7]9DG.GVT4#+8\94 M2/XQ1T(G;-1:\+[A':_[K93Q;UTA\1!(,9IF)354,AFN 1'>)I@*_IC 7YW% MZZ[*20_^])"!9G6;2,,>CAJ4&J2%T":2)55G4'!"4LF(^I%_4Q7BUWA*3N!M MI,A+8OAD%W)%PC'#)J%N4.S_05 QK'@B1B'XM?T.A> (W](WG,K[Q5=#+;KH MI;C6 4+!BWGF$7>O0.7P4FSYO> DTI0GWAV.A.."S_7$@ K&KOS V^PRP$6 MQGP;O6-6+P0RQ]$/F_G#I]]4JJO'>ENT2"U.3>U9)8W[J^KE7;OG4T[$:W!G MX.N_F#PS"^YA*IG'CPX'<()@B3DB8!\2T0GO(F.[@CF>DSI1SZC@SV56;#1- M,;70W6!56L*FF-M8X"&+F"]0W22T 7.B&N)_5Q!/48]6(C4RB\Z3#C(:04:Q MH4.M5V'6CLH!TNMD'3__()]Q:%EM7X1AX""24\GKR55*5=Z>"QJE!\6VV^B7 MJ0L56(&\!HO!@5H#"R'9PK\7-)(/>,2_:!7O[K \^A,-OK],;E>&SS_N+(FT+U M_KY+>#7*HKW:;)+YM4>1_+JILO?FR=\6BT>:Y+4!<%/8' 7VC#*=/I8*J?&/ M?K0OI;18@"58Y(JR+P)3(K(".-[J)(\/D^-69G>PN<_MB^#X@2E;XZSU M=C(1=5*R76$:N,;FI)JHAC)*SU%R*WCEX*EA=4B.&2-\\$4*ZY7_8I94'*^X5=?. M?>\%PW3TFH\06&AP:I#/UUG2?'S59$FZ?USTWJ.B 7&!?F['_%L3R?*+V]^O7IXY_2JB&@DML&$JPJL/)&+G=F42T82.#I1/D/5 M%^4KU\F-\9SK3#NK6N9FAMAY*+U,Y3_*C5$+NNM5NQ*BL!]HA7I(_.&&DH=U M!=%UGE&;NH;L6WA$K(!Y,*;,,['TU:%=W=D6QL$BL@VQJ(L6S4PF/BN"#N"A M+(/,-J3[8SOQ_ +QM@L9MP3;T4]8PC"K=5YND6@%W(LA(TUO?K[G7=/,#+[F M(S,$?SPF0_"FN(&W2)39L A"-,S#YQQ]O&)Y8W7'B@+6)!/;T4E8K6ZO \/4$GR<;_%/*#2?A#GU$9?9N =X&#@)^L6 \> MY,3A[8D_,6:R?!6;4-D# 8_$",ZH /MA.J?IX<+SM8V_Q:05LIG93Z&\$F< M$UPHG?$=V6+)Q[-8]I]@KSQP:B0G%WNV**C;&9D<3NXHL@<#6#"DI2/O+>CI M>H[F*W#8L %,X$RM0TS#7?4%+55#'5E-!SH_",1'Y6!PSHW MR5GVR ;HS^/U*469$:_F'97XIO;V:CKDP'"]LC8+L+$23.HI^:D&*+.=:M)Y M-!'-QS#'P+&,*^7PNY4DKGNS'(K4'KHTV+!3L/(&#$ @R.NR!D_ GF*^$<(0 M'6U#B7C?8D"Q@6^D("090B5>@0N/#WUZNC4:=^NLY D_/OO MKUY%& (A%1Z/-$_66!P[(7$<$N?BZ0F)\R4L\LP05AFL'*Y*J=FR5^D;A6X3 M3D_!HI7Z*T43N?6//0)2V0;:IXB13-$@L.S&.^X#R(VG"_VQK& \!1I,N_TE M!)!T)GF?:%[9'J?*J?4V2OXD,43O!A3N#FO=*>RF0@=>VYD;_\PW9D):TT7)-:F8'99*_)C#A# M!77!GJ4J:_TJ!W\+'IQ!_=VZFJ>ZMB_7 ?)28<^GQZ)1PR.\-QODGT_F,"*N MFNV8E",[0HKQ'"'[!?>(@YP4PPSD'IP,\1<@D B9>DE+8*"4 MXK_KLH''DJ(+<8 O3+:1O8/W^RMF<@@CCMNBV5QSR-.I7D# HUA+-00N'/61 MD52_/'MZ\9@8,W^Q$__[NNSUC!\V6GFSZ/76I52@0^)$NCO!GZMA]\P"UBO. M(B*;Z60QG3*'KZYH;OQ))"@=P:53(D/\.CIIVD.)AU.)JT2$-MG5%/Y[1&H1 M=]^BMU))B)^#2()BPDK:ZIXBZO=,HZ+(Z+CWB=XK3=2+,_'QL M)7_ZSTU MOZ*""I<5DHRXH1 :_U9EHW_>K;"K0K_RMD_/Y(9&QV1XI_^$TQE MGE3&\9?0@0EG6;-Q.C3"%] *_$E/M,R9&@)^0'QC[%5&YS8>\U0F1']61G+' M=."ZV'ZK;!1'K3N^,.U;6P$IJ7^TO7>/VPBQ^;QJM #V1F2>R:IBU,H;/Y)7D?[OP=_GZ'Y]!>"$]O9ZN&3!'!^RUC MSEKE#&RQ/^AO:MD>TM;%U95GJ\RR=-E.P''\"N5%R?1F6L13L=Q M(VOWA#?P>(/S$][@2VS]P(:*[8Q9@WP#>\PV=':-J,,0X2_DSYJW.Z>6=XB- MG3,,D321L=DVH8'D]$;)I4[HB$"4L,A_6/ZZ%3<^(@4:*ABW1NS$03/43AVV M[[M:=X,#H'T"#"XT&\O61 MMHN(_J+A7#LY:,N,%[1P"6^8+%D'J.>7Q142?!G".SG+TNZ9\ZN<(%XUM_7T MW==.P:K39<.6V5)W_[HS8QIWL !)-3=YC>FE=0.NU5Q =S>X EA4F\6U:]= M /N/L+UQ-*O*]Z9"T9;SE]_7T:Q,*N;G)MX,>_?^DU9PZL:V"\ @S"T^3:R: M^62"F46"'06:[XQ2Z .>$2NA#=-/'R>B_8$X&$= MUI$#D>0>T&D MD/*2LK:UC<62MK^6U2U3R<:'^^2_G-T,]9[VW\=U9!#&:U"FN0GN'3P@(Y MY!G@*%]E@O?0W7ZX7CL,X'JG[]@P$J0Q#25\J# ;#]FP+8!B& M1?5 ^0YP<795; +T^L.IYI$C%CNX?=K,*>X(9AU+*+4X-EA=+V2B#4'SR2&# ML)^[24.(^D:SLW<5PN=))09I8=X;LQ;"$'5JA4=>0!D/#G7 :]3]N#.L]A0279(D@?M/Z\6.E!E))]VLH5^ MRK>&T69KHM^%S,PS%XR]TV/!1QYG-M]+1 M1PT?/+G66]0\% PPS< 0VP.E$%[S HP9]@4VH903?1]?6 M$_GVCN_XX G/'A,\X4ISY"TBD1=\8 CUS^4&CR97"X15CXQ+2U$H<8<4A508 M!?B*/)6*F$"AD%[B8 &,B-:%^Q8?< M>[& E2U,CF#Z+:B97I%.9)=XRPVW&B =?,;)$>>4^A*1$P5!4%RV\FZ9JSCO MVFZ*E;[?N5-W8MK.FKG$&AA&OO/2]O8][9'?@55G1TT&KT.9UAX\OYC,IP<] M2\8Z:A8T;KG!IW<&GSRN#3FB'7EQ=KGG?*P-YK8>^9:TNS#8G#U;,FB_]F) MA:__=A:V P $,(U6DO03[5I[KST;=>J\["%T01S!1',#]JIDUV!%@1]ZTY4M M>%*0REEN2C3+2PHJ]4JD0\04L<\F?$>KW?OY*ZSB71QU%>^16>/QF./S[\XN M]SA(Q&KX:*VQUA5W&)P>8Z01$I_&)MW5*#WZ97TSFE5]0%/SHL1"Q:-=UDV! M@F9#$+//O[IOOK+%/:*UO;^=;)$M1K"T6]E^34W7 2ZVU!6[Z[@5WVK0K^T@*8>J-Z"3U+2^:YNN8F ON926E3E5B,I[ :H?U\X9C[-S MR+& #8KY]H$W#ZRC69+CPO(%'.DIAH6IUZ0P-IB"PDR4H]G[$J6@'/W]S8,5D[N^]HN]RX^B'_C?$ S@ MN HWWYX]/7]4A1ON#/Z7+R)?T8,\:.7F.);$"'L<"?@D-62!8F454S"0;\+: M50Q(0%J\S38J$JS<@C$=RCWC9Z]-D@JV(Y1+Y:S?AC+2R*93BE?#T,N:U6=1 M55M0$$EXD\3A-S1ZE'ZYL^7'J.=,9(6;'3@+/$T2*R\BW;@D'&@;!O 1I-Y/ M3EGIZ^V,P.,NLS[%V+[6,S5:AA"G)B>';7?G@Q(==7QC]45ODN#=%@A M_"SZD0%N(2;"E1B'H Z*[<.QO%O.^JH'X=JSX,QJ[5I@W#Q%O[WZ1W2%.K_1 M3TF1L&*[R,ILH[=O7V$>N%/RZ&>\Y/(TC8^5T"BH4G=)]!G<6J3:;-GS4.3]=P1]\ MHW\T558C)486\G\KL:??"Q)$_A5) NLXV%XRJ]2X4^]-2>;\"3 MV8F@R N65?JM,8B<,Q6U;!]_7%#LCH?N;:/_N!*21 M?ZY,43B\8SF\1]CN?E5;R-N*&0JI*UUQ]%N"O85P-F6%5-V&SQ]54@L$;BK; M-P*+A!E^*SSC>A_5691 M)1C](9-;PAC6B2?M@.^QMAIU&1$[%*(L2_M10@G0%9PR.O]EZA,H*#RWH:@3 M3;DX 0/T']2+P2!.>JM%LYIQV G[&J/$9&E:!VG_L1 /$%3W-C5.I3N@*7)D M)N0^6.1#9*[_5*D2"A O>!9W]UG&@"AZ=&7>.'/S@.M^1Z 2L$<^?"[C;INA MM>(CQX"Y"]2Q+,L4&=$VU]C?EAF$D<)F)S3I!AI!XLQ?N% M1@YG1-#8Y.MD8TE_10W#R7&4U5:Z[QV;HEW9;=D=Y48[LN"L=D [!]SWOE4Y MV,OMZ!(5=-?;K/8[Q?.)E4!NLC)/=-W!-8.SHI=O(*\\ [&@G /8^2PIWE?- M>C/?XHV=+C59E+):)H4-GDNG7TN4R%;49-)U[?@UT=QE8B>#Z R?]8K9HBF]L\&^EJ"4>V945G:@#,29)[,9#V#+EN5?9+&MAL8HIZ M$*ZEU;WE\MC.2VX VIU&0#E1.HZS^CUG#&ZQ$"9RRK[,15UZ- (L^A74:N6= M1#$^ 4O(0C\(F!9, 00*;_*EMDF5;]CNN\KF$EA-7#4_JYZ?9572D-$NL4?K M9J/0&=;EVW%'V0WDFI]=*< K<7R*GKQLF^'$N&8GQ$ M7V\*N[AHR:.03U/8;#JUT+36EV=R&DI0[#@;L]H>UG"0H#[)(+&/91.!M4Q) M/E@)(5O&[AQ*^VA<)8C *^P&8G^$!<>%T$]M)DR%8RFE(@45@ZP*R$?%V>3P ML>!6X/@WV#-]5YZ@4_/-%UKIW'R#"-(A,A(K@4TT$J;KG$DOI",OIX])-<6K M/**;V;2):W@APFZZSM:N8L:PH466-G-[+(*?6V^8OD$(+T(:#G]%7:39ZN3_ M@/]Z6%81N6:6297FHI_AN 0\,7#5US5'_K33+9:\A#3;N81?1CN?K$:]P10) M[236'G+)ZZ9V6Q,#Z@B3_A=/OT\L]<+%^?>4PJ/H /88ZD?@!Z?V"=O-Z&%. M0A(>1,X[2 #LK!2+?6_P]=.\8_]\N3%R3MMYL]/-]\M6W'N'@Y2)F 9U@K Y M 1\,8OBTG&^JK'"G=#MQPA4D2Y]";P;?9_RR@ MD&H;**8*)+.O_LMURER9=0#9[A:B]6/WMB2HRN,Z/NM9,Z3PP>KT12C5O$,[ M2E=WX"\)C0UV;J,$(?=#DB060);\W O3;TC+U+N,[Q2P9A247C*N6C;?7DP] MLFU$%I /2:&C&UCGE'()MJ2M^K&V7U^8_!4F(CR,QK(M)<&,_6?-/B?25G=T M?\+@QR7']TB04\W6O_T7DI2T7E\;R 69;(4WI";PSHBP]^T)N;=1TG2&/5..^;?#8) M9\?2%8*PL!@B8,/,1L!JZ$DS(V!FBAZACBT7\6J\:[&[L[U5(?+R0BI&/$ M5C(VF=3<&X]@:M1-.K,!=?F +;=O4Q'P1/'8^9V'XH!.]N:XV!1Y$\@4X[P" MN:A&/(CXB",<*JZ!J'8*;'A!D5;V83@.>'8*Z-%"GU)D?.5Z] SMT%+P=NTG MJ(5 2U!81(TBSZV;JWEX5F@@?]W$*Q^JKH),JO)1:4K(TI@&+2E%2!U:)J'2 MH00U0Y9'!I;738N1+.1N>V_;ROY4?9K7\4->6ID56&JWI)$JK&,*>]6X04%" MN%R:Z6OZ"(\%8]29MQ<"Z0I#!5&CEN,=9!3O2V(]MFDZ(D1A;57-@ M*P4"WWI @R4\+C#R '@M#O0 ( +:&WJ=#:%8#_$9+1'G#F"7K7)0@2VR$U7= MJIT%-P>",KF:?C%)*?$FY]1!4N00G C$-QC-6&F!3<1NQM2N(CG721FA.\68CH,2DL4]/:G=;3:(]7 M_PU3S*\..L7\N/S@?1*GG&W(C52>Q48ZCE;A8R>ZX(5!>GYIA"7XQN [&AFYT^TX MV3+,ZTE!Q#:*+Q<:]KA^2L>U%4?FOR_QOZ_QO[_@PYD'"/CM&%%,Q07&L,;F MF5:X'7[-\QX%AVSL%G,IB%+G&@;4]X20SQ?<,I4.H,51BNK%H":69-"/BDZ= M#QL?Y0D&MQM))!J+(Y50;*(]_[PJ\T5/+;^EAR*2WJ]/\I"0L/_^>^_ M'?\#&A(9'V5R9'YZ>2B=66_V;[&O*'$21GSW$QP?=FIX0':-?_LO-*L9T";& M?1#9VJ7) 5>*<=28G^<'C^N?)G!;6R8+"!3;1Y5_VQ5126@6%.=>RAJB?HY> M&F6@Z^T3P.&?SL5N96>+?&$#:NU0:0G(.K"T[>-5EPMR^.581XI4]P ".@!I M(K<\I!-)*!D7HA-E)M=>$\$J@I0W76[!X]EWKN5,7A"NA]]%+ 4Q 7ZL\1%3 M-YB2#0@-QN3K4E=,SXT25[J*WGY.6P0V8MQ,_FH1?(P]RR5=_"3U[GVZ#\3N M48?\Q:-B 6KK4#4T;C+Q=IT!&MF6&DH[$W-S^ZOQT^DY1,*@\S1KSRPL_%*8 M,#%O/48H=E9E:9767A!.8.P5H=ILQR_VNE%#- ZC?12ZF&4+7C-O+D6(.M^Z MCA11S!["6'-4@9NY_06L 7E[XRCY"I:-!\7DM+[J64[%^541B5*#]7P$6-V] MZ5OP#?L@#/3RK M03UT;:VZ1FJPG\[5\"NOY:;LD9SH(AT;^3@K.4=IL?#@8FBU\F1KPT=2IQ)R[D/\NL@7V3BZ-$H)"X ()^ZP MJ.D\R2 /NYQ,8W]HJ?OV/$TD-0-'+C<7BPD?YBQ7 .X^7JW--6!F(N.EV5=" M K&KZT6D;%BGLVTDMHF^J '2<2@:>@]9@;: SURT%GPJ\5F^+O([Z" M?O;[<$M?N=N4*"<>,RD*&IM+Z3\&EK>F$^\AI1:A;=&*'>"1ED@CUSA M+O-9,V[+0]1W1^ M( M!/,S5B%A[7OTQ%2@8"2O#QI&L@]95)RD)!;2>20EF&:)E!Y2 M 4.V,'\!T8S1-;'28K$?F;1'FY=D3]H"QM ZJ51,Q"1.V*-9I0N7_ZHQ%6OL M0TZB4R-7GS>@KD\POH]?Z!$1 !<#Y&8"6@(:V"U46X,MK6A/[5"(,(T2B[4A MYFJ9B'AYKL/C=D$*([^E@2O3T;,_/1LSL$?AD25N<:*712U MK=L[&9"0="D6*+L:_F(\@F#DX(\'3<#DJGMY[?&)O4HZS(!,LX+K@98K[JN!:<\>A 6?O6(O.S(LMYP 5NW[) M%$LZ!.9 E)+.E%MQUG^4(H:*PNP,G0E9X=H&!>T2Z!Y#<2,F[.'F2R5 0=Q- MS&IP9FY5*8V-JMV^TV] LZ!B_>XCW]'O=3?I[<)6Z'O5R',\(:YZ,>9VZE2Z M38TK062DA2*:N1?73>PA(< N@]@(R*EIS&#>@#<.U\:\S]AQ?> ,1*XY3Z;. MS130H@U:>O!\;#\=_K4Y'HB"DOXX&K;#7SF%O;"MQ/F+A^+Y[1_;RC;>XA9D M9!"RR.<94+5CCW $J8.7#X6_::&)T<(/VBIFQI%-ZAK* MA("C5VR!$!$;L;BL%*-*D+3V=%GE6<8_%P,#G@XS'T#7/5NW4;+O&P ,JT WZ M9O6=>@!%2[*1@(PTL]@;=&Y'RQ8-@.J I*+-JO2K9"NST@*QH:!6!415]+/R M)A<0A=6H8,%<#&JG4'Y#"(\,I\P5QM$Q ,H-MYZ^[G2V;046R/7YJ%TY)TTF MZ=R(,&8FGF:SF5/?%37-JQ53Z2;%O2-'U.&&8288JEY%;;Z5!M;CY>*@K80! M?.5(9(CZV=;H76$7 3AK.ND>P"1Q2>"=GU):FK$M$/1')9I M"=>.-I;3<4EOV_"<8TGBQ-K741PLGM7-Q,IBU,F/#&9/S/7\1@_W0K)E:1SJ M.!I 5&"1HKOFWW>IT>_FA48]"TDU.U<".0;R[2B\071#B(K7F-+ >DTU M0ROSYN4-H$1@13GYPZ)(N"+( Z$E)QD-UIP._5.5T=K\T^P5<>6QS4(8:D9E MY(40M\"*>, -/ #,I >TFD"5,4]3[BNBV&DK4* *7I6HXD2Y@:2RN9#N@5@6 M"C/P\C%A!C[*J9U";PXF5@0)_H0$.$0D0%\UI B=%X?;MQ%:3=;4J(Z,[-3D M_VQ,V*K""%!?U\Q%&X#\/:9(EVR M+%E8'3$QGQ8FDAF8H252Y*$9048,$>EO8^-! O%L3E(#_M\Y@C&VC.30R2Q' M=KU3#'XG0)%71(-3I');&O?VSKA>MB:$7"2ZOEU7E-BV.F#'\PI8GAB(BID; M!POD/7ANC"OC_MUQ]13*61P/F)X)ME7;_D(DYP/$001O>#;:T)M&29F5#7V_ M=I7T8YM,YI+10/1K:Y:H!8TMG&'_,6'(\6WF2;:>"V^BP)0RI*$<8QBK7:E8 M]M\@1H>KPV;V;;JR"D+[G[>I)!)6QF@-*X%LU:NY&BH6V[+LBG$1K5;Q%C!B MC%EDHG-U@01@,P;D59F/L\32K*!%K=>1 =0!#FG''9,R/!IX6=F@&K6I>'^V M7WOFYDR P)F;_:WGW"J+YB=>HC>E Y':?U6@L*Y); ,#S/M^U/OX<7CQ1_\T MZI_U3ZZ&%^>#D^CC6>_JW<7P0]0[/XW@0R<7'SY\,G_I70TNSB^CWK ?P;<& MI^9[;)'T+J/!I23_X7ON][T_>H.SWMNS/O_Y*.(7GYDGFE\_)>I5HO[-4Z+^ MS[\.QDGM#:\&_CT(CJ_N(H^]X;#WOD5G=63 MDT_#WLF7Z&((=^'C6?^J?]Z_O(PNWM7F\'9X.K+Y'Y5-0?#B^&E_#\BP^#RTN\C8/SW1Y> M'>B1F:C,$P?9._\2_??@_#26D<31P,QV8)YJ7GEYU;OZ='4Q_&)^>WYR]NET M/+>_,"CCJ-W@RM<*AA^+\)U/_ETUAM&'S\-/UY<]F,SB/-G M@_-W0_.X_H>^67)7#UOD[8R5ZV M+.\1/,HL9?\/&/WE^][9&>__A\'YX/)J:![UA_GQ=_/GF/X""_9[?XA'!9:0 M3LA@&)E5_P@C,I\?]LWS^Z=VO)V3B[,S^MN96=B_U!6L52IMKF!EN1]NG,X! MC-[W8!_,>KMK=75!O[CHG=-YB^GG_OFI.5.R/7C /O:'E^:DP#T\OY(K>=K[ M8#;VTK\^[GZ<#H9FR^ [Y@_X[SB"'1[TSO!C1H>:RW)&DN7\T@@,>+;Y!3\W M-B.[Y&-N+F7_'/[=^?R^CR."NW\Q-(\TWS7'C%Z$@_T\N.QWS3D;7,(H+CY= MR0#=1!EY[(YXS7&UGS&_/;]DF0./"F[)U?OAQ:??Z0(-SJ_ZP_/^U4Y7YT", MNSVD/.TW4*2[O$ZVBCHUM1P+LZ88^@<\19=1K!N+ T\ $P:4:^KO%SMYOXH M0HU5M@(&%0N)$DS+ILGA\!-;X,&%/9*#OK-1S4)@B\49'?&^7HV MX4Z"G%9' @?EIX[U@+LUD06;"O/;#B.6'US( AUWW0\5E/D M$/-LA*ICS[CU2;*VWD@.Y8;N'P'G#WCJ]XNB2YL;1[%E<605/O-N6\R]7.7, MGEV-GF\/;=5#$UIK8FP 4(]2E2"MF%6P(11X*&=W#XD\A0O(8P!:%BERH*4< MTC'/:.6F$(A<*@"*:Z'IDI(!R7Q[0C6@E C!LEY_%NE62Z48BJS-^\Z!'!25 M,G[UF%+&C:5*@X79BFRR!A'PH.EC;+REZ6@AA0%",%LQ?:$1.\B.R/'Q2K_ M7; WTGA4,Z\CL5PK[SPWX0EX5?!K;:TT$LMD5PNCXXL]]1$T7%H#&T98)O9" M67_9RBG^=5CHW/CW87J;SVY=_V+Y9&19VE4S)JY\CC6L"8L4C-TZAMSL;./U M/IP@7*64_M!M75V(3"VSQ\[C57-P+*JR5KPKE8IN\XGFR6%&R6DT6L]['!G) MH:D&DY+S64+E!08^2S0]XV@&/2+G9JP;U.%0?,TI-&+(CZ5E#=J'MCTD$F_F M@K!2U0?T>]?+DH_(1"GK='$-E:7\O:\9D:L '3,!4(%$T,GVT;K,L/1!:G[K M4- :@?G]'3\3;$2I<4AW"7=E(RC8ME6_8VRM5Z$C'4/@RDSS(@ >')YN>?V8 M=,OE&C.A9EOJ-O4)DW2(F*1&>X+ Y !P!&8.N,3HD1LOR%B>%.'( ,38>?F\ M&TV2C?":<1OQA@K9 &@DB7XGKBH$5F7KH52 >6D$.43U5! M=KAGB^W/(Q^^L7\MM]NLWU%;K_!C>WB/#5Q$S KTE-!U"=U?GA*Z?X4RA:XB M<>5"NP*#P#ORY3DA7JA#1ZLPY$Z-\G%0)QPH6R]46W&X@S?I;%)7$,.RR3P) M>?OO?2-9$V!5C\=PR'U=[=2;>M0CZ5'[78ZE"=,.LA@_Q/%!*B\8YT:EWJ:E MH)3BB%N=L!<;LPL;PR[<9M!FU6L#SIO0*AB;5^%GKQX5+)R?&/N!K ? M0;0_:""GG?#:-DEB,-21BQU%'_&H_A=^P9D+T!C2V(2[0=*-]AKV+HFULU#L:7W$-H;5D\OC4]^723+F\A8_K;D MBMW#@%;_!PVZ7>VV'S7;,.Y<*E.-@D K3HK1==KEGL!MP!BV>Q0NAD_X0,_7 ME[3!@VC00S%A?JELC:7@A,,>E5>%[@+5B[DXN)2\=;@8_^?+/#]2Z6YPG;CS M.V@\P!UHB238/#FDW1Z6\EGQ@.OL-Q2J %6,]+:I-I2^1FKC=KX(Q]NL>!9L M=J6!>[S:T&+'L\2FC9 [*KN!C9#*')(2N[L(<_/U?48%)S!XHRX]=4:*7X&( M(ZE;#0G[JQ)BW5Q$>MT%B\E_-?MF-JY4Z.H&8ZRR4-AL.Q@4OA33Q/A658^/ M,0Z,7V]3P&4@?$GBEE6!6YO,=6K 2),5UVR:%8%,B7Q+CI/482RY ;@I_1_.KR&6BK5+$)%,7AJD+,A.82 M:L\=RK!TYR&=X\ C^9;F1>I>4U2,?2B'G2_7NZ3SY2QQU!-$T0=E55QLOF5L M=DQUWU5<,4?1NQS:J4GU3<6.V8H5T3:.-4ET^@Z6)&;OOZGG= 2$][@X(LF@ M]Q'FZ^Y2: E=4BF_:V -%&C9?+0N2D4$22UFIQ:OX-Y7(2"KI:$()+[M05JG MY]C :[GZ,2Z%[B].]F5KI^Z 5\$)R7(K,[=+OSN7@FK.>E1Y* MPD^E^8A%:..RYWQ#F8036?-&^6WZ';Q06SWP>IM&Q9[$O2-(#&A0 M.\:^!+ %"(>IT3I$]HBV(+'F$BP"A1BQX@#T K0M5Y^"5<^,0_9YMN%JQFJ$ M6B:CTN"79![K,LLN%YI3R,D /.WY"RPSC4F?+2!X!]SYY+P(/H.\)PADBQ9B MWQ,^9/XYODG*YDDY7;?:+/$K#FNB"'4Z%NSJ([:9I#HQ'E.QLEUN*?EE1+"T MEPX1'Y;V*\/ NL?<-=MXD [+O[Z6R')SM+1'C04#!@B?]!Y M@IV^V>%4S7'Q " IJ@1>:4+"X8TI">,<8%DZ4;URHX4QD?TEBV2V*3-V&](Q MFB-H@RVHRSDJ.S\LK1%/#!4#U@W9X%2VE]L"^W$>I!"CWE-[,8!TGOR'[=T&0YE0ED;7S:V9IF:GQ,B3,&)@ MC[]G3#2IOV/S'BEV^6#("?SX:9'!I;A<(3I4 3YGR1WFD\=I8>/$KJZD BSM MLJXAQZ9:S 3ZQ]<^VOE!DB;11$[09\ALR?()-3O]Y$7N@.$-;RO+"ZV;XL9X M2RX==T@H)"$3H"T>F:[-_,L;;F+\U)KD@4H3L5TCU_R)]O1[ST15RT1HH#TR MGKS8_AQS4GJ8D;:AFAYPD"R%<;KI5.F"$[JFF0N^8?!6+"5WFF*5++-ML3F/ M:=7G1)&#V^Q$F4J.!B/F7%3%;#S^P(+&Z*HTJI$H7,BJY;G,J1K0A[;W5-/) MRIK-.)2KLW_SDA>1O28(T[ MUU"]!*0CM3%,A$B8D@&N']T'S"O>16VRI3B,L^6JU,'2BJ*#PH%Z2(VD_&]F M#Y8?II U,8[FDG)DE*B)HVF:NF814"E"&9),E1SQA9S-7!.@9+\I^#[2I/>! M;2^Z V*KU%@6BS1?0V,!W;PL"$6$5+$@(!?!A[HQ.Z]S9)#BF+)1XS8*SK/' M=HI)R%3?C7W:8JY8S(WTGW&A; ;0;H:N8,:0TB]0Y],Y[D9OI5#E--G04]'@ MC648;=D0S//,=9JG,N)PO%B,(OJ&,K \>8R62T,7+/2:)'S9 '1]34N)CK;- MFM-3%T$$'74'?AGN(IFDDA>UL)+M(X7Q--UR7A7W)%Z&K,1+FK6#$5@B70,E M/1P/$FSG7]X-WT9#>"2JR*B ?_KM'QL?69.[YM(DN/Q&!1D%6*QG*:HV7#_X M,_607)0JP>09PC9'0Z<4NE_ZI75+&)LT[O.+KNM.)A8*8+2+'LB2_BX!J%+, M9Z/9BT:60!DI!;IENGJ63Z?#O#8EX$5Q9SG2[-2J>%0S(Q]N(=8S*@D,MLBF MO,R#/7SQ;'H$&4J96!;T(;R^0.+0B3= M]YHGWYAO(T-'U\CL#%N\+%:N TI"#5)S_\\H(JEHDSC^==%ZH@ZOF#;"_]$X MR$[3*+N5V^T+^<=AYD &URS)7E@[.74\QHV3HM(EG*H)82E Y;?P>LY_=(T;\X>HWQD(&N-K#7RCJ=]MAZ2#8\'0JL"L8<))[W6^?UPTGM MA=JKE0>6:ALZ=!9;[N/4ANRAA"CFF@V6="OA5+CGC2;X%VA?!%0@],L(1Q9S M/G/WC99>>'XJ2UT_3?BE?:)Y0K;,T&^ZR;_O>?E""D,$DT=EO^9-^!BH,905 M)2D*?MXC.[71D+3E:2JM4O?A',?M66D%,OV_-:I3/WRER 2HDJ9JW]2D 6PW M/+/I!*'H@!D"5R>@%^HZB/&3G5$W9Y8SVX:S":5LF1G[,UB7C/CB*T$%U.C4'+%T):&9&A4CX$U1N<3MS MS?O%Y69AKURIYPN*LKQ&J,MD(SWO;;,B_,667G\[O*DV\78O-(-,UFBK2_8IK?=1L\CWZJW*[-S?EQ?.C8W=3/-2F H&I M9MA-\" _:K9K? *"_GY<9\=X2NM3P_A/X]'47$Y%+JSD0:ETP*Y?KXGY)DB> MOG8%7!9^"1QLA"Z*(_X_EW[VI *!Z$CP7"C5;/-PN$'J+\:QO^.$D,;A5J&( MN)]H&J3+55#J+WI+*APW1+VGL <-]DKO_=()@FH]VIWM(LQ SUK6JJZ0 H0 M)J5@A EA=BL;6P^)H:B$VGV MQ^;U-?D2I)N-,3?PQ;7@C\0OHT/E:! (!SM+QJD.U+;!61"B.:5,JRC4PAO1 M:&,+XOQGQZI:4'RJ3 8RK?IP]AERI2T"G8>N=.P4M?Q%96$JMO.!(,]59O*7 MQU13KYAV/A OPU,I_4&6TE-#H3J#T?:N(&4*NI0%24WLQ9-IOQT]_Q7N?479 M>C1>3DZ2SC8?F"*5*D2YE1W,0@M;!3)<80BK25)PN12DP I1J! M%&#G0$E?$RFF5#K+EEA#O\TXJ9!-!QQJ[2$T]NJ0#%KS[[2X=5"3+L:*WW/; MVBGU VDN?H2QR".EG;K5L=A5!,S$*4*%^ F?3DYPT,XOMD4LFKB-DEX$45AR M!1<[;T*VY+'368(PL?F\S6];DS -O%L7N'Q2^A@H(8TLJQ8I)NX*;&Q=6M-L@6P9(?5*D[BQ< MH#8P/"74<\KA,)L&UNG;FJ68[O<,X_JX$# 319<(2$N@=&Z[.U8NJ)EWLBZ) M-SQSYG79B$Y=*/M>="9=*D&"9(W]CG:D"*:8+V:;FEL8JVO(ZZ?\+C_""&T? M':E4304?=[A)YNF"\:LNR#'/)PZ57"_0@37K!<\&@+&9G5$V506-[G"CJ9JL M['.E[6(CI3]3VN,Y>\HVVVSSR^<'G6W>F]RR2(JL0A"HRVI!<0R477 M6ASJFFQ/\M6G;KRZZNT2!@5@9?N"QEVDDDGJKR)8Q94Q1LUJ=U[[6?$@H0@ MZ$#)VAE-6N[$/+P;BZ]07!'YL3Z*#L2GCHZMR"B!;T>=S@*JF)](4;?*NMC9 M,%L.6]CDPC-$-_Y10JL#KRS>;4N9O 5^R6T&S.%:FH^!W7:'+9G3;Y@1:$N] M2O-#M&7'6%% 3IRC$S9_ .<#NA\O-B0RS U%#,/*8V-51YRR37C&'=61L*<5 M0BVWB04'TU6%]_(8MWS,"LIM2VT(#*L9F3Q?)EG%F[#-5'$D>!$Z0>A. M]\>N9?DDBEA)*L-R PV-ZL1.E<@BDK@%6Z9$K^SZ:.D-&*75+2337W:Q[:V'$F[: M0\*8__SWWX[_,4RA-R8([=]>_N-0%GO_*$:NZF(^=6;#3W"X"2H_(M+)E7*\ MV:"$>$,*%N)]'?$&9 T;'T")QT$3]4(4"/:-8JQZB4QQ;X^/CE_#0/AGYE)Y M<_3\..I,D7,2_K-@-OAOBA5>ZT,4M,3/F!>.JJK4)(%N=7 EW6>L'/,G,S S M'YG1$FUVP>K FT2 _ZM!"C0,;(=Q:8>(PC6[F NET59E!EH=+$"L:84XK.NP M6H[-GB1D\V4+@J B924!1US0D'2XE=9%>IT45DFEW\PX0)O'E H:)D9 S90P)D6=N@UT&#Z#8CZ+7)+H MC9MQA$IK\5H'*K!>S MS#QU@AA43#<+V)'XV^UGG2^=2;=*'@T'/&L&0]PO.'UH">2"6O).D2FX$?1R MKZ03;%BZLZZR4XTWN,]JM)0XYZ>L2T[QS&8YU)&P$54WN:ZK4RD1BE_(],K< MGHT)U4OS!V%35-^DDN@[1RO%!>_26%4)!1\78<696C )RW*=3NH23= M]K-M#IIKA]>.1%8A5, AY,5\JVB-F+.<.V/R6R&4.EW/]%FW8.7VV7-M%^&_ M:^.E$GN64U8YD]ZY1TF(U'UJ+&$EF$1)&MMN57V,D2IXEJG5;68-QG?,B4EJ MN85RE^K)[KM!R<1XI"HRY)C/Y:W7 &Q?B #?Y?!UGJ+'6Z+'NG50FP"OA^IO M._T!75Q62M;6;B +VJ(J<]A>44R]M/^0F]9F$^" Z*<8L_!2'$B?QDX KDN( M$ LA=?\4R(ZP144^D\G?YJNT63GA.,?8'QF]\2I:[ M9/GQ4[+\KQ !RK#<>IVYUA?K6BC1&*-/:"E1%,3+0Q=7:EI%1UV34<98%VL. M"7J>3#!?/%5N)1/R-P!WJ@/ $.!MBX+RH$Z["+HFE88FC^VEU]3VE%3_AJ9J MFPU*(@L)1;8: :[:L,0&Q"NF8":I&F,*QSB@Y4VVU)_$E6;\7>7/:"FE\U'U M:]G"&61U2Z-"D16SD6AN1ET![H=G,-J/W!QEZGD8]XYVP;G<&JY 9"9JX_*>-K'C39]5?L25V M.Y!D"]7,U+N8NTYT#(;J; ;FRCW. _M:.VG:JPF*.B M1A)O1*X2LP'6=OG.V/<)LZXHS<:6]!8VL;&0HQH?&1[A9FU[?M8(3_GD>F93 M+N5Z-,]L+VO,;+@KSE8IA+;6\WFB3PJ"<43]ABQ]0:CI\#((OSVF#$(U"?]4 MW/,3#\/Q\\=T&$XX(?LN+U*(8WW$8HB]J/IJ=G'WP2-ZP25=#X4Z?-$>-SI) M-N;IT:"<09.-AQLCB)O7O_[C._:RQEO>RR,@0,#J?P>5SML>$L!LVQ)VSDNO M89)+,G3>'E+/3(87 M6@Q3V[+=8?1"OU+Y)[:L*%9DXVIJ:*+AMO_L7=]/ECHZ!]\:SX'Q!C+"=4S7 M8/X#L3EZ*.L%Y \SSO"X.FG:2 ]\;0O0!$'EE?(X!&853]^Z@U$'/O*PC)Y; M)-FI718H:'I8228DLU_3=(F[Y" S]N8AFXFY6M CFCP2&OYC6.NAFL,';PXG M-(?]6'YQ6N5D.]FC$.96#N;3*?3;X"29+U3CMN*WUZ\"27S"G1_*J#>FXKMA M>@L%N=U'L+=U<]B'[<3C)4O^YD6PY&>LO\ZL_CJ$33@[.]F;Y>]XI5!=OY3F M1S3PXU7EFQU4N:^68K__.J0>MDA2JNBR^F-%Q5!=KSC;5?(YF[!6B5- 2G^< MPF245$V)>4#]-:AU_ HD$!(EW3[RT,+P(6$[2L_V6T_W(SR;$CO64Z$9H 9& MW :QB(Z(XYKCXT%/U!:$+YQ]\X2_]_'_5^/QE]AJ8BS.I>KI%I-UC)5(@H;@Z%?> MI1*#W_6Z'PBSZ(?\]#C+7V]NUI^?1ZD@=PGUU-N'08E;N'ESC-WWY@?ZHAM4?F?[W]T[!#E3\U[=)? M9AW]R%':W6X*O]EB1^VIW;0_1W&TK_FE_V?.2/I0+;]47JEJ?]#(M)[\29;# M?57YN.8AK,FK8_SS4!UYVN[SCS8 S#Z M"0KW096HIQRA!KRJ'T,E6#F:CTT7MG^M';S3&B3X>5"=7^K[B<&9F*71X'_W M!:?SXM71F]_:<3JXV.9_'XP<3(WP0(;YPX)._7;T_/@Q0:>HX?L3,_8A,V-S MTEC:LRQHRU$<$PC?".7Y>L$-VDJ@+S,&9CG;J+HORE!<&YVR0'O :(#E#3:C MYUS%/[F@Q6BKQ%@4RQNK%LT7C9G9I3*'K2^WM8+3O!!R/5MNHJ@2=5FV\'"1 MK7*#SS;:"LO.@#H;V+,R*)-/B]L,>%.,N36C#UM?4/N0*1IDR#F Y>_F<^DS M^ VJ-S*;RW8[][&WI]BC[A2OC]Y@=XIL*A2>6]I,RI^19B/#8OPQX>*CS\D, MJ"$3Z%)V_!S9&J++E3%>S<^7Z\S8):_?/(^CSS?PSX\SZ%<6XZ2^Y,57\XTW MS]_$40_X,L5;^I"-;])9]+8PJ@PJ 3I]/"G1''__G__^YM4_[NQ+C\QA)ZS MAV2Q3J$QP6(*D'+[M0@B$.OZ+Z)Q_:=LRR]'QZ]WVIA*_F65+_^_9T;7'T^E=W3^!>&),3_N>'?2$.\&SMS^&R M;3'=X6I@ ,ZCJY//T#O5;/T'#*9B$>P))Z7.SD[,07OQ^CCJ&5-B;:&AO;D9 MI-E8.76OC-OC#IKYUQ=SV)Z_>!X'XN\ M_)JLC4H:0HCN[.QC'%T8ZV@ +B)5!B7A9-0?O5C; MHW:!TOC,F9;$ @76$=O"NB(5Q!PNH^2,)M M$8QIFHR17RW=^7GXS0XU,,4"XCC*T#/F#TW,E(R3N8 *5/,\8<^_ 1IFU3)Q MG"TS:A>W_;V,]\Z7J70'LH]E2JV%V7./J;_ZIBZ6/^/DG<\K1'H]Z?;0!Q;1 M(C=.-:B<%4 *R[ +J_6SS<"A!'7VD'_Z?%L( MA469[FG!';G"OA_2/L&=)2C$6IN+7=[0]5TCV57KR?*@M,B];FY/6GK-1]K! MJD^L55M8J[C&G7(]RABESO)FV44BZJW@% %#W ;2I$ *0#L#U>JEBM;+V')!(N ?:7XC5C-H85DV[%;1M$2!8L"-Y@/+!D18Z3 MUT5^AW7]&$^PC=H!VXIMX:R-Q.GNQ#)HV7Z.V.%:GLOD(V!34A_&Z7HAC$EF MAK=F\-16B;_'\Q&4A.V;%(RL&_96:3SED7&D5Y9FB2(%Q%=JYE0D\.^[=%1" M-&3[XND_+&T3I^KBV'8(P?:$#0%]C4.L-FS<03L!3B-->2[$P8/+3M.MS!8[ M:\J:$E4T7$]S6X7+1N8J(\)B(C.$)RF\DQ0&5\&(Q1O>*X&@3SPJHFRJ-RDF M-]8=ZEC M H]\3L!K9*!\#]JS(L9T3PEW'M61V$,TR7EN6ZX@-]PLV=+WC)L>H5F''7ZI M];?0(U-;<^A<@[E\=_61TUYZ)G% UNN<1-H#>B,AK! 0AW=X%!V)LFM%0]T7 M%M=$W(?R(YEYG>%= S9O1+9W0S(R\BI?"**DY-HX3:FYCQBU+W6J=#-#* M\Y;0GP%+F>W$*-Z"_[1#XDF((QT.E;[H/YO<\;I^[&T]KL6[K\:%L)6HK76K MV0/"GYM_KREMA-\06M#TFYEFR02Y=JNY3(/'):R-&^Z9Z#P/, 0@S"E[RL^P M!=KU3-/2JH*#7Q/H7K2"L\I'-,R%R^:ZQJ9H;X);(67G^'?JO^Y%0-?.B2J3 MN;+.O\O=S4!OF:^;3$WX51INX]N7QM Q-CAR-.)A1%J>@+0> M?J8L)@:BCZ+/3,^)7KF8=>9 )1;]9VRYC_%G^;)5S;$N#6)US<+TZ+%6AB; M_*T[3:?)>K:*F;V2PE!3R]N[HP0! P.-Q)MDH@Q+ZWW9^ ._3DQ(:%5\((;" M/H:C&608I 5T<[K89ZE^<73\RDRD[K=C]]O(_.*7SK7/K,*=Z24[L>"N0H$T M6.3-JD/^YJ2))VSQGQRTPC,,C>%=WWG;;9XS1UZK)-UY+O=:Z"G8(J;!<8D M4;F)0W"F/Y6X"<;CQ5=%C%>8PCOU^#C5X6!UHYK\U'-*M%CW M=R5_0;HI^!OS)T_B*8JP4Q1A(9TN[$GFSMT2S:\[DI4 M:P)HB9.I':+MIX]V1FL,[N]V%#M OIO:KESE*L]IV6#DB7@@,5]4\BICS<\? MUVC9L-<'MULF3CLTVM()/G6<&_V9T/46)?.$LG$HFU<'C;+9!T@&3M(VKQ8@ M6@+%@GPOA2&NX6IV8Q6:-E=K34:4L?7 .&0F)/.P; D-VRQ=OLTGHPF/WUH1 MXSIJ \M23RIT$:O/J:?;/K,IP$VG*47%28W0NT!';%!Q6%\DWB9-L"2-I8EM ME(/NR 2B$RG\A.8S2ECJ['A/J:. (E&GUR6O4*2-,PS&'ILXT&,NL/&=R UN MB)SM[F3!33Z"HZ86@!<. M84>E^HAL"TYR*E:M$8[F%T!QA@V(-V1 6ZHWKQ>G=1R.)52R!X>BCS?9LYK%YHZ]] \.;8>S/WY;\9I@G&;U_^*,08C"B;66#.WCENQ MHNRB4 L"GN4"XNR\U7)GRS* F&&RQH ^)4! P*& Z@[Q@;K/L8RQ/0W/3Q^- M.R@OG]H69B$[GZS!BV.>^"]'SU_>\[TB0^B:^I9?[3:_@AY+F4?8$$9'ANEM M/L,^3Z@RMPS(VWCU57%_]MMG>4AW94_=.8[G/NC*$*1U$73*,%<]62BX0FAP?^Z],_JIH$J%G3<"_4*:@_. MA*F0W@$+QS4WMX&STL*&H,5690B-[Y/8%#\H376$3JO[>ZZ56:JT-GHJINZD MDC,@>!#;@)6A(FT5#(CZ"S)0XH1;UIZB.8E]\FP@LRZ !DOG;MNNJ^R&<[]5 M@,W\EK6O!*=0JLMA;^]?NR9F$9!D![X,'X2=/,L0NC)V2)F+VA,6I-%@^ION M[I\'64NIOZES(?PS*(")RN-@A08+Z.J53@ T@P!U"=C9(^-$8B;-(67 M48'%HKX\(JJ$6Z6Z]#8$3-:K;;EMI_CT&3?.?UXT6>'UW$F-$6?4ENRTY%6? MA*?68N34O8\Q>V]K8DP6XI"L")]>(F8]XGAYX+@J< M?3)+H-9-AP5V?HZU=? A71HR $ I(&;VJ% !O:O"&'+K:EI MG]UTV#E3+QEZB*7+OPD$9=ZQ@J8JUJ3;%H#AJQTW*P1Q!E1]DU IP]V9F NW M2,D9S=*%\8A7I4U$DC>4PL-LZL=./^T MJNAA&P/]RLR7=T3XG@O69>$BDNWX@R?TJOJ_3ZZ[]9>GW7B_$GKOSQ:[@8QXW4KE<@78SC7UH6W38>5H:B M>IBHO!*XJ.NO+A*)$)ZC5*(R$RLZ:U^840 06%S7Q@DJS*1A@!+2(1P.#M\" M?&Q%V942@D17[( #^4(/V"9Y0;:"[$T!YL5=B_+9A$'3D,U%:Y1-S(]&=)H' MZ5PB_$75K7>I,_A\.98R\AHUT62'9'/:P7X_*;))! MV)Q5+CV&4WTW24GY6D(,8D&3W;T)]7A2?<859EA"/N&,) &8^+%?CF=A/CDA M<#NM)"VUC6*39^-6HJ;9.N5G'?^#*8G=5X27ZW]"[9,0:ZOA5FPY<*I7MN#-6;G!X.L MV7R99$4ET"@8:Y("^BXBV;SC J7[+'*G2Z6G8''K.",?&$_">=FA;D38>FE( M8_SO!+$O-;(Q9I-.? 2L*T\G-L8 QSZ6$+1.M'-Y1BJ^/J\H1#>JT>J_JF+H M3]=2+QJU5!_"N+(UXN"8W1NE9KFFB,!9&5]YZGRM*;$93:?&-C;+Q*<37(1+ M;CG@]LBX_[?Y&/T&JV5:2LQA4Z V5"^ 3 ,O,%CI4I!U![0\)B(3!* MUR:;=F*5S@F)8[6VY3LP5\,('^N#VRX.UF662[,]AXIA6'<),\PN\5.D^00, M)>8/MX[9%5:U)'EW2J+6=3,.C+Y*5HR,D>!H/6C*:HLML@^8?U0;2 I@N3#: MY&OM-;76\4VB*-%9&8%2Q?]I<]W1#8Y*6.-&5J5:1G=YS M_%ZT50%)$M"+9%6\NF;9!X/8D+E&@2^W,TC^EA9 XP63;[JTU1$=#+];ND\Q M+PQY#:9QDX\&9@HZT;4I# EIDR86HUD%NAFOY"7U+4"I^L=FM' LWVM#;LE1 MS>!,D9$?1Z-U!6%,+H>9J[%=P*EV=5\K#V-LC5$8K26D>[=>3-KSJ<)C(H. MR[3Q2I"HK98,"3YN!R/I3_ME\8)$=NIG;S6\-<7*T M%#86B;O$'IV@X0%IM74QODFX#M[8ES=686L>&AT2F:PMZ4S] 0O*?GN^26Y^ M7,^7Y"$MV H9Y_/4'4H8":+:I<2E+O0G7T[@<0R_JT9:Z@?(EH\+.P8+(\_& MV.K&F=CLQ%DDAX>^(P(##^=BK(%7.B[LYT5I:Z# 0@ ?]:-%%MDY6'0;(&&; M6(:G"?4T#,\=XDMU&(EJR6+0"F*S?32SR-9S,S;TD)F5S2\U0ZDC*4>0].O% M$MALVT?+EJ2;IDN^XG&8!%$K*>+QBE#=1VP%!9^ZEC=[Q2^EK7YYC2^%CP\@"W;4E^<\P;Y&MR= MDV\VK"Z\&DM_LHD-S^ 2FEMO[0',*O L] A$ 5#3:6=9H'ZM% MFNZ ;* 1&P>]PRU#5*3(N45PV)[2LRH]^^9OEIY]H.IG%75<&!-JB584%K>T M7([1AFQV#%^%5ZJ%W!H4)]19H(1LO3BN52?WYB4LI1$>1K@K4E#EQGOI/*S- M8.)2.XL%\#,SPTXBMJR %B$D(M9$^$4R !1IN]\MS>-<9,='F$@QO3S*P:]B M24*!-X;=/ 8<^!Y8SZZW,@I/V8@%4Q^YN)7=LUCAJ>0?'ZNAMY8EE38S:Z9$*]?>3[[2=$GM1R0[8VR=P=&C4O&8T-**["PB+6TH] M>P0.BNFR,]V?>-OKH^&UU3 M;>2E:38U7'>KO%J_4:Z-U. *#TZP\O# ZP1:/H9B_^#T8Z=[7:V$C!&=;J<# MY>(AC0-S+B:VJ$[7>KE:S?KHT:%3)G[<2!(J;XZ.7SX=SK9_GTV3(??TU7@B4$ M'!WF3K67H-\3/D9,A ;OF^> :7.)EDY M@FB$LT>X/P<"R;D\G>IQD%1I=%-H?@DM5KR2PWYI#+%2/R,X'ENP::^-Q] M%ODV?'"D+EEN16LA2-D;2ZAA+9Q0Q:[^:111.3['?;!ETM7B1!O=FN:%Y6LB5#Q0W2>BD"$HB/]D@T7*H=U*UL8(6HU'Z8,@ M5E+I$^R6SE*R>6E%N%0EV.X(\WM>6'(!!;(KT89.C56%!C%CW>3[4,8MMP&L MGO5\CC6^;%;APRKW0 R23_\=K9)O]+W9BJE\P4XKT8"Y3JZU@2?F1A.P;I%> MYRN$)"58:URLQRNB?ZGS])C0/"8;*$JNKX$.?V7)$G$E Y!CH4YDS/37O77F$JAT_N+^;IP?]W1:IMLIEPI7%A\^U+?AB$C[JGFOF M,QO!"N*/UT;4+A%* 'V?DT*#%)=85UAVFV0\-VD1=\KY,Y+=9PZ5W3SNQLBJ M4Q;JF55$;_9,#5BM-LD WFH5W2/_1 M<*N[3I)P-SAD"\R+K^;M<2#_0+"S<,1W^ R!MDRBQ57[&P((?OF; 0CVQFO: MNZXJ;6Y3@T/]L%[4E=];7A>>*=$^2^XP:+;(G<=5TZR%JZL(V%F:,;'^33U7 MS?ZF\DVV$M$B+2D9.YXEF3$?KA/HE+2MPH5]KUB91+&5]4,.TW)C]:G42_KR ME6K;C03&$:*\XW)W I!#53^6R>PU8ISF_LQ.&6>P#XAQ,J6PBI../X%NJ+>< M+96#X.J(3U9)9A&$OBWI*7,^06S1V"^E]N\PI8K391^MZTH Q,]; 2#=:U\9 MZX[C]@7ZK>CE<*;3.)NE\7*\]VJ?4H.&%KF/,VRX'-:RK+T$WF+Q50@32O3\ M6 IQS5_ G@-;5P0-66%L]($U0F4B,07:_V^=(CS53 _ MU_I9[+?YXZ[77M@\?/5I-X#_@;9$"8&;I)AC(MZG!JK&M*\1/XR';XOWZ7EXT6ZT$ .]*6PI M?&.^R]!TN4'R>3GE@C1GDG2IX2;[LZQ16U7 E?S(FA&@B-EM($F=%1*,P]94 MJJC0ZQ:Q"G]RZ19%C*GM8-^\VI;1B26K 7.G!:>KL37P6B&&/D^\DJ#!(%@$]%L+J\9Y:3I3WR;^28I*OR^B#]2_IB*![ M*M7\"'7)[Q9$%L<=S2=-/:L;C%D&P0@O';(R\=_ZB]NLH-;EB5,"&RO^&8YS ME]@BW!][IVNHY*^6F:L]6ZS7).*KCM$Y&^6UJQ&.0L22;1DVDC$88%5C=<^\JCDA!+!Q% M]:*"SEH)\Q-4NUK80!P);5-X!=$A8-L+\7<\C1'R'N8+1BN"$V*^O0J_CL M/&5>3V?QD6SR#3ZH4?/M@P24-%'D :8QQ0=Z=]-\"#I2DII?&.V^7*;)C)7X MY%KPB%Q4"^H2[#X0>!W644#H-5W/ .0/K:760F52]=& M*Y%$X*Z0H97^0W0)0L?=WYU-1MPSY4<>)4;DF,/;+( M);,ZA")..?(_$O,6K2F89ODF3[6 M3WY]Q7GU^LB^A, Z7$\%PJ>B7J&KL330.>XD1'9;1X-9* M&#K4$,8&>'8%@#KXZ!.80X$Y?GT"?E M(XQ$OX5RH-G&\NWD0C/5"K;_WA1&O/>I"ISC'@(UR(,5"TRJ!Q6GE*V3U=Q= MKN%;1WFHB0WF4".D&J96"02"UL=H3->:<RO:N?G&I7Q&M.-Q2MJ^/- M=8/X-*=Z=2I:=9RG0S;A'O)L*,A@&1?0?3(9=S(9,5J[*$1BVH@&\9Y+7*\: M\:@_BG=)N35G@%M==\-J/%3\\*$DW_>-'+?MA'YD'KV'U9Z]V9L?O21=0Y?LU!]8DQ ".T!FTC.^.<]_ P6@L-1C%N3G%5 M\*?J@JJ8%=\6G76Q7S4D$'!PK@!>7<>)"([AY8UAW&B=B[DNE_^Z\KOWZR6JQI%<I% M=EWKZGI(PDY]O+6;V!',?K("[ 'Q(%O:N[QPH^#\B?5FY574+X&?;E=]L9Y1 M!NPVSR:NRP^MP2*7U\/\6^>^RZ1YG6M;HCAUA)VH/;BLPDIP"R^"&&303 ^I M670-[0HID*E;%HR,SU-]C[[*48I_X!Q]5"R94*U!AY7E^RPIJT,(.@@A0T(?]3R>@ICZ M[J$/0O4J%GPS$@!;51@OQHL,Z:L"P@774$).>N,[FB9KB!>M+JI.YZC M+F:>1^DLO]-U1%HH !Y+=8JV$2PQ,,^(QA2M#1CJ!:O M(@YO6ZZZXY>2UCW.=7 ^R>?F[NIV2Y9%?^6B,LQY:FS,E>JZ72^N.YYXY?+W M$7GW%L((SX#.;[%;>Y)D$W,?-]"($$LJ?OW'?>Z!M]^_[/G-Z.W/S7A^],LK M6(@:@6=U9^?)^=PA@M6T>CN2-%?8@\VE0716)G9*SG*+K3TH!>/K9RY:-DY; M@^5PZ0!F ;_I2/#A[;K,D+_XU$4AS-BH'PZ#DN79CRBD^9!G84^7ABDH'W1E MX)I"%=@6BL#JQ;$))U#?5"<:,*,GJJ[%A]#X?]$]IAA*IG1S&"WQ&W3Y+W26 MM*"ZDN@T*Z$9!W7&5*J=FW5$?2D%..6T 738R\<CYL7&W8^B6BD.[[FZ9%,D/\^N#5>YO]T>Y'Q^]?-V@W%$K M/ 9AO@?:?:O(TGVKM+SZ3EDEV$8MK79V"I^']^7EFWUM-7 M1\]?PEJXQB.*;+I"OB,=(51ME/,G?Y8/LP=[M(<.BPNC:3AHXVV3.[7K?8LJ M5Y>O/F1="KCC\\2( -A[VT<*H0OX!=>4R@(.G+.-:6UIG(6@X)GY%CD1_L,: MOE/W'GTV78VN&GX][@+[<*%$:VRT4Y]8[XLJW1)=W:XWI4@YLD#Q9<+M:<%YD\MZ>YW@K\WWVO5X?>(Q#^UU-HA:.I*=SS3P,M? MF@'?9*-LI7;FS]I'G](2,CEHF<$/6AF(*79 U_MD_ZZW3DJ+35NYY74=\]JB MX)UOV,"UV=B%&-:FV]XA=4_;508+UF[4A^TLP_XO"7$FE"5-;(*][8H)@;KNX **EPY>7/ M#!WNP9T[W9\[IY. LB<8![:Y)]NQ5&)7].M=[AP<,57PVH7 />9"[%2\VL;I&7QK$T,A<2Y.KQ MN^:EMN(:$)K+M=$#8^\KR4CZ=WFV>7U[AZRHHDEJ"!^X>TX&I=-0-^_,%%O\ M3YP..5,<81).V 3Y\LZ\+_A5J(/(,!#\!HVYS6%VXFRWV^!.D=F6 MI2U0LDV^6Y72C^L]8=QD=#KDV!^8,JP%>=49="NH1;0U7FWE11F$-@&7CO]>C@^2#1%[I MQ9Z!8,#\__W#S?N[Q@];F/=B2V&>WL"'&Z*MR&.&B09L9Q(9);H&<4[DQUV; M E:]4>;)5VH*MR[&-TF)_P92(N;]SQ:W:2G\':-D\36:$4H,% 13;:#$M.AF M5M,<$C-Z*ELPY5Q!T3'0HB-!GY .Y<0T"TV,)H/63Q8X2B/+.HD045FY:ZZ8 M<%,UA_8[8_>4F0S7,.VVP$ZB#L?(_SSHB8]JG58267GA7&)$Y-[KDM\[YPZ?>:!K M;\L[JO]5Z&CC8:3+%3H/+@+ YB V_=+;(H5U ).^K2#Y8^$7F3#*$"U*V\<; MLY!(08K'0OA"F^U*SU5O#MC8QX5%H*^)2]^ MKYBZ"@?Q7H]3)I6M;OIH+=$+E@'I4Q;999%?/?_[9)$;Q/$#25\ZK+IZ5Y7V MH?!@J5F22'YQ=/PZAEZ#;_"_O^!=P7+S$)HQQ9@8_'F<%>/UO$3I+3H1NQAB MV8:(%%\ BTILO-C=HZBWV 0JTZNXL\;.M*$,KE;"H,$]R5.*K^CFV_6.M1/S M*W/ZQ "J..2JJQL8[F4R2ZV4=.-,?*4/@HZB&XTYHC#RUEQ3?L &1+,%<=7, MOD[4?&2MFE7B'9,<[;72;[;F5&)K@+;"L*TY*A@09O).I&\K54QMB^7@094R M;O@'9+CHZUE+6J<[>$B+9"ZQT\D$RR\MBHH3%$ZM:^#6E'YM::PM88V-KTZL M.K?=8AGKQ:57/E>2-KM<>(EM,FJ5A&PZ.?U_!SZSUX[>D%=_#UR[[A$&A,W& MH1/#5H\,T"NQ'<_62-_:,3H?-MH,(9N"29::HUMTW6%09WG7LE)^$8HWVGL. M[=S=P(6!HPB^#9U21U1HQ]EZ1!(7QE!ER=+7H%F,8@_3"T'L5]G+E7>%BA->1C5B )/-K+ 5\X[5CJKCY+*HZ$> MLD!NELB?ECFQ&F$^:4D-#R 3'DW66$=M%&[:GH*P60JLJZ^Z+;1C?IG*WS2/ MWIB'HR5N2X5*#,1S;[DQW,PU*W_#6E+TFP<\6RF.O4.'(_0O+ M>VO0O[KO2O,36R0?3P]C#5OL3S4K=H)=1I2SNBGS)F6+4"8^*%)RBP+ %C)&:\B3&ROJOZ\U\P=V:BI2XD^[62Z[9N-9/W Z6HX4Y&-64[,/U?9S"-8TD,: 9@%YTU< MY[,*X(8N :+>;'"' FW(!5*+<'0.W!8'R)420X@4!]-H.P3M[\A2%S*$0^&F MV+T])VWU2?[7^!> M(-):1+62PRZIS4L8+MX-5RBPW/M[4Q>6@;G"8S MV\D$H+Q(SR]!0#W?FD9B[?=EZYIS3+.A4YNV3\AWL-8W"-22[>$@AFA)(^%4 M1JJ!C[]I&,^"]8&ITYA=SZNT$L1<$%,(.3D1$7*;!Y)K/L\GCOT1F'D2A*)Q MA:'EGJO:!D_W>J=[3?O<<$H J]FXVXCSQ-9/]2I=DNZBPF)ZC1 W;-_C25J. MBVSD3+EI5I3,M5;FRK*V$?07X*(1S 4M2#[&:A!ASUEA9;^Q\2CW666/?D=. M \\UIC4Z07DU>PVN L]U?"O%(@_[!GK?H>ON31Y>!("!9K9PK(KE/D#2/(Z] MEY;G*9*?H!1620;K1G5M9*2$2)Z$1TJ&7-\!A6RB0RLWB7'(QU*+MBJ=BS#R M\C%:7%4)S*I0Q:>KO^O5U^?=ZGC7JZ!*#N#3?59._Z]R[G\+]UU%T>C [;J1 MJ**MD:!A^_I>"J8<9,LUIL\*Z[#6'_#7(&O@H%=)ELG)5ZHO)JOW*<_N\NS' M!YUGWX>L.DX2I&*=K(WN\O5LHJ(P-9?!D=]6X?_\<>&3L->G\87],-,-3U8K5LL4)@:J 9&EJ@))GB*.SU MPA8RZC1II&N[*9CI0?Q6Y4[2*?!AEL0CRW!#5V[B$C9@M:(EL18^B5KQ9T7* M;R#$ZH2)9X+XC6L;/D+JX:(LG,V#OWL4:L1?0KM9* #B,5#?P8U.03 MY5UE:?;0<&BR%\+K\2M@<9L/Y,Y2@!&$C+M@![L6?H%%<--LLAYG "!NPF(X M%(:#3.12OY=A2P(4!PR7T&@)B\WP%D3R;0$XHFQ&1X3/L#Z_-8G9"^(0ED0S MZ^( ::6=Z\-C)7:/=48/C)OP@IZ/04CN@2_AN.15<@CQ]%[":I*5XQG>30[= M@IWM@K>A[6!S-QW?&X:NDU3O,@VUJSQ59[F\/NU;[QBUL[41Y-A=.-2Q#9?. M-C662]<-&"IU&X+&>>Z,*6FJP0Q!(F(/-;7>Y@U94V^710IY=A"48/B4P/B> ME3?JXVY=:%GB.CD$3T+*B6NI=T*@0HT3]GIZ=/S\Y;-C"S%,HT_ <3^)+E=8 M7G$%4UF;\9@56L\$A1X\Y?CH^,W+9Z^M_YA"NWOB"]WA:1VH!!%D/L# 8Q>> MHE(MVR$@NC5;27C1&C!5^X8J8%4MKHI@5=5HZGVA4K6CX'9B4&%3V%"XKU*W MPZ0J*"GJJEJ/E#JO?I:Z/G#".?A"2ZR]4].YK(V&33+E-EM 7=:F6.Q&6IZZ MFM>MU*&D@?>NLVB8!Q;H&R+;EL:9N4ZYH1WT&TBD,G_C2^9:I:%:"=2CL'-Z M6AJ6LJC+IL.M^/A@1"T/0IWRCJD%AJE9,I#'R>*K "5#I'?8_5BSI->^%\'< ME05Y,DQV-4SNN[(VCX4E12Y@;5M)"T:[M@T.*HP1I% -"%,(!_2_= M[1+?ZN#F:ZZUVG6!T:%J:=;/Z)$D*&9ARU"@ZR9W$2!T^3<%3J51GT)&(R6$2ML]?@$/R#,B,9@P)O2?*0ML(<#?#O4NMH9C7!T8U4]]YY5V=V5W M3M>?1390,XAN]SL\/BO_R"JJ B_,$2KR!'' ,RP0F.B%06ML9"3)G-PY!^36 M3YJLN8B:/M2TM'4%H)5S?YOE,U4YYT@^C7T#'5R\U#2$;)OH0'PT MT 6)5)5^\9C-Q)1E3!$^/^RBLJK-LJ.%?CL6V4&"KO$9*[FQ#O(%X2?D/NK4 M%!!31"O /IE74Q/H4M6V"!Y?-SV&2D/B6=# H/B^*O%'&A?2Y04M2G$S*"ZK M2^MP0<.4H"H;^I#]DP1/&]<5F46QG$/M@DRX;)RQ#EH:_W)=5@HM8ON;:2HU MOK"D.'N;D5*+4H1SZ;SMXLZ$)7,P=E7H&F"O!4]? M!"ALJLC"#Y-*7DMOKTF='P8?I.H&-A2V[:2 /')Z\$I**_EM'61SFQ: R:!2 M>*1R5!_IUFM\_Z#HA&R\10L+;W%C.U,I:H#,FR/HE^2:; 7!SXL4[\Y?<66K M_OL/OYW#!V0LQUW>3'Q+<,I=*VOS_6N(C4P3:[K+LG/8T%*76WK?NI#"\?&+ M-UC@QL?QICW^V=.F._S27BBP M#PC>NK'0#F2NV/"-Q.B3785$0T9&;DC@LZUP3)77TI_@*.?S98IHD7^NBZR< M9"QU+1Y6#F'UQ+WXDQDF']2^O-T;\_+%\Z-C-"^O=N .L 9<#7^/"/#TVQ(0 MC5"LN#;N?6'&51L^9A,)+$%C*!J]PGZR^00&'!NEJS4"M\10A:=CO9P@<&R7*4^&PQ85VV81KQ6MDN.B_ N\Q4;UOP[EH4BDL 6.%P1 MM$<22, ]6R00ZVE=P)T7#B,ZRQ*'THJ]/TW6*T+(E&-P$J@PDJ)DD'J#VM%% MMLKQ5'!]<:R[@]B:#A5[YUB=1H4VBJRCZ#-'.K%(4PZ8F1O@?1B"ZFG!K50N ML!C@IXTLCHA,6C5%-2F9K= \D4D3^L)AVB-'"\,26-=_J+5=NC!=U6Q26-\" M)H>Q$-"G6*_$&VPSG\U'$%2+>ZT@J&AV*+?9"RZPG4/3EJQ9>SS^0/ S*BK^ M^FA?[O[QJZ,76Z TE^OB-KM-9@^*G(EZ2,IPFRZ(Q\RFZ$N,5YES+ 71%$:Y M2PI(T@.P5_B<;$&%M$!2E1BJR )SI4PG;6XR!5-2%0USE?6ZM7 -]4,>,AWN M&.+PX,:24!=OF=F19G!',(G$,ZOET'#^7XF;F#)\7'KEJ,9T5@36+ ?\FIIP MB%C@>V^$95),9EP_0X!];,;!$')9>HN?XEW!(2+^ CQ"&X^8'\-PW#ZD M)" ^6,(VH1*K-;<<(DRJ%1%Q!JPLGEWJ U30^CME?@@V3<(D5\V'1" M>/LME><-7-)(A@;*9Y;21_\8# ;!V2:&-.2::5QQ_\1RU+YF2ZR1B=YWL4!M";QV0 G6!@L@"MQ713 _/S-7V0?M$7JD/H&,6_ MW?]%>[L>TE M3ZA!JP\=H-X(I\P4^8 69T=5%EX[NQ@A85@.IXH4?*5<0S^E=,+I.(:,&!/G-LL!8N(F2MH= M096D[]&?2Q#(R@R[\6XO/C('':LC X[._8SA>=4\KXZ>'S]LA4LMU1X"(S61 M*MZ,S L)$VN((L!N/)G4NS5=; MMX&,9&3#Q90*?,+RF<=T]A38^"9UZ"B%B M2UKV("V4:M3K^924-GH[9!W!E$&GS9#'EWC *TJ;6ZE$K14N.[R MR/@%SA-*U)JJ%>!:(YE9!): @Y3YT@=Q#0T6FXZ7_HL^-K$);I77)SH]$)*< M'X[]: I[.1V_[HU_ZYS3F@R?Y1:!Q*)R=&.)PL;$;T#CT-&=PN855%VV\)B$ M?:2V3G\75"FRF7]ECCAC@Z M&_"I@*EF.7%X$B;A==^FKH/X9/"E\\D:.Y\8<35/Q/<&T,?:J!9[M8*;5$,= MG91>A"*!@FOSB-FF\7[6=N5J<)N(<[NR27'DM2,FQ_4N+R:V3ZZ-H<22"N$_ M4+^SNM_B/,,_R-SL[U%(XYO,5&;9U]2L'^1K0)'F1:"([WW;X"/5Z=9!,TBB MI+7GPU@(/&[723SZFJ9+CA!1-7LI27%U2##+I*25>LQ?>,X:[--1*EH$42BS M]!H>@2QXM;S:E.4HS=Y17GHN.Q%;<[Z1>AU)5C4:B MZUA0*QODUN-5S[&2:@Y%49R 0R(\['D3MN_ -E2:(13ZA4SPD8EDM[$MP]-Y M?Y3G?;HN0.H]K

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`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͠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

    ;#O.G231)4KR#S'-RF=497D(\$#P((U^ &6;@ M=/ IK_!:M[OL5ACUQY^K) MY^/@)+M2C(,S!":R?9)L$N(L>)N". V. BJ+PA:XY66$8+?M1J.2Q\@ICI%I MKQ>BX*5.!PQ/P2*Y@5LX!1EN$&9L'W:RDLL2" A!Z^#J@$^G&EBVD?3F[_"> M8!; M%8@UP:/[ M<96SN(QAFE(78"**DO#;4*KU2:PD6/VB_B7L^3KVHZQJ)203!C M?'TDOS@J+QG1C)&UYEAYRC*4X1RKG+\&^9NF&I@_F.0H[:+L@F"P(YJ-^5._ MYQ8]G7L2K+[[MP3K$"P"0 R'6G^+4M"T@*RJ8)'&.R$Z$.M)FL3&OA*K*FC8 M4MQCB'IF1=>4O?U?0-%*T/8P8;NLXUB!B564@^CKR[@;;^$YC:$XA#-X\-ME M%:_>0B%_XJR*;6Z!Z+-I/2?:/BJJ)$X9%/O(NA"&0$U6-3\2+1@G?*JDQ\NJ MA;160@C5N/*[%4GXNTMM;;Z>5#@)5G\6U_I M$5Y 9HQ$E1;Z!D;AV0+=F_FNKI/;UD]_#_73/833R]VM9.HGF4ZI8B]X!W?* M<*03"@$N)61731/LD9L>1 4W4&!4^CB-"@+FV7J![)C/V*SZ"E.QMS?Z?2!=ZHX= %5;J/%1UD[?*N%<^^I.N,N8F MVR#V"0!A.*32;O6#6B[.=;Z0=*QV)_&)(G1BO1QL9BH-G!UD;!H)'DK5%?YI M!PP^YF#=2:.=!]X%&O$'9((D[K$OA)6'QNE&X;)-LT +$]C8?NT_#;)<6F9- MN#^\-3I,N8/MK$UC;=6!!^!H9(8!V<2/.)4 '39@BF\VG6";]7??+#(?#*+1 M8^>-S;8RZ:\U]O:Z]L-Q>M*N#4=S&IYC@SP:+HR\U4-FR94*1L_'P9NZA)'@ MXW?1$A\J@GE>*%%65!:,]G;;#SGI+1W%D78A&-49O8I28QH-V4PGR)\$?\D! M>"+U*4^I+5=<*)OJ4U+IY'615 *=?!WA]+F[,Z;H+&#'\FDY'K+:NDG2" >V M)Y?Y->C&&U7(0F&,69N.B8!G4L_B?-XPQ&S35?9M*DS#(%-^'GW!@,99E<=? MK(+_.5IR'[R\3J<.\MX,C04!Y\?WF1^\2:/X2UY7",8&I!V23S'SSI4MCCR. MZP*=CXQO_K5J,"TL*$WS:P8H!V;$#J'2[V[5*Z6+)++PL(C'V(&SNL"-' 5 MM9I.ND<$DG<>314WS,HRT1>(F/BYAHEB&R]2;DT 0ZHB3CA7$N4CW&.D_Z#0]+!')I456JZ]0T\E-K&>LL0%+?';O]L MVC=P)Z_YMM3@OEAI6(90>(,'728=6LE-,KF[*I#&%V!U9($/_-93(S!\AGT$ MW-IBS.U]=C,3DL8R!/9[[-?98W'G;1FD%X.@9KV- =V1,0Z(+T9)LMFNL?? M'-MB_UX740*Q)"J?A=3Q&4:- MYCDZ:RN M2;L"6T6%'I\E.@-6UI1NK?E[)M6K**T'4T[QN.7[[FCZ M.&3[-OFQ)V\DZAJ$$/9 W7+'G;AC"VWY/7'&67RIIG5*H17MR]DRR+V8!X_C M ND/Y]T/W?)I^X$-XM#N(9;H#0E?81V<-R>1()YWK\[D%*#=^_$ R?R (;I; MD E1"0P+[X.AQ,)H[8R&34#;XBHIJIHD4&%UV-*52-Q:C8:$H18&I@]^W'^Z M>XPH/DJNQJ-9?_ 97WVNWWCV=S%[TLQ08[H2C'@4#\Q:;LX-:6WO]<$!V:UB ML#(8@\40#HH:Z[VY[9ZE-+)XZ19PD$4,?(-A+K3'ZTJ%,@I\XPRR$QP1M@D" M.V+H!(?$^B@L3\"(33)+8K@!8RYV*.BZ=@?0%1YEE)2:\V9U51>$3W$/9GK?MFE;5A$",^E(6%61E.5 ;'K+/ECF 01U MAEZF,KAY]BX*#]'>17ZEB@R]4!%0:#XE:.3H LA?N$=-)KL]AAMWRV M]1T]!/DM@Q/!7BJ#;:S@NXH5;#$:GA1&PZX_DZ=7 >S3-N 2�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end XML 132 wald-20241231_htm.xml IDEA: XBRL DOCUMENT 0001840199 2024-01-01 2024-12-31 0001840199 dei:BusinessContactMember 2024-01-01 2024-12-31 0001840199 us-gaap:CommonClassAMember 2024-01-01 2024-12-31 0001840199 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001840199 us-gaap:CommonClassAMember 2024-12-31 0001840199 us-gaap:CommonClassBMember 2024-12-31 0001840199 2024-12-31 0001840199 2023-12-31 0001840199 us-gaap:NonrelatedPartyMember 2024-12-31 0001840199 us-gaap:NonrelatedPartyMember 2023-12-31 0001840199 us-gaap:RelatedPartyMember 2024-12-31 0001840199 us-gaap:RelatedPartyMember 2023-12-31 0001840199 us-gaap:CommonClassAMember 2023-12-31 0001840199 srt:ParentCompanyMember us-gaap:CommonClassAMember 2024-12-31 0001840199 us-gaap:CommonClassBMember 2023-12-31 0001840199 srt:ParentCompanyMember us-gaap:CommonClassBMember 2024-12-31 0001840199 2023-01-01 2023-12-31 0001840199 2022-07-29 2022-12-31 0001840199 wald:ObagiSkincareMember 2022-01-01 2022-07-27 0001840199 2022-01-01 2022-07-27 0001840199 us-gaap:CommonStockMember wald:ObagiCosmeceuticalsLLCMember 2021-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:ObagiCosmeceuticalsLLCMember 2021-12-31 0001840199 us-gaap:RetainedEarningsMember wald:ObagiCosmeceuticalsLLCMember 2021-12-31 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:ObagiCosmeceuticalsLLCMember 2021-12-31 0001840199 wald:ObagiCosmeceuticalsLLCMember 2021-12-31 0001840199 us-gaap:RetainedEarningsMember wald:ObagiCosmeceuticalsLLCMember 2022-01-01 2022-07-27 0001840199 wald:ObagiCosmeceuticalsLLCMember 2022-01-01 2022-07-27 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:ObagiCosmeceuticalsLLCMember 2022-01-01 2022-07-27 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:ObagiCosmeceuticalsLLCMember 2022-01-01 2022-07-27 0001840199 us-gaap:CommonStockMember wald:ObagiCosmeceuticalsLLCMember 2022-07-27 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:ObagiCosmeceuticalsLLCMember 2022-07-27 0001840199 us-gaap:RetainedEarningsMember wald:ObagiCosmeceuticalsLLCMember 2022-07-27 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:ObagiCosmeceuticalsLLCMember 2022-07-27 0001840199 wald:ObagiCosmeceuticalsLLCMember 2022-07-27 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2022-07-27 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2022-07-27 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2022-07-27 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2022-07-27 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2022-07-27 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2022-07-27 0001840199 wald:WaldencastPlcMember 2022-07-27 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2022-01-01 2022-07-27 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2022-07-28 2022-12-31 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2022-12-31 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2022-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2022-12-31 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2022-12-31 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2022-12-31 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2022-12-31 0001840199 wald:WaldencastPlcMember 2022-12-31 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2023-01-01 2023-12-31 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2023-12-31 0001840199 wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2024-12-31 0001840199 us-gaap:CommonClassBMember us-gaap:CommonStockMember wald:WaldencastPlcMember 2024-12-31 0001840199 us-gaap:AdditionalPaidInCapitalMember wald:WaldencastPlcMember 2024-12-31 0001840199 us-gaap:RetainedEarningsMember wald:WaldencastPlcMember 2024-12-31 0001840199 us-gaap:AccumulatedOtherComprehensiveIncomeMember wald:WaldencastPlcMember 2024-12-31 0001840199 us-gaap:NoncontrollingInterestMember wald:WaldencastPlcMember 2024-12-31 0001840199 wald:WaldencastPlcMember 2024-12-31 0001840199 wald:ObagiMergerMember 2024-01-01 2024-12-31 0001840199 wald:ObagiMergerMember 2023-01-01 2023-12-31 0001840199 wald:ObagiMergerMember 2022-07-29 2022-12-31 0001840199 wald:ObagiMergerMember 2022-01-01 2022-07-27 0001840199 wald:MilkTransactionMember 2024-01-01 2024-12-31 0001840199 wald:MilkTransactionMember 2023-01-01 2023-12-31 0001840199 wald:MilkTransactionMember 2022-07-29 2022-12-31 0001840199 wald:MilkTransactionMember 2022-01-01 2022-07-27 0001840199 2022-12-31 0001840199 2022-07-28 0001840199 2021-12-31 0001840199 2022-07-27 0001840199 2022-07-28 2022-12-31 0001840199 us-gaap:IPOMember 2021-03-18 2021-03-18 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember us-gaap:IPOMember 2021-03-18 2021-03-18 0001840199 us-gaap:CommonClassAMember us-gaap:CommonStockMember us-gaap:IPOMember 2021-03-18 0001840199 us-gaap:IPOMember 2021-03-18 0001840199 2021-07-15 0001840199 us-gaap:WarrantMember us-gaap:IPOMember 2021-03-18 2021-03-18 0001840199 wald:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001840199 wald:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001840199 wald:InventoryPurchasesMember us-gaap:SupplierConcentrationRiskMember wald:VendorOneMember 2024-01-01 2024-12-31 0001840199 wald:InventoryPurchasesMember us-gaap:SupplierConcentrationRiskMember wald:VendorTwoMember 2024-01-01 2024-12-31 0001840199 wald:InventoryPurchasesMember us-gaap:SupplierConcentrationRiskMember wald:VendorOneMember 2023-01-01 2023-12-31 0001840199 us-gaap:AccountsPayableMember us-gaap:LenderConcentrationRiskMember wald:VendorOneMember 2023-01-01 2023-12-31 0001840199 wald:CorporateCreditCardsMember 2024-12-31 0001840199 wald:LeaseDepositsMember 2024-12-31 0001840199 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0001840199 wald:ComputerHardwareSoftwareAndEquipmentMember 2024-12-31 0001840199 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-12-31 0001840199 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-12-31 0001840199 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0001840199 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0001840199 srt:MinimumMember 2024-01-01 2024-12-31 0001840199 srt:MaximumMember 2024-01-01 2024-12-31 0001840199 wald:FounderAwardsMember 2022-08-31 0001840199 wald:ObagiMergerMember 2022-07-28 0001840199 wald:ObagiMergerMember us-gaap:CommonClassAMember 2022-07-28 2022-07-28 0001840199 wald:ObagiMergerMember 2022-07-28 2022-07-28 0001840199 wald:MilkTransactionMember us-gaap:CommonClassBMember 2022-07-28 2022-07-28 0001840199 wald:MilkTransactionMember 2022-07-28 2022-07-28 0001840199 us-gaap:CommonClassAMember 2022-07-28 0001840199 wald:MilkTransactionMember 2022-07-28 0001840199 wald:CedarwalkMember wald:WaldencastPlcMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember wald:ObagiChinaBusinessMember 2022-07-28 0001840199 us-gaap:RelatedPartyMember wald:ObagiChinaBusinessMember 2022-01-01 2022-07-27 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:ObagiSkincareMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:MilkMakeupMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:RelatedPartyMember wald:ObagiSkincareMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:RelatedPartyMember wald:MilkMakeupMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:RelatedPartyMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:ObagiSkincareMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:MilkMakeupMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember 2022-07-28 0001840199 wald:ObagiSkincareMember 2022-07-28 2022-12-31 0001840199 wald:ObagiSkincareMember 2024-01-01 2024-12-31 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:RelatedPartyMember 2022-07-28 2022-12-31 0001840199 wald:TretinoinDistributionAndSupplyAgreementMember 2024-01-01 2024-12-31 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:TrademarksAndTradeNamesMember wald:ObagiSkincareMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:TrademarksAndTradeNamesMember wald:MilkMakeupMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:TrademarksAndTradeNamesMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:TrademarksAndTradeNamesMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:CustomerRelationshipsMember wald:ObagiSkincareMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:CustomerRelationshipsMember wald:MilkMakeupMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:CustomerRelationshipsMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember us-gaap:CustomerRelationshipsMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:TretinoinDistributionAndSupplyAgreementMember wald:ObagiSkincareMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:TretinoinDistributionAndSupplyAgreementMember wald:MilkMakeupMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:TretinoinDistributionAndSupplyAgreementMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:TretinoinDistributionAndSupplyAgreementMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:FormulationsMember wald:ObagiSkincareMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:FormulationsMember wald:MilkMakeupMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:FormulationsMember 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember wald:FormulationsMember 2022-07-28 2022-07-28 0001840199 wald:ObagiAndMilkBusinessCombinationsMember 2022-07-28 2022-12-31 0001840199 wald:ObagiAndMilkBusinessCombinationsMember 2022-01-01 2022-12-31 0001840199 wald:ObagiVietnamImportExportTradingMTVCompanyLimitedMember 2023-03-01 2023-03-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember wald:ObagiSkincareMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember wald:MilkMakeupMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember wald:ObagiSkincareMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember wald:MilkMakeupMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember wald:ObagiSkincareMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember wald:MilkMakeupMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember 2024-01-01 2024-12-31 0001840199 us-gaap:RoyaltyMember wald:ObagiSkincareMember 2024-01-01 2024-12-31 0001840199 us-gaap:RoyaltyMember wald:MilkMakeupMember 2024-01-01 2024-12-31 0001840199 us-gaap:RoyaltyMember 2024-01-01 2024-12-31 0001840199 wald:MilkMakeupMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember wald:ObagiSkincareMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember wald:MilkMakeupMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember wald:ObagiSkincareMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember wald:MilkMakeupMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember wald:ObagiSkincareMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember wald:MilkMakeupMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember 2023-01-01 2023-12-31 0001840199 us-gaap:RoyaltyMember wald:ObagiSkincareMember 2023-01-01 2023-12-31 0001840199 us-gaap:RoyaltyMember wald:MilkMakeupMember 2023-01-01 2023-12-31 0001840199 us-gaap:RoyaltyMember 2023-01-01 2023-12-31 0001840199 wald:ObagiSkincareMember 2023-01-01 2023-12-31 0001840199 wald:MilkMakeupMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember wald:ObagiSkincareMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember wald:MilkMakeupMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember wald:ObagiSkincareMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember wald:MilkMakeupMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember us-gaap:SalesChannelThroughIntermediaryMember 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember wald:ObagiSkincareMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember wald:MilkMakeupMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember 2022-07-29 2022-12-31 0001840199 us-gaap:ProductMember 2022-01-01 2022-07-27 0001840199 us-gaap:RoyaltyMember wald:ObagiSkincareMember 2022-07-29 2022-12-31 0001840199 us-gaap:RoyaltyMember wald:MilkMakeupMember 2022-07-29 2022-12-31 0001840199 us-gaap:RoyaltyMember 2022-07-29 2022-12-31 0001840199 us-gaap:RoyaltyMember 2022-01-01 2022-07-27 0001840199 wald:ObagiSkincareMember 2022-07-29 2022-12-31 0001840199 wald:MilkMakeupMember 2022-07-29 2022-12-31 0001840199 wald:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001840199 wald:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001840199 wald:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001840199 wald:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001840199 wald:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001840199 wald:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-07-28 2022-12-31 0001840199 wald:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-07-28 2022-12-31 0001840199 wald:CustomerThreeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-07-28 2022-12-31 0001840199 wald:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-07-27 0001840199 wald:CustomerTwoMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember srt:NorthAmericaMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember srt:NorthAmericaMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember srt:NorthAmericaMember 2022-07-28 2022-12-31 0001840199 us-gaap:ProductMember srt:NorthAmericaMember 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember wald:RestOfTheWorldMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember wald:RestOfTheWorldMember 2023-01-01 2023-12-31 0001840199 us-gaap:ProductMember wald:RestOfTheWorldMember 2022-07-28 2022-12-31 0001840199 us-gaap:ProductMember wald:RestOfTheWorldMember 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember 2022-07-28 2022-12-31 0001840199 us-gaap:RoyaltyMember 2022-07-28 2022-12-31 0001840199 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember country:US 2024-01-01 2024-12-31 0001840199 us-gaap:ProductMember country:US 2023-01-01 2023-12-31 0001840199 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-07-28 2022-12-31 0001840199 us-gaap:ProductMember country:US 2022-07-28 2022-12-31 0001840199 us-gaap:ProductMember country:CN 2022-07-28 2022-12-31 0001840199 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember country:US 2022-01-01 2022-07-27 0001840199 us-gaap:ProductMember country:VN 2022-01-01 2022-07-27 0001840199 wald:ObagiSkincareMember 2022-12-31 0001840199 wald:MilkMakeupMember 2022-12-31 0001840199 wald:ObagiSkincareMember 2023-12-31 0001840199 wald:MilkMakeupMember 2023-12-31 0001840199 wald:ObagiSkincareMember 2024-12-31 0001840199 wald:MilkMakeupMember 2024-12-31 0001840199 wald:ObagiSkincareMember 2022-01-01 2022-12-31 0001840199 us-gaap:TrademarksAndTradeNamesMember 2024-12-31 0001840199 us-gaap:CustomerRelationshipsMember 2024-12-31 0001840199 wald:TretinoinDistributionAndSupplyAgreementMember 2024-12-31 0001840199 wald:FormulationsMember 2024-12-31 0001840199 us-gaap:PatentsMember 2024-12-31 0001840199 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001840199 us-gaap:CustomerRelationshipsMember 2023-12-31 0001840199 wald:TretinoinDistributionAndSupplyAgreementMember 2023-12-31 0001840199 wald:FormulationsMember 2023-12-31 0001840199 us-gaap:PatentsMember 2023-12-31 0001840199 us-gaap:SecuredDebtMember wald:A2022TermLoanMember us-gaap:LineOfCreditMember 2024-12-31 0001840199 us-gaap:SecuredDebtMember wald:A2022TermLoanMember us-gaap:LineOfCreditMember 2023-12-31 0001840199 wald:NotePayableDirectorsAndOfficersInsuranceMember us-gaap:NotesPayableOtherPayablesMember 2024-12-31 0001840199 wald:NotePayableDirectorsAndOfficersInsuranceMember us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2022RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-12-31 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2022RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001840199 wald:NotePayableDirectorsAndOfficersInsuranceMember us-gaap:NotesPayableOtherPayablesMember 2024-07-31 0001840199 wald:NotePayableDirectorsAndOfficersInsuranceMember us-gaap:NotesPayableOtherPayablesMember 2024-07-01 2024-07-31 0001840199 wald:NotePayableDirectorsAndOfficersInsuranceMember us-gaap:NotesPayableOtherPayablesMember 2023-08-31 0001840199 wald:NotePayableDirectorsAndOfficersInsuranceMember us-gaap:NotesPayableOtherPayablesMember 2023-08-01 2023-08-31 0001840199 us-gaap:SecuredDebtMember wald:A2022TermLoanMember us-gaap:LineOfCreditMember 2022-06-30 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2022RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-06-30 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2022TermLoanMember us-gaap:LineOfCreditMember 2022-06-30 2022-06-30 0001840199 wald:A2022TermLoanMember us-gaap:LineOfCreditMember wald:AlternateBaseRateMember wald:VariableRateComponentOneMember 2022-06-30 2022-06-30 0001840199 wald:A2022TermLoanMember us-gaap:LineOfCreditMember wald:ApplicableRateMember wald:VariableRateComponentThreeMember 2022-06-30 2022-06-30 0001840199 wald:A2022TermLoanMember us-gaap:LineOfCreditMember wald:AlternateBaseRateMember wald:VariableRateComponentOneMember 2024-01-01 2024-12-31 0001840199 2022-06-30 0001840199 wald:A2022TermLoanMember us-gaap:LineOfCreditMember 2024-12-31 0001840199 wald:A2022TermLoanMember 2024-12-31 0001840199 wald:A2022RevolvingCreditFacilityMember 2024-12-31 0001840199 wald:A2022CreditAgreementMember 2024-12-31 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2022RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-04-26 2024-04-26 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2022RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-04-26 0001840199 srt:MinimumMember 2024-12-31 0001840199 srt:MaximumMember 2024-12-31 0001840199 srt:WarehouseMember stpr:TX 2024-01-01 2024-12-31 0001840199 srt:OfficeBuildingMember stpr:TX 2024-01-01 2024-12-31 0001840199 wald:InterestRateCollarMember 2024-12-31 0001840199 wald:InterestRateCollarInitialFixedPaymentMember 2024-01-01 2024-12-31 0001840199 wald:InterestRateCollarMember 2023-12-31 0001840199 wald:InterestRateCollarMember 2024-01-01 2024-12-31 0001840199 wald:InterestRateCollarMember 2023-01-01 2023-12-31 0001840199 wald:InterestRateCollarMember 2022-07-28 2022-12-31 0001840199 wald:InterestRateCollarInitialFixedPaymentMember 2022-07-28 2022-12-31 0001840199 wald:PublicWarrantsMember 2021-03-18 2021-03-18 0001840199 wald:SponsorWarrantsMember 2021-03-18 2021-03-18 0001840199 wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember us-gaap:CommonClassAMember 2021-12-20 2021-12-20 0001840199 wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember wald:SponsorWarrantsMember 2021-12-20 2021-12-20 0001840199 wald:BeautyVenturesLLCMember us-gaap:CommonClassAMember 2021-03-01 2021-03-01 0001840199 wald:BeautyVenturesLLCMember wald:SponsorWarrantsMember 2021-03-01 2021-03-01 0001840199 wald:BeautyVenturesLLCMember 2021-03-01 2021-03-01 0001840199 wald:SponsorWarrantsMember 2022-07-28 2022-07-28 0001840199 wald:PublicWarrantsMember 2024-01-01 2024-12-31 0001840199 wald:PublicWarrantsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-12-31 0001840199 wald:PublicWarrantsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-12-31 0001840199 wald:PublicWarrantsMember 2024-12-31 0001840199 wald:PrivatePlacementWarrantsMember 2024-01-01 2024-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember 2024-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember 2024-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001840199 wald:InterestRateCollarMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001840199 wald:InterestRateCollarMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001840199 wald:InterestRateCollarMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember 2023-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001840199 wald:PublicDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember 2023-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001840199 wald:PrivateDerivativeWarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001840199 wald:WaldencastPlcMember 2021-12-31 0001840199 wald:WaldencastPlcMember 2022-01-01 2022-07-27 0001840199 wald:ComputerHardwareSoftwareAndEquipmentMember 2023-12-31 0001840199 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001840199 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001840199 us-gaap:MachineryAndEquipmentMember 2024-12-31 0001840199 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001840199 us-gaap:SoftwareDevelopmentMember 2024-12-31 0001840199 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001840199 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001840199 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001840199 us-gaap:EmployeeStockMember wald:A2022IncentiveAwardPlanMember 2024-12-31 0001840199 us-gaap:EmployeeStockMember wald:A2022IncentiveAwardPlanMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:ShareBasedPaymentArrangementEmployeesAndNonEmployeesMember wald:LongTermIncentiveAwardsMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:ShareBasedPaymentArrangementFounderMember wald:LongTermIncentiveAwardsMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:ShareBasedPaymentArrangementBoardOfDirectorsMember wald:LongTermIncentiveAwardsMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:LongTermIncentiveAwardsMember 2023-05-01 2023-05-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:LongTermIncentiveAwardsMember 2023-01-01 2023-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:LongTermIncentiveAwardsMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:OneTimStockGrantMember 2022-11-30 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:OneTimStockGrantMember 2022-11-01 2022-11-30 0001840199 wald:StockGrowthIncentive2027AwardsSGIAwardsMember 2024-01-01 2024-12-31 0001840199 wald:StockGrowthIncentive2027AwardsSGIAwardsMember 2024-08-01 2024-08-31 0001840199 2024-04-01 2024-04-30 0001840199 wald:StockGrowthIncentiveAwardsSGIAwardsMember 2024-01-01 2024-12-31 0001840199 wald:StockGrowthIncentive2025AwardsSGIAwardsMember 2023-01-01 2023-01-31 0001840199 2023-01-01 2023-01-31 0001840199 wald:StockGrowthIncentive2025AwardsSGIAwardsMember 2023-01-01 2023-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:WaldencastPlcMember 2023-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:WaldencastPlcMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:WaldencastPlcMember 2024-12-31 0001840199 wald:ObagiMergerMember 2022-07-27 2022-07-27 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:ObagiMergerMember 2022-07-27 2022-07-27 0001840199 wald:MilkTransactionMember 2022-07-27 2022-07-27 0001840199 us-gaap:StockAppreciationRightsSARSMember wald:MilkTransactionMember 2022-07-27 2022-07-27 0001840199 wald:ObagiAndMilkBusinessCombinationsMember 2022-07-27 2022-07-27 0001840199 wald:ObagiAndMilkBusinessCombinationsMember 2022-07-27 0001840199 wald:ShareBasedPaymentArrangementFounderMember 2022-08-12 2022-08-12 0001840199 2022-08-12 2022-08-12 0001840199 us-gaap:EmployeeStockOptionMember wald:ShareBasedPaymentArrangementFounderMember 2022-08-01 2022-08-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:ShareBasedPaymentArrangementFounderMember 2022-08-12 2022-08-12 0001840199 wald:FounderAwardsMember 2022-07-29 2022-12-31 0001840199 wald:ReplacementAwardsMember 2022-07-29 2022-12-31 0001840199 srt:MinimumMember wald:FounderAwardsMember 2022-07-29 2022-12-31 0001840199 srt:MaximumMember wald:FounderAwardsMember 2022-07-29 2022-12-31 0001840199 srt:MinimumMember 2022-07-28 2022-12-31 0001840199 srt:MaximumMember 2022-07-28 2022-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001840199 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001840199 wald:PredecessorIncentivePlanMember 2021-01-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember 2021-01-01 2021-01-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-01-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-12-01 2021-12-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-01-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-31 0001840199 us-gaap:EmployeeStockOptionMember wald:PredecessorIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-12-01 2021-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:PredecessorIncentivePlanMember 2021-01-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:PredecessorIncentivePlanMember 2021-01-01 2021-01-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember wald:LongTermIncentiveAwardsMember 2022-11-01 2022-11-30 0001840199 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001840199 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001840199 us-gaap:WarrantMember 2022-07-28 2022-12-31 0001840199 us-gaap:WarrantMember 2022-01-01 2022-07-27 0001840199 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001840199 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001840199 us-gaap:EmployeeStockOptionMember 2022-07-28 2022-12-31 0001840199 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-07-27 0001840199 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember 2022-07-28 2022-12-31 0001840199 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-07-27 0001840199 wald:BailiwickOfJerseyAndTheCaymanIslandsMember 2024-01-01 2024-12-31 0001840199 country:GB 2024-01-01 2024-12-31 0001840199 us-gaap:DomesticCountryMember 2024-12-31 0001840199 us-gaap:DomesticCountryMember 2023-12-31 0001840199 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0001840199 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001840199 us-gaap:ForeignCountryMember us-gaap:InlandRevenueHongKongMember 2024-12-31 0001840199 us-gaap:ForeignCountryMember us-gaap:InlandRevenueHongKongMember 2023-12-31 0001840199 us-gaap:ForeignCountryMember wald:GeneralDepartmentOfTaxationVietnamMember 2024-12-31 0001840199 us-gaap:ForeignCountryMember wald:GeneralDepartmentOfTaxationVietnamMember 2023-12-31 0001840199 us-gaap:CommonClassAMember 2023-09-01 2023-09-30 0001840199 us-gaap:CommonClassAMember 2023-09-30 0001840199 us-gaap:CommonClassAMember 2023-09-01 2023-11-30 0001840199 us-gaap:CommonClassAMember 2023-11-01 2023-11-30 0001840199 wald:PrivatePlacementWarrantsMember us-gaap:RelatedPartyMember 2021-03-18 2021-03-18 0001840199 us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0001840199 us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:SponsorMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:InvestorDirectorsMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:AaronChatterleyMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:ObagiMergerMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:MilkTransactionMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:MilkTransactionMember us-gaap:RelatedPartyMember us-gaap:CommonClassBMember 2022-08-01 2022-08-31 0001840199 us-gaap:RelatedPartyMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-08-01 2022-08-31 0001840199 wald:ForwardPurchaseAgreementMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:PrivatePlacementWarrantsMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-08-01 2022-08-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:ProductMember us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:ProductMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:ProductMember us-gaap:RelatedPartyMember 2022-07-28 2022-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:RelatedPartyMember us-gaap:SupplyCommitmentMember 2024-01-01 2024-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:RelatedPartyMember us-gaap:SupplyCommitmentMember 2023-01-01 2023-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:RelatedPartyMember us-gaap:SupplyCommitmentMember 2022-07-28 2022-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:RelatedPartyMember 2024-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:RelatedPartyMember 2023-12-31 0001840199 wald:ObagiChinaBusinessMember us-gaap:RelatedPartyMember 2022-07-28 2022-12-31 0001840199 us-gaap:RelatedPartyMember wald:MilkMakeupMember 2024-01-01 2024-12-31 0001840199 us-gaap:RelatedPartyMember wald:MilkMakeupMember 2022-07-28 2022-12-31 0001840199 wald:SkintrinsiqDevicesMember 2024-01-01 2024-12-31 0001840199 2022-07-27 2022-07-27 0001840199 srt:ScenarioForecastMember us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember 2025-03-11 0001840199 srt:ScenarioForecastMember us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2025-03-12 0001840199 srt:ScenarioForecastMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2027-03-12 0001840199 srt:ScenarioForecastMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-03-12 0001840199 srt:ScenarioForecastMember us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember 2025-03-11 2025-03-11 0001840199 us-gaap:SecuredDebtMember wald:A2025TermLoanMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2025-03-18 2025-03-18 0001840199 us-gaap:SecuredDebtMember wald:A2025TermLoanMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2025-03-18 0001840199 us-gaap:RevolvingCreditFacilityMember wald:A2025TermLoanMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2025-03-18 0001840199 srt:ParentCompanyMember 2024-12-31 0001840199 srt:ParentCompanyMember 2023-12-31 0001840199 srt:ParentCompanyMember us-gaap:CommonClassAMember 2023-12-31 0001840199 srt:ParentCompanyMember us-gaap:CommonClassBMember 2023-12-31 0001840199 srt:ParentCompanyMember us-gaap:CommonClassBMember 2022-12-31 0001840199 srt:ParentCompanyMember 2024-01-01 2024-12-31 0001840199 srt:ParentCompanyMember 2023-01-01 2023-12-31 0001840199 srt:ParentCompanyMember 2022-07-29 2022-12-31 0001840199 srt:ParentCompanyMember 2022-12-31 0001840199 srt:ParentCompanyMember 2022-07-28 shares iso4217:USD iso4217:USD shares pure wald:segment wald:director wald:operatingLease wald:individual wald:tranche wald:installment 0001840199 false FY 2024 X0 0.3333 P3D P10Y 0.33 P12M P12M 1 1 http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants 20-F false true 2024-12-31 --12-31 false false 001-40207 Waldencast plc 81 Fulham Road 81 Fulham Road London SW3 6RD GB Michel Brousset London SW3 6RD GB 44 (0)20 3196 0264 Class A ordinary shares, par value $0.0001 per share WALD NASDAQ Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share WALDW NASDAQ 2024-12-31 --12-31 112026440 10666528 No No Yes Yes Non-accelerated Filer true false false false U.S. GAAP false 34 Deloitte & Touche LLP Costa Mesa, California 14802000 21089000 1500000 1487000 25484000 21330000 792000 1101000 53104000 55684000 7513000 5277000 427000 1359000 103622000 107327000 5831000 5931000 526438000 582863000 329589000 334620000 9839000 11589000 541000 380000 975860000 1042710000 25087000 28069000 0 18000 2766000 2400000 29479000 8529000 19560000 23698000 76892000 62714000 137137000 151264000 5021000 28647000 12724000 15531000 14044000 15229000 105000 52000 245923000 273437000 25000000 25000000 0.0001 0.0001 0 0 0 0 0.0001 0.0001 1000000000 1000000000 112026440 101228857 11000 9000 0.0001 0.0001 100000000 100000000 10666528 20847553 1000 2000 951260000 871527000 -289204000 -246761000 251000 -151000 662319000 624626000 67618000 144647000 729937000 769273000 975860000 1042710000 273868000 218138000 92373000 73760000 82124000 76561000 60657000 30868000 191744000 141577000 31716000 42892000 245297000 223508000 90722000 58155000 5031000 0 68715000 0 250328000 223508000 159437000 58155000 -58584000 -81931000 -127721000 -15263000 17155000 18906000 6230000 6652000 -23627000 10337000 -6793000 0 3574000 -1769000 798000 971000 10046000 -31012000 1361000 -5681000 -48538000 -112943000 -126360000 -20944000 110000 -6975000 -5803000 113000 -48648000 -105968000 -120557000 -21057000 -6205000 -15987000 -24990000 0 -42443000 -89981000 -95567000 -21057000 -0.39 -0.39 -0.99 -0.99 -1.11 -1.11 -2.63 -2.63 109295742 109295742 91158500 91158500 86460560 86460560 8000002 8000002 -48648000 -105968000 -120557000 -21057000 450000 -147000 -36000 96000 -48198000 -106115000 -120593000 -20961000 -6148000 -16012000 -24997000 0 -42050000 -90103000 -95596000 -20961000 8000002000 4000000 100113000 -64849000 -25000 39239000 -21057000 -21057000 96000 96000 13113000 188000 71000 13372000 8000002000 4000000 87000000 -86094000 0 4906000 8645000 1000 0 0 174000 -61213000 0 0 -61038000 4478054 44882000 44882000 33300000 3000 332997000 333000000 11800000 1000 117999000 118000000 28237506 3000 21104225 2000 292250000 185656000 477911000 -95567000 -24990000 -120557000 7736000 7736000 -29000 -7000 -36000 86460560 8000 21104225 2000 796038000 -156780000 -29000 160659000 799898000 14000000 1000 69999000 70000000 1068000 1068000 256672 256672 -89981000 -15987000 -105968000 511625 9235000 9235000 1473000 1473000 1204000 1204000 -122000 -25000 -147000 101228857 9000 20847553 2000 871527000 -246761000 -151000 144647000 769273000 10181025 10181025 -42443000 -6205000 -48648000 616558 9391000 9392000 530000 530000 402000 48000 450000 112026440 11000 10666528 1000 951260000 -289204000 251000 67618000 729937000 -48648000 -105968000 -120557000 -21057000 9392000 9235000 7736000 0 60015000 60498000 26982000 8190000 1986000 1721000 740000 0 -996000 0 0 0 23627000 -10337000 6793000 0 0 106000 592000 0 1712000 1575000 677000 767000 5856000 4058000 12186000 0 -1185000 -7021000 -5823000 90000 5031000 0 68715000 0 0 3643000 0 0 -112000 -62000 2000 -35000 3158000 2071000 204000 -3524000 -309000 816000 -265000 0 -2580000 1300000 -6382000 13008000 2236000 -996000 213000 -658000 377000 -138000 250000 352000 -2982000 4382000 -1021000 9635000 -18000 -354000 43000 0 -2677000 -2560000 -724000 0 1803000 1680000 -39336000 1481000 -8820000 -29775000 -74977000 -10037000 304000 455000 247000 248000 2708000 1591000 1340000 661000 0 0 44883000 0 0 0 465010000 0 0 0 122653000 0 92000 52000 0 0 -2920000 -1994000 -544367000 -909000 0 70000000 118000000 0 0 1068000 0 0 0 0 333000000 0 0 0 175000000 0 8750000 8777000 4348000 1375000 15000000 35000000 14117000 6000000 0 49117000 0 0 1632000 2420000 0 0 1770000 1452000 0 0 0 0 6304000 742000 530000 1473000 0 0 0 1204000 0 0 5582000 44329000 629465000 3883000 -6158000 12560000 10121000 -7063000 -116000 -147000 -36000 96000 22576000 10163000 78000 13444000 16302000 22576000 10163000 6477000 0 0 152000 3000 15125000 17331000 5550000 5053000 146000 318000 406000 43000 0 0 0 13113000 0 0 277824000 0 0 0 200087000 0 0 0 650000 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">ORGANIZATION AND DESCRIPTION OF BUSINESS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successor</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Waldencast</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” or the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), formerly known as Waldencast Acquisition Corp., is a Bailiwick of Jersey (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Jersey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) company. Waldencast was originally incorporated on December 8, 2020 as a Cayman Islands exempted company and a blank check company solely for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March 18, 2021, Waldencast consummated an initial public offering of 34,500,000 units (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IPO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Public Warrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) to acquire one Class A ordinary share (together, a “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), at $10.00 per Unit.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination (as defined below), on July 26, 2022, Waldencast obtained shareholder approval to change its jurisdiction of incorporation. Pursuant to the Cayman Companies Act (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cayman Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and the Companies (Jersey) Law 1991, as amended (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Jersey Companies Law</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), Waldencast effected a deregistration under the Cayman Act and a domestication </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">under</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part 18C of the Jersey Companies Law. This was accomplished by filing a memorandum and articles of association with the Registrar of Companies in Jersey (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Domestication</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Upon the effective time of the Domestication, Waldencast Acquisition Corp. was renamed Waldencast.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), Waldencast acquired (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Milk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), as more fully described in “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations.” Following the closing of the Business Combination, the Company conducts its business through the following operating and reportable segments: (i) Obagi Medical and (ii) Milk Makeup. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, over-the-counter and prescription products. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup develops and sells cosmetic, skin care and other beauty products. The brand creates vegan, cruelty-free, clean formulas from its Milk headquarters in downtown New York City. Milk’s products are offered through its U.S. website, www.milkmakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, Waldencast is organized as an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP (“</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Waldencast Partners LP</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands exempted limited partnership and indirect </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary of Waldencast, which is an entity that is classified as a partnership for U.S. federal income tax purposes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Global Holdings Limited is a holding company incorporated that conducts all operations through its wholly-owned subsidiaries. On July 15, 2021, ZhongHua Finance Acquisition Fund I, L.P., Obagi’s sole shareholder, transferred its 4,000,000 ordinary shares to its affiliate, Cedarwalk Skincare Ltd. (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cedarwalk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which became the new sole shareholder of Obagi. This transfer between affiliates did not result in any change of control.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Business Combination, Obagi carved out and distributed all of the outstanding shares of its subsidiary, Obagi Hong Kong Limited (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi Hong Kong</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” or “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi HK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) to its shareholder, Cedarwalk (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi China Distribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). All sales of Obagi products in the People’s Republic of China, inclusive of the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">China Region</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) prior to the Business Combination had been conducted through the Obagi China Business (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi China Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which were not acquired by Waldencast in the Business Combination.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">we,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” or “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and applicable rules and regulations of the Securities and Exchange Commission (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”).</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Predecessor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Under the acquisition method of accounting, Waldencast’s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the relevant financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successor Period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) are presented on a measurement basis different from those for the period prior to the Closing Date (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Predecessor Period(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Periods, which include Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022, the year ended December 31, 2023, and the year ended December 31, 2024, are presented on a different basis of accounting and are therefore, not comparable.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts in the consolidated financial statements and notes have been reclassified to conform to current year presentation. These reclassifications had no effect on net income or loss. These include reclassifying research and development costs into selling, general and administrative costs and reclassifying gondolas into furniture and fixtures.</span></div> Successor 34500000 1 1 10.00 4000000 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and applicable rules and regulations of the Securities and Exchange Commission (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”).</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Predecessor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Under the acquisition method of accounting, Waldencast’s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the relevant financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successor Period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) are presented on a measurement basis different from those for the period prior to the Closing Date (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Predecessor Period(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Periods, which include Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022, the year ended December 31, 2023, and the year ended December 31, 2024, are presented on a different basis of accounting and are therefore, not comparable.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">JOBS Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), or do not have a class of securities registered under the Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, will adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This may make comparison of the Company’s consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, goodwill valuation, inventory valuation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company’s consolidated balance sheets and consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailer located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions, monitoring payment frequency, and requiring customer advance payments in certain circumstances. The Company generally does not require collateral. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, one U.S. customer accounted for 33% and 27% of accounts receivable, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company purchased approximately 15% and 12% of inventory from two vendors, respectively. During the year ended December 31, 2023 the Company purchased approximately 17% of inventory from one vendor. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, no vendor exceeded 10% of accounts payable. As of December 31, 2023, one vendor accounted for 18% of accounts payable.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company’s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December 31, 2024, the Company’s cash and cash equivalents, and restricted cash balance was $14.8 million and $1.5 million respectively. Restricted cash is composed of $0.7 million held as collateral for corporate credit cards and $0.8 million held as a lease deposit through the end of the lease in November 2030. As of December 31, 2023 the Company’s cash and cash equivalents, and restricted cash balance was $21.1 million and $1.5 million respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company’s products are produced by third-party contract manufacturers (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMOs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FIFO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional products are charged to cost of goods sold at the time the product is shipped to the Company’s customer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FOB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) shipping point or FOB destination point.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis and determines the need, if any, to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. It accounts for losses that may occur when the inventory cannot be sold at its full cost. If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). Each period, Management will evaluate whether any additional write downs are required (generally, by stock keeping unit (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SKU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and/or lot). Specific write downs may relate to known matters, such as quality concerns or a discontinued product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements may give the Company’s customers the right to return products. In addition, when customer arrangements do not give the Company’s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under Accounting Standards Codification (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company accrues for replacement costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments” for further discussion of the interest rate collar.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for Public Warrants and Private Placement Warrants (each as defined in “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments”) as liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company’s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments” for further discussion of the warrants, including the FPA Warrants (as defined therein).</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management’s judgment and conditions that existed at each reporting date. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_148" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fair Value Measurements” for further details.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company’s term loan, which approximate current market rates. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capitalized Software and Website Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) implementation costs, and (iii) other software-related costs (e.g., website development costs).</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Inventory</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments are required to begin production of inventory at certain of the Company’s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Marketing and Advertising</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally expenses the costs of advertising and marketing as incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company’s assets are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED USEFUL LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, and formulations. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company’s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers. Payment terms are generally short-term in nature and are determined based on the financial stability of the customer. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i) customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii) formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer’s remittance advice or to the customer’s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that each of its products is distinct and represents a separate performance obligation. The Company does not have any contracts that contain multiple performance obligations. The transaction price is equal to the consideration the Company expects to be entitled to. When measuring revenue and determining the consideration the Company expects to be entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s distributors charge us fees for certain services rendered by them, including packing and shipping, marketing and advertising the Company’s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are not distinct from the distributors’ purchase of products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and when assumption of the risks and rewards occur. For distributors (other than the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company’s designated warehouse/distribution center by the customer’s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi’s operations in the U.S. heavily depend on a single distributor, referred to as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which manages sales to healthcare professionals in the physician-dispensed channel as well as retail and spa customers. For DTC sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promotional Products</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company provides promotional products (e.g., samples and testers) alongside a related saleable product, their cost is recognized in cost of sales at the same time the related product’s revenue is recognized.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates royalty revenue from products in China by Obagi Hong Kong and in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi Medical brand name in the Japanese retail skincare channels. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. The Company recognizes revenue for the sales-based royalty at the later of when the local operators make sales of the products or when the purchase obligation has been satisfied.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. There were no total capitalizable costs to obtain a contract during the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company’s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) for ASC 340-40-25-4 related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Cost of goods sold consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, freight and inventory inspection costs, depreciation and amortization of product-related intangible asset and supply agreements, and amortization of the inventory fair value step-up related to the Business Combination.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Costs related to shipping, handling, warehousing and distribution for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, were $8.7 million, $6.6 million, and $2.0 million, respectively. These costs include costs that are incurred in order to get the product from the distribution centers to the end consumer and are included within selling, general and administrative expense (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SG&amp;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;A expenses. Amounts billed to customers for shipping and handling are included in revenue. In the Predecessor period, the Company only included shipping and handling costs in SG&amp;A expense. The costs related to shipping and handling for the period from January 1, 2022 to July 27, 2022 (Predecessor Period) were $0.6 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Advertising costs are expensed in the period in which they are incurred. Total advertising costs, included in SG&amp;A expense on the consolidated statements of operations and comprehensive loss, were $43.5 million, $16.3 million, $11.7 million, and $6.8 million for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period), respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Research and development costs are included in SG&amp;A expense on the consolidated statements of operations and comprehensive loss. All periods presented reflect this classification.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Replacement Options</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested options granted under those plans (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Replacement Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value and derived service period of the stock options issued to founders (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Founder Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option’s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock is equal to the price of the Company’s ordinary shares on the grant date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award’s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition is deemed probable.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $22.5 million was recorded as of December 31, 2024 and $19.8 million was recorded as of December 31, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority’s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December 31, 2024 and December 31, 2023, the Company had no uncertain positions in the consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no amounts accrued for interest and penalties as of December 31, 2024, December 31, 2023, or December 31, 2022.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Basic net loss per share attributable to shareholders of ordinary shares is computed by dividing the Company’s net loss attributable to holders of ordinary shares by the weighted-average number of ordinary shares outstanding during the period. Diluted net income per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net loss per share that is not attributable to the Company is reflected in net loss attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder’s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder’s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company’s chief operating decision maker (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CODM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Company has two operating and reportable segments: Obagi Medical and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company’s CODM is its Chief Executive Officer.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company adopted this accounting standard in the fourth quarter of 2024, which resulted in expanded disclosures within our notes to the consolidated financial statements. There was no other impact on our consolidated financial statements. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 18</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Segment Reporting”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional detail.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree’s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2023 for an EGC company, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company adopted this accounting standard as of January 1, 2024, with no material impact on its consolidated financial statements and related disclosures. Future acquisitions will be evaluated under this guidance.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Yet Adopted</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income – Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance will require disaggregated disclosures and of certain cost and expense categories presented on the face of the income statement. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, goodwill valuation, inventory valuation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company’s consolidated balance sheets and consolidated statements of operations and comprehensive loss.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailer located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers’ financial conditions, monitoring payment frequency, and requiring customer advance payments in certain circumstances. The Company generally does not require collateral. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, one U.S. customer accounted for 33% and 27% of accounts receivable, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company purchased approximately 15% and 12% of inventory from two vendors, respectively. During the year ended December 31, 2023 the Company purchased approximately 17% of inventory from one vendor. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, no vendor exceeded 10% of accounts payable. As of December 31, 2023, one vendor accounted for 18% of accounts payable.</span></div> 0.33 0.27 0.15 0.12 0.17 0.18 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.</span></div> <div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company’s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December 31, 2024, the Company’s cash and cash equivalents, and restricted cash balance was $14.8 million and $1.5 million respectively. Restricted cash is composed of $0.7 million held as collateral for corporate credit cards and $0.8 million held as a lease deposit through the end of the lease in November 2030. As of December 31, 2023 the Company’s cash and cash equivalents, and restricted cash balance was $21.1 million and $1.5 million respectively.</span></div> 14800000 1500000 700000 800000 21100000 1500000 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company’s products are produced by third-party contract manufacturers (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CMOs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FIFO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional products are charged to cost of goods sold at the time the product is shipped to the Company’s customer.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FOB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) shipping point or FOB destination point.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis and determines the need, if any, to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. It accounts for losses that may occur when the inventory cannot be sold at its full cost. If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). Each period, Management will evaluate whether any additional write downs are required (generally, by stock keeping unit (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SKU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and/or lot). Specific write downs may relate to known matters, such as quality concerns or a discontinued product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Returns</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements may give the Company’s customers the right to return products. In addition, when customer arrangements do not give the Company’s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under Accounting Standards Codification (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company accrues for replacement costs.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC 815</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments” for further discussion of the interest rate collar.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for Public Warrants and Private Placement Warrants (each as defined in “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments”) as liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company’s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments” for further discussion of the warrants, including the FPA Warrants (as defined therein).</span></div> <div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management’s judgment and conditions that existed at each reporting date. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_148" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fair Value Measurements” for further details.</span></div>The fair values of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company’s term loan, which approximate current market rates. <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capitalized Software and Website Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) implementation costs, and (iii) other software-related costs (e.g., website development costs).</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.</span></div> P3Y <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Inventory</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments are required to begin production of inventory at certain of the Company’s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Marketing and Advertising</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally expenses the costs of advertising and marketing as incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.</span></div> P12M <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company’s assets are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED USEFUL LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.</span></div> The estimated useful lives of the Company’s assets are as follows:<div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED USEFUL LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware, software and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">854 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,027 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,036 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,931 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> P3Y P3Y P5Y P3Y P5Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span>—Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, and formulations. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span>—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss. <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company’s consolidated statements of operations and comprehensive loss.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span> and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers. Payment terms are generally short-term in nature and are determined based on the financial stability of the customer. </span></div>The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i) customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii) formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer’s remittance advice or to the customer’s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable. <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that each of its products is distinct and represents a separate performance obligation. The Company does not have any contracts that contain multiple performance obligations. The transaction price is equal to the consideration the Company expects to be entitled to. When measuring revenue and determining the consideration the Company expects to be entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s distributors charge us fees for certain services rendered by them, including packing and shipping, marketing and advertising the Company’s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are not distinct from the distributors’ purchase of products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and when assumption of the risks and rewards occur. For distributors (other than the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company’s designated warehouse/distribution center by the customer’s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi’s operations in the U.S. heavily depend on a single distributor, referred to as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which manages sales to healthcare professionals in the physician-dispensed channel as well as retail and spa customers. For DTC sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promotional Products</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company provides promotional products (e.g., samples and testers) alongside a related saleable product, their cost is recognized in cost of sales at the same time the related product’s revenue is recognized.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates royalty revenue from products in China by Obagi Hong Kong and in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi Medical brand name in the Japanese retail skincare channels. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. The Company recognizes revenue for the sales-based royalty at the later of when the local operators make sales of the products or when the purchase obligation has been satisfied.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. There were no total capitalizable costs to obtain a contract during the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div>The Company’s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company’s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) for ASC 340-40-25-4 related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Costs related to shipping, handling, warehousing and distribution for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, were $8.7 million, $6.6 million, and $2.0 million, respectively. These costs include costs that are incurred in order to get the product from the distribution centers to the end consumer and are included within selling, general and administrative expense (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SG&amp;A</span>”). The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;A expenses. Amounts billed to customers for shipping and handling are included in revenue. In the Predecessor period, the Company only included shipping and handling costs in SG&amp;A expense. P30D P90D <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Cost of goods sold consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, freight and inventory inspection costs, depreciation and amortization of product-related intangible asset and supply agreements, and amortization of the inventory fair value step-up related to the Business Combination.</span></div> 8700000 6600000 2000000.0 600000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span>—Advertising costs are expensed in the period in which they are incurred. 43500000 16300000 11700000 6800000 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Research and development costs are included in SG&amp;A expense on the consolidated statements of operations and comprehensive loss. All periods presented reflect this classification.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Replacement Options</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested options granted under those plans (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Replacement Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value and derived service period of the stock options issued to founders (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Founder Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option’s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock is equal to the price of the Company’s ordinary shares on the grant date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award’s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition is deemed probable.</span></div> 0.50 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $22.5 million was recorded as of December 31, 2024 and $19.8 million was recorded as of December 31, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority’s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December 31, 2024 and December 31, 2023, the Company had no uncertain positions in the consolidated financial statements.</span></div>The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. 22500000 19800000 0 0 0 0 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span>—Basic net loss per share attributable to shareholders of ordinary shares is computed by dividing the Company’s net loss attributable to holders of ordinary shares by the weighted-average number of ordinary shares outstanding during the period. Diluted net income per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net loss per share that is not attributable to the Company is reflected in net loss attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder’s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder’s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.</span></div> <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company’s chief operating decision maker (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CODM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Company has two operating and reportable segments: Obagi Medical and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company’s CODM is its Chief Executive Officer.</span></div> 2 2 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</span></div> <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance expands public entities’ segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company adopted this accounting standard in the fourth quarter of 2024, which resulted in expanded disclosures within our notes to the consolidated financial statements. There was no other impact on our consolidated financial statements. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 18</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Segment Reporting”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional detail.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree’s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2023 for an EGC company, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company adopted this accounting standard as of January 1, 2024, with no material impact on its consolidated financial statements and related disclosures. Future acquisitions will be evaluated under this guidance.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Yet Adopted</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting Comprehensive Income – Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance will require disaggregated disclosures and of certain cost and expense categories presented on the face of the income statement. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">BUSINESS COMBINATIONS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022, Waldencast consummated its initial business combination with (i) Obagi, pursuant to an Agreement and Plan of Merger dated November 15, 2021, by and among Waldencast, Obagi Merger Sub, Inc., a Cayman Islands exempted company limited by shares and an indirect wholly-owned subsidiary of Waldencast (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Sub</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), and Obagi (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi Merger Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), and (ii), Milk, pursuant to an Equity Purchase Agreement dated November 15, 2021, by and among Waldencast, Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Holdco Purchaser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and a subsidiary of Waldencast, Waldencast Partners LP together with Holdco Purchaser, (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchasers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), certain members of Milk (the “</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Milk Members</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Members</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equityholder Representative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Milk Equity Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” and together with the Obagi Merger Agreement, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Obagi Merger Agreement, at the effective time of the Obagi Merger (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi Merger Effective Time</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) Merger Sub merged with and into Obagi (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi Merger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and the separate corporate existence of Merger Sub ceased, with Obagi surviving as an indirect subsidiary of the Company. At the Obagi Merger Effective Time, all outstanding ordinary shares of Obagi, $0.50 par value (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi common shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $345.4 million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Milk Equity Purchase Agreement, at the effective time of the Milk Transaction (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Milk Purchase Effective Time</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) the Purchasers acquired from the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Members</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all of their equity in Milk in exchange for (i) 21,104,225 limited partnership units in Waldencast Partners LP (“Waldencast LP Units”) (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $121.6 million </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the “</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Milk Transaction</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if such option is exercised, exchangeable at the option of Waldencast </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into one Waldencast Class A ordinary share or cash, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon consummation of the Business Combination </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast became organized in an “Up-C” structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP, which is an indirect subsidiary of Waldencast.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Business Combination, Waldencast was deemed to be the accounting acquirer and continues as the SEC registrant. Obagi and Milk were deemed to be the accounting acquirees, however Obagi is considered the predecessor entity for purposes of financial reporting. Waldencast was determined to be the accounting acquirer based on evaluation of the following factors:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The owners of Waldencast have the largest voting interest in the combined company;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The original owner of Waldencast, Waldencast Long-Term Capital LLC (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), and its affiliates nominated the majority of the initial members who will serve on the Board (the former owner of Obagi nominated one director, and Milk nominated no directors); and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Waldencast’s existing management holds executive management roles for the post-combination company, whilst Obagi and Milk management team members report into the current Waldencast executive team.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the Obagi Merger Effective Time, Obagi carved out and distributed the Obagi China Business to Cedarwalk pursuant to the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned 24.5% of the fully diluted Waldencast Class A ordinary shares as of the Obagi Merger Effective Time. Prior to the Obagi China Distribution, the pre-tax losses for the Obagi China Business were $8.0 million for the period from January 1, 2022 to July 27, 2022 (Predecessor Period).</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Related Party Transactions” for more information on ongoing transactions with the Obagi China Business following the close of the Obagi Merger. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi and Milk Purchase Price Allocation:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Purchase Price:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">662,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total identifiable assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">579,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">212,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">791,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities assumed:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">66,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">513,171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">190,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">703,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">268,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">403,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill recognized for these acquisitions is attributable to improving the product offerings, expanding into additional markets and the expected cash flows resulting from these efforts, and assembled workforce. Goodwill recognized is not expected to be deductible for local tax purposes. During the period from July 28, 2022 to December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Medical reporting unit. During the year ended December 31, 2024, the Company recorded an additional non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit. See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Goodwill”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 18</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment Reporting”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for amounts related to revenue and earnings associated with Obagi Medical and Milk Makeup subsequent to the acquisition date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Liability</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company recognized a liability with respect to a related party supply contract executed on the Closing Date between Obagi and Obagi Hong Kong. The fair value of the related party liability was determined using the present value of after-tax cash flows related to unfavorable discounts provided to the Obagi China Business included in the Supply Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supply Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” as further detailed in “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_169" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Related Party Transactions”). As of the Obagi Merger Effective Time, the Company recognized a related party liability of $22.1 million. During the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022, the Company amortized $2.3 million, $4.1 million, and $12.2 million, respectively, of the related party liability into the related party revenue recognized on the sale of products to the Obagi China Business. During the year ended </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, the Company recorded $3.4 million in Other income due to the termination of an interim supply agreement and the associated release of the remaining related party liability. The parties operated under this interim supply agreement, which terminated in July 2023, until December 2024, at which point the remaining related party liability was amortized and released. As a result, the Company did not have a remaining related party liability as of December 31, 2024. The Company had a related party liability of $5.9 million, included in Other current liabilities, as of December 31, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">505,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">157,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">662,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets acquired in connection with the Business Combination are classified as Level 3 in the fair value hierarchy. The estimate of the fair values of the acquired amortizable intangible assets were determined using a multi-period excess earnings income approach by discounting the incremental after-tax cash flows over multiple periods. Significant estimates used in the determination include estimating future cash flows over multiple periods, terminal value, and discounting such cash flows at a rate of return that reflects the relative risk of the cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Costs </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, Waldencast incurred transactions costs of $9.4 million which were incurred during the period from July 28, 2022 to December 31, 2022. Transaction costs consisted of advisory, legal, accounting and management fees, which are included in SG&amp;A expenses on the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited ASC 805 Pro Forma </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma combined financial information presents the Company’s results as though the Business Combination had occurred on January 1, 2021, for the year ended December 31, 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pro forma net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net loss attributable to Waldencast plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,790)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma results include adjustments such as inventory step-up, amortization of acquired intangible assets, and interest expense on debt financing in connection with the Business Combination. Material, nonrecurring pro forma adjustments directly attributable to the Business Combination include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">• Cost of goods sold related to acquired inventory step-up of $10.0 million was removed from net income for the year ended December 31, 2022; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Transaction related costs of $66.1 million were removed from net income for the year ended December 31, 2022. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated pro forma financial information was prepared in accordance with accounting standards and is not necessarily indicative of the results of operations that would have occurred if the Business Combination had been completed on the date indicated, nor is it indicative of the future operating results of the Company. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results do not reflect events that either have occurred or may occur after the Business Combination, including, but not limited to, the anticipated realization of operating synergies in subsequent periods. They also do not give effect to certain charges that the Company expects to incur in connection with these acquisitions, including, but not limited to, additional professional fees and employee integration. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SA Distributor Transaction</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, as part of our strategy to internalize distribution channels in key markets, certain of Obagi's subsidiaries entered into and consummated a Purchase Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vietnam Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” with Obagi Vietnam and the Company’s Southeast Asia Distributor (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SA Distributor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam, from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, an indirect subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve months ending December 31, 2026, subject to setoff for any owed obligations. The acquisition was determined to be an asset acquisition with the primary asset being the recovery of $1.6 million of inventory held by the SA Distributor. No fair value was allocated to the earnout liability as the Company concluded the earnout projections would not be achieved. In June 2024, Obagi entered into a Settlement and Release Agreement with the SA Distributor, which, among other things, extinguished the SA Distributor’s right to receive an earnout and the SA Distributor’s 40% interest in the outstanding equity of Obagi Blue Sea Holding, LLC.</span></div> 0.50 28237506 345400000 21104225 121600000 1 1 0 0.245 -8000000.0 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi and Milk Purchase Price Allocation:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Purchase Price:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477,911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,942 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,681 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">662,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total identifiable assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">579,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">212,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">791,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities assumed:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">66,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">513,171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">190,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">703,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">268,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">403,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 345398000 121629000 467027000 277824000 200087000 477911000 136112000 3935000 140047000 22100000 0 22100000 781434000 325651000 1107085000 15850000 2092000 17942000 650000 819000 1469000 15214000 3866000 19080000 327000 199000 526000 31026000 30945000 61971000 4307000 520000 4827000 359000 0 359000 1245000 8436000 9681000 505300000 157500000 662800000 4811000 8232000 13043000 227000 0 227000 579316000 212609000 791925000 18699000 6442000 25141000 12912000 5483000 18395000 6461000 10105000 16566000 28073000 0 28073000 66145000 22030000 88175000 513171000 190579000 703750000 781434000 325651000 1107085000 268263000 135072000 403335000 68700000 5000000.0 22100000 2300000 4100000 12200000 3400000 5900000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">505,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">157,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">662,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 414000000 145000000 559000000 P14Y 25000000 11000000 36000000 P11Y 38900000 0 38900000 P5Y 27400000 1500000 28900000 P8Y 505300000 157500000 662800000 9400000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma combined financial information presents the Company’s results as though the Business Combination had occurred on January 1, 2021, for the year ended December 31, 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pro forma net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net loss attributable to Waldencast plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,790)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 200547000 -86930000 -25140000 -61790000 10000000.0 66100000 0.40 1600000 0.40 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">REVENUE</span><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates its revenue from customers by sales channel, as well as by revenue source and geographic region, based on the location of the end customer, as it believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Sales Channel</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is primarily generated from product sales. Direct sales revenue listed in the table below includes (i) sales to physicians through the Physician Channel Provider, (ii) DTC sales via the Company’s e-commerce platforms, and (iii) sales directly to retailers. Distributors revenue includes products sold through distributors other than the Physician Channel Provider.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by sales channel was as follows for the periods indicated: </span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk <br/>Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,571 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,602 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273,868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk <br/>Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,649 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,487 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk <br/>Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, three customers accounted for 18%, 17%, and 10% of the Company’s revenue, respectively. For the year ended December 31, 2023, two customers accounted for 28% and 20% of the Company’s revenue, respectively. During the period from July 28, 2022 to December 31, 2022, three customers accounted for 29%, 18%, and 16% of the Company’s revenue, respectively. During the period from January 1, 2022 to July 27, 2022, two customers accounted for 44% and 20% of the Company’s revenue, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Channel Provider is an authorized wholesale distributor and service provider for the Company in the U.S. Revenue from sales to physicians and e-commerce customers made through this provider are considered direct sales revenue. The Physician Channel Provider is also a distributor of the Company’s products to other channels, such as the spa channel, and the related sales are considered distributor revenue.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Geographic Region</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273,868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, and 2023, only one country, the United States, accounted for more than 10% of the Company’s total revenues, with net product sales amounting to $192.6 million and $145.3 million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July 28, 2022 to December 31, 2022, the two countries that accounted for more than 10% of the Company’s total revenues were the United States and China, respectively, with net product sales amounting to $54.3 million and $17.0 million, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from January 1, 2022 to July 27, 2022, (Predecessor Period) the two countries that accounted for more than 10% of the Company’s total revenues were the United States and Vietnam, with net product sales amounting to $43.8 million and $14.9 million, respectively.</span></div> <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by sales channel was as follows for the periods indicated: </span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk <br/>Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,571 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,266 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,602 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273,868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk <br/>Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,649 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,467 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,487 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk <br/>Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 103168000 120362000 223530000 41630000 4209000 45839000 144798000 124571000 269369000 4468000 31000 4499000 149266000 124602000 273868000 72446000 97222000 169668000 40203000 3245000 43448000 112649000 100467000 213116000 5002000 20000 5022000 117651000 100487000 218138000 30276000 30192000 60468000 39649000 28826000 1091000 29917000 31080000 59102000 31283000 90385000 70729000 1988000 0 1988000 3031000 61090000 31283000 92373000 73760000 0.18 0.17 0.10 0.28 0.20 0.29 0.18 0.16 0.44 0.20 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,369 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273,868 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 202261000 154357000 56630000 44443000 67108000 58759000 33755000 26286000 269369000 213116000 90385000 70729000 4499000 5022000 1988000 3031000 273868000 218138000 92373000 73760000 0.10 192600000 145300000 0.10 54300000 17000000.0 0.10 43800000 14900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">GOODWILL</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated goodwill acquired in the Obagi Merger to its Obagi Medical reporting unit and goodwill acquired in the Milk Transaction to its Milk Makeup reporting unit. The fair value of each reporting unit was determined as of the Closing Date as part of the Business Combination (see “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations”). The following table presents changes in goodwill by reportable segment:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199,548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">334,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">334,620 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,031)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,031)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,517 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment on an annual basis on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at an interim date if indicators of a potential impairment exist. The goodwill impairment test is conducted at the reporting unit level. The fair value of the Company’s reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the Company’s most recent projected long-term financial forecasts for revenue, earnings, capital expenditures, and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the respective reporting unit. Under the guideline public company method, fair value is estimated using market multiples of various financial metrics observed for the reporting unit’s comparable public companies. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately after the Business Combination (see “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations”), the Company concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Medical reporting unit was less than its carrying amount. Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Medical reporting unit. The annual impairment test performed for fiscal 2022 did not indicate a further impairment of goodwill at the time it was performed.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual impairment test performed for fiscal 2023 did not indicate an impairment of goodwill at the time it was performed.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its annual goodwill impairment analysis using the qualitative approach on October 1, 2024, and the analysis concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Medical reporting unit was less than its carrying amount. Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the year ended December 31, 2024, the Company recorded a non-cash impairment charge of $5.0 million within the Obagi Medical reporting unit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a qualitative review of the Milk Makeup reporting unit on October 1, 2024, which did not indicate that the fair value of the reporting unit was less than the carrying value. On that basis, management concluded that there was no change in the fair value. As a result, the goodwill balance for the Milk Makeup reporting unit has not changed.</span></div>Changes in market conditions, laws and regulations, and key assumptions made in future qualitative or quantitative assessments, such as expected cash flows, competitive factors, discount rates, and value indications from market transactions, could negatively impact the results of future impairment testing and could result in the recognition of additional future impairment charges. The following table presents changes in goodwill by reportable segment:<div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199,548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">334,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">334,620 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,031)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,031)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194,517 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 199548000 135072000 334620000 199548000 135072000 334620000 0 5031000 194517000 135072000 329589000 68700000 5000000.0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">INTANGIBLE ASSETS—NET</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December 31, 2024:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102,169)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">663,902 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(137,464)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526,438 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December 31, 2023:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,989)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499,655 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">663,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80,735)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">582,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the non-cash goodwill impairment charge within the Obagi Medical reporting unit during the year ended December 31, 2024, the Company also performed a quantitative analysis on Obagi Medical's definite lived intangibles. The Company concluded there was no impairment to these assets.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) was $56.7 million, $56.7 million,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.0 million, and $7.7 million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization for each of the years between 2025 through 2029, and thereafter are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526,438 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December 31, 2024:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102,169)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457,706 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,449)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">663,902 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(137,464)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526,438 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December 31, 2023:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,644 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,989)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499,655 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">663,598 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80,735)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">582,863 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the non-cash goodwill impairment charge within the Obagi Medical reporting unit during the year ended December 31, 2024, the Company also performed a quantitative analysis on Obagi Medical's definite lived intangibles. The Company concluded there was no impairment to these assets.</span></div> P14Y 559875000 102169000 457706000 P11Y 36000000 6449000 29551000 P5Y 38900000 18885000 20015000 P8Y 28900000 9943000 18957000 P20Y 227000 18000 209000 663902000 137464000 526438000 P14Y 559644000 59989000 499655000 P11Y 36000000 4532000 31468000 P5Y 38900000 11105000 27795000 P8Y 28900000 5101000 23799000 P20Y 154000 8000 146000 663598000 80735000 582863000 56700000 56700000 24000000.0 7700000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization for each of the years between 2025 through 2029, and thereafter are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526,438 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 56737000 56737000 53496000 48957000 48957000 261554000 526438000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">DEBT</span><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:45.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,137 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note Payable — Directors and Officers (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D&amp;O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">”) Insurance</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company entered into an agreement with a financing company for $1.6 million to finance its D&amp;O insurance policy. The terms of the agreement stipulated equal monthly payments of principal and interest payments of $0.2 million over a ten-month period, ending in May 2025. Interest is accrued on this loan at an annual rate of 8.25%.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an agreement with a financing company for $2.4 million to finance its D&amp;O insurance policy. The terms of the agreement stipulated equal monthly payments of principal and interest payments of $0.2 million over a ten-month period, ending in May 2024, which had been fully repaid as of December 31, 2024. Interest was accrued on this loan at an annual rate of 8.2%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Waldencast Finco Limited, a wholly-owned subsidiary of the Company (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Credit Agreement Borrower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), together with Waldencast and certain of its subsidiaries as guarantors (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Credit Agreement Parent Guarantor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), entered into the 2022 Credit Agreement with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Credit Agreement Lenders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and JPMorgan, as administrative agent for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Credit Agreement Lenders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Credit Agreement Lenders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The 2022 Credit Agreement provides the Company with access to a term loan of $175.0 million (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and a revolving credit capacity with a current borrowing capacity of up to $45.0 million (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Revolving Credit Facility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), of which up to $7.5 million may be available, at 2022 Credit Agreement Borrower’s option, to be drawn in form of letters of credit (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Letter of Credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The 2022 Credit Agreement is secured by the assets of the Company. The 2022 Credit Agreement restricts the Company’s ability to make certain distributions or dividends, subject to a number of enumerated exceptions.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. Borrowings under the 2022 Credit Agreement may accrue interest at a rate per annum equal to, at the 2022 Credit Agreement Borrower’s election, either alternate base rate plus an applicable margin of 2.5% per annum or a term benchmark rate plus an applicable margin of 3.5% per annum. As of December 31, 2024, borrowings under the 2022 Credit Agreement consisted entirely of term benchmark borrowings at a borrowing rate of 7.9% per annum. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2022 Credit Agreement, the Company incurred $6.3 million of debt issuance costs. As of December 31, 2024, the weighted average interest rate was 8.7% for the 2022 Term Loan and 8.7% for the 2022 Revolving Credit Facility. The current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $15.3 million and $15.0 million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and the 2022 Revolving Credit Facility was $1.2 million and $0.5 million, respectively. The accrued interest was $1.4 million as of December 31, 2024. Unamortized debt issuance costs on the 2022 Letter of Credit is $0.1 million, which is recorded in other current assets in the consolidated balance sheets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities under the Company’s 2022 Credit Agreement and the Note Payable as of December 31, 2024 are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:81.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unpaid principal</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waiver and Consent and Amendment to the 2022 Credit Agreement</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2024, the 2022 Credit Agreement Borrower, 2022 Credit Agreement Parent Guarantor, JPMorgan and the required lenders entered into an amendment (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third Amendment</span>”) to the 2022 Credit Agreement. Among other things, the Third Amendment: (i) waived certain historical breaches of the financial covenant, (ii) modified the existing financial covenants, (iii) reduced the revolving commitments of the lenders by $5.0 million in the aggregate to $45.0 million, (iv) lowered the existing minimum liquidity covenant to $10.0 million and (v) extended the Covenant Relief Period until December 31, 2024. <div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:45.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,793 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,137 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 153125000 161875000 830000 968000 15000000 0 2339000 3050000 166616000 159793000 29479000 8529000 137137000 151264000 1600000 200000 P10M 0.0825 2400000 200000 P10M 0.082 175000000.0 45000000.0 7500000 P4Y 0.025 0.035 0.079 6300000 0.087 0.087 15300000 15000000.0 1200000 500000 1400000 100000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities under the Company’s 2022 Credit Agreement and the Note Payable as of December 31, 2024 are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:81.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unpaid principal</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 31142000 137813000 0 0 0 168955000 -5000000.0 45000000.0 10000000.0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">LEASES</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate properties for office and warehouse spaces with initial terms between approximately 1 and 11 years.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s lease contracts include options to extend the leases for up to 5 years. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract contains a lease at inception of the arrangement based on whether the Company has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether the Company has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset that the Company does not own. Right of use (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of any changes in market conditions but generally, these termination options are not exercised and not considered in the determination of the lease term. Lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. ROU assets are recognized on the balance sheet based on the lease liability adjusted for any initial direct costs, lease incentives received, and prepaid rent. The Company may elect to apply the short-term lease exception for leases with a term of 12 months or less. These leases will be not be recognized as an ROU asset or lease liability. The short-term lease payments will be expensed on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IBR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), because the interest rate implicit in most of the Company’s leases is not readily determinable. The IBR is a hypothetical rate based on the Company’s understanding of what its credit rating would be, and resulting interest the Company would pay, to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Lease payments may be fixed or variable, however, only fixed payments or in-substance fixed payments are included in the Company’s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligation for those payments is incurred. The Company has elected not </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to separate non-lease components from lease components and accounts for them as a single lease component. The Company has also elected the short-term lease recognition exemption for all leases that qualify.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically accounted for leases in accordance with ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which operating leases were not recorded on the balance sheet. Adoption of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC 842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) was not required in interim periods preceding December 31, 2022. Upon consummation of the Business Combination, Obagi and Milk adopted ASC 842 as a matter of policy alignment. The period from January 1, 2022 to July 27, 2022 (Predecessor Period) does not reflect the impact of ASC 842 adoption, as the Company did not adopt the standard as of an interim 2022 period.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s lease expenses of $3.7 million and $3.5 million during the year ended December 31, 2024 and year ended December 31, 2023, respectively, were composed of operating lease costs. The Company does not have any finance leases, short-term lease costs or variable lease costs. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company’s operating leases was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the undiscounted future minimum lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2024 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:83.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,883 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total reported lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Leases</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and July 2022, Obagi entered into a lease for a warehouse and office space, respectively, in Texas as part of their plans to relocate headquarters from California. The warehouse and office space leases will expire in 2032 and 2033, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warehouse space was never made operational and in 2023, the Company permanently decided not to use the warehouse with no intention to occupy or utilize the space in the future, and actively began marketing the space for sublease. The Company entered into a sublease for the warehouse space that will run through February 2032 with </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual rent of $0.3 million. The sublease does not contain a provision for early termination or extension at the end of the lease. As a result, the Company recorded an impairment charge of $0.8 million during the year ended December 31, 2023 which was the excess of the carrying value of the associated lease right-of-use asset over its fair value. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Obagi vacated the Texas office space and relocated its headquarters back to California, permanently deciding to not use the office with no intention to occupy or utilize the space in the future, and actively began marketing the space for sublease. The Company has entered into a sublease for the office space that will run through December 2025 with annual rent of $0.4 million. The sublease does not contain a provision for early termination or extension at the end of the lease. As a result, the Company recorded an impairment charge of $2.7 million during the year ended December 31, 2023 which was the excess of the carrying value of the associated office lease right-of-use asset over its fair value.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair values using discounted cash flows from the estimated net sublease rental income as of the date the decision to sublease was made. The impairment charges are included in selling, general and administrative expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosures Related to Periods Prior to the Adoption of ASC 842 </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Obagi China Distribution, the Company leased office space under three non-cancelable operating leases expiring between September 2023 and February 2032. Rent expense related to the Company’s operating leases was $0.9 million for the period from January 1, 2022 to July 27, 2022 (Predecessor Period).</span></div> P1Y P11Y P5Y 3700000 3500000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company’s operating leases was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td></tr></table></div> 3826000 3309000 1166000 131000 446000 4081000 P6Y18D P6Y11M1D P7Y9M 0.059 0.059 0.059 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the undiscounted future minimum lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2024 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:83.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,883 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total reported lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,490 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3797000 2899000 2452000 2504000 2548000 4173000 18373000 2883000 15490000 800000 400000 2700000 3 900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">FINANCIAL INSTRUMENTS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Collar</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, the Company entered into an interest rate collar with Wells Fargo Bank, N.A. (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Wells Fargo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) in October 2022 for a notional value of $160.0 million and a fixed cash payment of $0.8 million. Under the terms of the interest rate collar, the Company was required to pay Wells Fargo if the monthly SOFR-based interest fell below the defined interest rate floor of 2.55%; conversely, the Company was entitled to receive payment from Wells Fargo if the monthly SOFR-based interest rate rose above the defined interest rate cap of 5.25%. Settlement in cash occurred monthly, if contractually required, until termination of the agreement, which occurred in October 2024. As of December 31, 2024, the Company no longer had an interest rate collar.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This derivative instrument has not been designated for hedge accounting, therefore the change in fair value is recognized in current period earnings. The fair value of these contracts, included in other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was zero and $0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December 31, 2024 and December 31, 2023, respectively. The non-cash gain from the change in fair value was $0.1 million during the year ended December 31, 2024, recognized in other expenses, net. The non-cash losses from the change in fair value during the year ended December 31, 2023 and from July 28, 2022 to December 31, 2022 were $0.1 million and $0.6 million, respectively, and are recognized in other expenses, net. Receipts of $0.1 million were exchanged on the interest rate collar contract during each year ended December 31, 2024 and year ended December 31, 2023. No payments or receipts were exchanged on the interest rate collar contract during the period from July 28, 2022 to December 31, 2022 aside from the initial fixed cash payment of $0.8 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Waldencast’s IPO, the Company issued 11,499,950 Public Warrants to third-party investors. Simultaneously with the closing of the IPO, Waldencast completed the private sale of 5,933,333 warrants (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) to the Sponsor. Also, in connection with the IPO, on February 22, 2021, Waldencast, the Sponsor and Zeno Investment Master Fund (f/k/a Dynamo Master Fund, a member of the Sponsor (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Zeno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), entered into a Forward Purchase Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor FPA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell Mountain Trust (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Burwell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor’s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Waldencast Class A ordinary shares and 5,333,333 warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor FPA Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) in connection with the closing of the Business Combination. In addition, Waldencast and Beauty Ventures LLC (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Beauty Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) entered into a Forward Purchase Agreement on March 1, 2021 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third-Party FPA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”, and </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">together with the Sponsor FPA, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FPAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and 5,766,666 warrants (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third-Party FPA Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” and together with the Sponsor FPA Warrants, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FPA Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) for an aggregate commitment amount of $173.0 million, in connection with the closing of Waldencast’s initial business combination. Finally, in connection with the Business Combination, Waldencast issued 1,000,000 warrants to settle $1.5 million working capital loans with its Sponsor, the terms of which are identical to the Sponsor FPA Warrants (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sponsor Loan Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Sponsor Loan Warrants and Third-Party FPA Warrants are collectively referred to as the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement Warrants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, all of the above-noted warrants, totaling 29,533,282, remained issued and outstanding. The Company recognized a gain of $23.6 million, a loss of $10.3 million, and a gain of $6.8 million from the change in fair value of the Public Warrants and Private Placement Warrants in the Company’s consolidated statements of operations and comprehensive loss during the year ended December 31, 2024, during the year ended December 31, 2023, and for the period from July 28, 2022 to December 31, 2022, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Domestication, Public Warrants and Private Placement Warrants each entitle the holder to purchase one share of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued and only whole warrants can trade. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire June 27, 2027 or earlier upon redemption or liquidation.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem the Public Warrants:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">in whole and not in part;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption, based on the redemption date and the “fair market value” of the Class A ordinary shares;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">at a price of $0.01 per warrant if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption the warrant holders (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reference Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) equals or exceeds $18.00 per share (as adjusted);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">at a price of $0.01 per warrant if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and number of Class A ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants.</span></div>The terms of the Third-Party FPA Warrants are identical to the Public Warrants. The Sponsor Loan Warrants and Sponsor FPA Warrants are also identical to the Public Warrants, except that they and the Class A ordinary shares issuable upon the exercise of such warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Loan Warrants and Sponsor FPA Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees, thereafter they will be redeemable by the Company and exercisable by such holders on the same basis as Public Warrants. 160000000.0 800000 0.0255 0.0525 0 100000 -100000 100000 600000 100000 0 0 800000 11499950 5933333 16000000 5333333 17300000 5766666 173000000.0 1000000 1500000 29533282 23600000 -10300000 6800000 1 11.50 P30D P30D 0.01 P20D P30D 18.00 0.01 10.00 18.00 P30D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">FAIR VALUE MEASUREMENTS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information by year about the Company’s financial instruments that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate collar</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private derivative warrants are classified as Level 2 financial instruments. The fair value of the Level 2 Private Placement Warrant liabilities has been measured based on the fair value of Public Warrant liabilities. The interest rate collar has been measured at net present value by projecting future cash flows and discounting the future amounts to a present value using market-based observable inputs including interest rate curves and credit spreads.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For goodwill (see “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Goodwill”), fair value assessments of the reporting units and the reporting units’ net assets performed for goodwill impairment tests are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Except for the initial valuation of long-lived assets in connection with the Business Combination (see “</span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Combinations”</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and impairment of goodwill discussed above, no long-lived assets were remeasured at fair value on a nonrecurring basis during the periods presented.</span></div> <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information by year about the Company’s financial instruments that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate collar</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1983000 1983000 0 0 3038000 0 3038000 0 61000 0 61000 0 11155000 11155000 0 0 17492000 0 17492000 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUPPLEMENTAL BALANCE SHEET DISCLOSURES</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, accounts receivable, net consisted of accounts receivable of $25.6 million, less allowance for doubtful accounts of $0.1 million. As of December 31, 2023, accounts receivable, net consisted of accounts receivable of $22.9 million, less allowance for doubtful accounts of $1.6 million.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the allowance for doubtful accounts were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.909%"><tr><td style="width:1.0%"></td><td style="width:33.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision (recovery) for bad debts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(996)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-off of uncollectible accounts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,552 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,684 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware, software and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">742 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">854 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,027 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,036 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,931 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property and equipment for the year ended December 31, 2024, the year ended December 31, 2023, and the period from July 28, 2022 to December 31, 2022 were $3.3 million, $3.8 million, and $2.9 million, respectively. Depreciation expense for property and equipment for the period from January 1, 2022 to July 27, 2022 (Predecessor Period) was $0.5 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense pertains to property and equipment utilized as part of the Company’s SG&amp;A activities and therefore has not been allocated to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of other current liabilities consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales returns and damages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,560 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,698 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no related party liability as of December 31, 2024 due to the change in contract terms, which resulted in a release of the liability. The related party liability of $5.9 million as of December 31, 2023 reflects the remaining unamortized fair value of the related party inventory contract executed on the acquisition date between Obagi and the Obagi China Business (see “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span>. Business Combinations”). 25600000 100000 22900000 1600000 <div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the allowance for doubtful accounts were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.909%"><tr><td style="width:1.0%"></td><td style="width:33.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,552 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision (recovery) for bad debts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(996)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-off of uncollectible accounts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,552 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1552000 994000 1061000 671000 -996000 558000 -67000 390000 448000 0 0 0 108000 1552000 994000 1061000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,104 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,684 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 8354000 10336000 44750000 45348000 53104000 55684000 742000 689000 9848000 7611000 598000 812000 1739000 854000 2100000 2070000 15027000 12036000 9196000 6105000 5831000 5931000 3300000 3800000 2900000 500000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of other current liabilities consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales returns and damages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,560 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,698 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 9155000 8702000 2723000 2527000 1424000 1357000 0 590000 0 5856000 3832000 2901000 2426000 1765000 19560000 23698000 0 5900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">STOCK-BASED COMPENSATION</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Award Plan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s 2022 Incentive Award Plan (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) provides for incentives to be provided to selected officers, employees, non-employee directors and consultants of the Company in the form of options, stock appreciation rights, restricted stock, restricted stock units, stock bonuses or other stock-based awards granted under the 2022 Plan. The 2022 Plan became effective on July 27, 2022 in connection with the closing of the Business Combination. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional maximum number of ordinary shares authorized under the 2022 Plan for the fiscal year ended December 31, 2024 was 23,042,449</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Reserve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Share Reserve automatically increases on January 1st of each calendar year by 3% of the total ordinary shares then issued and outstanding, or such lesser amount as determined by the Board. All shares reserved for issuance under the 2022 Plan may be granted as incentive stock options. As of December 31, 2024, taking into account previous grants and forfeitures, the Company had 5,533,142</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ordinary</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares remaining available for future issuances under the 2022 Plan.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company granted an aggregate of 3,828,878 Restricted Stock Unit (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RSU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) incentive awards to employees and non employees of the Company, generally vesting over one to three years. Some portion vested immediately with the balance vesting annually. Of these awards 312,830 were granted to the Founders, </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2024, the Company granted an aggregate of 319,471 RSUs to directors, typically vesting immediately or over one to three years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company approved incentive awards to employees of Waldencast, Milk, and Obagi. The long-term incentive awards (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LTI Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) are restricted stock units that vest based on both a service condition and meeting either a net sales or EBITDA target in calendar year 2022. These LTI Awards were granted to employees in November 2022. The performance targets for the LTI Awards</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were met for Milk in 2022. The Company granted LTI Awards will vest one-third each year beginning on February 15, 2023, subject to continued service through such dates. In May 2023, the Board approved a modification to the LTI Awards by waiving the performance conditions for most Obagi and Waldencast employees totaling 137,537 RSUs. The conditions were not waived for the former Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast, resulting in forfeiture of 360,000 RSUs. Based on the financial statements prepared by the Company for the period ended December 31, 2022, the Board certified that the applicable performance goals were not met and, accordingly, that the </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 RSUs granted to the Company’s founders would not vest. No additional grants of RSUs were made for the year ended December 31, 2024 or for the year ended December 31, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company approved a one-time stock grant for certain Milk employees that were not eligible to participate in the LTI award program. A total of 10,000 awards were approved under this program. These awards are service-based restricted stock units that will cliff vest three years from the grant date, subject to continued employment with the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Growth Incentive</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company granted an aggregate of 2,557,119 strategic growth incentive 2027 awards</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in performance vested share units to certain Company employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the Company’s Net Revenue and earnings before interest, taxes, depreciation, and amortizations (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EBITDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) targets for the year ended December 31, 2027. These awards had a grant date fair value per share ranging between $2.88 and $6.48. Some of the awards require a one-year post vesting holding period once the shares have been awarded. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company granted an aggregate of 2,290,000 strategic growth incentive 2025 awards</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in performance vested share units to certain Company employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the Company’s net revenue and EBITDA targets for the year ended December 31, 2025. These awards had a grant date fair value per share of $8.88 and require a one-year post vesting holding period once the shares have been awarded.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity for the year ended December 31, 2024 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,296,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,705,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(567,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(851,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,583,255 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.61 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk’s legacy incentive award plans and outstanding unvested awards granted under those plans. The Company assumed 5,906,300 stock options and 1,776,827 restricted stock units as replacement awards pursuant to the Obagi Merger Agreement, as well as 237,724 stock options and 2,808,131 share appreciation rights as replacement awards pursuant to the Milk Merger Agreement. The total post-combination incremental stock-based compensation was $18.3 million, which is expected to be recognized over the remaining requisite service periods, where $47.7 million represents the fair value of the equity awards as part of the equity purchase consideration. The awards that were replaced had been contingent on a performance condition and as such, the Company is required to use an attribution model in which compensation cost for each vesting tranche is recognized as if each vesting tranche were a separate award.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022 the Company granted a total of 11,500,000 stock options to the two founders of Waldencast that vest based on service over the six-year period from August 2022 through August 2028. The options were granted with four vesting tranches, each tranche with a different exercise price, subject to their continued employment with the Company. Additionally, the Company granted 692,000 founders service-based restricted stock units that cliff vest in August 2025, subject to their continued employment with the Company.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December 31, 2024 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,915,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,628,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,137,358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,168,975</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,137,358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.48 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,156 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for Replacement Options based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:56.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Founder Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Replacement Options</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.87% - 2.92%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.79% - 2.80% </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 - 9.9</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.77% - 44.76%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term for Founder Awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">For Founder Awards, the expected stock price volatility is the median historical volatility of Waldencast’s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for Replacement Options, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-compensation expense for the years ended December 31, 2024 and 2023, and the period from July 28, 2022 to December 31, 2022, was $9.4 million, $9.2 million, and $7.7 million, respectively. The unrecognized compensation cost as of December 31, 2024 for stock options and restricted stock was $16.1 million and $13.0 million, respectively. These costs are expected to be recognized over a weighted-average service period of 3.5 and 2.3 years for stock options and restricted stock, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Predecessor established a Stock Incentive Plan (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Predecessor Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), under which stock options, stock awards, and restricted stock units (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Predecessor Restricted Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) of the Company could be granted to eligible employees, directors, and consultants. Under the Predecessor Incentive Plan, the Company was authorized to issue of a maximum number of 1,500,000 shares of Obagi common stock. Incentive stock options were </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to have an exercise price at or above the fair market value of the stock on the date of the grant. The Company’s stock options and Predecessor Restricted Stock granted during the period from January 1, 2022 to July 27, 2022 (Predecessor Period) had service-based and performance-based vesting conditions. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vested over five years, with 25% of options vesting in four equal quarterly installments at the end of each three-month period through the first anniversary of the grant, and the remaining 75% vesting in a series of five equal annual installments over the five-year period measured from the grant date. The Predecessor Restricted Stock vested in five equal annual installments at the end of each year, over the five-year period from the grant date. Award holders had a ten-year period to exercise the options before they expire. Notwithstanding achievement of the service-based condition, the options and the Predecessor Restricted Stock did not vest or become exercisable until a qualifying transaction was consummated prior to the expiration date. A qualifying transaction consisted of either a change in control event or an underwritten initial public offering by the Company of its equity securities on a U.S. or foreign exchange, which occurred upon Waldencast’s acquisition of Obagi.</span></div> 23042449 0.03 5533142 3828878 312830 319471 137537 360000 0 0 10000 P3Y 2557119 2 2.88 6.48 P1Y 2290000 2 8.88 P1Y <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity for the year ended December 31, 2024 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,296,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,705,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(567,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(851,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,583,255 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.61 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2296831 8.72 6705468 3.69 567745 5.84 851298 8.87 7583255 4.61 5906300 1776827 237724 2808131 18300000 47700000 11500000 2 P6Y 4 692000 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December 31, 2024 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,915,358 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,628,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,137,358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,168,975</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,137,358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.48 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,156 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18915358 9.10 P7Y3M18D 47792000 0 0 150000 0.68 1628000 5.73 17137358 10.48 P6Y4M24D 1156000 9168975 7.31 P5Y 1156000 17137358 10.48 P6Y4M24D 1156000 <div style="margin-bottom:12pt;margin-top:15pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for Replacement Options based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:56.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Founder Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Replacement Options</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.87% - 2.92%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.79% - 2.80% </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 - 9.9</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.77% - 44.76%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term for Founder Awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">For Founder Awards, the expected stock price volatility is the median historical volatility of Waldencast’s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for Replacement Options, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.</span></div> 0.0287 0.0292 0.0279 0.0280 P4Y8M12D P9Y10M24D 2.30 0.3977 0.4476 0.5000 0.50 2.0 2.5 2.3 0 9400000 9200000 7700000 16100000 13000000.0 P3Y6M P2Y3M18D 1500000 P5Y 0.25 4 P3M 0.75 5 P5Y 5 P5Y P10Y SHAREHOLDERS’ EQUITY<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Capital</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s Memorandum of Association (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Constitutional Document</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), its authorized share capital consists of 1,000,000,000 Class A ordinary shares, 100,000,000 Class B ordinary shares and 25,000,000 Preferred Shares, each having a par value of $0.0001. As of December 31, 2024, there were 112,026,440 and 10,666,528 Class A and Class B ordinary shares, respectively, issued and outstanding. The Company did not have any Preferred Shares issued and outstanding as of December 31, 2024.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Class A ordinary share is entitled to one vote per share. The Company can, at the discretion of its Board, declare dividends and distributions out of the funds of the Company lawfully available therefor. In the event of a voluntary or involuntary liquidation or wind-up, assets available for distribution among the holders of Class A ordinary shares will be distributed on a pro rata basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Class B ordinary share is entitled to one vote per share and will vote together with holders of Class A ordinary shares as a single class. Class B ordinary shares are non-economic shares that are not entitled to dividends. Upon a liquidation, dissolution or winding up of the Company, the holders of Class B ordinary shares will not be entitled to receive any assets of the Company, except to the extent of the par value of their shares, pro rata with the distributions that are shared with the Class A ordinary shares.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations,” Class B ordinary shares were issued by the Company to the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Members</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in connection with the Business Combination, giving rise to noncontrolling interest in the Company’s controlled subsidiary, Waldencast Partners LP. As such, the Constitutional Document prohibits issuances of additional shares of Class B ordinary shares, unless issued to a noncontrolling interest in connection with the Company’s Up-C structure. Class B ordinary shares are convertible into Class A ordinary shares on a one-to-one basis at the option of the holder. If such option is exercised, the exchanged Class B ordinary shares will automatically be surrendered and retired for no consideration. If the Company issues or redeems Class B ordinary shares, Waldencast Partners LP is obligated to issue or redeem a corresponding number of Waldencast LP partnership units, such that the number of issued and outstanding partnership units at any time will correspond and be equivalent to the then number of issued and outstanding Class B ordinary shares.</span></div> 1000000000 100000000 25000000 0.0001 0.0001 0.0001 112026440 10666528 0 0 one NET LOSS PER SHARE<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the weighted average ownership percentages during the period to calculate the net loss per share attributable to public shareholders and the noncontrolling interest holders. The following table sets forth the computation of basic and diluted net loss using the treasury stock method: </span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except for share and per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105,968)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributed to Class A shareholders - basic and diluted EPS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89,981)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,295,742</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,158,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average diluted shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,295,742</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,158,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.39)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.99)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.63)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:43.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,137,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,915,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774,800</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,583,255</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,296,831</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,802,419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,842</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,253,895</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,745,471</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,787,856</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009,642</span></td></tr></table></div> The following table sets forth the computation of basic and diluted net loss using the treasury stock method: <div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except for share and per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(105,968)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributed to Class A shareholders - basic and diluted EPS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89,981)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,295,742</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,158,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average diluted shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,295,742</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,158,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.39)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.99)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.63)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -48648000 -105968000 -120557000 -21057000 -6205000 -15987000 -24990000 0 -42443000 -42443000 -89981000 -89981000 -95567000 -95567000 -21057000 -21057000 109295742 91158500 86460560 8000002 0 0 0 0 109295742 91158500 86460560 8000002 -0.39 -0.39 -0.99 -0.99 -1.11 -1.11 -2.63 -2.63 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:43.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,137,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,915,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774,800</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,583,255</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,296,831</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,802,419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,842</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,253,895</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,745,471</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,787,856</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009,642</span></td></tr></table></div> 29533282 29533282 29533282 0 17137358 18915358 20452155 774800 7583255 2296831 2802419 234842 54253895 50745471 52787856 1009642 INCOME TAX BENEFIT<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, incorporated in the Bailiwick of Jersey migrated its place of residence on October 29, 2024. It was tax resident in the Bailiwick of Jersey prior to this date, resident in the United Kingdom in the period thereafter, and subject to taxation in the U.S. and various states jurisdictions throughout. ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) indicates that the federal statutory income tax rate of a foreign reporting entity be used when preparing the rate reconciliation disclosure. As such, the Company and its wholly-owned subsidiaries use the statutory income tax rate in the Bailiwick of Jersey and the Cayman Islands of 0% through October 29, 2024, and the statutory income tax rate in the United Kingdom for the period thereafter of 25.0%.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated pretax loss for the periods presented were generated by domestic and foreign operations as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor (Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,538)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112,943)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the periods presented consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred (income) expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,185)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,021)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,975)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense related to the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S./foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax benefit, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True-Ups</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Withholding tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2024, a valuation allowance of $22.5 million has been provided for predominantly on the deferred tax assets related to the Company’s investment in Waldencast Partners LP. If or when recognized, the tax benefits related to any reversal of valuation allowance will be accounted for as a reduction of income tax expense.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December 31, 2024 and December 31, 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest to foreign related parties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible interest carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below market contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Waldencast LP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">48,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,015)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(39,685)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,666)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax (liabilities) assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,523</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,044)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15,229)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2023 were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:44.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do not expire</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2043</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, state</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do not expire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, Hong Kong</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, Vietnam</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IRC</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) annual use of the Company’s net operating losses (“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NOLs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and research and development (“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) credit carryforwards may be limited in the event that a cumulative change in ownership of more than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.0%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> occurs within a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-year period. The Company has not undergone an analysis to determine whether this limitation would apply to the utilization of the NOL carryforward. However, as the federal NOLs do not expire, the Company does not believe that any potential limitations to federal or state NOLs, or federal credit carryforwards, if applicable, would be material to the financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations and comprehensive loss. There were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrecognized tax benefits as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or December 31, 2023. The Company does not expect material changes to its unrecognized tax benefits for the twelve month period following the reporting date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ctive taxing authority examinations in any of the Company's major tax jurisdictions other than in relation to Obagi Cosmeceuticals LLC for the 2021 tax year. There have been no findings or adjustments related to this open tax examination. The Company remains subject to examination for federal and state income tax purposes for the tax years ending 2020 through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> 0 0.250 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated pretax loss for the periods presented were generated by domestic and foreign operations as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor (Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82,868)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,538)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112,943)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2684000 -82868000 -125281000 -17676000 -51222000 -30075000 -1079000 -3268000 -48538000 -112943000 -126360000 -20944000 <div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the periods presented consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred (income) expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,185)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,021)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,975)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 784000 12000 0 0 268000 32000 20000 19000 243000 2000 0 4000 1295000 46000 20000 23000 -144000 -7927000 -4557000 38000 -976000 906000 -1266000 52000 -66000 0 0 0 -1185000 -7021000 -5823000 90000 110000 -6975000 -5803000 113000 <div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense related to the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:43.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at Bailiwick of Jersey/United Kingdom for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S./foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax benefit, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True-Ups</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Withholding tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 0.043 0 0 0 0.100 0.159 0.207 0.177 0.017 0.021 0.024 0.014 0.035 -0.001 0.002 -0.001 0.009 0.018 0.011 0.000 -0.056 -0.104 -0.061 -0.169 0 0 0 0.086 0 0 0 -0.113 -0.122 0 0 0 0.005 0.005 0 0 -0.016 0 0 0 0 0 -0.114 0 -0.002 0.062 0.046 -0.006 22500000 <div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December 31, 2024 and December 31, 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest to foreign related parties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,217 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible interest carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below market contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Waldencast LP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">48,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,016)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,015)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,035)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(39,685)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,666)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax (liabilities) assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,523</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,044)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15,229)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2388000 2771000 1763000 2222000 1205000 1421000 19016000 20669000 3217000 2134000 10000 0 864000 1112000 457000 482000 3790000 5077000 0 1469000 2256000 2811000 13147000 9059000 0 962000 48113000 50189000 1658000 1016000 0 92000 778000 1015000 37035000 43543000 215000 0 39685000 45666000 8427000 4523000 22471000 19752000 14044000 15229000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2023 were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:44.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do not expire</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2043</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2042</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, state</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do not expire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, Hong Kong</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, Vietnam</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr></table></div> 42539000 75142000 25383000 64984000 387000 387000 88000 121000 0 375000 0 1929000 0 0 RELATED PARTY TRANSACTIONS<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Waldencast</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Subscription Agreement with PIPE Investors</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company entered into subscription agreements (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Subscription Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with certain investors (collectively, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 PIPE Investors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PIPE Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 PIPE Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The 2023 Subscription Agreements relating to approximately $68.0 million of proceeds were consummated in September 2023, with the remaining approximately $2.0 million of proceeds related to the closing of the 2023 Subscription Agreements in November 2023, following receipt of regulatory approvals (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 PIPE Closings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” and the date on which such Closing occurred, the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PIPE Closing Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2023 PIPE Investment, we agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain of our Class A ordinary shares that are held by the parties thereto from time to time, subject to the restrictions on transfer therein (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 PIPE Registration Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The 2023 PIPE Registration Rights terminate with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into indemnification agreements with each of its directors and executive officers. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from an indemnitee’s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company’s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. During the year ended December 31, 2024, the total expense related to the indemnification agreements was $4.6 million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prior to the Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Rights</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company filed a registration statement on Form F-1 to register up to 121,120,063 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the sponsor shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,104,225 Class A ordinary shares issuable in exchange for 21,104,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 11,800,000 Class A ordinary shares issued in the PIPE investments; (vii) 33,300,000 Class A ordinary shares issued pursuant to the FPAs; and (viii) 18,033,332 Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transactions with Cedarwalk in Connection with the Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Obagi China Distribution, the Company entered into an Intellectual Property License Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), a Global Supply Services Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supply Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), and a Transition Services Agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transition Services Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with Obagi Hong Kong, which is owned by Cedarwalk, the former owner of Obagi and a beneficial holder of 24.5% of the Company’s fully diluted Class A ordinary shares as of the closing of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the IP License Agreement, the Company exclusively licenses intellectual property relating to the Obagi brand to the Obagi China Business, and the Company retains the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The Obagi China Business pays the Company a royalty on gross sales of licensed products. The IP License Agreement is perpetual subject to certain conditions. During the year ended December 31, 2024, net revenue generated from related party royalties was $0.1 million. During the year ended December 31, 2023, net revenue generated from related party royalties was $0.3 million. During the period from July 28, 2022 to December 31, 2022, net revenue generated from related party royalties was $0.2 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Supply Agreement, the Company supplies or causes to be supplied through certain Obagi CMOs products for distribution and sale in the China Region by the Obagi China Business. The parties operated under an interim supply agreement, which terminated in July 2023. However, the parties continued to operate under the interim supply agreement terms until December 2024, at which point the remaining related party liability was released as the Company had fulfilled its contractual obligations related to pricing. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products until the Obagi China Business has been added as a party to Obagi’s CMO agreements, at which time it will then order directly from the CMOs. During the year ended December 31, 2024, net revenue generated from supplying products to the Obagi China Business was $2.8 million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the related cost of goods sold was $0.8 million. During the year ended December 31, 2023, net revenue generated from supplying products to the Obagi China Business was $5.6 million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the related cost of goods sold was $1.7 million. During the period from July 28, 2022 to December 31, 2022, net revenue generated from supplying products to the Obagi China Business was $17.0 million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the related cost of goods sold was $5.1 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company had $0.8</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. As of December 31, 2023, the Company had $1.1</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Transition Services Agreement, the Company provided Obagi Hong Kong and its affiliates certain transition services to enable them to conduct the Obagi China Business as a going concern in the China Region. The transition services were provided for an initial term of up to <span style="-sec-ix-hidden:f-1529">twelve</span> (12) months, with an option for Obagi China Business to extend the service period for up to an additional <span style="-sec-ix-hidden:f-1530">twelve</span> (12) months solely as to certain R&amp;D services. Obagi Hong Kong did not elect to extend the services and as a result the Transition Services Agreement expired on July 27, 2023. Services under the agreement were to be charged at the reasonable, fully-loaded costs of providing the services, but such services were to be provided at no charge for a certain period of time or up to a specified dollar value of services (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Threshold Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Company determined that the Threshold Amount may be applied towards a combination of the Company’s services or inventory purchases made by the Obagi China Business under the Supply Agreement. Due to the fact that the Threshold Amount had not been reached at the time of expiration, the Company received no fees from the Obagi China Business during the year ended December 31, 2024 or the year ended December 31, 2023. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. Milk also receives certain services </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from an employee of Milk Studios. During the year ended December 31, 2024 and the year ended December 31, 2023, the Company incurred administrative fees of $0.3 million in connection with the sublease and services, which is recorded in SG&amp;A expenses in the consolidated statements of operations and comprehensive loss. During the period from July 28, 2022 to December 31, 2022, the Company incurred administrative fees of $0.1 million, which is recorded in SG&amp;A expenses in the consolidated statements of operations and comprehensive loss. </span></div>One of the cofounders of Milk Makeup and a shareholder of the Company is party to an influencer agreement with Milk Makeup pursuant to which the shareholder provides certain brand services to Milk Makeup. Milk incurred $0.1 million in fees pursuant to this agreement during the year ended December 31, 2024 and the year ended December 31, 2023. 14000000 5.00 70000000 68000000 2000000 P30D 4600000 121120063 8545000 80000 20000 28237506 21104225 21104225 11800000 33300000 18033332 0.245 100000 300000 200000 2800000 800000 5600000 1700000 17000000.0 5100000 800000 1100000 300000 100000 100000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitments represent unconditional purchase obligations to purchase goods or services, primarily inventory, that are enforceable and legally binding on the Company and specify all significant terms, including fixed or minimum quantities to be purchased, price provisions, and the approximate timing of the transaction. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into a certain development and production agreement with a third-party vendor in which the Company was committed to purchase from the vendor certain units of Skintrinsiq devices totaling</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.7 million. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, the Company did not have any associated future minimum payments due to the vendor ceasing all its operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the SEC investigation described below, the Company is not involved in any material litigation nor, to management’s knowledge, was any material litigation threatened against the Company, which if adversely determined could have a material adverse impact on the Company. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit and Governance Committee of the Board, engaged in a review of certain accounting practices applied to the Company’s financial statements for the Predecessor Periods and Successor Period through December 31, 2022. The Company proactively and voluntarily self-reported the review to the SEC. In connection with this matter, the Company received a document subpoena from the SEC in September 2023. Although the Company is fully cooperating with the SEC’s investigation and continues to respond to requests related to this matter, it cannot predict when the SEC will complete its investigation or its outcome and potential impact such outcome may have on the Company’s business. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company could have a material adverse effect on its business, financial condition and results of operations.</span></div> 5700000 SEGMENT REPORTING<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. Prior to the consummation of the Business Combination, the Predecessor operated its business and reported its results through a single operating and reportable segment. Following the Business Combination, the Company determined that it has two operating and reportable segments: Obagi Medical and Milk Makeup. See. “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Business Combinations.” Each segment represents a business unit that focuses on distinct products, markets, and customers.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi Medical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- this segment consists of the business of Obagi. Obagi’s business activities include developing, marketing, and selling skin health products. These assets and activities are conducted by Obagi Global Holdings Limited and its wholly-owned subsidiaries. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk Makeup</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - this segment consists of the business of Milk. Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Milk generates revenue from the sale of cosmetics to retailers, including off-price retailers, and sales DTC via its website. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Summary of Significant Accounting Policies.”</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's chief operating decision maker (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CODM”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is its Chief Executive Officer, who utilizes adjusted gross profit as the financial measure for assessing the performance of each segment. The CODM evaluates each segment's performance by comparing the current period's adjusted gross margin to those of prior periods and allocates resources based on the adjusted gross margin.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes segment revenue and significant segments expenses:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:40.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,602 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:44.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(45,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold. The period from January 1, 2022 to July 27, 2022 did have any adjustments to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles total consolidated adjusted gross profit to consolidated net loss before and after income taxes:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:43.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the fair value of the related party liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued product write-off</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the inventory fair value adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization impact of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The period from January 1, 2022 to July 27, 2022 did not have any adjustments to cost of goods sold.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented. All of the Company’s and the Predecessor’s long-lived assets are located in the U.S.</span></div> 2 2 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes segment revenue and significant segments expenses:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:40.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,602 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273,868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218,138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:44.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Medical</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(45,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted gross cost of goods sold excludes the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination, the amortization of the inventory fair value step-up as a result of the Business Combination, and the Supply Agreement and Formulations intangible assets are amortized to cost of goods sold. The period from January 1, 2022 to July 27, 2022 did have any adjustments to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles total consolidated adjusted gross profit to consolidated net loss before and after income taxes:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:43.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">203,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the fair value of the related party liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discontinued product write-off</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the inventory fair value adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization impact of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,031 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,574)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The period from January 1, 2022 to July 27, 2022 did not have any adjustments to cost of goods sold.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the advance purchase of specific products for the market in Vietnam sold through the SA Distributor that became obsolete when the contract was terminated.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Supply Agreement and Formulations intangible assets are amortized to cost of goods sold.</span></div> 149266000 124602000 273868000 117651000 100487000 218138000 30697000 39618000 33922000 33801000 118569000 84984000 203553000 83729000 66686000 150415000 61090000 31283000 92373000 73760000 -45611000 -12408000 30868000 15479000 18875000 34354000 42892000 203553000 150415000 34354000 42892000 -2260000 -4058000 -12186000 0 2864000 0 0 0 0 1691000 10035000 0 11205000 11205000 4789000 0 245297000 223508000 90722000 58155000 5031000 0 68715000 0 17155000 18906000 6230000 6652000 -23627000 10337000 -6793000 0 3574000 -1769000 798000 971000 -48538000 -112943000 -126360000 -20944000 EMPLOYEE BENEFIT PLAN<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a Section 401(k) retirement plan and pension plans for employees in the U.S. and the United Kingdom. During the year ended December 31, 2024, the year ended December 31, 2023, the period from July 28, 2022 to December 31, 2022, and the period from January 1, 2022 to July 27, 2022 (Predecessor Period) the Company’s contributions to the plan were $1.3 million, $1.2 million, $0.3 million, and $0.4 million, respectively.</span></div> 1300000 1200000 300000 400000 SUBSEQUENT EVENTS <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2025, the Company canceled 11,500,000 of founder stock options and concurrently granted 5,730,000 replacement stock options. These new options vest in three equal annual tranches on each grant date anniversary. The founders have five years to exercise each tranche after it vests. The stock options are subject to continued employment with the Company.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Credit Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2025, the Company entered into a credit agreement (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2025 Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) with TCW Asset Management Company, LLC and the 2025 Credit Agreement lenders. The 2025 Credit Agreement provides for a five-year secured first lien (i) term loan facility in an aggregate principal amount of $175.0 million (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and (ii) revolving loan facility in an aggregate principal amount of up to $30.0 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the initial borrowings under the 2025 Credit Agreement were used to (i) repay and terminate the 2022 Credit Agreement, (ii) pay fees and expenses relating to the 2025 Credit Agreement and (iii) fund working capital and for general corporate purposes.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the issuance date of these financial statements, the 2025 Term Loans’ outstanding balance is $175.0 million. The 2025 revolving loan facility has $15.0 million drawn with $15.0 million remaining available. The 2022 Credit Agreement including its revolving line of credit has been fully extinguished.</span></div> 11500000 5730000 5730000 5730000 P5Y P5Y 175000000 30000000 175000000 15000000 15000000 CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company financial statements for Waldencast plc should be read in conjunction with the Company’s Consolidated Financial Statements and the accompanying notes thereto. For purposes of this condensed financial information, the Company’s wholly owned and majority owned subsidiaries are recorded based upon its proportionate share of its subsidiaries’ net assets (similar to presenting them on the equity method). Waldencast has no material operations of its own and conducts substantially all of its activities through its wholly owned subsidiaries. Waldencast has no significant assets or liabilities other than derivative warrant liabilities, note payable, and cash, most expenditures paid by Waldencast are allocated to its subsidiaries. Waldencast Finco Limited, a wholly-owned indirect subsidiary of Waldencast, is the borrower under the 2022 Credit Agreement. The terms and conditions of the 2022 Credit Agreement (see “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i0172b2739fac441a8912c01c337314eb_136" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Debt” for definition) limit the ability of Waldencast’s wholly owned subsidiaries to make certain distributions or dividends, subject to a number of enumerated exceptions. Due to the aforementioned restrictions, substantially all of the Successor period net assets of Waldencast’s subsidiaries are restricted. Since the restricted net assets of consolidated subsidiaries exceed 25% of the consolidated net assets of the Company and its subsidiaries, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X. This information should be read in conjunction with the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following condensed financial statements have been presented on a “parent-only” basis. Under a parent-only presentation, Waldencast’s investment in its subsidiaries is presented under the equity method of accounting. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED BALANCE SHEETS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intercompany receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">697,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">797,920 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note payable</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHAREHOLDERS’ EQUITY:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 112,026,440 and 101,228,857 outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized; and 10,666,528 and 20,847,553 outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">951,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">871,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(289,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(246,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL CONTROLLING SHAREHOLDERS’ EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">662,319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">624,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS’ EQUITY</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">729,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">769,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735,788 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">797,920 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:50.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.626%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENTS OF OPERATIONS </span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense (income), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1691">Change in fair value of derivative warrant liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before equity in undistributed earnings of subsidiaries</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) — foreign currency translation adjustments, net of tax</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(122)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,050)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90,103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,596)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:50.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.626%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENTS OF CASH FLOW </span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89,981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18,417)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from PIPE investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of PIPE transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of note payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax refund (withholding)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses paid on behalf of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,982)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,551)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,282)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following condensed financial statements have been presented on a “parent-only” basis. Under a parent-only presentation, Waldencast’s investment in its subsidiaries is presented under the equity method of accounting. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED BALANCE SHEETS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intercompany receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">697,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">797,920 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note payable</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,647 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHAREHOLDERS’ EQUITY:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 112,026,440 and 101,228,857 outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B ordinary shares, $0.0001 par value, 100,000,000 shares authorized; and 10,666,528 and 20,847,553 outstanding as of December 31, 2024 and December 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">951,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">871,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(289,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(246,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL CONTROLLING SHAREHOLDERS’ EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">662,319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">624,626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS’ EQUITY</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">729,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">769,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">735,788 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">797,920 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 472000 419000 37431000 51964000 37903000 52383000 697885000 745537000 735788000 797920000 830000 0 5021000 28647000 5851000 28647000 0.0001 0.0001 1000000000 1000000000 112026440 101228857 11000 9000 0.0001 0.0001 100000000 100000000 10666528 20847553 1000 2000 951260000 871527000 -289204000 -246761000 251000 -151000 662319000 624626000 67618000 144647000 729937000 769273000 735788000 797920000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:50.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.626%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENTS OF OPERATIONS </span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,259)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense (income), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1691">Change in fair value of derivative warrant liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before equity in undistributed earnings of subsidiaries</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) — foreign currency translation adjustments, net of tax</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(122)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,050)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90,103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,596)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 0 0 18393000 1259000 0 -18393000 -1259000 0 24000 -14000 19000 -23627000 10337000 6793000 5209000 -11582000 6812000 0 0 0 5209000 -11582000 6812000 -47652000 -78399000 -102379000 -42443000 -89981000 -95567000 393000 -122000 -29000 -42050000 -90103000 -95596000 <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:50.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.626%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENTS OF CASH FLOW </span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89,981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18,417)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from PIPE investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of PIPE transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from note payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of note payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax refund (withholding)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(66,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses paid on behalf of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,982)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,470</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,551)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,282)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - End of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -42443000 -89981000 -95567000 -47652000 -78399000 -102379000 23627000 -10337000 6793000 -18417000 -1245000 19000 0 0 6400000 0 0 6400000 0 70000000 0 0 1069000 0 1632000 0 0 1770000 0 0 -558000 1204000 0 32750000 30575000 6000000 0 66250000 300000 14700000 33603000 8982000 18470000 -1551000 -3282000 53000 -2796000 3137000 419000 3215000 78000 472000 419000 3215000 true <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and review our cybersecurity policies, processes, and practices. To help protect our information systems from cybersecurity threats, we use a suite of security and business continuity tools that are designed to help us proactively identify, monitor, escalate, investigate, resolve, and recover from security incidents in a timely manner. Our cybersecurity training and testing program helps ensure awareness and knowledge of cybersecurity best practices purvey all departments. Our information technology department, in connection with management and legal, assesses risks based on probability and potential impact to key business systems and processes. With over 21 years of experience, our recently appointed Chief Technology Officer (“</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) has expertise in managing information security, developing cybersecurity strategies and internal awareness programs, implementing effective cybersecurity programs, and executing business continuity and incident response plans, including regular disaster recovery testing, who leads the assessment and management of such risks. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a risk-based approach to cybersecurity and have implemented cybersecurity policies and practices throughout our operations that are designed to address cybersecurity threats and incidents.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the risk factor captioned “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are dependent on information technology systems and infrastructure; if we, or the third parties we rely on, fail to protect sensitive information of our consumers and information technology systems against security breaches, it could damage our reputation and brand and substantially harm our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” in Part I, “Item 3.D. Risk Factors” for additional description of cybersecurity risks and potential related impacts on the Company.</span></div> We regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities, and review our cybersecurity policies, processes, and practices. To help protect our information systems from cybersecurity threats, we use a suite of security and business continuity tools that are designed to help us proactively identify, monitor, escalate, investigate, resolve, and recover from security incidents in a timely manner. true true true With over 21 years of experience, our recently appointed Chief Technology Officer (“<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) has expertise in managing information security, developing cybersecurity strategies and internal awareness programs, implementing effective cybersecurity programs, and executing business continuity and incident response plans, including regular disaster recovery testing, who leads the assessment and management of such risks. </span><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a risk-based approach to cybersecurity and have implemented cybersecurity policies and practices throughout our operations that are designed to address cybersecurity threats and incidents.</span></div> false <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year.</span></div> Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year Our Board oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year true The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year The Audit and Governance Committee of the board oversees our risk management program, which focuses on the most significant risks we face. Meetings of the Audit and Governance Committee include discussions of specific risk areas throughout the year true true

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